9316 genotypes with 23882 annotations displayed
of selected term and subterms
|
Searched Term: abnormal immune system physiology
|
1700016L21RikTg(Itgax-HBEGF/EGFP)57Lan/0
(C.FVB-1700016L21RikTg(Itgax-HBEGF/EGFP)57Lan)
|
abnormal T cell activation
|
J:93488
|
decreased cytotoxic T cell cytolysis
|
J:93488
|
1700016L21RikTg(Itgax-HBEGF/EGFP)57Lan/0
(B6.FVB-1700016L21RikTg(Itgax-HBEGF/EGFP)57Lan/J)
|
abnormal NK cell physiology
|
J:96123
|
abnormal NK T cell physiology
|
J:96123
|
decreased circulating interferon-gamma level
|
J:96123
|
decreased circulating interleukin-12 level
|
J:96123
|
decreased interferon-gamma secretion
|
J:96123
|
decreased interleukin-4 secretion
|
J:96123
|
decreased interleukin-12b secretion
|
J:125611
|
impaired natural killer cell mediated cytotoxicity
|
J:125611
|
sepsis
|
J:113232
|
1700016L21RikTg(Itgax-HBEGF/EGFP)57Lan/0
(C.FVB-1700016L21RikTg(Itgax-HBEGF/EGFP)57Lan/J)
|
abnormal NK cell physiology
|
J:96123
|
decreased circulating interferon-gamma level
|
J:96123
|
decreased circulating interleukin-12 level
|
J:96123
|
decreased interferon-gamma secretion
|
J:96123
|
1700016L21RikTg(Itgax-HBEGF/EGFP)57Lan/0
(involves: C57BL/6 * FVB/N)
|
decreased interferon-gamma secretion
|
J:137452
|
increased susceptibility to Orthomyxoviridae infection
|
J:137452
|
1700016L21RikTg(Itgax-HBEGF/EGFP)57Lan/0
(NOD.FVB-1700016L21RikTg(Itgax-HBEGF/EGFP)57Lan/Jdk)
|
abnormal professional antigen presenting cell physiology
|
J:137009
|
decreased susceptibility to autoimmune diabetes
|
J:137009
|
increased interferon-gamma secretion
|
J:137009
|
increased tumor necrosis factor secretion
|
J:137009
|
insulitis
|
J:137009
|
1700016L21RikTg(Itgax-HBEGF/EGFP)57Lan/0
(involves: FVB/N)
|
abnormal response to infection
|
J:189122
|
decreased interleukin-17 secretion
|
J:193548
|
decreased susceptibility to bacterial infection
|
J:210086
|
1700016L21RikTg(Itgax-HBEGF/EGFP)57Lan/0
(B6.FVB-1700016L21RikTg(Itgax-HBEGF/EGFP)57Lan)
|
abnormal circulating cytokine level
|
J:194800
|
abnormal susceptibility to infection
|
J:194800
|
impaired neutrophil recruitment
|
J:194800
|
increased susceptibility to bacterial infection
|
J:194800
|
1700067K01Riktm2a(KOMP)Wtsi/1700067K01Riktm2a(KOMP)Wtsi
(C57BL/6N-1700067K01Riktm2a(KOMP)Wtsi/Wtsi)
|
blood in lymph vessels
|
J:239583
|
4933434E20Riktm1a(EUCOMM)Wtsi/4933434E20Riktm1a(EUCOMM)Wtsi
(C57BL/6N-4933434E20Riktm1a(EUCOMM)Wtsi/Wtsi)
|
blood in lymph vessels
|
J:239583
|
5730403I07Rikem8Gpt/5730403I07Rikem8Gpt
(involves: C57BL/6JGpt)
|
abnormal regulatory T cell physiology
|
J:329871
|
abnormal T cell physiology
|
J:329871
|
increased inflammatory response
|
J:329871
|
increased interferon-gamma secretion
|
J:329871
|
9030622O22Rikem1Eem/9030622O22Rik+ Foxa2tm1.1Khk/Foxa2+
(involves: 129P2/OlaHsd * C57BL/6 * CD-1)
|
respiratory system inflammation
|
J:284174
|
9030622O22Rikem1Eem/9030622O22Rikem1Eem
(involves: C57BL/6 * CD-1)
|
lung inflammation
|
J:284174
|
A1cfTg(Myh6-cre/Esr1*)1Jmk/A1cf+ Tg(Myh6-2A)#Know/0
(involves: BALB/c * C57BL/6 * FVB/N)
|
heart inflammation
|
J:128060
|
A4gnttm1Jnaka/A4gnttm1Jnaka
(B6.129S6-A4gnttm1Jnaka)
|
stomach inflammation
|
J:184485
|
A930024E05Rikem2Zfa/A930024E05Rikem2Zfa Satb1em1Zfa/Satb1em1Zfa Tg(Rorc-cre)1Litt/0
(involves: C57BL/6 * FVB)
|
increased susceptibility to bacterial infection
|
J:259392
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:259392
|
A930024E05Rikem2Zfa/A930024E05Rikem2Zfa Tg(Rorc-cre)1Litt/0
(involves: C57BL/6 * FVB)
|
abnormal interleukin secretion
|
J:259392
|
increased susceptibility to bacterial infection
|
J:259392
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:259392
|
Ay/a Apoetm1Unc/Apoetm1Unc
(involves: 129P2/OlaHsd * C57BL/6J * KK/TaJcl)
|
abnormal inflammatory response
|
J:177084
|
AA467197em1Nyam/AA467197em1Nyam
(C57BL/6J-AA467197em1Nyam)
|
increased IgG level
|
J:347271
|
kidney inflammation
|
J:347271
|
liver inflammation
|
J:347271
|
lung inflammation
|
J:347271
|
AA467197em1Nyam/AA467197em1Nyam
(C.B6-AA467197em1Nyam)
|
increased susceptibility to autoimmune disorder
|
J:347271
|
AabprNZB/Slc/?
(involves: NZB/Slc * NZW/Slc)
|
increased B cell proliferation
|
J:87690
|
Abattm1c(EUCOMM)Hmgu/Abattm1c(EUCOMM)Hmgu Tg(Cd4-cre)1Cwi/0
(involves: 129S4/SvJaeSor * C57BL/6 * C57BL/6N * DBA/2)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:333883
|
decreased T cell proliferation
|
J:333883
|
Abca1tm1Jdm/Abca1tm1Jdm
(DBA/1LacJ-Abca1tm1Jdm)
|
impaired macrophage phagocytosis
|
J:63265
|
Abca1tm1Jdm/Abca1tm1Jdm
(involves: C57BL/6 * DBA/1LacJ)
|
impaired macrophage phagocytosis
|
J:132254
|
Abca1tm1Jdm/Abca1tm1Jdm Abcg1tm1Dgen/Abcg1tm1Dgen
(involves: 129P2/OlaHsd * C57BL/6 * DBA/1LacJ)
|
abnormal chemokine secretion
|
J:130777
|
abnormal cytokine secretion
|
J:130777
|
Abca1tm1Jdm/Abca1tm1Jdm Tgm2tm1Gml/Tgm2tm1Gml
(involves: C57BL/6 * DBA/1LacJ)
|
impaired macrophage phagocytosis
|
J:132254
|
Abca1tm1Jp/Abca1tm1Jp Abcg1tm1Tall/Abcg1tm1Tall Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6)
|
increased interleukin-17 secretion
|
J:190966
|
increased interleukin-23 secretion
|
J:190966
|
Abca1tm1Jp/Abca1tm1Jp Abcg1tm1Tall/Abcg1tm1Tall Tg(Itgax-cre,-EGFP)4097Ach/0
(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J)
|
increased interleukin-17 secretion
|
J:190966
|
increased interleukin-23 secretion
|
J:190966
|
Abca1tm1Wpfl/Abca1tm1Wpfl
(involves: 129P2/OlaHsd * C57BL/6J)
|
glomerulonephritis
|
J:64390
|
uterus inflammation
|
J:64390
|
Abcb1atm1Bor/Abcb1atm1Bor
(FVB.129P2-Abcb1atm1Bor/TacImx)
|
abnormal lymphocyte physiology
|
J:51190
|
colitis
|
J:51190
|
increased IgA level
|
J:51190
|
increased IgE level
|
J:51190
|
increased IgG1 level
|
J:51190
|
increased IgG2 level
|
J:51190
|
increased IgG2a level
|
J:51190
|
increased IgG2b level
|
J:51190
|
increased IgG3 level
|
J:51190
|
increased IgM level
|
J:51190
|
increased immunoglobulin level
|
J:51190
|
large intestinal inflammation
|
J:51190
|
Abcb1atm1Bor/Abcb1atm1Bor Abcb1btm1Bor/Abcb1btm1Bor
(FVBTac.129P2-Abcb1btm1Bor Abcb1atm1Bor)
|
abnormal T cell physiology
|
J:102640
|
increased interferon-gamma secretion
|
J:102640
|
increased interleukin-2 secretion
|
J:102640
|
Abcb4tm1Bor/Abcb4tm1Bor
(either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * FVB/N))
|
bile duct inflammation
|
J:15531,
J:21232
|
liver inflammation
|
J:15531
|
Abcb4tm1Bor/Abcb4tm1Bor
(involves: 129P2/OlaHsd * FVB/N)
|
bile duct inflammation
|
J:175015
|
liver inflammation
|
J:175015
|
Abcb4tm1Bor/Abcb4tm1Bor
(FVB.129P2-Abcb4tm1Bor/J)
|
bile duct inflammation
|
J:105357
|
Abcb4tm1Bor/Abcb4tm1Bor
(involves: 129P2/OlaHsd * BALB/c)
|
bile duct inflammation
|
J:168123
|
Abcc1tm1Bor/Abcc1tm1Bor
(involves: 129P2/OlaHsd * FVB)
|
abnormal mast cell physiology
|
J:44110
|
decreased inflammatory response
|
J:44110
|
Abcc4tm1Kruh/Abcc4tm1Kruh
(B6.129-Abcc4tm1Kruh)
|
increased susceptibility to induced colitis
|
J:117326
|
intestinal inflammation
|
J:117326
|
small intestinal inflammation
|
J:117326
|
Abcd1tm1Kds/Y Abcd2tm1Apuj/Abcd2tm1Apuj
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6J)
|
increased inflammatory response
|
J:94583
|
Abcg1tm1Dgen/Abcg1tm1Dgen
(B6.129P2-Abcg1tm1Dgen)
|
abnormal macrophage physiology
|
J:117028
|
Abcg1tm1Dgen/Abcg1tm1Dgen
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal chemokine secretion
|
J:130777
|
abnormal cytokine secretion
|
J:130777
|
lung inflammation
|
J:132952
|
Abcg2tm1.1Ssf/Abcg2tm1.1Ssf
(involves: 129 * C57BL/6 * FVB)
|
liver inflammation
|
J:201884
|
Abhd5tm1.1Lqyu/Abhd5tm1.1Lqyu Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6 * DBA)
|
liver inflammation
|
J:199570
|
Abhd16atm1a(EUCOMM)Wtsi/Abhd16atm1a(EUCOMM)Wtsi
(involves: C57BL/6N * C57BL/6NTac)
|
abnormal macrophage physiology
|
J:232688
|
decreased interleukin-1 beta secretion
|
J:232688
|
decreased interleukin-6 secretion
|
J:232688
|
decreased macrophage cytokine production
|
J:232688
|
decreased tumor necrosis factor secretion
|
J:232688
|
Abi1tm1Pen/Abi1+ Abi2tm1Pen/Abi2tm1Pen
(Not Specified)
|
decreased interleukin-2 secretion
|
J:104623
|
decreased T cell proliferation
|
J:104623
|
Abl1m1/Abl1m1
(either: 129S/SvEv-Abl1m1 or (involves: 129S/SvEv * CD-1) or (involves: 129S/SvEv * C57BL/6 * DBA/2))
|
increased susceptibility to infection
|
J:14644
|
Abl1m1/Abl1m1
(involves: 129S/SvEv)
|
abnormal splenocyte physiology
|
J:34903
|
Abl1m1/Abl1m1
(involves: 129S/SvEv * C57BL/6)
|
abnormal B cell calcium ion homeostasis
|
J:148105
|
Abl1tm1Mlg/Abl1tm1Mlg
(involves: 129S/SvEv * C57BL/6J)
|
lung inflammation
|
J:72875
|
Abl1tm1Mlg/Abl1tm1Mlg
(involves: 129S/SvEv * C57BL/6J * CBA)
|
increased susceptibility to infection
|
J:34643
|
Abl1tm1Mlg/Abl1tm1Mlg Tg(ACTB-Abl1*K290R)1Spg/0
(involves: 129S/SvEv * C57BL/6J * CBA)
|
increased susceptibility to infection
|
J:34643
|
AbmmDBA/2J/?
(involves: BALB/cByJ * DBA/2J)
|
myocarditis
|
J:52296
|
Abraxas2tm1.2Bwng/Abraxas2tm1.2Bwng
(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NCrl)
|
increased inflammatory response
|
J:245949
|
Acacatm1Dejs/Acacatm1Dejs Tg(Cd4-cre)1Cwi/?
(involves: C57BL/6 * DBA/2)
|
abnormal T cell physiology
|
J:209886
|
Acacatm1Dejs/Acacatm1Dejs Tg(Cd4-cre)1Cwi/? Tg(TcraTcrb)1100Mjb/?
(involves: C57BL/6 * DBA/2)
|
increased T cell proliferation
|
J:209886
|
Acantm2Afos/Acantm2Afos
(involves: C57BL/6)
|
decreased susceptibility to induced arthritis
|
J:122102
|
Acbd5tm1a(EUCOMM)Wtsi/Acbd5tm1a(EUCOMM)Wtsi
(C57BL/6N-Atm1Brd Acbd5tm1a(EUCOMM)Wtsi/WtsiCnbc)
|
brain inflammation
|
J:299448
|
Ace2em1(ACE2)Yowa/Ace2em1(ACE2)Yowa
(C57BL/6-Ace2em1(ACE2)Yowa)
|
abnormal circulating cytokine level
|
J:288243
|
increased circulating interferon-gamma level
|
J:288243
|
increased circulating interleukin-9 level
|
J:288243
|
increased susceptibility to Coronaviridae infection
|
J:288243
|
interstitial pneumonia
|
J:288243
|
Ace2em1Cya/Y
(C57BL/6J-Ace2em1Cya/Cya)
|
increased susceptibility to induced colitis
|
J:299383
|
intestinal inflammation
|
J:299383
|
Ace2em2(ACE2)Gpt/Y
(C57BL/6JGpt-Ace2em2(ACE2)Gpt/Gpt)
|
increased susceptibility to Coronaviridae infection
|
J:302150
|
lung inflammation
|
J:302150
|
Ace2em#Yngh/Y
(involves: Kunming)
|
increased susceptibility to induced colitis
|
J:221616
|
Ace2tm1a(KOMP)Wtsi/Y Tg(FOXJ1-cre)F26Htzm/0
(involves: C57BL/6N * C57BL/6NTac)
|
increased susceptibility to bacterial infection
|
J:282139
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:282139
|
lung inflammation
|
J:282139
|
Ace2tm1a(KOMP)Wtsi/Ace2tm1a(KOMP)Wtsi Tg(FOXJ1-cre)F26Htzm/0
(involves: C57BL/6N * C57BL/6NTac)
|
increased susceptibility to bacterial infection
|
J:282139
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:282139
|
lung inflammation
|
J:282139
|
Ace2tm1Cof/Ace2tm1Cof
(involves: 129S6/SvEvTac * C57BL/6)
|
increased incidence of corneal inflammation
|
J:289503
|
Ace2tm1Lex/Ace2tm1Lex
(B6;129S5-Ace2tm1Lex/Mmucd)
|
lung inflammation
|
J:264991
|
Ace2tm1Pngr/Y
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal cytokine level
|
J:124548
|
heart inflammation
|
J:124548
|
Ace2tm1Pngr/Y
(B6.129P2-Ace2tm1Pngr/J)
|
decreased susceptibility to Coronaviridae infection
|
J:286299
|
Ace2tm1Pngr/Y
(involves: 129P2/OlaHsd)
|
increased susceptibility to bacterial infection
|
J:282139
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:282139
|
lung inflammation
|
J:282139,
J:100334
|
Ace2tm1Pngr/Y
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased susceptibility to Orthomyxoviridae infection
|
J:277074
|
increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality
|
J:277074
|
lung inflammation
|
J:277074
|
Ace2tm1Pngr/Ace2tm1Pngr
(involves: 129P2/OlaHsd)
|
increased susceptibility to bacterial infection
|
J:282139
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:282139
|
lung inflammation
|
J:282139,
J:100334
|
Ace2tm1Pngr/Ace2tm1Pngr
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased susceptibility to Orthomyxoviridae infection
|
J:277074
|
increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality
|
J:277074
|
lung inflammation
|
J:277074
|
Ace2tm1Pngr/Ace2tm1Pngr
(B6.129P2-Ace2tm1Pngr/J)
|
decreased susceptibility to Coronaviridae infection
|
J:286299
|
Acetm1Keb/Acetm1Keb
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
|
kidney inflammation
|
J:33018
|
Acetm1Mcf/Acetm1Mcf
(Not Specified)
|
kidney inflammation
|
J:32114
|
tubulointerstitial nephritis
|
J:32114
|
Acetm1Unc/Acetm1Unc
(involves: 129P2/OlaHsd * C57BL/6J)
|
kidney inflammation
|
J:25284
|
Acetm6Keb/Acetm6Keb
(involves: 129 * C57BL/6)
|
abnormal interleukin level
|
J:122178
|
Acetm9Keb/Acetm9Keb
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
kidney inflammation
|
J:185888
|
Acer1tm1a(EUCOMM)Wtsi/Acer1tm1a(EUCOMM)Wtsi
(C57BL/6N-Acer1tm1a(EUCOMM)Wtsi)
|
skin inflammation
|
J:235775
|
Ackr1tm1Scp/Ackr1tm1Scp
(involves: 129P2/OlaHsd * C57BL/6)
|
increased inflammatory response
|
J:64222
|
Ackr1tm1Scp/Ackr1tm1Scp
(involves: 129P2/OlaHsd)
|
abnormal circulating chemokine level
|
J:162629
|
Ackr1tm1Skmz/Ackr1tm1Skmz
(involves: 129P2/OlaHsd * C57BL/6J)
|
abnormal chemokine level
|
J:82938
|
Ackr2tm1Gjg/Ackr2tm1Gjg
(involves: 129/Sv * C57BL/6)
|
dermatitis
|
J:97607
|
increased inflammatory response
|
J:97806
|
Ackr3tm1Jgo/Ackr3+
(involves: 129S/SvEvBrd * C57BL/6)
|
lung inflammation
|
J:136246
|
Ackr3tm1Jgo/Ackr3tm1Jgo
(involves: 129S/SvEvBrd * C57BL/6)
|
lung inflammation
|
J:136246
|
Ackr4tm1.1Rjbn/Ackr4tm1.1Rjbn
(B6.129S6-Ackr4tm1.1Rjbn)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:166490
|
abnormal chemokine level
|
J:166490
|
abnormal circulating chemokine level
|
J:166490
|
decreased T cell proliferation
|
J:166490
|
increased interleukin-23 secretion
|
J:166490
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:166490
|
Acla1BXSB/Slc/Acla1BXSB/Slc
(involves: BXSB/Slc * NZW/Slc)
|
increased autoantibody level
|
J:49899
|
Acla1NZW/Slc/Acla1BXSB/Slc
(involves: BXSB/Slc * NZW/Slc)
|
increased autoantibody level
|
J:49899
|
Acla2BXSB/Slc/Acla2BXSB/Slc
(involves: BXSB/Slc * NZW/Slc)
|
increased autoantibody level
|
J:49899
|
Acla2NZW/Slc/Acla2BXSB/Slc
(involves: BXSB/Slc * NZW/Slc)
|
increased autoantibody level
|
J:49899
|
Acod1tm1a(KOMP)Wtsi/Acod1tm1a(KOMP)Wtsi
(involves: C57BL/6N)
|
abnormal macrophage physiology
|
J:235002
|
Acot11tm1Deco/Acot11tm1Deco
(involves: 129S6/SvEvTac * C57BL/6)
|
decreased inflammatory response
|
J:182660
|
Acox1lampe1/Acox1lampe1
(involves: C57BL/6J)
|
liver inflammation
|
J:174942
|
Acox2em1Jynz/Acox2em1Jynz
(involves: C57BL/6N)
|
liver inflammation
|
J:323193
|
Acp1tm1Lex/Acp1tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
|
increased interleukin-6 secretion
|
J:171883
|
Acp5tm1Ahdm/Acp5tm1Ahdm
(involves: 129S/SvEv)
|
abnormal osteoclast physiology
|
J:36232
|
Acsl3Gt(OST148301)Lex/Acsl3Gt(OST148301)Lex
(B6;129S5-Acsl3Gt(OST148301)Lex/Orl)
|
abnormal humoral immune response
|
J:82809
|
Acsl6tm1.1Jeme/Acsl6tm1.1Jeme
(involves: BALB/cJ * C57BL/6)
|
abnormal microglial cell activation
|
J:267563
|
Acsns1A/J/Acsns1A/J
(involves: A/J * SM/J)
|
decreased susceptibility to parasitic infection
|
J:75549
|
Acsns2SM/J/Acsns2SM/J
(involves: A/J * SM/J)
|
increased susceptibility to parasitic infection
|
J:75549
|
Acsns2SM/J/Acsns2SM/J Acsns3SM/J/Acsns3SM/J
(involves: A/J * SM/J)
|
increased susceptibility to parasitic infection
|
J:75549
|
Acsns3SM/J/Acsns3SM/J
(involves: A/J * SM/J)
|
increased susceptibility to parasitic infection
|
J:75549
|
Acss2em22Gpt/Acss2em22Gpt
(C57BL/6JGpt-Acss2em22Gpt/Gpt)
|
decreased interleukin-1 beta secretion
|
J:346990
|
decreased susceptibility to endotoxin shock
|
J:346990
|
Actbtm4(cre/ERT2)Npa/Actb+ Sgpl1tm1.1Npa/Sgpl1tm1.1Npa
(involves: BALB/cJ * C57BL/6)
|
abnormal type IV hypersensitivity reaction
|
J:199525
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:199525
|
Actn4tm1a(EUCOMM)Wtsi/Actn4tm1a(EUCOMM)Wtsi
(C57BL/6N-Actn4tm1a(EUCOMM)Wtsi/Wtsi)
|
blood in lymph vessels
|
J:239583
|
Actn4tm1Mrpk/Actn4tm1Mrpk
(involves: 129 * C57BL/6)
|
abnormal lymphocyte chemotaxis
|
J:83911
|
Acvr1tm1Emsh/Acvr1+
(chimera involves: BALB/c * C57BL/6 * CD-1)
|
increased inflammatory response
|
J:194134
|
Adatm1Mw/Adatm1Mw
(involves: 129S7/SvEvBrd)
|
abnormal dendritic cell physiology
|
J:138722
|
Adatm1Mw/Adatm1Mw Tg(PLADA)4118Rkmb/0
(involves: 129S7/SvEvBrd * C57BL/6)
|
decreased immunoglobulin level
|
J:73418
|
lung inflammation
|
J:73418
|
Adam7tm1Tigm/Adam7tm1Tigm
(involves: C57BL/6)
|
spermatic granuloma
|
J:226260
|
Adam8tm1.1Mdz/Adam8tm1.1Mdz
(DBA/1LacJ-Adam8tm1.1Mdz)
|
decreased susceptibility to induced arthritis
|
J:155243
|
Adam17m1Btlr/Adam17m1Btlr
(C57BL/6J-Adam17m1Btlr)
|
decreased circulating tumor necrosis factor level
|
J:166602
|
increased susceptibility to induced colitis
|
J:166602
|
Adam17tm1.1Srj/Adam17tm1.1Srj
(involves: 129S/SvEv * C57BL/6 * SJL)
|
abnormal chemokine level
|
J:163380
|
abnormal interleukin secretion
|
J:163380
|
increased interleukin-10 secretion
|
J:163380
|
increased susceptibility to induced colitis
|
J:163380
|
skin inflammation
|
J:163380
|
Adam17tm1.2Bbl/Adam17tm1.2Bbl Il17atm1Yiw/Il17atm1Yiw Sox9tm3(cre)Crm/Sox9+
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * SJL)
|
dermatitis
|
J:229771
|
Adam17tm1.2Bbl/Adam17tm1.2Bbl Il23atm1Dnax/Il23atm1Dnax Sox9tm3(cre)Crm/Sox9+
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * SJL)
|
dermatitis
|
J:229771
|
Adam17tm1.2Bbl/Adam17tm1.2Bbl Sox9tm3(cre)Crm/Sox9+
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6)
|
increased circulating interleukin-17 level
|
J:144795
|
increased interleukin-17 secretion
|
J:144795
|
Adam17tm1.2Bbl/Adam17tm1.2Bbl Sox9tm3(cre)Crm/Sox9+
(B6.129(SJL)-Sox9tm3(cre)Crm Adam17tm1.2Bbl)
|
abnormal circulating chemokine level
|
J:229771
|
dermatitis
|
J:229771
|
increased IgE level
|
J:229771
|
Adam17tm1Bbl/Adam17tm1Bbl Lyz2tm1(cre)Ifo/0
(involves: 129P2/OlaHsd)
|
abnormal macrophage physiology
|
J:139846
|
decreased circulating tumor necrosis factor level
|
J:139846
|
decreased susceptibility to endotoxin shock
|
J:139846
|
Adam17tm1Bbl/Adam17tm1Bbl Tg(Mx1-cre)1Cgn/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
decreased circulating tumor necrosis factor level
|
J:139846
|
decreased susceptibility to endotoxin shock
|
J:139846
|
Adam17tm1Ckww/Adam17tm1Ckww
(Not Specified)
|
abnormal dendritic cell physiology
|
J:138782
|
Adam17tm1Imx/Adam17tm1Imx
(involves: 129 * C57BL/6)
|
increased incidence of corneal inflammation
|
J:51053
|
Adam17tm1Imx/Adam17tm1Imx
(B6.129-Adam17tm1Imx)
|
enhanced leukocyte tethering or rolling
|
J:174865
|
Adam17tm1Rain/Adam17tm1Rain
(involves: C57BL/6)
|
enhanced leukocyte tethering or rolling
|
J:174865
|
Adam17woe/Adam17woe
(C57BL/6-Adam17woe)
|
dermatitis
|
J:160781
|
increased incidence of corneal inflammation
|
J:160781
|
Adam29em1Otin/Adam29em1Otin
(C57BL/6-Adam29em1Otin)
|
increased inflammatory response
|
J:353244
|
Adamdec1tm1Dgen/Adamdec1+
(B6.129P2-Adamdec1tm1Dgen)
|
increased susceptibility to induced colitis
|
J:301741
|
Adamdec1tm1Dgen/Adamdec1tm1Dgen
(B6.129P2-Adamdec1tm1Dgen)
|
decreased circulating interleukin-10 level
|
J:301741
|
increased circulating interleukin-1 beta level
|
J:301741
|
increased circulating interleukin-6 level
|
J:301741
|
increased susceptibility to bacterial infection
|
J:301741
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:301741
|
increased susceptibility to colitis induced morbidity/mortality
|
J:301741
|
increased susceptibility to induced colitis
|
J:301741
|
intestinal inflammation
|
J:301741
|
Adamts2tm1Prc/Adamts2tm1Prc
(involves: 129 * 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased interferon-gamma secretion
|
J:271185
|
Adamts5tm1.1Eam/Adamts5+
(involves: 129S5/SvEvBrd)
|
decreased susceptibility to induced arthritis
|
J:97590
|
Adamts5tm1.1Eam/Adamts5tm1.1Eam
(involves: 129S5/SvEvBrd)
|
decreased susceptibility to induced arthritis
|
J:97590
|
Adamts5tm1Lex/Adamts5tm1Lex Tg(CMV-cre)1Cgn/0
(involves: 129S5/SvEvBrd * BALB/cJ)
|
osteoarthritis
|
J:105138
|
Adamts5tm2.2Lex/Adamts5tm2.2Lex
(B6.129S5-Adamts5tm2.2Lex)
|
decreased susceptibility to induced arthritis
|
J:175366
|
Adamts13tm1Dgi/Adamts13tm1Dgi
(involves: 129X1/SvJ * C57BL/6J * CASA/Rk)
|
increased susceptibility to bacterial infection
|
J:101752
|
Adamts14Gt(511E11)Cmhd/Adamts14Gt(511E11)Cmhd
(involves: 129 * 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased interferon-gamma secretion
|
J:271185
|
increased interleukin-2 secretion
|
J:271185
|
Adamts14Gt(511E11)Cmhd/Adamts14Gt(511E11)Cmhd Adamts2tm1Prc/Adamts2tm1Prc
(involves: 129 * 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal T cell activation
|
J:271185
|
dermatitis
|
J:271185
|
increased interferon-gamma secretion
|
J:271185
|
increased interleukin-2 secretion
|
J:271185
|
increased T cell proliferation
|
J:271185
|
Adamts18tm1.1Wzha/Adamts18tm1.1Wzha
(involves: 129 * C57BL/6)
|
increased acute inflammation
|
J:258487
|
increased susceptibility to induced colitis
|
J:258487
|
Adarem3Qwan/Adarem3Qwan
(Not Specified)
|
abnormal chemokine level
|
J:325221
|
increased circulating interleukin-1 level
|
J:325221
|
increased circulating interleukin-6 level
|
J:325221
|
increased circulating interleukin-17 level
|
J:325221
|
increased CXCL10 level
|
J:325221
|
Adartm1Olds/Adartm1Olds
(involves: 129S/SvEv * C57BL/6J)
|
increased susceptibility to Orthomyxoviridae infection
|
J:169014
|
increased susceptibility to Paramyxoviridae infection
|
J:169014
|
Adartm2Phs/Adartm2Phs
(B6.Cg-Adartm2Phs)
|
abnormal circulating interferon-beta level
|
J:142338
|
increased circulating interferon-alpha level
|
J:142338
|
Adaz1NZM2328/J/Adaz1NZM2328/J
(involves: C57L/J * NZM2328/J)
|
increased anti-double stranded DNA antibody level
|
J:71397
|
Adcy7tm1.1Pcst/Adcy7tm1.1Pcst Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased tumor necrosis factor secretion
|
J:191067
|
peritoneal inflammation
|
J:191067
|
Adcy9Gt(OST193739)Lex/Adcy9Gt(OST193739)Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
|
increased IgG1 level
|
J:103485
|
Adcy9tm1b(EUCOMM)Wtsi/Adcy9tm1b(EUCOMM)Wtsi
(C57BL/6N-Adcy9tm1b(EUCOMM)Wtsi/Wtsi)
|
blood in lymph vessels
|
J:239583
|
Adcyap1tm1Clw/Adcyap1tm1Clw
(B6.129S4-Adcyap1tm1Clw)
|
abnormal regulatory T cell physiology
|
J:194151
|
abnormal T cell activation
|
J:194151
|
increased microglial cell activation
|
J:194151
|
Adcyap1r1tm1Bbt/Adcyap1r1tm1Bbt
(involves: 129 * C57BL/6J)
|
increased susceptibility to bacterial infection
|
J:73990
|
Adgrd1tm1b(EUCOMM)Wtsi/Adgrd1tm1b(EUCOMM)Wtsi
(C57BL/6N-Adgrd1tm1b(EUCOMM)Wtsi/Wtsi)
|
increased anti-nuclear antigen antibody level
|
J:211773
|
Adgre1m2Btlr/Adgre1m2Btlr
(C57BL/6J-Adgre1m2Btlr)
|
abnormal macrophage physiology
|
J:195410
|
Adgre1m3Btlr/Adgre1m3Btlr
(C57BL/6J-Adgre1m3Btlr)
|
abnormal macrophage physiology
|
J:234244
|
Adgre1tm1Stst/Adgre1tm1Stst
(B6.129S1-Emr1tm1Stst)
|
abnormal immune tolerance
|
J:99213
|
abnormal regulatory T cell physiology
|
J:99213
|
Adgre5tm1Kake/Adgre5tm1Kake
(B6.129S6-Adgre5tm1Kake)
|
decreased susceptibility to bacterial infection
|
J:118705
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:118705
|
Adgrg3tm1Zgwg/Adgrg3tm1Zgwg
(involves: 129 * C57BL/6)
|
abnormal IgG1 level
|
J:222670
|
abnormal IgG2 level
|
J:222670
|
abnormal IgG level
|
J:222670
|
abnormal immune system physiology
|
J:222670
|
abnormal immunoglobulin level
|
J:222670
|
decreased IgA level
|
J:222670
|
decreased IgG1 level
|
J:222670
|
decreased IgG2b level
|
J:222670
|
decreased IgG3 level
|
J:222670
|
decreased IgM level
|
J:222670
|
increased B cell apoptosis
|
J:222670
|
increased IgG1 level
|
J:222670
|
increased IgG2a level
|
J:222670
|
Adh5tm1.1Llli/Adh5tm1.1Llli Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(B6.Cg-Adh5tm1.1Llli Speer6-ps1Tg(Alb-cre)21Mgn)
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:173666
|
Adh5tm1Stam/Adh5tm1Stam
(B6.129-Adh5tm1Stam)
|
increased susceptibility to bacterial infection
|
J:88337
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:88337
|
Adipoqtm1Chan/Adipoq+
(B6.129-Adipoqtm1Chan)
|
abnormal leukocyte physiology
|
J:122020
|
Adipoqtm1Chan/Adipoqtm1Chan
(B6.129-Adipoqtm1Chan)
|
abnormal leukocyte physiology
|
J:122020
|
Adm2em1Zhan/Adm2em1Zhan
(Not Specified)
|
increased inflammatory response
|
J:266495
|
increased susceptibility to infection
|
J:266495
|
liver inflammation
|
J:266495
|
Admtm1Tfjt/Adm+
(involves: C57BL/6 * CBA)
|
blood vessel inflammation
|
J:102946
|
Adora2atm1Map/Adora2atm1Map
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
decreased interleukin-10 secretion
|
J:147023
|
Adora2btm1.1Msit/Adora2btm1.1Msit
(either: (involves: C57BL/6) or (involves: C57BL/6 * CD-1 * ICR))
|
abnormal macrophage physiology
|
J:169155
|
increased interleukin-6 secretion
|
J:169155
|
increased tumor necrosis factor secretion
|
J:169155
|
Adora2btm1Dgen/Adora2btm1Dgen
(B6.129P2-Adora2btm1Dgen)
|
abnormal dendritic cell physiology
|
J:138722
|
decreased interleukin-10 secretion
|
J:147023
|
Adora2btm1Kra/Adora2btm1Kra
(involves: 129 * C57BL/6J)
|
abnormal cytokine level
|
J:111715
|
abnormal inflammatory response
|
J:111715
|
abnormal interleukin level
|
J:111715
|
abnormal leukocyte adhesion
|
J:111715
|
abnormal leukocyte migration
|
J:111715
|
abnormal tumor necrosis factor level
|
J:111715
|
decreased interleukin-10 secretion
|
J:111715
|
enhanced leukocyte tethering or rolling
|
J:111715
|
increased circulating interleukin-6 level
|
J:111715
|
Adora2btm1Till/Adora2btm1Till
(B6.129P2-Adora2btm1Till)
|
abnormal cellular extravasation
|
J:125297
|
increased interleukin-6 secretion
|
J:125297
|
increased susceptibility to type I hypersensitivity reaction
|
J:125297
|
Adora3tm1(ADORA3)Msth/Adora3tm1(ADORA3)Msth
(involves: 129S7/SvEvBrd * C57BL/6J)
|
abnormal mast cell physiology
|
J:104494
|
decreased mast cell degranulation
|
J:104494
|
Adora3tm1Jbsn/Adora3tm1Jbsn
(either: (involves: 129P2/OlaHsd * C57BL/6 * DBA/2) or (involves: 129P2/OlaHsd * C57BL/6))
|
abnormal mast cell physiology
|
J:60293
|
decreased tumor necrosis factor secretion
|
J:60293
|
Adora3tm1Jbsn/Adora3tm1Jbsn
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
decreased acute inflammation
|
J:120442
|
Adora3tm1Jbsn/Adora3tm1Jbsn
(B6.129P2-Adora3tm1Jbsn)
|
abnormal mast cell degranulation
|
J:123463
|
impaired neutrophil recruitment
|
J:123463
|
Adprhtm1Jlms/Adprhtm1Jlms
(involves: 129X1/SvJ * C57BL/6J)
|
increased susceptibility to infection
|
J:123619
|
Adrb2tm1Bkk/Adrb2tm1Bkk
(involves: 129S1/Sv * 129X1/SvJ)
|
abnormal osteoclast physiology
|
J:97566
|
Adrb2tm1Bkk/Adrb2tm1Bkk
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * DBA/2 * FVB/N)
|
increased tumor necrosis factor secretion
|
J:204379
|
Ads1NZB/Ads1NZB
(involves: NZB * NZW)
|
increased anti-double stranded DNA antibody level
|
J:7239,
J:7111
|
increased susceptibility to autoimmune disorder
|
J:7111
|
Ads1NZB/Ads1NZW
(involves: NZB * NZW)
|
increased anti-double stranded DNA antibody level
|
J:7111
|
increased susceptibility to autoimmune disorder
|
J:7111
|
Ads2NZB/Ads2NZB
(involves: NZB * NZW)
|
increased anti-double stranded DNA antibody level
|
J:7111
|
increased susceptibility to autoimmune disorder
|
J:7111
|
Ads2NZB/Ads2NZW
(involves: NZB * NZW)
|
increased anti-double stranded DNA antibody level
|
J:7111
|
increased susceptibility to autoimmune disorder
|
J:7111
|
Ads3NZB/Ads3NZW
(involves: NZB * NZW)
|
abnormal immunoglobulin level
|
J:7111
|
increased susceptibility to autoimmune disorder
|
J:7111
|
Ads3NZW/Ads3NZW
(involves: NZB * NZW)
|
abnormal immunoglobulin level
|
J:7111
|
increased anti-double stranded DNA antibody level
|
J:7239
|
increased susceptibility to autoimmune disorder
|
J:7111
|
Ads4NZB/Ads4NZB
(involves: NZB * NZW)
|
decreased anti-double stranded DNA antibody level
|
J:11074
|
Ads4NZB/Ads4NZW
(involves: NZB * NZW)
|
abnormal immunoglobulin level
|
J:7111
|
increased susceptibility to autoimmune disorder
|
J:7111
|
Ads4NZW/Ads4NZW
(involves: NZB * NZW)
|
abnormal immunoglobulin level
|
J:7111
|
increased susceptibility to autoimmune disorder
|
J:7111
|
Adtrptm1.1Clu/Adtrptm1.1Clu
(involves: 129S4/SvJaeSor * C57BL/6)
|
increased inflammatory response
|
J:295059
|
Aec1NOD/Uf/Aec1NOD/Uf Aec2NOD/Uf/Aec2NOD/Uf
(B6.NOD-Aec2NOD/Uf Aec1NOD/Uf)
|
increased anti-nuclear antigen antibody level
|
J:129282
|
increased susceptibility to autoimmune disorder
|
J:128900
|
lacrimal gland inflammation
|
J:129282
|
salivary gland inflammation
|
J:129282
|
Aem1C57BL/6/Aem1NZB
(involves: C57BL/6 * NZB)
|
decreased autoantibody level
|
J:7191
|
Aem2C57BL/6/Aem2C57BL/6
(involves: C57BL/6 * NZB)
|
decreased autoantibody level
|
J:59427
|
Aem2C57BL/6/Aem2NZB
(involves: C57BL/6 * NZB)
|
decreased autoantibody level
|
J:59427
|
Aem2C57BL/6/Aem2NZB Aem3C57BL/6/Aem3NZB
(involves: C57BL/6 * NZB)
|
decreased autoantibody level
|
J:59427
|
Aem3C57BL/6/?
(involves: C57BL/6 * NZB)
|
abnormal immune system physiology
|
J:59427
|
Agbl4Tn(pb-Act-RFP)1.080115015-HRAZhu/Agbl4Tn(pb-Act-RFP)1.080115015-HRAZhu
(involves: FVB/N)
|
increased susceptibility to Herpesvirales infection
|
J:231311
|
increased susceptibility to Herpesvirales infection induced morbidity/mortality
|
J:231311
|
increased susceptibility to Poxviridae infection
|
J:231311
|
increased susceptibility to Poxviridae infection induced morbidity/mortality
|
J:231311
|
Agbl5em1Zfa/Agbl5em1Zfa
(Not Specified)
|
increased susceptibility to Herpesvirales infection
|
J:231311
|
increased susceptibility to Herpesvirales infection induced morbidity/mortality
|
J:231311
|
increased susceptibility to Poxviridae infection
|
J:231311
|
increased susceptibility to Poxviridae infection induced morbidity/mortality
|
J:231311
|
Agertm1.1Arnd/Agertm1.1Arnd
(B6.129P2-Agertm1.1Arnd)
|
decreased circulating interleukin-6 level
|
J:104998
|
Agertm1.1Arnd/Agertm1.1Arnd
(involves: 129P2/OlaHsd)
|
abnormal immune system physiology
|
J:113376
|
Agkem1Qiz/Agkem1Qiz
(involves: C57BL/6 * DBA/2)
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:282052
|
Agnm1MRL/MpJ/Agnm1MRL/MpJ
(involves: C3H/HeJ-Faslpr * MRL/MpJ-Faslpr)
|
glomerulonephritis
|
J:97786
|
increased susceptibility to systemic lupus erythematosus
|
J:97786
|
Agnm2C3H/HeJ/Agnm2MRL/MpJ
(involves: C3H/HeJ-Faslpr * MRL/MpJ-Faslpr)
|
glomerulonephritis
|
J:97786
|
increased susceptibility to systemic lupus erythematosus
|
J:97786
|
Agnm2MRL/MpJ/Agnm2MRL/MpJ
(involves: C3H/HeJ-Faslpr * MRL/MpJ-Faslpr)
|
glomerulonephritis
|
J:97786
|
increased susceptibility to systemic lupus erythematosus
|
J:97786
|
Agnm3C3H/HeJ/Agnm3MRL/MpJ
(involves: C3H/HeJ-Faslpr * MRL/MpJ-Faslpr)
|
glomerulonephritis
|
J:97786
|
increased susceptibility to systemic lupus erythematosus
|
J:97786
|
Agnm3MRL/MpJ/Agnm3MRL/MpJ
(involves: C3H/HeJ-Faslpr * MRL/MpJ-Faslpr)
|
glomerulonephritis
|
J:97786
|
increased susceptibility to systemic lupus erythematosus
|
J:97786
|
Agp1NZB/Agp1NZB
(involves: NZB * NZW)
|
increased susceptibility to type III hypersensitivity reaction
|
J:6920
|
Agp1NZB/Agp1NZW
(involves: NZB * NZW)
|
increased susceptibility to type III hypersensitivity reaction
|
J:6920
|
Agp2NZB/Agp2NZW
(involves: NZB * NZW)
|
increased susceptibility to type III hypersensitivity reaction
|
J:6920
|
Agp2NZW/Agp2NZW
(involves: NZB * NZW)
|
increased susceptibility to type III hypersensitivity reaction
|
J:6920
|
Agpat2Gt(OST438470)Lex/Agpat2Gt(OST438470)Lex
(involves: 129S5/SvEvBrd * C57BL/6)
|
brown adipose tissue inflammation
|
J:186035
|
granulomatous inflammation
|
J:186035
|
liver inflammation
|
J:186035
|
Agr2tm1.1Lpkn/Agr2tm1.1Lpkn Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+
(involves: 129 * 129S6/SvEvTac * C57BL/6)
|
colitis
|
J:156704
|
Agr2tm1.2Erle/Agr2tm1.2Erle
(involves: 129S4/SvJae * FVB/N)
|
increased susceptibility to induced colitis
|
J:148339
|
Agr2tm1.2Lpkn/Agr2tm1.2Lpkn
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6)
|
colitis
|
J:156704
|
ileum inflammation
|
J:156704
|
Agttm1Afu/Agttm1Afu
(involves: C57BL/6 * CBA)
|
tubulointerstitial nephritis
|
J:46506
|
Agttm1Unc/Agttm1Unc
(involves: 129P2/OlaHsd * C57BL/6J)
|
tubulointerstitial nephritis
|
J:24156
|
Agtpbp1atms/Agtpbp1atms
(MRL/Mp-Agtpbp1atms)
|
abnormal T cell physiology
|
J:103944
|
Agtr1atm1Unc/Agtr1atm1Unc Agtr1btm1Cof/Agtr1btm1Cof
(involves: 129P2/OlaHsd * C57BL/6)
|
kidney inflammation
|
J:137944
|
Ahi1tm1Jgg/Ahi1tm1Jgg Tg(TCF/Lef1-lacZ)34Efu/0
(involves: 129S1/Sv * 129X1/SvJ)
|
kidney inflammation
|
J:154321
|
Ahnaktm1Vtm/Ahnaktm1Vtm
(involves: 129S1/Sv * C57BL/6)
|
abnormal T cell activation
|
J:131148
|
abnormal T-helper 1 physiology
|
J:131148
|
decreased interferon-gamma secretion
|
J:131148
|
decreased interleukin-2 secretion
|
J:131148
|
decreased T cell proliferation
|
J:131148
|
increased interleukin-4 secretion
|
J:131148
|
increased susceptibility to parasitic infection
|
J:131148
|
Ahrb-1/Ahrb-1
(C57BL/6J)
|
increased inflammatory response
|
J:5244,
J:5387
|
Ahrb-1/Ahrb-1
(involves: C57BL/6J * DBA/2J)
|
abnormal immune system physiology
|
J:5387
|
Ahrtm1Bra/Ahrtm1Bra
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal cytokine secretion
|
J:148870
|
abnormal Langerhans cell physiology
|
J:148870
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:148870
|
Ahrtm1Bra/Ahrtm1Bra
(B6.129-Ahrtm1Bra/J)
|
abnormal chemokine level
|
J:118646
|
abnormal cytokine level
|
J:118646
|
abnormal interleukin level
|
J:118646
|
abnormal macrophage physiology
|
J:118646
|
abnormal tumor necrosis factor level
|
J:118646
|
increased susceptibility to bacterial infection
|
J:118646
|
lung inflammation
|
J:118646,
J:100359
|
Ahrtm1Gonz/Ahrtm1Gonz
(involves: 129S4/SvJae * C57BL/6N)
|
bile duct inflammation
|
J:25048
|
colitis
|
J:44690
|
folliculitis
|
J:44690
|
heart inflammation
|
J:44690
|
increased inflammatory response
|
J:25048
|
Ahrtm1Yfk/Ahrtm1Yfk
(involves: 129S/SvEv * C57BL/6J)
|
urinary bladder inflammation
|
J:179919
|
Aia1NZB/Omr/Aia1NZB/Omr
(involves: NZB/Omr * NZC/Omr)
|
increased susceptibility to autoimmune hemolytic anemia
|
J:6517
|
Aia1NZB/Omr/Aia1NZC/Omr
(involves: NZB/Omr * NZC/Omr)
|
increased susceptibility to autoimmune hemolytic anemia
|
J:6517
|
Aicdaem1Jaych/Aicdaem1Jaych
(involves: C57BL/6J)
|
abnormal class switch recombination
|
J:305843
|
increased IgM level
|
J:305843
|
Aicdam1Btlr/Aicdam1Btlr
(C57BL/6J-Aicdam1Btlr)
|
abnormal humoral immune response
|
J:265155
|
decreased IgE level
|
J:265155
|
increased IgM level
|
J:265155
|
Aicdam2Btlr/Aicdam2Btlr
(C57BL/6J-Aicdam2Btlr)
|
abnormal humoral immune response
|
J:265156
|
decreased IgE level
|
J:265156
|
increased IgM level
|
J:265156
|
Aicdatm1(cre)Mnz/Aicda+ Ightm3Mnz/Igh+ Myctm37Mnz/Myc+
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal B cell physiology
|
J:145691
|
Aicdatm1(cre)Mnz/Aicda+ Ightm3Mnz/Igh+ Myctm39Mnz/Myc+
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal B cell physiology
|
J:145691
|
Aicdatm1.1Fwa/Aicdatm1.1Fwa
(involves: 129S6/SvEvTac)
|
abnormal class switch recombination
|
J:209271
|
abnormal somatic hypermutation frequency
|
J:209271
|
Aicdatm1Hon/Aicda+
(involves: C57BL/6 * CBA)
|
abnormal class switch recombination
|
J:136224,
J:141427
|
abnormal somatic hypermutation frequency
|
J:141427
|
Aicdatm1Hon/Aicdatm1.1Fwa
(involves: 129S/SvEv * C57BL/6NCrlj * CBA/JNCrlj)
|
abnormal class switch recombination
|
J:209271
|
Aicdatm1Hon/Aicdatm1Hon
(involves: C57BL/6 * CBA)
|
abnormal class switch recombination
|
J:141427,
J:73659,
J:120658
|
abnormal somatic hypermutation frequency
|
J:136224,
J:141427
|
decreased IgA level
|
J:169227
|
decreased IgG1 level
|
J:169227,
J:73659
|
decreased IgG2a level
|
J:73659
|
decreased IgG2b level
|
J:169227
|
decreased IgG3 level
|
J:169227
|
decreased IgG level
|
J:169227
|
increased IgM level
|
J:169227,
J:73659
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:169227
|
Aicdatm1Hon/Aicdatm1Hon Bcl6tm1.1Jwan/Bcl6tm1.1Jwan
(involves: 129S6/SvEvTac * C57BL/6NCrlj * CBA/JNCrlj)
|
abnormal somatic hypermutation frequency
|
J:190534
|
Aicdatm1Hon/Aicdatm1Hon Ightm3Mnz/Ightm4.1Mnz Trp53bp1tm1Jc/Trp53bp1tm1Jc
(involves: 129 * C57BL/6 * CBA)
|
abnormal class switch recombination
|
J:159173
|
Aicdatm1Hon/Aicdatm1Hon Ighmtm1.1(IGH-2)Cog/Ighm+
(involves: 129P2/OlaHsd * C57BL/6 * CBA * FVB/N)
|
abnormal B cell physiology
|
J:157575
|
Aicdatm1Hon/Aicdatm3Mnz
(involves: C57BL/6 * CBA)
|
abnormal class switch recombination
|
J:141427
|
abnormal somatic hypermutation frequency
|
J:141427
|
Aicdatm1Hon/Aicdatm4Mnz
(involves: C57BL/6 * CBA)
|
abnormal class switch recombination
|
J:141427
|
abnormal somatic hypermutation frequency
|
J:141427
|
Aicdatm2.1Hon/Aicdatm2.1Hon
(C57BL/6-Aicdatm2.1Hon)
|
abnormal somatic hypermutation frequency
|
J:169227
|
decreased IgG1 level
|
J:169227
|
increased susceptibility to bacterial infection
|
J:169227
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:169227
|
Aicdatm3.1Mnz/Aicdatm3.1Mnz
(involves: C57BL/6)
|
abnormal class switch recombination
|
J:147109
|
abnormal somatic hypermutation frequency
|
J:147109
|
Aicdatm3Mnz/Aicda+
(involves: C57BL/6 * CBA)
|
abnormal class switch recombination
|
J:141427
|
abnormal somatic hypermutation frequency
|
J:141427
|
Aicdatm4.1Mnz/Aicdatm4.1Mnz
(involves: C57BL/6)
|
abnormal class switch recombination
|
J:147109
|
abnormal somatic hypermutation frequency
|
J:147109
|
Aicdatm4Mnz/Aicda+
(involves: C57BL/6 * CBA)
|
abnormal class switch recombination
|
J:141427
|
abnormal somatic hypermutation frequency
|
J:141427
|
Aif1tm1Nsib/Aif1tm1Nsib
(involves: 129S/SvEv * C57BL/6)
|
decreased susceptibility to induced arthritis
|
J:204462
|
Aim2Gt(CSG445)Byg/Aim2Gt(CSG445)Byg
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal macrophage physiology
|
J:158969
|
decreased circulating interleukin-18 level
|
J:158969
|
decreased interleukin-1 beta secretion
|
J:158969
|
decreased interleukin-18 secretion
|
J:158969
|
increased interferon-beta secretion
|
J:158969
|
increased susceptibility to bacterial infection
|
J:158969
|
increased susceptibility to Herpesvirales infection
|
J:158969
|
increased susceptibility to Poxviridae infection
|
J:158969
|
Aim2Gt(CSG445)Byg/Aim2Gt(CSG445)Byg
(B6.129P2-Aim2Gt(CSG445)Byg/J)
|
abnormal interferon secretion
|
J:234263
|
decreased interleukin-1 beta secretion
|
J:234263
|
decreased macrophage apoptosis
|
J:234263
|
Aim2tm1.1Vmd/Aim2tm1.1Vmd
(C57BL/6-Aim2tm1.1Vmd)
|
abnormal cytokine secretion
|
J:160545
|
abnormal macrophage physiology
|
J:160545
|
decreased interleukin-1 beta secretion
|
J:160545
|
decreased interleukin-18 secretion
|
J:160545
|
increased interferon-beta secretion
|
J:160545
|
increased susceptibility to bacterial infection
|
J:160545
|
increased tumor necrosis factor secretion
|
J:160545
|
Aim2tm1.2Arte/Aim2tm1.2Arte Dnase2atm1Osa/Dnase2atm1Osa Ifnar1tm1Agt/Ifnar1tm1Agt
(involves: 129 * BALB/c * C57BL/6 * C57BL/6J)
|
increased autoantibody level
|
J:238323
|
increased circulating interleukin-10 level
|
J:238323
|
increased circulating tumor necrosis factor level
|
J:238323
|
rheumatoid arthritis
|
J:238323
|
Aim2tm1Ktak/Aim2tm1Ktak
(involves: 129S4/SvJae * C57BL/6)
|
decreased circulating interleukin-18 level
|
J:188013
|
decreased interferon-gamma secretion
|
J:188013
|
decreased interleukin-1 beta secretion
|
J:188013
|
decreased interleukin-18 secretion
|
J:188013
|
increased susceptibility to bacterial infection
|
J:188013
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:188013
|
Aimp1Gt(OST58507)Lex/Aimp1Gt(OST58507)Lex
(involves: 129S5/SvEvBrd * C57BL/6)
|
decreased inflammatory response
|
J:95974
|
Airetm1.1Doi/Airetm1.1Doi
(involves: 129S2/SvPas * C57BL/6)
|
increased autoantibody level
|
J:119475
|
increased susceptibility to autoimmune disorder
|
J:83422
|
stomach inflammation
|
J:119475
|
Airetm1.1Doi/Airetm1.1Doi
(B6.129S2-Airetm1.1Doi/Doi)
|
increased autoantibody level
|
J:107432
|
increased incidence of corneal inflammation
|
J:107432
|
lung inflammation
|
J:107432
|
salivary gland inflammation
|
J:107432
|
stomach inflammation
|
J:107432
|
Airetm1.1Doi/Airetm1.1Doi
(NOD.129S2(B6)-Airetm1.1Doi/Doi)
|
increased autoantibody level
|
J:107432
|
increased incidence of corneal inflammation
|
J:107432
|
liver inflammation
|
J:107432
|
lung inflammation
|
J:107432
|
ovary inflammation
|
J:107432
|
pancreas inflammation
|
J:107432
|
prostate gland inflammation
|
J:107432
|
salivary gland inflammation
|
J:107432
|
stomach inflammation
|
J:107432
|
thyroid gland inflammation
|
J:107432
|
Airetm1.1Doi/Airetm1.1Doi
(C.129S2-Airetm1.1Doi/Doi)
|
increased autoantibody level
|
J:107432
|
increased incidence of corneal inflammation
|
J:107432
|
liver inflammation
|
J:107432
|
lung inflammation
|
J:107432
|
ovary inflammation
|
J:107432
|
prostate gland inflammation
|
J:107432
|
salivary gland inflammation
|
J:107432
|
stomach inflammation
|
J:107432
|
Airetm1.1Doi/Airetm1.1Doi
(SJL.129S2-Airetm1.1Doi/Doi)
|
increased autoantibody level
|
J:107432
|
liver inflammation
|
J:107432
|
lung inflammation
|
J:107432
|
ovary inflammation
|
J:107432
|
pancreas inflammation
|
J:107432
|
prostate gland inflammation
|
J:107432
|
salivary gland inflammation
|
J:107432
|
stomach inflammation
|
J:107432
|
Airetm1.1Doi/Airetm1.1Doi
(involves: 129S2/SvPas * C57BL/6 * NOD)
|
liver inflammation
|
J:107432
|
lung inflammation
|
J:107432
|
pancreas inflammation
|
J:107432
|
salivary gland inflammation
|
J:107432
|
stomach inflammation
|
J:107432
|
Airetm1.1Doi/Airetm1.1Doi
(NOD.129S2-Airetm1.1Doi)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:135154
|
chronic pancreas inflammation
|
J:135154
|
insulitis
|
J:135154
|
lacrimal gland inflammation
|
J:135154
|
lung inflammation
|
J:135154
|
salivary gland inflammation
|
J:135154
|
stomach inflammation
|
J:135154
|
thyroid gland inflammation
|
J:135154
|
uveitis
|
J:135154
|
Airetm1.1Doi/Airetm1.1Doi H2b/H2b
(NOD.Cg-Airetm1.1Doi H2b/Doi)
|
stomach inflammation
|
J:107432
|
Airetm1.1Doi/Airetm1.1Doi Idd3C57BL/6/Idd3C57BL/6 Idd5C57BL/10SnJ/Idd5C57BL/10SnJ
(NOD.Cg-Idd3C57BL/6 Idd5C57BL/10SnJ Airetm1.1Doi/Doi)
|
stomach inflammation
|
J:107432
|
Airetm1.1Doi/Airetm1.1Doi Il1r1tm1Imx/Il1r1+
(involves: 129S2/SvPas * 129S7/SvEvBrd * NOD)
|
keratoconjunctivitis
|
J:163691
|
lacrimal gland inflammation
|
J:163691
|
Airetm1.1Doi/Airetm1.1Doi Il1r1tm1Imx/Il1r1tm1Imx
(involves: 129S2/SvPas * 129S7/SvEvBrd * NOD)
|
keratoconjunctivitis
|
J:163691
|
lacrimal gland inflammation
|
J:163691
|
Airetm1Mand/Aire+
(involves: 129P2/OlaHsd * C57BL/6)
|
lacrimal gland inflammation
|
J:135154
|
salivary gland inflammation
|
J:135154
|
Airetm1Mand/Aire+
(NOD.129P2-Airetm1Mand)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:135154,
J:188686
|
abnormal chemokine level
|
J:188686
|
chronic pancreas inflammation
|
J:135154
|
CNS inflammation
|
J:135154
|
increased autoantibody level
|
J:188686
|
increased CXCL10 level
|
J:188686
|
increased inflammatory response
|
J:188686
|
increased susceptibility to autoimmune diabetes
|
J:135154,
J:188686
|
insulitis
|
J:135154
|
lacrimal gland inflammation
|
J:135154
|
salivary gland inflammation
|
J:135154
|
thyroid gland inflammation
|
J:135154
|
Airetm1Mand/Airetm1.1Doi
(NOD.129-Airetm1Mand/Airetm1.1Doi)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:135154
|
chronic pancreas inflammation
|
J:135154
|
insulitis
|
J:135154
|
lacrimal gland inflammation
|
J:135154
|
lung inflammation
|
J:135154
|
salivary gland inflammation
|
J:135154
|
stomach inflammation
|
J:135154
|
thyroid gland inflammation
|
J:135154
|
uveitis
|
J:135154
|
Airetm1Mand/Airetm1Mand
(involves: 129P2/OlaHsd * C57BL/6)
|
eye inflammation
|
J:135154
|
lacrimal gland inflammation
|
J:135154
|
salivary gland inflammation
|
J:135154
|
Airetm1Mmat/Airetm1Mmat
(involves: C57BL/6 * CBA)
|
autoimmune response
|
J:96580
|
lacrimal gland inflammation
|
J:96580
|
pancreas inflammation
|
J:96580
|
parotid gland inflammation
|
J:96580
|
stomach inflammation
|
J:96580
|
submandibular gland inflammation
|
J:96580
|
Airetm1Mmat/Airetm1Mmat
(C.Cg-Airetm1Mmat)
|
increased autoantibody level
|
J:96580
|
stomach inflammation
|
J:96580
|
Airetm1Mmat/Airetm1Mmat
(B6.Cg-Airetm1Mmat)
|
autoimmune response
|
J:96580
|
salivary gland inflammation
|
J:96580
|
Airetm1Mmat/Airetm2Mmat
(involves: C57BL/6 * CBA)
|
autoimmune response
|
J:141379
|
Airetm1Pltn/Airetm1Pltn
(involves: 129S4/SvJae * C57BL/6)
|
increased autoantibody level
|
J:77873
|
increased T cell proliferation
|
J:77873
|
liver inflammation
|
J:77873
|
Airetm1Pltn/Airetm1Pltn
(B6.129S4-Airetm1Pltn)
|
liver inflammation
|
J:115076
|
Airetm1Ptsn/Airetm1Ptsn
(C57BL/6-Airetm1Ptsn)
|
abnormal T cell activation
|
J:145910
|
increased autoantibody level
|
J:145910
|
parotid gland inflammation
|
J:145910
|
sublingual gland inflammation
|
J:145910
|
uveitis
|
J:145910
|
vitreous body inflammation
|
J:145910
|
Airetm1Ptsn/Airetm1Ptsn
(C.B6-Airetm1Ptsn)
|
abnormal adaptive immunity
|
J:174653
|
abnormal cytokine level
|
J:174653
|
abnormal regulatory T cell physiology
|
J:174653
|
abnormal T-helper 1 physiology
|
J:174653
|
abnormal T-helper 17 cell physiology
|
J:174653
|
decreased susceptibility to fungal infection
|
J:174653
|
increased interleukin-6 secretion
|
J:174653
|
increased interleukin-12 secretion
|
J:174653
|
increased interleukin-23 secretion
|
J:174653
|
increased susceptibility to autoimmune disorder
|
J:174653
|
increased susceptibility to fungal infection
|
J:174653
|
increased tumor necrosis factor secretion
|
J:174653
|
stomach inflammation
|
J:174653
|
Airetm2Mmat/Airetm2Mmat
(involves: C57BL/6 * CBA)
|
abnormal thymus physiology
|
J:141379
|
autoimmune response
|
J:141379
|
Ak7Gt(OST434404)Lex/Ak7Gt(OST434404)Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
|
rhinosinusitis
|
J:185566
|
Ak7Tg(tetO-Hmox1)67Sami/Ak7Tg(tetO-Hmox1)67Sami
(FVB/N-Ak7Tg(tetO-Hmox1)67Sami)
|
respiratory system inflammation
|
J:186062
|
rhinitis
|
J:186062
|
Akap12tm1Ihg/Akap12tm1Ihg
(involves: 129S4/SvJae * C57BL/6)
|
liver inflammation
|
J:138882
|
Akap13tm1Segj/Akap13+
(involves: 129)
|
abnormal lymphocyte physiology
|
J:111574
|
abnormal splenocyte physiology
|
J:181088
|
decreased IgG1 level
|
J:181088
|
Akip1em1Cya/Akip1em1Cya
(C57BL/6N-Akip1em1Cya)
|
decreased susceptibility to endotoxin shock
|
J:326919
|
decreased susceptibility to viral infection
|
J:326919
|
Aknatm1Mak/Aknatm1Mak
(B6.129P2-Aknatm1Mak)
|
alveolitis
|
J:233952
|
increased acute inflammation
|
J:233952
|
increased susceptibility to fungal infection
|
J:233952
|
lung inflammation
|
J:233952
|
Aknatm2Mak/Aknatm2Mak
(B6.129-Aknatm2Mak)
|
increased susceptibility to fungal infection
|
J:233952
|
Akr1a1Gt(OST222400)Lex/Akr1a1Gt(OST222400)Lex
(B6.129S5-Akr1a1Gt(OST222400)Lex)
|
abnormal osteoclast physiology
|
J:164548
|
Akr1b8tm1Dgen/Akr1b8tm1Dgen
(Not Specified)
|
abnormal interferon level
|
J:301852
|
abnormal interleukin level
|
J:301852
|
increased susceptibility to induced colitis
|
J:301852
|
Akr1c21em1Wany/Akr1c21em1Wany
(involves: C57BL/6)
|
increased acute inflammation
|
J:322353
|
increased interleukin level
|
J:322353
|
lung inflammation
|
J:322353
|
Akt1tm1Pnt/Akt1tm1Pnt Akt2tm1.1Mbb/Akt2tm1.1Mbb Akt3tm1Mbb/Akt3tm1Mbb Tg(Lck-cre)1Cwi/0
(involves: 129P2/OlaHsd)
|
increased T cell apoptosis
|
J:135903
|
Akt1tm1Pnt/Akt1tm1Pnt Akt2tm1.1Mbb/Akt2tm1.1Mbb Tg(Lck-cre)1Cwi/0
(involves: 129P2/OlaHsd)
|
increased T cell apoptosis
|
J:135903
|
Aktiptm1a(EUCOMM)Hmgu/Aktiptm1a(EUCOMM)Hmgu Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6N)
|
kidney inflammation
|
J:276210
|
liver inflammation
|
J:276210
|
lung inflammation
|
J:276210
|
peritoneal inflammation
|
J:276210
|
Alan2B10.O20/Dem/Alan2B10.O20/Dem
(involves: B10.O20/Dem * O20/A)
|
abnormal immune system physiology
|
J:67657
|
Alan2B10.O20/Dem/Alan2O20/A
(involves: B10.O20/Dem * O20/A)
|
abnormal immune system physiology
|
J:67657
|
Aldh18a1tm1a(KOMP)Wtsi/Aldh18a1+
(C57BL/6N-Aldh18a1tm1a(KOMP)Wtsi/Wtsi)
|
skin inflammation
|
J:232539
|
Aldobtm1(KOMP)Vlcg/Aldobtm1(KOMP)Vlcg
(C57BL/6NTac-Aldobtm1(KOMP)Vlcg)
|
liver inflammation
|
J:220330
|
Alms1Gt(XH152)Byg/Alms1Gt(XH152)Byg
(involves: 129P2/OlaHsd * C57BL/6J)
|
tubulointerstitial nephritis
|
J:100403
|
Alox5tm1Bhk/Alox5tm1Bhk
(either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * C57BL/6 * DBA/2))
|
abnormal inflammatory response
|
J:68714
|
abnormal neutrophil physiology
|
J:68714
|
decreased acute inflammation
|
J:68714
|
decreased susceptibility to type I hypersensitivity reaction
|
J:68714
|
impaired neutrophil chemotaxis
|
J:68714
|
impaired neutrophil recruitment
|
J:68714
|
Alox5tm1Fun/Alox5tm1Fun
(involves: 129S2/SvPas * C57BL/6)
|
abnormal immune system physiology
|
J:21372
|
decreased inflammatory response
|
J:21372,
J:75371
|
Alox5tm1Fun/Alox5tm1Fun
(B6.129S2-Alox5tm1Fun/J)
|
decreased susceptibility to experimental autoimmune uveoretinitis
|
J:108446
|
Alox5aptm1Bhk/Alox5aptm1Bhk
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
decreased susceptibility to type I hypersensitivity reaction
|
J:39229
|
Alox5aptm1Bhk/Alox5aptm1Bhk
(involves: 129P2/OlaHsd * 129S/SvEv)
|
decreased acute inflammation
|
J:39229
|
impaired neutrophil recruitment
|
J:39229
|
Alox5aptm1Jdm/Alox5ap+
(DBA/1LacJ-Alox5aptm1Jdm)
|
decreased susceptibility to induced arthritis
|
J:100736
|
Alox5aptm1Jdm/Alox5aptm1Jdm
(DBA/1LacJ-Alox5aptm1Jdm)
|
decreased inflammatory response
|
J:100736
|
decreased susceptibility to induced arthritis
|
J:100736
|
Alox8tm1a(KOMP)Wtsi/Alox8tm1a(KOMP)Wtsi
(C57BL/6N-Alox8tm1a(KOMP)Wtsi/MbpMmucd)
|
abnormal susceptibility to Orthomyxoviridae infection
|
J:277623
|
increased interleukin-6 secretion
|
J:277623
|
lung inflammation
|
J:277623
|
Alox15tm1Fun/Alox15tm1Fun
(involves: 129/Sv * C57BL/6)
|
abnormal immune system physiology
|
J:44778
|
Alox15tm1Fun/Alox15tm1Fun
(B6.129S2-Alox15tm1Fun/J)
|
dermatitis
|
J:119405
|
Alpk1em1Dlka/Alpk1em1Dlka Crb1rd8/Crb1rd8
(involves: C57BL/6N)
|
abnormal circulating chemokine level
|
J:344848
|
increased circulating CXCL10 level
|
J:344848
|
Als2tm1Jei/Als2tm1Jei
(involves: 129P2/OlaHsd * C57BL/6J)
|
CNS inflammation
|
J:104446
|
Altretm1.1Hbgl/Altretm1.1Hbgl Foxp3tm4(YFP/icre)Ayr/Y
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
|
abnormal regulatory T cell physiology
|
J:342907
|
increased interleukin-17 secretion
|
J:342907
|
increased regulatory T cell apoptosis
|
J:342907
|
amdA/J/amdA/J
(involves: A/J * C57BL/6J)
|
myocarditis
|
J:2843,
J:11025
|
amdDBA/2J/amdDBA/2J
(B10.D2-H8b/(57N)SnJ)
|
myocarditis
|
J:11025
|
AmfrGt(IST12797A11)Tigm/AmfrGt(IST12797A11)Tigm
(C57BL/6-AmfrGt(IST12797A11)Tigm)
|
liver inflammation
|
J:221247
|
Ampd3tm1Tm/Ampd3tm1Tm
(Not Specified)
|
lung inflammation
|
J:201211
|
anan/anan
(involves: C57BL/6 * C57BL/10Sg * C57BR/c)
|
increased anti-nuclear antigen antibody level
|
J:169366
|
anan/anan+
(involves: C57BL/6 * C57BL/10Sg * C57BR/c)
|
increased anti-nuclear antigen antibody level
|
J:169366
|
anaya/anaya
(involves: C57BL/6 * C57BL/10Sg * C57BR/c)
|
increased anti-nuclear antigen antibody level
|
J:169366
|
andra/andra
(involves: C57BL/6 * C57BL/10Sg * C57BR/c)
|
increased anti-nuclear antigen antibody level
|
J:169366
|
Angptl2tm1Yo/Angptl2tm1Yo
(B6.Cg-Angptl2tm1Yo)
|
impaired macrophage chemotaxis
|
J:152387
|
Ank1ity16/Ank1+
(involves: 129S1/Sv * 129X1/SvJ * DBA/2J)
|
increased susceptibility to bacterial infection
|
J:199427
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:199427
|
Ank1ity16/Ank1ity16
(involves: 129S1/Sv * 129X1/SvJ * DBA/2J)
|
glomerulonephritis
|
J:199427
|
increased susceptibility to bacterial infection
|
J:199427
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:199427
|
Ank1MRI23420/Ank1+
(SJL/J-Ank1MRI23420)
|
decreased susceptibility to parasitic infection
|
J:187820
|
decreased susceptibility to parasitic infection induced morbidity/mortality
|
J:187820
|
Ank1nb/Ank1+
(involves: C57BL/6J * WB/Re)
|
decreased susceptibility to parasitic infection
|
J:111131
|
Ank1nb/Ank1nb
(involves: C57BL/6J * WB/Re)
|
decreased susceptibility to parasitic infection
|
J:111131
|
Ank1Rbc2/Ank1+
(involves: 129S1/Sv * BALB/c)
|
decreased susceptibility to parasitic infection
|
J:148127
|
Ankank/Ankank
(involves: C3HeB/FeJ * C57BL/6J * JGBF/LeJ)
|
autoimmune arthritis
|
J:63420
|
Ankrd2tm1Krc/Ankrd2tm1Krc
(involves: 129 * Black Swiss)
|
abnormal inflammatory response
|
J:214867
|
Ano5em1Huyi/Ano5em1Huyi
(C57BL/6N-Ano5em1Huyi)
|
periodontium inflammation
|
J:294237
|
Ano5em2Huyi/Ano5em2Huyi
(C57BL/6-Ano5em2Huyi)
|
abnormal osteoclast physiology
|
J:336715
|
osteomyelitis
|
J:336715
|
Anpeptm1.1Lsha/Anpeptm1.1Lsha
(B6.Cg-Anpeptm1.1Lsha)
|
abnormal macrophage physiology
|
J:163945
|
Anta/Anta+
(involves: C57BL/6 * C57BL/10 * C57BR/cd)
|
glomerulonephritis
|
J:169366
|
increased anti-nuclear antigen antibody level
|
J:169366
|
Anth2CBA/J/?
(involves: A/J * CBA/J)
|
decreased susceptibility to bacterial infection
|
J:9501
|
AnthC3H/HeNCrj/AnthC3H/HeNCrj
(involves: C3H/HeNCrj * C57BL/6NCrj)
|
decreased susceptibility to bacterial infection
|
J:11149
|
AnthC3H/HeNCrj/AnthC57BL/6NCrj
(involves: C3H/HeNCrj * C57BL/6NCrj)
|
decreased susceptibility to bacterial infection
|
J:11149
|
Antxr2tm1.2Lepp/Antxr2tm1.2Lepp
(involves: C57BL/6)
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:150952
|
anx/anx
(B6C3Fe a/a-anx/J)
|
abnormal inflammatory response
|
J:103396
|
Anxa1tm1Rjf/Anxa1+
(Not Specified)
|
increased inflammatory response
|
J:81498
|
Anxa1tm1Rjf/Anxa1tm1Rjf
(Not Specified)
|
abnormal leukocyte physiology
|
J:81498
|
impaired macrophage phagocytosis
|
J:81498
|
increased inflammatory response
|
J:81498
|
Anxa1tm1Rjf/Anxa1tm1Rjf
(involves: BALB/c)
|
increased susceptibility to induced colitis
|
J:142735
|
Anxa5tm1Epo/Anxa5tm1Epo
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal cytokine secretion
|
J:117249
|
abnormal inflammatory response
|
J:117249
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:117249
|
Anxa7tm1Pll/Anxa7+
(Not Specified)
|
pancreas inflammation
|
J:58572
|
Anxa8tm1Resc/Anxa8tm1Resc Tg(Pgk1-cre)1Lni/0
(involves: 129 * C57BL/6J * BALB/c)
|
impaired leukocyte tethering or rolling
|
J:225224
|
Aoahtm1Rsm/Aoahtm1Rsm
(involves: 129S6/SvEvTac)
|
abnormal humoral immune response
|
J:90493
|
Aoc3tm1Salm/Aoc3tm1Salm
(involves: 129S6/SvEvTac * 129S7/SvEvBrd)
|
abnormal cellular extravasation
|
J:95656
|
abnormal leukocyte adhesion
|
J:95656
|
abnormal leukocyte migration
|
J:95656
|
decreased inflammatory response
|
J:95656
|
impaired leukocyte tethering or rolling
|
J:95656
|
Aod1aA/J/?
(involves: A/J * C57BL/6J)
|
ovary inflammation
|
J:83714
|
Aod1bC57BL/6J/?
(involves: A/J * C57BL/6J)
|
ovary inflammation
|
J:83714
|
Aod3A/J/?
(A/J)
|
ovary inflammation
|
J:78005
|
aol/aol
(involves: C3H * C57BL/6)
|
osteoarthritis
|
J:115238
|
Ap3b1m1Btlr/Ap3b1m1Btlr
(C57BL/6J-Ap3b1m1Btlr)
|
increased susceptibility to Herpesvirales infection
|
J:132673
|
Ap3b1pe/Ap3b1pe Hps1ep/Hps1ep
(involves: C3H/He * C3HeB/FeJ * C57BL/6J)
|
lung inflammation
|
J:85431
|
Apba3tm1.1Ski/Apba3tm1.1Ski Lyz2tm1(cre)Ifo/Lyz2+
(B6.129-Apba3tm1.1Ski Lyz2tm1(cre)Ifo)
|
decreased susceptibility to endotoxin shock
|
J:176742
|
Apba3tm1.2Ski/Apba3tm1.2Ski
(B6.129-Apba3tm1.2Ski)
|
abnormal macrophage physiology
|
J:176742
|
decreased circulating interleukin-12 level
|
J:176742
|
decreased circulating tumor necrosis factor level
|
J:176742
|
decreased interleukin-12 secretion
|
J:176742
|
decreased susceptibility to endotoxin shock
|
J:176742
|
decreased tumor necrosis factor secretion
|
J:176742
|
ApcMin/Apc+
(C57BL/6J-ApcMin/J)
|
abnormal interleukin secretion
|
J:305794
|
ApcMin/Apc+ Esr2tm1Mma/Esr2tm1Mma
(involves: 129S2/SvPas * C57BL/6J)
|
colitis
|
J:118600
|
ApcMin/Apc+ Mapkapk2tm1.2Gkl/Mapkapk2tm1.2Gkl
(involves: BALB/cJ * C57BL/6J)
|
abnormal chemokine secretion
|
J:262876
|
decreased interleukin-6 secretion
|
J:262876
|
Apctm1Kk/Apctm1Kk Tg(Lck-cre)1Cwi/?
(involves: 129S6/SvEvTac * C57BL/6 * DBA/2)
|
increased circulating tumor necrosis factor level
|
J:128606
|
Apctm1Tno/Apc+ Ptentm2Mak/Ptentm2Mak Tg(Cyp1a1-cre/ERT)1Dwi/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * CBA)
|
peritoneal inflammation
|
J:143082
|
Apctm2.1Cip/Apc+ Atg7tm1Tchi/Atg7tm1Tchi Tg(Vil1-cre/ERT2)23Syr/0
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj * DBA/2)
|
abnormal immune system physiology
|
J:227287
|
increased interleukin-1 beta secretion
|
J:227287
|
increased interleukin-10 secretion
|
J:227287
|
Apctm2.1Cip/Apctm2.1Cip Lect2tm1Ymg/Lect2tm1Ymg Tg(Ttr-cre/Esr1*)1Vco/0
(B6.Cg-Lect2tm1Ymg Apctm2.1Cip Tg(Ttr-cre/Esr1*)1Vco)
|
abnormal chemokine level
|
J:184496
|
abnormal neutrophil physiology
|
J:184496
|
abnormal NK T cell physiology
|
J:184496
|
decreased interferon-gamma secretion
|
J:184496
|
increased interleukin-4 secretion
|
J:184496
|
liver inflammation
|
J:184496
|
Apctm2.1Cip/Apctm2.1Cip Tg(Ttr-cre/Esr1*)1Vco/0
(B6.Cg-Apctm2.1Cip Tg(Ttr-cre/Esr1*)1Vco)
|
abnormal NK T cell physiology
|
J:184496
|
increased interferon-gamma secretion
|
J:184496
|
increased interleukin-4 secretion
|
J:184496
|
liver inflammation
|
J:184496
|
Apctm2Rak/Apc+ Trp53tm1Brn/Trp53tm1Brn Tg(Pdx1-cre)6Tuv/0
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6J * FVB/N * SJL)
|
abnormal cytokine level
|
J:234310
|
Apcstm1Mpe/Apcs+
(B6.Cg-Apcstm1Mpe)
|
glomerulonephritis
|
J:90502
|
increased autoantibody level
|
J:90502
|
Apcstm1Mpe/Apcstm1Mpe
(B6.Cg-Apcstm1Mpe)
|
decreased susceptibility to bacterial infection
|
J:125473
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:125473
|
glomerulonephritis
|
J:90502
|
increased autoantibody level
|
J:90502
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:125473
|
Apcstm1Mpe/Apcstm1Mpe
(129.Cg-Apcstm1Mpe)
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:125473
|
glomerulonephritis
|
J:90502
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:125473
|
Apcstm1Smae/Apcstm1Smae
(involves: 129S/SvEv * C57BL/6)
|
decreased susceptibility to endotoxin shock
|
J:71194
|
increased autoantibody level
|
J:71194
|
Apex1tm1Cur/Apex1+
(involves: 129S1/Sv)
|
increased circulating interleukin-1 alpha level
|
J:119957
|
increased circulating interleukin-10 level
|
J:119957
|
Apex1tm1Ecf/Apex1+
(either: (involves: 129/Sv) or (involves: 129/Sv * C57BL/6))
|
heart inflammation
|
J:70397
|
myocarditis
|
J:70397
|
pericarditis
|
J:70397
|
Apex2tm1Yun/Y
(B6.129S-Apex2tm1Yun)
|
decreased splenocyte proliferation
|
J:95267
|
AplfGt(RRF189)Byg/AplfGt(RRF189)Byg
(involves: 129P2/OlaHsd * C57BL/6J)
|
abnormal class switch recombination
|
J:168260
|
Apoa4tm1Bres/Apoa4tm1Bres
(B6.129S4-Apoa4tm1Bres)
|
increased susceptibility to induced colitis
|
J:91357
|
Apobtm2Sgy/Apobtm2Sgy Ldlrtm1Her/Ldlrtm1Her Tg(Ins-Igf2)1Fbos/?
(involves: 129S7/SvEvBrd * C57BL/6 * C57BL/6J * SJL)
|
aortitis
|
J:227165
|
Apobec3Gt(XN450)Byg/Apobec3Gt(XN450)Byg
(B6.Cg-Apobec3Gt(XN450)Byg)
|
increased susceptibility to Retroviridae infection
|
J:118597
|
Apobec3Gt(XN450)Byg/Apobec3Gt(XN450)Byg
(B6.129P2-Apobec3Gt(XN450)Byg)
|
abnormal immunoglobulin level
|
J:138778
|
increased susceptibility to Retroviridae infection
|
J:138778
|
Apobec3Gt(XN450)Byg/Apobec3Gt(XN450)Byg
(129P2/OlaHsd-Apobec3Gt(XN450)Byg)
|
abnormal immunoglobulin level
|
J:138778
|
increased susceptibility to Retroviridae infection
|
J:138778
|
Apobec3Gt(XN450)Byg/Apobec3Rfv3-s H2b/H2b
(involves: A.BY * C57BL/6)
|
abnormal immunoglobulin level
|
J:138778
|
Apobec3Gt(XN450)Byg/Apobec3Rfv3-s H2b/H2d
(involves: BALB/c * C57BL/6)
|
abnormal immunoglobulin level
|
J:138778
|
increased susceptibility to Retroviridae infection
|
J:138778
|
increased susceptibility to Retroviridae infection induced morbidity/mortality
|
J:138778
|
Apobec3Rfv3-r/Apobec3+
((B10.A x A)F1)
|
decreased susceptibility to Retroviridae infection
|
J:6147
|
Apoetm1Bres/Apoetm1Bres Bcl2tm1Irt/Bcl2tm1Irt Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased macrophage apoptosis
|
J:144243
|
Apoetm1Bres/Apoetm1Bres Cx3cr1tm1Ifc/Cx3cr1tm1Ifc
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
impaired macrophage chemotaxis
|
J:81822
|
Apoetm1Bres/Apoetm1Bres Mapk9tm1Flv/Mapk9tm1Flv
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
|
abnormal macrophage physiology
|
J:94044
|
Apoetm1Unc/Apoetm1Unc
(B6.129P2-Apoetm1Unc/J)
|
abnormal B cell activation
|
J:133606
|
abnormal immune serum protein physiology
|
J:61564
|
abnormal immune system physiology
|
J:61564
|
blood vessel inflammation
|
J:91058
|
decreased interferon-gamma secretion
|
J:47027
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:61564
|
increased anti-double stranded DNA antibody level
|
J:133606
|
increased anti-nuclear antigen antibody level
|
J:133606
|
increased autoantibody level
|
J:133606
|
increased IgM level
|
J:61564
|
increased immunoglobulin level
|
J:133606
|
increased susceptibility to systemic lupus erythematosus
|
J:133606
|
Apoetm1Unc/Apoetm1Unc
(involves: 129P2/OlaHsd * C57BL/6)
|
lung inflammation
|
J:83615
|
Apoetm1Unc/Apoetm1Unc
(B6.129P2-Apoetm1Unc)
|
abnormal cell-mediated immunity
|
J:125366
|
abnormal dendritic cell physiology
|
J:125366
|
increased susceptibility to parasitic infection
|
J:125366
|
Apoetm1Unc/Apoetm1Unc
(B6.Cg-Apoetm1Unc Faslpr)
|
increased anti-double stranded DNA antibody level
|
J:133606
|
increased anti-nuclear antigen antibody level
|
J:133606
|
increased immunoglobulin level
|
J:133606
|
increased susceptibility to systemic lupus erythematosus
|
J:133606
|
Apoetm1Unc/Apoetm1Unc Cbstm1Unc/Cbstm1Unc Tg(Mt1-CBS)25Waku/0
(involves: 129P2/OlaHsd * C3H * C57BL/6)
|
increased circulating tumor necrosis factor level
|
J:168131
|
Apoetm1Unc/Apoetm1Unc Ccr1tm1Gao/Ccr1tm1Gao
(involves: 129P2/OlaHsd * 129S4/SvJae)
|
increased interferon-gamma secretion
|
J:128063
|
Apoetm1Unc/Apoetm1Unc Ccr2tm1Ifc/Ccr2tm1Ifc
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
impaired macrophage chemotaxis
|
J:111471
|
Apoetm1Unc/Apoetm1Unc Ccr5tm1Blck/Ccr5tm1Blck
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal cytokine secretion
|
J:128063
|
abnormal lymphocyte physiology
|
J:128063
|
decreased interferon-gamma secretion
|
J:128063
|
increased interleukin-10 secretion
|
J:128063
|
Apoetm1Unc/Apoetm1Unc Ccr5tm1Kuz/Ccr5tm1Kuz
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal cytokine secretion
|
J:128063
|
abnormal lymphocyte physiology
|
J:128063
|
decreased interferon-gamma secretion
|
J:128063
|
increased interleukin-10 secretion
|
J:128063
|
Apoetm1Unc/Apoetm1Unc Cd36tm1Mfe/Cd36tm1Mfe
(involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6)
|
abnormal macrophage physiology
|
J:61672
|
Apoetm1Unc/Apoetm1Unc Cx3cl1tm1Sgs/Cx3cl1tm1Sgs
(B6.129-Apoetm1Unc Cx3cl1tm1Sgs)
|
impaired macrophage chemotaxis
|
J:95279
|
Apoetm1Unc/Apoetm1Unc Cxcl10tm1Adl/Cxcl10tm1Adl
(B6.129-Cxcl10tm1Adl Apoetm1Unc)
|
impaired macrophage chemotaxis
|
J:166204
|
Apoetm1Unc/Apoetm1Unc Cyp4f13Gt(OST14770)Lex/Cyp4f13Gt(OST14770)Lex
(involves: 129P2/OlaHsd * 129S5/SvEvBrd * C57BL/6)
|
abnormal macrophage chemotaxis
|
J:289999
|
Apoetm1Unc/Apoetm1Unc Cyp19a1tm1Esi/Cyp19a1tm1Esi
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6)
|
increased circulating C-reactive protein level
|
J:184647
|
increased circulating interleukin-6 level
|
J:184647
|
increased circulating tumor necrosis factor level
|
J:184647
|
Apoetm1Unc/Apoetm1Unc Faslpr/Faslpr
(MRL.Cg-Apoetm1Unc Faslpr)
|
increased anti-double stranded DNA antibody level
|
J:133606
|
increased anti-nuclear antigen antibody level
|
J:133606
|
increased autoantibody level
|
J:133606
|
increased immunoglobulin level
|
J:133606
|
increased susceptibility to systemic lupus erythematosus
|
J:133606
|
Apoetm1Unc/Apoetm1Unc Faslpr/Faslpr
(B6.Cg-Apoetm1Unc Faslpr)
|
decreased autoantibody level
|
J:121671
|
glomerulonephritis
|
J:121671
|
increased anti-double stranded DNA antibody level
|
J:121671
|
increased autoantibody level
|
J:121671
|
increased IgG level
|
J:121671
|
Apoetm1Unc/Apoetm1Unc Faslgld/Faslgld
(B6.Cg-Faslgld Apoetm1Unc)
|
blood vessel inflammation
|
J:91058
|
impaired macrophage phagocytosis
|
J:91058
|
increased anti-nuclear antigen antibody level
|
J:200141,
J:91058
|
increased autoantibody level
|
J:91058
|
increased IgG level
|
J:91058
|
kidney inflammation
|
J:200141
|
Apoetm1Unc/Apoetm1Unc Gja5tm1Mchn/Gja5tm1Mchn Tg(TIE2-lacZ)182Sato/0
(involves: 129P2/OlaHsd * BALB/c * C57BL/6)
|
abnormal neutrophil physiology
|
J:162224
|
alveolitis
|
J:162224
|
Apoetm1Unc/Apoetm1Unc Glg1Gt(RST092)Byg/Glg1+
(B6J.129P2-Apoetm1Unc Glg1Gt(RST092)Byg)
|
impaired macrophage chemotaxis
|
J:226586
|
Apoetm1Unc/Apoetm1Unc Hptm1Alev/Hptm1Alev
(involves: 129)
|
abnormal macrophage chemotaxis
|
J:134942
|
Apoetm1Unc/Apoetm1Unc Hsd11b1tm1Lex/Hsd11b1tm1Lex
(B6.129-Hsd11b1tm1Lex Apoetm1Unc)
|
abnormal cytokine secretion
|
J:199430
|
decreased tumor necrosis factor secretion
|
J:199430
|
Apoetm1Unc/Apoetm1Unc Il1r1tm1Imx/Il1r1tm1Imx
(B6.129-Il1r1tm1Imx Apoetm1Unc)
|
decreased circulating interleukin-6 level
|
J:148173
|
Apoetm1Unc/Apoetm1Unc Il1rntm1Dih/Il1rntm1Dih
(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)
|
abnormal macrophage chemotaxis
|
J:132570
|
Apoetm1Unc/Apoetm1Unc Il10tm1Cgn/Il10tm1Cgn
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal circulating cytokine level
|
J:105858
|
increased circulating interferon-gamma level
|
J:105858
|
increased circulating interleukin-12 level
|
J:105858
|
Apoetm1Unc/Apoetm1Unc Itgb3tm1Hyn/Itgb3tm1Hyn
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
|
lung inflammation
|
J:83615
|
Apoetm1Unc/Apoetm1Unc Klf15tm2Jain/Klf15tm2Jain Tg(Tagln-cre)1Jjl/0
(involves: 129P2/OlaHsd * FVB/N)
|
blood vessel inflammation
|
J:203920
|
Apoetm1Unc/Apoetm1Unc Ncf1tm1Shl/Ncf1tm1Shl
(involves: 129P2/OlaHsd * 129S2/SvPas)
|
decreased acute inflammation
|
J:123854
|
Apoetm1Unc/Apoetm1Unc Nck1tm1Paw/Nck1tm1Paw Nck2tm3Paw/Nck2tm3Paw Tg(Cdh5-cre/ERT2)1Rha/0
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6)
|
decreased inflammatory response
|
J:326659
|
Apoetm1Unc/Apoetm1Unc Nfe2l2tm1Mym/Nfe2l2tm1Mym
(involves: 129P2/OlaHsd * C57BL/6J)
|
abnormal macrophage physiology
|
J:143903
|
Apoetm1Unc/Apoetm1Unc Soat1tm1Far/Soat1tm1Far
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J)
|
skin inflammation
|
J:61147
|
Apoetm1Unc/Apoetm1Unc Spp1tm1Blh/Spp1tm1Blh
(involves: 129P2/OlaHsd * 129S6/SvEvTac * Black Swiss * C57BL/6J)
|
abnormal macrophage physiology
|
J:86531
|
Apoetm1Unc/Apoetm1Unc Tg(CAG-IL1RN)1Cga/?
(involves: 129P2/OlaHsd * C57BL/6 * DBA/1 * FVB)
|
decreased circulating serum amyloid protein level
|
J:132570
|
Apoetm1Unc/Apoetm1Unc Tg(CAG-IL1RN)2Cga/?
(involves: 129P2/OlaHsd * C57BL/6 * DBA/1 * FVB)
|
decreased circulating serum amyloid protein level
|
J:132570
|
Apoetm1Unc/Apoetm1Unc Tg(MSR1-Plau)1Ddi/0
(involves: 129P2/OlaHsd * C57BL/6 * SJL)
|
heart inflammation
|
J:101486
|
Apoetm1Unc/Apoetm1Unc Thbs4tm1Olsa/Thbs4tm1Olsa
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased chemokine level
|
J:345752
|
increased circulating interleukin-10 level
|
J:345752
|
increased circulating tumor necrosis factor level
|
J:345752
|
Apoetm2(APOE*3)Mae/Apoetm2(APOE*3)Mae
(involves: 129P2/OlaHsd * C57BL/6J)
|
decreased interleukin-6 secretion
|
J:86768
|
decreased tumor necrosis factor secretion
|
J:86768
|
Apoetm3(APOE*4)Mae/Apoetm3(APOE*4)Mae
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal response to infection
|
J:138241
|
increased interleukin-6 secretion
|
J:86768
|
increased tumor necrosis factor secretion
|
J:86768
|
Apol6em1Hsul/Apol6em1Hsul
(Not Specified)
|
decreased inflammatory response
|
J:344362
|
Apptm2.1Ldad/Apptm2.1Ldad
(involves: 129 * C57BL/6J)
|
myositis
|
J:166989
|
Apptm3.1Tcs/Apptm3.1Tcs Mapttm1.1(MAPT)Tcs/Mapttm1.1(MAPT)Tcs
(involves: 129S/SvEv * C57BL/6)
|
CNS inflammation
|
J:278451
|
Appl1Gt(XM073)Byg/Appl1Gt(XM073)Byg
(B6.129P2-Appl1Gt(XM073)Byg)
|
increased T cell proliferation
|
J:164696
|
Appl1tm1.2Test/Appl1tm1.2Test
(involves: 129X1/SvJ)
|
increased T cell proliferation
|
J:164696
|
Aprttm1Dwm/Aprttm1Dwm
(129P2/OlaHsd-Aprttm1Dwm)
|
pyelonephritis
|
J:38450
|
Aprttm1Jat/Aprttm1Jat
(involves: 129S2/SvPas * Black Swiss)
|
kidney inflammation
|
J:33255
|
Aprttm1Jat/Aprttm1Jat
(involves: 129S2/SvPas * C57BL/6J)
|
kidney inflammation
|
J:33255
|
Aprttm1Vri/Aprttm1Vri
(involves: 129P2/OlaHsd * C57BL/6)
|
kidney inflammation
|
J:50874
|
Aqp3m1Btlr/Aqp3m1Btlr
(C57BL/6J-Aqp3m1Btlr)
|
increased susceptibility to induced colitis
|
J:153279
|
Aqp4tm1.1Lmno/Aqp4tm1.1Lmno
(B6.Cg-Aqp4tm1.1Lmno)
|
increased susceptibility to parasitic infection
|
J:193622
|
increased susceptibility to parasitic infection induced morbidity/mortality
|
J:193622
|
Aqp4tm1.1Mysi/Aqp4tm1.1Mysi
(involves: C57BL/6JJcl * C57BL/6NCrlj * CBA/JNCrlj)
|
abnormal microglial cell physiology
|
J:214906
|
Aqp9tm1Nlsn/Aqp9tm1Nlsn
(involves: 129S1/Sv)
|
decreased susceptibility to parasitic infection
|
J:123305
|
Aqp12tm1Rai/Aqp12tm1Rai
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased susceptibility to induced pancreatitis
|
J:155920
|
Artm1Verh/Y Rnase10tm1(cre)Hht/Rnase10+
(involves: 129S7/SvEvBrd * C57BL/6)
|
testis inflammation
|
J:173897
|
Aregtm1Dle/Aregtm1Dle Egftm1Dle/Egftm1Dle Tgfatm1Unc/Tgfatm1Unc
(involves: 129P2/OlaHsd * C57BL/6)
|
dermatitis
|
J:54980
|
Aregtm2c(EUCOMM)Hmgu/Aregtm2c(EUCOMM)Hmgu Foxp3tm4(YFP/icre)Ayr/Foxp3+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6N)
|
increased susceptibility to Orthomyxoviridae infection
|
J:224904
|
Aregtm2c(EUCOMM)Hmgu/Aregtm2c(EUCOMM)Hmgu Tg(Cd4-cre)1Cwi/0
(involves: C57BL/6 * C57BL/6N * DBA/2)
|
increased susceptibility to Orthomyxoviridae infection
|
J:224904
|
Arel1em1Bbc/Arel1+
(C57BL/6J-Arel1em1Bbc)
|
decreased acute inflammation
|
J:280563
|
decreased response to antigen
|
J:280563
|
Arel1em1Bbc/Arel1em1Bbc
(C57BL/6J-Arel1em1Bbc)
|
decreased acute inflammation
|
J:280563
|
decreased response to antigen
|
J:280563
|
Arg1tm1.1Pmu/Arg1tm1.1Pmu
(involves: C57BL/6 * NZB)
|
increased macrophage nitric oxide production
|
J:143229
|
Arg1tm1Ekoe/Arg1tm1Ekoe
(involves: 129P2/OlaHsd)
|
abnormal macrophage physiology
|
J:183882
|
Arg1tm1Pmu/Arg1tm1Pmu Lyz2tm1(cre)Ifo/?
(B6.Cg-Arg1tm1Pmu Lyz2tm1(cre)Ifo)
|
decreased susceptibility to parasitic infection
|
J:143229
|
Arg1tm1Pmu/Arg1tm1Pmu Tg(Tek-cre)1Ywa/?
(B6.Cg-Tg(Tek-cre)1Ywa Arg1tm1Pmu)
|
abnormal macrophage physiology
|
J:143229
|
decreased susceptibility to bacterial infection
|
J:143229
|
increased macrophage nitric oxide production
|
J:143229
|
Arhgap15tm1Ehi/Arhgap15tm1Ehi
(B6.129-Arhgap15tm1Ehi)
|
abnormal neutrophil physiology
|
J:174896
|
decreased susceptibility to bacterial infection
|
J:174896
|
Arhgap17Gt(RRN062)Byg/Arhgap17Gt(RRN062)Byg
(B6.129P2-Arhgap17Gt(RRN062)Byg)
|
increased susceptibility to induced colitis
|
J:277297
|
increased tumor necrosis factor secretion
|
J:277297
|
Arhgap25tm1a(KOMP)Wtsi/Arhgap25tm1a(KOMP)Wtsi
(involves: C57BL/6N)
|
abnormal cellular extravasation
|
J:240521
|
abnormal neutrophil physiology
|
J:240521
|
enhanced leukocyte migration
|
J:240521
|
enhanced leukocyte tethering or rolling
|
J:240521
|
increased acute inflammation
|
J:240521
|
Arhgap45em1Ciphe/Arhgap45em1Ciphe
(C57BL/6-Arhgap45em1Ciphe)
|
decreased lymphocyte chemotaxis
|
J:309971
|
Arhgdiatm1Ytk/Arhgdiatm1Ytk
(involves: 129S/SvEv * C57BL/6 * DBA)
|
tubulointerstitial nephritis
|
J:57995
|
Arhgdiatm1Ytk/Arhgdiatm1Ytk Arhgdibtm1Miyo/Arhgdibtm1Miyo
(involves: 129S/SvEv)
|
abnormal T cell physiology
|
J:140671
|
decreased T cell proliferation
|
J:140671
|
enhanced B cell migration
|
J:140671
|
increased B cell proliferation
|
J:140671
|
increased circulating interleukin-5 level
|
J:140671
|
Arhgdibtm1Len/Arhgdibtm1Len
(involves: 129S4/SvJae * C57BL/6)
|
increased B cell proliferation
|
J:42604
|
Arhgef1tm1.1Rmt/Arhgef1tm1.1Rmt
(C57BL/6-Arhgef1tm1.1Rmt)
|
abnormal marginal zone B cell physiology
|
J:113295
|
decreased IgM level
|
J:113295
|
Arhgef1tm1Djle/Arhgef1tm1Djle
(involves: 129S4/SvJae * C57BL/6)
|
abnormal neutrophil physiology
|
J:129331
|
Arhgef1tm1Kdf/Arhgef1tm1Kdf
(involves: 129S1/Sv * 129X1/SvJ)
|
abnormal humoral immune response
|
J:99463
|
abnormal lymphocyte physiology
|
J:99463
|
decreased B cell proliferation
|
J:99463
|
decreased IgG level
|
J:99463
|
decreased IgM level
|
J:99463
|
increased T cell proliferation
|
J:99463
|
Arhgef2Gt(IST13976A8)Tigm/Arhgef2Gt(IST13976A8)Tigm
(involves: C57BL/6N)
|
abnormal macrophage physiology
|
J:209086
|
decreased interferon-beta secretion
|
J:209086
|
increased susceptibility to Orthomyxoviridae infection
|
J:209086
|
Arhgef4tm1a(KOMP)Wtsi/Arhgef4tm1a(KOMP)Wtsi
(C57BL/6N-Arhgef4tm1a(KOMP)Wtsi/Wtsi)
|
decreased IgE level
|
J:165965
|
decreased IgG1 level
|
J:165965
|
Arhgef5tm1.1Dwu/Arhgef5tm1.1Dwu
(involves: 129S1/Sv * 129S6/SvEvTac)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:157812
|
abnormal dendritic cell physiology
|
J:157812
|
decreased interleukin-4 secretion
|
J:157812
|
Arhgef6tm1Kdf/Arhgef6tm1Kdf
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal humoral immune response
|
J:137269
|
abnormal T cell physiology
|
J:137269
|
decreased B cell proliferation
|
J:137269
|
decreased interleukin-2 secretion
|
J:137269
|
decreased T cell proliferation
|
J:137269
|
enhanced B cell migration
|
J:137269
|
Arhgef12tm1.1Wet/Arhgef12tm1.1Wet Tg(Lck-cre)548Jxm/0
(involves: 129 * C57BL/6 * CBA)
|
abnormal T cell proliferation
|
J:149560
|
Arid1atm1.1Mag/Arid1atm1.1Mag Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+
(involves: 129S6/SvEvTac * CD-1)
|
increased interleukin-6 secretion
|
J:219794
|
Arid3atm1Pwt/Arid3atm1Pwt
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal class switch recombination
|
J:169178
|
decreased IgG1 level
|
J:169178
|
decreased IgM level
|
J:169178
|
Arid4atm1Alb/Arid4atm1Alb Arid4btm1Alb/Arid4b+
(involves: 129S7/SvEvBrd)
|
hemophagocytosis
|
J:141004
|
Arid5atm1Rnis/Arid5atm1Rnis
(B6.Cg-Arid5atm1Rnis)
|
decreased circulating interleukin-6 level
|
J:197418
|
decreased circulating tumor necrosis factor level
|
J:197418
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:197418
|
Arid5bGt(ROSA)75Sor/Arid5bGt(ROSA)75Sor
(involves: 129S4/SvJaeSor)
|
kidney inflammation
|
J:117491
|
Arigg1NZB/BlNJ/?
(involves: BALB/cByJ * NZB/BlNJ)
|
increased anti-erythrocyte antigen antibody level
|
J:93737
|
Arigg2NZB/BlNJ/?
(involves: BALB/cByJ * NZB/BlNJ)
|
increased anti-erythrocyte antigen antibody level
|
J:93737
|
Arigg3NZB/BlNJ/?
(involves: BALB/cByJ * NZB/BlNJ)
|
increased anti-erythrocyte antigen antibody level
|
J:93737
|
Arigg4NZB/BlNJ/?
(involves: BALB/cByJ * NZB/BlNJ)
|
increased anti-erythrocyte antigen antibody level
|
J:93737
|
Arigg5NZB/BlNJ/?
(involves: BALB/cByJ * NZB/BlNJ)
|
increased anti-erythrocyte antigen antibody level
|
J:93737
|
Arigg6NZB/BlNJ/?
(involves: BALB/cByJ * NZB/BlNJ)
|
increased anti-erythrocyte antigen antibody level
|
J:93737
|
Arigg7NZB/BlNJ/?
(involves: BALB/cByJ * NZB/BlNJ)
|
increased anti-erythrocyte antigen antibody level
|
J:93737
|
Arigg8BALB/cByJ/?
(involves: BALB/cByJ * NZB/BlNJ)
|
increased anti-erythrocyte antigen antibody level
|
J:93737
|
Arigg9NZB/BlNJ/?
(involves: BALB/cByJ * NZB/BlNJ)
|
increased anti-erythrocyte antigen antibody level
|
J:93737
|
Arigg10BALB/cByJ/?
(involves: BALB/cByJ * NZB/BlNJ)
|
increased anti-erythrocyte antigen antibody level
|
J:93737
|
Arigm1BALB/cByJ/?
(involves: BALB/cByJ * NZB/BlNJ)
|
increased IgM level
|
J:93737
|
Arigm2NZB/BlNJ/?
(involves: BALB/cByJ * NZB/BlNJ)
|
increased IgM level
|
J:93737
|
Arigm3NZB/BlNJ/?
(involves: BALB/cByJ * NZB/BlNJ)
|
increased IgM level
|
J:93737
|
Arigm4NZB/BlNJ/?
(involves: BALB/cByJ * NZB/BlNJ)
|
increased IgM level
|
J:93737
|
Arigm5NZB/BlNJ/?
(involves: BALB/cByJ * NZB/BlNJ)
|
increased IgM level
|
J:93737
|
Arigm6NZB/BlNJ/?
(involves: BALB/cByJ * NZB/BlNJ)
|
increased IgM level
|
J:93737
|
Arigm7NZB/BlNJ/?
(involves: BALB/cByJ * NZB/BlNJ)
|
increased IgM level
|
J:93737
|
Arih1em3Gpt/Arih1em3Gpt Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
(involves: 129S4/SvJae * C57BL/6JGpt)
|
decreased interferon-beta secretion
|
J:330879
|
decreased interleukin-6 secretion
|
J:330879
|
increased susceptibility to Herpesvirales infection
|
J:330879
|
increased susceptibility to Herpesvirales infection induced morbidity/mortality
|
J:330879
|
Arih1em3Gpt/Arih1em3Gpt Lyz2em1(icre)Gpt/Lyz2+
(C57BL/6JGpt-Arih1em3Gpt Lyz2em1(icre)Gpt)
|
decreased circulating interferon-beta level
|
J:330879
|
decreased circulating interleukin-6 level
|
J:330879
|
decreased interferon-beta secretion
|
J:330879
|
decreased interleukin-6 secretion
|
J:330879
|
increased susceptibility to Herpesvirales infection
|
J:330879
|
increased susceptibility to Herpesvirales infection induced morbidity/mortality
|
J:330879
|
Arih2tm1Mak/Arih2tm1Mak
(involves: 129P2/OlaHsd * C57BL/6)
|
dermatitis
|
J:191066
|
heart inflammation
|
J:191066
|
increased inflammatory response
|
J:191066
|
liver inflammation
|
J:191066
|
lung inflammation
|
J:191066
|
Arih2tm1Mak/Arih2tm1Mak
(B6.129P2-Arih2tm1Mak)
|
abnormal dendritic cell physiology
|
J:191066
|
increased inflammatory response
|
J:191066
|
Arl3Gt(OST263303)Lex/Arl3Gt(OST263303)Lex
(involves: 129S5/SvEvBrd)
|
bile duct inflammation
|
J:107331
|
Arnttm1.1Gonz/Arnttm1.2Gonz Tg(Lck-cre)I57Jxm/0
(involves: 129X1/SvJ * ICR)
|
abnormal immune system physiology
|
J:85934
|
Arpc4tm1c(EUCOMM)Wtsi/Arpc4tm1c(EUCOMM)Wtsi Krt14tm1(cre)Wbm/Krt14+
(B6.Cg-Arpc4tm1c(EUCOMM)Wtsi Krt14tm1(cre)Wbm)
|
dermatitis
|
J:253986
|
Arrb2tm1Rjl/Arrb2tm1Rjl
(involves: 129X1/SvJ * C57BL/6)
|
abnormal circulating tumor necrosis factor level
|
J:112607
|
abnormal lymphocyte physiology
|
J:76872
|
increased acute inflammation
|
J:112607
|
increased circulating interleukin-6 level
|
J:112607
|
increased interleukin-6 secretion
|
J:112607
|
increased interleukin-12b secretion
|
J:112607
|
increased susceptibility to endotoxin shock
|
J:112607
|
increased tumor necrosis factor secretion
|
J:112607
|
Art2atm1Fkn/Art2atm1Fkn Art2btm1Fkn/Art2btm1Fkn
(NOD.129S4(B6)-Art2atm1Fkn Art2btm1Fkn/Lt)
|
decreased T cell apoptosis
|
J:108097
|
Art2atm1Fkn/Art2atm1Fkn Art2btm1Fkn/Art2btm1Fkn Cd38tm1Lnd/Cd38tm1Lnd
(NOD.129(B6)-Cd38tm1Lnd Art2atm1Fkn Art2btm1Fkn/Lt)
|
decreased susceptibility to autoimmune diabetes
|
J:108097
|
Arti1C57BL/6J/Arti1C57BL/6J Arti2C57BL/6J/Arti2C57BL/6J
(involves: C57BL/6J * DBA/2J)
|
abnormal thymus involution
|
J:85261
|
Arti1DBA/2J/Arti1DBA/2J Arti2DBA/2J/Arti2DBA/2J
(involves: C57BL/6J * DBA/2J)
|
abnormal thymus involution
|
J:85261
|
Arvm2MRL/MpJ/Arvm2MRL/MpJ
(involves: C3H/HeJ-Faslpr * MRL/MpJ-Faslpr)
|
abnormal immune system physiology
|
J:63511
|
asa/asa
(either: A/J or BALB/c or DBA/2J)
|
increased autoantibody level
|
J:2843
|
myocarditis
|
J:2843
|
Asah1tm1.2Geno/Asah1tm1.2Geno
(involves: C57BL/6)
|
abnormal circulating cytokine level
|
J:285931
|
increased circulating CXCL10 level
|
J:285931
|
lung inflammation
|
J:285931
|
Asah1tm1Medin/Asah1tm1Medin
(involves: 129S6/SvEvTac * CD-1)
|
abnormal chemokine secretion
|
J:232306
|
abnormal circulating chemokine level
|
J:232306
|
increased circulating interleukin-12b level
|
J:232306
|
Asb2tm1.1Lutz/Asb2tm1.1Lutz Tg(Mx1-cre)1Cgn/0
(involves: 129S2/SvPas * C57BL/6 * CBA)
|
abnormal dendritic cell physiology
|
J:200966
|
Asbb1BALB/c/Asbb1BALB/c
(involves: BALB/c * C57BL/6J)
|
increased susceptibility to systemic lupus erythematosus
|
J:76486
|
Asbb2BALB/c/Asbb2C57BL/6J
(involves: BALB/c * C57BL/6J)
|
increased susceptibility to systemic lupus erythematosus
|
J:76486
|
Asbb2C57BL/6J/Asbb2C57BL/6J
(involves: BALB/c * C57BL/6J)
|
increased susceptibility to systemic lupus erythematosus
|
J:76486
|
Asbb3C57BL/6J/Asbb3C57BL/6J
(involves: BALB/c * C57BL/6J)
|
increased susceptibility to systemic lupus erythematosus
|
J:76486
|
Asf1bm1Btlr/Asf1bm1Btlr
(C57BL/6J-Asf1bm1Btlr)
|
increased IgE level
|
J:267479
|
Asgr1tm1Sau/Asgr1tm1Sau
(B6.129S4-Asgr1tm1Sau)
|
increased susceptibility to bacterial infection
|
J:136946
|
Asgr2tm1Her/Asgr2tm1Her
(B6.129S7-Asgr2tm1Her)
|
increased susceptibility to bacterial infection
|
J:136946
|
Ash1lGt(AL0395)Wtsi/Ash1lGt(AL0395)Wtsi
(involves: 129P2/OlaHsd * C57BL/6J)
|
blepharitis
|
J:227516
|
Ash1lTn(pb-Act-RFP)1.AF0-180T25Zhu/Ash1lTn(pb-Act-RFP)1.AF0-180T25Zhu
(B6.FVB-Ash1lTn(pb-Act-RFP)1.AF0-180T25Zhu)
|
glomerulonephritis
|
J:208213
|
increased autoantibody level
|
J:208213
|
increased circulating interleukin-6 level
|
J:208213
|
increased circulating tumor necrosis factor level
|
J:208213
|
increased IgA level
|
J:208213
|
increased IgG1 level
|
J:208213
|
increased IgG2a level
|
J:208213
|
increased IgG2b level
|
J:208213
|
increased IgM level
|
J:208213
|
increased interleukin-6 secretion
|
J:208213
|
increased susceptibility to autoimmune disorder
|
J:208213
|
increased susceptibility to bacterial infection
|
J:208213
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:208213
|
increased susceptibility to endotoxin shock
|
J:208213
|
increased susceptibility to induced arthritis
|
J:208213
|
increased tumor necrosis factor secretion
|
J:208213
|
Ash1lTn(pb-Act-RFP)1.AF0-180T25Zhu/Ash1lTn(pb-Act-RFP)1.AF0-180T25Zhu Il6tm1Kopf/Il6tm1Kopf
(B6.Cg-Ash1lTn(pb-Act-RFP)1.AF0-180T25Zhu Il6tm1Kopf)
|
abnormal inflammatory response
|
J:208213
|
increased susceptibility to induced arthritis
|
J:208213
|
Asm1MRL/MpJ/?
(involves: C3H/HeJ-Faslpr * MRL/MpJ-Faslpr)
|
abnormal immune system physiology
|
J:66459
|
Asm2MRL/MpJ/?
(involves: C3H/HeJ-Faslpr * MRL/MpJ-Faslpr)
|
salivary gland inflammation
|
J:66459
|
Asq1IQI/Asq1IQI
(involves: IQI * C57BL/6CrSlc)
|
salivary gland inflammation
|
J:127310
|
Asxl1tm1.1Mjxu/Asxl1+
(involves: 129 * C57BL/6)
|
abnormal neutrophil physiology
|
J:208085
|
Atf2Tg(Gzma-Klra1)7Wum/Atf2+
(involves: C57BL/6)
|
abnormal NK cell physiology
|
J:61178
|
decreased circulating interferon-gamma level
|
J:61178
|
Atf2tm1Glm/Atf2tm1Glm
(involves: 129S2/SvPas)
|
eye inflammation
|
J:30611
|
increased susceptibility to bacterial infection
|
J:30611
|
Atf2tm1Glm/Atf2tm1Glm
(C.Cg-Atf2tm1Glm)
|
abnormal cytokine secretion
|
J:67176
|
increased susceptibility to endotoxin shock
|
J:67176
|
increased susceptibility to Herpesvirales infection
|
J:67176
|
increased susceptibility to Picornaviridae infection
|
J:67176
|
Atf3tm1Dron/Atf3tm1Dron
(involves: 129X1/SvJ * C57BL/6)
|
abnormal T-helper 2 physiology
|
J:140112
|
decreased IgG2a level
|
J:140112
|
increased interleukin-4 secretion
|
J:140112
|
increased interleukin-5 secretion
|
J:140112
|
increased interleukin-13 secretion
|
J:140112
|
lung inflammation
|
J:140112
|
Atg3tm1.1Ywh/Atg3tm1.1Ywh Gt(ROSA)26Sortm1(cre/ERT)Brn/Gt(ROSA)26Sor+
(involves: 129P2/OlaHsd * 129S/SvEv * 129S4/SvJaeSor * C57BL/6)
|
increased T cell apoptosis
|
J:172749
|
Atg3tm1.1Ywh/Atg3tm1.1Ywh Tg(Lck-cre)548Jxm/0
(involves: 129S/SvEv * 129S4/SvJaeSor * C57BL/6 * CBA)
|
decreased T cell proliferation
|
J:172749
|
increased T cell apoptosis
|
J:172749
|
Atg5tm1Myok/Atg5tm1Myok Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * 129S/SvEv)
|
abnormal circulating chemokine level
|
J:235399
|
abnormal macrophage physiology
|
J:235399
|
decreased circulating interleukin-10 level
|
J:235399
|
glomerulonephritis
|
J:235399
|
increased anti-double stranded DNA antibody level
|
J:235399
|
increased anti-nuclear antigen antibody level
|
J:235399
|
increased autoantibody level
|
J:235399
|
increased circulating interleukin-1 beta level
|
J:235399
|
increased circulating interleukin-6 level
|
J:235399
|
increased circulating interleukin-12b level
|
J:235399
|
increased IgG level
|
J:235399
|
increased susceptibility to systemic lupus erythematosus
|
J:235399
|
Atg5tm1Nmz/Atg5tm1Nmz Tg(CAG-EGFP/Map1lc3b)53Nmz/?
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal thymus physiology
|
J:140583
|
Atg5tm1Nmz/Atg5tm1Nmz Tg(Cd4-cre)1Cwi/?
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
|
abnormal T cell physiology
|
J:211733
|
decreased T cell proliferation
|
J:211733
|
Atg7tm1Tchi/Atg7tm1Tchi Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * C57BL/6NCrlj * CBA/JNCrlj)
|
abnormal circulating chemokine level
|
J:235399
|
abnormal macrophage physiology
|
J:235399
|
decreased circulating interleukin-10 level
|
J:235399
|
glomerulonephritis
|
J:235399
|
increased anti-double stranded DNA antibody level
|
J:235399
|
increased anti-nuclear antigen antibody level
|
J:235399
|
increased autoantibody level
|
J:235399
|
increased circulating interleukin-1 beta level
|
J:235399
|
increased circulating interleukin-6 level
|
J:235399
|
increased circulating interleukin-12b level
|
J:235399
|
increased IgG level
|
J:235399
|
increased susceptibility to systemic lupus erythematosus
|
J:235399
|
Atg7tm1Tchi/Atg7tm1Tchi Lyz2tm1(cre)Ifo/Lyz2+ Tg(CAG-EGFP/Map1lc3b)53Nmz/0
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj * DBA/2)
|
abnormal circulating chemokine level
|
J:235399
|
abnormal macrophage physiology
|
J:235399
|
decreased circulating interleukin-10 level
|
J:235399
|
increased circulating interleukin-1 beta level
|
J:235399
|
increased circulating interleukin-6 level
|
J:235399
|
Atg7tm1Tchi/Atg7tm1Tchi Xbp1tm2Glm/Xbp1tm2Glm Tg(Defa6-icre)1Rsb/0
(involves: 129S6/SvEvTac * C57BL/6 * CBA)
|
small intestinal inflammation
|
J:206084
|
Atg7tm1Tchi/Atg7tm1Tchi Xbp1tm2Glm/Xbp1tm2Glm Tg(Vil1-cre)997Gum/0
(involves: 129S6/SvEvTac * C57BL/6 * CBA * SJL)
|
ileum inflammation
|
J:206084
|
intestinal inflammation
|
J:206084
|
Atg9atm1Aki/Atg9atm1Aki
(involves: 129/Sv * C57BL/6)
|
abnormal innate immunity
|
J:155552
|
increased interferon-beta secretion
|
J:155552
|
increased interleukin-6 secretion
|
J:155552
|
Atg16l1tm1.1Mvlc/Atg16l1tm1.1Mvlc
(C57BL/6-Atg16l1tm1.1Mvlc)
|
abnormal macrophage physiology
|
J:206931
|
increased circulating interleukin-1 beta level
|
J:206931
|
increased macrophage cytokine production
|
J:206931
|
increased susceptibility to bacterial infection
|
J:206931
|
Atg16l1tm1a(EUCOMM)Wtsi/Atg16l1tm1a(EUCOMM)Wtsi
(C57BL/6N-Atg16l1tm1a(EUCOMM)Wtsi/Wtsi)
|
blood in lymph vessels
|
J:239583
|
Atg16l1tm1Aki/Atg16l1tm1Aki
(involves: 129/Sv * C57BL/6)
|
abnormal macrophage physiology
|
J:141420
|
increased interleukin-1 beta secretion
|
J:141420
|
increased interleukin-18 secretion
|
J:141420
|
increased susceptibility to induced colitis
|
J:141420
|
Atg16l1tm1c(EUCOMM)Wtsi/Atg16l1tm1c(EUCOMM)Wtsi Tcrdtm1Mom/Tcrdtm1Mom Tg(Vil1-cre)997Gum/0
(involves: 129P2/OlaHsd * C57BL/6J * C57BL/6N * SJL)
|
abnormal cytokine level
|
J:340266
|
increased susceptibility to colitis induced morbidity/mortality
|
J:340266
|
Atg16l1tm1c(EUCOMM)Wtsi/Atg16l1tm1c(EUCOMM)Wtsi Tg(Defa6-icre)1Rsb/0
(involves: C57BL/6)
|
increased susceptibility to colitis induced morbidity/mortality
|
J:340266
|
increased susceptibility to induced colitis
|
J:340266
|
Atg16l1tm1c(EUCOMM)Wtsi/Atg16l1tm1c(EUCOMM)Wtsi Tg(Vil1-cre)997Gum/?
(involves: C57BL/6J * C57BL/6N * SJL)
|
abnormal chemokine level
|
J:221019
|
abnormal circulating interleukin level
|
J:221019
|
abnormal cytokine level
|
J:221019
|
cecum inflammation
|
J:221019
|
increased circulating interleukin-1 beta level
|
J:221019
|
increased circulating interleukin-6 level
|
J:221019
|
increased susceptibility to bacterial infection
|
J:221019
|
Atg16l1tm1Kuv/Atg16l1tm1Kuv Tg(Vil1-cre)997Gum/0
(B6.Cg-Atg16l1tm1Kuv Tg(Vil1-cre)997Gum)
|
increased susceptibility to induced colitis
|
J:269933
|
small intestinal inflammation
|
J:269933
|
Atg16l1tm1Kuv/Atg16l1tm1Kuv Tg(Vil1-cre)997Gum/0 Xbp1tm2Glm/Xbp1tm2Glm
(B6.Cg-Atg16l1tm1Kuv Xbp1tm2Glm Tg(Vil1-cre)997Gum)
|
small intestinal inflammation
|
J:269933
|
Atg16l1tm1Kuv/Atg16l1tm1Kuv Xbp1tm2Glm/Xbp1tm2Glm Tg(Vil1-cre)997Gum/0
(involves: 129S6/SvEvTac * C57BL/6 * SJL)
|
ileum inflammation
|
J:206084
|
intestinal inflammation
|
J:206084
|
Atl1tm1.2Cbla/Atl1tm1.2Cbla Reep1Gt(OST398247)Tigm/Reep1Gt(OST398247)Tigm
(B6.Cg-Reep1Gt(OST398247)Tigm Atl1tm1.2Cbla)
|
increased susceptibility to otitis media
|
J:334532
|
Atmm1Btlr/Atmm1Btlr
(C57BL/6J-Atmm1Btlr)
|
decreased response to antigen
|
J:265252
|
impaired humoral immune response
|
J:265252
|
increased IgM level
|
J:265252
|
Atmm5Btlr/Atmm5Btlr
(C57BL/6J-Atmm5Btlr)
|
decreased interleukin-1 beta secretion
|
J:272824
|
impaired macrophage phagocytosis
|
J:272824
|
Atmtm1Awb/Atmtm1Awb
(involves: 129S6/SvEvTac)
|
abnormal class switch recombination
|
J:150435
|
Atmtm1Awb/Atmtm1Awb Paxxem1Spj/Paxxem1Spj
(involves: A/J * C57BL/6NTac)
|
abnormal class switch recombination
|
J:236776
|
Atmtm1Bal/Atmtm1Bal
(involves: 129S4/SvJae)
|
abnormal microglial cell physiology
|
J:44190
|
abnormal T cell physiology
|
J:35914
|
decreased IgG2a level
|
J:35914
|
decreased IgG2b level
|
J:35914
|
decreased IgG3 level
|
J:35914
|
decreased IgG level
|
J:35914
|
Atmtm1Fwa/Atmtm1Fwa
(involves: 129S4/SvJae)
|
abnormal class switch recombination
|
J:191288
|
Atmtm1Pmc/Atmtm1Pmc Trp73tm2Mak/Trp73tm2Mak
(involves: 129P2/OlaHsd * C57BL/6J)
|
decreased thymocyte apoptosis
|
J:157905
|
Atmtm1Shzh/Atmtm2.1Fwa Gt(ROSA)26Sortm1(cre/ERT2)Thl/Gt(ROSA)26Sor+
(involves: 129 * 129S6/SvEvTac)
|
abnormal class switch recombination
|
J:191288
|
Atmintm1.1Jhh/Atmintm1.1Jhh Cd79atm1(cre)Reth/Cd79a+
(B6.Cg-Cd79atm1(Cre)Reth Atmintm1.1Jhh)
|
decreased IgG1 level
|
J:230105
|
increased B cell apoptosis
|
J:230105
|
Atmintm1.1Jhh/Atmintm1.1Jhh Cd79atm1(cre)Reth/Cd79a+ Tg(IghMyc)22Bri/0
(B6.Cg-Cd79atm1(Cre)Reth Atmintm1.1Jhh Tg(IghMyc)22Bri)
|
increased B cell apoptosis
|
J:230105
|
Atmintm1.2Jhh/Atmintm1.2Jhh Cd79atm1(cre)Reth/Cd79a+
(involves: BALB/c * C57BL/6)
|
abnormal B cell physiology
|
J:191832
|
Atp5if1em1Jpy/Atp5if1em1Jpy
(C57BL/6J-Atp5if1em1Jpy)
|
decreased susceptibility to colitis induced morbidity/mortality
|
J:312819
|
Atp6v1hem1Xhd/Atp6v1h+
(involves: C57BL/6)
|
abnormal osteoclast physiology
|
J:239439
|
Atp7aMo-3Btlr/Y
(C57BL/6J-Atp7aMo-3Btlr)
|
decreased susceptibility to prion infection
|
J:188598
|
Atp7aMo-blo/Y
(B6.Cg-Atp7aMo-blo/J)
|
osteoarthritis
|
J:36378
|
Atp11cambr/Y
(C57BL/6-Atp11cambr)
|
abnormal humoral immune response
|
J:171924
|
Atp11cm1Btlr/Y
(involves: C57BL/6J)
|
decreased IgA level
|
J:171925
|
decreased IgG1 level
|
J:171925
|
decreased IgM level
|
J:171925
|
Atrtm1Bal/Atrtm2Bal Ndor1Tg(UBC-cre/ERT2)1Ejb/0
(involves: 129S/SvEv * 129S2/SvPas * C57BL/6)
|
abnormal thymus involution
|
J:123200
|
kidney inflammation
|
J:123200
|
Atxn3tm1a(KOMP)Wtsi/Atxn3tm1a(KOMP)Wtsi
(C57BL/6N-Atxn3tm1a(KOMP)Wtsi/Wtsi)
|
increased anti-nuclear antigen antibody level
|
J:211773
|
AU040320em1Janc/AU040320em2Janc
(FVB/N-AU040320em1Janc AU040320em2Janc)
|
decreased susceptibility to Parvoviridae infection
|
J:229089
|
Aviltm2(cre)Fawa/Aviltm2(cre)Fawa
(B6J.129P2-Aviltm2(cre)Fawa)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:265529
|
Avpr1atm1Sbhu/Avpr1atm1Sbhu
(involves: C57BL/6)
|
abnormal immunoglobulin level
|
J:105892
|
decreased IgG2b level
|
J:105892
|
increased IgG2a level
|
J:105892
|
AW112010em2Flv/AW112010em2Flv
(involves: C57BL/6N)
|
decreased circulating interleukin-6 level
|
J:267975
|
decreased circulating interleukin-12b level
|
J:267975
|
decreased interleukin-6 secretion
|
J:267975
|
decreased interleukin-12b secretion
|
J:267975
|
decreased susceptibility to induced colitis
|
J:267975
|
increased susceptibility to bacterial infection
|
J:267975
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:267975
|
Awat2tm1.2Golc/Y
(involves: 129 * C57BL/6 * C57BL/6J)
|
blepharitis
|
J:308387
|
eye inflammation
|
J:308387
|
Awat2tm1.2Golc/Awat2tm1.2Golc
(involves: 129 * C57BL/6 * C57BL/6J)
|
blepharitis
|
J:308387
|
eye inflammation
|
J:308387
|
Axltm1Grl/Axltm1Grl Mertktm1Grl/Mertktm1Grl
(involves: C57BL/6J)
|
increased anti-double stranded DNA antibody level
|
J:70420
|
Axltm1Grl/Axltm1Grl Mertktm1Grl/Mertktm1Grl Tyro3tm1Grl/Tyro3tm1Grl
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
|
abnormal B cell activation
|
J:70420
|
abnormal macrophage physiology
|
J:70420
|
abnormal professional antigen presenting cell physiology
|
J:70420
|
abnormal susceptibility to autoimmune disorder
|
J:70420
|
abnormal T cell activation
|
J:70420
|
increased anti-double stranded DNA antibody level
|
J:70420
|
increased autoantibody level
|
J:70420
|
increased B cell proliferation
|
J:70420
|
increased circulating tumor necrosis factor level
|
J:70420
|
increased splenocyte apoptosis
|
J:54681
|
increased T cell proliferation
|
J:70420
|
joint inflammation
|
J:70420
|
Axltm1Grl/Axltm1Grl Tyro3tm1Grl/Tyro3tm1Grl
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
|
increased anti-double stranded DNA antibody level
|
J:70420
|
Azi2tm1Aki/Azi2tm1Aki
(Not Specified)
|
abnormal dendritic cell physiology
|
J:204786
|
decreased interferon-alpha secretion
|
J:204786
|
decreased interleukin-6 secretion
|
J:204786
|
decreased tumor necrosis factor secretion
|
J:204786
|
Azi2tm1Aki/Azi2tm1Aki Tbkbp1tm1Aki/Tbkbp1tm1Aki
(Not Specified)
|
abnormal dendritic cell physiology
|
J:204786
|
decreased interferon-alpha secretion
|
J:204786
|
decreased interleukin-6 secretion
|
J:204786
|
decreased tumor necrosis factor secretion
|
J:204786
|
B2mtm1Jae/B2mtm1Jae
(involves: 129S2/SvPas * C57BL/6J)
|
abnormal cytotoxic T cell physiology
|
J:80910
|
B2mtm1Jae/B2mtm1Jae
(B6.129S2-B2mtm1Jae)
|
decreased interleukin-4 secretion
|
J:64283
|
decreased susceptibility to parasitic infection
|
J:64283
|
increased interleukin-3 secretion
|
J:64283
|
increased tumor necrosis factor secretion
|
J:64283
|
B2mtm1Jae/B2mtm1Jae Foxp3sfOtcspf/Y
(involves: 129/Rl * 129S2/SvPas)
|
abnormal interleukin level
|
J:20865
|
abnormal tumor necrosis factor level
|
J:20865
|
dermatitis
|
J:20865
|
increased IgG level
|
J:20865
|
increased IgM level
|
J:20865
|
increased immunoglobulin level
|
J:20865
|
B2mtm1Jae/B2mtm1Jae Rr94tm3.2Litt/Rr94tm3.2Litt
(involves: 129P2/OlaHsd * 129S2/SvPas * FVB/N)
|
increased T cell proliferation
|
J:158962
|
B2mtm1Jae/B2mtm1Jae Tnftm2Gkl/Tnf+
(involves: 129S/SvEv * 129S2/SvPas * C57BL/6J)
|
small intestinal inflammation
|
J:108572
|
B2mtm1Unc/B2m+
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased level of surface class I molecules
|
J:64451
|
B2mtm1Unc/B2mtm1Unc
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased level of surface class I molecules
|
J:64451
|
B2mtm1Unc/B2mtm1Unc
(NOD.129P2-B2mtm1Unc)
|
decreased susceptibility to autoimmune diabetes
|
J:121685,
J:17000
|
B2mtm1Unc/B2mtm1Unc
(involves: 129P2/OlaHsd * NOD/Lt)
|
insulitis
|
J:93557
|
B2mtm1Unc/B2mtm1Unc
(B6.129P2-B2mtm1Unc/DcrJ)
|
abnormal interleukin level
|
J:123934
|
abnormal tumor necrosis factor level
|
J:123934
|
decreased IgG level
|
J:110885
|
decreased susceptibility to autoimmune diabetes
|
J:135214
|
decreased susceptibility to bacterial infection
|
J:123934
|
increased IgM level
|
J:110885
|
increased susceptibility to infection induced morbidity/mortality
|
J:123934
|
B2mtm1Unc/B2mtm1Unc Cd4tm1Mak/Cd4tm1Mak Cd8atm2.1(Cd4)Asin/Cd8atm2.1(Cd4)Asin
(involves: 129 * C57BL/6)
|
abnormal T cell physiology
|
J:180236
|
B2mtm1Unc/B2mtm1Unc Ciitatm1Ccum/Ciitatm1Ccum
(NOD.Cg-B2mtm1Unc Ciitatm1Ccum)
|
decreased susceptibility to autoimmune diabetes
|
J:107051
|
B2mtm1Unc/B2mtm1Unc Emv30b/Emv30b Prkdcscid/Prkdcscid Tg(B2M)55Hpl/? Mcph1Tg(HLA-A2.1)1Enge/?
(NOD.Cg-B2mtm1Unc Mcph1Tg(HLA-A2.1)1Enge Emv30b Prkdcscid Tg(B2M)55Hpl/Dvs)
|
decreased susceptibility to autoimmune diabetes
|
J:109851
|
B2mtm1Unc/B2mtm1Unc Il2tm1Hor/Il2tm1Hor
(involves: 129 * C57BL/6)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:51450
|
colitis
|
J:39981,
J:51450
|
B2mtm1Unc/B2mtm1Unc Prkdcscid/Prkdcscid
(NOD.Cg-B2mtm1Unc Prkdcscid)
|
abnormal NK cell physiology
|
J:102141
|
abnormal response to transplant
|
J:102141
|
decreased level of surface class I molecules
|
J:102141
|
B2mtm1Unc/B2mtm1Unc Tg(B2M)55Hpl/0
(NOD.Cg-B2mtm1Unc Tg(B2M)55Hpl/Dvs)
|
decreased susceptibility to autoimmune diabetes
|
J:71837
|
B2mtm1Unc/B2mtm1Unc Tg(B2M)55Hpl/Tg(B2M)55Hpl Mcph1Tg(HLA-A2.1)1Enge/Mcph1Tg(HLA-A2.1)1Enge
(NOD.Cg-B2mtm1Unc Mcph1Tg(HLA-A2.1)1Enge Tg(B2M)55Hpl)
|
increased susceptibility to autoimmune diabetes
|
J:109851
|
B2mtm1Unc/B2mtm1Unc Tg(GFAP-B2m)9Mdos/?
(involves: 129P2/OlaHsd * C57BL/6 * NOD/ShiLtJ)
|
decreased susceptibility to autoimmune diabetes
|
J:135214
|
B2mtm1Unc/B2mtm1Unc Tg(GFAP-B2m)#Mdos/?
(involves: 129P2/OlaHsd * C57BL/6 * NOD/ShiLtJ)
|
decreased susceptibility to autoimmune diabetes
|
J:135214
|
B2mtm1Unc/B2mtm1Unc Tg(HLA-A/H2-D/B2M)1Dvs/0
(NOD.Cg-B2mtm1Unc Tg(HLA-A/H2-D/B2M)1Dvs)
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:121685
|
abnormal cell-mediated immunity
|
J:121685
|
abnormal cytotoxic T cell physiology
|
J:121685
|
increased susceptibility to autoimmune diabetes
|
J:121685
|
B2mtm1Unc/B2mtm1Unc Tg(TcraAI4)1Dvs/0 Tg(TcrbAI4)1Dvs/0
(NOD.Cg-B2mtm1Unc Tg(TcraAI4)1Dvs Tg(TcrbAI4)1Dvs)
|
decreased susceptibility to autoimmune diabetes
|
J:93553
|
B2mtm1Unc/B2mtm1Unc X/Yaa
(BXSB.129P2(B6)-B2mtm1Unc/Dcr)
|
increased anti-nuclear antigen antibody level
|
J:179430
|
increased susceptibility to systemic lupus erythematosus
|
J:179430
|
B3gnt2Gt(OST237555)Lex/B3gnt2Gt(OST237555)Lex
(involves: 129S5/SvEvBrd * C57BL/6N)
|
abnormal macrophage physiology
|
J:125556
|
increased interleukin-1 beta secretion
|
J:125556
|
increased interleukin-6 secretion
|
J:125556
|
increased T cell proliferation
|
J:125556
|
increased tumor necrosis factor secretion
|
J:125556
|
B3gnt5tm1Nari/B3gnt5tm1Nari
(involves: 129P2/OlaHsd * C57BL/6)
|
increased IgG2a level
|
J:161366
|
increased IgG2b level
|
J:161366
|
increased IgG level
|
J:161366
|
B3gnt6tm1Lx/B3gnt6tm1Lx
(involves: 129S1/Sv * C57BL/6J)
|
increased interferon-gamma secretion
|
J:123826
|
increased interleukin-2 secretion
|
J:123826
|
increased susceptibility to induced colitis
|
J:123826
|
increased tumor necrosis factor secretion
|
J:123826
|
B3gnt6tm1Lx/B3gnt6tm1Lx C1galt1tm1.1Rpmc/C1galt1tm1.1Rpmc Tg(Vil1-cre)997Gum/0
(involves: 129S1/Sv * C57BL/6J * SJL)
|
small intestinal inflammation
|
J:239765
|
B4galt1tm1Yiw/B4galt1tm1Yiw
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
|
abnormal leukocyte physiology
|
J:106669
|
abnormal neutrophil physiology
|
J:106669
|
decreased acute inflammation
|
J:106669
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:106669
|
impaired macrophage chemotaxis
|
J:89125
|
impaired neutrophil recruitment
|
J:89125
|
B4galt1tm1Yiw/B4galt1tm1Yiw
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal IgM level
|
J:117891
|
glomerulonephritis
|
J:117891
|
increased IgA level
|
J:117891
|
B4gat1tm1Mifu/B4gat1tm1Mifu
(B6.Cg-B4gat1tm1Mifu)
|
impaired leukocyte tethering or rolling
|
J:120722
|
B4gat1tm1Mifu/B4gat1tm1Mifu Gcnt1tm1Jxm/Gcnt1tm1Jxm
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal leukocyte migration
|
J:120722
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:120722
|
impaired leukocyte tethering or rolling
|
J:120722
|
B9d2/Tgfb1tm1Flv/B9d2/Tgfb1tm1Flv Tg(Cd4-cre)1Cwi/0
(involves: 129S6/SvEvTac * C57BL/6 * SJL)
|
abnormal regulatory T cell physiology
|
J:204761
|
B9d2/Tgfb1tm1Flv/Tgfb1tm2Flv Tg(Cd4-cre)1Cwi/0
(involves: 129S6/SvEvTac * C57BL/6 * DBA/2)
|
abnormal inflammatory response
|
J:123547
|
abnormal interferon level
|
J:123547
|
abnormal interleukin level
|
J:123547
|
abnormal T cell activation
|
J:123547
|
colitis
|
J:123547
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:123547
|
increased anti-double stranded DNA antibody level
|
J:123547
|
increased anti-nuclear antigen antibody level
|
J:123547
|
increased T cell proliferation
|
J:123547
|
B9d2/Tgfb1tm1Flv/Tgfb1tm2Flv Tnfrsf4tm2(cre)Nik/Tnfrsf4+
(involves: 129S6/SvEvTac * 129X1/SvJ)
|
colitis
|
J:169839
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:169839
|
liver inflammation
|
J:169839
|
lung inflammation
|
J:169839
|
B9d2/Tgfb1tm1Flv/B9d2/Tgfb1tm1Flv Tg(Cd4-cre)1Cwi/?
(involves: 129S6/SvEvTac * C57BL/6 * DBA/2)
|
abnormal inflammatory response
|
J:123547
|
B9d2/Tgfb1tm1Flv/B9d2/Tgfb1tm1Flv Tg(Cd4-cre)1Cwi/0
(involves: 129S6/SvEvTac * C57BL/6 * SJL)
|
abnormal regulatory T cell physiology
|
J:204761
|
B9d2/Tgfb1tm1Flv/B9d2+ Tnfrsf4tm2(cre)Nik/Tnfrsf4+
(involves: 129S6/SvEvTac * 129X1/SvJ)
|
colitis
|
J:169839
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:169839
|
liver inflammation
|
J:169839
|
lung inflammation
|
J:169839
|
B9d2tm1a(EUCOMM)Wtsi/B9d2tm1a(EUCOMM)Wtsi
(C57BL/6N-B9d2tm1a(EUCOMM)Wtsi/Wtsi)
|
blood in lymph vessels
|
J:239583
|
Baa1BALB/cJ/Baa1NZW/LacJ
(involves: BALB/cJ * NZW/LacJ)
|
increased IgM level
|
J:35434
|
Baa2BALB/cJ/Baa2NZW/LacJ
(involves: BALB/cJ * NZW/LacJ)
|
increased IgM level
|
J:35434
|
Bach2m2Anu/Bach2m2Anu
(C57BL/6NCrlAnu-Bach2m2Anu)
|
increased IgM level
|
J:104190
|
Bach2tm1Igar/Bach2tm1Igar
(involves: 129P2/OlaHsd * C57BL/6J)
|
abnormal B cell physiology
|
J:91110
|
abnormal class switch recombination
|
J:91110
|
abnormal somatic hypermutation frequency
|
J:91110
|
decreased IgA level
|
J:91110
|
decreased IgG1 level
|
J:91110
|
decreased IgG2a level
|
J:91110
|
decreased IgG2b level
|
J:91110
|
decreased IgG3 level
|
J:91110
|
decreased IgG level
|
J:91110
|
increased IgM level
|
J:91110
|
Badtm1Sjk/Badtm1Sjk
(either: 129X1/SvJ or (involves: 129X1/SvJ * C57BL/6))
|
abnormal B cell physiology
|
J:84987
|
abnormal T cell physiology
|
J:84987
|
Bag4tm1Yeh/Bag4tm1Yeh
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal macrophage physiology
|
J:83559
|
increased circulating interleukin-6 level
|
J:83559
|
increased inflammatory response
|
J:83559
|
increased interleukin-6 secretion
|
J:83559
|
Bahd1tm1.1Ics/Bahd1+
(involves: C57BL/6)
|
decreased susceptibility to bacterial infection
|
J:169470
|
Bak1tm1Thsn/Bak1tm1Thsn Baxtm1Sjk/Baxtm1Sjk
(involves: 129S1/Sv * 129S1/SvImJ * 129X1/SvJ * C57BL/6)
|
abnormal splenocyte physiology
|
J:66872
|
Bak1tm1Thsn/Bak1tm1Thsn Baxtm1Sjk/Baxtm2Sjk Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ)
|
abnormal B cell physiology
|
J:100463
|
increased IgA level
|
J:100463
|
increased IgG level
|
J:100463
|
increased IgM level
|
J:100463
|
increased immunoglobulin level
|
J:100463
|
Bak1tm1Thsn/Bak1tm1Thsn Baxtm1Sjk/Baxtm2Sjk Tg(Mx1-cre)1Cgn/0
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)
|
autoimmune arthritis
|
J:100463
|
glomerulonephritis
|
J:100463
|
increased anti-double stranded DNA antibody level
|
J:100463
|
increased susceptibility to autoimmune disorder
|
J:100463
|
Bak1tm1Thsn/Bak1tm1Thsn Baxtm2Sjk/Baxtm2Sjk Tg(Lck-cre)1Cwi/?
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
|
decreased thymocyte apoptosis
|
J:220951
|
Bank1tm1Kuro/Bank1tm1Kuro
(Not Specified)
|
abnormal B cell physiology
|
J:113321
|
abnormal lymphocyte physiology
|
J:113321
|
increased B cell proliferation
|
J:113321
|
increased IgG2a level
|
J:113321
|
increased IgM level
|
J:113321
|
Bap1tm1.1Geno/Bap1tm1.1Geno Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
(involves: C57BL/6 * C57BL/6NTac)
|
heart inflammation
|
J:187380
|
Batf2tm1Kmm/Batf2tm1Kmm
(129S6/SvEvTac-Batf2tm1Kmm)
|
increased susceptibility to parasitic infection induced morbidity/mortality
|
J:101977
|
Batf3tm1Kmm/Batf3tm1Kmm
(involves: 129S6/SvEvTac * BALB/cJ)
|
abnormal cytotoxic T cell physiology
|
J:141064
|
abnormal dendritic cell antigen presentation
|
J:141064
|
abnormal dendritic cell physiology
|
J:141064
|
abnormal immune system physiology
|
J:141064
|
decreased cytotoxic T cell cytolysis
|
J:141064
|
Batf3tm1Kmm/Batf3tm1Kmm
(involves: 129S6/SvEvTac)
|
abnormal cytotoxic T cell physiology
|
J:181366
|
Batf3tm1Kmm/Batf3tm1Kmm Id2tm1Gtbz/Id2tm1Gtbz
(B6.Cg-Batf3tm1Kmm Id2tm1Gtbz)
|
abnormal dendritic cell physiology
|
J:194760
|
Batftm1.1Ejt/Batftm1.1Ejt
(involves: 129S/Sv * C57BL/6 * FVB/N)
|
abnormal class switch recombination
|
J:160935
|
decreased IgA level
|
J:160935
|
decreased IgE level
|
J:160935
|
decreased IgG1 level
|
J:160935
|
decreased IgG2c level
|
J:160935
|
decreased IgM level
|
J:160935
|
decreased interleukin-4 secretion
|
J:160935
|
decreased interleukin-17 secretion
|
J:160935
|
Batftm1.1Kmm/Batftm1.1Kmm
(129S6/SvEvTac-Batftm1.1Kmm)
|
decreased interleukin-17 secretion
|
J:150643
|
decreased interleukin-21 secretion
|
J:150643
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:150643
|
Bbaa1C3H/HeNCr/Bbaa1C3H/HeNCr
(involves: C3H/HeNCr * C57BL/6NCr)
|
abnormal inflammatory response
|
J:52017
|
Bbaa1C3H/HeNCr/Bbaa1C57BL/6NCr
(involves: C3H/HeNCr * C57BL/6NCr)
|
abnormal inflammatory response
|
J:52017
|
Bbaa2C3H/HeNCr/Bbaa2C3H/HeNCr
(involves: C3H/HeNCr * C57BL/6NCr)
|
abnormal immune system physiology
|
J:52017
|
Bbaa3C3H/HeNCr/Bbaa3C3H/HeNCr
(involves: C3H/HeNCr * C57BL/6NCr)
|
abnormal inflammatory response
|
J:73060
|
Bbaa3C3H/HeNCr/Bbaa3C57BL/6NCr
(involves: C3H/HeNCr * C57BL/6NCr)
|
abnormal inflammatory response
|
J:52017
|
Bbaa5C57BL/6NCr/Bbaa5C57BL/6NCr
(involves: C3H/HeNCr * C57BL/6NCr)
|
increased IgM level
|
J:52017
|
Bbaa9C57BL/6NCr/Bbaa9C3H/HeNCr
(involves: C3H/HeNCr * C57BL/6NCr)
|
abnormal immunoglobulin level
|
J:52017
|
Bbaa9C57BL/6NCr/Bbaa9C57BL/6NCr
(involves: C3H/HeNCr * C57BL/6NCr)
|
abnormal immunoglobulin level
|
J:52017
|
Bbaa10C3H/HeN/?
(involves: C3H/HeN * C57BL/6N)
|
increased inflammatory response
|
J:73060
|
Bbaa11C3H/HeN/?
(involves: C3H/HeN * C57BL/6N)
|
increased inflammatory response
|
J:73060
|
Bbaa12C3H/HeN/?
(involves: C3H/HeN * C57BL/6N)
|
increased inflammatory response
|
J:73060
|
Bbaa13C3H/HeN/?
(involves: C3H/HeN * C57BL/6N)
|
increased inflammatory response
|
J:73060
|
Bbaa14C3H/HeJ/?
(involves: C3H/HeN * C57BL/6N)
|
increased IgG level
|
J:73060
|
increased inflammatory response
|
J:73060
|
Bbaa15C3H/HeN/?
(involves: C3H/HeN * C57BL/6N)
|
increased IgG level
|
J:73060
|
Bbaa16C3H/HeN/?
(involves: C3H/HeN * C57BL/6N)
|
increased inflammatory response
|
J:73060
|
Bbaa17C3H/HeN/?
(involves: C3H/HeN * C57BL/6N)
|
increased inflammatory response
|
J:73060
|
Bbaa18C3H/HeN/?
(involves: C3H/HeN * C57BL/6N)
|
increased inflammatory response
|
J:73060
|
Bbaa19C3H/HeN/?
(involves: C3H/HeN * C57BL/6N)
|
increased IgG level
|
J:73060
|
Bbaa20C3H/HeJ/?
(involves: C3H/HeN * C57BL/6N)
|
increased inflammatory response
|
J:73060
|
Bbaa21C3H/HeN/?
(involves: C3H/HeN * C57BL/6N)
|
increased susceptibility to bacterial infection
|
J:73060
|
Bbaa22C3H/HeN/?
(involves: C3H/HeN * C57BL/6N)
|
increased inflammatory response
|
J:73060
|
Bbaa23C3H/HeN/?
(involves: C3H/HeN * C57BL/6N)
|
increased inflammatory response
|
J:73060
|
Bbc3tm1Ast/Bbc3tm1Ast
(involves: C57BL/6 * NZB)
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:132819
|
Bbs4Gt1Nk/Bbs4Gt1Nk
(involves: 129S7/SvEvBrd)
|
increased immunoglobulin level
|
J:134093
|
Bbs12tm1.1Vmar/Bbs12tm1.1Vmar
(involves: 129S6/SvEvTac * C57BL/6)
|
decreased circulating interleukin-6 level
|
J:189019
|
decreased circulating tumor necrosis factor level
|
J:189019
|
decreased inflammatory response
|
J:189019
|
Bbxtm1a(EUCOMM)Wtsi/Bbxtm1a(EUCOMM)Wtsi
(involves: C57BL/6 * C57BL/6N)
|
increased IgA level
|
J:213427
|
Bcap31tm1.1Bwang/Bcap31tm1.1Bwang Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased inflammatory response
|
J:292505
|
increased interleukin-1 beta secretion
|
J:292505
|
increased microglial cell activation
|
J:292505
|
increased tumor necrosis factor secretion
|
J:292505
|
Bcap31tm1.1Bwang/Bcap31tm1.1Bwang Tg(Lck-cre)548Jxm/0
(involves: C57BL/6 * CBA)
|
abnormal T cell activation
|
J:274469
|
decreased interferon-gamma secretion
|
J:274469
|
decreased interleukin-2 secretion
|
J:274469
|
decreased T cell proliferation
|
J:274469
|
increased thymocyte apoptosis
|
J:274469
|
Bcas1tm1Himo/Bcas1tm1Himo
(C57BL/6-Bcas1tm1Himo)
|
brain inflammation
|
J:242041
|
Bcat1tm1.2Eaa/Bcat1tm1.2Eaa
(involves: C57BL/6)
|
abnormal T cell physiology
|
J:216027
|
Bcl2tm1Dlo/Bcl2tm1Dlo
(B6.129P2-Bcl2tm1Dlo)
|
abnormal lymphocyte physiology
|
J:104487,
J:73316
|
increased B cell apoptosis
|
J:73316
|
increased splenocyte apoptosis
|
J:153846
|
increased T cell apoptosis
|
J:73316
|
Bcl2tm1Dlo/Bcl2tm1Dlo Bcl2l11tm1.1Ast/Bcl2l11+
(B6.129-Bcl2tm1Dlo Bcl2l11tm1.1Ast)
|
abnormal lymphocyte physiology
|
J:73316
|
increased T cell apoptosis
|
J:73316
|
Bcl2tm1Dlo/Bcl2tm1Dlo Bcl2l11tm1.1Ast/Bcl2l11tm1.1Ast
(B6.129-Bcl2tm1Dlo Bcl2l11tm1.1Ast)
|
abnormal lymphocyte physiology
|
J:73316
|
decreased B cell apoptosis
|
J:73316
|
increased T cell apoptosis
|
J:73316
|
Bcl2tm1Dlo/Bcl2tm1Dlo Bcl2l11tm3.1Boui/Bcl2l11tm3.1Boui
(B6.Cg-Bcl2tm1Dlo Bcl2l11tm3.1Boui)
|
decreased splenocyte apoptosis
|
J:153846
|
Bcl2tm1Dlo/Bcl2tm1Dlo Biktm1Ast/Biktm1Ast
(B6.Cg-Bcl2tm1Dlo Biktm1Ast)
|
abnormal lymphocyte physiology
|
J:104487
|
Bcl2tm1Irt/Bcl2tm1Irt Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased macrophage apoptosis
|
J:144243
|
Bcl2tm1Lbox/Bcl2tm1Lbox
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
abnormal B cell activation
|
J:114637
|
decreased B cell proliferation
|
J:114637
|
increased B cell apoptosis
|
J:114637
|
Bcl2tm1Sjk/Bcl2tm1Sjk
(involves: 129S2/SvPas * C57BL/6)
|
abnormal thymus involution
|
J:15224
|
increased T cell apoptosis
|
J:15224
|
Bcl2tm1Tsu/Bcl2tm1Tsu
(involves: 129P2/OlaHsd * ICR)
|
abnormal T cell physiology
|
J:22391
|
Bcl2tm2.1Lbox/Bcl2+
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
abnormal B cell physiology
|
J:175730
|
Bcl2tm2.1Lbox/Bcl2tm2.1Lbox
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
abnormal B cell physiology
|
J:175730
|
Bcl2a1atm1.1Tac/Bcl2a1atm1.1Tac Bcl2a1btm1.1Tac/Bcl2a1btm1.1Tac Bcl2a1dtm1.1Tac/Bcl2a1dtm1.1Tac
(involves: BALB/cJ * C57BL/6NTac)
|
abnormal dendritic cell physiology
|
J:258915
|
Bcl2a1atm1Prys/Bcl2a1atm1Prys
(involves: 129/Sv * C57BL/6J * SJL)
|
abnormal neutrophil physiology
|
J:74478
|
decreased inflammatory response
|
J:74478
|
decreased susceptibility to parasitic infection
|
J:74478
|
Bcl2a1atm1Sen/Bcl2a1atm1Sen
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal neutrophil physiology
|
J:52127
|
Bcl2l1tm1Cant/Bcl2l1tm1Cant
(involves: 129S6/SvEvTac)
|
abnormal memory T cell physiology
|
J:77507
|
abnormal T cell physiology
|
J:77507
|
decreased interleukin-2 secretion
|
J:77507
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:77507
|
decreased T cell proliferation
|
J:77507
|
Bcl2l1tm1Dlo/Bcl2l1tm1.1Mam Tg(Aicda-cre)9Mbu/0
(B6.Cg-Bcl2l1tm1Dlo/Bcl2l1tm1.1Mam Tg(Aicda-cre)9Mbu)
|
decreased IgG1 level
|
J:166069
|
Bcl2l11tm1.1Ast/Bcl2l11+
(involves: 129S1/Sv * C57BL/6)
|
abnormal lymphocyte physiology
|
J:58641
|
glomerulonephritis
|
J:58641
|
increased IgA level
|
J:58641
|
increased IgG level
|
J:58641
|
increased IgM level
|
J:58641
|
increased susceptibility to autoimmune disorder
|
J:58641
|
Bcl2l11tm1.1Ast/Bcl2l11tm1.1Ast
(involves: 129S1/Sv * C57BL/6)
|
abnormal B cell proliferation
|
J:90963
|
abnormal lymphocyte physiology
|
J:58641
|
decreased B cell apoptosis
|
J:90963
|
glomerulonephritis
|
J:58641
|
increased anti-double stranded DNA antibody level
|
J:132217
|
increased anti-histone antibody level
|
J:132217
|
increased anti-nuclear antigen antibody level
|
J:132217
|
increased anti-single stranded DNA antibody level
|
J:132217
|
increased autoantibody level
|
J:132217
|
increased IgA level
|
J:58641
|
increased IgG level
|
J:58641
|
increased IgM level
|
J:58641
|
increased inflammatory response
|
J:58641
|
increased susceptibility to autoimmune disorder
|
J:58641
|
Bcl2l11tm1.1Ast/Bcl2l11tm1.1Ast
(B6.129S1-Bcl2l11tm1.1Ast)
|
abnormal lymphocyte physiology
|
J:73316
|
abnormal response to infection
|
J:123409
|
decreased B cell apoptosis
|
J:73316
|
decreased T cell apoptosis
|
J:73316,
J:133084
|
Bcl2l11tm1.1Ast/Bcl2l11tm1.1Ast
(involves: 129S1/Sv)
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:132819
|
decreased splenocyte apoptosis
|
J:266833
|
decreased thymocyte apoptosis
|
J:266833
|
Bcl2l11tm1.1Ast/Bcl2l11tm1.1Ast
(B6.129S1-Bcl2l11tm1.1Ast/J)
|
decreased T cell apoptosis
|
J:153652
|
Bcl2l11tm1.1Ast/Bcl2l11tm1.1Ast Biktm1Ast/Biktm1Ast
(B6.Cg-Bcl2l11tm1.1Ast Biktm1Ast)
|
abnormal lymphocyte physiology
|
J:103605
|
Bcl2l11tm1.1Ast/Bcl2l11tm1.1Ast Bmftm1Rjd/Bmftm1Rjd
(B6.129S-Bcl2l11tm1.1Ast Bmftm1Rjd)
|
decreased T cell apoptosis
|
J:153652
|
Bcl2l11tm1.1Ast/Bcl2l11tm1.1Ast Faslpr/Faslpr
(B6.Cg-Bcl2l11tm1.1Ast Faslpr)
|
increased anti-double stranded DNA antibody level
|
J:132217
|
increased anti-histone antibody level
|
J:132217
|
increased anti-nuclear antigen antibody level
|
J:132217
|
increased anti-single stranded DNA antibody level
|
J:132217
|
increased autoantibody level
|
J:132217
|
increased susceptibility to autoimmune disorder
|
J:132217
|
Bcl2l11tm1.1Ast/Bcl2l11tm1.1Ast Mlf1tm1Swm/Mlf1tm1Swm
(involves: 129S1/Sv * C57BL/6)
|
decreased splenocyte apoptosis
|
J:266833
|
decreased thymocyte apoptosis
|
J:266833
|
Bcl2l11tm1Sjk/Bcl2l11tm1Sjk
(involves: 129X1/SvJ)
|
abnormal B cell physiology
|
J:100463
|
increased immunoglobulin level
|
J:100463
|
Bcl2l11tm3Rjd/Bcl2l11tm3Rjd
(B6.129S6-Bcl2l11tm3Rjd)
|
decreased thymocyte apoptosis
|
J:137061
|
Bcl2l14tm1.1Boui/Bcl2l14tm1.1Boui
(involves: C57BL/6)
|
abnormal susceptibility to induced colitis
|
J:296081
|
Bcl3m1Btlr/Bcl3m1Btlr
(C57BL/6J-Bcl3m1Btlr)
|
abnormal humoral immune response
|
J:255184
|
decreased IgE level
|
J:255184
|
decreased IgG level
|
J:255184
|
Bcl3m2Btlr/Bcl3m2Btlr
(C57BL/6J-Bcl3m2Btlr)
|
decreased IgD level
|
J:264818
|
increased IgM level
|
J:264818
|
Bcl3tm1Rsch/Bcl3tm1Rsch
(involves: 129P2/OlaHsd * CD-1)
|
abnormal cytokine secretion
|
J:116724
|
abnormal innate immunity
|
J:116724
|
increased susceptibility to bacterial infection
|
J:116724
|
Bcl3tm1Rsch/Bcl3tm1Rsch
(B6.Cg-Bcl3tm1Rsch)
|
abnormal cytokine secretion
|
J:116724
|
abnormal macrophage physiology
|
J:116724
|
Bcl3tm1Sbn/Bcl3tm1Sbn
(involves: 129S4/SvJae * C57BL/6)
|
abnormal class switch recombination
|
J:39747
|
abnormal cytotoxic T cell physiology
|
J:39747
|
decreased IgG2a level
|
J:39747
|
decreased interferon-gamma secretion
|
J:39747
|
decreased interleukin-12 secretion
|
J:39747
|
increased susceptibility to parasitic infection
|
J:39747
|
Bcl3tm1Sbn/Bcl3tm1Sbn
(involves: 129S4/SvJae)
|
abnormal B cell physiology
|
J:207111
|
decreased B cell proliferation
|
J:207111
|
increased B cell proliferation
|
J:207111
|
Bcl3tm1Ver/Bcl3tm1Ver
(involves: 129P2/OlaHsd * FVB/NJ)
|
abnormal humoral immune response
|
J:38092
|
increased susceptibility to bacterial infection
|
J:38092
|
Bcl6tm1.1Dent/Bcl6tm1.1Dent Tg(Cd4-cre)1Cwi/0
(involves: 129S/SvEv * C57BL/6 * DBA/2 * FVB/N)
|
decreased IgG level
|
J:202372
|
decreased interleukin-4 secretion
|
J:202372
|
increased interleukin-10 secretion
|
J:202372
|
Bcl6tm1.1Jwan/Bcl6tm1.1Jwan
(involves: 129S6/SvEvTac)
|
abnormal somatic hypermutation frequency
|
J:190534
|
Bcl6tm1.1Meln/Bcl6tm1.1Meln
(involves: 129 * C57BL/6 * FVB/N)
|
abnormal adaptive immunity
|
J:194821
|
abnormal germinal center B cell physiology
|
J:194821
|
abnormal professional antigen presenting cell physiology
|
J:194821
|
decreased IgG1 level
|
J:194821
|
decreased IgG2a level
|
J:194821
|
decreased IgG level
|
J:194821
|
Bcl6tm1.1Mtto/Bcl6tm1.1Mtto Cd79atm1(cre)Reth/Cd79a+
(involves: BALB/c * C57BL/6 * C57BL/6JJcl)
|
abnormal humoral immune response
|
J:190943
|
abnormal memory B cell physiology
|
J:190943
|
abnormal somatic hypermutation frequency
|
J:190943
|
Bcl6tm1.1Mtto/Bcl6tm1.1Mtto Tg(Cd4-cre)1Cwi/0
(involves: C57BL/6 * C57BL/6JJcl * DBA/2)
|
abnormal humoral immune response
|
J:190943
|
abnormal somatic hypermutation frequency
|
J:190943
|
Bcl6tm1.1Toka/Bcl6+ Tg(TcraTcrb)425Cbn/0
(involves: BALB/c * C57BL/6 * NZB)
|
decreased T cell proliferation
|
J:174014
|
Bcl6tm1.1Toka/Bcl6tm1.1Toka Tg(IghelMD4)4Ccg/0
(involves: C57BL/6 * NZB)
|
abnormal germinal center B cell physiology
|
J:174014
|
increased activation-induced B cell apoptosis
|
J:174014
|
Bcl6tm1Gdba/Bcl6tm1Gdba Tg(Adipoq-cre)1Evdr/0
(involves: C57BL/6 * FVB/NJ)
|
white adipose tissue inflammation
|
J:271078
|
Bcl6tm1Htno/Bcl6tm1Htno
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
lung inflammation
|
J:55952
|
myocarditis
|
J:55952
|
Bcl6tm1Rdf/Bcl6tm1Rdf
(involves: 129S1/Sv)
|
abnormal B cell physiology
|
J:40769
|
abnormal humoral immune response
|
J:40769
|
abnormal immune system physiology
|
J:40769
|
abnormal T-helper 2 physiology
|
J:40769
|
decreased IgG level
|
J:40769
|
decreased IgM level
|
J:40769
|
heart inflammation
|
J:40769
|
increased inflammatory response
|
J:40769
|
increased susceptibility to bacterial infection
|
J:40769
|
liver inflammation
|
J:40769
|
lung inflammation
|
J:40769
|
Bcl6tm1Sdt/Bcl6tm1Sdt
(involves: 129/Sv * C57BL/6)
|
abnormal chemokine level
|
J:123621
|
abnormal immune system physiology
|
J:123621
|
Bcl6tm1Sdt/Bcl6tm1Sdt Bcl6btm2Dent/Bcl6btm2Dent
(involves: 129/Sv * C57BL/6)
|
abnormal immune system physiology
|
J:123621
|
Bcl6tm2Rdf/Bcl6tm2Rdf
(involves: 129S1/Sv)
|
abnormal B cell physiology
|
J:40769
|
abnormal humoral immune response
|
J:40769
|
abnormal immune system physiology
|
J:40769
|
abnormal T-helper 2 physiology
|
J:40769
|
decreased B cell proliferation
|
J:40769
|
decreased IgG level
|
J:40769
|
decreased IgM level
|
J:40769
|
heart inflammation
|
J:40769
|
increased inflammatory response
|
J:40769
|
increased susceptibility to bacterial infection
|
J:40769
|
liver inflammation
|
J:40769
|
lung inflammation
|
J:40769
|
Bcl6btm1Dtf/Bcl6btm1Dtf
(involves: 129P2/OlaHsd)
|
abnormal response to infection
|
J:99818
|
decreased T cell proliferation
|
J:99818
|
Bcl10m1Btlr/Bcl10m1Btlr
(C57BL/6J-Bcl10m1Btlr)
|
abnormal humoral immune response
|
J:265122
|
decreased IgG level
|
J:265122
|
increased IgE level
|
J:265122
|
increased IgM level
|
J:265122
|
Bcl10tm1Mak/Bcl10tm1Mak
(involves: 129P2/OlaHsd)
|
abnormal cytotoxic T cell physiology
|
J:67297
|
abnormal dendritic cell physiology
|
J:111706
|
abnormal immune cell physiology
|
J:67297
|
abnormal response to infection
|
J:67297
|
abnormal T cell activation
|
J:67297
|
decreased B cell proliferation
|
J:109545,
J:67297
|
decreased IgG level
|
J:67297
|
decreased IgM level
|
J:67297
|
decreased immunoglobulin level
|
J:67297
|
decreased T cell proliferation
|
J:109545,
J:67297
|
increased susceptibility to infection
|
J:67297
|
Bcl10tm1Swm/Bcl10tm1Swm
(involves: 129P2/OlaHsd)
|
abnormal humoral immune response
|
J:85147
|
abnormal marginal zone B cell physiology
|
J:85147
|
decreased B cell proliferation
|
J:85147
|
increased susceptibility to bacterial infection
|
J:85147
|
Bcl10tm1Swm/Bcl10tm1Swm
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal cytokine secretion
|
J:122394
|
abnormal dendritic cell physiology
|
J:122394
|
Bcl11atm1Pwt/Bcl11atm1Pwt Commd10Tg(Vav1-icre)A2Kio/Commd10+
(involves: C57BL/6 * C57BL/10 * CBA/Ca)
|
decreased circulating interferon-alpha level
|
J:207383
|
Bcl11atm2.1Peli/Bcl11atm2.1Peli Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
(involves: 129P2/OlaHsd * 129S1/Sv)
|
increased B cell apoptosis
|
J:194616
|
Bcl11btm1Avram/Bcl11btm1Avram Tg(Cd4-cre)1Cwi/?
(involves: 129 * C57BL/6 * DBA/2)
|
abnormal thymocyte activation
|
J:128515
|
Bcl11btm1Jpk/Bcl11btm1Jpk
(involves: BALB/c * C57BL/6 * CBA)
|
increased thymocyte apoptosis
|
J:83651
|
Bclaf1tm1Raz/Bclaf1+
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased T cell proliferation
|
J:158087
|
Bclaf1tm1Raz/Bclaf1tm1Raz
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased T cell proliferation
|
J:158087
|
Bcrtm1Hkp/Bcrtm1Hkp
(involves: 129S2/SvPas)
|
abnormal neutrophil physiology
|
J:23804
|
increased susceptibility to endotoxin shock
|
J:23804
|
sepsis
|
J:23804
|
Bcs1ltm1.1Levp/Bcs1ltm1.1Levp
(B6.129-Bcs1ltm1.1Levp)
|
liver inflammation
|
J:273501
|
Bdkrb1tm1Bdr/Bdkrb1tm1Bdr
(involves: 129P2/OlaHsd)
|
abnormal acute inflammation
|
J:63271
|
decreased susceptibility to endotoxin shock
|
J:135789
|
Bdkrb1tm2Bdr/Bdkrb1tm2Bdr Bdkrb2tm1Jfh/Bdkrb2tm1Jfh
(involves: 129S7/SvEvBrd * C57BL/6)
|
decreased susceptibility to endotoxin shock
|
J:135789
|
Becn1tm1.1Bflu/Becn1tm1.1Bflu Tg(Cd4-cre)1Cwi/0
(involves: 129S1/Sv * C57BL/6 * DBA/2)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:203090
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:203090
|
decreased T cell proliferation
|
J:203090
|
increased T cell apoptosis
|
J:203090
|
Becn1tm1Ebr/Becn1tm1Ebr Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd)
|
abnormal circulating chemokine level
|
J:235399
|
abnormal macrophage physiology
|
J:235399
|
decreased circulating interleukin-10 level
|
J:235399
|
glomerulonephritis
|
J:235399
|
increased anti-double stranded DNA antibody level
|
J:235399
|
increased anti-nuclear antigen antibody level
|
J:235399
|
increased autoantibody level
|
J:235399
|
increased circulating interleukin-1 beta level
|
J:235399
|
increased circulating interleukin-6 level
|
J:235399
|
increased circulating interleukin-12b level
|
J:235399
|
increased IgG level
|
J:235399
|
increased susceptibility to systemic lupus erythematosus
|
J:235399
|
Becn1tm1Smoc/Becn1tm1Smoc Foxp3tm4(YFP/icre)Ayr/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal regulatory T cell physiology
|
J:306129
|
Becn1tm1Smoc/Becn1tm1Smoc Zfp91tm1Smoc/Zfp91tm1Smoc Foxp3tm4(YFP/icre)Ayr/Y
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal regulatory T cell physiology
|
J:306129
|
Belr1BALB/cJ/Belr1BALB/cJ
(involves: BALB/cJ * C57BL/6J)
|
decreased susceptibility to parasitic infection
|
J:133125
|
Belr1BALB/cJ/Belr1BALB/cJ
(B6.C-H2d/bByJ)
|
decreased susceptibility to parasitic infection
|
J:133125
|
Berr1WLA/Pas/?
(involves: C57BL/6JRj * WLA/Pas)
|
decreased susceptibility to parasitic infection
|
J:78027
|
Berr2WLA/Pas/?
(involves: C57BL/6JRj * WLA/Pas)
|
decreased susceptibility to parasitic infection
|
J:78027
|
Best3tm1.1Zhoj/Best3tm1.1Zhoj Tg(Tagln-cre)1Her/0
(involves: C57BL/6 * SJL)
|
aortitis
|
J:338981
|
Bgntm1Mfy/Y
(involves: 129S4/SvJae * C57BL/6)
|
osteoarthritis
|
J:76203
|
Bgntm1Mfy/Y Fmodtm1Aol/Fmodtm1Aol
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6)
|
osteoarthritis
|
J:76203
|
Bgntm1Mfy/Y Fmodtm1Aol/Fmodtm1Aol
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
|
accelerated temporomandibular joint osteoarthritis
|
J:112779,
J:117908
|
Bgntm1Mfy/Bgntm1Mfy
(involves: 129S4/SvJae)
|
osteoarthritis
|
J:222369
|
Bgntm1Mfy/Bgntm1Mfy Epyctm1Mhok/Epyctm1Mhok
(involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6J)
|
osteoarthritis
|
J:222369
|
Bgntm1Mfy/Bgntm1Mfy Fmodtm1Aol/Fmodtm1Aol
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
|
accelerated temporomandibular joint osteoarthritis
|
J:117908
|
bhe/bhe
(Not Specified)
|
chronic inflammation
|
J:85113
|
Bhlhe40tm1Tan/Bhlhe40tm1Tan
(either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:72651
|
abnormal immune system physiology
|
J:72651
|
abnormal susceptibility to autoimmune disorder
|
J:72651
|
abnormal T cell activation
|
J:72651
|
decreased interleukin-2 secretion
|
J:72651
|
decreased T cell proliferation
|
J:72651
|
increased anti-nuclear antigen antibody level
|
J:72651
|
increased IgE level
|
J:72651
|
increased IgG1 level
|
J:72651
|
Bhlhe41tm1.2Cdon/Bhlhe41tm1.2Cdon
(B6.129S6-Bhlhe41tm1.2Cdon)
|
decreased interferon-gamma secretion
|
J:157740
|
decreased interleukin-2 secretion
|
J:157740
|
decreased interleukin-5 secretion
|
J:157740
|
decreased interleukin-13 secretion
|
J:157740
|
decreased T cell proliferation
|
J:157740
|
increased interleukin-4 secretion
|
J:157740
|
increased interleukin-17 secretion
|
J:157740
|
Bidtm1Sjk/Bidtm1Sjk
(involves: 129X1/SvJ * C57BL/6)
|
decreased susceptibility to endotoxin shock
|
J:117693
|
Bin1tm1Gcp/Bin1tm2Gcp Tg(Wap-cre)11738Mam/0
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N * SJL)
|
endometrium inflammation
|
J:117330
|
Bin3tm1Gcp/Bin3tm1Gcp
(involves: 129 * C57BL/6)
|
liver inflammation
|
J:133313
|
lung inflammation
|
J:133313
|
Birc2tm1Rbr/Birc2tm1Rbr Birc3tm1.1Rbr/Birc3tm1.1Rbr Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * C57BL/6 * NZB)
|
decreased B cell apoptosis
|
J:172843
|
Birc2tm2.1Jda/Birc2tm2.1Jda
(B6.Cg-Birc2tm2.1Jda)
|
increased interferon-gamma secretion
|
J:199221
|
increased T cell proliferation
|
J:199221
|
Birc3tm1Jda/Birc3tm1Jda
(B6.Cg-Birc3tm1Jda)
|
decreased B cell apoptosis
|
J:166899
|
decreased IgG1 level
|
J:166899
|
increased B cell proliferation
|
J:166899
|
increased IgA level
|
J:166899
|
increased IgG3 level
|
J:166899
|
increased IgM level
|
J:166899
|
Birc3tm1Jda/Birc3tm1Jda
(involves: 129 * C57BL/6)
|
increased interferon-gamma secretion
|
J:199221
|
increased T cell proliferation
|
J:199221
|
Birc3tm1Rgk/Birc3tm1Rgk
(B6.129X1-Birc3tm1Rgk)
|
abnormal cytokine secretion
|
J:144012
|
abnormal immune cell physiology
|
J:144012
|
abnormal interleukin-1 beta secretion
|
J:144012
|
abnormal interleukin-12 secretion
|
J:144012
|
abnormal macrophage physiology
|
J:144012
|
abnormal T cell physiology
|
J:144012
|
abnormal tumor necrosis factor secretion
|
J:144012
|
decreased susceptibility to endotoxin shock
|
J:144012
|
Birc5tm1Mak/Birc5tm1Mak Tg(Lck-cre)I57Jxm/0
(involves: 129P2/OlaHsd)
|
increased T cell apoptosis
|
J:90892
|
Birc6tm1Nai/Birc6tm1Nai
(involves: 129S4/SvJae * C57BL/6J)
|
increased thymocyte apoptosis
|
J:96768
|
Bld/Bld+
(involves: BALB/cCi)
|
increased incidence of corneal inflammation
|
J:5076
|
Blkm1Btlr/Blkm1Btlr
(C57BL/6J-Blkm1Btlr)
|
increased IgE level
|
J:255004
|
increased interleukin-1 beta secretion
|
J:255004
|
Blmtm3Brd/Blmtm3Brd
(involves: 129S7/SvEvBrd * C57BL/6)
|
decreased IgM level
|
J:66261
|
Blmtm4Ches/Blmtm4Ches Cd19tm1(cre)Cgn/Cd19+ Nsmce2tm2.1Ofc/Nsmce2tm2.1Ofc
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * SJL)
|
abnormal B cell physiology
|
J:227197
|
Blmtm4Ches/Blmtm4Ches Trp53bp1tm1Jc/Trp53bp1tm1Jc Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * 129S6/SvEvTac)
|
abnormal class switch recombination
|
J:194603
|
Blmhtm1Geh/Blmhtm1Geh
(either: (involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J))
|
dermatitis
|
J:54585
|
Blnkm1Btlr/Blnkm1Btlr
(C57BL/6J-Blnkm1Btlr)
|
decreased IgG level
|
J:159439
|
decreased IgM level
|
J:159439
|
Blnkm1Btlr/Blnkm1Btlr
(involves: C57BL/6J)
|
decreased IgM level
|
J:185495
|
Blnktm1Achn/Blnk+
(involves: 129S4/SvJae * 129X1/SvJ * BALB/c * C3H * C57BL/6)
|
decreased B cell proliferation
|
J:82430
|
Blnktm1Achn/Blnk+ Btktm1Wk/Btktm1Wk Tg(IGH-Btk)1Witt/0
(involves: 129S4/SvJae * 129X1/SvJ * BALB/c * C3H * C57BL/6)
|
abnormal B cell physiology
|
J:82430
|
decreased B cell proliferation
|
J:82430
|
Blnktm1Achn/Blnktm1Achn
(involves: 129X1/SvJ)
|
decreased immunoglobulin level
|
J:58805
|
Blnktm1Dkit/Blnktm1Dkit
(involves: C57BL/6)
|
abnormal B cell apoptosis
|
J:143854
|
decreased IgG3 level
|
J:143854
|
decreased IgM level
|
J:143854
|
increased anti-double stranded DNA antibody level
|
J:94297
|
increased B cell apoptosis
|
J:143854
|
Blnktm1Dkit/Blnktm1Dkit Prkcdtm1Kin/Prkcdtm1Kin
(involves: 129P2/OlaHsd * C57BL/6 * NZB)
|
abnormal B cell proliferation
|
J:143854
|
abnormal immunoglobulin level
|
J:143854
|
increased B cell apoptosis
|
J:143854
|
increased IgA level
|
J:143854
|
increased IgG1 level
|
J:143854
|
increased IgG2b level
|
J:143854
|
increased IgG3 level
|
J:143854
|
increased IgM level
|
J:143854
|
Blnktm1Kplm/Blnktm1Kplm
(involves: 129P2/OlaHsd)
|
abnormal B cell activation
|
J:61130,
J:131161
|
decreased B cell proliferation
|
J:61130
|
increased B cell apoptosis
|
J:131161
|
Blnktm1Kplm/Blnktm1Kplm Plcg2tm1.1Kuro/Plcg2+
(involves: 129P2/OlaHsd)
|
abnormal B cell activation
|
J:131161
|
increased B cell apoptosis
|
J:131161
|
Blnktm1Kplm/Blnktm1Kplm Plcg2tm1.1Kuro/Plcg2tm1.1Kuro
(involves: 129P2/OlaHsd)
|
increased B cell apoptosis
|
J:131161
|
Blnktm1Pjln/Blnktm1Pjln
(involves: BALB/c)
|
decreased IgG3 level
|
J:58740
|
decreased IgM level
|
J:58740
|
Blnktm1Pjln/Blnktm1Pjln Btktm1Gsv/Y
(involves: 129P2/OlaHsd * BALB/c * C57BL/6)
|
decreased IgG3 level
|
J:94768
|
decreased IgM level
|
J:94768
|
decreased immunoglobulin level
|
J:94768
|
Blnktm1Pjln/Blnktm1Pjln Btktm1Gsv/Y Tg(CD19-BTK*K430R)XK24Rwhe/?
(involves: 129P2/OlaHsd * BALB/c * C57BL/6 * FVB)
|
decreased IgG3 level
|
J:94768
|
decreased IgM level
|
J:94768
|
decreased immunoglobulin level
|
J:94768
|
Bloc1s3rp/Bloc1s3rp
(involves: C57BL/10ScSn * C57BL/Tb)
|
abnormal NK cell physiology
|
J:6801
|
Bloc1s6pa/Bloc1s6pa
(B6.Cg-Bloc1s6pa/J)
|
abnormal NK cell physiology
|
J:6801
|
lung inflammation
|
J:4098
|
Bmal1em1Bwu/Bmal1em1Bwu
(C57BL/6-Bmal1em1Bwu)
|
abnormal macrophage physiology
|
J:340220
|
Bmal1tm1Bra/Bmal1tm1Bra
(B6.129-Bmal1tm1Bra)
|
impaired leukocyte tethering or rolling
|
J:191844
|
increased circulating fibrinogen level
|
J:191844
|
increased incidence of corneal inflammation
|
J:110697
|
Bmal1tm1Bra/Bmal1tm1Bra
(involves: 129/Sv * C57BL/6)
|
decreased IgG1 level
|
J:118522
|
Bmftm1.1Ast/Bmftm1.1Ast
(B6.Cg-Bmftm1.1Anst)
|
decreased B cell apoptosis
|
J:133084
|
decreased T cell apoptosis
|
J:133084
|
increased immunoglobulin level
|
J:133084
|
Bmftm1Rjd/Bmftm1Rjd
(B6.129S6-Bmftm1Rjd)
|
decreased T cell apoptosis
|
J:153652
|
Bmgr2C57BL/6J/? Prf1tm1Sdz/Prf1tm1Sdz
(involves: 129S6/SvEvTac * C57BL/6J)
|
abnormal response to transplant
|
J:116666
|
Bmgr3129S6/SvEvTac/Bmgr3129S6/SvEvTac Prf1tm1Sdz/Prf1tm1Sdz
(involves: 129S6/SvEvTac * C57BL/6J)
|
abnormal response to transplant
|
J:116666
|
Bmgr4C57BL/6J/? Ebmgr1129S6/SvEvTac/Ebmgr1129S6/SvEvTac Prf1tm1Sdz/Prf1tm1Sdz
(involves: 129S6/SvEvTac * C57BL/6J)
|
abnormal response to transplant
|
J:116666
|
Bmgr4C57BL/6J/? Prf1tm1Sdz/Prf1tm1Sdz
(involves: 129S6/SvEvTac * C57BL/6J)
|
abnormal response to transplant
|
J:116666
|
Bmi1tm1Brn/Bmi1tm1Brn
(either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * FVB))
|
abnormal thymus involution
|
J:17712
|
decreased IgM level
|
J:17712
|
decreased splenocyte proliferation
|
J:17712
|
lung inflammation
|
J:17712
|
Bmp5se-Ca/Bmp5+
(SEACGn.CB-Bmp5se-Ca)
|
granulomatous inflammation
|
J:5086
|
Bmp5se-Ca/Bmp5se-Ca
(CBA/Ca-Bmp5se-Ca)
|
granulomatous inflammation
|
J:5086
|
Bmp5se-Ca/Bmp5se-Ca
(SEACGn.CB-Bmp5se-Ca)
|
granulomatous inflammation
|
J:5086
|
Bmp5se/Bmp5se
(SEC/1Gn)
|
granulomatous inflammation
|
J:5086
|
Bmp5se/Bmp5se
(SEAC/Gn)
|
granulomatous inflammation
|
J:5086
|
Bmp7tm1.1Dgra/Bmp7tm1.1Dgra Tg(Prrx1-cre)1Cjt/0
(involves: 129S6/SvEvTac * C57BL/6J * C57BL/6NTac * SJL/J)
|
joint inflammation
|
J:221175
|
osteoarthritis
|
J:221175
|
Bmp7tm1Rob/Bmp7+ Bmp8atm1Blh/Bmp8atm1Blh
(involves: 129S/SvEv * 129S6/SvEvTac * Black Swiss * C57BL/6)
|
granulomatous inflammation
|
J:78867
|
Bmp8atm1Blh/Bmp8a+ Bmp8btm1Blh/Bmp8b+
(involves: 129/Sv * 129S6/SvEvTac * Black Swiss)
|
granulomatous inflammation
|
J:46927
|
Bmp8atm1Blh/Bmp8atm1Blh
(involves: 129S6/SvEvTac * Black Swiss)
|
granulomatous inflammation
|
J:46927
|
Bmpr1atm2.1Bhr/Bmpr1atm2.1Bhr Tg(CAG-cre/Esr1*)5Amc/0
(involves: 129S7/SvEvBrd * C57BL/6 * CBA)
|
stomach inflammation
|
J:163367
|
Bmpr1atm2.1Bhr/Bmpr1atm2.1Bhr Tg(Col1a1-cre/Esr1*)1Mis/0
(involves: 129S7/SvEvBrd)
|
abnormal osteoclast physiology
|
J:143588
|
Bmpr1atm2.1Bhr/Bmpr1atm2.2Bhr Tg(Gdf5-cre,-ALPP)1Kng/0
(involves: 129 * C57BL/6 * FVB/N-Tg(Gdf5-cre-ALPP)1Kng)
|
osteoarthritis
|
J:97780
|
Bmpr2tm1Kmi/Bmpr2+
(involves: 129S4/SvJae * C57BL/6J)
|
abnormal leukocyte physiology
|
J:117167
|
Bmxtm1Ali/Bmxtm1Ali
(involves: 129S1/Sv * 129X1/SvJ)
|
decreased susceptibility to induced arthritis
|
J:173099
|
Bod1lem1Bltn/Bod1lem1Bltn Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * C57BL/6J)
|
decreased IgG1 level
|
J:337726
|
decreased IgG level
|
J:337726
|
Bod1lem1Bltn/Bod1lem1Bltn Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
(involves: C57BL/6J * C57BL/6NTac)
|
abnormal class switch recombination
|
J:337726
|
decreased IgG1 level
|
J:337726
|
Bpgmm1Pgrs/Bpgmm1Pgrs
(involves: C57BL/6 * C57BL/10J)
|
decreased susceptibility to parasitic infection induced morbidity/mortality
|
J:301620
|
Bpgmm1Pgrs/Bpgmm1Pgrs
(involves: A/J)
|
decreased susceptibility to parasitic infection induced morbidity/mortality
|
J:301620
|
Bpitm1.1Buls/Bpitm1.1Buls
(involves: BALB/cJ * C57BL/6J)
|
abnormal circulating interleukin level
|
J:346703
|
abnormal immune cell physiology
|
J:346703
|
abnormal interleukin secretion
|
J:346703
|
decreased circulating interferon-gamma level
|
J:346703
|
increased susceptibility to induced colitis
|
J:346703
|
Bpifa1m1Ingm/Bpifa1m1Ingm
(involves: C3HeB/FeJ)
|
increased interleukin-1 alpha secretion
|
J:195535
|
increased interleukin-1 beta secretion
|
J:195535
|
increased susceptibility to bacterial infection
|
J:195535
|
increased susceptibility to otitis media
|
J:221346
|
increased tumor necrosis factor secretion
|
J:195535
|
lung inflammation
|
J:195535
|
Bpifa1tm1(KOMP)Vlcg/Bpifa1tm1(KOMP)Vlcg
(involves: C57BL/6J * C57BL/6NTac)
|
increased susceptibility to bacterial infection
|
J:171589
|
Bpifa1tm1.1Jpst/Bpifa1tm1.1Jpst Scgb1a1tm1(cre/ERT)Blh/Scgb1a1tm1(cre/ERT)Blh
(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * SJL)
|
increased susceptibility to Orthomyxoviridae infection
|
J:265391
|
increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality
|
J:265391
|
Bpifa1tm1.2Jpst/Bpifa1tm1.2Jpst
(involves: BALB/cJ * C57BL/6 * C57BL/6J * SJL)
|
increased susceptibility to Orthomyxoviridae infection
|
J:265391
|
increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality
|
J:265391
|
Bptfem1Zfa/Bptfem1Zfa Tg(Rorc-cre)1Litt/0
(involves: C57BL/6 * FVB)
|
increased susceptibility to bacterial infection
|
J:259392
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:259392
|
Braftm1Bbd/Braf+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
|
abnormal immune system physiology
|
J:170095
|
increased splenocyte apoptosis
|
J:170095
|
increased thymocyte apoptosis
|
J:170095
|
Braftm1Bbd/Braf+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * CD-1)
|
abnormal immune system physiology
|
J:170095
|
increased splenocyte apoptosis
|
J:170095
|
increased thymocyte apoptosis
|
J:170095
|
Braftm1Bbd/Braf+
(B6.129-Braftm1Bbd)
|
abnormal immune system physiology
|
J:170095
|
increased splenocyte apoptosis
|
J:170095
|
increased thymocyte apoptosis
|
J:170095
|
Braftm1Mmcm/Braftm1Mmcm Cd207tm2.1(cre)Bjec/Cd207+
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
liver inflammation
|
J:211690
|
lung inflammation
|
J:211690
|
Braftm1Mmcm/Braftm1Mmcm Tg(Itgax-cre)1-1Reiz/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
cytokine storm
|
J:211690
|
granulomatous inflammation
|
J:211690
|
increased inflammatory response
|
J:211690
|
Brca1tm2.1Cxd/Brca1tm2.1Cxd Shld1em1Nus/Shld1em1Nus
(involves: 129S6/SvEvTac * C57BL/6NCrl)
|
abnormal class switch recombination
|
J:307190
|
Brca1tm2.1Cxd/Brca1tm2.1Cxd Trp53bp1tm1Jc/Trp53bp1tm1Jc
(involves: 129 * 129S6/SvEvTac)
|
abnormal class switch recombination
|
J:307190
|
Brca1tm2Mak/Brca1tm2Mak Tg(Lck-cre)548Jxm/?
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
decreased T cell proliferation
|
J:63282
|
Brca1tm2Mak/Brca1tm2Mak Tg(Lck-cre)548Jxm/? Tg(TcrLCMV)327Sdz/?
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
decreased T cell proliferation
|
J:63282
|
Brca1tm5.1Cxd/Brca1tm5.1Cxd
(involves: 129S6/SvEvTac * FVB/N)
|
dermatitis
|
J:155810
|
Brca2tm1Hst/Brca2tm1Hst
(involves: 129S7/SvEvBrd * C57BL/6)
|
sepsis
|
J:82434
|
Brca2tm1Mak/Brca2tm2Mak Tg(Lck-cre)548Jxm/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
increased T cell apoptosis
|
J:79697
|
Brd2em1(IMPC)Wtsi/Brd2em1(IMPC)Wtsi
(C57BL/6N-Brd2em1(IMPC)Wtsi/WtsiIeg)
|
blood in lymph vessels
|
J:239583
|
Brd2Gt(RRT234)Byg/Brd2+
(B6.129P2-Brd2Gt(RRT234)Byg)
|
increased circulating interleukin-1 beta level
|
J:159964
|
increased circulating tumor necrosis factor level
|
J:159964
|
Brf1tm1Arte/Brf1tm1Arte Tg(Cyp1a1-cre)1Dwi/0
(involves: C57BL/6 * CBA)
|
liver inflammation
|
J:285667
|
Bsgtm1.1Znc/Bsgtm1.1Znc Tg(Lck-cre)19Hhan/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA)
|
abnormal T cell activation
|
J:207886
|
increased T cell proliferation
|
J:207886
|
Bsgtm1Tmu/Bsgtm1Tmu
(involves: 129S2/SvPas * C57BL/6J)
|
interstitial pneumonia
|
J:46376
|
Bsgtm1Tmu/Bsgtm1Tmu
(involves: 129/Sv * 129S2/SvPas)
|
interstitial pneumonia
|
J:46376
|
Bsgtm1Tmu/Bsgtm1Tmu
(involves: 129S2/SvPas)
|
decreased circulating complement protein level
|
J:287636
|
glomerulonephritis
|
J:287636
|
increased susceptibility to systemic lupus erythematosus
|
J:287636
|
Bst1tm1Thir/Bst1tm1Thir
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal B cell physiology
|
J:111424
|
abnormal humoral immune response
|
J:111424
|
decreased IgA level
|
J:111424
|
decreased IgG3 level
|
J:111424
|
Bst2tm1.1Bsz/Bst2tm1.1Bsz
(involves: C57BL/6)
|
increased susceptibility to Retroviridae infection
|
J:180252
|
Btbd8em1Lych/Btbd8em1Lych
(involves: C57BL/6)
|
decreased macrophage cytokine production
|
J:349252
|
decreased susceptibility to induced colitis
|
J:349252
|
Btkm2Anu/Btkm2Anu
(C57BL/6NCrlAnu-Btkm2Anu)
|
increased IgM level
|
J:104190
|
Btktm1Gsv/Y
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal B cell calcium ion homeostasis
|
J:94768
|
abnormal humoral immune response
|
J:120989
|
abnormal immune system physiology
|
J:35769
|
decreased IgG3 level
|
J:35769
|
decreased IgM level
|
J:35769
|
decreased immunoglobulin level
|
J:120989
|
Btktm1Gsv/Y Tg(CD19-BTK*K430R)XK24Rwhe/?
(involves: 129P2/OlaHsd * C57BL/6 * FVB)
|
decreased B cell apoptosis
|
J:120989
|
decreased immunoglobulin level
|
J:120989
|
Btktm1Wk/Btktm1Wk
(involves: 129S4/SvJae * C57BL/6)
|
abnormal B cell activation
|
J:28968
|
decreased B cell proliferation
|
J:82298
|
decreased IgG3 level
|
J:28968,
J:82298
|
decreased IgM level
|
J:28968,
J:82298
|
Btktm1Wk/Btktm1Wk Cd40tm1Geha/Cd40tm1Geha
(involves: 129S4/SvJae * C57BL/6)
|
abnormal humoral immune response
|
J:82298
|
decreased B cell proliferation
|
J:82298
|
decreased IgA level
|
J:82298
|
decreased IgG2a level
|
J:82298
|
decreased IgG2b level
|
J:82298
|
decreased IgG3 level
|
J:82298
|
decreased IgM level
|
J:82298
|
Btktm1Wk/Btktm1Wk Tectm1Welm/Tectm1Welm
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal humoral immune response
|
J:66080
|
decreased B cell proliferation
|
J:66080
|
decreased IgG2a level
|
J:66080
|
decreased IgG3 level
|
J:66080
|
decreased IgM level
|
J:66080
|
decreased immunoglobulin level
|
J:66080
|
Btktm1Wk/Btktm1Wk Tg(IGH-Btk)1Witt/0
(involves: 129S4/SvJae * 129X1/SvJ * BALB/c * C3H * C57BL/6)
|
decreased B cell proliferation
|
J:82430
|
Btkvila/Btkvila
(C57BL/6JAnu-Btkvila/AnuApb)
|
decreased IgD level
|
J:104190
|
increased IgE level
|
J:104190
|
increased IgG level
|
J:104190
|
Btkxid/Y
(CBA/HN-Btkxid)
|
decreased B cell proliferation
|
J:81429
|
Btkxid/Y
(involves: CBA/HN * DBA/2N)
|
decreased B cell proliferation
|
J:81429
|
Btkxid/?
(involves: BALB/c * CBA/N)
|
decreased B cell proliferation
|
J:108696
|
decreased IgG3 level
|
J:108696
|
decreased IgM level
|
J:108696
|
Btkxid/? Ptpn6me/Ptpn6me
(involves: C57BL/6J * CBA/N * NFS)
|
increased autoantibody level
|
J:30994
|
increased IgM level
|
J:30994
|
increased splenocyte proliferation
|
J:30994
|
Btkxid/? Tg(IGH-Btk)1Witt/0
(involves: BALB/c * C3H * C57BL/6 * CBA/N)
|
decreased B cell proliferation
|
J:108696
|
decreased IgG3 level
|
J:108696
|
decreased IgM level
|
J:108696
|
Btkxid/? Tg(IGH-Btk)1Witt/Tg(IGH-Btk)1Witt
(involves: BALB/c * C3H * C57BL/6 * CBA/N)
|
decreased B cell proliferation
|
J:108696
|
decreased IgG3 level
|
J:108696
|
decreased IgM level
|
J:108696
|
Btkxid/Btkxid
(CBA/CaHN-Btkxid/J)
|
abnormal macrophage physiology
|
J:92639
|
abnormal neutrophil physiology
|
J:92639
|
decreased acute inflammation
|
J:92639
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:92639
|
impaired neutrophil phagocytosis
|
J:92639
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:128518
|
increased susceptibility to induced colitis
|
J:92639
|
Btkxid/Btkxid
(involves: CBA/HN * DBA/2N)
|
abnormal B cell physiology
|
J:81429
|
abnormal B cell proliferation
|
J:81429
|
Btkxid/Btkxid
(CBA/HN-Btkxid)
|
autoimmune response
|
J:125114
|
decreased B cell proliferation
|
J:81429
|
Btlatm1Dgra/Btlatm1Dgra
(involves: C57BL/6)
|
abnormal peripheral T cell anergy
|
J:147751
|
abnormal T cell activation
|
J:147751
|
Btlatm1Dgra/Btlatm1Dgra Tg(TcraTcrb)425Cbn/?
(involves: C57BL/6)
|
abnormal peripheral T cell anergy
|
J:147751
|
Btlatm1Dgra/Btlatm1Dgra Tg(TcraTcrb)1100Mjb/?
(involves: C57BL/6)
|
abnormal peripheral T cell anergy
|
J:147751
|
Btlatm1Kay/Btlatm1Kay
(involves: 129S6/SvEvTac * C57BL/6J)
|
abnormal T cell activation
|
J:89864
|
Btlatm1Kmm/Btlatm1Kmm
(involves: 129S/SvEv)
|
abnormal humoral immune response
|
J:84084
|
increased B cell proliferation
|
J:84084
|
increased IgG1 level
|
J:84084
|
increased IgG2a level
|
J:84084
|
increased IgG2b level
|
J:84084
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:84084
|
increased T cell proliferation
|
J:84084
|
Btlatm1Kmm/Btlatm1Kmm
(B6.129S-Btlatm1Kmm)
|
abnormal T cell activation
|
J:119356
|
decreased interferon-gamma secretion
|
J:119356
|
decreased interleukin-2 secretion
|
J:119356
|
decreased T cell proliferation
|
J:119356
|
increased length of allograft survival
|
J:119356
|
increased T cell proliferation
|
J:119356
|
Btlatm1Kmm/Btlatm1Kmm Pdcd1tm1Hon/Pdcd1tm1Hon
(B6.129S-Pdcd1tm1Hon Btlatm1Kmm)
|
decreased length of allograft survival
|
J:119356
|
increased T cell proliferation
|
J:119356
|
Btlatm1Kmm/Btlatm1Kmm Tg(DO11.10)10Dlo/?
(involves: 129S/SvEv * BALB/c * C3H * C57BL/6)
|
increased T cell proliferation
|
J:84084
|
Btn2a2tm1.2Wrth/Btn2a2tm1.2Wrth
(C57BL/6-Btn2a2tm1.2Wrth)
|
abnormal T-helper 1 physiology
|
J:232636
|
abnormal T-helper 2 physiology
|
J:232636
|
increased anti-nuclear antigen antibody level
|
J:232636
|
increased IgG1 level
|
J:232636
|
increased IgG2c level
|
J:232636
|
increased IgG level
|
J:232636
|
increased response to antigen
|
J:232636
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:232636
|
Btnl2em1Wche/Btnl2em1Wche
(C57BL/6-Btnl2em1Wche)
|
abnormal cytokine level
|
J:321348
|
large intestinal inflammation
|
J:321348
|
Btrctm1Paga/Btrctm1Paga Fbxw11tm1Ybn/Fbxw11tm1Ybn Tg(Vil1-cre/ERT2)23Syr/?
(involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6 * DBA/2)
|
increased circulating interleukin-1 beta level
|
J:206654
|
intestinal inflammation
|
J:206654
|
Bub1btm1.1Hsl/Bub1b+
(involves: 129 * C57BL/6)
|
increased B cell proliferation
|
J:201641
|
Bxs6BXSB/MpJ/Bxs6BXSB/MpJ
(involves: BXSB/MpJ * C57BL/10ScSnOlaHsd)
|
autoimmune response
|
J:145903
|
glomerulonephritis
|
J:145903
|
increased autoantibody level
|
J:145903
|
Bxs6BXSB/MpJ/Bxs6BXSB/MpJ
(B10.BXSB-(D13Mit3-D13Mit78))
|
autoimmune response
|
J:145049
|
increased anti-double stranded DNA antibody level
|
J:145049
|
increased anti-single stranded DNA antibody level
|
J:145049
|
increased autoantibody level
|
J:145049
|
Bxs6BXSB/MpJ/Bxs6BXSB/MpJ Gpab1C57BL/6J/?
(involves: BXSB/MpJ * C57BL/10ScSnOlaHsd)
|
autoimmune response
|
J:145903
|
increased autoantibody level
|
J:145903
|
Bxs6BXSB/MpJ/Bxs6BXSB/MpJ X/Yaa
(B10.BXSB-(D13Mit3-D13Mit78) Yaa)
|
autoimmune response
|
J:145049
|
glomerulonephritis
|
J:145049
|
increased anti-double stranded DNA antibody level
|
J:145049
|
increased anti-single stranded DNA antibody level
|
J:145049
|
increased autoantibody level
|
J:145049
|
C1galt1ptl1/C1galt1ptl1
(C57BL/6-C1galt1ptl1)
|
glomerulonephritis
|
J:115272
|
kidney inflammation
|
J:115272
|
C1galt1ptl1/C1galt1ptl1 Rag1tm1Bal/Rag1tm1Bal
(involves: 129S4/SvJae * C57BL/6)
|
kidney inflammation
|
J:115272
|
C1qatm1Mjw/C1qatm1Mjw
(involves: 129P2/Ola * 129S/SvEv * C57BL/6)
|
glomerulonephritis
|
J:47315
|
increased anti-histone antibody level
|
J:47315
|
increased anti-nuclear antigen antibody level
|
J:47315
|
increased susceptibility to bacterial infection
|
J:83712
|
C1qatm1Mjw/C1qatm1Mjw Sle16129S6/SvEvTac/Sle16129S6/SvEvTac
(involves: 129S/SvEv * 129X1/Sv * C57BL/6)
|
increased anti-chromatin antibody level
|
J:118645
|
increased anti-double stranded DNA antibody level
|
J:118645
|
increased anti-nuclear antigen antibody level
|
J:118645
|
increased anti-single stranded DNA antibody level
|
J:118645
|
increased susceptibility to systemic lupus erythematosus
|
J:118645
|
C1qatm1Mjw/C1qatm1Mjw Sle16129S6/SvEvTac/Sle16C57BL/6
(involves: 129S/SvEv * 129X1/Sv * C57BL/6)
|
increased anti-chromatin antibody level
|
J:118645
|
increased anti-double stranded DNA antibody level
|
J:118645
|
increased anti-nuclear antigen antibody level
|
J:118645
|
increased anti-single stranded DNA antibody level
|
J:118645
|
increased susceptibility to systemic lupus erythematosus
|
J:118645
|
C1qatm1Mjw/C1qatm1Mjw Sle18C57BL/6/Sle18C57BL/6
(involves: 129S/SvEv * 129X1/Sv * C57BL/6)
|
increased anti-nuclear antigen antibody level
|
J:118645
|
increased susceptibility to systemic lupus erythematosus
|
J:118645
|
C1qatm1Mjw/C1qatm1Mjw Sle18C57BL/6/Sle18C57BL/6
(involves: 129P2/Ola * 129S/SvEv * C57BL/6)
|
increased anti-nuclear antigen antibody level
|
J:118645
|
increased susceptibility to systemic lupus erythematosus
|
J:118645
|
C1qatm1Mjw/C1qatm1Mjw Sle19C57BL/6/?
(involves: 129S/SvEv * 129X1/Sv * C57BL/6)
|
increased anti-nuclear antigen antibody level
|
J:118645
|
increased susceptibility to systemic lupus erythematosus
|
J:118645
|
C1qatm1Mjw/C1qatm1Mjw Sle19C57BL/6/?
(involves: 129P2/Ola * 129S/SvEv * C57BL/6)
|
increased anti-nuclear antigen antibody level
|
J:118645
|
increased susceptibility to systemic lupus erythematosus
|
J:118645
|
C1qatm1Mjw/C1qatm1Mjw Sle21129P2/Ola/? Sle18C57BL/6/Sle18C57BL/6
(involves: 129P2/Ola * 129S/SvEv * C57BL/6)
|
increased anti-nuclear antigen antibody level
|
J:118645
|
increased susceptibility to systemic lupus erythematosus
|
J:118645
|
C1qatm1Mjw/C1qatm1Mjw Sle21129P2/Ola/Sle21129P2/Ola
(involves: 129P2/Ola * 129S/SvEv * C57BL/6)
|
increased anti-chromatin antibody level
|
J:118645
|
increased anti-double stranded DNA antibody level
|
J:118645
|
increased anti-nuclear antigen antibody level
|
J:118645
|
increased anti-single stranded DNA antibody level
|
J:118645
|
increased susceptibility to systemic lupus erythematosus
|
J:118645
|
C1qatm1Mjw/C1qatm1Mjw Sle21129P2/Ola/Sle21C57BL/6
(involves: 129P2/Ola * 129S/SvEv * C57BL/6)
|
increased anti-chromatin antibody level
|
J:118645
|
increased anti-double stranded DNA antibody level
|
J:118645
|
increased anti-nuclear antigen antibody level
|
J:118645
|
increased anti-single stranded DNA antibody level
|
J:118645
|
increased susceptibility to systemic lupus erythematosus
|
J:118645
|
C1qtnf3tm1Yiw/C1qtnf3tm1Yiw
(involves: C57BL/6NSlc)
|
increased IgG level
|
J:211893
|
increased susceptibility to induced arthritis
|
J:211893
|
joint inflammation
|
J:211893
|
C1qtnf4em1Smoc/C1qtnf4em1Smoc
(C57BL/6JSmoc-C1qtnf4em1Smoc/Smoc)
|
increased circulating interleukin-6 level
|
J:302282
|
increased circulating interleukin-18 level
|
J:302282
|
increased circulating tumor necrosis factor level
|
J:302282
|
increased susceptibility to endotoxin shock
|
J:302282
|
increased tumor necrosis factor secretion
|
J:302282
|
C1qtnf6tm1Yiw/C1qtnf6tm1Yiw
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased anti-nuclear antigen antibody level
|
J:227217
|
increased autoantibody level
|
J:227217
|
C1qtnf6tm1Yiw/C1qtnf6tm1Yiw
(B6.129P2-C1qtnf6tm1Yiw)
|
abnormal complement pathway
|
J:227217
|
abnormal complement protein level
|
J:227217
|
increased circulating complement protein level
|
J:227217
|
increased IgG level
|
J:227217
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:227217
|
increased susceptibility to induced arthritis
|
J:227217
|
increased susceptibility to type III hypersensitivity reaction
|
J:227217
|
C3tm1Crr/C3tm1Crr
(involves: 129S4/SvJae * C57BL/6)
|
abnormal cell-mediated immunity
|
J:30152
|
abnormal humoral immune response
|
J:64282
|
abnormal immune system physiology
|
J:44240
|
abnormal mast cell physiology
|
J:44240
|
abnormal tumor necrosis factor level
|
J:44240
|
decreased circulating interleukin-6 level
|
J:166640,
J:152533
|
decreased circulating tumor necrosis factor level
|
J:152533
|
increased susceptibility to bacterial infection
|
J:44240,
J:30152
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:205353
|
liver inflammation
|
J:30152
|
C3tm1Crr/C3tm1Crr
(B6.129S4-C3tm1Crr)
|
abnormal inflammatory response
|
J:113463
|
brain inflammation
|
J:123658
|
decreased susceptibility to autoimmune hemolytic anemia
|
J:145432
|
C3tm1Crr/C3tm1Crr
(B6;129S4-C3tm1Crr/J)
|
decreased susceptibility to Coronaviridae infection
|
J:286325
|
increased susceptibility to bacterial infection
|
J:136745
|
C3tm1Crr/C3tm1Crr
(involves: 129S4/SvJae)
|
glomerulonephritis
|
J:44715
|
C3tm1Crr/C3tm1Crr C4btm1Crr/C4btm1Crr Faslpr/Faslpr
(involves: 129S4/SvJae * C57BL/6 * MRL)
|
abnormal immune system physiology
|
J:127292
|
increased anti-double stranded DNA antibody level
|
J:127292
|
increased anti-nuclear antigen antibody level
|
J:127292
|
C3tm1Crr/C3tm1Crr Cd59atm1Bpm/Cd59atm1Bpm
(B6.129-Cd59atm1Bpm C3tm1Crr)
|
increased T cell proliferation
|
J:122201
|
C3tm1Crr/C3tm1Crr Faslpr/Faslpr
(involves: 129S4/SvJae * C57BL/6 * MRL)
|
decreased susceptibility to autoimmune disorder
|
J:127292
|
C3tm1Crr/C3tm1Crr Fcer1gtm1Rav/Fcer1gtm1Rav Tg(Ins2-TFRC/OVA)296Wehi/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
decreased susceptibility to autoimmune diabetes
|
J:122114
|
C3tm1Crr/C3tm1Crr Tg(Ins2-TFRC/OVA)296Wehi/0
(involves: 129S4/SvJae * C57BL/6)
|
decreased susceptibility to autoimmune diabetes
|
J:122114
|
increased interferon-gamma secretion
|
J:122114
|
increased T cell proliferation
|
J:122114
|
insulitis
|
J:122114
|
C3tm1Crr/C3tm1Crr Zbtb20Tg(PDGFB-APPSwInd)20Lms/?
(involves: 129S4/SvJae * C57BL/6)
|
increased microglial cell activation
|
J:135902
|
C3tm1Hrc/C3tm1Hrc
(either: (involves: 129S2/SvPas * C57BL/6) or (involves: 129X1/SvJ * C57BL/6))
|
increased susceptibility to bacterial infection
|
J:56193
|
C3tm1Hrc/C3tm1Hrc
(B6.129-C3tm1Hrc)
|
impaired complement alternative pathway
|
J:177350
|
C3tm1Hrc/C3tm1Hrc Cr1ltm1Hmo/Cr1ltm1Hmo
(involves: 129/Sv * 129X1/SvJ * C57BL/6)
|
abnormal complement pathway
|
J:76578
|
C3tm1Hrc/C3tm1Hrc Lama2dy/Lama2dy
(either: (involves: 129S2/SvPas * 129P1/ReJ) or (involves: 129X1/SvJ * 129P1/ReJ))
|
decreased IgM level
|
J:102959
|
increased IgG level
|
J:102959
|
increased IgM level
|
J:102959
|
C3tm1Pkna/C3tm1Pkna
(D1.129P2-C3tm1Pkna)
|
decreased susceptibility to induced arthritis
|
J:88872
|
C3ar1tm1Cge/C3ar1tm1Cge
(involves: 129S4/SvJae * C57BL/6)
|
decreased circulating interleukin-6 level
|
J:166640
|
C3ar1tm1Raw/C3ar1+
(involves: 129X1/SvJ * C57BL/6)
|
abnormal immune system physiology
|
J:68807
|
C3ar1tm1Raw/C3ar1tm1Raw
(involves: 129X1/SvJ * C57BL/6)
|
increased circulating interleukin-1 beta level
|
J:68807
|
increased susceptibility to endotoxin shock
|
J:68807
|
C3ar1tm1Raw/C3ar1tm1Raw
(B6.129X1(B6)-C3ar1tm1Raw)
|
abnormal adaptive immunity
|
J:80071
|
abnormal eosinophil physiology
|
J:80071
|
abnormal interleukin level
|
J:80071
|
abnormal T-helper 2 physiology
|
J:80071
|
decreased IgE level
|
J:80071
|
decreased IgG1 level
|
J:80071
|
decreased interleukin-4 secretion
|
J:80071
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:93791
|
impaired neutrophil recruitment
|
J:80071
|
increased circulating interleukin-1 beta level
|
J:93791
|
increased susceptibility to type I hypersensitivity reaction
|
J:80071
|
C3ar1tm1Raw/C3ar1tm1Raw Cpn1tm1Raw/Cpn1tm1Raw
(B6.129-C3ar1tm1Raw Cpn1tm1Raw)
|
increased acute inflammation
|
J:148315
|
C4btm1Crr/C4btm1Crr
(involves: 129S4/SvJae * C57BL/6)
|
abnormal humoral immune response
|
J:64282
|
decreased susceptibility to bacterial infection
|
J:30152
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:30152
|
liver inflammation
|
J:30152
|
C4btm1Crr/C4btm1Crr
(involves: 129S4/SvJae * C57BL/6J)
|
abnormal immune system physiology
|
J:111811
|
glomerulonephritis
|
J:111811
|
increased anti-double stranded DNA antibody level
|
J:111811
|
increased anti-nuclear antigen antibody level
|
J:111811
|
increased anti-single stranded DNA antibody level
|
J:111811
|
C4btm1Crr/C4btm1Crr
(involves: 129S4/SvJae)
|
decreased susceptibility to Coronaviridae infection
|
J:286325
|
glomerulonephritis
|
J:44715
|
C4btm1Crr/C4btm1Crr Faslpr/Faslpr
(involves: 129S4/SvJae * C57BL/6 * MRL)
|
abnormal immune system physiology
|
J:127292
|
increased anti-double stranded DNA antibody level
|
J:127292
|
increased anti-nuclear antigen antibody level
|
J:127292
|
C4bptm1Raw/C4bptm1Raw
(B6.129-C4bptm1Raw)
|
increased circulating interleukin-6 level
|
J:244020
|
C5ar1tm1Cge/C5ar1tm1Cge
(involves: 129S4/SvJae)
|
abnormal humoral immune response
|
J:35529
|
impaired neutrophil recruitment
|
J:69177
|
increased susceptibility to bacterial infection
|
J:69177
|
C5ar1tm1Cge/C5ar1tm1Cge
(involves: 129S4/SvJae * C57BL/6)
|
decreased circulating interleukin-6 level
|
J:166640
|
C5ar1tm1Song/C5ar1tm1Song
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal neutrophil physiology
|
J:184056
|
C5ar2tm1Cge/C5ar2tm1Cge
(B6.129S1-C5ar2tm1Cge)
|
abnormal immune cell physiology
|
J:104092
|
increased inflammatory response
|
J:104092
|
C9em1Sjlg/C9+
(C57BL/6-C9em1Sjlg)
|
impaired complement classical pathway
|
J:301607
|
C9em1Sjlg/C9em1Sjlg
(C57BL/6-C9em1Sjlg)
|
decreased interleukin-1 beta secretion
|
J:301607
|
decreased susceptibility to endotoxin shock
|
J:301607
|
impaired complement classical pathway
|
J:301607
|
C9orf72em1Eggn/C9orf72em1Eggn
(involves: C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:240357
|
C9orf72em5Lutzy/C9orf72em5Lutzy
(C57BL/6-C9orf72em5Lutzy)
|
abnormal macrophage physiology
|
J:101977
|
abnormal microglial cell physiology
|
J:101977
|
C9orf72tm1.1Eggn/C9orf72+
(involves: C57BL/6 * C57BL/6N)
|
abnormal circulating interleukin level
|
J:240357
|
decreased circulating interleukin-2 level
|
J:240357
|
dermatitis
|
J:240357
|
increased autoantibody level
|
J:240357
|
increased IgG level
|
J:240357
|
increased IgM level
|
J:240357
|
C9orf72tm1.1Eggn/C9orf72tm1.1Eggn
(involves: C57BL/6 * C57BL/6N)
|
abnormal circulating cytokine level
|
J:240357
|
brain inflammation
|
J:240357
|
dermatitis
|
J:240357
|
increased anti-double stranded DNA antibody level
|
J:240357
|
increased autoantibody level
|
J:240357
|
increased IgG level
|
J:240357
|
increased IgM level
|
J:240357
|
increased susceptibility to autoimmune disorder
|
J:240357
|
liver inflammation
|
J:240357
|
C9orf72tm1Eggn/C9orf72+
(involves: C57BL/6 * C57BL/6N)
|
dermatitis
|
J:240357
|
C9orf72tm1Eggn/C9orf72tm1Eggn
(involves: C57BL/6 * C57BL/6N)
|
abnormal circulating cytokine level
|
J:240357
|
dermatitis
|
J:240357
|
increased anti-double stranded DNA antibody level
|
J:240357
|
increased susceptibility to autoimmune disorder
|
J:240357
|
Cabin1tm1.1Che/Cabin1tm1.1Che
(involves: 129S4/SvJae * BALB/c)
|
abnormal cytokine secretion
|
J:72760
|
abnormal humoral immune response
|
J:72760
|
increased IgE level
|
J:72760
|
increased IgG1 level
|
J:72760
|
increased IgG2b level
|
J:72760
|
Cacna1ctm2Itl/Cacna1c+
(involves: 129S6/SvEvTac * C57BL/6NTac)
|
dermatitis
|
J:201506
|
Cacna2d2du-td/Cacna2d2du-td
(involves: DBA/2J)
|
abnormal thymus involution
|
J:12166
|
Cacna2d2tm1Svi/Cacna2d2tm1Svi
(involves: 129S1/Sv * C57BL/6J)
|
rhinitis
|
J:92396
|
Cacnb3tm1Acv/Cacnb3tm1Acv
(involves: 129S1/Sv * 129X1/SvJ)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:115345
|
abnormal interleukin secretion
|
J:115345
|
decreased interferon-gamma secretion
|
J:115345
|
Cacnb4lh/Cacnb4lh
(B6EiC3Sn a/A-Cacnb4lh/J)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:115345
|
abnormal interleukin secretion
|
J:115345
|
abnormal thymus involution
|
J:5281
|
decreased interferon-gamma secretion
|
J:115345
|
decreased interleukin-2 secretion
|
J:115345
|
Cacnb4lh/Cacnb4lh
(BALB/cGn-Cacnb4lh)
|
abnormal thymus involution
|
J:12166
|
increased length of allograft survival
|
J:5766
|
Cacnb4lh/Cacnb4lh
(involves: BALB/cGn)
|
increased IgG1 level
|
J:5883
|
Cadm1Gt(Ayu21-W34)Imeg/Cadm1Gt(Ayu21-W34)Imeg
(involves: C57BL/6 * CBA/JNCrlj)
|
decreased interferon-gamma secretion
|
J:178612
|
decreased interleukin-2 secretion
|
J:178612
|
decreased interleukin-4 secretion
|
J:178612
|
decreased T cell proliferation
|
J:178612
|
Calcrtm1Rda/Calcrtm1Rda Tg(CMV-cre)1Cgn/0
(B6.Cg-Calcrtm1Rda Tg(CMV-cre)1Cgn)
|
abnormal osteoclast physiology
|
J:150982
|
Camk2gtm1.1Irt/Camk2gtm1.1Irt
(involves: C57BL/6 * C57BL/6J)
|
decreased macrophage apoptosis
|
J:154647
|
Camk2gtm1.1Irt/Camk2gtm1.1Irt
(involves: C57BL/6J)
|
increased susceptibility to colitis induced morbidity/mortality
|
J:243363
|
increased susceptibility to induced colitis
|
J:243363
|
Camltm1Rjb/Camltm2Rjb Tg(Lck-cre)1Cwi/0
(involves: 129 * C57BL/6 * DBA/2)
|
increased T cell apoptosis
|
J:100536
|
Camptm1Rlg/Camp+
(involves: 129X1/SvJ * C57BL/6)
|
increased susceptibility to bacterial infection
|
J:72924
|
Camptm1Rlg/Camptm1Rlg
(involves: 129X1/SvJ * C57BL/6)
|
increased incidence of corneal inflammation
|
J:199719
|
increased susceptibility to bacterial infection
|
J:72924
|
increased susceptibility to fungal infection
|
J:199719
|
Camptm1Rlg/Camptm1Rlg
(129X1(B6)-Camptm1Rlg/Kini)
|
increased susceptibility to bacterial infection
|
J:109553
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:109553
|
Cap2tm1a(EUCOMM)Wtsi/Cap2tm1a(EUCOMM)Wtsi
(involves: C57BL/6J * C57BL/6N)
|
eye inflammation
|
J:234044
|
increased susceptibility to infection
|
J:234044
|
Capgtm1Djk/Capgtm1Djk
(involves: 129S4/SvJae)
|
abnormal macrophage physiology
|
J:86517
|
impaired macrophage phagocytosis
|
J:86517
|
Capgtm1Djk/Capgtm1Djk
(involves: 129S4/SvJae * BALB/c * C57BL/6)
|
abnormal dendritic cell physiology
|
J:86277
|
impaired macrophage phagocytosis
|
J:86277
|
impaired neutrophil chemotaxis
|
J:86277
|
increased susceptibility to bacterial infection
|
J:86277
|
Capgtm1Djk/Capgtm1Djk Gsntm1Djk/Gsntm1Djk
(involves: 129S4/SvJae)
|
abnormal macrophage physiology
|
J:86517
|
impaired macrophage phagocytosis
|
J:86517
|
Capn1tm1Dgen/Capn1tm1Dgen
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal leukocyte adhesion
|
J:183585
|
CapopNOD/CapopNOD
(involves: C57BL/6 * NOD)
|
decreased T cell apoptosis
|
J:68151
|
Capza2tm1b(KOMP)Wtsi/Capza2tm1b(KOMP)Wtsi
(C57BL/6N-Capza2tm1b(KOMP)Wtsi/Wtsi)
|
blood in lymph vessels
|
J:239583
|
Car2tm1(KOMP)Vlcg/Car2tm1(KOMP)Vlcg
(involves: C57BL/6 * C57BL/6NTac)
|
increased susceptibility to bacterial infection
|
J:216402
|
pyelonephritis
|
J:216402
|
Card9tm1Jrld/Card9tm1Jrld
(involves: 129P2/OlaHsd)
|
abnormal dendritic cell physiology
|
J:111706
|
increased susceptibility to fungal infection
|
J:111706
|
Card9tm1Tks/Card9tm1Tks
(B6.129-Card9tm1Tks)
|
abnormal chemokine secretion
|
J:141143
|
abnormal cytokine secretion
|
J:122394
|
abnormal dendritic cell physiology
|
J:122394
|
abnormal macrophage physiology
|
J:141143,
J:122394
|
decreased interleukin-6 secretion
|
J:160680
|
decreased interleukin-10 secretion
|
J:160680
|
decreased interleukin-12b secretion
|
J:160680
|
decreased interleukin-23 secretion
|
J:160680
|
decreased tumor necrosis factor secretion
|
J:160680
|
increased susceptibility to bacterial infection
|
J:122394
|
Card9tm1Xlin/Card9tm1Xlin
(involves: 129/Sv * C57BL/6)
|
abnormal cytokine level
|
J:117799
|
abnormal innate immunity
|
J:117799
|
abnormal macrophage physiology
|
J:117799
|
increased susceptibility to bacterial infection
|
J:117799
|
Card11em1Welu/Card11+
(involves: C57BL/6)
|
impaired humoral immune response
|
J:292926
|
Card11em1Welu/Card11em1Welu
(involves: C57BL/6)
|
decreased B cell proliferation
|
J:292926
|
decreased IgG level
|
J:292926
|
decreased IgM level
|
J:292926
|
impaired humoral immune response
|
J:292926
|
Card11em2Welu/Card11em2Welu
(involves: C57BL/6)
|
increased B cell proliferation
|
J:292926
|
Card11m1Btlr/Card11m1Btlr
(C57BL/6J-Card11m1Btlr)
|
abnormal cytokine secretion
|
J:149767
|
abnormal cytotoxic T cell physiology
|
J:139069
|
abnormal NK cell physiology
|
J:139069
|
abnormal T cell activation
|
J:139069
|
decreased B cell proliferation
|
J:149767,
J:139069
|
decreased IgG1 level
|
J:149767,
J:139069
|
decreased IgG2a level
|
J:149767,
J:139069
|
decreased IgG2b level
|
J:149767,
J:139069
|
decreased IgG2c level
|
J:149767
|
decreased IgG3 level
|
J:149767,
J:139069
|
decreased IgM level
|
J:149767,
J:139069
|
decreased immunoglobulin level
|
J:139069
|
decreased interferon-gamma secretion
|
J:139069
|
decreased interleukin-2 secretion
|
J:139069
|
decreased T cell proliferation
|
J:149767,
J:139069
|
dermatitis
|
J:149767,
J:139069
|
Card11M2Btlr/Card11M2Btlr
(involves: C57BL/6J)
|
decreased IgM level
|
J:198555
|
Card11M4Btlr/Card11M4Btlr
(C57BL/6J-Card11M4Btlr)
|
decreased IgM level
|
J:254856
|
impaired humoral immune response
|
J:254856
|
Card11M5Btlr/Card11+
(C57BL/6J-Card11M5Btlr)
|
decreased IgM level
|
J:254879
|
impaired humoral immune response
|
J:254879
|
Card11M5Btlr/Card11M5Btlr
(C57BL/6J-Card11M5Btlr)
|
decreased IgM level
|
J:254879
|
impaired humoral immune response
|
J:254879
|
Card11m8Btlr/Card11m8Btlr
(C57BL/6J-Card11m8Btlr)
|
decreased IgG level
|
J:274940
|
decreased IgM level
|
J:274940
|
decreased response to antigen
|
J:274940
|
impaired humoral immune response
|
J:274940
|
Card11tm1.1Litt/Card11tm1.1Litt Gt(ROSA)26Sortm1(cre/ERT2)Thl/Gt(ROSA)26Sor+ Tg(TcraTcrb)425Cbn/?
(involves: 129/Sv * 129P2/OlaHsd * BALB/c * C57BL/6)
|
abnormal T cell activation
|
J:180410
|
Card11tm1.1Litt/Card11tm1.1Litt Tnfrsf4tm2(cre)Nik/Tnfrsf4+
(involves: 129P2/OlaHsd * 129X1/SvJ)
|
abnormal T cell activation
|
J:180410
|
respiratory system inflammation
|
J:180410
|
Card11tm1Litt/Card11tm1Litt
(involves: 129P2/OlaHsd)
|
abnormal B cell proliferation
|
J:89322
|
abnormal T cell activation
|
J:89322
|
abnormal T cell proliferation
|
J:89322
|
decreased IgA level
|
J:89322
|
decreased IgG1 level
|
J:89322
|
decreased IgG2b level
|
J:89322
|
decreased IgG3 level
|
J:89322
|
decreased IgM level
|
J:89322
|
decreased immunoglobulin level
|
J:89322
|
Card11tm1Pngr/Card11tm1Pngr
(involves: 129P2/OlaHsd)
|
abnormal B cell physiology
|
J:84036
|
abnormal interleukin-2 secretion
|
J:84036
|
abnormal T cell activation
|
J:84036
|
decreased B cell proliferation
|
J:84036
|
decreased IgA level
|
J:84036
|
decreased IgE level
|
J:84036
|
decreased IgG1 level
|
J:84036
|
decreased IgG2a level
|
J:84036
|
decreased IgG2b level
|
J:84036
|
decreased IgG3 level
|
J:84036
|
decreased IgG level
|
J:84036
|
decreased IgM level
|
J:84036
|
decreased immunoglobulin level
|
J:84036
|
Card11tm1Vmd/Card11+
(involves: 129S6/SvEvTac * C57BL/6N)
|
decreased B cell proliferation
|
J:95800
|
Card11tm1Vmd/Card11tm1Vmd
(involves: 129S6/SvEvTac * C57BL/6N)
|
abnormal B cell physiology
|
J:95800
|
decreased B cell proliferation
|
J:95800
|
decreased IgA level
|
J:95800
|
decreased IgG1 level
|
J:95800
|
decreased IgG2a level
|
J:95800
|
decreased IgG2b level
|
J:95800
|
decreased IgG3 level
|
J:95800
|
decreased IgG level
|
J:95800
|
decreased IgM level
|
J:95800
|
decreased T cell proliferation
|
J:95800
|
Card11tm1Xav/Card11tm1Xav
(involves: 129 * C57BL/6)
|
abnormal T cell activation
|
J:132226
|
decreased circulating interleukin-4 level
|
J:132226
|
decreased circulating interleukin-5 level
|
J:132226
|
decreased IgE level
|
J:132226
|
lung inflammation
|
J:132226
|
Card11unm/Card11unm
(C57BL/6JSfdAnu-Card11unm/Anu)
|
abnormal immune system physiology
|
J:84042
|
abnormal T cell activation
|
J:84042
|
decreased IgG3 level
|
J:84042
|
decreased IgM level
|
J:84042
|
decreased immunoglobulin level
|
J:84042
|
dermatitis
|
J:84042
|
erythroderma
|
J:84042
|
increased IgE level
|
J:84042
|
increased immunoglobulin level
|
J:84042
|
increased inflammatory response
|
J:84042
|
Card14em1Maak/Card14em1Maak
(C57BL/6JJmsSlc-Card14em1Maak)
|
skin inflammation
|
J:360877
|
Card14em1Tshu/Card14em1Tshu
(C57BL/6-Card14em1Tshu)
|
decreased susceptibility to chemically induced skin inflammation
|
J:289239
|
Card14em2Tshu/Card14+
(involves: C57BL/6)
|
skin inflammation
|
J:289239
|
Card14em3Tshu/Card14+
(involves: C57BL/6)
|
skin inflammation
|
J:289239
|
Card14em3Tshu/Card14+ Il17atm1Cdon/Il17atm1Cdon
(involves: C57BL/6)
|
decreased inflammatory response
|
J:289239
|
Card14em9Lutzy/Card14+
(C57BL/6J-Card14em9Lutzy/J)
|
skin inflammation
|
J:262723
|
Card14tm1Lex/Card14tm1Lex
(B6.129S-Card14tm1Lex)
|
decreased susceptibility to chemically induced skin inflammation
|
J:253409
|
Card19tm1Rwen/Card19tm1Rwen
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased autoantibody level
|
J:336763
|
Card19tm1Rwen/Card19tm1Rwen Tg(IghelMD4)4Ccg/0
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal B cell activation
|
J:336763
|
Card19tm1Rwen/Card19tm1Rwen Tg(IghelMD4)4Ccg/0 Tg(ML5sHEL)5Ccg/0
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6JSfd)
|
decreased B cell proliferation
|
J:336763
|
increased B cell apoptosis
|
J:336763
|
carmelo/carmelo
(involves: 129S1/SvImJ * C57BL/6J)
|
decreased susceptibility to parasitic infection induced morbidity/mortality
|
J:220661
|
Carmil2bas/Carmil2bas
(involves: C3HeB/FeJ * C57BL/6)
|
decreased interferon-gamma secretion
|
J:205441
|
decreased interleukin-2 secretion
|
J:205441
|
decreased T cell proliferation
|
J:205441
|
Carmil2bas/Carmil2tm1a(KOMP)Mbp
(involves: C3HeB/FeJ * C57BL/6 * C57BL/6N)
|
decreased interleukin-2 secretion
|
J:205441
|
decreased T cell proliferation
|
J:205441
|
Casp1tm1Flv/Casp1tm1Flv Casp4del/Casp4del
(involves: 129S2/SvPas * C57BL/6)
|
abnormal cytokine secretion
|
J:24258
|
decreased circulating interferon-gamma level
|
J:115310
|
decreased interferon-gamma secretion
|
J:115310
|
decreased interleukin-1 alpha secretion
|
J:24258
|
decreased interleukin-1 beta secretion
|
J:24258
|
decreased interleukin-6 secretion
|
J:24258
|
decreased interleukin-18 secretion
|
J:115310
|
decreased susceptibility to endotoxin shock
|
J:43088
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:57101
|
decreased thymocyte apoptosis
|
J:24258
|
decreased tumor necrosis factor secretion
|
J:24258
|
impaired neutrophil chemotaxis
|
J:124226
|
increased susceptibility to bacterial infection
|
J:117251
|
Casp1tm1Flv/Casp1tm1Flv Casp4del/Casp4del
(B6.129S2-Casp1tm1Flv)
|
decreased interleukin-1 beta secretion
|
J:160545
|
increased susceptibility to induced colitis
|
J:173245
|
Casp1tm1Flv/Casp1tm1Flv Casp4del/Casp4del Il1r1tm1Imx/Il1r1tm1Imx
(involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6)
|
decreased susceptibility to endotoxin shock
|
J:43088
|
Casp1tm1Flv/Casp1tm1Flv Casp4del/Casp4del Slc11a1r/Slc11a1r
(involves: 129S2/SvPas)
|
increased susceptibility to bacterial infection
|
J:124378
|
Casp1tm1Flv/Casp1tm1Flv Casp4del/Casp4del Slc11a1s/Slc11a1s
(B6.129S2-Casp1tm1Flv)
|
cecum inflammation
|
J:124378
|
increased susceptibility to bacterial infection
|
J:124378
|
Casp1tm1Sesh/Casp1+ Casp4del/Casp4+
(involves: 129S2/SvPas * C57BL/6)
|
decreased interleukin-1 beta secretion
|
J:22964
|
Casp1tm1Sesh/Casp1+ Casp4del/Casp4+
(involves: 129S1/SvImJ * 129S2/SvPas * NOD)
|
abnormal macrophage physiology
|
J:99748
|
Casp1tm1Sesh/Casp1tm1Sesh Casp4del/Casp4del
(involves: 129S2/SvPas * C57BL/6)
|
abnormal inflammatory response
|
J:80568
|
abnormal macrophage physiology
|
J:22964
|
abnormal neutrophil physiology
|
J:80568
|
decreased circulating interleukin-1 alpha level
|
J:22964
|
decreased circulating interleukin-1 beta level
|
J:22964
|
decreased circulating interleukin-6 level
|
J:22964
|
decreased circulating tumor necrosis factor level
|
J:22964
|
decreased interleukin-1 alpha secretion
|
J:22964
|
decreased interleukin-1 beta secretion
|
J:88212,
J:22964
|
decreased susceptibility to endotoxin shock
|
J:22964,
J:40691
|
decreased T cell apoptosis
|
J:40691
|
Casp1tm1Sesh/Casp1tm1Sesh Casp4del/Casp4del
(NOD.129S2(B6)-Casp1tm1Sesh Casp4del/LtJ)
|
decreased interleukin-1 alpha secretion
|
J:87250
|
decreased interleukin-1 beta secretion
|
J:87250
|
decreased interleukin-18 secretion
|
J:87250
|
Casp1tm1Sesh/Casp1tm1Sesh Casp4del/Casp4del
(C3N.129S2-Casp1tm1Sesh Casp4del)
|
abnormal response to infection
|
J:86761
|
Casp1tm1Sesh/Casp1tm1Sesh Casp4del/Casp4del
(B10.Cg-Casp1tm1Sesh Casp4del H2r H2-T18b)
|
decreased inflammatory response
|
J:63488
|
decreased susceptibility to bacterial infection
|
J:63488
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:63488
|
Casp1tm1Sesh/Casp1tm1Sesh Casp4del/Casp4del
(involves: 129 * 129S2/SvPas * C57BL/6)
|
decreased interleukin-1 beta secretion
|
J:50775
|
Casp1tm1Sesh/Casp1tm1Sesh Casp4del/Casp4del
(C3.129S2-Casp1tm1Sesh Casp4del)
|
abnormal macrophage physiology
|
J:136368
|
decreased interleukin-1 beta secretion
|
J:136368
|
increased susceptibility to bacterial infection
|
J:136368
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:136368
|
Casp1tm1Sesh/Casp1tm1Sesh Casp4del/Casp4del
(B6.129S2(NOD)-Casp1tm1Sesh Casp4del)
|
decreased circulating interleukin-1 alpha level
|
J:193522
|
decreased circulating interleukin-1 beta level
|
J:193522
|
decreased circulating interleukin-18 level
|
J:193522
|
decreased interleukin-1 alpha secretion
|
J:193522
|
decreased interleukin-1 beta secretion
|
J:193522
|
decreased interleukin-18 secretion
|
J:193522
|
decreased macrophage apoptosis
|
J:193522
|
decreased susceptibility to endotoxin shock
|
J:193522
|
Casp1tm1Sesh/Casp1tm1Sesh Casp4del/Casp4del Slc11a1r/Slc11a1s
(involves: 129/Sv * 129S2/SvPas * C57BL/6)
|
increased susceptibility to bacterial infection
|
J:112400
|
Casp1tm1Sesh/Casp1tm1Sesh Casp4del/Casp4del Slc11a1s/Slc11a1s
(B6.129S2-Casp1tm1Sesh Casp4del)
|
abnormal macrophage physiology
|
J:112400
|
increased susceptibility to bacterial infection
|
J:112400
|
Casp1tm1Sesh/Casp1tm1Sesh Casp4del/Casp4del Tg(Casp4)#Gne/0
(involves: 129S2/SvPas * C57BL/6 * NOD/ShiLtJ)
|
decreased circulating interleukin-1 beta level
|
J:193522
|
decreased circulating interleukin-18 level
|
J:193522
|
decreased interleukin-1 alpha secretion
|
J:193522
|
decreased interleukin-1 beta secretion
|
J:193522
|
decreased interleukin-18 secretion
|
J:193522
|
decreased macrophage apoptosis
|
J:193522
|
decreased susceptibility to endotoxin shock
|
J:193522
|
Casp1tm1Sesh/Casp1tm1Sesh Nlrp1aNeut1/Nlrp1aNeut1
(involves: 129S2/SvPas * C57BL/6)
|
increased circulating interleukin-18 level
|
J:191055
|
Casp2tm1Vaux/Casp2tm1Vaux Casp9tm1Flv/Casp9tm1Flv
(involves: 129S1/Sv * C57BL/6)
|
abnormal T cell physiology
|
J:91156
|
Casp2tm1Yuan/Casp2tm1Yuan
(involves: 129S4/SvJae * C57BL/6J * DBA/2)
|
abnormal B cell apoptosis
|
J:47601
|
Casp3tm1Flv/Casp3tm1Flv
(involves: 129S1/Sv * C57BL/6)
|
abnormal osteoclast physiology
|
J:94703
|
Casp3tm1Flv/Casp3tm1Flv Casp7tm1Flv/Casp7+
(B6.129S-Casp3tm1Flv Casp7tm1Flv)
|
decreased thymocyte apoptosis
|
J:105496
|
Casp3tm1Flv/Casp3tm1Flv Casp7tm1Flv/Casp7tm1Flv
(B6.129S-Casp3tm1Flv Casp7tm1Flv)
|
decreased thymocyte apoptosis
|
J:105496
|
Casp3tm1Mak/Casp3tm1Mak
(B6.129P2-Casp3tm1Mak)
|
decreased inflammatory response
|
J:97650,
J:179279
|
Casp4tm1.1Vmd/Casp4tm1.1Vmd
(involves: C57BL/6)
|
decreased circulating interleukin-1 alpha level
|
J:193522
|
decreased circulating interleukin-1 beta level
|
J:193522
|
decreased circulating interleukin-18 level
|
J:193522
|
decreased interleukin-1 alpha secretion
|
J:193522
|
decreased interleukin-1 beta secretion
|
J:193522
|
decreased macrophage apoptosis
|
J:193522
|
decreased susceptibility to endotoxin shock
|
J:193522
|
Casp4tm1Yuan/Casp4tm1Yuan
(involves: 129S4/SvJae * C57BL/6J * DBA/2)
|
decreased circulating interleukin-1 alpha level
|
J:46167
|
decreased circulating interleukin-1 beta level
|
J:46167
|
decreased susceptibility to endotoxin shock
|
J:46167
|
Casp4tm1Yuan/Casp4tm1Yuan
(B6.129S4(D2)-Casp4tm1Yuan/J)
|
decreased interleukin-1 beta secretion
|
J:270123
|
decreased interleukin-18 secretion
|
J:270123
|
Casp8tm1.1Raz/Casp8tm1.1Raz Ripk3tm1Vmd/Ripk3tm1Vmd
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ)
|
abnormal macrophage physiology
|
J:170815
|
decreased macrophage apoptosis
|
J:170815
|
decreased thymocyte apoptosis
|
J:170814
|
increased inflammatory response
|
J:170815
|
Casp8tm1Clie/Casp8tm1Clie Tg(Alb1-cre)7Gsc/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
liver inflammation
|
J:218665
|
Casp8tm1Hed/Casp8tm1Hed Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd)
|
abnormal adaptive immunity
|
J:116713
|
abnormal immunoglobulin level
|
J:116713
|
decreased B cell proliferation
|
J:116713
|
Casp8tm1Hed/Casp8tm1Hed Tg(KRT14-cre)1Efu/0
(Not Specified)
|
abnormal T cell physiology
|
J:167299
|
dermatitis
|
J:167299
|
increased IgE level
|
J:167299
|
increased IgG1 level
|
J:167299
|
Casp8tm1Raz/Casp8tm1Raz Tg(Lck-cre)548Jxm/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:82759
|
abnormal T cell activation
|
J:107455
|
abnormal T cell physiology
|
J:107455
|
abnormal T cell proliferation
|
J:107455
|
decreased T cell apoptosis
|
J:82759
|
decreased T cell proliferation
|
J:82759
|
Casp9tm1Flv/Casp9tm1Flv
(involves: 129S1/Sv * C57BL/6)
|
abnormal thymocyte apoptosis
|
J:49088
|
decreased T cell apoptosis
|
J:91156
|
Casp9tm1Mak/Casp9tm1Mak
(either: (involves: 129P2/OlaHsd * C57BL/6J) or (involves: 129P2/OlaHsd * CD-1))
|
abnormal splenocyte apoptosis
|
J:49087
|
abnormal thymocyte apoptosis
|
J:49087
|
Casp12tm1Dwni/Casp12tm1Dwni
(involves: 129S1/SvImJ * C57BL/6)
|
decreased susceptibility to bacterial infection
|
J:144912
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:144912
|
increased circulating interleukin-18 level
|
J:144912
|
increased interferon-gamma secretion
|
J:144912
|
increased interleukin-1 beta secretion
|
J:144912
|
increased susceptibility to endotoxin shock
|
J:144912
|
CasrNuf/CasrNuf
(involves: 102/El * C3H/He)
|
tongue inflammation
|
J:92612
|
Cav1tm1Mls/Cav1tm1Mls
(involves: 129/Sv * C57BL/6 * SJL)
|
abnormal chemokine secretion
|
J:115914
|
abnormal cytokine level
|
J:115914
|
abnormal macrophage physiology
|
J:115914
|
abnormal neutrophil physiology
|
J:139304
|
decreased susceptibility to endotoxin shock
|
J:139304
|
impaired neutrophil recruitment
|
J:115914
|
increased circulating CXCL10 level
|
J:115914
|
increased circulating interferon-gamma level
|
J:115914
|
increased circulating interleukin-6 level
|
J:115914
|
increased circulating tumor necrosis factor level
|
J:115914
|
increased susceptibility to bacterial infection
|
J:115914
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:115914
|
lung inflammation
|
J:87282
|
Cav1tm1Mls/Cav1tm1Mls Cav3tm1Mls/Cav3tm1Mls
(involves: 129/Sv * C57BL/6J * SJL)
|
heart inflammation
|
J:77372
|
Cbfa2t2tm1Swh/Cbfa2t2tm1Swh
(either: B6.129S6-Cbfa2t2tm1Swh or (involves: 129S6/SvEvTac * C57BL/6))
|
small intestinal inflammation
|
J:102172
|
Cbfbtm1Itan/Cbfbtm1Itan Tg(Cd4-cre)1Cwi/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
increased IgA level
|
J:125953
|
increased IgE level
|
J:125953
|
increased IgG1 level
|
J:125953
|
increased immunoglobulin level
|
J:125953
|
lung inflammation
|
J:125953
|
Cbltm1.1Hua/Cbltm1.1Hua Lattm1Les/Lattm1Les
(involves: 129P2/OlaHsd)
|
liver inflammation
|
J:91369
|
lung inflammation
|
J:91369
|
Cbltm1.1Hua/Cbltm1.1Hua Lcp2tm1Gak/Lcp2tm1Gak
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ)
|
abnormal cytokine secretion
|
J:91369
|
liver inflammation
|
J:91369
|
lung inflammation
|
J:91369
|
Cbltm1Ddlb/Cbltm1Ddlb
(involves: 129S1/Sv)
|
abnormal T cell physiology
|
J:81965
|
Cbltm1Ddlb/Cbltm2Wlan
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal T cell activation
|
J:103366
|
abnormal T cell physiology
|
J:103366
|
Cbltm1Wlan/Cbltm1Wlan
(involves: 129S1/Sv * C57BL/6)
|
abnormal T cell physiology
|
J:81965
|
Cbltm2Hua/Cbltm2Hua Cblbtm1Hua/Cblbtm1Hua Tg(Lck-cre)I57Jxm/0
(involves: 129P2/OlaHsd * C57BL/6 * ICR)
|
abnormal immune system physiology
|
J:80427
|
dermatitis
|
J:80427
|
increased T cell proliferation
|
J:80427
|
Cblbtm1Hua/Cblbtm1Hua
(Not Specified)
|
increased T cell proliferation
|
J:89761
|
Cblbtm1Hua/Cblbtm1Hua
(B6.129P2-Cblbtm1Hua)
|
increased interleukin-2 secretion
|
J:94685
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:94685
|
increased T cell proliferation
|
J:94685
|
Cblbtm1Hua/Cblbtm1Hua Ubash3btm1Jni/Ubash3btm1Jni Ubash3atm1Jni/Ubash3atm1Jni
(Not Specified)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:89761
|
increased T cell proliferation
|
J:89761
|
Cblbtm1Pngr/Cblbtm1Pngr
(involves: 129 * C57BL/6)
|
abnormal mast cell physiology
|
J:126361
|
increased interleukin-6 secretion
|
J:126361
|
increased tumor necrosis factor secretion
|
J:126361
|
Cblbtm1Pngr/Cblbtm1Pngr
(B6.129P2-Cblbtm1Pngr)
|
increased T cell proliferation
|
J:141390
|
Cblbtm1Pngr/Cblbtm1Pngr Itktm1Litt/Itktm1Litt
(B6.129-Itktm1Litt Cblbtm1Pngr)
|
decreased interleukin-2 secretion
|
J:141390
|
Cblbtm1Pngr/Cblbtm1Pngr Vav1tm1Tyb/Vav1tm1Tyb Wastm1Sbs/Wastm1Sbs
(involves: 129P2/OlaHsd * 129S2/SvPas * 129S6/SvEvTac)
|
abnormal T cell physiology
|
J:79550
|
Cblbtm1Pngr/Cblbtm1Pngr Wastm1Sbs/Wastm1Sbs
(Not Specified)
|
abnormal T cell physiology
|
J:79550
|
Cblbtm1Wlan/Cblbtm1Wlan
(involves: 129X1/SvJ * C57BL/6)
|
abnormal mast cell physiology
|
J:126361
|
increased interleukin-6 secretion
|
J:126361
|
increased tumor necrosis factor secretion
|
J:126361
|
Cbliftm1a(KOMP)Wtsi/Cbliftm1a(KOMP)Wtsi
(C57BL/6N-Cbliftm1a(KOMP)Wtsi)
|
increased susceptibility to bacterial infection
|
J:236022
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:236022
|
Cbstm1Unc/Cbstm1Unc
(involves: 129P2/OlaHsd * C57BL/6J)
|
abnormal interleukin level
|
J:101303
|
abnormal tumor necrosis factor level
|
J:101303
|
liver inflammation
|
J:101303
|
Cbx2tm1Cim/Cbx2tm1Cim
(involves: 129P2/OlaHsd * BALB/c)
|
decreased splenocyte proliferation
|
J:38487
|
Cbx4tm1.1Gxu/Cbx4tm1.2Gxu Tg(Foxn1-cre)1Tbo/0
(involves: 129S2/SvPas * C57BL/6J)
|
abnormal thymus physiology
|
J:194053
|
Cbx4tm1.2Gxu/Cbx4tm1.2Gxu
(involves: 129S2/SvPas * C57BL/6J)
|
abnormal thymus physiology
|
J:194053
|
Cbx5tm1.1Ics/Cbx5tm1.1Ics
(involves: 129S2/SvPas * C57BL/6)
|
abnormal T-helper 2 physiology
|
J:186702
|
Cbx6tm1a(EUCOMM)Wtsi/Cbx6tm1a(EUCOMM)Wtsi
(C57BL/6N-Cbx6tm1a(EUCOMM)Wtsi/Wtsi)
|
blood in lymph vessels
|
J:239583
|
Cby1tm1Ktkm/Cby1tm1Ktkm
(B6.129-Cby1tm1Ktkm)
|
increased susceptibility to bacterial infection
|
J:147413
|
increased susceptibility to otitis media
|
J:147413
|
sinus inflammation
|
J:147413
|
Cc2d1atm1a(KOMP)Wtsi/Cc2d1atm1a(KOMP)Wtsi
(involves: C57BL/6J * C57BL/6N)
|
decreased interferon-beta secretion
|
J:190401
|
decreased interleukin-6 secretion
|
J:190401
|
Ccar2Gt(XN876)Byg/Ccar2Gt(XN876)Byg
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased tumor necrosis factor secretion
|
J:156677
|
Ccbe1tm1Mlkn/Ccbe1tm1Mlkn
(either: B6.129-Ccbe1tm1Mlkn or (involves: 129 * C57BL/6))
|
abnormal macrophage physiology
|
J:196696
|
Ccdc50em2Gpt/Ccdc50em2Gpt
(C57BL/6J-Ccdc50em2Gpt)
|
decreased susceptibility to Herpesvirales infection
|
J:345495
|
decreased susceptibility to Herpesvirales infection induced morbidity/mortality
|
J:345495
|
increased circulating interferon-beta level
|
J:345495
|
increased interferon-beta secretion
|
J:345495
|
Ccdc86tm1Hfuj/Ccdc86+
(involves: C57BL/6NTac)
|
decreased T cell apoptosis
|
J:151722
|
Ccdc88bm1Pgrs/Ccdc88bm1Pgrs
(involves: C57BL/6J * C57BL/10J)
|
decreased interferon-gamma secretion
|
J:230618
|
decreased susceptibility to parasitic infection
|
J:230618
|
decreased susceptibility to parasitic infection induced morbidity/mortality
|
J:230618
|
decreased T cell proliferation
|
J:230618
|
decreased tumor necrosis factor secretion
|
J:230618
|
Ccdc88bm1Pgrs/Ccdc88bm1Pgrs
(involves: 129S1/SvImJ * C57BL/6J * C57BL/10J)
|
decreased susceptibility to parasitic infection induced morbidity/mortality
|
J:230618
|
Ccdc92tm1a(KOMP)Mbp/Ccdc92tm1a(KOMP)Mbp
(C57BL/6N-Ccdc92tm1a(KOMP)Mbp)
|
decreased circulating interleukin-1 beta level
|
J:332421
|
decreased circulating interleukin-18 level
|
J:332421
|
decreased inflammatory response
|
J:332421
|
Ccdc171m1Anu/Ccdc171+
(C57BL/NCrlAnu-Ccdc171m1Anu/Anu)
|
decreased IgD level
|
J:104190
|
increased IgM level
|
J:104190
|
Ccdc171m1Anu/Ccdc171m1Anu
(C57BL/NCrlAnu-Ccdc171m1Anu/Anu)
|
decreased IgD level
|
J:104190
|
increased IgM level
|
J:104190
|
Cckbrtm1Tom/Cckbrtm1Tom
(involves: 129S4/SvJae * C57BL/6J)
|
decreased susceptibility to endotoxin shock
|
J:143853
|
Ccl1tm1Sman/Ccl1tm1Sman
(B6.129-Ccl1tm1Sman)
|
abnormal inflammatory response
|
J:138942
|
abnormal regulatory T cell physiology
|
J:138942
|
Ccl2tm1.1Pame/Ccl2tm1.1Pame Tg(Nes-cre)1Kln/0
(involves: C57BL/6 * SJL)
|
abnormal leukocyte migration
|
J:171379
|
increased susceptibility to bacterial infection
|
J:171379
|
Ccl2tm1.1Pame/Ccl2tm1.1Pame Tg(Tek-cre)12Flv/0
(involves: C3H * C57BL/6)
|
abnormal leukocyte migration
|
J:171379
|
increased susceptibility to bacterial infection
|
J:171379
|
Ccl2tm1.1Tyos/Ccl2tm1.1Tyos
(involves: 129S1/Sv * C57BL/6)
|
abnormal chemokine level
|
J:151874
|
abnormal chemokine secretion
|
J:151874
|
abnormal neutrophil physiology
|
J:151874
|
impaired macrophage chemotaxis
|
J:151874
|
Ccl2tm1.1Tyos/Ccl2tm1.1Tyos
(involves: 129S1/Sv)
|
abnormal dendritic cell chemotaxis
|
J:199611
|
abnormal dendritic cell physiology
|
J:199611
|
Ccl2tm1Lex/Ccl2tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6)
|
impaired macrophage chemotaxis
|
J:191510
|
Ccl2tm1Rol/Ccl2tm1Rol
(involves: 129S4/SvJae * 129X1/SvJ * C57BL/6)
|
decreased interferon-gamma secretion
|
J:45920
|
decreased interleukin-4 secretion
|
J:45920
|
decreased interleukin-5 secretion
|
J:45920
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:45920
|
impaired macrophage chemotaxis
|
J:45920
|
Ccl2tm1Rol/Ccl2tm1Rol
(involves: 129S4/SvJae * C57BL/6)
|
abnormal macrophage chemotaxis
|
J:116878
|
abnormal T cell physiology
|
J:116878
|
decreased interferon-gamma secretion
|
J:116878
|
decreased interleukin-1 beta secretion
|
J:116878
|
decreased interleukin-12b secretion
|
J:116878
|
decreased susceptibility to induced colitis
|
J:116878
|
impaired macrophage chemotaxis
|
J:108533
|
Ccl2tm1Rol/Ccl2tm1Rol
(involves: 129S4/SvJae)
|
abnormal macrophage physiology
|
J:155025
|
decreased inflammatory response
|
J:155025
|
impaired macrophage chemotaxis
|
J:147697
|
increased circulating interferon-gamma level
|
J:155025
|
increased circulating interleukin-10 level
|
J:155025
|
increased circulating tumor necrosis factor level
|
J:155025
|
increased susceptibility to infection induced morbidity/mortality
|
J:155025
|
increased susceptibility to parasitic infection
|
J:155025
|
Ccl2tm1Rol/Ccl2tm1Rol
(B6.129S4-Ccl2tm1Rol)
|
abnormal chemokine level
|
J:151874,
J:118606
|
abnormal chemokine secretion
|
J:151874
|
abnormal cytokine secretion
|
J:68145
|
abnormal macrophage chemotaxis
|
J:109290
|
abnormal neutrophil physiology
|
J:151874
|
decreased interferon-gamma secretion
|
J:68145
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:68145
|
impaired macrophage chemotaxis
|
J:151874,
J:68145,
J:118606
|
increased IgG1 level
|
J:68145
|
increased IgG level
|
J:147328
|
increased interleukin-10 secretion
|
J:68145
|
Ccl2tm1Rol/Ccl2tm1Rol
(SJL.129S4-Ccl2tm1Rol)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:68145
|
Ccl2tm1Rol/Ccl2tm1Rol
(B6.129S4-Ccl2tm1Rol/J)
|
abnormal microglial cell physiology
|
J:141739
|
Ccl2tm1Rol/Ccl2tm1Rol Cx3cr1tm1Litt/Cx3cr1tm1Litt
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J)
|
abnormal macrophage physiology
|
J:200877
|
increased microglial cell activation
|
J:200877
|
Ccl2tm1Rol/Ccl2tm1Rol Mpztm1Msch/Mpz+
(involves: 129S4/SvJae * 129S7/SvEvBrd)
|
abnormal cytokine level
|
J:133028
|
Ccl2tm1Rol/Ccl2tm1Rol Tg(Ccr2-EGFP)8Pame/0
(involves: 129S4/SvJae * C57BL/6J)
|
abnormal leukocyte migration
|
J:171379
|
Ccl2tm1Tyos/Ccl2tm1Tyos
(involves: 129S1/Sv * C57BL/6)
|
abnormal chemokine level
|
J:151874
|
abnormal chemokine secretion
|
J:151874
|
Ccl3tm1Unc/Ccl3tm1Unc
(involves: 129P2/OlaHsd)
|
abnormal susceptibility to Orthomyxoviridae infection
|
J:107677
|
cecum inflammation
|
J:107677
|
decreased susceptibility to bacterial infection
|
J:107677
|
decreased susceptibility to Orthomyxoviridae infection
|
J:107677
|
decreased susceptibility to Picornaviridae infection
|
J:28704
|
Ccl3tm1Unc/Ccl3tm1Unc
(B6.129P2-Ccl3tm1Unc/J)
|
decreased susceptibility to type III hypersensitivity reaction
|
J:94599
|
Ccl3tm1Unc/Ccl3tm1Unc
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased microglial cell activation
|
J:153059
|
Ccl3tm1Unc/Ccl3tm1Unc Hexbtm1Rlp/Hexbtm1Rlp
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
abnormal tumor necrosis factor level
|
J:90687
|
CNS inflammation
|
J:90687
|
Ccl4em1Narl/Ccl4em1Narl
(C57BL/6JNarl-Ccl4em1Narl)
|
decreased inflammatory response
|
J:346348
|
decreased susceptibility to autoimmune diabetes
|
J:346348
|
Ccl5tm1Hso/Ccl5tm1Hso
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased interferon-gamma secretion
|
J:75842
|
decreased interleukin-2 secretion
|
J:75842
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:75842
|
decreased T cell proliferation
|
J:75842
|
Ccl11tm1Mer/Ccl11tm1Mer
(involves: 129S6/SvEvTac * NIH Black Swiss)
|
impaired eosinophil recruitment
|
J:38945
|
Ccl11tm1Mer/Ccl11tm1Mer Ccl24tm1Mer/Ccl24tm1Mer
(129S.129S6(Cg)-Ccl24tm1Mer Ccl11tm1Mer)
|
abnormal immune system physiology
|
J:102034
|
abnormal inflammatory response
|
J:102034
|
Ccl17tm1.1Ifo/Ccl17tm1.1Ifo
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:159098
|
increased length of allograft survival
|
J:159098
|
Ccl17tm2.1(cre)Ifo/Ccl17+ Hif1atm3Rsjo/Hif1atm3Rsjo
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal interleukin-1 beta secretion
|
J:187773
|
abnormal leukocyte migration
|
J:187773
|
abnormal tumor necrosis factor secretion
|
J:187773
|
Ccl21atm1Yout/Ccl21atm1Yout
(involves: C57BL/6NCrlj * CBA/JNCrlj)
|
lacrimal gland inflammation
|
J:244640
|
Ccl22tm1(KOMP)Vlcg/Ccl22tm1(KOMP)Vlcg
(involves: C57BL/6NTac)
|
abnormal dendritic cell physiology
|
J:236051
|
Ccl24tm1Mer/Ccl24tm1Mer
(129S.129S6-Ccl24tm1Mer)
|
abnormal immune system physiology
|
J:98708,
J:102034
|
Ccl24tm1Mer/Ccl24tm1Mer
(involves: 129S6/SvEvTac * C57BL/6J)
|
abnormal immune system physiology
|
J:98708
|
Ccl25tm1.1Mal/Ccl25tm1.1Mal Tnftm2Gkl/Tnf+
(involves: 129S/SvEv * 129S2/SvPas * C57BL/6)
|
intestinal inflammation
|
J:136667
|
Ccl27aem1Nax/Ccl27aem1Nax Ccl27alem1Nax/Ccl27alem1Nax Ccl27bem1Nax/Ccl27bem1Nax
(involves: C57BL/6)
|
impaired leukocyte migration
|
J:330550
|
increased interleukin-17 secretion
|
J:330550
|
increased susceptibility to chemically induced skin inflammation
|
J:330550
|
Ccl27aem1Nax/Ccl27aem1Nax Ccl27alem1Nax/Ccl27alem1Nax Ccl27bem1Nax/Ccl27bem1Nax Ccr10tm1.1Nax/Ccr10+
(involves: C57BL/6)
|
impaired leukocyte migration
|
J:330550
|
increased interleukin-10 secretion
|
J:330550
|
uterus inflammation
|
J:330550
|
Ccl28tm1Takna/Ccl28tm1Takna
(C57BL/6J-Ccl28tm1Takna)
|
decreased IgA level
|
J:256896
|
increased IgG level
|
J:256896
|
increased susceptibility to induced colitis
|
J:256896
|
Ccm2tm1Kwhi/Ccm2tm1.1Kwhi Tg(Pdgfb-icre/ERT2,-EGFP)1Frut/?
(involves: C57BL/6 * CBA)
|
CNS inflammation
|
J:173947
|
Ccn3tm1.1Ecan/Ccn3tm1.1Ecan
(B6.Cg-Ccn3tm1.1Ecan)
|
abnormal osteoclast physiology
|
J:158478
|
Ccnd3tm1.1(Ccnd2)Iaai/Ccnd3tm1.1(Ccnd2)Iaai
(involves: 129S6/SvEvTac)
|
decreased B cell proliferation
|
J:192031
|
decreased T cell proliferation
|
J:192031
|
Ccnd3tm1Pisc/Ccnd3tm1Pisc
(Not Specified)
|
decreased B cell proliferation
|
J:192031
|
decreased T cell proliferation
|
J:88120,
J:192031
|
Ccnd3tm1Pisc/Ccnd3tm1Pisc Cdkn1btm1Mlf/Cdkn1btm1Mlf
(involves: 129S4/SvJaeSor)
|
decreased T cell proliferation
|
J:192031
|
Ccnd3tm1Pisc/Ccnd3tm1Pisc Rag2tm1Fwa/Rag2tm1Fwa
(involves: 129S/SvEv)
|
increased T cell proliferation
|
J:88120
|
Ccnd3tm1Pisc/Ccnd3tm1Pisc Rb1tm2Brn/Rb1tm2Brn Tg(Mx1-cre)1Cgn/0
(involves: 129 * C57BL/6 * CBA)
|
decreased T cell proliferation
|
J:192031
|
Ccne1tm1Jro/Ccne1tm1Jro
(either: 129-Ccne1tm1Jro or B6.129-Ccne1tm1Jro)
|
increased splenocyte proliferation
|
J:99695
|
Ccnt1Gt(RRR115)Byg/Ccnt1Gt(RRR115)Byg
(involves: 129P2/OlaHsd)
|
abnormal thymus physiology
|
J:130071
|
autoimmune response
|
J:130071
|
lacrimal gland inflammation
|
J:130071
|
salivary gland inflammation
|
J:130071
|
Ccpg1tm1a(EUCOMM)Hmgu/Ccpg1tm1a(EUCOMM)Hmgu
(C57BL/6N-Ccpg1tm1a(EUCOMM)Hmgu)
|
pancreas inflammation
|
J:256708
|
Ccr1tm1Cge/Ccr1tm1Cge
(involves: 129S4/SvJae)
|
decreased tumor necrosis factor secretion
|
J:43569
|
glomerulonephritis
|
J:115119
|
impaired neutrophil recruitment
|
J:43569
|
increased IgG2a level
|
J:115119
|
increased interferon-gamma secretion
|
J:115119
|
increased susceptibility to type IV hypersensitivity reaction
|
J:115119
|
increased tumor necrosis factor secretion
|
J:115119
|
lung inflammation
|
J:43569
|
Ccr1tm1Cge/Ccr1tm1Cge
(involves: 129S4/SvJae * C57BL/6)
|
cecum inflammation
|
J:107677
|
decreased susceptibility to bacterial infection
|
J:107677
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:63952
|
increased length of allograft survival
|
J:59235
|
Ccr1tm1Cge/Ccr1tm1Cge
(involves: 129S4/SvJae * BALB/c)
|
abnormal chemokine secretion
|
J:169909
|
abnormal circulating chemokine level
|
J:169909
|
abnormal macrophage physiology
|
J:169909
|
decreased circulating interferon-gamma level
|
J:169909
|
decreased interleukin-10 secretion
|
J:169909
|
decreased susceptibility to bacterial infection
|
J:169909
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:169909
|
decreased tumor necrosis factor secretion
|
J:169909
|
increased interleukin-12 secretion
|
J:169909
|
increased macrophage nitric oxide production
|
J:169909
|
increased tumor necrosis factor secretion
|
J:169909
|
Ccr1tm1Cge/Ccr1tm1Cge
(C.129S4-Ccr1tm1Cge)
|
decreased interleukin-13 secretion
|
J:95242
|
decreased susceptibility to Riboviria infection
|
J:95242
|
Ccr1tm1Gao/Ccr1tm1Gao
(involves: 129S4/SvJae * C57BL/6)
|
abnormal neutrophil physiology
|
J:41324
|
granulomatous inflammation
|
J:41324
|
increased susceptibility to fungal infection
|
J:41324
|
increased susceptibility to parasitic infection
|
J:41324
|
Ccr1tm1Gao/Ccr1tm1Gao
(involves: C57BL/6)
|
decreased susceptibility to type III hypersensitivity reaction
|
J:94599
|
Ccr1tm1Gao/Ccr1tm1Gao
(B6.129S4-Ccr1tm1Gao)
|
abnormal cellular extravasation
|
J:104744
|
abnormal leukocyte adhesion
|
J:104744
|
bronchiolitis
|
J:162707
|
increased susceptibility to Coronaviridae infection
|
J:162707
|
increased susceptibility to Coronaviridae infection induced morbidity/mortality
|
J:162707
|
Ccr2tm1.1Dnc/Ccr2tm1.1Dnc
(Not Specified)
|
abnormal dendritic cell chemotaxis
|
J:223508
|
Ccr2tm1Blck/Ccr2tm1Blck
(B6.129P2-Ccr2tm1Blck)
|
abnormal cellular extravasation
|
J:104744
|
abnormal leukocyte adhesion
|
J:104744
|
Ccr2tm1Blck/Ccr2tm1Blck Faslpr/Faslpr
(MRL.Cg-Ccr2tm1Blck Faslpr)
|
abnormal interferon level
|
J:113343
|
abnormal tumor necrosis factor level
|
J:113343
|
glomerulonephritis
|
J:113343
|
kidney inflammation
|
J:113343
|
Ccr2tm1Brv/Ccr2tm1Brv
(involves: 129S1/Sv * ICR)
|
impaired macrophage chemotaxis
|
J:111517
|
increased susceptibility to bacterial infection
|
J:111517
|
liver inflammation
|
J:111517
|
Ccr2tm1Ifc/Ccr2+
(involves: 129S4/SvJae * C57BL/6)
|
impaired macrophage chemotaxis
|
J:121703
|
Ccr2tm1Ifc/Ccr2tm1Ifc
(B6.129S4-Ccr2tm1Ifc/J)
|
abnormal leukocyte migration
|
J:106738
|
abnormal leukocyte physiology
|
J:122119
|
abnormal microglial cell physiology
|
J:106738
|
abnormal osteoclast physiology
|
J:149360
|
decreased acute inflammation
|
J:106738
|
decreased interferon-gamma secretion
|
J:106738
|
increased susceptibility to Coronaviridae infection
|
J:106738
|
increased susceptibility to Coronaviridae infection induced morbidity/mortality
|
J:106738
|
Ccr2tm1Ifc/Ccr2tm1Ifc
(involves: 129S4/SvJae * C57BL/6)
|
abnormal immune serum protein physiology
|
J:118971
|
abnormal Langerhans cell physiology
|
J:112594
|
abnormal macrophage chemotaxis
|
J:44345
|
abnormal microglial cell physiology
|
J:121703
|
decreased inflammatory response
|
J:44345
|
decreased interferon-gamma secretion
|
J:75838,
J:44345
|
decreased interleukin-2 secretion
|
J:44345
|
decreased interleukin-6 secretion
|
J:75838
|
decreased splenocyte proliferation
|
J:75838
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:75838
|
decreased susceptibility to type I hypersensitivity reaction
|
J:118971
|
decreased T cell proliferation
|
J:75838
|
impaired macrophage chemotaxis
|
J:81363,
J:44345,
J:121703
|
increased interferon-gamma secretion
|
J:61542
|
increased tumor necrosis factor secretion
|
J:61542
|
Ccr2tm1Ifc/Ccr2tm1Ifc
(B6.129S4-Ccr2tm1Ifc)
|
decreased susceptibility to induced colitis
|
J:161138
|
impaired leukocyte tethering or rolling
|
J:154558
|
Ccr2tm1Ifc/Ccr2tm1Ifc Tg(APPSWE)2576Kha/0
(involves: 129S4/SvJae * C57BL/6 * SJL)
|
abnormal microglial cell physiology
|
J:121703
|
Ccr2tm1Mae/Ccr2tm1Mae
(involves: 129P2/OlaHsd * C57BL/6J)
|
abnormal cytokine secretion
|
J:110814
|
decreased inflammatory response
|
J:110814
|
increased susceptibility to induced colitis
|
J:110814
|
Ccr2tm1Mae/Ccr2tm1Mae
(B6.129P2-Ccr2tm1Mae)
|
bronchiolitis
|
J:162707
|
increased IgG level
|
J:147328
|
increased susceptibility to Coronaviridae infection
|
J:162707
|
Ccr2tm1Mae/Ccr2tm1Mae
(involves: 129P2/OlaHsd)
|
abnormal chemokine secretion
|
J:151874
|
abnormal leukocyte migration
|
J:171379
|
impaired macrophage chemotaxis
|
J:191510,
J:151874
|
Ccr2tm1Mae/Ccr2tm1Mae
(involves: 129P2/OlaHsd * BALB/c)
|
abnormal leukocyte physiology
|
J:162714
|
impaired macrophage chemotaxis
|
J:162714
|
Ccr2tm2.1Ifc/Ccr2tm2.1Ifc Cx3cr1tm1Litt/Cx3cr1+
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
abnormal leukocyte physiology
|
J:166664
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:166664
|
Ccr2tm2.1Ifc/Ccr2tm2.1Ifc Cx3cr1tm1Litt/Cx3cr1tm1Litt
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
abnormal leukocyte physiology
|
J:166664
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:166664
|
Ccr3tm1Cge/Ccr3tm1Cge
(involves: 129S4/SvJae * BALB/c)
|
abnormal eosinophil physiology
|
J:74509,
J:75347
|
abnormal mast cell physiology
|
J:74509
|
decreased circulating interleukin-4 level
|
J:115273
|
impaired eosinophil chemotaxis
|
J:74509
|
impaired eosinophil recruitment
|
J:74509,
J:75347
|
increased mast cell degranulation
|
J:74509
|
Ccr4tm1Pwr/Ccr4tm1Pwr
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal chemokine secretion
|
J:70088
|
abnormal cytokine secretion
|
J:120221
|
abnormal splenocyte physiology
|
J:70088
|
decreased IgE level
|
J:120221
|
decreased interleukin-1 beta secretion
|
J:70088
|
decreased interleukin-4 secretion
|
J:120221
|
decreased interleukin-5 secretion
|
J:120221
|
decreased interleukin-10 secretion
|
J:120221
|
decreased interleukin-13 secretion
|
J:120221
|
decreased susceptibility to endotoxin shock
|
J:70088
|
decreased susceptibility to fungal infection
|
J:120221
|
decreased tumor necrosis factor secretion
|
J:70088
|
increased IgE level
|
J:120221
|
increased IgG1 level
|
J:120221
|
increased interferon-gamma secretion
|
J:120221
|
increased interleukin-4 secretion
|
J:120221
|
increased interleukin-5 secretion
|
J:120221
|
increased interleukin-10 secretion
|
J:120221
|
increased tumor necrosis factor secretion
|
J:120221
|
Ccr4tm1Pwr/Ccr4tm1Pwr
(B6.129P2-Ccr4tm1Pwr)
|
increased length of allograft survival
|
J:95239
|
Ccr5tm1Blck/Ccr5tm1Blck
(B6.129P2-Ccr5tm1Blck)
|
abnormal cellular extravasation
|
J:104744
|
abnormal leukocyte adhesion
|
J:104744
|
increased length of allograft survival
|
J:105072
|
Ccr5tm1Brv/Ccr5tm1Brv
(either: (involves: 129S1/Sv * ICR) or (involves: 129S1/Sv * 129X1/SvJ * ICR))
|
abnormal cytokine secretion
|
J:46941
|
decreased interleukin-1 beta secretion
|
J:46941
|
decreased interleukin-6 secretion
|
J:46941
|
decreased susceptibility to endotoxin shock
|
J:46941
|
increased IgG1 level
|
J:46941
|
increased interferon-gamma secretion
|
J:46941
|
increased interleukin-4 secretion
|
J:46941
|
increased susceptibility to bacterial infection
|
J:46941
|
increased susceptibility to type IV hypersensitivity reaction
|
J:46941
|
Ccr5tm1Kuz/Ccr5tm1Kuz
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal cytokine level
|
J:110814
|
abnormal NK T cell physiology
|
J:100869
|
decreased microglial cell activation
|
J:153059
|
decreased susceptibility to induced colitis
|
J:110814
|
decreased susceptibility to Retroviridae infection
|
J:132342
|
impaired macrophage chemotaxis
|
J:153059,
J:84243,
J:64293
|
increased susceptibility to fungal infection
|
J:64293
|
Ccr5tm1Kuz/Ccr5tm1Kuz
(B6.129P2-Ccr5tm1Kuz)
|
bronchiolitis
|
J:162707
|
increased susceptibility to Coronaviridae infection
|
J:162707
|
Ccr5tm1Kuz/Ccr5tm1Kuz
(involves: 129P2/OlaHsd)
|
decreased inflammatory response
|
J:227458
|
Ccr5tm1Kuz/Ccr5tm1Kuz Cxcr4tm1Qma/Cxcr4tm1Qma
(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6)
|
decreased susceptibility to Retroviridae infection
|
J:132342
|
Ccr5tm1Sush/Ccr5tm1Sush
(B6.129P2-Ccr5tm1Sush)
|
abnormal leukocyte physiology
|
J:94937
|
decreased T cell proliferation
|
J:94937
|
Ccr6tm1(EGFP)Irw/Ccr6tm1(EGFP)Irw
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal B cell physiology
|
J:120122
|
abnormal follicular dendritic cell physiology
|
J:113363
|
abnormal T cell physiology
|
J:85086
|
impaired B cell migration
|
J:120122
|
increased T cell proliferation
|
J:85086
|
Ccr6tm1(EGFP)Irw/Ccr6tm1(EGFP)Irw
(B6.129S6-Ccr6tm1(EGFP)Irw)
|
decreased interleukin-4 secretion
|
J:132012
|
decreased interleukin-12 secretion
|
J:132012
|
decreased susceptibility to bacterial infection
|
J:132012
|
decreased tumor necrosis factor secretion
|
J:132012
|
increased interferon-gamma secretion
|
J:132012
|
Ccr6tm1.1Jmf/Ccr6tm1.1Jmf
(B6.129-Ccr6tm1.1Jmf)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:152716
|
abnormal dendritic cell physiology
|
J:152716
|
abnormal interleukin secretion
|
J:152716
|
decreased inflammatory response
|
J:152716
|
Ccr6tm1Gma/Ccr6tm1Gma
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:68191
|
decreased inflammatory response
|
J:68191
|
Ccr6tm1Lira/Ccr6tm1Lira
(involves: 129)
|
abnormal follicular dendritic cell antigen presentation
|
J:113363
|
abnormal T cell physiology
|
J:123150
|
Ccr6tm1Lira/Ccr6tm1Lira
(involves: 129 * C57BL/6)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:148286
|
abnormal macrophage physiology
|
J:124358
|
decreased IgA level
|
J:76461
|
decreased IgG3 level
|
J:76461
|
decreased inflammatory response
|
J:124358
|
decreased interleukin-10 secretion
|
J:124358
|
decreased interleukin-12 secretion
|
J:124358
|
decreased macrophage cytokine production
|
J:124358
|
decreased macrophage nitric oxide production
|
J:124358
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:148286
|
decreased tumor necrosis factor secretion
|
J:124358
|
increased IgM level
|
J:76461
|
increased susceptibility to Riboviria infection
|
J:76461
|
Ccr6tm1Lira/Ccr6tm1Lira
(B6.129-Ccr6tm1Lira)
|
decreased IgE level
|
J:71096
|
decreased interleukin-5 secretion
|
J:71096
|
decreased susceptibility to type I hypersensitivity reaction
|
J:71096
|
impaired eosinophil recruitment
|
J:71096
|
Ccr7tm1Dgen/Ccr7tm1Dgen
(involves: 129P2/OlaHsd * C57BL/6)
|
chronic inflammation
|
J:101679
|
Ccr7tm1Rfor/Ccr7tm1Rfor
(involves: 129P2/OlaHsd * BALB/c)
|
abnormal B cell activation
|
J:57976
|
abnormal class switch recombination
|
J:57976
|
abnormal dendritic cell physiology
|
J:57976
|
abnormal humoral immune response
|
J:57976
|
abnormal leukocyte migration
|
J:57976
|
abnormal T cell physiology
|
J:57976
|
decreased IgG3 level
|
J:57976
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:57976
|
impaired B cell migration
|
J:57976
|
increased IgE level
|
J:57976
|
increased IgG1 level
|
J:57976
|
increased IgG2a level
|
J:57976
|
Ccr7tm1Rfor/Ccr7tm1Rfor
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6)
|
abnormal dendritic cell physiology
|
J:134784
|
Ccr7tm1Rfor/Ccr7tm1Rfor
(B6.129P2-Ccr7tm1Rfor)
|
abnormal dendritic cell physiology
|
J:183989
|
abnormal leukocyte migration
|
J:93960,
J:110910
|
increased inflammatory response
|
J:110910
|
increased susceptibility to autoimmune disorder
|
J:110910
|
lacrimal gland inflammation
|
J:110910
|
parotid gland inflammation
|
J:110910
|
salivary gland inflammation
|
J:110910
|
submandibular gland inflammation
|
J:110910
|
Ccr7tm1Rfor/Ccr7tm1Rfor
(B6.129P2(C)-Ccr7tm1Rfor/J)
|
decreased susceptibility to bacterial infection
|
J:210086
|
Ccr7tm1Rfor/Ccr7tm1Rfor
(involves: 129P2/OlaHsd)
|
abnormal dendritic cell chemotaxis
|
J:223508
|
Ccr7tm1Rfor/Ccr7tm1Rfor Tg(DO11.10)10Dlo/?
(involves: 129P2/OlaHsd * BALB/c * C3H * C57BL/6)
|
abnormal leukocyte migration
|
J:123482
|
abnormal regulatory T cell physiology
|
J:123482
|
Ccr8tm1Lira/Ccr8tm1Lira
(involves: 129S/SvEv * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:118417
|
Ccr9tm1.1Mal/Ccr9tm1.1Mal Tnftm2Gkl/Tnf+
(involves: 129S/SvEv * 129S2/SvPas * C57BL/6)
|
intestinal inflammation
|
J:136667
|
Ccr10tm1Cge/Ccr10tm1Cge
(C.129S4-Ccr10tm1Cge)
|
abnormal leukocyte migration
|
J:140728
|
decreased IgA level
|
J:140728
|
Ccrl2tm1Lex/Ccrl2tm1Lex
(involves: 129S/SvEvBrd * C57BL/6)
|
decreased susceptibility to type I hypersensitivity reaction
|
J:140110
|
Ccrl2tm1Ssoz/Ccrl2tm1Ssoz
(B6.129-Ccrl2tm1Ssoz)
|
abnormal dendritic cell chemotaxis
|
J:165873
|
abnormal hypersensitivity reaction
|
J:165873
|
abnormal T-helper 2 physiology
|
J:165873
|
decreased interleukin-4 secretion
|
J:165873
|
decreased interleukin-5 secretion
|
J:165873
|
decreased interleukin-13 secretion
|
J:165873
|
Cd1tm1Gru/Cd1tm1Gru
(involves: 129S2/SvPas * BALB/c)
|
decreased interleukin-4 secretion
|
J:47769
|
decreased susceptibility to infection induced morbidity/mortality
|
J:126220
|
myocarditis
|
J:126220
|
Cd1d1tm1.1Aben/Cd1d1tm1.1Aben Lyz2tm1(cre)Ifo/Lyz2+
(B6.Cg-Cd1d1tm1.1Aben Lyz2tm1(cre)Ifo)
|
decreased interferon-gamma secretion
|
J:183087
|
decreased interleukin-4 secretion
|
J:183087
|
Cd1d1tm1.1Aben/Cd1d1tm1.1Aben Tg(Itgax-cre,-EGFP)4097Ach/0
(C57BL/6-Cd1d1tm1.1Aben Tg(Itgax-cre,-EGFP)4097Ach)
|
decreased interferon-gamma secretion
|
J:183087
|
decreased interleukin-4 secretion
|
J:183087
|
Cd1d1tm1.1Boes/Cd1d1tm1.1Boes
(involves: C57BL/6)
|
abnormal dendritic cell antigen presentation
|
J:151699
|
abnormal interleukin-4 secretion
|
J:151699
|
abnormal NK T cell physiology
|
J:151699
|
decreased interleukin-2 secretion
|
J:151699
|
Cd1d1tm1.1Boes/Cd1d1tm1.1Boes Cd74tm1Doi/Cd74tm1Doi
(involves: 129S2/SvPas * C57BL/6)
|
abnormal dendritic cell antigen presentation
|
J:151699
|
Cd1d1tm1.2Aben/Cd1d1tm1.2Aben
(B6(C)-Cd1d1tm1.2Aben/J)
|
abnormal T cell activation
|
J:177038
|
increased susceptibility to bacterial infection
|
J:177038
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:177038
|
lung inflammation
|
J:177038
|
Cd1d1tm1Crw/Cd1d1tm1Crw
(B6.129S4-Cd1d1tm1Crw)
|
decreased IgG level
|
J:99107
|
decreased susceptibility to induced arthritis
|
J:99107
|
Cd1d1tm1Luc/Cd1d1tm1Luc
(B6.129S6-Cd1d1tm1Luc)
|
autoimmune response
|
J:122245
|
Cd1d1tm1Luc/Cd1d1tm1Luc
(involves: 129S6/SvEvTac * C57BL/6)
|
decreased acute inflammation
|
J:93915
|
decreased interferon-gamma secretion
|
J:93915,
J:39748
|
decreased interleukin-4 secretion
|
J:39748
|
decreased tumor necrosis factor secretion
|
J:93915
|
Cd1d1tm1Luc/Cd1d1tm1Luc
(C.129S6-Cd1d1tm1Luc)
|
decreased interleukin-4 secretion
|
J:121187
|
glomerulonephritis
|
J:121187
|
increased anti-double stranded DNA antibody level
|
J:121187
|
increased anti-nuclear antigen antibody level
|
J:121187
|
increased IgG3 level
|
J:121187
|
kidney inflammation
|
J:121187
|
Cd1d1tm1Luc/Cd1d1tm1Luc Cx3cr1tm1Litt/Cx3cr1tm1Litt
(B6.129-Cd1d1tm1Luc Cx3cr1tm1Litt)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:129712
|
Cd1d1tm2Aben/Del(3Cd1d2-Cd1d1)1Crw
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
abnormal antigen presentation
|
J:174337
|
Cd1d1tm2Aben/Cd1d1tm2Aben
(B6.129P2-Cd1d1tm2Aben)
|
abnormal antigen presentation
|
J:174337
|
Cd1d1tm2Aben/Cd1d1tm2Aben
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal antigen presentation
|
J:174337
|
Cd2apem1Irgu/Cd2apem1Irgu
(C57BL/6-Cd2apem1Irgu)
|
kidney inflammation
|
J:294238
|
Cd2aptm1Shaw/Cd2aptm1Shaw
(involves: 129X1/SvJ)
|
decreased T cell proliferation
|
J:57971
|
Cd2bp2tm1.1Tbh/Cd2bp2tm1.1Tbh Tg(Mx1-cre)1Cgn/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * C57BL/6N * CBA/J)
|
impaired macrophage phagocytosis
|
J:283435
|
Cd3em1Btlr/Cd3em1Btlr
(C57BL/6J-Cd3em1Btlr)
|
increased T cell apoptosis
|
J:132486
|
Cd3em1Btlr/Cd3em1Btlr
(involves: C57BL/6J)
|
abnormal class switch recombination
|
J:185495
|
Cd3etm1Mal/Cd3etm1Mal
(C57BL/6-Cd3etm1Mal)
|
abnormal regulatory T cell physiology
|
J:125748
|
Cd3etm1Mal/Cd3etm1Mal Nlrp1aNeut1/Nlrp1aNeut1
(involves: C57BL/6)
|
increased susceptibility to infection induced morbidity/mortality
|
J:191055
|
skin inflammation
|
J:191055
|
Cd3gtm1.1Cage/Cd3gtm1.1Cage
(B6.129P2-Cd3gtm1.1Cage)
|
abnormal response to infection
|
J:153813
|
increased T cell apoptosis
|
J:153813
|
Cd3gtm1.1Cage/Cd3gtm1.1Cage Tg(TcrLCMV)318Sdz/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N)
|
abnormal response to infection
|
J:142387
|
abnormal T cell physiology
|
J:142387
|
Cd3gtm1Amk/Cd3gtm1Amk
(involves: 129P2/OlaHsd)
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:77504
|
abnormal T cell activation
|
J:77504
|
abnormal T cell physiology
|
J:77504
|
abnormal T cell proliferation
|
J:77504
|
decreased cytotoxic T cell cytolysis
|
J:77504
|
Cd4del/Cd4del
(C57BR/cdJ-Cd4del)
|
decreased IgG level
|
J:46692
|
decreased IgM level
|
J:46692
|
decreased immunoglobulin level
|
J:46692
|
Cd4em1Litt/Cd4em1Litt Rr386em1Pdi/Rr386em1Pdi
(involves: C57BL/6J)
|
abnormal lymphocyte activation involved in immune response
|
J:333574
|
Cd4m1Btlr/Cd4m1Btlr
(C57BL/6J-Cd4m1Btlr)
|
impaired humoral immune response
|
J:212900
|
Cd4tm1(cre/ERT2)Thbu/Cd4+ Gfm1tm1c(EUCOMM)Wtsi/Gfm1tm1c(EUCOMM)Wtsi
(involves: C57BL/6 * C57BL/6N * SJL)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:302272
|
Cd4tm1Doi/Cd4tm1Doi Lag3tm1Doi/Lag3tm1Doi
(involves: 129 * C57BL/6)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:33272
|
Cd4tm1Doi/Cd4tm1Litt Lag3tm1Doi/Lag3+
(involves: 129 * C57BL/6)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:33272
|
Cd4tm1Knw/Cd4tm1Knw
(B6.129S-Cd4tm1Knw/J)
|
increased susceptibility to parasitic infection
|
J:87828
|
Cd4tm1Knw/Cd4tm1Knw
(NOD.Cg-Cd4tm1Knw)
|
decreased susceptibility to autoimmune diabetes
|
J:93553
|
Cd4tm1Knw/Cd4tm1Knw Tg(TcraAI4)1Dvs/0 Tg(TcrbAI4)1Dvs/0
(NOD.Cg-Cd4tm1Knw Tg(TcraAI4)1Dvs Tg(TcrbAI4)1Dvs)
|
increased susceptibility to autoimmune diabetes
|
J:93553
|
Cd4tm1Litt/Cd4tm1Litt
(involves: 129S2/SvPas)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:50435
|
decreased T cell proliferation
|
J:50435
|
Cd4tm1Litt/Cd4tm1Litt Foxp3sfOtcspf/Y
(involves: 129/Rl * 129S2/SvPas)
|
abnormal cytokine secretion
|
J:20865
|
increased IgG level
|
J:20865
|
increased IgM level
|
J:20865
|
increased interleukin-4 secretion
|
J:20865
|
increased interleukin-6 secretion
|
J:20865
|
increased tumor necrosis factor secretion
|
J:20865
|
Cd4tm1Litt/Cd4tm1Nik Tg(Lck-cre)3778Nik/0
(involves: 129S2/SvPas * 129X1/SvJ * C57BL/6 * DBA/2)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:73479
|
abnormal interleukin-4 secretion
|
J:73479
|
abnormal T-helper 2 physiology
|
J:73479
|
decreased T cell proliferation
|
J:73479
|
Cd4tm1Litt/Cd4tm1Nik Tg(Lck-cre)3785Nik/0
(involves: 129S2/SvPas * 129X1/SvJ * C57BL/6 * DBA/2)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:73479
|
increased T cell apoptosis
|
J:73479
|
increased T cell proliferation
|
J:73479
|
Cd4tm1Litt/Cd4tm1Nik Tg(Lck-icre)3779Nik/0
(involves: 129S2/SvPas * 129X1/SvJ * C57BL/6 * DBA/2)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:73479
|
decreased T cell proliferation
|
J:73479
|
Cd4tm1Mak/Cd4tm1Mak
(involves: 129S2/SvPas * C57BL/6 * DBA/2)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:68957
|
increased susceptibility to Picornaviridae infection
|
J:92227
|
Cd4tm1Mak/Cd4tm1Mak
(PL.129S2(B6)-Cd4tm1Mak/Rdgz)
|
brain inflammation
|
J:92227
|
increased susceptibility to Picornaviridae infection
|
J:92227
|
Cd4tm1Mak/Cd4tm1Mak
(SJL.129S2(B6)-Cd4tm1Mak/Rdgz)
|
brain inflammation
|
J:92227
|
increased susceptibility to Picornaviridae infection
|
J:92227
|
Cd4tm1Mak/Cd4tm1Mak Cd8atm1Mak/Cd8atm1Mak
(involves: 129S2/SvPas * C57BL/6 * DBA/2)
|
decreased cytotoxic T cell cytolysis
|
J:12572
|
increased length of allograft survival
|
J:12572
|
Cd4tm1Mak/Cd4tm1Mak Cd8atm1Mak/Cd8atm1Mak
(involves: 129S2/SvPas)
|
increased susceptibility to viral infection
|
J:110749
|
Cd4tm1Mak/Cd4tm1Mak Igh-Jtm2(3H9-VDJ*)Mwg/Igh-J+
(B6.Cg-Cd4tm1Mak Igh-Jtm2(3H9-VDJ*)Mwg)
|
increased anti-double stranded DNA antibody level
|
J:142389
|
Cd4tm1Mak/Cd4tm1Mak Tnftm2Gkl/Tnf+
(involves: 129S/SvEv * 129S2/SvPas * C57BL/6J)
|
small intestinal inflammation
|
J:108572
|
Cd4tm1Nik/Cd4tm1Nik Tnfrsf4tm2(cre)Nik/Tnfrsf4+
(involves: 129X1/SvJ)
|
abnormal regulatory T cell physiology
|
J:152472
|
Cd5tm1.1Chra/Cd5tm1.1Chra
(involves: C57BL/6 * FVB/N)
|
abnormal T cell anergy
|
J:189919
|
abnormal T cell physiology
|
J:189919
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:189919
|
decreased T cell proliferation
|
J:189919
|
increased T cell proliferation
|
J:189919
|
Cd5tm1.1Chra/Cd5tm1.1Chra Tg(Tcra2D2,Tcrb2D2)1Kuch/0
(involves: C57BL/6 * FVB/N)
|
decreased interferon-gamma secretion
|
J:189919
|
decreased interleukin-2 secretion
|
J:189919
|
decreased T cell proliferation
|
J:189919
|
increased interferon-gamma secretion
|
J:189919
|
increased interleukin-6 secretion
|
J:189919
|
increased interleukin-17 secretion
|
J:189919
|
Cd5tm1Cgn/Cd5tm1Cgn
(B6.129P2-Cd5tm1Cgn)
|
abnormal T cell anergy
|
J:189919
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:189919
|
increased T cell proliferation
|
J:189919
|
Cd5ltm1Nto/Cd5ltm1Nto
(involves: 129P2/OlaHsd * C57BL/6)
|
increased susceptibility to bacterial infection
|
J:82352
|
Cd6tm1Linf/Cd6tm1Linf
(D1.Cg-Cd6tm1Linf)
|
abnormal B cell physiology
|
J:238478
|
decreased B cell proliferation
|
J:238478
|
decreased IgM level
|
J:238478
|
decreased interleukin-6 secretion
|
J:238478
|
Cd7tm1Bfh/Cd7tm1Bfh
(B6.129-Cd7tm1Bfh)
|
decreased cytotoxic T cell cytolysis
|
J:48758
|
decreased interferon-gamma secretion
|
J:48758
|
Cd8am1Btlr/Cd8am1Btlr
(C57BL/6J-Cd8am1Btlr)
|
increased susceptibility to Herpesvirales infection
|
J:221492
|
Cd8am2Btlr/Cd8am2Btlr
(C57BL/6J-Cd8am2Btlr)
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:236677
|
increased CD8-positive, alpha-beta memory T cell proliferation
|
J:236677
|
Cd8atm1Mak/Cd8atm1Mak
(involves: 129S2/SvPas * C57BL/6 * DBA/2)
|
abnormal cytotoxic T cell physiology
|
J:68956
|
increased susceptibility to Picornaviridae infection
|
J:92227
|
Cd8atm1Mak/Cd8atm1Mak
(PL.129S2(B6)-Cd8atm1Mak/Rdgz)
|
increased susceptibility to Picornaviridae infection
|
J:92227
|
Cd8atm1Mak/Cd8atm1Mak
(SJL.129S2(B6)-Cd8atm1Mak/Rdgz)
|
increased susceptibility to Picornaviridae infection
|
J:92227
|
Cd8atm1Mak/Cd8atm1Mak
(B6.129S2-Cd8atm1Mak)
|
abnormal response to transplant
|
J:91742
|
Cd8atm1Mak/Cd8atm1Mak Il15tm1Imx/Il15tm1Imx X/Yaa
(BXSB.Cg-Cd8atm1Mak Il15tm1Imx/Dcr)
|
increased anti-nuclear antigen antibody level
|
J:179430
|
increased IgG1 level
|
J:179430
|
increased IgG2a level
|
J:179430
|
increased IgG2b level
|
J:179430
|
increased susceptibility to systemic lupus erythematosus
|
J:179430
|
Cd8atm1Mak/Cd8atm1Mak X/Yaa
(BXSB.129S2(B6)-Cd8atm1Mak/4Dcr)
|
increased susceptibility to systemic lupus erythematosus
|
J:179430
|
Cd8b1M1Btlr/Cd8b1M1Btlr
(C57BL/6J-Cd8b1M1Btlr)
|
enhanced humoral immune response
|
J:255009
|
increased IgG level
|
J:255009
|
Cd8b1tm1Litt/Cd8b1tm1Litt
(involves: 129S4/SvJae * C57BL/6J)
|
abnormal cytotoxic T cell physiology
|
J:112551
|
Cd14hdl/Cd14hdl
(C57BL/6-Cd14hdl)
|
abnormal interferon secretion
|
J:98908
|
decreased susceptibility to endotoxin shock
|
J:98908
|
decreased tumor necrosis factor secretion
|
J:98908
|
increased susceptibility to Riboviria infection
|
J:98908
|
Cd14tm1Frm/Cd14+
(involves: 129S4/SvJae * C57BL/6J)
|
abnormal cytokine secretion
|
J:65107
|
decreased interleukin-6 secretion
|
J:65107
|
decreased tumor necrosis factor secretion
|
J:65107
|
Cd14tm1Frm/Cd14tm1Frm
(involves: 129S4/SvJae * C57BL/6J)
|
abnormal cytokine secretion
|
J:65107
|
decreased interleukin-6 secretion
|
J:65107
|
decreased tumor necrosis factor secretion
|
J:65107
|
Cd14tm1Frm/Cd14tm1Frm
(involves: 129S4/SvJae)
|
abnormal interferon secretion
|
J:98908
|
decreased susceptibility to endotoxin shock
|
J:98908
|
increased susceptibility to Riboviria infection
|
J:98908
|
Cd14tm1Frm/Cd14tm1Frm
(B6.129S4-Cd14tm1Frm)
|
abnormal cytokine level
|
J:96680
|
abnormal interleukin level
|
J:96680
|
abnormal tumor necrosis factor level
|
J:96680
|
Cd14tm1Smg/Cd14tm1Smg
(involves: 129S1/Sv * C57BL/6)
|
decreased circulating interleukin-6 level
|
J:32729
|
decreased circulating tumor necrosis factor level
|
J:32729
|
decreased interleukin-6 secretion
|
J:32729
|
decreased susceptibility to bacterial infection
|
J:32729
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:32729
|
decreased susceptibility to endotoxin shock
|
J:32729
|
decreased tumor necrosis factor secretion
|
J:32729
|
Cd14tm1Smg/Cd14tm1Smg
(C.129S1-CD14tm1Smg)
|
abnormal macrophage physiology
|
J:116691
|
abnormal neutrophil physiology
|
J:127072
|
decreased susceptibility to bacterial infection
|
J:127072
|
decreased tumor necrosis factor secretion
|
J:116691
|
Cd14tm1Smg/Cd14tm1Smg
(B6.129S1-CD14tm1Smg)
|
decreased susceptibility to bacterial infection
|
J:127072
|
Cd14tm1Smg/Cd14tm1Smg
(involves: 129S1/Sv)
|
abnormal tumor necrosis factor level
|
J:103464
|
Cd14tm1Smg/Cd14tm1Smg Tlr4Lps-d/Tlr4Lps-d
(C3.129S1-CD14tm1Smg)
|
abnormal macrophage physiology
|
J:116691
|
decreased tumor necrosis factor secretion
|
J:116691
|
Cd19tm1(cre)Cgn/Cd19+ Ctnnbl1tm1.1Crad/Ctnnbl1tm1.1Crad
(involves: 129P2/OlaHsd * C57BL/6 * SJL)
|
decreased B cell proliferation
|
J:232010
|
Cd19tm1(cre)Cgn/Cd19+ Ell2tm1.1Cmil/Ell2tm1.1Cmil
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
|
decreased IgA level
|
J:234692
|
decreased IgG1 level
|
J:234692
|
decreased IgM level
|
J:234692
|
decreased immunoglobulin level
|
J:234692
|
impaired humoral immune response
|
J:234692
|
Cd19tm1(cre)Cgn/Cd19+ Ell2tm2.1Cmil/Ell2tm2.1Cmil
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
|
decreased IgA level
|
J:234692
|
decreased IgG1 level
|
J:234692
|
decreased IgM level
|
J:234692
|
decreased immunoglobulin level
|
J:234692
|
Cd19tm1(cre)Cgn/Cd19+ Ep300tm2Reck/Ep300+
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6)
|
abnormal adaptive immunity
|
J:147840
|
abnormal humoral immune response
|
J:147840
|
arteritis
|
J:147840
|
decreased B cell proliferation
|
J:147840
|
glomerulonephritis
|
J:147840
|
increased anti-double stranded DNA antibody level
|
J:147840
|
increased B cell apoptosis
|
J:147840
|
increased IgG2b level
|
J:147840
|
increased immunoglobulin level
|
J:147840
|
increased susceptibility to systemic lupus erythematosus
|
J:147840
|
kidney inflammation
|
J:147840
|
Cd19tm1(cre)Cgn/Cd19+ Ep300tm2Reck/Ep300+
(involves: 129/Sv * 129P2/OlaHsd * FVB/N)
|
increased susceptibility to systemic lupus erythematosus
|
J:147840
|
Cd19tm1(cre)Cgn/Cd19+ Fastm1Ach/Fastm1Ach
(involves: 129P2/OlaHsd * BALB/c)
|
increased anti-nuclear antigen antibody level
|
J:123556
|
increased immunoglobulin level
|
J:123556
|
Cd19tm1(cre)Cgn/Cd19+ Fastm1Cgn/Fastm1Cgn
(B6.Cg-Cd19tm1(cre)Cgn Fastm1Cgn)
|
increased anti-single stranded DNA antibody level
|
J:114948
|
Cd19tm1(cre)Cgn/Cd19+ Gna12tm1Citb/Gna12tm1Citb Gna13tm2.1Soff/Gna13tm2.1Soff
(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6N)
|
abnormal B cell physiology
|
J:117663
|
Cd19tm1(cre)Cgn/Cd19+ Gt(ROSA)26Sortm1(ITK/SYK)Jrld/Gt(ROSA)26Sor+
(involves: 129P2/OlaHsd)
|
abnormal T cell activation
|
J:160931
|
increased T cell proliferation
|
J:160931
|
Cd19tm1(cre)Cgn/Cd19+ Gt(ROSA)26Sortm2(CARD11*L225LI)Jrld/Gt(ROSA)26Sor+
(involves: 129P2/OlaHsd)
|
abnormal B cell activation
|
J:228288
|
increased B cell proliferation
|
J:228288
|
Cd19tm1(cre)Cgn/Cd19+ Gt(ROSA)26Sortm2(Cd74/MOG)Awai/Gt(ROSA)26Sor+
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal B cell physiology
|
J:140751
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:140751
|
Cd19tm1(cre)Cgn/Cd19+ Gt(ROSA)26Sortm2(Cd74/MOG)Awai/Gt(ROSA)26Sor+ Il10tm1Roer/Il10tm1Roer
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal B cell physiology
|
J:140751
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:140751
|
Cd19tm1(cre)Cgn/Cd19+ Gt(ROSA)26Sortm4(Ikbkb)Rsky/Gt(ROSA)26Sor+
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal B cell physiology
|
J:113365
|
decreased B cell apoptosis
|
J:113365
|
Cd19tm1(cre)Cgn/Cd19+ Ifnar1tm1Uka/Ifnar1tm1Uka
(B6.129P2-Cd19tm1(cre)Cgn Ifnar1tm1Uka)
|
decreased IgG1 level
|
J:129128
|
decreased IgG2a level
|
J:129128
|
decreased IgG3 level
|
J:129128
|
decreased IgM level
|
J:129128
|
Cd19tm1(cre)Cgn/Cd19+ Igbp1tm1Imku/Y
(involves: 129P2/OlaHsd)
|
abnormal B cell physiology
|
J:74619
|
abnormal somatic hypermutation frequency
|
J:74619
|
decreased B cell proliferation
|
J:74619
|
decreased immunoglobulin level
|
J:74619
|
Cd19tm1(cre)Cgn/Cd19+ Ikbkbtm1Cgn/Ikbkbtm1.1Cgn
(involves: 129P2/OlaHsd * C57BL/6)
|
increased B cell proliferation
|
J:79132
|
Cd19tm1(cre)Cgn/Cd19+ Ikbkbtm2Mka/Ikbkbtm2Mka
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6)
|
abnormal B cell activation
|
J:82995
|
decreased B cell proliferation
|
J:82995
|
decreased IgG level
|
J:82995
|
decreased IgM level
|
J:82995
|
increased B cell apoptosis
|
J:82995
|
Cd19tm1(cre)Cgn/Cd19+ Ikbkgtm1.1Mpa/Y
(involves: 129P2/OlaHsd * C57BL/6)
|
increased B cell proliferation
|
J:79132
|
Cd19tm1(cre)Cgn/Cd19+ Il10tm1Roer/Il10tm1Roer
(involves: 129P2/OlaHsd)
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:151551
|
decreased circulating interleukin-10 level
|
J:151551
|
Cd19tm1(cre)Cgn/Cd19+ Inpp5dtm1Rav/Inpp5dtm1Rav Ptentm1Hwu/Ptentm1Hwu
(involves: 129P2/OlaHsd * 129S4/SvJae)
|
abnormal B cell physiology
|
J:166155
|
increased B cell proliferation
|
J:166155
|
Cd19tm1(cre)Cgn/Cd19+ Ltbtm1Avt/Ltbtm1Avt
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal adaptive immunity
|
J:79129
|
Cd19tm1(cre)Cgn/Cd19+ Map3k7tm1Aki/Map3k7tm1.1Aki
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal B cell physiology
|
J:112597
|
decreased B cell proliferation
|
J:112597
|
decreased IgG1 level
|
J:112597
|
decreased IgG3 level
|
J:112597
|
decreased IgG level
|
J:112597
|
decreased immunoglobulin level
|
J:112597
|
Cd19tm1(cre)Cgn/Cd19+ Mcl1tm2Sjk/Mcl1tm3Sjk
(involves: 129P2/OlaHsd * 129X1/SvJ)
|
increased B cell apoptosis
|
J:86906
|
Cd19tm1(cre)Cgn/Cd19+ Myd88em1.1Rsky/Myd88+
(involves: C57BL/6NTac)
|
increased IgM level
|
J:308792
|
Cd19tm1(cre)Cgn/Cd19+ Myd88em1.1Rsky/Myd88em1.1Rsky
(involves: C57BL/6NTac)
|
increased B cell proliferation
|
J:308792
|
Cd19tm1(cre)Cgn/Cd19+ Pax5tm1Mbu/Pax5tm3Mbu
(involves: 129P2/OlaHsd * 129S2/SvPas)
|
abnormal class switch recombination
|
J:75504
|
decreased IgG1 level
|
J:75504
|
decreased IgG3 level
|
J:75504
|
decreased IgG level
|
J:75504
|
decreased immunoglobulin level
|
J:75504
|
Cd19tm1(cre)Cgn/Cd19+ Pdia3tm1Gjh/Pdia3tm1Gjh
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal B cell physiology
|
J:112606
|
Cd19tm1(cre)Cgn/Cd19+ Prdm1tm1Clme/Prdm1tm1Clme
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ)
|
decreased IgG level
|
J:101890
|
decreased IgM level
|
J:101890
|
decreased immunoglobulin level
|
J:101890
|
Cd19tm1(cre)Cgn/Cd19+ Ptentm1Hwu/Ptentm1Hwu
(involves: 129P2/OlaHsd * 129S4/SvJae)
|
abnormal B cell physiology
|
J:83213
|
abnormal class switch recombination
|
J:114881
|
decreased IgG level
|
J:114881
|
increased B cell apoptosis
|
J:83213
|
increased B cell proliferation
|
J:155314,
J:83213
|
increased IgM level
|
J:114881
|
Cd19tm1(cre)Cgn/Cd19+ Ptentm1Hwu/Ptentm1Hwu Tg(IghelMD4)4Ccg/0 Tg(ML5sHEL)5Ccg/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
abnormal peripheral B cell anergy
|
J:155314
|
Cd19tm1(cre)Cgn/Cd19+ Ptpn6tm1Rsky/Ptpn6tm1Rsky
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal humoral immune response
|
J:123568
|
abnormal immune system physiology
|
J:123568
|
decreased B cell proliferation
|
J:123568
|
increased susceptibility to systemic lupus erythematosus
|
J:123568
|
Cd19tm1(cre)Cgn/Cd19+ Rbpjtm1Hon/Rbpjtm1Hon
(involves: 129P2/OlaHsd * C57BL/6)
|
increased IgG3 level
|
J:76240
|
increased susceptibility to bacterial infection
|
J:76240
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:76240
|
Cd19tm1(cre)Cgn/Cd19+ Slc3a2tm1.1Mgin/Slc3a2tm1.1Mgin
(involves: 129 * C57BL/6 * SJL)
|
abnormal B cell activation
|
J:148000
|
abnormal B cell physiology
|
J:148000
|
abnormal class switch recombination
|
J:148000
|
decreased B cell proliferation
|
J:148000
|
decreased IgG level
|
J:148000
|
decreased IgM level
|
J:148000
|
Cd19tm1(cre)Cgn/Cd19+ Slc3a2tm1.1Mgin/Slc3a2tm1Yai
(involves: 129 * C57BL/6 * SJL)
|
decreased IgG3 level
|
J:148000
|
decreased IgM level
|
J:148000
|
Cd19tm1(cre)Cgn/Cd19+ Tgfbr2tm1Roes/Tgfbr2tm1Roes
(involves: 129P2/OlaHsd * BALB/c)
|
abnormal B cell physiology
|
J:90558
|
decreased IgA level
|
J:90558
|
increased IgG level
|
J:90558
|
increased IgM level
|
J:90558
|
Cd19tm1(cre)Cgn/Cd19+ Tnfaip3tm1.1Awai/Tnfaip3tm1.1Awai
(involves: 129P2/OlaHsd)
|
increased anti-nuclear antigen antibody level
|
J:175422
|
increased B cell proliferation
|
J:175422
|
increased IgA level
|
J:175422
|
increased IgG2a level
|
J:175422
|
increased IgM level
|
J:175422
|
Cd19tm1(cre)Cgn/Cd19+ Tnfaip3tm2Ama/Tnfaip3+
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased B cell apoptosis
|
J:163917
|
increased autoantibody level
|
J:163917
|
increased immunoglobulin level
|
J:163917
|
increased susceptibility to autoimmune disorder
|
J:163917
|
Cd19tm1(cre)Cgn/Cd19+ Traf2tm1Rbr/Traf2tm1Rbr
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal B cell physiology
|
J:132877
|
Cd19tm1(cre)Cgn/Cd19+ Traf2tm1Rbr/Traf2tm1Rbr Traf3tm1Rbr/Traf3tm1Rbr
(involves: 129P2/OlaHsd * C57BL/6 * SJL)
|
abnormal B cell physiology
|
J:132877
|
Cd19tm1(cre)Cgn/Cd19+ Traf3tm1Rbr/Traf3tm1Rbr
(involves: 129P2/OlaHsd * C57BL/6 * SJL)
|
abnormal B cell physiology
|
J:132877
|
Cd19tm1(cre)Cgn/Cd19+ Ube2ntm1Aki/Ube2ntm1Aki
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal B cell physiology
|
J:112287
|
abnormal humoral immune response
|
J:112287
|
decreased B cell proliferation
|
J:112287
|
decreased immunoglobulin level
|
J:112287
|
increased B cell apoptosis
|
J:112287
|
Cd19tm1(cre)Cgn/Cd19+ Wacem2Cya/Wacem2Cya
(B6.Cg-Cd19tm1(cre)Cgn Wacem2Cya)
|
decreased B cell proliferation
|
J:345327
|
decreased IgG1 level
|
J:345327
|
decreased IgG2b level
|
J:345327
|
decreased IgG3 level
|
J:345327
|
decreased IgM level
|
J:345327
|
impaired humoral immune response
|
J:345327
|
Cd19tm1(cre)Cgn/Cd19tm1(cre)Cgn
(involves: 129P2/OlaHsd)
|
abnormal B cell physiology
|
J:27463
|
abnormal immunoglobulin level
|
J:27463
|
decreased IgE level
|
J:27463
|
decreased IgG1 level
|
J:27463
|
decreased IgM level
|
J:27463
|
Cd19tm1(cre)Cgn/Cd19tm1(cre)Cgn Ightm1Mnz/Ightm1Mnz
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal B cell physiology
|
J:75653
|
Cd19tm1(cre)Cgn/Cd19tm1(cre)Cgn Ightm2Mnz/Ightm2Mnz
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal B cell physiology
|
J:75653
|
Cd19tm1(cre/ERT2)Rsky/Cd19+ Myd88em1.1Rsky/Myd88+
(involves: 129P2/OlaHsd * C57BL/6NTac)
|
increased IgM level
|
J:308792
|
Cd19tm1Tft/Cd19tm1Tft
(Not Specified)
|
abnormal B cell physiology
|
J:27236
|
decreased B cell proliferation
|
J:27236
|
decreased IgA level
|
J:27236
|
decreased IgG1 level
|
J:27236
|
decreased IgG2a level
|
J:27236
|
decreased IgG2b level
|
J:27236
|
decreased IgG3 level
|
J:27236
|
decreased IgM level
|
J:27236
|
Cd19tm1Tft/Cd19tm1Tft
(involves: 129/Sv * C57BL/6)
|
decreased tumor necrosis factor secretion
|
J:66111
|
Cd19tm1Tft/Cd19tm1Tft
(involves: 129 * C57BL/6)
|
abnormal humoral immune response
|
J:71174
|
decreased B cell proliferation
|
J:71174
|
decreased IgA level
|
J:71174
|
decreased IgG1 level
|
J:71174
|
decreased IgG2b level
|
J:71174
|
decreased IgM level
|
J:71174
|
Cd19tm1Tft/Cd19tm1Tft
(B6.Cg-Cd19tm1Tft)
|
abnormal B cell physiology
|
J:136210
|
decreased anti-double stranded DNA antibody level
|
J:136210
|
decreased anti-nuclear antigen antibody level
|
J:136210
|
decreased circulating interferon-gamma level
|
J:136210
|
decreased circulating interleukin-4 level
|
J:136210
|
decreased circulating interleukin-6 level
|
J:136210
|
decreased circulating interleukin-10 level
|
J:136210
|
decreased circulating tumor necrosis factor level
|
J:136210
|
decreased IgA level
|
J:136210
|
decreased IgG1 level
|
J:136210
|
decreased IgG2a level
|
J:136210
|
decreased IgG2b level
|
J:136210
|
decreased IgG3 level
|
J:136210
|
decreased IgM level
|
J:136210
|
decreased interleukin-10 secretion
|
J:106487
|
increased interferon-gamma secretion
|
J:106487
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:106487
|
Cd19tm1Tft/Cd19tm1Tft Lyntm1Sor/Lyntm1Sor
(involves: 129S4/SvJaeSor * C57BL/6)
|
abnormal humoral immune response
|
J:71174
|
decreased anti-double stranded DNA antibody level
|
J:71174
|
decreased B cell proliferation
|
J:71174
|
decreased susceptibility to systemic lupus erythematosus
|
J:71174
|
Cd22m1Btlr/Cd22m1Btlr
(C57BL/6J-Cd22m1Btlr)
|
abnormal humoral immune response
|
J:173079
|
Cd22m1Btlr/Cd22m1Btlr
(involves: C57BL/6J)
|
decreased IgM level
|
J:185495
|
Cd22m2Btlr/Cd22m2Btlr
(C57BL/6J-Cd22m2Btlr)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:215821
|
Cd22tm1.1(CD22)Lnit/Cd22tm1.1(CD22)Lnit
(involves: 129S4/SvJae)
|
abnormal B cell calcium ion homeostasis
|
J:189017
|
abnormal B cell physiology
|
J:189017
|
impaired B cell migration
|
J:189017
|
Cd22tm1Eac/Cd22+ Lyntm1Ard/Lyn+ Ptpn6me-v/Ptpn6+ Tg(IghelMD4)4Ccg/0
(involves: 129P2/OlaHsd * C57BL/6)
|
increased IgM level
|
J:110531
|
Cd22tm1Eac/Cd22tm1Eac
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal B cell activation
|
J:37451
|
abnormal B cell proliferation
|
J:37451,
J:132991
|
decreased IgG1 level
|
J:37451
|
decreased IgG3 level
|
J:37451
|
decreased IgM level
|
J:37451
|
increased B cell apoptosis
|
J:132991
|
Cd22tm1Lam/Cd22tm1Lam
(involves: 129 * C57BL/6)
|
abnormal B cell activation
|
J:125719
|
Cd22tm1Lam/Cd22tm1Lam Ightm1.2Rsky/Igh+
(involves: 129 * BALB/c * C57BL/6)
|
abnormal class switch recombination
|
J:125719
|
Cd22tm1Lam/Cd22tm1Lam Ightm1.2Rsky/Ightm1.2Rsky
(involves: 129 * BALB/c * C57BL/6)
|
abnormal B cell activation
|
J:125719
|
Cd22tm1Msn/Cd22tm1Msn
(either: (involves: 129S/SvEv * BALB/c) or (involves: 129S/SvEv * C57BL/6J))
|
abnormal B cell activation
|
J:76974
|
abnormal B cell calcium ion homeostasis
|
J:76974
|
abnormal immune system physiology
|
J:76974
|
abnormal immunoglobulin level
|
J:76974
|
increased anti-double stranded DNA antibody level
|
J:76974,
J:76975
|
increased IgG2a level
|
J:76975
|
increased IgG level
|
J:76975
|
increased IgM level
|
J:76974
|
Cd22tm1Tft/Cd22tm1Tft
(involves: 129P2/OlaHsd * C57BL/6)
|
increased B cell proliferation
|
J:92736
|
Cd22tm2Lnit/Cd22tm2Lnit
(involves: 129P2/OlaHsd * C57BL/6)
|
autoimmune response
|
J:198790
|
Cd22tm2Tft/Cd22tm2Tft
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
|
decreased B cell proliferation
|
J:92736
|
increased B cell proliferation
|
J:92736
|
Cd22tm2Tft/Cd22tm2Tft
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal peripheral B cell anergy
|
J:208364
|
decreased B cell proliferation
|
J:208364
|
increased activation-induced B cell apoptosis
|
J:208364
|
Cd22tm3Lnit/Cd22tm3Lnit
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
abnormal B cell physiology
|
J:198790
|
abnormal immune system physiology
|
J:198790
|
autoimmune response
|
J:198790
|
increased B cell apoptosis
|
J:198790
|
increased IgG1 level
|
J:198790
|
Cd22tm3Tft/Cd22tm3Tft
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
|
decreased B cell proliferation
|
J:92736
|
increased B cell proliferation
|
J:92736
|
Cd24atm1Pjln/Cd24atm1Pjln
(C57BL/6-Cd24atm1Pjln)
|
increased susceptibility to parasitic infection
|
J:76695
|
Cd27tm1Jbo/Cd27tm1Jbo
(either: B6.129P2-CD27tm1Jbo or 129P2/OlaHsd-Tnfrsf7tm1Jbo)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:65516
|
abnormal cytotoxic T cell physiology
|
J:65516
|
abnormal T cell physiology
|
J:65516
|
Cd27tm1Jbo/Cd27tm1Jbo
(B6.129P2-Cd27tm1Jbo)
|
increased T cell apoptosis
|
J:198200
|
Cd28tm1.1Huen/Cd28tm1.1Huen Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
(involves: C57BL/6 * C57BL/6NTac)
|
abnormal regulatory T cell physiology
|
J:191101
|
Cd28tm1Jmg/Cd28tm1Jmg
(involves: 129S2/SvPas * 129X1/SvJ * C57BL/6)
|
abnormal cytokine secretion
|
J:124570
|
abnormal germinal center B cell physiology
|
J:124570
|
decreased immunoglobulin level
|
J:124570
|
decreased interleukin-2 secretion
|
J:124570
|
Cd28tm1Jmg/Cd28tm1Jmg
(B6.129X1-Cd28tm1Jmg)
|
decreased interleukin-2 secretion
|
J:149888
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:149888
|
increased susceptibility to type I hypersensitivity reaction
|
J:149888
|
Cd28tm1Jmg/Cd28tm1Mak
(involves: 129S2/SvPas * 129X1/SvJ * C57BL/6)
|
abnormal cytokine secretion
|
J:124570
|
abnormal germinal center B cell physiology
|
J:124570
|
decreased immunoglobulin level
|
J:124570
|
decreased interleukin-2 secretion
|
J:124570
|
decreased T cell proliferation
|
J:149888,
J:124570
|
Cd28tm1Ltu/Cd28tm1Ltu Foxp3tm4(YFP/icre)Ayr/Foxp3+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
decreased T cell proliferation
|
J:194503
|
increased susceptibility to autoimmune disorder
|
J:194503
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:194503
|
skin inflammation
|
J:194503
|
Cd28tm1Mak/Cd28+ Cd5tm1Cgn/Cd5tm1Cgn
(either: (involves: 129P2/OlaHsd * 129S2/SvPas * BALB/c * C57BL/6) or (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * DBA/1 * LP))
|
abnormal T cell clonal deletion
|
J:110925
|
Cd28tm1Mak/Cd28tm1Mak
(involves: 129S2/SvPas * C57BL/6 * DBA/2)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:14194
|
abnormal class switch recombination
|
J:14194
|
decreased IgG1 level
|
J:14194
|
decreased IgG2b level
|
J:14194
|
decreased immunoglobulin level
|
J:14194
|
decreased interleukin-2 secretion
|
J:14194
|
decreased T cell proliferation
|
J:14194
|
increased IgG2a level
|
J:14194
|
Cd28tm1Mak/Cd28tm1Mak
(NOD.129S2-Cd28tm1Mak)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:61905
|
abnormal response to transplant
|
J:61905
|
increased susceptibility to autoimmune diabetes
|
J:93421
|
increased T cell proliferation
|
J:93421
|
Cd28tm1Mak/Cd28tm1Mak
(involves: 129S2/SvPas)
|
abnormal class switch recombination
|
J:123989
|
abnormal regulatory T cell physiology
|
J:191101
|
decreased interferon-gamma secretion
|
J:205441
|
decreased interleukin-2 secretion
|
J:205441,
J:130882
|
decreased T cell proliferation
|
J:205441,
J:130882,
J:123989
|
Cd28tm1Mak/Cd28tm1Mak
(involves: 129S2/SvPas * NOD)
|
abnormal T-helper 1 physiology
|
J:35353
|
abnormal T-helper 2 physiology
|
J:35353
|
decreased IgG2a level
|
J:35353
|
decreased interleukin-2 secretion
|
J:35353
|
decreased interleukin-4 secretion
|
J:35353
|
decreased T cell proliferation
|
J:35353
|
increased interferon-gamma secretion
|
J:35353
|
increased susceptibility to autoimmune diabetes
|
J:35353
|
Cd28tm1Mak/Cd28tm1Mak
(involves: 129S2/SvPas * C57BL/6)
|
abnormal NK cell physiology
|
J:95353
|
decreased circulating interferon-gamma level
|
J:95353
|
decreased circulating interleukin-4 level
|
J:95353
|
decreased interleukin-2 secretion
|
J:149888
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:149888
|
decreased T cell proliferation
|
J:149888
|
increased susceptibility to type I hypersensitivity reaction
|
J:149888
|
increased T cell apoptosis
|
J:149888
|
Cd28tm1Mak/Cd28tm1Mak
(B6.129S2-Cd28tm1Mak)
|
abnormal cytotoxic T cell physiology
|
J:76373
|
Cd28tm1Mak/Cd28tm1Mak
(B6.129S2-Cd28tm1Mak/J)
|
brain inflammation
|
J:57613
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:57613
|
Cd28tm1Mak/Cd28tm1Mak Cd5tm1Cgn/Cd5+
(either: (involves: 129P2/OlaHsd * 129S2/SvPas * BALB/c * C57BL/6) or (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * DBA/1 * LP))
|
abnormal T cell clonal deletion
|
J:110925
|
Cd28tm1Mak/Cd28tm1Mak Cd5tm1Cgn/Cd5tm1Cgn
(either: (involves: 129P2/OlaHsd * 129S2/SvPas * BALB/c * C57BL/6) or (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * DBA/1 * LP))
|
abnormal T cell clonal deletion
|
J:110925
|
Cd28tm1Mak/Cd28tm1Mak Cd40lgtm1Flv/Cd40lgtm1Flv
(NOD.Cg-Cd40lgtm1Flv Cd28tm1Mak)
|
increased susceptibility to autoimmune diabetes
|
J:93421
|
insulitis
|
J:93421
|
Cd28tm1Mak/Cd28tm1Mak Ndfip1Gt(RRD002)Byg/Ndfip1Gt(RRD002)Byg
(involves: 129P2/OlaHsd * 129S2/SvPas)
|
esophageal inflammation
|
J:205692
|
increased interleukin-2 secretion
|
J:205692
|
increased interleukin-4 secretion
|
J:205692
|
Cd28tm1Mak/Cd28tm1Mak Stat6tm1Gru/Stat6tm1Gru
(C.129S2(B6)-Cd28tm1Mak Stat6tm1Gru)
|
increased susceptibility to parasitic infection
|
J:90987
|
Cd28tm1Mak/Cd28tm1Mak Tg(Cd4-cre)1Cwi/? Traf6tm2Ywc/Traf6tm2Ywc
(involves: 129S2/SvPas * C57BL/6 * DBA/2)
|
decreased interleukin-2 secretion
|
J:130882
|
decreased T cell proliferation
|
J:130882
|
Cd28tm1Mak/Cd28tm1Mak Tg(TcrLCMV)327Sdz/0
(involves: 129S2/SvPas * C57BL/6 * DBA/2)
|
abnormal T cell anergy
|
J:123989
|
decreased cytotoxic T cell cytolysis
|
J:123989
|
decreased splenocyte proliferation
|
J:123989
|
decreased T cell proliferation
|
J:123989
|
Cd28tm1Mak/Cd28tm1Mak Tnfsf9tm1Thw/Tnfsf9tm1Thw
(involves: 129 * 129S2/SvPas * C57BL/6)
|
abnormal cytotoxic T cell physiology
|
J:76373
|
increased length of allograft survival
|
J:76373
|
Cd28tm1Mak/Cd28tm1Mak Tnfsf14tm1Kpf/Tnfsf14tm1Kpf
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
|
increased length of allograft survival
|
J:77250
|
Cd28tm1Pjl/Cd28tm1Pjl
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal class switch recombination
|
J:83722
|
abnormal cytotoxic T cell physiology
|
J:83722
|
abnormal immunoglobulin level
|
J:83722
|
decreased IgG1 level
|
J:83722
|
decreased IgG2a level
|
J:83722
|
decreased IgM level
|
J:83722
|
decreased interleukin-12 secretion
|
J:83722
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:83722
|
increased splenocyte proliferation
|
J:83722
|
Cd28tm1Pjl/Cd28tm1Pjl Tg(DO11.10)10Dlo/0
(involves: 129P2/OlaHsd * BALB/c * C3H * C57BL/6)
|
abnormal T cell activation
|
J:25536
|
abnormal T cell proliferation
|
J:25536
|
abnormal thymocyte activation
|
J:25536
|
decreased interleukin-2 secretion
|
J:25536
|
Cd28tm1Pjl/Cd28tm1Pjl Tnfrsf9tm1Byk/Tnfrsf9tm1Byk
(either: B6.Cg-Cd28tm1Pjl Tnfrsf9tm1Byk or C.Cg-Cd28tm1Pjl Tnfrsf9tm1Byk)
|
abnormal class switch recombination
|
J:83722
|
abnormal cytotoxic T cell physiology
|
J:83722
|
decreased IgG1 level
|
J:83722
|
decreased IgG2a level
|
J:83722
|
decreased IgM level
|
J:83722
|
decreased interleukin-12 secretion
|
J:83722
|
decreased splenocyte proliferation
|
J:83722
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:83722
|
Cd28tm1Shr/Cd28tm1Shr
(involves: 129S4/SvJae * BALB/c * C57BL/6)
|
decreased interleukin-2 secretion
|
J:68642
|
decreased T cell proliferation
|
J:68642
|
Cd28tm1Shr/Cd28tm1Shr Ctla4tm1Shr/Ctla4+
(C.129S4-Cd28tm1Shr Ctla4tm1Shr)
|
increased susceptibility to autoimmune disorder
|
J:125259
|
Cd28tm1Shr/Cd28tm1Shr Ctla4tm1Shr/Ctla4tm1Shr
(C.129S4-Cd28tm1Shr Ctla4tm1Shr)
|
abnormal interferon level
|
J:68642
|
abnormal interleukin secretion
|
J:68642
|
decreased T cell proliferation
|
J:68642
|
increased length of allograft survival
|
J:68642
|
Cd33tm1Avrk/Cd33tm1Avrk
(involves: 129X1/SvJ * C57BL/6)
|
decreased inflammatory response
|
J:83728
|
Cd36obl/Cd36obl
(C57BL/6-Cd36obl)
|
abnormal cell-mediated immunity
|
J:96018
|
abnormal macrophage physiology
|
J:96018
|
endophthalmitis
|
J:96018
|
increased susceptibility to bacterial infection
|
J:96018
|
Cd36tm1Frm/Cd36tm1Frm
(involves: 129S4/SvJae)
|
abnormal microglial cell physiology
|
J:140907
|
Cd36tm1Frm/Cd36tm1Frm
(involves: 129S4/SvJae * C57BL/6J)
|
abnormal chemokine level
|
J:80658
|
abnormal macrophage physiology
|
J:80658
|
Cd36tm1Frm/Cd36tm1Frm
(B6.129S4-Cd36tm1Frm)
|
abnormal response to infection
|
J:100140
|
decreased interleukin-6 secretion
|
J:100140
|
decreased interleukin-12 secretion
|
J:100140
|
decreased tumor necrosis factor secretion
|
J:100140
|
impaired macrophage phagocytosis
|
J:100140
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:100140
|
sepsis
|
J:100140
|
Cd36tm1Mfe/Cd36tm1Mfe
(B6.129S1-Cd36tm1Mfe)
|
decreased IgG1 level
|
J:130897
|
decreased IgG2a level
|
J:130897
|
decreased IgG2c level
|
J:130897
|
decreased IgG level
|
J:130897
|
decreased IgM level
|
J:130897
|
decreased immunoglobulin level
|
J:130897
|
Cd36tm1Mfe/Cd36tm1Mfe
(involves: 129S1/Sv)
|
abnormal macrophage chemotaxis
|
J:89664
|
Cd37tm1Hor/Cd37tm1Hor
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal class switch recombination
|
J:63315
|
abnormal humoral immune response
|
J:63315
|
decreased IgG1 level
|
J:63315
|
Cd38tm1Lnd/Cd38tm1Lnd
(involves: 129P2/OlaHsd * C57BL/6J)
|
abnormal humoral immune response
|
J:49170
|
Cd38tm1Lnd/Cd38tm1Lnd
(NOD.129P2(B6)-Cd38tm1Lnd/LtJ)
|
increased susceptibility to autoimmune diabetes
|
J:108097
|
increased T cell apoptosis
|
J:108097
|
insulitis
|
J:108097
|
Cd40m1Btlr/Cd40m1Btlr
(C57BL/6J-Cd40m1Btlr)
|
impaired humoral immune response
|
J:221482
|
Cd40m2Btlr/Cd40m2Btlr
(C57BL/6J-Cd40m2Btlr)
|
abnormal humoral immune response
|
J:254828
|
decreased IgG level
|
J:254828
|
Cd40tm1Arah/Cd40tm1Arah
(B6.129S1-Cd40tm1Arah)
|
abnormal immunoglobulin level
|
J:120512
|
abnormal response to transplant
|
J:120512
|
decreased IgE level
|
J:120512
|
decreased IgG1 level
|
J:120512
|
decreased IgG2b level
|
J:120512
|
decreased IgG level
|
J:120512
|
decreased IgM level
|
J:120512
|
increased IgG3 level
|
J:120512
|
increased IgM level
|
J:120512
|
Cd40tm1Geha/Cd40tm1Geha
(involves: 129S4/SvJae * C57BL/6)
|
decreased IgA level
|
J:82298
|
decreased IgG1 level
|
J:82298
|
decreased IgG2a level
|
J:82298
|
decreased IgG2b level
|
J:82298
|
Cd40tm1Kik/Cd40tm1Kik
(B6.129P2-Cd40tm1Kik/J)
|
abnormal dendritic cell physiology
|
J:86998
|
increased susceptibility to bacterial infection
|
J:86998
|
Cd40tm1Kik/Cd40tm1Kik
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal humoral immune response
|
J:25007
|
decreased IgA level
|
J:25007
|
decreased IgE level
|
J:25007
|
decreased IgG1 level
|
J:25007
|
decreased IgG2a level
|
J:25007
|
decreased IgG2b level
|
J:25007
|
decreased IgG3 level
|
J:25007
|
decreased immunoglobulin level
|
J:25007
|
decreased susceptibility to type II hypersensitivity reaction
|
J:61673
|
Cd40tm1Kik/Cd40tm1Kik Tg(Tnfsf13b)1Fma/?
(B6.Cg-Cd40tm1Kik Tg(Tnfsf13b)1Fma)
|
abnormal B cell activation
|
J:113556
|
abnormal class switch recombination
|
J:113556
|
glomerulonephritis
|
J:113556
|
increased anti-double stranded DNA antibody level
|
J:113556
|
Cd40tm1Kik/Cd40tm1Kik Traf3ip2tm1.1Lix/Traf3ip2tm1.1Lix
(involves: 129 * 129P2/OlaHsd * BALB/c)
|
abnormal B cell physiology
|
J:138560
|
Cd40lgm1Btlr/Y
(involves: C57BL/6J)
|
abnormal class switch recombination
|
J:185495
|
decreased IgG level
|
J:185495
|
Cd40lgm1Btlr/Cd40lgm1Btlr
(C57BL/6J-Cd40lgm1Btlr)
|
decreased IgG level
|
J:162147
|
Cd40lgm1Btlr/Cd40lgm1Btlr
(involves: C57BL/6J)
|
abnormal class switch recombination
|
J:185495
|
decreased IgG level
|
J:185495
|
Cd40lgtm1Flv/Y Faslpr/Faslpr
(involves: 129P2/OlaHsd * 129S2/SvPas * MRL)
|
decreased autoantibody level
|
J:38492
|
decreased IgG level
|
J:38492
|
decreased immunoglobulin level
|
J:38492
|
Cd40lgtm1Flv/Y Faslpr/Faslpr Tcratm1Mjo/Tcratm1Mjo
(involves: 129P2/OlaHsd * 129S2/SvPas * MRL)
|
decreased autoantibody level
|
J:38492
|
increased anti-double stranded DNA antibody level
|
J:38492
|
Cd40lgtm1Flv/Cd40lgtm1Flv
(involves: 129S2/SvPas * C57BL/6)
|
abnormal adaptive immunity
|
J:25010
|
abnormal class switch recombination
|
J:25010
|
abnormal immune system physiology
|
J:25010
|
abnormal T-helper 2 physiology
|
J:25010
|
decreased IgA level
|
J:25010
|
decreased IgD level
|
J:25010
|
decreased IgE level
|
J:25010
|
decreased IgG1 level
|
J:25010
|
decreased IgG3 level
|
J:25010
|
decreased immunoglobulin level
|
J:25010
|
Cd40lgtm1Flv/Cd40lgtm1Flv
(NOD.129S2-Cd40lgtm1Flv)
|
decreased susceptibility to autoimmune diabetes
|
J:93421
|
Cd40lgtm1Flv/Cd40lgtm1Flv Faslpr/Faslpr
(involves: 129P2/OlaHsd * 129S2/SvPas * MRL)
|
decreased autoantibody level
|
J:38492
|
decreased IgG level
|
J:38492
|
decreased immunoglobulin level
|
J:38492
|
Cd40lgtm1Flv/Cd40lgtm1Flv Faslpr/Faslpr Tcratm1Mjo/Tcratm1Mjo
(involves: 129P2/OlaHsd * 129S2/SvPas * MRL)
|
decreased autoantibody level
|
J:38492
|
increased anti-double stranded DNA antibody level
|
J:38492
|
Cd40lgtm1Imx/Y
(involves: 129S2/SvPas * C57BL/6)
|
abnormal antigen presentation
|
J:21137
|
abnormal class switch recombination
|
J:21137
|
abnormal immune system physiology
|
J:21137
|
decreased IgA level
|
J:21137
|
decreased IgE level
|
J:21137
|
decreased IgG1 level
|
J:21137
|
decreased IgG2b level
|
J:21137
|
decreased immunoglobulin level
|
J:21137
|
Cd40lgtm1Imx/Y
(B6.129S2-Cd40lgtm1Imx/J)
|
abnormal leukocyte adhesion
|
J:108988
|
Cd40lgtm1Imx/Cd40lgtm1Imx
(involves: 129S2/SvPas * C57BL/6J * BALB/c)
|
abnormal T cell clonal deletion
|
J:110925
|
Cd40lgtm1Imx/Cd40lgtm1Imx
(involves: 129S2/SvPas * C57BL/6)
|
increased susceptibility to prion infection
|
J:115487
|
Cd40lgtm1Parl/Y Commd10Tg(Vav1-icre)A2Kio/Commd10+
(involves: 129 * C57BL/6 * C57BL/10 * CBA/Ca)
|
decreased IgM level
|
J:213459
|
increased IgG1 level
|
J:213459
|
Cd40lgtm1Parl/Y Tg(Tek-cre)1Ywa/0
(involves: 129 * C57BL/6 * CD-1 * SJL)
|
decreased IgA level
|
J:213459
|
decreased IgG1 level
|
J:213459
|
decreased IgG2a level
|
J:213459
|
decreased IgG3 level
|
J:213459
|
decreased IgM level
|
J:213459
|
Cd40lgtm1Parl/Cd40lgtm1Parl Commd10Tg(Vav1-icre)A2Kio/Commd10+
(involves: 129 * C57BL/6 * C57BL/10 * CBA/Ca)
|
decreased IgM level
|
J:213459
|
increased IgG1 level
|
J:213459
|
Cd40lgtm1Parl/Cd40lgtm1Parl Tg(Tek-cre)1Ywa/0
(involves: 129 * C57BL/6 * CD-1 * SJL)
|
decreased IgA level
|
J:213459
|
decreased IgG1 level
|
J:213459
|
decreased IgG2a level
|
J:213459
|
decreased IgG3 level
|
J:213459
|
decreased IgM level
|
J:213459
|
Cd44tm1.1Ugu/Cd44tm1.1Ugu
(involves: 129/Sv * C57BL/6)
|
abnormal T-helper 1 physiology
|
J:62867
|
abnormal T-helper 2 physiology
|
J:62867
|
Cd44tm1.1Ugu/Cd44tm1.1Ugu
(B6.129(Cg)-Cd44tm1.1Ugu)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:199279
|
Cd44tm1.1Ugu/Cd44tm1.1Ugu
(SJL.129(Cg)-Cd44tm1.1Ugu)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:199279
|
decreased T cell proliferation
|
J:199279
|
Cd44tm1.1Ugu/Cd44tm1.1Ugu Il10tm1Cgn/Il10tm1Cgn
(involves: 129/Sv * C57BL/6)
|
abnormal immune system physiology
|
J:62867
|
Cd44tm1Hbg/Cd44+ Tnftm2Gkl/Tnf+
(involves: 129S/SvEv * 129S1/Sv * 129X1/SvJ * C57BL/6)
|
ileum inflammation
|
J:145626
|
Cd44tm1Hbg/Cd44tm1Hbg
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal leukocyte migration
|
J:68069
|
abnormal neutrophil physiology
|
J:94850
|
Cd44tm1Hbg/Cd44tm1Hbg
(involves: 129S1/Sv * 129X1/SvJ)
|
abnormal response to infection
|
J:86947
|
increased acute inflammation
|
J:131974
|
Cd44tm1Hbg/Cd44tm1Hbg Tg(TNF)197Gkl/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)
|
autoimmune arthritis
|
J:97992
|
increased circulating interleukin-1 level
|
J:97992
|
increased circulating interleukin-6 level
|
J:97992
|
increased interleukin-1 secretion
|
J:97992
|
increased interleukin-6 secretion
|
J:97992
|
Cd44tm1Mak/Cd44+
(involves: 129P2/OlaHsd * C57BL/6J)
|
abnormal leukocyte migration
|
J:99032
|
Cd44tm1Mak/Cd44tm1Mak
(involves: 129P2/OlaHsd * C57BL/6J)
|
abnormal leukocyte migration
|
J:99032
|
increased susceptibility to parasitic infection
|
J:72658
|
Cd44tm1Mak/Cd44tm1Mak
(B6.129P2-Cd44tm1Mak)
|
abnormal circulating cytokine level
|
J:69351
|
abnormal leukocyte migration
|
J:108245
|
decreased activation-induced cell death of T cells
|
J:69351
|
impaired macrophage phagocytosis
|
J:111216
|
impaired natural killer cell mediated cytotoxicity
|
J:110889
|
increased circulating interferon-gamma level
|
J:69351
|
increased circulating interleukin-2 level
|
J:69351
|
increased circulating tumor necrosis factor level
|
J:69351
|
liver inflammation
|
J:69351
|
lung inflammation
|
J:111216,
J:108245
|
Cd44tm1Mak/Cd44tm1Mak
(D1.129P2-Cd44tm1Mak)
|
increased susceptibility to induced arthritis
|
J:95275
|
Cd44tm1Mak/Cd44tm1Mak
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal chemokine secretion
|
J:155691
|
abnormal circulating chemokine level
|
J:155691
|
abnormal interleukin secretion
|
J:155691
|
decreased acute inflammation
|
J:114341
|
decreased circulating tumor necrosis factor level
|
J:155691
|
increased interleukin-1 beta secretion
|
J:155691
|
increased interleukin-6 secretion
|
J:155691
|
increased interleukin-10 secretion
|
J:155691
|
increased tumor necrosis factor secretion
|
J:155691
|
peritoneal inflammation
|
J:155691
|
Cd44tm1Mak/Cd44tm1Mak Itgaltm1Mak/Itgaltm1Mak
(B6.129P2-Cd44tm1Mak Itgaltm1Mak)
|
impaired natural killer cell mediated cytotoxicity
|
J:110889
|
Cd44tm1Ugu/Cd44tm1Ugu
(involves: 129/Sv * C57BL/6)
|
abnormal T-helper 1 physiology
|
J:62867
|
abnormal T-helper 2 physiology
|
J:62867
|
Cd44tm2.1Ugu/Cd44tm2.1Ugu
(B6.129-Cd44tm2.1Ugu)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:199279
|
decreased T cell proliferation
|
J:199279
|
Cd44tm2Kmz/Cd44tm2Kmz
(DBA/1LacJ-Cd44tm2Kmz)
|
decreased susceptibility to induced arthritis
|
J:74268
|
Cd44tm2Kmz/Cd44tm2Kmz
(involves: BALB/c * DBA/1)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:114317
|
abnormal leukocyte adhesion
|
J:114317
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:114317
|
impaired leukocyte tethering or rolling
|
J:114317
|
impaired neutrophil recruitment
|
J:114317
|
Cd44tm2Kmz/Cd44tm2Kmz Selltm2Hyn/Selltm2Hyn
(involves: 129S2/SvPas * BALB/c * DBA/1)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:114317
|
abnormal leukocyte adhesion
|
J:114317
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:114317
|
impaired leukocyte tethering or rolling
|
J:114317
|
impaired neutrophil recruitment
|
J:114317
|
Cd47tm1Fpl/Cd47+
(B6.129S7-Cd47tm1Fpl)
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:36489
|
Cd47tm1Fpl/Cd47tm1Fpl
(involves: 129S7/SvEvBrd)
|
impaired neutrophil recruitment
|
J:148196
|
Cd47tm1Fpl/Cd47tm1Fpl
(B6.129S7-Cd47tm1Fpl)
|
abnormal neutrophil physiology
|
J:36489
|
impaired granulocyte bactericidal activity
|
J:36489
|
impaired neutrophil chemotaxis
|
J:36489
|
impaired neutrophil phagocytosis
|
J:36489
|
increased susceptibility to bacterial infection
|
J:36489
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:36489
|
Cd47tm1Fpl/Cd47tm1Fpl
(involves: 129S7/SvEvBrd * C57BL/6)
|
abnormal cytokine level
|
J:134866
|
abnormal tumor necrosis factor level
|
J:134866
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:134866
|
increased susceptibility to bacterial infection
|
J:134866
|
Cd48tm1Rsr/Cd48tm1Rsr
(B6.129S4-Cd48tm1Rsr)
|
abnormal T cell activation
|
J:53718
|
decreased T cell proliferation
|
J:53718
|
Cd53tm1.1Nmg/Cd53tm1.1Nmg
(involves: C57BL/6J)
|
abnormal B cell physiology
|
J:260065
|
Cd55tm1Mme/Cd55tm1Mme
(involves: 129P2/OlaHsd * C57BL/6)
|
increased susceptibility to experimental autoimmune myasthenia gravis
|
J:80116
|
Cd55tm1Song/Cd55tm1Song
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal complement pathway
|
J:52968
|
impaired complement alternative pathway
|
J:52968
|
impaired complement classical pathway
|
J:52968
|
Cd55tm1Song/Cd55tm1Song
(involves: 129S6/SvEvTac)
|
abnormal complement pathway
|
J:76578
|
Cd55tm1Song/Cd55tm1Song
(B6.129S6-Cd55tm1Song)
|
increased susceptibility to experimental autoimmune myasthenia gravis
|
J:113567
|
Cd55tm1Song/Cd55tm1Song Cd59atm1Bpm/Cd59atm1Bpm
(B6.129-Cd55tm1Song Cd59atm1Bpm)
|
abnormal complement pathway
|
J:113567
|
increased susceptibility to experimental autoimmune myasthenia gravis
|
J:113567
|
myositis
|
J:113567
|
Cd59atm1Bpm/Cd59atm1Bpm
(involves: 129 * C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:89014
|
Cd59atm1Bpm/Cd59atm1Bpm
(involves: 129)
|
abnormal complement pathway
|
J:148367
|
increased susceptibility to induced arthritis
|
J:146711
|
Cd59atm1Bpm/Cd59atm1Bpm
(B6.129-Cd59atm1Bpm)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:119703,
J:123582
|
abnormal complement pathway
|
J:92414
|
abnormal humoral immune response
|
J:119703
|
decreased B cell proliferation
|
J:119703
|
decreased IgG level
|
J:119703
|
decreased susceptibility to Poxviridae infection
|
J:122201
|
increased susceptibility to experimental autoimmune myasthenia gravis
|
J:113567
|
increased susceptibility to Orthomyxoviridae infection
|
J:123582
|
increased T cell proliferation
|
J:122201
|
lung inflammation
|
J:123582
|
myositis
|
J:113567
|
Cd59atm1Bpm/Cd59atm1Bpm
(involves: 129 * BALB/c)
|
increased susceptibility to Orthomyxoviridae infection
|
J:123582
|
Cd59atm1Song/Cd59atm1Song
(involves: 129S6/SvEvTac)
|
abnormal complement pathway
|
J:76578
|
Cd59atm1Song/Cd59atm1Song Cd55tm1Song/Cd55tm1Song
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal complement pathway
|
J:76578
|
Cd68tm1Shnd/Cd68tm1Shnd
(either: B6.129-Cd68tm1Shnd or (involves: 129S1/Sv * 129X1/SvJ))
|
abnormal dendritic cell antigen presentation
|
J:175275
|
Cd68tm1Xfen/Cd68tm1Xfen
(C57BL/6J-Cd68tm1Xfen)
|
abnormal osteoclast physiology
|
J:178120
|
Cd69tm1Fsm/Cd69tm1Fsm
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal humoral immune response
|
J:61329
|
increased IgG2a level
|
J:61329
|
increased IgM level
|
J:61329
|
Cd69tm1Naka/Cd69tm1Naka
(C.129P2-Cd69tm1Naka)
|
decreased susceptibility to induced arthritis
|
J:84940
|
impaired neutrophil chemotaxis
|
J:84940
|
impaired neutrophil recruitment
|
J:84940
|
Cd69tm1Naka/Cd69tm1Naka
(B6.129P2-Cd69tm1Naka)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:184704
|
abnormal humoral immune response
|
J:184704
|
abnormal memory T cell physiology
|
J:184704
|
abnormal T cell physiology
|
J:184704
|
decreased interferon-gamma secretion
|
J:184704
|
decreased tumor necrosis factor secretion
|
J:184704
|
Cd70tm1.1Jda/Cd70tm1.1Jda
(B6.Cg-Cd70tm1.1Jda)
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:193042
|
abnormal immune system physiology
|
J:193042
|
abnormal T cell physiology
|
J:193042
|
increased susceptibility to Riboviria infection
|
J:193042
|
Cd72b/Cd72b Faslpr/Faslpr
(involves: C57BL/6 * C57BL/6JJmsSlc * MRL/Mp)
|
autoimmune response
|
J:204782
|
decreased anti-double stranded DNA antibody level
|
J:204782
|
decreased anti-nuclear antigen antibody level
|
J:204782
|
decreased IgG level
|
J:204782
|
decreased susceptibility to autoimmune disorder
|
J:204782
|
Cd72c/Cd72c
(involves: C57BL/6 * MRL)
|
increased B cell proliferation
|
J:204782
|
Cd72c/Cd72c Faslpr/Faslpr
(involves: C57BL/6 * C57BL/6JJmsSlc * MRL/Mp)
|
autoimmune response
|
J:204782
|
increased anti-chromatin antibody level
|
J:204782
|
increased anti-double stranded DNA antibody level
|
J:204782
|
increased anti-single stranded DNA antibody level
|
J:204782
|
increased IgG level
|
J:204782
|
increased susceptibility to systemic lupus erythematosus
|
J:204782
|
liver inflammation
|
J:204782
|
lung inflammation
|
J:204782
|
Cd72tm1Jrp/Cd72tm1Jrp
(either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * C57BL/6))
|
abnormal B cell activation
|
J:76990
|
abnormal B cell calcium ion homeostasis
|
J:76990
|
increased B cell proliferation
|
J:76990
|
increased IgM level
|
J:76990
|
Cd72tm1Jrp/Cd72tm1Jrp Tg(BCL2)22Wehi/0
(either: (involves: 129P2/OlaHsd * C57BL/6JWehi * SJL/JWehi) or (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6JWehi * SJL/JWehi))
|
abnormal B cell physiology
|
J:76990
|
Cd72tm1Tsub/Cd72tm1Tsub
(involves: C57BL/6J)
|
glomerulonephritis
|
J:204782
|
increased anti-chromatin antibody level
|
J:204782
|
increased anti-double stranded DNA antibody level
|
J:204782
|
increased anti-single stranded DNA antibody level
|
J:204782
|
increased B cell proliferation
|
J:204782
|
lung inflammation
|
J:204782
|
Cd72tm1Tsub/Cd72tm1Tsub Faslpr/Faslpr
(involves: C57BL/6J * C57BL/6JJmsSlc * MRL/Mp)
|
autoimmune response
|
J:204782
|
glomerulonephritis
|
J:204782
|
increased anti-chromatin antibody level
|
J:204782
|
increased anti-double stranded DNA antibody level
|
J:204782
|
increased anti-single stranded DNA antibody level
|
J:204782
|
liver inflammation
|
J:204782
|
lung inflammation
|
J:204782
|
Cd74tm1Doi/Cd74tm1Doi
(either: (involves: 129/Sv * B10.BR) or (involves: 129/Sv * C57BL/6))
|
abnormal antigen presentation
|
J:4119
|
abnormal level of surface class II molecules
|
J:45185
|
Cd74tm1Doi/Cd74tm1Doi
(involves: 129S2/SvPas)
|
abnormal dendritic cell antigen presentation
|
J:151699
|
Cd74tm1Doi/Cd74tm1Doi H2-DMatm1Doi/H2-DMatm1Doi
(involves: 129S2/SvPas * C57BL/6)
|
abnormal professional antigen presenting cell physiology
|
J:42482
|
Cd74tm1Eae/Cd74tm1Eae
(involves: 129S2/SvPas)
|
abnormal level of surface class II molecules
|
J:65917
|
decreased B cell proliferation
|
J:113050,
J:132865
|
decreased IgM level
|
J:113050
|
Cd74tm1Liz/Cd74tm1Liz
(involves: 129S/SvEv * C57BL/6J)
|
abnormal antigen presentation
|
J:72243
|
abnormal antigen presentation via MHC class II
|
J:65918
|
abnormal level of surface class II molecules
|
J:65918
|
decreased interferon-gamma secretion
|
J:72243
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:72243
|
decreased T cell proliferation
|
J:72243
|
defective assembly of class II molecules
|
J:65918
|
Cd74tm1Liz/Cd74tm1Liz
(B6.129S-Cd74tm1Liz)
|
abnormal antigen presentation
|
J:125654
|
abnormal antigen presentation via MHC class II
|
J:28966
|
abnormal level of surface class II molecules
|
J:28966
|
abnormal T-helper 1 physiology
|
J:125654
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:125654
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:125654
|
decreased T cell proliferation
|
J:28966
|
defective assembly of class II molecules
|
J:28966
|
Cd74tm1Liz/Cd74tm1Liz
(involves: 129S/SvEv * C57BL/6)
|
abnormal antigen presentation via MHC class II
|
J:111565
|
Cd74tm1Liz/Cd74tm1Liz
(involves: 129S/SvEv * BALB/cAn)
|
abnormal antigen presentation via MHC class II
|
J:110927,
J:113714
|
abnormal dendritic cell antigen presentation
|
J:110927
|
abnormal professional antigen presenting cell physiology
|
J:113714
|
Cd74tm1Liz/Cd74tm1Liz
(involves: 129S/SvEv * BALB/c * C57BL)
|
abnormal antigen presentation via MHC class II
|
J:110927
|
abnormal dendritic cell antigen presentation
|
J:110927
|
abnormal T cell proliferation
|
J:110927
|
Cd74tm1Liz/Cd74tm1Liz
(involves: 129S/SvEv * C57BL * C57BL/10 * C57BR)
|
abnormal antigen presentation via MHC class II
|
J:110927
|
abnormal dendritic cell antigen presentation
|
J:110927
|
abnormal T cell proliferation
|
J:110927
|
Cd74tm1Liz/Cd74tm1Liz H2-DMatm1Luc/H2-DMatm1Luc Tg(CD74)AR194Ayr/?
(involves: 129S/SvEv * 129S4/SvJae * C57BL/6J * DBA/2J)
|
abnormal antigen presentation via MHC class II
|
J:88717
|
Cd74tm1Liz/Cd74tm1Liz H2-DMatm1Luc/H2-DMatm1Luc Tg(CD74*)1Ayr/0
(involves: 129S/SvEv * 129S4/SvJae * C57BL/6J * DBA/2J)
|
abnormal antigen presentation via MHC class II
|
J:88717
|
Cd74tm2Liz/Cd74tm1Liz
(involves: 129S/SvEv * C57BL/6)
|
abnormal antigen presentation via MHC class II
|
J:28966
|
increased T cell proliferation
|
J:28966
|
Cd74tm2Liz/Cd74tm2Liz
(involves: 129S/SvEv * C57BL/6)
|
decreased interleukin-2 secretion
|
J:72243
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:72243
|
Cd74tm3Liz/Cd74tm3Liz
(involves: 129S/SvEv * C57BL/6)
|
abnormal antigen presentation via MHC class II
|
J:82880
|
abnormal level of surface class II molecules
|
J:82880
|
decreased interleukin-2 secretion
|
J:72243
|
defective assembly of class II molecules
|
J:82880
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:72243
|
Cd79am1Anu/Cd79am1Anu
(involves: C57BL/6JSfdAnu * C57BL/10Sg * C57BR/cd)
|
decreased IgG level
|
J:104190
|
Cd79am1Btlr/Cd79am1Btlr
(involves: C57BL/6J * C57BL/10J)
|
abnormal humoral immune response
|
J:174338
|
decreased IgG level
|
J:174338
|
decreased IgM level
|
J:174338
|
Cd79am1Btlr/Cd79am1Btlr
(involves: C57BL/6J)
|
abnormal class switch recombination
|
J:185495
|
decreased IgG level
|
J:185495
|
decreased IgM level
|
J:185495
|
Cd79am2Btlr/Cd79am2Btlr
(C57BL/6J-Cd79am2Btlr)
|
decreased IgM level
|
J:254836
|
impaired humoral immune response
|
J:254836
|
Cd79atm1(cre)Reth/Cd79a+ Commd3tm1.1Ksuz/Commd3tm1.1Ksuz
(involves: BALB/c * C57BL/6NSlc * SJL)
|
abnormal follicular B cell physiology
|
J:278399
|
decreased IgG1 level
|
J:278399
|
decreased IgG2b level
|
J:278399
|
decreased IgG2c level
|
J:278399
|
decreased IgM level
|
J:278399
|
Cd79atm1(cre)Reth/Cd79a+ Commd8tm1.1Ksuz/Commd8tm1.1Ksuz
(involves: BALB/c * C57BL/6NSlc * SJL)
|
abnormal follicular B cell physiology
|
J:278399
|
decreased IgG1 level
|
J:278399
|
decreased IgG2b level
|
J:278399
|
decreased IgG2c level
|
J:278399
|
decreased IgG3 level
|
J:278399
|
decreased IgM level
|
J:278399
|
Cd79atm1(cre)Reth/Cd79a+ Ctnnbl1tm1.1Crad/Ctnnbl1tm1.1Crad
(involves: 129P2/OlaHsd * BALB/c * C57BL/6 * SJL)
|
abnormal B cell proliferation
|
J:232010
|
abnormal class switch recombination
|
J:232010
|
decreased B cell proliferation
|
J:232010
|
Cd79atm1(cre)Reth/Cd79a+ Eif4btm1.1Tnr/Eif4btm1.1Tnr Eif4htm1c(EUCOMM)Wtsi/Eif4htm1c(EUCOMM)Wtsi
(involves: BALB/c * C57BL/6 * C57BL/6N)
|
decreased IgG1 level
|
J:344730
|
Cd79atm1(cre)Reth/Cd79a+ Huwe1tm1.1Mak/Y
(B6.Cg-Cd79atm1(cre)Reth Huwe1tm1.1Mak)
|
abnormal class switch recombination
|
J:181705
|
abnormal humoral immune response
|
J:181705
|
decreased B cell proliferation
|
J:181705
|
decreased IgA level
|
J:181705
|
decreased IgG1 level
|
J:181705
|
decreased IgG2a level
|
J:181705
|
decreased IgG3 level
|
J:181705
|
decreased IgM level
|
J:181705
|
increased B cell apoptosis
|
J:181705
|
increased susceptibility to Riboviria infection
|
J:181705
|
Cd79atm1(cre)Reth/Cd79a+ Huwe1tm1.1Mak/Y Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * C57BL/6 * SJL)
|
abnormal class switch recombination
|
J:181705
|
decreased IgG1 level
|
J:181705
|
decreased IgM level
|
J:181705
|
Cd79atm1(cre)Reth/Cd79a+ Inpp5dtm1Rav/Inpp5dtm1Rav
(involves: 129 * BALB/c * C57BL/6)
|
increased anti-chromatin antibody level
|
J:178833
|
increased anti-double stranded DNA antibody level
|
J:178833
|
increased anti-nuclear antigen antibody level
|
J:178833
|
increased anti-single stranded DNA antibody level
|
J:178833
|
increased autoantibody level
|
J:178833
|
increased IgG level
|
J:178833
|
increased susceptibility to systemic lupus erythematosus
|
J:178833
|
Cd79atm1(cre)Reth/Cd79a+ Nr4a1tm1Pcn/Nr4a1tm1Pcn
(involves: 129 * BALB/c)
|
increased B cell proliferation
|
J:306652
|
Cd79atm1(cre)Reth/Cd79a+ Nr4a1tm1Pcn/Nr4a1tm1Pcn Nr4a3em1Juz/Nr4a3em1Juz
(involves: 129 * BALB/c * C57BL/6)
|
decreased B cell apoptosis
|
J:306652
|
increased B cell proliferation
|
J:306652
|
Cd79atm1(cre)Reth/Cd79a+ Orai1tm1Smua/Orai1tm1Smua
(involves: BALB/c * C57BL/6J)
|
abnormal B cell activation
|
J:345485
|
abnormal B cell physiology
|
J:345485
|
Cd79atm1(cre)Reth/Cd79a+ Orai1tm1Smua/Orai1tm1Smua Orai3em1.1Treb/Orai3em1.1Treb
(involves: BALB/c * C57BL/6J * C57BL/6N)
|
abnormal B cell activation
|
J:345485
|
abnormal B cell physiology
|
J:345485
|
decreased B cell proliferation
|
J:345485
|
Cd79atm1(cre)Reth/Cd79a+ Orai3em1.1Treb/Orai3em1.1Treb
(involves: BALB/c * C57BL/6J * C57BL/6N)
|
abnormal B cell activation
|
J:345485
|
Cd79atm1(cre)Reth/Cd79a+ Phf5atm1.1Oux/Phf5atm1.1Oux
(involves: BALB/c * C57BL/6J)
|
abnormal B cell physiology
|
J:345807
|
Cd79atm1(cre)Reth/Cd79a+ Slc39a10tm1.1Tfk/Slc39a10tm1.1Tfk
(involves: 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6J)
|
decreased IgA level
|
J:213935
|
decreased IgE level
|
J:213935
|
decreased IgG1 level
|
J:213935
|
decreased IgG2b level
|
J:213935
|
decreased IgG2c level
|
J:213935
|
decreased IgG3 level
|
J:213935
|
decreased IgM level
|
J:213935
|
decreased immunoglobulin level
|
J:213935
|
Cd79atm1(cre)Reth/Cd79a+ Wastm1.1Ldn/Y
(involves: BALB/c * C57BL/6)
|
abnormal B cell physiology
|
J:182528
|
increased anti-chromatin antibody level
|
J:182528
|
increased anti-double stranded DNA antibody level
|
J:182528
|
increased anti-single stranded DNA antibody level
|
J:182528
|
increased autoantibody level
|
J:182528
|
increased IgM level
|
J:182528
|
Cd79atm1(cre)Reth/Cd79a+ Wastm1.1Ldn/Was+
(involves: BALB/c * C57BL/6)
|
abnormal B cell proliferation
|
J:182528
|
Cd79atm1(cre)Reth/Cd79a+ Wastm1.1Ldn/Wastm1.1Ldn
(involves: BALB/c * C57BL/6)
|
abnormal B cell physiology
|
J:182528
|
increased anti-chromatin antibody level
|
J:182528
|
increased anti-double stranded DNA antibody level
|
J:182528
|
increased anti-single stranded DNA antibody level
|
J:182528
|
increased autoantibody level
|
J:182528
|
increased IgM level
|
J:182528
|
Cd79atm1.1Cgn/Cd79atm1.1Cgn
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal B cell activation
|
J:71100
|
decreased IgG1 level
|
J:71100
|
Cd79atm1.1Rsky/Cd79atm1.1Rsky
(involves: C57BL/6)
|
abnormal humoral immune response
|
J:179254
|
decreased IgG2b level
|
J:179254
|
decreased IgG2c level
|
J:179254
|
decreased IgG3 level
|
J:179254
|
increased anti-single stranded DNA antibody level
|
J:179254
|
increased IgG2b level
|
J:179254
|
increased IgG2c level
|
J:179254
|
Cd79atm2Cgn/Cd79atm2Cgn
(involves: C57BL/6 * C.B-20)
|
decreased immunoglobulin level
|
J:80885
|
Cd79atm4Cgn/Cd79atm4.1Cgn Tg(Cr2-cre)3Cgn/0
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased IgD level
|
J:91091
|
decreased IgM level
|
J:91091
|
Cd79atm5.1Cgn/Cd79a+ Ightm1.2Rsky/Igh+
(involves: 129 * BALB/c * C57BL/6)
|
abnormal class switch recombination
|
J:125719
|
Cd79atm5.1Cgn/Cd79atm5.1Cgn Ightm1.2Rsky/Igh+
(involves: 129 * BALB/c * C57BL/6)
|
abnormal class switch recombination
|
J:125719
|
Cd79atm5.1Cgn/Cd79atm5.1Cgn Ightm1.2Rsky/Ightm1.2Rsky
(involves: 129 * BALB/c * C57BL/6)
|
abnormal class switch recombination
|
J:125719
|
Cd79atm6Cgn/Cd79atm6Cgn
(involves: C57BL/6)
|
abnormal B cell physiology
|
J:113407
|
abnormal humoral immune response
|
J:113407
|
abnormal immunoglobulin level
|
J:113407
|
decreased B cell proliferation
|
J:113407
|
decreased IgG2a level
|
J:113407
|
decreased IgG3 level
|
J:113407
|
decreased IgM level
|
J:113407
|
Cd79atm7Cgn/Cd79atm7Cgn
(involves: C57BL/6)
|
abnormal immune system physiology
|
J:113407
|
Cd79bm1Ghost/Cd79bm1Ghost
(B10.Cg-Ptprca Cd79bm1Ghost H2a)
|
decreased IgA level
|
J:157450
|
decreased IgG level
|
J:157450
|
Cd79btm1Gzmn/Cd79btm1Gzmn
(involves: 129/Sv * C57BL/6)
|
abnormal immune system physiology
|
J:124400
|
decreased IgG1 level
|
J:124400
|
increased IgD level
|
J:124400
|
increased IgM level
|
J:124400
|
Cd79btm2.1Mnz/Cd79btm2.1Mnz
(involves: 129/Sv * C57BL/6)
|
abnormal B cell activation
|
J:66840
|
Cd79btm3Mnz/Cd79btm3Mnz
(involves: 129/Sv * C57BL/6)
|
abnormal B cell physiology
|
J:128768
|
abnormal immune system physiology
|
J:128768
|
decreased B cell proliferation
|
J:128768
|
Cd80tm1Lbgn/Cd80tm1Lbgn
(C3.Cg-Cd80tm1Lbgn)
|
abnormal T cell physiology
|
J:110947
|
Cd80tm1Shr/Cd80tm1Shr
(involves: 129S4/SvJae)
|
abnormal immunoglobulin level
|
J:39089
|
decreased B cell proliferation
|
J:74662
|
Cd80tm1Shr/Cd80tm1Shr Cd86tm1Shr/Cd86tm1Shr
(B6.129S4-Cd80tm1Shr Cd86tm1Shr)
|
brain inflammation
|
J:57613
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:57613
|
decreased T cell proliferation
|
J:57613
|
increased interferon-gamma secretion
|
J:57613
|
increased tumor necrosis factor secretion
|
J:57613
|
Cd80tm1Shr/Cd80tm1Shr Cd86tm2Shr/Cd86tm2Shr
(involves: 129S4/SvJae)
|
abnormal T cell physiology
|
J:57090
|
abnormal T cell proliferation
|
J:57090
|
decreased IgG1 level
|
J:39089
|
decreased IgG2a level
|
J:39089
|
decreased IgG level
|
J:39089
|
increased IgG3 level
|
J:39089
|
increased IgM level
|
J:39089
|
increased susceptibility to autoimmune diabetes
|
J:113109
|
Cd80tm1Shr/Cd80tm1Shr Cd86tm2Shr/Cd86tm2Shr
(involves: 129S4/SvJae * NOD)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:61905
|
abnormal cytokine secretion
|
J:61905
|
increased susceptibility to autoimmune diabetes
|
J:61905
|
insulitis
|
J:61905
|
Cd80tm1Shr/Cd80tm1Shr Cd86tm2Shr/Cd86tm2Shr
(129.SJL-Cd86tm2Shr)
|
decreased interleukin-2 secretion
|
J:78992
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:78992
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:78992
|
Cd80tm1Shr/Cd80tm1Shr Cd86tm2Shr/Cd86tm2Shr
(involves: 129S4/SvJae * C57BL/6J * SJL)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:78992
|
Cd80tm1Shr/Cd80tm1Shr Cd86tm2Shr/Cd86tm2Shr Ctla4tm1Shr/Ctla4tm1Shr
(involves: 129S4/SvJae * BALB/c)
|
abnormal cytokine secretion
|
J:57090
|
abnormal T cell physiology
|
J:57090
|
increased T cell proliferation
|
J:57090
|
Cd80tm1Shr/Cd80tm1Shr Cd86tm2Shr/Cd86tm2Shr Tg(Ighm-Ctla4Ig/Cd80)1Jbs/0
(involves: 129S4/SvJae * FVB/N * NOD)
|
decreased susceptibility to autoimmune diabetes
|
J:113109
|
insulitis
|
J:113109
|
Cd81tm1Geha/Cd81tm1Geha
(involves: 129S4/SvJae * C57BL/6)
|
increased B cell proliferation
|
J:43975
|
increased IgA level
|
J:43975
|
increased IgG3 level
|
J:43975
|
increased IgM level
|
J:43975
|
Cd81tm1Lvy/Cd81tm1Lvy
(involves: 129S1/Sv * 129X1/SvJ)
|
abnormal T-helper 2 physiology
|
J:40394
|
decreased IgG1 level
|
J:40394
|
decreased IgG level
|
J:40394
|
decreased susceptibility to parasitic infection
|
J:126000
|
Cd81tm1Lvy/Cd81tm1Lvy
(CByJ.129-Cd81tm1Lvy)
|
abnormal T-helper 2 physiology
|
J:46171
|
decreased susceptibility to type I hypersensitivity reaction
|
J:46171
|
Cd81tm1Tmiy/Cd81tm1Tmiy
(involves: 129/Sv * C57BL/6)
|
abnormal macrophage physiology
|
J:83795
|
abnormal T cell proliferation
|
J:41830
|
decreased B cell proliferation
|
J:41830
|
increased B cell proliferation
|
J:41830
|
Cd81tm1Tmiy/Cd81tm1Tmiy Cd9tm1Mek/Cd9tm1Mek
(involves: 129/Sv * C57BL/6)
|
abnormal macrophage physiology
|
J:83795
|
Cd82tm1Kjbr/Cd82tm1Kjbr
(Not Specified)
|
abnormal cellular extravasation
|
J:326451
|
abnormal neutrophil physiology
|
J:326451
|
impaired leukocyte tethering or rolling
|
J:326451
|
increased susceptibility to bacterial infection
|
J:326451
|
Cd83lcd4/Cd83lcd4
(involves: C57BL/6J)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:92721
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:92721
|
decreased T cell proliferation
|
J:92721
|
Cd83tm1Tft/Cd83tm1Tft
(involves: 129S4/SvJae * C57BL/6)
|
abnormal humoral immune response
|
J:75700
|
decreased IgA level
|
J:75700
|
decreased IgG1 level
|
J:75700
|
decreased IgG2a level
|
J:75700
|
decreased IgG2b level
|
J:75700
|
decreased IgG3 level
|
J:75700
|
decreased IgM level
|
J:75700
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:75700
|
Cd84tm1Pls/Cd84tm1Pls
(C57BL/6J-Cd84tm1Pls)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:157915
|
decreased IgG level
|
J:157915
|
decreased interleukin-21 secretion
|
J:157915
|
Cd84tm1Pls/Cd84tm1Pls Tg(TcraTcrb)425Cbn/?
(B6.Cg-Cd84tm1Pls Tg(TcraTcrb)425Cbn)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:157915
|
Cd86tm1Shr/Cd86tm1Shr
(NOD.129S4-Cd86tm1Shr)
|
abnormal T cell proliferation
|
J:142046
|
decreased susceptibility to autoimmune diabetes
|
J:71352
|
decreased T cell proliferation
|
J:93421
|
increased autoantibody level
|
J:142046
|
increased interferon-gamma secretion
|
J:142046
|
increased susceptibility to autoimmune diabetes
|
J:93421
|
Cd86tm1Shr/Cd86tm1Shr
(involves: 129S4/SvJae)
|
abnormal humoral immune response
|
J:39089
|
decreased IgG level
|
J:39089
|
Cd86tm1Shr/Cd86tm1Shr
(B6.129S4-Cd86tm1Shr)
|
decreased T cell proliferation
|
J:57613
|
increased interferon-gamma secretion
|
J:57613
|
Cd86tm1Shr/Cd86tm1Shr Marchf1tm1.1Sish/Marchf1tm1.1Sish
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
|
decreased interleukin-12 secretion
|
J:157516
|
decreased tumor necrosis factor secretion
|
J:157516
|
Cd86tm2Shr/Cd86tm2Shr Icostm1Flv/Icostm1Flv
(involves: 129S1/Sv * 129S4/SvJaeSor)
|
abnormal cytokine level
|
J:112600
|
Cd93tm1Mbo/Cd93tm1Mbo
(either: 129/Sv or B6.129-Cd93tm1Mbo or (involves: 129/Sv * C57BL/6))
|
impaired macrophage phagocytosis
|
J:88610
|
Cd96tm1.1Mjs/Cd96tm1.1Mjs
(B6.129P2(Cg)-Cd96tm1.1Mjs)
|
abnormal NK cell physiology
|
J:209990
|
increased inflammatory response
|
J:209990
|
increased susceptibility to endotoxin shock
|
J:209990
|
Cd99Gt(Ayu21-B6T44)Imeg/Cd99Gt(Ayu21-B6T44)Imeg
(involves: C57BL/6 * C57BL/6NSlc)
|
abnormal splenocyte physiology
|
J:212222
|
Cd99l2tm1.1Dvst/Cd99l2tm1.1Dvst Tg(Tek-cre)1Ywa/0
(involves: 129S6/SvEvTac * BALB/c * C57BL/6)
|
abnormal cellular extravasation
|
J:193021
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:193021
|
Cd99l2tm1.2Dvst/Cd99l2tm1.2Dvst
(involves: 129S6/SvEvTac * BALB/c * C57BL/6)
|
abnormal cellular extravasation
|
J:193021
|
Cd109tm1Mat/Cd109tm1Mat
(involves: 129S6/SvEvTac * C57BL/6J)
|
skin inflammation
|
J:188696
|
Cd151tm1Lka/Cd151tm1Lka
(C57BL/6-Cd151tm1Lka)
|
abnormal T cell proliferation
|
J:91605
|
Cd151tm1Nki/Cd151tm1Nki
(involves: 129P2/OlaHsd * FVB/N)
|
tubulointerstitial nephritis
|
J:114988
|
Cd160tm1Yxf/Cd160tm1Yxf
(C57BL/6-Cd160tm1Yxf)
|
decreased interferon-gamma secretion
|
J:222131
|
Cd160tm1Yxf/Cd160tm1Yxf Rag1tm1Mom/Rag1tm1Mom
(B6.Cg-Rag1tm1Mom Cd160tm1Yxf)
|
decreased interferon-gamma secretion
|
J:222131
|
Cd163tm1(KOMP)Vlcg/Cd163tm1(KOMP)Vlcg
(involves: C57BL/6NTac)
|
abnormal circulating cytokine level
|
J:224919
|
abnormal macrophage chemotaxis
|
J:224919
|
Cd163tm1(KOMP)Vlcg/Cd163tm1(KOMP)Vlcg
(involves: C57BL/6NTac)
|
lung inflammation
|
J:233977
|
Cd177tm1(KOMP)Vlcg/Cd177tm1(KOMP)Vlcg
(involves: C57BL/6NTac)
|
abnormal neutrophil physiology
|
J:225335
|
Cd180tm1Kmiy/Cd180tm1Kmiy
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal humoral immune response
|
J:63145
|
decreased IgG2b level
|
J:137066
|
decreased IgG3 level
|
J:137066
|
Cd180tm1Kmiy/Cd180tm1Kmiy
(involves: 129P2/OlaHsd * C57BL/6 * NZB * NZW)
|
decreased IgG2a level
|
J:137066
|
decreased IgG3 level
|
J:137066
|
Cd180tm1Kmiy/Cd180tm1Kmiy Faslpr/Faslpr
(MRL.Cg-Cd180tm1Kmiy Faslpr)
|
blood vessel inflammation
|
J:137066
|
decreased IgG2a level
|
J:137066
|
decreased IgG3 level
|
J:137066
|
glomerulonephritis
|
J:137066
|
increased anti-nuclear antigen antibody level
|
J:137066
|
increased autoantibody level
|
J:137066
|
Cd200tm1Jods/Cd200tm1Jods
(C57BL/6-Cd200tm1Jods)
|
abnormal cytokine level
|
J:95862
|
abnormal immune system physiology
|
J:65982
|
abnormal macrophage physiology
|
J:65982
|
abnormal microglial cell physiology
|
J:65982
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:65982
|
increased susceptibility to experimental autoimmune uveoretinitis
|
J:79906
|
increased susceptibility to induced arthritis
|
J:65982
|
Cd200r1tm1.1Rmgo/Cd200r1tm1.1Rmgo
(C57BL/6-Cd200r1tm1.1Rmgo)
|
abnormal dendritic cell physiology
|
J:134313
|
abnormal professional antigen presenting cell physiology
|
J:135069
|
abnormal response to transplant
|
J:135069
|
increased interleukin-12b secretion
|
J:135069
|
increased tumor necrosis factor secretion
|
J:135069
|
Cd200r1tm1.1Rmgo/Cd200r1tm1.1Rmgo Tg(tetO/CMV-CD200)1Rmgo/Tg(tetO/CMV-CD200)1Rmgo
(involves: C57BL/6)
|
abnormal dendritic cell physiology
|
J:134313
|
Cd200r1tm1Eakj/Cd200r1tm1Eakj
(Not Specified)
|
abnormal macrophage physiology
|
J:326965
|
decreased interferon-beta secretion
|
J:192198
|
decreased interleukin-1 beta secretion
|
J:192198
|
decreased interleukin-6 secretion
|
J:192198
|
decreased susceptibility to Herpesvirales infection
|
J:192198
|
decreased susceptibility to Herpesvirales infection induced morbidity/mortality
|
J:192198
|
Cd207tm1(Hbegf/EGFP)Bjec/Cd207+
(involves: C57BL/6 * SJL)
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:137517
|
increased susceptibility to Orthomyxoviridae infection
|
J:137452
|
Cd207tm1(Hbegf/EGFP)Bjec/Cd207+
(involves: C57BL/6)
|
abnormal type IV hypersensitivity reaction
|
J:179630
|
Cd207tm1.1Cfg/Cd207tm1.1Cfg
(involves: C57BL/6)
|
decreased IgA level
|
J:217719
|
decreased IgG1 level
|
J:217719
|
decreased IgG2a level
|
J:217719
|
decreased IgG3 level
|
J:217719
|
decreased IgM level
|
J:217719
|
Cd207tm2.1(cre)Bjec/Cd207+ Tgfbr1tm1.1Karl/Tgfbr1tm1.1Karl
(involves: 129S4/SvJaeSor * C57BL/6)
|
abnormal type IV hypersensitivity reaction
|
J:179630
|
Cd209atm1.1Cfg/Cd209atm1.1Cfg
(involves: C57BL/6)
|
decreased IgG2b level
|
J:217719
|
increased inflammatory response
|
J:217719
|
increased T cell proliferation
|
J:217719
|
Cd209btm1.1Cfg/Cd209btm1.1Cfg
(involves: C57BL/6)
|
impaired macrophage phagocytosis
|
J:288225
|
increased IgG2b level
|
J:217719
|
increased IgG3 level
|
J:217719
|
increased IgM level
|
J:217719
|
increased susceptibility to bacterial infection
|
J:288225
|
urinary bladder inflammation
|
J:288225
|
Cd209btm1Anjm/Cd209btm1Anjm
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal macrophage physiology
|
J:94698
|
impaired macrophage phagocytosis
|
J:94698
|
increased susceptibility to bacterial infection
|
J:94698
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:94698
|
Cd209btm1Anjm/Cd209btm1Anjm
(B6.129P2-Cd209btm1Anjm)
|
decreased interleukin-1 beta secretion
|
J:159646
|
decreased interleukin-18 secretion
|
J:159646
|
decreased susceptibility to endotoxin shock
|
J:159646
|
decreased susceptibility to induced colitis
|
J:159646
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:94698
|
Cd209dtm1.1Cfg/Cd209dtm1.1Cfg
(involves: C57BL/6 * C57BL/6J)
|
increased circulating tumor necrosis factor level
|
J:153503
|
increased susceptibility to bacterial infection
|
J:153503
|
Cd209dtm1.1Cfg/Cd209dtm1.1Cfg
(involves: C57BL/6)
|
increased B cell proliferation
|
J:217719
|
Cd226tm1.1Cln/Cd226tm1.1Cln
(B6.129P2-Cd226tm1.1Cln)
|
decreased inflammatory response
|
J:209990
|
decreased T cell proliferation
|
J:159749
|
impaired natural killer cell mediated cytotoxicity
|
J:159749
|
Cd226tm1.1Cln/Cd226tm1.1Cln Tg(TcraTcrb)1100Mjb/0
(B6.Cg-Cd226tm1.1Cln Tg(TcraTcrb)1100Mjb)
|
abnormal T cell activation
|
J:159749
|
decreased cytotoxic T cell cytolysis
|
J:159749
|
decreased interferon-gamma secretion
|
J:159749
|
decreased T cell proliferation
|
J:159749
|
Cd226tm1Shib/Cd226tm1Shib
(involves: BALB/c)
|
abnormal immune system physiology
|
J:165704
|
decreased cytotoxic T cell cytolysis
|
J:165704
|
impaired natural killer cell mediated cytotoxicity
|
J:165704
|
Cd244aChip/Cd244a+
(C57BL/6J-Cd244aChip)
|
abnormal NK cell physiology
|
J:196519
|
impaired natural killer cell mediated cytotoxicity
|
J:196519
|
Cd244aChip/Cd244aChip
(C57BL/6J-Cd244aChip)
|
abnormal NK cell physiology
|
J:196519
|
impaired natural killer cell mediated cytotoxicity
|
J:196519
|
Cd244atm1Kmle/Cd244atm1Kmle
(involves: C57BL/6)
|
impaired natural killer cell mediated cytotoxicity
|
J:166054
|
increased natural killer cell mediated cytotoxicity
|
J:92740
|
Cd247m1Btlr/Cd247m1Btlr
(C57BL/6J-Cd247m1Btlr)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:158794
|
Cd247tm1Lov/Cd247tm1Lov
(involves: 129S4/SvJae)
|
abnormal T-helper 1 physiology
|
J:46914
|
Cd247tm1Lov/Cd247tm1Lov Fcer1gtm1Rav/Fcer1gtm1Rav
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
abnormal T cell activation
|
J:46914
|
abnormal T-helper 1 physiology
|
J:46914
|
impaired natural killer cell mediated cytotoxicity
|
J:64764
|
Cd247tm1Mal/Cd247tm1Mal
(involves: C57BL/6)
|
abnormal thymocyte activation
|
J:110847
|
Cd247tm1Mal/Cd247tm1Mal Lcktm1Mak/Lcktm1Mak
(involves: 129S2/SvPas * C57BL/6)
|
abnormal thymocyte activation
|
J:110847
|
Cd247tm1Mhu/Cd247tm1Mhu
(involves: 129S7/SvEvBrd * C57BL/6)
|
decreased splenocyte proliferation
|
J:15579
|
decreased T cell proliferation
|
J:15579
|
Cd247tm1Tks/Cd247tm1Tks
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal T cell proliferation
|
J:15271
|
Cd247tm1Tks/Cd247tm1Tks
(B6.129P2-Cd247tm1Tks)
|
abnormal NK cell physiology
|
J:66403
|
increased interferon-gamma secretion
|
J:66403
|
increased natural killer cell mediated cytotoxicity
|
J:66403
|
Cd247tm2.1Lov/Cd247tm2.1Lov
(Not Specified)
|
abnormal regulatory T cell physiology
|
J:192915
|
abnormal T cell physiology
|
J:192915
|
decreased thymocyte apoptosis
|
J:192915
|
Cd247tm2.1Lov/Cd247tm2.1Lov
(B6.Cg-Cd247tm2.1Lov)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:192915
|
Cd274tm1.1Lex/Cd274tm1.1Lex
(involves: 129S5/SvEvBrd)
|
abnormal cytokine secretion
|
J:126829
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:126829
|
Cd274tm1Igu/Cd274tm1Igu Vsirtm1Lex/Vsirtm1Lex
(involves: 129S5/SvEvBrd * C57BL/6)
|
abnormal T cell activation
|
J:222944
|
Cd274tm1Lpc/Cd274tm1Lpc
(B6.129S-Cd274tm1Lpc)
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:89781
|
decreased T cell apoptosis
|
J:89781
|
increased susceptibility to autoimmune disorder
|
J:89781
|
Cd274tm1Lpc/Cd274tm1Lpc
(involves: 129S/SvEv)
|
abnormal chemokine secretion
|
J:158023
|
increased tumor necrosis factor secretion
|
J:158023
|
Cd274tm1Lpc/Cd274tm1Lpc
(involves: 129S/SvEv * C57BL/6)
|
abnormal dendritic cell physiology
|
J:152305
|
decreased susceptibility to Riboviria infection
|
J:136330
|
decreased susceptibility to Riboviria infection induced morbidity/mortality
|
J:136330
|
decreased T cell apoptosis
|
J:136330
|
increased IgG1 level
|
J:162539
|
increased IgG2c level
|
J:162539
|
increased susceptibility to bacterial infection
|
J:162539
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:162539
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:142815
|
Cd274tm1Lpc/Cd274tm1Lpc
(C.129S-Cd274tm1Lpc)
|
abnormal regulatory T cell physiology
|
J:165841
|
abnormal T follicular helper cell physiology
|
J:165841
|
decreased IgG1 level
|
J:165841
|
decreased IgG2a level
|
J:165841
|
decreased interleukin-17 secretion
|
J:165841
|
increased interferon-gamma secretion
|
J:165841
|
increased interleukin-4 secretion
|
J:165841
|
increased susceptibility to induced arthritis
|
J:165841
|
increased T cell proliferation
|
J:165841
|
Cd274tm1Shr/Cd274tm1Shr
(C.B6-Cd274tm1Shr)
|
abnormal interleukin secretion
|
J:123785
|
increased interferon-gamma secretion
|
J:123785
|
increased susceptibility to autoimmune diabetes
|
J:123785
|
Cd274tm1Shr/Cd274tm1Shr Pdcd1lg2tm3Shr/Pdcd1lg2tm3Shr
(C.B6-Cd274tm1Shr Pdcd1lg2tm3Shr)
|
abnormal dendritic cell physiology
|
J:123785
|
decreased interleukin-4 secretion
|
J:123785
|
increased interferon-gamma secretion
|
J:123785
|
increased interleukin-2 secretion
|
J:123785
|
Cd274tm1Shr/Cd274tm1Shr Tg(TcraTcrb)1100Mjb/0
(involves: C57BL/6)
|
increased susceptibility to autoimmune diabetes
|
J:153040
|
Cd274tm2Shr/Cd274tm2Shr
(involves: 129/Sv * 129S4/SvJae)
|
abnormal cytokine secretion
|
J:113851
|
decreased susceptibility to parasitic infection
|
J:113851
|
Cd274tm2Shr/Cd274tm2Shr Pdcd1lg2tm4Shr/Pdcd1lg2tm4Shr
(involves: 129S4/SvJae)
|
abnormal immune system physiology
|
J:160970
|
Cd276tm1Lpc/Cd276tm1Lpc
(B6.129-Cd276tm1Lpc)
|
abnormal T-helper 1 physiology
|
J:237700
|
abnormal T-helper 2 physiology
|
J:237700
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:237700
|
increased susceptibility to type I hypersensitivity reaction
|
J:237700
|
Cd276tm1Lpc/Cd276tm1Lpc
(D1J.129-Cd276tm1Lpc)
|
abnormal T-helper 1 physiology
|
J:237700
|
abnormal T-helper 17 cell physiology
|
J:237700
|
decreased susceptibility to induced arthritis
|
J:237700
|
Cd276tm1Mak/Cd276tm1Mak
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal T-helper 1 physiology
|
J:84973
|
increased anti-single stranded DNA antibody level
|
J:84973
|
increased inflammatory response
|
J:84973
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:84973
|
increased T cell proliferation
|
J:84973
|
Cd276tm1Mak/Cd276tm1Mak
(C.129P2-Cd276tm1Mak)
|
abnormal T-helper 1 physiology
|
J:84973
|
increased inflammatory response
|
J:84973
|
increased interferon-gamma secretion
|
J:84973
|
Cd276tm1Wwh/Cd276tm1Wwh
(B6.Cg-B7h3tm1Wwh)
|
abnormal cytokine secretion
|
J:95550
|
abnormal response to transplant
|
J:95550
|
Cd300atm1Shib/Cd300atm1Shib
(B6JJcl.C-Cd300atm1Shib)
|
abnormal chemokine secretion
|
J:189144
|
abnormal mast cell physiology
|
J:189144
|
increased interleukin-10 secretion
|
J:189144
|
increased interleukin-13 secretion
|
J:189144
|
increased tumor necrosis factor secretion
|
J:189144
|
Cd300c2tm1Shib/Cd300c2tm1Shib
(B6.Cg-Cd300c2tm1Shib)
|
increased B cell proliferation
|
J:177613
|
Cd300lftm1Gne/Cd300lftm1Gne
(involves: C57BL/6N)
|
increased interleukin-1 alpha secretion
|
J:156819
|
increased interleukin-1 beta secretion
|
J:156819
|
increased interleukin-12 secretion
|
J:156819
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:156819
|
Cd300lftm1Toki/Cd300lftm1Toki
(Not Specified)
|
abnormal interleukin secretion
|
J:190979
|
abnormal mast cell physiology
|
J:190979
|
increased interleukin-4 secretion
|
J:190979
|
increased interleukin-5 secretion
|
J:190979
|
increased interleukin-13 secretion
|
J:190979
|
increased susceptibility to type I hypersensitivity reaction
|
J:190979
|
respiratory system inflammation
|
J:190979
|
Cd302tm1.1Dnjh/Cd302tm1.1Dnjh
(involves: C57BL/6)
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:301848
|
abnormal dendritic cell physiology
|
J:301848
|
Cdcs1C3H/HeJBir/Cdcs1C3H/HeJBir
(involves: B6.129P2-Il10tm1Cgn/Lt * C3Bir.129P2(B6)-Il10tm1Cgn/Lt)
|
abnormal immune system physiology
|
J:72978
|
Cdcs1C3H/HeJBir/Cdcs1C57BL/6J
(involves: C3H/HeJBir-Il10tm1Cgn * C57BL/6J-Il10tm1Cgn)
|
colitis
|
J:72978
|
Cdcs2C3H/HeJBir/Cdcs2C3H/HeJBir
(involves: B6.129P2-Il10tm1Cgn/Lt * C3Bir.129P2(B6)-Il10tm1Cgn/Lt)
|
intestinal inflammation
|
J:72978
|
Cdcs2C3H/HeJBir/Cdcs2C57BL/6J
(involves: B6.129P2-Il10tm1Cgn/Lt * C3Bir.129P2(B6)-Il10tm1Cgn/Lt)
|
intestinal inflammation
|
J:72978
|
Cdcs3C3H/HeJBir/Cdcs3C3H/HeJBir
(involves: B6.129P2-Il10tm1Cgn/Lt * C3Bir.129P2(B6)-Il10tm1Cgn/Lt)
|
intestinal inflammation
|
J:72978
|
Cdcs4C3H/HeJBir/Cdcs4C57BL/6J
(involves: C3H/HeJBir * C57BL/6J)
|
intestinal inflammation
|
J:72978
|
Cdcs4C57BL/6J/Cdcs4C57BL/6J
(involves: C3H/HeJBir * C57BL/6J)
|
intestinal inflammation
|
J:72978
|
Cdcs5C57BL/6J/Cdcs5C57BL/6J
(involves: C3H/HeJBir * C57BL/6J)
|
intestinal inflammation
|
J:72978
|
Cdcs6C57BL/6J/?
(involves: B6.129P2-Il10tm1Cgn/Lt * C3Bir.129P2(B6)-Il10tm1Cgn/Lt)
|
intestinal inflammation
|
J:72978
|
Cdcs7C3H/HeJBir/Cdcs7C3H/HeJBir
(involves: C3H/HeJBir * C57BL/6J)
|
intestinal inflammation
|
J:78917
|
Cdcs8C57BL/6J/Cdcs8C57BL/6J
(involves: C3H/HeJBir * C57BL/6J)
|
intestinal inflammation
|
J:78917
|
Cdcs9C3H/HeJBir/Cdcs9C3H/HeJBir
(involves: C3H/HeJBir * C57BL/6J)
|
intestinal inflammation
|
J:78917
|
Cdcs9C3H/HeJBir/Cdcs9C57BL/6J
(involves: C3H/HeJBir * C57BL/6J)
|
intestinal inflammation
|
J:78917
|
Cdcs10C3H/HeJBir/Cdcs10C3H/HeJBir
(involves: C3H/HeJBir-Il10tm1Cgn * C57BL/6J-Il10tm1Cgn)
|
intestinal inflammation
|
J:78917
|
Cdcs10C3H/HeJBir/Cdcs10C57BL/6J
(involves: C3H/HeJBir-Il10tm1Cgn * C57BL/6J-Il10tm1Cgn)
|
intestinal inflammation
|
J:72978
|
Cdh1tm1Mlec/Cdh1tm1Mlec
(involves: 129S2/SvPas)
|
increased susceptibility to bacterial infection
|
J:142843
|
Cdh5tm3(Cdh5/Ctnna1)Dvst/Cdh5tm3(Cdh5/Ctnna1)Dvst
(involves: 129 * C57BL/6)
|
abnormal cellular extravasation
|
J:177191
|
abnormal leukocyte migration
|
J:177191
|
Cdh5tm4(Cdh5/Fkbp,Ptprb/Mtor*)Dvst/Cdh5tm4(Cdh5/Fkbp,Ptprb/Mtor*)Dvst
(involves: C57BL/6)
|
abnormal cellular extravasation
|
J:178759
|
impaired neutrophil recruitment
|
J:178759
|
Cdh5tm5Dvst/Cdh5tm5Dvst
(B6.Cg-Cdh5tm5Dvst)
|
abnormal cellular extravasation
|
J:209801
|
Cdh5tm6Dvst/Cdh5tm6Dvst
(B6.Cg-Cdh5tm6Dvst)
|
abnormal cellular extravasation
|
J:209801
|
Cdh17M1Btlr/Cdh17M1Btlr
(C57BL/6J-Cdh17M1Btlr)
|
increased susceptibility to induced colitis
|
J:272090
|
Cdh17tm1Ohn/Cdh17tm1Ohn
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased IgG level
|
J:96738
|
Cdk2tm2Sgo/Cdk2tm2Sgo Cdk4tm2.1Bbd/Cdk4tm2.1Bbd Polr2atm1(cre/ERT2)Bbd/?
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
increased susceptibility to autoimmune diabetes
|
J:125217
|
Cdk4tm1Kiyo/Cdk4+ Lin9tm1Orc/Lin9+
(involves: 129S1/Sv)
|
decreased susceptibility to autoimmune diabetes
|
J:111333
|
Cdk6tm1Bbd/Cdk6tm1Bbd
(involves: 129S1/Sv * 129X1/SvJ * CD-1)
|
decreased T cell proliferation
|
J:92529
|
Cdk6tm1Phin/Cdk6tm1Phin
(involves: 129S4/SvJae)
|
abnormal thymocyte activation
|
J:144975
|
decreased thymocyte apoptosis
|
J:144975
|
Cdk6tm3.1Phin/Cdk6tm3.1Phin
(involves: 129 * C57BL/6 * FVB/N)
|
increased T cell apoptosis
|
J:174697
|
Cdkn1atm1Led/Cdkn1atm1Led
(involves: 129S6/SvEvTac)
|
increased anti-double stranded DNA antibody level
|
J:76041
|
increased anti-histone antibody level
|
J:76041
|
increased anti-single stranded DNA antibody level
|
J:76041
|
increased autoantibody level
|
J:76041
|
increased T cell proliferation
|
J:76041
|
Cdkn1atm1Led/Cdkn1atm1Led Gadd45atm1Ajf/Gadd45atm1Ajf
(either: (involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6) or (involves: 129S6/SvEvTac * 129X1/SvJ * C57BL/6))
|
abnormal T cell activation
|
J:76041
|
glomerulonephritis
|
J:76041
|
increased anti-double stranded DNA antibody level
|
J:76041
|
increased anti-histone antibody level
|
J:76041
|
increased anti-single stranded DNA antibody level
|
J:76041
|
increased autoantibody level
|
J:76041
|
increased IgG1 level
|
J:76041
|
increased IgM level
|
J:76041
|
increased inflammatory response
|
J:76041
|
increased T cell proliferation
|
J:76041
|
Cdkn1atm1Tyj/Cdkn1atm1Tyj
(B6;129S2-Cdkn1atm1Tyj/J)
|
decreased susceptibility to induced arthritis
|
J:108569
|
impaired macrophage chemotaxis
|
J:108569
|
Cdkn1atm1Tyj/Cdkn1atm1Tyj
(involves: 129S2/SvPas * C57BL/6)
|
abnormal self tolerance
|
J:60292
|
abnormal thymus physiology
|
J:70894
|
glomerulonephritis
|
J:60292,
J:70894
|
increased anti-double stranded DNA antibody level
|
J:60292
|
increased anti-histone antibody level
|
J:60292
|
increased anti-nuclear antigen antibody level
|
J:60292
|
increased IgG1 level
|
J:60292
|
increased T cell proliferation
|
J:60292
|
Cdkn1btm1Jro/Cdkn1btm1Jro
(involves: 129S4/SvJaeSor * C57BL/6)
|
decreased T cell proliferation
|
J:71780
|
Cdkn1btm1Mlf/Cdkn1btm1Mlf
(involves: 129S4/SvJaeSor * C57BL/6J)
|
increased T cell proliferation
|
J:33400
|
Cdkn1btm1Mlf/Cdkn1btm1Mlf Myctm1Atp/Myc+
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * FVB/N)
|
decreased T cell proliferation
|
J:73369
|
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
(involves: 129S6/SvEvTac * FVB/N)
|
increased splenocyte proliferation
|
J:71394
|
Cdkn2ctm1Yxi/Cdkn2ctm1Yxi
(involves: 129/Sv * C57BL/6 * DBA/2)
|
abnormal T cell physiology
|
J:50053
|
Cdsntm1.1Ics/Cdsntm1.1Ics Tg(KRT14-cre/ERT2)1Ipc/0
(involves: 129S2/SvPas)
|
skin inflammation
|
J:153292
|
Ceacam1Hv2-r/Ceacam1Hv2-r
(SJL/J)
|
decreased susceptibility to Coronaviridae infection
|
J:92495
|
decreased susceptibility to viral infection
|
J:25438
|
Ceacam1tm1.1Fta/Ceacam1tm1.1Fta
(C57BL/6(FVB)-Ceacam1tm1.1Fta)
|
decreased susceptibility to Coronaviridae infection
|
J:198335
|
decreased susceptibility to Coronaviridae infection induced morbidity/mortality
|
J:198335
|
Ceacam1tm1Bcn/Ceacam1tm1Bcn
(either: (involves: 129S1/Sv * 129X1/SvJ * BALB/c) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))
|
decreased susceptibility to Coronaviridae infection induced morbidity/mortality
|
J:70815
|
Ceacam1tm1Rsb/Ceacam1tm1Rsb Tg(Lck-cre)1Cwi/0
(involves: 129)
|
abnormal cytokine secretion
|
J:116136
|
increased interferon-gamma secretion
|
J:116136
|
increased interleukin-2 secretion
|
J:116136
|
increased T cell proliferation
|
J:116136
|
Ceacam1tm2Bcn/Ceacam1tm2Bcn
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
decreased susceptibility to Coronaviridae infection
|
J:92376
|
Ceat1CBA/J/Ceat1NOD
(involves: CBA/J * NOD-H2k)
|
increased susceptibility to experimental autoimmune thyroiditis
|
J:77545
|
Ceat1NOD/Ceat1NOD
(involves: CBA/J * NOD-H2k)
|
increased susceptibility to experimental autoimmune thyroiditis
|
J:77545
|
Cebpatm1Dgt/Cebpatm1Dgt Tg(Mx1-cre)1Cgn/0
(involves: 129S6/SvEvTac * C57BL/6 * CBA)
|
sepsis
|
J:94682
|
Cebpatm8.1Nerl/Cebpatm8.1Nerl
(involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)
|
liver inflammation
|
J:136134
|
Cebpbtm1.1Acle/Cebpbtm1.1Acle
(involves: 129P2/OlaHsd * BALB/c * C57BL/6)
|
abnormal osteoclast physiology
|
J:150006
|
Cebpbtm1.1Elgaz/Cebpbtm1.1Elgaz Lyz2em1.1(cre)Elgaz/Lyz2+
(BALB/cJ-Cebpbtm1.1Elgaz Lyz2em1.1Elgaz/Elgaz)
|
decreased circulating interleukin-10 level
|
J:247885
|
decreased susceptibility to bacterial infection
|
J:247885
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:247885
|
increased circulating interleukin-6 level
|
J:247885
|
increased circulating tumor necrosis factor level
|
J:247885
|
Cebpbtm1Aki/Cebpbtm1Aki
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal macrophage physiology
|
J:153025
|
abnormal T-helper 1 physiology
|
J:153025
|
decreased susceptibility to endotoxin shock
|
J:153025
|
granulomatous inflammation
|
J:153025
|
increased susceptibility to bacterial infection
|
J:153025
|
Cebpbtm1Kish/Cebpbtm1Kish
(involves: 129P2/OlaHsd)
|
abnormal macrophage physiology
|
J:77003
|
impaired macrophage phagocytosis
|
J:77003
|
increased interleukin-12 secretion
|
J:126085
|
increased susceptibility to bacterial infection
|
J:77003
|
Cebpbtm1Pfj/Cebpbtm1Pfj
(involves: 129S1/Sv * C57BL/6)
|
abnormal osteoclast physiology
|
J:150006
|
abnormal tumor necrosis factor level
|
J:192313
|
Cebpbtm1Vpo/Cebpbtm1Vpo
(involves: 129S/SvEv * MF1)
|
abnormal cell-mediated immunity
|
J:25215
|
abnormal humoral immune response
|
J:25215
|
abnormal innate immunity
|
J:25215
|
abnormal macrophage physiology
|
J:25215
|
abnormal T-helper 1 physiology
|
J:25215
|
abnormal T-helper 2 physiology
|
J:25215
|
decreased circulating interleukin-12 level
|
J:25215
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:25215
|
glomerulonephritis
|
J:25215
|
increased circulating interleukin-6 level
|
J:25215
|
increased IgG level
|
J:25215
|
increased susceptibility to fungal infection
|
J:25215
|
Cebpbtm2.1Acle/Cebpbtm2.1Acle
(involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)
|
increased circulating interleukin-6 level
|
J:155795
|
Cebpbtm3Nerl/Cebpbtm3Nerl
(either: B6.129P2-Cebpbtm3Nerl or (involves: 129P2/OlaHsd * C57BL/6))
|
myositis
|
J:153686
|
Cebpdtm1Pfj/Cebpdtm1Pfj
(involves: 129S1/Sv * C57BL/6)
|
abnormal cytokine level
|
J:192313
|
decreased inflammatory response
|
J:192313
|
Cebpetm1Kgx/Cebpetm1Kgx
(involves: 129S6/SvEvTac * NIH Black Swiss)
|
abnormal neutrophil physiology
|
J:76024
|
colitis
|
J:76024
|
conjunctivitis
|
J:76024
|
increased inflammatory response
|
J:76024
|
increased susceptibility to bacterial infection
|
J:76024
|
lung inflammation
|
J:76024
|
osteomyelitis
|
J:76024
|
peritoneal inflammation
|
J:76024
|
rhinitis
|
J:76024
|
Cebpetm1Kgx/Cebpetm1Kgx
(involves: 129S6/SvEvTac)
|
abnormal neutrophil physiology
|
J:76024
|
colitis
|
J:76024
|
conjunctivitis
|
J:76024
|
increased inflammatory response
|
J:76024
|
increased susceptibility to bacterial infection
|
J:76024
|
lung inflammation
|
J:76024
|
osteomyelitis
|
J:76024
|
peritoneal inflammation
|
J:76024
|
pleuritis
|
J:76024
|
rhinitis
|
J:76024
|
Cebpgtm1Aki/Cebpgtm1Aki
(involves: 129P2/OlaHsd)
|
abnormal NK cell physiology
|
J:58801
|
impaired natural killer cell mediated cytotoxicity
|
J:58801
|
Celf4tm1a(EUCOMM)Wtsi/Celf4tm1a(EUCOMM)Wtsi
(C57BL/6N-Celf4tm1a(EUCOMM)Wtsi/Wtsi)
|
blood in lymph vessels
|
J:239583
|
Celsr1ctb-2J/Celsr1ctb-2J
(STOCK Celsr1ctb-2J/GrsrJ)
|
increased susceptibility to otitis media
|
J:229303
|
Celsr1ctb/Celsr1ctb
(CByJ.Cg-Celsr1ctb/GrsrJ)
|
increased susceptibility to otitis media
|
J:229303
|
Cerktm1Fbor/Cerktm1Fbor
(involves: BALB/c)
|
increased susceptibility to bacterial infection
|
J:131522
|
Cers3tm1.1Rsnd/Cers3tm1.1Rsnd
(involves: 129P2/OlaHsd * C57BL/6)
|
increased susceptibility to fungal infection
|
J:179754
|
Cers6tm1.1Arte/Cers6tm1.1Arte
(involves: BALB/cJ * C57BL/6N)
|
decreased inflammatory response
|
J:215519
|
Ces2atm1(KOMP)Vlcg/Ces2atm1(KOMP)Vlcg
(C57BL6/N-Ces2atm1(KOMP)Vlcg)
|
liver inflammation
|
J:335459
|
Cfap53em1(IMPC)Wtsi/Cfap53em1(IMPC)Wtsi
(C57BL/6N-Cfap53em1(IMPC)Wtsi/Wtsi)
|
blood in lymph vessels
|
J:239583
|
Cfbtm1Hrc/Cfb+ Cfhtm1Mbo/Cfhtm1Mbo
(involves: 129S/Sv * C57BL/6)
|
decreased circulating complement protein level
|
J:78193
|
Cfbtm1Hrc/Cfbtm1Hrc
(involves: 129S/Sv * C57BL/6)
|
abnormal complement pathway
|
J:42679
|
impaired complement alternative pathway
|
J:42679
|
Cfbtm1Hrc/Cfbtm1Hrc
(involves: 129S/Sv)
|
decreased susceptibility to Coronaviridae infection
|
J:286325
|
impaired complement classical pathway
|
J:130108
|
Cfbtm1Mbo/Cfbtm1Mbo
(involves: 129/Sv * C57BL/6)
|
increased susceptibility to bacterial infection
|
J:83712
|
Cfbtm1Pkna/Cfbtm1Pkna
(D1.129P2-Cfbtm1Pkna)
|
decreased susceptibility to induced arthritis
|
J:88872
|
Cfdtm1Yxu/Cfdtm1Yxu
(involves: 129P2/OlaHsd * C57BL/6J)
|
impaired complement alternative pathway
|
J:73125
|
Cfdtm1Yxu/Cfdtm1Yxu
(B6.129P2-Cfdtm1Yxu)
|
impaired complement alternative pathway
|
J:94855
|
increased susceptibility to bacterial infection
|
J:94855
|
Cfhtm1.1Song/Cfhtm1.1Song
(involves: C57BL/6)
|
decreased circulating complement protein level
|
J:240426
|
decreased complement C5 level
|
J:240426
|
decreased serum complement activity
|
J:240426
|
Cfhtm1Mbo/Cfh+
(involves: 129/Sv * C57BL/6)
|
decreased circulating complement protein level
|
J:78193
|
Cfhtm1Mbo/Cfhtm1Mbo
(involves: 129/Sv * C57BL/6)
|
decreased circulating complement protein level
|
J:78193
|
glomerulonephritis
|
J:78193
|
increased susceptibility to type III hypersensitivity reaction
|
J:78193
|
Cfhtm1Mbo/Cfhtm1Mbo
(involves: 129)
|
abnormal complement protein level
|
J:125860
|
decreased circulating complement protein level
|
J:125860,
J:131403
|
glomerulonephritis
|
J:131403
|
Cfhtm1Mbo/Cfhtm1Mbo Tg(CAG-Cfh*)#Mcp/0
(involves: 129/Sv * C57BL/6 * CBA)
|
abnormal circulating complement protein level
|
J:125860
|
abnormal complement protein level
|
J:125860
|
Cfiem1Jiwe/Cfiem1Jiwe
(involves: C57BL/6J)
|
abnormal complement protein level
|
J:308307
|
impaired complement alternative pathway
|
J:308307
|
Cfitm1Mcp/Cfitm1Mcp
(involves: 129/Sv * C57BL/6)
|
decreased circulating complement protein level
|
J:131403
|
Cflartm1Ywh/Cflartm1Ywh Tg(Lck-cre)548Jxm/0
(involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6 * CBA)
|
increased thymocyte apoptosis
|
J:100558
|
Cfmq1129X1/SvJ/Cfmq1C57BL/6J Cftrtm1Unc/Cftrtm1Unc
(involves: 129X1/SvJ * C57BL/6J)
|
intestinal inflammation
|
J:101842
|
Cfmq2129X1/SvJ/Cfmq2129X1/SvJ Cftrtm1Unc/Cftrtm1Unc
(involves: 129X1/SvJ * C57BL/6J)
|
intestinal inflammation
|
J:101842
|
Cfmq3129X1/SvJ/Cfmq3C57BL/6J Cftrtm1Unc/Cftrtm1Unc
(involves: 129X1/SvJ * C57BL/6J)
|
intestinal inflammation
|
J:101842
|
Cfptm1Cmst/Cfptm1Cmst
(B6.129P2-Cfptm1Cmst)
|
sepsis
|
J:131526
|
Cfptm1Song/Y
(involves: 129 * C57BL/6)
|
abnormal complement pathway
|
J:130108
|
impaired complement alternative pathway
|
J:130108
|
impaired complement classical pathway
|
J:130108
|
Cfptm1Song/Cfptm1Song
(involves: 129 * C57BL/6)
|
decreased susceptibility to induced arthritis
|
J:165497
|
impaired complement alternative pathway
|
J:165497
|
Cfptm2.1Song/Cfptm2.1Song Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129 * 129P2/OlaHsd * C57BL/6 * SJL)
|
decreased susceptibility to induced arthritis
|
J:165497
|
impaired complement alternative pathway
|
J:165497
|
Cfptm2.1Song/Cfptm2.1Song Tg(EIIa-cre)C5379Lmgd/0
(involves: 129 * C57BL/6 * FVB/N * SJL)
|
impaired complement alternative pathway
|
J:165497
|
Cftrtm1Bay/Cftrtm1Bay
(involves: 129S7/SvEvBrd * C57BL/6J)
|
acute pancreas inflammation
|
J:15244
|
Cftrtm1Cam/Cftrtm1Cam
(involves: 129S/SvEv)
|
increased susceptibility to infection
|
J:23850
|
peritoneal inflammation
|
J:23850
|
Cftrtm1Hgu/Cftrtm1Hgu
(involves: 129P2/OlaHsd)
|
increased susceptibility to bacterial infection
|
J:24119
|
lung inflammation
|
J:24119
|
Cftrtm1Kth/Cftrtm1Kth
(involves: 129S7/SvEvBrd * C57BL/6J)
|
peritoneal inflammation
|
J:29074
|
Cftrtm1Kth/Cftrtm1Kth
(B6.129S7-Cftrtm1Kth)
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:112450
|
lung inflammation
|
J:112450
|
Cftrtm1Unc/Cftrtm1Unc
(B6.129P2-Cftrtm1Unc/J)
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:112450
|
lung inflammation
|
J:58571,
J:112450
|
Cftrtm1Unc/Cftrtm1Unc
(involves: 129P2/OlaHsd)
|
abnormal thymus involution
|
J:2079
|
peritoneal inflammation
|
J:2079
|
Cftrtm1Unc/Cftrtm1Unc
(B6.129P2-Cftrtm1Unc)
|
lung inflammation
|
J:44904
|
Cftrtm1Unc/Cftrtm1Unc Tg(FABPCFTR)1Jaw/0 Tg(Scgb1a1-Scnn1b)6608Bouc/0
(involves: 129P2/OlaHsd * C3H * C57BL/6 * FVB/N)
|
respiratory system inflammation
|
J:191673
|
Cftrtm2Cam/Cftrtm2Cam
(involves: 129S/SvEv)
|
peritoneal inflammation
|
J:27734
|
Cftrtm2Mrc/Cftrtm2Mrc
(B6.129S6-Cftrtm2Mrc)
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:112450
|
lung inflammation
|
J:112450
|
Cftrtm3Hgu/Cftrtm3Hgu
(involves: 129P2/OlaHsd)
|
gallbladder inflammation
|
J:32766
|
peritoneal inflammation
|
J:32766
|
Cftrtm3Mrc/Cftrtm3Mrc
(B6.129S6-Cftrtm3Mrc)
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:112450
|
lung inflammation
|
J:112450
|
Cgastm1a(EUCOMM)Hmgu/Cgastm1a(EUCOMM)Hmgu
(C57BL/6N-Cgastm1a(EUCOMM)Hmgu)
|
abnormal dendritic cell physiology
|
J:201167
|
abnormal immune cell physiology
|
J:201167
|
abnormal macrophage physiology
|
J:201167
|
abnormal plasmacytoid dendritic cell physiology
|
J:201167
|
decreased circulating interferon-alpha level
|
J:201167
|
decreased circulating interferon-beta level
|
J:201167
|
increased susceptibility to Herpesvirales infection
|
J:201167
|
increased susceptibility to Herpesvirales infection induced morbidity/mortality
|
J:201167
|
Cgastm1a(EUCOMM)Hmgu/Cgastm1a(EUCOMM)Hmgu
(involves: C57BL/6N)
|
abnormal interferon secretion
|
J:234263
|
Cgastm1a(EUCOMM)Hmgu/Cgastm1a(EUCOMM)Hmgu Trex1tm1Tld/Trex1tm1Tld
(involves: 129P2/OlaHsd * C57BL/6N)
|
increased susceptibility to Retroviridae infection
|
J:234263
|
Cgastm1d(EUCOMM)Hmgu/Cgastm1d(EUCOMM)Hmgu
(involves: BALB/c * C57BL/6JJcl * C57BL/6N)
|
increased susceptibility to Flaviviridae infection
|
J:207826
|
increased susceptibility to Flaviviridae infection induced morbidity/mortality
|
J:207826
|
increased susceptibility to Herpesvirales infection
|
J:207826
|
increased susceptibility to Poxviridae infection
|
J:207826
|
increased susceptibility to Poxviridae infection induced morbidity/mortality
|
J:207826
|
Cgastm1d(EUCOMM)Hmgu/Cgastm1d(EUCOMM)Hmgu
(involves: C57BL/6N)
|
increased susceptibility to Retroviridae infection
|
J:265023
|
Cgnz1NZM2328/J/Cgnz1NZM2328/J
(involves: C57L/J * NZM2328/J)
|
increased susceptibility to systemic lupus erythematosus
|
J:71397
|
kidney inflammation
|
J:71397
|
Ch25htm1Rus/Ch25htm1Rus
(B6.129S6-Ch25htm1Rus)
|
increased IgA level
|
J:170807
|
increased IgG2a level
|
J:170807
|
increased IgG2b level
|
J:170807
|
increased IgG3 level
|
J:170807
|
Char2aC3H/HeJ/Char2aC3H/HeJ
(involves: C3H/HeJ * C57BL/6J)
|
increased susceptibility to parasitic infection
|
J:117548
|
Char2bC3H/HeJ/Char2bC3H/HeJ
(involves: C3H/HeJ * C57BL/6J)
|
increased susceptibility to parasitic infection
|
J:117548
|
Char3C3H/He/Char3C57BL/6
(involves: C3H/He * C57BL/6)
|
decreased susceptibility to parasitic infection
|
J:72455
|
Char3C57BL/6/Char3C57BL/6
(involves: C3H/He * C57BL/6)
|
decreased susceptibility to parasitic infection
|
J:72455
|
Char4C57BL/6J/Char4C57BL/6J
(involves: A/J * C57BL/6J)
|
decreased susceptibility to parasitic infection
|
J:71471
|
Char9A/J/Char9C57BL/6J
(involves: A/J * C57BL/6J)
|
decreased susceptibility to parasitic infection
|
J:122131
|
Char9C57BL/6J/Char9C57BL/6J
(involves: A/J * C57BL/6J)
|
decreased susceptibility to parasitic infection
|
J:122131
|
Char11A/J/Char11C57BL/6J
(involves: A/J * C57BL/6J)
|
decreased susceptibility to parasitic infection
|
J:106220
|
Char11C57BL/6J/Char11C57BL/6J
(involves: A/J * C57BL/6J)
|
decreased susceptibility to parasitic infection
|
J:106220
|
Chchd10em8Lutzy/Chchd10+
(C57BL/6NJ-Chchd10em8Lutzy/J)
|
increased susceptibility to otitis media
|
J:272524
|
Chd2Gt(RRBO46)Byg/Chd2+
(involves: 129P2/OlaHsd * C57BL/6)
|
arteritis
|
J:146176
|
heart inflammation
|
J:146176
|
interstitial pneumonia
|
J:146743
|
liver inflammation
|
J:146743
|
myocarditis
|
J:146743
|
Chd4tm1.1Kge/Chd4tm1.1Kge Tg(Lck-cre)1Cwi/0
(involves: C57BL/6 * SJL)
|
abnormal T cell physiology
|
J:109547
|
Chd4tm1.1Kge/Chd4tm1.2Kge Tg(CAG-Bgeo/GFP)21Lbe/0 Tg(Lck-cre)1Cwi/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
decreased T cell proliferation
|
J:109547
|
Chd4tm1.2Kge/Chd4tm1.2Kge Tg(Lck-cre)1Cwi/0
(involves: C57BL/6 * DBA/2 * SJL)
|
decreased T cell proliferation
|
J:109547
|
Chd7Flo/Chd7+
(involves: C3HeB/FeJ)
|
keratoconjunctivitis sicca
|
J:104123
|
Chd7Looper/Chd7+
(BALB/c-Chd7Looper)
|
blepharitis
|
J:252089
|
conjunctivitis
|
J:252089
|
Chd7Ome/Chd7+
(involves: BALB/cByJ * C57BL/6J)
|
increased susceptibility to otitis media
|
J:187200
|
Chd7Trooper/Chd7+
(BALB/c-Chd7Trooper)
|
blepharitis
|
J:262283
|
conjunctivitis
|
J:262283
|
Chd7Whi/Chd7+
(involves: C3HeB/FeJ)
|
keratoconjunctivitis sicca
|
J:104123
|
Chi3l1tm1Eli/Chi3l1tm1Eli
(B6.Cg-Chi3l1tm1Eli)
|
abnormal dendritic cell physiology
|
J:148490
|
abnormal plasmacytoid dendritic cell physiology
|
J:148490
|
abnormal T-helper 2 physiology
|
J:148490
|
decreased IgE level
|
J:148490
|
decreased interleukin-4 secretion
|
J:148490
|
decreased interleukin-13 secretion
|
J:148490
|
decreased splenocyte proliferation
|
J:148490
|
impaired eosinophil recruitment
|
J:148490
|
impaired neutrophil recruitment
|
J:148490
|
increased T cell apoptosis
|
J:148490
|
Chi3l1tm1Eli/Chi3l1tm1Eli Tg(Scgb1a1-rtTA,tetO-Il13)1Eli/0
(involves: C57BL/6 * CBA)
|
abnormal T-helper 2 physiology
|
J:148490
|
Chia1tm1.1Lof/Chia1tm1.1Lof
(C57BL/6-Chia1tm1.1Lof)
|
decreased interleukin-13 secretion
|
J:257728
|
Chit1tm1Eli/Chit1tm1Eli
(involves: C57BL/6)
|
decreased susceptibility to bacterial infection
|
J:189872
|
Chit1tm1Eli/Chit1tm1Eli Tg(Scgb1a1-Il13)2Eli/0
(involves: C57BL/6 * CBA)
|
decreased susceptibility to bacterial infection
|
J:189872
|
Chit1tm1Eli/Chit1tm1Eli Tg(Scgb1a1-rtTA,tetO-CHIT1)#Eli/0
(involves: C57BL/6)
|
decreased susceptibility to bacterial infection
|
J:189872
|
Chrm1tm1Jwe/Chrm1tm1Jwe
(involves: 129S6/SvEvTac * CF-1)
|
decreased cytotoxic T cell cytolysis
|
J:106393
|
Chrna3tm1Bay/Chrna3tm1Bay
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased susceptibility to bacterial infection
|
J:54994
|
urinary bladder inflammation
|
J:54994
|
Chrna4tm1Jpc/Chrna4tm1Jpc
(involves: C57BL/6)
|
decreased IgG level
|
J:103908
|
decreased immunoglobulin level
|
J:103908
|
increased IgG level
|
J:103908
|
Chrna7tm1Bay/Chrna7tm1Bay
(B6.Cg-Chrna7tm1Bay)
|
abnormal interleukin level
|
J:89610
|
abnormal tumor necrosis factor level
|
J:89610
|
Chrna7tm1Bay/Chrna7tm1Bay
(involves: 129S7/SvEvBrd * C57BL/6)
|
decreased IgG level
|
J:103908
|
decreased immunoglobulin level
|
J:103908
|
Chrnb2tm1Jpc/Chrnb2tm1Jpc
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal immune system physiology
|
J:103908
|
abnormal immunoglobulin level
|
J:103908
|
decreased immunoglobulin level
|
J:103908
|
increased B cell proliferation
|
J:103908
|
increased IgG level
|
J:103908
|
Chrnb2tm1Mdb/Chrnb2tm1Mdb Chrnb4tm1Mdb/Chrnb4tm1Mdb
(involves: 129S7/SvEvBrd * C57BL/6J)
|
increased susceptibility to bacterial infection
|
J:73590
|
urinary bladder inflammation
|
J:73590
|
Chst1tm1(KOMP)Vlcg/Chst1tm1(KOMP)Vlcg Chst2tm1Tmu/Chst2tm1Tmu Chst4tm1Sdr/Chst4tm1Sdr
(involves: 129S2/SvPas * C57BL/6NTac)
|
abnormal leukocyte migration
|
J:204813
|
Chst2tm1Tmu/Chst2tm1Tmu
(involves: 129S2/SvPas * C57BL/6J)
|
abnormal leukocyte migration
|
J:92231
|
abnormal leukocyte physiology
|
J:92231
|
Chst2tm1Tmu/Chst2tm1Tmu Chst4tm1Sdr/Chst4tm1Sdr
(involves: 129S2/SvPas)
|
abnormal leukocyte migration
|
J:204813
|
Chst3tm1Tmu/Chst3tm1Tmu
(involves: 129S2/SvPas)
|
increased T cell proliferation
|
J:217719
|
Chst4tm1Mifu/Chst4tm1Mifu
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal leukocyte migration
|
J:113195
|
impaired leukocyte tethering or rolling
|
J:113195
|
Chst4tm1Mifu/Chst4tm1Mifu Gcnt1tm1Jxm/Gcnt1tm1Jxm
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal leukocyte migration
|
J:113195
|
impaired leukocyte tethering or rolling
|
J:113195
|
Chst4tm1Sdr/Chst4tm1Sdr
(involves: C57BL/6)
|
abnormal leukocyte adhesion
|
J:86759
|
abnormal leukocyte migration
|
J:86759
|
Chst11tm1a(KOMP)Wtsi/Chst11tm1a(KOMP)Wtsi
(C57BL/6N-Chst11tm1a(KOMP)Wtsi/Wtsi)
|
blood in lymph vessels
|
J:239583
|
Chsy1skt/Chsy1skt Pde6b+/Pde6b+
(mixed)
|
kidney inflammation
|
J:286529
|
Chsy1tm1Lex/Chsy1tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
|
autoimmune arthritis
|
J:171883
|
Chuktm1Lex/Chuktm1Lex Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * 129S/SvEvBrd)
|
impaired macrophage chemotaxis
|
J:159873
|
impaired neutrophil chemotaxis
|
J:159873
|
impaired neutrophil recruitment
|
J:159873
|
Chuktm1Mka/Chuktm1Mka
(B6.129-Chuktm1Mka)
|
abnormal B cell physiology
|
J:113556
|
Chuktm1Mpa/Chuktm1Mpa Ikbkbtm2Cgn/Ikbkbtm2Cgn Tg(Alb1-cre)7Gsc/0
(involves: C57BL/6 * FVB/N)
|
increased susceptibility to endotoxin shock
|
J:137861
|
Chuktm2Mka/Chuktm2Mka
(B6.Cg-Chuktm2Mka)
|
abnormal B cell physiology
|
J:113556
|
Chuktm2Mka/Chuktm2Mka Tg(Tnfsf13b)1Fma/?
(B6.Cg-Chuktm2Mka Tg(Tnfsf13b)1Fma)
|
abnormal B cell activation
|
J:113556
|
increased anti-double stranded DNA antibody level
|
J:113556
|
Chuktm2Yhu/Chuktm2Yhu
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
skin inflammation
|
J:197037
|
Chuktm2Yhu/Chuktm2Yhu Tg(Lor-CHUK)8Yhu/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)
|
lung inflammation
|
J:197037
|
Cia2DBA/1J/Cia2DBA/1J
(involves: DBA/1J * SWR/J)
|
abnormal immune system physiology
|
J:53356
|
Cia2DBA/1J/Cia2DBA/1J
(involves: DBA/1J * FVB/N)
|
increased susceptibility to induced arthritis
|
J:116665
|
Cia2DBA/1J/Cia2SWR/J
(involves: DBA/1J * SWR/J)
|
abnormal immune system physiology
|
J:53356
|
Cia5C57BL/10/Cia5C57BL/10
(involves: B10.RIII * RIIIS/J)
|
abnormal inflammatory response
|
J:50472
|
Cia5bRIIIS/J/?
(involves: C57BL/10 * RIIIS/J)
|
decreased susceptibility to induced arthritis
|
J:101767
|
Cia5bRIIIS/J/Cia5bRIIIS/J Cia32B10.RIII/Cia32RIIIS/J
(involves: C57BL/10 * RIIIS/J)
|
decreased susceptibility to induced arthritis
|
J:101767
|
Cia5cRIIIS/J/?
(involves: C57BL/10 * RIIIS/J)
|
decreased susceptibility to induced arthritis
|
J:101767
|
Cia6C57BL/10SnSg/Cia6C57BL/10SnSg
(involves: B10.Q * DBA/1)
|
abnormal inflammatory response
|
J:57012
|
Cia6C57BL/10SnSg/Cia6DBA/1J
(involves: B10.Q * DBA/1)
|
abnormal inflammatory response
|
J:57012
|
Cia6DBA/1J/Cia6DBA/1J
(involves: B10.Q * DBA/1)
|
decreased inflammatory response
|
J:57012
|
Cia7DBA/1J/Cia7C57BL/10SnSg
(involves: B10.Q * DBA/1)
|
increased inflammatory response
|
J:57012
|
Cia7DBA/1J/Cia7DBA/1J
(involves: B10.Q * DBA/1)
|
increased inflammatory response
|
J:57012
|
increased susceptibility to induced arthritis
|
J:122130
|
Cia8DBA/1J/Cia8DBA/1J
(involves: B10.Q * DBA/1)
|
increased inflammatory response
|
J:57012
|
Cia9C57BL/10SnSg/Cia9NOD/ShiLtJ
(involves: B10.D1-H2q/SgJ * NOD.C3-H2q/Rhd)
|
increased inflammatory response
|
J:69981
|
Cia9NOD/ShiLtJ/Cia9NOD/ShiLtJ
(involves: B10.D1-H2q/SgJ * NOD.C3-H2q/Rhd)
|
abnormal immune system physiology
|
J:69981
|
Cia10C57BL/10/Cia10C57BL/10
(involves: C57BL/10 * RIIIS/J)
|
abnormal inflammatory response
|
J:50472
|
Cia10C57BL/10/Cia10C57BL/10 Cia5C57BL/10/Cia5C57BL/10
(involves: C57BL/10 * RIIIS/J)
|
abnormal inflammatory response
|
J:50472
|
Cia23C57BL/10SnSg/Cia23C57BL/10SnSg
(involves: B10.D1-H2q/SgJ * NOD.C3-H2q/Rhd)
|
abnormal inflammatory response
|
J:69981
|
Cia23C57BL/10SnSg/Cia23NOD/ShiLtJ
(involves: B10.D1-H2q/SgJ * NOD.C3-H2q/Rhd)
|
abnormal inflammatory response
|
J:69981
|
Cia23C57BL/10SnSg/Cia23NOD/ShiLtJ Cia9C57BL/10SnSg/Cia9C57BL/10SnSg
(involves: B10.D1-H2q/SgJ * NOD.C3-H2q/Rhd)
|
decreased inflammatory response
|
J:69981
|
Cia26RIIIS/J/Cia26RIIIS/J Cia30B10.RIII/?
(involves: B10.RIII * RIIIS/J)
|
autoimmune arthritis
|
J:95848
|
Cia27DBA/1J/?
(involves: DBA/1J * FVB/N)
|
increased IgG level
|
J:116665,
J:94347
|
Cia30RIIIS/J/Cia30RIIIS/J Cia5B10.RIII/Cia5B10.RIII
(involves: B10.RIII * RIIIS/J)
|
decreased susceptibility to induced arthritis
|
J:95848
|
Cia31B10.RIII/Cia31RIIIS/J Cia5B10.RIII/Cia5B10.RIII
(involves: B10.RIII * RIIIS/J)
|
autoimmune arthritis
|
J:95848
|
Cia31B10.RIII/Cia31RIIIS/J Cia5RIIIS/J/Cia5RIIIS/J
(involves: C57BL/10 * RIIIS/J)
|
decreased susceptibility to induced arthritis
|
J:101767
|
Cia32B10.RIII/Cia32RIIIS/J Cia5B10.RIII/Cia5B10.RIII
(involves: B10.RIII * RIIIS/J)
|
autoimmune arthritis
|
J:95848
|
Cia34DBA/1J/Cia34DBA/1J
(involves: C57BL/10 * DBA/1J)
|
decreased autoantibody level
|
J:122130
|
decreased susceptibility to induced arthritis
|
J:122130
|
Cia35C57BL/10SnSg/Cia35C57BL/10SnSg Cia42DBA/1J/Cia42DBA/1J
(involves: B10.Q * DBA/1)
|
decreased susceptibility to induced arthritis
|
J:122130
|
Cia35C57BL/10SnSg/Cia35DBA/1J
(involves: C57BL/10 * DBA/1J)
|
increased autoantibody level
|
J:122130
|
increased susceptibility to induced arthritis
|
J:122130
|
Cia35C57BL/10SnSg/Cia35DBA/1J Cia42DBA/1J/Cia42DBA/1J
(involves: B10.Q * DBA/1)
|
decreased susceptibility to induced arthritis
|
J:122130
|
Cia35DBA/1J/Cia35DBA/1J Cia42DBA/1J/Cia42DBA/1J
(involves: B10.Q * DBA/1)
|
decreased susceptibility to induced arthritis
|
J:122130
|
Cia36DBA/1J/Cia36DBA/1J
(involves: C57BL/10 * DBA/1J)
|
decreased autoantibody level
|
J:122130
|
decreased susceptibility to induced arthritis
|
J:122130
|
Cia37C57BL/10SnSg/Cia37DBA/1J
(involves: C57BL/10 * DBA/1J)
|
increased autoantibody level
|
J:122130
|
increased susceptibility to induced arthritis
|
J:122130
|
Cia38DBA/1J/Cia38DBA/1J
(involves: C57BL/10 * DBA/1J)
|
increased autoantibody level
|
J:122130
|
increased susceptibility to induced arthritis
|
J:122130
|
Cia39C57BL/10Sn/Cia39C57BL/10Sn
(involves: B10.Q/Lund-H2q * B10.RIII/Lund-H2r)
|
decreased susceptibility to induced arthritis
|
J:97801
|
Cia39RIII/WySn/Cia39RIII/WySn
(involves: B10.Q/Lund-H2q * B10.RIII/Lund-H2r)
|
autoimmune arthritis
|
J:97801
|
Cia40C57BL/10SnSg/Cia40C57BL/10SnSg
(involves: C57BL/10SnSg * DBA/1J * NFS/N)
|
increased susceptibility to induced arthritis
|
J:106522
|
Cia43DBA/1J/Cia43FVB/N
(involves: DBA/1J * FVB/N)
|
increased susceptibility to induced arthritis
|
J:146242
|
Cia43FVB/N/Cia43FVB/N
(involves: DBA/1J * FVB/N)
|
increased susceptibility to induced arthritis
|
J:146242
|
Ciaaq1DBA/1J/Ciaaq1DBA/1J
(involves: DBA/1J * FVB/NJ)
|
increased autoantibody level
|
J:122919
|
Ciaaq1DBA/1J/Ciaaq1FVB/NJ
(involves: DBA/1J * FVB/NJ)
|
increased autoantibody level
|
J:122919
|
Cigs2tm1.1Anse/Cigs2+ Il4tm1(CD2)Mmrs/Il4+
(involves: 129 * BALB/cJ * C57BL/6)
|
decreased IgE level
|
J:181313
|
decreased IgG1 level
|
J:181313
|
decreased interleukin-4 secretion
|
J:181313
|
Cigs2tm1.1Anse/Cigs2tm1.1Anse
(involves: BALB/cJ * C57BL/6)
|
abnormal class switch recombination
|
J:181313
|
abnormal humoral immune response
|
J:181313
|
abnormal susceptibility to infection
|
J:181313
|
decreased IgE level
|
J:181313
|
decreased IgG1 level
|
J:181313
|
decreased interleukin-4 secretion
|
J:181313
|
decreased interleukin-13 secretion
|
J:181313
|
increased IgG2b level
|
J:181313
|
Cigs2tm1.1Kubo/Cigs2tm1.1Kubo
(B6.Cg-Cigs2tm1.1Kubo)
|
abnormal interleukin secretion
|
J:129048
|
abnormal mast cell physiology
|
J:129048
|
abnormal neutrophil physiology
|
J:129048
|
decreased interleukin-4 secretion
|
J:167446,
J:129048
|
decreased interleukin-13 secretion
|
J:129048
|
Ciitam1Btlr/Ciitam1Btlr
(C57BL/6J-Ciitam1Btlr)
|
impaired humoral immune response
|
J:221483
|
Ciitatm1.1Dim/Ciitatm1.1Dim
(involves: 129S2/SvPas * C57BL/6 * SJL)
|
abnormal level of surface class II molecules
|
J:51885
|
Ciitatm1Adm/Ciita+
(involves: 129S1/Sv * C57BL/6)
|
abnormal immune system physiology
|
J:117111
|
Ciitatm1Adm/Ciitatm1Adm
(involves: 129S1/Sv * C57BL/6)
|
abnormal immune system physiology
|
J:117111
|
Ciitatm1Ccum/Ciitatm1Ccum
(involves: 129S2/SvPas * C57BL/6J)
|
abnormal B cell physiology
|
J:96421
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:31601
|
abnormal cytokine secretion
|
J:64283
|
abnormal dendritic cell physiology
|
J:96421
|
abnormal level of surface class II molecules
|
J:31601,
J:96421
|
abnormal lymphocyte physiology
|
J:96421
|
abnormal MHC II cell surface expression on macrophages
|
J:31601
|
abnormal susceptibility to infection
|
J:64283
|
abnormal T cell physiology
|
J:31601
|
decreased susceptibility to parasitic infection
|
J:64283
|
decreased T cell proliferation
|
J:31601
|
increased susceptibility to parasitic infection
|
J:64283
|
Ciitatm1Ccum/Ciitatm1Ccum
(NOD.129S2(B6)-Ciitatm1Ccum)
|
abnormal inflammatory response
|
J:106081
|
abnormal level of surface class II molecules
|
J:106081
|
decreased susceptibility to autoimmune diabetes
|
J:107051
|
insulitis
|
J:107051
|
pancreas inflammation
|
J:106081
|
periinsulitis
|
J:106081
|
Ciitatm1Ccum/Ciitatm1Ccum
(involves: 129S2/SvPas * C57BL/6)
|
abnormal level of surface class II molecules
|
J:67941
|
Ciitatm1Jpyt/Ciitatm1Jpyt
(involves: 129P2/OlaHsd * C57BL/6J)
|
decreased IgG level
|
J:57100
|
increased IgM level
|
J:57100
|
Ciitatm1Jpyt/Ciitatm1Jpyt
(B6.129P2-Ciitatm1Jpyt)
|
abnormal T-helper 1 physiology
|
J:125654
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:125654
|
Ciitatm2Wrth/Ciitatm2Wrth
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal immunoglobulin level
|
J:92170
|
Cimap2Retro/Cimap2+
(involves: C57BL/6J)
|
increased cytotoxic T cell cytolysis
|
J:223336
|
Cimap2Retro/Cimap2Retro
(involves: C57BL/6J)
|
increased cytotoxic T cell cytolysis
|
J:223336
|
increased interferon-gamma secretion
|
J:223336
|
increased susceptibility to Riboviria infection induced morbidity/mortality
|
J:223336
|
increased T cell proliferation
|
J:223336
|
Cimap2tm1a(KOMP)Wtsi/Cimap2+
(involves: C57BL/6)
|
decreased cytotoxic T cell cytolysis
|
J:223336
|
Cinda1BALB/c/?
(involves: BALB/c * CcS-4/Dem)
|
increased T cell proliferation
|
J:40728
|
Cinda2STS/A/?
(involves: BALB/c * CcS-4/Dem)
|
increased T cell proliferation
|
J:40728
|
Cinda3O20/A/Cinda3O20/A
(involves: O20/A * OcB-9/Dem)
|
decreased T cell proliferation
|
J:95917
|
Cinda3OcB9/Dem/Cinda3O20/A
(involves: O20/A * OcB-9/Dem)
|
increased T cell proliferation
|
J:95917
|
Cinda4OcB9/Dem/Cinda4O20/A
(involves: O20/A * OcB-9/Dem)
|
increased T cell proliferation
|
J:95917
|
Cinda4OcB9/Dem/Cinda4OcB9/Dem
(involves: O20/A * OcB-9/Dem)
|
increased T cell proliferation
|
J:95917
|
Cinda5OcB9/Dem/Cinda5O20/A
(involves: O20/A * OcB-9/Dem)
|
increased T cell proliferation
|
J:95917
|
Cinda5OcB9/Dem/Cinda5OcB9/Dem
(involves: O20/A * OcB-9/Dem)
|
increased T cell proliferation
|
J:95917
|
Cishtm1.1Cdon/Cishtm1.1Cdon Tg(Cd4-cre)1Cwi/0
(involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6 * DBA/2)
|
increased interleukin-4 secretion
|
J:204829
|
increased interleukin-5 secretion
|
J:204829
|
increased interleukin-10 secretion
|
J:204829
|
increased interleukin-13 secretion
|
J:204829
|
increased susceptibility to type I hypersensitivity reaction
|
J:204829
|
Cishtm1.2Cdon/Cishtm1.2Cdon
(B6.129S6(Cg)-Cishtm1.2Cdon)
|
abnormal immune system physiology
|
J:204829
|
increased interleukin-4 secretion
|
J:204829
|
increased interleukin-5 secretion
|
J:204829
|
increased interleukin-9 secretion
|
J:204829
|
increased interleukin-13 secretion
|
J:204829
|
increased susceptibility to type I hypersensitivity reaction
|
J:204829
|
increased T cell proliferation
|
J:204829
|
lung inflammation
|
J:204829
|
Cks1btm1Sir/Cks1btm1Sir Tg(IghMyc)22Bri/?
(involves: C57BL * C57BL/6 * SJL)
|
decreased B cell proliferation
|
J:121564
|
Clca1tm1.1Lex/Clca1tm1.1Lex
(involves: 129S/SvEvBrd)
|
abnormal chemokine level
|
J:125158
|
increased inflammatory response
|
J:125158
|
lung inflammation
|
J:125158
|
Clca1tm1Dgen/Clca1tm1Dgen
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal inflammatory response
|
J:112942
|
Clcn2tm1Tjj/Clcn2tm1Tjj
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal microglial cell physiology
|
J:122365
|
Clcn3tm1Lamb/Clcn3tm1Lamb
(involves: 129S1/Sv * 129X1/SvJ)
|
abnormal neutrophil physiology
|
J:112692
|
impaired neutrophil phagocytosis
|
J:112692
|
sepsis
|
J:112692
|
Clcn3tm1Tjj/Clcn3tm1Tjj
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal microglial cell physiology
|
J:77635
|
Clcn7tm1.1Teti/Clcn7+
(involves: 129S2/SvPas * C57BL/6)
|
abnormal osteoclast physiology
|
J:203761
|
Clcn7tm1Tjj/Clcn7tm1Tjj
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal osteoclast physiology
|
J:67273
|
Clcn7tm2Tjj/Clcn7tm2Tjj
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal osteoclast physiology
|
J:67273
|
Clcn7tm4.1Tjj/Clcn7tm4.1Tjj
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal osteoclast physiology
|
J:160702
|
Clcnkam1Btlr/Clcnkam1Btlr
(C57BL/6J-Clcnkam1Btlr)
|
increased susceptibility to induced colitis
|
J:271974
|
Clec1atm1Yiw/Clec1atm1Yiw
(involves: C57BL/6J * C57BL/6NSlc)
|
abnormal dendritic cell antigen presentation
|
J:329240
|
decreased CD8-positive, alpha-beta memory T cell proliferation
|
J:329240
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:329240
|
Clec1btm1.1Ksi/Clec1btm1.1Ksi
(involves: C57BL/6)
|
abnormal lymphatic system physiology
|
J:165898
|
Clec1btm2Mlkn/Clec1btm2Mlkn Tg(Pf4-icre)Q3Rsko/0
(involves: C57BL/6 * SJL)
|
lymph node hemorrhage
|
J:205423
|
Clec2htm1.1Apma/Clec2htm1.1Apma
(B6(Cg)-Clec2htm1.1Apma)
|
kidney inflammation
|
J:322835
|
Clec2htm1.1Apma/Clec2htm1.1Apma Rag1tm1Mom/Rag1tm1Mom
(B6.Cg-Rag1tm1Mom Clec2htm1.1Apma)
|
kidney inflammation
|
J:322835
|
Clec4a2tm1.1Cfg/Clec4a2tm1.1Cfg
(involves: C57BL/6)
|
increased B cell proliferation
|
J:217719
|
increased IgG2a level
|
J:217719
|
increased IgG2b level
|
J:217719
|
increased IgG3 level
|
J:217719
|
increased inflammatory response
|
J:217719
|
Clec4a2tm1Yiw/Clec4a2tm1Yiw
(involves: 129P2/OlaHsd * C57BL/6J)
|
abnormal circulating interleukin level
|
J:217720
|
abnormal immune system physiology
|
J:217720
|
enthesitis
|
J:217720
|
increased anti-nuclear antigen antibody level
|
J:217720
|
increased autoantibody level
|
J:217720
|
increased circulating interleukin-4 level
|
J:217720
|
increased circulating interleukin-10 level
|
J:217720
|
increased circulating interleukin-17 level
|
J:217720
|
increased circulating interleukin-23 level
|
J:217720
|
increased IgG1 level
|
J:217720
|
increased IgG3 level
|
J:217720
|
increased IgG level
|
J:217720
|
increased inflammatory response
|
J:217720
|
increased susceptibility to induced arthritis
|
J:217720
|
joint inflammation
|
J:217720
|
salivary gland inflammation
|
J:217720
|
Clec4b1em#Tsak/Clec4b1em#Tsak
(involves: C57BL/6N)
|
abnormal adaptive immunity
|
J:258645
|
abnormal cytokine level
|
J:258645
|
abnormal cytokine secretion
|
J:258645
|
decreased interferon-gamma secretion
|
J:258645
|
decreased interleukin-12 secretion
|
J:258645
|
increased susceptibility to bacterial infection
|
J:258645
|
Clec4dtm1.1Cfg/Clec4dtm1.1Cfg
(involves: C57BL/6)
|
decreased B cell proliferation
|
J:217719
|
decreased T cell proliferation
|
J:217719
|
increased interferon-gamma secretion
|
J:203221
|
increased interleukin-6 secretion
|
J:203221
|
increased interleukin-10 secretion
|
J:203221
|
increased interleukin-17 secretion
|
J:203221
|
increased susceptibility to bacterial infection
|
J:203221
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:203221
|
increased tumor necrosis factor secretion
|
J:203221
|
lung inflammation
|
J:203221
|
Clec4dtm1.1Shoy/Clec4dtm1.1Shoy
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal antigen presentation
|
J:203159
|
abnormal chemokine secretion
|
J:203159
|
abnormal immune serum protein physiology
|
J:203159
|
abnormal immune system physiology
|
J:203159
|
abnormal interferon-gamma secretion
|
J:203159
|
abnormal interleukin-17 secretion
|
J:203159
|
abnormal response to infection
|
J:203159
|
decreased circulating interleukin-17 level
|
J:203159
|
decreased IgG level
|
J:203159
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:203159
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:203159
|
decreased tumor necrosis factor secretion
|
J:203159
|
granulomatous inflammation
|
J:203159
|
lung inflammation
|
J:203159
|
Clec4etm1.1Cfg/Clec4etm1.1Cfg
(B6.Cg-Clec4etm1.1Cfg)
|
abnormal macrophage physiology
|
J:136334
|
decreased tumor necrosis factor secretion
|
J:136334
|
increased susceptibility to fungal infection
|
J:136334
|
Clec4etm1Tks/Clec4etm1Tks
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal chemokine secretion
|
J:172959
|
decreased interleukin-6 secretion
|
J:172959
|
decreased interleukin-10 secretion
|
J:172959
|
decreased susceptibility to fungal infection
|
J:172959
|
decreased tumor necrosis factor secretion
|
J:172959
|
Clec4etm1Tks/Clec4etm1Tks
(involves: 129S1/Sv * 129X1/SvJ)
|
abnormal chemokine secretion
|
J:203159
|
abnormal immune serum protein physiology
|
J:203159
|
abnormal interferon-gamma secretion
|
J:203159
|
abnormal interleukin-17 secretion
|
J:203159
|
abnormal response to infection
|
J:203159
|
decreased circulating interleukin-17 level
|
J:203159
|
decreased IgG level
|
J:203159
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:203159
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:203159
|
decreased tumor necrosis factor secretion
|
J:203159
|
Clec4ftm1Ymed/Clec4ftm1Ymed
(B6.129S7-Clec4ftm1Ymed)
|
abnormal macrophage cytokine production
|
J:203199
|
decreased interferon-gamma secretion
|
J:203199
|
Clec4gtm1.1Fhe/Clec4gtm1.1Fhe
(B6.129-Clec4gtm1.1Fhe)
|
abnormal immune system physiology
|
J:200968
|
decreased susceptibility to Adenoviridae infection
|
J:194891
|
liver inflammation
|
J:200968
|
Clec4ntm1.2Mgne/Clec4ntm1.2Mgne
(involves: C57BL/6 * C57BL/6J)
|
abnormal chemokine secretion
|
J:209284
|
abnormal interferon secretion
|
J:209284
|
abnormal interleukin secretion
|
J:209284
|
abnormal macrophage physiology
|
J:209284
|
abnormal neutrophil physiology
|
J:209284
|
abnormal susceptibility to fungal infection
|
J:209284
|
abnormal tumor necrosis factor secretion
|
J:209284
|
decreased interferon-gamma secretion
|
J:209284
|
decreased interleukin-17 secretion
|
J:209284
|
decreased tumor necrosis factor secretion
|
J:209284
|
impaired macrophage phagocytosis
|
J:209284
|
impaired neutrophil phagocytosis
|
J:209284
|
increased interferon-gamma secretion
|
J:209284
|
increased interleukin-1 alpha secretion
|
J:209284
|
increased interleukin-1 beta secretion
|
J:209284
|
increased interleukin-6 secretion
|
J:209284
|
increased interleukin-17 secretion
|
J:209284
|
increased susceptibility to fungal infection
|
J:209284
|
increased tumor necrosis factor secretion
|
J:209284
|
Clec4ntm1Yiw/Clec4ntm1Yiw
(B6.129P2-Clec4ntm1Yiw)
|
decreased interferon-gamma secretion
|
J:160680
|
decreased interleukin-6 secretion
|
J:160680
|
decreased interleukin-10 secretion
|
J:160680
|
decreased interleukin-12b secretion
|
J:160680
|
decreased interleukin-17 secretion
|
J:160680
|
decreased interleukin-23 secretion
|
J:160680
|
decreased tumor necrosis factor secretion
|
J:160680
|
increased susceptibility to infection induced morbidity/mortality
|
J:160680
|
Clec4ntm1Yiw/Clec4ntm1Yiw
(involves: 129P2/OlaHsd)
|
increased susceptibility to fungal infection
|
J:209284
|
Clec5atm1Cua/Clec5atm1Cua
(involves: C57BL/6)
|
decreased susceptibility to induced arthritis
|
J:158811
|
Clec7atm1.1Bpip/Clec7atm1.1Bpip Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * C57BL/6J)
|
abnormal macrophage physiology
|
J:203908
|
decreased tumor necrosis factor secretion
|
J:203908
|
impaired macrophage phagocytosis
|
J:203908
|
increased susceptibility to fungal infection
|
J:203908
|
Clec7atm1Gdb/Clec7atm1Gdb
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal cytokine secretion
|
J:116669
|
abnormal inflammatory response
|
J:116669
|
abnormal macrophage physiology
|
J:116669
|
abnormal neutrophil physiology
|
J:116669
|
increased susceptibility to fungal infection
|
J:116669
|
Clec7atm1Gdb/Clec7atm1Gdb
(B6.129S6-Clec7atm1Gdb)
|
abnormal circulating interleukin level
|
J:179011
|
decreased circulating interleukin-17 level
|
J:179011
|
increased susceptibility to fungal infection
|
J:179011
|
lung inflammation
|
J:179011
|
Clec7atm1Yiw/Clec7atm1Yiw
(C.129P2-Clec7atm1Yiw)
|
abnormal cytokine secretion
|
J:116670
|
abnormal dendritic cell physiology
|
J:116670
|
abnormal macrophage physiology
|
J:116670
|
increased susceptibility to fungal infection
|
J:116670
|
Clec7atm1Yiw/Clec7atm1Yiw
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal dendritic cell physiology
|
J:122394
|
Clec7atm1Yiw/Clec7atm1Yiw Myd88tm1Aki/Myd88tm1Aki
(involves: 129P2/OlaHsd * BALB/cA * C57BL/6J)
|
abnormal cytokine secretion
|
J:116670
|
abnormal dendritic cell physiology
|
J:116670
|
Clec9atm1.1Crs/Clec9atm1.1Crs
(C57BL/6-Clec9atm1.1Crs)
|
abnormal dendritic cell antigen presentation
|
J:178441
|
Clec9atm1.1Kens/Clec9atm1.1Kens
(involves: C57BL/6)
|
abnormal humoral immune response
|
J:181366
|
Clec9atm1Crs/Clec9atm1Crs
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal dendritic cell antigen presentation
|
J:147472
|
Clec10am1/Clec10am1
(NC/Nga)
|
dermatitis
|
J:283174
|
Clec10atm1Hed/Clec10atm1Hed
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
|
dermatitis
|
J:283174
|
Clec12atm1Gdb/Clec12atm1Gdb
(involves: C57BL/6)
|
increased susceptibility to bacterial infection
|
J:224869
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:224869
|
Clec12atm1Jrld/Clec12atm1Jrld
(B6J.129-Clec12atm1Jrld)
|
abnormal chemokine secretion
|
J:210326
|
abnormal neutrophil physiology
|
J:210326
|
increased inflammatory response
|
J:210326
|
increased tumor necrosis factor secretion
|
J:210326
|
Clic4tm1.1Aidi/Clic4tm1.1Aidi
(involves: C57BL/6 * C57BL/6J)
|
abnormal chemokine secretion
|
J:175404
|
decreased circulating interleukin-6 level
|
J:175404
|
decreased circulating tumor necrosis factor level
|
J:175404
|
decreased interleukin-6 secretion
|
J:175404
|
decreased interleukin-12 secretion
|
J:175404
|
decreased susceptibility to endotoxin shock
|
J:175404
|
decreased tumor necrosis factor secretion
|
J:175404
|
increased susceptibility to bacterial infection
|
J:175404
|
Clic4tm1.1Yus/Clic4tm1.1Yus
(involves: 129S4/SvJae * C57BL/6J)
|
impaired macrophage phagocytosis
|
J:183611
|
Cln3em1Dprc/Cln3em1Dprc
(C57BL/6-Cln3em1Dprc)
|
increased microglial cell activation
|
J:294634
|
Cln3tm1Nbm/Cln3tm1Nbm
(involves: 129S6/SvEvTac * C57BL/6J)
|
abnormal dendritic cell physiology
|
J:233445
|
abnormal macrophage physiology
|
J:233445
|
decreased macrophage cytokine production
|
J:233445
|
Clnktm1Rygo/Clnktm1Rygo
(B6.129P2-Clnktm1Rygo)
|
abnormal interferon-gamma secretion
|
J:131738
|
abnormal NK T cell physiology
|
J:131738
|
decreased interleukin-4 secretion
|
J:131738
|
increased natural killer cell mediated cytotoxicity
|
J:131738
|
Clnktm1Rygo/Clnktm1Rygo
(involves: 129P2/OlaHsd * BALB/c)
|
increased interferon-gamma secretion
|
J:131621
|
increased natural killer cell mediated cytotoxicity
|
J:131621
|
Clnktm1Rygo/Clnktm1Rygo Lcp2tm1Geha/Lcp2tm1Geha
(involves: 129P2/OlaHsd * 129S4/SvJae * BALB/c)
|
decreased interferon-gamma secretion
|
J:131621
|
impaired natural killer cell mediated cytotoxicity
|
J:131621
|
Clnktm1Vei/Clnktm1Vei
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal mast cell physiology
|
J:91590
|
increased natural killer cell mediated cytotoxicity
|
J:91590
|
ClppGt(IST11134F10)Tigm/ClppGt(IST11134F10)Tigm
(involves: C57BL/6N)
|
abnormal T cell activation
|
J:203140
|
dermatitis
|
J:203140
|
ClppGt(IST13563G11)Tigm/ClppGt(IST13563G11)Tigm
(involves: C57BL/6N)
|
abnormal T cell activation
|
J:203140
|
dermatitis
|
J:203140
|
Clptm1ltm1d(EUCOMM)Wtsi/Clptm1l+
(involves: 129S4/SvJaeSor * BALB/cJ * C57BL/6N)
|
abnormal class switch recombination
|
J:265892
|
Cltatm1.2Fmb/Cltatm1.2Fmb
(involves: C57BL/6)
|
abnormal class switch recombination
|
J:235591
|
Clutm1Jakh/Clutm1Jakh
(involves: Black Swiss * FVB/N)
|
heart inflammation
|
J:65660
|
myocarditis
|
J:65660
|
Cma1tm1Mfg/Cma1tm1Mfg
(either: (involves: 129 * C57BL/6) or (involves: 129 * BALB/c))
|
abnormal mast cell physiology
|
J:98963
|
Cmahtm1Avrk/Cmahtm1Avrk Dock2m1Hsd/Dock2m1Hsd
(B6NHsd.Cg-Dock2m1Hsd Cmahtm1Avrk)
|
abnormal B cell activation
|
J:144035
|
Cmahtm1Avrk/Cmahtm1Avrk Dock2m1Hsd/Dock2m1Hsd Siaetm1.2Avrk/Siaetm1.2Avrk
(B6NHsd.Cg-Siaetm1.2Avrk Dock2m1Hsd Cmahtm1Avrk)
|
abnormal B cell activation
|
J:144035
|
Cmahtm1Ykoz/Cmahtm1Ykoz
(B6.129P2-Cmahtm1Ykoz)
|
abnormal B cell physiology
|
J:121365
|
abnormal humoral immune response
|
J:121365
|
abnormal interleukin secretion
|
J:121365
|
abnormal T cell physiology
|
J:121365
|
decreased interferon-gamma secretion
|
J:121365
|
increased B cell proliferation
|
J:121365
|
increased IgG1 level
|
J:121365
|
Cmastm1.1Bwei/Cmastm1.1Bwei Tg(NPHS2-cre)295Lbh/0
(involves: 129P2/OlaHsd * C57BL/6 * SJL)
|
tubular nephritis
|
J:286022
|
CmcsCBA/N/?
(involves: CBA/N * DBA/2)
|
abnormal immune system physiology
|
J:94127
|
CmcsDBA/2/?
(involves: CBA/N * DBA/2)
|
abnormal immune system physiology
|
J:94127
|
Cmklr1tm1Dgen/Cmklr1tm1Dgen
(B6.Cg-Cmklr1tm1Dgen)
|
abnormal dendritic cell physiology
|
J:157190
|
abnormal macrophage chemotaxis
|
J:157190
|
abnormal professional antigen presenting cell physiology
|
J:157190
|
increased susceptibility to endotoxin shock
|
J:157190
|
lung inflammation
|
J:157190
|
Cmklr1tm1Drg/Cmklr1tm1Drg
(Not Specified)
|
impaired macrophage chemotaxis
|
J:133968
|
impaired neutrophil recruitment
|
J:133968
|
Cms1DBA/2J/?
(involves: C57BL/6J * DBA/2J)
|
decreased susceptibility to fungal infection
|
J:55132
|
Cms2DBA/2J/?
(involves: C57BL/6J * DBA/2J)
|
decreased susceptibility to infection
|
J:55132
|
Cmtm4tm1d(EUCOMM)Wtsi/Cmtm4tm1d(EUCOMM)Wtsi
(involves: C57BL/6J * C57BL/6N)
|
decreased inflammatory response
|
J:333836
|
decreased susceptibility to chemically induced skin inflammation
|
J:333836
|
Cmtm7tm2a(EUCOMM)Hmgu/Cmtm7+ Rag1tm1Fwa/Rag1tm1Fwa
(chimera involves: C57BL/6 * C57BL/6N)
|
abnormal B cell physiology
|
J:207033
|
decreased B cell proliferation
|
J:207033
|
decreased IgG2b level
|
J:207033
|
decreased IgM level
|
J:207033
|
Cmtr1tm1b(EUCOMM)Hmgu/Cmtr1tm1b(EUCOMM)Hmgu Emx1tm1(cre)Krj/Emx1+ Tg(Thy1-YFP)HJrs/0
(involves: 129S2/SvPas * C57BL/6J * C57BL/6N * CBA)
|
abnormal susceptibility to Riboviria infection
|
J:300305
|
Cnmdtm1Ska/Cnmdtm1Ska
(involves: C57BL/6 * CBA)
|
abnormal osteoclast physiology
|
J:81137
|
Cnn2tm1.2Jin/Cnn2tm1.2Jin
(B6.129X1-Cnn2tm1.2Jin)
|
abnormal macrophage chemotaxis
|
J:141867
|
abnormal macrophage physiology
|
J:141867
|
Cnpy3tm1Kmiy/Cnpy3tm1Kmiy
(involves: C57BL/6)
|
abnormal lymphocyte physiology
|
J:128513
|
abnormal macrophage physiology
|
J:128513
|
decreased interleukin-6 secretion
|
J:128513
|
decreased tumor necrosis factor secretion
|
J:128513
|
Cnr2tm1Zim/Cnr2tm1Zim
(involves: 129 * C57BL/6)
|
abnormal macrophage physiology
|
J:62417
|
Cntftm1Mpin/Cntftm1Mpin
(B6.129S2-Cntftm1Mpin)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:126852
|
Cog6tm1a(EUCOMM)Wtsi/Cog6tm1a(EUCOMM)Wtsi
(C57BL/6N-Cog6tm1a(EUCOMM)Wtsi/Wtsi)
|
increased anti-nuclear antigen antibody level
|
J:211773
|
Col1a1Aga2/Col1a1+
(C3HeB/FeJ-Col1a1Aga2)
|
lung inflammation
|
J:185988
|
Col1a1M1Jrt/Col1a1+
(involves: C3H/HeJ * C57BL/6J * FVB/NJ)
|
osteoarthritis
|
J:216423
|
Col1a1M1Jrt/Col1a1+
(involves: C57BL/6 * FVB/N)
|
autoimmune arthritis
|
J:228439
|
Col1a1tm1(tetO-Fos)Wag/Col1a1+ Tg(KRT5-rtTA)T2D6Sgkd/0
(involves: 129S4/SvJae * C57BL/6 * FVB/N)
|
skin inflammation
|
J:201145
|
Col1a1tm1(tetO-Irf4)Sing/Col1a1tm1(tetO-Irf4)Sing Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+ Irf4tm1Mak/Irf4+
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
abnormal class switch recombination
|
J:203903
|
Col1a1tm1(tetO-Irf4)Sing/Col1a1tm1(tetO-Irf4)Sing Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+ Irf4tm1Mak/Irf4tm1Mak
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
abnormal class switch recombination
|
J:203903
|
Col1a1tm1(tetO-Stat1)Biat/Col1a1tm1(tetO-Stat1)Biat Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae Stat1tm1Dlv/Stat1tm1Dlv
(involves: 129S/SvEv * 129S4/SvJae * C57BL/6)
|
abnormal susceptibility to infection induced morbidity/mortality
|
J:212694
|
Col1a1tm1(tetO-Yod1*)Hpl/Col1a1tm1(tetO-Yod1*)Hpl Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
(involves: 129S4/SvJae * C57BL/6)
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:194608
|
abnormal professional antigen presenting cell physiology
|
J:194608
|
Col1a1tm1(tetO-Yod1*)Hpl/Col1a1tm1(tetO-Yod1*)Hpl Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae Tap1tm1Arp/Tap1tm1Arp
(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)
|
abnormal professional antigen presenting cell physiology
|
J:194608
|
Col1a1tm1Jae/Col1a1tm1Jae
(involves: 129S4/SvJae * C57BL/6)
|
abnormal osteoclast physiology
|
J:53079
|
Col1a1tm3(tetO-Fosl1,-DsRed)Wag/Col1a1+ Tg(Cebpb-tTA)5Bjd/0
(involves: 129S4/SvJae * C57BL/6 * NMRI)
|
decreased circulating interleukin-6 level
|
J:210545
|
liver inflammation
|
J:210545
|
Col2a1tm1Prc/Col2a1+ Col9a1tm1Jae/Col9a1tm1Jae
(involves: 129/Sv * 129S2/SvPas)
|
osteoarthritis
|
J:117910
|
Col3a1m1Btlr/Col3a1m1Btlr
(C57BL/6J-Col3a1m1Btlr)
|
increased susceptibility to induced colitis
|
J:271973
|
Col3a1Tsk2/Col3a1+
(C3H101H-Col3a1Tsk2/H)
|
adipose tissue inflammation
|
J:31216
|
skin inflammation
|
J:31216
|
Col4a1tm1.1Ics/Col4a1+
(involves: 129S2/SvPas * C57BL/6)
|
kidney inflammation
|
J:240798
|
Col4a1tm1.1Ics/Col4a1tm1.1Ics
(involves: 129S2/SvPas * C57BL/6)
|
kidney inflammation
|
J:240798
|
Col4a2em1(IMPC)Wtsi/Col4a2em1(IMPC)Wtsi
(C57BL/6N-Col4a2em1(IMPC)Wtsi/WtsiOulu)
|
blood in lymph vessels
|
J:239583
|
Col4a3tm1.1Rkl/Col4a3+
(involves: C57BL/6)
|
glomerulonephritis
|
J:167404
|
Col4a3tm1Dec/Col4a3tm1Dec
(involves: 129X1/SvJ * C57BL/6)
|
glomerulonephritis
|
J:37963
|
Col4a3tm1Dec/Col4a3tm1Dec
(129-Col4a3tm1Dec/J)
|
glomerulonephritis
|
J:158731
|
Col4a3tm1Dec/Col4a3tm1Dec
(B6.129X1-Col4a3tm1Dec)
|
glomerulonephritis
|
J:167404
|
Col4a3tm1Dec/Col4a3tm1Dec Itga1tm1Gdnr/Itga1tm1Gdnr
(involves: 129S4/SvJae * 129X1/SvJ * BALB/c)
|
tubular nephritis
|
J:71378
|
Col4a3tm1Dec/Col4a3tm1Dec Sostdc1tm1Myan/Sostdc1tm1Myan
(involves: 129X1/SvJ)
|
glomerulonephritis
|
J:158731
|
Col4a3tm1Jhm/Col4a3tm1Jhm
(involves: 129S1/Sv * 129X1/SvJ)
|
glomerulonephritis
|
J:37017
|
Col4a3tm1Jhm/Col4a3tm1Jhm Mmp9tm1Tvu/Mmp9tm1Tvu
(involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ)
|
glomerulonephritis
|
J:63137
|
Col4a4bwk/Col4a4bwk
(NON;NZO-Col4a4bwk/J)
|
kidney inflammation
|
J:223185
|
tubulointerstitial nephritis
|
J:223185
|
Col4a4bwk/Col4a4bwk
(D2.NON(NZO)-Col4a4bwk/GrsrJ)
|
kidney inflammation
|
J:223185
|
Col4a4bwk/Col4a4bwk
(129S1.NON(NZO)-Col4a4bwk/PgnJ)
|
kidney inflammation
|
J:223185
|
Col4a5tm1Yseg/Y
(B6.Cg-Col4a5tm1Yseg)
|
tubulointerstitial nephritis
|
J:102306
|
Col9a1tm1Jae/Col9a1tm1Jae
(either: (involves: 129S2/SvPas * BALB/c) or (involves: 129S2/SvPas * C57BL))
|
osteoarthritis
|
J:18628
|
Col9a1tm1Jae/Col9a1tm1Jae
(involves: 129S2/SvPas)
|
osteoarthritis
|
J:117910
|
Col10a1tm1Ksec/Col10a1tm1Ksec
(involves: 129S/SvEv * C57BL/6)
|
decreased interleukin-2 secretion
|
J:193886
|
decreased interleukin-4 secretion
|
J:193886
|
decreased interleukin-10 secretion
|
J:193886
|
decreased interleukin-17 secretion
|
J:193886
|
increased interleukin-4 secretion
|
J:193886
|
Col11a1cho/Col11a1+
(involves: C57BL/6Fr)
|
osteoarthritis
|
J:106282
|
Col13a1tm1Pih/Col13a1tm1Pih
(either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J))
|
myositis
|
J:71939
|
Col17a1em1Dcr/Col17a1em1Dcr Lamc2jeb/Lamc2jeb
(B6.Cg-Lamc2jeb Col17a1em1Dcr/Dcr)
|
ear inflammation
|
J:352187
|
Col17a1em2Dcr/Col17a1em2Dcr Lamc2jeb/Lamc2jeb
(C57BL/6J-Col17a1em2Dcr/Dcr)
|
ear inflammation
|
J:352187
|
Col17a1tm1.1(COL17A1)Zliu/Col17a1tm1.1(COL17A1)Zliu
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased mast cell degranulation
|
J:261781
|
Col17a1tm1Shzu/Col17a1tm1Shzu Tg(KRT14-COL17A1)1Shzu/0
(involves: 129S/SvEv * C57BL/6J * C57BL/6Ncr)
|
decreased autoantibody level
|
J:121695
|
Col17a1tm1Tiin/Col17a1tm1Tiin
(involves: C57BL/6)
|
increased autoantibody level
|
J:220622
|
increased IgE level
|
J:220622
|
skin inflammation
|
J:220622
|
Colec11tm1Lex/Colec11tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6)
|
abnormal complement protein level
|
J:234934
|
Colgalt2tm1.1Hwei/Colgalt2tm1.1Hwei
(involves: C57BL/6J)
|
increased circulating interleukin-1 beta level
|
J:310468
|
increased circulating interleukin-4 level
|
J:310468
|
increased circulating interleukin-6 level
|
J:310468
|
increased circulating interleukin-9 level
|
J:310468
|
increased T cell apoptosis
|
J:310468
|
Commd10Tg(Vav1-icre)A2Kio/0 Map3k7tm1.1Arte/Map3k7tm1.1Arte
(involves: C57BL/10 * C57BL/6J * C57BL/6NTac * CBA/Ca)
|
decreased interleukin-6 secretion
|
J:332172
|
decreased interleukin-10 secretion
|
J:332172
|
decreased interleukin-12b secretion
|
J:332172
|
decreased tumor necrosis factor secretion
|
J:332172
|
Commd10Tg(Vav1-icre)A2Kio/? Tnfrsf14tm1.1Kro/Tnfrsf14tm1.1Kro
(involves: C57BL/6NCrl * C57BL/10 * CBA * SJL)
|
decreased susceptibility to Herpesvirales infection
|
J:243038
|
Comptm1Mbri/Comptm1Mbri
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
osteoarthritis
|
J:125086
|
Comttm1Kara/Comttm1Kara
(involves: 129S4/SvJaeSor)
|
increased interferon-gamma secretion
|
J:137276
|
Copatm1.1Shum/Copa+
(B6(CBA)-Copatm1.1Shum)
|
abnormal T cell activation
|
J:288425
|
bronchiolitis
|
J:288425
|
lung inflammation
|
J:288425
|
Copg1em1Geha/Copg1em1Geha
(involves: C57BL/6)
|
abnormal B cell physiology
|
J:345528
|
abnormal IgG level
|
J:345528
|
decreased circulating interferon-gamma level
|
J:345528
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:345528
|
increased T cell apoptosis
|
J:345528
|
Cops5tm1Rpar/Cops5tm1Rpar Tg(Lck-cre)548Jxm/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA * SJL)
|
increased T cell apoptosis
|
J:132114
|
Cops6Gt(RRI087)Byg/Cops6+
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased thymocyte apoptosis
|
J:172038
|
Cops8tm1Nwe/Cops8tm1.1Nwe Tg(Cd4-cre)1Cwi/?
(involves: 129S1/Sv * C57BL/6 * DBA/2)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:126339
|
abnormal T cell activation
|
J:126339
|
decreased interleukin-2 secretion
|
J:126339
|
decreased T cell proliferation
|
J:126339
|
Coq6em1Shcm/Coq6em1Shcm
(C57BL/6-Coq6em1Shcm)
|
increased susceptibility to bacterial infection
|
J:360514
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:360514
|
Cora1BALB/c/Cora1BALB/c
(involves: BALB/c * STS/A)
|
abnormal cytokine secretion
|
J:52119
|
Cora1STS/A/Cora1STS/A
(involves: BALB/c * STS/A)
|
abnormal cytokine secretion
|
J:52119
|
Coro1akoy/Coro1akoy
(C57BL/6-Coro1akoy)
|
abnormal T cell physiology
|
J:141431
|
Coro1aLmb3-C57BL/6Scr/Coro1aLmb3-C57BL/6Scr
(MRL.Cg-Coro1aC57BL/6Scr Faslpr)
|
decreased autoantibody level
|
J:125557
|
decreased susceptibility to systemic lupus erythematosus
|
J:125557
|
glomerulonephritis
|
J:125557
|
Coro1aLmb3-MRL/MpScr/Coro1aLmb3-MRL/MpScr
(B6.MRL-Coro1aMRL/MpScr Faslpr)
|
increased susceptibility to systemic lupus erythematosus
|
J:125557
|
Coro1aptcd/Coro1aptcd
(B6.CTS-Coro1aptcd)
|
abnormal T cell activation
|
J:141431
|
abnormal T cell physiology
|
J:141431
|
increased T cell apoptosis
|
J:141431
|
Coro1aptcd/Coro1atm1Achn
(B6.Cg-Coro1aptcd Coro1atm1Achn)
|
abnormal T cell activation
|
J:141431
|
abnormal T cell physiology
|
J:141431
|
Coro1atm1Achn/Coro1atm1Achn
(involves: 129X1/SvJ * C57BL/6)
|
abnormal leukocyte migration
|
J:111593
|
Coro1atm1Achn/Coro1atm1Achn
(B6.129X1-Coro1atm1Achn)
|
increased T cell apoptosis
|
J:141431
|
Coro1atm1Achn/Coro1atm1Achn
(involves: 129X1/SvJ)
|
decreased interleukin-6 secretion
|
J:177785
|
decreased tumor necrosis factor secretion
|
J:177785
|
increased mast cell degranulation
|
J:177785
|
Coro1atm1Achn/Coro1atm1Achn Coro1btm1.1Nfoe/Coro1btm1.1Nfoe
(involves: 129X1/SvJ * C57BL/6N)
|
decreased interleukin-6 secretion
|
J:177785
|
decreased tumor necrosis factor secretion
|
J:177785
|
increased mast cell degranulation
|
J:177785
|
increased susceptibility to type I hypersensitivity reaction
|
J:177785
|
Coro1atm1Jpie/Coro1atm1Jpie
(involves: 129 * C57BL/6)
|
abnormal T cell activation
|
J:133258
|
abnormal thymocyte activation
|
J:133258
|
decreased interleukin-2 secretion
|
J:133258
|
decreased susceptibility to bacterial infection
|
J:133404
|
decreased T cell proliferation
|
J:133258
|
impaired macrophage phagocytosis
|
J:133404
|
Coro1ctm1a(KOMP)Wtsi/Coro1ctm1a(KOMP)Wtsi
(C57BL/6N-Coro1ctm1a(KOMP)Wtsi/Wtsi)
|
blood in lymph vessels
|
J:239583
|
Cox4i2tm1Hutt/Cox4i2+
(B6.129-Cox4i2tm1Hutt)
|
lung inflammation
|
J:187640
|
Cox4i2tm1Hutt/Cox4i2tm1Hutt
(B6.129-Cox4i2tm1Hutt)
|
lung inflammation
|
J:187640
|
Cox10tm1Ctm/Cox10tm1Ctm Slc6a3tm1.1(cre)Bkmn/?
(B6.Cg-Cox10tm1Ctm Slc6a3tm1.1(cre)Bkmn)
|
abnormal chemokine secretion
|
J:231810
|
increased interleukin-1 beta secretion
|
J:231810
|
increased microglial cell activation
|
J:231810
|
Cptm1Hrs/Cptm1Hrs Hephsla/Y
(involves: 129X1/SvJ * C57BL/6)
|
eye inflammation
|
J:136925
|
Cpa1tm1.1Satom/Cpa1tm1.1Satom
(involves: C57BL/6NCrl * FVB/N)
|
pancreas inflammation
|
J:300042
|
Cpa3tm3(icre)Hrr/Cpa3+
(B6.129P2-Cpa3tm3(icre)Hrr)
|
abnormal inflammatory response
|
J:178942
|
Cpa3tm3(icre)Hrr/Cpa3+
(involves: 129P2/OlaHsd * BALB/c * C57BL/6)
|
decreased susceptibility to type I hypersensitivity reaction
|
J:178942
|
Cpa3tm3(icre)Hrr/Cpa3+ Fgfr1tm1Upir/Fgfr1tm1Upir Fgfr2tm1Dor/Fgfr2tm1Dor Tg(KRT5-cre)5132Jlj/0
(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * C57BL/6J * DBA/2J)
|
skin inflammation
|
J:221184
|
Cpb2tm1Efp/Cpb2+ Plgtm1Dco/Plg+
(involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6)
|
abnormal inflammatory response
|
J:80114
|
Cpb2tm1Efp/Cpb2tm1Efp Plgtm1Dco/Plg+
(involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6)
|
abnormal inflammatory response
|
J:80114
|
Cpb2tm1Mng/Cpb2tm1Mng
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal chemokine level
|
J:107340
|
abnormal tumor necrosis factor level
|
J:107340
|
Cpb2tm1Nok/Cpb2tm1Nok
(involves: 129P2/OlaHsd * BALB/c)
|
impaired complement alternative pathway
|
J:93733
|
increased inflammatory response
|
J:93733
|
Cpn1tm1Raw/Cpn1tm1Raw
(B6.129S1-Cpn1tm1Raw)
|
abnormal complement pathway
|
J:148315
|
increased acute inflammation
|
J:148315
|
Cpsf6em1Bcgen/Cpsf6+
(Not Specified)
|
decreased susceptibility to Riboviria infection
|
J:346988
|
increased interferon-beta secretion
|
J:346988
|
Cpt2tm1b(KOMP)Wtsi/Cpt2tm1b(KOMP)Wtsi
(C57BL/6N-Cpt2tm1b(KOMP)Wtsi/Wtsi)
|
blood in lymph vessels
|
J:239583
|
Cr1ltm1Hmo/Cr1ltm1Hmo
(involves: 129X1/SvJ)
|
increased inflammatory response
|
J:59432
|
Cr2M1Btlr/Cr2M1Btlr
(C57BL/6J-Cr2M1Btlr)
|
decreased IgG level
|
J:267527
|
impaired humoral immune response
|
J:267527
|
Cr2tm1.1Jhws/Cr2tm1.1Jhws
(Not Specified)
|
abnormal germinal center B cell physiology
|
J:205353
|
decreased IgG2b level
|
J:205353
|
decreased IgG2c level
|
J:205353
|
decreased IgG3 level
|
J:205353
|
decreased IgM level
|
J:205353
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:205353
|
Cr2tm1Crr/Cr2tm1Crr
(involves: 129S7/SvEvBrd * C57BL/6)
|
abnormal humoral immune response
|
J:31942,
J:69452
|
decreased IgG2a level
|
J:31942
|
decreased IgG2b level
|
J:31942
|
decreased IgG3 level
|
J:31942
|
decreased IgG level
|
J:31942,
J:69452
|
decreased IgM level
|
J:69452
|
decreased immunoglobulin level
|
J:69452
|
decreased tumor necrosis factor secretion
|
J:66111
|
Cr2tm1Crr/Cr2tm1Crr
(involves: 129S7/SvEvBrd * C57BL/6J)
|
increased anti-double stranded DNA antibody level
|
J:111811
|
Cr2tm1Crr/Cr2tm1Crr Ggta1tm1Jbl/Ggta1tm1Jbl
(involves: 129S2/SvPas * 129S7/SvEvBrd)
|
abnormal humoral immune response
|
J:113488
|
Cr2tm1Hmo/Cr2tm1Hmo
(involves: 129S7/SvEvBrd)
|
decreased IgG level
|
J:35112
|
decreased IgM level
|
J:35112
|
Cr2tm1Hmo/Cr2tm1Hmo
(B6.129S7-Cr2tm1Hmo)
|
increased susceptibility to bacterial infection
|
J:94855
|
Cr2tm1Hmo/Cr2tm1Hmo
(involves: 129S7/SvEvBrd * C57BL/6)
|
abnormal B cell activation
|
J:151991
|
abnormal B cell physiology
|
J:151991
|
abnormal class switch recombination
|
J:151991
|
Cr2tm1Tft/Cr2tm1Tft
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
|
abnormal adaptive immunity
|
J:95979
|
decreased IgG1 level
|
J:95979
|
decreased IgG2b level
|
J:95979
|
decreased IgG3 level
|
J:95979
|
decreased IgG level
|
J:95979
|
decreased IgM level
|
J:95979
|
increased susceptibility to bacterial infection
|
J:95979
|
Cr2tm2.1(HLA-A)Crr/Cr2tm2.1(HLA-A)Crr
(involves: C57BL/6)
|
abnormal B cell physiology
|
J:151991
|
abnormal class switch recombination
|
J:151991
|
Cr2tm2.1(HLA-A)Crr/Cr2tm2.1(HLA-A)Crr Tg(IghelMD4)4Ccg/?
(involves: C57BL/6)
|
abnormal B cell activation
|
J:151991
|
Cr2tm2.1Jhws/Cr2tm2.1Jhws
(B6.129-Cr2tm2.1Jhws)
|
abnormal germinal center B cell physiology
|
J:205353
|
decreased IgG3 level
|
J:205353
|
decreased IgM level
|
J:205353
|
increased IgM level
|
J:205353
|
Cracr2atm1.1Ygwa/Cracr2atm1.1Ygwa Tg(Cd4-cre)1Cwi/0
(B6.Cg-Cracr2atm1.1Ygwa Tg(Cd4-cre)1Cwi)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:259523
|
decreased interleukin-2 secretion
|
J:259523
|
Creb3l3tm1.1Sad/Creb3l3tm1.1Sad
(involves: 129 * C57BL/6 * FVB/N)
|
decreased acute inflammation
|
J:140018
|
decreased circulating serum amyloid protein level
|
J:140018
|
CrebbpGt(U-San)112Imeg/Crebbp+
(involves: C57BL/6 * CBA)
|
abnormal tumor necrosis factor level
|
J:75361
|
Crhtm1Maj/Crhtm1Maj
(involves: 129S2/SvPas * C57BL/6)
|
abnormal cell-mediated immunity
|
J:98419
|
abnormal cytokine secretion
|
J:98419
|
abnormal inflammatory response
|
J:98419
|
abnormal professional antigen presenting cell physiology
|
J:98419
|
decreased inflammatory response
|
J:90690,
J:72196
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:98419
|
decreased T cell proliferation
|
J:98419
|
increased circulating interleukin-6 level
|
J:72196
|
Crim1em1(IMPC)Wtsi/Crim1em1(IMPC)Wtsi
(C57BL/6N-Crim1em1(IMPC)Wtsi/WtsiOrl)
|
blood in lymph vessels
|
J:239583
|
Crim1Gt(KST264)Byg/Crim1Gt(KST264)Byg
(involves: 129P2/OlaHsd * C57BL/6 * CD-1)
|
kidney inflammation
|
J:172334
|
Crispld2tm1Lex/Crispld2tm1Lex
(B6;129S5-Crispld2tm1Lex/Mmucd)
|
abnormal immune system physiology
|
J:171883
|
Crl1A/WySnJ/Crl1A/WySnJ
(B10.A-H2a/SgSnJ)
|
abnormal B cell physiology
|
J:5442
|
Crl1AKR/J/Crl1AKR/J
(involves: AKR/J * DBA/2J)
|
abnormal B cell physiology
|
J:5442
|
Crl1DBA/2J/Crl1DBA/2J
(involves: AKR/J * DBA/2J)
|
abnormal B cell physiology
|
J:5442
|
Crlf2tm1Jni/Crlf2tm1Jni
(involves: 129P2/OlaHsd)
|
respiratory system inflammation
|
J:187770
|
Crlf2tm1Wjl/Crlf2tm1Wjl
(involves: BALB/c)
|
abnormal cytokine secretion
|
J:107431
|
abnormal T cell proliferation
|
J:107431
|
decreased immunoglobulin level
|
J:107431
|
decreased splenocyte proliferation
|
J:107431
|
lung inflammation
|
J:107431
|
Crlf2tm1Wjl/Crlf2tm1Wjl
(Not Specified)
|
colitis
|
J:175844
|
Crocctm1Tili/Crocctm1Tili
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
lung inflammation
|
J:98885
|
Crotem1Akw/Crotem1Akw Ldlrtm1Her/Ldlrtm1Her
(B6.Cg-Crotem1Akw Ldlrtm1Her)
|
blood vessel inflammation
|
J:331161
|
Crptm1Hjf/Crp+
(C57BL/6-Crptm1Hjf)
|
decreased circulating C-reactive protein level
|
J:170409
|
Crptm1Hjf/Crptm1Hjf
(C57BL/6-Crptm1Hjf)
|
decreased circulating C-reactive protein level
|
J:170409
|
Crsl/Crsl+
(involves: C3HeB/FeJ)
|
keratoconjunctivitis sicca
|
J:104123
|
Crtamtm1Achn/Crtamtm1Achn
(involves: 129 * C57BL/6)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:145314
|
abnormal interleukin secretion
|
J:145314
|
abnormal T cell activation
|
J:145314
|
abnormal T-helper 1 physiology
|
J:145314
|
decreased interferon-gamma secretion
|
J:145314
|
decreased interleukin-17 secretion
|
J:145314
|
increased susceptibility to bacterial infection
|
J:145314
|
increased T cell proliferation
|
J:145314
|
Crtamtm1Tks/Crtamtm1Tks
(B6.Cg-Crtamtm1Tks)
|
abnormal response to infection
|
J:152770
|
Crtc1tm1a(EUCOMM)Wtsi/Crtc1+
(C57BL/6N-Crtc1tm1a(EUCOMM)Wtsi/Ics)
|
increased IgG2b level
|
J:165965
|
Cry1tm1Jhjh/Cry1tm1Jhjh Cry2tm1Jhjh/Cry2tm1Jhjh
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal T cell activation
|
J:159504
|
increased circulating interleukin-1 beta level
|
J:159504
|
increased circulating interleukin-6 level
|
J:159504
|
increased circulating tumor necrosis factor level
|
J:159504
|
increased susceptibility to induced arthritis
|
J:159504
|
increased tumor necrosis factor secretion
|
J:159504
|
Cry2tm1Jhjh/Cry2tm1Jhjh
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal osteoclast physiology
|
J:163112
|
Csf1op/Csf1op
(B6C3Fe a/a-Csf1op/J)
|
abnormal Langerhans cell physiology
|
J:112594
|
abnormal splenocyte physiology
|
J:19549
|
Csf1op/Csf1op
(B6;C3Fe a/a-Csf1op/J)
|
impaired macrophage chemotaxis
|
J:147697
|
Csf1op/Csf1op Csf2tm1Ard/Csf2tm1Ard
(involves: 129P2/OlaHsd * C57BL/6)
|
interstitial pneumonia
|
J:19089
|
lung inflammation
|
J:19089
|
Csf1op/Csf1op Galctwi/Galctwi
(involves: C3HeB/Fe * C57BL/6J * CE/J)
|
impaired macrophage chemotaxis
|
J:170081
|
Csf1op/Csf1op Sh3bp2tm1Bjro/Sh3bp2tm1Bjro
(involves: 129S4/SvJae * BALB/cJ * C57BL/6J)
|
increased circulating tumor necrosis factor level
|
J:117880
|
liver inflammation
|
J:117880
|
Csf1tm1.1(CSF1)Flv/Csf1tm1.1(CSF1)Flv Csf2/Il3tm1.1(CSF2,IL3)Flv/Csf2/Il3tm1.1(CSF2,IL3)Flv Il2rgtm1.1Flv/Il2rgtm1.1Flv Rag2tm1.1Flv/Rag2tm1.1Flv Tg(SIRPA)1Flv/0 Thpotm1.1(TPO)Flv/Thpotm1.1(TPO)Flv
(involves: 129S4/SvJae * BALB/cAnNTac)
|
abnormal response to transplant
|
J:207289
|
Csf1tm1.1(CSF1)Flv/Csf1tm1.1(CSF1)Flv Csf2/Il3tm1.1(CSF2,IL3)Flv/Csf2/Il3tm1.1(CSF2,IL3)Flv Il2rgtm1.1Flv/Il2rgtm1.1Flv Rag2tm1.1Flv/Rag2tm1.1Flv Thpotm1.1(TPO)Flv/Thpotm1.1(TPO)Flv
(involves: 129S4/SvJae * BALB/cAnNTac)
|
abnormal response to transplant
|
J:207289
|
Csf1tm1.1(CSF1)Flv/Csf1tm1.1(CSF1)Flv Il2rgtm1.1Flv/Il2rgtm1.1Flv Csf2/Il3tm1.1(CSF2,IL3)Flv/Csf2/Il3tm1.1(CSF2,IL3)Flv Rag2tm1.1Flv/Rag2tm1.1Flv Tg(SIRPA)1Flv/0 Thpotm1.1(TPO)Flv/Thpotm1.1(TPO)Flv
(involves: 129S4/SvJae * BALB/cAnNTac)
|
abnormal response to transplant
|
J:207289
|
Csf1tm1.1(CSF1)Flv/Csf1tm1.1(CSF1)Flv Il2rgtm1.1Flv/Il2rgtm1.1Flv Csf2/Il3tm1.1(CSF2,IL3)Flv/Csf2/Il3tm1.1(CSF2,IL3)Flv Rag2tm1.1Flv/Rag2tm1.1Flv Thpotm1.1(TPO)Flv/Thpotm1.1(TPO)Flv
(involves: 129S4/SvJae * BALB/cAnNTac)
|
abnormal response to transplant
|
J:207289
|
Csf1tm1.1(CSF1)Flv/Csf1tm1.1(CSF1)Flv Il2rgtm1.1Flv/Il2rgtm1.1Flv Rag2tm1.1Flv/Rag2tm1.1Flv
(involves: 129P2/OlaHsd * 129S/SvEv * 129S4/SvJae * BALB/cAnNTac)
|
abnormal immune system physiology
|
J:177073
|
Csf1rtm1Ers/Csf1rtm1Ers
(involves: 129X1/SvJ * C3Heb/FeJ * C57BL/6J)
|
abnormal circulating cytokine level
|
J:73663
|
Csf1rtm1Ers/Csf1rtm1Ers
(FVB.129X1-Csf1rtm1Ers)
|
abnormal Langerhans cell physiology
|
J:112594
|
Csf2/Il3tm1.1(CSF2,IL3)Flv/Csf2/Il3tm1.1(CSF2,IL3)Flv Il2rgtm1.1Flv/Il2rgtm1.1Flv Rag2tm1.1Flv/Rag2tm1.1Flv
(involves: 129S4/SvJae * BALB/cAnNCr * BALB/cAnNTac)
|
abnormal response to transplant
|
J:168302
|
Csf2tm1Ard/Csf2tm1Ard
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal leukocyte physiology
|
J:86386
|
abnormal MHC II cell surface expression on macrophages
|
J:86386
|
impaired macrophage chemotaxis
|
J:86386
|
increased susceptibility to bacterial infection
|
J:18747,
J:53659
|
increased susceptibility to fungal infection
|
J:18747
|
increased susceptibility to parasitic infection
|
J:67766
|
lung inflammation
|
J:18747
|
Csf2tm1Dran/Csf2tm1Dran Ifngtm1Ts/Ifngtm1Ts Il3tm1Glli/Il3tm1Glli
(involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6)
|
increased IgE level
|
J:83086
|
increased IgG1 level
|
J:83086
|
increased immunoglobulin level
|
J:83086
|
increased inflammatory response
|
J:83086
|
Csf2tm1Dran/Csf2tm1Dran Il3tm1Glli/Il3tm1Glli
(B6.129S2-Csf2tm1Dran Il3tm1Glli)
|
abnormal leukocyte physiology
|
J:83086
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:67404
|
glomerulonephritis
|
J:83086
|
increased anti-double stranded DNA antibody level
|
J:83086
|
lung inflammation
|
J:67404
|
Csf2tm1Dran/Csf2tm1Dran Il3tm1Glli/Il3tm1Glli
(C.129S2-Csf2tm1Dran Il3tm1Glli)
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:67404
|
lung inflammation
|
J:67404
|
Csf2tm1Mlg/Csf2tm1Mlg
(involves: 129S2/SvPas)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:148120
|
Csf2raem1Szut/Csf2raem1Szut
(C57BL/6-Csf2raem1Szut)
|
impaired macrophage phagocytosis
|
J:322934
|
lung inflammation
|
J:322934
|
Csf2rbtm1Cgb/Csf2rbtm1Cgb
(involves: 129S1/Sv * C57BL/6)
|
lung inflammation
|
J:29737
|
Csf2rbtm1Clsc/Csf2rbtm1Clsc Csf2rb2tm1Cgb/Csf2rb2tm1Cgb
(C.129S1-Csf2rb2tm1Cgb Csf2rbtm1Clsc)
|
abnormal dendritic cell physiology
|
J:130939
|
abnormal interleukin secretion
|
J:130939
|
abnormal plasmacytoid dendritic cell physiology
|
J:130939
|
abnormal T cell activation
|
J:130939
|
abnormal T cell physiology
|
J:130939
|
decreased interleukin-4 secretion
|
J:130939
|
decreased interleukin-5 secretion
|
J:130939
|
decreased interleukin-13 secretion
|
J:130939
|
decreased susceptibility to type I hypersensitivity reaction
|
J:130939
|
decreased T cell proliferation
|
J:130939
|
impaired eosinophil recruitment
|
J:130939
|
increased IgG1 level
|
J:130939
|
Csf2rbtm1Mur/Csf2rbtm1Mur
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal eosinophil physiology
|
J:35829
|
lung inflammation
|
J:35829
|
Csf2rbtm1Mur/Csf2rbtm1Mur
(involves: 129P2/OlaHsd)
|
abnormal eosinophil physiology
|
J:24122
|
increased susceptibility to infection
|
J:24122
|
lung inflammation
|
J:24122
|
Csf2rbtm1Mur/Csf2rbtm1Mur Il3tm1Tyb/Il3tm1Tyb
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
|
abnormal eosinophil physiology
|
J:35829
|
lung inflammation
|
J:35829
|
Csf3tm1Ard/Csf3tm1Ard
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal neutrophil physiology
|
J:20400
|
increased susceptibility to bacterial infection
|
J:20400
|
Csf3tm1Ard/Csf3tm1Ard Junbtm3Wag/Junbtm3Wag Tg(KRT5-cre)1Tak/0
(involves: 129/Sv * 129P2/OlaHsd * C3H * C57BL/6)
|
increased susceptibility to systemic lupus erythematosus
|
J:155575
|
Csf3rtm1Link/Csf3rtm1Link
(involves: 129X1/SvJ)
|
impaired neutrophil chemotaxis
|
J:79825
|
Csf3rtm1Link/Csf3rtm1Link
(B6.129X1-Csf3rtm1Link)
|
impaired neutrophil chemotaxis
|
J:79567
|
Csf3rtm2Link/Csf3rtm2Link
(B6.129X1-Csf3rtm2Link)
|
abnormal neutrophil physiology
|
J:79567
|
Csf3rtm4(Epor)Link/Csf3rtm4(Epor)Link
(involves: 129X1/SvJ * C57BL/6)
|
impaired neutrophil chemotaxis
|
J:79825
|
Csf3rtm4(Epor)Link/Csf3rtm4(Epor)Link
(B6.129X1-Csf3rtm4(Epor)Link)
|
impaired neutrophil chemotaxis
|
J:79567
|
Csgalnact1tm1.1Migar/Csgalnact1tm1.1Migar
(involves: C57BL/6N * C57BL/6NCrlj * CBA/JNCrlj)
|
periodontium inflammation
|
J:269621
|
Csktm1Tara/Csktm2Tara Elanetm1(cre)Roes/Elane+
(involves: 129P2/OlaHsd * CB20 * C57BL/6)
|
abnormal granulocyte physiology
|
J:89716
|
increased acute inflammation
|
J:89716
|
increased susceptibility to bacterial infection
|
J:89716
|
Cspg4tm1Wbst/Cspg4tm1Wbst
(involves: 129S1/Sv * 129X1/SvJ)
|
abnormal macrophage physiology
|
J:184220
|
Cst7tm1.2Arte/Cst7tm1.2Arte
(involves: C57BL/6)
|
abnormal eosinophil physiology
|
J:258944
|
abnormal hypersensitivity reaction
|
J:258944
|
increased susceptibility to parasitic infection
|
J:258944
|
Cstbtm1Rm/Cstbtm1Rm
(either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))
|
increased incidence of corneal inflammation
|
J:50587
|
uveitis
|
J:50587
|
Ct55em1Xdzg/Ct55em1Xdzg
(involves: C57BL/6)
|
decreased susceptibility to induced colitis
|
J:280149
|
Ctc1tm1.1Schg/Ctc1tm1.1Schg
(involves: 129S7/SvEvBrd * C57BL/6)
|
decreased splenocyte proliferation
|
J:184809
|
ctl/ctl
(A/WySnJ-ctl/GrsrJ)
|
autoimmune arthritis
|
J:91389
|
Ctl1NZB/BlN/Ctl1C57BL/10
(involves: C57BL/10 * NZB/BlN)
|
abnormal T cell physiology
|
J:6736
|
Ctla4tm1All/Ctla4tm1All
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * NOD)
|
increased acute inflammation
|
J:109887
|
Ctla4tm1All/Ctla4tm1All Rag1tm1Mom/Rag1tm1Mom Tg(TcrAND)53Hed/0
(involves: 129S/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
abnormal T cell activation
|
J:119845
|
increased interleukin-4 secretion
|
J:119845
|
increased T cell proliferation
|
J:119845
|
Ctla4tm1All/Ctla4tm1All Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * NOD * SJL)
|
abnormal splenocyte physiology
|
J:109887
|
increased acute inflammation
|
J:109887
|
insulitis
|
J:109887
|
Ctla4tm1All/Ctla4tm1All Tg(TcrAND)53Hed/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
abnormal T cell activation
|
J:119845
|
Ctla4tm1All/Ctla4tm1All Tg(TcraTcrb)8Rest/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased interferon-gamma secretion
|
J:140448
|
Ctla4tm1Mak/Ctla4tm1Mak
(involves: 129P2/OlaHsd * BALB/c)
|
increased interferon-gamma secretion
|
J:140085
|
increased interleukin-2 secretion
|
J:140085
|
increased interleukin-4 secretion
|
J:140085
|
increased interleukin-17 secretion
|
J:140085
|
Ctla4tm1Saka/Ctla4tm1Saka Foxp3tm1(cre)Saka/Y
(involves: BALB/c)
|
abnormal immunoglobulin level
|
J:140085
|
abnormal regulatory T cell physiology
|
J:140085
|
increased autoantibody level
|
J:140085
|
increased IgE level
|
J:140085
|
increased IgG level
|
J:140085
|
increased inflammatory response
|
J:140085
|
increased interferon-gamma secretion
|
J:140085
|
increased interleukin-2 secretion
|
J:140085
|
increased interleukin-4 secretion
|
J:140085
|
lung inflammation
|
J:140085
|
myocarditis
|
J:140085
|
salivary gland inflammation
|
J:140085
|
stomach inflammation
|
J:140085
|
Ctla4tm1Shr/Ctla4tm1Shr
(either: (involves: 129S4/SvJae * BALB/c) or (involves: 129S4/SvJae * C57BL/6))
|
abnormal cytokine secretion
|
J:30393
|
increased T cell proliferation
|
J:30393
|
joint inflammation
|
J:30393
|
lung inflammation
|
J:30393
|
myocarditis
|
J:30393
|
pancreas inflammation
|
J:30393
|
salivary gland inflammation
|
J:30393
|
Ctla4tm1Shr/Ctla4tm1Shr
(B6.129S4-Ctla4tm1Shr)
|
abnormal regulatory T cell physiology
|
J:146644
|
abnormal T cell physiology
|
J:146644
|
autoimmune response
|
J:146644
|
Ctla4tm1Shr/Ctla4tm1Shr Rag2tm1Fwa/Rag2tm1Fwa Tg(DO11.10)10Dlo/0
(involves: 129S/Sv * BALB/c * C3H * C57BL/6)
|
abnormal cytokine secretion
|
J:110446
|
abnormal T cell physiology
|
J:110446
|
Ctla4tm1Shr/Ctla4tm1Shr Tg(DO11.10)10Dlo/0
(involves: 129S4/SvJae * BALB/c * C3H * C57BL/6)
|
abnormal T cell physiology
|
J:57090
|
increased T cell proliferation
|
J:57090
|
Ctnnb1tm1(Nfkbia)Rsu/Ctnnb1+
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal macrophage physiology
|
J:71744
|
conjunctivitis
|
J:71744
|
increased inflammatory response
|
J:71744
|
increased susceptibility to otitis media
|
J:71744
|
increased susceptibility to parasitic infection
|
J:71744
|
keratoconjunctivitis sicca
|
J:71744
|
Ctnnb1tm2(Nfkbia)Rsu/Ctnnb1+ Tg(CMV-cre)1Cgn/0
(involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)
|
abnormal macrophage physiology
|
J:71744
|
increased inflammatory response
|
J:71744
|
increased susceptibility to otitis media
|
J:71744
|
keratoconjunctivitis sicca
|
J:71744
|
Ctnnb1tm2Kem/Ctnnb1+ Ppargtm1.1(tTA)Jmgr/Pparg+ Tg(tetO-cre)1Jaw/0
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal osteoclast physiology
|
J:178340
|
Ctnnb1tm2Kem/Ctnnb1tm2Kem Ppargtm1.1(tTA)Jmgr/Pparg+ Tg(tetO-cre)1Jaw/0
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal osteoclast physiology
|
J:178340
|
Ctnnb1tm4Wbm/Ctnnb1tm4Wbm Tg(Pdx1-cre)6Tuv/0
(involves: 129P2/OlaHsd * FVB/N)
|
pancreas inflammation
|
J:119908
|
Ctps1tm1c(KOMP)Wtsi/Ctps1tm1c(KOMP)Wtsi Commd10Tg(Vav1-icre)A2Kio/0
(B6.Cg-Ctps1tm1c(KOMP)Wtsi Commd10Tg(Vav1-icre)A2Kio)
|
decreased T cell proliferation
|
J:348981
|
Ctps1tm1c(KOMP)Wtsi/Ctps1tm1c(KOMP)Wtsi Ctps2tm1c(EUCOMM)Hmgu/Ctps2+ Tg(Cd4-cre)1Cwi/0
(involves: 129S/Sv * C57BL/6 * DBA/2)
|
decreased T cell proliferation
|
J:348981
|
Ctps1tm1c(KOMP)Wtsi/Ctps1tm1c(KOMP)Wtsi Ctps2tm1c(EUCOMM)Hmgu/Ctps2tm1c(EUCOMM)Hmgu Tg(Cd4-cre)1Cwi/0
(involves: 129S/Sv * C57BL/6 * DBA/2)
|
decreased T cell proliferation
|
J:348981
|
Ctps1tm1c(KOMP)Wtsi/Ctps1tm1c(KOMP)Wtsi Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
(B6.Cg-Ctps1tm1c(KOMP)Wtsi Gt(ROSA)26Sortm1(cre/ERT2)Tyj)
|
abnormal thymus physiology
|
J:348981
|
decreased IgM level
|
J:348981
|
decreased T cell proliferation
|
J:348981
|
impaired humoral immune response
|
J:348981
|
Ctps1tm1c(KOMP)Wtsi/Ctps1tm1c(KOMP)Wtsi Tg(Cd4-cre)1Cwi/0
(involves: 129S/Sv * C57BL/6 * DBA/2)
|
decreased T cell proliferation
|
J:348981
|
Ctps1tm1c(KOMP)Wtsi/Ctps1tm1c(KOMP)Wtsi Tg(Cd4-cre)1Cwi/0 Foxp3sf/Y Rag1tm1Mom/Rag1+
(mixed)
|
decreased inflammatory response
|
J:348981
|
decreased T cell proliferation
|
J:348981
|
Ctps1tm1c(KOMP)Wtsi/Ctps1tm1c(KOMP)Wtsi Tg(Cd8a-cre)1Itan/0
(B6(129S4)-Ctps1tm1c(KOMP)Wtsi Tg(Cd8a-cre)1Itan)
|
decreased T cell proliferation
|
J:348981
|
Ctrb1em1Toth/Ctrb1em1Toth
(C57BL/6N-Ctrb1em1Toth)
|
increased susceptibility to induced pancreatitis
|
J:294171,
J:294035
|
Ctrcm1/Ctrcm1
(C57BL/6-Ctrcm1)
|
increased susceptibility to induced pancreatitis
|
J:291240
|
Ctrq1C3H/HeJ/Ctrq1C3H/HeJ
(involves: C3H/HeJ * C57BL/6J)
|
increased susceptibility to bacterial infection
|
J:106111
|
Ctrq2C3H/HeJ/Ctrq2C3H/HeJ
(involves: C3H/HeJ * C57BL/6J)
|
decreased susceptibility to bacterial infection
|
J:106111
|
Ctrq2C3H/HeJ/Ctrq2C57BL/6J
(involves: C3H/HeJ * C57BL/6J)
|
decreased susceptibility to bacterial infection
|
J:106111
|
Ctrq3C3H/HeJ/Ctrq3C3H/HeJ
(involves: C3H/HeJ * C57BL/6J)
|
increased susceptibility to bacterial infection
|
J:106111
|
Ctrq3C3H/HeJ/Ctrq3C57BL/6J
(involves: C3H/HeJ * C57BL/6J)
|
increased susceptibility to bacterial infection
|
J:106111
|
Ctsbtm1Jde/Ctsb+
(NOD.129P2-Ctsbtm1Jde)
|
decreased susceptibility to autoimmune diabetes
|
J:153355
|
insulitis
|
J:153355
|
Ctsbtm1Jde/Ctsbtm1Jde
(NOD.129P2-Ctsbtm1Jde)
|
decreased susceptibility to autoimmune diabetes
|
J:153355
|
insulitis
|
J:153355
|
salivary gland inflammation
|
J:153355
|
Ctsctm1Ley/Ctsctm1Ley
(either: 129X1/SvJ-Ctsctm1Ley or (involves: 129X1/SvJ * C57BL/6))
|
abnormal cytotoxic T cell physiology
|
J:77312
|
abnormal T cell physiology
|
J:77312
|
Ctsctm1Ley/Ctsctm1Ley
(B6.129X1-Ctsctm1Ley)
|
abnormal chemokine level
|
J:131520
|
abnormal leukocyte migration
|
J:131520
|
abnormal response to infection
|
J:131520
|
decreased circulating interleukin-6 level
|
J:131520
|
impaired neutrophil recruitment
|
J:131520
|
increased circulating interleukin-6 level
|
J:88160
|
sepsis
|
J:88160
|
Ctsdtm1Cptr/Ctsdtm1Cptr
(either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd))
|
abnormal antigen presentation
|
J:47432
|
CtseC57BL/6JOlaHsd/CtseC57BL/6JOlaHsd
(involves: 129S2/SvPasHsd * C57BL/6JOlaHsd)
|
abnormal dendritic cell antigen presentation
|
J:128538
|
abnormal dendritic cell physiology
|
J:128538
|
abnormal immune system physiology
|
J:128538
|
Ctsetm1Kjy/Ctse+
(involves: C57BL/6)
|
increased IgE level
|
J:108745
|
Ctsetm1Kjy/Ctsetm1Kjy
(involves: C57BL/6)
|
dermatitis
|
J:108745
|
increased circulating interleukin-1 beta level
|
J:108745
|
increased circulating interleukin-18 level
|
J:108745
|
increased IgE level
|
J:108745
|
increased interleukin-4 secretion
|
J:108745
|
increased interleukin-5 secretion
|
J:108745
|
Ctsgtm1.1Roes/Ctsgtm1.1Roes
(involves: 129P2/OlaHsd)
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:77597
|
increased susceptibility to infection induced morbidity/mortality
|
J:77597
|
Ctsgtm1.1Roes/Ctsgtm1.1Roes Elanetm1(cre)Roes/Elanetm1(cre)Roes
(involves: 129P2/OlaHsd)
|
decreased susceptibility to endotoxin shock
|
J:77597
|
increased susceptibility to fungal infection
|
J:77597
|
Ctsktm1(cre)Ska/Ctsk+ Esr1tm1Mma/Esr1tm1Mma
(involves: 129S2/SvPas * C57BL/6 * SJL)
|
abnormal osteoclast physiology
|
J:127179
|
Ctsktm1(cre)Ska/Ctsk+ Plekhm1tm1.1Hzhao/Plekhm1tm1.1Hzhao
(involves: C57BL/6J * C57BL/6NCrlj * CBA/JNCrlj)
|
abnormal osteoclast physiology
|
J:236517
|
Ctsktm1(cre)Ska/Ctsk+ Snx10tm1c(EUCOMM)Raba/Snx10tm1c(EUCOMM)Raba
(involves: 129S4/SvJae * C57BL/6 * C57BL/6J * C57BL/6NCrlj * CBA/JNCrlj)
|
abnormal osteoclast physiology
|
J:224711
|
Ctsktm1.1Rbar/Ctsktm1.1Rbar Tg(Mx1-cre)1Cgn/0
(involves: C57BL/6 * CBA)
|
abnormal osteoclast physiology
|
J:194492
|
Ctsktm1Mbs/Ctsktm1Mbs
(B6.129-Ctsktm1Mbs)
|
abnormal osteoclast physiology
|
J:128098
|
Ctsktm1Psa/Ctsktm1Psa
(involves: 129X1/SvJ * C57BL/6J)
|
abnormal osteoclast physiology
|
J:50934
|
Ctslnkt/Ctslnkt
(either: (involves: 129S2/SvPas * BALB/c) or (involves: 129S2/SvPas * C57BL/6) or (involves: 129S2/SvPas * DBA/2))
|
dermatitis
|
J:54856
|
increased inflammatory response
|
J:54856
|
liver inflammation
|
J:54856
|
lymph node inflammation
|
J:54856
|
Ctslnkt/Ctslnkt
(B6.Cg-Ctslnkt)
|
dermatitis
|
J:78460
|
Ctslnkt/Ctslnkt
(C.Cg-Ctslnkt)
|
dermatitis
|
J:78460
|
Ctsltm1Alpk/Ctsltm1Alpk
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal osteoclast physiology
|
J:99755
|
dermatitis
|
J:99755
|
folliculitis
|
J:99755
|
granulomatous inflammation
|
J:99755
|
Ctsltm1Alpk/Ctsltm1Alpk
(B6.129P2-Ctsltm1Alpk)
|
granulomatous inflammation
|
J:99755
|
Ctsltm1Cptr/Ctsl+
(NOD.129P2-Ctsltm1Cptr)
|
decreased susceptibility to autoimmune diabetes
|
J:153355
|
insulitis
|
J:153355
|
Ctsltm1Cptr/Ctsltm1Cptr
(NOD.129P2-Ctsltm1Cptr)
|
decreased susceptibility to autoimmune diabetes
|
J:153355
|
salivary gland inflammation
|
J:153355
|
Ctssm1Btlr/Ctssm1Btlr
(C57BL/6J-Ctssm1Btlr)
|
decreased IgG level
|
J:267491
|
impaired humoral immune response
|
J:267491
|
Ctsstm1Eae/Ctss+
(NOD.D1-Ctsstm1Eae)
|
insulitis
|
J:153355
|
Ctsstm1Eae/Ctsstm1Eae
(involves: C57BL/6 * DBA/1LacJ)
|
abnormal B lymphocyte antigen presentation
|
J:53399
|
decreased susceptibility to induced arthritis
|
J:53399
|
Ctsstm1Eae/Ctsstm1Eae
(NOD.D1-Ctsstm1Eae)
|
decreased susceptibility to autoimmune diabetes
|
J:153355
|
insulitis
|
J:153355
|
salivary gland inflammation
|
J:153355
|
Ctsstm1Hap/Ctsstm1Hap
(B6.129S2-Ctsstm1Hap)
|
abnormal B cell physiology
|
J:96401
|
abnormal cytokine secretion
|
J:96401
|
abnormal humoral immune response
|
J:96401
|
abnormal interleukin secretion
|
J:96401
|
abnormal professional antigen presenting cell physiology
|
J:96401
|
abnormal T cell physiology
|
J:96401
|
decreased IgG level
|
J:96401
|
decreased IgM level
|
J:96401
|
decreased susceptibility to experimental autoimmune myasthenia gravis
|
J:96401
|
Ctsstm1Hap/Ctsstm1Hap Ldlrtm1Her/Ldlrtm1Her
(B6.129S-Ctsstm1Hap Ldlrtm1Her)
|
abnormal leukocyte migration
|
J:82520
|
Cttntm1.2Dvst/Cttntm1.2Dvst
(either: B6.Cg-Cttntm1.2Dvst or (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * DBA/2 * SJL))
|
abnormal cellular extravasation
|
J:177602
|
abnormal leukocyte adhesion
|
J:177602
|
abnormal leukocyte migration
|
J:177602
|
abnormal neutrophil physiology
|
J:177602
|
Cuedc2tm1Qxia/Cuedc2tm1Qxia
(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NTac)
|
abnormal macrophage physiology
|
J:211782
|
increased macrophage cytokine production
|
J:211782
|
increased susceptibility to induced colitis
|
J:211782
|
Cul5tm1.1(KOMP)Vlcg/Cul5+
(involves: C57BL/6NTac)
|
decreased interleukin-1 alpha secretion
|
J:244502
|
decreased interleukin-6 secretion
|
J:244502
|
decreased tumor necrosis factor secretion
|
J:244502
|
Cux1tm1Rhsc/Cux1tm1Rhsc
(involves: 129S1/Sv * C57BL/6J)
|
abnormal tumor necrosis factor level
|
J:100055
|
Cux1tm2Ejn/Cux1tm2Ejn
(involves: 129S4/SvJae * C57BL/6)
|
increased susceptibility to bacterial infection
|
J:74660
|
rhinitis
|
J:74660
|
Cuzd1tm1Ljm/Cuzd1tm1Ljm
(involves: 129S6/SvEvTac * Black Swiss)
|
increased susceptibility to induced pancreatitis
|
J:80980
|
Cwc27tm1Lex/Cwc27tm1Lex
(B6;129S5-Cwc27tm1Lex/Mmucd)
|
abnormal immune system physiology
|
J:171883
|
Cx3cl1tm1.1Yono/Cx3cl1tm1.1Yono
(involves: C57BL/6J)
|
abnormal dendritic cell physiology
|
J:271242
|
decreased inflammatory response
|
J:271242
|
Cx3cl1tm1Sgs/Cx3cl1tm1Sgs Ldlrtm1Her/Ldlrtm1Her
(involves: B6.129S4-Cx3cl1tm1Sgs * B6.129S7-Ldlrtm1Her/J)
|
impaired macrophage chemotaxis
|
J:95279
|
Cx3cr1tm1Ifc/Cx3cr1tm1Ifc
(involves: 129S4/SvJae * C57BL/6)
|
abnormal NK cell physiology
|
J:82033
|
abnormal response to transplant
|
J:82033
|
impaired macrophage chemotaxis
|
J:82033
|
Cx3cr1tm1Litt/Cx3cr1+
(B6.129P2-Cx3cr1tm1Litt)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:129712
|
Cx3cr1tm1Litt/Cx3cr1+ Psen1tm1Mpm/Psen1tm1Mpm Tg(APPSwe,tauP301L)1Lfa/0 Tg(Thy1-YFP)HJrs/0
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)
|
abnormal microglial cell physiology
|
J:159680
|
Cx3cr1tm1Litt/Cx3cr1tm1Litt
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal leukocyte physiology
|
J:162714
|
impaired macrophage chemotaxis
|
J:162714
|
Cx3cr1tm1Litt/Cx3cr1tm1Litt
(involves: 129P2/OlaHsd)
|
abnormal dendritic cell physiology
|
J:271242,
J:95694
|
decreased inflammatory response
|
J:271242
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:95694
|
Cx3cr1tm1Litt/Cx3cr1tm1Litt
(B6.129P2-Cx3cr1tm1Litt)
|
abnormal leukocyte physiology
|
J:124722
|
abnormal microglial cell physiology
|
J:110266,
J:265696
|
abnormal NK cell physiology
|
J:129712
|
brain inflammation
|
J:129712
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:129712
|
Cx3cr1tm1Litt/Cx3cr1tm1Litt H2-Ab1b-tm1Hpl/H2-Ab1+
(involves: 129P2/OlaHsd * 129S4/SvJae)
|
abnormal response to infection
|
J:95694
|
Cx3cr1tm1Zm/Cx3cr1tm1Zm
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal splenocyte physiology
|
J:103047
|
Cx3cr1tm2.1(cre/ERT2)Litt/Cx3cr1+ Vps35Gt(RRK261)Byg/Vps35Gt(RRK261)Byg
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased interleukin-1 beta secretion
|
J:292365
|
decreased interleukin-6 secretion
|
J:292365
|
decreased tumor necrosis factor secretion
|
J:292365
|
increased interleukin-4 secretion
|
J:292365
|
increased interleukin-10 secretion
|
J:292365
|
Cx3cr1tm3(Hbegf)Litt/Cx3cr1tm3(Hbegf)Litt Tg(Itgax-cre)1-1Reiz/?
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
decreased susceptibility to bacterial infection
|
J:210086
|
Cxcl5tm1.1Mkch/Cxcl5tm1.1Mkch
(B6.129P2-Cxcl5tm1.1Mkch)
|
decreased interferon-alpha secretion
|
J:208901
|
decreased interleukin-1 alpha secretion
|
J:208901
|
decreased interleukin-6 secretion
|
J:208901
|
decreased susceptibility to bacterial infection
|
J:208901
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:208901
|
decreased tumor necrosis factor secretion
|
J:208901
|
Cxcl5tm1Gscw/Cxcl5tm1Gscw
(involves: 129)
|
abnormal circulating chemokine level
|
J:162629
|
abnormal neutrophil physiology
|
J:162629
|
decreased circulating interleukin-6 level
|
J:162629
|
decreased susceptibility to bacterial infection
|
J:162629
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:162629
|
decreased susceptibility to endotoxin shock
|
J:162629
|
Cxcl5tm1Gscw/Cxcl5tm1Gscw Ackr1tm1Scp/Ackr1tm1Scp
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6)
|
abnormal circulating chemokine level
|
J:162629
|
Cxcl9tm1Jmf/Cxcl9tm1Jmf
(either: B6.129S4-Cxcl9tm1Jmf or (involves: 129S4/SvJae * C57BL/6))
|
decreased IgG level
|
J:121818
|
decreased immunoglobulin level
|
J:121818
|
Cxcl9tm1Jmf/Cxcl9tm1Jmf
(B6.129S4-Cxcl9tm1Jmf)
|
abnormal cytokine secretion
|
J:120743
|
decreased inflammatory response
|
J:120743
|
Cxcl10tm1Adl/Cxcl10tm1Adl
(involves: 129S4/SvJae * 129X1/SvJ)
|
decreased IgG2a level
|
J:75584
|
decreased interferon-gamma secretion
|
J:75584
|
decreased splenocyte proliferation
|
J:75584
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:75584
|
Cxcl10tm1Adl/Cxcl10tm1Adl
(involves: 129S4/SvJae * C57BL/6)
|
abnormal interferon level
|
J:75584
|
abnormal T cell physiology
|
J:75584
|
increased susceptibility to Hepadnaviridae infection
|
J:75584
|
Cxcl10tm1Adl/Cxcl10tm1Adl
(B6.129S4-Cxcl10tm1Adl)
|
abnormal cytokine secretion
|
J:120743
|
CNS inflammation
|
J:87076
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:87076
|
increased susceptibility to Herpesvirales infection
|
J:120743
|
Cxcl12tm3.1(HBEGF/EGFP)Tng/Cxcl12+
(B6.Cg-Cxcl12tm3.1(HBEGF/EGFP)Tng)
|
increased B cell apoptosis
|
J:164657
|
Cxcl13tm1Cys/Cxcl13tm1Cys
(involves: 129X1/SvJ * C57BL/6)
|
abnormal B cell physiology
|
J:78282
|
Cxcl13tm1Cys/Cxcl13tm1Cys
(B6.129X1-Cxcl13tm1Cys)
|
impaired B cell migration
|
J:118931
|
Cxcl13tm1Mmi/Cxcl13tm1Mmi
(involves: C57BL/6)
|
abnormal B cell physiology
|
J:84804
|
abnormal leukocyte adhesion
|
J:84804
|
abnormal leukocyte migration
|
J:84804
|
Cxcl15tm1Lira/Cxcl15tm1Lira
(involves: 129 * C57BL/6J)
|
increased susceptibility to bacterial infection
|
J:67605
|
Cxcl16tm1Syon/Cxcl16tm1Syon
(B6.129P2-Cxcl16tm1Syon)
|
decreased circulating interferon-gamma level
|
J:155199
|
decreased circulating interleukin-4 level
|
J:155199
|
decreased interferon-gamma secretion
|
J:155199
|
decreased interleukin-4 secretion
|
J:155199
|
decreased susceptibility to bacterial infection
|
J:155199
|
Cxcr2tm1a(EUCOMM)Wtsi/Cxcr2tm1a(EUCOMM)Wtsi
(C57BL/6N-Cxcr2tm1a(EUCOMM)Wtsi/Wtsi)
|
increased anti-nuclear antigen antibody level
|
J:211773
|
Cxcr2tm1Mwm/Cxcr2+
(C.129S2(B6)-Cxcr2tm1Mwm/J)
|
impaired neutrophil recruitment
|
J:63935
|
Cxcr2tm1Mwm/Cxcr2tm1Mwm
(involves: 129S2/SvPas * C57BL/6J)
|
impaired neutrophil chemotaxis
|
J:19570
|
increased circulating interleukin-6 level
|
J:19570
|
Cxcr2tm1Mwm/Cxcr2tm1Mwm
(C.129S2(B6)-Cxcr2tm1Mwm/J)
|
abnormal chemokine level
|
J:73947
|
abnormal cytokine secretion
|
J:72824
|
abnormal eosinophil physiology
|
J:73947
|
abnormal interleukin level
|
J:73947,
J:87365
|
abnormal leukocyte physiology
|
J:94170
|
abnormal neutrophil physiology
|
J:93946,
J:73947
|
abnormal NK T cell physiology
|
J:66399
|
abnormal T cell physiology
|
J:73947
|
abnormal T-helper 1 physiology
|
J:73947
|
abnormal T-helper 2 physiology
|
J:73947
|
decreased susceptibility to fungal infection
|
J:73947
|
decreased susceptibility to induced arthritis
|
J:142880
|
impaired neutrophil chemotaxis
|
J:65905,
J:72824
|
impaired neutrophil recruitment
|
J:65425,
J:63935,
J:93116
|
increased IgE level
|
J:73947
|
increased susceptibility to bacterial infection
|
J:65905
|
increased susceptibility to Herpesvirales infection
|
J:87365
|
increased susceptibility to parasitic infection
|
J:72824
|
Cxcr2tm1Mwm/Cxcr2tm1Mwm
(involves: 129S2/SvPas * BALB/c)
|
abnormal neutrophil physiology
|
J:113489
|
Cxcr2tm1Mwm/Cxcr2tm1Mwm
(involves: 129S2/SvPas)
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:208901
|
Cxcr2tm1Rmra/Cxcr2tm1Rmra Tg(Mx1-cre)1Cgn/0
(involves: 129S/SvEv * C57BL/6 * C57BL/6NTac * CBA)
|
abnormal neutrophil physiology
|
J:204482
|
Cxcr3tm1Raks/Cxcr3tm1Raks
(B6.129P2-Cxcr3tm1Raks)
|
kidney inflammation
|
J:152790
|
Cxcr3tm1Wwh/Y
(B6.Cg-Cxcr3tm1Wwh)
|
abnormal cellular extravasation
|
J:107646
|
abnormal interferon level
|
J:91359
|
impaired macrophage chemotaxis
|
J:107646
|
increased length of allograft survival
|
J:65916
|
lung inflammation
|
J:91359
|
Cxcr3tm1Wwh/Cxcr3tm1Wwh
(B6.Cg-Cxcr3tm1Wwh)
|
abnormal cellular extravasation
|
J:96905,
J:107646
|
abnormal interferon level
|
J:91359
|
decreased susceptibility to Riboviria infection
|
J:96905
|
decreased susceptibility to Riboviria infection induced morbidity/mortality
|
J:96905
|
impaired macrophage chemotaxis
|
J:107646
|
increased length of allograft survival
|
J:65916
|
lung inflammation
|
J:91359
|
Cxcr4tm1.1Bala/Cxcr4+
(B6.129S2-Cxcr4tm1.1Bala)
|
abnormal immune system physiology
|
J:186735
|
abnormal NK cell physiology
|
J:178789
|
decreased B cell apoptosis
|
J:186735
|
increased IgG level
|
J:186735
|
increased IgM level
|
J:186735
|
increased immunoglobulin level
|
J:186735
|
Cxcr4tm1Qma/Cxcr4tm1Qma
(involves: 129X1/SvJ * C57BL/6)
|
decreased susceptibility to Retroviridae infection
|
J:132342
|
increased susceptibility to Retroviridae infection induced morbidity/mortality
|
J:132342
|
Cxcr4tm1Yiw/Cxcr4tm1Yiw Tg(Lck-cre)1Jtak/0
(involves: 129P2/OlaHsd)
|
abnormal leukocyte migration
|
J:164872
|
decreased susceptibility to induced arthritis
|
J:164872
|
Cxcr4tm1Yzo/Cxcr4tm1Yzo
(Not Specified)
|
abnormal B cell physiology
|
J:167314
|
Cxcr4tm2Yzo/Cxcr4tm2Yzo Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd)
|
decreased immunoglobulin level
|
J:94911
|
Cxcr4tm3.1Yzo/Cxcr4tm3.1Yzo
(Not Specified)
|
abnormal B cell physiology
|
J:167314
|
Cxcr5tm1.1Namt/Cxcr5tm1.1Namt Tg(Itgax-cre)1-1Reiz/0
(involves: C57BL/6 * C57BL/6J * CBA)
|
abnormal dendritic cell chemotaxis
|
J:241561
|
decreased susceptibility to prion infection
|
J:241561
|
Cxcr5tm1.1Namt/Cxcr5tm1.1Namt Tg(Itgax-cre)1-1Reiz/0 Tg(Prnp)a20Cwe/0
(involves: C57BL/6 * C57BL/6J * CBA)
|
decreased susceptibility to prion infection
|
J:241561
|
Cxcr5tm1Lipp/Cxcr5tm1Lipp
(involves: 129S2/SvPas * CD-1)
|
abnormal leukocyte migration
|
J:37126
|
Cxv1F/St/Cxv1F/St
(involves: AKR/J * F/St)
|
abnormal immune cell physiology
|
J:7030
|
Cxv2DBA/2J/?
(involves: C57BL/6J * DBA/2J)
|
abnormal immune cell physiology
|
J:6143
|
Cybanmf333/Cybanmf333
(A.B6 Tyr+-Cybanmf333/J)
|
abnormal neutrophil physiology
|
J:132359
|
increased inflammatory response
|
J:132359
|
increased susceptibility to bacterial infection
|
J:132359
|
lung inflammation
|
J:132359
|
sepsis
|
J:132359
|
Cybatm1Dgh/Cybatm1Dgh
(B6.Cg-Cybatm1Dgh)
|
abnormal T cell activation
|
J:231269
|
decreased inflammatory response
|
J:231269
|
Cybbtm1.1Abk/Cybbtm1.1Abk Lyz2tm1(cre)Ifo/?
(B6.Cg-Lyz2tm1(cre)Ifo Cybbtm1.1Abk)
|
abnormal macrophage chemotaxis
|
J:245699
|
Cybbtm1Din/Y
(involves: 129S/SvEv * C57BL/6)
|
abnormal immune system physiology
|
J:22868
|
abnormal macrophage physiology
|
J:22868
|
abnormal neutrophil physiology
|
J:22868
|
increased inflammatory response
|
J:22868
|
increased susceptibility to bacterial infection
|
J:22868
|
increased susceptibility to infection
|
J:22868
|
Cybbtm1Din/Cybbtm1Din
(B6.129S-Cybbtm1Din)
|
granulomatous inflammation
|
J:146231
|
increased acute inflammation
|
J:110181
|
Cybbtm1Din/Cybbtm1Din
(B6.129S-Cybbtm1Din/J)
|
abnormal circulating chemokine level
|
J:235399
|
abnormal macrophage physiology
|
J:235399
|
decreased circulating interleukin-10 level
|
J:235399
|
glomerulonephritis
|
J:235399
|
increased anti-double stranded DNA antibody level
|
J:235399
|
increased anti-nuclear antigen antibody level
|
J:235399
|
increased autoantibody level
|
J:235399
|
increased circulating interleukin-1 beta level
|
J:235399
|
increased circulating interleukin-6 level
|
J:235399
|
increased circulating interleukin-12b level
|
J:235399
|
increased IgG level
|
J:235399
|
increased susceptibility to systemic lupus erythematosus
|
J:235399
|
Cyldtm1.1Awai/Cyldtm1.1Awai
(Not Specified)
|
abnormal B cell physiology
|
J:126113
|
abnormal class switch recombination
|
J:126113
|
abnormal humoral immune response
|
J:126113
|
decreased IgG3 level
|
J:126113
|
decreased IgM level
|
J:126113
|
increased IgA level
|
J:126113
|
increased IgG1 level
|
J:126113
|
increased IgG2a level
|
J:126113
|
increased IgG2b level
|
J:126113
|
Cyldtm1.1Mpa/Cyldtm1.1Mpa Faddtm1Mpa/Faddtm1Mpa Tg(Vil1-cre)997Gum/0
(B6.Cg-Faddtm1Mpa Cyldtm1.1Mpa Tg(Vil1-cre)997Gum)
|
cecum inflammation
|
J:175865
|
Cyldtm1.1Mpa/Cyldtm1.1Mpa Ikbkgtm1.1Mpa/Y Tg(Vil1-cre)997Gum/0
(B6.Cg-Cyldtm1.1Mpa Ikbkgtm1.1Mpa Tg(Vil1-cre)997Gum)
|
colitis
|
J:175865
|
Cyldtm1.1Mpa/Cyldtm1.1Mpa Ikbkgtm1.1Mpa/Ikbkgtm1.1Mpa Tg(Vil1-cre)997Gum/0
(B6.Cg-Cyldtm1.1Mpa Ikbkgtm1.1Mpa Tg(Vil1-cre)997Gum)
|
colitis
|
J:175865
|
Cyldtm1Jdgl/Cyldtm1Jdgl
(involves: 129 * C57BL/6J)
|
decreased susceptibility to bacterial infection
|
J:124327
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:124327
|
Cyldtm1Lex/Cyldtm1Lex
(involves: 129S5/SvEvBrd * C57BL/6)
|
abnormal inflammatory response
|
J:114972
|
increased susceptibility to induced colitis
|
J:114972
|
Cyp2c70em1Sjka/Cyp2c70em1Sjka
(C57BL/6-Cyp2c70em1Sjka)
|
liver inflammation
|
J:330641
|
Cyp2c70em1Utr/Cyp2c70em1Utr
(C57BL/6J-Cyp2c70em1Utr)
|
liver inflammation
|
J:302190
|
Cyp2ctm1104Arte/Cyp2ctm1104Arte
(B6NTac(Cg)-Cyp2ctm1104Arte/Arte)
|
liver inflammation
|
J:241121
|
Cyp2ctm1897.1(Alb-CYP2C9)Arte/Cyp2ctm1897.1(Alb-CYP2C9)Arte
(B6(Cg)-Cyp2ctm1897.1(Alb-CYP2C9)Arte/Arte)
|
liver inflammation
|
J:241121
|
Cyp2g1tm1(rtTA)Lane/Cyp2g1+ Tg(SFTPC-rtTA,tetO-Tnf)320-1Gwho/0
(involves: 129 * C57BL/6 * SJL)
|
rhinitis
|
J:157842
|
Cyp4v3em1Xsu/Cyp4v3em1Xsu
(C57BL/6J-Cyp4v3em1Xsu)
|
increased microglial cell activation
|
J:321817
|
Cyp7b1tm1Rus/Cyp7b1tm1Rus
(involves: 129S/SvEv * C57BL/6J)
|
decreased IgA level
|
J:170807
|
Cyp11a1tm2Bcc/Cyp11a1tm2Bcc
(Not Specified)
|
decreased T cell apoptosis
|
J:133007
|
Cyp19a1tm1Esi/Cyp19a1tm1Esi
(involves: 129S6/SvEvTac * C57BL/6)
|
increased autoantibody level
|
J:92438
|
increased IgG level
|
J:92438
|
kidney inflammation
|
J:92438
|
salivary gland inflammation
|
J:92438
|
Cyp19a1tm1Sih/Cyp19a1tm1Sih
(involves: 129S/SvEv)
|
increased anti-single stranded DNA antibody level
|
J:216958
|
increased autoantibody level
|
J:216958
|
increased susceptibility to autoimmune disorder
|
J:216958
|
lacrimal gland inflammation
|
J:216958
|
salivary gland inflammation
|
J:216958
|
Cypr1STS/A/?
(involves: BALB/c * STS/A)
|
abnormal cytokine secretion
|
J:52119
|
Cypr2BALB/c/?
(involves: BALB/c * STS/A)
|
abnormal cytokine secretion
|
J:52119
|
Cypr3BALB/c/?
(involves: BALB/c * STS/A)
|
abnormal cytokine secretion
|
J:52119
|
Cyrenem1Vokh/Cyrenem1Vokh
(C57BL/6-Cyrenem1Vokh)
|
abnormal class switch recombination
|
J:306598
|
Cyrentm1.1(KOMP)Vlcg/Cyrentm1.1(KOMP)Vlcg
(involves: C57BL/6NTac)
|
abnormal class switch recombination
|
J:265834
|
Cyribm1Ivdi/Cyribm1Ivdi
(involves: 129S1/Sv * 129X1/SvJ * DBA/2J)
|
increased circulating interleukin-6 level
|
J:282597
|
increased circulating interleukin-10 level
|
J:282597
|
increased circulating tumor necrosis factor level
|
J:282597
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:282597
|
Cyribtm1c(KOMP)Wtsi/Cyribtm1d(KOMP)Wtsi Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * BcA17/Skmn * C57BL/6N)
|
abnormal circulating chemokine level
|
J:282597
|
abnormal neutrophil physiology
|
J:282597
|
increased circulating CXCL10 level
|
J:282597
|
increased circulating interleukin-6 level
|
J:282597
|
increased circulating interleukin-10 level
|
J:282597
|
increased circulating tumor necrosis factor level
|
J:282597
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:282597
|
Cys1cpk/Cys1cpk
(129.B6-Cys1cpk)
|
liver inflammation
|
J:116210
|
Cysltr1tm1Ykn/Cysltr1tm1Ykn
(involves: C57BL/6)
|
decreased susceptibility to type I hypersensitivity reaction
|
J:77087
|
respiratory system inflammation
|
J:88647
|
Cysltr1tm1Ykn/Cysltr1tm1Ykn Cysltr2tm1Ykn/Cysltr2tm1Ykn
(involves: BALB/c * C57BL/6)
|
abnormal immune system physiology
|
J:198383
|
Cysltr1tm1Ykn/Cysltr1tm1Ykn Cysltr2tm1Ykn/Cysltr2tm1Ykn Oxgr1tm1(KOMP)Vlcg/Oxgr1tm1(KOMP)Vlcg
(involves: BALB/c * C57BL/6 * C57BL/6NTac)
|
abnormal immune system physiology
|
J:198383
|
Cysltr2tm1Ykn/Cysltr2tm1Ykn
(C57BL/6-Cysltr2tm1Ykn)
|
decreased susceptibility to type I hypersensitivity reaction
|
J:94488
|
Cysltr2tm1Ykn/Cysltr2tm1Ykn
(C.B6-Cysltr2tm1Ykn)
|
autoimmune response
|
J:182213
|
Cyth2tm1d(EUCOMM)Wtsi/Cyth2tm1d(EUCOMM)Wtsi
(involves: C57BL/6N)
|
decreased susceptibility to type I hypersensitivity reaction
|
J:307633
|
Cytiptm1Tes/Cytiptm1Tes
(involves: 129S1/Sv * FVB/N)
|
abnormal cellular extravasation
|
J:110320
|
abnormal leukocyte migration
|
J:110320
|
Cytiptm1Wtw/Cytiptm1Wtw
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal response to transplant
|
J:112168
|
Cytl1tm1Chun/Cytl1tm1Chun
(involves: 129S4/SvJae * C57BL/6)
|
increased susceptibility to induced arthritis
|
J:175377
|
Dapp1Gt(OST111213)Lex/Dapp1Gt(OST111213)Lex
(B6.Cg-Dapp1Gt(OST111213)Lex)
|
abnormal humoral immune response
|
J:110009
|
decreased B cell proliferation
|
J:110009
|
decreased IgG3 level
|
J:110009
|
increased susceptibility to bacterial infection
|
J:110009
|
Dapp1tm1Mnz/Dapp1tm1Mnz
(B6.129P2-Dapp1tm1Mnz)
|
abnormal B cell activation
|
J:86182
|
decreased B cell proliferation
|
J:86182
|
decreased IgG3 level
|
J:86182
|
decreased IgM level
|
J:86182
|
DbaclC57BL/6Jcl/DbaclC57BL/6Jcl
(NOD.B6-(D4Mit193-D4Mit17))
|
increased susceptibility to autoimmune diabetes
|
J:144964
|
insulitis
|
J:144964
|
DbnlGt(betageo)11Byg/DbnlGt(betageo)11Byg
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal T cell activation
|
J:119847
|
abnormal T cell physiology
|
J:119847
|
decreased IgG1 level
|
J:119847
|
decreased IgM level
|
J:119847
|
decreased immunoglobulin level
|
J:119847
|
decreased interleukin-2 secretion
|
J:119847
|
decreased T cell proliferation
|
J:119847
|
Dbr1Gt(YTA280)Byg/Dbr1+
(involves: 129P2/OlaHsd)
|
abnormal class switch recombination
|
J:223318
|
Dcbld2tm1a(KOMP)Wtsi/Dcbld2tm1a(KOMP)Wtsi
(C57BL/6N-Dcbld2tm1a(KOMP)Wtsi/Wtsi)
|
increased anti-nuclear antigen antibody level
|
J:211773
|
Dckm1Btlr/Dckm1Btlr
(C57BL/6J-Dckm1Btlr)
|
decreased IgG level
|
J:236696
|
decreased response to antigen
|
J:236696
|
increased IgE level
|
J:236696
|
Dckmemi/Dckmemi
(C57BL/6J-Dckmemi)
|
abnormal response to infection
|
J:184080
|
increased T cell apoptosis
|
J:184080
|
increased T cell proliferation
|
J:184080
|
Dclk1tm1a(EUCOMM)Wtsi/Dclk1+
(C57BL/6N-Dclk1tm1a(EUCOMM)Wtsi/Wtsi)
|
increased anti-nuclear antigen antibody level
|
J:211773
|
Dclk1tm1a(EUCOMM)Wtsi/Dclk1tm1a(EUCOMM)Wtsi
(C57BL/6N-Dclk1tm1a(EUCOMM)Wtsi/Wtsi)
|
increased anti-nuclear antigen antibody level
|
J:211773
|
Dclre1atm1Rleg/Dclre1atm1Rleg
(involves: 129S7/SvEvBrd)
|
increased susceptibility to bacterial infection
|
J:102381
|
Dclre1cm1Btlr/Dclre1cm1Btlr
(C57BL/6J-Dclre1cm1Btlr)
|
decreased IgM level
|
J:217790
|
decreased response to antigen
|
J:217790
|
impaired humoral immune response
|
J:217790
|
Dclre1ctm2.1Jpdv/Dclre1ctm2.2Jpdv Tg(Cr2-cre)3Cgn/0
(involves: 129S2/SvPas * C57BL/6)
|
abnormal class switch recombination
|
J:153841
|
Dclre1ctm2Mcow/Dclre1ctm2Mcow
(involves: 129/Sv * C57BL/6)
|
abnormal leukocyte physiology
|
J:96535
|
decreased B cell proliferation
|
J:96535
|
decreased T cell proliferation
|
J:96535
|
Dcntm1Ioz/Dcn+
(either: C.Cg-Dcntm1Ioz or C3.Cg-Dcntm1Ioz)
|
decreased susceptibility to bacterial infection
|
J:68640
|
Dcntm1Ioz/Dcntm1Ioz
(involves: 129S1/Sv * 129X1/SvJ * Black Swiss)
|
tubular nephritis
|
J:75298
|
Dcntm1Ioz/Dcntm1Ioz
(either: C.Cg-Dcntm1Ioz or C3.Cg-Dcntm1Ioz)
|
decreased susceptibility to bacterial infection
|
J:68640
|
Dcntm1Ioz/Dcntm1Ioz
(C.129(Cg)-Dcntm1Ioz)
|
abnormal humoral immune response
|
J:92428
|
Dcstamptm1Suda/Dcstamptm1Suda
(Not Specified)
|
abnormal macrophage physiology
|
J:100555
|
abnormal osteoclast physiology
|
J:100555
|
Ddctm1.1Rhrs/Ddctm1.1Rhrs Tg(Ggt1-cre)M3Egn/0
(involves: 129 * C57BL/6 * SJL)
|
tubulointerstitial nephritis
|
J:175630
|
Ddctm1.1Rhrs/Ddctm1.1Rhrs Tg(Ggt1-cre)M3Egn/0
(129.Cg-Ddctm1.1Rhrs Tg(Ggt1-cre)M3Egn)
|
tubulointerstitial nephritis
|
J:175630
|
Ddit3tm1Dron/Ddit3tm1Dron
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
decreased susceptibility to Retroviridae infection
|
J:112354
|
Ddit3tm1Dron/Ddit3tm1Dron
(B6.129-Ddit3tm1Dron)
|
abnormal macrophage activation involved in immune response
|
J:153833
|
decreased macrophage apoptosis
|
J:153833
|
Ddit3tm1Dron/Ddit3tm1Dron Tg(Col2a1-rtTA,tetO-COMP*)2Jath/0
(involves: 129X1/SvJ * 129S1/Sv * C57BL/6)
|
decreased inflammatory response
|
J:233238
|
Ddit3tm2.1Dron/Ddit3tm2.1Dron
(B6.129S(Cg)-Ddit3tm2.1Dron/J)
|
white adipose tissue inflammation
|
J:214136
|
Ddx19bem1Chaw/Ddx19b+
(C57BL/6-Ddx19bem1Chaw)
|
increased interferon-alpha secretion
|
J:289833
|
increased interferon-beta secretion
|
J:289833
|
Ddx41tm1.1Arte/Ddx41tm1.1Arte Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * C57BL/6N)
|
increased susceptibility to Retroviridae infection
|
J:265023
|
Ddx41tm1.1Arte/Ddx41tm1.1Arte Tg(Itgax-cre)1-1Reiz/0
(involves: C57BL/6 * C57BL/6N * CBA)
|
increased susceptibility to Retroviridae infection
|
J:265023
|
Ddx46em1Caox/Ddx46+
(involves: C57BL/6J)
|
abnormal innate immunity
|
J:271836
|
abnormal macrophage physiology
|
J:271836
|
decreased susceptibility to Riboviria infection
|
J:271836
|
increased circulating interferon-beta level
|
J:271836
|
increased interferon-beta secretion
|
J:271836
|
increased interleukin-1 beta secretion
|
J:271836
|
increased interleukin-6 secretion
|
J:271836
|
increased macrophage cytokine production
|
J:271836
|
increased tumor necrosis factor secretion
|
J:271836
|
Ddx60tm1b(EUCOMM)Wtsi/Ddx60tm1b(EUCOMM)Wtsi
(involves: C57BL/6N)
|
decreased circulating interferon-beta level
|
J:228452
|
increased circulating interferon-alpha level
|
J:228452
|
increased susceptibility to Riboviria infection
|
J:228452
|
increased susceptibility to Riboviria infection induced morbidity/mortality
|
J:228452
|
Ddx60tm1b(EUCOMM)Wtsi/Ddx60tm1b(EUCOMM)Wtsi Mavstm1Tsse/Mavstm1Tsse
(involves: 129 * C57BL/6N)
|
increased susceptibility to Riboviria infection induced morbidity/mortality
|
J:228452
|
Def6Gt(OST307148)Lex/Def6Gt(OST307148)Lex
(involves: 129S5/SvEvBrd * C57BL/6)
|
abnormal cytokine secretion
|
J:106469
|
decreased T cell apoptosis
|
J:106469
|
increased anti-nuclear antigen antibody level
|
J:106469
|
increased IgG level
|
J:106469
|
increased immunoglobulin level
|
J:106469
|
Defb1tm1Jmw/Defb1+
(B6.129S5-Defb1tm1Jmw)
|
increased susceptibility to bacterial infection
|
J:76529
|
Defb1tm1Jmw/Defb1tm1Jmw
(B6.129S5-Defb1tm1Jmw)
|
increased susceptibility to bacterial infection
|
J:76529
|
Defb3tm1Lex/Defb3tm1Lex
(B6;129S5-Defb3tm1Lex/Mmucd)
|
increased susceptibility to bacterial infection
|
J:168725
|
Defb3tm1Xen/Defb3tm1Xen
(involves: C57BL/6)
|
increased incidence of corneal inflammation
|
J:199719
|
increased susceptibility to fungal infection
|
J:199719
|
Del(1Aim2-Ifi205)1Stsn/+ Trex1tm1Tld/Trex1tm1Tld
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6N)
|
heart inflammation
|
J:234263
|
increased autoantibody level
|
J:234263
|
increased inflammatory response
|
J:234263
|
kidney inflammation
|
J:234263
|
myositis
|
J:234263
|
stomach inflammation
|
J:234263
|
Del(1Aim2-Ifi205)1Stsn/Del(1Aim2-Ifi205)1Stsn
(B6(129S4)-Del(1Aim2-Ifi205)1Stsn)
|
abnormal interferon secretion
|
J:234263
|
decreased interleukin-1 beta secretion
|
J:234263
|
decreased macrophage apoptosis
|
J:234263
|
Del(1Aim2-Ifi205)1Stsn/Del(1Aim2-Ifi205)1Stsn
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6N)
|
stomach inflammation
|
J:234263
|
Del(1Aim2-Ifi205)1Stsn/Del(1Aim2-Ifi205)1Stsn Trex1tm1Tld/Trex1tm1Tld
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6N)
|
heart inflammation
|
J:234263
|
increased autoantibody level
|
J:234263
|
increased inflammatory response
|
J:234263
|
kidney inflammation
|
J:234263
|
myositis
|
J:234263
|
stomach inflammation
|
J:234263
|
Del(3Cd1d2-Cd1d1)1Crw/Del(3Cd1d2-Cd1d1)1Crw
(involves: 129S4/SvJae * C57BL/6)
|
abnormal antigen presentation
|
J:174337
|
abnormal NK T cell physiology
|
J:112657
|
decreased interleukin-4 secretion
|
J:39749
|
Del(3Cd1d2-Cd1d1)1Crw/Del(3Cd1d2-Cd1d1)1Crw Tg(TcraAV19AJ33)1Shima/0
(involves: 129S4/SvJae * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:112657
|
increased interleukin-10 secretion
|
J:112657
|
Del(3Cd1d2-Cd1d1)1Sbp/Del(3Cd1d2-Cd1d1)1Sbp
(either: B6NTac.129S6-Del(3Cd1d2-Cd1d1)1Sbp or (involves: 129S6/SvEvTac * C57BL/6NTac))
|
abnormal immune tolerance
|
J:58315
|
Del(3Cd1d2-Cd1d1)1Sbp/Del(3Cd1d2-Cd1d1)1Sbp
(involves: 129S6/SvEvTac)
|
abnormal dendritic cell antigen presentation
|
J:151699
|
Del(3Gbp2-ps-Gbp5)1Ktak/Del(3Gbp2-ps-Gbp5)1Ktak
(involves: C57BL/6)
|
increased susceptibility to parasitic infection
|
J:187397
|
increased susceptibility to parasitic infection induced morbidity/mortality
|
J:187397
|
Del(6Ephb6-Trpv6)1Mhed/+
(involves: 129S/SvEv)
|
dermatitis
|
J:133151
|
Del(6Ephb6-Trpv6)1Mhed/Del(6Ephb6-Trpv6)1Mhed
(involves: 129S/SvEv)
|
dermatitis
|
J:133151
|
Del(6Gimap5-Gimap3)1Yout/Del(6Gimap5-Gimap3)1Yout
(involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj)
|
abnormal T cell physiology
|
J:209926
|
Del(6Snca)1Slab/Del(6Snca)1Slab Tg(Th-SNCA*)1Mgsp/0
(involves: C57BL/6J * C57BL/6JOlaHsd * CBA/Ca)
|
brain inflammation
|
J:108310
|
Del(7Mrgpra2a-Mrgpra2b)1Xzd/Del(7Mrgpra2a-Mrgpra2b)1Xzd
(C57BL/6J-Del(7Mrgpra2a-Mrgpra2b)1Xzd)
|
abnormal neutrophil physiology
|
J:332494
|
decreased interleukin-1 beta secretion
|
J:332494
|
increased susceptibility to bacterial infection
|
J:332494
|
Del(7Pira1-Lilra6)1Fgla/Del(7Pira1-Lilra6)1Fgla
(involves: C57BL/6)
|
decreased susceptibility to graft versus host disease
|
J:290663
|
Del(7Pira1-Lilra6)1Fgla/Del(7Pira1-Lilra6)1Fgla Il2rgtm1Wjl/Il2rgtm1Wjl Rag2tm1Fwa/Rag2tm1Fwa
(involves: C57BL/6J * C57BL/6NTac)
|
abnormal response to transplant
|
J:290663
|
Del(8Ddx19a-Ddx19b)1Chaw/+
(C57BL/6-Del(8Ddx19a-Ddx19b)1Chaw)
|
decreased susceptibility to Picornaviridae infection
|
J:289833
|
decreased susceptibility to Picornaviridae infection induced morbidity/mortality
|
J:289833
|
increased interferon-alpha secretion
|
J:289833
|
increased interferon-beta secretion
|
J:289833
|
Del(8Ddx19a-Ddx19b)2Chaw/+
(C57BL/6-Del(8Ddx19a-Ddx19b)2Chaw)
|
increased interferon-alpha secretion
|
J:289833
|
increased interferon-beta secretion
|
J:289833
|
Del(8Defa1-Def)2Xzd/Del(8Defa1-Def)2Xzd Tg(KRT14-cre)1Amc/0
(involves: C57BL/6J * CBA)
|
increased susceptibility to bacterial infection
|
J:332494
|
Del(9Casp1-Casp4)1Bhk/Del(9Casp1-Casp4)1Bhk
(129-Del(9Casp1-Casp4)1Bhk)
|
abnormal macrophage physiology
|
J:189777
|
decreased interleukin-1 alpha secretion
|
J:189777
|
decreased interleukin-1 beta secretion
|
J:189777
|
Del(9Hspb2-Cryab)1Wawr/Del(9Hspb2-Cryab)1Wawr
(involves: 129S4/SvJae)
|
osteoarthritis
|
J:72926
|
Del(10Prmt2-Col6a1)1Yah/+
(involves: 129P2/OlaHsd * C57BL/6 * SJL)
|
abnormal cytokine level
|
J:167506
|
abnormal macrophage physiology
|
J:167506
|
lung inflammation
|
J:167506
|
respiratory system inflammation
|
J:167506
|
Del(10Prtn3-Elane)1Deje/Del(10Prtn3-Elane)1Deje
(involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ)
|
abnormal neutrophil physiology
|
J:137674
|
impaired neutrophil recruitment
|
J:137674
|
Del(11Cxcl16-Zmynd15)1Ifc/Del(11Cxcl16-Zmynd15)1Ifc
(B6.129S-Ldlrtm1Her Del(11Cxcl16-Zmynd15)1Ifc)
|
abnormal macrophage physiology
|
J:123851
|
Del(11Jmjd6-Mettl23)1Ysfk/Del(11Jmjd6-Mettl23)1Ysfk
(involves: C57BL/6)
|
impaired macrophage chemotaxis
|
J:90288
|
impaired macrophage phagocytosis
|
J:90288
|
Del(11Nlrp1a-Nlrp1c-ps)1Smas/Del(11Nlrp1a-Nlrp1c-ps)1Smas
(Not Specified)
|
increased susceptibility to Riboviria infection
|
J:191055
|
Del(13Naip1-Naip5)1Vnce/Del(13Naip1-Naip5)1Vnce
(involves: C57BL/6)
|
decreased inflammatory response
|
J:294930
|
Del(13Naip1-Naip5)1Vnce/Del(13Naip1-Naip5)1Vnce Nlrc4em2Vnce/Nlrc4em2Vnce
(involves: C57BL/6)
|
decreased inflammatory response
|
J:294930
|
Del(13Naip1-Naip5)1Vnce/Del(13Naip1-Naip5)1Vnce Nlrp3tm1Vmd/Nlrp3tm1Vmd
(involves: C57BL/6J * C57BL/6N)
|
decreased inflammatory response
|
J:294930
|
Del(14Ltb4r2-Ltb4r1)1Bodd/+
(involves: 129S4/SvJaeSor * C57BL/6)
|
decreased susceptibility to induced arthritis
|
J:131779
|
Del(14Ltb4r2-Ltb4r1)1Bodd/Del(14Ltb4r2-Ltb4r1)1Bodd
(involves: 129S4/SvJaeSor * C57BL/6)
|
decreased susceptibility to induced arthritis
|
J:131779
|
impaired neutrophil chemotaxis
|
J:163271
|
Del(14Trim13-Dleu2)4Rdf/Del(14Trim13-Dleu2)4Rdf
(involves: 129S1/Sv * 129S4/SvJaeSor * C57BL/6)
|
abnormal B cell proliferation
|
J:156946
|
Del(17Trem1-Trem3)1Jkt/Del(17Trem1-Trem3)1Jkt
(involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)
|
abnormal chemokine level
|
J:194295
|
abnormal circulating chemokine level
|
J:194295
|
abnormal cytokine level
|
J:194295
|
abnormal cytokine secretion
|
J:194295
|
impaired neutrophil chemotaxis
|
J:194295
|
increased circulating interleukin-1 alpha level
|
J:194295
|
increased circulating interleukin-6 level
|
J:194295
|
increased circulating interleukin-10 level
|
J:194295
|
increased circulating tumor necrosis factor level
|
J:194295
|
increased interleukin-1 alpha secretion
|
J:194295
|
increased interleukin-1 beta secretion
|
J:194295
|
increased interleukin-6 secretion
|
J:194295
|
increased interleukin-10 secretion
|
J:194295
|
increased interleukin-17 secretion
|
J:194295
|
increased susceptibility to bacterial infection
|
J:194295
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:194295
|
Del(19Poll-Dcpd)1Nmt/Del(19Poll-Dcpd)1Nmt
(involves: 129P2/OlaHsd)
|
sinus inflammation
|
J:75779
|
Dennd1btm1.2Achn/Dennd1btm1.2Achn
(involves: C57BL/6)
|
abnormal interleukin secretion
|
J:229307
|
abnormal T-helper 2 physiology
|
J:229307
|
Derm1NC/Nga/Derm1NC/Nga
(involves: MSM/Ms * NC/Nga)
|
dermatitis
|
J:68698
|
DermsBALB/cByJ/?
(involves: BALB/cByJ * C3H/HeJ * C57BL/6J * DBA/2J)
|
dermatitis
|
J:80574
|
DermsDBA/2J/?
(involves: BALB/cByJ * C3H/HeJ * C57BL/6J * DBA/2J)
|
dermatitis
|
J:80574
|
Dffbem1(IMPC)Wtsi/Dffbem1(IMPC)Wtsi
(C57BL/6N-Dffbem1(IMPC)Wtsi/Wtsi)
|
increased anti-nuclear antigen antibody level
|
J:211773
|
Dgkatm1Xpz/Dgkatm1Xpz
(involves: 129 * C57BL/6)
|
abnormal lymphocyte anergy
|
J:113564
|
increased interleukin-2 secretion
|
J:113564
|
Dgkatm1Xpz/Dgkatm1Xpz Dgkztm1Gak/Dgkztm1Gak
(involves: 129 * 129X1/SvJ * C57BL/6)
|
abnormal thymocyte activation
|
J:113564
|
Dgkztm1Gak/Dgkztm1Gak
(involves: 129X1/SvJ * C57BL/6)
|
abnormal cytokine level
|
J:293120
|
abnormal cytokine secretion
|
J:293120
|
abnormal inflammatory response
|
J:293120
|
abnormal interferon level
|
J:85149
|
abnormal macrophage physiology
|
J:293120
|
abnormal T cell activation
|
J:85149
|
abnormal T cell physiology
|
J:85149
|
decreased interleukin-6 secretion
|
J:293120
|
decreased susceptibility to induced arthritis
|
J:293120
|
decreased susceptibility to Riboviria infection
|
J:85149
|
increased T cell proliferation
|
J:85149
|
Dgkztm1Gak/Dgkztm1Gak
(B6.129X1-Dgkztm1Gak)
|
abnormal interleukin-2 secretion
|
J:113564
|
abnormal lymphocyte anergy
|
J:113564
|
Dh/Dh+
(B6.CBA-Dh)
|
decreased immunoglobulin level
|
J:5834
|
Dh/Dh+ Foxn1nu/Foxn1nu
(involves: N:NIH(S))
|
increased IgA level
|
J:6062
|
Dh/Dh+ H2d/H2d
(NZB.Cg-Dh)
|
decreased B cell proliferation
|
J:12036
|
decreased IgG1 level
|
J:12036
|
decreased IgG level
|
J:12036
|
decreased IgM level
|
J:12036
|
decreased susceptibility to graft versus host disease
|
J:12036
|
glomerulonephritis
|
J:12036
|
increased anti-erythrocyte antigen antibody level
|
J:12036
|
increased anti-nuclear antigen antibody level
|
J:12036
|
increased anti-single stranded DNA antibody level
|
J:12036
|
increased autoantibody level
|
J:12036
|
increased T cell proliferation
|
J:12036
|
Dhrs4tm1Lex/Dhrs4tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
|
abnormal humoral immune response
|
J:171883
|
decreased IgG2a level
|
J:171883
|
Dhx15tm1c(EUCOMM)Wtsi/Dhx15tm1c(EUCOMM)Wtsi Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * C3H * C57BL/6N)
|
decreased B cell proliferation
|
J:284624
|
Dhx58tm1Aki/Dhx58tm1Aki
(involves: 129/Sv * C57BL/6)
|
decreased circulating interferon-beta level
|
J:156867
|
decreased interferon-beta secretion
|
J:156867
|
decreased interleukin-6 secretion
|
J:156867
|
increased susceptibility to Picornaviridae infection
|
J:156867
|
increased susceptibility to Picornaviridae infection induced morbidity/mortality
|
J:156867
|
Dhx58tm1Gnb/Dhx58tm1Gnb
(involves: 129P2/OlaHsd * C57BL/6J)
|
abnormal interferon secretion
|
J:146113
|
abnormal susceptibility to Riboviria infection
|
J:146113
|
decreased interferon-alpha secretion
|
J:146113
|
decreased interferon-beta secretion
|
J:146113
|
decreased susceptibility to Riboviria infection
|
J:146113
|
increased circulating interferon-gamma level
|
J:146113
|
increased circulating interleukin-12 level
|
J:146113
|
increased interferon-alpha secretion
|
J:146113
|
increased interferon-beta secretion
|
J:146113
|
increased susceptibility to Picornaviridae infection
|
J:146113
|
Dhx58tm1Itl/Dhx58tm1Itl
(C57BL/6-Dhx58tm1Itl)
|
decreased interferon-beta secretion
|
J:187386
|
decreased interferon-gamma secretion
|
J:187386
|
decreased tumor necrosis factor secretion
|
J:187386
|
increased susceptibility to Flaviviridae infection
|
J:187386
|
increased susceptibility to Flaviviridae infection induced morbidity/mortality
|
J:187386
|
increased T cell apoptosis
|
J:187386
|
Dhx58tm2.1Aki/Dhx58tm2.1Aki
(involves: 129/Sv * C57BL/6)
|
decreased interferon-beta secretion
|
J:156867
|
decreased interleukin-6 secretion
|
J:156867
|
increased susceptibility to Picornaviridae infection
|
J:156867
|
increased susceptibility to Picornaviridae infection induced morbidity/mortality
|
J:156867
|
Diaph1M1Btlr/Diaph1+
(C57BL/6J-Diaph1M1Btlr)
|
decreased IgE level
|
J:254820
|
Diaph1M1Btlr/Diaph1M1Btlr
(C57BL/6J-Diaph1M1Btlr)
|
decreased IgE level
|
J:254820
|
increased susceptibility to Herpesvirales infection induced morbidity/mortality
|
J:254820
|
Diaph1tm1.1Sna/Diaph1tm1.1Sna
(B6.Cg-Diaph1tm1.1Sna)
|
abnormal humoral immune response
|
J:126090
|
abnormal leukocyte migration
|
J:126090
|
decreased T cell proliferation
|
J:126090
|
Diaph1tm1Asal/Diaph1tm1Asal
(involves: 129S1/Sv * C57BL/6)
|
dermatitis
|
J:124319
|
Dice1bC57BL/10Sn/Dice1bC57BL/10Sn
(involves: B10.D2-H2d/oSnJ * BALB/cAnN)
|
decreased susceptibility to parasitic infection
|
J:95337
|
Dicer1Gt(RRF266)Byg/Dicer1Gt(RRF266)Byg
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased susceptibility to Riboviria infection
|
J:123635
|
increased susceptibility to Herpesvirales infection
|
J:123635
|
increased susceptibility to Riboviria infection
|
J:123635
|
Dicer1tm1Bdh/Dicer1tm1Bdh Aicdatm1(cre)Njen/Aicda+
(involves: 129 * C57BL/6)
|
abnormal germinal center B cell physiology
|
J:181782
|
abnormal humoral immune response
|
J:181782
|
decreased immunoglobulin level
|
J:181782
|
Dicer1tm1Bdh/Dicer1tm1Bdh Foxp3tm4(YFP/icre)Ayr/Y
(involves: 129S1/Sv * 129X1/SvJ)
|
blood vessel inflammation
|
J:138683
|
liver inflammation
|
J:138683
|
lung inflammation
|
J:138683
|
Dicer1tm1Bdh/Dicer1tm1Bdh Foxp3tm4(YFP/icre)Ayr/Foxp3tm4(YFP/icre)Ayr
(involves: 129S1/Sv * 129X1/SvJ)
|
blood vessel inflammation
|
J:138683
|
liver inflammation
|
J:138683
|
lung inflammation
|
J:138683
|
Dicer1tm1Bdh/Dicer1tm1Bdh Tg(Foxp3-EGFP/icre)1aJbs/0
(involves: 129 * NOD/ShiLt)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:138808
|
abnormal regulatory T cell physiology
|
J:138808
|
liver inflammation
|
J:138808
|
lung inflammation
|
J:138808
|
Dicer1tm1Dli/Dicer1tm1Dli Tg(Cd4-cre)1Cwi/?
(involves: 129 * C57BL/6 * DBA/2)
|
abnormal cytotoxic T cell physiology
|
J:100546
|
abnormal T-helper 1 physiology
|
J:100546
|
abnormal T-helper 2 physiology
|
J:100546
|
decreased T cell proliferation
|
J:100546
|
increased T cell apoptosis
|
J:100546
|
Dicer1tm1Tara/Dicer1tm1Tara Foxn1tm3(cre)Nrm/Foxn1+
(involves: 129P2/OlaHsd * C57BL/6NHsd)
|
abnormal thymus involution
|
J:180783
|
abnormal thymus physiology
|
J:180783
|
increased susceptibility to induced arthritis
|
J:180783
|
Dido1tm3Cmar/Dido1tm3.1Cmar Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+
(involves: 129S/SvEv * C57BL/6)
|
liver inflammation
|
J:328215
|
Dis3tm1.1Uba/Dis3tm1.1Uba Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NTac)
|
abnormal class switch recombination
|
J:302856
|
Dkc1tm1Ppp/Y
(involves: 129S1/Sv)
|
lung inflammation
|
J:81054
|
Dkk3tm1Cni/Dkk3tm1Cni
(involves: 129X1/SvJ * C57BL/6)
|
increased IgM level
|
J:106922
|
Dlg1tm1Rlh/Dlg1tm1Rlh Tg(Cd4-cre)1Cwi/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:191788
|
abnormal cytokine secretion
|
J:191788
|
abnormal T-helper 1 physiology
|
J:191788
|
abnormal T-helper 2 physiology
|
J:191788
|
decreased interferon-gamma secretion
|
J:191788
|
decreased interleukin-2 secretion
|
J:191788
|
decreased tumor necrosis factor secretion
|
J:191788
|
increased interleukin-4 secretion
|
J:191788
|
increased interleukin-5 secretion
|
J:191788
|
Dlk1tm1.1Jvs/Dlk1+ Myf5tm3(cre)Sor/Myf5+
(involves: 129P2/SvPas * 129S4/SvJaeSor * C57BL/6 * FVB/N)
|
increased inflammatory response
|
J:167124
|
Dlk1tm1Srba/Dlk1tm1Srba
(involves: 129X1/SvJ * C57BL/6)
|
increased IgG1 level
|
J:145076
|
increased IgG2a level
|
J:145076
|
increased IgG2b level
|
J:145076
|
increased IgG2c level
|
J:145076
|
increased IgG3 level
|
J:145076
|
increased IgM level
|
J:145076
|
increased immunoglobulin level
|
J:145076
|
Dll1tm1Gos/Dll1+
(C3Fe.129-Dll1tm1Gos)
|
decreased IgA level
|
J:150183
|
decreased IgG1 level
|
J:150183
|
decreased IgG2b level
|
J:150183
|
decreased IgG3 level
|
J:150183
|
Dmbt1tm1Janm/Dmbt1tm1Janm
(involves: 129P2/OlaHsd * C57BL/6)
|
increased susceptibility to induced colitis
|
J:130258
|
Dmdem1Eno/Y
(involves: C57BL/6J)
|
myositis
|
J:253191
|
Dmdem4Eno/Y
(C57BL/6-Dmdem4Eno)
|
myositis
|
J:285447
|
Dmdem4Eno/Dmdem4Eno
(C57BL/6-Dmdem4Eno)
|
myositis
|
J:285447
|
Dmdmdx/Y
(C57BL/10ScSn-Dmdmdx/J)
|
increased interferon-gamma secretion
|
J:150572
|
increased interleukin-2 secretion
|
J:150572
|
increased interleukin-4 secretion
|
J:150572
|
increased interleukin-6 secretion
|
J:150572
|
increased interleukin-12 secretion
|
J:150572
|
increased tumor necrosis factor secretion
|
J:150572
|
Dmdmdx/Y
(involves: C57BL/10ScSn)
|
diaphragmitis
|
J:140282
|
myositis
|
J:140282
|
Dmdmdx/Y Terctm1Rdp/Terctm1Rdp
(involves: 129/Sv * C57BL/6J * C57BL/10ScSn * SJL)
|
myositis
|
J:167294
|
Dmdmdx/Y Tg(DMD*)#Spc/0
(involves: 129P2/OlaHsd * C57BL/10ScSn * DBA/2)
|
myositis
|
J:280218
|
Dmdmdx/Y Utrntm1Jrs/Utrn+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/10ScSn)
|
diaphragmitis
|
J:140282
|
myositis
|
J:140282
|
Dmdmdx/Dmdmdx
(C57BL/10ScSn-Dmdmdx/J)
|
increased interferon-gamma secretion
|
J:150572
|
increased interleukin-2 secretion
|
J:150572
|
increased interleukin-4 secretion
|
J:150572
|
increased interleukin-6 secretion
|
J:150572
|
increased interleukin-12 secretion
|
J:150572
|
increased tumor necrosis factor secretion
|
J:150572
|
myositis
|
J:226314
|
Dmdmdx/Dmdmdx
(D2.B10-Dmdmdx/J)
|
heart inflammation
|
J:226314
|
myositis
|
J:226314
|
Dmdmdx/Dmdmdx Dusp1tm1Brv/Dusp1tm1Brv
(involves: 129S2/SvPas * C57BL/6 * C57BL/10ScSn)
|
myositis
|
J:162340
|
Dmdtm1.1Know/Dmdtm1.1Know
(involves: C3H)
|
decreased susceptibility to Picornaviridae infection
|
J:207775
|
myocarditis
|
J:207775
|
Dmdtm1Kmf/Y
(involves: C57BL/6)
|
myositis
|
J:233298
|
Dmp1tm1Mis/Dmp1tm1Mis
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased susceptibility to bacterial infection
|
J:241769
|
Dmtf1tm1Cjs/Dmtf1tm1Cjs
(involves: 129/Sv * C57BL/6)
|
abnormal T cell physiology
|
J:63444
|
Dmxl2tm1a(EUCOMM)Wtsi/Dmxl2tm1a(EUCOMM)Wtsi
(C57BL/6N-Atm1Brd Dmxl2tm1a(EUCOMM)Wtsi/WtsiH)
|
blood in lymph vessels
|
J:239583
|
Dnaaf5em1Slb/Dnaaf5em1Slb
(C57BL/6-Dnaaf5em1Slb)
|
sinus inflammation
|
J:342770
|
Dnaaf5em1Slb/Dnaaf5em2Slb
(C57BL/6-Dnaaf5em1Slb Dnaaf5em2Slb)
|
sinus inflammation
|
J:342770
|
Dnah5Tg1Htz/Dnah5Tg1Htz
(involves: C57BL/6 * CBA/J)
|
increased susceptibility to otitis media
|
J:76189
|
sinus inflammation
|
J:76189
|
Dnai1tm1.1Leo/Dnai1tm1.1Leo Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+
(involves: 129 * C57BL/6)
|
rhinosinusitis
|
J:155730
|
Dnajc3m1Btlr/Dnajc3m1Btlr
(C57BL/6J-Dnajc3m1Btlr)
|
increased susceptibility to induced colitis
|
J:265248
|
Dnase1tm1Tmo/Dnase1+
(involves: 129P2/OlaHsd * C57BL/6)
|
glomerulonephritis
|
J:62549
|
increased anti-nuclear antigen antibody level
|
J:62549
|
kidney inflammation
|
J:62549
|
Dnase1tm1Tmo/Dnase1tm1Tmo
(involves: 129P2/OlaHsd * C57BL/6)
|
glomerulonephritis
|
J:62549
|
increased anti-nuclear antigen antibody level
|
J:62549
|
increased susceptibility to systemic lupus erythematosus
|
J:62549
|
kidney inflammation
|
J:62549
|
Dnase1tm1Tmo/Dnase1tm1Tmo
(involves: 129P2/OlaHsd * CD-1)
|
decreased susceptibility to systemic lupus erythematosus
|
J:110060
|
Dnase1tm2092.1Arte/Dnase1tm2092.1Arte
(involves: C57BL/6)
|
glomerulonephritis
|
J:277126
|
increased anti-double stranded DNA antibody level
|
J:277126
|
increased anti-histone antibody level
|
J:277126
|
increased anti-nuclear antigen antibody level
|
J:277126
|
increased autoantibody level
|
J:277126
|
increased susceptibility to systemic lupus erythematosus
|
J:277126
|
Dnase2atm1Osa/Dnase2atm1Osa Ifnar1tm1Agt/Ifnar1tm1Agt
(involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6)
|
abnormal cytokine level
|
J:114982
|
increased anti-double stranded DNA antibody level
|
J:114982
|
increased autoantibody level
|
J:238323
|
increased circulating interleukin-10 level
|
J:238323
|
increased circulating interleukin-18 level
|
J:114982
|
increased circulating tumor necrosis factor level
|
J:238323,
J:114982
|
joint inflammation
|
J:238323,
J:114982
|
rheumatoid arthritis
|
J:238323,
J:114982
|
Dnase2atm1Osa/Dnase2atm2Osa Tg(Mx1-cre)1Cgn/0
(involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6 * CBA)
|
abnormal cytokine level
|
J:114982
|
increased circulating interleukin-18 level
|
J:114982
|
increased circulating tumor necrosis factor level
|
J:114982
|
joint inflammation
|
J:114982
|
rheumatoid arthritis
|
J:114982
|
Dnmt3btm1Enl/Dnmt3btm6Enl
(involves: 129S4/SvJae * C57BL/6)
|
increased thymocyte apoptosis
|
J:106540
|
Dnmt3btm1Enl/Dnmt3btm7Enl
(involves: 129S4/SvJae * C57BL/6)
|
increased thymocyte apoptosis
|
J:106540
|
Dnmt3btm6Enl/Dnmt3btm6Enl
(involves: 129S4/SvJae * C57BL/6)
|
increased thymocyte apoptosis
|
J:106540
|
Dnmt3btm6Enl/Dnmt3btm7Enl
(involves: 129S4/SvJae * C57BL/6)
|
increased thymocyte apoptosis
|
J:106540
|
Dnmt3btm7Enl/Dnmt3btm7Enl
(involves: 129S4/SvJae * C57BL/6)
|
increased thymocyte apoptosis
|
J:106540
|
Dntttm1Gfn/Dntttm1Gfn Faslpr/Faslpr
(involves: 129S2/SvPas * C57BL/6 * MRL/MpJ)
|
decreased autoantibody level
|
J:110248
|
Dock2m1Btlr/Dock2m1Btlr
(involves: C57BL/6J)
|
abnormal class switch recombination
|
J:185495
|
abnormal humoral immune response
|
J:173592
|
decreased IgG level
|
J:185495
|
Dock2m1Hsd/Dock2m1Hsd Irf5tm1Ttg/Irf5tm1Ttg
(B6NHsd.Cg-Irf5tm1Ttg Dock2m1Hsd)
|
abnormal response to infection
|
J:182658
|
decreased interferon-alpha secretion
|
J:182658
|
Dock2m1Hsd/Dock2m1Hsd Siaetm1.2Avrk/Siaetm1.2Avrk
(B6NHsd.Cg-Siaetm1.2Avrk Dock2m1Hsd)
|
abnormal B cell activation
|
J:144035
|
abnormal immunoglobulin level
|
J:144035
|
glomerulonephritis
|
J:144035
|
increased anti-double stranded DNA antibody level
|
J:144035
|
increased anti-histone antibody level
|
J:144035
|
increased anti-single stranded DNA antibody level
|
J:144035
|
increased B cell proliferation
|
J:144035
|
increased IgE level
|
J:144035
|
increased IgG1 level
|
J:144035
|
increased IgG2a level
|
J:144035
|
increased IgG2b level
|
J:144035
|
increased IgG3 level
|
J:144035
|
increased IgM level
|
J:144035
|
Dock2m2Btlr/Dock2m2Btlr
(C57BL/6J-Dock2m2Btlr)
|
abnormal humoral immune response
|
J:173670
|
Dock2m2Btlr/Dock2m2Btlr
(involves: C57BL/6J)
|
abnormal class switch recombination
|
J:185495
|
abnormal humoral immune response
|
J:185495
|
decreased IgG level
|
J:185495
|
Dock2m3Btlr/Dock2m3Btlr
(C57BL/6J-Dock2m3Btlr)
|
abnormal humoral immune response
|
J:191187
|
abnormal immune system physiology
|
J:191187
|
Dock2m6Btlr/Dock2m6Btlr
(C57BL/6J-Dock2m6Btlr)
|
decreased IgE level
|
J:236689
|
decreased response to antigen
|
J:236689
|
Dock2m7Btlr/Dock2m7Btlr
(C57BL/6J-Dock2m7Btlr)
|
increased IgE level
|
J:255181
|
Dock2tm1Tsas/Dock2tm1Tsas
(involves: C57BL/6)
|
abnormal leukocyte migration
|
J:71005
|
Dock2tm1Tsas/Dock2tm1Tsas
(B6.Cg-Dock2tm1Tsas)
|
impaired neutrophil chemotaxis
|
J:113266
|
Dock2tm1Tsas/Dock2tm1Tsas Tg(Tcra2B4)1Mmd/? Tg(Tcrb2B4)1Mmd/?
(involves: C57BL/6)
|
abnormal T cell physiology
|
J:84581
|
Dock3tm1Dasc/Dock3tm1Dasc
(B6.Cg-Dock3tm1Dasc)
|
abnormal microglial cell physiology
|
J:144341
|
Dock8cpm/Dock8cpm
(C57BL/6JSfdAnu-Dock8cpm)
|
abnormal humoral immune response
|
J:155516
|
Dock8m1Anu/Dock8m1Anu
(C57BL/6NCrlAnu-Dock8m1Anu)
|
decreased IgM level
|
J:104190
|
Dock8m1Btlr/Dock8m1Btlr
(C57BL/6J-Dock8m1Btlr)
|
decreased IgG level
|
J:234247
|
impaired humoral immune response
|
J:234247
|
Dock8m2Anu/Dock8m2Anu
(C57BL/6NCrlAnu-Dock8m2Anu)
|
decreased IgM level
|
J:104190
|
Dock8M3Btlr/Dock8M3Btlr
(C57BL/6J-Dock8M3Btlr)
|
decreased IgG level
|
J:272531
|
impaired humoral immune response
|
J:272531
|
Dock8pri/Dock8pri
(C57BL/6JAnu-Dock8pri)
|
abnormal humoral immune response
|
J:155516
|
Dock8pri/Dock8pri
(involves: C57BL/6JAnu)
|
abnormal cellular extravasation
|
J:238772
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:238772
|
Dock8tm1Ysfk/Dock8tm1Ysfk
(B6.Cg-Dock8tm1Ysfk)
|
abnormal dendritic cell physiology
|
J:185165
|
decreased IgG level
|
J:185165
|
decreased T cell proliferation
|
J:185165
|
Dock8tm1Ysfk/Dock8tm1Ysfk Tg(TcrAND)53Hed/0
(involves: C57BL/6 * SJL)
|
dermatitis
|
J:305132
|
Dock10tm1a(EUCOMM)Hmgu/Dock10tm1a(EUCOMM)Hmgu
(C57BL/6N-Dock10tm1a(EUCOMM)Hmgu/Ieg)
|
abnormal B cell physiology
|
J:236911
|
abnormal follicular B cell physiology
|
J:236911
|
Dock10tm1Thar/Dock10tm1Thar
(involves: C57BL/6)
|
abnormal microglial cell chemotaxis
|
J:300632
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:300632
|
impaired macrophage chemotaxis
|
J:300632
|
Dock11tm1Thar/Dock11tm1Thar
(involves: C57BL/6)
|
impaired macrophage chemotaxis
|
J:300632
|
Dok1tm1Ppp/Dok1tm1Ppp
(129S1/Sv-Dok1tm1Ppp)
|
abnormal T cell proliferation
|
J:95640
|
Dok1tm1Ppp/Dok1tm1Ppp Dok2tm1Ppp/Dok2tm1Ppp
(129S1/Sv-Dok1tm1Ppp Dok2tm1Ppp)
|
abnormal leukocyte physiology
|
J:95334
|
Dok1tm1Yyam/Dok1tm1Yyam
(involves: 129S4/SvJae * C57BL/6)
|
decreased IgM level
|
J:95641
|
increased B cell proliferation
|
J:95641
|
Dok1tm1Yyam/Dok1tm1Yyam Dok2tm1Yyam/Dok2tm1Yyam
(B6.129-Dok1tm1Yyam Dok2tm1Yyam)
|
abnormal leukocyte physiology
|
J:95335
|
Dok1tm1Yyam/Dok1tm1Yyam Dok2tm1Yyam/Dok2tm1Yyam
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
abnormal macrophage physiology
|
J:163407
|
Dok1tm1Yyam/Dok1tm1Yyam Dok2tm1Yyam/Dok2tm1Yyam Dok3tm1Brs/Dok3tm1Brs
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
abnormal macrophage physiology
|
J:163407
|
Dok2tm1Ppp/Dok2tm1Ppp
(129S1/Sv-Dok2tm1Ppp)
|
abnormal granulocyte physiology
|
J:95334
|
Dok3tm1Kplm/Dok3tm1Kplm
(involves: 129P2/OlaHsd)
|
abnormal B cell calcium ion homeostasis
|
J:280795
|
abnormal B cell physiology
|
J:280795
|
enhanced humoral immune response
|
J:280795
|
increased B cell proliferation
|
J:280795
|
increased IgG3 level
|
J:280795
|
increased IgM level
|
J:280795
|
Dpcd/PollGt(OST280355)Lex/Dpcd/PollGt(OST280355)Lex
(involves: 129S5/SvEvBrd * C57BL/6Brd)
|
increased susceptibility to otitis media
|
J:185566
|
Dpp3tm1d(EUCOMM)Hmgu/Dpp3tm1d(EUCOMM)Hmgu
(involves: BALB/c * C57BL/6 * C57BL/6J * C57BL/6N * SJL)
|
abnormal interferon-gamma secretion
|
J:294242
|
increased interleukin-1 beta secretion
|
J:294242
|
increased interleukin-6 secretion
|
J:294242
|
increased interleukin-10 secretion
|
J:294242
|
increased tumor necrosis factor secretion
|
J:294242
|
Dpp4em1Rba/Dpp4+
(C57BL/6J-Dpp4em1Rba)
|
decreased susceptibility to Coronaviridae infection induced morbidity/mortality
|
J:279834
|
increased susceptibility to Coronaviridae infection
|
J:279834
|
lung inflammation
|
J:279834
|
Dpp4em1Rba/Dpp4em1Rba
(C57BL/6J-Dpp4em1Rba)
|
increased susceptibility to Coronaviridae infection
|
J:279723,
J:279834
|
increased susceptibility to Coronaviridae infection induced morbidity/mortality
|
J:279834
|
lung inflammation
|
J:279834
|
Dpp4tm1(DPP4)Vlcg/?
(involves: 129S6/SvEvTac * C57BL/6NTac)
|
increased susceptibility to Coronaviridae infection
|
J:223728
|
interstitial pneumonia
|
J:223728
|
lung inflammation
|
J:223728
|
Dpp4tm1(DPP4)Vlcg/?
(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NTac)
|
increased susceptibility to Coronaviridae infection
|
J:238079
|
lung inflammation
|
J:238079
|
pleuritis
|
J:238079
|
Dpp4tm1.1(DPP4)Pbmj/Dpp4tm1.1(DPP4)Pbmj
(involves: C57BL/6 * C57BL/6NTac)
|
increased susceptibility to Coronaviridae infection
|
J:242025
|
increased susceptibility to Coronaviridae infection induced morbidity/mortality
|
J:242025
|
lung inflammation
|
J:242025
|
Drd1tm1Jcd/Drd1tm1Jcd Drd2tm1Ebo/Drd2+
(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)
|
small intestinal inflammation
|
J:91781
|
Drd1tm2Jcd/Drd1+ Tg(Camk2a-cre)2Gsc/0
(involves: 129S4/SvJae * FVB/N)
|
abnormal microglial cell physiology
|
J:120070
|
Drd2tm1Low/Drd2tm1Low
(B6.129S2-Drd2tm1Low/J)
|
increased interleukin-1 beta secretion
|
J:194407
|
Droshatm1Litt/Droshatm1.1Litt Foxp3tm4(YFP/icre)Ayr/Y
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)
|
abnormal interferon-gamma secretion
|
J:138683
|
abnormal interleukin-4 secretion
|
J:138683
|
abnormal T cell activation
|
J:138683
|
blood vessel inflammation
|
J:138683
|
liver inflammation
|
J:138683
|
lung inflammation
|
J:138683
|
Droshatm1Litt/Droshatm1.1Litt Foxp3tm4(YFP/icre)Ayr/Foxp3tm4(YFP/icre)Ayr
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)
|
abnormal interferon-gamma secretion
|
J:138683
|
abnormal interleukin-4 secretion
|
J:138683
|
abnormal T cell activation
|
J:138683
|
blood vessel inflammation
|
J:138683
|
liver inflammation
|
J:138683
|
lung inflammation
|
J:138683
|
Droshatm1Litt/Droshatm1.1Litt Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+
(involves: 129 * 129P2/OlaHsd * C57BL/6 * FVB/N)
|
abnormal interferon-gamma secretion
|
J:138683
|
Droshatm1Litt/Droshatm1.1Litt Tg(Cd4-cre)1Cwi/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N)
|
abnormal immune system physiology
|
J:138683
|
intestinal inflammation
|
J:138683
|
liver inflammation
|
J:138683
|
lung inflammation
|
J:138683
|
Dsc1tm1Dga/Dsc1tm1Dga
(involves: C57BL/6J)
|
dermatitis
|
J:73102
|
Dsg2m1Btlr/Dsg2m1Btlr
(C57BL/6J-Dsg2m1Btlr)
|
increased susceptibility to induced colitis
|
J:271975
|
Dsg2m2Btlr/Dsg2m2Btlr
(C57BL/6J-Dsg2m2Btlr)
|
increased susceptibility to induced colitis
|
J:271976
|
Dsg2m3Btlr/Dsg2m3Btlr
(C57BL/6J-Dsg2m3Btlr)
|
increased susceptibility to induced colitis
|
J:271977
|
Dsg2tm1d(EUCOMM)Wtsi/Dsg2tm1d(EUCOMM)Wtsi
(involves: C57BL/6J * C57BL/6N)
|
heart inflammation
|
J:235770
|
Dsg2tm3.1Leu/Dsg2tm3.1Leu Tg(Vil1-cre)20Syr/0
(involves: 129S7/SvEvBrd * C57BL/6 * DBA/2)
|
increased susceptibility to colitis induced morbidity/mortality
|
J:302333
|
increased susceptibility to induced colitis
|
J:302333
|
Dsg3bal/Dsg3bal
(C57BL/6J-Dsg3bal/J)
|
increased IgE level
|
J:18223
|
Dsg3sqk/Dsg3sqk
(C57BL/6-Dsg3sqk)
|
conjunctivitis
|
J:219200
|
increased susceptibility to infection
|
J:219200
|
Dsg3tm1Stan/Dsg3tm1Stan
(involves: 129X1/SvJ * C57BL/6J)
|
conjunctivitis
|
J:40804
|
Dsg4lah-J/Dsg4lah-J
(involves: DBA/1LacJ)
|
dermatitis
|
J:83117
|
increased IgE level
|
J:83117
|
Dsg4lah/Dsg4lah
(LAH/Pas)
|
dermatitis
|
J:33849
|
Dspptm1Kul/Dspptm1Kul
(B6;129-Dspptm1Kul/Mmnc)
|
periodontium inflammation
|
J:241990
|
Dssc1C3H/HeJ/Dssc1C57BL/6J
(involves: C3H/HeJ * C57BL/6J)
|
colitis
|
J:52852
|
Dssc1C57BL/6J/Dssc1C57BL/6J
(involves: C3H/HeJ * C57BL/6J)
|
colitis
|
J:52852
|
Dssc2C3H/HeJ/Dssc2C3H/HeJ
(involves: C3H/HeJ * C57BL/6J)
|
colitis
|
J:52852
|
Dssc2C3H/HeJ/Dssc2C57BL/6J
(involves: C3H/HeJ * C57BL/6J)
|
colitis
|
J:52852
|
DstTg4/DstTg4
(involves: C57BL/6 * CD-1)
|
conjunctivitis
|
J:209161
|
Dtnbp1sdy-Btlr/Dtnbp1sdy-Btlr
(C57BL/6J-Dtnbp1sdy-Btlr)
|
impaired natural killer cell mediated cytotoxicity
|
J:133620
|
increased susceptibility to Herpesvirales infection
|
J:133620
|
Dtx1tm1.1Mzl/Dtx1tm1.1Mzl Tg(Cd4-cre)1Cwi/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
|
abnormal thymocyte activation
|
J:151605
|
increased anti-double stranded DNA antibody level
|
J:151605
|
increased anti-histone antibody level
|
J:151605
|
increased autoantibody level
|
J:151605
|
increased interleukin-2 secretion
|
J:151605
|
increased T cell proliferation
|
J:151605
|
Dtx1tm1.2Mzl/Dtx1tm1.2Mzl
(B6.129-Dtx1tm1.2Mzl)
|
abnormal lymphocyte physiology
|
J:151605
|
abnormal regulatory T cell physiology
|
J:151605
|
abnormal T cell anergy
|
J:151605
|
abnormal thymocyte activation
|
J:151605
|
decreased thymocyte apoptosis
|
J:151605
|
glomerulonephritis
|
J:151605
|
increased anti-double stranded DNA antibody level
|
J:151605
|
increased anti-histone antibody level
|
J:151605
|
increased B cell proliferation
|
J:151605
|
increased interferon-gamma secretion
|
J:151605
|
increased interleukin-2 secretion
|
J:151605
|
increased interleukin-4 secretion
|
J:151605
|
increased T cell proliferation
|
J:151605
|
liver inflammation
|
J:151605
|
lung inflammation
|
J:151605
|
Ducm1129X1/SvJ/Ducm1129X1/SvJ
(involves: 129X1/SvJ * C57BL/6J)
|
abnormal professional antigen presenting cell physiology
|
J:86617
|
Ducm1129X1/SvJ/Ducm1C57BL/6J
(involves: 129X1/SvJ * C57BL/6J)
|
abnormal professional antigen presenting cell physiology
|
J:86617
|
Dusp1tm1Brv/Dusp1tm1Brv
(involves: 129S2/SvPas)
|
abnormal cytokine secretion
|
J:118832
|
lung inflammation
|
J:118832
|
Dusp1tm1Brv/Dusp1tm1Brv
(involves: 129S2/SvPas * C57BL/6)
|
increased circulating interleukin-6 level
|
J:118833
|
increased circulating interleukin-10 level
|
J:118833
|
increased circulating tumor necrosis factor level
|
J:118833
|
increased interleukin-6 secretion
|
J:118833
|
increased susceptibility to endotoxin shock
|
J:118833
|
increased tumor necrosis factor secretion
|
J:118833
|
Dusp1tm1Brv/Dusp1tm1Brv
(involves: 129S2/SvPas * various)
|
increased mast cell degranulation
|
J:125919
|
increased susceptibility to type I hypersensitivity reaction
|
J:125919
|
Dusp1tm1Brv/Dusp1tm1Brv
(C3.129S2-Dusp1tm1Brv)
|
abnormal chemokine secretion
|
J:164929
|
increased interleukin-1 beta secretion
|
J:164929
|
increased interleukin-6 secretion
|
J:164929
|
increased susceptibility to bacterial infection
|
J:164929
|
lung inflammation
|
J:164929
|
Dusp1tm1Lex/Dusp1tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6)
|
abnormal chemokine level
|
J:126383
|
abnormal innate immunity
|
J:126383
|
abnormal interleukin level
|
J:126383
|
increased circulating interferon-gamma level
|
J:126383
|
increased circulating interleukin-6 level
|
J:126383
|
increased circulating interleukin-10 level
|
J:126383
|
increased circulating tumor necrosis factor level
|
J:126383
|
increased susceptibility to endotoxin shock
|
J:126383
|
increased susceptibility to induced arthritis
|
J:126383
|
Dusp2tm1Cmac/Dusp2tm1Cmac
(B6.Cg-Dusp2tm1Cmac)
|
abnormal cytokine secretion
|
J:112609
|
abnormal macrophage activation involved in immune response
|
J:112609
|
abnormal mast cell physiology
|
J:112609
|
decreased susceptibility to induced arthritis
|
J:112609
|
Dusp4Gt(XG164)Byg/Dusp4Gt(XG164)Byg
(B6.129P2-Dusp4Gt(XG164)Byg)
|
increased interleukin-10 secretion
|
J:180366
|
increased T cell proliferation
|
J:180366
|
Dusp4tm1Jmol/Dusp4tm1Jmol
(involves: 129)
|
decreased B cell apoptosis
|
J:140567
|
Dusp4tm1Plev/Dusp4tm1Plev
(involves: 129/Sv * C57BL/6)
|
abnormal macrophage physiology
|
J:170774
|
decreased IgG2a level
|
J:170774
|
decreased interferon-gamma secretion
|
J:170774
|
decreased interleukin-10 secretion
|
J:170774
|
increased IgG1 level
|
J:170774
|
increased interleukin-4 secretion
|
J:170774
|
increased interleukin-6 secretion
|
J:170774
|
increased interleukin-12 secretion
|
J:170774
|
increased interleukin-13 secretion
|
J:170774
|
increased susceptibility to parasitic infection
|
J:170774
|
increased tumor necrosis factor secretion
|
J:170774
|
Dusp5tm1.1Achn/Dusp5tm1.1Achn
(involves: C57BL/6NCrl)
|
abnormal susceptibility to parasitic infection
|
J:218203
|
increased T cell proliferation
|
J:218203
|
Dusp5tm1.1Achn/Dusp5tm1.1Achn Rag2tm1.1Cgn/Rag2tm1.1Cgn
(involves: C57BL/6NCrl)
|
abnormal eosinophil physiology
|
J:218203
|
abnormal susceptibility to parasitic infection
|
J:218203
|
Dusp5tm1a(KOMP)Wtsi/Dusp5tm1a(KOMP)Wtsi
(C57BL/6-Dusp5tm1a(KOMP)Wtsi)
|
abnormal T cell physiology
|
J:240637
|
increased T cell apoptosis
|
J:240637
|
increased T cell proliferation
|
J:240637
|
Dusp5tm1d(KOMP)Wtsi/Dusp5tm1d(KOMP)Wtsi
(B6(Cg)-Dusp5tm1d(KOMP)Wtsi)
|
increased T cell apoptosis
|
J:240637
|
Dusp10tm1Flv/Dusp10tm1Flv
(involves: 129S6/SvEvTac)
|
abnormal adaptive immunity
|
J:92104
|
abnormal cytokine secretion
|
J:92104
|
abnormal interleukin secretion
|
J:92104
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:92104
|
decreased T cell proliferation
|
J:92104
|
increased interferon-gamma secretion
|
J:92104
|
increased susceptibility to type I hypersensitivity reaction
|
J:92104
|
increased tumor necrosis factor secretion
|
J:92104
|
Dusp11Gt(BB0198)Wtsi/Dusp11Gt(BB0198)Wtsi
(B6.129P2-Dusp11Gt(BB0198)Wtsi)
|
abnormal macrophage activation involved in immune response
|
J:301503
|
increased circulating interleukin-1 beta level
|
J:301503
|
increased circulating interleukin-6 level
|
J:301503
|
increased circulating tumor necrosis factor level
|
J:301503
|
increased macrophage cytokine production
|
J:301503
|
increased susceptibility to endotoxin shock
|
J:301503
|
Dusp14Gt(OST210117)Lex/Dusp14Gt(OST210117)Lex
(B6.129S5-Dusp14Gt(OST210117)Lex)
|
abnormal cytokine secretion
|
J:209403
|
abnormal humoral immune response
|
J:209403
|
abnormal T cell activation
|
J:209403
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:209403
|
increased T cell proliferation
|
J:209403
|
Dusp22tm1Tht/Dusp22tm1Tht
(B6.129S7-Dusp22tm1Tht)
|
abnormal B cell activation
|
J:213253
|
abnormal cytokine level
|
J:213253
|
abnormal T cell activation
|
J:213253
|
decreased B cell proliferation
|
J:213253
|
decreased IgG3 level
|
J:213253
|
decreased IgM level
|
J:213253
|
decreased immunoglobulin level
|
J:213253
|
increased circulating interferon-gamma level
|
J:213253
|
increased circulating interleukin-6 level
|
J:213253
|
increased circulating interleukin-17 level
|
J:213253
|
increased circulating tumor necrosis factor level
|
J:213253
|
increased inflammatory response
|
J:213253
|
increased interferon-gamma secretion
|
J:213253
|
increased interleukin-2 secretion
|
J:213253
|
increased interleukin-4 secretion
|
J:213253
|
increased interleukin-17 secretion
|
J:213253
|
increased susceptibility to autoimmune disorder
|
J:213253
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:213253
|
increased T cell proliferation
|
J:213253
|
kidney inflammation
|
J:213253
|
liver inflammation
|
J:213253
|
lung inflammation
|
J:213253
|
Dyrk1atm1Jdc/Dyrk1atm1Jdc Tg(Mx1-cre)1Cgn/0
(involves: 129/Sv * C57BL/6J * C57BL/6NTac * CBA/J)
|
increased T cell apoptosis
|
J:223138
|
Dysfim/Dysf+ Large1myd/Large1myd
(involves: C57BL/6 * SJL/J)
|
myositis
|
J:221523
|
Dysfim/Dysfim Fktntm1Ttd/Fktntm2(FCMD)Ttd
(involves: 129S7/SvEvBrd * C57BL/6 * SJL/J)
|
myositis
|
J:221523
|
Dysfim/Dysfim Large1myd/Large1myd
(involves: C57BL/6 * SJL/J)
|
myositis
|
J:221523
|
Dysftm1Kcam/Dysftm1Kcam
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
myositis
|
J:171870
|
E2f1tm1Meg/E2f1tm1Meg
(NOD.Cg-E2f1tm1Meg)
|
increased interferon-gamma secretion
|
J:93708
|
increased interleukin-4 secretion
|
J:93708
|
increased susceptibility to autoimmune diabetes
|
J:93708
|
insulitis
|
J:93708
|
salivary gland inflammation
|
J:93708
|
E2f1tm1Meg/E2f1tm1Meg
(involves: 129S4/SvJae * C57BL/6)
|
decreased T cell proliferation
|
J:76318
|
E2f2tm1Zubi/E2f2tm1Zubi
(involves: 129S1/Sv * C57BL/6)
|
abnormal immune system physiology
|
J:76318
|
glomerulonephritis
|
J:76318
|
increased anti-double stranded DNA antibody level
|
J:76318
|
increased inflammatory response
|
J:76318
|
increased susceptibility to autoimmune disorder
|
J:76318
|
increased T cell proliferation
|
J:76318
|
liver inflammation
|
J:76318
|
lung inflammation
|
J:76318
|
E2f2tm1Zubi/E2f2tm1Zubi Tg(TcraH-Y,TcrbH-Y)71Vbo/?
(involves: 129S1/Sv * C57BL/6 * C57BL/6J * DBA/2J)
|
abnormal immune system physiology
|
J:76318
|
increased inflammatory response
|
J:76318
|
increased susceptibility to autoimmune disorder
|
J:76318
|
increased T cell proliferation
|
J:76318
|
E2f3tm1Lees/E2f3tm1Lees
(involves: 129S2/SvPas * C57BL/6)
|
lung inflammation
|
J:75765
|
E2f4tm1Lees/E2f4tm1Lees
(involves: 129S2/SvPas * C57BL/6)
|
increased susceptibility to bacterial infection
|
J:64193
|
increased susceptibility to otitis media
|
J:64193
|
rhinitis
|
J:64193
|
E2f4tm1Lees/E2f4tm1Lees Rb1tm1Tyj/Rb1+
(involves: 129S2/SvPas * C57BL/6)
|
increased susceptibility to infection
|
J:81082
|
Eae1A/J/Eae1A/J
(involves: A/J * C57BL/10SnJ)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:30574
|
Eae1PL/J/Eae1PL/J
(involves: C57BL/10SnJ * PL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:30574
|
Eae2B10.RIII/Eae2RIIIS/J
(involves: B10.RIII * RIIIS/J)
|
autoimmune arthritis
|
J:95848
|
Eae2RIIIS/J/Eae2RIIIS/J
(involves: B10.RIII * RIIIS/J)
|
decreased susceptibility to induced arthritis
|
J:95848
|
Eae2bC57BL/10SnSg/Eae2bC57BL/10SnSg
(involves: B10.RIII * RIIIS/J)
|
CNS inflammation
|
J:96204
|
Eae4ABH/?
(involves: ABH * NOD)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:29171
|
Eae5B10.S/DvTe/Eae5SJL/J
(involves: B10.S/DvTe * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:49054
|
Eae5SJL/J/Eae5SJL/J
(involves: B10.S/DvTe * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:49054
|
Eae7B10.S/DvTe/Eae7B10.S/DvTe
(involves: B10.S/DvTe * SJL/J)
|
brain inflammation
|
J:49054
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:49054
|
Eae7B10.S/DvTe/Eae7SJL/J
(involves: B10.S/DvTe * SJL/J)
|
brain inflammation
|
J:49054
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:49054
|
Eae7SJL/J/Eae7SJL/J
(involves: B10.S/DvTe * SJL/J)
|
brain inflammation
|
J:49054
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:49054
|
Eae9B10.S/DvTe/Eae9SJL/J
(involves: B10.S/DvTe * SJL/J)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:49054
|
Eae10SJL/J/Eae10SJL/J
(involves: B10.S/DvTe * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:49054
|
Eae11SJL/J/?
(involves: B10.S/DvTe * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:53193
|
Eae12SJL/J/Eae12SJL/J
(involves: B10.S/DvTe * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:53193
|
Eae13SJL/J/?
(involves: B10.S/DvTe * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:53193
|
Eae14C57BL/10/?
(involves: B10.S/DvTe * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:69083
|
Eae16SJL/J/?
(involves: B10.S/DvTe * SJL/J)
|
increased inflammatory response
|
J:67840
|
Eae17SJL/J/?
(involves: B10.S/DvTe * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:69083
|
Eae18NOD/Eae18NOD
(involves: ABH * NOD)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:29171
|
Eae21SJL/J/?
(involves: B10.S/DvTe * SJL/J)
|
increased inflammatory response
|
J:67840
|
Eae22SJL/J/?
(involves: B10.S/DvTe * SJL/J)
|
increased inflammatory response
|
J:67840
|
Eae23SJL/J/?
(involves: B10.S/DvTe * SJL/J)
|
increased inflammatory response
|
J:67840
|
Eae25SJL/J/?
(involves: B10.S/DvTe * SJL/J)
|
increased inflammatory response
|
J:69083
|
Eae26B10.RIII/Eae26B10.RIII
(involves: B10.RIII * RIIIS/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:73850
|
Eae26B10.RIII/Eae26RIIIS/J
(involves: B10.RIII * RIIIS/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:73850
|
Eae27C57BL/10SnSg/Eae27RIIIS/J
(involves: B10.RIII * RIIIS/J)
|
CNS inflammation
|
J:96204
|
Eae27RIIIS/J/Eae27RIIIS/J
(involves: B10.RIII * RIIIS/J)
|
CNS inflammation
|
J:96204
|
Eae33C57BL/10SnSg/?
(involves: B10.S * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:99793
|
Eae34C57BL/10SnSg/?
(involves: B10.S * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:99793
|
Eae35C57BL/10SnSg/?
(involves: B10.S * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:99793
|
Eae36SJL/J/?
(involves: B10.S * SJL/J)
|
increased susceptibility to autoimmune disorder
|
J:99793
|
Eae37C57BL/10SnSg/?
(involves: B10.S * SJL/J)
|
increased susceptibility to autoimmune disorder
|
J:99793
|
Eae38C57BL/10SnSg/?
(involves: B10.S * SJL/J)
|
increased susceptibility to autoimmune disorder
|
J:99793
|
Eae39C57BL/10SnSg/Eae39RIIIS/J
(involves: B10.RIII * RIIIS/J)
|
CNS inflammation
|
J:96204
|
Eae39RIIIS/J/Eae39RIIIS/J
(involves: B10.RIII * RIIIS/J)
|
CNS inflammation
|
J:96204
|
Eae41C57BL/10SnSg/Eae41C57BL/10SnSg
(involves: B10.RIII * RIIIS/J)
|
CNS inflammation
|
J:96204
|
Eae42C57BL/10SnSg/?
(involves: B10.S * SJL/J)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:34892
|
Eae42SJL/J/?
(involves: B10.S * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:34892
|
Eae43B10.S/DvTe/?
(involves: B10.S/DvTe * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:53193
|
Eae43B10.S/DvTe/Eae43B10.S/DvTe
(involves: B10.S/DvTe * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:49054
|
Eae44aB10.S/DvTe/Eae44aB10.S/DvTe
(involves: B10.S/DvTe * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:56752
|
Eae44aB10.S/DvTe/Eae44aSJL/J
(involves: B10.S/DvTe * SJL/J)
|
brain inflammation
|
J:49054
|
Eae44aSJL/J/Eae44aSJL/J
(involves: B10.S/DvTe * SJL/J)
|
brain inflammation
|
J:49054
|
Eae44bB10.S/DvTe/Eae44bSJL/J
(involves: B10.S/DvTe * SJL/J)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:56752
|
Eae44bSJL/J/Eae44bSJL/J
(involves: B10.S/DvTe * SJL/J)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:56752
|
Eaf1tm1.1Zhow/Eaf1tm1.1Zhow Eaf2tm1Zhow/Eaf2tm1Zhow Tg(Pbsn-cre)4Prb/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J * DBA/2)
|
prostate gland inflammation
|
J:288972
|
Eaf1tm1.1Zhow/Eaf1tm1.1Zhow Tg(Pbsn-cre)4Prb/0
(B6(Cg)-Eaf1tm1.1Zhow Tg(Pbsn-cre)4Prb)
|
prostate gland inflammation
|
J:288972
|
Eaf2tm1Zhow/Eaf2tm1Zhow
(involves: 129P2/OlaHsd)
|
prostate gland inflammation
|
J:288972
|
Eamcd1A/WySn/Eamcd1A/WySn
(B10.A-(D1Mit65-D1Mit334))
|
myocarditis
|
J:145043
|
Eamcd2A/WySn/Eamcd2A/WySn
(involves: A.SW-H2s/J * B10.S-H2s/J)
|
myocarditis
|
J:96562
|
Ebag9tm1Rehm/Ebag9tm1Rehm
(either: (involves: 129P2/OlaHsd * BALB/c) or (involves: 129P2/OlaHsd * C57BL/6))
|
abnormal cytotoxic T cell physiology
|
J:152534
|
abnormal memory T cell physiology
|
J:152534
|
decreased susceptibility to bacterial infection
|
J:152534
|
Ebf1m1Btlr/Ebf1m1Btlr
(C57BL/6J-Ebf1m1Btlr)
|
decreased IgD level
|
J:265157
|
Ebf1m2Btlr/Ebf1m2Btlr
(C57BL/6J-Ebf1m2Btlr)
|
abnormal humoral immune response
|
J:265158
|
decreased IgD level
|
J:265158
|
decreased IgM level
|
J:265158
|
increased IgM level
|
J:265158
|
increased tumor necrosis factor secretion
|
J:265158
|
Ebf1m6Btlr/Ebf1m6Btlr
(C57BL/6J-Ebf1m6Btlr)
|
decreased IgD level
|
J:272842
|
Ebf1tm1.1Rug/Ebf1tm1.1Rug Polr2atm1(cre/ERT2)Bbd/Polr2a+
(involves: C57BL/6 * SJL)
|
abnormal germinal center B cell physiology
|
J:182210
|
decreased B cell proliferation
|
J:182210
|
decreased IgG1 level
|
J:182210
|
decreased IgG3 level
|
J:182210
|
increased B cell apoptosis
|
J:182210
|
Ebf1tm1Rug/Ebf1tm1Rug
(involves: 129S2/SvPas)
|
decreased IgM level
|
J:52607
|
Ebi3Gt716Lex/Ebi3Gt716Lex
(involves: 129S5/SvEvBrd * C57BL/6)
|
abnormal T cell activation
|
J:286951
|
brain inflammation
|
J:286951
|
decreased interleukin-10 secretion
|
J:286951
|
increased interferon-gamma secretion
|
J:286951
|
increased susceptibility to Coronaviridae infection
|
J:286951
|
increased susceptibility to Coronaviridae infection induced morbidity/mortality
|
J:286951
|
Ebi3Gt716Lex/Ebi3Gt716Lex Tg(DO11.10)10Dlo/0
(involves: 129S5/SvEvBrd * BALB/c * C3H * C57BL/6)
|
abnormal circulating interleukin level
|
J:134148
|
decreased susceptibility to bacterial infection
|
J:134148
|
increased circulating interleukin-17 level
|
J:134148
|
increased interleukin-17 secretion
|
J:134148
|
Ebi3tm1Nkma/Ebi3tm1Nkma Faslpr/Faslpr
(MRL.Cg-Ebi3tm1Nkma Faslpr)
|
abnormal cytokine level
|
J:181669
|
decreased circulating interferon-gamma level
|
J:181669
|
increased circulating interleukin-4 level
|
J:181669
|
increased IgE level
|
J:181669
|
increased IgG1 level
|
J:181669
|
increased IgG level
|
J:181669
|
increased immunoglobulin level
|
J:181669
|
Ebi3tm1Rsb/Ebi3tm1Rsb
(involves: 129X1/SvJ * C57BL/6)
|
abnormal immune system physiology
|
J:81014
|
decreased interleukin-4 secretion
|
J:81014
|
decreased susceptibility to induced colitis
|
J:81014
|
increased interferon-gamma secretion
|
J:81014
|
increased susceptibility to parasitic infection
|
J:97822
|
Ecm1tm1Bsun/Ecm1tm1Bsun
(involves: 129 * C57BL/6)
|
abnormal T-helper 2 physiology
|
J:168252
|
decreased IgE level
|
J:168252
|
decreased susceptibility to type I hypersensitivity reaction
|
J:168252
|
increased susceptibility to autoimmune disorder
|
J:168252
|
EdaTa-6J/Y
(C57BL/6J Aw-J-EdaTa-6J/J)
|
blepharitis
|
J:99510
|
conjunctivitis
|
J:99510
|
corneal limbitis
|
J:99510
|
eye inflammation
|
J:99510
|
increased incidence of corneal inflammation
|
J:99510
|
Edil3Tg(lacZ)1Tq/Edil3Tg(lacZ)1Tq
(Not Specified)
|
increased susceptibility to induced arthritis
|
J:254384
|
Edil3tm1Tq/Edil3tm1Tq
(B6.129S6-Edil3tm1Tq)
|
abnormal cellular extravasation
|
J:141063
|
abnormal leukocyte adhesion
|
J:141063
|
abnormal neutrophil physiology
|
J:141063
|
enhanced leukocyte tethering or rolling
|
J:141063
|
Edil3tm1Tq/Edil3tm1Tq Itgaltm1Bll/Itgaltm1Bll
(involves: 129 * C57BL/6)
|
abnormal cellular extravasation
|
J:141063
|
abnormal neutrophil physiology
|
J:141063
|
Ednrbtm1Nrd/Ednrbtm1Nrd Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/Gt(ROSA)26Sor+ H2az2Tg(Wnt1-cre)11Rth/H2az2+
(involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6 * CBA/J)
|
decreased IgA level
|
J:233811
|
large intestinal inflammation
|
J:233811
|
Ednrbtm1Ywa/Ednrb+
(involves: 129S/SvEvBrd)
|
decreased acute inflammation
|
J:103977
|
Ednrbtm1Ywa/Ednrbtm1Ywa
(involves: 129S5/SvEvBrd)
|
decreased acute inflammation
|
J:103977
|
Eef1a2wst/Eef1a2wst
(B6C3Fe a/a-Eef1a2wst/J)
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:6766
|
Eef1e1Gt(OST377244)Lex/Eef1e1+
(involves: 129S5/SvEvBrd * C57BL/6)
|
decreased splenocyte apoptosis
|
J:96923
|
increased splenocyte proliferation
|
J:96923
|
Efhd2tm1(KOMP)Vlcg/Efhd2tm1(KOMP)Vlcg
(C57BL/6-Efhd2tm1(KOMP)Vlcg)
|
abnormal response to infection
|
J:228565
|
increased IgE level
|
J:228565
|
increased IgG1 level
|
J:228565
|
increased IgG2a level
|
J:228565
|
increased IgM level
|
J:228565
|
Efnb1tm1.1Jwu/Efnb1tm1.1Jwu Efnb2tm1.1Jwu/Efnb2tm1.1Jwu Tg(Lck-cre)I540Jxm/0
(B6.Cg-Efnb2tm1.1Jwu Efnb1tm1.1Jwu Tg(Lck-cre)I540Jxm)
|
increased length of allograft survival
|
J:178148
|
increased susceptibility to Riboviria infection
|
J:178148
|
increased thymocyte apoptosis
|
J:178148
|
Efnb2tm5.1Kln/Efnb2tm5.1Kln
(involves: C57BL/6)
|
abnormal lymph circulation
|
J:95885
|
Efnb2tm6Kln/Efnb2tm6Kln
(involves: C57BL/6)
|
abnormal lymph circulation
|
J:95885
|
Efstm1Kale/Efs+
(either: (involves: 129X1/SvJ) or (involves: 129X1/SvJ * C57BL/6J))
|
increased IgA level
|
J:103757
|
increased IgG level
|
J:103757
|
increased inflammatory response
|
J:103757
|
small intestinal inflammation
|
J:103757
|
Efstm1Kale/Efstm1Kale
(either: (involves: 129X1/SvJ) or (involves: 129X1/SvJ * C57BL/6J))
|
abnormal interleukin secretion
|
J:103757
|
abnormal T cell physiology
|
J:103757
|
increased IgA level
|
J:103757
|
increased IgG level
|
J:103757
|
increased immunoglobulin level
|
J:103757
|
increased inflammatory response
|
J:103757
|
increased interferon-gamma secretion
|
J:103757
|
kidney inflammation
|
J:103757
|
liver inflammation
|
J:103757
|
lung inflammation
|
J:103757
|
small intestinal inflammation
|
J:103757
|
EgfrMhdadsk5/Egfr+
(involves: 129S1/SvImJ * C3HeB/FeJ)
|
increased susceptibility to Coronaviridae infection
|
J:243599
|
increased susceptibility to Coronaviridae infection induced morbidity/mortality
|
J:243599
|
Egfrtm1Dwt/Egfrtm1Dwt Sox9tm3(cre)Crm/Sox9+
(involves: 129S6/SvEvTac * 129S7/SvEvBrd)
|
dermatitis
|
J:229771
|
increased IgE level
|
J:229771
|
Egfrtm1Msi/Egfrtm1Msi Tg(Alb1-cre)7Gsc/?
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
increased circulating tumor necrosis factor level
|
J:125912
|
Egfrtm1Msi/Egfrtm1Msi Tg(Mx1-cre)1Cgn/?
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
increased circulating tumor necrosis factor level
|
J:125912
|
Egr1tm1Jmi/Egr1tm1Jmi
(B6.129-Egr1tm1Jmi)
|
abnormal circulating tumor necrosis factor level
|
J:128421
|
liver inflammation
|
J:128421
|
Egr1tm1Jmi/Egr1tm1Jmi
(involves: 129 * C57BL/6)
|
abnormal microglial cell physiology
|
J:135238
|
abnormal tumor necrosis factor level
|
J:105638
|
decreased inflammatory response
|
J:152898
|
Egr1tm1Jmi/Egr1tm1Jmi Tg(Scgb1a1-rtTA,-tTS,tetO-TGFB1*)1Eli/?
(involves: 129 * C57BL/6)
|
lung inflammation
|
J:92469
|
Ehbp1l1tm1a(EUCOMM)Wtsi/Ehbp1l1tm1a(EUCOMM)Wtsi
(C57BL/6N-Ehbp1l1tm1a(EUCOMM)Wtsi/Wtsi)
|
blood in lymph vessels
|
J:239583
|
Ehmt2tm1.1Cza/Ehmt2tm1.1Cza Tg(Cd4-cre)1Cwi/0
(involves: C57BL/6 * DBA/2 * SJL)
|
decreased IgG1 level
|
J:160938
|
decreased interleukin-4 secretion
|
J:160938
|
increased IgG2a level
|
J:160938
|
increased interferon-gamma secretion
|
J:160938
|
increased susceptibility to parasitic infection
|
J:160938
|
Ehmt2tm1.1Cza/Ehmt2tm1.1Cza Tg(VAV1-cre)1Graf/0
(involves: C57BL/6 * SJL)
|
decreased interleukin-4 secretion
|
J:160938
|
decreased interleukin-5 secretion
|
J:160938
|
decreased interleukin-13 secretion
|
J:160938
|
increased interferon-gamma secretion
|
J:160938
|
increased interleukin-17 secretion
|
J:160938
|
increased susceptibility to parasitic infection
|
J:160938
|
Eif2ak2em1Btlr/Eif2ak2em1Btlr Zfp574em1Btlr/Zfp574em1Btlr
(C57BL/6J-Zfp574em1Btlr Eif2ak2em1Btlr)
|
abnormal B cell physiology
|
J:354285
|
abnormal class switch recombination
|
J:354285
|
abnormal humoral immune response
|
J:354285
|
Eif2ak2tm1Cwe/Eif2ak2tm1Cwe
(involves: 129S/SvEv * C57BL/6)
|
increased interleukin-4 secretion
|
J:66112
|
increased susceptibility to Picornaviridae infection
|
J:30617
|
increased susceptibility to type IV hypersensitivity reaction
|
J:66112
|
increased T cell proliferation
|
J:66112
|
Eif2ak2tm1Cwe/Eif2ak2tm1Cwe Rnaseltm1Slvm/Rnaseltm1Slvm
(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)
|
increased susceptibility to Picornaviridae infection
|
J:55974
|
Eif2ak2tm1Jcbe/Eif2ak2tm1Jcbe
(involves: 129S4/SvJae)
|
increased susceptibility to Orthomyxoviridae infection
|
J:63671
|
increased susceptibility to Riboviria infection
|
J:167126,
J:63671
|
Eif2ak3tm1.1Drc/Eif2ak3tm1.1Drc Tg(Ela1-cre)16Eps/0
(involves: 129S6/SvEvTac)
|
acute pancreas inflammation
|
J:129974
|
Eif2ak4m1Btlr/Eif2ak4m1Btlr
(C57BL/6J-Eif2ak4m1Btlr)
|
abnormal macrophage physiology
|
J:173669
|
increased susceptibility to Adenoviridae infection
|
J:173669
|
increased susceptibility to Herpesvirales infection
|
J:173669
|
Eif2ak4tm1.2Dron/Eif2ak4tm1.2Dron
(involves: 129S6/SvEvTac * C57BL/6 * CBA)
|
abnormal cytokine secretion
|
J:120813
|
abnormal dendritic cell physiology
|
J:120813
|
Eif2b5tm1Itl/Eif2b5tm1Itl
(involves: 129S/SvEv)
|
abnormal microglial cell physiology
|
J:192103
|
Eif4a1tm1.1Bea/Eif4a1tm1.1Bea Tg(Fcer2a-cre)5Mbu/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
decreased B cell proliferation
|
J:344730
|
decreased IgG1 level
|
J:344730
|
Eif4btm1.1Smoc/Eif4b+ Tg(SFTPC-rtTA)5Jaw/0 Tg(tetO-cre)1Jaw/0
(involves: 129 * C57BL/6)
|
increased susceptibility to Riboviria infection
|
J:311140
|
Eif4btm1.1Smoc/Eif4btm1.1Smoc Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+
(involves: 129 * C57BL/6)
|
increased susceptibility to induced colitis
|
J:311140
|
increased susceptibility to Orthomyxoviridae infection
|
J:311140
|
increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality
|
J:311140
|
lung inflammation
|
J:311140
|
Eif4btm1.1Smoc/Eif4btm1.1Smoc Tg(SFTPC-rtTA)5Jaw/0 Tg(tetO-cre)1Jaw/0
(involves: 129 * C57BL/6)
|
increased susceptibility to Orthomyxoviridae infection
|
J:311140
|
Elac2em1Afi/Elac2em1Afi
(C57BL/6N-Elac2em1Afi)
|
prostate gland inflammation
|
J:336403
|
ElaneM1Btlr/ElaneM1Btlr
(C57BL/6J-ElaneM1Btlr)
|
decreased tumor necrosis factor secretion
|
J:218967
|
Elanetm1(cre)Roes/Elanetm1(cre)Roes
(involves: 129)
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:77597
|
increased susceptibility to infection induced morbidity/mortality
|
J:77597
|
Elanetm1(cre)Roes/Elanetm1(cre)Roes
(involves: 129S6/SvEvTac)
|
impaired neutrophil recruitment
|
J:137674
|
Elanetm1Sds/Elanetm1Sds
(129X1/SvJ-Elanetm1Sds)
|
abnormal neutrophil physiology
|
J:47420
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:47420
|
increased susceptibility to bacterial infection
|
J:47420
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:47420
|
Elanetm1Sds/Elanetm1Sds
(involves: 129X1/SvJ * C57BL/6)
|
abnormal inflammatory response
|
J:113463
|
Elavl1tm1.1Atas/Elavl1tm1.1Atas Tnfrsf4tm2(cre)Nik/Tnfrsf4+
(involves: 129X1/SvJ * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:207013
|
decreased T cell proliferation
|
J:207013
|
Elavl1tm1.1Dkon/Elavl1tm1.1Dkon Lyz2tm1(cre)Ifo/Lyz2+
(B6.129P2-Elavl1tm1.1Dkon Lyz2tm1(cre)Ifo)
|
abnormal macrophage chemotaxis
|
J:184388
|
increased circulating interleukin-1 beta level
|
J:184388
|
increased circulating interleukin-6 level
|
J:184388
|
increased circulating interleukin-12 level
|
J:184388
|
increased circulating tumor necrosis factor level
|
J:184388
|
increased susceptibility to endotoxin shock
|
J:184388
|
increased susceptibility to induced colitis
|
J:184388
|
Elavl1tm1.1Dkon/Elavl1tm1.1Dkon Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased circulating interleukin-1 beta level
|
J:184388
|
increased circulating interleukin-6 level
|
J:184388
|
increased circulating interleukin-12 level
|
J:184388
|
increased circulating tumor necrosis factor level
|
J:184388
|
increased susceptibility to endotoxin shock
|
J:184388
|
Elavl1tm1Dkon/Elavl1tm1Dkon Tg(Lck-cre)I57Jxm/0
(B6.Cg-Elavl1tm1Dkon Tg(Lck-cre)I57Jxm)
|
abnormal T cell physiology
|
J:148866
|
abnormal thymocyte activation
|
J:148866
|
Elavl1tm1Lix/Elavl1tm1Lix Tg(Scgb1a1-rtTA)2Jaw/0 Tg(tetO-cre)1Jaw/0
(involves: 129 * C57BL/6)
|
decreased inflammatory response
|
J:204952
|
lung inflammation
|
J:204952
|
Elavl1tm1Thla/Elavl1tm1Thla Gt(ROSA)26Sortm1(cre/ERT2)Alj/Gt(ROSA)26Sor+
(involves: 129)
|
abnormal B cell physiology
|
J:155109
|
decreased B cell apoptosis
|
J:155109
|
increased T cell apoptosis
|
J:155109
|
Elf1tm1Jml/Elf1tm1Jml
(Not Specified)
|
abnormal B cell physiology
|
J:100734
|
Elf4em1Hdu/Elf4em1Hdu
(C57BL/6-Elf4em1Hdu)
|
abnormal interferon level
|
J:328935
|
abnormal interleukin level
|
J:328935
|
abnormal macrophage physiology
|
J:328935
|
abnormal tumor necrosis factor level
|
J:328935
|
increased susceptibility to viral infection
|
J:328935
|
Elf4tm1Nim/Elf4tm1Nim
(B6.129S1-Elf4tm1Nim)
|
abnormal inflammatory response
|
J:79568
|
abnormal lymphocyte physiology
|
J:79568
|
abnormal NK cell physiology
|
J:79568
|
decreased cytotoxic T cell cytolysis
|
J:79568
|
impaired natural killer cell mediated cytotoxicity
|
J:79568
|
increased B cell proliferation
|
J:79568
|
increased T cell proliferation
|
J:79568
|
Elmo1M1Btlr/Elmo1M1Btlr
(C57BL/6J-Elmo1M1Btlr)
|
decreased IgM level
|
J:265231
|
impaired humoral immune response
|
J:265231
|
Elovl3tm1Jaco/Elovl3tm1Jaco
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
|
dermatitis
|
J:88477
|
Elp1tm1.1Id/Elp1tm1.2Id
(involves: 129S1/Sv * C57BL/6 * C57BL/6J * CBA)
|
conjunctivitis
|
J:188923
|
Elp1tm1.2Id/Elp1tm1.2Id
(involves: 129S1/Sv * C57BL/6 * C57BL/6J * CBA)
|
conjunctivitis
|
J:188923
|
Elsgp1C57BL/6J/Elsgp1NZB/BlNJ
(involves: C57BL/6J * NZB/BlNJ)
|
abnormal immune serum protein physiology
|
J:63674
|
Elsgp1NZB/BlNJ/Elsgp1NZB/BlNJ
(involves: C57BL/6J * NZB/BlNJ)
|
abnormal immune serum protein physiology
|
J:63674
|
Elsgp1NZB/BlNJ/Elsgp1NZB/BlNJ Elsgp2NZB/BlNJ/Elsgp2NZB/BlNJ
(involves: C57BL/6J * NZB/BlNJ)
|
abnormal immune serum protein physiology
|
J:63674
|
Elsgp2C57BL/6J/Elsgp2NZB/BlNJ
(involves: C57BL/6J * NZB/BlNJ)
|
abnormal immune serum protein physiology
|
J:63674
|
Elsgp2NZB/BlNJ/Elsgp2NZB/BlNJ
(involves: C57BL/6J * NZB/BlNJ)
|
abnormal immune serum protein physiology
|
J:63674
|
Elsgp3C57BL/6J/Elsgp3NZB/BlNJ
(involves: C57BL/6J * NZB/BlNJ)
|
abnormal immune serum protein physiology
|
J:63674
|
Elsgp3NZB/BlNJ/Elsgp3NZB/BlNJ
(involves: C57BL/6J * NZB/BlNJ)
|
abnormal immune serum protein physiology
|
J:63674
|
Elsgp4NZB/BlNJ/Elsgp4NZB/BlNJ
(involves: BALB/cByJ * NZB/BlNJ)
|
abnormal immune serum protein physiology
|
J:89134
|
Elsgp4NZW/LacJ/?
(involves: BALB/cByJ * NZW/LacJ)
|
abnormal immune serum protein physiology
|
J:89134
|
Emv72a/Emv72a
(involves: BALB/cAnNCr * C57BL/6NCr)
|
abnormal cytotoxic T cell physiology
|
J:194735
|
Emv72b/Emv72b
(CAnNCr.B6NCr-Emv72b)
|
abnormal cytotoxic T cell physiology
|
J:194735
|
Emv72b/Emv72b
(involves: BALB/cAnNCr * C57BL/6NCr)
|
abnormal cytotoxic T cell physiology
|
J:194735
|
Endoutm1Tft/Endoutm1Tft Tg(IghelMD4)4Ccg/0 Tg(ML5sHEL)5Ccg/0
(involves: 129S/SvEv * C57BL/6 * C57BL/6JSfd)
|
decreased activation-induced B cell apoptosis
|
J:208364
|
increased autoantibody level
|
J:208364
|
Enpp1asj/Enpp1asj
(C57BL/6J-Enpp1asj/GrsrJ)
|
increased susceptibility to otitis media
|
J:251638
|
joint inflammation
|
J:174912
|
osteoarthritis
|
J:174912
|
osteomyelitis
|
J:174912
|
Enpp1ttw/Enpp1ttw
(involves: ICR)
|
osteoarthritis
|
J:19124,
J:37369
|
Enpp2tm1Lex/Enpp2+
(involves: 129S/SvEvBrd * C57BL/6J)
|
abnormal chemokine level
|
J:103485
|
decreased circulating interleukin-6 level
|
J:103485
|
decreased circulating tumor necrosis factor level
|
J:103485
|
decreased susceptibility to endotoxin shock
|
J:103485
|
Enpp3tm1Ktak/Enpp3tm1Ktak
(either: (involves: 129S4/SvJae * C57BL/6) or (involves: 129S4/SvJae * BALB/c * C57BL/6))
|
abnormal basophil physiology
|
J:223825
|
abnormal mast cell physiology
|
J:223825
|
increased IgE level
|
J:223825
|
increased interleukin-4 secretion
|
J:223825
|
increased susceptibility to type I hypersensitivity reaction
|
J:223825
|
intestinal inflammation
|
J:223825
|
lung inflammation
|
J:223825
|
Entpd1tm1Rdr/Entpd1tm1Rdr
(involves: 129S2/SvPas)
|
abnormal neutrophil physiology
|
J:129091
|
Entpd5tm1Rre/Entpd5tm1Rre
(involves: 129S5/SvEvBrd * C57BL/6J)
|
liver inflammation
|
J:163795
|
Entpd7tm1Ktak/Entpd7tm1Ktak
(B6.Cg-Entpd7tm1Ktak)
|
decreased susceptibility to bacterial infection
|
J:191188
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:191188
|
Entpd8tm1Ktak/Entpd8tm1Ktak
(C.Cg-Entpd8tm1Ktak)
|
increased susceptibility to induced colitis
|
J:311564
|
Entpd8tm1Ktak/Entpd8tm1Ktak P2rx4tm1Ando/P2rx4tm1Ando
(involves: 129S4/SvJae * BALB/c * C57BL/6)
|
abnormal susceptibility to induced colitis
|
J:311564
|
Eomestm1.1Bflu/Eomestm1.1Bflu Tbx21tm1Glm/Tbx21tm1Glm Tg(Cd4-cre)1Cwi/0
(involves: 129S6/SvEvTac * C57BL/6 * DBA/2 * SJL)
|
abnormal leukocyte migration
|
J:163822
|
decreased interferon-gamma secretion
|
J:163822
|
increased interleukin-4 secretion
|
J:163822
|
increased interleukin-17 secretion
|
J:163822
|
Eomestm1.1Bflu/Eomestm1.1Bflu Tg(Cd4-cre)1Cwi/0
(involves: C57BL/6 * DBA/2 * SJL)
|
abnormal leukocyte migration
|
J:163822
|
Eomestm1Apr/Eomes+ Tbx21tm1Srnr/Tbx21tm1Srnr
(involves: C57BL/6)
|
decreased interferon-gamma secretion
|
J:112679
|
Eomestm1Srnr/Eomestm1Srnr Tbx21tm1Srnr/Tbx21tm1Srnr Tg(Cd4-cre)1Cwi/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
|
abnormal immune system physiology
|
J:137655
|
abnormal interleukin level
|
J:137655
|
abnormal leukocyte physiology
|
J:137655
|
increased susceptibility to Riboviria infection
|
J:137655
|
Epcamtm1.1Mcu/Epcamtm1.1Mcu Tg(CD207-cre)1Dhka/0
(involves: 129 * C57BL/6 * C57BL/6J * SJL/J)
|
abnormal Langerhans cell physiology
|
J:182665
|
increased susceptibility to type IV hypersensitivity reaction
|
J:182665
|
Epcamtm1.2Msiv/Epcamtm1.2Msiv
(involves: C57BL/6 * FVB/N * SJL)
|
small intestinal inflammation
|
J:210901
|
Epha1tm1Sld/Epha1tm1Sld
(involves: 129 * C57BL/6J)
|
endometrium inflammation
|
J:142722
|
vaginal inflammation
|
J:142722
|
Ephb6tm1Jwu/Ephb6tm1Jwu
(involves: 129)
|
abnormal cytokine secretion
|
J:94701
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:94701
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:94701
|
decreased T cell proliferation
|
J:94701
|
Epm2aTg(TcraK,TcrbK)TG-BFlv/Epm2a+ Tg(Ela1-TAg)18Bri/0
(involves: C57BL/6 * CBA/J * SJL)
|
pancreas inflammation
|
J:107545
|
Eps15tm1a(KOMP)Wtsi/Eps15tm1a(KOMP)Wtsi
(involves: C57BL/6 * C57BL/6N)
|
dermatitis
|
J:213427
|
Epyctm1Mhok/Epyctm1Mhok
(involves: 129S7/SvEvBrd * C57BL/6J)
|
osteoarthritis
|
J:222369
|
Erap1tm1.1Gnie/Erap1tm1.1Gnie
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal antigen presentation
|
J:143988
|
abnormal cytotoxic T cell physiology
|
J:143988
|
abnormal response to infection
|
J:143988
|
decreased interferon-gamma secretion
|
J:143988
|
decreased level of surface class I molecules
|
J:143988
|
decreased T cell proliferation
|
J:143988
|
Erap1tm1Iay/Erap1tm1Iay
(involves: C57BL/6)
|
abnormal cytotoxic T cell physiology
|
J:111047
|
decreased level of surface class I molecules
|
J:111047
|
Erap1tm1Luc/Erap1+
(involves: 129S6/SvEvTac)
|
abnormal antigen presentation
|
J:122479
|
decreased level of surface class I molecules
|
J:122479
|
Erap1tm1Luc/Erap1tm1Luc
(involves: 129S6/SvEvTac)
|
abnormal antigen presentation
|
J:122479
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:122479
|
abnormal lymphocyte physiology
|
J:122479
|
decreased level of surface class I molecules
|
J:122479
|
increased level of surface class I molecules
|
J:122479
|
Erap1tm1Nsha/Erap1tm1Nsha
(B6.129S6-Erap1tm1Nsha)
|
abnormal antigen presentation via MHC class I
|
J:112389,
J:116606
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:112389,
J:116606
|
abnormal cytokine secretion
|
J:116606
|
decreased level of surface class I molecules
|
J:112389
|
Erap1tm1Nsha/Erap1tm1Nsha Tap1tm1Arp/Tap1tm1Arp
(B6.129-Erap1tm1Nsha Tap1tm1Arp)
|
abnormal antigen presentation via MHC class I
|
J:112389
|
Erap1tm1Nsha/Erap1tm1Nsha Tap1tm1Arp/Tap1tm1Arp
(involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/10 * DBA/2)
|
abnormal antigen presentation via MHC class I
|
J:116606
|
Erars1DBA/2J/?
(involves: BXD2/TyJ * C57BL/6J * DBA/2J)
|
increased anti-nuclear antigen antibody level
|
J:96064
|
increased immunoglobulin level
|
J:96064
|
Erars2C57BL/6J/?
(involves: BXD2/TyJ * C57BL/6J * DBA/2J)
|
abnormal humoral immune response
|
J:96064
|
increased immunoglobulin level
|
J:96064
|
Erbb3tm1.1Dwt/Erbb3tm2.1Dwt Tg(Vil1-cre)997Gum/0
(involves: 129S6/SvEvTac * C57BL/6 * SJL)
|
increased susceptibility to induced colitis
|
J:152703
|
Erbb4tm1Grl/Erbb4tm1Grl Tg(Myh6-ERBB4)HT2Gass/0
(involves: 129S1/Sv * 129X1/SvJ)
|
lung inflammation
|
J:132190
|
Ercc1tm1Jhjh/Ercc1tm1Jhjh
(involves: C57BL/6 * FVB/N)
|
abnormal class switch recombination
|
J:92471
|
decreased B cell proliferation
|
J:92471
|
Ercc6l2em1Mengf/Ercc6l2em1Mengf
(Not Specified)
|
abnormal class switch recombination
|
J:311900
|
decreased IgA level
|
J:311900
|
decreased IgG1 level
|
J:311900
|
decreased IgG2b level
|
J:311900
|
decreased IgG3 level
|
J:311900
|
decreased IgG level
|
J:311900
|
Ercc6l2em2Mengf/Ercc6l2em2Mengf
(Not Specified)
|
abnormal class switch recombination
|
J:311900
|
Eregtm1Dwt/Eregtm1Dwt
(129S6/SvEvTac-Eregtm1Dwt)
|
increased susceptibility to induced colitis
|
J:93327
|
Eregtm1Sawa/Eregtm1Sawa
(involves: 129X1/SvJ * C57BL/6J)
|
dermatitis
|
J:92618
|
Ergtm1.1Iwamo/Ergtm1.1Iwamo Tg(Gdf5-cre,-ALPP)1Kng/?
(involves: 129S4/SvJaeSor * C57BL/6 * FVB/N)
|
increased susceptibility to induced arthritis
|
J:243715
|
osteoarthritis
|
J:243715
|
Ermp1em1Gjom/Ermp1+
(Not Specified)
|
kidney inflammation
|
J:361886
|
Ern1tm2.1Tiw/Ern1tm2.1Tiw Xbp1tm2Glm/Xbp1tm2Glm Tg(Vil1-cre)997Gum/0
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * SJL)
|
small intestinal inflammation
|
J:206084
|
Ern2m1Btlr/Ern2m1Btlr
(C57BL/6J-Ern2m1Btlr)
|
increased susceptibility to induced colitis
|
J:216045
|
Ern2M2Btlr/Ern2M2Btlr
(C57BL/6J-Ern2M2Btlr)
|
increased susceptibility to induced colitis
|
J:234237
|
Ern2m3Btlr/Ern2m3Btlr
(C57BL/6J-Ern2m3Btlr)
|
increased susceptibility to induced colitis
|
J:236686
|
Ern2tm1Dron/Ern2tm1Dron
(either: 129S6/SvEvTac-Ern2tm1Dron or B6.129S6-Ern2tm1Dron)
|
increased susceptibility to induced colitis
|
J:67934
|
Ero1aGt(XST171)Byg/Ero1aGt(XST171)Byg
(involves: 129P2/OlaHsd * C57BL/6J)
|
abnormal macrophage physiology
|
J:153833
|
decreased macrophage apoptosis
|
J:153833
|
Errfi1tm1Gvw/Errfi1tm1Gvw
(Not Specified)
|
accelerated temporomandibular joint osteoarthritis
|
J:100927
|
osteoarthritis
|
J:100927
|
Errfi1tm1Gvw/Errfi1tm1Gvw Rag2tm1Fwa/Rag2tm1Fwa
(involves: 129S/SvEv)
|
osteoarthritis
|
J:100927
|
Errfi1tm3.1Gvw/Errfi1tm3.1Gvw Tg(CMV-cre)1Cgn/0
(involves: 129 * 129S4/SvJaeSor * BALB/cJ)
|
osteoarthritis
|
J:206807
|
Errfi1tm3.1Gvw/Errfi1tm3.1Gvw Tg(Col2a1-cre)1Asz/0
(involves: 129S1/Sv * 129S4/SvJaeSor * C57BL/6 * CBA)
|
osteoarthritis
|
J:206807
|
Esamtm1Dvst/Esamtm1Dvst
(B6.129-Esam1tm1Dvst)
|
abnormal cellular extravasation
|
J:124397
|
abnormal leukocyte migration
|
J:124397
|
Esm1tm1.1Rha/Esm1tm1.1Rha
(involves: 129S6/SvEvTac * BALB/c * C57BL/6 * C57BL/6NTac)
|
abnormal cellular extravasation
|
J:246778
|
EsmrDBA/2NCrj/EsmrDBA/2NCrj
(involves: C57BL/6NCrj * DBA/2NCrj)
|
decreased susceptibility to parasitic infection
|
J:74563
|
Espl1Gt(XL058)Byg/Espl1+ Trp53tm1Tyj/Trp53tm1Tyj
(B6.129-Trp53tm1Tyj Espl1Gt(XL058)Byg)
|
increased splenocyte proliferation
|
J:174926
|
Espnje/? f/f Hps6ru/Hps6ru
(JE/LeJ)
|
abnormal mast cell degranulation
|
J:37255
|
Esr1tm1.1Lja/Esr1tm1.1Mma
(involves: 129P2/OlaHsd * 129S2/SvPas * 129X1/SvJ * C57BL/6)
|
abnormal osteoclast physiology
|
J:128135
|
Esr1tm1.1Mma/Esr1tm1.1Mma
(involves: 129S2/SvPas * C57BL/6)
|
abnormal immunoglobulin level
|
J:171276
|
abnormal thymus physiology
|
J:171276
|
Esr1tm1.1Ohl/Esr1tm1.1Ohl
(involves: 129S2/SvPas * C57BL/6)
|
abnormal immunoglobulin level
|
J:171276
|
abnormal thymus physiology
|
J:171276
|
Esr1tm1.1Scma/Esr1tm1.1Scma Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6)
|
abnormal osteoclast physiology
|
J:156947
|
Esr1tm1Arnal/Esr1tm1Arnal
(involves: C57BL/6)
|
abnormal immunoglobulin level
|
J:171276
|
Esr1tm1Ksk/Esr1tm1Ksk
(involves: 129P2/OlaHsd * C57BL/6J)
|
abnormal class switch recombination
|
J:82423
|
abnormal immunoglobulin level
|
J:82423
|
abnormal spleen physiology
|
J:88156
|
glomerulonephritis
|
J:88156
|
increased anti-double stranded DNA antibody level
|
J:88156
|
increased IgG3 level
|
J:88156
|
Esr1tm1Ksk/Esr1tm1Ksk
(involves: 129P2/OlaHsd)
|
spermatic granuloma
|
J:60490
|
Esr1tm1Ksk/Esr1tm1Ksk
(involves: 129P2/OlaHsd * C57BL/6N)
|
abnormal thymus physiology
|
J:111590
|
Esr1tm1Ksk/Esr1tm1Ksk Esr2tm1Unc/Esr2tm1Unc
(involves: 129P2/OlaHsd * C57BL/6J)
|
abnormal class switch recombination
|
J:82423
|
abnormal immunoglobulin level
|
J:82423
|
Esr1tm1Ksk/Esr1tm1Ksk Inhatm1Bay/Inhatm1Bay
(involves: 129P2/OlaHsd * 129S6/SvEvTac * 129S7/SvEvBrd)
|
liver inflammation
|
J:84989
|
Esr2tm1Unc/Esr2tm1Unc
(involves: 129P2/OlaHsd)
|
colitis
|
J:107308
|
urinary bladder inflammation
|
J:122274
|
Ess2tm1.1Nbioc/Ess2tm1.1Nbioc Tg(Cd4-cre)1Cwi/0
(involves: C57BL/6N * DBA/2)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:339504
|
Ets1tm1.1Dds/Ets1+
(129S6/SvEvTac-Ets1tm1.1Dds)
|
decreased thymocyte apoptosis
|
J:121460
|
increased splenocyte apoptosis
|
J:121460
|
Ets1tm1.1Dds/Ets1tm1.1Dds
(129S6/SvEvTac-Ets1tm1.1Dds)
|
decreased thymocyte apoptosis
|
J:121460
|
increased splenocyte apoptosis
|
J:121460
|
Ets1tm1Fwa/Ets1tm1Fwa
(B6.129S4-Ets1tm1Fwa)
|
decreased B cell proliferation
|
J:93845
|
increased B cell apoptosis
|
J:93845
|
Ets1tm2Jml/Ets1tm2Jml
(involves: 129X1/SvJ * C57BL/6)
|
abnormal leukocyte physiology
|
J:50627
|
abnormal NK cell physiology
|
J:50627
|
abnormal T cell activation
|
J:50627
|
decreased T cell proliferation
|
J:50627
|
impaired natural killer cell mediated cytotoxicity
|
J:50627
|
Evltm1Lfr/Evltm1Lfr
(involves: 129X1/SvJ * C57BL/6)
|
abnormal leukocyte migration
|
J:94077
|
exf/exf
(involves: C3H/HeN(MTV-))
|
conjunctivitis
|
J:5649
|
increased susceptibility to bacterial infection
|
J:5649
|
Exo1tm2Wed/Exo1tm2Wed
(involves: 129 * C57BL/6)
|
abnormal class switch recombination
|
J:198719
|
abnormal somatic hypermutation frequency
|
J:198719
|
Exph5tm1Tiz/Exph5tm1Tiz
(B6NJcl.Cg-Exph5tm1Tiz/Tiz)
|
abnormal interleukin secretion
|
J:313415
|
abnormal T-helper 2 physiology
|
J:313415
|
increased interleukin-5 secretion
|
J:313415
|
increased interleukin-13 secretion
|
J:313415
|
increased susceptibility to type I hypersensitivity reaction
|
J:313415
|
Extl1em1Caox/Extl1em1Caox Tg(Itgax-cre)1-1Reiz/0
(involves: C57BL/6 * CBA)
|
abnormal dendritic cell chemotaxis
|
J:333437
|
abnormal dendritic cell migration
|
J:333437
|
abnormal dendritic cell physiology
|
J:333437
|
chronic inflammation
|
J:333437
|
decreased acute inflammation
|
J:333437
|
increased circulating interleukin-6 level
|
J:333437
|
increased circulating interleukin-17 level
|
J:333437
|
increased circulating tumor necrosis factor level
|
J:333437
|
increased IgG level
|
J:333437
|
increased immunoglobulin level
|
J:333437
|
increased interleukin-6 secretion
|
J:333437
|
increased susceptibility to autoimmune disorder
|
J:333437
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:333437
|
Eya4tm1Jse/Eya4tm1Jse
(involves: 129S6/SvEvTac * CBA/J)
|
increased susceptibility to otitis media
|
J:131873
|
Ezh2tm1Tara/Ezh2tm1Tara Ighg1tm1(cre)Cgn/Ighg1+
(involves: 129P2/OlaHsd)
|
decreased B cell proliferation
|
J:199122
|
decreased IgG1 level
|
J:199122
|
decreased IgG2b level
|
J:199122
|
decreased IgG3 level
|
J:199122
|
Ezrtm2Aim/Ezrtm2Aim Tg(Cd4-cre)1Cwi/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
decreased interleukin-2 secretion
|
J:143487
|
F2tm1Jld/F2tm1Jld Tg(Mx1-cre)1Cgn/0
(B6.Cg-F2tm1Jld Tg(Mx1-cre)1Cgn)
|
increased susceptibility to bacterial infection
|
J:144572
|
F2tm2Jld/F2+
(B6.129P2-F2tm2Jld)
|
decreased susceptibility to endotoxin shock
|
J:174629
|
F2tm2Jld/F2+
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2J)
|
decreased susceptibility to induced arthritis
|
J:174629
|
F2rtm1Ajc/F2rtm1Ajc F2rl1tm1Cgh/F2rl1tm1Cgh
(involves: 129S4/SvJae * C57BL/6)
|
increased susceptibility to endotoxin shock
|
J:132733
|
F2rtm1Pago/F2rtm1Pago
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased inflammatory response
|
J:124648
|
decreased susceptibility to induced colitis
|
J:94420
|
F2rtm1Pago/F2rtm1Pago
(involves: 129P2/OlaHsd)
|
abnormal cytokine level
|
J:133917
|
decreased susceptibility to endotoxin shock
|
J:133917
|
F2rl1tm1Bpd/F2rl1tm1Bpd
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased inflammatory response
|
J:124648
|
increased inflammatory response
|
J:96196
|
increased susceptibility to induced pancreatitis
|
J:96196
|
F2rl1tm1Bpd/F2rl1tm1Bpd
(B6.129P2-F2rl1tm1Bpd)
|
decreased susceptibility to endotoxin shock
|
J:88245
|
F2rl1tm1Cgh/F2rl1tm1Cgh
(involves: 129S4/SvJae * C57BL/6)
|
glomerulonephritis
|
J:124303
|
impaired leukocyte tethering or rolling
|
J:76626
|
F2rl1tm1Jkaw/F2rl1tm1Jkaw
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:106127
|
F2rl1tm1Mslb/F2rl1tm1Mslb
(involves: 129X1/SvJ * C57BL/6)
|
decreased IgE level
|
J:79757
|
decreased inflammatory response
|
J:79757
|
F2rl1tm1Wrf/F2rl1tm1Wrf
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased susceptibility to induced arthritis
|
J:81119
|
F2rl1tm1Wrf/F2rl1tm1Wrf
(involves: 129P2/OlaHsd)
|
decreased circulating interleukin-18 level
|
J:102762
|
liver inflammation
|
J:102762
|
F3tm1.1Dwr/F3tm1.1Dwr
(involves: 129S1/Sv * 129X1/SvJ * MF1 * Swiss)
|
abnormal cellular extravasation
|
J:91165
|
abnormal leukocyte adhesion
|
J:91165
|
decreased circulating interleukin-1 beta level
|
J:91165
|
decreased circulating interleukin-6 level
|
J:91165
|
decreased circulating tumor necrosis factor level
|
J:91165
|
decreased susceptibility to endotoxin shock
|
J:91165
|
impaired leukocyte tethering or rolling
|
J:91165
|
F3tm1Dco/F3tm1Dco Tg(F3)1Nmk/0
(B6.Cg-F3tm1Dco Tg(F3)1Nmk)
|
abnormal interleukin level
|
J:88245
|
decreased susceptibility to endotoxin shock
|
J:88245
|
F3tm1Gjb/F3+
(involves: 129X1/SvJ * C57BL/6)
|
abnormal chemokine secretion
|
J:128891
|
abnormal macrophage physiology
|
J:128891
|
decreased interleukin-6 secretion
|
J:128891
|
F8tm1Kaz/Y
(involves: 129S4/SvJae * C57BL/6)
|
abnormal immune tolerance
|
J:178969
|
F11tm1Gjb/F11tm1Gjb Proctm1Fjc/Proctm1Fjc
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal lymph circulation
|
J:67398
|
lung inflammation
|
J:67398
|
lymph node hemorrhage
|
J:67398
|
F11rtm1.1Dej/F11rtm1.1Dej
(Not Specified)
|
abnormal dendritic cell physiology
|
J:92592
|
increased susceptibility to type IV hypersensitivity reaction
|
J:92592
|
Faddtm1Mpa/Faddtm1Mpa Ikbkgtm1.1Mpa/Ikbkgtm1.1Mpa Tg(Alb1-cre)7Gsc/0
(involves: C57BL/6 * FVB/N)
|
liver inflammation
|
J:118336
|
Faddtm1Mpa/Faddtm1Mpa Mogtm1(cre)Gkl/Mog+
(involves: C57BL/6 * SJL)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:167475
|
Faddtm1Mpa/Faddtm1Mpa Myd88tm1Aki/Myd88tm1Aki Tg(Vil1-cre)997Gum/0
(B6.Cg-Faddtm1Mpa Myd88tm1Aki Tg(Vil1-cre)997Gum)
|
cecum inflammation
|
J:175865
|
Faddtm1Mpa/Faddtm1Mpa Tg(Vil1-cre)997Gum/0
(B6.Cg-Faddtm1Mpa Tg(Vil1-cre)997Gum)
|
cecum inflammation
|
J:175865
|
colitis
|
J:175865
|
Faddtm1Mpa/Faddtm1Mpa Tnftm1Gkl/Tnftm1Gkl Tg(Vil1-cre)997Gum/0
(B6.Cg-Faddtm1Mpa Tnftm1Gkl Tg(Vil1-cre)997Gum)
|
cecum inflammation
|
J:175865
|
colitis
|
J:175865
|
Faddtm2.1Wnt/Faddtm2.1Wnt Tg(Cd4-cre)1Cwi/?
(B6.Cg-Tg(Cd4-cre)1Cwi Faddtm2.1Wnt)
|
abnormal T cell proliferation
|
J:162312
|
abnormal thymocyte apoptosis
|
J:162312
|
increased susceptibility to parasitic infection
|
J:162312
|
Fads1Gt(IST11525H2)Tigm/Fads1+
(C57BL/6-Fads1Gt(IST11525H2)Tigm)
|
decreased interferon-gamma secretion
|
J:186265
|
decreased tumor necrosis factor secretion
|
J:186265
|
Fads1Gt(IST11525H2)Tigm/Fads1Gt(IST11525H2)Tigm
(C57BL/6-Fads1Gt(IST11525H2)Tigm)
|
decreased interferon-gamma secretion
|
J:186265
|
decreased tumor necrosis factor secretion
|
J:186265
|
Fads2tm1Mtna/Fads2tm1Mtna
(involves: 129S6/SvEvTac * C57BL/6J)
|
dermatitis
|
J:153293
|
Fads2tm1Wst/Fads2tm1Wst
(involves: 129P2/OlaHsd)
|
abnormal macrophage physiology
|
J:140341
|
Fahtm1Mgo/Fahtm1Mgo
(involves: 129S7/SvEvBrd * PT)
|
kidney inflammation
|
J:77295
|
Fahtm1Mgo/Fahtm1Mgo
(involves: 129S7/SvEvBrd * C57BL)
|
liver inflammation
|
J:27735
|
Fahtm1Mgo/Fahtm1Mgo Hgdaku/Hgd+
(involves: 129S7/SvEvBrd * NB)
|
kidney inflammation
|
J:77295
|
Faimtm1Kplm/Faimtm1Kplm
(involves: 129P2/OlaHsd * C57BL/6)
|
increased B cell apoptosis
|
J:164184
|
increased thymocyte apoptosis
|
J:164184
|
liver inflammation
|
J:164184
|
Fam3dem1Wko/Fam3dem1Wko
(C57BL/6-Fam3dem1Wko)
|
abnormal cytokine level
|
J:300819
|
abnormal neutrophil physiology
|
J:304594
|
colitis
|
J:300819
|
increased susceptibility to colitis induced morbidity/mortality
|
J:300819
|
increased susceptibility to induced colitis
|
J:300819
|
Fam13atm1e(KOMP)Wtsi/Fam13atm1e(KOMP)Wtsi
(C57BL/6N-Fam13atm1e(KOMP)Wtsi)
|
white adipose tissue inflammation
|
J:258290
|
Fam20ctm1.1Cqi/Fam20ctm1.1Cqi Tg(Col1a1-cre)2Bek/0
(involves: 129S6/SvEvTac * CD-1)
|
dental pulp inflammation
|
J:225679
|
periodontium inflammation
|
J:225679
|
Fam72atm1.1(KOMP)Vlcg/Fam72atm1.1(KOMP)Vlcg
(C57BL/6NTac-Fam72atm1.1(KOMP)Vlcg)
|
abnormal class switch recombination
|
J:326431
|
abnormal somatic hypermutation frequency
|
J:326431
|
increased B cell apoptosis
|
J:326431
|
Fam72atm1.1(KOMP)Vlcg/Fam72atm1.1(KOMP)Vlcg Msh2tm1Mak/Msh2tm1Mak
(C57BL/6NTac-Fam72atm1.1(KOMP)Vlcg Msh2tm1Mak)
|
abnormal class switch recombination
|
J:326431
|
abnormal somatic hypermutation frequency
|
J:326431
|
Fam76bGt(IST14004H1)Tigm/Fam76bGt(IST14004H1)Tigm
(C57BL/6-Fam76bGt(IST14004H1)Tigm)
|
abnormal macrophage physiology
|
J:358021
|
increased inflammatory response
|
J:358021
|
increased interleukin-6 secretion
|
J:358021
|
increased microglial cell activation
|
J:358021
|
increased tumor necrosis factor secretion
|
J:358021
|
Fam210bem1Cya/Fam210bem1Cya
(involves: C57BL/6N)
|
abnormal splenocyte physiology
|
J:351618
|
glomerulonephritis
|
J:351618
|
increased anti-double stranded DNA antibody level
|
J:351618
|
increased anti-nuclear antigen antibody level
|
J:351618
|
increased IgG level
|
J:351618
|
Fan1tm1a(KOMP)Wtsi/Fan1tm1a(KOMP)Wtsi
(129S1.B6-Fan1tm1a(KOMP)Wtsi)
|
tubulointerstitial nephritis
|
J:242198
|
Farp2tm1Akum/Farp2tm1Akum
(B6.Cg-Farp2tm1Akum)
|
abnormal osteoclast physiology
|
J:166376
|
Faslpr-cg/Faslpr-cg
(CBA/KlJms-Faslpr-cg/J)
|
abnormal hypersensitivity reaction
|
J:24805,
J:81770
|
autoimmune response
|
J:24805,
J:81770
|
increased anti-nuclear antigen antibody level
|
J:24805
|
increased autoantibody level
|
J:81770
|
increased IgG level
|
J:24805,
J:81770
|
increased IgM level
|
J:24805,
J:81770
|
increased immunoglobulin level
|
J:24805
|
Faslpr/Fas+ Tg(TcraTcrb)1100Mjb/?
(involves: C57BL/6 * MRL/Mp)
|
liver inflammation
|
J:72817
|
Faslpr/Faslpr
(MRL/Mp-Faslpr)
|
abnormal cytotoxic T cell physiology
|
J:7488
|
abnormal immune system physiology
|
J:28885
|
abnormal interleukin level
|
J:8267
|
abnormal T cell physiology
|
J:8267
|
abnormal T cell proliferation
|
J:8267
|
abnormal T-helper 2 physiology
|
J:6257
|
abnormal type III hypersensitivity reaction
|
J:28885
|
blood vessel inflammation
|
J:28885
|
decreased interleukin-2 secretion
|
J:6638,
J:7488
|
glomerulonephritis
|
J:27634,
J:13757,
J:28885
|
increased anti-double stranded DNA antibody level
|
J:27634,
J:131138,
J:6257
|
increased anti-erythrocyte antigen antibody level
|
J:27634
|
increased anti-nuclear antigen antibody level
|
J:27634,
J:28885
|
increased anti-single stranded DNA antibody level
|
J:27634
|
increased autoantibody level
|
J:28885
|
increased IgA level
|
J:28885
|
increased IgG1 level
|
J:13757,
J:28885
|
increased IgG2a level
|
J:13757,
J:28885
|
increased IgG2b level
|
J:28885
|
increased IgG level
|
J:27634
|
increased IgM level
|
J:28885
|
increased immunoglobulin level
|
J:13757,
J:28885,
J:6257
|
increased susceptibility to autoimmune disorder
|
J:108760
|
lacrimal gland inflammation
|
J:18512
|
lymph node hemorrhage
|
J:27634
|
salivary gland inflammation
|
J:18512
|
submandibular gland inflammation
|
J:21965
|
thyroid gland inflammation
|
J:28171
|
Faslpr/Faslpr
(NOD.MRL(B6)-Faslpr)
|
decreased susceptibility to autoimmune diabetes
|
J:64051
|
Faslpr/Faslpr
(MRL/MpJ-Faslpr/J)
|
abnormal immunoglobulin level
|
J:122315
|
CNS inflammation
|
J:14151
|
conjunctivitis
|
J:123192
|
decreased IgG level
|
J:122315
|
glomerulonephritis
|
J:92084,
J:122315,
J:127199,
J:7454
|
increased anti-double stranded DNA antibody level
|
J:92084,
J:122315,
J:7454
|
increased anti-nuclear antigen antibody level
|
J:111811,
J:92084,
J:14151,
J:7454
|
increased autoantibody level
|
J:92084,
J:14151
|
increased IgG level
|
J:92084
|
increased immunoglobulin level
|
J:122315,
J:7454
|
increased susceptibility to systemic lupus erythematosus
|
J:92084
|
lymph node hemorrhage
|
J:7454
|
salivary gland inflammation
|
J:92084
|
Faslpr/Faslpr
(NOD.MRL-Faslpr)
|
decreased susceptibility to autoimmune diabetes
|
J:78679
|
Faslpr/Faslpr
(involves: C3H * MRL/Mp)
|
autoimmune response
|
J:1060
|
increased anti-nuclear antigen antibody level
|
J:34296
|
increased susceptibility to systemic lupus erythematosus
|
J:34296
|
increased susceptibility to type III hypersensitivity reaction
|
J:34296
|
Faslpr/Faslpr
(B6.MRL-Faslpr/J)
|
abnormal NK cell physiology
|
J:115033
|
brain inflammation
|
J:120427
|
CNS inflammation
|
J:120427
|
decreased B cell apoptosis
|
J:135830
|
increased anti-double stranded DNA antibody level
|
J:132217
|
increased anti-histone antibody level
|
J:132217
|
increased anti-nuclear antigen antibody level
|
J:132217
|
increased anti-single stranded DNA antibody level
|
J:132217
|
increased autoantibody level
|
J:132217
|
increased susceptibility to bacterial infection
|
J:136745
|
increased susceptibility to Picornaviridae infection
|
J:120427
|
Faslpr/Faslpr
(MRL-Faslpr)
|
abnormal T-helper 2 physiology
|
J:6257
|
glomerulonephritis
|
J:126261
|
increased anti-double stranded DNA antibody level
|
J:126261
|
increased anti-nuclear antigen antibody level
|
J:126261
|
increased IgG level
|
J:126261
|
increased IgM level
|
J:126261
|
increased immunoglobulin level
|
J:6257
|
Faslpr/Faslpr
(MRL.Cg-Irf1tm1Mak Faslpr)
|
glomerulonephritis
|
J:114771
|
increased anti-double stranded DNA antibody level
|
J:114771
|
Faslpr/Faslpr
(C3.MRL-Faslpr/J)
|
abnormal B cell activation
|
J:7454
|
decreased interleukin-2 secretion
|
J:7454
|
glomerulonephritis
|
J:7454
|
increased anti-double stranded DNA antibody level
|
J:7454
|
increased anti-nuclear antigen antibody level
|
J:7454
|
increased autoantibody level
|
J:7454
|
increased immunoglobulin level
|
J:7454
|
lymph node hemorrhage
|
J:7454
|
Faslpr/Faslpr
(B6.MRL-Faslpr)
|
decreased interleukin-2 secretion
|
J:6638
|
glomerulonephritis
|
J:135036,
J:7454
|
increased anti-double stranded DNA antibody level
|
J:7454
|
increased anti-nuclear antigen antibody level
|
J:6638,
J:135036
|
increased autoantibody level
|
J:135036,
J:7454
|
increased immunoglobulin level
|
J:7454
|
lymph node hemorrhage
|
J:7454
|
Faslpr/Faslpr
(AK.MRL-Faslpr)
|
glomerulonephritis
|
J:7454
|
increased anti-double stranded DNA antibody level
|
J:7454
|
increased anti-nuclear antigen antibody level
|
J:7454
|
increased autoantibody level
|
J:7454
|
increased immunoglobulin level
|
J:7454
|
lymph node hemorrhage
|
J:7454
|
Faslpr/Faslpr
(C3.MRL-Faslpr)
|
abnormal interleukin level
|
J:8267
|
abnormal T cell physiology
|
J:8267
|
abnormal T cell proliferation
|
J:8267
|
lacrimal gland inflammation
|
J:1028
|
salivary gland inflammation
|
J:1028
|
Faslpr/Faslpr
(MRL/MpJ-Faslpr)
|
abnormal leukocyte adhesion
|
J:126009
|
autoimmune response
|
J:125114
|
blood vessel inflammation
|
J:137066
|
glomerulonephritis
|
J:125114,
J:132514,
J:137066
|
impaired leukocyte tethering or rolling
|
J:126009
|
increased anti-nuclear antigen antibody level
|
J:137066
|
increased autoantibody level
|
J:137066
|
increased immunoglobulin level
|
J:125114
|
Faslpr/Faslpr
(involves: MRL/Mp)
|
decreased macrophage apoptosis
|
J:154647
|
increased susceptibility to bacterial infection
|
J:50903
|
Faslpr/Faslpr
(involves: C57BL/6 * MRL/Mp)
|
increased anti-double stranded DNA antibody level
|
J:73396
|
increased anti-single stranded DNA antibody level
|
J:73396
|
increased IgA level
|
J:73396
|
increased IgG1 level
|
J:73396
|
increased IgG2a level
|
J:73396
|
increased IgG2b level
|
J:73396
|
increased IgG3 level
|
J:73396
|
increased IgM level
|
J:73396
|
Faslpr/Faslpr
(involves: 129P2/OlaHsd * MRL)
|
glomerulonephritis
|
J:45448
|
kidney inflammation
|
J:45448
|
Faslpr/Faslpr Fcer1gtm1Tks/Fcer1gtm1Tks
(MRL.Cg-Fcer1gtm1Tks Faslpr)
|
arteritis
|
J:106188
|
decreased susceptibility to type III hypersensitivity reaction
|
J:106188
|
glomerulonephritis
|
J:106188
|
increased anti-double stranded DNA antibody level
|
J:106188
|
increased IgG level
|
J:106188
|
Faslpr/Faslpr Havcr1tm1Kuch/Havcr1tm1Kuch
(B6.Cg-Havcr1tm1Kuch Faslpr)
|
abnormal immunoglobulin level
|
J:186484
|
increased anti-double stranded DNA antibody level
|
J:186484
|
increased autoantibody level
|
J:186484
|
increased IgG1 level
|
J:186484
|
increased IgG2a level
|
J:186484
|
increased IgG2b level
|
J:186484
|
increased IgG3 level
|
J:186484
|
increased susceptibility to systemic lupus erythematosus
|
J:186484
|
Faslpr/Faslpr Hspa13tm1.1Smoc/Hspa13tm1.1Smoc Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * 129S * C57BL/6 * MRL/Mp)
|
decreased autoantibody level
|
J:303927
|
decreased susceptibility to systemic lupus erythematosus
|
J:303927
|
Faslpr/Faslpr Ifnar1tm1Agt/Ifnar1tm1Agt
(MRL.Cg-Ifnar1tm1Agt Faslpr)
|
glomerulonephritis
|
J:92084
|
increased anti-nuclear antigen antibody level
|
J:92084
|
increased autoantibody level
|
J:92084
|
increased IgA level
|
J:92084
|
increased IgG2b level
|
J:92084
|
increased IgG3 level
|
J:92084
|
increased IgG level
|
J:92084
|
increased IgM level
|
J:92084
|
increased susceptibility to systemic lupus erythematosus
|
J:92084
|
salivary gland inflammation
|
J:92084
|
Faslpr/Faslpr Ifnar1tm1Agt/Ifnar1tm1Agt Ifngr1tm1Agt/Ifngr1tm1Agt
(MRL.Cg-Ifngr1tm1Agt Ifnar1tm1Agt Faslpr)
|
decreased anti-nuclear antigen antibody level
|
J:92084
|
decreased autoantibody level
|
J:92084
|
decreased IgG level
|
J:92084
|
decreased susceptibility to systemic lupus erythematosus
|
J:92084
|
glomerulonephritis
|
J:92084
|
increased IgG level
|
J:92084
|
increased susceptibility to systemic lupus erythematosus
|
J:92084
|
salivary gland inflammation
|
J:92084
|
Faslpr/Faslpr Ifngtm1Ts/Ifng+
(MRL.Cg-Ifngtm1Ts Faslpr)
|
abnormal macrophage chemotaxis
|
J:123834
|
glomerulonephritis
|
J:123834
|
increased autoantibody level
|
J:123834
|
Faslpr/Faslpr Ifngtm1Ts/Ifngtm1Ts
(MRL.Cg-Ifngtm1Ts Faslpr)
|
abnormal macrophage chemotaxis
|
J:123834
|
kidney inflammation
|
J:123834
|
lung inflammation
|
J:123834
|
Faslpr/Faslpr Ifngtm1Ts/Ifngtm1Ts
(involves: 129S7/SvEvBrd * DBA/1 * MRL/Mp)
|
decreased anti-double stranded DNA antibody level
|
J:39600
|
decreased anti-nuclear antigen antibody level
|
J:39600
|
decreased autoantibody level
|
J:39600
|
decreased IgA level
|
J:39600
|
decreased IgG2a level
|
J:39600
|
decreased IgG2b level
|
J:39600
|
decreased IgM level
|
J:39600
|
decreased immunoglobulin level
|
J:39600
|
decreased susceptibility to systemic lupus erythematosus
|
J:39600
|
Faslpr/Faslpr Ifngr1tm1Agt/Ifngr1tm1Agt
(MRL.Cg-Ifngr1tm1Agt Faslpr)
|
decreased anti-nuclear antigen antibody level
|
J:92084
|
decreased autoantibody level
|
J:92084
|
decreased IgA level
|
J:92084
|
decreased IgG2a level
|
J:92084
|
decreased IgG2b level
|
J:92084
|
decreased IgG3 level
|
J:92084
|
decreased IgM level
|
J:92084
|
decreased susceptibility to systemic lupus erythematosus
|
J:92084
|
glomerulonephritis
|
J:92084
|
increased IgG1 level
|
J:92084
|
increased IgG level
|
J:92084
|
Faslpr/Faslpr Igh-Jtm2(3H9-VDJ*)Mwg/Igh-J+
(MRL.Cg-Faslpr Igh-Jtm2(3H9-VDJ*)Mwg)
|
increased anti-double stranded DNA antibody level
|
J:131138
|
Faslpr/Faslpr Ighmtm1Cgn/Ighmtm1Cgn
(involves: 129S2/SvPas * C57BL/6 * MRL/Mp)
|
abnormal humoral immune response
|
J:119584
|
abnormal immunoglobulin level
|
J:119584
|
decreased IgM level
|
J:119584
|
increased autoantibody level
|
J:119584
|
Faslpr/Faslpr Il4tm1Cgn/Il4tm1Cgn
(MRL.Cg-Il4tm1Cgn Faslpr)
|
glomerulonephritis
|
J:132514
|
lacrimal gland inflammation
|
J:132514
|
Faslpr/Faslpr Il4tm1Cgn/Il4tm1Cgn
(involves: 129P2/OlaHsd * C57BL/6J * MRL/Mp)
|
decreased anti-nuclear antigen antibody level
|
J:39600
|
decreased IgA level
|
J:39600
|
decreased IgE level
|
J:39600
|
decreased IgG1 level
|
J:39600
|
decreased IgG3 level
|
J:39600
|
decreased immunoglobulin level
|
J:39600
|
decreased susceptibility to systemic lupus erythematosus
|
J:39600
|
Faslpr/Faslpr Il27ratm1Mak/Il27ratm1Mak
(MRL.Cg-Il27ratm1Mak Faslpr)
|
abnormal T-helper 2 physiology
|
J:122148
|
decreased anti-double stranded DNA antibody level
|
J:122148
|
decreased IgG2a level
|
J:122148
|
decreased interferon-gamma secretion
|
J:122148
|
decreased susceptibility to systemic lupus erythematosus
|
J:122148
|
glomerulonephritis
|
J:122148
|
increased circulating interleukin-4 level
|
J:122148
|
increased circulating interleukin-5 level
|
J:122148
|
increased IgE level
|
J:122148
|
increased IgG1 level
|
J:122148
|
Faslpr/Faslpr Irf1tm1Mak/Irf1+
(MRL.Cg-Irf1tm1Mak Faslpr)
|
glomerulonephritis
|
J:114771
|
increased anti-double stranded DNA antibody level
|
J:114771
|
Faslpr/Faslpr Irf1tm1Mak/Irf1tm1Mak
(MRL.Cg-Irf1tm1Mak Faslpr)
|
abnormal cytokine secretion
|
J:114771
|
decreased anti-double stranded DNA antibody level
|
J:114771
|
glomerulonephritis
|
J:114771
|
Faslpr/Faslpr Itfg2Gt(OST215121)Lex/Itfg2Gt(OST215121)Lex
(involves: 129S5/SvEvBrd * C57BL/6J * MRL/Mp)
|
increased anti-double stranded DNA antibody level
|
J:205951
|
increased anti-nuclear antigen antibody level
|
J:205951
|
increased IgG2a level
|
J:205951
|
increased IgM level
|
J:205951
|
increased susceptibility to systemic lupus erythematosus
|
J:205951
|
Faslpr/Faslpr Nos2tm1Mrl/Nos2tm1Mrl
(involves: 129S7/SvEvBrd * MRL)
|
abnormal immunoglobulin level
|
J:42666
|
decreased IgG level
|
J:42666
|
decreased IgM level
|
J:42666
|
Faslpr/Faslpr Pou2af1tm1Pmt/Pou2af1tm1Pmt
(involves: 129P2/OlaHsd * C57BL/6 * MRL)
|
autoimmune response
|
J:125114
|
decreased immunoglobulin level
|
J:125114
|
Faslpr/Faslpr Selptm1Bay/Selptm1Bay
(MRL.Cg-Selptm1Bay Faslpr)
|
abnormal chemokine secretion
|
J:127199
|
abnormal leukocyte adhesion
|
J:126009
|
dermatitis
|
J:127199
|
glomerulonephritis
|
J:127199
|
impaired leukocyte tethering or rolling
|
J:126009
|
Faslpr/Faslpr Selplgtm1Fur/Selplgtm1Fur
(MRL.Cg-Selplgtm1Fur Faslpr)
|
abnormal chemokine level
|
J:127199
|
dermatitis
|
J:127199
|
glomerulonephritis
|
J:127199
|
Faslpr/Faslpr Sh2d1arpl/Sh2d1arpl
(MRL/Mp-Faslpr Sh2d1arpl)
|
abnormal immune system physiology
|
J:126261
|
increased anti-nuclear antigen antibody level
|
J:126261
|
Faslpr/Faslpr Spp1tm1Rit/Spp1tm1Rit
(involves: 129S7/SvEvBrd * C57BL/6 * MRL/Mp)
|
increased anti-double stranded DNA antibody level
|
J:73396
|
increased anti-single stranded DNA antibody level
|
J:73396
|
increased IgA level
|
J:73396
|
increased IgG1 level
|
J:73396
|
increased IgG2a level
|
J:73396
|
increased IgG2b level
|
J:73396
|
increased IgG3 level
|
J:73396
|
increased IgM level
|
J:73396
|
kidney inflammation
|
J:73396
|
Faslpr/Faslpr Tcratm1Mjo/Tcratm1Mjo
(involves: 129P2/OlaHsd * MRL)
|
kidney inflammation
|
J:45448
|
Faslpr/Faslpr Tcratm1Mjo/Tcratm1Mjo
(involves: 129P2/OlaHsd * 129S2/SvPas * MRL)
|
decreased autoantibody level
|
J:38492
|
decreased immunoglobulin level
|
J:38492
|
Faslpr/Faslpr Tg(CD2-Foxj1)#Stlp/0
(MRL.Cg-Faslpr Tg(CD2-Foxj1)#Stlp)
|
abnormal T cell physiology
|
J:122222
|
decreased susceptibility to systemic lupus erythematosus
|
J:122222
|
increased anti-nuclear antigen antibody level
|
J:122222
|
kidney inflammation
|
J:122222
|
liver inflammation
|
J:122222
|
lung inflammation
|
J:122222
|
salivary gland inflammation
|
J:122222
|
Faslpr/Faslpr Tg(Ins2-Fasl)24Ach/0
(NOD.Cg-Faslpr Tg(Ins2-Fasl)24Ach)
|
decreased susceptibility to autoimmune diabetes
|
J:81416
|
Faslpr/Faslpr Tg(INS-Il10)#Sar/0
(NOD.Cg-Faslpr Tg(INS-Il10)#Sar)
|
increased susceptibility to autoimmune diabetes
|
J:64051
|
insulitis
|
J:64051
|
Faslpr/Faslpr Tlr7tm1Flv/Y
(involves: 129S1/Sv * C57BL/6 * MRL/Mp)
|
abnormal B cell activation
|
J:113557
|
abnormal plasmacytoid dendritic cell physiology
|
J:113557
|
decreased autoantibody level
|
J:113557
|
decreased IgG2a level
|
J:113557
|
decreased IgG3 level
|
J:113557
|
decreased susceptibility to systemic lupus erythematosus
|
J:113557
|
increased anti-chromatin antibody level
|
J:113557
|
increased autoantibody level
|
J:113557
|
Faslpr/Faslpr Tlr9tm1Aki/Tlr9tm1Aki
(B6.Cg-Tlr9tm1Aki Faslpr)
|
autoimmune response
|
J:135036
|
decreased IgM level
|
J:135036
|
glomerulonephritis
|
J:135036
|
increased IgG level
|
J:135036
|
Faslpr/Faslpr Tlr9tm1Aki/Tlr9tm1Aki
(MRL.Cg-Tlr9tm1Aki Faslpr)
|
abnormal B cell activation
|
J:113557
|
abnormal plasmacytoid dendritic cell physiology
|
J:113557
|
decreased autoantibody level
|
J:113557
|
glomerulonephritis
|
J:113557
|
increased autoantibody level
|
J:113557
|
increased circulating interferon-alpha level
|
J:113557
|
increased IgG2a level
|
J:113557
|
increased IgG3 level
|
J:113557
|
increased IgG level
|
J:113557
|
increased susceptibility to systemic lupus erythematosus
|
J:113557
|
kidney inflammation
|
J:113557
|
Faslpr/Faslpr Tnfrsf1atm1.1Gkl/Tnfrsf1atm1.1Gkl
(involves: 129/Sv * C57BL/6)
|
liver inflammation
|
J:92470
|
Faslpr/Faslpr Tnfrsf9tm1Byk/Tnfrsf9tm1Byk
(MRL.Cg-Tnfrsf9tm1Byk Faslpr)
|
increased anti-nuclear antigen antibody level
|
J:127197
|
increased immunoglobulin level
|
J:127197
|
increased interleukin-4 secretion
|
J:126929
|
increased susceptibility to systemic lupus erythematosus
|
J:127197
|
lacrimal gland inflammation
|
J:126929
|
Fastheo/Fastheo
(either: (involves: C57BL/6JAnu * C57BL/10SnSg * C57BR/cd) or (involves: C57BL/6JAnu * C57BL/10SnSg * C57BR/cd * CBA/CaJAnu))
|
increased anti-nuclear antigen antibody level
|
J:104190
|
Fastm1Ach/Fastm1Ach Tg(GZMB-cre)1Jcb/?
(involves: C57BL/6 * FVB/N)
|
increased anti-nuclear antigen antibody level
|
J:123556
|
Fastm1Ach/Fastm1Ach Tg(Itgax-cre,-EGFP)4097Ach/?
(Not Specified)
|
increased anti-nuclear antigen antibody level
|
J:123556
|
increased IgG level
|
J:123556
|
increased IgM level
|
J:123556
|
increased immunoglobulin level
|
J:123556
|
Fastm1Ach/Fastm1Ach Tg(Lck-cre)548Jxm/?
(involves: C57BL/6 * CBA)
|
increased anti-nuclear antigen antibody level
|
J:123556
|
Fastm1Cgn/Fastm1Cgn Cd19tm1(cre)Cgn/Cd19+ Tg(Cd4-cre)1Cwi/0
(B6.Cg-Tg(Cd4-cre)1Cwi Cd19tm1(cre)Cgn Fastm1Cgn)
|
increased anti-single stranded DNA antibody level
|
J:114948
|
Fastm1Cgn/Fastm1Cgn Mogtm1(cre)Gkl/Mog+
(involves: C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:114741
|
Fastm1Cgn/Fastm1Cgn Mogtm1(cre)Gkl/Mog+ Tnfrsf1atm1Mak/Tnfrsf1atm1Mak
(involves: 129S2/SvPas * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:114741
|
Fastm1Cgn/Fastm1Cgn Tg(Cd4-cre)1Cwi/0
(B6.Cg-Tg(Cd4-cre)1Cwi Fastm1Cgn)
|
abnormal thymus involution
|
J:114948
|
alveolitis
|
J:114948
|
increased anti-single stranded DNA antibody level
|
J:114948
|
increased inflammatory response
|
J:114948
|
increased T cell apoptosis
|
J:114948
|
kidney inflammation
|
J:114948
|
liver inflammation
|
J:114948
|
lung inflammation
|
J:114948
|
Fastm1Cgn/Fastm1Cgn Tnfrsf1atm1Mak/Tnfrsf1atm1Mak
(involves: 129S2/SvPas * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:114741
|
Fastm1Dlo/Fastm1Dlo
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal thymus involution
|
J:90750
|
increased immunoglobulin level
|
J:31847
|
Fastm1Osa/Fastm1Osa
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal hypersensitivity reaction
|
J:64296,
J:32125
|
abnormal T cell clonal deletion
|
J:32125
|
increased anti-double stranded DNA antibody level
|
J:32125
|
increased anti-single stranded DNA antibody level
|
J:32125
|
increased autoantibody level
|
J:32125
|
increased IgG1 level
|
J:32125
|
increased IgG2a level
|
J:32125
|
increased IgG2b level
|
J:32125
|
increased IgG3 level
|
J:32125
|
increased IgG level
|
J:32125
|
increased susceptibility to parasitic infection
|
J:81397
|
Fastm1Osa/Fastm1Osa Gzmatm1Simn/Gzmatm1Simn Gzmbtm1Ley/Gzmbtm1Ley
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
|
increased susceptibility to parasitic infection
|
J:81397
|
Fastm1Vbo/Fastm1Vbo Tg(Ins2-cre)25Mgn/0 Tg(Ins2-HA)165Bri/0 Tg(Tcra/Tcrb)1Vbo/0
(Not Specified)
|
increased susceptibility to autoimmune diabetes
|
J:85985
|
Fasldel1Hong/Fasldel1Hong
(either: (involves: 129 * BALB/c * C57BL/6) or (involves: 129X1/SvJ * C3H/HeJ * C57BL/6))
|
increased IgG level
|
J:112563
|
increased IgM level
|
J:112563
|
Faslgld/Faslgld
(C3H/HeJ-Faslgld/J)
|
decreased cytotoxic T cell cytolysis
|
J:17698
|
increased anti-double stranded DNA antibody level
|
J:7306
|
increased anti-nuclear antigen antibody level
|
J:7306,
J:29572
|
increased autoantibody level
|
J:7306
|
increased IgA level
|
J:7306,
J:29572
|
increased IgG1 level
|
J:7306
|
increased IgG2a level
|
J:7306
|
increased IgG2b level
|
J:7306
|
increased IgG level
|
J:29572
|
increased IgM level
|
J:7306,
J:29572
|
increased immunoglobulin level
|
J:7306,
J:29572
|
interstitial pneumonia
|
J:7306
|
Faslgld/Faslgld
(B6Smn.C3-Faslgld/J)
|
abnormal NK cell physiology
|
J:115033
|
abnormal osteoclast physiology
|
J:127179
|
brain inflammation
|
J:120427
|
CNS inflammation
|
J:120427
|
eye inflammation
|
J:136745
|
increased susceptibility to bacterial infection
|
J:136745
|
increased susceptibility to Picornaviridae infection
|
J:120427
|
liver inflammation
|
J:135830
|
Faslgld/Faslgld
(C3H/HeJ-Faslgld)
|
abnormal interleukin level
|
J:8267
|
abnormal T cell physiology
|
J:8267
|
abnormal T cell proliferation
|
J:8267
|
Faslgld/Faslgld
(involves: C3H/HeJ * C57BL/6)
|
dermatitis
|
J:153501
|
increased anti-nuclear antigen antibody level
|
J:153501
|
increased circulating tumor necrosis factor level
|
J:153501
|
increased IgE level
|
J:153501
|
increased IgG1 level
|
J:153501
|
increased IgG2a level
|
J:153501
|
increased IgG2b level
|
J:153501
|
increased IgG level
|
J:153501
|
increased susceptibility to systemic lupus erythematosus
|
J:153501
|
Faslgld/Faslgld
(involves: C3H/HeJ)
|
abnormal osteoclast physiology
|
J:156947
|
Faslgld/Faslgld
(B6.C3-Faslgld)
|
impaired macrophage phagocytosis
|
J:91058
|
increased anti-nuclear antigen antibody level
|
J:91058
|
increased autoantibody level
|
J:91058
|
Faslm1Btlr/Faslm1Btlr
(C57BL/6J-Faslm1Btlr)
|
abnormal humoral immune response
|
J:212067
|
Faslm2Btlr/Faslm2Btlr
(C57BL/6J-Faslm2Btlr)
|
decreased IgG level
|
J:224659
|
impaired humoral immune response
|
J:224659
|
Fasltm1.1Ast/Fasltm1.1Ast
(involves: BALB/cJ * C57BL/6)
|
decreased cytotoxic T cell cytolysis
|
J:153501
|
dermatitis
|
J:153501
|
glomerulonephritis
|
J:153501
|
increased anti-double stranded DNA antibody level
|
J:153501
|
increased anti-nuclear antigen antibody level
|
J:153501
|
increased circulating tumor necrosis factor level
|
J:153501
|
increased IgA level
|
J:153501
|
increased IgE level
|
J:153501
|
increased IgG1 level
|
J:153501
|
increased IgG2a level
|
J:153501
|
increased IgG2b level
|
J:153501
|
increased IgG level
|
J:153501
|
increased IgM level
|
J:153501
|
increased immunoglobulin level
|
J:153501
|
increased susceptibility to systemic lupus erythematosus
|
J:153501
|
Fasltm1.1Cgm/Fasltm1.1Cgm
(involves: 129S2/SvPas * C57BL/6 * C57BL/6N)
|
increased B cell proliferation
|
J:168406
|
increased IgM level
|
J:168406
|
increased T cell proliferation
|
J:168406
|
Fasltm1.1Lest/Fasltm1.1Lest
(involves: 129 * C57BL/6)
|
autoimmune response
|
J:87990
|
glomerulonephritis
|
J:87990
|
increased IgG level
|
J:87990
|
Fasltm1.1Lest/Fasltm1.1Lest
(B6.129-Fasltm1.1Lest)
|
glomerulonephritis
|
J:87990
|
Fasltm2.1Ast/Fasltm2.1Ast
(involves: BALB/cJ * C57BL/6)
|
abnormal cytotoxic T cell physiology
|
J:153501
|
Fastktm1.1Andp/Fastktm1.1Andp
(B6.129S6-Fastktm1.1Andp)
|
abnormal chemokine secretion
|
J:160443
|
abnormal neutrophil physiology
|
J:160443
|
decreased interleukin-6 secretion
|
J:160443
|
decreased interleukin-23 secretion
|
J:160443
|
decreased tumor necrosis factor secretion
|
J:160443
|
Fat1Gt(KST249)Byg/Fat1Gt(KST249)Byg Tg(Myl1-lacZ)1Ibdml/0
(involves: 129P2/OlaHsd)
|
myositis
|
J:199157
|
Fat1tm1.2Fhel/Fat1tm1.2Fhel Tg(Myl1-lacZ)1Ibdml/0
(involves: 129S6/SvEvTac * BALB/cJ * C57BL/6J * SJL)
|
myositis
|
J:199157
|
Fblim1tm1.1Chen/Fblim1tm1.1Chen
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
|
abnormal osteoclast physiology
|
J:186501
|
Fbn1tm1Lper/Fbn1+
(involves: 129/Sv * CD-1)
|
lung inflammation
|
J:167276
|
Fbn1tm2.1Hcd/Fbn1+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * FVB/N)
|
abnormal interleukin secretion
|
J:206074
|
increased anti-nuclear antigen antibody level
|
J:206074
|
increased autoantibody level
|
J:206074
|
increased interleukin-9 secretion
|
J:206074
|
increased interleukin-13 secretion
|
J:206074
|
Fbn1tm2Rmz/Fbn1tm2Rmz
(involves: 129S1/Sv * 129X1/SvJ)
|
aortitis
|
J:54081
|
lung inflammation
|
J:91815
|
Fbn1tm3.1Hcd/Fbn1+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * FVB/N)
|
abnormal interleukin secretion
|
J:206074
|
increased anti-nuclear antigen antibody level
|
J:206074
|
increased autoantibody level
|
J:206074
|
increased interleukin-9 secretion
|
J:206074
|
increased interleukin-13 secretion
|
J:206074
|
Fbn1Tsk/Fbn1+
(B6.Cg-Fbn1Tsk)
|
alveolitis
|
J:15018,
J:30961,
J:6566
|
increased autoantibody level
|
J:21987,
J:14166
|
increased susceptibility to type IV hypersensitivity reaction
|
J:7185
|
lung inflammation
|
J:30961,
J:6566
|
Fbn1Tsk/Fbn1+ Il4tm1Nnt/Il4tm1Nnt
(involves: C57BL/6 * C57BL/10 * DBA/2)
|
decreased interleukin-4 secretion
|
J:57957
|
Fbn1Tsk/Fbn1+ Il4ratm1Sz/Il4ra+
(involves: BALB/cJ * C57BL/6J * C57BL/10 * DBA/2)
|
increased autoantibody level
|
J:68448
|
Fbn1Tsk/Fbn1+ Stat6tm1Gru/Stat6tm1Gru
(involves: 129S2/SvPas * C57BL/10 * DBA/2)
|
decreased interleukin-4 secretion
|
J:57957
|
Fbxl4tm1.2Lrsn/Fbxl4tm1.2Lrsn
(involves: C57BL/6N)
|
liver inflammation
|
J:303084
|
Fbxl5tm2.1Kei/Fbxl5tm2.1Kei Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: C57BL/6 * DBA)
|
liver inflammation
|
J:176655
|
Fbxo7tm1a(EUCOMM)Wtsi/Fbxo7tm1a(EUCOMM)Wtsi
(involves: C57BL/6N)
|
increased susceptibility to bacterial infection
|
J:272313
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:272313
|
Fbxo11Jf/Fbxo11+
(involves: BALB/cAnNCrl * C3H/HeN)
|
abnormal cytokine secretion
|
J:85263
|
increased susceptibility to otitis media
|
J:85263
|
Fbxo11Jf/Fbxo11+
(involves: BALB/cAnNCrl * C3H/HeN * C57BL/6J)
|
increased susceptibility to otitis media
|
J:114851
|
Fbxo11Jf/Fbxo11+
(involves: BALB/cAnNCrl)
|
increased susceptibility to otitis media
|
J:250208
|
Fbxo11Jf/Fbxo11Mutt
(involves: BALB/c * C3H/HeN)
|
increased susceptibility to otitis media
|
J:114851
|
Fbxw7tm1Kei/Fbxw7tm1Kei Tg(Lck-cre)1Cwi/?
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal T cell activation
|
J:128523
|
increased T cell apoptosis
|
J:128523
|
Fcamrtm1Shib/Fcamrtm1Shib
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal follicular dendritic cell antigen presentation
|
J:150824
|
abnormal marginal zone B cell physiology
|
J:150824
|
abnormal somatic hypermutation frequency
|
J:150824
|
Fcamrtm2Shib/Fcamrtm2Shib
(BALB/c-Fcamrtm2Shib)
|
abnormal follicular dendritic cell antigen presentation
|
J:150824
|
abnormal marginal zone B cell physiology
|
J:150824
|
Fcer1atm1Ftl/Fcer1atm1Ftl
(CBy.129S2-Fcer1atm1Ftl)
|
abnormal humoral immune response
|
J:120702
|
abnormal mast cell physiology
|
J:120702
|
decreased circulating interleukin-4 level
|
J:120702
|
Fcer1atm1Knt/Fcer1atm1Knt
(either: (involves: 129 * C57BL/6) or (involves: 129 * C57BL/6 * DBA/2))
|
abnormal mast cell physiology
|
J:39250
|
decreased susceptibility to type I hypersensitivity reaction
|
J:113572,
J:39250
|
Fcer1atm1Knt/Fcer1atm1Knt
(involves: 129 * BALB/c)
|
abnormal mast cell physiology
|
J:78659
|
increased susceptibility to type I hypersensitivity reaction
|
J:78659
|
Fcer1atm1Knt/Fcer1atm1Knt Fcer2atm1Max/Fcer2atm1Max
(B6.Cg-Fcer1atm1Knt Fcer2atm1Max)
|
abnormal mast cell physiology
|
J:144620
|
Fcer1atm1Knt/Fcer1atm1Knt Fcer2atm1Max/Fcer2atm1Max Fcgr1tm1Jsv/Fcgr1tm1Jsv Fcgr2btm1Ttk/Fcgr2btm1Ttk Fcgr3tm1Jsv/Fcgr3tm1Jsv
(B6.Cg-Fcgr2btm1Ttk Fcgr3tm1Jsv Fcer1atm1Knt Fcgr1tm1Jsv Fcer2atm1Max)
|
abnormal macrophage physiology
|
J:144620
|
abnormal mast cell physiology
|
J:144620
|
increased susceptibility to type I hypersensitivity reaction
|
J:144620
|
Fcer1atm1Knt/Fcer1atm1Knt Tg(FCER1A)1Bhk/?
(B6.129-Fcer1atm1Knt Tg(FCER1A)1Bhk)
|
abnormal macrophage physiology
|
J:144620
|
increased tumor necrosis factor secretion
|
J:144620
|
Fcer1atm1Knt/Fcer1atm1Knt Tg(SV40/HTLV-FCER1A)1Bhk/0
(either: (involves: 129 * C57BL/6) or (involves: 129 * C57BL/6 * DBA/2))
|
abnormal type I hypersensitivity reaction
|
J:113572
|
Fcer1gtm1Rav/Fcer1gtm1Rav
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal dendritic cell antigen presentation
|
J:83995
|
abnormal immune cell physiology
|
J:39248
|
abnormal immunoglobulin level
|
J:78659
|
abnormal mast cell physiology
|
J:39248
|
abnormal NK cell physiology
|
J:39248
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:126520
|
decreased susceptibility to type I hypersensitivity reaction
|
J:78659,
J:39248
|
impaired macrophage phagocytosis
|
J:39248
|
increased IgE level
|
J:78659
|
Fcer1gtm1Rav/Fcer1gtm1Rav
(B6.129P2-Fcer1gtm1Rav)
|
decreased interleukin-1 beta secretion
|
J:160680
|
decreased interleukin-6 secretion
|
J:160680
|
decreased interleukin-10 secretion
|
J:160680
|
decreased interleukin-12b secretion
|
J:160680
|
decreased interleukin-23 secretion
|
J:160680
|
decreased tumor necrosis factor secretion
|
J:160680
|
Fcer1gtm1Rav/Fcer1gtm1Rav
(involves: 129P2/OlaHsd)
|
increased susceptibility to parasitic infection
|
J:163761
|
Fcer1gtm1Rav/Fcer1gtm1Rav Del(7Tyrobp-Hcst)1Ttk/Del(7Tyrobp-Hcst)1Ttk
(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6)
|
abnormal osteoclast physiology
|
J:147155
|
Fcer1gtm1Rav/Fcer1gtm1Rav Hexbtm1Rlp/Hexbtm1Rlp
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
increased immunoglobulin level
|
J:87617
|
Fcer1gtm1Rav/Fcer1gtm1Rav Tg(Ins2-TFRC/OVA)296Wehi/0
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased susceptibility to autoimmune diabetes
|
J:122114
|
decreased T cell proliferation
|
J:122114
|
Fcer1gtm1Rav/Fcer1gtm1Rav Tyrobptm1.1Viv/Tyrobptm1.1Viv
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased interferon-gamma secretion
|
J:100668
|
Fcer1gtm1Rav/Fcer1gtm1Rav Tyrobptm1Lll/Tyrobptm1Lll
(involves: 129P2/OlaHsd)
|
abnormal osteoclast physiology
|
J:147155
|
Fcer1gtm1Tks/Fcer1gtm1Tks
(involves: C57BL/6)
|
abnormal antigen presentation
|
J:112160
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:112160
|
abnormal chemokine secretion
|
J:141143
|
abnormal cytokine level
|
J:258645
|
abnormal macrophage physiology
|
J:141143
|
abnormal NK cell physiology
|
J:111365
|
abnormal NK T cell physiology
|
J:111365
|
decreased IgG1 level
|
J:112160
|
decreased IgG2a level
|
J:112160
|
decreased IgG2b level
|
J:112160
|
decreased IgG3 level
|
J:112160
|
decreased IgG level
|
J:112160
|
decreased inflammatory response
|
J:50023
|
decreased interferon-gamma secretion
|
J:111365,
J:112160
|
decreased interleukin-2 secretion
|
J:112160
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:112160
|
decreased T cell proliferation
|
J:112160
|
impaired macrophage phagocytosis
|
J:50023
|
impaired natural killer cell mediated cytotoxicity
|
J:111365
|
Fcer1gtm1Tks/Fcer1gtm1Tks
(C57BL/6-Fcer1gtm1Tks)
|
decreased susceptibility to autoimmune hemolytic anemia
|
J:145432
|
Fcer1gtm1Tks/Fcer1gtm1Tks
(involves: C57BL/6J)
|
abnormal chemokine secretion
|
J:203159
|
abnormal interferon-gamma secretion
|
J:203159
|
abnormal interleukin-17 secretion
|
J:203159
|
decreased tumor necrosis factor secretion
|
J:203159
|
Fcer2aHie/Fcer2aHie
(NZB)
|
increased IgE level
|
J:93999
|
Fcer2atm1Kik/Fcer2atm1Kik
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal cytokine secretion
|
J:129296
|
abnormal humoral immune response
|
J:19437
|
abnormal immune system physiology
|
J:129296
|
increased immunoglobulin level
|
J:129296
|
Fcer2atm1Max/Fcer2atm1Max
(involves: C57BL/6)
|
abnormal macrophage chemotaxis
|
J:57738
|
decreased IgG1 level
|
J:18952
|
decreased IgG2b level
|
J:18952
|
impaired eosinophil recruitment
|
J:57738
|
increased IgE level
|
J:57738,
J:18952,
J:107857
|
increased IgM level
|
J:18952
|
increased susceptibility to type I hypersensitivity reaction
|
J:57738
|
Fcer2atm1Max/Fcer2atm1Max Ighg1tm1.1Pyu/Ighg1+
(involves: 129 * BALB/cJ * C57BL/6 * C57BL/6J)
|
decreased IgG1 level
|
J:198154
|
decreased IgG2c level
|
J:198154
|
decreased IgG level
|
J:198154
|
increased IgE level
|
J:198154
|
increased IgG2a level
|
J:198154
|
increased susceptibility to type I hypersensitivity reaction
|
J:198154
|
Fcer2atm1Max/Fcer2atm1Max Ighg1tm1.1Pyu/Ighg1tm1.1Pyu
(involves: 129 * BALB/cJ * C57BL/6 * C57BL/6J)
|
abnormal immunoglobulin level
|
J:198154
|
decreased IgG2c level
|
J:198154
|
decreased IgG level
|
J:198154
|
increased IgE level
|
J:198154
|
increased IgG2a level
|
J:198154
|
increased susceptibility to type I hypersensitivity reaction
|
J:198154
|
Fcer2atm1Putt/Fcer2a+
(involves: 129S/SvEv * C57BL/6)
|
increased IgE level
|
J:69547
|
Fcer2atm1Putt/Fcer2atm1Putt
(involves: 129S/SvEv * C57BL/6)
|
abnormal B cell proliferation
|
J:69547
|
Fcgr1tm1Hoga/Fcgr1tm1Hoga
(involves: 129S1/Sv * 129X1/SvJ)
|
abnormal cell-mediated immunity
|
J:86281
|
abnormal macrophage antigen presentation
|
J:86281
|
decreased inflammatory response
|
J:86281
|
impaired macrophage phagocytosis
|
J:86281
|
increased IgG level
|
J:86281
|
Fcgr1tm1Jgjw/Fcgr1tm1Jgjw
(involves: 129 * C57BL/6)
|
abnormal dendritic cell antigen presentation
|
J:112436
|
Fcgr1tm1Jsv/Fcgr1tm1Jsv
(involves: 129P2/OlaHsd * BALB/c)
|
abnormal dendritic cell antigen presentation
|
J:83995
|
abnormal macrophage physiology
|
J:83995
|
abnormal type I hypersensitivity reaction
|
J:83995
|
decreased susceptibility to autoimmune hemolytic anemia
|
J:83995
|
decreased susceptibility to induced arthritis
|
J:83995
|
increased susceptibility to bacterial infection
|
J:83995
|
Fcgr1tm1Jsv/Fcgr1tm1Jsv Fcgr2btm1Ttk/Fcgr2btm1Ttk Fcgr3tm1Jsv/Fcgr3tm1Jsv
(involves: 129P2/OlaHsd * 129S4/SvJae * BALB/c * C57BL/6)
|
impaired macrophage phagocytosis
|
J:83995
|
Fcgr2btm1.2Jsv/Fcgr2b+ X/Yaa
(involves: C57BL/6 * FVB/N * SB/Le)
|
increased anti-chromatin antibody level
|
J:179175
|
increased anti-double stranded DNA antibody level
|
J:179175
|
increased susceptibility to systemic lupus erythematosus
|
J:179175
|
Fcgr2btm1.2Jsv/Fcgr2btm1.2Jsv Sle16C57BL/6/Sle16C57BL/6
(involves: C57BL/6 * FVB/N)
|
abnormal adaptive immunity
|
J:179175
|
increased immunoglobulin level
|
J:179175
|
increased susceptibility to induced arthritis
|
J:179175
|
kidney inflammation
|
J:179175
|
Fcgr2btm1Kgcs/Fcgr2b+
(involves: C57BL/6)
|
decreased B cell apoptosis
|
J:190890
|
increased anti-chromatin antibody level
|
J:190890
|
increased anti-double stranded DNA antibody level
|
J:190890
|
increased IgG1 level
|
J:190890
|
increased IgG3 level
|
J:190890
|
increased IgM level
|
J:190890
|
increased susceptibility to induced arthritis
|
J:190890
|
Fcgr2btm1Ttk/Fcgr2btm1.2Jsv Sle21129P2/Ola/Sle21C57BL/6
(involves: 129P2/Ola * 129S4/SvJae * C57BL/6 * FVB/N)
|
increased anti-chromatin antibody level
|
J:179175
|
increased anti-double stranded DNA antibody level
|
J:179175
|
increased anti-histone antibody level
|
J:179175
|
increased anti-single stranded DNA antibody level
|
J:179175
|
increased susceptibility to systemic lupus erythematosus
|
J:179175
|
Fcgr2btm1Ttk/Fcgr2btm1Ttk
(involves: 129S4/SvJae)
|
abnormal mast cell physiology
|
J:31133
|
increased IgA level
|
J:31133
|
increased IgG1 level
|
J:31133
|
increased IgG2a level
|
J:31133
|
increased IgG2b level
|
J:31133
|
increased IgG3 level
|
J:31133
|
increased IgG level
|
J:31133
|
increased IgM level
|
J:31133
|
increased susceptibility to type I hypersensitivity reaction
|
J:31133
|
Fcgr2btm1Ttk/Fcgr2btm1Ttk
(C.129S4-Fcgr2btm1Ttk)
|
decreased susceptibility to parasitic infection
|
J:120905
|
Fcgr2btm1Ttk/Fcgr2btm1Ttk
(B6.129S4-Fcgr2btm1Ttk)
|
abnormal hypersensitivity reaction
|
J:64152
|
glomerulonephritis
|
J:64152
|
increased immunoglobulin level
|
J:64152
|
increased inflammatory response
|
J:64152
|
kidney inflammation
|
J:64152
|
liver inflammation
|
J:64152
|
lung inflammation
|
J:64152
|
pancreas inflammation
|
J:64152
|
salivary gland inflammation
|
J:64152
|
Fcgr2btm1Ttk/Fcgr2btm1Ttk
(Not Specified)
|
increased susceptibility to induced arthritis
|
J:106191
|
Fcgr2btm1Ttk/Fcgr2btm1Ttk Il17atm1Yiw/Il17a+
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
glomerulonephritis
|
J:191090
|
kidney inflammation
|
J:191090
|
Fcgr2btm1Ttk/Fcgr2btm1Ttk Il17atm1Yiw/Il17atm1Yiw
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
decreased susceptibility to systemic lupus erythematosus
|
J:191090
|
increased anti-double stranded DNA antibody level
|
J:191090
|
increased anti-nuclear antigen antibody level
|
J:191090
|
Fcgr2btm1Ttk/Fcgr2btm1Ttk Pdcd1tm1Hon/Pdcd1tm1Hon
(involves: 129S2/SvPas * 129S4/SvJae * BALB/c)
|
abnormal cytokine level
|
J:207275
|
abnormal urine cytokine level
|
J:207275
|
increased autoantibody level
|
J:207275
|
urinary bladder inflammation
|
J:207275
|
Fcgr2btm1Ttk/Fcgr2btm1Ttk Sle21129P2/Ola/Sle21129P2/Ola
(B6.129S4-Fcgr2btm1Ttk)
|
abnormal adaptive immunity
|
J:179175
|
increased anti-chromatin antibody level
|
J:179175
|
increased anti-double stranded DNA antibody level
|
J:179175
|
increased anti-histone antibody level
|
J:179175
|
increased anti-single stranded DNA antibody level
|
J:179175
|
increased autoantibody level
|
J:179175
|
increased IgG2a level
|
J:179175
|
increased immunoglobulin level
|
J:179175
|
increased susceptibility to induced arthritis
|
J:179175
|
increased susceptibility to systemic lupus erythematosus
|
J:179175
|
kidney inflammation
|
J:179175
|
Fcgr2btm1Ttk/Fcgr2btm1Ttk Tg(Ins2-TFRC/OVA)296Wehi/0
(involves: 129S4/SvJae * C57BL/6)
|
increased susceptibility to autoimmune diabetes
|
J:122114
|
Fcgr2btm1Ttk/Fcgr2btm1Ttk Tlr7tm1Flv/Y X/Yaa
(B6.Cg-Fcgr2btm1Ttk Tlr7tm1Flv Yaa)
|
abnormal splenocyte physiology
|
J:127600
|
autoimmune response
|
J:127600
|
increased anti-nuclear antigen antibody level
|
J:127600
|
increased susceptibility to systemic lupus erythematosus
|
J:127600
|
Fcgr2btm1Ttk/Fcgr2btm1Ttk Traf3ip2tm1Sbn/Traf3ip2+
(involves: 129 * 129S4/SvJae * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:191090
|
increased anti-nuclear antigen antibody level
|
J:191090
|
increased autoantibody level
|
J:191090
|
increased IgG level
|
J:191090
|
increased susceptibility to systemic lupus erythematosus
|
J:191090
|
kidney inflammation
|
J:191090
|
Fcgr2btm1Ttk/Fcgr2btm1Ttk Traf3ip2tm1Sbn/Traf3ip2tm1Sbn
(involves: 129 * 129S4/SvJae * C57BL/6)
|
decreased susceptibility to systemic lupus erythematosus
|
J:191090
|
increased anti-double stranded DNA antibody level
|
J:191090
|
increased anti-nuclear antigen antibody level
|
J:191090
|
increased autoantibody level
|
J:191090
|
increased IgG level
|
J:191090
|
Fcgr2btm1Ttk/Fcgr2btm1Ttk Traf3ip2tm2Sbn/Traf3ip2tm2Sbn Cd79atm1(cre)Reth/Cd79a+
(involves: 129S4/SvJae * BALB/c * C57BL/6)
|
glomerulonephritis
|
J:191090
|
Fcgr2btm1Ttk/Fcgr2btm1Ttk X/Yaa
(B6.Cg-Fcgr2btm1Ttk Yaa)
|
autoimmune response
|
J:127600
|
increased anti-nuclear antigen antibody level
|
J:127600
|
increased susceptibility to systemic lupus erythematosus
|
J:127600
|
Fcgr3tm1Jsv/Fcgr3tm1Jsv
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal dendritic cell antigen presentation
|
J:83995
|
abnormal type I hypersensitivity reaction
|
J:83995
|
decreased mast cell degranulation
|
J:35057
|
decreased susceptibility to autoimmune hemolytic anemia
|
J:83995
|
decreased susceptibility to type II hypersensitivity reaction
|
J:35057
|
impaired macrophage phagocytosis
|
J:35057
|
impaired natural killer cell mediated cytotoxicity
|
J:35057
|
Fcgr3tm1Jsv/Fcgr3tm1Jsv
(B6.129P2-Fcgr3tm1Jsv/J)
|
abnormal neutrophil physiology
|
J:78297
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:126520
|
decreased susceptibility to induced arthritis
|
J:106191
|
impaired neutrophil recruitment
|
J:78297
|
Fcgr3tm1Jsv/Fcgr3tm1Jsv Sle21129P2/Ola/Sle21129P2/Ola
(B6.129P2-Fcgr3tm1Jsv)
|
increased anti-chromatin antibody level
|
J:179175
|
increased anti-double stranded DNA antibody level
|
J:179175
|
increased anti-histone antibody level
|
J:179175
|
increased anti-single stranded DNA antibody level
|
J:179175
|
Fcgr3tm1Ttk/Fcgr3tm1Ttk
(involves: 129X1/SvJ)
|
decreased susceptibility to type I hypersensitivity reaction
|
J:107371
|
Fcgr4tm1.1Rav/Fcgr4tm1.1Rav
(involves: C57BL/6)
|
decreased susceptibility to induced arthritis
|
J:167375
|
Fcgr4tm1Rav/Fcgr4tm1Rav Tg(Ctsk-cre)1Rda/0
(involves: C57BL/6)
|
autoimmune arthritis
|
J:197378
|
Fcgrttm1Dcr/Fcgrttm1Dcr
(either: 129 or (involves: 129 * C57BL/6))
|
decreased IgG level
|
J:94189
|
Fcgrttm1Dcr/Fcgrttm1Dcr
(B6.129X1-Fcgrttm1Dcr/DcrJ)
|
decreased IgG level
|
J:110885
|
Fcgrttm1Esw/Fcgrttm1Esw Tg(Tek-cre)1Ywa/0
(B6.Cg-Tg(Tek-cre)1Ywa Fcgrttm1Esw)
|
abnormal humoral immune response
|
J:146640
|
decreased IgG1 level
|
J:146640
|
Fcmrtm1.2Khl/Fcmrtm1.2Khl
(involves: C57BL/6)
|
abnormal granulocyte physiology
|
J:194323
|
increased T cell apoptosis
|
J:174871
|
Fcmrtm1Mak/Fcmrtm1Mak
(B6.129S2-Fcmrtm1Mak)
|
abnormal cytokine secretion
|
J:194323
|
abnormal granulocyte physiology
|
J:194323
|
decreased interleukin-6 secretion
|
J:194323
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:194323
|
decreased tumor necrosis factor secretion
|
J:194323
|
impaired granulocyte bactericidal activity
|
J:194323
|
increased susceptibility to bacterial infection
|
J:194323
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:194323
|
Fcmrtm1Ohno/Fcmrtm1Ohno
(B6.129-Fcmrtm1Ohno)
|
abnormal immunoglobulin level
|
J:190117
|
abnormal response to infection
|
J:190117
|
decreased IgG1 level
|
J:190117
|
decreased IgM level
|
J:190117
|
increased anti-chromatin antibody level
|
J:190117
|
increased anti-double stranded DNA antibody level
|
J:190117
|
increased IgG3 level
|
J:190117
|
increased IgM level
|
J:190117
|
Fcnatm1Tefu/Fcnatm1Tefu
(B6.129-Fcnatm1Tefu)
|
impaired lectin complement pathway
|
J:190858
|
increased susceptibility to bacterial infection
|
J:190858
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:190858
|
Fcnatm1Tefu/Fcnatm1Tefu Fcnbtm1Tefu/Fcnbtm1Tefu
(B6.129-Fcnatm1Tefu Fcnbtm1Yend)
|
impaired lectin complement pathway
|
J:190858
|
increased susceptibility to bacterial infection
|
J:190858
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:190858
|
Fcnbtm1Tefu/Fcnbtm1Tefu
(B6.129-Fcnbtm1Yend)
|
increased susceptibility to bacterial infection
|
J:190858
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:190858
|
Fcrlatm1.1Cln/Fcrlatm1.1Cln
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal humoral immune response
|
J:163261
|
increased IgG1 level
|
J:163261
|
Fcrlbtm1Pdb/Fcrlbtm1Pdb
(B6.129-Fcrlbtm1Pdb)
|
increased anti-nuclear antigen antibody level
|
J:165408
|
increased IgG1 level
|
J:165408
|
Fdxrtm1Xch/Fdxr+
(B6.Cg-Fdxrtm1Xch)
|
chronic liver inflammation
|
J:244082
|
Fem1atm1Seno/Fem1atm1Seno
(C57BL/6-Fem1atm1Seno)
|
increased susceptibility to colitis induced morbidity/mortality
|
J:228893
|
increased susceptibility to induced colitis
|
J:228893
|
Fen1tm3.1Bhsh/Fen1+
(Not Specified)
|
chronic inflammation
|
J:231218
|
glomerulonephritis
|
J:231218
|
increased anti-double stranded DNA antibody level
|
J:231218
|
increased anti-nuclear antigen antibody level
|
J:231218
|
increased susceptibility to autoimmune disorder
|
J:231218
|
interstitial pneumonia
|
J:231218
|
lung inflammation
|
J:231218
|
Fen1tm3.1Bhsh/Fen1tm3.1Bhsh
(Not Specified)
|
chronic inflammation
|
J:231218
|
glomerulonephritis
|
J:231218
|
increased anti-double stranded DNA antibody level
|
J:231218
|
increased anti-nuclear antigen antibody level
|
J:231218
|
increased susceptibility to autoimmune disorder
|
J:231218
|
interstitial pneumonia
|
J:231218
|
lung inflammation
|
J:231218
|
Fermt1tm1Ref/Fermt1tm1Ref
(involves: 129S1/Sv * 129X1/SvJ)
|
ileum inflammation
|
J:142913
|
large intestinal inflammation
|
J:142913
|
Fermt3tm2.1Ref/Fermt3tm2.1Ref Tg(Cd4-cre)1Cwi/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
|
abnormal T cell physiology
|
J:203436
|
Festm1Mcs/Festm1Mcs
(involves: 129X1/SvJ)
|
abnormal macrophage physiology
|
J:64748
|
conjunctivitis
|
J:64748
|
increased susceptibility to bacterial infection
|
J:64748
|
Festm2Pag/Festm2Pag
(involves: 129S1/Sv * 129X1/SvJ * CD-1)
|
increased susceptibility to endotoxin shock
|
J:98590
|
Ffar2tm1Dgen/Ffar2tm1Dgen
(involves: C57BL/6)
|
abnormal granulocyte physiology
|
J:153951
|
abnormal neutrophil physiology
|
J:153951
|
impaired neutrophil chemotaxis
|
J:153951
|
impaired neutrophil phagocytosis
|
J:153951
|
increased susceptibility to induced arthritis
|
J:153951
|
increased susceptibility to induced colitis
|
J:153951
|
lung inflammation
|
J:153951
|
Ffar2tm2Lex/Ffar2tm2Lex
(involves: 129S7/SvEvBrd * C57BL/6)
|
abnormal cytokine level
|
J:157383
|
abnormal inflammatory response
|
J:157383
|
decreased circulating tumor necrosis factor level
|
J:157383
|
decreased susceptibility to induced colitis
|
J:157383
|
decreased tumor necrosis factor secretion
|
J:157383
|
impaired neutrophil chemotaxis
|
J:157383
|
increased circulating tumor necrosis factor level
|
J:157383
|
large intestinal inflammation
|
J:157383
|
sepsis
|
J:157383
|
Fgatm1Jld/Fgatm1Jld
(involves: 129P2/OlaHsd * CF-1)
|
decreased circulating fibrinogen level
|
J:28436
|
Fgatm1Jld/Fgatm1Jld
(B6.129P2-Fgatm1Jld)
|
decreased circulating fibrinogen level
|
J:28436
|
Fgf7tm1Efu/Fgf7tm1Efu
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal immune system physiology
|
J:129368
|
abnormal response to transplant
|
J:129368
|
Fgfr1Hspy/Fgfr1+
(C3HeB/FeJ-Hspy)
|
increased susceptibility to otitis media
|
J:95895
|
Fgfr1tm1Upir/Fgfr1tm1Upir Fgfr2tm1Dor/Fgfr2tm1Dor Tg(KRT5-cre)5132Jlj/0
(involves: 129X1/SvJ * C57BL/6 * C57BL/6J * DBA/2J)
|
abnormal chemokine level
|
J:221184
|
dermatitis
|
J:221184
|
increased IgE level
|
J:158802
|
increased IgG1 level
|
J:158802
|
increased IgG2a level
|
J:158802
|
skin inflammation
|
J:158802,
J:221184
|
Fgfr2tm1Dsn/Fgfr2tm1Dsn Tg(KRT5-cre)5132Jlj/0
(involves: 129P2/OlaHsd * C57BL/6J * DBA/2J)
|
adipose tissue inflammation
|
J:119723
|
skin inflammation
|
J:119723
|
Fgfr2tm1Ewj/Fgfr2+ Tg(EIIa-cre)C5379Lmgd/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * FVB/N)
|
bronchiolectasis
|
J:101174
|
Fgfr3tm3.1Cxd/Fgfr3tm3.1Cxd
(involves: 129S6/SvEvTac)
|
abnormal osteoclast physiology
|
J:69849
|
Fggtm1Lord/Fgg+
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased circulating fibrinogen level
|
J:129828
|
Fggtm1Lord/Fggtm1Lord
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased circulating fibrinogen level
|
J:129828
|
Fggtm2Jld/Fggtm2Jld
(involves: 129P2/OlaHsd * Black Swiss * C57BL/6)
|
abnormal neutrophil physiology
|
J:90908
|
increased susceptibility to bacterial infection
|
J:90908
|
Fgl1tm1b(EUCOMM)Hmgu/Fgl1tm1b(EUCOMM)Hmgu
(involves: BALB/cJ * C57BL/6N)
|
dermatitis
|
J:269578
|
increased anti-double stranded DNA antibody level
|
J:269578
|
Fgl2tm1Pam/Fgl2+
(involves: 129X1/SvJ * C57BL/6)
|
decreased susceptibility to Coronaviridae infection
|
J:99453
|
Fgl2tm1Pam/Fgl2tm1Pam
(involves: 129X1/SvJ * C57BL/6)
|
decreased susceptibility to Coronaviridae infection
|
J:99453
|
decreased susceptibility to Coronaviridae infection induced morbidity/mortality
|
J:99453
|
Fgl2tm1Pam/Fgl2tm1Pam
(B6.129X1-Fgl2tm1Pam)
|
abnormal B cell physiology
|
J:130895
|
abnormal dendritic cell physiology
|
J:130895
|
abnormal regulatory T cell physiology
|
J:130895
|
abnormal T cell physiology
|
J:130895
|
decreased dendritic cell apoptosis
|
J:130895
|
decreased susceptibility to Coronaviridae infection
|
J:99453
|
decreased susceptibility to Coronaviridae infection induced morbidity/mortality
|
J:99453
|
glomerulonephritis
|
J:130895
|
increased IgA level
|
J:130895
|
increased IgG level
|
J:130895
|
increased IgM level
|
J:130895
|
increased T cell proliferation
|
J:130895
|
Fgl2tm1Pam/Fgl2tm1Pam
(involves: 129X1/SvJ * C57BL/6J)
|
increased length of allograft survival
|
J:98997
|
FgrMhdaali18/Fgr+
(C3HeB/FeJ-FgrMhdaali18)
|
dermatitis
|
J:112868
|
increased inflammatory response
|
J:112868
|
FgrMhdaali18/FgrMhdaali18
(C3HeB/FeJ-FgrMhdaali18)
|
autoimmune arthritis
|
J:112868
|
dermatitis
|
J:112868
|
Fgrtm1Hev/Fgrtm1Hev
(involves: 129S7/SvEvBrd * C57BL/6)
|
abnormal interferon-gamma secretion
|
J:131738
|
Fgrtm1Hev/Fgrtm1Hev
(B6.129S7-Fgrtm1Hev)
|
abnormal inflammatory response
|
J:113463
|
Fgrtm1Hev/Fgrtm1Hev Hcktm1Hev/Hcktm1Hev
(involves: 129S7/SvEvBrd * C57BL/6J)
|
abnormal macrophage physiology
|
J:59037
|
impaired macrophage phagocytosis
|
J:16994
|
increased susceptibility to bacterial infection
|
J:16994
|
Fgrtm1Hev/Fgrtm1Hev Hcktm1Hev/Hcktm1Hev Lyntm1Sor/Lyntm1Sor
(B6.Cg-Hcktm1Hev Fgrtm1Hev Lyntm1Sor)
|
abnormal inflammatory response
|
J:113463
|
abnormal neutrophil physiology
|
J:113463
|
Fhip2bem1Wwan/Fhip2bem1Wwan
(involves: C57BL/6)
|
abnormal cytokine level
|
J:302658,
J:285283
|
increased susceptibility to induced colitis
|
J:285283
|
liver inflammation
|
J:302658
|
Fhittm1Hbn/Fhit+
(involves: 129X1/SvJ * C57BL/6)
|
increased susceptibility to infection
|
J:71303
|
Fhittm1Hbn/Fhittm1Hbn
(involves: 129X1/SvJ * C57BL/6)
|
increased susceptibility to infection
|
J:71303
|
Fibcd1tm1Spte/Fibcd1tm1Spte
(B6.129S1-Fibcd1tm1Spte)
|
abnormal interferon secretion
|
J:340107
|
abnormal tumor necrosis factor level
|
J:340107
|
decreased cytokine level
|
J:340107
|
decreased susceptibility to fungal infection
|
J:340107
|
decreased susceptibility to infection induced morbidity/mortality
|
J:340107
|
increased cytokine level
|
J:340107
|
Fignfi/Fignfi
(mixed)
|
conjunctivitis
|
J:13035
|
eye inflammation
|
J:13035
|
Fis1tm1.1Itl/Fis1tm1.1Itl Tg(Ckmm-cre)5Khn/0
(involves: C57BL/6NTac * FVB)
|
increased circulating interferon-beta level
|
J:290485
|
increased circulating interleukin-6 level
|
J:290485
|
increased circulating interleukin-12b level
|
J:290485
|
increased circulating interleukin-13 level
|
J:290485
|
Fitm2tm1.1Dls/Fitm2tm1.1Dls Tg(Fabp4-cre)1Rev/?
(involves: 129S6/SvEvTac * C57BL/6J)
|
increased circulating tumor necrosis factor level
|
J:212437
|
Fkbp11Gt(OST298786)Lex/Fkbp11Gt(OST298786)Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
|
increased immunoglobulin level
|
J:103485
|
increased inflammatory response
|
J:103485
|
Fkrptm1Scbr/Fkrptm1Scbr Sox1tm1(cre)Take/Sox1+
(involves: C57BL/6NCrlj * CBA/JNCrlj)
|
myositis
|
J:207119
|
Fkrptm1Scbr/Fkrptm1Scbr Sox1tm1(cre)Take/Sox1+ Tg(CAG-LARGE)126Fmu/0
(involves: C57BL/6NCrlj * C57BL/10 * CBA/Ca * CBA/JNCrlj)
|
myositis
|
J:207119
|
Flgft/Flgft
(involves: C57BL/6)
|
skin inflammation
|
J:151110
|
Flgft/Flgft
(B6.Cg-Flgft)
|
increased IgE level
|
J:202453,
J:151110
|
increased IgG1 level
|
J:151110
|
increased IgG2a level
|
J:151110
|
increased IgG level
|
J:151110
|
increased interferon-gamma secretion
|
J:151110
|
increased interleukin-4 secretion
|
J:151110
|
increased interleukin-5 secretion
|
J:151110
|
increased interleukin-10 secretion
|
J:151110
|
increased interleukin-13 secretion
|
J:151110
|
increased interleukin-17 secretion
|
J:151110
|
increased splenocyte proliferation
|
J:151110
|
Flgft/Flgft
(Not Specified)
|
dermatitis
|
J:198332
|
Flgft/Flgft
(STOCK a/a Tmem79ma Flgft/J)
|
abnormal cytokine level
|
J:204304
|
dermatitis
|
J:204304
|
Flgft/Flgft Tmem79ma/Tmem79ma
(involves: CBA/CaGr)
|
blepharitis
|
J:202453
|
increased IgE level
|
J:202453
|
skin inflammation
|
J:202453
|
Flgtm1Amag/Flgtm1Amag
(involves: 129S6/SvEvTac * BALB/c * C57BL/6NTac)
|
abnormal humoral immune response
|
J:198332
|
dermatitis
|
J:198332
|
increased IgE level
|
J:198332
|
increased IgG1 level
|
J:198332
|
increased inflammatory response
|
J:229771
|
increased susceptibility to type IV hypersensitivity reaction
|
J:198332
|
Flgtm1Amag/Flgtm1Amag Tg(CD207-Dta)312Dhka/0
(involves: 129S6/SvEvTac * BALB/c * C57BL/6NTac * FVB)
|
decreased inflammatory response
|
J:229771
|
Fli1tm1.1Dkw/Fli1tm1.1Dkw
(B6.129S6-Fli1tm1.1Dkw)
|
abnormal class switch recombination
|
J:137876
|
abnormal humoral immune response
|
J:137876
|
decreased B cell proliferation
|
J:137876
|
decreased IgG1 level
|
J:137876
|
decreased IgG3 level
|
J:137876
|
Flicrem1Doi/Flicrem1Doi
(NOD/ShiLtDoi-Flicrem1Doi)
|
decreased susceptibility to autoimmune diabetes
|
J:241346
|
insulitis
|
J:241346
|
Flot1tm1.1Arte/Flot1tm1.1Arte
(involves: C57BL/6J)
|
abnormal leukocyte physiology
|
J:166672
|
impaired neutrophil chemotaxis
|
J:166672
|
impaired neutrophil recruitment
|
J:166672
|
Flt1tm1Msh/Flt1tm1Msh
(involves: 129S4/SvJae * C57BL/6J)
|
impaired macrophage chemotaxis
|
J:49507
|
Flt3m1Btlr/Flt3m1Btlr
(C57BL/6J-Flt3m1Btlr)
|
abnormal dendritic cell antigen presentation
|
J:159599
|
abnormal dendritic cell physiology
|
J:159599
|
abnormal macrophage physiology
|
J:105543
|
abnormal NK cell physiology
|
J:159599
|
decreased circulating interferon-alpha level
|
J:159599
|
decreased circulating interferon-gamma level
|
J:159599
|
decreased circulating interleukin-12 level
|
J:159599
|
decreased interferon-alpha secretion
|
J:159599
|
decreased interferon-gamma secretion
|
J:159599
|
decreased interleukin-12 secretion
|
J:159599
|
increased circulating interleukin-6 level
|
J:159599
|
increased circulating tumor necrosis factor level
|
J:159599
|
increased susceptibility to Herpesvirales infection
|
J:105543
|
increased susceptibility to Herpesvirales infection induced morbidity/mortality
|
J:159599
|
increased susceptibility to Riboviria infection
|
J:105543
|
Flt3ltm1Imx/Flt3ltm1Imx
(C57BL/6-Flt3ltm1Imx)
|
increased IgM level
|
J:62536
|
increased length of allograft survival
|
J:89868
|
Flt3ltm1Imx/Flt3ltm1Imx
(involves: C57BL/6)
|
abnormal dendritic cell antigen presentation
|
J:223508
|
abnormal dendritic cell chemotaxis
|
J:223508
|
abnormal memory T cell physiology
|
J:189122
|
abnormal T-helper 1 physiology
|
J:189122
|
increased susceptibility to parasitic infection
|
J:189122
|
Flt4Chy/Flt4+
(involves: C3H)
|
abnormal lymph circulation
|
J:72387
|
Flt4tm2Ali/Flt4+
(involves: 129S1/Sv * 129X1/SvJ * ICR)
|
abnormal lymph circulation
|
J:137909
|
Flvcr2tm1.2Tda/Flvcr2tm1.2Tda
(involves: C57BL/6J)
|
brain inflammation
|
J:287134
|
Flvcr2tm1a(EUCOMM)Hmgu/Flvcr2tm1a(EUCOMM)Hmgu
(C57BL/6N-Flvcr2tm1a(EUCOMM)Hmgu/Wtsi)
|
blood in lymph vessels
|
J:239583
|
Fmnl1tm1.2Sdb/Fmnl1tm1.2Sdb Lyz2tm1(cre)Ifo/Lyz2tm1(cre)Ifo
(involves: C3H * C57BL/6 * FVB/N)
|
abnormal macrophage physiology
|
J:250144
|
impaired macrophage chemotaxis
|
J:250144
|
Fmo1em1Anz/Fmo1em1Anz
(involves: C57BL/6N)
|
increased cytokine level
|
J:312983
|
Fmodtm1Aol/Fmodtm1Aol
(involves: 129S1/Sv * 129X1/SvJ * CD-1)
|
osteoarthritis
|
J:79115
|
Fmodtm1Aol/Fmodtm1Aol Lumtm1Chak/Lumtm1Chak
(involves: 129S1/Sv * 129X1/SvJ * CD-1)
|
osteoarthritis
|
J:79115
|
Fndc4tm1.1Mabo/Fndc4tm1.1Mabo
(involves: C57BL/6 * BALB/c)
|
increased susceptibility to induced colitis
|
J:236896
|
Fnip1Gt(RRM154)Byg/Fnip1Gt(RRM154)Byg
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased B cell apoptosis
|
J:189078
|
Fnip1LPAB.1/Fnip1LPAB.1
(C57BL/6J-Fnip1LPAB.1)
|
abnormal B cell physiology
|
J:187318
|
decreased IgE level
|
J:187318
|
decreased IgG1 level
|
J:187318
|
decreased IgG2a level
|
J:187318
|
decreased IgG level
|
J:187318
|
decreased IgM level
|
J:187318
|
increased B cell apoptosis
|
J:187318
|
Fnip1LPAB.1/Fnip1LPAB.1 Tg(IghMyc)22Bri/0
(involves: C57BL * C57BL/6J * SJL)
|
increased B cell apoptosis
|
J:187318
|
Fnip1m1Btlr/Fnip1m1Btlr
(C57BL/6J-Fnip1m1Btlr)
|
decreased IgM level
|
J:234285
|
Fnip1tm1.2Baba/Fnip1tm1.2Baba
(involves: C57BL/6 * C57BL/6J * FVB/N * SJL)
|
increased B cell apoptosis
|
J:189078
|
Fostm1Wag/Fostm1Wag
(involves: 129S2/SvPas * C57BL/6)
|
abnormal cytokine secretion
|
J:118693
|
abnormal macrophage physiology
|
J:118693
|
increased macrophage apoptosis
|
J:118693
|
increased macrophage cytokine production
|
J:118693
|
increased susceptibility to bacterial infection
|
J:118693
|
Fostm3.1Wag/Fostm3.1Wag
(involves: 129P2/OlaHsd * C57BL/6 * SJL)
|
decreased interleukin-10 secretion
|
J:175064
|
increased susceptibility to endotoxin shock
|
J:175064
|
increased tumor necrosis factor secretion
|
J:175064
|
Fostm4.1Wag/Fostm4.1Wag
(involves: 129P2/OlaHsd * C57BL/6 * SJL)
|
decreased interleukin-10 secretion
|
J:175064
|
increased interleukin-6 secretion
|
J:175064
|
increased susceptibility to endotoxin shock
|
J:175064
|
increased tumor necrosis factor secretion
|
J:175064
|
Fostm5.1Wag/Fostm5.1Wag
(involves: 129P2/OlaHsd * C57BL/6 * SJL)
|
decreased interleukin-10 secretion
|
J:175064
|
increased circulating tumor necrosis factor level
|
J:175064
|
increased interleukin-6 secretion
|
J:175064
|
increased susceptibility to endotoxin shock
|
J:175064
|
increased tumor necrosis factor secretion
|
J:175064
|
Fostm6.1Wag/Fostm6.1Wag
(involves: 129P2/OlaHsd * C57BL/6 * SJL)
|
increased circulating interleukin-6 level
|
J:175064
|
increased circulating interleukin-10 level
|
J:175064
|
increased circulating tumor necrosis factor level
|
J:175064
|
increased susceptibility to endotoxin shock
|
J:175064
|
Fostm7Wag/Fostm7Wag Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased interleukin-10 secretion
|
J:175064
|
increased circulating interleukin-6 level
|
J:175064
|
increased circulating interleukin-10 level
|
J:175064
|
increased circulating tumor necrosis factor level
|
J:175064
|
increased interleukin-6 secretion
|
J:175064
|
increased susceptibility to endotoxin shock
|
J:175064
|
increased tumor necrosis factor secretion
|
J:175064
|
Fosl2tm2.1Wag/Fosl2tm2.1Wag
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal osteoclast physiology
|
J:137646
|
Foxa1tm1(cre)Sew/Foxa1+ Mst1rtm1Sew/Mst1rtm1Sew
(involves: 129P2/OlaHsd * CD-1 * NIH Black Swiss)
|
decreased susceptibility to bacterial infection
|
J:105979
|
Foxa2tm1.1Khk/Foxa2+
(involves: 129P2/OlaHsd * C57BL/6 * CD-1)
|
respiratory system inflammation
|
J:284174
|
Foxc2tm1Miu/Foxc2+
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J)
|
abnormal lymph circulation
|
J:83436
|
Foxf1em1Vvk/Foxf1+
(involves: C57BL/6 * DBA/2)
|
lung inflammation
|
J:296328
|
Foxm1tm1Rhc/Foxm1tm1Rhc Tg(Tek-cre)1Ywa/0
(involves: 129X1/SvJ * C57BL/6 * SJL)
|
lung inflammation
|
J:167773
|
Foxn1nu-str/Foxn1nu-str
(AKR/J-Foxn1nu-str/J)
|
abnormal humoral immune response
|
J:30715
|
abnormal immune system physiology
|
J:30715
|
decreased immunoglobulin level
|
J:30715
|
increased length of allograft survival
|
J:30715
|
Foxn1nu/Foxn1+
(involves: BALB/c)
|
blepharitis
|
J:12543
|
increased incidence of corneal inflammation
|
J:12543
|
increased susceptibility to Herpesvirales infection
|
J:12543
|
Foxn1nu/Foxn1nu
(B6NTac.Cg-Foxn1nu/Tac)
|
decreased susceptibility to parasitic infection
|
J:64283
|
Foxn1nu/Foxn1nu
(involves: BALB/c)
|
abnormal circulating cytokine level
|
J:50903
|
blepharitis
|
J:12543
|
decreased circulating interleukin-2 level
|
J:50903
|
decreased circulating interleukin-6 level
|
J:50903
|
decreased circulating tumor necrosis factor level
|
J:50903
|
decreased interferon-gamma secretion
|
J:50903
|
decreased susceptibility to bacterial infection
|
J:50903
|
increased susceptibility to Herpesvirales infection
|
J:12543
|
increased susceptibility to Herpesvirales infection induced morbidity/mortality
|
J:12543
|
Foxn1nu/Foxn1nu
(involves: CBA)
|
abnormal spleen physiology
|
J:202299
|
abnormal T cell activation
|
J:202299
|
increased length of allograft survival
|
J:202299
|
Foxn1nu/Foxn1nu Fv4r/Fv4r
(involves: BALB/c)
|
decreased susceptibility to Retroviridae infection
|
J:5714,
J:5684
|
Foxn1nu/Foxn1nu Tgfb1tm1Doe/Tgfb1tm1Doe
(involves: 129S2/SvPas * BALB/c * CF-1)
|
abnormal T cell physiology
|
J:99033
|
decreased inflammatory response
|
J:99033
|
Foxn1nu/Foxn1tm1.1Dmsu Tg(CAG-cre/Esr1*)5Amc/0
(involves: 129/Sv * C57BL/6 * CBA * SJL)
|
increased thymocyte apoptosis
|
J:159773
|
Foxo1tm1.1Stlp/Foxo1tm1.1Stlp Tg(Lck-cre)1Cwi/0
(involves: 129S4/SvJae)
|
decreased T cell proliferation
|
J:154205
|
decreased thymocyte apoptosis
|
J:154205
|
Foxo1tm1Flv/Foxo1tm1Flv Foxp3tm4(YFP/icre)Ayr/Foxp3+
(involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ)
|
abnormal inflammatory response
|
J:189962
|
abnormal regulatory T cell physiology
|
J:189962
|
increased interferon-gamma secretion
|
J:189962
|
increased T cell proliferation
|
J:189962
|
Foxo1tm1Flv/Foxo1tm1Flv Ndor1Tg(UBC-cre/ERT2)1Ejb/0
(involves: 129S/SvEv * 129S6/SvEvTac * C57BL/6)
|
increased interferon-gamma secretion
|
J:189962
|
Foxo1tm1Flv/Foxo1tm1Flv Tg(Cd4-cre)1Cwi/?
(involves: 129S6/SvEvTac * C57BL/6 * DBA/2)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:147057
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:147057
|
abnormal T cell activation
|
J:147057
|
abnormal T cell physiology
|
J:147057
|
increased anti-double stranded DNA antibody level
|
J:147057
|
increased anti-nuclear antigen antibody level
|
J:147057
|
increased susceptibility to induced colitis
|
J:147057
|
increased T cell proliferation
|
J:147057
|
Foxo1tm2.1Dac/Foxo1tm2.1Dac
(B6.Cg-Foxo1tm2.1Dac)
|
decreased circulating tumor necrosis factor level
|
J:179687
|
Foxo3Gt(XAO26)Byg/Foxo3Gt(XAO26)Byg
(involves: 129P2/OlaHsd)
|
abnormal T cell activation
|
J:93593
|
abnormal T cell physiology
|
J:93593
|
increased inflammatory response
|
J:93593
|
increased T cell proliferation
|
J:93593
|
kidney inflammation
|
J:93593
|
lung inflammation
|
J:93593
|
salivary gland inflammation
|
J:93593
|
Foxo3tm1.1Rdp/Foxo3tm1.1Rdp
(involves: 129S6/SvEvTac * FVB/N)
|
dermatitis
|
J:118179
|
Foxo6tm1(KOMP)Vlcg/Foxo6tm1(KOMP)Vlcg
(B6J.B6NTac-Foxo6tm1(KOMP)Vlcg)
|
impaired macrophage chemotaxis
|
J:236585
|
Foxp1tm1.1Pwt/Foxp1tm1.1Pwt Tg(Cd4-cre)1Cwi/0
(involves: 129 * C57BL/6 * DBA/2)
|
abnormal T cell activation
|
J:156832
|
increased T cell apoptosis
|
J:156832
|
Foxp1tm1Rao/Foxp1tm1Rao
(B6.129-Foxp1tm1Rao)
|
abnormal B cell physiology
|
J:112644
|
Foxp3sf/Y
(either: 129Rl.Cg-Foxp3sf or (involves: 101/Rl * C3Hf/Rl * STOCK MR))
|
abnormal B cell physiology
|
J:11262
|
blepharitis
|
J:11262
|
dermatitis
|
J:11262
|
increased IgG level
|
J:11262
|
increased IgM level
|
J:11262
|
increased inflammatory response
|
J:11262
|
liver inflammation
|
J:11262
|
Foxp3sf/Y
(involves: 101/H * C3H/HeH * STOCK MR)
|
conjunctivitis
|
J:10398
|
Foxp3sf/?
(Not Specified)
|
liver inflammation
|
J:138808
|
lung inflammation
|
J:138808
|
Foxp3sf/Y
(B6.Cg-Foxp3sf)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:82560
|
Foxp3sf/Y
(B6.Cg-Foxp3sf/J)
|
lung inflammation
|
J:125129
|
salivary gland inflammation
|
J:125129
|
skin inflammation
|
J:125129
|
Foxp3tm1(CD2/CD52)Shori/Foxp3tm1(CD2/CD52)Shori
(involves: C57BL/6)
|
increased susceptibility to type IV hypersensitivity reaction
|
J:171378
|
Foxp3tm1(cre)Saka/Y
(involves: BALB/c)
|
increased autoantibody level
|
J:140085
|
stomach inflammation
|
J:140085
|
Foxp3tm1.1Ayr/Y
(involves: 129S1/Sv * 129X1/SvJ)
|
increased susceptibility to autoimmune disorder
|
J:82560
|
skin inflammation
|
J:82560
|
Foxp3tm1.1Ayr/Y
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
dermatitis
|
J:117743
|
increased susceptibility to autoimmune disorder
|
J:117743
|
liver inflammation
|
J:117743
|
lung inflammation
|
J:117743
|
lymph node inflammation
|
J:117743
|
Foxp3tm1.1Ayr/Foxp3tm1.1Ayr
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
dermatitis
|
J:117743
|
increased susceptibility to autoimmune disorder
|
J:117743
|
liver inflammation
|
J:117743
|
lung inflammation
|
J:117743
|
lymph node inflammation
|
J:117743
|
Foxp3tm1.1Ayr/Foxp3tm1.1Ayr Mir146tm1.1Bal/Mir146tm1.1Bal
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal lymphocyte physiology
|
J:167922
|
blepharitis
|
J:167922
|
conjunctivitis
|
J:167922
|
decreased interferon-gamma secretion
|
J:167922
|
dermatitis
|
J:167922
|
Foxp3tm1.1Mal/Foxp3tm1.1Mal Lattm1.1Mal/Lattm1.1Mal
(involves: 129S2/SvPas * C57BL/6)
|
abnormal regulatory T cell physiology
|
J:131351
|
Foxp3tm1Ayr/Y Tg(Cd4-cre)1Cwi/0
(involves: C57BL/6 * DBA/2)
|
dermatitis
|
J:97029
|
increased susceptibility to autoimmune disorder
|
J:97029
|
Foxp3tm1Kuch/? Il6tm1Kopf/Il6tm1Kopf
(involves: 129S2/SvPas * C57BL/6)
|
decreased circulating interleukin-6 level
|
J:123352
|
decreased interleukin-17 secretion
|
J:123352
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:123352
|
Foxp3tm1Tch/Y
(C.129X1-Foxp3tm1Tch)
|
abnormal chemokine level
|
J:117165
|
abnormal cytokine secretion
|
J:117165
|
abnormal inflammatory response
|
J:117165
|
abnormal lymphocyte physiology
|
J:117165
|
dermatitis
|
J:117165
|
increased circulating interferon-gamma level
|
J:117165
|
increased circulating interleukin-4 level
|
J:117165
|
increased circulating interleukin-5 level
|
J:117165
|
increased circulating interleukin-6 level
|
J:117165
|
increased circulating interleukin-10 level
|
J:117165
|
increased circulating tumor necrosis factor level
|
J:117165
|
increased IgE level
|
J:117165
|
increased IgG1 level
|
J:117165
|
respiratory system inflammation
|
J:117165
|
Foxp3tm1Tch/Y
(B6.129X1-Foxp3tm1Tch)
|
abnormal inflammatory response
|
J:117165
|
dermatitis
|
J:117165
|
increased IgE level
|
J:117165
|
respiratory system inflammation
|
J:117165
|
Foxp3tm1Tch/Y Stat6tm1Gru/Stat6tm1Gru
(C.129-Stat6tm1Gru Foxp3tm1Tch)
|
abnormal cytokine secretion
|
J:117165
|
increased circulating interferon-gamma level
|
J:117165
|
Foxp3tm2.1(EGFP/cre)Shori/Y Pdcd1tm1Hon/Pdcd1tm1Hon
(involves: 129 * 129S2/SvPas * C57BL/6)
|
increased susceptibility to autoimmune disorder
|
J:234397
|
pancreas inflammation
|
J:234397
|
Foxp3tm2Ayr/Foxp3+ Rnf128tm1Cdon/Rnf128tm1Cdon
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal regulatory T cell physiology
|
J:160681
|
Foxp3tm2Flv/Y
(involves: C57BL/6)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:118631
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:118631
|
abnormal immune system physiology
|
J:118631
|
blepharitis
|
J:118631
|
increased autoantibody level
|
J:118631
|
Foxp3tm3(HBEGF/GFP)Ayr/Foxp3+ Gpr174tm1Cys/Gpr174+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:222307
|
Foxp3tm3(HBEGF/GFP)Ayr/Foxp3tm3(HBEGF/GFP)Ayr
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:117743
|
abnormal dendritic cell physiology
|
J:117743
|
conjunctivitis
|
J:117743
|
dermatitis
|
J:117743
|
increased susceptibility to autoimmune disorder
|
J:117743
|
liver inflammation
|
J:117743
|
lung inflammation
|
J:117743
|
lymph node inflammation
|
J:117743
|
Foxp3tm3Tch/Y
(C.129X1-Foxp3tm3Tch)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:120636
|
abnormal cytokine secretion
|
J:120636
|
abnormal lymphocyte physiology
|
J:120636
|
abnormal regulatory T cell physiology
|
J:120636
|
colitis
|
J:120636
|
increased T cell proliferation
|
J:120636
|
Foxp3tm3Tch/Foxp3+
(C.129X1-Foxp3tm3Tch)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:120636
|
increased T cell apoptosis
|
J:120636
|
Foxp3tm4(YFP/icre)Ayr/Y Zfp91tm1Smoc/Zfp91tm1Smoc
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal regulatory T cell physiology
|
J:306129
|
increased susceptibility to autoimmune disorder
|
J:306129
|
increased susceptibility to induced colitis
|
J:306129
|
Foxp3tm4(YFP/icre)Ayr/Foxp3+ Nr4a2tm1.1Pcn/Nr4a2tm1.1Pcn
(involves: 129S1/Sv * 129X1/SvJ)
|
abnormal regulatory T cell physiology
|
J:205658
|
Foxp3tm4(YFP/icre)Ayr/Foxp3tm4(YFP/icre)Ayr Ikzf4tm1Djr/Ikzf4tm1Djr
(involves: 129S1/Sv * 129X1/SvJ)
|
chronic inflammation
|
J:294549
|
glomerulonephritis
|
J:294549
|
granulomatous inflammation
|
J:294549
|
increased immunoglobulin level
|
J:294549
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:294549
|
small intestinal inflammation
|
J:294549
|
Foxp3tm8Ayr/Y
(B6.129-Foxp3tm8Ayr)
|
autoimmune response
|
J:157377
|
Foxp3tm9(EGFP/cre/ERT2)Ayr/Foxp3+ Il1r2tm1.1Mchc/Il1r2tm1.1Mchc
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * C57BL/6NTac)
|
abnormal adaptive immunity
|
J:347877
|
increased IgG level
|
J:347877
|
Foxq1sa/Foxq1sa
(involves: 101/Rl * C3H/Rl)
|
impaired natural killer cell mediated cytotoxicity
|
J:7649
|
Foxq1sa/Foxq1sa Lystbg/Lystbg
(involves: 101/Rl * C3H/Rl * C57BL/6J * C57BL10/Rl)
|
increased susceptibility to infection
|
J:5311
|
interstitial pneumonia
|
J:15166,
J:5311
|
Foxq1sa/Foxq1sa Lystbg/Lystbg
(involves: 101/Rl * C3H/Rl * C57BL10/Rl)
|
interstitial pneumonia
|
J:5311
|
lung inflammation
|
J:5311
|
Fpr1tm1Gao/Fpr1tm1Gao
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal innate immunity
|
J:53354
|
impaired neutrophil chemotaxis
|
J:53354
|
increased susceptibility to bacterial infection
|
J:53354
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:53354
|
Fpr2tm1.1Jimw/Fpr2tm1.1Jimw Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * 129X1/SvJ)
|
decreased susceptibility to induced colitis
|
J:197568
|
Fpr2tm1.2Jimw/Fpr2tm1.2Jimw
(B6.129X1-Fpr2tm1.2Jimw)
|
abnormal cytokine secretion
|
J:160074
|
abnormal dendritic cell physiology
|
J:160074
|
abnormal innate immunity
|
J:160074
|
decreased IgE level
|
J:160074
|
decreased IgG1 level
|
J:160074
|
decreased IgG2b level
|
J:160074
|
decreased immunoglobulin level
|
J:160074
|
decreased inflammatory response
|
J:160074
|
decreased interferon-gamma secretion
|
J:160074
|
decreased interleukin-2 secretion
|
J:160074
|
decreased interleukin-4 secretion
|
J:160074
|
decreased interleukin-5 secretion
|
J:160074
|
decreased interleukin-13 secretion
|
J:160074
|
impaired macrophage chemotaxis
|
J:160074
|
impaired neutrophil chemotaxis
|
J:160074
|
Fpr2tm1.2Jimw/Fpr2tm1.2Jimw
(involves: 129X1/SvJ)
|
abnormal dendritic cell chemotaxis
|
J:199611
|
abnormal dendritic cell physiology
|
J:199611
|
colitis
|
J:197568
|
decreased acute inflammation
|
J:197568
|
Fpr2tm1Rjf/Fpr2tm1Rjf
(involves: 129S/SvEv * C57BL/6)
|
abnormal neutrophil physiology
|
J:159658
|
impaired macrophage chemotaxis
|
J:159658
|
increased acute inflammation
|
J:159658
|
increased susceptibility to induced arthritis
|
J:159658
|
fpw/fpw
(involves: C3H/HeJ * C57BL/6J)
|
decreased circulating interferon-gamma level
|
J:151726
|
decreased circulating interleukin-1 alpha level
|
J:151726
|
decreased circulating interleukin-6 level
|
J:151726
|
increased circulating interleukin-10 level
|
J:151726
|
increased circulating tumor necrosis factor level
|
J:151726
|
Frmd8em2Smoc/Frmd8em2Smoc Tg(Vil1-cre)997Gum/0
(involves: C57BL/6J * SJL)
|
increased susceptibility to colitis induced morbidity/mortality
|
J:338904
|
increased susceptibility to induced colitis
|
J:338904
|
FrylGt(Ayu21-T312)Imeg/FrylGt(Ayu21-T312)Imeg
(B6J.Cg-FrylGt(Ayu21-T312)Imeg)
|
kidney inflammation
|
J:260667
|
Fscn1Gt(OST124903)Lex/Fscn1Gt(OST124903)Lex
(B6.129S5-Fscn1Gt(OST124903)Lex)
|
abnormal dendritic cell chemotaxis
|
J:169408
|
abnormal dendritic cell physiology
|
J:169408
|
abnormal Langerhans cell physiology
|
J:169408
|
Fth1tm1.1Lck/Fth1tm1.1Lck Tg(Mx1-cre)1Cgn/0
(B6.Cg-Fth1tm1.1Lck Tg(Mx1-cre)1Cgn)
|
liver inflammation
|
J:166515
|
Ftotm1.2Pzg/Ftotm1.2Pzg
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6)
|
dermatitis
|
J:166984
|
Ftotm1.3Pzg/Ftotm1.3Pzg
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6)
|
dermatitis
|
J:166984
|
Fts/Fts+
(B6.Cg-Fts)
|
abnormal T cell physiology
|
J:108193
|
Furintm1Jwmc/Furintm1Jwmc Tg(Cd4-cre)1Cwi/0
(involves: 129P2/OlaHsd * C57BL/6 * SJL)
|
abnormal regulatory T cell physiology
|
J:204761
|
FusGt(U3NeoSV1)HO14Ggh/FusGt(U3NeoSV1)HO14Ggh
(B6.129S2-FusGt(U3NeoSV1)HO14Ggh)
|
abnormal immunoglobulin level
|
J:60213
|
Fut2tm1Sdo/Fut2tm1Sdo
(B6.129X1-Fut2tm1Sdo)
|
increased susceptibility to fungal infection
|
J:90993
|
Fut4tm1Jbl/Fut4tm1Jbl
(B6.129S2-Fut4tm1Jbl)
|
impaired leukocyte tethering or rolling
|
J:79397
|
Fut4tm1Jbl/Fut4tm1Jbl Fut7tm1Jbl/Fut7tm1Jbl
(B6.129S2-Fut7tm1Jbl Fut4tm1Jbl)
|
abnormal leukocyte migration
|
J:79397
|
abnormal leukocyte physiology
|
J:79397
|
abnormal neutrophil physiology
|
J:79397
|
decreased susceptibility to bacterial infection
|
J:115682
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:79388
|
impaired leukocyte tethering or rolling
|
J:79397
|
Fut7tm1Jbl/Fut7tm1Jbl
(involves: 129S2/SvPas * C57BL/6J * DBA/2J)
|
abnormal granulocyte physiology
|
J:35023
|
abnormal immune system physiology
|
J:35023
|
abnormal leukocyte adhesion
|
J:35023
|
abnormal leukocyte migration
|
J:35023
|
abnormal leukocyte physiology
|
J:35023
|
abnormal leukocyte tethering or rolling
|
J:35023
|
impaired neutrophil recruitment
|
J:35023
|
Fut7tm1Jbl/Fut7tm1Jbl
(B6.129S2-Fut7tm1Jbl)
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:79388,
J:74776
|
impaired neutrophil recruitment
|
J:79397
|
Fut8em1(IMPC)Wtsi/Fut8em1(IMPC)Wtsi
(C57BL/6N-Fut8em1(IMPC)Wtsi/Wtsi)
|
blood in lymph vessels
|
J:239583
|
Fv4r/Fv4+
(involves: AKR/J * BALB/c * FRG)
|
decreased susceptibility to Retroviridae infection
|
J:5714,
J:5684
|
Fxntm1Mkn/Fxntm1Mkn Tg(FXN)YG8Pook/0
(involves: 129/Sv * C57BL/6 * CBA)
|
brain inflammation
|
J:216422
|
Fxntm1Mkn/Fxntm1Pand
(involves: 129/Sv * C57BL/6)
|
brain inflammation
|
J:216422
|
Fyb1tm1Gak/Fyb1tm1Gak
(involves: 129S1/Sv * 129X1/SvJ)
|
abnormal leukocyte adhesion
|
J:111368
|
abnormal T cell physiology
|
J:126545
|
decreased interleukin-2 secretion
|
J:111368,
J:126545
|
decreased T cell proliferation
|
J:111368,
J:126545
|
Fyntm1Rmp/Fyntm1Rmp
(involves: 129S2/SvPas * C57BL/6)
|
abnormal T cell activation
|
J:70886
|
abnormal thymocyte activation
|
J:70886
|
decreased T cell proliferation
|
J:70886
|
Fyntm1Rmp/Fyntm1Rmp
(B6.129S2-Fyntm1Rmp)
|
abnormal eosinophil physiology
|
J:114287
|
abnormal interleukin-4 secretion
|
J:114287
|
decreased IgE level
|
J:114287
|
decreased interleukin-2 secretion
|
J:114287
|
increased interleukin-5 secretion
|
J:114287
|
increased susceptibility to type I hypersensitivity reaction
|
J:114287
|
Fyntm1Sor/Fyntm1Sor
(either: 129S7/SvEvBrd-Fyntm1Sor or (involves: 129S7/SvEvBrd * C57BL/6J))
|
abnormal immune cell physiology
|
J:2242
|
abnormal T cell clonal deletion
|
J:2242
|
abnormal T cell physiology
|
J:2242
|
abnormal thymocyte activation
|
J:2242
|
decreased interleukin-2 secretion
|
J:2242
|
decreased T cell proliferation
|
J:2242
|
increased IgG2a level
|
J:2242
|
increased IgM level
|
J:2242
|
Fyntm1Sor/Fyntm1Sor
(B6.129S7-Fyntm1Sor)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:93886
|
abnormal NK cell physiology
|
J:187430
|
abnormal T cell proliferation
|
J:93886
|
decreased IgE level
|
J:93886
|
decreased interferon-gamma secretion
|
J:187430
|
Fyntm1Sor/Fyntm1Sor
(involves: 129S7/SvEvBrd)
|
abnormal chemokine level
|
J:80658
|
abnormal macrophage physiology
|
J:80658
|
Fyntm1Sor/Fyntm1Sor Lcktm1Litt/Lcktm1.1Litt Tnfrsf4tm2(cre)Nik/Tnfrsf4+
(involves: 129S7/SvEvBrd * 129X1/SvJ)
|
abnormal regulatory T cell physiology
|
J:152472
|
decreased T cell proliferation
|
J:152472
|
Fyntm1Yik/Fyntm1Yik
(involves: C57BL/6 * CBA)
|
abnormal cytokine secretion
|
J:99347
|
abnormal interleukin secretion
|
J:99347
|
increased susceptibility to experimental autoimmune uveoretinitis
|
J:99347
|
increased tumor necrosis factor secretion
|
J:99347
|
G6pc2tm1.1Pesa/G6pc2tm1.1Pesa
(NOD.129S2-G6pc2tm1.1Pesa)
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:160286
|
decreased interferon-gamma secretion
|
J:160286
|
decreased T cell proliferation
|
J:160286
|
G6pc3tm1Jyc/G6pc3tm1Jyc
(involves: 129S4/SvJae * C57BL/6)
|
abnormal neutrophil physiology
|
J:120741
|
impaired granulocyte bactericidal activity
|
J:120741
|
increased susceptibility to bacterial infection
|
J:120741
|
Gab2tm1Gsf/Gab2tm1Gsf
(involves: BALB/c)
|
abnormal response to infection
|
J:122213
|
decreased susceptibility to Retroviridae infection
|
J:122429
|
Gab2tm1Hhg/Gab2tm1Hhg
(involves: 129S4/SvJae)
|
decreased mast cell degranulation
|
J:70424
|
decreased susceptibility to type I hypersensitivity reaction
|
J:70424
|
Gab2tm1Thir/Gab2tm1Thir
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal mast cell physiology
|
J:75092
|
Gab2tm3.1Thir/Gab2tm3.1Thir
(involves: 129T/SvJcl * C57BL/6Jcl)
|
decreased mast cell degranulation
|
J:178045
|
decreased susceptibility to type I hypersensitivity reaction
|
J:178045
|
Gab2tm4.1Thir/Gab2tm4.1Thir
(involves: 129T/SvJcl * C57BL/6Jcl)
|
decreased mast cell degranulation
|
J:178045
|
decreased susceptibility to type I hypersensitivity reaction
|
J:178045
|
Gab3em1Khoe/Gab3em1Khoe
(C57BL/6-Gab3em1Khoe)
|
abnormal NK cell physiology
|
J:291290
|
Gab3m1Khoe/Gab3m1Khoe
(C57BL/6-Gab3m1Khoe)
|
abnormal NK cell physiology
|
J:291290
|
Gabpb2Gt(RRJ488)Byg/Gabpb2Gt(RRJ488)Byg
(involves: 129P2/OlaHsd)
|
increased B cell proliferation
|
J:141846
|
increased IgG1 level
|
J:141846
|
increased IgM level
|
J:141846
|
Gabrb3tm2.1Geh/Gabrb3tm2.1Geh Tg(Cd4-cre)1Cwi/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:333883
|
Gad2tm1Miya/Gad2tm1Miya
(NOD.129P2-Gad2tm1Miya)
|
pancreas inflammation
|
J:88785
|
Gadd45atm1Ajf/Gadd45atm1Ajf
(either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129X1/SvJ * C57BL/6))
|
glomerulonephritis
|
J:76041
|
increased anti-double stranded DNA antibody level
|
J:76041
|
increased anti-histone antibody level
|
J:76041
|
increased anti-single stranded DNA antibody level
|
J:76041
|
increased autoantibody level
|
J:76041
|
increased IgG1 level
|
J:76041
|
increased IgM level
|
J:76041
|
increased inflammatory response
|
J:76041
|
increased T cell proliferation
|
J:76041
|
Gadd45btm1Flv/Gadd45btm1Flv
(involves: 129S6/SvEvTac)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:87396
|
abnormal dendritic cell physiology
|
J:87396
|
abnormal T-helper 1 physiology
|
J:87396
|
abnormal T-helper 2 physiology
|
J:87396
|
decreased interferon-gamma secretion
|
J:87396
|
decreased interleukin-2 secretion
|
J:87396
|
decreased interleukin-4 secretion
|
J:87396
|
decreased interleukin-6 secretion
|
J:87396
|
decreased interleukin-12 secretion
|
J:87396
|
Gadd45btm1Flv/Gadd45btm1Flv
(B6.129S6-Gadd45btm1Flv)
|
abnormal T-helper 1 physiology
|
J:118837
|
glomerulonephritis
|
J:118837
|
increased interferon-gamma secretion
|
J:118837
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:118837
|
increased T cell proliferation
|
J:118837
|
Gadd45btm1Flv/Gadd45btm1Flv Gadd45gtm1Flv/Gadd45gtm1Flv
(involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6)
|
glomerulonephritis
|
J:118837
|
increased anti-double stranded DNA antibody level
|
J:118837
|
increased anti-histone antibody level
|
J:118837
|
increased IgG1 level
|
J:118837
|
increased IgM level
|
J:118837
|
Gadd45gtm1Flv/Gadd45gtm1Flv
(involves: 129S1/Sv)
|
abnormal NK cell physiology
|
J:87396
|
abnormal T-helper 1 physiology
|
J:69475
|
abnormal type IV hypersensitivity reaction
|
J:69475
|
decreased interferon-gamma secretion
|
J:87396,
J:69475
|
Galctm1Wngr/Galctm1Wngr
(involves: 129S2/SvPas)
|
abnormal immune system physiology
|
J:78691
|
Galctwi/Galctwi
(B6.CE-Galctwi/J)
|
abnormal osteoclast physiology
|
J:165361
|
Galctwi/Galctwi
(involves: CE/J)
|
CNS inflammation
|
J:78223
|
Galctwi/Galctwi Glb1tm1Adz/Glb1tm1Adz
(involves: 129P2/OlaHsd * C57BL/6J * CE/J)
|
abnormal macrophage physiology
|
J:63197
|
Galctwi/Galctwi Il6+/?
(involves: 129S2/SvPas * C57BL/6J * CE/J)
|
abnormal tumor necrosis factor level
|
J:56656
|
Galctwi/Galctwi Il6tm1Kopf/Il6tm1Kopf
(involves: 129S2/SvPas * C57BL/6J * CE/J)
|
abnormal tumor necrosis factor level
|
J:56656
|
Galnt1tm1.1Jxm/Galnt1tm1.1Jxm
(B6NHsd.Cg-Galnt1tm1.1Jxm)
|
abnormal immune system physiology
|
J:128982
|
decreased IgG level
|
J:128982
|
impaired leukocyte tethering or rolling
|
J:128982
|
GaltGt(E285B04)Wrst/GaltGt(E285B04)Wrst
(involves: 129P2/OlaHsd * C57BL/6J)
|
brain inflammation
|
J:234753
|
liver inflammation
|
J:234753
|
Gapttm1.1Wz/Gapttm1.1Wz
(Not Specified)
|
increased B cell proliferation
|
J:138146
|
increased IgG2b level
|
J:138146
|
increased IgG3 level
|
J:138146
|
increased IgM level
|
J:138146
|
Gasa1BALB/cCrSlc/Gasa1BALB/cCrSlc
(involves: BALB/cCrSlc * C57BL/6)
|
stomach inflammation
|
J:54699
|
Gasa1BALB/cCrSlc/Gasa1C57BL/6
(involves: BALB/cCrSlc * C57BL/6)
|
stomach inflammation
|
J:54699
|
Gasa2BALB/cCrSlc/Gasa2BALB/cCrSlc
(involves: BALB/cCrSlc * C57BL/6)
|
stomach inflammation
|
J:54699
|
Gasa2BALB/cCrSlc/Gasa2BALB/cCrSlc Gasa4BALB/cCrSlc/Gasa4C57BL/6
(involves: BALB/cCrSlc * C57BL/6)
|
stomach inflammation
|
J:75277
|
Gasa2BALB/cCrSlc/Gasa2C57BL/6
(involves: BALB/cCrSlc * C57BL/6)
|
stomach inflammation
|
J:54699
|
Gasa3BALB/cCrSlc/Gasa3C57BL/6
(involves: BALB/cCrSlc * C57BL/6)
|
stomach inflammation
|
J:75277
|
Gasa4BALB/cCrSlc/Gasa4C57BL/6
(involves: BALB/cCrSlc * C57BL/6)
|
stomach inflammation
|
J:75277
|
Gasttm1Lcs/Gasttm1Lcs
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
|
stomach inflammation
|
J:97527
|
Gata1tm6Sho/Gata1tm6Sho
(involves: 129S1/Sv * BALB/c)
|
decreased circulating interleukin-4 level
|
J:115273
|
decreased circulating interleukin-13 level
|
J:115273
|
Gata1tm6Sho/Gata1tm6Sho
(C.129S1-Gata1tm6Sho)
|
autoimmune response
|
J:182213
|
Gata3tm1.1Mbu/Gata3tm1.1Mbu
(involves: 129P2/OlaHsd * C57BL/6 * SJL)
|
abnormal humoral immune response
|
J:123631
|
decreased interleukin-4 secretion
|
J:123631
|
increased interferon-gamma secretion
|
J:123631
|
Gata3tm1Iho/Gata3tm1Iho Il13tm1(YFP/cre)Lky/Il13+
(involves: 129S4/SvJae)
|
increased susceptibility to parasitic infection
|
J:178986
|
Gata3tm1Iho/Gata3tm1Iho Tg(Lck-cre)1Cwi/0
(involves: BALB/c)
|
increased T cell apoptosis
|
J:86996
|
Gata3tm1Jfz/Gata3tm1Jfz Tg(Cd4-cre)1Cwi/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
|
decreased interleukin-13 secretion
|
J:172134
|
Gata3tm1Jfz/Gata3tm1Jfz Tg(Tnfrsf4-cre)1Nik/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
decreased IgE level
|
J:93538
|
increased susceptibility to parasitic infection
|
J:93538
|
Gata5tm1.2Nemr/Gata5tm1.2Nemr
(Not Specified)
|
kidney inflammation
|
J:227997
|
Gata5tm1Eno/Gata5tm1Eno
(involves: 129S6/SvEvTac * C57BL/6)
|
urethritis
|
J:63036
|
vaginal inflammation
|
J:63036
|
Gatmem1Btlr/Gatmem1Btlr
(C57BL/6J-Gatmem1Btlr)
|
increased susceptibility to induced colitis
|
J:252049
|
Gatmem1Btlr/Gatmm1Btlr
(C57BL/6J-Gatmem1Btlr/Gatmm1Btlr)
|
increased susceptibility to induced colitis
|
J:252049
|
Gatmm1Btlr/Gatm+
(C57BL/6J-Gatmm1Btlr)
|
increased susceptibility to induced colitis
|
J:252049
|
Gatmm1Btlr/Gatmm1Btlr
(C57BL/6J-Gatmm1Btlr)
|
increased susceptibility to induced colitis
|
J:252049
|
Gba1tm1.1Pmis/Gba1tm1.1Pmis Tg(Mx1-cre)1Cgn/0
(involves: C57BL/6 * CBA)
|
abnormal circulating chemokine level
|
J:167081
|
abnormal circulating cytokine level
|
J:167081
|
decreased circulating interleukin-1 alpha level
|
J:167081
|
decreased circulating interleukin-1 beta level
|
J:167081
|
decreased circulating interleukin-6 level
|
J:167081
|
decreased circulating tumor necrosis factor level
|
J:167081
|
increased circulating interferon-gamma level
|
J:167081
|
increased circulating interleukin-2 level
|
J:167081
|
increased circulating interleukin-3 level
|
J:167081
|
increased circulating interleukin-9 level
|
J:167081
|
increased circulating interleukin-10 level
|
J:167081
|
increased circulating interleukin-13 level
|
J:167081
|
Gba1tm1.1Pmis/Gba1tm1.2Pmis Tg(Mx1-cre)1Cgn/0
(involves: C57BL/6 * CBA)
|
abnormal circulating chemokine level
|
J:167081
|
abnormal circulating cytokine level
|
J:167081
|
decreased circulating interleukin-1 alpha level
|
J:167081
|
decreased circulating interleukin-1 beta level
|
J:167081
|
decreased circulating interleukin-6 level
|
J:167081
|
decreased circulating tumor necrosis factor level
|
J:167081
|
increased circulating interferon-gamma level
|
J:167081
|
increased circulating interleukin-2 level
|
J:167081
|
increased circulating interleukin-3 level
|
J:167081
|
increased circulating interleukin-9 level
|
J:167081
|
increased circulating interleukin-10 level
|
J:167081
|
increased circulating interleukin-13 level
|
J:167081
|
Gba1tm1Karl/Gba1tm1.1Karl Tg(Mx1-cre)1Cgn/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)
|
abnormal response to transplant
|
J:113751
|
Gba1tm1Rlp/Gba1tm1Rlp
(involves: 129S4/SvJae * C57BL/6)
|
abnormal inflammatory response
|
J:76409
|
abnormal spleen physiology
|
J:76409
|
increased IgG level
|
J:76409
|
liver inflammation
|
J:76409
|
lung inflammation
|
J:76409
|
lymph node inflammation
|
J:76409
|
skin inflammation
|
J:76409
|
Gbp2tm1.1Kpf/Gbp2tm1.1Kpf
(involves: 129P2/OlaHsd)
|
increased susceptibility to parasitic infection
|
J:192526
|
increased susceptibility to parasitic infection induced morbidity/mortality
|
J:192526
|
Gbp2btm1Tigm/Gbp2btm1Tigm
(B6.129S5-Gbp2btm1Tigm/Jdmm)
|
abnormal macrophage physiology
|
J:172364
|
increased susceptibility to bacterial infection
|
J:172364
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:172364
|
Gbp5tm1Tigm/Gbp5tm1Tigm
(B6.Cg-Gbp5tm1Tigm)
|
decreased circulating interleukin-1 beta level
|
J:183942
|
decreased circulating interleukin-18 level
|
J:183942
|
decreased interleukin-1 beta secretion
|
J:183942
|
decreased interleukin-18 secretion
|
J:183942
|
impaired neutrophil recruitment
|
J:183942
|
increased susceptibility to bacterial infection
|
J:183942
|
Gbp7tm1Ddgd/Gbp7tm1Ddgd
(B6.129P2-Gbp7tm1Ddgd)
|
increased susceptibility to bacterial infection
|
J:314959
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:314959
|
Gcatm1Roes/Gcatm1Roes
(involves: 129P2/OlaHsd * 129S2/SvPas)
|
decreased susceptibility to endotoxin shock
|
J:81436
|
Gcc2em1Cya/Gcc2em1Cya
(C57BL/6J-Gcc2em1Cya)
|
increased autoantibody level
|
J:346915
|
Gcnt1tm1Jxm/Gcnt1tm1Jxm
(involves: 129/Sv * C57BL/6)
|
abnormal acute inflammation
|
J:86387
|
abnormal immune system physiology
|
J:86387
|
abnormal inflammatory response
|
J:86387
|
Gcnt1tm1Jxm/Gcnt1tm1Jxm
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal leukocyte migration
|
J:113195
|
impaired leukocyte tethering or rolling
|
J:113195
|
Gcnt3tm1.1Jxm/Gcnt3tm1.1Jxm
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
decreased IgA level
|
J:149909
|
decreased IgG1 level
|
J:149909
|
decreased IgG2a level
|
J:149909
|
decreased IgG2b level
|
J:149909
|
increased susceptibility to induced colitis
|
J:149909
|
Gdnftm1Lmgd/Gdnf+
(B6.129-Gdnftm1Lmgd)
|
tubulointerstitial nephritis
|
J:103081
|
Gfaptm1Pkny/Gfaptm1Pkny Ppt1tm1Hof/Ppt1tm1Hof Vimtm1Cba/Vimtm1Cba
(involves: 129P2/OlaHsd * 129S2/SvPas * 129S6/SvEvTac * C57BL/6)
|
abnormal cytokine level
|
J:177265
|
brain inflammation
|
J:177265
|
Gfaptm1Pkny/Gfaptm1Pkny Vimtm1Cba/Vimtm1Cba
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
|
decreased inflammatory response
|
J:123278
|
Gfertm1.1Crg/Gfertm1.1Crg Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129 * C57BL/6 * DBA)
|
liver inflammation
|
J:227242
|
Gfi1Gen/Gfi1+
(C57BL/6J-Gfi1Gen)
|
abnormal NK cell physiology
|
J:182679
|
decreased NK cell degranulation
|
J:182679
|
Gfi1tm1Tmo/Gfi1tm1Tmo
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal cytokine secretion
|
J:75143
|
increased interleukin-1 beta secretion
|
J:75143
|
increased interleukin-10 secretion
|
J:75143
|
increased susceptibility to endotoxin shock
|
J:75143
|
increased tumor necrosis factor secretion
|
J:75143
|
Gfi1tm1Wep/Gfi1tm1Wep
(B6.129-Gfi1tm1Wep)
|
abnormal T cell proliferation
|
J:117105
|
Gfi1tm1Wep/Gfi1tm1Wep Tg(Cd4-cre)1Cwi/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
|
abnormal T cell proliferation
|
J:117105
|
abnormal T-helper 2 physiology
|
J:117105
|
Gfustm1Jbl/Gfustm1Jbl
(involves: 129S2/SvPas * C57BL/6J)
|
large intestinal inflammation
|
J:82239
|
ggld/ggld
(MRL/MpJ-Faslpr/J-ggld)
|
decreased IgG1 level
|
J:14258
|
Ggt5tm1Mwl/Ggt5tm1Mwl
(involves: 129S7/SvEvBrd * C57BL/6J)
|
decreased acute inflammation
|
J:77691
|
Ggta1tm1Jbl/Ggta1+ Ightm1Jiac/Ightm1Jiac Igktm1Jiac/Igktm1Jiac
(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)
|
abnormal B cell physiology
|
J:133032
|
Ggta1tm1Jbl/Ggta1tm1Jbl
(involves: 129S2/SvPas)
|
abnormal humoral immune response
|
J:113488,
J:90851
|
abnormal immunoglobulin level
|
J:113488
|
abnormal response to transplant
|
J:90851
|
decreased IgG level
|
J:90851
|
increased IgM level
|
J:90851
|
Ghrtm1c(KOMP)Wtsi/Ghrtm1c(KOMP)Wtsi Tg(Fabp4-cre)1Rev/0
(involves: C57BL/6N)
|
increased circulating interleukin-6 level
|
J:206358
|
Ghrtm1Jjk/Ghrtm1Jjk
(involves: 129P2/OlaHsd * BALB/c)
|
decreased susceptibility to autoimmune diabetes
|
J:59132
|
Ghrhtm1Salv/Ghrhtm1Salv
(involves: 129 * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:177054
|
Ghrhrlit/Ghrhrlit
(C57BL/6J-Ghrhrlit)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:85381
|
Gimap1m1Btlr/Gimap1m1Btlr
(C57BL/6J-Gimap1m1Btlr)
|
decreased IgD level
|
J:267546
|
increased IgM level
|
J:267546
|
Gimap1tm1.1Gwb/Gimap1tm1.1Gwb Tg(CD2-icre)4Kio/0
(involves: 129 * C57BL/6 * C57BL/10 * CBA/Ca)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:160782
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:160782
|
Gimap4tm1Jcbs/Gimap4tm1Jcbs
(B6.129P2-Gimap4tm1Jcbs)
|
abnormal T cell physiology
|
J:135744
|
Gimap5m1Btlr/Gimap5m1Btlr
(involves: C57BL/6J)
|
abnormal B cell physiology
|
J:160090
|
abnormal B cell proliferation
|
J:160090
|
abnormal NK T cell physiology
|
J:160090
|
abnormal response to transplant
|
J:160090
|
colitis
|
J:160090
|
decreased B cell proliferation
|
J:160090
|
decreased circulating interferon-gamma level
|
J:160090
|
decreased circulating interleukin-4 level
|
J:160090
|
decreased IgG1 level
|
J:160090
|
decreased IgG2a level
|
J:160090
|
decreased IgG2b level
|
J:160090
|
decreased IgG3 level
|
J:160090
|
decreased IgG level
|
J:160090
|
decreased IgM level
|
J:160090
|
decreased interferon-gamma secretion
|
J:160090
|
decreased interleukin-4 secretion
|
J:160090
|
decreased tumor necrosis factor secretion
|
J:160090
|
intestinal inflammation
|
J:160090
|
Gimap5tm1Wlr/Gimap5tm1Wlr
(either: B6.129-Gimap5tm1Wlr or C.129-Gimap5tm1Wlr)
|
abnormal response to transplant
|
J:143620
|
Gimap6tm1.1Gwb/Gimap6tm1.1Gwb Tg(CD2-icre)4Kio/0
(involves: C57BL/6 * C57BL/10 * CBA/Ca)
|
abnormal T cell physiology
|
J:262059
|
increased T cell apoptosis
|
J:262059
|
Git2Gt(XG510)Byg/Git2Gt(XG510)Byg Tg(TcraH-Y,TcrbH-Y)71Vbo/0
(involves: 129 * C57BL/6J * DBA/2J)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:160613
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:160613
|
Git2tm1Hsb/Git2tm1Hsb
(involves: C57BL/6 * CBA)
|
abnormal neutrophil physiology
|
J:112663
|
impaired neutrophil chemotaxis
|
J:112663
|
increased susceptibility to fungal infection
|
J:112663
|
lung inflammation
|
J:112663
|
Gja1M1Jrt/Gja1+
(involves: C3H/HeJ * C57BL/6J)
|
heart inflammation
|
J:101733
|
Gja1tm1.1Kwi/Gja1+
(involves: 129P2/OlaHsd)
|
abnormal neutrophil physiology
|
J:129091
|
Gja1tm1Kwi/Gja1tm5(cre/ERT)Kwi
(involves: 129P2/OlaHsd)
|
abnormal neutrophil physiology
|
J:129091
|
Gjb1tm1Kwi/Y Gjc2tm1(EGFP)Kwi/Gjc2tm1(EGFP)Kwi
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
optic nerve inflammation
|
J:219594
|
spinal cord inflammation
|
J:219594
|
Gjc2tm1(EGFP)Kwi/Gjc2tm1(EGFP)Kwi Gjb1tm1Kwi/Gjb1tm1Kwi
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
optic nerve inflammation
|
J:219594
|
spinal cord inflammation
|
J:219594
|
Gkn2tm1.1(KOMP)Vlcg/Gkn2tm1.1(KOMP)Vlcg
(involves: C57BL/6NTac)
|
abnormal chemokine level
|
J:234656
|
abnormal cytokine level
|
J:234656
|
abnormal innate immunity
|
J:234656
|
abnormal interleukin level
|
J:234656
|
abnormal susceptibility to bacterial infection
|
J:234656
|
abnormal T-helper 1 physiology
|
J:234656
|
abnormal tumor necrosis factor level
|
J:234656
|
increased susceptibility to bacterial infection
|
J:234656
|
stomach inflammation
|
J:234656
|
Glb1tm1Jmat/Glb1tm1Jmat
(involves: C57BL/6 * CBA * ICR)
|
abnormal macrophage chemotaxis
|
J:102576
|
Glg1Gt(RST092)Byg/Glg1+
(B6J.129P2-Glg1Gt(RST092)Byg)
|
abnormal cellular extravasation
|
J:226586
|
abnormal leukocyte adhesion
|
J:226586
|
enhanced leukocyte tethering or rolling
|
J:226586
|
Glis2tm1Amj/Glis2tm1Amj
(involves: 129P2/OlaHsd * C57BL/6)
|
glomerulonephritis
|
J:134208
|
GlmpGt(P084H04)Wrst/GlmpGt(P084H04)Wrst
(involves: 129S2/SvPas * C57BL/6)
|
liver inflammation
|
J:208774
|
Glmptm1Lex/Glmptm1Lex
(B6;129S5-Glmptm1Lex/Mmucd)
|
abnormal immune system physiology
|
J:171883
|
liver inflammation
|
J:171883
|
Glt8d2tm1Lex/Glt8d2tm1Lex
(B6;129S5-Glt8d2tm1Lex/Mmucd)
|
abnormal adaptive immunity
|
J:171883
|
decreased IgG1 level
|
J:171883
|
decreased IgG2a level
|
J:171883
|
Gm614tm1.1Cya/Gm614tm1.1Cya Ighg1tm1(cre)Cgn/Ighg1+
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N)
|
decreased susceptibility to systemic lupus erythematosus
|
J:307345
|
increased B cell apoptosis
|
J:307345
|
Gm5544tm1a(KOMP)Wtsi/Gm5544tm1a(KOMP)Wtsi
(C57BL/6N-Gm5544tm1a(KOMP)Wtsi/Wtsi)
|
blood in lymph vessels
|
J:239583
|
Gm16685em1Osb/Gm16685em1Osb
(C57BL/6N-Gm16685em1Osb)
|
decreased susceptibility to colitis induced morbidity/mortality
|
J:303079
|
Gm36723em1Flv/Gm36723em1Flv
(C57BL/6-Gm36723em1Flv)
|
abnormal NK cell physiology
|
J:258967
|
decreased interferon-gamma secretion
|
J:258967
|
decreased susceptibility to bacterial infection
|
J:258967
|
impaired natural killer cell mediated cytotoxicity
|
J:258967
|
Gm40600em1Cya/Gm40600em1Cya
(C57BL/6-Gm40600em1Cya)
|
decreased IgA level
|
J:311878
|
decreased IgE level
|
J:311878
|
decreased IgG1 level
|
J:311878
|
decreased IgG2b level
|
J:311878
|
decreased IgG2c level
|
J:311878
|
decreased IgG3 level
|
J:311878
|
decreased IgG level
|
J:311878
|
decreased IgM level
|
J:311878
|
increased IgA level
|
J:311878
|
increased IgE level
|
J:311878
|
increased IgG1 level
|
J:311878
|
increased IgG2b level
|
J:311878
|
increased IgG2c level
|
J:311878
|
increased IgG3 level
|
J:311878
|
increased IgG level
|
J:311878
|
increased IgM level
|
J:311878
|
Gm41610em1Scrp/Gm41610em1Scrp
(C57BL/6-Gm41610em1Scrp)
|
decreased susceptibility to endotoxin shock
|
J:302605
|
increased circulating interleukin-5 level
|
J:302605
|
increased circulating interleukin-13 level
|
J:302605
|
Gmfgtm1Jyw/Gmfgtm1Jyw
(B6.Cg-Gmfgtm1Jyw)
|
abnormal marginal zone B cell physiology
|
J:345500
|
decreased lymphocyte chemotaxis
|
J:345500
|
impaired B cell migration
|
J:345500
|
increased IgM level
|
J:345500
|
Gmnntm1.1Kio/Gmnntm1.2Kio Tg(CD2-icre)4Kio/0
(involves: 129S4/SvJae * C57BL/10 * CBA/Ca)
|
decreased T cell proliferation
|
J:159657
|
Gna11tm1Soff/Gna11tm1Soff
(involves: 129S7/SvEvBrd)
|
decreased susceptibility to type I hypersensitivity reaction
|
J:146132
|
Gna11tm1Soff/Gna11tm1Soff Gnaqtm2Soff/Gnaqtm2Soff Tg(Tek-icre/ERT2)1Soff/?
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * FVB/N)
|
decreased susceptibility to type I hypersensitivity reaction
|
J:146132
|
Gna12tm1.1Cgh/Gna12tm1.1Cgh Gna13tm2Cgh/Gna13tm2Cgh Tg(Mx1-cre)1Cgn/0
(involves: 129S4/SvJae * C57BL/6 * CBA)
|
decreased B cell apoptosis
|
J:174313
|
Gna12tm1Citb/Gna12tm1Citb Gna13tm2.1Soff/Gna13tm2.1Soff Tg(Lck-cre)548Jxm/0
(involves: 129S1/Sv * C57BL/6 * CBA)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:149560
|
increased interleukin-2 secretion
|
J:149560
|
increased susceptibility to autoimmune diabetes
|
J:149560
|
increased susceptibility to type IV hypersensitivity reaction
|
J:149560
|
increased T cell proliferation
|
J:149560
|
Gnai1tm1Drs/Gnai1tm1Drs Gnai3tm1Lbi/Gnai3tm1Lbi
(involves: 129S/SvEv)
|
decreased interleukin-10 secretion
|
J:104683
|
increased tumor necrosis factor secretion
|
J:104683
|
Gnai2tm1Lbi/Gnai2tm1Lbi
(involves: 129S7/SvEvBrd * C57BL/6J)
|
colitis
|
J:24434
|
Gnai2tm1Lbi/Gnai2tm1Lbi
(involves: 129S7/SvEvBrd)
|
abnormal cytokine level
|
J:121471
|
abnormal cytokine secretion
|
J:30507
|
abnormal immune system physiology
|
J:30507
|
abnormal neutrophil physiology
|
J:121471
|
colitis
|
J:24434
|
increased circulating interferon-gamma level
|
J:121471
|
increased circulating interleukin-4 level
|
J:121471
|
increased circulating interleukin-5 level
|
J:121471
|
increased IgA level
|
J:30507
|
increased IgG level
|
J:30507
|
increased immunoglobulin level
|
J:30507
|
increased inflammatory response
|
J:30507
|
increased interferon-gamma secretion
|
J:30507
|
increased interleukin-2 secretion
|
J:30507
|
increased susceptibility to parasitic infection
|
J:121471
|
increased T cell proliferation
|
J:30507
|
increased tumor necrosis factor secretion
|
J:30507
|
large intestinal inflammation
|
J:30507
|
peritoneal inflammation
|
J:30507
|
Gnai2tm1Lbi/Gnai2tm1Lbi
(either: 129 or (involves: 129S7/SvEvBrd * C57BL/6J))
|
abnormal cytokine secretion
|
J:24434
|
increased IgG level
|
J:24434
|
increased IgM level
|
J:24434
|
Gnai2tm1Lbi/Gnai2tm1Lbi
(129-Gnai2tm1Lbi)
|
abnormal cytokine secretion
|
J:91100
|
increased interleukin-1 beta secretion
|
J:91100
|
increased tumor necrosis factor secretion
|
J:91100
|
Gnai2tm1Lbi/Gnai2tm1Lbi
(B6.129S7-Gnai2tm1Lbi)
|
abnormal cellular extravasation
|
J:120069
|
abnormal eosinophil physiology
|
J:120069
|
abnormal leukocyte adhesion
|
J:120069
|
abnormal T cell physiology
|
J:121161
|
Gnai2tm1Lbi/Gnai2tm1Lbi
(involves: 129S7/SvEvBrd * C57BL/6)
|
abnormal cytokine secretion
|
J:91100
|
colitis
|
J:91100
|
increased interleukin-1 beta secretion
|
J:91100
|
increased tumor necrosis factor secretion
|
J:91100
|
Gnai2tm2.1Lbi/Gnai2tm2.1Lbi Tg(Cd4-cre)1Cwi/0
(involves: 129S/SvEv * C57BL/6 * C57BL/6NTac * DBA)
|
increased susceptibility to induced colitis
|
J:194587
|
Gnai3tm1Lbi/Gnai3tm1Lbi
(B6.129S-Gnai3tm1Lbi)
|
abnormal T cell physiology
|
J:121161
|
GnasOedsml/Gnas+
(involves: 101/H * C3H/HeH)
|
abnormal inflammatory response
|
J:65007
|
Gnb1lGt(OST35527)Lex/Gnb1l+
(B6;129S5-Gnb1lGt(OST35527)Lex/Orl)
|
glomerulonephritis
|
J:82809
|
Gnetm1.1Masn/Gnetm1.1Masn
(involves: 129P2/OlaHsd * C57BL/6)
|
kidney inflammation
|
J:184315
|
Gnptabnym/Gnptabnym
(involves: BALB/cAnNHsd * C3H/HeNHsd)
|
brain inflammation
|
J:218156
|
Gnptabtm1Dkji/Gnptabtm1Dkji
(involves: 129 * C57BL/6)
|
increased interleukin-6 secretion
|
J:231531
|
Gnptabtm1Kkol/Gnptabtm1Kkol
(involves: 129 * C57BL/6)
|
abnormal osteoclast physiology
|
J:202751
|
Golm1Gt(KST273)Byg/Golm1Gt(KST273)Byg
(involves: 129P2/OlaHsd * C57BL/6)
|
kidney inflammation
|
J:151282
|
liver inflammation
|
J:151282
|
Gon4ljusty/Gon4ljusty
(C3HeB/FeJ-Gon4ljusty)
|
abnormal humoral immune response
|
J:163412
|
decreased immunoglobulin level
|
J:163412
|
Gpa33tm1Jkhh/Gpa33tm1Jkhh
(B6.129-Gpa33tm1Jkhh)
|
abnormal immune tolerance
|
J:224768
|
increased susceptibility to induced colitis
|
J:224768
|
increased susceptibility to type IV hypersensitivity reaction
|
J:224768
|
Gpa33tm1Jkhh/Gpa33tm1Jkhh
(involves: 129 * C57BL/6)
|
increased susceptibility to colitis induced morbidity/mortality
|
J:231808
|
increased susceptibility to induced colitis
|
J:231808
|
Gpc3tm1Fil/Y
(B6.Cg-Gpc3tm1Fil)
|
increased susceptibility to bacterial infection
|
J:73877
|
lung inflammation
|
J:73877
|
rhinitis
|
J:73877
|
Gpc3tm1Fil/Gpc3tm1Fil
(B6.Cg-Gpc3tm1Fil)
|
increased susceptibility to bacterial infection
|
J:73877
|
lung inflammation
|
J:73877
|
Gpdc1C3H/HeN/Gpdc1C3H/HeN
(involves: C3H/HeN-Gnai2tm1Uru * C57BL/6J-Gna2tm1Uru)
|
colitis
|
J:95140
|
Gpdc2C3H/HeN/Gpdc2C3H/HeN
(involves: C3H/HeN-Gnai2tm1Uru * C57BL/6J-Gna2tm1Uru)
|
colitis
|
J:95140
|
Gpdc3C3H/HeN/?
(involves: C3H/HeN-Gnai2tm1Uru * C57BL/6J-Gna2tm1Uru)
|
colitis
|
J:95140
|
Gpnmbtm1Ari/Gpnmbtm1Ari
(C57BL/6-Gpnmbtm1Ari)
|
abnormal dendritic cell physiology
|
J:215931
|
Gpr15tm1.1Litt/Gpr15tm1.1Litt
(B6.129P2-Gpr15tm1.1Litt)
|
abnormal regulatory T cell physiology
|
J:199126
|
increased susceptibility to bacterial infection
|
J:199126
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:199126
|
increased susceptibility to induced colitis
|
J:199126
|
Gpr15tm1.1Litt/Gpr15tm1.1Litt
(involves: 129P2/OlaHsd * C57BL/6)
|
increased interferon-gamma secretion
|
J:199126
|
increased interleukin-17 secretion
|
J:199126
|
Gpr15tm1.1Litt/Gpr15tm1.1Litt Rag2tm1Fwa/Rag2tm1Fwa Tg(TcraTcrb)425Cbn/0
(involves: 129P2/OlaHsd * 129S/SvEv * BALB/c * C57BL/6)
|
abnormal immune system physiology
|
J:199126
|
Gpr15lgtm1Lex/Gpr15lgtm1Lex
(B6;129S5-Gpr15lgtm1Lex/Mmucd)
|
increased IgG2a level
|
J:171883
|
Gpr18tm1Lex/Gpr18tm1Lex
(involves: 129S/SvEv * C57BL/6)
|
increased susceptibility to bacterial infection
|
J:226433
|
Gpr21tm1Dgen/Gpr21tm1Dgen
(B6.129P2-Gpr21tm1Dgen)
|
abnormal circulating chemokine level
|
J:181127
|
decreased circulating serum amyloid protein level
|
J:181127
|
Gpr31btm1Ktak/Gpr31btm1Ktak
(B6.Cg-Gpr31btm1Ktak)
|
abnormal dendritic cell physiology
|
J:271242
|
decreased inflammatory response
|
J:271242
|
increased susceptibility to bacterial infection
|
J:271242
|
Gpr34tm1.1Shbg/Gpr34tm1.1Shbg
(B6.Cg-Gpr34tm1.1Shbg)
|
abnormal chemokine secretion
|
J:168120
|
abnormal cytokine secretion
|
J:168120
|
abnormal leukocyte migration
|
J:168120
|
increased interferon-gamma secretion
|
J:168120
|
increased interleukin-2 secretion
|
J:168120
|
increased interleukin-4 secretion
|
J:168120
|
increased interleukin-5 secretion
|
J:168120
|
increased interleukin-10 secretion
|
J:168120
|
increased interleukin-12 secretion
|
J:168120
|
increased susceptibility to fungal infection
|
J:168120
|
increased susceptibility to type IV hypersensitivity reaction
|
J:168120
|
increased tumor necrosis factor secretion
|
J:168120
|
Gpr35em1Niess/Gpr35em1Niess
(C57BL/6N-Gpr35em1Niess)
|
increased susceptibility to induced colitis
|
J:300275
|
Gpr35em2Niess/Gpr35em2Niess Cx3cr1tm2.1(cre/ERT2)Litt/Cx3cr1+
(involves: 129P2/OlaHsd * C57BL/6N)
|
increased susceptibility to induced colitis
|
J:300275
|
Gpr35tm1(KOMP)Vlcg/Gpr35tm1(KOMP)Vlcg
(C57BL/6N-Gpr35tm1(KOMP)Vlcg/MbpMmucd)
|
abnormal chemokine level
|
J:306520
|
abnormal interleukin level
|
J:306520
|
decreased susceptibility to colitis induced morbidity/mortality
|
J:306520
|
decreased susceptibility to induced colitis
|
J:306520
|
Gpr55tm1.1Mijr/Gpr55tm1.1Mijr
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal osteoclast physiology
|
J:153225
|
Gpr65tm1Witt/Gpr65tm1Witt
(B6.Cg-Gpr65tm1Witt)
|
abnormal immune cell physiology
|
J:96112
|
abnormal leukocyte physiology
|
J:96112
|
Gpr65tm1Witt/Gpr65tm1Witt
(C.Cg-Gpr65tm1Witt)
|
abnormal leukocyte physiology
|
J:96112
|
Gpr65Tn(sb-lacZ,GFP)T1.88Jtak/Gpr65Tn(sb-lacZ,GFP)T1.88Jtak
(B6.Cg-Gpr65Tn(sb-lacZ,GFP)T1.88Jtak)
|
abnormal interleukin-1 beta secretion
|
J:208788
|
abnormal macrophage physiology
|
J:146233
|
decreased tumor necrosis factor secretion
|
J:146233
|
Gpr68tm1.1Yaxu/Gpr68tm1.1Yaxu
(B6.Cg-Gpr68tm1.1Yaxu)
|
abnormal osteoclast physiology
|
J:149315
|
Gpr68tm1.1Yaxu/Gpr68tm1.1Yaxu
(involves: 129S4/SvJae * C57BL/6 * FVB/N)
|
abnormal macrophage physiology
|
J:149315
|
abnormal osteoclast physiology
|
J:149315
|
Gpr68tm1Yaxu/Gpr68tm1Yaxu
(involves: C57BL/6)
|
abnormal macrophage physiology
|
J:149315
|
abnormal osteoclast physiology
|
J:149315
|
Gpr84tm1Lex/Gpr84tm1Lex
(involves: 129S/SvEvBrd * C57BL/6)
|
abnormal T-helper 2 physiology
|
J:186985
|
increased interleukin-4 secretion
|
J:186985
|
increased interleukin-5 secretion
|
J:186985
|
increased interleukin-13 secretion
|
J:186985
|
Gpr89tm1.1Ymae/Gpr89tm1.1Ymae Tg(KRT5-cre)1Tak/0
(involves: C3H * C57BL/6)
|
dermatitis
|
J:189574
|
Gpr101em7036Tac/Y
(C57BL/6NTac-Gpr101em7036Tac)
|
abnormal microglial cell activation
|
J:347398
|
increased circulating tumor necrosis factor level
|
J:347398
|
increased inflammatory response
|
J:347398
|
Gpr108tm1.1Brs/Gpr108tm1.1Brs
(involves: 129S6/SvEvTac)
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:266821
|
decreased tumor necrosis factor secretion
|
J:266821
|
increased interleukin-6 secretion
|
J:266821
|
increased susceptibility to endotoxin shock
|
J:266821
|
increased tumor necrosis factor secretion
|
J:266821
|
Gpr132tm1Witt/Gpr132tm1Witt
(B6.129X1-Gpr132tm1Witt)
|
impaired macrophage chemotaxis
|
J:96613
|
Gpr132tm1Witt/Gpr132tm1Witt
(involves: 129X1/SvJ * BALB/c)
|
abnormal lymphocyte physiology
|
J:69473
|
increased anti-nuclear antigen antibody level
|
J:69473
|
increased B cell proliferation
|
J:69473
|
increased IgA level
|
J:69473
|
increased IgG1 level
|
J:69473
|
increased immunoglobulin level
|
J:69473
|
increased inflammatory response
|
J:69473
|
increased T cell proliferation
|
J:69473
|
kidney inflammation
|
J:69473
|
liver inflammation
|
J:69473
|
lung inflammation
|
J:69473
|
Gpr132tm1Witt/Gpr132tm1Witt Ldlrtm1Her/Ldlrtm1Her
(B6.129-Ldlrtm1Her Gpr132tm1Witt)
|
decreased macrophage apoptosis
|
J:100498
|
Gpr174tm1Cys/Y
(B6.129-Gpr174tm1Cys)
|
abnormal regulatory T cell physiology
|
J:222307
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:222307
|
increased T cell proliferation
|
J:222307
|
Gpr174tm1Cys/Gpr174+
(B6.129-Gpr174tm1Cys)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:222307
|
Gpr182tm2c(KOMP)Wtsi/Gpr182tm2c(KOMP)Wtsi Tg(Cdh5-cre/ERT2)1Rha/0
(B6.Cg-Gpr182tm2c(KOMP)Wtsi Tg(Cdh5-cre/ERT2)1Rha)
|
abnormal circulating chemokine level
|
J:305796
|
increased circulating CXCL10 level
|
J:305796
|
Gpr183tm1.1Cys/Gpr183tm1.1Cys
(B6.129P2-Gpr183tm1.1Cys)
|
abnormal follicular B cell physiology
|
J:151077
|
Gpr183tm1.2Rbr/Gpr183tm1.2Rbr
(involves: C57BL/6 * FVB/N * SJL)
|
abnormal B cell physiology
|
J:151883
|
Gpr183tm1.2Rbr/Gpr183tm1.2Rbr Ightm1Rbr/Ightm1Rbr Tg(IgkHyHEL10)1Rbr/0
(involves: C57BL/6 * FVB/N * SJL)
|
abnormal B cell physiology
|
J:151883
|
abnormal B cell proliferation
|
J:151883
|
decreased IgG1 level
|
J:151883
|
decreased IgM level
|
J:151883
|
impaired B cell migration
|
J:151883
|
Gpr183tm1Lex/Gpr183tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6)
|
abnormal circulating interferon-beta level
|
J:211122
|
increased circulating interferon-alpha level
|
J:211122
|
increased circulating interferon-gamma level
|
J:211122
|
Gprc5atm1Rlo/Gprc5atm1Rlo
(involves: 129 * C57BL/6)
|
lung inflammation
|
J:127821
|
Gpsm3Gt(IST12408A1)Tigm/Gpsm3Gt(IST12408A1)Tigm
(involves: C57BL/6N)
|
abnormal leukocyte migration
|
J:193270
|
abnormal leukocyte physiology
|
J:193270
|
decreased susceptibility to induced arthritis
|
J:193270
|
Gpx1tm1Kola/Gpx1tm1Kola
(involves: 129S2/SvPas * BALB/c * CF-1)
|
increased inflammatory response
|
J:79183
|
Gpx1tm1Ysh/Gpx1+ Gpx2tm2Coh/Gpx2tm2Coh
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
|
intestinal inflammation
|
J:71506
|
Gpx1tm1Ysh/Gpx1tm1Ysh Gpx2tm2Coh/Gpx2+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
|
intestinal inflammation
|
J:71506
|
Gpx1tm1Ysh/Gpx1tm1Ysh Gpx2tm2Coh/Gpx2tm2Coh
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
|
colitis
|
J:71506
|
intestinal inflammation
|
J:71506
|
small intestinal inflammation
|
J:71506
|
Gpx7tm1Whle/Gpx7tm1Whle
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal humoral immune response
|
J:193993
|
glomerulonephritis
|
J:193993
|
increased anti-nuclear antigen antibody level
|
J:193993
|
Gpx8tm1Lex/Gpx8tm1Lex
(B6;129S5-Gpx8tm1Lex/Mmucd)
|
dermatitis
|
J:171883
|
Graptm1Gsf/Graptm1Gsf
(B6.129-Graptm1Gsf)
|
increased T cell proliferation
|
J:76243
|
Grass1C57BL/6J/Grass1C57BL/6J
(involves: C57BL/6J * DBA/2J)
|
decreased susceptibility to bacterial infection
|
J:134374
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:134374
|
sepsis
|
J:134374
|
Grass1C57BL/6J/Grass1DBA/2J
(involves: C57BL/6J * DBA/2J)
|
increased susceptibility to bacterial infection
|
J:134374
|
sepsis
|
J:134374
|
Grass1DBA/2J/Grass1DBA/2J
(involves: C57BL/6J * DBA/2J)
|
increased susceptibility to bacterial infection
|
J:134374
|
sepsis
|
J:134374
|
Grb2tm1Lnit/Grb2tm1Lnit Cd79atm1(cre)Reth/Cd79a+
(involves: BALB/c * BALB/cJ)
|
abnormal B cell physiology
|
J:171222
|
abnormal memory B cell physiology
|
J:171222
|
decreased IgG3 level
|
J:171222
|
decreased IgG level
|
J:171222
|
increased B cell apoptosis
|
J:171222
|
increased B cell proliferation
|
J:171222
|
increased IgM level
|
J:171222
|
Grb2tm1Paw/Grb2+
(involves: 129S1/Sv * 129X1/SvJ * BALB/c)
|
decreased susceptibility to Retroviridae infection
|
J:122429
|
Greb1em1Rkom/Greb1em1Rkom
(C57BL/6NJ-Greb1em1Rkom)
|
abnormal response to transplant
|
J:346713
|
Grem2em1Stpg/Grem2em1Stpg
(involves: 129S7/SvEvBrd * C57BL/6 * C57BL/6J)
|
ovary inflammation
|
J:318711
|
Grem2tm1Akh/Grem2tm1Akh
(involves: 129/Sv * C57BL/6)
|
abnormal chemokine level
|
J:250034
|
increased inflammatory response
|
J:250034
|
increased interleukin-10 secretion
|
J:250034
|
Grhl3tm1a(EUCOMM)Wtsi/Grhl3+
(C57BL/6N-Grhl3tm1a(EUCOMM)Wtsi/Ics)
|
decreased IgE level
|
J:165965
|
GrhprGt(OST383093)Lex/GrhprGt(OST383093)Lex
(involves: 129S5/SvEvBrd * C57BL/6)
|
urinary bladder inflammation
|
J:181969
|
Grk2tm1Gwd/Grk2tm1Gwd Cd79atm1(cre)Reth/Cd79a+
(involves: 129 * BALB/c * C57BL/6)
|
abnormal B cell physiology
|
J:176118
|
Grk2tm1Gwd/Grk2tm1Mca Tg(Cd4-cre)1Cwi/0
(involves: 129 * C57BL/6 * DBA/2)
|
abnormal T cell physiology
|
J:176118
|
impaired leukocyte tethering or rolling
|
J:176118
|
Grk6tm1.1Mca/Grk6tm1.1Mca
(involves: 129S4/SvJae * C57BL/6J)
|
abnormal B cell physiology
|
J:76872
|
abnormal T cell physiology
|
J:76872
|
Grk6tm1.1Mca/Grk6tm1.1Mca
(B6.129S4-Grk6tm1.1Mca)
|
glomerulonephritis
|
J:225063
|
impaired macrophage phagocytosis
|
J:225063
|
increased anti-double stranded DNA antibody level
|
J:225063
|
increased IgG level
|
J:225063
|
Grntm1.1Aidi/Grntm1.1Aidi
(involves: C57BL/6 * C57BL/6J)
|
abnormal chemokine secretion
|
J:156824
|
abnormal macrophage physiology
|
J:156824
|
abnormal microglial cell physiology
|
J:156824
|
increased interleukin-6 secretion
|
J:156824
|
increased interleukin-12 secretion
|
J:156824
|
increased susceptibility to bacterial infection
|
J:156824
|
increased tumor necrosis factor secretion
|
J:156824
|
Grntm1.1Aidi/Grntm1.1Aidi
(involves: C57BL/6J)
|
kidney inflammation
|
J:268827
|
Grntm1.1Far/Grntm1.1Far
(involves: 129S4/SvJae * FVB/N)
|
abnormal macrophage physiology
|
J:170823
|
Grntm1.1Far/Grntm1.1Far
(involves: 129S4/SvJae * C57BL/6J * FVB/N)
|
increased interleukin-1 beta secretion
|
J:188324
|
increased interleukin-6 secretion
|
J:188324
|
increased interleukin-10 secretion
|
J:188324
|
increased tumor necrosis factor secretion
|
J:188324
|
Grntm2.1Far/Grntm2.1Far
(involves: 129S4/SvJae * C57BL/6)
|
abnormal macrophage physiology
|
J:259651
|
Gsdma3Ae/Gsdma3+
(involves: C57BL/6J * CAST/Ei)
|
skin inflammation
|
J:180149
|
Gsdma3M2Btlr/Gsdma3M2Btlr
(involves: C57BL/6J)
|
dermatitis
|
J:209203
|
Gsdmaem1Cya/Gsdmaem1Cya
(C57BL/6J-Gsdmaem1Cya)
|
increased susceptibility to bacterial infection
|
J:326434
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:326434
|
Gsdmdem1Fcw/Gsdmdem2Fcw
(involves: C57BL/6)
|
abnormal macrophage apoptosis
|
J:226781
|
decreased interleukin-1 beta secretion
|
J:226781
|
Gsdmdem1Flv/Gsdmdem1Flv
(C57BL/6N-Gsdmdem1Flv)
|
increased susceptibility to Riboviria infection induced morbidity/mortality
|
J:243487
|
Gsdmdem3Fcw/Gsdmdem3Fcw
(involves: C57BL/6)
|
abnormal macrophage apoptosis
|
J:226781
|
decreased interleukin-1 beta secretion
|
J:226781
|
Gsdmdem4Fcw/Gsdmdem4Fcw
(C57BL/6N-Gsdmdem4Fcw/J)
|
abnormal macrophage apoptosis
|
J:101977
|
abnormal susceptibility to bacterial infection
|
J:101977
|
Gsdmdm1Btlr/Gsdmdm1Btlr
(C57BL/6J-Gsdmdm1Btlr)
|
decreased interleukin-1 beta secretion
|
J:267555
|
Gsk3atm1Dral/Gsk3atm1Dral Gsk3btm1Dral/Gsk3btm1Dral
(involves: 129P2/OlaHsd)
|
increased circulating interleukin-6 level
|
J:200517
|
Gsntm1Djk/Gsntm1Djk
(either: (involves: 129S4/SvJae * BALB/c) or (involves: 129S4/SvJae * C57BL/6))
|
abnormal immune system physiology
|
J:24346
|
abnormal osteoclast physiology
|
J:60625
|
decreased inflammatory response
|
J:24346
|
impaired neutrophil chemotaxis
|
J:24346
|
impaired neutrophil recruitment
|
J:24346
|
Gsta4tm1Pzim/Gsta4+
(involves: 129S1/Sv * 129S6/SvEvTac)
|
increased susceptibility to bacterial infection
|
J:87983
|
Gsta4tm1Pzim/Gsta4tm1Pzim
(involves: 129S1/Sv * 129S6/SvEvTac)
|
increased susceptibility to bacterial infection
|
J:87983
|
Gstcdtm1b(EUCOMM)Wtsi/Gstcdtm1b(EUCOMM)Wtsi
(C57BL/6-Gstcdtm1b(EUCOMM)Wtsi)
|
increased tumor necrosis factor secretion
|
J:279480
|
Gstk1tm1Pgb/Gstk1tm1Pgb
(BALB/c-Gstk1tm1Pgb)
|
glomerulonephritis
|
J:177201
|
urethritis
|
J:177201
|
urinary bladder inflammation
|
J:177201
|
Gstt2em1Rmah/Gstt2em1Rmah
(Not Specified)
|
decreased interleukin-12 secretion
|
J:358834
|
decreased tumor necrosis factor secretion
|
J:358834
|
increased inflammatory response
|
J:358834
|
increased interleukin-6 secretion
|
J:358834
|
increased interleukin-10 secretion
|
J:358834
|
increased interleukin-12 secretion
|
J:358834
|
increased tumor necrosis factor secretion
|
J:358834
|
Gstz1tm1Pgb/Gstz1tm1Pgb
(BALB/c-Gstz1tm1Pgb/AnuApb)
|
chronic inflammation
|
J:91519
|
liver inflammation
|
J:91519
|
Gt(ROSA)26Sorem1(DPP4)Yowa/Gt(ROSA)26Sorem1(DPP4)Yowa
(C57BL/6-Gt(ROSA)26Sorem1(DPP4)Yowa)
|
increased susceptibility to Coronaviridae infection
|
J:279060
|
Gt(ROSA)26Sorem1(Ube2s)Chaw/?
(involves: C57BL/6)
|
decreased interferon level
|
J:306461
|
increased susceptibility to Picornaviridae infection induced morbidity/mortality
|
J:306461
|
Gt(ROSA)26Sortm1(B4galt1)Clib/Gt(ROSA)26Sortm1(B4galt1)Clib Tg(Nes-cre)Wme/?
(involves: 129S6/SvEvTac * C57BL/6 * CBA)
|
decreased acute inflammation
|
J:209737
|
decreased circulating interleukin-6 level
|
J:209737
|
decreased susceptibility to induced colitis
|
J:209737
|
Gt(ROSA)26Sortm1(CAG-Bcl3,-EGFP)Hoev/Gt(ROSA)26Sor+ Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd)
|
abnormal class switch recombination
|
J:208980
|
decreased B cell apoptosis
|
J:208980
|
decreased B cell proliferation
|
J:208980
|
decreased IgG1 level
|
J:208980
|
decreased IgG2b level
|
J:208980
|
decreased IgG3 level
|
J:208980
|
decreased IgM level
|
J:208980
|
Gt(ROSA)26Sortm1(CAG-CAMK2G*T287D,-EGFP)Whua/Gt(ROSA)26Sor+ Tg(Vil1-cre)997Gum/0
(involves: 129 * C57BL/6)
|
decreased susceptibility to induced colitis
|
J:243363
|
Gt(ROSA)26Sortm1(CAG-Foxn1/ERT2,-GFP)Cbln/Gt(ROSA)26Sor+ Foxn1tm3(cre)Nrm/Foxn1+
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal thymus involution
|
J:208852
|
Gt(ROSA)26Sortm1(CARD14*)Ribt/Gt(ROSA)26Sor+ Malt1tm1c(EUCOMM)Hmgu/Malt1tm1c(EUCOMM)Hmgu Tg(KRT14-cre/ERT)20Efu/0
(involves: 129S6/SvEvTac * C57BL/6NCrl * CD-1)
|
skin inflammation
|
J:292094
|
Gt(ROSA)26Sortm1(CARD14*)Ribt/Gt(ROSA)26Sor+ Tg(KRT14-cre/ERT)20Efu/0
(involves: 129S6/SvEvTac * C57BL/6NCrl * CD-1)
|
skin inflammation
|
J:292094
|
Gt(ROSA)26Sortm1(cre/ERT2)Thl/Gt(ROSA)26Sor+ Mcl1tm1Ywh/Mcl1tm1Ywh
(involves: 129/Sv * 129S6/SvEvTac * C57BL/6)
|
increased T cell apoptosis
|
J:137400
|
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+ Il1r2tm1.1Mchc/Il1r2tm1.1Mchc
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * C57BL/6NTac)
|
abnormal adaptive immunity
|
J:347877
|
increased IgG level
|
J:347877
|
Gt(ROSA)26Sortm1(DTA)Jpmb/Gt(ROSA)26Sor+ Tg(Plp1-cre/ERT)3Pop/0
(involves: 129S/SvEv * C57BL/6 * DBA/2)
|
autoimmune response
|
J:234435
|
CNS inflammation
|
J:234435
|
lymph node inflammation
|
J:234435
|
Gt(ROSA)26Sortm1(DTA)Jpmb/Gt(ROSA)26Sor+ Tg(Trpv1-cre)1Hoon/0
(involves: 129S1/Sv)
|
decreased inflammatory response
|
J:169256
|
Gt(ROSA)26Sortm1(DTA)Lky/? Il5tm1.1(icre)Lky/Il5+ Rag1tm1Mom/Rag1tm1Mom
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6)
|
abnormal immune system physiology
|
J:206097
|
Gt(ROSA)26Sortm1(DTA)Lky/Gt(ROSA)26Sor+ Il13tm1(YFP/cre)Lky/Il13tm1(YFP/cre)Lky
(involves: 129P2/OlaHsd * 129S4/SvJae)
|
decreased IgG1 level
|
J:178986
|
decreased interleukin-5 secretion
|
J:178986
|
decreased interleukin-13 secretion
|
J:178986
|
increased susceptibility to parasitic infection
|
J:178986
|
Gt(ROSA)26Sortm1(DTA)Lky/Gt(ROSA)26Sortm1(DTA)Lky Tg(Cd4-cre)1Cwi/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:133382
|
increased susceptibility to parasitic infection
|
J:133382
|
Gt(ROSA)26Sortm1(DUX4)Sqh/Gt(ROSA)26Sor+ Tg(ACTA1-cre/Esr1*)2Kesr/0
(involves: 129S6/SvEvTac * C3H * C57BL/6)
|
abnormal acute inflammation
|
J:268959
|
Gt(ROSA)26Sortm1(ETV6/SYK)Hjum/Gt(ROSA)26Sor+ Cd79atm3(cre/ERT2)Reth/Cd79a+
(involves: 129S6/SvEvTac * BALB/c)
|
abnormal circulating chemokine level
|
J:208904
|
abnormal cytokine level
|
J:208904
|
increased B cell apoptosis
|
J:208904
|
increased B cell proliferation
|
J:208904
|
increased circulating interferon-gamma level
|
J:208904
|
increased circulating interleukin-6 level
|
J:208904
|
increased circulating interleukin-10 level
|
J:208904
|
increased circulating tumor necrosis factor level
|
J:208904
|
increased IgM level
|
J:208904
|
increased interferon-gamma secretion
|
J:208904
|
increased interleukin-10 secretion
|
J:208904
|
increased tumor necrosis factor secretion
|
J:208904
|
Gt(ROSA)26Sortm1(ETV6/SYK)Hjum/Gt(ROSA)26Sor+ Cd79atm3(cre/ERT2)Reth/Cd79a+ Tg(BCL2)22Wehi/0
(involves: 129S6/SvEvTac * BALB/c * C57BL/6JWehi * SJL/JWehi)
|
abnormal B cell physiology
|
J:208904
|
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+ Ighg1tm1(cre)Cgn/Ighg1+ Prdm1tm2Masu/Prdm1tm2Masu
(involves: 129P2/OlaHsd * 129X1/SvJ)
|
abnormal germinal center B cell physiology
|
J:167612
|
decreased IgG1 level
|
J:167612
|
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+ Il22tm1.1(icre)Stck/Il22+
(involves: 129X1/SvJ * C57BL/6N)
|
abnormal susceptibility to bacterial infection
|
J:220074
|
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+ Krastm4Tyj/Kras+ Tg(Pdx1-cre)89.1Dam/0
(involves: 129 * C57BL/6 * CBA)
|
increased susceptibility to induced pancreatitis
|
J:289183
|
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+ Plcg1tm1Gcrp/Plcg1tm1Rwen Tg(Cd4-cre)1Cwi/0
(involves: 129X1/SvJ * C57BL/6 * DBA/2)
|
abnormal regulatory T cell physiology
|
J:157757
|
abnormal T cell activation
|
J:157757
|
decreased interferon-gamma secretion
|
J:157757
|
decreased interleukin-2 secretion
|
J:157757
|
decreased T cell proliferation
|
J:157757
|
dermatitis
|
J:157757
|
increased T cell apoptosis
|
J:157757
|
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+ Cd19tm1(cre)Cgn/Cd19+ Rev3ltm1.1Diaz/Rev3ltm1.1Diaz
(involves: 129P2/OlaHsd * 129X1/SvJ * BALB/c * C57BL/6 * C57BL/6NTac)
|
abnormal class switch recombination
|
J:188723
|
abnormal somatic hypermutation frequency
|
J:188723
|
decreased B cell proliferation
|
J:188723
|
Gt(ROSA)26Sortm1(gp80,EGFP)Eces/Gt(ROSA)26Sor+ Cd19tm1(cre)Cgn/Cd19+
(either: (involves: 129/Sv * 129P2/OlaHsd * C57BL/6) or (involves: 129/Sv * 129P2/OlaHsd * BALB/c * C57BL/6))
|
abnormal class switch recombination
|
J:172031
|
decreased B cell apoptosis
|
J:172031
|
decreased IgA level
|
J:172031
|
decreased IgG1 level
|
J:172031
|
decreased IgG2a level
|
J:172031
|
decreased IgG3 level
|
J:172031
|
increased IgE level
|
J:172031
|
Gt(ROSA)26Sortm1(gp80,EGFP)Eces/Gt(ROSA)26Sor+ Ighg1tm1(cre)Cgn/Ighg1+
(either: (involves: 129/Sv * 129P2/OlaHsd * C57BL/6) or (involves: 129/Sv * 129P2/OlaHsd * BALB/c * C57BL/6))
|
abnormal class switch recombination
|
J:172031
|
decreased IgA level
|
J:172031
|
decreased IgG1 level
|
J:172031
|
decreased IgG2a level
|
J:172031
|
decreased IgG2b level
|
J:172031
|
decreased IgG3 level
|
J:172031
|
increased IgE level
|
J:172031
|
Gt(ROSA)26Sortm1(HA)Libl/Gt(ROSA)26Sortm1(HA)Libl Mogtm1(cre)Gkl/? Tg(TcraCl4,TcrbCl4)1Shrm/0
(involves: 129/Sv * BALB/c * C57BL/6)
|
brain inflammation
|
J:137838
|
optic nerve inflammation
|
J:137838
|
spinal cord inflammation
|
J:137838
|
Gt(ROSA)26Sortm1(HBEGF)Awai/Gt(ROSA)26Sortm1(HBEGF)Awai Mogtm1(cre)Gkl/?
(involves: C57BL/6)
|
abnormal immune system physiology
|
J:131076
|
Gt(ROSA)26Sortm1(ITK/SYK)Jrld/Gt(ROSA)26Sor+ Tg(Cd4-cre)1Cwi/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
abnormal T cell activation
|
J:160931
|
increased T cell proliferation
|
J:160931
|
Gt(ROSA)26Sortm1(MAML1)Wsp/Gt(ROSA)26Sor+ Tg(Cd4-cre)1Cwi/0
(B6.Cg-Tg(Cd4-cre)1Cwi Gt(ROSA)26Sortm1(MAML1)Wsp)
|
abnormal immunoglobulin level
|
J:113262
|
abnormal T-helper 1 physiology
|
J:113262
|
abnormal T-helper 2 physiology
|
J:113262
|
decreased susceptibility to parasitic infection
|
J:113262
|
increased susceptibility to parasitic infection
|
J:113262
|
Gt(ROSA)26Sortm1(MAML1)Wsp/Gt(ROSA)26Sor+ Tg(KRT14-rtTA)F42Efu/0 Tg(tetO-cre)1Jaw/0
(involves: 129 * C57BL/6 * FVB)
|
conjunctivitis
|
J:194073
|
Gt(ROSA)26Sortm1(Mirn155)Rsky/Gt(ROSA)26Sortm1(Mirn155)Rsky
(involves: BALB/c * C57BL/6)
|
abnormal humoral immune response
|
J:121084
|
Gt(ROSA)26Sortm1(Nfatc2*)Rao/Gt(ROSA)26Sor+ Tg(Cd4-cre)1Cwi/0
(involves: C57BL/6 * DBA/2)
|
abnormal interferon level
|
J:148341
|
abnormal T cell activation
|
J:148341
|
Gt(ROSA)26Sortm1(OVAL/fla,GFP)Vnce/Gt(ROSA)26Sor+ Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * C57BL/6J)
|
abnormal circulating cytokine level
|
J:260047
|
glomerulonephritis
|
J:260047
|
increased inflammatory response
|
J:260047
|
joint inflammation
|
J:260047
|
small intestinal inflammation
|
J:260047
|
Gt(ROSA)26Sortm1(OVAL/fla,GFP)Vnce/Gt(ROSA)26Sor+ Lyz2tm1(cre)Ifo/Lyz2+ Pycardtm1Vmd/Pycardtm1Vmd
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6J)
|
increased circulating interferon-gamma level
|
J:260047
|
increased circulating interleukin-6 level
|
J:260047
|
increased circulating tumor necrosis factor level
|
J:260047
|
Gt(ROSA)26Sortm1(OVAL/fla,GFP)Vnce/Gt(ROSA)26Sor+ Tg(S100A8-cre,-EGFP)1Ilw/0
(involves: C3H * C57BL/6 * C57BL/6J)
|
abnormal circulating cytokine level
|
J:260047
|
increased circulating interleukin-18 level
|
J:260047
|
Gt(ROSA)26Sortm1(Ptpn22*)Draw/Gt(ROSA)26Sor+ Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * C57BL/6)
|
glomerulonephritis
|
J:201448
|
increased anti-double stranded DNA antibody level
|
J:201448
|
increased autoantibody level
|
J:201448
|
Gt(ROSA)26Sortm1(Stat3*A661C*N663C)Sbkv/Gt(ROSA)26Sortm1(Stat3*A661C*N663C)Sbkv Tg(Cd4-cre)1Cwi/0
(involves: C57BL/6 * DBA/2)
|
increased circulating interleukin-17 level
|
J:205858
|
increased interleukin-17 secretion
|
J:205858
|
lung inflammation
|
J:205858
|
Gt(ROSA)26Sortm1.1(CAG-Trp53*,-EGFP)Medz/Gt(ROSA)26Sortm1.1(CAG-Trp53*,-EGFP)Medz
(involves: C57BL/6)
|
decreased thymocyte apoptosis
|
J:158953
|
Gt(ROSA)26Sortm1.1(DUX4*)Plj/Gt(ROSA)26Sor+ Tg(ACTA1-cre/Esr1*)2Kesr/0
(involves: C3H * C57BL/6)
|
increased acute inflammation
|
J:256652
|
Gt(ROSA)26Sortm1.1(DUX4*)Plj/Gt(ROSA)26Sortm1.1(DUX4*)Plj
(B6(Cg)-Gt(ROSA)26Sortm1.1(DUX4*)Plj)
|
preputial gland inflammation
|
J:256652
|
Gt(ROSA)26Sortm1.1(Loxl2)Acan/Gt(ROSA)26Sortm1.1(Loxl2)Acan
(Not Specified)
|
epididymis inflammation
|
J:220689
|
increased inflammatory response
|
J:220689
|
Gt(ROSA)26Sortm1.1(Ubc-BCL3)Sbn/Gt(ROSA)26Sor+ Cd79atm1(cre)Reth/Cd79a+
(involves: BALB/c * C57BL/6)
|
decreased B cell proliferation
|
J:207111
|
Gt(ROSA)26Sortm1Jus/Gt(ROSA)26Sor+ Tg(MMTV-cre)4Mam/0
(involves: C57BL/6J * C57BL/6N * FVB/N)
|
abnormal thymus physiology
|
J:202090
|
increased inflammatory response
|
J:202090
|
intestinal inflammation
|
J:202090
|
kidney inflammation
|
J:202090
|
liver inflammation
|
J:202090
|
meningitis
|
J:202090
|
stomach inflammation
|
J:202090
|
Gt(ROSA)26Sortm1Jus/Gt(ROSA)26Sor+ Tg(Mx1-cre)1Cgn/0
(involves: C57BL/6 * C57BL/6J * C57BL/6N * CBA)
|
abnormal thymus physiology
|
J:202090
|
increased inflammatory response
|
J:202090
|
intestinal inflammation
|
J:202090
|
kidney inflammation
|
J:202090
|
liver inflammation
|
J:202090
|
meningitis
|
J:202090
|
stomach inflammation
|
J:202090
|
Gt(ROSA)26Sortm2(CAG-Notch2*)Uzs/Gt(ROSA)26Sor+ Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J)
|
abnormal marginal zone B cell physiology
|
J:179036
|
decreased IgG1 level
|
J:179036
|
decreased IgG3 level
|
J:179036
|
decreased IgM level
|
J:179036
|
increased B cell proliferation
|
J:179036
|
Gt(ROSA)26Sortm2(CAG-Nr5a1)Fjd/Gt(ROSA)26Sor+ Pgrtm2(cre)Lyd/Pgr+
(involves: 129S1/Sv * 129X1/SvJ)
|
uterus inflammation
|
J:269597
|
Gt(ROSA)26Sortm2(cre/ERT2)Brn/0 Tg(Sftpc-Grem1)105Mmyl/0
(involves: 129P2/OlaHsd * C57BL/6N)
|
lung inflammation
|
J:82809
|
Gt(ROSA)26Sortm2(ITK/Syk)Hjum/Gt(ROSA)26Sor+ Tg(Cd4-cre)1Cwi/0
(involves: 129S6/SvEvTac * C57BL/6 * DBA/2)
|
abnormal circulating cytokine level
|
J:207306
|
abnormal cytokine secretion
|
J:207306
|
abnormal immunoglobulin level
|
J:207306
|
increased circulating interferon-gamma level
|
J:207306
|
increased circulating interleukin-2 level
|
J:207306
|
increased circulating interleukin-4 level
|
J:207306
|
increased circulating interleukin-6 level
|
J:207306
|
increased circulating interleukin-10 level
|
J:207306
|
increased circulating tumor necrosis factor level
|
J:207306
|
increased IgA level
|
J:207306
|
increased IgG level
|
J:207306
|
increased IgM level
|
J:207306
|
increased inflammatory response
|
J:207306
|
increased interferon-gamma secretion
|
J:207306
|
increased interleukin-2 secretion
|
J:207306
|
increased interleukin-4 secretion
|
J:207306
|
increased interleukin-6 secretion
|
J:207306
|
increased interleukin-10 secretion
|
J:207306
|
increased tumor necrosis factor secretion
|
J:207306
|
Gt(ROSA)26Sortm2(ITK/Syk)Hjum/Gt(ROSA)26Sor+ Tg(Lck-cre)I57Jxm/0
(involves: 129S6/SvEvTac * ICR)
|
abnormal circulating cytokine level
|
J:207306
|
abnormal cytokine secretion
|
J:207306
|
abnormal immunoglobulin level
|
J:207306
|
increased circulating interferon-gamma level
|
J:207306
|
increased circulating interleukin-2 level
|
J:207306
|
increased circulating interleukin-4 level
|
J:207306
|
increased circulating interleukin-6 level
|
J:207306
|
increased circulating interleukin-10 level
|
J:207306
|
increased circulating tumor necrosis factor level
|
J:207306
|
increased IgA level
|
J:207306
|
increased IgG level
|
J:207306
|
increased IgM level
|
J:207306
|
increased inflammatory response
|
J:207306
|
increased interferon-gamma secretion
|
J:207306
|
increased interleukin-2 secretion
|
J:207306
|
increased interleukin-4 secretion
|
J:207306
|
increased interleukin-6 secretion
|
J:207306
|
increased interleukin-10 secretion
|
J:207306
|
increased tumor necrosis factor secretion
|
J:207306
|
Gt(ROSA)26Sortm2(Lmp1/CD40)Uzs/Gt(ROSA)26Sor+ Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * BALB/c * C57BL/6)
|
abnormal B cell activation
|
J:137122
|
abnormal B cell physiology
|
J:137122
|
abnormal class switch recombination
|
J:137122
|
abnormal humoral immune response
|
J:137122
|
abnormal T cell activation
|
J:137122
|
increased B cell proliferation
|
J:137122
|
Gt(ROSA)26Sortm2(Lmp1/CD40)Uzs/Gt(ROSA)26Sor+ Tg(Cr2-cre)3Cgn/0
(involves: BALB/c * C57BL/6)
|
abnormal immune system physiology
|
J:137122
|
Gt(ROSA)26Sortm2(Mirn150)Rsky/Gt(ROSA)26Sortm2(Mirn150)Rsky
(involves: C57BL/6 * SJL/J)
|
increased B cell apoptosis
|
J:127234
|
Gt(ROSA)26Sortm2(Nfatc2*)Rao/Gt(ROSA)26Sor+ Tg(Cd4-cre)1Cwi/0
(involves: C57BL/6 * DBA/2)
|
abnormal interferon level
|
J:148341
|
abnormal T cell activation
|
J:148341
|
Gt(ROSA)26Sortm2(sb11)Njen/Gt(ROSA)26Sor+ TgTn(sb-T2/Onc2)6070Njen/0
(involves: 129 * C57BL/6 * C57BL/6J)
|
increased susceptibility to infection
|
J:153656
|
Gt(ROSA)26Sortm2.1(CAG-PSTPIP1*)Dtg/Gt(ROSA)26Sor+
(involves: BALB/cJ * C57BL/6)
|
increased circulating interleukin-1 alpha level
|
J:196002
|
increased circulating interleukin-1 beta level
|
J:196002
|
increased circulating tumor necrosis factor level
|
J:196002
|
Gt(ROSA)26Sortm2.1(Cd74/MOG)Awai/Gt(ROSA)26Sor+
(involves: C57BL/6 * BALB/cJ)
|
abnormal humoral immune response
|
J:140751
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:140751
|
Gt(ROSA)26Sortm2.1(Mirn150)Rsky/Gt(ROSA)26Sortm2.1(Mirn150)Rsky
(involves: C57BL/6 * SJL/J)
|
increased B cell apoptosis
|
J:127234
|
Gt(ROSA)26Sortm2Sho/Gt(ROSA)26Sor+ Lef1tm1Hhx/Lef1tm1Hhx Tg(GZMB-cre)1Jcb/0
(involves: 129S4/SvJaeSor * C57BL/6 * FVB/N)
|
abnormal memory T cell physiology
|
J:189838
|
Gt(ROSA)26Sortm3(CAG-Il17a)Awai/Gt(ROSA)26Sor+ Tg(Cd4-cre)1Cwi/0
(involves: C57BL/6 * DBA/2)
|
abnormal immune system physiology
|
J:144710
|
abnormal neutrophil physiology
|
J:144710
|
increased circulating interleukin-17 level
|
J:144710
|
increased interleukin-17 secretion
|
J:144710
|
Gt(ROSA)26Sortm3(CAG-MIR17-92,-EGFP)Rsky/Gt(ROSA)26Sortm3(CAG-MIR17-92,-EGFP)Rsky Tg(CD2-icre)4Kio/0
(involves: C57BL/6 * C57BL/10 * CBA/Ca)
|
abnormal B cell activation
|
J:133215
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:133215
|
abnormal immune system physiology
|
J:133215
|
abnormal immunoglobulin level
|
J:133215
|
abnormal T cell activation
|
J:133215
|
increased anti-double stranded DNA antibody level
|
J:133215
|
increased anti-single stranded DNA antibody level
|
J:133215
|
increased B cell proliferation
|
J:133215
|
increased IgG2a level
|
J:133215
|
increased IgG2b level
|
J:133215
|
increased IgG3 level
|
J:133215
|
increased IgM level
|
J:133215
|
Gt(ROSA)26Sortm3.1(CAG-Il17a)Awai/Gt(ROSA)26Sor+
(involves: BALB/c * C57BL/6)
|
increased interleukin-17 secretion
|
J:144710
|
skin inflammation
|
J:144710
|
Gt(ROSA)26Sortm4(HIF2A*)Kael/Gt(ROSA)26Sortm4(HIF2A*)Kael Tg(Vil1-cre/ERT2)23Syr/0
(involves: 129S6/SvEvTac * C57BL/6 * DBA/2)
|
increased susceptibility to colitis induced morbidity/mortality
|
J:307422
|
Gt(ROSA)26Sortm4(Ikbkb)Rsky/Gt(ROSA)26Sor+ Ighg1tm1(cre)Cgn/Ighg1+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased IgG1 level
|
J:167612
|
increased IgM level
|
J:167612
|
Gt(ROSA)26Sortm4(Ikbkb)Rsky/Gt(ROSA)26Sor+ Ighg1tm1(cre)Cgn/Ighg1+ Prdm1tm2Masu/Prdm1tm2Masu
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal germinal center B cell physiology
|
J:167612
|
decreased IgG1 level
|
J:167612
|
Gt(ROSA)26Sortm7(Pik3ca*,EGFP)Rsky/Gt(ROSA)26Sortm13(CAG-MYC,-CD2*)Rsky Ighg1tm1(cre)Cgn/Ighg1+
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal class switch recombination
|
J:191824
|
Gt(ROSA)26Sortm9(cre/ESR1)Arte/? Tnfaip3tm1Homy/Tnfaip3tm1Homy
(involves: 129S6/SvEvTac * C57BL/6J * C57BL/6NTac)
|
abnormal circulating cytokine level
|
J:212681
|
abnormal circulating interleukin level
|
J:212681
|
increased circulating interferon-gamma level
|
J:212681
|
increased circulating interleukin-1 beta level
|
J:212681
|
increased circulating interleukin-6 level
|
J:212681
|
increased circulating tumor necrosis factor level
|
J:212681
|
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+ Map3k14tm1.1Gne/Map3k14tm1.1Gne
(B6(Cg)-Map3k14tm1.1Gne Gt(ROSA)26Sortm9(cre/ESR1)Arte)
|
abnormal immunoglobulin level
|
J:240453
|
decreased B cell proliferation
|
J:240453
|
decreased IgA level
|
J:240453
|
decreased IgG1 level
|
J:240453
|
decreased IgM level
|
J:240453
|
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+ Ripk3tm1Arte/Ripk3tm1Arte
(involves: C57BL/6NTac)
|
intestinal inflammation
|
J:209137
|
Gt(ROSA)26Sortm10(Lmp1)Rsky/Gt(ROSA)26Sor+
(involves: BALB/cJ)
|
increased B cell proliferation
|
J:181546
|
Gt(ROSA)26Sortm10(Lmp1)Rsky/Gt(ROSA)26Sor+ Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * BALB/cJ)
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:181546
|
abnormal immune system physiology
|
J:181546
|
increased B cell proliferation
|
J:181546
|
Gt(ROSA)26Sortm11(Lmp1)Rsky/Gt(ROSA)26Sor+
(involves: C57BL/6)
|
increased B cell proliferation
|
J:181546
|
Gt(ROSA)26Sortm11(Lmp1)Rsky/Gt(ROSA)26Sor+ Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:181546
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:181546
|
abnormal immune system physiology
|
J:181546
|
increased B cell proliferation
|
J:181546
|
increased interferon-gamma secretion
|
J:181546
|
increased tumor necrosis factor secretion
|
J:181546
|
Gt(ROSA)26Sortm11(Lmp1)Rsky/Gt(ROSA)26Sor+ Cd19tm1(cre/ERT2)Rsky/Cd19+
(involves: 129P2/OlaHsd * C57BL/6J)
|
abnormal T cell physiology
|
J:217520
|
Gucy1b1tm1.1Frb/Gucy1b1tm1.1Frb
(involves: 129 * C57BL/6 * FVB/N)
|
peritoneal inflammation
|
J:121321
|
Gucy2ctm1Gar/Gucy2ctm1Gar
(either: (involves: 129S6/SvEvTac * Black Swiss) or (involves: 129S6/SvEvTac * C57BL/6J))
|
decreased susceptibility to bacterial infection
|
J:43046
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:43046
|
Gucy2ctm1Gian/Gucy2ctm1Gian
(involves: 129P2/OlaHsd * Black Swiss)
|
decreased susceptibility to infection
|
J:43682
|
Gulp1tm1.2Kimj/Gulp1tm1.2Kimj
(involves: 129S4/SvJae * C57BL/6 * SJL)
|
abnormal osteoclast physiology
|
J:340688
|
Gvhd1C57BL/10J/Gvhd1C57BL/10J
(involves: B10.D2-H2d * C57BL/10J)
|
increased susceptibility to graft versus host disease
|
J:52834
|
Gvhd1C57BL/10J/Gvhd1C57BL/10J Gvhd2C57BL/10J/Gvhd2C57BL/10J
(involves: B10.D2-H2d * C57BL/10J)
|
increased susceptibility to graft versus host disease
|
J:52834
|
Gvhd2C57BL/10J/Gvhd2C57BL/10J
(involves: B10.D2-H2d * DBA/2J)
|
increased susceptibility to graft versus host disease
|
J:52834
|
Gvhd4DBA/2J/Gvhd4DBA/2J
(involves: C57BL/10 * DBA/2J)
|
increased anti-single stranded DNA antibody level
|
J:66655
|
Gvhd4DBA/2J/Gvhd4DBA/2J Gvhd5DBA/2J/Gvhd5DBA/2J
(involves: C57BL/10 * DBA/2J)
|
increased anti-single stranded DNA antibody level
|
J:66655
|
Gvhd5DBA/2J/Gvhd5DBA/2J
(involves: C57BL/10 * DBA/2J)
|
increased anti-single stranded DNA antibody level
|
J:66655
|
Gy/Y
(involves: 101/H * C3H/HeH)
|
blepharitis
|
J:8335
|
Gzmatm1Ley/Gzmatm1Ley
(involves: 129X1/SvJ * C57BL/6)
|
decreased cytotoxic T cell cytolysis
|
J:49361
|
Gzmatm1Simn/Gzmatm1Simn Gzmbtm1Ley/Gzmbtm1Ley
(involves: 129S2/SvPas * C57BL/6)
|
abnormal leukocyte physiology
|
J:44204
|
Gzmatm1Simn/Gzmatm1Simn Gzmbtm1Ley/Gzmbtm1Ley
(B6.Cg-Gzmatm1Simn Gzmbtm1Ley)
|
increased susceptibility to Flaviviridae infection
|
J:90852
|
increased susceptibility to parasitic infection
|
J:81397
|
Gzmatm1Simn/Gzmatm1Simn Gzmbtm1Ley/Gzmbtm1Ley Prf1tm1Sdz/Prf1tm1Sdz
(B6.Cg-Gzmatm1Simn Gzmbtm1Ley Prf1tm1Sdz)
|
increased susceptibility to Flaviviridae infection
|
J:90852
|
increased susceptibility to parasitic infection
|
J:81397
|
Gzmbtm1Ley/Gzmbtm1Ley
(involves: 129S2/SvPas * C57BL/6J)
|
decreased cytotoxic T cell cytolysis
|
J:23560
|
Gzmbtm1Ley/Gzmbtm1Ley
(B6.129S2-Gzmbtm1Ley)
|
impaired natural killer cell mediated cytotoxicity
|
J:113213
|
Gzmbtm1Ley/Gzmbtm1Ley
(involves: 129X1/SvJ)
|
abnormal NK cell physiology
|
J:126114
|
decreased T cell apoptosis
|
J:126114
|
Gzmbtm1Ley/Gzmbtm1Ley Serpinb9tm1.1Pib/Serpinb9tm1.1Pib
(involves: 129S2/SvPas * BALB/cJ * C57BL/6J)
|
decreased cytotoxic T cell apoptosis
|
J:252016
|
Gzmbtm1Ley/Gzmbtm1Ley Serpinb9tm1Arp/Serpinb9tm1Arp
(involves: 129S2/SvPas * C57BL/6)
|
abnormal cytotoxic T cell physiology
|
J:113349
|
Gzmbtm2.1Ley/Gzmbtm2.1Ley
(129X1/SvJ-Gzmbtm2.1Ley)
|
decreased cytotoxic T cell cytolysis
|
J:96538
|
Gzmbtm2Ley/Gzmbtm2Ley
(129X1/SvJ-Gzmbtm2Ley)
|
abnormal immune system physiology
|
J:96538
|
decreased cytotoxic T cell cytolysis
|
J:96538
|
Gzmmtm1(cre)Mjs/Gzmmtm1(cre)Mjs
(C57BL/6-Gzmmtm1(cre)Mjs)
|
increased susceptibility to Herpesvirales infection
|
J:113213
|
H2-Aab-tm1Blt/H2-Aab-tm1Blt
(C57BL/6-H2-Aab-tm1Blt)
|
abnormal MHC II cell surface expression on macrophages
|
J:67924
|
abnormal splenocyte physiology
|
J:16372
|
H2-Ab1b-tm1.1Jssh/H2-Ab1b-tm1.1Jssh
(C57BL/6-H2-Ab1b-tm1.1Jssh)
|
abnormal dendritic cell antigen presentation
|
J:201198
|
H2-Ab1b-tm1.1Sish/H2-Ab1b-tm1.1Sish
(involves: 129S1/Sv * 129X1/SvJ)
|
abnormal dendritic cell physiology
|
J:157516
|
decreased interleukin-12 secretion
|
J:157516
|
decreased tumor necrosis factor secretion
|
J:157516
|
H2-Ab1b-tm1Doi/H2-Ab1+
(involves: 129S2/SvPas * C57BL/6 * NOD/Lt)
|
insulitis
|
J:93557
|
H2-Ab1b-tm1Doi/H2-Ab1b-tm1Doi
(involves: 129S2/SvPas * C57BL/6)
|
abnormal B cell physiology
|
J:65736
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:65736
|
abnormal cytokine secretion
|
J:64283
|
abnormal immune system physiology
|
J:65736
|
abnormal T cell physiology
|
J:65736
|
decreased IgG1 level
|
J:65736
|
decreased susceptibility to parasitic infection
|
J:64283
|
increased susceptibility to parasitic infection
|
J:64283
|
H2-Ab1b-tm1Doi/H2-Ab1b-tm1Doi
(involves: 129S2/SvPas * C57BL/6 * NOD/Lt)
|
insulitis
|
J:93557
|
H2-Ab1b-tm1Gru/H2-Ab1b-tm1Gru
(involves: 129S2/SvPas * C57BL/6J)
|
abnormal humoral immune response
|
J:74418
|
abnormal response to transplant
|
J:91742
|
decreased IgG level
|
J:74418
|
increased IgM level
|
J:74418
|
H2-Ab1b-tm1Gru/H2-Ab1b-tm1Gru
(B6.129S2-H2-Ab1b-tm1Gru)
|
abnormal B cell physiology
|
J:91341
|
abnormal lymphocyte physiology
|
J:91341
|
H2-Ab1b-tm1Gru/H2-Ab1b-tm1Gru
(involves: 129S2/SvPas * C57BL/6)
|
abnormal level of surface class II molecules
|
J:67941
|
decreased IgG1 level
|
J:67941
|
decreased IgM level
|
J:67941
|
H2-Ab1b-tm1Gru/H2-Ab1b-tm1Gru Ighmtm1Cgn/Ighmtm1Cgn Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell/Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell
(NOD.Cg-Ighmtm1Cgn H2-Ab1b-tm1Gru Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell)
|
heart inflammation
|
J:113267
|
H2-Ab1b-tm1Gru/H2-Ab1b-tm1Gru Rag1tm1Mom/Rag1tm1Mom Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell/Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell
(NOD.Cg-Rag1tm1Mom H2-Ab1b-tm1Gru Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell)
|
abnormal response to transplant
|
J:113267
|
heart inflammation
|
J:113267
|
increased autoantibody level
|
J:113267
|
myocarditis
|
J:113267
|
H2-Ab1b-tm1Gru/H2-Ab1b-tm1Gru Rag1tm1Mom/Rag1tm1Mom Tg(HLA-DQA1,HLA-DQB1)73Myl/0
(NOD.Cg-Rag1tm1Mom H2-Ab1b-tm1Gru Tg(HLA-DQA1,HLA-DQB1)73Myl)
|
abnormal response to transplant
|
J:88055
|
myocarditis
|
J:88055
|
H2-Ab1b-tm1Gru/H2-Ab1b-tm1Gru Runx1tm1Toku/Runx1tm1Toku Runx3tm1Itan/Runx3tm1Itan Tg(Cd4-cre)1Cwi/0
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * DBA/2)
|
abnormal interferon secretion
|
J:131081
|
H2-Ab1b-tm1Gru/H2-Ab1b-tm1Gru Tg(Ab1TL)1Gru/0
(B6.Cg-H2-Ab1b-tm1Gru Tg(Ab1TL)1Gru)
|
abnormal macrophage antigen presentation
|
J:91341
|
abnormal professional antigen presenting cell physiology
|
J:91341
|
H2-Ab1b-tm1Gru/H2-Ab1b-tm1Gru Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell/Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell
(NOD.Cg-H2-Ab1b-tm1Gru Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell)
|
autoimmune response
|
J:87013,
J:86540
|
decreased susceptibility to autoimmune disorder
|
J:87013
|
heart inflammation
|
J:87013,
J:86540
|
increased autoantibody level
|
J:113267
|
lung inflammation
|
J:86540
|
myositis
|
J:86540
|
salivary gland inflammation
|
J:86540
|
H2-Ab1b-tm1Gru/H2-Ab1b-tm1Gru Tg(CD4,HLA-DQA1,HLA-DQB1)N8Ell/Tg(CD4,HLA-DQA1,HLA-DQB1)N8Ell
(NOD.Cg-H2-Ab1b-tm1Gru Tg(CD4,HLA-DQA1,HLA-DQB1)N8Ell)
|
increased autoantibody level
|
J:113509
|
thyroid gland inflammation
|
J:113509
|
H2-Ab1b-tm1Gru/H2-Ab1b-tm1Gru Tg(HLA-DQA1,HLA-DQB1)1Dv/0 Tg(HLA-DRB1)31Dmz/0 Tg(Ins2-CD80)3B7Flv/0
(involves: 129S2/SvPas * C57BL/6 * C57BL/10SnJ * CBA * SJL)
|
decreased susceptibility to autoimmune diabetes
|
J:68641
|
salivary gland inflammation
|
J:68641
|
H2-Ab1b-tm1Gru/H2-Ab1b-tm1Gru Tg(HLA-DQA1,HLA-DQB1)1Dv/0 Tg(Ins2-CD80)3B7Flv/0
(B6.Cg-H2-Ab1b-tm1Gru Tg(HLA-DQA1,HLA-DQB1)1Dv Tg(Ins2-CD80)3B7Flv)
|
increased susceptibility to autoimmune diabetes
|
J:59245
|
salivary gland inflammation
|
J:59245
|
H2-Ab1b-tm1Gru/H2-Ab1b-tm1Gru Tg(HLA-DQA1,HLA-DQB1)1Dv/0 Tg(Ins2-CD80)3B7Flv/0
(involves: 129S2/SvPas * C57BL/6 * C57BL/10SnJ * CBA)
|
decreased interleukin-6 secretion
|
J:68641
|
increased interferon-gamma secretion
|
J:68641
|
increased susceptibility to autoimmune diabetes
|
J:68641
|
H2-Ab1b-tm1Gru/H2-Ab1b-tm1Gru Tg(HLA-DQA1,HLA-DQB1)70Myl/0
(NOD.Cg-H2-Ab1b-tm1Gru Tg(HLA-DQA1,HLA-DQB1)70Myl)
|
heart inflammation
|
J:88055
|
increased autoantibody level
|
J:88055
|
insulitis
|
J:88055
|
myocarditis
|
J:88055
|
salivary gland inflammation
|
J:88055
|
H2-Ab1b-tm1Gru/H2-Ab1b-tm1Gru Tg(HLA-DQA1,HLA-DQB1)73Myl/0
(NOD.Cg-H2-Ab1b-tm1Gru Tg(HLA-DQA1,HLA-DQB1)73Myl)
|
heart inflammation
|
J:88055
|
increased autoantibody level
|
J:88055
|
insulitis
|
J:88055
|
myocarditis
|
J:88055
|
salivary gland inflammation
|
J:88055
|
H2-Ab1b-tm1Gru/H2-Ab1b-tm1Gru Tg(HLA-DRB1)31Dmz/0 Tg(Ins2-CD80)3B7Flv/0
(involves: 129S2/SvPas * C57BL/6 * CBA * SJL)
|
decreased susceptibility to autoimmune diabetes
|
J:68641
|
salivary gland inflammation
|
J:68641
|
H2-Ab1b-tm1Gru/H2-Ab1b-tm1Gru Tg(Ins2-CD80)3B7Flv/0
(involves: 129S2/SvPas * C57BL/6 * CBA)
|
decreased susceptibility to autoimmune diabetes
|
J:68641
|
H2-Ab1b-tm1Koni/H2-Ab1b-tm1.1Koni Tg(Tek-cre)12Flv/0
(involves: 129X1/SvJ * C3H * C57BL/6 * C57BL/6J)
|
abnormal T cell activation
|
J:131774
|
decreased level of surface class II molecules
|
J:131774
|
H2-Ab1b-tm1Wug/H2-Ab1b-tm1Wug
(involves: C57BL/6)
|
abnormal B cell physiology
|
J:204951
|
abnormal dendritic cell physiology
|
J:204951
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:204951
|
H2-Ab1b-tm1Wug/H2-Ab1b-tm1Wug Cd19tm1(cre)Cgn/Cd19+
(involves: 129S2/SvPas * C57BL/6)
|
abnormal B cell physiology
|
J:204951
|
abnormal dendritic cell physiology
|
J:204951
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:204951
|
H2-Ab1bm12/H2-Ab1bm12
(B6(C)-H2-Ab1bm12/KhEgJ)
|
abnormal level of surface class II molecules
|
J:100194
|
abnormal T cell physiology
|
J:100123
|
decreased susceptibility to autoimmune disorder
|
J:100123
|
decreased susceptibility to experimental autoimmune myasthenia gravis
|
J:100213
|
decreased susceptibility to parasitic infection
|
J:48242
|
H2-Ab1bm12/H2-Ab1bm12
(NZB.B6(C)-H2-Ab1bm12)
|
abnormal immunoglobulin level
|
J:104189
|
abnormal level of surface class II molecules
|
J:104189
|
autoimmune response
|
J:4554
|
increased anti-double stranded DNA antibody level
|
J:104189
|
increased anti-erythrocyte antigen antibody level
|
J:4554
|
increased anti-single stranded DNA antibody level
|
J:104189
|
H2-Ab1g7-em1Dvs/H2-Ab1g7-em1Dvs H2-D1b-em5Dvs/H2-D1b-em5Dvs H2-K1d-em1Dvs/H2-K1d-em1Dvs
(NOD/ShiLtDvs-H2-K1d-em1Dvs H2-Ab1g7-em1Dvs H2-D1em5Dvs/Dvs)
|
decreased susceptibility to autoimmune diabetes
|
J:257229
|
H2-D1b-em1Dvs/H2-D1b-em1Dvs
(NOD/ShiLtDvs-H2-D1b-em1Dvs/Dvs)
|
abnormal immune system physiology
|
J:257229
|
decreased susceptibility to autoimmune diabetes
|
J:257229
|
H2-D1b-em2Dvs/H2-D1b-em2Dvs
(NOD/ShiLtDvs-H2-D1b-em2Dvs/Dvs)
|
abnormal immune system physiology
|
J:257229
|
decreased susceptibility to autoimmune diabetes
|
J:257229
|
H2-D1b-em3Dvs/H2-D1b-em3Dvs
(NOD/ShiLtDvs-H2-D1b-em3Dvs/Dvs)
|
abnormal immune system physiology
|
J:257229
|
decreased susceptibility to autoimmune diabetes
|
J:257229
|
H2-D1b-em4Dvs/H2-D1b-em4Dvs
(NOD/ShiLtDvs-H2-D1b-em4Dvs/Dvs)
|
abnormal immune system physiology
|
J:257229
|
decreased susceptibility to autoimmune diabetes
|
J:257229
|
H2-D1b-em5Dvs/H2-D1b-em5Dvs H2-K1d-em1Dvs/H2-K1d-em1Dvs
(NOD/ShiLtDvs-H2-K1d-em1Dvs H2-D1b-em5Dvs/Dvs)
|
decreased susceptibility to autoimmune diabetes
|
J:257229
|
H2-D1b-em5Dvs/H2-D1b-em5Dvs H2-K1d-em1Dvs/H2-K1d-em1Dvs Tg(HLA-A/H2-D/B2M)1Dvs/?
(NOD/ShiLtDvs-H2-K1d-em1Dvs H2-D1b-em5Dvs Tg(HLA-A/H2-D/B2M)1Dvs/Dvs)
|
autoimmune response
|
J:257229
|
increased susceptibility to autoimmune diabetes
|
J:257229
|
insulitis
|
J:257229
|
H2-D1b-em5Dvs/H2-D1b-em5Dvs H2-K1d-em1Dvs/H2-K1d-em1Dvs Tg(HLA-B39/H2-D/B2m)2Dvs/?
(NOD/ShiLtDvs-H2-K1d-em1Dvs H2-D1b-em5Dvs Tg(HLA-B39/H2-D/B2M)2Dvs/Dvs)
|
autoimmune response
|
J:257229
|
increased susceptibility to autoimmune diabetes
|
J:257229
|
insulitis
|
J:257229
|
H2-D1b-tm1Bpe/H2-D1b-tm1Bpe H2-K1b-tm1Bpe/H2-K1b-tm1Bpe
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased susceptibility to Riboviria infection induced morbidity/mortality
|
J:54709
|
H2-D1b-tm1Bpe/H2-D1b-tm1Bpe H2-K1b-tm1Bpe/H2-K1b-tm1Bpe
(B6.129P-H2-D1b-tm1Bpe H2-K1b-tm1Bpe)
|
abnormal cytotoxic T cell physiology
|
J:118960
|
H2-D1b-tm1Bpe/H2-D1b-tm1Bpe H2-K1b-tm1Bpe/H2-K1b-tm1Bpe Klra1tm1.1Wyok/Klra1tm1.1Wyok Tg(H2-Dd)28Bee/0
(involves: 129P2/OlaHsd * BALB/cJ * C57BL/6NTac * DBA/2)
|
abnormal NK cell physiology
|
J:252851
|
H2-D1b-tm1Bpe/H2-D1b-tm1Bpe H2-K1b-tm1Bpe/H2-K1b-tm1Bpe X/Yaa
(BXSB.129P2(B6)-H2-K1b-tm1Bpe H2-D1b-tm1Bpe/Dcr)
|
increased susceptibility to systemic lupus erythematosus
|
J:179430
|
H2-D1bm14/H2-D1bm14
(C57BL/6)
|
abnormal T cell activation
|
J:97717
|
spinal cord inflammation
|
J:97717
|
H2-DMatm1Doi/H2-DMatm1Doi
(involves: 129S2/SvPas * C57BL/6)
|
abnormal professional antigen presenting cell physiology
|
J:31624
|
H2-DMatm1Liz/H2-DMatm1Liz
(involves: BALB/cJ)
|
abnormal antigen presentation via MHC class II
|
J:113714
|
abnormal professional antigen presenting cell physiology
|
J:111565,
J:113714
|
defective assembly of class II molecules
|
J:113714
|
H2-DMatm1Lkrl/H2-DMatm1Lkrl
(involves: 129P2/OlaHsd)
|
abnormal antigen presentation
|
J:31786
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:31786
|
abnormal professional antigen presenting cell physiology
|
J:31786
|
H2-DMatm1Luc/H2-DMatm1Luc
(involves: 129S4/SvJae)
|
abnormal antigen presentation via MHC class II
|
J:31625
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:31625
|
abnormal level of surface class II molecules
|
J:45185
|
decreased interferon-gamma secretion
|
J:45185
|
increased susceptibility to bacterial infection
|
J:45185
|
H2-DMatm1Luc/H2-DMatm1Luc
(involves: 129S4/SvJae * C57BL/6)
|
abnormal antigen presentation
|
J:72243
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:72243
|
H2-DMatm1Luc/H2-DMatm1Luc
(B6.129S4-H2-Dmatm1Luc)
|
abnormal antigen presentation
|
J:125654
|
abnormal T-helper 1 physiology
|
J:125654
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:125654
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:125654
|
H2-DMatm1Luc/H2-DMatm1Luc Cd74tm1Doi/Cd74tm1Doi
(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)
|
abnormal level of surface class II molecules
|
J:45185
|
increased susceptibility to parasitic infection
|
J:45185
|
H2-DMatm2Liz/H2-DMatm2Liz
(involves: C57BL/6 * C57BL/10 * C57BR * CBA)
|
abnormal antigen presentation via MHC class II
|
J:111565
|
abnormal professional antigen presenting cell physiology
|
J:111565
|
decreased T cell proliferation
|
J:111565
|
H2-K1d-em4Dvs/H2-K1d-em4Dvs
(NOD/ShiLtDvs-H2-K1d-em4Dvs/Dvs)
|
abnormal immune system physiology
|
J:257229
|
decreased susceptibility to autoimmune diabetes
|
J:257229
|
H2-K1d-em5Dvs/H2-K1d-em5Dvs
(NOD/ShiLtDvs-H2-K1d-em5Dvs/Dvs)
|
abnormal immune system physiology
|
J:257229
|
decreased susceptibility to autoimmune diabetes
|
J:257229
|
H2-K1d-em7Dvs/H2-K1d-em7Dvs
(NOD/ShiLtDvs-H2-K1d-em7Dvs/Dvs)
|
abnormal immune system physiology
|
J:257229
|
decreased susceptibility to autoimmune diabetes
|
J:257229
|
H2-M3tm1Crw/H2-M3tm1Crw
(B6.129-H2-M3tm1Crw)
|
abnormal cytotoxic T cell physiology
|
J:118960
|
abnormal innate immunity
|
J:118960
|
decreased interferon-gamma secretion
|
J:118960
|
decreased macrophage nitric oxide production
|
J:118960
|
impaired natural killer cell mediated cytotoxicity
|
J:118960
|
increased susceptibility to bacterial infection
|
J:118960
|
H2-Oatm1Dma/H2-Oatm1Dma
(involves: 129/Sv * C57BL/6)
|
abnormal antigen presentation via MHC class II
|
J:65235
|
H2-Oatm1Lkar/H2-Oatm1Lkar
(involves: 129P2/OlaHsd)
|
abnormal antigen presentation via MHC class II
|
J:85084
|
increased IgG1 level
|
J:85084
|
H2-Obem1Tvg/H2-Obem1Tvg
(C57BL/6J-H2-Obem1Tvg/Tvg)
|
decreased susceptibility to Retroviridae infection
|
J:254532
|
defective assembly of class II molecules
|
J:254532
|
H2-Obvic1/H2-Obvic1
(I/LnJ)
|
decreased susceptibility to Retroviridae infection
|
J:163153
|
decreased susceptibility to viral infection
|
J:81554,
J:60602
|
H2-Obvic1/H2-Obvic1
(C3N.I-H2-Obvic1)
|
decreased susceptibility to Retroviridae infection
|
J:254532
|
H2-Obvic1/H2-Obvic1
(B6.I-H2-Obvic1)
|
decreased susceptibility to Retroviridae infection
|
J:254532
|
H2-Obvic1/H2-Obvic1
(C.I-H2-Obvic1)
|
decreased susceptibility to Retroviridae infection
|
J:254532
|
H2-T18b/H2-T18b H2-T3tm1Luc/H2-T3tm1Luc
(C57BL/6-H2-T3tm1Luc)
|
increased interferon-gamma secretion
|
J:142515
|
H2-T18b/H2-T18b H2-T3tm1Luc/H2-T3tm1Luc Tcratm1Mom/Tcratm1Mom
(B6.Cg-Tcratm1Mom H2-T3tm1Luc)
|
colitis
|
J:142515
|
increased interleukin-4 secretion
|
J:142515
|
H2-T23tm1Cant/H2-T23tm1Cant
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:142087,
J:123555
|
abnormal memory T cell physiology
|
J:123555
|
increased susceptibility to bacterial infection
|
J:89808
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:89808
|
increased susceptibility to Herpesvirales infection
|
J:89808
|
H2-T23tm2Cant/H2-T23tm2Cant
(involves: 129S6/SvEvTac)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:123555
|
H2-T23tm2Cant/H2-T23tm2Cant
(B6.129S6-H2-T23tm2Cant)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:142087
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:142087
|
H2-T23tm2Cant/H2-T23tm2Cant Tg(Tcra2D2,Tcrb2D2)1Kuch/?
(involves: 129S6/SvEvTac)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:142087
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:142087
|
H2-T23tm3Cant/H2-T23tm3Cant
(B6.129S6-H2-T23tm3Cant)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:142087
|
H2-T23tm3Cant/H2-T23tm3Cant Tg(Tcra2D2,Tcrb2D2)1Kuch/?
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:142087
|
H2-T23tm3Cant/H2-T23tm3Cant Tg(TcraTcrb)425Cbn/?
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:142087
|
H2b/H2b
(NOD.B10SnJ-H2b)
|
decreased susceptibility to autoimmune diabetes
|
J:14178
|
periinsulitis
|
J:14178
|
H2b/H2b Nfkbidtm1Clay/Nfkbidtm1Clay Rag2tm1Fwa/Rag2tm1Fwa Tg(TcraN15,TcrbN15)L2Elre/?
(involves: 129S/SvEv * 129S6/SvEvTac * C57BL/6)
|
abnormal thymocyte activation
|
J:132071
|
decreased interleukin-2 secretion
|
J:132071
|
decreased T cell proliferation
|
J:132071
|
H2b/H2b Rag2tm1Fwa/Rag2tm1Fwa Tg(TcraN15,TcrbN15)L2Elre/?
(involves: 129S/SvEv * C57BL/6)
|
abnormal cytotoxic T cell physiology
|
J:133112
|
increased T cell proliferation
|
J:133112
|
H2b/H2d
((C57BL/6 x DBA/2)F1)
|
abnormal cytokine secretion
|
J:106141
|
decreased susceptibility to parasitic infection
|
J:106141
|
increased autoantibody level
|
J:106141
|
H2b/H2d Tg(Ins2-E3)1Dvs/0
(involves: BALB/c * C57BL/6 * DBA/2J)
|
increased length of allograft survival
|
J:109763
|
H2b/H2g7
(NOD.B10SnJ-H2b)
|
decreased susceptibility to autoimmune diabetes
|
J:14178
|
H2b/H2g7 Tg(TcraR28,TcrbR28)KRNDim/0
(involves: C57BL/6 * NOD * SJL)
|
mitral valve inflammation
|
J:275827
|
rheumatoid arthritis
|
J:36815,
J:275827
|
H2d/H2d
(DBA/2)
|
abnormal cytokine secretion
|
J:106141
|
decreased susceptibility to parasitic infection
|
J:106141
|
increased autoantibody level
|
J:106141
|
H2d/H2d Tg(TcraP1.5,TcrbP1.5)29Amsv/0 Trap1atm1.1Jvde/Y
(involves: 129 * BALB/cJ * C57BL/10 * DBA/2)
|
abnormal T cell clonal deletion
|
J:180807
|
H2d/H2d Trap1atm1.1Jvde/Y
(involves: 129 * BALB/cJ * C57BL/10 * DBA/2)
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:180807
|
abnormal immune tolerance
|
J:180807
|
H2dlAb1-Ea/H2dlAb1-Ea
(B6.129S2-H2dlAb1-Ea/J)
|
increased susceptibility to bacterial infection
|
J:123934
|
H2dlAb1-Ea/H2dlAb1-Ea
(involves: 129S2/SvPas * C57BL/6)
|
abnormal immunoglobulin level
|
J:57484
|
decreased IgG1 level
|
J:57484
|
decreased IgG2a level
|
J:57484
|
increased IgM level
|
J:57484
|
H2dlAb1-Ea/H2dlAb1-Ea Rag1tm1Mom/Rag1tm1Mom Tg(HLA-DRA,HLA-DRB5*0101)hiKito/0 Tg(TRATL3A6,TRBTL3A6)#Kito/0
(involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6)
|
brain inflammation
|
J:189816
|
H2dlAb1-Ea/H2dlAb1-Ea Rag1tm1Mom/Rag1tm1Mom Tg(HLA-DRA,HLA-DRB5*0101)loKito/0 Tg(TRATL3A6,TRBTL3A6)#Kito/0
(involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6)
|
brain inflammation
|
J:189816
|
H2dlAb1-Ea/H2dlAb1-Ea Tg(HLA-DRA,HLA-DRB5*0101)hiKito/0 Tg(TRATL3A6,TRBTL3A6)#Kito/0
(involves: 129S2/SvPas * C57BL/6)
|
abnormal cytokine secretion
|
J:189816
|
brain inflammation
|
J:189816
|
CNS inflammation
|
J:189816
|
increased inflammatory response
|
J:189816
|
increased interferon-gamma secretion
|
J:189816
|
increased interleukin-17 secretion
|
J:189816
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:189816
|
H2dlAb1-Ea/H2dlAb1-Ea Tg(HLA-DRA,HLA-DRB5*0101)loKito/0 Tg(TRATL3A6,TRBTL3A6)#Kito/0
(involves: 129S2/SvPas * C57BL/6)
|
brain inflammation
|
J:189816
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:189816
|
H2g7/H2g7 Ins2tm1Jja/Ins2tm1Jja Rag1tm1Mom/Rag1tm1Mom Tg(TcraBDC12-4.1)10Jos/0 Tg(TcrbBDC12-4.1)82Gse/0
(involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6 * FVB * NOD)
|
increased susceptibility to autoimmune diabetes
|
J:111874
|
H2g7/H2g7 Rag1tm1Mom/Rag1tm1Mom Tg(TcraBDC12-4.1)10Jos/0 Tg(TcrbBDC12-4.1)82Gse/0
(involves: 129S7/SvEvBrd * C57BL/6 * FVB * NOD)
|
increased susceptibility to autoimmune diabetes
|
J:111874
|
insulitis
|
J:111874
|
H2g7/H2g7 Tg(Ins2-Vtcn1)#Xxz/0 Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0
(involves: C57BL/6 * NOD * SJL)
|
decreased interferon-gamma secretion
|
J:177612
|
decreased interleukin-17 secretion
|
J:177612
|
decreased susceptibility to autoimmune diabetes
|
J:177612
|
H2g7/H2g7 Tg(TcraAI4)1Dvs/0 Tg(TcrbAI4)1Dvs/0
(B6.NOD-(D17Mit21-D17Mit10) Tg(TcraAI4)1Dvs Tg(TcrbAI4)1Dvs)
|
increased susceptibility to autoimmune diabetes
|
J:167508
|
H2g7/H2g7 Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0
(B6.Cg-H2g7 Tg(TcraBDC2.5,TcrbBDC2.5)1Doi)
|
decreased susceptibility to autoimmune diabetes
|
J:86926
|
H2g7/H2g7 Tg(TcraBDC12-4.1)10Jos/0 Tg(TcrbBDC12-4.1)82Gse/0
(involves: 129S7/SvEvBrd * C57BL/6 * FVB * NOD)
|
decreased susceptibility to autoimmune diabetes
|
J:111874
|
insulitis
|
J:111874
|
H2g7/H2q Rag1tm1Mom/Rag1tm1Mom Tg(TcraBDC12-4.1)10Jos/0 Tg(TcrbBDC12-4.1)82Gse/0
(involves: 129S7/SvEvBrd * C57BL/6 * FVB * NOD)
|
increased susceptibility to autoimmune diabetes
|
J:111874
|
H2h2/H2g7
(NOD.Cg-H2h2)
|
decreased susceptibility to autoimmune diabetes
|
J:14178
|
H2h2/H2h2
(NOD.Cg-H2h2)
|
decreased susceptibility to autoimmune diabetes
|
J:14178
|
insulitis
|
J:14178
|
periinsulitis
|
J:14178
|
H2h4/H2g7
(NOD.Cg-H2h4)
|
decreased susceptibility to autoimmune diabetes
|
J:14178
|
H2h4/H2h4
(NOD.Cg-H2h4)
|
abnormal cytokine secretion
|
J:54563
|
decreased susceptibility to autoimmune diabetes
|
J:14178
|
insulitis
|
J:14178
|
periinsulitis
|
J:14178
|
thyroid gland inflammation
|
J:54563
|
H2i5/H2g7
(NOD.Cg-H2i5)
|
decreased susceptibility to autoimmune diabetes
|
J:14178
|
H2i5/H2i5
(NOD.Cg-H2i5)
|
decreased susceptibility to autoimmune diabetes
|
J:14178
|
periinsulitis
|
J:14178
|
H2i7/H2g7
(NOD.Cg-H2i7)
|
decreased susceptibility to autoimmune diabetes
|
J:14178
|
H2i7/H2g7
((NOD x NOD.Cg-H2i7)F1)
|
insulitis
|
J:14178
|
H2i7/H2i7
(NOD.Cg-H2i7)
|
decreased susceptibility to autoimmune diabetes
|
J:14178
|
periinsulitis
|
J:14178
|
H2k/H2g7
(NOD.Cg-H2k)
|
decreased susceptibility to autoimmune diabetes
|
J:14178
|
H2k/H2k
(NOD.Cg-H2k)
|
increased susceptibility to autoimmune diabetes
|
J:14178
|
periinsulitis
|
J:14178
|
H2q/? Ncf1m1J/Ncf1m1J
(B6.Cg-Ncf1m1J H2q)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:92437
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:92437
|
increased susceptibility to induced arthritis
|
J:92437
|
increased susceptibility to type IV hypersensitivity reaction
|
J:92437
|
rheumatoid arthritis
|
J:92437
|
H2q/H2q Rag1tm1Mom/Rag1tm1Mom Tg(TcraBDC12-4.1)10Jos/0 Tg(TcrbBDC12-4.1)82Gse/0
(involves: 129S7/SvEvBrd * C57BL/6 * FVB * NOD)
|
decreased susceptibility to autoimmune diabetes
|
J:111874
|
H2u/H2u Rag1tm1Mom/Rag1tm1Mom Tg(Tcra19,Tcrb19)#Stl/0
(either: (involves: 129S7/SvEvBrd * C57BL/6 * PL/J) or (involves: 129S7/SvEvBrd * C57BL/6 * C57BL/10 * PL/J))
|
increased susceptibility to autoimmune disorder
|
J:19795
|
H2u/H2u Tg(Tcra19,Tcrb19)#Stl/0
(either: (involves: C57BL/6 * PL/J) or (involves: C57BL/6 * C57BL/10 * PL/J))
|
increased susceptibility to autoimmune disorder
|
J:19795
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:19795
|
H2u/H2u Tg(TCRA)B1Jg/? Tg(TCRB)C14Jg/?
(involves: C57BL/6 * C57BL/10SnSg * DBA/2 * PL/J)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:92991
|
increased autoantibody level
|
J:92991
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:92991
|
H2axtm1Fwa/H2axtm1Fwa
(involves: 129S6/SvEvTac)
|
abnormal class switch recombination
|
J:84879
|
H2axtm1Nus/H2axtm1Nus
(Not Specified)
|
abnormal class switch recombination
|
J:194603,
J:120658
|
decreased IgG level
|
J:73342
|
H13tm1b(KOMP)Wtsi/H13tm1b(KOMP)Wtsi
(C57BL/6N-H13tm1b(KOMP)Wtsi/Wtsi)
|
blood in lymph vessels
|
J:239583
|
Habp2tm1Lex/Habp2tm1Lex
(involves: 129S7/SvEvBrd * BALB/c * C57BL/6)
|
liver inflammation
|
J:207454
|
Hamptm1Svl/Hamptm1Svl
(involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6)
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:199427
|
Hapstr1tm1.1Menm/Hapstr1tm1.1Menm Tg(CAG-cre/Esr1*)5Amc/0
(involves: C57BL/6 * C57BL/6J * CBA)
|
large intestinal inflammation
|
J:348964
|
Havcr1tm1Kuch/Havcr1tm1Kuch
(B6.Cg-Havcr1tm1Kuch)
|
abnormal B cell physiology
|
J:186484
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:186484
|
abnormal dendritic cell physiology
|
J:186484
|
autoimmune response
|
J:186484
|
increased anti-double stranded DNA antibody level
|
J:186484
|
Havcr1tm1Vlcg/Havcr1tm1Vlcg
(B6.129-Havcr1tm1Vlcg)
|
increased interleukin-5 secretion
|
J:187793
|
increased interleukin-13 secretion
|
J:187793
|
Havcr1tm1Vlcg/Havcr1tm1Vlcg
(C.129-Havcr1tm1Vlcg)
|
abnormal cytokine secretion
|
J:187793
|
increased interleukin-4 secretion
|
J:187793
|
increased interleukin-5 secretion
|
J:187793
|
increased interleukin-10 secretion
|
J:187793
|
increased interleukin-13 secretion
|
J:187793
|
increased interleukin-17 secretion
|
J:187793
|
respiratory system inflammation
|
J:187793
|
Havcr2tm1Bmed/Havcr2tm1Bmed
(B6.Cg-Havcr2tm1Bmed)
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:189839
|
decreased activation-induced cell death of T cells
|
J:189839
|
decreased interferon-gamma secretion
|
J:189839
|
decreased susceptibility to Orthomyxoviridae infection
|
J:189839
|
decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality
|
J:189839
|
decreased T cell proliferation
|
J:189839
|
Havcr2tm1Vlcg/Havcr2tm1Vlcg
(B6.129-Havcr2tm1Vlcg)
|
decreased interferon-gamma secretion
|
J:209885
|
Havcr2tm1Vlcg/Havcr2tm1Vlcg Tg(TcraTcrb)1100Mjb/?
(B6.Cg-Havcr2tm1Vlcg Tg(TcraTcrb)1100Mjb)
|
decreased interferon-gamma secretion
|
J:209885
|
Hax1tm1.1Gach/Hax1tm1.1Gach
(involves: BALB/c)
|
decreased IgG2a level
|
J:174159
|
Hbatm1(HBA)Tow/Hbatm1(HBA)Tow Hbbtm2(HBG1,HBB*)Tow/Hbbtm2(HBG1,HBB*)Tow Slc12a4Rbc10/Slc12a4+
(involves: 129 * BALB/c * C57BL/6J)
|
liver inflammation
|
J:227339
|
Hbnr1CBA/Hbnr1SWR
(involves: CBA * SWR)
|
decreased susceptibility to parasitic infection
|
J:82261,
J:85787
|
Hbnr1SWR/Hbnr1SWR
(involves: CBA * SWR)
|
decreased susceptibility to parasitic infection
|
J:82261,
J:110034,
J:85787
|
Hbnr2CBA/Hbnr2SWR
(involves: CBA * SWR)
|
granulomatous inflammation
|
J:85787
|
Hbnr2SWR/?
(involves: CBA * SWR)
|
decreased susceptibility to parasitic infection
|
J:82261
|
Hbnr2SWR/Hbnr2SWR
(involves: CBA * SWR)
|
decreased IgE level
|
J:85787
|
decreased susceptibility to parasitic infection
|
J:110034
|
granulomatous inflammation
|
J:85787
|
Hbnr3CBA/Hbnr3SWR
(involves: CBA * SWR)
|
decreased susceptibility to parasitic infection
|
J:85787
|
increased susceptibility to parasitic infection
|
J:82261
|
Hbnr3SWR/Hbnr3SWR
(involves: CBA * SWR)
|
increased susceptibility to parasitic infection
|
J:82261,
J:85787
|
Hbnr4SWR/Hbnr4SWR
(involves: CBA * SWR)
|
abnormal immune serum protein physiology
|
J:85787
|
Hbnr5CBA/Hbnr5SWR
(involves: CBA * SWR)
|
decreased susceptibility to parasitic infection
|
J:85787
|
Hbnr5SWR/Hbnr5SWR
(involves: CBA * SWR)
|
decreased susceptibility to parasitic infection
|
J:85787
|
Hbnr6SWR/Hbnr6SWR
(involves: CBA * SWR)
|
increased IgE level
|
J:85787
|
Hbnr7CBA/Hbnr7SWR
(involves: CBA * SWR)
|
decreased IgG1 level
|
J:85787
|
Hbnr7SWR/Hbnr7SWR
(involves: CBA * SWR)
|
decreased IgG2b level
|
J:85787
|
Hbnr8CBA/Hbnr8SWR
(involves: CBA * SWR)
|
decreased susceptibility to parasitic infection
|
J:85787
|
Hbnr8SWR/Hbnr8SWR
(involves: CBA * SWR)
|
decreased susceptibility to parasitic infection
|
J:85787
|
Hc0/Hc0
(involves: C57BL/10SnJ)
|
increased susceptibility to bacterial infection
|
J:44240
|
Hc0/Hc0 Tg(TcrbBL17)1Lmor/0
(involves: DBA/1J * SWR/J)
|
decreased susceptibility to induced arthritis
|
J:134111
|
Hc1/? Tg(TcrbBL17)1Lmor/0
(involves: DBA/1J * SWR/J)
|
increased susceptibility to induced arthritis
|
J:134111
|
Hcfc2em1Btlr/Hcfc2em1Btlr
(C57BL/6J-Hcfc2em1Btlr)
|
decreased tumor necrosis factor secretion
|
J:251008
|
Hcfc2fkls/Hcfc2+
(involves: C57BL/6J)
|
decreased interferon-beta secretion
|
J:251008
|
decreased tumor necrosis factor secretion
|
J:251008
|
Hcfc2fkls/Hcfc2fkls
(C57BL/6J-Hcfc2fkls)
|
abnormal innate immunity
|
J:94077
|
Hcfc2fkls/Hcfc2fkls
(involves: C57BL/6J)
|
decreased circulating interferon-alpha level
|
J:251008
|
decreased circulating interferon-beta level
|
J:251008
|
decreased interferon-beta secretion
|
J:251008
|
decreased tumor necrosis factor secretion
|
J:251008
|
increased susceptibility to Herpesvirales infection
|
J:251008
|
increased susceptibility to Herpesvirales infection induced morbidity/mortality
|
J:251008
|
increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality
|
J:251008
|
Hcfc2fkls/Hcfc2min
(involves: C57BL/6J)
|
decreased tumor necrosis factor secretion
|
J:251008
|
Hcfc2fkls/Hcfc2sca
(involves: C57BL/6J)
|
decreased tumor necrosis factor secretion
|
J:251008
|
Hcktm1Ern/Hcktm1Ern
(involves: 129S1/Sv * C57BL/6)
|
abnormal immune system physiology
|
J:111432
|
abnormal macrophage physiology
|
J:111432
|
increased circulating tumor necrosis factor level
|
J:111432
|
increased interleukin-5 secretion
|
J:111432
|
lung inflammation
|
J:111432
|
Hcktm1Hev/Hcktm1Hev
(involves: 129S7/SvEvBrd * C57BL/6J)
|
impaired macrophage phagocytosis
|
J:16994
|
Hcktm1Hev/Hcktm1Hev
(B6.129S7-Hcktm1Hev)
|
abnormal inflammatory response
|
J:113463
|
abnormal neutrophil physiology
|
J:113463
|
Hcls1tm1Wtn/Hcls1tm1Wtn
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal B cell physiology
|
J:28146
|
abnormal humoral immune response
|
J:28146
|
decreased T cell proliferation
|
J:28146
|
Hcls1tm2Wtn/Hcls1tm2Wtn
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal B cell physiology
|
J:28146
|
abnormal humoral immune response
|
J:28146
|
decreased T cell proliferation
|
J:28146
|
Hcsttm1.1Cln/Hcsttm1.1Cln
(involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)
|
impaired natural killer cell mediated cytotoxicity
|
J:80426
|
Hcsttm1.1Cln/Hcsttm1.1Cln
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased interferon-gamma secretion
|
J:100668
|
Hcsttm1.1Cln/Hcsttm1.1Cln
(B6.129P2-Hcsttm1.1Cln)
|
abnormal osteoclast physiology
|
J:147155
|
Hcsttm1.1Cln/Hcsttm1.1Cln Tyrobptm1Lll/Tyrobptm1Lll
(B6.Cg-Hcsttm1.1Cln Tyrobptm1Lll)
|
abnormal NK T cell physiology
|
J:147867
|
abnormal response to infection
|
J:147867
|
Hcsttm1.1Dnax/Hcsttm1.1Dnax
(involves: C57BL/6)
|
abnormal NK T cell physiology
|
J:147867,
J:148086
|
abnormal response to infection
|
J:147867
|
decreased interferon-gamma secretion
|
J:147867
|
impaired natural killer cell mediated cytotoxicity
|
J:148086
|
increased interferon-gamma secretion
|
J:148086
|
increased interleukin-4 secretion
|
J:148086
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:148086
|
Hdac1tm1.1Pmt/Hdac1tm1.1Pmt Hdac2tm1.1Pmt/Hdac2tm1.1Pmt Cd79atm1(cre)Reth/Cd79a+
(involves: 129P2/OlaHsd * BALB/c * C57BL/6 * FVB/N)
|
increased B cell apoptosis
|
J:157903
|
Hdac1tm1.1Pmt/Hdac1tm1.1Pmt Hdac2tm1.1Pmt/Hdac2tm1.1Pmt Tg(Fcer2a-cre)5Mbu/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA * FVB/N)
|
decreased B cell proliferation
|
J:157903
|
increased B cell apoptosis
|
J:157903
|
Hdac1tm1.1Shmc/Hdac1tm1.1Shmc Hdac2tm1.1Shmc/Hdac2tm1.1Shmc Tg(Lck-cre)1Cwi/0
(involves: 129S7/SvEvBrd)
|
increased T cell proliferation
|
J:194769
|
increased thymocyte apoptosis
|
J:194769
|
Hdac6tm1.1Pmt/Y
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased IgG level
|
J:132629
|
decreased IgM level
|
J:132629
|
Hdac6tm1.1Pmt/Hdac6tm1.1Pmt
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased IgG level
|
J:132629
|
decreased IgM level
|
J:132629
|
Hdac6tm1.1Pmt/Hdac6tm1.1Pmt
(involves: 129P2/OlaHsd)
|
decreased circulating interleukin-10 level
|
J:228570
|
decreased interleukin-10 secretion
|
J:228570
|
Hdac11tm1.2Mrl/Hdac11tm1.2Mrl
(involves: C57BL/6NTac)
|
decreased interferon-gamma secretion
|
J:222335
|
increased interleukin-10 secretion
|
J:228570
|
Hectd3tm1Lex/Hectd3tm1Lex
(FVB.129S5(B6)-Hectd3tm1Lex)
|
decreased circulating interferon-beta level
|
J:266602
|
decreased circulating interleukin-1 beta level
|
J:266602
|
decreased circulating interleukin-6 level
|
J:266602
|
decreased circulating tumor necrosis factor level
|
J:266602
|
decreased susceptibility to bacterial infection
|
J:266602
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:266602
|
Heg1tm1Mlkn/Heg1tm1Mlkn
(either: B6.129-Heg1tm1Mlkn or (involves: 129 * C57BL/6))
|
abnormal lymph circulation
|
J:146528
|
Hellstm1a(EUCOMM)Wtsi/Hellstm1a(EUCOMM)Wtsi
(C57BL/6N-Hellstm1a(EUCOMM)Wtsi/Ieg)
|
decreased IgG1 level
|
J:165965
|
Hephl1cw-thd/Hephl1cw-thd
(SJL/J)
|
abnormal humoral immune response
|
J:15004
|
Hexbtm1Rlp/Hexbtm1Rlp
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
CNS inflammation
|
J:90687
|
increased circulating interleukin-4 level
|
J:87617
|
increased immunoglobulin level
|
J:87617
|
Hfgi1C57BL/6Ola/?
(involves: C57BL/6Ola * BALB/cOla)
|
stomach inflammation
|
J:123483
|
Hfgi2C57BL/6Ola/?
(involves: C57BL/6Ola * BALB/cOla)
|
stomach inflammation
|
J:123483
|
Hic1tm1Sbb/Hic1+
(involves: 129S4/SvJae * C57BL/6)
|
dermatitis
|
J:81448
|
Hif1atm1Kats/Hif1atm1Kats
(involves: 129 * C57BL/6)
|
abnormal cytokine level
|
J:117857
|
abnormal interleukin secretion
|
J:117857
|
increased interferon-gamma secretion
|
J:117857
|
increased tumor necrosis factor secretion
|
J:117857
|
Hif1atm3Rsjo/Hif1atm3Rsjo Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+ Hprt1tm1(Pck1-cre)Vhh/Y
(involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ)
|
kidney inflammation
|
J:130751
|
Hif1atm3Rsjo/Hif1atm3Rsjo Hprt1tm1(Pck1-cre)Vhh/Y Vhltm1Jae/Vhltm1Jae
(involves: 129 * BALB/c * C57BL/6)
|
kidney inflammation
|
J:106705
|
Hif1atm3Rsjo/Hif1atm3Rsjo Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ)
|
abnormal leukocyte physiology
|
J:117348
|
abnormal macrophage physiology
|
J:107682
|
decreased inflammatory response
|
J:107682
|
decreased susceptibility to induced arthritis
|
J:107682
|
decreased tumor necrosis factor secretion
|
J:107682
|
impaired macrophage chemotaxis
|
J:107682
|
Hif1atm3Rsjo/Hif1atm3Rsjo Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6)
|
decreased interleukin-1 alpha secretion
|
J:148597
|
decreased interleukin-1 beta secretion
|
J:148597
|
decreased interleukin-6 secretion
|
J:148597
|
decreased interleukin-12 secretion
|
J:148597
|
decreased susceptibility to endotoxin shock
|
J:148597
|
decreased tumor necrosis factor secretion
|
J:148597
|
Hif1atm3Rsjo/Hif1atm3Rsjo Tg(Fabp1-cre)1Jig/0
(involves: 129S1/Sv * 129X1/SvJ * BALB/c * FVB/N)
|
increased susceptibility to induced colitis
|
J:93476
|
Hif1atm3Rsjo/Hif1atm3Rsjo Tg(Itgax-cre)1-1Reiz/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)
|
abnormal leukocyte migration
|
J:187773
|
Hif1atm3Rsjo/Hif1atm3Rsjo Tg(Lck-cre)1Jtak/0
(involves: 129S1/Sv * 129X1/SvJ)
|
increased interferon-gamma secretion
|
J:117857
|
Hivep2tm1Sis/Hivep2tm1Sis
(either: (involves: BALB/cA * C57BL/6NCrlj * CBA/JNCrlj) or (involves: C57BL/6J * C57BL/6NCrlj * CBA/JNCrlj))
|
CNS inflammation
|
J:263351
|
Hivep3tm1Glm/Hivep3tm1Glm
(involves: 129 * C57BL/6)
|
decreased interleukin-2 secretion
|
J:100058
|
Hivep3tm1Glm/Hivep3tm1Glm
(Not Specified)
|
abnormal osteoclast physiology
|
J:184764
|
hlb258/?
(involves: 129S4/SvJae * C57BL/6J)
|
decreased circulating fibrinogen level
|
J:82961
|
Hmgb1tm1.1Dltg/Hmgb1tm1.1Dltg Tg(Pdx1-cre)6Tuv/0
(involves: C57BL/6 * FVB/N)
|
increased circulating interleukin-6 level
|
J:225260
|
increased circulating tumor necrosis factor level
|
J:225260
|
increased susceptibility to induced pancreatitis
|
J:225260
|
Hmgb1tm1.1Ttg/Hmgb1tm1.1Ttg Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd)
|
abnormal macrophage physiology
|
J:205499
|
impaired macrophage phagocytosis
|
J:205499
|
increased circulating interleukin-1 beta level
|
J:205499
|
increased circulating interleukin-18 level
|
J:205499
|
increased interleukin-1 beta secretion
|
J:205499
|
increased interleukin-18 secretion
|
J:205499
|
increased macrophage apoptosis
|
J:205499
|
increased susceptibility to bacterial infection
|
J:205499
|
increased susceptibility to endotoxin shock
|
J:205499
|
Hmgb1tm1.1Ttg/Hmgb1tm1.1Ttg Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129P2/OlaHsd * C57BL/6 * DBA)
|
increased circulating interleukin-1 beta level
|
J:205499
|
increased circulating interleukin-18 level
|
J:205499
|
Hmgb1tm1.1Ttg/Hmgb1tm1.1Ttg Tg(Itgax-cre)1-1Reiz/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
increased circulating interleukin-1 beta level
|
J:205499
|
increased circulating interleukin-18 level
|
J:205499
|
Hmgn5tm1.2Mbus/Y
(involves: 129S4/SvJae * C57BL/6J)
|
decreased IgE level
|
J:199604
|
increased IgA level
|
J:199604
|
Hmgn5tm1.2Mbus/Hmgn5tm1.2Mbus
(involves: 129S4/SvJae * C57BL/6J)
|
decreased IgE level
|
J:199604
|
increased IgA level
|
J:199604
|
Hmgxb3tm1a(EUCOMM)Wtsi/Hmgxb3tm1a(EUCOMM)Wtsi
(C57BL/6N-Hmgxb3tm1a(EUCOMM)Wtsi/Wtsi)
|
blood in lymph vessels
|
J:239583
|
Hmgxb4tm1.2Zhji/Hmgxb4tm1.2Zhji
(B6(Cg)-Hmgxb4tm1.2Zhji)
|
decreased macrophage nitric oxide production
|
J:302603
|
decreased susceptibility to endotoxin shock
|
J:302603
|
Hmox1tm1.1Gkl/Hmox1tm1.1Gkl Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129 * 129P2/OlaHsd * BALB/cJ * C57BL/6)
|
decreased interferon-beta secretion
|
J:148498
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:148498
|
decreased susceptibility to Paramyxoviridae infection
|
J:148498
|
increased circulating tumor necrosis factor level
|
J:148498
|
increased interferon-gamma secretion
|
J:148498
|
increased splenocyte proliferation
|
J:148498
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:148498
|
Hmox1tm1.1Hes/Hmox1tm1.1Hes Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * C57BL/6J * C57BL/6N)
|
decreased inflammatory response
|
J:214639
|
decreased interleukin-1 beta secretion
|
J:214639
|
decreased interleukin-6 secretion
|
J:214639
|
decreased tumor necrosis factor secretion
|
J:214639
|
Hmox1tm1.2Gkl/Hmox1tm1.2Gkl
(involves: 129 * BALB/cJ * C57BL/6)
|
increased inflammatory response
|
J:148498
|
liver inflammation
|
J:148498
|
Hmox1tm1Mlee/Hmox1tm1Mlee
(involves: 129S2/SvPas * BALB/c)
|
increased susceptibility to parasitic infection
|
J:153083
|
increased susceptibility to parasitic infection induced morbidity/mortality
|
J:153083
|
Hmox1tm1Poss/Hmox1tm1Poss
(involves: 129S2/SvPas * C57BL/6)
|
chronic inflammation
|
J:79254
|
glomerulonephritis
|
J:79254
|
liver inflammation
|
J:79254
|
lung inflammation
|
J:79254
|
Hnf1btm1Mya/Hnf1btm3Mya Tg(Alb1-cre)7Gsc/0
(involves: 129S2/SvPas * C57BL/6 * FVB/N)
|
liver inflammation
|
J:75935
|
Hnf1btm2Ics/Hnf1b+
(involves: 129 * C57BL/6N)
|
chronic pancreas inflammation
|
J:306082
|
Hnrnpa2b1tm1.1Caox/Hnrnpa2b1tm1.1Caox Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd)
|
abnormal interferon level
|
J:283622
|
decreased circulating interferon-beta level
|
J:283622
|
decreased interferon-beta secretion
|
J:283622
|
increased susceptibility to Herpesvirales infection
|
J:283622
|
increased susceptibility to Herpesvirales infection induced morbidity/mortality
|
J:283622
|
Hnrnpdtm1Rjsc/Hnrnpdtm1Rjsc
(involves: 129S6/SvEvTac * C57BL/6J)
|
abnormal macrophage physiology
|
J:116112
|
increased circulating tumor necrosis factor level
|
J:116112
|
increased susceptibility to bacterial infection
|
J:116112
|
increased susceptibility to endotoxin shock
|
J:116112
|
Hnrnpltm1.1Tmo/Hnrnpltm1.1Tmo Tg(Lck-cre)548Jxm/0
(B6.Cg-Hnrnpltm1.1Tmo Tg(Lck-cre)548Jxm)
|
increased T cell proliferation
|
J:188749
|
Hnrnpllthdr/Hnrnpllthdr
(C57BL/6JSfdAnu-Hnrnpllthdr/Anu)
|
abnormal memory T cell physiology
|
J:142641
|
Hoxa5tm1Rob/Hoxa5tm1Rob
(involves: 129S/SvEv * C57BL/6 * MF1)
|
lung inflammation
|
J:113378
|
Hoxa11osem1Kaf/Hoxa11osem1Kaf
(C57BL/6-Hoxa11osem1Kaf)
|
abnormal cytokine secretion
|
J:344661
|
increased susceptibility to induced colitis
|
J:344661
|
intestinal inflammation
|
J:344661
|
Hoxc4tm2.1Mrc/Hoxc4tm2.1Mrc
(involves: 129S/SvEv * C57BL/6)
|
abnormal class switch recombination
|
J:148278
|
abnormal somatic hypermutation frequency
|
J:148278
|
decreased IgA level
|
J:148278
|
decreased IgE level
|
J:148278
|
decreased IgG1 level
|
J:148278
|
decreased IgG2a level
|
J:148278
|
decreased IgG2b level
|
J:148278
|
decreased IgG3 level
|
J:148278
|
decreased IgM level
|
J:148278
|
Hptm1Skl/Hptm1Skl Hpxtm1Altr/Hpxtm1Altr
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6J)
|
liver inflammation
|
J:80539
|
Hpgdstm1Urad/Hpgdstm1Urad
(B6.129-Hpgdstm1Urad)
|
abnormal cytokine secretion
|
J:107651
|
increased acute inflammation
|
J:107651
|
increased inflammatory response
|
J:107651
|
increased susceptibility to type I hypersensitivity reaction
|
J:197334
|
Hpi1C57BL/6J/?
(involves: A/J * C57BL/6J)
|
abnormal inflammatory response
|
J:69153
|
Hpi1C57BL/6J/Hpi1C57BL/6J Hpi2C57BL/6J/Hpi2C57BL/6J
(involves: A/J * C57BL/6J)
|
abnormal inflammatory response
|
J:69153
|
Hpi2C57BL/6J/?
(involves: A/J * C57BL/6J)
|
abnormal inflammatory response
|
J:69153
|
Hprt1b-m3/Y Impdh1tm1Bmi/Impdh1tm1Bmi
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6)
|
decreased cytotoxic T cell cytolysis
|
J:85443
|
decreased interleukin-4 secretion
|
J:85443
|
decreased splenocyte proliferation
|
J:85443
|
decreased T cell proliferation
|
J:85443
|
Hprt1b-m3/Y Impdh2tm1Bmi/Impdh2+
(involves: 129P2/OlaHsd)
|
abnormal cytotoxic T cell physiology
|
J:86045
|
Hprt1tm1(CAG-Tgfbr1*)Lba/Y Tg(Cd4-cre)1Cwi/0
(involves: 129 * C57BL/6 * DBA/2)
|
abnormal T cell activation
|
J:148747
|
Hprt1tm1(CAG-Tgfbr1*)Lba/Hprt1tm1(CAG-Tgfbr1*)Lba Tg(Cd4-cre)1Cwi/0
(involves: 129 * C57BL/6 * DBA/2)
|
abnormal T cell activation
|
J:148747
|
Hprt1tm1(Pck1-cre)Vhh/Y Vhltm1Jae/Vhltm1Jae
(involves: 129P2/OlaHsd * 129S4/SvJae * BALB/c * C57BL/6)
|
kidney inflammation
|
J:106705
|
Hps1ep/Hps1ep
(involves: C3HeB/FeJ * C57BL/6J)
|
abnormal macrophage physiology
|
J:7869
|
Hps1ep/Hps1ep
(B6.C3Fe-Hps1ep/J)
|
abnormal NK cell physiology
|
J:6801
|
alveolitis
|
J:110157
|
Hps5ru2-Btlr/Hps5ru2-Btlr
(C57BL/6J-Hps5ru2-Btlr)
|
increased susceptibility to bacterial infection
|
J:133272
|
increased susceptibility to Herpesvirales infection
|
J:133272
|
Hpsetm1.2Mdh/Hpsetm1.2Mdh
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal dendritic cell chemotaxis
|
J:209913
|
decreased acute inflammation
|
J:209913
|
impaired eosinophil recruitment
|
J:209913
|
Hrhr/Hrhr
(HRS/J)
|
decreased T cell proliferation
|
J:6375
|
Hrhr/Hrhr Tg(CD2-Stat6*V625A*T626A)78Mhk/0
(involves: C3H * SKH1)
|
blepharitis
|
J:230018
|
eye inflammation
|
J:230018
|
Meibomian gland inflammation
|
J:230018
|
uveitis
|
J:230018
|
Hrm1Enu/Hrm1Enu
(BALB/cJ-Hrm1Enu)
|
granulomatous inflammation
|
J:108173
|
Hrrh/Hrrh
(Not Specified)
|
eye inflammation
|
J:16021
|
HrUSP/HrUSP
(either: (involves: A/J * BALB/c) or (involves: BALB/c * C57BL/6) or (involves: BALB/c * DBA/2))
|
abnormal immunoglobulin level
|
J:21316
|
abnormal thymus involution
|
J:21316
|
decreased IgM level
|
J:21316
|
glomerulonephritis
|
J:21316
|
increased IgG level
|
J:21316
|
increased susceptibility to autoimmune disorder
|
J:21316
|
lymph node inflammation
|
J:21316
|
Hrgtm1Wja/Hrgtm1Wja
(involves: 129P2/OlaHsd * C57BL/6)
|
increased circulating fibrinogen level
|
J:134621
|
Hrh1Bphs-r/Hrh1Bphs-s
((C3H/HeJ x SJL/J)F1)
|
abnormal immune system physiology
|
J:77938
|
abnormal response to infection
|
J:77938
|
increased susceptibility to bacterial infection
|
J:77938
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:77938
|
Hrh1Bphs-s/Hrh1Bphs-s
(C3.SJL-Hrh1Bphs-s)
|
abnormal response to infection
|
J:77938
|
increased susceptibility to bacterial infection
|
J:77938
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:77938
|
Hrh1tm1Wtn/Hrh1tm1Wtn
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased B cell proliferation
|
J:111704
|
decreased IgG3 level
|
J:111704
|
decreased IgM level
|
J:111704
|
decreased interferon-gamma secretion
|
J:111704
|
decreased interleukin-2 secretion
|
J:111704
|
decreased T cell proliferation
|
J:111704
|
increased interleukin-4 secretion
|
J:111704
|
Hrh1tm1Wtn/Hrh1tm1Wtn
(B6.129P2-Hrh1tm1Wtn)
|
decreased inflammatory response
|
J:110367
|
decreased interferon-gamma secretion
|
J:110367
|
decreased interleukin-5 secretion
|
J:110367
|
decreased interleukin-13 secretion
|
J:110367
|
increased IgG level
|
J:110367
|
increased IgM level
|
J:110367
|
Hrh3Eae8-r/?
(B10.S-H2s/SgMcdJ)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:34892
|
Hrh3Eae8-r/Hrh3Eae8-r
(involves: B10.S/DvTe * SJL/J)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:49054
|
Hrh3Eae8-s/?
(involves: B10.S * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:49054
|
Hrh3tm1Twl/Hrh3tm1Twl
(B6.129X1-Hrh3tm1Twl)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:122269
|
Hrh4tm1Lex/Hrh4+
(involves: 129S/SvEv * C57BL/6)
|
abnormal mast cell physiology
|
J:132140
|
Hrh4tm1Lex/Hrh4tm1Lex
(involves: 129S/SvEv * C57BL/6)
|
abnormal mast cell physiology
|
J:131785
|
Hrh4tm1Lex/Hrh4tm1Lex
(involves: 129S/SvEv * BALB/c)
|
abnormal chemokine level
|
J:131785
|
abnormal dendritic cell physiology
|
J:131785
|
abnormal interleukin level
|
J:131785
|
decreased IgE level
|
J:131785
|
decreased IgG1 level
|
J:131785
|
decreased inflammatory response
|
J:131785
|
Hrl129S6/SvEvTac/HrlC57BL/6J
(involves: 129S6/SvEvTac * C57BL/6J)
|
decreased susceptibility to Herpesvirales infection
|
J:86189
|
HrlC57BL/6J/HrlC57BL/6J
(involves: 129S6/SvEvTac * C57BL/6J)
|
decreased susceptibility to Herpesvirales infection
|
J:86189
|
Hsd17b11Gt(OST237628)Lex/Hsd17b11Gt(OST237628)Lex
(B6;129S5-Hsd17b11Gt(OST237628)Lex/Mmucd)
|
increased IgG2a level
|
J:171883
|
Hsd17b13tm1Lex/Hsd17b13tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6N)
|
liver inflammation
|
J:273927
|
Hsd17b14tm1Lex/Hsd17b14tm1Lex
(B6;129S5-Hsd17b14tm1Lex/Mmucd)
|
increased IgG2a level
|
J:171883
|
Hsf1tm1Ijb/Hsf1tm1Ijb
(either: (involves: 129S6/SvEvTac * 129X1/SvJ) or (involves: 129S6/SvEvTac * BALB/c) or (involves: 129S6/SvEvTac * C57BL/6J) or (involves: 129S6/SvEvTac * ICR))
|
increased susceptibility to bacterial infection
|
J:58383
|
increased tumor necrosis factor secretion
|
J:58383
|
Hsf1tm1Ijb/Hsf1tm1Ijb Tg(TTR-V30M)15Imeg/0
(involves: 129S6/SvEvTac * BALB/c * C57BL/6)
|
increased interleukin-1 beta secretion
|
J:156658
|
increased tumor necrosis factor secretion
|
J:156658
|
Hsh2dtm1Viss/Hsh2dtm1Viss
(B6.129-Hsh2dtm1Viss)
|
increased interleukin-2 secretion
|
J:111408
|
increased T cell proliferation
|
J:111408
|
Hsh2dtm1Viss/Hsh2dtm1Viss
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:111408
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:111408
|
Hsp90aa1tm1.1Udon/Hsp90aa1tm1.1Udon
(involves: C57BL/6)
|
abnormal dendritic cell antigen presentation
|
J:177143
|
abnormal dendritic cell physiology
|
J:177143
|
decreased interferon-gamma secretion
|
J:177143
|
Hsp90b1tm1Zhli/Hsp90b1tm1.1Zhli Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * 129S/SvEv)
|
abnormal cytokine secretion
|
J:118427
|
abnormal inflammatory response
|
J:118427
|
abnormal macrophage physiology
|
J:118427
|
increased susceptibility to bacterial infection
|
J:118427
|
Hspa1btm1Clib/Hspa1btm1Clib
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased interleukin-6 secretion
|
J:76801
|
Hspa12atm1.1Zdi/Hspa12atm1.1Zdi
(involves: 129 * C57BL/6)
|
increased susceptibility to endotoxin shock
|
J:302787
|
Hspa13tm1.1Smoc/Hspa13tm1.1Smoc Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * 129S * C57BL/6)
|
abnormal class switch recombination
|
J:303927
|
abnormal humoral immune response
|
J:303927
|
abnormal somatic hypermutation frequency
|
J:303927
|
decreased autoantibody level
|
J:303927
|
decreased IgA level
|
J:303927
|
decreased IgE level
|
J:303927
|
decreased IgG1 level
|
J:303927
|
decreased IgG2b level
|
J:303927
|
decreased IgG2c level
|
J:303927
|
decreased IgG3 level
|
J:303927
|
decreased IgG level
|
J:303927
|
decreased IgM level
|
J:303927
|
Hspb1tm1.1Jdn/Hspb1tm1.1Jdn
(B6.129S2(Cg)-Hspb1tm1.1Jdn)
|
abnormal chemokine secretion
|
J:209117
|
abnormal macrophage physiology
|
J:209117
|
abnormal neutrophil physiology
|
J:209117
|
increased inflammatory response
|
J:209117
|
increased interleukin-6 secretion
|
J:209117
|
Hspb8tm1.1Depr/Hspb8tm1.1Depr
(B.129-Hspb8tm1.1Depr)
|
decreased circulating interleukin-6 level
|
J:186292
|
Hspg2tm1Rdgr/Hspg2tm1Rdgr
(involves: 129S1/Sv * 129X1/SvJ)
|
osteoarthritis
|
J:121855
|
Htr2ctm1Jul/Y
(B6.129S-Htr2ctm1Jul)
|
abnormal tumor necrosis factor level
|
J:50262
|
Htr3atm1Ckn/Htr3atm1Ckn
(involves: 129S1/Sv * C57BL/6J * DBA/2)
|
kidney inflammation
|
J:90942
|
prostate gland inflammation
|
J:90942
|
pyelonephritis
|
J:90942
|
seminal vesiculitis
|
J:90942
|
tubulointerstitial nephritis
|
J:90942
|
Htra2mnd2/Htra2mnd2
(B6.Cg-Htra2mnd2)
|
abnormal interleukin level
|
J:76481
|
abnormal tumor necrosis factor level
|
J:76481
|
Hvcn1Gt(RRN293)Byg/Hvcn1Gt(RRN293)Byg
(B6.129P2-Hvcn1Gt(RRN293)Byg)
|
abnormal macrophage physiology
|
J:148032
|
abnormal neutrophil physiology
|
J:148032
|
hvlk/hvlk
(C57BL/6J-hvlk)
|
increased susceptibility to Herpesvirales infection
|
J:105543
|
Hyal1tm1Stn/Hyal1tm1Stn
(involves: 129X1/SvJ * C57BL/6J)
|
osteoarthritis
|
J:136860
|
Hydinhyrh/Hydinhyrh
(involves: C57BL/6J * C57BL/10J * RIII)
|
rhinitis
|
J:137815
|
Ibdq1C57BL/6J/Ibdq1SAMP1/YitFcs
(involves: C57BL/6J * SAMP1/YitFc)
|
ileum inflammation
|
J:84661
|
Ibdq1SAMP1/YitFcs/Ibdq1SAMP1/YitFcs
(involves: C57BL/6J * SAMP1/YitFc)
|
ileum inflammation
|
J:84661
|
Ibdq2SAMP1/YitFcs/Ibdq2SAMP1/YitFcs
(involves: AKR/J * SAMP1/YitFcs)
|
small intestinal inflammation
|
J:105411
|
IbtkGt(XF224)Byg/IbtkGt(XF224)Byg
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal splenocyte physiology
|
J:174707
|
Ica1tm1Mdos/Ica1tm1Mdos
(NOD.129-Ica1tm1Mdos)
|
abnormal T cell physiology
|
J:83526
|
decreased susceptibility to autoimmune diabetes
|
J:83526
|
Icam1tm1Alb/Icam1tm1Alb
(B6.Cg-Icam1tm1Alb)
|
abnormal leukocyte adhesion
|
J:100242
|
abnormal leukocyte tethering or rolling
|
J:100242
|
Icam1tm1Bay/Icam1tm1Bay
(involves: 129S7/SvEvBrd * C57BL/6J)
|
abnormal cellular extravasation
|
J:14565
|
abnormal immune system physiology
|
J:14565
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:14565
|
Icam1tm1Bay/Icam1tm1Bay
(B6.129S7-Icam1tm1Bay)
|
abnormal cellular extravasation
|
J:48271
|
abnormal leukocyte migration
|
J:24239
|
abnormal leukocyte tethering or rolling
|
J:48271
|
decreased susceptibility to endotoxin shock
|
J:123460
|
Icam1tm1Bay/Icam1tm1Bay
(either: B6.129S7-Icam1tm1Bay or (involves: 129S7/SvEvBrd * C57BL/6))
|
abnormal leukocyte tethering or rolling
|
J:31374
|
Icam1tm1Bay/Icam1tm1Bay
(B6.129S7-Icam1tm1Bay/J)
|
decreased susceptibility to parasitic infection induced morbidity/mortality
|
J:193592
|
Icam1tm1Bay/Icam1tm1Bay
(involves: 129S7/SvEvBrd * C57BL/6)
|
decreased susceptibility to induced colitis
|
J:111227
|
impaired neutrophil recruitment
|
J:112286
|
large intestinal inflammation
|
J:111227
|
Icam1tm1Bay/Icam1tm1Bay Seletm2Alb/Seletm2Alb Selptm1Bay/Selptm1Bay
(involves: 129S7/SvEvBrd * C57BL/6)
|
decreased acute inflammation
|
J:112286
|
impaired neutrophil chemotaxis
|
J:112286
|
Icam1tm1Bay/Icam1tm1Bay Selltm1Tft/Selltm1Tft
(B6.129-Selltm1Tft Icam1tm1Bay)
|
abnormal cellular extravasation
|
J:48271
|
abnormal inflammatory response
|
J:124291
|
abnormal leukocyte tethering or rolling
|
J:48271
|
abnormal macrophage physiology
|
J:124291
|
abnormal mast cell physiology
|
J:124291
|
impaired macrophage chemotaxis
|
J:124291
|
Icam1tm1Bay/Icam1tm1Bay Selptm1Bay/Selptm1Bay
(involves: 129S7/SvEvBrd * C57BL/6J)
|
abnormal leukocyte migration
|
J:24239
|
Icam1tm1Bay/Icam1tm1Bay Selptm1Bay/Selptm1Bay
(either: B6.129S7-Selptm1Bay Icam1tm1Bay or (involves: 129S7/SvEvBrd * C57BL/6))
|
impaired leukocyte tethering or rolling
|
J:31374
|
Icam1tm1Jcgr/Icam1tm1Jcgr
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
abnormal interleukin level
|
J:18743
|
abnormal T cell physiology
|
J:18743
|
abnormal tumor necrosis factor level
|
J:18743
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:18743
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:18743
|
Icam1tm1Jcgr/Icam1tm1Jcgr Tg(INS-Il10)#Sar/0
(NOD.Cg-Icam1tm1Jcgr Tg(INS-Il10)#Sar)
|
decreased susceptibility to autoimmune diabetes
|
J:66103
|
periinsulitis
|
J:66103
|
Icam1tm1Jcgr/Icam1tm1Jcgr Vcam1tm1Dmil/Vcam1tm1Dmil
(involves: 129S4/SvJae * C57BL/6)
|
impaired macrophage chemotaxis
|
J:227109
|
Icam2tm1Jcgr/Icam2tm1Jcgr
(involves: 129S4/SvJae * C57BL/6)
|
abnormal eosinophil physiology
|
J:54748
|
IchsC57BL/6J/IchsC57BL/6J
(involves: A/J * C57BL/6J * C57BL/6JOlaHsd)
|
abnormal type I hypersensitivity reaction
|
J:63737
|
IchsC57BL/6JOlaHsd/IchsC57BL/6JOlaHsd
(involves: A/J * C57BL/6J * C57BL/6JOlaHsd)
|
abnormal type I hypersensitivity reaction
|
J:63737
|
Icostm1.1Wks/Icostm1.1Wks
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal B cell physiology
|
J:155586
|
abnormal class switch recombination
|
J:155586
|
abnormal immune system physiology
|
J:155586
|
decreased IgA level
|
J:155586
|
decreased IgG1 level
|
J:155586
|
decreased IgG2b level
|
J:155586
|
decreased IgG2c level
|
J:155586
|
decreased interleukin-4 secretion
|
J:155586
|
decreased interleukin-21 secretion
|
J:155586
|
Icostm1Dgry/Icostm1Dgry
(B6.129P2-Icostm1Dgry)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:123477
|
abnormal immune system physiology
|
J:123477
|
abnormal interleukin secretion
|
J:123477
|
abnormal response to infection
|
J:123477
|
abnormal T cell physiology
|
J:123477
|
decreased IgG level
|
J:123477
|
decreased interleukin-4 secretion
|
J:123477
|
decreased interleukin-5 secretion
|
J:123477
|
Icostm1Flv/Icos+
(NOD.129S1-Icostm1Flv)
|
insulitis
|
J:131529
|
Icostm1Flv/Icostm1Flv
(involves: 129/Sv * C57BL/6)
|
abnormal immunoglobulin level
|
J:87123
|
abnormal interferon level
|
J:87123
|
abnormal interleukin level
|
J:87123
|
abnormal T-helper 2 physiology
|
J:87123
|
decreased IgE level
|
J:87123
|
decreased IgG1 level
|
J:87123
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:87123
|
Icostm1Flv/Icostm1Flv
(NOD.129S1-Icostm1Flv)
|
decreased anti-insulin autoantibody level
|
J:131529
|
decreased autoantibody level
|
J:131529
|
decreased IgG level
|
J:131529
|
decreased interferon-gamma secretion
|
J:131529
|
decreased susceptibility to autoimmune diabetes
|
J:131529
|
insulitis
|
J:131529
|
Icostm1Flv/Icostm1Flv
(involves: 129S1/Sv)
|
abnormal cytokine secretion
|
J:112600
|
Icostm1Flv/Icostm1Flv Tg(Cd4-Maf)6666Glm/0
(involves: 129S1/Sv * C57BL/6)
|
abnormal cytokine secretion
|
J:112600
|
Icostm1Flv/Icostm1Flv Tg(TcraTcrb)425Cbn/0
(involves: 129S1/Sv * C57BL/6)
|
abnormal cytokine secretion
|
J:112600
|
Icostm1Mak/Icostm1Mak
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal B cell physiology
|
J:66702
|
abnormal class switch recombination
|
J:66702
|
abnormal immune system physiology
|
J:66702
|
abnormal T cell physiology
|
J:66702
|
decreased IgA level
|
J:155586
|
decreased IgE level
|
J:66702
|
decreased IgG1 level
|
J:66702,
J:155586
|
decreased IgG2b level
|
J:155586
|
decreased IgG2c level
|
J:155586
|
decreased interleukin-21 secretion
|
J:155586
|
decreased T cell proliferation
|
J:66702
|
Icostm1Shr/Icostm1Shr
(Not Specified)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:87124
|
abnormal immunoglobulin level
|
J:87124
|
abnormal interleukin level
|
J:87124
|
decreased IgE level
|
J:87124
|
decreased IgG1 level
|
J:87124
|
decreased IgG2a level
|
J:87124
|
decreased IgG level
|
J:87124
|
increased IgG3 level
|
J:87124
|
Icostm1Tkan/Icostm1Tkan
(involves: 129S7/SvEvBrd * C57BL/6)
|
abnormal NK cell physiology
|
J:95353
|
decreased circulating interferon-gamma level
|
J:95353
|
decreased circulating interleukin-4 level
|
J:95353
|
Icosltm1Cdon/Icosltm1Cdon
(involves: 129S6/SvEvTac)
|
abnormal immunoglobulin level
|
J:86697
|
abnormal interferon level
|
J:86697
|
abnormal interleukin secretion
|
J:86697
|
abnormal T-helper 2 physiology
|
J:86697
|
decreased IgE level
|
J:86697
|
decreased IgG1 level
|
J:86697
|
decreased IgG2a level
|
J:86697
|
decreased IgG level
|
J:86697
|
decreased IgM level
|
J:86697
|
Icosltm1Kplm/Icosltm1Kplm
(involves: 129P2/OlaHsd)
|
abnormal humoral immune response
|
J:84893
|
abnormal immune serum protein physiology
|
J:84893
|
decreased IgA level
|
J:84893
|
decreased IgG2a level
|
J:84893
|
decreased IgG2b level
|
J:84893
|
decreased interleukin-4 secretion
|
J:84893
|
decreased interleukin-10 secretion
|
J:84893
|
increased interferon-gamma secretion
|
J:84893
|
Icosltm1Mak/Icosltm1Mak
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal class switch recombination
|
J:84668
|
abnormal immune system physiology
|
J:84668
|
decreased IgG1 level
|
J:84668
|
decreased inflammatory response
|
J:84668
|
Id1tm1Zhu/Id1+ Id3tm1Zhu/Id3tm1Zhu
(involves: 129S1/Sv * 129S4/SvJaeSor)
|
increased susceptibility to otitis media
|
J:311050
|
Id1tm1Zhu/Id1tm1Zhu Id3tm1Zhu/Id3+
(involves: 129S1/Sv * 129S4/SvJaeSor)
|
increased susceptibility to otitis media
|
J:311050
|
Id2tm1Ago/Id2tm1Ago Tg(TcraTcrb)1100Mjb/0
(B6.Cg-Id2tm1Ago Tg(TcraTcrb)1100Mjb)
|
abnormal T cell activation
|
J:116119
|
Id2tm1Mais/Id2tm1Mais
(involves: 129X1/SvJ * C57BL/6)
|
abnormal immune system physiology
|
J:146624
|
Id3tm1Zhu/Id3tm1Zhu
(involves: 129/Sv * C57BL/6)
|
abnormal T cell physiology
|
J:56950
|
decreased B cell proliferation
|
J:56950
|
decreased immunoglobulin level
|
J:56950
|
Id3tm1Zhu/Id3tm1Zhu
(involves: 129S4/SvJaeSor)
|
increased autoantibody level
|
J:93916
|
lacrimal gland inflammation
|
J:93916
|
salivary gland inflammation
|
J:93916
|
Id3tm2.1Zhu/Id3tm2.1Zhu Tg(Lck-cre)#Zhu/0
(involves: 129S6/SvEvTac * C57BL/6 * SJL * SJL/J)
|
parotid gland inflammation
|
J:172701
|
submandibular gland inflammation
|
J:172701
|
Idc/Idc+
(involves: 101 * C3H)
|
blepharitis
|
J:6686
|
Idd1NOD/Uf/Idd1NOD/Uf
(involves: C57BL/6 * NOD/Uf)
|
periinsulitis
|
J:33172
|
Idd3A/J/Idd3A/J
(NOD.A-Idd3A/J)
|
increased susceptibility to autoimmune diabetes
|
J:120349
|
Idd3C57BL/6/Idd3C57BL/6
(NOD.B6-Idd3C57BL/6)
|
decreased susceptibility to autoimmune diabetes
|
J:120349
|
Idd3C57BL/10SnJ/Idd3C57BL/10SnJ Idd5.2C57BL/10SnJ/Idd5.2C57BL/10SnJ
(involves: C57BL/10SnJ * NOD/MrkTac)
|
insulitis
|
J:143549
|
Idd3C57BL/10SnJ/Idd3C57BL/10SnJ Idd5C57BL/10SnJ/Idd5C57BL/10SnJ
(involves: C57BL/10 * NOD/MrkTac)
|
pancreas inflammation
|
J:88667
|
Idd3CAST/EiJ/Idd3CAST/EiJ
(NOD.CAST-Idd3CAST/EiJ)
|
increased susceptibility to autoimmune diabetes
|
J:120349
|
Idd3CZECHI/EiJ/Idd3CZECHI/EiJ
(NOD.CZECH-Idd3CZECHI/EiJ)
|
decreased susceptibility to autoimmune diabetes
|
J:120349
|
Idd3NOD/?
(involves: C57BL/10 * NOD)
|
pancreas inflammation
|
J:17906
|
Idd3SWR/J/Idd3SWR/J
(NOD.SWR-Idd3SWR/J)
|
increased susceptibility to autoimmune diabetes
|
J:120349
|
Idd4.3C57L/Idd4.3C57L
(involves: C57L/J * NOD)
|
abnormal cytokine secretion
|
J:118951
|
abnormal macrophage physiology
|
J:118951
|
increased susceptibility to autoimmune diabetes
|
J:118951
|
Idd4C57BL/6/Idd4C57BL/6
(involves: C57BL/6 * DBA/2)
|
increased T cell proliferation
|
J:25969
|
Idd4C57BL/6/Idd4C57BL/6
(involves: C57BL/6 * NOD)
|
increased T cell proliferation
|
J:25969
|
Idd4C57BL/6J/?
(involves: C57BL/6J * NOD)
|
pancreas inflammation
|
J:73763
|
Idd4NOD/Jsd/?
(involves: NOD/Jsd * NOR/LtJ)
|
pancreas inflammation
|
J:99002
|
Idd4NOD/Jsd/Idd4NOD/Jsd Idd9NOD/Jsd/Idd9NOD/Jsd
(involves: NOD/Jsd * NOR/LtJ)
|
pancreas inflammation
|
J:99002
|
Idd4NOD/Idd4NOD
(B6.NOD-Idd4)
|
abnormal cytokine secretion
|
J:85823
|
Idd4NOR/LtJ/?
(involves: NOD/Jsd * NOR/LtJ)
|
pancreas inflammation
|
J:99002
|
Idd5NOD/Uf/Idd5NOD/Uf
(involves: C57BL/6 * NOD/Uf)
|
periinsulitis
|
J:33172
|
Idd6.1C3H/HeJ/Idd6.1C3H/HeJ
(involves: C3H/HeJ * NOD)
|
decreased susceptibility to autoimmune diabetes
|
J:115021
|
Idd6.2C3H/HeJ/Idd6.2C3H/HeJ
(involves: C3H/HeJ * NOD)
|
decreased susceptibility to autoimmune diabetes
|
J:115021
|
Idd6.3C3H/HeJ/Idd6.3C3H/HeJ
(involves: C3H/HeJ * NOD)
|
decreased susceptibility to autoimmune diabetes
|
J:115021
|
Idd6C3H/HeJ/Idd6C3H/HeJ
(NOD.C3-Idd6C3H/HeJ)
|
decreased interferon-gamma secretion
|
J:137837
|
decreased interleukin-4 secretion
|
J:137837
|
Idd6C57BL/6/Idd6NOD
(involves: C57BL/6 * NOD)
|
decreased T cell proliferation
|
J:72360
|
Idd6NOD/Idd6NOD
(involves: C57BL/6 * NOD)
|
decreased T cell proliferation
|
J:72360
|
Idd6NOD/Idd6NOD
(B6.NOD-Idd6)
|
abnormal NK cell physiology
|
J:85823
|
Idd7NOD/ShiLt/Idd7NOD/ShiLt
(involves: C57BL/6 * NOD/ShiLt)
|
abnormal T cell clonal deletion
|
J:131557
|
Idd9NOD/Jsd/?
(involves: NOD/Jsd * NOR/LtJ)
|
pancreas inflammation
|
J:99002
|
Idd9NOR/LtJ/?
(involves: NOD/Jsd * NOR/LtJ)
|
pancreas inflammation
|
J:99002
|
Idd10NOD/ShiLt/Idd10NOD/ShiLt Idd3NOD/Idd3NOD
(B6.NOD-Idd3NOD Idd10NOD/Lt)
|
abnormal cytokine secretion
|
J:85823
|
abnormal NK T cell physiology
|
J:85823
|
Idd13NOD/ShiLt/Idd13NOD/ShiLt
(B6.NOD-Idd13)
|
abnormal cytokine secretion
|
J:85823
|
abnormal NK T cell physiology
|
J:85823
|
Idd16.1ALR/LtJ/Idd16.1ALR/LtJ
(involves: ALR/LtJ * NOD/LtJ)
|
pancreas inflammation
|
J:98187
|
Ido1tm1Alm/Ido1tm1Alm
(involves: 129X1/SvJ * C57BL/6 * CBA)
|
abnormal cytokine secretion
|
J:120813
|
abnormal dendritic cell physiology
|
J:120813
|
Ido1tm1Alm/Ido1tm1Alm
(involves: 129X1/SvJ * BALB/c)
|
abnormal cytokine level
|
J:170565
|
epididymis inflammation
|
J:170565
|
Ido1tm1Alm/Ido1tm1Alm
(involves: 129X1/SvJ * C57BL/6J * FVB/N)
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:211949
|
increased interferon-gamma secretion
|
J:211949
|
increased interleukin-6 secretion
|
J:211949
|
increased tumor necrosis factor secretion
|
J:211949
|
Ido1tm1Alm/Ido1tm1Alm
(involves: 129X1/SvJ * C57BL/6J)
|
abnormal macrophage physiology
|
J:282516
|
Ido2em1Lamn/Ido2em1Lamn
(involves: BALB/c * C57BL/6J)
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:342726
|
Ido2em1Lamn/Ido2em1Lamn Tg(TcraR28,TcrbR28)KRNDim/0
(involves: C57BL/6 * C57BL/6J * SJL)
|
autoimmune arthritis
|
J:342726
|
Ido2em2Lamn/Ido2em2Lamn
(involves: BALB/c * C57BL/6J)
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:342726
|
Ido2em2Lamn/Ido2em2Lamn Tg(TcraR28,TcrbR28)KRNDim/0
(involves: C57BL/6 * C57BL/6J * SJL)
|
autoimmune arthritis
|
J:342726
|
Ido2tm1.2Gcp/Ido2tm1.2Gcp
(involves: C57BL/6J * FVB/N)
|
abnormal chemokine secretion
|
J:211949
|
abnormal regulatory T cell physiology
|
J:211949
|
decreased interferon-gamma secretion
|
J:211949
|
decreased interleukin-6 secretion
|
J:211949
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:211949
|
decreased tumor necrosis factor secretion
|
J:211949
|
Iduatm1Efn/Iduatm1Efn
(involves: C57BL/6)
|
abnormal microglial cell physiology
|
J:81974
|
increased susceptibility to otitis media
|
J:123676
|
Ier3tm1Mxw/Ier3tm1Mxw
(involves: 129 * C57BL/6)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:157504
|
abnormal interleukin level
|
J:157504
|
abnormal macrophage physiology
|
J:157504
|
abnormal response to infection
|
J:157504
|
abnormal tumor necrosis factor level
|
J:157504
|
abnormal tumor necrosis factor secretion
|
J:157504
|
impaired macrophage phagocytosis
|
J:157504
|
increased susceptibility to parasitic infection
|
J:157504
|
Ier3tm1Mxw/Ier3tm1Mxw
(involves: C57BL/6)
|
decreased susceptibility to induced colitis
|
J:194587
|
Ier3tm1Mxw/Ier3tm1Mxw Rag1tm1Mom/Rag1tm1Mom
(involves: 129S7/SvEvBrd * C57BL/6)
|
decreased susceptibility to induced colitis
|
J:194587
|
If1l/If1l
(involves: BALB/c)
|
abnormal circulating interferon level
|
J:5113
|
abnormal response to infection
|
J:38004
|
If1l/If1l
(B6.C-Ifi44lH28-c If1l/(HW81)aByJ)
|
abnormal response to infection
|
J:38004
|
Ifi30tm1Cres/Ifi30tm1Cres
(involves: 129S1/Sv * C57BL/6)
|
abnormal professional antigen presenting cell physiology
|
J:72708
|
Ifi35em1Hhl/Ifi35em1Hhl
(C57BL/6-Ifi35em1Hhl)
|
decreased circulating interleukin-6 level
|
J:298909
|
decreased circulating tumor necrosis factor level
|
J:298909
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:298909
|
decreased susceptibility to endotoxin shock
|
J:298909
|
Ifi44tm1b(KOMP)Wtsi/Ifi44tm1b(KOMP)Wtsi
(involves: C57BL/6N)
|
decreased CXCL10 secretion
|
J:297991
|
decreased interleukin-1 beta secretion
|
J:297991
|
increased susceptibility to Riboviria infection
|
J:297991
|
Ifi47tm1Gat/Ifi47tm1Gat
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased susceptibility to parasitic infection
|
J:87535
|
Ifi204tm1.1Cjul/Ifi204tm1.1Cjul
(B6.129(Cg)-Ifi204tm1.1Cjul)
|
decreased circulating interferon-beta level
|
J:270123
|
decreased circulating interleukin-1 beta level
|
J:270123
|
decreased circulating interleukin-6 level
|
J:270123
|
decreased circulating tumor necrosis factor level
|
J:270123
|
decreased interferon-beta secretion
|
J:270123
|
decreased interleukin-6 secretion
|
J:270123
|
decreased susceptibility to endotoxin shock
|
J:270123
|
decreased tumor necrosis factor secretion
|
J:270123
|
Ifi207em1(IMPC)Wtsi/Ifi207+
(C57BL/6N-Ifi207em1(IMPC)Wtsi)
|
increased susceptibility to Retroviridae infection
|
J:354143
|
Ifi207em1(IMPC)Wtsi/Ifi207em1(IMPC)Wtsi
(C57BL/6N-Ifi207em1(IMPC)Wtsi)
|
decreased interferon-beta secretion
|
J:354143
|
increased susceptibility to Retroviridae infection
|
J:354143
|
Ifih1Rgsc422/Ifih1+
(D2JJcl.B6JJcl-Ifih1Rgsc422)
|
abnormal chemokine level
|
J:209917
|
abnormal cytokine level
|
J:209917
|
abnormal dendritic cell antigen presentation
|
J:209917
|
abnormal macrophage activation involved in immune response
|
J:209917
|
abnormal T cell activation
|
J:209917
|
autoimmune response
|
J:209917
|
chronic liver inflammation
|
J:209917
|
glomerulonephritis
|
J:209917
|
increased anti-double stranded DNA antibody level
|
J:209917
|
increased anti-nuclear antigen antibody level
|
J:209917
|
increased IgA level
|
J:209917
|
increased IgG level
|
J:209917
|
increased IgM level
|
J:209917
|
increased immunoglobulin level
|
J:209917
|
increased inflammatory response
|
J:209917
|
increased susceptibility to systemic lupus erythematosus
|
J:209917
|
skin inflammation
|
J:209917
|
Ifih1Rgsc422/Ifih1+ Ifnar1tm1Agt/Ifnar1+
(involves: 129S2/SvPas * C57BL/6JJcl * DBA/2JJcl)
|
glomerulonephritis
|
J:209917
|
Ifih1Rgsc422/Ifih1+ Mavstm1Aki/Mavs+
(involves: C57BL/6JJcl * DBA/2JJcl)
|
glomerulonephritis
|
J:209917
|
Ifih1Rgsc422/Ifih1Rgsc422
(D2JJcl.B6JJcl-Ifih1Rgsc422)
|
glomerulonephritis
|
J:209917
|
increased susceptibility to systemic lupus erythematosus
|
J:209917
|
Ifih1tm1.1Cln/Ifih1tm1.1Cln
(involves: 129X1/SvJ * C57BL/6)
|
abnormal cytokine secretion
|
J:110201
|
decreased interferon-alpha secretion
|
J:110201
|
decreased interleukin-6 secretion
|
J:110201
|
increased susceptibility to Picornaviridae infection
|
J:110201
|
Ifih1tm1.1Cln/Ifih1tm1.1Cln
(involves: 129X1/SvJ)
|
decreased interferon-beta secretion
|
J:240099
|
Ifih1tm1Aki/Ifih1tm1Aki
(involves: 129/Sv * C57BL/6)
|
abnormal dendritic cell physiology
|
J:137522
|
abnormal interferon level
|
J:137522
|
abnormal interleukin level
|
J:137522
|
increased susceptibility to Picornaviridae infection
|
J:137522
|
Ifih1tm1Aki/Ifih1tm1Aki Ticam1tm1Aki/Ticam1tm1Aki
(involves: 129P2/OlaHsd)
|
abnormal interferon level
|
J:137522
|
abnormal interleukin level
|
J:137522
|
Ifit1tm1(KOMP)Vlcg/Ifit1tm1(KOMP)Vlcg
(involves: C57BL/6NTac)
|
increased susceptibility to Riboviria infection
|
J:187549
|
increased susceptibility to Riboviria infection induced morbidity/mortality
|
J:187549
|
Ifit1tm1(KOMP)Vlcg/Ifit1tm1(KOMP)Vlcg
(involves: C57BL/6 * C57BL/6NTac)
|
abnormal interferon level
|
J:205203
|
abnormal T cell physiology
|
J:205203
|
brain inflammation
|
J:205203
|
increased susceptibility to Coronaviridae infection
|
J:205203
|
increased susceptibility to Coronaviridae infection induced morbidity/mortality
|
J:205203
|
Ifit2tm1.1Ebsb/Ifit2tm1.1Ebsb
(B6NCrl.129P2(C)-Ifit2tm1.1Ebsb)
|
decreased circulating interleukin-1 beta level
|
J:199862
|
decreased circulating interleukin-6 level
|
J:199862
|
decreased circulating interleukin-12b level
|
J:199862
|
decreased circulating tumor necrosis factor level
|
J:199862
|
decreased interleukin-6 secretion
|
J:199862
|
decreased tumor necrosis factor secretion
|
J:199862
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:199862
|
Ifit2tm1.1Ebsb/Ifit2tm1.1Ebsb
(B6.129P2(C)-Ifit2tm1.1Ebsb)
|
enhanced humoral immune response
|
J:233986
|
increased IgE level
|
J:233986
|
increased IgG1 level
|
J:233986
|
increased IgG3 level
|
J:233986
|
increased IgM level
|
J:233986
|
Ifit2tm1.1Gcs/Ifit2+
(involves: C57BL/6)
|
increased susceptibility to Riboviria infection induced morbidity/mortality
|
J:195382
|
Ifit2tm1.1Gcs/Ifit2tm1.1Gcs
(involves: C57BL/6)
|
increased susceptibility to Riboviria infection
|
J:195382
|
increased susceptibility to Riboviria infection induced morbidity/mortality
|
J:195382
|
Ifitm1tm1.1Ieg/Ifitm1tm1.1Ieg
(B6.129P2-Ifitm1tm1.1Ieg)
|
increased IgE level
|
J:192287
|
Ifitm3tm1Masu/Ifitm3tm1Masu
(involves: 129P2/OlaHsd * C57BL/6)
|
increased susceptibility to Orthomyxoviridae infection
|
J:183865
|
increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality
|
J:183865
|
increased susceptibility to Riboviria infection
|
J:209781
|
Ifna6tm1Aki/Ifna6+ Myd88tm1Aki/Myd88tm1Aki
(involves: 129P2/OlaHsd)
|
decreased interferon-alpha secretion
|
J:124340
|
Ifnar1m1Btlr/Ifnar1m1Btlr
(C57BL/6J-Ifnar1m1Btlr)
|
abnormal macrophage physiology
|
J:142790
|
decreased interferon-alpha secretion
|
J:142790
|
decreased interferon-beta secretion
|
J:142790
|
increased susceptibility to Adenoviridae infection
|
J:142790
|
increased susceptibility to Herpesvirales infection
|
J:142790
|
increased susceptibility to Orthomyxoviridae infection
|
J:142790
|
increased susceptibility to Riboviria infection
|
J:142790
|
Ifnar1m2Btlr/Ifnar1m2Btlr
(involves: C57BL/6J)
|
decreased interferon-beta secretion
|
J:198556
|
Ifnar1tm1Agt/Ifnar1tm1Agt
(involves: 129S2/SvPas)
|
abnormal cytokine secretion
|
J:114555
|
abnormal dendritic cell physiology
|
J:114555
|
abnormal immunoglobulin level
|
J:101427
|
abnormal inflammatory response
|
J:114555
|
abnormal NK cell physiology
|
J:79552,
J:139001
|
impaired natural killer cell mediated cytotoxicity
|
J:79552
|
increased susceptibility to Coronaviridae infection
|
J:144400
|
increased susceptibility to Coronaviridae infection induced morbidity/mortality
|
J:144400
|
increased susceptibility to Herpesvirales infection
|
J:197569,
J:81243
|
increased susceptibility to Herpesvirales infection induced morbidity/mortality
|
J:115139
|
increased susceptibility to Paramyxoviridae infection
|
J:160878
|
increased susceptibility to Paramyxoviridae infection induced morbidity/mortality
|
J:160878
|
increased susceptibility to Picornaviridae infection
|
J:137522
|
increased susceptibility to Poxviridae infection
|
J:101427
|
Ifnar1tm1Agt/Ifnar1tm1Agt
(involves: 129S2/SvPas * C57BL/6)
|
abnormal susceptibility to infection
|
J:120938
|
Ifnar1tm1Agt/Ifnar1tm1Agt
(B6.129S2-Ifnar1tm1Agt)
|
abnormal response to infection
|
J:116703
|
decreased interferon-alpha secretion
|
J:125611
|
decreased interferon-beta secretion
|
J:125611
|
decreased interleukin-6 secretion
|
J:199862
|
decreased tumor necrosis factor secretion
|
J:199862
|
impaired natural killer cell mediated cytotoxicity
|
J:118750
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:199862
|
Ifnar1tm1Agt/Ifnar1tm1Agt
(involves: 129S2/SvPas * BALB/c * C57BL/6 * SJL)
|
increased susceptibility to Orthomyxoviridae infection
|
J:119783
|
Ifnar1tm1Agt/Ifnar1tm1Agt
(involves: 129S2/SvPas * 129S6/SvEvTac)
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:54482
|
abnormal interferon-gamma secretion
|
J:54482
|
increased circulating interleukin-12 level
|
J:54482
|
increased susceptibility to Riboviria infection
|
J:54482
|
Ifnar1tm1Agt/Ifnar1tm1Agt
(involves: 129S2/SvPas * BALB/c)
|
abnormal cytokine level
|
J:291874
|
decreased susceptibility to Coronaviridae infection
|
J:291874
|
decreased T cell apoptosis
|
J:291874
|
increased susceptibility to Coronaviridae infection induced morbidity/mortality
|
J:291874
|
increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality
|
J:291874
|
Ifnar1tm1Agt/Ifnar1tm1Agt Ifngr1tm1Agt/Ifngr1tm1Agt
(involves: 129S2/SvPas * 129S7/SvEvBrd)
|
abnormal immunoglobulin level
|
J:101427
|
increased susceptibility to Herpesvirales infection
|
J:81243
|
increased susceptibility to Herpesvirales infection induced morbidity/mortality
|
J:115139
|
increased susceptibility to Poxviridae infection
|
J:101427
|
increased susceptibility to Togaviridae infection
|
J:81243
|
Ifnar1tm1Agt/Ifnar1tm1Agt Myd88tm1Aki/Myd88+
(B6.129-Myd88tm1Aki Ifnar1tm1Agt)
|
increased susceptibility to parasitic infection
|
J:140485
|
Ifnar1tm1Agt/Ifnar1tm1Agt Myd88tm1Aki/Myd88tm1Aki
(involves: 129P2/OlaHsd * 129S2/SvPas)
|
abnormal leukocyte migration
|
J:171379
|
Ifnar1tm1Agt/Ifnar1tm1Agt Myd88tm1Aki/Myd88tm1Aki
(B6.129-Myd88tm1Aki Ifnar1tm1Agt)
|
increased susceptibility to parasitic infection
|
J:140485
|
increased susceptibility to parasitic infection induced morbidity/mortality
|
J:140485
|
Ifnar1tm1Agt/Ifnar1tm1Agt Otulintm1c(EUCOMM)Hmgu/Otulintm1c(EUCOMM)Hmgu Tg(KRT14-cre)1Cgn/0
(involves: 129S2/SvPas * C57BL/6 * C57BL/6N * DBA/2)
|
dermatitis
|
J:312394
|
Ifnar1tm1Agt/Ifnar1tm1Agt Slamf1tm1Oono/Slamf1tm1Oono
(B6.129-Slamf1tm1Oono Ifnar1tm1Agt)
|
increased susceptibility to Paramyxoviridae infection
|
J:117810
|
Ifnar1tm1Agt/Ifnar1tm1Agt Tg(CD46)373Zbz/Tg(CD46)373Zbz
(involves: 129S2/SvPas * C3H/He * C57BL/6)
|
brain inflammation
|
J:160878
|
increased susceptibility to Paramyxoviridae infection
|
J:160878
|
increased susceptibility to Paramyxoviridae infection induced morbidity/mortality
|
J:160878
|
lung inflammation
|
J:160878
|
meningitis
|
J:160878
|
Ifnar1tm1Agt/Ifnar1tm1Agt Tg(Hmgcr-MX1)LStae/Tg(Hmgcr-MX1)LStae
(involves: 129S2/SvPas * BALB/c * C57BL/6 * SJL)
|
decreased susceptibility to Orthomyxoviridae infection
|
J:119783
|
decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality
|
J:119783
|
Ifnar1tm1Agt/Ifnar1tm1Agt Ythdf3em1Caox/Ythdf3em1Caox
(involves: C57BL/6J)
|
abnormal macrophage physiology
|
J:276397
|
Ifnar1tm1Pjh/Ifnar1tm1Pjh
(involves: 129S2/SvPas * BALB/c)
|
abnormal macrophage physiology
|
J:36004
|
increased susceptibility to Picornaviridae infection
|
J:36004
|
increased susceptibility to Picornaviridae infection induced morbidity/mortality
|
J:36004
|
increased susceptibility to Togaviridae infection
|
J:36004
|
increased susceptibility to Togaviridae infection induced morbidity/mortality
|
J:36004
|
Ifnar1tm1Pjh/Ifnar1tm1Pjh
(B6.129S2-Ifnar1tm1Pjh)
|
impaired natural killer cell mediated cytotoxicity
|
J:125812
|
Ifnar2m1Btlr/Ifnar2m1Btlr
(C57BL/6J-Ifnar2m1Btlr)
|
abnormal macrophage physiology
|
J:147329
|
decreased interferon-alpha secretion
|
J:147329
|
decreased interferon-beta secretion
|
J:147329
|
increased susceptibility to Adenoviridae infection
|
J:147329
|
increased susceptibility to Herpesvirales infection
|
J:147329
|
increased susceptibility to Orthomyxoviridae infection
|
J:147329
|
increased susceptibility to Riboviria infection
|
J:147329
|
Ifnar2tm1Pjh/Ifnar2tm1Pjh
(B6.Cg-Ifnar2tm1Pjh)
|
impaired natural killer cell mediated cytotoxicity
|
J:125812
|
Ifnar2tm1Pjh/Ifnar2tm1Pjh
(involves: C57BL/6)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:132662
|
abnormal cytotoxic T cell physiology
|
J:132662
|
decreased IgG1 level
|
J:132662
|
decreased IgG2a level
|
J:132662
|
decreased IgG level
|
J:132662
|
decreased interferon-gamma secretion
|
J:132662
|
Ifnar2tm1Pjh/Ifnar2tm1Pjh Il6sttm1Ern/Il6sttm1Ern
(involves: 129S1/Sv)
|
increased circulating interleukin-6 level
|
J:168781
|
increased susceptibility to endotoxin shock
|
J:168781
|
Ifnb1tm1Acgp/Ifnb1tm1Acgp
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased circulating interferon-beta level
|
J:61048
|
increased susceptibility to Poxviridae infection
|
J:61048
|
Ifnb1tm1Acgp/Ifnb1tm1Acgp
(involves: 129P2/OlaHsd)
|
decreased tumor necrosis factor secretion
|
J:86527
|
increased T cell proliferation
|
J:86527
|
Ifnb1tm1Acgp/Ifnb1tm1Acgp
(B6.129P2-Ifnb1tm1Acgp)
|
abnormal macrophage physiology
|
J:136368
|
decreased interleukin-1 beta secretion
|
J:136368
|
Ifnb1tm1Tl/Ifnb1tm1Tl
(B10.129P2-Ifnb1tm1Tl)
|
abnormal macrophage physiology
|
J:83021
|
abnormal microglial cell physiology
|
J:83021
|
CNS inflammation
|
J:83021
|
increased interferon-gamma secretion
|
J:83021
|
increased interleukin-4 secretion
|
J:83021
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:83021
|
increased tumor necrosis factor secretion
|
J:83021
|
Ifnb1tm1Tl/Ifnb1tm1Tl
(B6.129P2-Ifnb1tm1Tl)
|
decreased circulating interferon-alpha level
|
J:172226
|
decreased circulating interferon-beta level
|
J:172226
|
decreased susceptibility to bacterial infection
|
J:172226
|
Ifnb1tm1Ttg/Ifnb1tm1Ttg
(involves: C57BL/6)
|
abnormal response to infection
|
J:116703
|
Ifnb1tm2.1Lien/Ifnb1tm2.1Lien Tyrc-2J/Tyrc-2J Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased circulating interferon-alpha level
|
J:172226
|
decreased circulating interferon-beta level
|
J:172226
|
decreased susceptibility to bacterial infection
|
J:172226
|
Ifnetm1.2Pjh/Ifnetm1.2Pjh
(involves: C57BL/6)
|
increased susceptibility to bacterial infection
|
J:197569
|
increased susceptibility to Herpesvirales infection
|
J:197569
|
Ifngtm1.1Hayg/Ifngtm1.1Hayg
(involves: 129S4/SvJae * C57BL/6J)
|
abnormal circulating cytokine level
|
J:220784
|
abnormal cytokine level
|
J:220784
|
abnormal T cell activation
|
J:220784
|
Ifngtm1Ts/Ifngtm1Ts
(involves: 129S7/SvEvBrd * C57BL/6)
|
abnormal macrophage physiology
|
J:66802
|
abnormal MHC II cell surface expression on macrophages
|
J:66802
|
abnormal NK cell physiology
|
J:66802,
J:115033
|
abnormal type IV hypersensitivity reaction
|
J:55740
|
decreased length of allograft survival
|
J:44346
|
decreased susceptibility to parasitic infection
|
J:189794
|
decreased susceptibility to parasitic infection induced morbidity/mortality
|
J:189794
|
increased splenocyte proliferation
|
J:66802
|
increased susceptibility to bacterial infection
|
J:66802
|
Ifngtm1Ts/Ifngtm1Ts
(NOD.129S7-Ifngtm1Ts)
|
abnormal susceptibility to autoimmune disorder
|
J:33427
|
decreased susceptibility to autoimmune diabetes
|
J:95105
|
Ifngtm1Ts/Ifngtm1Ts
(NOD.Cg-Ifngtm1Ts Prkdcscid)
|
decreased susceptibility to autoimmune diabetes
|
J:72818
|
Ifngtm1Ts/Ifngtm1Ts
(NOD.129S7(B6)-Ifngtm1Ts/DvsJ)
|
abnormal cytotoxic T cell physiology
|
J:72818
|
abnormal diapedesis
|
J:72818
|
decreased susceptibility to autoimmune diabetes
|
J:72818
|
Ifngtm1Ts/Ifngtm1Ts
(involves: 129S7/SvEvBrd)
|
abnormal cytokine level
|
J:112600
|
abnormal immunoglobulin level
|
J:29170
|
abnormal response to infection
|
J:110721,
J:29170
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:29170
|
impaired natural killer cell mediated cytotoxicity
|
J:73948
|
increased IgG1 level
|
J:110721
|
increased interleukin-17 secretion
|
J:132905
|
increased susceptibility to bacterial infection
|
J:110856
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:110856
|
increased susceptibility to Herpesvirales infection
|
J:29170
|
increased susceptibility to Herpesvirales infection induced morbidity/mortality
|
J:29170
|
Ifngtm1Ts/Ifngtm1Ts
(B6.129S7-Ifngtm1Ts/J)
|
abnormal circulating cytokine level
|
J:47459
|
abnormal cytokine secretion
|
J:120556
|
abnormal dendritic cell antigen presentation
|
J:134949
|
abnormal dendritic cell chemotaxis
|
J:134949
|
abnormal dendritic cell physiology
|
J:134949
|
abnormal humoral immune response
|
J:45665
|
abnormal immune tolerance
|
J:45665
|
abnormal immunoglobulin level
|
J:45665
|
abnormal Langerhans cell physiology
|
J:134949
|
abnormal macrophage chemotaxis
|
J:136628
|
abnormal type IV hypersensitivity reaction
|
J:45665
|
decreased interferon-gamma secretion
|
J:120556
|
decreased interleukin-10 secretion
|
J:120556,
J:134949
|
decreased length of allograft survival
|
J:44346
|
glomerulonephritis
|
J:118730
|
increased circulating interleukin-6 level
|
J:47459
|
increased interleukin-4 secretion
|
J:120556
|
increased interleukin-12 secretion
|
J:134949
|
increased susceptibility to bacterial infection
|
J:47459
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:47459
|
increased susceptibility to parasitic infection
|
J:50832
|
increased susceptibility to parasitic infection induced morbidity/mortality
|
J:50832
|
increased susceptibility to type IV hypersensitivity reaction
|
J:118730
|
stomach inflammation
|
J:120556
|
Ifngtm1Ts/Ifngtm1Ts
(B6.129S7-Ifngtm1Ts)
|
abnormal B cell physiology
|
J:112084
|
abnormal cytokine secretion
|
J:18801,
J:110826
|
abnormal immunoglobulin level
|
J:18801
|
abnormal response to infection
|
J:18801,
J:110826
|
abnormal response to transplant
|
J:42090
|
decreased IgG2a level
|
J:18801
|
decreased IgG3 level
|
J:18801
|
increased IgE level
|
J:18801
|
increased IgG1 level
|
J:18801,
J:112048
|
increased interleukin-2 secretion
|
J:112048
|
increased interleukin-5 secretion
|
J:112048
|
increased interleukin-10 secretion
|
J:112048
|
increased susceptibility to Coronaviridae infection
|
J:112048
|
increased susceptibility to Coronaviridae infection induced morbidity/mortality
|
J:112048
|
increased susceptibility to parasitic infection
|
J:18801
|
increased susceptibility to parasitic infection induced morbidity/mortality
|
J:18801,
J:110826
|
Ifngtm1Ts/Ifngtm1Ts
(involves: 129S7/SvEvBrd * C57BL/6J)
|
increased susceptibility to bacterial infection
|
J:15723
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:15723
|
Ifngtm1Ts/Ifngtm1Ts
(C.129S7-Ifngtm1Ts)
|
abnormal cytokine secretion
|
J:110826
|
abnormal humoral immune response
|
J:45665
|
abnormal immune tolerance
|
J:45665
|
abnormal immunoglobulin level
|
J:45665
|
abnormal response to infection
|
J:110826
|
increased interleukin-5 secretion
|
J:110826
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:83180
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:34161
|
increased susceptibility to parasitic infection
|
J:110826
|
increased susceptibility to parasitic infection induced morbidity/mortality
|
J:110826
|
Ifngtm1Ts/Ifngtm1Ts
(involves: 129S7/SvEvBrd * BALB/c)
|
abnormal susceptibility to infection
|
J:39478
|
decreased IgE level
|
J:114213
|
decreased inflammatory response
|
J:114213
|
Ifngtm1Ts/Ifngtm1Ts
(involves: 129S7/SvEvBrd * DBA/1 * MRL/Mp)
|
decreased anti-double stranded DNA antibody level
|
J:39600
|
decreased anti-nuclear antigen antibody level
|
J:39600
|
decreased autoantibody level
|
J:39600
|
decreased IgA level
|
J:39600
|
decreased IgG2a level
|
J:39600
|
decreased IgG2b level
|
J:39600
|
decreased IgG3 level
|
J:39600
|
decreased IgM level
|
J:39600
|
decreased immunoglobulin level
|
J:39600
|
decreased susceptibility to autoimmune disorder
|
J:39600
|
Ifngtm1Ts/Ifngtm1Ts
(C.129S7(B6)-Ifngtm1Ts/J)
|
abnormal adaptive immunity
|
J:115144
|
abnormal circulating cytokine level
|
J:47459
|
abnormal cytokine secretion
|
J:115144
|
abnormal cytotoxic T cell physiology
|
J:115144
|
abnormal inflammatory response
|
J:115144
|
abnormal macrophage physiology
|
J:115144
|
abnormal NK cell physiology
|
J:115144
|
abnormal uterine NK cell physiology
|
J:56503
|
decreased susceptibility to parasitic infection
|
J:50832
|
increased circulating interleukin-6 level
|
J:47459
|
increased susceptibility to bacterial infection
|
J:47459
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:47459
|
Ifngtm1Ts/Ifngtm1Ts
(involves: 129S7/SvEvBrd * A/WySn * C57BL/10SnSg * Swiss)
|
decreased IgG2a level
|
J:119207
|
decreased IgG level
|
J:119207
|
decreased susceptibility to autoimmune disorder
|
J:119207
|
increased IgG1 level
|
J:119207
|
Ifngtm1Ts/Ifngtm1Ts Nlrp1aNeut1/Nlrp1aNeut1
(involves: 129S7/SvEvBrd * C57BL/6)
|
brain inflammation
|
J:191055
|
Ifngtm1Ts/Ifngtm1Ts Socs1tm1Jni/Socs1tm1Jni
(involves: 129S7/SvEvBrd)
|
increased interleukin-17 secretion
|
J:132905
|
Ifngtm1Ts/Ifngtm1Ts Tg(SFTPC-Il18)AThos/0
(involves: 129S7/SvEvBrd * C57BL/6 * C57BL/6N * DBA/2)
|
lung inflammation
|
J:147547
|
Ifngtm1Ts/Ifngtm1Ts Tgfb1tm1Doe/Tgfb1tm1Doe
(C.129-Ifngtm1Ts Tgfb1tm1Doe)
|
liver inflammation
|
J:69346
|
Ifngtm1Ts/Ifngtm1Ts Tnftm2Gkl/Tnf+
(involves: 129S/SvEv * 129S7/SvEvBrd * C57BL/6J)
|
small intestinal inflammation
|
J:108572
|
Ifngtm1Ts/Ifngtm1Ts Tnfrsf1atm1Blt/Tnfrsf1atm1Blt Tnfrsf1btm1Mwm/Tnfrsf1btm1Mwm
(involves: 129P2/OlaHsd * 129S2/SvPas * 129S7/SvEvBrd * C57BL/6)
|
increased susceptibility to fungal infection
|
J:119206
|
lung inflammation
|
J:119206
|
Ifngtm1Yiw/Ifngtm1Yiw
(involves: 129X1/SvJ * C57BL/6)
|
decreased inflammatory response
|
J:41632,
J:88226
|
Ifngtm1Yiw/Ifngtm1Yiw
(B6.129X1-Ifngtm1Yiw)
|
abnormal circulating interferon level
|
J:91691
|
increased susceptibility to Coronaviridae infection
|
J:91691,
J:50405
|
increased susceptibility to Coronaviridae infection induced morbidity/mortality
|
J:91691,
J:50405
|
liver inflammation
|
J:50405
|
peritoneal inflammation
|
J:50405
|
Ifngtm1Yiw/Ifngtm1Yiw
(C.129X1-Ifngtm1Yiw)
|
abnormal circulating interferon level
|
J:91691
|
increased susceptibility to Coronaviridae infection
|
J:91691
|
increased susceptibility to Coronaviridae infection induced morbidity/mortality
|
J:91691
|
Ifngr1m1Btlr/Ifngr1m1Btlr
(C57BL/6J-Ifngr1m1Btlr)
|
decreased tumor necrosis factor secretion
|
J:236694
|
Ifngr1tm1.1Rds/Ifngr1tm1.1Rds Commd10Tg(Vav1-icre)A2Kio/Commd10+
(B6NTac.Cg-Ifngr1tm1.1Rds Commd10Tg(Vav1-icre)A2Kio)
|
increased susceptibility to bacterial infection
|
J:206257
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:206257
|
Ifngr1tm1.1Rds/Ifngr1tm1.1Rds Tg(Itgax-cre,-EGFP)4097Ach/0
(B6NTac.Cg-Ifngr1tm1.1Rds Tg(Itgax-cre,-EGFP)4097Ach)
|
decreased interferon-gamma secretion
|
J:206257
|
decreased interleukin-12b secretion
|
J:206257
|
increased susceptibility to bacterial infection
|
J:206257
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:206257
|
Ifngr1tm1.1Rost/Ifngr1tm1.1Rost
(involves: BALB/cJ * C57BL/6)
|
abnormal chemokine level
|
J:152785
|
decreased circulating interferon-gamma level
|
J:152785
|
decreased circulating interleukin-12 level
|
J:152785
|
Ifngr1tm1.2Rds/Ifngr1tm1.2Rds
(C57BL/6NTac-Ifngr1tm1.2Rds)
|
decreased interleukin-12b secretion
|
J:206257
|
increased susceptibility to bacterial infection
|
J:206257
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:206257
|
Ifngr1tm1Agt/Ifngr1tm1Agt
(involves: 129S7/SvEvBrd)
|
abnormal immunoglobulin level
|
J:38363,
J:101427
|
abnormal response to infection
|
J:115139
|
abnormal uterine NK cell physiology
|
J:56503
|
aortitis
|
J:115139
|
arteritis
|
J:115139
|
decreased circulating tumor necrosis factor level
|
J:17878
|
decreased IgG2a level
|
J:38363
|
decreased susceptibility to endotoxin shock
|
J:17878
|
increased circulating interferon-gamma level
|
J:314959
|
increased circulating interleukin-1 beta level
|
J:314959
|
increased circulating interleukin-6 level
|
J:174397
|
increased interferon-gamma secretion
|
J:38363
|
increased susceptibility to bacterial infection
|
J:314959,
J:174397
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:314959,
J:174397
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:38363
|
increased susceptibility to Herpesvirales infection
|
J:81243
|
increased susceptibility to Herpesvirales infection induced morbidity/mortality
|
J:115139
|
increased susceptibility to parasitic infection
|
J:114203
|
increased susceptibility to Poxviridae infection
|
J:101427
|
increased tumor necrosis factor secretion
|
J:38363
|
Ifngr1tm1Agt/Ifngr1tm1Agt
(involves: 129S7/SvEvBrd * C57BL/6)
|
abnormal cytotoxic T cell physiology
|
J:63815
|
decreased IgG2a level
|
J:63815
|
decreased IgG3 level
|
J:63815
|
decreased susceptibility to experimental autoimmune myasthenia gravis
|
J:53577
|
increased interferon-gamma secretion
|
J:99347
|
increased interleukin-6 secretion
|
J:99347
|
increased splenocyte proliferation
|
J:99347
|
increased susceptibility to bacterial infection
|
J:63815
|
increased susceptibility to experimental autoimmune uveoretinitis
|
J:99347
|
increased susceptibility to Riboviria infection
|
J:63815
|
increased susceptibility to Riboviria infection induced morbidity/mortality
|
J:63815
|
Ifngr1tm1Agt/Ifngr1tm1Agt
(B6.129S7-Ifngr1tm1Agt/J)
|
abnormal circulating chemokine level
|
J:152785
|
decreased circulating interleukin-12 level
|
J:152785
|
decreased susceptibility to bacterial infection
|
J:147443
|
increased interferon-gamma secretion
|
J:138728
|
increased susceptibility to graft versus host disease
|
J:138728
|
Ifngr1tm1Agt/Ifngr1tm1Agt
(involves: 129S7/SvEvBrd * DBA/1OlaHsd)
|
decreased IgG2a level
|
J:40634
|
increased susceptibility to induced arthritis
|
J:40634
|
Ifngr1tm1Agt/Ifngr1tm1Agt Tg(GZMB-Tax)#Lera/0
(involves: 129S7/SvEvBrd * C57BL/6)
|
abnormal osteoclast physiology
|
J:147601
|
Ifngr1tm1Dmer/Ifngr1tm1Dmer
(B6.Cg-Ifngr1tm1Dmer)
|
abnormal response to infection
|
J:202844
|
Ifngr1tm1Dmer/Ifngr1tm1Dmer Tg(Thy1-cre)1Vln/0
(B6.Cg-Ifngr1tm1Dmer Tg(Thy1-cre)1Vln)
|
abnormal response to infection
|
J:202844
|
Ifngr2tm1Pbro/Ifngr2tm1Pbro
(involves: 129S1/Sv)
|
abnormal class switch recombination
|
J:48016
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:48016
|
increased susceptibility to bacterial infection
|
J:48016
|
Ifngr2tm1Pbro/Ifngr2tm1Pbro
(NOD.129S1-Ifngr2tm1Pbro)
|
abnormal cytotoxic T cell physiology
|
J:72818
|
abnormal diapedesis
|
J:72818
|
abnormal T-helper 2 physiology
|
J:65986
|
decreased susceptibility to autoimmune diabetes
|
J:72818
|
Ifnktm1.1(KOMP)Vlcg/Ifnktm1.1(KOMP)Vlcg
(C57BL/6NTac-Ifnktm1.1(KOMP)Vlcg)
|
decreased susceptibility to chemically induced skin inflammation
|
J:322130
|
Ifnl3em1Mtba/Ifnl3em1Mtba
(involves: C57BL/6)
|
abnormal circulating interferon level
|
J:287260
|
increased susceptibility to Orthomyxoviridae infection
|
J:287260
|
increased susceptibility to Riboviria infection
|
J:287260
|
increased susceptibility to viral infection
|
J:287260
|
Ifnlr1tm1b(EUCOMM)Wtsi/Ifnlr1tm1b(EUCOMM)Wtsi
(B6(Cg)-Ifnlr1tm1b(EUCOMM)Wtsi)
|
increased susceptibility to Orthomyxoviridae infection
|
J:287260
|
increased susceptibility to Riboviria infection
|
J:287260
|
increased susceptibility to viral infection
|
J:287260
|
Ifnlr1tm1Palu/Ifnlr1tm1Palu
(B6.Cg-Ifnlr1tm1Palu)
|
abnormal susceptibility to infection
|
J:131989
|
Igdcc4em1Bcgen/Igdcc4em1Bcgen
(involves: C57BL/6J)
|
decreased susceptibility to Orthomyxoviridae infection
|
J:320015
|
decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality
|
J:320015
|
Igf1rtm1Jcbr/Igf1rtm1Jcbr Ndor1Tg(UBC-cre/ERT2)1Ejb/0
(B6.Cg-Ndor1Tg(UBC-cre/ERT2)1Ejb Igf1rtm1Jcbr)
|
decreased susceptibility to type I hypersensitivity reaction
|
J:241924
|
Igf1rtm2Arge/Igf1rtm2Arge Tg(BGLAP-cre)1Clem/0
(involves: 129 * FVB/N)
|
abnormal osteoclast physiology
|
J:80190
|
Igfbp1tm1Taub/Igfbp1tm1Taub
(involves: 129X1/SvJ * C57BL/6)
|
liver inflammation
|
J:81123
|
Igh-7tm1.1Lam/Igh-7tm1.1Lam
(involves: BALB/c)
|
decreased IgE level
|
J:146733
|
Igh-7tm1Gach/Igh-7tm1Gach
(BALB/c-Igh-7tm1Gach)
|
enhanced B cell migration
|
J:143266
|
increased IgE level
|
J:143266
|
Igh-7tm1Lam/Igh-7tm1Lam
(involves: BALB/c)
|
decreased IgE level
|
J:146733
|
Igh-7tm1Lcwu/Igh-7tm1Lcwu
(involves: C57BL/6)
|
decreased IgE level
|
J:161452
|
Igh-7tm1Led/Igh-7tm1Led
(C.129S4-Igh-7tm1Led)
|
impaired eosinophil recruitment
|
J:133373
|
Igh-7tm1Led/Igh-7tm1Led Lyntm1Ard/Lyntm1Ard
(involves: 129P2/OlaHsd * 129S4/SvJae)
|
abnormal circulating complement protein level
|
J:161523
|
increased anti-double stranded DNA antibody level
|
J:161523
|
increased anti-nuclear antigen antibody level
|
J:161523
|
increased IgA level
|
J:161523
|
increased IgM level
|
J:161523
|
Igh-8tm1.1Aak/Igh-8tm1.1Aak
(involves: 129S2/SvPas * C57BL/6)
|
abnormal class switch recombination
|
J:171251
|
Igh-8tm1Aak/Igh-8tm1Aak
(involves: 129S2/SvPas * C57BL/6)
|
abnormal class switch recombination
|
J:107063
|
Igh-8tm1Schr/Igh-8tm1Schr
(involves: 129P2/OlaHsd * Black Swiss)
|
increased IgM level
|
J:49847
|
Igh-8tm1Schr/Igh-8tm1Schr
(C.129P2(BKSW)-Igh-8tm1Schr)
|
increased IgG level
|
J:75577
|
increased IgM level
|
J:75577
|
increased susceptibility to bacterial infection
|
J:75577
|
Igh-8tm2(Ighg1)Aak/Igh-8tm2(Ighg1)Aak
(involves: 129S2/SvPas)
|
abnormal class switch recombination
|
J:130574
|
decreased IgG3 level
|
J:130574
|
Igh-Jtm1(CB20)Riho/Igh-J+
(involves: C57BL/10 * DBA/1)
|
increased susceptibility to induced arthritis
|
J:179456
|
Igh-Jtm1(CB20)Riho/Igh-Jtm1(CB20)Riho
(involves: C57BL/10 * DBA/1)
|
increased susceptibility to induced arthritis
|
J:179456
|
Igh-Jtm1(Ighel)Cys/Igh-Jtm1(Ighel)Cys Myd88tm1Aki/Myd88tm1Aki Igkj1tm1(IgkHyHEL10)Mnz/0
(involves: 129P2/OlaHsd)
|
increased IgM level
|
J:115059
|
Igh-Jtm1(VDJ-KL25)Zbz/Igh-J+
(involves: C57BL/6 * C57BL/6J * BALB/cJ)
|
increased IgG level
|
J:86411
|
increased IgM level
|
J:86411
|
Igh-Jtm1(VDJ-VI10)Zbz/Igh-J+
(involves: C57BL/6 * C57BL/6J * BALB/cJ)
|
abnormal immune serum protein physiology
|
J:86411
|
Igh-Jtm1.1Lave/Igh-Jtm1.1Lave
(Not Specified)
|
abnormal immunoglobulin level
|
J:179317
|
decreased IgM level
|
J:155798
|
increased IgG level
|
J:155798
|
Igh-Jtm1.1Lave/Igh-Jtm1.1Lave Igk-Jtm1.1Lave/Igk-Jtm1.1Lave
(Not Specified)
|
abnormal B cell clonal deletion
|
J:179317
|
abnormal B cell physiology
|
J:205708
|
abnormal immunoglobulin level
|
J:179317
|
Igh-Jtm1Aigl/Igh-J+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:111543
|
Igh-Jtm1Aigl/Igh-J+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:111543
|
Igh-Jtm1Aigl/Igh-J+ Mogtm1Dpd/Mogtm1Dpd Tg(Tcra2D2,Tcrb2D2)1Kuch/0
(involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6)
|
CNS inflammation
|
J:151335
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:151335
|
Igh-Jtm1Aigl/Igh-J+ Tg(Tcra2D2,Tcrb2D2)1Kuch/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
CNS inflammation
|
J:151335
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:151335
|
Igh-Jtm1Aigl/Igh-Jtm1Aigl Tg(H2-Kb-Tcra,-Tcrb)1640Kurs/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/N * SJL/J)
|
increased autoantibody level
|
J:149511
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:149511
|
Igh-Jtm1Dhu/Igh-J+ Il2tm1Hor/Il2tm1Hor
(involves: 129/Sv * C57BL/6)
|
colitis
|
J:29999
|
Igh-Jtm1Dhu/Igh-Jtm1Dhu Il2tm1Hor/Il2tm1Hor
(involves: 129/Sv * C57BL/6)
|
colitis
|
J:29999
|
Igh-Jtm1Dhu/Igh-Jtm1Dhu Wdr1rede/Wdr1rede
(involves: 129S7/SvEvBrd * BALB/c * C57BL/6)
|
abnormal immune system physiology
|
J:134092
|
Igh-Jtm1Dim/Igh-J+ Igk-Jtm1Dim/Igk-J+
(involves: 129S4/SvJae * C57BL/6)
|
increased IgG level
|
J:107241
|
increased IgM level
|
J:107241
|
Igh-Jtm1Jkbv/Igh-Jtm1Jkbv
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased IgM level
|
J:70038
|
Igh-Jtm1Jkbv/Igh-Jtm1Jkbv Igkctm1Jkbv/Igkctm1Jkbv Tg(IGH@yH1)2BJkbv/0 Tg(IGK@yK1)9.2CJkbv/0
(involves: 129P2/OlaHsd)
|
abnormal immunoglobulin level
|
J:23827
|
Igh-Jtm1Jkbv/Igh-Jtm1Jkbv Igkctm1Jkbv/Igkctm1Jkbv Tg(IGH@yH1)2BJkbv/Tg(IGH@yH1)2BJkbv Tg(IGK@yK1)9.2CJkbv/Tg(IGK@yK1)9.2CJkbv
(involves: 129P2/OlaHsd)
|
abnormal immunoglobulin level
|
J:137738
|
Igh-Jtm1Jkbv/Igh-Jtm1Jkbv Igkctm1Jkbv/Igkctm1Jkbv Tg(IGH@yH2)J9.2Jkbv/0 Tg(IGK@yK2)J23.1Jkbv/0
(involves: 129P2/OlaHsd * C57BL/6J)
|
abnormal immunoglobulin level
|
J:70620
|
Igh-Jtm1Jkbv/Igh-Jtm1Jkbv Igkctm1Jkbv/Igkctm1Jkbv Tg(IGH@yH2)J9.2Jkbv/0 Tg(IGK@yK2)J23.1Jkbv/Tg(IGK@yK2)J23.1Jkbv
(involves: 129P2/OlaHsd)
|
abnormal immunoglobulin level
|
J:137738
|
Igh-Jtm1Jkbv/Igh-Jtm1Jkbv Igkctm1Jkbv/Igkctm1Jkbv Tg(IGH@yH2BM)7Amgn/0 Tg(IGK@yK2)J23.1Jkbv/0
(involves: 129P2/OlaHsd)
|
abnormal immunoglobulin level
|
J:139792
|
Igh-Jtm1Jkbv/Igh-Jtm1Jkbv Igkctm1Jkbv/Igkctm1Jkbv Tg(IGH@yH2CM)2Amgn/0 Tg(IGK@yK2)J23.1Jkbv/0
(involves: 129P2/OlaHsd)
|
abnormal immunoglobulin level
|
J:139792
|
Igh-Jtm1Jkbv/Igh-Jtm1Jkbv Igkctm1Jkbv/Igkctm1Jkbv Tg(IGH@yHG1/2)1Amgn/0 Tg(IGK@yK2)J23.1Jkbv/0
(involves: 129P2/OlaHsd)
|
abnormal immunoglobulin level
|
J:139792
|
Igh-Jtm1Jkbv/Igh-Jtm1Jkbv Igkctm1Jkbv/Igkctm1Jkbv Tg(IGH@yHG4)1Amgn/0 Tg(IGK@yK2)J23.1Jkbv/0
(involves: 129P2/OlaHsd)
|
abnormal immunoglobulin level
|
J:139792
|
Igh-Jtm1Jkbv/Igh-Jtm1Jkbv Tg(IGH@yH1)2BJkbv/0 Tg(IGK@yK1)9.2CJkbv/0
(involves: 129P2/OlaHsd)
|
abnormal immunoglobulin level
|
J:23827
|
Igh-Jtm1Jkbv/Igh-Jtm1Jkbv Tg(IGH@yH1)2BJkbv/Tg(IGH@yH1)2BJkbv
(involves: 129P2/OlaHsd)
|
abnormal immunoglobulin level
|
J:137738
|
Igh-Jtm1Jkbv/Igh-Jtm1Jkbv Tg(IGH@yH2)J9.2Jkbv/0
(involves: 129P2/OlaHsd)
|
abnormal immunoglobulin level
|
J:137738
|
Igh-Jtm1Mcdl/Igh-Jtm1Mcdl Igk-Jtm1Mcdl/Igk-Jtm1Mcdl Rag1tm1Mom/Rag1tm1Mom Tg(DO11.10)10Dlo/?
(involves: 129S/Sv * BALB/c * C3H * C57BL/6)
|
increased IgE level
|
J:100072
|
increased IgG level
|
J:100072
|
Igh-Jtm2(3H9-VDJ*)Mwg/Igh-J+
(involves: 129P2/OlaHsd * BALB/c * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:126940
|
Igh-Jtm2(3H9-VDJ*)Mwg/Igh-J+
(involves: 129P2/OlaHsd * BALB/c)
|
increased anti-double stranded DNA antibody level
|
J:131138
|
Igh-Jtm2(3H9-VDJ*)Mwg/Igh-J+
(B6.129P2-Igh-Jtm2(3H9-VDJ*)Mwg)
|
increased anti-double stranded DNA antibody level
|
J:142389
|
Igh-Jtm2.1(4E10)Lave/Igh-Jtm2.1(4E10)Lave
(involves: C57BL/6)
|
decreased IgG1 level
|
J:205708
|
decreased IgG2b level
|
J:205708
|
decreased IgG3 level
|
J:205708
|
decreased IgG level
|
J:205708
|
decreased IgM level
|
J:205708
|
Igh-Jtm2.1(4E10)Lave/Igh-Jtm2.1(4E10)Lave Igk-Jtm2.1(4E10)Lave/Igk-Jtm2.1(4E10)Lave
(involves: C57BL/6)
|
abnormal B cell physiology
|
J:205708
|
Igh-Jtm3(3H9-VDJ*)Mwg/Igh-Jtm3(3H9-VDJ*)Mwg
(involves: 129P2/OlaHsd * BALB/c * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:126940
|
Igh-Jtm3.1(48d)Lave/Igh-Jtm3.1(48d)Lave
(involves: C57BL/6)
|
decreased IgG1 level
|
J:205708
|
decreased IgG2b level
|
J:205708
|
decreased IgM level
|
J:205708
|
Igh-Vtm1Jjk/Igh-Vtm1Jjk
(involves: 129S4/SvJae * C57BL/6)
|
abnormal adaptive immunity
|
J:62284
|
increased susceptibility to bacterial infection
|
J:62284
|
IghdeltaD/Igh+
(involves: C57BL/6 * DBA/2)
|
decreased immunoglobulin level
|
J:95981
|
IghdeltaD/IghdeltaD
(involves: C57BL/6 * DBA/2)
|
abnormal immunoglobulin level
|
J:95981
|
decreased IgG1 level
|
J:95981
|
increased IgA level
|
J:95981
|
Ightm1(Ighppc1-5)Cche/Igh+
(B6.Cg-Ightm1(Ighppc1-5)Cche)
|
increased autoantibody level
|
J:138356
|
Ightm1(Myc)Janz/Igh+
(involves: 129X1/SvJ * C57BL/6)
|
increased B cell apoptosis
|
J:96785
|
increased B cell proliferation
|
J:96785
|
Ightm1(Myc)Janz/Igh+ Mdm4tm1.1Wahl/Mdm4tm1.1Wahl
(involves: 129S/Sv * C57BL/6)
|
increased splenocyte proliferation
|
J:150341
|
Ightm1.1(b12)Nemz/Ightm1.1(b12)Nemz
(involves: C57BL/6N * FVB/N)
|
decreased IgM level
|
J:205766
|
Ightm1.1(b12)Nemz/Ightm1.1(b12)Nemz Igktm1.1(b12)Nemz/Igktm1.1(b12)Nemz
(involves: C57BL/6N * C57BL/6NTac * FVB/N)
|
decreased IgM level
|
J:205766
|
Ightm1.1(Igh564)Tik/Ightm1.1(Igh564)Tik Igktm1(Igk564)Tik/Igktm1(Igk564)Tik
(B6.129S4-Igktm1(Igk564)Tik Ightm1(Igh564)Tik)
|
glomerulonephritis
|
J:113555
|
Ightm1.1(Rr361-HBB)Aak/Ightm1.1(Rr361-HBB)Aak
(129.129S2(Cg)-Ightm1.1(Rr361-HBB)Aak)
|
abnormal class switch recombination
|
J:333279
|
decreased IgA level
|
J:333279
|
decreased IgE level
|
J:333279
|
decreased IgG1 level
|
J:333279
|
decreased IgG2a level
|
J:333279
|
decreased IgG2b level
|
J:333279
|
Ightm1.1Hws/Ightm1.1Hws
(BALB/cJ-Ightm1.1Hws)
|
decreased IgM level
|
J:119391
|
decreased immunoglobulin level
|
J:119391
|
Ightm1.1Hws/Ightm1.1Hws
(involves: BALB/c)
|
increased IgG3 level
|
J:142069
|
increased IgM level
|
J:142069
|
Ightm1.1Rsky/Ightm1.1Rsky
(BALB/c-Ightm1.1Rsky)
|
abnormal class switch recombination
|
J:125719
|
decreased IgM level
|
J:125719
|
Ightm1.1Twin/Ightm1.1Twin
(involves: 129 * 129S4/SvJae * C57BL/6)
|
abnormal marginal zone B cell physiology
|
J:174233
|
decreased IgG3 level
|
J:174233
|
decreased IgG level
|
J:174233
|
decreased IgM level
|
J:174233
|
Ightm1.1Vmd/Igh+
(involves: C57BL/6)
|
abnormal class switch recombination
|
J:201147
|
Ightm1.1Vmd/Ightm1.1Vmd
(involves: C57BL/6)
|
abnormal class switch recombination
|
J:201147
|
decreased IgG1 level
|
J:201147
|
decreased IgG3 level
|
J:201147
|
increased IgE level
|
J:201147
|
Ightm1.2Rsky/Igh+
(BALB/c-Ightm1.2Rsky)
|
increased IgG1 level
|
J:125719
|
Ightm1.2Rsky/Ightm1.2Rsky
(BALB/c-Ightm1.2Rsky)
|
abnormal B cell activation
|
J:125719
|
abnormal B cell proliferation
|
J:125719
|
decreased IgA level
|
J:125719
|
decreased IgD level
|
J:125719
|
decreased IgE level
|
J:125719
|
decreased IgM level
|
J:125719
|
decreased immunoglobulin level
|
J:125719
|
Ightm1.2Rsky/Ightm1.2Rsky Tg(CD19-cre/ERT2)1Cgn/?
(involves: BALB/c)
|
abnormal B cell activation
|
J:125719
|
abnormal class switch recombination
|
J:125719
|
Ightm1Cog/Ightm1Cog
(involves: 129S2/SvPas * C57BL/6)
|
decreased IgA level
|
J:80654
|
decreased IgE level
|
J:80654
|
decreased IgG1 level
|
J:80654
|
decreased IgG2a level
|
J:80654
|
decreased IgG2b level
|
J:80654
|
decreased IgG3 level
|
J:80654
|
decreased IgM level
|
J:80654
|
decreased immunoglobulin level
|
J:80654
|
Ightm1Cys/Igh+ Tg(Igk)5Cys/0
(B6.Cg-Ightm1Cys Tg(Igk)5Cys)
|
abnormal B cell physiology
|
J:118931
|
Ightm1Ktom/Ightm1Ktom
(involves: ICR)
|
abnormal B cell physiology
|
J:59894
|
abnormal immunoglobulin level
|
J:178635
|
Ightm1Ktom/Ightm1Ktom Igktm1Ktom/Igktm1Ktom Tc(HSA14)SC20Ktom/0 Tc(HSA2)W23Ktom/0
(involves: C57BL/6NCrlj * CBA/JNCrlj * ICR)
|
abnormal B cell physiology
|
J:59894
|
Ightm1Ktom/Ightm1Ktom Tc(HSA2)W23Ktom/0
(involves: C57BL/6NCrlj * CBA/JNCrlj * ICR)
|
abnormal B cell physiology
|
J:59894
|
Ightm1Mnz/Ightm1Mnz
(B6.129P2-Ightm1Mnz)
|
abnormal B cell physiology
|
J:75653
|
increased B cell apoptosis
|
J:75653
|
increased B cell proliferation
|
J:75653
|
increased IgG level
|
J:75653
|
increased IgM level
|
J:75653
|
Ightm1Mnz/Ightm1Mnz Dis3tm1.1Uba/Dis3tm1.1Uba Aicdatm1(cre)Uba/Aicda+
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6)
|
abnormal somatic hypermutation frequency
|
J:302856
|
Ightm1Mnz/Ightm1Mnz Lyntm1Sor/Lyntm1Sor
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6)
|
abnormal B cell physiology
|
J:75653
|
increased B cell proliferation
|
J:75653
|
Ightm1Rbr/Igh+ Tg(IgkHyHEL10)1Rbr/0
(involves: C57BL/6)
|
increased IgA level
|
J:132538
|
increased IgG1 level
|
J:132538
|
increased IgG2a level
|
J:132538
|
increased IgG2b level
|
J:132538
|
increased IgG3 level
|
J:132538
|
increased IgM level
|
J:132538
|
increased immunoglobulin level
|
J:132538
|
Ightm1Rbr/Igh+ Tg(IgkHyHEL10)1Rbr/0 Tg(ML5sHEL)5Ccg/0
(involves: C57BL/6 * C57BL/6JSfd)
|
abnormal B cell anergy
|
J:132538
|
Ightm2.1(4E10)Nemz/Ightm2.1(4E10)Nemz Igktm2.1(4E10)Nemz/Igktm2.1(4E10)Nemz
(involves: C57BL/6 * C57BL/6N * C57BL/6NTac * FVB/N)
|
decreased IgG level
|
J:101977
|
decreased IgM level
|
J:101977
|
Ightm2.1Fwa/Ightm2.1Fwa
(involves: 129S/SvEv * C57BL/6)
|
abnormal class switch recombination
|
J:161437
|
abnormal somatic hypermutation frequency
|
J:161437
|
decreased IgG1 level
|
J:161437
|
increased IgE level
|
J:161437
|
Ightm2.1Hws/Ightm2.1Hws
(involves: BALB/c * C57BL/6NCrl * DBA/2NCrl)
|
abnormal humoral immune response
|
J:124421
|
decreased IgG level
|
J:124421
|
decreased IgM level
|
J:124421
|
Ightm2.1Hws/Ightm2.1Hws
(involves: BALB/c)
|
decreased IgM level
|
J:142069
|
increased anti-nuclear antigen antibody level
|
J:142069
|
Ightm2Cgn/Igh+ Igktm2Rsky/Igk+
(involves: 129P2/OlaHsd)
|
abnormal class switch recombination
|
J:150435
|
Ightm2Cgn/Igh+ Igktm2Rsky/Igk+ Prkdcscid/Prkdcscid
(involves: 129P2/OlaHsd * BALB/c * C57BL/Ka)
|
abnormal class switch recombination
|
J:150435
|
Ightm2Cgn/Igh+ Rr158tm1Cgn/Rr158tm1Cgn Arhgef1tm1.1Rmt/Arhgef1tm1.1Rmt
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal B cell migration
|
J:113295
|
Ightm2Cgn/Ightm2Cgn Igktm1Rsky/Igktm1Rsky Lig4tm1Fwa/Lig4tm1Fwa Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129P2/OlaHsd * 129S2/SvPas * 129S6/SvEvTac)
|
abnormal class switch recombination
|
J:126758
|
Ightm2Cgn/Ightm2Cgn Igktm1Rsky/Igktm1Rsky Trp53tm1Tyj/Trp53tm1Tyj Xrcc4tm1Fwa/Xrcc4tm1Fwa
(involves: 129P2/OlaHsd * 129S2/SvPas * 129S6/SvEvTac)
|
abnormal class switch recombination
|
J:126758
|
Ightm2Mnz/Ightm2Mnz
(B6.129P2-Ightm2Mnz)
|
increased B cell proliferation
|
J:75653
|
increased IgG level
|
J:75653
|
increased IgM level
|
J:75653
|
Ightm2Mnz/Ightm2Mnz Lyntm1Sor/Lyntm1Sor
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6)
|
abnormal B cell physiology
|
J:75653
|
increased B cell proliferation
|
J:75653
|
Ightm3Cgn/Ightm3Cgn
(involves: C57BL/6)
|
abnormal immune system physiology
|
J:76117
|
Ightm3Hws/Ightm3Hws
(involves: BALB/c)
|
abnormal immunoglobulin level
|
J:142069
|
decreased IgG1 level
|
J:142069
|
decreased IgG2a level
|
J:142069
|
decreased IgG2b level
|
J:142069
|
decreased IgM level
|
J:142069
|
increased IgM level
|
J:142069
|
Ightm4.1Cog/Ightm4.1Cog
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
abnormal class switch recombination
|
J:184094
|
decreased IgA level
|
J:184094
|
increased IgM level
|
J:184094
|
Ightm4Cog/Igh+
(involves: 129S2/SvPas * C57BL/6)
|
decreased IgM level
|
J:109988
|
increased IgA level
|
J:109988
|
Ightm5.1Cgn/Ightm5.1Cgn
(BALB/c-Ightm5.1Cgn)
|
abnormal B cell activation
|
J:88472
|
Ightm7(VHB1-8)Cgn/Igh+
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal somatic hypermutation frequency
|
J:48835
|
Ightm8(VHB1-8)Cgn/Igh+
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal somatic hypermutation frequency
|
J:48835
|
Ightm9(VHB1-8)Cgn/Igh+
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal somatic hypermutation frequency
|
J:48835
|
Ightm12Cgn/Ightm12Cgn
(involves: 129P2/OlaHsd)
|
abnormal somatic hypermutation frequency
|
J:66031
|
Ighatm1(Myc)Janz/Igha+
(involves: 129S1/Sv * C57BL/6)
|
increased B cell apoptosis
|
J:90901
|
increased B cell proliferation
|
J:90901
|
Ighatm1(Myc)Janz/Igha+ Tg(Igk-V21-Bax)1967Bvn/0
(involves: 129S1/Sv * C57BL/6 * FVB/N)
|
abnormal B cell apoptosis
|
J:90901
|
increased IgG level
|
J:90901
|
increased IgM level
|
J:90901
|
Ighatm1Grh/Ighatm1Grh
(involves: 129S7/SvEvBrd * C57BL/6)
|
abnormal dendritic cell physiology
|
J:125472
|
abnormal immunoglobulin level
|
J:125472
|
abnormal memory T cell physiology
|
J:125472
|
abnormal T cell activation
|
J:53217
|
decreased IgA level
|
J:53217,
J:125472
|
decreased IgE level
|
J:53217
|
decreased IgG3 level
|
J:53217
|
decreased interferon-gamma secretion
|
J:53217
|
decreased T cell proliferation
|
J:125472
|
increased IgG1 level
|
J:53217,
J:125472
|
increased IgG2a level
|
J:53217
|
increased IgG2b level
|
J:53217
|
increased IgG level
|
J:53217
|
increased IgM level
|
J:53217,
J:125472
|
increased interferon-gamma secretion
|
J:125472
|
increased interleukin-4 secretion
|
J:53217
|
increased susceptibility to Orthomyxoviridae infection
|
J:125472
|
Ighatm1Grh/Ighatm1Grh
(involves: 129 * C57BL/6)
|
increased susceptibility to parasitic infection
|
J:140515,
J:74568
|
Ighatm2Grh/Ighatm2Grh
(involves: 129S7/SvEvBrd * C57BL/6)
|
abnormal class switch recombination
|
J:72521
|
Ighddmit/Ighddmit
(C57BL/6JAnu-Ighddmit/AnuApb)
|
abnormal immunoglobulin level
|
J:104190
|
IghdM1Btlr/IghdM1Btlr
(C57BL/6J-IghdM1Btlr)
|
decreased IgD level
|
J:255202
|
Ighdm2Btlr/Ighdm2Btlr
(C57BL/6J-Ighdm2Btlr)
|
decreased IgD level
|
J:255203
|
Ighdtm1Cgn/Ighdtm1Cgn
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal immune system physiology
|
J:64281
|
decreased IgE level
|
J:64281
|
Ighdtm1Lam/Ighdtm1Lam
(involves: 129S2/SvPas * C57BL/6)
|
abnormal B cell physiology
|
J:111020
|
decreased IgG2b level
|
J:111020
|
increased IgA level
|
J:111020
|
IgheM1Btlr/IgheM1Btlr
(C57BL/6J-IgheM1Btlr)
|
decreased IgE level
|
J:267480
|
Ighg1em1Wliu/Ighg1em1Wliu
(C57BL/6-Ighg1em1Wliu)
|
enhanced humoral immune response
|
J:266937
|
increased anti-double stranded DNA antibody level
|
J:266937
|
increased anti-nuclear antigen antibody level
|
J:266937
|
increased autoantibody level
|
J:266937
|
increased IgG1 level
|
J:266937
|
Ighg1tm1(cre)Cgn/Ighg1+ Irf4tm1Rdf/Irf4tm1.1Rdf
(involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6)
|
abnormal class switch recombination
|
J:112643
|
decreased IgG1 level
|
J:112643
|
Ighg1tm1(cre)Cgn/Ighg1+ Myd88em1.1Rsky/Myd88+
(involves: 129P2/OlaHsd * C57BL/6NTac)
|
abnormal somatic hypermutation frequency
|
J:308792
|
increased IgM level
|
J:308792
|
Ighg1tm1.1Ksho/Ighg1+
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal B cell physiology
|
J:39568
|
decreased IgG1 level
|
J:39568
|
Ighg1tm1.1Ksho/Ighg1tm1.1Ksho
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal B cell physiology
|
J:39568
|
decreased IgG1 level
|
J:39568
|
Ighg1tm1.1Pyu/Ighg1+
(B6.C(Cg)-Ighg1tm1.1Pyu)
|
decreased IgG1 level
|
J:198154
|
decreased IgG2c level
|
J:198154
|
increased IgE level
|
J:198154
|
increased IgG2a level
|
J:198154
|
increased susceptibility to type I hypersensitivity reaction
|
J:198154
|
Ighg1tm1.1Pyu/Ighg1tm1.1Pyu
(B6.C(Cg)-Ighg1tm1.1Pyu)
|
decreased IgG1 level
|
J:198154
|
decreased IgG2c level
|
J:198154
|
increased IgE level
|
J:198154
|
increased IgG2a level
|
J:198154
|
increased IgG2b level
|
J:198154
|
increased susceptibility to type I hypersensitivity reaction
|
J:198154
|
Ighg1tm1Ksho/Ighg1+
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal B cell physiology
|
J:39568
|
decreased IgG1 level
|
J:39568
|
Ighg1tm1Ksho/Ighg1tm1Ksho
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal B cell physiology
|
J:39568
|
decreased IgG1 level
|
J:39568
|
Ighg1tm2Cgn/Ighg1+
((C57BL/6 x 129P2/OlaHsd)F1)
|
abnormal class switch recombination
|
J:146428
|
decreased IgG1 level
|
J:146428
|
Ighg1tm3Cgn/Ighg1+
(involves: 129P2/OlaHsd * BALB/c * C57BL/6)
|
abnormal class switch recombination
|
J:166887
|
decreased IgG1 level
|
J:166887
|
Ighg2cem1Wliu/Ighg2cem1Wliu
(C57BL/6J-Ighg2cem1Wliu)
|
abnormal dendritic cell physiology
|
J:322180
|
abnormal macrophage activation involved in immune response
|
J:322180
|
abnormal macrophage physiology
|
J:322180
|
decreased susceptibility to induced colitis
|
J:322180
|
increased IgG2c level
|
J:322180
|
Ighg2cem2Wliu/Ighg2cem2Wliu
(C57BL/6J-Ighg2cem2Wliu)
|
abnormal macrophage activation involved in immune response
|
J:322180
|
decreased IgG2c level
|
J:322180
|
impaired macrophage phagocytosis
|
J:322180
|
Ighmtm1(Bcl6)Rdf/?
(involves: 129/Sv * C57BL/6)
|
abnormal B cell proliferation
|
J:98937
|
decreased immunoglobulin level
|
J:98937
|
Ighmtm1.1(IGH-2)Cog/Ighmtm1.1(IGH-2)Cog
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
decreased B cell proliferation
|
J:157575
|
decreased IgA level
|
J:157575
|
decreased IgG1 level
|
J:157575
|
decreased IgG2a level
|
J:157575
|
decreased IgG3 level
|
J:157575
|
decreased IgG level
|
J:157575
|
decreased IgM level
|
J:157575
|
increased B cell proliferation
|
J:157575
|
Ighmtm1.1Aak/Ighmtm1.1Aak
(involves: 129S2/SvPas * C57BL/6)
|
abnormal class switch recombination
|
J:171251
|
Ighmtm1Bhe/Ighmtm1Bhe
(C.Cg-Ighmtm1Bhe)
|
abnormal complement pathway
|
J:177421
|
abnormal immune serum protein physiology
|
J:177421
|
impaired complement classical pathway
|
J:177421
|
Ighmtm1Cgn/Ighm+
(NOD.129S2-Ighmtm1Cgn)
|
increased susceptibility to autoimmune diabetes
|
J:37287
|
Ighmtm1Cgn/Ighm+ Tg(Igh-6/Igh-V125)2Jwt/0 Tg(Igk-C/Igk-V125)1Jwt/0
(NOD.Cg-Ighmtm1Cgn Tg(Igh-6/Igh-V125)2Jwt Tg(Igk-C/Igk-V125)1Jwt)
|
increased susceptibility to autoimmune diabetes
|
J:91865
|
insulitis
|
J:91865
|
Ighmtm1Cgn/Ighm+ Tg(Igh-6/Igh-V281)3Jwt/0
(NOD.Cg-Ighmtm1Cgn Tg(Igh-6/Igh-V281)3Jwt)
|
insulitis
|
J:91865
|
Ighmtm1Cgn/Ighmtm1Cgn
(involves: 129S2/SvPas * C57BL/6)
|
abnormal response to infection
|
J:119344
|
decreased IgM level
|
J:64298
|
Ighmtm1Cgn/Ighmtm1Cgn
(NODCaj.129S2-Ighmtm1Cgn)
|
insulitis
|
J:93190
|
Ighmtm1Cgn/Ighmtm1Cgn
(NOD.129S2-Ighmtm1Cgn)
|
decreased susceptibility to autoimmune diabetes
|
J:37287
|
Ighmtm1Cgn/Ighmtm1Cgn
(B6.129S2-Ighmtm1Cgn/J)
|
abnormal cytokine secretion
|
J:118565
|
abnormal humoral immune response
|
J:119584
|
decreased IgE level
|
J:125656
|
decreased IgG1 level
|
J:125656
|
decreased IgG level
|
J:119584,
J:125656
|
decreased immunoglobulin level
|
J:119584
|
increased susceptibility to parasitic infection
|
J:74568
|
Ighmtm1Cgn/Ighmtm1Cgn
(involves: 129S2/SvPas)
|
abnormal antigen presentation
|
J:112160
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:112160
|
decreased IgA level
|
J:157450
|
decreased IgG level
|
J:157450
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:112160
|
decreased T cell proliferation
|
J:112160
|
increased susceptibility to induced arthritis
|
J:157619
|
increased susceptibility to parasitic infection
|
J:163761
|
Ighmtm1Cgn/Ighmtm1Cgn
(NOD.129S2-Ighmtm1Cgn/DvsJ)
|
abnormal T cell proliferation
|
J:80859
|
decreased susceptibility to autoimmune diabetes
|
J:80859
|
Ighmtm1Cgn/Ighmtm1Cgn Igkctm1Bgmn/Igkctm1Bgmn Igltm2.1Bgmn/Igltm2.1Bgmn
(involves: 129)
|
decreased IgG level
|
J:130864
|
decreased IgM level
|
J:130864
|
Ighmtm1Cgn/Ighmtm1Cgn Tg(Igh-6/Igh-V125)2Jwt/0 Tg(Igk-C/Igk-V125)1Jwt/0
(NOD.Cg-Ighmtm1Cgn Tg(Igh-6/Igh-V125)2Jwt Tg(Igk-C/Igk-V125)1Jwt)
|
insulitis
|
J:91865
|
Ighmtm1Cgn/Ighmtm1Cgn Tg(Igh-6/Igh-V281)3Jwt/0
(NOD.Cg-Ighmtm1Cgn Tg(Igh-6/Igh-V281)3Jwt)
|
insulitis
|
J:91865
|
Ighmtm1Cgn/Ighmtm1Cgn Tg(Igh-VB1-8/Igh-6m)1Mjsk/?
(NODCaj.Cg-Ighmtm1Cgn Tg(Igh-VB1-8/Igh-6m)1Mjsk/FswJ)
|
increased susceptibility to autoimmune diabetes
|
J:93190
|
Ighmtm1Cgn/Ighmtm1Cgn Tg(IghelMD4)4Ccg/Tg(IghelMD4)4Ccg
(NOD.Cg-Ighmtm1Cgn Tg(IghelMD4)4Ccg/DvsJ)
|
abnormal B lymphocyte antigen presentation
|
J:80859
|
abnormal T cell proliferation
|
J:80859
|
decreased susceptibility to autoimmune diabetes
|
J:80859
|
insulitis
|
J:80859
|
Ighmtm1Cgn/Ighmtm1Cgn Tgfb1tm1Doe/Tgfb1tm1Doe
(involves: 129S2/SvPas * C57BL/6 * CF-1)
|
abnormal inflammatory response
|
J:99033
|
Ighmtm1Cgn/Ighmtm1Cgn Tnftm2Gkl/Tnf+
(involves: 129S/SvEv * 129S2/SvPas * C57BL/6J)
|
small intestinal inflammation
|
J:108572
|
Ighmtm1Cgn/Ighmtm1Cgn Trex1tm1Tld/Trex1tm1Tld
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
|
increased inflammatory response
|
J:181257
|
kidney inflammation
|
J:181257
|
myocarditis
|
J:181257
|
tubular nephritis
|
J:181257
|
Ighmtm1Cgn/Ighmtm1Cgn X/Yaa
(BXSB.129S2(B6)-Ighmtm1Cgn/Dcr)
|
decreased susceptibility to systemic lupus erythematosus
|
J:206236
|
Ighmtm1Che/Ighmtm1Che
(involves: 129S4/SvJae * C57BL/6)
|
abnormal B cell physiology
|
J:47425
|
abnormal follicular dendritic cell antigen presentation
|
J:47425
|
abnormal humoral immune response
|
J:47425
|
abnormal immune system physiology
|
J:47425
|
decreased IgG1 level
|
J:47425
|
decreased IgG2b level
|
J:47425
|
decreased IgM level
|
J:47425
|
increased IgA level
|
J:47425
|
increased IgG2a level
|
J:47425
|
increased IgG3 level
|
J:47425
|
Ighmtm1Che/Ighmtm1Che
(involves: 129 * C57BL/6)
|
increased susceptibility to parasitic infection
|
J:74568
|
Ighmtm1Fbb/Ighmtm1Fbb
(involves: BALB/cJ)
|
increased susceptibility to Riboviria infection
|
J:57600
|
Ighmtm1Msn/Ighm+
(involves: 129S/SvEv)
|
decreased IgM level
|
J:49405
|
Ighmtm1Msn/Ighmtm1Msn
(involves: 129S/SvEv)
|
decreased IgG1 level
|
J:49405
|
decreased IgM level
|
J:49405
|
increased IgG3 level
|
J:49405
|
Ighmtm1Msn/Ighmtm1Msn
(involves: 129S/SvEv * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:111817
|
increased autoantibody level
|
J:111817
|
kidney inflammation
|
J:111817
|
Ighmtm1Msn/Ighmtm1Msn
(B6.129S-Ighmtm1Msn)
|
decreased IgM level
|
J:80656
|
Ighmtm1Msn/Ighmtm1Msn Tg(Igh-6)1Msn/?
(B6.129S-Ighmtm1Msn)
|
decreased IgM level
|
J:80656
|
Ighmtm1Sls/Ighmtm1Sls
(Not Specified)
|
abnormal class switch recombination
|
J:99465
|
decreased IgG1 level
|
J:99465
|
decreased IgG2b level
|
J:99465
|
decreased IgG3 level
|
J:99465
|
decreased IgG level
|
J:99465
|
increased IgM level
|
J:99465
|
Ighmtm2.1Bgmn/Ighmtm2.1Bgmn
(involves: 129/Sv * C57BL/6 * CBA)
|
abnormal immune system physiology
|
J:118453
|
decreased immunoglobulin level
|
J:118453
|
Ighmtm3Bgmn/Ighmtm3Bgmn
(involves: 129)
|
abnormal B cell activation
|
J:131633
|
decreased B cell proliferation
|
J:131633
|
decreased IgM level
|
J:131633
|
Ighmtm3Bgmn/Ighmtm3Bgmn Igkctm1Bgmn/Igkctm1Bgmn Igltm2.1Bgmn/Igltm2.1Bgmn
(involves: 129P2/OlaHsd * 129/Sv)
|
decreased IgG level
|
J:130864
|
decreased IgM level
|
J:130864
|
Ighmtm4Bgmn/Ighmtm4Bgmn
(involves: 129)
|
abnormal B cell activation
|
J:131633
|
decreased B cell proliferation
|
J:131633
|
decreased IgM level
|
J:131633
|
Igk-Jtm1Cog/Igk-Jtm1Cog
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal B cell physiology
|
J:110100
|
Igktm1Dhu/Igktm1Dhu Tg(H2-Ea-HA)HACIIAjca/0 Tg(Tcra/Tcrb)1Vbo/0
(C.Cg-Igktm1Dhu Tg(H2-Ea-HA)HACIIAjca Tg(Tcra/Tcrb)1Vbo)
|
autoimmune arthritis
|
J:209872
|
Igktm1Dhu/Igktm1Dhu Tg(H2-Ea-HA)HACIIAjca/0 Tg(TcraS106-1,TcrbS106-1)TS1SWAjca/0
(C.Cg-Igktm1Dhu Tg(H2-Ea-HA)HACIIAjca Tg(TcraS106-1,TcrbS106-1)TS1SWAjca)
|
decreased susceptibility to autoimmune disorder
|
J:209872
|
Igkctm1(IGKC)Mnz/Rr166tm4.1Wtg
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6)
|
abnormal B cell physiology
|
J:193015
|
abnormal immunoglobulin level
|
J:193015
|
Igkctm1Bgmn/Igkctm1Bgmn
(involves: 129P2/OlaHsd)
|
abnormal humoral immune response
|
J:28868
|
Igkctm1Bgmn/Igkctm1Bgmn Igltm2.1Bgmn/Igltm2.1Bgmn
(involves: 129P2/OlaHsd)
|
decreased IgG level
|
J:130864
|
decreased IgM level
|
J:130864
|
Igkctm1Jkbv/Igkctm1Jkbv
(Not Specified)
|
abnormal immunoglobulin level
|
J:137738
|
Igkctm1Jkbv/Igkctm1Jkbv Tg(IGK@yK1)9.2CJkbv/0
(involves: 129P2/OlaHsd)
|
abnormal immunoglobulin level
|
J:137738
|
Igkctm1Jkbv/Igkctm1Jkbv Tg(IGK@yK1)9.2CJkbv/Tg(IGK@yK1)9.2CJkbv
(involves: 129P2/OlaHsd)
|
abnormal immunoglobulin level
|
J:137738
|
Igkctm1Jkbv/Igkctm1Jkbv Tg(IGK@yK2)J23.1Jkbv/0
(involves: 129P2/OlaHsd)
|
abnormal immunoglobulin level
|
J:137738
|
Igkrstm1Nemz/Igkrstm1Nemz Tg(BCL2)22Wehi/?
(involves: 129 * C57BL)
|
increased anti-double stranded DNA antibody level
|
J:132125
|
Igkrstm1Nemz/Igkrstm1Nemz Tg(UBC-scFv)2Nemz/?
(involves: 129 * C57BL/6 * DBA/2)
|
abnormal B cell clonal deletion
|
J:132125
|
Igll1tm1Cgn/Igll1tm1Cgn
(involves: 129S2/SvPas * C57BL/6)
|
decreased IgG1 level
|
J:64284
|
decreased IgG2b level
|
J:64284
|
decreased IgG3 level
|
J:64284
|
decreased IgG level
|
J:64284
|
Ignpq1BALB/cAJcl/Ignpq1HIGA/Nsc
(involves: BALB/cAJcl * HIGA/Nsc)
|
increased IgA level
|
J:116904
|
Ignpq1HIGA/Nsc/Ignpq1HIGA/Nsc
(involves: BALB/cAJcl * HIGA/Nsc)
|
increased IgA level
|
J:116904
|
Ignpq2BALB/cAJcl/Ignpq2HIGA/Nsc
(involves: BALB/cAJcl * HIGA/Nsc)
|
increased IgA level
|
J:116904
|
Ignpq2HIGA/Nsc/Ignpq2HIGA/Nsc
(involves: BALB/cAJcl * HIGA/Nsc)
|
increased IgA level
|
J:116904
|
Ignpq3BALB/cAJcl/Ignpq3HIGA/Nsc
(involves: BALB/cAJcl * HIGA/Nsc)
|
glomerulonephritis
|
J:116904
|
Ignpq3HIGA/Nsc/Ignpq3HIGA/Nsc
(involves: BALB/cAJcl * HIGA/Nsc)
|
glomerulonephritis
|
J:116904
|
Igs2tm1(CAG-Ptgs2os)Scrp/Igs2tm1(CAG-Ptgs2os)Scrp
(involves: C57BL/6)
|
abnormal circulating cytokine level
|
J:325487
|
increased circulating interleukin-10 level
|
J:325487
|
Igtpem1Myam/Igtpem1Myam Irgm1em1Myam/Irgm1em1Myam
(C57BL/6-Irgm1em1Myam Igtpem1Myam)
|
increased susceptibility to parasitic infection
|
J:308470
|
Igtpem1Myam/Igtpem1Myam Irgm1em1Myam/Irgm1em1Myam Irgm2em2Myam/Irgm2em2Myam
(C57BL/6-Irgm1em1Myam Igtpem1Myam Irgm2em2Myam)
|
increased susceptibility to parasitic infection
|
J:308470
|
Igtptm1Gvw/Igtptm1Gvw
(involves: 129S1/Sv * C57BL/6)
|
increased circulating interferon-gamma level
|
J:59891
|
increased circulating interleukin-12b level
|
J:59891
|
increased susceptibility to parasitic infection
|
J:99144,
J:59891
|
Iigp1tm1.1Jcho/Iigp1tm1.1Jcho
(involves: C57BL/6)
|
increased susceptibility to parasitic infection
|
J:135070
|
Ikbipem1Bcgen/Ikbipem1Bcgen Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd)
|
abnormal cytokine level
|
J:282971
|
decreased macrophage cytokine production
|
J:282971
|
increased circulating interleukin-6 level
|
J:282971
|
increased circulating tumor necrosis factor level
|
J:282971
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:282971
|
increased susceptibility to induced colitis
|
J:282971
|
lung inflammation
|
J:282971
|
Ikbkbem1Macc/Ikbkb+
(involves: C57BL/6NCrl)
|
abnormal T cell activation
|
J:290616
|
Ikbkbem1Macc/Ikbkbem1Macc
(involves: C57BL/6NCrl)
|
abnormal T cell activation
|
J:290616
|
IkbkbM1Btlr/Ikbkb+
(C57BL/6J-IkbkbM1Btlr)
|
abnormal B cell physiology
|
J:225271
|
abnormal response to infection
|
J:225271
|
increased response to antigen
|
J:225271
|
IkbkbM1Btlr/IkbkbM1Btlr
(C57BL/6J-IkbkbM1Btlr)
|
abnormal B cell physiology
|
J:225271
|
increased susceptibility to viral infection
|
J:225271
|
Ikbkbtm1.1Cgn/Ikbkbtm1.1Cgn
(involves: C57BL/6)
|
decreased interleukin-6 secretion
|
J:79132,
J:85810
|
Ikbkbtm1Cgn/Ikbkbtm1Cgn Il20ratm1Rsab/Il20ratm1Rsab Tg(KRT14-cre)1Cgn/0
(involves: C57BL/6 * DBA/2)
|
skin inflammation
|
J:208995
|
Ikbkbtm1Cgn/Ikbkbtm1Cgn Il22tm1Jcrd/Il22tm1Jcrd Tg(KRT14-cre)1Cgn/0
(involves: C57BL/6 * DBA/2)
|
skin inflammation
|
J:208995
|
Ikbkbtm1Cgn/Ikbkbtm1Cgn Il22ra1tm1Rsab/Il22ra1tm1Rsab Tg(KRT14-cre)1Cgn/0
(involves: C57BL/6 * DBA/2)
|
skin inflammation
|
J:208995
|
Ikbkbtm1Cgn/Ikbkbtm1Cgn Tg(KRT14-cre)1Cgn/0
(involves: C57BL/6 * DBA/2)
|
skin inflammation
|
J:208995
|
Ikbkbtm1Cgn/Ikbkbtm1Cgn Tnfrsf1atm2Gkl/Tnfrsf1atm2Gkl Tg(KRT14-cre)1Cgn/0
(involves: 129S/SvEv * C57BL/6 * DBA/2)
|
skin inflammation
|
J:208995
|
Ikbkbtm1Lex/Ikbkbtm1Lex Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * 129S/SvEvBrd)
|
impaired macrophage chemotaxis
|
J:159873
|
impaired neutrophil chemotaxis
|
J:159873
|
impaired neutrophil recruitment
|
J:159873
|
Ikbkbtm2.1Cgn/Ikbkbtm2.1Cgn
(involves: C57BL/6)
|
decreased interleukin-6 secretion
|
J:79132
|
Ikbkbtm2Cgn/Ikbkbtm2.1Cgn Tg(Cd4-cre)1Cwi/0
(involves: C57BL/6 * DBA/2)
|
abnormal humoral immune response
|
J:85810
|
decreased IgE level
|
J:85810
|
Ikbkbtm2Mka/Ikbkbtm2.1Mka Tg(Vil-cre)1Mka/0
(involves: 129/Sv * C57BL/6)
|
decreased acute inflammation
|
J:83313
|
decreased circulating tumor necrosis factor level
|
J:83313
|
impaired neutrophil recruitment
|
J:83313
|
Ikbkbtm2Mka/Ikbkbtm2Mka Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129/Sv * 129P2/OlaHsd)
|
increased macrophage apoptosis
|
J:80159
|
Ikbketm1Tman/Ikbketm1Tman
(B6.Cg-Ikbketm1Tman)
|
increased susceptibility to Orthomyxoviridae infection
|
J:119791
|
lung inflammation
|
J:119791
|
Ikbkgm1Btlr/Y
(C57BL/6J-Ikbkgm1Btlr)
|
decreased tumor necrosis factor secretion
|
J:139558
|
Ikbkgtm1.1Chtr/Y Tg(Alb1-cre)7Gsc/0
(involves: C57BL/6 * FVB/N * SJL)
|
abnormal NK cell physiology
|
J:151485
|
abnormal NK T cell physiology
|
J:151485
|
increased interferon-gamma secretion
|
J:151485
|
liver inflammation
|
J:151485
|
Ikbkgtm1.1Chtr/Ikbkgtm1.1Chtr Tg(Alb1-cre)7Gsc/0
(involves: C57BL/6 * FVB/N * SJL)
|
abnormal NK cell physiology
|
J:151485
|
abnormal NK T cell physiology
|
J:151485
|
increased circulating tumor necrosis factor level
|
J:151485
|
increased interferon-gamma secretion
|
J:151485
|
liver inflammation
|
J:151485
|
Ikbkgtm1.1Dwat/Y Tnfrsf1atm1Imx/Tnfrsf1atm1Imx
(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NTac)
|
liver inflammation
|
J:202106
|
Ikbkgtm1.1Mpa/Y Tg(Cd4-cre)1Cwi/0
(involves: C57BL/6 * DBA/2)
|
increased T cell apoptosis
|
J:85810
|
Ikbkgtm1.1Mpa/Y Tg(Vil1-cre)997Gum/0
(B6.Cg-Ikbkgtm1.1Mpa Tg(Vil1-cre)997Gum)
|
colitis
|
J:175865
|
Ikbkgtm1.1Mpa/Ikbkgtm1.1Mpa Tg(Alb1-cre)7Gsc/0
(involves: C57BL/6 * FVB/N)
|
abnormal cytokine secretion
|
J:118336
|
abnormal inflammatory response
|
J:118336
|
increased susceptibility to endotoxin shock
|
J:137861
|
liver inflammation
|
J:118336
|
Ikbkgtm1.1Mpa/Ikbkgtm1.1Mpa Tg(Vil1-cre)997Gum/0
(B6.Cg-Ikbkgtm1.1Mpa Tg(Vil1-cre)997Gum)
|
colitis
|
J:175865
|
Ikbkgtm1Dwb/Ikbkgtm1Dwb
(Not Specified)
|
abnormal chemokine secretion
|
J:136353
|
abnormal humoral immune response
|
J:136353
|
decreased interleukin-6 secretion
|
J:136353
|
decreased interleukin-12b secretion
|
J:136353
|
decreased susceptibility to endotoxin shock
|
J:136353
|
decreased tumor necrosis factor secretion
|
J:136353
|
Ikbkgtm1Mak/Y
(involves: 129P2/OlaHsd * C57BL/6)
|
increased interleukin-6 secretion
|
J:61666
|
Ikbkgtm1Mka/Ikbkg+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
|
erythroderma
|
J:63054
|
Ikbkgtm1Mpa/Y
(involves: C57BL/6)
|
decreased interleukin-6 secretion
|
J:63055
|
decreased tumor necrosis factor secretion
|
J:63055
|
Ikbkgtm1Mpa/Ikbkg+
(involves: C57BL/6)
|
skin inflammation
|
J:63055
|
Ikzf1m1Btlr/Ikzf1m1Btlr
(C57BL/6J-Ikzf1m1Btlr)
|
abnormal natural killer cell mediated cytotoxicity
|
J:265249
|
enhanced humoral immune response
|
J:265249
|
increased IgG level
|
J:265249
|
increased response to antigen
|
J:265249
|
Ikzf1tm1Kast/Ikzf1tm1Kast
(involves: 129S2/SvPas)
|
abnormal B cell activation
|
J:82813
|
decreased B cell proliferation
|
J:82813
|
decreased IgG3 level
|
J:82813
|
Ikzf1tm1Kge/Ikzf1+
(involves: 129S4/SvJae * C57BL/6)
|
abnormal thymocyte activation
|
J:29355
|
increased T cell proliferation
|
J:29355
|
Ikzf1tm1Kge/Ikzf1+
(involves: 129S4/SvJae * BALB/c)
|
abnormal thymocyte activation
|
J:29355
|
increased T cell proliferation
|
J:29355
|
Ikzf1tm1Kge/Ikzf1tm1Kge
(involves: 129S4/SvJae * C57BL/6)
|
increased susceptibility to bacterial infection
|
J:20671
|
lung inflammation
|
J:20671
|
Ikzf1tm1Kge/Ikzf1tm1Kge
(involves: 129S4/SvJae * BALB/c)
|
increased susceptibility to bacterial infection
|
J:20671
|
lung inflammation
|
J:20671
|
Ikzf1tm2Kge/Ikzf1tm2Kge
(involves: 129S4/SvJae)
|
increased T cell proliferation
|
J:37317
|
Ikzf1tm3Kge/Ikzf1tm3Kge Tg(CD2-icre)4Kio/?
(involves: C57BL/10 * CBA/Ca)
|
abnormal B cell physiology
|
J:209927
|
impaired B cell migration
|
J:209927
|
Ikzf1tm3Kge/Ikzf1tm3Kge Tg(CD19-cre/ERT2)1Cgn/?
(Not Specified)
|
abnormal B cell apoptosis
|
J:209927
|
Ikzf2tm1.1Etms/Ikzf2tm1.1Etms Tg(Cd4-cre)1Cwi/0
(involves: C57BL/6 * DBA/2)
|
abnormal regulatory T cell physiology
|
J:160098
|
Ikzf3tm1Kge/Ikzf3tm1Kge
(involves: 129S4/SvJae * C57BL/6)
|
abnormal type III hypersensitivity reaction
|
J:81805
|
autoimmune response
|
J:81805
|
decreased IgG2b level
|
J:50626
|
decreased IgG3 level
|
J:50626
|
decreased IgM level
|
J:50626
|
glomerulonephritis
|
J:81805
|
increased anti-double stranded DNA antibody level
|
J:81805
|
increased anti-histone antibody level
|
J:81805
|
increased anti-nuclear antigen antibody level
|
J:81805
|
increased anti-single stranded DNA antibody level
|
J:81805
|
increased autoantibody level
|
J:81805,
J:50626
|
increased B cell proliferation
|
J:50626
|
increased IgE level
|
J:50626
|
increased IgG1 level
|
J:50626
|
increased IgG2a level
|
J:50626
|
increased T cell proliferation
|
J:50626
|
Ikzf4tm1.1Etms/Ikzf4tm1.1Etms
(Not Specified)
|
chronic inflammation
|
J:294549
|
decreased T cell proliferation
|
J:295208
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:295208
|
Ikzf4tm1Djr/Ikzf4tm1Djr Tg(Cd4-cre)1Cwi/0
(involves: C57BL/6 * DBA/2)
|
chronic inflammation
|
J:294549
|
Il1atm1Yiw/Il1atm1Yiw
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
decreased circulating interleukin-1 alpha level
|
J:47429
|
decreased interleukin-1 beta secretion
|
J:47429
|
Il1atm1Yiw/Il1atm1Yiw Il1btm1Yiw/Il1btm1Yiw
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
decreased circulating interleukin-1 alpha level
|
J:47429
|
decreased circulating interleukin-1 beta level
|
J:47429
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:165513
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:165513
|
Il1atm1Yiw/Il1atm1Yiw Il1btm1Yiw/Il1btm1Yiw
(involves: 129S1/Sv * 129X1/SvJ * BALB/c)
|
impaired neutrophil recruitment
|
J:50775
|
Il1atm1Yiw/Il1atm1Yiw Il1btm1Yiw/Il1btm1Yiw Tg(KRT14-CASP1)1Miz/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
dermatitis
|
J:78602
|
Il1atm1Yiw/Il1atm1Yiw Nlrp1aNeut1/Nlrp1aNeut1
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal inflammatory response
|
J:191055
|
Il1btm1Dch/Il1btm1Dch
(involves: 129S2/SvPas)
|
decreased interleukin-1 beta secretion
|
J:33465
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:33465
|
increased susceptibility to bacterial infection
|
J:112400
|
Il1btm1Lvp/Il1btm1Lvp
(involves: 129S7/SvEvBrd * C57BL/6)
|
abnormal interleukin-6 secretion
|
J:27234
|
abnormal lymphocyte physiology
|
J:67001
|
decreased acute inflammation
|
J:27234
|
decreased circulating interleukin-1 beta level
|
J:27234
|
decreased inflammatory response
|
J:27234
|
decreased interferon-gamma secretion
|
J:67001
|
decreased interleukin-2 secretion
|
J:67001
|
decreased interleukin-4 secretion
|
J:67001
|
decreased susceptibility to experimental autoimmune myasthenia gravis
|
J:67001
|
Il1btm1Lvp/Il1btm1Lvp
(involves: 129S7/SvEvBrd)
|
abnormal macrophage physiology
|
J:136368
|
decreased interleukin-1 beta secretion
|
J:136368
|
decreased susceptibility to Togaviridae infection
|
J:52841
|
decreased susceptibility to Togaviridae infection induced morbidity/mortality
|
J:52841
|
decreased susceptibility to viral infection
|
J:135243
|
decreased tumor necrosis factor secretion
|
J:82394
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:136368
|
Il1btm1Yiw/Il1btm1Yiw
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
decreased circulating interleukin-1 beta level
|
J:47429
|
Il1r1em1Qizh/Il1r1em1Qizh
(C57BL/6-Il1r1em1Qizh)
|
increased circulating interleukin-6 level
|
J:338375
|
increased circulating tumor necrosis factor level
|
J:338375
|
increased susceptibility to induced arthritis
|
J:338375
|
Il1r1tm1Imx/Il1r1tm1Imx
(involves: 129 * C57BL/6)
|
decreased circulating interleukin-6 level
|
J:43088
|
increased susceptibility to bacterial infection
|
J:58851
|
osteomyelitis
|
J:58851
|
Il1r1tm1Imx/Il1r1tm1Imx
(involves: 129S7/SvEvBrd)
|
abnormal neutrophil physiology
|
J:113110
|
Il1r1tm1Imx/Il1r1tm1Imx
(involves: 129S7/SvEvBrd * C57BL/6)
|
abnormal neutrophil physiology
|
J:112999
|
decreased susceptibility to experimental autoimmune uveoretinitis
|
J:115094
|
Il1r1tm1Imx/Il1r1tm1Imx
(B6.129S7-Il1r1tm1Imx/J)
|
decreased circulating interleukin-6 level
|
J:125570
|
decreased circulating interleukin-18 level
|
J:125570
|
decreased interleukin-6 secretion
|
J:148779,
J:125570
|
decreased tumor necrosis factor secretion
|
J:125570
|
increased circulating interleukin-1 beta level
|
J:125570
|
increased circulating interleukin-18 level
|
J:125570
|
increased susceptibility to bacterial infection
|
J:125570
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:125570
|
increased susceptibility to induced arthritis
|
J:125570
|
sepsis
|
J:125570
|
Il1r1tm1Imx/Il1r1tm1Imx Tnfrsf1atm1Imx/Tnfrsf1atm1Imx
(involves: 129S7/SvEvBrd * C57BL/6)
|
abnormal chemokine level
|
J:126652
|
decreased interleukin-6 secretion
|
J:115094
|
decreased susceptibility to experimental autoimmune uveoretinitis
|
J:115094
|
impaired neutrophil recruitment
|
J:126652
|
increased susceptibility to bacterial infection
|
J:58851
|
interstitial pneumonia
|
J:126652
|
lung inflammation
|
J:126652
|
osteomyelitis
|
J:58851
|
Il1r1tm1Imx/Il1r1tm1Imx Vsig4tm1Gne/Vsig4tm1Gne
(B6.Cg-Il1r1tm1Imx Vsig4tm1Gne)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:281762
|
increased susceptibility to induced colitis
|
J:281762
|
Il1r1tm1Quan/Il1r1tm1Quan
(involves: C57BL/6)
|
abnormal inflammatory response
|
J:219864
|
abnormal microglial cell activation
|
J:219864
|
Il1r1tm1Quan/Il1r1tm1Quan Lyz2tm1(cre)Ifo/Lyz2tm1(cre)Ifo
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal inflammatory response
|
J:219864
|
abnormal microglial cell activation
|
J:219864
|
Il1r1tm1Quan/Il1r1tm1Quan Tg(Tek-cre)12Flv/0
(involves: C3H * C57BL/6)
|
abnormal inflammatory response
|
J:219864
|
abnormal microglial cell activation
|
J:219864
|
Il1r1tm1Roml/Il1r1tm1Roml
(involves: 129S1/Sv * C57BL/6)
|
decreased circulating interleukin-6 level
|
J:42373
|
decreased circulating serum amyloid protein level
|
J:42373
|
decreased interleukin-6 secretion
|
J:42373
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:42373
|
increased susceptibility to bacterial infection
|
J:42373
|
Il1r1tm1Roml/Il1r1tm1Roml
(NOD.Cg-Il1r1tm1Roml)
|
decreased susceptibility to autoimmune diabetes
|
J:87251
|
Il1r1tm1Roml/Il1r1tm1Roml
(C.Cg-Il1r1tm1Roml)
|
decreased immunoglobulin level
|
J:82863
|
decreased T cell proliferation
|
J:82863
|
Il1r1tm1Roml/Il1r1tm1Roml
(involves: 129S1/Sv * BALB/c)
|
impaired neutrophil chemotaxis
|
J:124226
|
Il1r1tm1Roml/Il1r1tm1Roml
(involves: 129S1/Sv)
|
decreased susceptibility to induced arthritis
|
J:120707
|
Il1r1tm1Roml/Il1r1tm1Roml Mefvtm5.1(MEFV)Chae/Mefvtm5.1(MEFV)Chae
(involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6)
|
increased interleukin-1 beta secretion
|
J:172117
|
Il1r1tm1Roml/Il1r1tm1Roml Nlrp1aNeut1/Nlrp1aNeut1
(involves: 129S1/Sv * C57BL/6)
|
increased susceptibility to Riboviria infection
|
J:191055
|
Il1r1tm1Roml/Il1r1tm1Roml Nlrp3tm1Hhf/Nlrp3+ Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129 * C57BL/6)
|
skin inflammation
|
J:150054
|
Il1r2tm1.2Mchc/Il1r2tm1.2Mchc
(involves: BALB/cJ * C57BL/6J * C57BL/6NTac)
|
abnormal T cell physiology
|
J:347877
|
increased circulating interleukin-1 alpha level
|
J:347877
|
increased circulating interleukin-6 level
|
J:347877
|
increased inflammatory response
|
J:347877
|
Il1r2tm1Yiw/Il1r2tm1Yiw
(B6.129P2-Il1r2tm1Yiw)
|
abnormal macrophage physiology
|
J:274653
|
increased macrophage cytokine production
|
J:274653
|
increased susceptibility to induced arthritis
|
J:274653
|
Il1r2tm1Yiw/Il1r2tm1Yiw Il1rntm1Yiw/Il1rntm1Yiw
(B6.129-Il1r2tm1Yiw Il1rntm1Yiw)
|
increased circulating tumor necrosis factor level
|
J:274653
|
Il1raptm1Roml/Il1raptm1Roml
(involves: 129S1/Sv)
|
decreased interleukin-6 secretion
|
J:68065
|
Il1rl1tm1Anjm/Il1rl1tm1Anjm
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal eosinophil physiology
|
J:61108
|
abnormal interleukin secretion
|
J:61108
|
abnormal T-helper 2 physiology
|
J:61108
|
decreased interleukin-4 secretion
|
J:61108
|
decreased interleukin-5 secretion
|
J:61108
|
granulomatous inflammation
|
J:61108
|
Il1rl1tm1Anjm/Il1rl1tm1Anjm
(involves: 129P2/OlaHsd)
|
decreased IgE level
|
J:159464
|
Il1rl1tm1Anjm/Il1rl1tm1Anjm
(C.129P2-Il1rl1tm1Anjm)
|
increased susceptibility to induced pancreatitis
|
J:184801
|
Il1rl1tm1Brl/Il1rl1tm1Brl
(involves: 129S/SvEv * C57BL/6)
|
abnormal response to infection
|
J:63507
|
decreased interleukin-5 secretion
|
J:63507
|
Il1rl2tm1Hblu/Il1rl2tm1Hblu
(involves: 129 * C57BL/6)
|
abnormal dendritic cell physiology
|
J:296074
|
abnormal macrophage activation involved in immune response
|
J:296074
|
Il1rl2tm1Hblu/Il1rl2tm1Hblu
(involves: 129)
|
decreased interleukin-9 secretion
|
J:256437
|
decreased interleukin-17 secretion
|
J:193548
|
decreased susceptibility to induced colitis
|
J:256437
|
Il1rntm1.1Cga/Il1rntm1.1Cga Lyz2tm1(cre)Ifo/Lyz2+
(D1.Cg-Il1rntm1.1Cga Lyz2tm1(cre)Ifo)
|
abnormal chemokine secretion
|
J:162760
|
increased interferon-gamma secretion
|
J:162760
|
increased interleukin-1 beta secretion
|
J:162760
|
increased interleukin-6 secretion
|
J:162760
|
increased interleukin-17 secretion
|
J:162760
|
increased susceptibility to induced arthritis
|
J:162760
|
increased T cell proliferation
|
J:162760
|
Il1rntm1Dih/Il1rn+
(involves: 129S/SvEv * C57BL/6J)
|
decreased susceptibility to bacterial infection
|
J:36387
|
increased susceptibility to endotoxin shock
|
J:36387
|
Il1rntm1Dih/Il1rntm1Dih
(involves: 129S/SvEv * C57BL/6J)
|
decreased circulating interleukin-1 level
|
J:36387
|
decreased susceptibility to bacterial infection
|
J:36387
|
increased acute inflammation
|
J:61600,
J:88605
|
increased circulating interleukin-6 level
|
J:61600
|
increased circulating serum amyloid protein level
|
J:61600
|
increased susceptibility to endotoxin shock
|
J:36387
|
Il1rntm1Nick/Il1rn+
(involves: 129P2/OlaHsd * MF1)
|
aortitis
|
J:59410
|
Il1rntm1Nick/Il1rntm1Nick
(involves: 129P2/OlaHsd * MF1)
|
aortitis
|
J:59410
|
chronic inflammation
|
J:59410
|
Il1rntm1Nick/Il1rntm1Nick
(involves: 129P2/OlaHsd * MF1 * BALB/cAnNHsd)
|
aortitis
|
J:89034
|
skin inflammation
|
J:89034
|
Il1rntm1Nick/Il1rntm1Nick
(involves: BALB/cAnNHsd)
|
aortitis
|
J:89034
|
rheumatoid arthritis
|
J:89034
|
skin inflammation
|
J:89034
|
Il1rntm1Nick/Il1rntm1Nick
(involves: BALB/cAnNHsd * C57BL/6)
|
aortitis
|
J:89034
|
rheumatoid arthritis
|
J:89034
|
Il1rntm1Sush/Il1rntm1Sush
(involves: 129P2/OlaHsd * C57BL/6)
|
granulomatous inflammation
|
J:97684
|
Il1rntm1Yiw/Il1rntm1Yiw
(C.129-Il1rntm1Yiw)
|
increased interleukin-17 secretion
|
J:143719
|
rheumatoid arthritis
|
J:143719
|
Il1rntm1Yiw/Il1rntm1Yiw Il17atm1Yiw/Il17a+
(involves: 129P2/OlaHsd * BALB/cA * C57BL/6J)
|
decreased susceptibility to induced arthritis
|
J:83408
|
Il2m1/Il2m1
(MRL/MpJ)
|
abnormal T cell activation
|
J:75331
|
Il2tm1.1Flv/Il2tm1.1Flv
(NOD/ShiLtJ-Il2tm1.1Flv)
|
abnormal susceptibility to autoimmune disorder
|
J:150823
|
Il2tm1.1Kasm/Il2tm1.1Kasm Ndor1Tg(UBC-cre/ERT2)1Ejb/?
(involves: 129S/SvEv * C57BL/6)
|
decreased circulating interleukin-17 level
|
J:190168
|
Il2tm1Hor/Il2+
(NOD.129P2(B6)-Il2tm1Hor/DvsJ)
|
increased susceptibility to autoimmune diabetes
|
J:120349
|
Il2tm1Hor/Il2tm1Hor
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:39981,
J:39989,
J:15573
|
abnormal class switch recombination
|
J:15573
|
abnormal cytotoxic T cell physiology
|
J:39981
|
abnormal level of surface class II molecules
|
J:15223
|
abnormal lymphocyte physiology
|
J:15223
|
abnormal susceptibility to Riboviria infection
|
J:26861
|
abnormal thymocyte activation
|
J:37220,
J:39989
|
colitis
|
J:37220,
J:29999,
J:15223
|
decreased cytotoxic T cell cytolysis
|
J:15573,
J:26198,
J:26861
|
decreased splenocyte proliferation
|
J:79241
|
decreased T cell proliferation
|
J:39989,
J:26198
|
impaired natural killer cell mediated cytotoxicity
|
J:15573
|
increased B cell proliferation
|
J:16662
|
increased IgA level
|
J:15223
|
increased IgE level
|
J:16662
|
increased IgG1 level
|
J:39989,
J:15223,
J:16662
|
increased IgG2a level
|
J:16662
|
increased IgG2b level
|
J:16662
|
increased length of allograft survival
|
J:26198
|
increased T cell proliferation
|
J:15223,
J:16662
|
Il2tm1Hor/Il2tm1Hor
(C.129P2-Il2tm1Hor)
|
abnormal regulatory T cell physiology
|
J:112603
|
heart inflammation
|
J:29799
|
increased B cell proliferation
|
J:29799
|
increased IgG level
|
J:29799
|
increased inflammatory response
|
J:29799
|
increased susceptibility to autoimmune hemolytic anemia
|
J:29799
|
increased T cell proliferation
|
J:29799
|
liver inflammation
|
J:29799
|
lung inflammation
|
J:29799
|
pancreas inflammation
|
J:29799
|
Il2tm1Hor/Il2tm1Hor
(B6.129P2-Il2tm1Hor)
|
increased T cell proliferation
|
J:28924
|
Il2tm1Hor/Il2tm1Hor
(B6.129P2-Il2tm1Hor/J)
|
abnormal circulating cytokine level
|
J:190168
|
abnormal response to transplant
|
J:113547
|
abnormal T cell activation
|
J:190168
|
abnormal T cell proliferation
|
J:190168
|
decreased circulating interferon-gamma level
|
J:190168
|
decreased circulating interleukin-4 level
|
J:190168
|
decreased circulating interleukin-13 level
|
J:190168
|
increased susceptibility to autoimmune disorder
|
J:113547
|
lacrimal gland inflammation
|
J:125129
|
large intestinal inflammation
|
J:125129
|
salivary gland inflammation
|
J:125129
|
Il2tm1Hor/Il2tm1Hor
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased circulating interleukin-17 level
|
J:120176
|
Il2tm1Hor/Il2tm1Hor Il4tm1Cgn/Il4tm1Cgn
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal susceptibility to Riboviria infection
|
J:26861
|
decreased cytotoxic T cell cytolysis
|
J:26861
|
decreased IgG level
|
J:16662,
J:26861
|
increased B cell proliferation
|
J:16662
|
increased T cell proliferation
|
J:16662
|
Il2tm1Hor/Il2tm1Hor Rag2tm1Fwa/Rag2+
(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)
|
colitis
|
J:29999
|
Il2tm1Hor/Il2tm1Hor Tg(DO11.10)10Dlo/?
(C.Cg-Il2tm1Hor Tg(DO11.10)10Dlo)
|
abnormal regulatory T cell physiology
|
J:88349
|
increased T cell proliferation
|
J:88349
|
Il2tm1Hor/Il2tm1Hor Tg(Pgk1-HA)1.1Vbo/? Tg(Tcra/Tcrb)1Vbo/?
(C.Cg-Il2tm1Hor Tg(Pgk1-HA)1.1Vbo Tg(Tcra/Tcrb)1Vbo)
|
abnormal regulatory T cell physiology
|
J:112603
|
Il2raM1J/Il2raM1J
(involves: 129S4/SvJae * C57BL/6)
|
abnormal regulatory T cell physiology
|
J:268677
|
Il2ratm1Dw/Il2ratm1Dw
(involves: 129S4/SvJae * C57BL/6)
|
abnormal B cell physiology
|
J:64279
|
abnormal T cell physiology
|
J:64279
|
colitis
|
J:64279
|
increased IgA level
|
J:64279
|
increased IgG1 level
|
J:64279
|
increased IgG2a level
|
J:64279
|
increased IgG2b level
|
J:64279
|
increased IgG level
|
J:64279
|
Il2ratm1Dw/Il2ratm1Dw
(B6.129S4-Il2ratm1Dw)
|
abnormal regulatory T cell physiology
|
J:125748
|
abnormal T cell activation
|
J:125748
|
Il2ratm1Dw/Il2ratm1Dw
(B6.129S4-Il2ratm1Dw/J)
|
lacrimal gland inflammation
|
J:125129
|
large intestinal inflammation
|
J:125129
|
lung inflammation
|
J:125129
|
salivary gland inflammation
|
J:125129
|
Il2ratm1Dw/Il2ratm1Dw Tg(Pgk1-HA)1.1Vbo/? Tg(Tcra/Tcrb)1Vbo/?
(C.Cg-Il2ratm1Dw Tg(Pgk1-HA)1.1Vbo Tg(Tcra/Tcrb)1Vbo)
|
abnormal regulatory T cell physiology
|
J:112603
|
Il2rbm2Btlr/Il2rbm2Btlr
(C57BL/6J-Il2rbm2Btlr)
|
increased IgE level
|
J:272832
|
Il2rbM3Btlr/Il2rbM3Btlr
(C57BL/6J-Il2rbM3Btlr)
|
increased IgM level
|
J:272833
|
Il2rbtm1Mak/Il2rbtm1Mak
(either: (involves: 129P2/OlaHsd) or (involves: 129S2/SvPas))
|
abnormal B cell activation
|
J:25940
|
abnormal T cell activation
|
J:25940
|
increased anti-nuclear antigen antibody level
|
J:25940
|
increased IgE level
|
J:25940
|
increased IgG1 level
|
J:25940
|
increased susceptibility to autoimmune hemolytic anemia
|
J:25940
|
Il2rbtm1Mak/Il2rbtm1Mak
(B6.129-Il2rbtm1Mak)
|
abnormal response to transplant
|
J:113547
|
abnormal T cell activation
|
J:113547
|
decreased T cell proliferation
|
J:113547
|
increased anti-double stranded DNA antibody level
|
J:113547
|
increased susceptibility to autoimmune hemolytic anemia
|
J:113547
|
Il2rbtm1Mak/Il2rbtm1Mak
(C.129-Il2rbtm1Mak)
|
abnormal T cell activation
|
J:113547
|
abnormal T cell clonal deletion
|
J:113547
|
decreased T cell proliferation
|
J:113547
|
increased anti-double stranded DNA antibody level
|
J:113547
|
increased susceptibility to autoimmune hemolytic anemia
|
J:113547
|
liver inflammation
|
J:113547
|
Il2rbtm1Mak/Il2rbtm1Mak
(D2.129-Il2rbtm1Mak)
|
abnormal T cell clonal deletion
|
J:113547
|
Il2rgtm1.1Flv/Y Rag2tm1.1Flv/Rag2tm1.1Flv
(involves: 129S4/SvJae * BALB/cAnNTac)
|
abnormal response to transplant
|
J:168303
|
increased susceptibility to bacterial infection
|
J:168303
|
Il2rgtm1.1Flv/Il2rgtm1.1Flv Csf2/Il3tm1.1(CSF2,IL3)Flv/Csf2/Il3tm1.1(CSF2,IL3)Flv Rag2tm1.1Flv/Rag2tm1.1Flv
(involves: 129S4/SvJae * BALB/cAnNCr * BALB/cAnNTac)
|
abnormal response to transplant
|
J:168302
|
Il2rgtm1.1Flv/Il2rgtm1.1Flv Rag2tm1.1Flv/Rag2tm1.1Flv
(involves: 129S4/SvJae * BALB/cAnNTac)
|
abnormal response to transplant
|
J:168303
|
increased susceptibility to bacterial infection
|
J:168303
|
Il2rgtm1.1Flv/Il2rgtm1.1Flv Rag2tm1.1Flv/Rag2tm1.1Flv Thpotm1.1(TPO)Flv/Thpotm1.1(TPO)Flv
(involves: 129S4/SvJae * BALB/cAnNTac)
|
abnormal response to transplant
|
J:168301
|
Il2rgtm1Cgn/Y
(involves: 129 * CB20)
|
abnormal class switch recombination
|
J:22521
|
abnormal thymocyte activation
|
J:22521
|
decreased IgE level
|
J:22521
|
decreased IgM level
|
J:22521
|
decreased T cell proliferation
|
J:22521
|
impaired natural killer cell mediated cytotoxicity
|
J:22521
|
Il2rgtm1Cgn/Il2rgtm1Cgn
(involves: 129 * CB20)
|
abnormal class switch recombination
|
J:22521
|
abnormal thymocyte activation
|
J:22521
|
decreased IgE level
|
J:22521
|
decreased IgM level
|
J:22521
|
decreased T cell proliferation
|
J:22521
|
impaired natural killer cell mediated cytotoxicity
|
J:22521
|
Il2rgtm1Cgn/Il2rgtm1Cgn Rag2tm1Fwa/Rag2tm1Fwa
(involves: 129P2/OlaHsd * 129S/SvEv)
|
abnormal interleukin secretion
|
J:142654
|
increased susceptibility to bacterial infection
|
J:142654
|
Il2rgtm1Sug/Y
(either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129S6/SvEvTac * C57BL/6))
|
abnormal immune serum protein physiology
|
J:31167
|
abnormal immunoglobulin level
|
J:31167
|
decreased IgG3 level
|
J:31167
|
decreased IgG level
|
J:31167
|
Il2rgtm1Wjl/Y
(involves: 129S4/SvJae * C57BL/6)
|
abnormal basophil physiology
|
J:24117
|
abnormal cell-mediated immunity
|
J:108209
|
abnormal immune serum protein physiology
|
J:108209
|
abnormal mast cell physiology
|
J:24117
|
abnormal thymocyte activation
|
J:24117
|
cecum inflammation
|
J:24117
|
decreased immunoglobulin level
|
J:24117
|
decreased interferon-gamma secretion
|
J:24117
|
decreased interleukin-2 secretion
|
J:24117
|
decreased interleukin-4 secretion
|
J:24117
|
decreased T cell proliferation
|
J:24117
|
impaired natural killer cell mediated cytotoxicity
|
J:24117
|
Il2rgtm1Wjl/Y Prkdcscid/Prkdcscid
(NOD.Cg-Prkdcscid Il2rgtm1Wjl/Sz)
|
abnormal response to transplant
|
J:109833,
J:140388
|
decreased immunoglobulin level
|
J:109833
|
Il2rgtm1Wjl/Y Rag1tm1Mom/Rag1tm1Mom
(NOD.Cg-Rag1tm1Mom Il2rgtm1Wjl/SzJ)
|
abnormal adaptive immunity
|
J:140388
|
abnormal innate immunity
|
J:140388
|
abnormal response to transplant
|
J:140388
|
Il2rgtm1Wjl/Il2rgtm1Wjl
(B6.129S4-Il2rgtm1Wjl/J)
|
abnormal dendritic cell physiology
|
J:123902
|
Il2rgtm1Wjl/Il2rgtm1Wjl Prkdcscid/Prkdcscid
(NOD.Cg-Prkdcscid Il2rgtm1Wjl/Sz)
|
abnormal response to transplant
|
J:109833
|
decreased immunoglobulin level
|
J:109833
|
Il2rgtm1Wjl/Il2rgtm1Wjl Rag2tm1Fwa/Rag2tm1Fwa
(involves: 129S/SvEv * 129S4/SvJae)
|
abnormal interferon secretion
|
J:140483
|
increased susceptibility to bacterial infection
|
J:140483
|
lung inflammation
|
J:140483
|
Il3tm1Glli/Il3tm1Glli
(either: (involves: 129S2/SvPas * BALB/c) or (involves: 129S2/SvPas * C57BL/6))
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:80640
|
increased susceptibility to parasitic infection
|
J:80500
|
Il3tm1Glli/Il3tm1Glli KitW/KitW-v
(involves: 129S2/SvPas * C57BL/6 * WB)
|
increased susceptibility to parasitic infection
|
J:80500
|
Il4/Il13tm3Anjm/Il4/Il13tm3Anjm
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal immune system physiology
|
J:89095
|
abnormal splenocyte physiology
|
J:72587
|
abnormal susceptibility to infection
|
J:113543
|
abnormal T-helper 2 physiology
|
J:89095
|
decreased IgE level
|
J:113543,
J:72587
|
decreased IgG1 level
|
J:72587
|
decreased IgG level
|
J:89095
|
decreased susceptibility to parasitic infection
|
J:72587
|
granulomatous inflammation
|
J:113543
|
increased susceptibility to parasitic infection
|
J:113543,
J:89095
|
increased susceptibility to parasitic infection induced morbidity/mortality
|
J:60609
|
Il4/Il13tm3Anjm/Il4/Il13tm3Anjm
(C.129P2/OlaHsd-Il4/Il13tm3Anjm)
|
abnormal interleukin-4 secretion
|
J:91403
|
decreased IgE level
|
J:91403
|
decreased interferon-gamma secretion
|
J:91403
|
decreased interleukin-5 secretion
|
J:91403
|
decreased interleukin-13 secretion
|
J:91403
|
decreased susceptibility to autoimmune disorder
|
J:91403
|
increased IgG2a level
|
J:91403
|
Il4/Il13tm3Anjm/Il4/Il13tm3Anjm
(involves: 129P2/OlaHsd * BALB/c)
|
abnormal splenocyte physiology
|
J:60609
|
abnormal susceptibility to infection
|
J:60609,
J:131994
|
decreased IgG1 level
|
J:178986
|
decreased inflammatory response
|
J:60609,
J:165513
|
ileum inflammation
|
J:60609
|
increased susceptibility to parasitic infection
|
J:60609
|
increased susceptibility to parasitic infection induced morbidity/mortality
|
J:60609
|
Il4/Il13tm3Anjm/Il4/Il13tm3Anjm
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal immune system physiology
|
J:89095
|
abnormal splenocyte physiology
|
J:72587
|
abnormal susceptibility to infection
|
J:113543
|
abnormal T-helper 2 physiology
|
J:89095
|
decreased IgE level
|
J:113543,
J:72587
|
decreased IgG1 level
|
J:72587
|
decreased IgG level
|
J:89095
|
decreased susceptibility to parasitic infection
|
J:72587
|
granulomatous inflammation
|
J:113543
|
increased susceptibility to parasitic infection
|
J:113543,
J:89095
|
increased susceptibility to parasitic infection induced morbidity/mortality
|
J:60609
|
Il4/Il13tm3Anjm/Il4/Il13tm3Anjm
(C.129P2/OlaHsd-Il4/Il13tm3Anjm)
|
abnormal interleukin-4 secretion
|
J:91403
|
decreased IgE level
|
J:91403
|
decreased interferon-gamma secretion
|
J:91403
|
decreased interleukin-5 secretion
|
J:91403
|
decreased interleukin-13 secretion
|
J:91403
|
decreased susceptibility to autoimmune disorder
|
J:91403
|
increased IgG2a level
|
J:91403
|
Il4/Il13tm3Anjm/Il4/Il13tm3Anjm
(involves: 129P2/OlaHsd * BALB/c)
|
abnormal splenocyte physiology
|
J:60609
|
abnormal susceptibility to infection
|
J:60609,
J:131994
|
decreased IgG1 level
|
J:178986
|
decreased inflammatory response
|
J:60609,
J:165513
|
ileum inflammation
|
J:60609
|
increased susceptibility to parasitic infection
|
J:60609
|
increased susceptibility to parasitic infection induced morbidity/mortality
|
J:60609
|
Il4tm1(CD2)Mmrs/Il4tm1(CD2)Mmrs
(involves: 129)
|
decreased IgE level
|
J:178986
|
decreased IgG1 level
|
J:178986
|
decreased interleukin-4 secretion
|
J:181313
|
Il4tm1.1Wep/Il4+
(C.129P2-Il4tm1.1Wep)
|
decreased IgE level
|
J:138827
|
Il4tm1.1Wep/Il4+ Stat6tm1Gru/Stat6tm1Gru
(C.129-Stat6tm1Gru Il4tm1.1Wep)
|
decreased IgE level
|
J:138827
|
impaired eosinophil recruitment
|
J:138827
|
Il4tm1.1Wep/Il4tm1.1Wep
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased interleukin-4 secretion
|
J:67964
|
Il4tm1.1Wep/Il4tm1.1Wep
(C.129P2-Il4tm1.1Wep)
|
decreased IgE level
|
J:138827
|
impaired eosinophil recruitment
|
J:138827
|
Il4tm1.1Wep/Il4tm1.1Wep Stat6tm1Gru/Stat6tm1Gru
(C.129-Stat6tm1Gru Il4tm1.1Wep)
|
decreased IgE level
|
J:138827
|
impaired eosinophil recruitment
|
J:138827
|
Il4tm1Cgn/Il4tm1Cgn
(B6.Cg-Il4tm1Cgn)
|
abnormal humoral immune response
|
J:89095
|
abnormal T-helper 2 physiology
|
J:89095
|
Il4tm1Cgn/Il4tm1Cgn
(NOD.129P2-Il4tm1Cgn)
|
decreased susceptibility to autoimmune disorder
|
J:95105
|
increased susceptibility to autoimmune disorder
|
J:95105
|
Il4tm1Cgn/Il4tm1Cgn
(NOD.Cg-H2b Il4tm1Cgn)
|
lacrimal gland inflammation
|
J:105803
|
salivary gland inflammation
|
J:105803
|
Il4tm1Cgn/Il4tm1Cgn
(involves: 129P2/OlaHsd * NOD)
|
abnormal cytokine secretion
|
J:85924
|
decreased IgG1 level
|
J:85924
|
Il4tm1Cgn/Il4tm1Cgn
(either: NOD.129-Il4tm1Cgn or (involves: 129 * NOD))
|
autoimmune response
|
J:85924
|
insulitis
|
J:85924
|
Il4tm1Cgn/Il4tm1Cgn
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal cytokine secretion
|
J:704
|
decreased IgE level
|
J:704
|
decreased IgG1 level
|
J:704
|
granulomatous inflammation
|
J:113543
|
Il4tm1Cgn/Il4tm1Cgn
(MRL.129P2-Il4tm1Cgn)
|
lacrimal gland inflammation
|
J:132514
|
Il4tm1Cgn/Il4tm1Cgn
(involves: 129P2/OlaHsd * C57BL/6J * MRL/Mp)
|
decreased IgE level
|
J:39600
|
decreased IgG1 level
|
J:39600
|
Il4tm1Cgn/Il4tm1Cgn
(involves: 129P2/OlaHsd * A/WySn * C57BL/10SnSg * Swiss)
|
decreased IgG1 level
|
J:119207
|
increased IgG2a level
|
J:119207
|
Il4tm1Cgn/Il4tm1Cgn Ndfip1Gt(RRD002)Byg/Ndfip1Gt(RRD002)Byg
(involves: 129P2/OlaHsd)
|
esophageal inflammation
|
J:205692
|
increased inflammatory response
|
J:205692
|
increased interleukin-2 secretion
|
J:205692
|
lung inflammation
|
J:205692
|
Il4tm1Cgn/Il4tm1Cgn Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0
(NOD.Cg-Il4tm1Cgn Tg(TcraBDC2.5,TcrbBDC2.5)1Doi)
|
decreased susceptibility to autoimmune diabetes
|
J:85924
|
insulitis
|
J:85924
|
Il4tm1Kopf/Il4tm1Kopf
(involves: 129S2/SvPas * C57BL/6)
|
abnormal response to infection
|
J:14593
|
decreased IgE level
|
J:14593
|
decreased IgG1 level
|
J:14593
|
decreased interleukin-3 secretion
|
J:14593
|
decreased interleukin-4 secretion
|
J:14593
|
decreased interleukin-5 secretion
|
J:14593
|
decreased interleukin-10 secretion
|
J:14593
|
increased IgG level
|
J:14593
|
Il4tm1Kopf/Il4tm1Kopf
(involves: 129S2/SvPas)
|
decreased IgE level
|
J:113065
|
decreased interleukin-5 secretion
|
J:113065
|
Il4tm1Kopf/Il4tm1Kopf Lyntm1Ard/Lyntm1Ard
(involves: 129P2/OlaHsd * 129S2/SvPas)
|
abnormal circulating complement protein level
|
J:161523
|
decreased IgE level
|
J:161523
|
decreased IgG1 level
|
J:161523
|
increased anti-double stranded DNA antibody level
|
J:161523
|
increased anti-nuclear antigen antibody level
|
J:161523
|
increased IgA level
|
J:161523
|
increased IgG2a level
|
J:161523
|
increased IgG2b level
|
J:161523
|
increased IgM level
|
J:161523
|
Il4tm1Lky/Il4+ Lattm1.1Mal/Lattm1.1Mal
(involves: 129S2/SvPas * C57BL/6)
|
abnormal T-helper 2 physiology
|
J:151840
|
Il4tm1Lky/Il4tm1Lky Itktm1Litt/Itktm1Litt
(involves: 129S4/SvJae * BALB/c * C57BL/6J)
|
abnormal cytokine secretion
|
J:129883
|
abnormal response to infection
|
J:129883
|
abnormal T-helper 2 physiology
|
J:129883
|
Il4tm1Nnt/Il4tm1Nnt
(C57BL/6-Il4tm1Nnt/J)
|
abnormal T-helper 2 physiology
|
J:37196
|
CNS inflammation
|
J:125605
|
decreased IgE level
|
J:37196
|
decreased IgG1 level
|
J:37196
|
decreased IgM level
|
J:37196
|
decreased interleukin-4 secretion
|
J:37196
|
decreased interleukin-5 secretion
|
J:37196
|
decreased interleukin-10 secretion
|
J:120556,
J:37196
|
granulomatous inflammation
|
J:37196
|
increased IgA level
|
J:37196
|
increased interferon-gamma secretion
|
J:120556,
J:37196
|
stomach inflammation
|
J:120556
|
Il4tm1Nnt/Il4tm1Nnt
(involves: C57BL/6)
|
abnormal interleukin-4 secretion
|
J:91403
|
decreased susceptibility to autoimmune disorder
|
J:91403
|
Il4tm1Rao/Il4tm1Rao
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal mast cell physiology
|
J:78089
|
abnormal T-helper 2 physiology
|
J:78089
|
decreased interleukin-4 secretion
|
J:78089
|
decreased interleukin-13 secretion
|
J:78089
|
Il4tm2.1Kubo/Il4tm2.1Kubo
(B6.Cg-Il4tm2.1Kubo)
|
decreased IgE level
|
J:167446
|
decreased IgG1 level
|
J:167446
|
decreased interleukin-4 secretion
|
J:167446
|
impaired eosinophil recruitment
|
J:167446
|
increased IgG2c level
|
J:167446
|
increased interleukin-5 secretion
|
J:167446
|
increased interleukin-13 secretion
|
J:167446
|
Il4tm2Nnt/Il4tm2Nnt
(BALB/c-Il4tm2Nnt/J)
|
abnormal dendritic cell antigen presentation
|
J:141937
|
decreased IgE level
|
J:31486
|
decreased IgG1 level
|
J:31486
|
decreased interleukin-5 secretion
|
J:141937
|
decreased interleukin-13 secretion
|
J:141937
|
decreased susceptibility to autoimmune disorder
|
J:141937
|
increased interferon-gamma secretion
|
J:141937
|
Il4tm2Nnt/Il4tm2Nnt
(BALB/c-Il4tm2Nnt)
|
abnormal splenocyte physiology
|
J:60609
|
abnormal susceptibility to infection
|
J:60609
|
ileum inflammation
|
J:60609
|
increased susceptibility to parasitic infection
|
J:60609
|
increased susceptibility to parasitic infection induced morbidity/mortality
|
J:60609
|
Il4tm2Nnt/Il4tm2Nnt Tgfb1tm1Doe/Tgfb1tm1Doe
(C.Cg-Tgfb1tm1Doe Il4tm2Nnt)
|
liver inflammation
|
J:69346
|
Il4tm3.1Kubo/Il4tm3.1Kubo
(B6.Cg-Il4tm3.1Kubo)
|
decreased interleukin-4 secretion
|
J:167446
|
Il4ppqNZB/Slc/Il4ppqNZW/Slc
(involves: NZB/Slc * NZW/Slc)
|
abnormal cytokine secretion
|
J:117863
|
Il4raM1Btlr/Il4raM1Btlr
(C57BL/6J-Il4raM1Btlr)
|
decreased IgE level
|
J:267558
|
Il4raM2Btlr/Il4raM2Btlr
(C57BL/6J-Il4raM2Btlr)
|
decreased IgE level
|
J:272804
|
Il4ratm1Fbb/Il4ratm1Fbb
(involves: BALB/c)
|
abnormal susceptibility to infection
|
J:55526
|
Il4ratm1Fbb/Il4ratm1Fbb
(involves: BALB/cJ)
|
abnormal circulating cytokine level
|
J:133518
|
abnormal circulating interferon-gamma level
|
J:133518
|
abnormal cytokine secretion
|
J:114751
|
abnormal immune system physiology
|
J:114751
|
abnormal macrophage physiology
|
J:114751
|
granulomatous inflammation
|
J:114751
|
impaired macrophage chemotaxis
|
J:114751
|
increased circulating interleukin-4 level
|
J:133518
|
increased susceptibility to infection
|
J:114751
|
increased susceptibility to parasitic infection
|
J:114751
|
liver inflammation
|
J:114751
|
Il4ratm1Fbb/Il4ratm2Fbb Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * BALB/c)
|
abnormal immune system physiology
|
J:114751
|
abnormal macrophage physiology
|
J:114751
|
decreased susceptibility to parasitic infection
|
J:114751
|
granulomatous inflammation
|
J:114751
|
increased susceptibility to parasitic infection
|
J:114751
|
liver inflammation
|
J:114751
|
Il4ratm1Sz/Il4ratm1Sz
(BALB/c-Il4ratm1Sz/J)
|
abnormal susceptibility to infection
|
J:131994
|
abnormal T-helper 2 physiology
|
J:43656
|
decreased IgE level
|
J:43656
|
decreased IgG1 level
|
J:43656
|
decreased interleukin-4 secretion
|
J:43656
|
decreased interleukin-5 secretion
|
J:43656
|
decreased interleukin-10 secretion
|
J:43656
|
increased IgG2a level
|
J:43656
|
Il4ratm1Sz/Il4ratm1Sz
(BALB/c-Il4ratm1Sz)
|
increased IgG2a level
|
J:110429
|
increased susceptibility to parasitic infection
|
J:110429
|
Il4ratm1Tch/Il4ratm1Tch
(involves: 129X1/SvJ * BALB/c)
|
abnormal immune serum protein physiology
|
J:86215
|
decreased T cell proliferation
|
J:86215
|
increased IgE level
|
J:86215
|
increased IgG level
|
J:86215
|
respiratory system inflammation
|
J:86215
|
Il4ratm2Tch/Il4ratm2Tch
(C.129X1-Il4ratm2Tch)
|
abnormal T-helper 2 physiology
|
J:152376
|
increased circulating interleukin-4 level
|
J:152376
|
increased IgE level
|
J:152376
|
increased susceptibility to type I hypersensitivity reaction
|
J:152376
|
respiratory system inflammation
|
J:152376
|
Il4ratm2Tch/Il4ratm2Tch Tg(Scgb1a1-rtTA,tetO-Il13)1Eli/?
(B6.Cg-Il4ratm2Tch Tg(Scgb1a1-rtTA,tetO-IL13)1Eli)
|
respiratory system inflammation
|
J:152376
|
Il4ratm3.1Tch/Il4ratm3.1Tch
(C.129X1-Il4ratm3.1Tch)
|
abnormal macrophage activation involved in immune response
|
J:160806
|
increased IgE level
|
J:160806
|
increased interleukin-4 secretion
|
J:160806
|
increased susceptibility to type I hypersensitivity reaction
|
J:160806
|
Il5tm1.1(icre)Lky/Il5+
(C57BL/6-Il5tm1.1(icre)Lky)
|
decreased circulating interleukin-5 level
|
J:206097
|
Il5tm1Anjm/Il5tm1Anjm
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal mast cell physiology
|
J:113543
|
abnormal susceptibility to infection
|
J:113543
|
decreased IgE level
|
J:113543
|
granulomatous inflammation
|
J:113543
|
increased susceptibility to parasitic infection
|
J:113543
|
Il5tm1Anjm/Il5tm1Anjm Il9tm1Anjm/Il9tm1Anjm
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal humoral immune response
|
J:113543
|
abnormal interleukin level
|
J:113543
|
abnormal mast cell physiology
|
J:113543
|
abnormal susceptibility to infection
|
J:113543
|
decreased IgE level
|
J:113543
|
granulomatous inflammation
|
J:113543
|
increased susceptibility to parasitic infection
|
J:113543
|
Il5tm1Kopf/Il5tm1Kopf
(C57BL/6-Il5tm1Kopf)
|
granulomatous inflammation
|
J:107418
|
increased interferon-gamma secretion
|
J:107418
|
Il5tm1Ktk/Il5+
(B6.129S4-Il5tm1Ktk)
|
decreased interleukin-5 secretion
|
J:180790
|
Il5tm1Ktk/Il5tm1Ktk
(B6.129S4-Il5tm1Ktk)
|
decreased interleukin-5 secretion
|
J:180790
|
Il5tm2Anjm/Il5tm2Anjm Il9tm1Anjm/Il9tm1Anjm
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal immunoglobulin level
|
J:113543
|
abnormal interleukin level
|
J:113543
|
abnormal susceptibility to infection
|
J:113543
|
granulomatous inflammation
|
J:113543
|
increased susceptibility to parasitic infection
|
J:113543
|
Il5tm3Anjm/Il5tm3Anjm
(involves: 129P2/OlaHsd * C57BL/6)
|
granulomatous inflammation
|
J:113543
|
Il5tm3Anjm/Il5tm3Anjm Il9tm1Anjm/Il9tm1Anjm
(involves: 129P2/OlaHsd * C57BL/6)
|
granulomatous inflammation
|
J:113543
|
Il5ratm1Ktk/Il5ratm1Ktk
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal immune system physiology
|
J:33140
|
decreased IgA level
|
J:33140
|
decreased IgG3 level
|
J:33140
|
decreased IgM level
|
J:33140
|
decreased immunoglobulin level
|
J:33140
|
increased susceptibility to parasitic infection
|
J:33140
|
Il5ratm1Ktk/Il5ratm1Ktk
(B6.129P2-Il5ratm1Ktk)
|
decreased B cell proliferation
|
J:89849
|
decreased IgA level
|
J:89849
|
decreased IgG1 level
|
J:89849
|
decreased IgG3 level
|
J:89849
|
decreased IgM level
|
J:89849
|
Il5ratm1Ktk/Il5ratm1Ktk Lyntm1Tya/Lyntm1Tya
(involves: 129P2/OlaHsd * C57BL/6)
|
glomerulonephritis
|
J:91089
|
increased anti-double stranded DNA antibody level
|
J:91089
|
increased IgA level
|
J:91089
|
increased IgM level
|
J:91089
|
increased immunoglobulin level
|
J:91089
|
Il6tm1Kopf/Il6+ Tg(ED-L2-IL1RN/IL1B)#Tcw/?
(B6.Cg-Il6tm1Kopf Tg(ED-L2-IL1RN/IL1B)#Tcw)
|
esophageal inflammation
|
J:180282
|
Il6tm1Kopf/Il6tm1Kopf
(involves: 129S2/SvPas * C57BL/6)
|
abnormal acute phase protein level
|
J:17360
|
decreased cytotoxic T cell cytolysis
|
J:17360
|
increased susceptibility to bacterial infection
|
J:17360
|
increased susceptibility to induced colitis
|
J:79073
|
increased susceptibility to Poxviridae infection
|
J:17360
|
Il6tm1Kopf/Il6tm1Kopf
(B6.129S2-Il6tm1Kopf/J)
|
abnormal interleukin-6 secretion
|
J:109359
|
decreased interferon-gamma secretion
|
J:123351
|
decreased susceptibility to induced arthritis
|
J:208213
|
increased interleukin-4 secretion
|
J:123351
|
Il6tm1Kopf/Il6tm1Kopf
(involves: 129S2/SvPas)
|
abnormal inflammatory response
|
J:160966
|
abnormal T cell physiology
|
J:159479
|
decreased interleukin-17 secretion
|
J:159479
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:161073
|
Il6tm1Kopf/Il6tm1Kopf Il6sttm1Ern/Il6sttm1Ern
(involves: 129S1/Sv * 129S2/SvPas)
|
decreased susceptibility to endotoxin shock
|
J:168781
|
Il6tm1Kopf/Il6tm1Kopf Junbtm3Wag/Junbtm3Wag Tg(KRT5-cre)1Tak/0
(involves: 129/Sv * 129P2/OlaHsd * 129S2/SvPas * C3H * C57BL/6)
|
skin inflammation
|
J:155575
|
Il6tm1Kopf/Il6tm1Kopf Tg(ED-L2-IL1RN/IL1B)#Tcw/?
(B6.Cg-Il6tm1Kopf Tg(ED-L2-IL1RN/IL1B)#Tcw)
|
esophageal inflammation
|
J:180282
|
Il6tm1Mur/Il6tm1Mur
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal neutrophil physiology
|
J:25684
|
increased susceptibility to bacterial infection
|
J:25684
|
Il6tm1Mur/Il6tm1Mur
(involves: 129/Sv * C57BL/6)
|
abnormal interferon level
|
J:40579
|
brain inflammation
|
J:40579
|
increased susceptibility to parasitic infection
|
J:40579
|
Il6tm1Mur/Il6tm1Mur
(B6.129P2(B6)-Il6tm1Mur)
|
abnormal inflammatory response
|
J:85581
|
abnormal microglial cell physiology
|
J:85581
|
abnormal osteoclast physiology
|
J:65093
|
Il6tm1Poli/Il6tm1Poli
(involves: 129S/SvEv * MF1)
|
abnormal macrophage physiology
|
J:79314
|
abnormal neutrophil physiology
|
J:79314
|
abnormal osteoclast physiology
|
J:17249
|
abnormal T-helper 1 physiology
|
J:79314
|
abnormal T-helper 2 physiology
|
J:79314
|
decreased circulating interleukin-12 level
|
J:79314
|
decreased IgA level
|
J:79314
|
decreased IgE level
|
J:79314
|
increased circulating interleukin-10 level
|
J:79314
|
increased IgG2a level
|
J:79314
|
increased susceptibility to fungal infection
|
J:79314
|
Il6tm1Poli/Il6tm1Poli
(involves: 129S/SvEv * C57BL/6)
|
decreased inflammatory response
|
J:68063
|
impaired neutrophil recruitment
|
J:68063
|
Il6tm1Poli/Il6tm1Poli
(CAnNCrl.129S(Cg)-Il6tm1Poli)
|
abnormal B cell proliferation
|
J:42869
|
abnormal immune system physiology
|
J:96706
|
decreased inflammatory response
|
J:42869
|
Il6ratm1.1(IL6R)Csk/Il6ratm1.1(IL6R)Csk
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal circulating serum amyloid protein level
|
J:207264
|
Il6ratm1.1Drew/Il6ratm1.1Drew Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: C57BL/6 * C57BL/6N * SJL)
|
decreased acute inflammation
|
J:160966
|
Il6ratm1.1Jcbr/Il6ratm1.1Jcbr Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased circulating interleukin-1 beta level
|
J:188445
|
decreased circulating tumor necrosis factor level
|
J:188445
|
decreased susceptibility to parasitic infection
|
J:188445
|
Il6ratm1.1Jcbr/Il6ratm1.1Jcbr Tg(Alb1-cre)7Gsc/0
(involves: C57BL/6 * FVB/N)
|
decreased circulating interleukin-1 beta level
|
J:188445
|
decreased circulating tumor necrosis factor level
|
J:188445
|
decreased susceptibility to parasitic infection
|
J:188445
|
increased circulating interleukin-6 level
|
J:166367
|
increased circulating tumor necrosis factor level
|
J:166367
|
Il6ratm1.2Drew/Il6ratm1.2Drew
(involves: C57BL/6 * C57BL/6N * FVB/N * SJL)
|
abnormal inflammatory response
|
J:160966
|
Il6ratm1.2Jcbr/Il6ratm1.2Jcbr
(involves: C57BL/6)
|
decreased circulating interleukin-1 beta level
|
J:188445
|
decreased circulating tumor necrosis factor level
|
J:188445
|
decreased susceptibility to parasitic infection
|
J:188445
|
decreased susceptibility to parasitic infection induced morbidity/mortality
|
J:188445
|
liver inflammation
|
J:202764
|
Il6ratm1Saj/Il6ratm1Saj
(involves: 129P2/OlaHsd * C57BL/6J)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:159479
|
Il6sttm1Ard/Il6sttm1Ard
(involves: 129S1/Sv * C57BL/6)
|
cecum inflammation
|
J:79555
|
conjunctivitis
|
J:79555
|
decreased IgA level
|
J:79555
|
decreased IgG level
|
J:79555
|
decreased immunoglobulin level
|
J:79555
|
increased inflammatory response
|
J:79555
|
increased susceptibility to induced colitis
|
J:79073
|
increased susceptibility to parasitic infection
|
J:79555
|
Il6sttm1Ern/Il6sttm1Ern
(involves: 129S1/Sv * C57BL/6)
|
abnormal inflammatory response
|
J:139226
|
decreased susceptibility to induced colitis
|
J:79073
|
increased susceptibility to induced arthritis
|
J:142883
|
stomach inflammation
|
J:87206
|
Il6sttm1Ern/Il6sttm1Ern
(involves: 129S1/Sv)
|
increased circulating interleukin-6 level
|
J:168781
|
increased interleukin-6 secretion
|
J:168781
|
increased susceptibility to endotoxin shock
|
J:168781
|
Il6sttm1Ern/Il6sttm1Ern Stat1tm1Rds/Stat1tm1Rds
(involves: 129S1/Sv)
|
abnormal inflammatory response
|
J:139226
|
Il6sttm1Ern/Il6sttm1Ern Stat3tm1Aki/Stat3+
(involves: 129P2/OlaHsd * 129S1/Sv)
|
decreased circulating interleukin-6 level
|
J:168781
|
decreased susceptibility to endotoxin shock
|
J:168781
|
Il6sttm1Ern/Il6sttm1Ern Tiraptm1.1Pjh/Tiraptm1.1Pjh
(involves: 129S1/Sv)
|
decreased circulating interleukin-6 level
|
J:168781
|
decreased susceptibility to endotoxin shock
|
J:168781
|
Il6sttm1Kish/Il6sttm1Kish
(involves: 129P2/OlaHsd * CD-1)
|
abnormal osteoclast physiology
|
J:88710
|
Il6sttm1Thir/Il6sttm1Thir
(Not Specified)
|
abnormal B cell physiology
|
J:59922
|
abnormal dendritic cell antigen presentation
|
J:113335
|
decreased interleukin-4 secretion
|
J:59922
|
increased IgG2a level
|
J:59922
|
increased IgG2b level
|
J:59922
|
increased interferon-gamma secretion
|
J:59922
|
Il6sttm1Thir/Il6sttm1Thir
(involves: 129 * C57BL/6)
|
abnormal T cell activation
|
J:133059
|
abnormal T cell clonal deletion
|
J:133059
|
abnormal thymocyte activation
|
J:133059
|
increased anti-double stranded DNA antibody level
|
J:133059
|
increased anti-nuclear antigen antibody level
|
J:133059
|
increased anti-single stranded DNA antibody level
|
J:133059
|
increased autoantibody level
|
J:133059
|
increased IgA level
|
J:133059
|
increased IgG1 level
|
J:133059
|
increased IgG2a level
|
J:133059
|
increased IgG2b level
|
J:133059
|
rheumatoid arthritis
|
J:133059
|
Il6sttm1Wme/Il6sttm1Wme
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal immunoglobulin level
|
J:67677
|
increased IgE level
|
J:67677
|
increased IgG level
|
J:67677
|
Il6sttm2Thir/Il6sttm2Thir
(Not Specified)
|
abnormal dendritic cell antigen presentation
|
J:113335
|
decreased IgG1 level
|
J:59922
|
decreased IgG2a level
|
J:59922
|
decreased IgG2b level
|
J:59922
|
decreased interferon-gamma secretion
|
J:59922
|
increased IgM level
|
J:59922
|
Il6sttm3Thir/Il6sttm3Thir
(Not Specified)
|
decreased IgA level
|
J:59922
|
decreased IgG2a level
|
J:59922
|
decreased IgG2b level
|
J:59922
|
Il7tm2.1Iku/Il7tm2.1Iku Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * DBA)
|
abnormal NK T cell physiology
|
J:190615
|
Il7rtm1Abra/Il7rtm1Abra
(B6.129S4-Il7rtm1Abra)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:125360
|
abnormal T cell proliferation
|
J:125360
|
Il7rtm1Imx/Il7rtm1Imx Tg(Lck-Il7r)1676Trma/?
(involves: 129S7/SvEvBrd * C57BL/6 * SJL)
|
decreased T cell proliferation
|
J:66400
|
increased thymocyte apoptosis
|
J:66400
|
Il9tm1Anjm/Il9tm1Anjm
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal response to infection
|
J:82881
|
granulomatous inflammation
|
J:82881,
J:113543
|
increased susceptibility to parasitic infection
|
J:82881
|
Il9tm1Anjm/Il9tm1Anjm
(involves: C57BL/6)
|
abnormal cytokine secretion
|
J:115764
|
Il9tm1Flv/Il9tm1Flv
(BALB/c-Il9tm1Flv)
|
increased susceptibility to parasitic infection
|
J:208730
|
Il9rtm1Jcrd/Il9rtm1Jcrd
(involves: C57BL/6)
|
abnormal regulatory T cell physiology
|
J:151907
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:151907
|
Il10tm1.1Roer/Il10tm1.1Roer
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal cytokine secretion
|
J:94537
|
abnormal hypersensitivity reaction
|
J:94537
|
abnormal innate immunity
|
J:94537
|
increased susceptibility to bacterial infection
|
J:94537
|
intestinal inflammation
|
J:94537
|
Il10tm1.1Roer/Il10tm1.1Roer
(involves: 129P2/OlaHsd)
|
decreased circulating interleukin-10 level
|
J:151551
|
increased susceptibility to endotoxin shock
|
J:151551
|
Il10tm1Cgn/Il10tm1Cgn
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal cytokine level
|
J:35020
|
abnormal immune system physiology
|
J:35020
|
abnormal interferon level
|
J:35020,
J:107077,
J:125760
|
abnormal interleukin level
|
J:35020,
J:107077,
J:51636
|
abnormal Langerhans cell physiology
|
J:51636
|
abnormal level of surface class II molecules
|
J:15222
|
abnormal response to infection
|
J:15222
|
abnormal tumor necrosis factor level
|
J:107077,
J:51636
|
abnormal type IV hypersensitivity reaction
|
J:35510
|
cecum inflammation
|
J:35020
|
chronic inflammation
|
J:15222
|
colitis
|
J:68476
|
decreased length of allograft survival
|
J:44346
|
decreased T cell proliferation
|
J:125760
|
increased IgE level
|
J:62283
|
increased IgG1 level
|
J:62283
|
increased IgG2a level
|
J:62283
|
increased interferon-gamma secretion
|
J:15222
|
increased susceptibility to parasitic infection
|
J:123927
|
increased susceptibility to type IV hypersensitivity reaction
|
J:51636
|
intestinal inflammation
|
J:35020,
J:107077,
J:15222
|
large intestinal inflammation
|
J:35020
|
small intestinal inflammation
|
J:35020
|
Il10tm1Cgn/Il10tm1Cgn
(involves: 129P2/OlaHsd)
|
abnormal cytokine secretion
|
J:117122
|
abnormal inflammatory response
|
J:117122
|
increased circulating interleukin-12 level
|
J:118833
|
increased circulating tumor necrosis factor level
|
J:118833
|
increased susceptibility to endotoxin shock
|
J:117122,
J:118833
|
intestinal inflammation
|
J:113376
|
Il10tm1Cgn/Il10tm1Cgn
(B6.129P2-Il10tm1Cgn/J)
|
abnormal chemokine level
|
J:157787
|
abnormal cytokine level
|
J:157787,
J:139972
|
abnormal regulatory T cell physiology
|
J:125748
|
cecum inflammation
|
J:157787
|
increased circulating interferon-gamma level
|
J:157787
|
increased circulating interleukin-1 alpha level
|
J:157787
|
increased circulating interleukin-1 beta level
|
J:157787,
J:139972
|
increased circulating interleukin-2 level
|
J:157787
|
increased circulating interleukin-6 level
|
J:157787,
J:139972
|
increased circulating interleukin-12 level
|
J:157787
|
increased circulating interleukin-17 level
|
J:157787
|
increased circulating tumor necrosis factor level
|
J:157787
|
increased susceptibility to induced colitis
|
J:157787
|
increased susceptibility to parasitic infection
|
J:157787
|
large intestinal inflammation
|
J:149347
|
Il10tm1Cgn/Il10tm1Cgn
(involves: 129P2/OlaHsd * C57BL/6 * DBA/1)
|
colitis
|
J:84100
|
Il10tm1Cgn/Il10tm1Cgn
(involves: 129P2/OlaHsd * 129S/SvEv)
|
colitis
|
J:59872
|
Il10tm1Cgn/Il10tm1Cgn
(B10.129P2(B6)-Il10tm1Cgn/J)
|
decreased length of allograft survival
|
J:44346
|
Il10tm1Cgn/Il10tm1Cgn
(B6.129P2-Il10tm1Cgn)
|
abnormal circulating interleukin-6 level
|
J:191723
|
abnormal circulating interleukin-12b level
|
J:191723
|
Il10tm1Cgn/Il10tm1Cgn Il4tm1Cgn/Il4tm1Cgn
(involves: 129P2/OlaHsd * C57BL/6)
|
increased interferon-gamma secretion
|
J:111712
|
Il10tm1Cgn/Il10tm1Cgn Il12btm1Jm/Il12btm1Jm
(involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6)
|
increased interleukin-13 secretion
|
J:111712
|
Il10tm1Cgn/Il10tm1Cgn Il27ratm1Mak/Il27ratm1Mak
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal T-helper 1 physiology
|
J:136179
|
abnormal T-helper 2 physiology
|
J:136179
|
colitis
|
J:136179
|
decreased interferon-gamma secretion
|
J:136179
|
decreased susceptibility to induced colitis
|
J:136179
|
increased interleukin-13 secretion
|
J:136179
|
Il10tm1Cgn/Il10tm1Cgn Nfil3tm1Look/Nfil3tm1Look
(involves: 129P2/OlaHsd * 129X1/SvJ)
|
colitis
|
J:209365
|
increased interleukin-12 secretion
|
J:209365
|
Il10tm1Cgn/Il10tm1Cgn Nfil3tm1Pbro/Nfil3tm1Pbro
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6)
|
colitis
|
J:209365
|
increased interleukin-12 secretion
|
J:209365
|
Il10tm1Cgn/Il10tm1Cgn Rps6ka4tm1Jsca/Rps6ka4tm1Jsca Rps6ka5tm1Jsca/Rps6ka5tm1Jsca
(B6.Cg-Il10tm1Cgn Rps6ka5tm1Jsca Rps6ka4tm1Jsca)
|
decreased interleukin-10 secretion
|
J:139576
|
increased interleukin-6 secretion
|
J:139576
|
increased interleukin-12a secretion
|
J:139576
|
increased interleukin-12b secretion
|
J:139576
|
increased tumor necrosis factor secretion
|
J:139576
|
Il10tm1Cgn/Il10tm1Cgn Tg(MUC1)79.24Gend/0
(B6.Cg-Il10tm1Cgn Tg(MUC1)79.24Gend)
|
large intestinal inflammation
|
J:149347
|
Il10tm1Cgn/Il10tm1Cgn Tg(Vil1-cre)997Gum/? Tlr5tm1.1Gewr/Tlr5tm1.1Gewr
(involves: 129P2/OlaHsd * C57BL/6J * C57BL/6NTac * SJL)
|
colitis
|
J:229155
|
Il10tm1Cgn/Il10tm1Cgn Tlr5tm1.1Gewr/Tlr5tm1.1Gewr
(involves: 129P2/OlaHsd * C57BL/6J * C57BL/6NTac)
|
colitis
|
J:229155
|
Il10tm1Cgn/Il10tm1Cgn Vdrtm1Mbd/Vdrtm1Mbd
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:107077
|
abnormal cytokine level
|
J:107077
|
abnormal thymus involution
|
J:107077
|
colitis
|
J:107077
|
decreased T cell proliferation
|
J:107077
|
increased T cell apoptosis
|
J:107077
|
intestinal inflammation
|
J:107077
|
Il10tm1Keny/Il10+ Nfil3tm1.1Kubo/Nfil3tm1.1Kubo
(involves: 129 * C57BL/6)
|
decreased interleukin-10 secretion
|
J:172134
|
Il10tm1Mhry/Il10tm1Mhry
(involves: 129P2/OlaHsd * C57BL/6)
|
intestinal inflammation
|
J:117628
|
Il10tm1Roer/Il10tm1Roer Foxp3tm4(YFP/icre)Ayr/Y
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal regulatory T cell physiology
|
J:134513
|
abnormal type IV hypersensitivity reaction
|
J:134513
|
colitis
|
J:134513
|
decreased interleukin-10 secretion
|
J:134513
|
lung inflammation
|
J:134513
|
Il10tm1Roer/Il10tm1Roer Tg(Cd4-cre)1Cwi/0
(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * DBA/2)
|
abnormal cytokine secretion
|
J:94537
|
abnormal hypersensitivity reaction
|
J:94537
|
increased susceptibility to parasitic infection
|
J:94537
|
intestinal inflammation
|
J:94537
|
liver inflammation
|
J:94537
|
peritoneal inflammation
|
J:94537
|
Il10tm2Roer/Il10tm2Roer Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal cytokine secretion
|
J:117122
|
abnormal inflammatory response
|
J:117122
|
increased susceptibility to endotoxin shock
|
J:117122
|
Il10tm2Roer/Il10tm2Roer Tg(Cd4-cre)1Cwi/0
(involves: C57BL/6 * DBA/2)
|
abnormal inflammatory response
|
J:117122
|
increased susceptibility to endotoxin shock
|
J:117122
|
Il10ram1Jskg/Il10ram1Jskg
(B6.Cg-Il10ram1Jskg)
|
colitis
|
J:146644
|
Il10raNZW/Il10ra+
((NZB x NZW)F1)
|
increased anti-chromatin antibody level
|
J:102087
|
increased IgG level
|
J:102087
|
Il10ratm1.1Jack/Il10ratm1.1Jack Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * BALB/c * C57BL/6)
|
abnormal chemokine level
|
J:157787
|
abnormal cytokine level
|
J:157787
|
increased circulating interferon-gamma level
|
J:157787
|
increased circulating interleukin-1 alpha level
|
J:157787
|
increased circulating interleukin-1 beta level
|
J:157787
|
increased circulating interleukin-2 level
|
J:157787
|
increased circulating interleukin-12 level
|
J:157787
|
increased circulating interleukin-17 level
|
J:157787
|
increased circulating tumor necrosis factor level
|
J:157787
|
increased susceptibility to parasitic infection
|
J:157787
|
Il10ratm1.1Tlg/Il10ratm1.1Tlg Tg(Cd4-cre)1Cwi/?
(B6.Cg-Tg(Cd4-cre)1Cwi Il10ratm1.1Tlg)
|
autoimmune response
|
J:189797
|
decreased splenocyte proliferation
|
J:189797
|
Il10ratm1.2Jack/Il10ratm1.2Jack
(involves: 129P2/OlaHsd * BALB/c * C57BL/6 * DBA/2)
|
abnormal chemokine level
|
J:157787
|
abnormal cytokine level
|
J:157787
|
cecum inflammation
|
J:157787
|
increased circulating interferon-gamma level
|
J:157787
|
increased circulating interleukin-1 alpha level
|
J:157787
|
increased circulating interleukin-1 beta level
|
J:157787
|
increased circulating interleukin-2 level
|
J:157787
|
increased circulating interleukin-6 level
|
J:157787
|
increased circulating interleukin-12 level
|
J:157787
|
increased circulating interleukin-17 level
|
J:157787
|
increased circulating tumor necrosis factor level
|
J:157787
|
increased susceptibility to induced colitis
|
J:157787
|
increased susceptibility to parasitic infection
|
J:157787
|
Il10rbtm1Agt/Il10rbtm1Agt
(involves: 129S2/SvPas * C57BL/6)
|
colitis
|
J:134156
|
increased interferon-gamma secretion
|
J:134156
|
increased interleukin-17 secretion
|
J:134156
|
large intestinal inflammation
|
J:45917
|
Il10rbtm1Agt/Il10rbtm1Agt Tg(Cd4-TGFBR2)16Flv/?
(involves: 129S2/SvPas * C3H * C57BL/6)
|
abnormal cytokine level
|
J:134156
|
abnormal cytokine secretion
|
J:134156
|
colitis
|
J:134156
|
increased circulating interferon-gamma level
|
J:134156
|
increased circulating interleukin-6 level
|
J:134156
|
increased circulating tumor necrosis factor level
|
J:134156
|
increased interferon-gamma secretion
|
J:134156
|
increased interleukin-17 secretion
|
J:134156
|
increased tumor necrosis factor secretion
|
J:134156
|
liver inflammation
|
J:134156
|
lung inflammation
|
J:134156
|
proctitis
|
J:134156
|
Il11tm2.1Moto/Il11tm2.1Moto Tg(BGLAP-cre)1Clem/0
(involves: C57BL/6NCrlj * CBA/JNCrlj * FVB/NJ)
|
abnormal circulating interleukin level
|
J:345337
|
Il11ra1tm1Wehi/Il11ra1tm1Wehi Il6tm1Kopf/Il6tm1Kopf
(involves: 129/Sv * C57BL/6)
|
increased susceptibility to induced colitis
|
J:79073
|
Il12am1Btlr/Il12am1Btlr
(C57BL/6J-Il12am1Btlr)
|
increased susceptibility to Herpesvirales infection
|
J:267667
|
Il12atm1Cab/Il12atm1Cab
(involves: 129S4/SvJae * C57BL/6)
|
decreased circulating interferon-gamma level
|
J:54482
|
decreased circulating interleukin-12 level
|
J:54482
|
Il12atm1Cab/Il12atm1Cab
(B6.129S4-Il12atm1Cab)
|
abnormal NK cell physiology
|
J:79552
|
decreased circulating interferon-gamma level
|
J:79552
|
Il12atm1Cab/Il12atm1Cab Il23atm1.1Thak/Il23atm1.1Thak
(B6.Cg-Il12atm1Cab Il23atm1.1Thak)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:143970
|
Il12atm1Jm/Il12atm1Jm
(129S1/Sv-Il12atm1Jm)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:34164
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:34164
|
increased susceptibility to parasitic infection
|
J:34164
|
Il12atm1Jm/Il12atm1Jm
(C.129S1-Il12atm1Jm)
|
impaired natural killer cell mediated cytotoxicity
|
J:125611
|
Il12atm1Jm/Il12atm1Jm
(involves: 129S1/Sv)
|
abnormal NK cell physiology
|
J:139001
|
Il12atm1Jm/Il12atm1Jm Il12btm1Jm/Il12btm1Jm
(B6.129S1-Il12atm1Jm Il12btm1Jm)
|
impaired natural killer cell mediated cytotoxicity
|
J:125611
|
Il12atm1Jm/Il12atm1Jm Rag2tm1Fwa/Rag2tm1Fwa
(involves: 129S/SvEv * 129S1/Sv * 129S6/SvEvTac)
|
abnormal interferon secretion
|
J:140483
|
decreased susceptibility to bacterial infection
|
J:140483
|
lung inflammation
|
J:140483
|
Il12btm1Jm/Il12btm1Jm
(B6.129S1-Il12btm1Jm/J)
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:111568
|
abnormal granulocyte physiology
|
J:111568
|
abnormal lymphocyte physiology
|
J:120806
|
abnormal macrophage physiology
|
J:111568
|
abnormal NK cell physiology
|
J:120806
|
decreased circulating interferon-gamma level
|
J:120806
|
decreased interleukin-17 secretion
|
J:111568
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:120806
|
increased susceptibility to bacterial infection
|
J:120806
|
Il12btm1Jm/Il12btm1Jm
(129S1/Sv-Il12btm1Jm)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:34164
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:34164
|
increased susceptibility to parasitic infection
|
J:34164
|
Il12btm1Jm/Il12btm1Jm
(involves: 129S1/SvImJ)
|
abnormal T-helper 1 physiology
|
J:46514
|
decreased interferon-gamma secretion
|
J:46514
|
impaired natural killer cell mediated cytotoxicity
|
J:46514
|
Il12btm1Jm/Il12btm1Jm
(involves: 129S1/Sv)
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:161073
|
Il12btm1Jm/Il12btm1Jm Il18tm1Aki/Il18tm1Aki
(involves: 129P2/OlaHsd * 129S1/SvImJ)
|
abnormal T-helper 1 physiology
|
J:46514
|
decreased interferon-gamma secretion
|
J:46514
|
impaired natural killer cell mediated cytotoxicity
|
J:46514
|
Il12btm1Jm/Il12btm1Jm Rag2tm1Fwa/Rag2tm1Fwa
(involves: 129S/SvEv * 129S1/Sv)
|
abnormal chemokine secretion
|
J:140483
|
abnormal interferon secretion
|
J:140483
|
increased susceptibility to bacterial infection
|
J:140483
|
lung inflammation
|
J:140483
|
Il12btm1Jm/Il12btm1Jm Tnftm2Gkl/Tnf+
(involves: 129S/SvEv * 129S1/Sv * C57BL/6J)
|
small intestinal inflammation
|
J:108572
|
Il12rb1tm1Jm/Il12rb1tm1Jm
(involves: 129S1/Sv * C57BL/6J)
|
abnormal lymphocyte physiology
|
J:42105
|
decreased circulating interferon-gamma level
|
J:42105
|
decreased interferon-gamma secretion
|
J:42105
|
Il12rb2Ifnm-d/Il12rb2Ifnm-d Tlr4lps-del/Tlr4lps-del
(C57BL/10ScCr)
|
abnormal dendritic cell physiology
|
J:91014
|
abnormal granulocyte physiology
|
J:91014
|
abnormal immune cell physiology
|
J:91014
|
abnormal macrophage physiology
|
J:91014
|
abnormal NK cell physiology
|
J:91014
|
decreased interferon-gamma secretion
|
J:91014,
J:70821
|
increased interleukin-4 secretion
|
J:91014
|
increased susceptibility to bacterial infection
|
J:91014,
J:70821
|
Il12rb2tm1Jm/Il12rb2tm1Jm
(either: (involves: 129S1/Sv * BALB/cByJ) or (involves: 129S1/Sv * C57BL/6J))
|
abnormal lymphocyte physiology
|
J:65891
|
abnormal NK cell physiology
|
J:65891
|
Il12rb2tm1Jm/Il12rb2tm1Jm
(B6;129S1-Il12rb2tm1Jm/J)
|
abnormal B cell activation
|
J:106805
|
abnormal T cell activation
|
J:106805
|
glomerulonephritis
|
J:106805
|
increased anti-nuclear antigen antibody level
|
J:106805
|
increased circulating interleukin-12 level
|
J:120061
|
increased interleukin-6 secretion
|
J:106805
|
liver inflammation
|
J:106805
|
parotid gland inflammation
|
J:106805
|
salivary gland inflammation
|
J:106805
|
submandibular gland inflammation
|
J:106805
|
Il13tm1(YFP/cre)Lky/Il13+ Il4tm1(CD2)Mmrs/Il4+ Gt(ROSA)26Sortm1(DTA)Lky/Gt(ROSA)26Sor+
(involves: 129P2/OlaHsd * 129S4/SvJae)
|
increased susceptibility to parasitic infection
|
J:178986
|
Il13tm1.1Anjm/Il13tm1.1Anjm
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased circulating interleukin-13 level
|
J:67965
|
decreased IgE level
|
J:67965
|
decreased interleukin-4 secretion
|
J:67965
|
decreased interleukin-5 secretion
|
J:67965
|
decreased interleukin-10 secretion
|
J:67965
|
increased IgG2b level
|
J:67965
|
increased IgM level
|
J:67965
|
increased interferon-gamma secretion
|
J:67965
|
Il13tm1.1Anjm/Il13tm1.1Anjm
(C.129P2-Il13tm1.1Anjm)
|
abnormal dendritic cell antigen presentation
|
J:141937
|
decreased IgE level
|
J:91403
|
decreased interleukin-5 secretion
|
J:141937
|
decreased interleukin-13 secretion
|
J:141937,
J:91403
|
decreased susceptibility to autoimmune disorder
|
J:141937,
J:91403
|
increased IgG2a level
|
J:91403
|
increased interferon-gamma secretion
|
J:141937
|
Il13tm1.1Anjm/Il13tm1.1Anjm Tg(DO11.10)10Dlo/0
(involves: 129P2/OlaHsd * BALB/c * C3H * C57BL/6)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:91403
|
decreased interleukin-13 secretion
|
J:91403
|
Il13tm1Anjm/Il13+ Il4tm1.1Wep/Il4+
(involves: 129P2/OlaHsd * BALB/c * C57BL/6)
|
decreased interleukin-4 secretion
|
J:69099
|
Il13tm1Anjm/Il13tm1Anjm
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal interleukin secretion
|
J:82881
|
decreased interleukin-4 secretion
|
J:82881
|
decreased interleukin-5 secretion
|
J:82881
|
decreased interleukin-9 secretion
|
J:82881
|
granulomatous inflammation
|
J:82881,
J:113543
|
increased susceptibility to parasitic infection
|
J:113543
|
Il13tm1Anjm/Il13tm1Anjm
(C.129P2-Il13tm1Anjm)
|
decreased interleukin-4 secretion
|
J:69099
|
decreased interleukin-13 secretion
|
J:69099
|
Il13tm1Anjm/Il13tm1Anjm Il5tm3Anjm/Il5tm3Anjm
(involves: 129P2/OlaHsd * C57BL/6)
|
granulomatous inflammation
|
J:113543
|
increased susceptibility to parasitic infection
|
J:113543
|
Il13tm2Anjm/Il13tm2Anjm
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal splenocyte physiology
|
J:72587
|
abnormal T-helper 2 physiology
|
J:89095
|
decreased susceptibility to parasitic infection induced morbidity/mortality
|
J:60609
|
increased susceptibility to parasitic infection
|
J:89095
|
Il13tm2Anjm/Il13tm2Anjm
(C.129P2(B6)-Il13tm2Anjm)
|
abnormal response to transplant
|
J:110188
|
abnormal type I hypersensitivity reaction
|
J:123772
|
increased length of allograft survival
|
J:110188
|
increased susceptibility to type I hypersensitivity reaction
|
J:123772
|
Il13tm2Anjm/Il13tm2Anjm
(involves: 129)
|
decreased circulating interleukin-13 level
|
J:67965
|
decreased IgE level
|
J:67965
|
decreased interleukin-4 secretion
|
J:67965
|
decreased interleukin-5 secretion
|
J:67965
|
decreased interleukin-10 secretion
|
J:67965
|
increased IgG2b level
|
J:67965
|
increased IgM level
|
J:67965
|
increased interferon-gamma secretion
|
J:67965
|
Il13tm2Anjm/Il13tm2Anjm
(involves: 129P2/OlaHsd * BALB/c * C57BL/6)
|
abnormal chemokine level
|
J:131994
|
abnormal macrophage physiology
|
J:176092
|
abnormal susceptibility to infection
|
J:131994
|
decreased susceptibility to bacterial infection
|
J:176092
|
decreased susceptibility to parasitic infection
|
J:60609
|
decreased susceptibility to parasitic infection induced morbidity/mortality
|
J:60609
|
impaired eosinophil recruitment
|
J:126675
|
impaired neutrophil recruitment
|
J:105813
|
Il13tm2Anjm/Il13tm2Anjm
(B6.129P2-Il13tm2Anjm)
|
abnormal antigen presentation
|
J:131969
|
abnormal leukocyte physiology
|
J:131969
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:131969
|
Il13ra1tm1Twy/Y
(C.Cg-Il13ra1tm1Twy)
|
abnormal response to infection
|
J:130488
|
abnormal T-helper 2 physiology
|
J:130488
|
decreased IgE level
|
J:130488
|
decreased susceptibility to parasitic infection
|
J:130488
|
increased circulating interleukin-5 level
|
J:130488
|
increased IgA level
|
J:130488
|
increased IgG1 level
|
J:130488
|
increased IgG3 level
|
J:130488
|
Il13ra2tm1Gru/Il13ra2tm1Gru
(C.Cg-Il13ra2tm1Gru)
|
abnormal macrophage physiology
|
J:82376
|
decreased circulating interleukin-13 level
|
J:82376
|
decreased interleukin-4 secretion
|
J:82376
|
decreased susceptibility to endotoxin shock
|
J:82376
|
increased IgA level
|
J:82376
|
increased IgE level
|
J:82376
|
increased IgG2a level
|
J:82376
|
increased IgG2b level
|
J:82376
|
increased interferon-gamma secretion
|
J:82376
|
increased interleukin-10 secretion
|
J:82376
|
Il15m1Hwata/Il15m1Hwata
(Not Specified)
|
abnormal interleukin secretion
|
J:184570
|
decreased interferon-gamma secretion
|
J:184570
|
Il15tm1Imx/Il15tm1Imx
(involves: C57BL/6)
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:95221
|
abnormal cytokine secretion
|
J:97620
|
abnormal immune system physiology
|
J:60915
|
abnormal susceptibility to infection
|
J:60915
|
decreased IgG level
|
J:97620
|
decreased IgM level
|
J:97620
|
decreased immunoglobulin level
|
J:97620
|
decreased interferon-gamma secretion
|
J:97620
|
decreased interleukin-12 secretion
|
J:97620
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:84009
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:87137
|
impaired natural killer cell mediated cytotoxicity
|
J:97620
|
increased susceptibility to Herpesvirales infection induced morbidity/mortality
|
J:97038
|
increased susceptibility to parasitic infection
|
J:97620
|
increased susceptibility to Poxviridae infection induced morbidity/mortality
|
J:60915
|
Il15tm1Imx/Il15tm1Imx
(C57BL/6-Il15tm1Imx)
|
abnormal dendritic cell physiology
|
J:123902
|
Il15tm1Imx/Il15tm1Imx X/Yaa
(BXSB.B6-Il15tm1Imx/Dcr)
|
increased susceptibility to systemic lupus erythematosus
|
J:179430
|
Il15ratm1.1Nsl/Il15ratm1.1Nsl
(involves: 129X1/SvJ * C57BL/6)
|
abnormal T cell apoptosis
|
J:73738
|
increased thymocyte apoptosis
|
J:73738
|
Il15ratm1.1Nsl/Il15ratm1.1Nsl
(B6.129X1-Il15ratm1.1Nsl)
|
abnormal T cell activation
|
J:92705
|
abnormal T cell proliferation
|
J:92705
|
increased interleukin-2 secretion
|
J:92705
|
increased T cell proliferation
|
J:92705
|
Il15ratm1.1Nsl/Il15ratm1.1Nsl Tg(TcrAND)53Hed/?
(involves: 129X1/SvJ * C57BL/6 * SJL)
|
increased T cell proliferation
|
J:92705
|
Il15ratm1Ama/Il15ratm1Ama
(involves: 129X1/SvJ)
|
abnormal NK cell physiology
|
J:119213
|
decreased T cell proliferation
|
J:142570
|
impaired natural killer cell mediated cytotoxicity
|
J:142570
|
Il15ratm1Ama/Il15ratm2.1Ama Lyz2tm1(cre)Ifo/0 Tg(Itgax-cre)1-1Reiz/0
(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * CBA)
|
abnormal immune system physiology
|
J:155298
|
Il15ratm1Ama/Il15ratm2.1Ama Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6J)
|
abnormal immune system physiology
|
J:155298
|
abnormal NK cell physiology
|
J:155298
|
Il15ratm1Ama/Il15ratm2.1Ama Tg(Itgax-cre)1-1Reiz/0
(involves: 129X1/SvJ * C57BL/6J * CBA)
|
abnormal NK cell physiology
|
J:155298
|
Il15ratm1Wjl/Il15ratm1Wjl
(involves: 129 * C57BL/6)
|
abnormal T cell physiology
|
J:142570
|
decreased T cell proliferation
|
J:142570
|
Il16tm1Korn/Il16tm1Korn
(either: B6.129X1-Il16tm1Korn or C.129X1-Il16tm1Korn)
|
abnormal T cell physiology
|
J:97739
|
Il17a/Il17ftm1.1Impr/Il17a/Il17ftm1.1Impr
(involves: C57BL/6)
|
decreased interleukin-17 secretion
|
J:187400
|
increased T cell proliferation
|
J:187400
|
Il17a/Il17ftm1.1Impr/Il17a/Il17ftm1.1Impr
(involves: C57BL/6)
|
decreased interleukin-17 secretion
|
J:187400
|
increased T cell proliferation
|
J:187400
|
Il17atm1Cdon/Il17atm1Cdon
(involves: C57BL/6)
|
chronic inflammation
|
J:136279
|
decreased IgG1 level
|
J:136279
|
decreased IgG2a level
|
J:136279
|
decreased IgG2b level
|
J:136279
|
decreased IgM level
|
J:136279
|
decreased interleukin-17 secretion
|
J:136279
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:136279
|
increased susceptibility to induced colitis
|
J:136279
|
Il17atm1Yiw/Il17atm1Yiw
(involves: 129P2/OlaHsd * C57BL/6J)
|
decreased IgG level
|
J:79127
|
decreased immunoglobulin level
|
J:79127
|
decreased interferon-gamma secretion
|
J:79127
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:79127
|
Il17atm1Yiw/Il17atm1Yiw
(involves: 129P2/OlaHsd * BALB/cA * C57BL/6J)
|
abnormal interleukin level
|
J:79127
|
abnormal Langerhans cell physiology
|
J:79127
|
decreased IgE level
|
J:79127
|
decreased IgG1 level
|
J:79127
|
decreased immunoglobulin level
|
J:79127
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:79127
|
Il17atm1Yiw/Il17atm1Yiw
(involves: 129P2/OlaHsd * C57BL/6)
|
increased susceptibility to bacterial infection
|
J:143719
|
Il17atm1Yiw/Il17atm1Yiw
(involves: 129P2/OlaHsd)
|
abnormal immune system physiology
|
J:144710
|
Il17atm1Yiw/Il17atm1Yiw
(B6.129P2-Il17atm1Yiw)
|
increased susceptibility to infection induced morbidity/mortality
|
J:160680
|
Il17atm1Yiw/Il17atm1Yiw Il1rntm1Yiw/Il1rntm1Yiw
(involves: 129P2/OlaHsd * BALB/cA * C57BL/6J)
|
decreased susceptibility to induced arthritis
|
J:83408
|
Il17atm1Yiw/Il17atm1Yiw Il17ftm1Yiw/Il17ftm1Yiw
(involves: 129P2/OlaHsd * C57BL/6)
|
increased susceptibility to bacterial infection
|
J:143719
|
Il17atm1Yiw/Il17atm1Yiw Il17ftm1Yiw/Il17ftm1Yiw Il1rntm1Yiw/Il1rntm1Yiw
(involves: 129 * BALB/c)
|
rheumatoid arthritis
|
J:143719
|
Il17atm1Yiw/Il17atm1Yiw Il17ftm2Yiw/Il17ftm2Yiw
(involves: 129P2/OlaHsd * BALB/c)
|
decreased IgG3 level
|
J:143719
|
increased IgG1 level
|
J:143719
|
increased IgG2a level
|
J:143719
|
increased IgG2b level
|
J:143719
|
increased susceptibility to bacterial infection
|
J:143719
|
nasal inflammation
|
J:143719
|
Il17atm1Yiw/Il17atm1Yiw Il17ftm2Yiw/Il17ftm2Yiw
(B6.129P2-Il17atm1Yiw Il17ftm2Yiw)
|
decreased IgG3 level
|
J:143719
|
increased IgG1 level
|
J:143719
|
increased IgG2a level
|
J:143719
|
increased IgG2b level
|
J:143719
|
increased susceptibility to infection induced morbidity/mortality
|
J:160680
|
Il17atm1Yiw/Il17atm1Yiw Tg(CD2-Rorc)#Staka/0
(involves: 129P2/OlaHsd * C57BL/6)
|
increased susceptibility to autoimmune disorder
|
J:230700
|
Il17bem1Cya/Il17bem1Cya
(C57BL/6-Il17bem1Cya)
|
abnormal cytokine level
|
J:339366
|
increased macrophage cytokine production
|
J:339366
|
increased susceptibility to induced colitis
|
J:339366
|
Il17bGt(371C12)Cmhd/Il17bGt(371C12)Cmhd
(B6.129-Il17bGt(371C12)Cmhd)
|
abnormal chemokine secretion
|
J:229778
|
abnormal interleukin secretion
|
J:229778
|
decreased interleukin-4 secretion
|
J:229778
|
increased interleukin-1 beta secretion
|
J:229778
|
increased interleukin-5 secretion
|
J:229778
|
increased interleukin-6 secretion
|
J:229778
|
increased interleukin-13 secretion
|
J:229778
|
increased susceptibility to bacterial infection
|
J:229778
|
increased susceptibility to induced colitis
|
J:229778
|
increased tumor necrosis factor secretion
|
J:229778
|
Il17ctm1.1Cdon/Il17ctm1.1Cdon
(involves: 129S6/SvEvTac)
|
decreased interferon-gamma secretion
|
J:177650
|
decreased interleukin-17 secretion
|
J:177650
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:177650
|
Il17ftm1Awai/Il17f+
(involves: 129S6/SvEvTac * C57BL/6)
|
decreased interleukin-17 secretion
|
J:144710
|
Il17ftm1Awai/Il17ftm1Awai
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal immune system physiology
|
J:144710
|
decreased interleukin-17 secretion
|
J:144710
|
Il17ftm1Cdon/Il17ftm1Cdon
(involves: C57BL/6)
|
chronic inflammation
|
J:136279
|
decreased acute inflammation
|
J:136279
|
decreased interleukin-17 secretion
|
J:136279
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:136279
|
decreased susceptibility to induced colitis
|
J:136279
|
increased IgG2a level
|
J:136279
|
Il17ftm1Yiw/Il17ftm1Yiw
(involves: 129P2/OlaHsd * C57BL/6)
|
increased susceptibility to bacterial infection
|
J:143719
|
Il17ftm1Yiw/Il17ftm1Yiw Il1rntm1Yiw/Il1rntm1Yiw
(involves: 129 * BALB/c)
|
rheumatoid arthritis
|
J:143719
|
Il17ratm1.2Kurs/Il17ratm1.2Kurs
(involves: 129S4/SvJae * BALB/cJ * C57BL/6 * SJL)
|
abnormal interleukin secretion
|
J:196483
|
increased interleukin-6 secretion
|
J:196483
|
increased interleukin-17 secretion
|
J:196483
|
skin inflammation
|
J:196483
|
Il17ratm1Koll/Il17ratm1Koll
(involves: 129 * C57BL/6)
|
abnormal interleukin-5 secretion
|
J:139080
|
abnormal interleukin-13 secretion
|
J:139080
|
decreased inflammatory response
|
J:139080
|
impaired neutrophil recruitment
|
J:71097
|
increased susceptibility to infection
|
J:71097
|
Il17ratm1Koll/Il17ratm1Koll
(involves: 129)
|
decreased interleukin-9 secretion
|
J:158594
|
decreased interleukin-17 secretion
|
J:177650
|
impaired neutrophil recruitment
|
J:136279
|
Il17rbtm1Anjm/Il17rbtm1Anjm
(BALB/c-Il17rbtm1Anjm)
|
decreased IgE level
|
J:159464
|
increased susceptibility to parasitic infection
|
J:159464
|
Il17rbtm1Anjm/Il17rbtm1Anjm Il1rl1tm1Anjm/Il1rl1tm1Anjm
(involves: 129P2/OlaHsd * BALB/c)
|
decreased IgE level
|
J:159464
|
increased susceptibility to parasitic infection
|
J:159464
|
Il17rbtm1Bud/Il17rbtm1Bud
(B6.129-Il17rbtm1Bud)
|
decreased inflammatory response
|
J:139080
|
decreased interleukin-5 secretion
|
J:139080
|
decreased interleukin-13 secretion
|
J:139080
|
Il17rbtm1Lex/Il17rbtm1Lex
(C.129-Il17rbtm1Lex)
|
abnormal chemokine secretion
|
J:159874
|
decreased interleukin-5 secretion
|
J:159874
|
decreased interleukin-6 secretion
|
J:159874
|
Il17rbtm1Tgi/Il17rb+
(Not Specified)
|
decreased susceptibility to induced colitis
|
J:229778
|
Il17rbtm1Tgi/Il17rbtm1Tgi
(B6.Cg-Il17rbtm1Tgi)
|
abnormal interleukin secretion
|
J:184570
|
decreased interleukin-9 secretion
|
J:184570
|
decreased interleukin-10 secretion
|
J:184570
|
decreased interleukin-13 secretion
|
J:184570
|
decreased interleukin-17 secretion
|
J:184570
|
Il17rbtm1Tgi/Il17rbtm1Tgi
(C.Cg-Il17rbtm1Tgi)
|
abnormal interleukin secretion
|
J:184570
|
decreased interleukin-5 secretion
|
J:184570
|
decreased interleukin-9 secretion
|
J:184570
|
decreased interleukin-10 secretion
|
J:184570
|
decreased interleukin-13 secretion
|
J:184570
|
decreased interleukin-17 secretion
|
J:184570
|
Il17rbtm1Tgi/Il17rbtm1Tgi
(Not Specified)
|
decreased susceptibility to induced colitis
|
J:229778
|
Il17rctm1Lex/Il17rctm1Lex
(involves: C57BL/6)
|
abnormal chemokine level
|
J:159874
|
decreased inflammatory response
|
J:159874
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:159874
|
increased interleukin-17 secretion
|
J:159874
|
Il17retm1Lex/Il17retm1Lex
(B6.129S5-Il17retm1Lex)
|
increased susceptibility to induced colitis
|
J:178967
|
Il17retm1Sdl/Il17retm1Sdl
(involves: C57BL/6)
|
increased susceptibility to bacterial infection
|
J:178966
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:178966
|
Il18tm1Aki/Il18tm1Aki
(involves: 129P2/OlaHsd)
|
abnormal macrophage physiology
|
J:112400
|
abnormal T-helper 1 physiology
|
J:46514
|
decreased circulating interferon-gamma level
|
J:46514
|
decreased circulating interleukin-18 level
|
J:122588,
J:46514
|
decreased interferon-gamma secretion
|
J:46514
|
impaired natural killer cell mediated cytotoxicity
|
J:46514
|
increased susceptibility to bacterial infection
|
J:112400
|
Il18tm1Aki/Il18tm1Aki
(C.129P2-Il18tm1Aki)
|
stomach inflammation
|
J:120594
|
Il18tm1Aki/Il18tm1Aki
(B6.129P2-Il18tm1Aki)
|
impaired neutrophil chemotaxis
|
J:125285
|
increased susceptibility to bacterial infection
|
J:125285
|
increased susceptibility to induced colitis
|
J:173245
|
Il18tm1Aki/Il18tm1Aki Il1btm1Dch/Il1btm1Dch
(involves: 129P2/OlaHsd * 129S2/SvPas)
|
increased susceptibility to bacterial infection
|
J:112400
|
Il18tm1Aki/Il18tm1Aki Nlrp1aNeut1/Nlrp1aNeut1
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal inflammatory response
|
J:191055
|
myocarditis
|
J:191055
|
Il18tm1Aki/Il18tm1Aki Tg(KRT14-CASP1)1Miz/0
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased IgE level
|
J:78602
|
decreased IgG1 level
|
J:78602
|
Il18tm1Khe/Il18tm1Khe
(involves: 129P2/OlaHsd)
|
decreased circulating interferon-gamma level
|
J:62263
|
decreased circulating interleukin-18 level
|
J:62263
|
decreased susceptibility to endotoxin shock
|
J:62263
|
increased circulating tumor necrosis factor level
|
J:62263
|
Il18tm1Khe/Il18tm1Khe
(B6.129P2-Il18tm1Khe)
|
abnormal cytokine level
|
J:138759
|
decreased circulating interferon-gamma level
|
J:138759
|
decreased circulating interleukin-6 level
|
J:138759
|
decreased circulating interleukin-18 level
|
J:138759
|
decreased interferon-gamma secretion
|
J:138759
|
decreased susceptibility to bacterial infection
|
J:138759
|
decreased tumor necrosis factor secretion
|
J:138759
|
Il18tm1Liew/Il18tm1Liew
(involves: 129P2/OlaHsd * CD-1)
|
abnormal interferon level
|
J:86621
|
abnormal interleukin level
|
J:86621
|
abnormal tumor necrosis factor level
|
J:86621
|
increased susceptibility to bacterial infection
|
J:86621
|
increased susceptibility to parasitic infection
|
J:86621
|
sepsis
|
J:86621
|
Il18bptm1(KOMP)Vlcg/Il18bptm1(KOMP)Vlcg
(C57BL/6-Il18bptm1(KOMP)Vlcg)
|
decreased interferon-gamma secretion
|
J:255309
|
increased circulating interferon-gamma level
|
J:255309
|
Il18bptm1.1(KOMP)Vlcg/Il18bptm1.1(KOMP)Vlcg
(involves: C57BL/6N)
|
abnormal circulating chemokine level
|
J:261967
|
abnormal macrophage activation involved in immune response
|
J:261967
|
increased circulating interferon-gamma level
|
J:261967
|
increased circulating interleukin-18 level
|
J:261967
|
Il18r1tm1Aki/Il18r1tm1Aki
(either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * C57BL/6))
|
abnormal T-helper 1 physiology
|
J:70298
|
decreased interferon-gamma secretion
|
J:70298
|
impaired natural killer cell mediated cytotoxicity
|
J:70298
|
Il18raptm1Yeh/Il18raptm1Yeh
(Not Specified)
|
abnormal cytokine secretion
|
J:98417
|
abnormal leukocyte physiology
|
J:98417
|
Il19tm2Vlcg/Il19tm2Vlcg
(B6.Cg-Il19tm2Vlcg)
|
decreased interleukin-6 secretion
|
J:229575
|
decreased interleukin-10 secretion
|
J:229575
|
decreased interleukin-13 secretion
|
J:229575
|
increased interferon-gamma secretion
|
J:229575
|
increased interleukin-1 beta secretion
|
J:229575
|
increased interleukin-6 secretion
|
J:229575
|
increased interleukin-12 secretion
|
J:229575
|
increased susceptibility to colitis induced morbidity/mortality
|
J:229575
|
increased susceptibility to induced colitis
|
J:229575
|
increased tumor necrosis factor secretion
|
J:229575
|
Il20tm1Lex/Il20tm1Lex
(B6;129S5-Il20tm1Lex/Mmucd)
|
abnormal type IV hypersensitivity reaction
|
J:171883
|
Il20rbtm1Uwe/Il20rbtm1Uwe
(B6.129P2-Il20rbtm1Uwe)
|
abnormal cytotoxic T cell physiology
|
J:143497
|
abnormal T-helper 1 physiology
|
J:143497
|
decreased interleukin-4 secretion
|
J:143497
|
decreased interleukin-10 secretion
|
J:143497
|
increased interferon-gamma secretion
|
J:143497
|
increased interleukin-2 secretion
|
J:143497
|
increased T cell proliferation
|
J:143497
|
Il20rbtm1Uwe/Il20rbtm1Uwe
(C.129P2-Il20rbtm1Uwe)
|
increased susceptibility to type IV hypersensitivity reaction
|
J:143497
|
Il21tm1Lex/Il21tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
|
abnormal interleukin level
|
J:123351
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:123351
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:137377
|
Il21tm1Lex/Il21tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:137867
|
abnormal germinal center B cell physiology
|
J:137867
|
decreased IgG1 level
|
J:137867
|
Il21tm1Llit/Il21tm1Llit
(involves: 129 * C57BL/6J)
|
abnormal class switch recombination
|
J:114783
|
increased IgE level
|
J:114783
|
Il21rtm1Day/Il21rtm1Day
(involves: BALB/c * C57BL/6)
|
abnormal dendritic cell physiology
|
J:144708
|
abnormal Langerhans cell physiology
|
J:144708
|
abnormal memory T cell physiology
|
J:76043
|
abnormal NK cell physiology
|
J:76043
|
abnormal plasmacytoid dendritic cell physiology
|
J:144708
|
abnormal T cell activation
|
J:76043
|
abnormal T cell physiology
|
J:76043
|
abnormal thymocyte activation
|
J:76043
|
decreased cytotoxic T cell cytolysis
|
J:76043
|
decreased IgE level
|
J:144708
|
decreased IgG1 level
|
J:76043,
J:144708
|
decreased IgG2a level
|
J:144708
|
decreased IgG2b level
|
J:76043
|
decreased interferon-gamma secretion
|
J:144708
|
decreased interleukin-4 secretion
|
J:144708
|
decreased interleukin-13 secretion
|
J:144708
|
decreased interleukin-17 secretion
|
J:123352
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:144708
|
impaired natural killer cell mediated cytotoxicity
|
J:76043
|
increased IgE level
|
J:76043
|
increased interferon-gamma secretion
|
J:76043,
J:123352
|
Il21rtm1Day/Il21rtm1Day
(C57BL/6-Il21rtm1Day)
|
abnormal susceptibility to infection
|
J:111712
|
abnormal T-helper 2 physiology
|
J:111712
|
decreased IgG1 level
|
J:111712
|
decreased IgG2b level
|
J:111712
|
decreased interleukin-4 secretion
|
J:111712
|
decreased interleukin-13 secretion
|
J:111712
|
decreased interleukin-21 secretion
|
J:111712
|
Il21rtm1Kopf/Il21rtm1Kopf
(involves: 129/Sv * BALB/c)
|
abnormal immunoglobulin level
|
J:137508
|
abnormal lymphocyte physiology
|
J:137508
|
decreased IgA level
|
J:137508
|
decreased IgG1 level
|
J:137508
|
impaired eosinophil recruitment
|
J:137508
|
increased IgE level
|
J:137508
|
Il21rtm1Kopf/Il21rtm1Kopf
(B6.129-Il21rtm1Kopf)
|
abnormal immune system physiology
|
J:137508
|
abnormal immunoglobulin level
|
J:137508
|
abnormal leukocyte physiology
|
J:137508
|
abnormal lymphocyte physiology
|
J:137508
|
abnormal T-helper 1 physiology
|
J:137508
|
abnormal T-helper 2 physiology
|
J:137508
|
decreased IgA level
|
J:137508
|
decreased IgG1 level
|
J:137508
|
granulomatous inflammation
|
J:137508
|
impaired eosinophil recruitment
|
J:137508
|
increased IgE level
|
J:137508
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:137377
|
Il21rtm1Wjl/Il21rtm1Wjl
(involves: 129 * C57BL/6)
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:95221
|
abnormal immunoglobulin level
|
J:80474
|
decreased cytotoxic T cell cytolysis
|
J:95221
|
decreased IgG1 level
|
J:80474
|
decreased IgG2a level
|
J:80474
|
decreased IgG2b level
|
J:80474
|
decreased IgG3 level
|
J:80474
|
decreased interleukin-17 secretion
|
J:124293
|
increased IgE level
|
J:80474
|
Il21rtm1Wjl/Il21rtm1Wjl
(NOD.Cg-Il21rtm1Wjl)
|
decreased interleukin-17 secretion
|
J:139075
|
decreased susceptibility to autoimmune diabetes
|
J:139075
|
decreased T cell proliferation
|
J:139075
|
Il21rtm1Wjl/Il21rtm1Wjl Il4tm1Cgn/Il4tm1Cgn
(involves: 129 * C57BL/6)
|
abnormal immunoglobulin level
|
J:80474
|
decreased IgA level
|
J:80474
|
decreased IgG1 level
|
J:80474
|
decreased IgG2a level
|
J:80474
|
decreased IgG2b level
|
J:80474
|
decreased IgG3 level
|
J:80474
|
decreased IgM level
|
J:80474
|
Il21rtm1Wjl/Il21rtm1Wjl X/Yaa
(BXSB.129(Cg)-Il21rtm1Wjl/Dcr)
|
decreased susceptibility to systemic lupus erythematosus
|
J:144484
|
Il22tm1.1(icre)Stck/Il22tm1.1(icre)Stck
(involves: 129X1/SvJ * C57BL/6N)
|
increased susceptibility to bacterial infection
|
J:220074
|
Il22tm1.1Lex/Il22tm1.1Lex
(involves: 129S5/SvEvBrd * C57BL/6)
|
abnormal cytokine secretion
|
J:118261
|
ear inflammation
|
J:118261
|
Il22tm1.1Lex/Il22tm1.1Lex
(involves: 129S5/SvEvBrd)
|
abnormal circulating cytokine level
|
J:179011
|
colitis
|
J:161073
|
decreased circulating interleukin-1 alpha level
|
J:179011
|
decreased circulating interleukin-12 level
|
J:179011
|
decreased circulating interleukin-12b level
|
J:179011
|
decreased circulating tumor necrosis factor level
|
J:179011
|
increased circulating interleukin-17 level
|
J:179011
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:161073
|
increased susceptibility to fungal infection
|
J:179011
|
lung inflammation
|
J:179011
|
Il22tm1Flv/Il22+
(B6.Cg-Il22tm1Flv)
|
increased susceptibility to endotoxin shock
|
J:126103
|
Il22tm1Flv/Il22tm1Flv
(B6.Cg-Il22tm1Flv)
|
increased susceptibility to endotoxin shock
|
J:126103
|
liver inflammation
|
J:126103
|
Il22tm1Flv/Il22tm1Flv
(involves: 129/Sv * C57BL/6)
|
increased susceptibility to induced colitis
|
J:189217
|
Il22tm1Jcrd/Il22tm1Jcrd
(Not Specified)
|
increased interleukin-17 secretion
|
J:193548
|
Il22ra2tm2Vlcg/Il22ra2tm2Vlcg
(B6.Cg-Il22ra2tm2Vlcg)
|
colitis
|
J:189217
|
Il23atm1.1Thak/Il23atm1.1Thak
(C57BL/6-Il23atm1.1Thak)
|
decreased interferon-gamma secretion
|
J:143970
|
decreased interleukin-17 secretion
|
J:143970
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:143970
|
decreased T cell proliferation
|
J:143970
|
Il23atm1Dnax/Il23atm1Dnax
(involves: 129 * C57BL/6)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:95542
|
decreased interleukin-17 secretion
|
J:95542
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:95542
|
Il23atm1Dnax/Il23atm1Dnax
(B6.Cg-Il23atm1Dnax)
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:111568
|
abnormal granulocyte physiology
|
J:111568
|
abnormal interleukin level
|
J:111568
|
abnormal macrophage physiology
|
J:111568
|
Il23atm1Dnax/Il23atm1Dnax
(Not Specified)
|
decreased interleukin-17 secretion
|
J:193548
|
Il23atm1Gdy/Il23a+
(B6.Cg-Il23atm1Gdy)
|
increased susceptibility to induced colitis
|
J:139557
|
Il23atm1Gdy/Il23atm1Gdy
(B6.Cg-Il23atm1Gdy)
|
increased susceptibility to induced colitis
|
J:139557
|
Il23atm1Ngh/Il23atm1Ngh
(involves: 129S/SvEv * C57BL/6)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:88235
|
abnormal memory T cell physiology
|
J:88235
|
decreased IgA level
|
J:88235
|
decreased IgG2a level
|
J:88235
|
decreased immunoglobulin level
|
J:88235
|
Il23atm1Ngh/Il23atm1Ngh
(involves: 129 * C57BL/6)
|
abnormal circulating interleukin level
|
J:216867
|
abnormal memory T cell physiology
|
J:120806
|
decreased susceptibility to induced colitis
|
J:216867
|
granulomatous inflammation
|
J:120806
|
increased circulating interleukin-17 level
|
J:216867
|
increased susceptibility to bacterial infection
|
J:120806
|
Il23atm1Ngh/Il23atm1Ngh
(involves: 129)
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:161073
|
Il23rtm1.1Kuch/Il23rtm1.1Kuch
(involves: C57BL/6)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:151907
|
decreased interleukin-9 secretion
|
J:151907
|
Il23rtm1.1Ngh/Il23rtm1.1Ngh
(involves: C57BL/6)
|
abnormal circulating interleukin level
|
J:216867
|
decreased susceptibility to induced colitis
|
J:216867
|
increased circulating interleukin-17 level
|
J:216867
|
Il23rtm1.1Ngh/Il23rtm1.1Ngh Rag2tm1Fwa/Rag2tm1Fwa
(involves: 129S/SvEv * C57BL/6)
|
abnormal circulating interleukin level
|
J:216867
|
decreased interleukin-17 secretion
|
J:216867
|
Il23rtm1Kuch/Il23rtm1Kuch
(C57BL/6-Il23rtm1Kuch)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:148248
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:148248
|
Il25tm1.1Cdon/Il25tm1.1Cdon
(involves: 129S6/SvEvTac)
|
abnormal chemokine secretion
|
J:229778
|
abnormal interleukin secretion
|
J:229778
|
decreased interleukin-1 beta secretion
|
J:229778
|
decreased interleukin-4 secretion
|
J:229778,
J:158594
|
decreased interleukin-5 secretion
|
J:229778,
J:158594
|
decreased interleukin-9 secretion
|
J:158594
|
decreased interleukin-13 secretion
|
J:229778,
J:158594
|
decreased susceptibility to bacterial infection
|
J:229778
|
decreased susceptibility to induced colitis
|
J:229778
|
decreased tumor necrosis factor secretion
|
J:229778
|
increased susceptibility to type I hypersensitivity reaction
|
J:158594
|
lung inflammation
|
J:158594
|
Il25tm1Anjm/Il25tm1Anjm
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal interleukin secretion
|
J:123748
|
decreased interleukin-5 secretion
|
J:123748
|
decreased interleukin-13 secretion
|
J:123748
|
increased IgE level
|
J:123748
|
increased susceptibility to parasitic infection
|
J:123748
|
Il25tm1Cdon/Il25tm1Cdon Tg(Vil1-cre)997Gum/0
(involves: 129S6/SvEvTac * C57BL/6J * C57BL/6N * SJL)
|
decreased susceptibility to induced colitis
|
J:229778
|
Il25tm1Dart/Il25tm1Dart
(C57BL/6-Il25tm1Dart)
|
abnormal interferon level
|
J:123808
|
abnormal interleukin level
|
J:123808
|
abnormal response to infection
|
J:123808
|
decreased IgG2a level
|
J:123808
|
increased susceptibility to parasitic infection
|
J:123808
|
intestinal inflammation
|
J:123808
|
Il25tm1Dart/Il25tm1Dart
(involves: C57BL/6)
|
abnormal interleukin level
|
J:125296
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:125296
|
Il27tm1Cua/Il27tm1Cua
(C57BL/6-Il27tm1Cua)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:147706
|
increased susceptibility to type IV hypersensitivity reaction
|
J:147706
|
Il27tm1Lex/Il27tm1Lex
(involves: 129S/SvEvBrd)
|
increased circulating interleukin-12b level
|
J:187660
|
increased interferon-gamma secretion
|
J:187660
|
increased susceptibility to parasitic infection induced morbidity/mortality
|
J:187660
|
Il27ratm1Fjs/Il27ratm1Fjs
(B6.Cg-Il27ratm1Fjs)
|
abnormal T-helper 1 physiology
|
J:94856
|
decreased susceptibility to bacterial infection
|
J:94856
|
Il27ratm1Mak/Il27ratm1Mak
(B6.129P2-Il27ratm1Mak)
|
abnormal T-helper 1 physiology
|
J:116610,
J:89509
|
decreased circulating interferon-gamma level
|
J:116610
|
decreased interferon-gamma secretion
|
J:116610,
J:89509
|
decreased susceptibility to experimental autoimmune uveoretinitis
|
J:116610
|
increased circulating interferon-gamma level
|
J:88618
|
increased circulating interleukin-1 beta level
|
J:88618
|
increased circulating interleukin-4 level
|
J:88618
|
increased circulating interleukin-6 level
|
J:88618
|
increased circulating interleukin-12 level
|
J:88618
|
increased circulating tumor necrosis factor level
|
J:88618
|
increased interferon-gamma secretion
|
J:88618
|
increased interleukin-4 secretion
|
J:88618
|
increased susceptibility to bacterial infection
|
J:89509
|
increased susceptibility to parasitic infection
|
J:89509
|
increased T cell proliferation
|
J:89509
|
Il27ratm1Mak/Il27ratm1Mak
(involves: 129P2/OlaHsd * C57BL/6)
|
increased susceptibility to induced arthritis
|
J:151552
|
Il31ratm1Ngh/Il31ratm1Ngh
(involves: C57BL/6)
|
abnormal interleukin level
|
J:123198
|
abnormal macrophage physiology
|
J:123198
|
granulomatous inflammation
|
J:123198
|
increased IgE level
|
J:123198
|
increased susceptibility to parasitic infection
|
J:123198
|
increased T cell proliferation
|
J:123198
|
Il33tm1(KOMP)Vlcg/Il33tm1(KOMP)Vlcg
(C57BL/6-Il33tm1(KOMP)Vlcg)
|
impaired macrophage chemotaxis
|
J:232676
|
Il33tm1Aki/Il33tm1Aki
(involves: 129X1/SvJ * C57BL/6)
|
abnormal T-helper 2 physiology
|
J:182160
|
decreased IgE level
|
J:182160
|
increased susceptibility to parasitic infection
|
J:182160
|
Il33tm1Amgn/Il33tm1Amgn
(B6.129-Il33tm1Amgn)
|
abnormal immune cell physiology
|
J:192531
|
increased susceptibility to parasitic infection
|
J:192531
|
Il33tm1Snak/Il33tm1Snak
(involves: C57BL/6 * CBA)
|
decreased inflammatory response
|
J:165513
|
decreased interleukin-1 alpha secretion
|
J:165513
|
decreased interleukin-1 beta secretion
|
J:165513
|
decreased interleukin-6 secretion
|
J:165513
|
decreased susceptibility to endotoxin shock
|
J:165513
|
increased susceptibility to induced colitis
|
J:165513
|
lung inflammation
|
J:165513
|
Il34tm1b(EUCOMM)Wtsi/Il34tm1b(EUCOMM)Wtsi
(involves: BALB/cJ * C57BL/6N)
|
decreased interferon-gamma secretion
|
J:187643
|
decreased susceptibility to fungal infection
|
J:187643
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:187643
|
increased susceptibility to Flaviviridae infection
|
J:187643
|
increased susceptibility to Flaviviridae infection induced morbidity/mortality
|
J:187643
|
Il36atm1Yiw/Il36atm1Yiw
(B6.129P2-Il36atm1Yiw)
|
abnormal cytokine level
|
J:263315
|
Il36gtm1Lex/Il36gtm1Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
|
abnormal interleukin level
|
J:264077
|
abnormal tumor necrosis factor level
|
J:264077
|
increased macrophage apoptosis
|
J:264077
|
increased susceptibility to Orthomyxoviridae infection
|
J:264077
|
increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality
|
J:264077
|
Il36gtm1Lex/Il36gtm1Lex
(involves: 129S5/SvEvBrd)
|
decreased interleukin-9 secretion
|
J:256437
|
decreased susceptibility to induced colitis
|
J:256437
|
impaired neutrophil recruitment
|
J:280917
|
increased susceptibility to Herpesvirales infection
|
J:280917
|
increased susceptibility to Herpesvirales infection induced morbidity/mortality
|
J:280917
|
Il36gtm1Lex/Il36gtm1Lex
(involves: 129S5/SvEvBrd * C57BL/6)
|
abnormal cytokine level
|
J:296074
|
abnormal macrophage activation involved in immune response
|
J:296074
|
impaired macrophage phagocytosis
|
J:296074
|
increased susceptibility to bacterial infection
|
J:296074
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:296074
|
Il36rntm1Hblu/Il36rn+ Tg(KRT14-Il1f6)1Hblu/?
(involves: 129 * C57BL/6 * DBA/2)
|
skin inflammation
|
J:126327
|
Il36rntm1Hblu/Il36rntm1Hblu
(C.129(B6)-Il36rntm1Hblu)
|
increased susceptibility to chemically induced skin inflammation
|
J:260118
|
Il36rntm1Hblu/Il36rntm1Hblu Tg(KRT14-Il1f6)1Hblu/?
(involves: 129 * C57BL/6 * DBA/2)
|
skin inflammation
|
J:126327
|
Il36rntm1Kopf/Il36rntm1Kopf
(B6.129S5-Il36rntm1Kopf)
|
dermatitis
|
J:193548
|
Ilf3tm1.1Itl/Ilf3tm1.1Itl
(Not Specified)
|
increased susceptibility to Adenoviridae infection
|
J:167126
|
Ilktm1Star/Ilktm1Star Tg(KRT14-cre)1Amc/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)
|
skin inflammation
|
J:172934
|
Ilktm1Star/Ilktm1Star Tg(NPHS2-cre)295Lbh/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
tubulointerstitial nephritis
|
J:129286,
J:129244
|
Ilktm1Star/Ilktm2Star Tg(Acp5-cre)1Star/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal osteoclast physiology
|
J:197593
|
Im1Bioz:BP1/?
(involves: Bioz:BP1 * Bioz:MP1)
|
abnormal humoral immune response
|
J:46394
|
Im2Bioz:BP1/?
(involves: Bioz:BP1 * Bioz:MP1)
|
abnormal humoral immune response
|
J:37251
|
Im2Bioz:BP1/Im2Bioz:BP1
(involves: Bioz:BP1 * Bioz:MP1)
|
abnormal humoral immune response
|
J:65671
|
Im3Bioz:BP1/?
(involves: Bioz:BP1 * Bioz:MP1)
|
abnormal humoral immune response
|
J:46394
|
Im4Bioz:BP1/?
(involves: Bioz:BP1 * Bioz:MP1)
|
abnormal humoral immune response
|
J:37251
|
Im5Bioz:BP1/?
(involves: Bioz:BP1 * Bioz:MP1)
|
abnormal humoral immune response
|
J:37251
|
Im6Bioz:BP1/?
(involves: Bioz:BP1 * Bioz:MP1)
|
abnormal humoral immune response
|
J:37251
|
Im7Bioz:BP1/?
(involves: Bioz:BP1 * Bioz:MP1)
|
abnormal humoral immune response
|
J:37251
|
Imh1NZB/Imh1NZB
(involves: NZB * NZW)
|
increased IgM level
|
J:26266
|
increased susceptibility to systemic lupus erythematosus
|
J:26266
|
Imh1NZB/Imh1NZW
(involves: NZB * NZW)
|
increased IgM level
|
J:26266
|
increased susceptibility to systemic lupus erythematosus
|
J:22353
|
Imm1NZW/Imm1NZB
(involves: NZB * NZW)
|
abnormal immune system physiology
|
J:26266
|
Imm1NZW/Imm1NZW
(involves: NZB * NZW)
|
abnormal immune system physiology
|
J:26266
|
Immp2lTg(HLA-A/H2-D)2Enge/?
((C57BL/6 x CBA)F1)
|
abnormal cytotoxic T cell physiology
|
J:31937
|
Impdh1tm1Bmi/Impdh1tm1Bmi
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
decreased T cell proliferation
|
J:85443
|
Impdh1tm1Bmi/Impdh1tm1Bmi Impdh2tm1Bmi/Impdh2+
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal cytotoxic T cell physiology
|
J:85443
|
decreased splenocyte proliferation
|
J:85443
|
decreased T cell proliferation
|
J:85443
|
Imraq1DBA/2J/?
(involves: C57BL/6J * DBA/2J)
|
increased IgG level
|
J:100370
|
Imraq2DBA/2J/? Imraq3C57BL/6J/?
(involves: C57BL/6J * DBA/2J)
|
increased IgG level
|
J:100370
|
Imrfq1C57BL/6J/? Imrfq2C57BL/6J/?
(involves: C57BL/6J * DBA/2J)
|
increased IgG level
|
J:100370
|
In(2a;Itch)18H/In(2a;Itch)18H
(involves: 101/H * C3H/HeH)
|
chronic inflammation
|
J:24934
|
increased inflammatory response
|
J:45910
|
interstitial pneumonia
|
J:24934
|
lung inflammation
|
J:24934
|
Inavatm1.1Itl/Inavatm1.1Itl
(involves: 129S6/SvEvTac * C57BL/6NTac)
|
increased susceptibility to bacterial infection
|
J:257317
|
increased susceptibility to induced colitis
|
J:257317
|
Inca1tm1Cmt/Inca1tm1Cmt
(involves: 129 * C57BL/6N)
|
increased IgA level
|
J:175667
|
Ing1Gt(OST206270)Lex/Ing1Gt(OST206270)Lex
(involves: 129S5/SvEvBrd * C57BL/6)
|
increased thymocyte apoptosis
|
J:118602
|
Ing4Gt(XG370)Byg/Ing4Gt(XG370)Byg
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal chemokine level
|
J:161381
|
increased circulating interleukin-6 level
|
J:161381
|
increased interleukin-6 secretion
|
J:161381
|
Inhatm1Bay/Inhatm1Bay
(involves: 129S7/SvEvBrd * C57BL/6)
|
chronic liver inflammation
|
J:20450
|
Inhbbtm1Jae/Inhbbtm1Jae
(either: (129S4/SvJae-Inhbbtm1Jae) or (involves: 129S4/SvJae * BALB/c) or (involves: 129S4/SvJae * C57BL/6))
|
increased incidence of corneal inflammation
|
J:16995
|
Inpp1tm1a(KOMP)Wtsi/Inpp1tm1a(KOMP)Wtsi
(involves: C57BL/6 * C57BL/6N)
|
decreased susceptibility to bacterial infection
|
J:213427
|
Inpp5del20/Inpp5del20
(B6.129-Inpp5del20)
|
increased circulating interleukin-6 level
|
J:173266
|
increased IgG2a level
|
J:173266
|
increased IgM level
|
J:173266
|
increased immunoglobulin level
|
J:173266
|
Inpp5dm1Anu/Inpp5dm1Anu
(C57BL/6JAnu-Inpp5dm1Anu)
|
lung inflammation
|
J:104190
|
Inpp5dm1Btlr/Inpp5dm1Btlr
(C57BL/6J-Inpp5dm1Btlr)
|
abnormal eosinophil physiology
|
J:140987
|
abnormal neutrophil physiology
|
J:140987
|
decreased cytotoxic T cell cytolysis
|
J:140987
|
impaired natural killer cell mediated cytotoxicity
|
J:140987
|
Inpp5dm4Btlr/Inpp5dm4Btlr
(C57BL/6J-Inpp5dm4Btlr)
|
increased interferon-beta secretion
|
J:272854
|
increased tumor necrosis factor secretion
|
J:272854
|
Inpp5dtm1.1Wgk/Inpp5dtm1.1Wgk
(involves: 129S6/SvEvTac * C57BL/6J)
|
abnormal leukocyte physiology
|
J:94861
|
decreased susceptibility to graft versus host disease
|
J:95215,
J:94861
|
Inpp5dtm1Dmt/Inpp5dtm1Dmt
(involves: 129P2/OlaHsd)
|
abnormal leukocyte physiology
|
J:77739
|
Inpp5dtm1Dmt/Inpp5dtm1Dmt
(B6.129P2/OlaHsd-Inpp5dtm1Dmt)
|
increased circulating interleukin-6 level
|
J:173266
|
Inpp5dtm1Rav/Inpp5dtm1Rav Cd79atm1(cre)Reth/Cd79a+ Tg(IghAb36-65)1Wys/0
(involves: 129 * BALB/c * C57BL/6 * FVB/N)
|
abnormal B cell anergy
|
J:178833
|
increased autoantibody level
|
J:178833
|
Inpp5dtm1Rav/Inpp5dtm1Rav Tg(Cd4-cre)1Cwi/?
(involves: C57BL/6 * DBA/2)
|
abnormal cytotoxic T cell physiology
|
J:122796
|
abnormal humoral immune response
|
J:122796
|
abnormal interferon level
|
J:122796
|
abnormal interleukin secretion
|
J:122796
|
decreased susceptibility to parasitic infection
|
J:122796
|
Inpp5dtm1Rkh/Inpp5dtm1Rkh
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
|
abnormal macrophage chemotaxis
|
J:48193
|
Inpp5dtm1Rkh/Inpp5dtm1Rkh
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal interleukin level
|
J:173301
|
ileum inflammation
|
J:173301
|
increased circulating interleukin-6 level
|
J:117320
|
intestinal inflammation
|
J:173301
|
Inpp5dtm1Rkh/Inpp5dtm1Rkh
(involves: 129S1/Sv * 129X1/SvJ)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:110864
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:110864
|
abnormal cell-mediated immunity
|
J:110864
|
abnormal macrophage chemotaxis
|
J:110864
|
abnormal osteoclast physiology
|
J:78771
|
abnormal T cell physiology
|
J:110864
|
enhanced B cell migration
|
J:110864
|
increased circulating interleukin-6 level
|
J:78771
|
increased mast cell degranulation
|
J:120426
|
Inpp5dtm1Wgk/Inpp5dtm1.1Wgk Tg(Mx1-cre)1Cgn/0
(B6.Cg-Inpp5dtm1Wgk/Inpp5dtm1.1Wgk Tg(Mx1-cre)1Cgn)
|
abnormal leukocyte physiology
|
J:144110
|
Inpp5dtm1Wgk/Inpp5dtm1Wgk Tg(Mx1-cre)1Cgn/0
(B6.Cg-Inpp5dtm1Wgk Tg(Mx1-cre)1Cgn)
|
decreased susceptibility to graft versus host disease
|
J:144110
|
Ins1tm1Jja/Ins1tm1Jja
(NOD.129S2-Ins1tm1Jja)
|
decreased susceptibility to autoimmune diabetes
|
J:85309
|
Ins1tm1Jja/Ins1tm1Jja Ins2tm1Jja/Ins2tm1Jja Tg(Ins2*Y16A)1Ell/0
(NOD.Cg-Ins1tm1Jja Ins2tm1Jja Tg(Ins2*Y16A)1Ell)
|
decreased susceptibility to autoimmune diabetes
|
J:98583
|
salivary gland inflammation
|
J:98583
|
Ins1tm1Jja/Ins1tm1Jja Ins2tm1Jja/Ins2tm1Jja Tg(Ins2*Y16A)3Ell/0
(NOD.Cg-Ins1tm1Jja Ins2tm1Jja Tg(Ins2*Y16A)3Ell)
|
decreased anti-insulin autoantibody level
|
J:98583
|
decreased susceptibility to autoimmune diabetes
|
J:98583
|
salivary gland inflammation
|
J:98583
|
Ins1tm1Jja/Ins1tm1Jja Ins2tm1Mnt/Ins2tm1Mnt Tg(Aire-cre)1Mnt/0
(involves: 129S2/SvPas * 129S4/SvJaeSor * C57BL/6 * FVB/N)
|
abnormal immune system physiology
|
J:152798
|
abnormal interferon-gamma secretion
|
J:152798
|
abnormal T cell physiology
|
J:152798
|
increased anti-insulin autoantibody level
|
J:152798
|
pancreas inflammation
|
J:152798
|
Ins1tm1Jja/Ins1tm1Jja Tg(Ins2*Y16A)1Ell/0
(NOD.Cg-Ins1tm1Jja Tg(Ins2*Y16A)1Ell)
|
increased susceptibility to autoimmune diabetes
|
J:98583
|
Ins1tm1Jja/Ins1tm1Jja Tg(Ins2*Y16A)3Ell/0
(NOD.Cg-Ins1tm1Jja Tg(Ins2*Y16A)3Ell)
|
autoimmune response
|
J:98583
|
Ins2Akita/Ins2+
(C57BL/6-Ins2Akita/J)
|
abnormal response to transplant
|
J:76224
|
Ins2C95S/Ins2+
(C3HeB/FeJ-Ins2C95S)
|
increased susceptibility to autoimmune diabetes
|
J:122098
|
Ins2C95S/Ins2C95S
(C3HeB/FeJ-Ins2C95S)
|
increased susceptibility to autoimmune diabetes
|
J:122098
|
Ins2tm1Jja/Ins2tm1Jja
(NOD.129S2-Ins2tm1Jja)
|
increased anti-insulin autoantibody level
|
J:85309
|
insulitis
|
J:85309
|
Ins2tm1Jja/Ins2tm1Jja Tg(Ins2*Y16A)3Ell/0
(NOD.Cg-Ins2tm1Jja Tg(Ins2*Y16A)3Ell)
|
autoimmune response
|
J:98583
|
increased anti-insulin autoantibody level
|
J:98583
|
Insrm1Btlr/Insrm1Btlr
(C57BL/6J-Insrm1Btlr)
|
increased susceptibility to induced colitis
|
J:267534
|
Insrtm1Khn/Insrtm1Khn Leprtm1.1Chua/Leprtm1.1Chua Tg(Pomc1-cre)16Lowl/0
(involves: 129 * 129S4/SvJae * 129S6/SvEvTac * C57BL/6J * FVB/N)
|
liver inflammation
|
J:192274
|
ovary inflammation
|
J:192274
|
white adipose tissue inflammation
|
J:192274
|
Ip6k2tm1.1Snyd/Ip6k2tm1.1Snyd
(B6.129-Ip6k2tm1.1Snyd)
|
abnormal B cell physiology
|
J:212482
|
Irak1tm1.1Pcoh/?
(involves: 129P2/OlaHsd)
|
decreased interferon-alpha secretion
|
J:205798
|
Irak1tm1.1Pcoh/? Irak2tm1.1Pcoh/?
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased interferon-alpha secretion
|
J:205798
|
Irak1tm1Jth/Y
(B6.Cg-Irak1tm1Jth)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:82302
|
Irak1tm1Jth/Y Irak2tm1Aki/Irak2tm1Aki
(involves: 129/Sv * C57BL/6)
|
abnormal dendritic cell physiology
|
J:136290
|
abnormal macrophage physiology
|
J:136290
|
decreased susceptibility to endotoxin shock
|
J:136290
|
Irak1tm1Jth/Y Tg(Myh6-Tnf)1Brgi/?
(involves: 129/Sv * C57BL/6J * SJL)
|
myocarditis
|
J:84829
|
Irak1tm1Jth/Irak1tm1Jth
(B6.Cg-Irak1tm1Jth)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:82302
|
Irak1tm1Jth/Irak1tm1Jth Tg(Myh6-Tnf)1Brgi/?
(involves: 129/Sv * C57BL/6J * SJL)
|
myocarditis
|
J:84829
|
Irak2tm1.1Pcoh/?
(involves: C57BL/6)
|
decreased interferon-alpha secretion
|
J:205798
|
Irak2tm1Aki/Irak2tm1Aki
(involves: 129/Sv * C57BL/6)
|
abnormal macrophage physiology
|
J:136290
|
decreased susceptibility to endotoxin shock
|
J:136290
|
Irak2tm1Jth/Irak2tm1Jth
(involves: 129 * C57BL/6)
|
abnormal chemokine level
|
J:149258
|
decreased circulating interleukin-6 level
|
J:149258
|
decreased circulating tumor necrosis factor level
|
J:149258
|
decreased interleukin-6 secretion
|
J:149258
|
decreased susceptibility to endotoxin shock
|
J:149258
|
decreased tumor necrosis factor secretion
|
J:149258
|
Irak3tm1Flv/Irak3tm1Flv
(involves: 129S1/Sv * C57BL/6)
|
abnormal inflammatory response
|
J:78189
|
abnormal innate immunity
|
J:78189
|
abnormal osteoclast physiology
|
J:98035
|
increased interleukin-6 secretion
|
J:78189
|
increased interleukin-12b secretion
|
J:78189
|
increased susceptibility to endotoxin shock
|
J:78189
|
increased tumor necrosis factor secretion
|
J:78189
|
Irak3tm1Flv/Irak3tm1Flv
(NOD.129S1(B6)-Irak3tm1Flv)
|
abnormal dendritic cell physiology
|
J:229884
|
abnormal professional antigen presenting cell physiology
|
J:229884
|
abnormal T cell activation
|
J:229884
|
increased anti-insulin autoantibody level
|
J:229884
|
increased susceptibility to autoimmune diabetes
|
J:229884
|
insulitis
|
J:229884
|
Irak4m1Btlr/Irak4m1Btlr
(C57BL/6J-Irak4m1Btlr)
|
decreased tumor necrosis factor secretion
|
J:133271
|
Irak4m1Btlr/Irak4m1Btlr Ticam1Lps2/Ticam1Lps2
(involves: C57BL/6J)
|
decreased tumor necrosis factor secretion
|
J:187583
|
Irak4tm1Aki/Irak4tm1Aki
(involves: 129X1/SvJ * C57BL/6)
|
abnormal cytokine secretion
|
J:125729
|
decreased B cell proliferation
|
J:125729
|
decreased interferon-alpha secretion
|
J:125729
|
decreased interleukin-6 secretion
|
J:125729
|
decreased interleukin-12b secretion
|
J:125729
|
decreased susceptibility to endotoxin shock
|
J:125729
|
decreased tumor necrosis factor secretion
|
J:125729
|
Irak4tm1Gram/Irak4tm1Gram
(involves: BALB/c)
|
abnormal chemokine secretion
|
J:121912
|
abnormal cytokine secretion
|
J:121912
|
Irak4tm1Lix/Irak4tm1Lix
(involves: C57BL/6)
|
abnormal chemokine secretion
|
J:125732
|
decreased acute inflammation
|
J:125732
|
decreased circulating interleukin-6 level
|
J:125732
|
decreased circulating tumor necrosis factor level
|
J:125732
|
decreased interferon-alpha secretion
|
J:125732
|
decreased interferon-beta secretion
|
J:125732
|
decreased interleukin-6 secretion
|
J:125732
|
decreased susceptibility to endotoxin shock
|
J:125732
|
decreased tumor necrosis factor secretion
|
J:125732
|
Irak4tm1Yeh/Irak4tm1Yeh
(involves: 129P2/OlaHsd * C57BL/6J)
|
abnormal cytokine level
|
J:76098
|
abnormal cytokine secretion
|
J:76098
|
abnormal macrophage physiology
|
J:76098
|
abnormal NK cell physiology
|
J:76098
|
decreased B cell proliferation
|
J:76098
|
decreased circulating interferon-gamma level
|
J:76098
|
decreased circulating interleukin-1 level
|
J:76098
|
decreased circulating interleukin-6 level
|
J:76098
|
decreased circulating tumor necrosis factor level
|
J:76098
|
decreased interleukin-6 secretion
|
J:76098
|
decreased susceptibility to endotoxin shock
|
J:76098
|
decreased tumor necrosis factor secretion
|
J:76098
|
increased susceptibility to bacterial infection
|
J:76098
|
Irak4tm2Aki/Irak4tm2Aki
(involves: 129X1/SvJ * C57BL/6)
|
abnormal cytokine secretion
|
J:125729
|
decreased B cell proliferation
|
J:125729
|
decreased interferon-alpha secretion
|
J:125729
|
decreased interleukin-6 secretion
|
J:125729
|
decreased interleukin-12b secretion
|
J:125729
|
decreased susceptibility to endotoxin shock
|
J:125729
|
decreased tumor necrosis factor secretion
|
J:125729
|
Irav1C57BL/J/Irav1DBA/2J
(involves: C57BL/6J * DBA/2J)
|
abnormal cell-mediated immunity
|
J:122129
|
abnormal cytokine secretion
|
J:122129
|
Irav1DBA/2J/Irav1DBA/2J
(involves: C57BL/6J * DBA/2J)
|
abnormal cell-mediated immunity
|
J:122129
|
abnormal cytokine secretion
|
J:122129
|
Irf1M1Btlr/Irf1+
(C57BL/6J-Irf1M1Btlr)
|
impaired natural killer cell mediated cytotoxicity
|
J:162995
|
increased susceptibility to Herpesvirales infection
|
J:162995
|
Irf1M1Btlr/Irf1M1Btlr
(C57BL/6J-Irf1M1Btlr)
|
decreased interferon-alpha secretion
|
J:162995
|
decreased interferon-beta secretion
|
J:162995
|
impaired natural killer cell mediated cytotoxicity
|
J:162995
|
increased susceptibility to Herpesvirales infection
|
J:162995
|
Irf1tm1Cwe/Irf1tm1Cwe
(involves: 129/Sv * C57BL/6)
|
abnormal cytokine level
|
J:110672
|
abnormal immune system physiology
|
J:43086
|
abnormal immunoglobulin level
|
J:101427
|
abnormal macrophage physiology
|
J:43086
|
decreased circulating interleukin-2 level
|
J:110672
|
decreased susceptibility to induced arthritis
|
J:43086
|
increased circulating interferon-gamma level
|
J:110672
|
increased circulating interleukin-3 level
|
J:110672
|
increased circulating interleukin-4 level
|
J:110672
|
increased circulating interleukin-5 level
|
J:110672
|
increased circulating interleukin-6 level
|
J:110672
|
increased susceptibility to Poxviridae infection
|
J:101427
|
Irf1tm1Cwe/Irf1tm1Cwe
(involves: 129)
|
abnormal circulating interleukin-4 level
|
J:84367
|
abnormal circulating interleukin-10 level
|
J:84367
|
abnormal cytokine level
|
J:84367
|
abnormal T cell proliferation
|
J:84367
|
decreased circulating interferon-gamma level
|
J:84367
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:84367
|
increased circulating interleukin-5 level
|
J:84367
|
increased circulating interleukin-6 level
|
J:84367
|
increased circulating interleukin-13 level
|
J:84367
|
Irf1tm1Mak/Irf1tm1Mak
(either: (involves: 129S2/SvPas * C57BL/6J) or (involves: 129S2/SvPas * C57BL/6J * DBA/2))
|
abnormal response to infection
|
J:64286
|
Irf1tm1Mak/Irf1tm1Mak
(B6.129S2-Irf1tm1Mak/J)
|
abnormal lymphocyte physiology
|
J:91927
|
decreased interferon-gamma secretion
|
J:91927
|
Irf2tm1Mak/Irf2tm1Mak
(either: (involves: 129S2/SvPas * C57BL/6J) or (involves: 129S2/SvPas * C57BL/6J * DBA/2))
|
abnormal immune system physiology
|
J:64286
|
abnormal response to infection
|
J:64286
|
decreased B cell proliferation
|
J:64286
|
decreased IgG2a level
|
J:64286
|
Irf2tm1Mak/Irf2tm1Mak
(involves: 129S2/SvPas * C57BL/6)
|
dermatitis
|
J:66034
|
Irf3tm1Ttg/Irf3tm1Ttg
(involves: 129S/SvEv * C57BL/6J)
|
abnormal circulating interferon level
|
J:98127
|
increased susceptibility to Picornaviridae infection
|
J:98127
|
Irf3tm1Ttg/Irf3tm1Ttg Irf7tm1Ttg/Irf7tm1Ttg
(involves: 129P2/OlaHsd * 129S/SvEv)
|
decreased interferon-beta secretion
|
J:158969
|
decreased interleukin-1 beta secretion
|
J:158969
|
increased susceptibility to bacterial infection
|
J:158969
|
increased susceptibility to Herpesvirales infection
|
J:158969
|
increased susceptibility to Paramyxoviridae infection
|
J:158969
|
Irf3tm1Ttg/Irf3tm1Ttg Irf9tm1Ttg/Irf9tm1Ttg
(involves: 129S/SvEv * C57BL/6J)
|
abnormal cytokine secretion
|
J:98127
|
Irf3tm1Ttg/Irf3tm1Ttg Sting1em1Jmin/Sting1em1Jmin
(involves: 129S/SvEv * C57BL/6N)
|
lung inflammation
|
J:251372
|
Irf4m1Btlr/Irf4m1Btlr
(C57BL/6J-Irf4m1Btlr)
|
abnormal B cell activation
|
J:160882
|
decreased IgG level
|
J:160882
|
decreased IgM level
|
J:160882
|
Irf4m1Btlr/Irf4m1Btlr
(involves: C57BL/6J)
|
abnormal class switch recombination
|
J:185495
|
decreased IgG level
|
J:185495
|
decreased IgM level
|
J:185495
|
Irf4M2Btlr/Irf4+
(C57BL/6J-Irf4M2Btlr)
|
abnormal B cell activation
|
J:234245
|
decreased IgG level
|
J:234245
|
decreased IgM level
|
J:234245
|
Irf4M2Btlr/Irf4M2Btlr
(C57BL/6J-Irf4M2Btlr)
|
abnormal B cell activation
|
J:234245
|
decreased IgG level
|
J:234245
|
decreased IgM level
|
J:234245
|
Irf4tm1.1Rdf/Irf4tm1.1Rdf
(involves: 129S1/Sv * 129S4/SvJae * C57BL/6)
|
abnormal B cell physiology
|
J:112643
|
decreased B cell proliferation
|
J:112643
|
decreased IgG1 level
|
J:112643
|
Irf4tm1Mak/Irf4tm1Mak
(involves: 129P2/OlaHsd)
|
abnormal immune system physiology
|
J:42683
|
decreased B cell proliferation
|
J:42683
|
decreased immunoglobulin level
|
J:42683
|
decreased T cell proliferation
|
J:42683
|
increased susceptibility to Riboviria infection
|
J:42683
|
Irf4tm1Mak/Irf4tm1Mak
(B6.129P2-Irf4tm1Mak)
|
increased susceptibility to bacterial infection
|
J:78909
|
Irf4tm1Mak/Irf4tm1Mak
(involves: 129P2/OlaHsd * C57BL/6)
|
increased susceptibility to bacterial infection
|
J:81744
|
Irf4tm1Rdf/Irf4tm1.1Rdf
(involves: 129S1/Sv * 129S4/SvJae * C57BL/6)
|
abnormal B cell physiology
|
J:112643
|
Irf5tm1Ttg/Irf5tm1Ttg
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal T-helper 1 physiology
|
J:97567
|
decreased circulating interleukin-6 level
|
J:97567
|
decreased circulating interleukin-12b level
|
J:97567
|
decreased circulating tumor necrosis factor level
|
J:97567
|
decreased susceptibility to bacterial infection
|
J:97567
|
Irf5tm1Ttg/Irf5tm1Ttg
(B6.129P2-Irf5tm1Ttg)
|
abnormal response to infection
|
J:182658
|
decreased interferon-alpha secretion
|
J:182658
|
decreased interleukin-6 secretion
|
J:182658
|
decreased tumor necrosis factor secretion
|
J:182658
|
Irf7m1Btlr/Irf7+
(C57BL/6J-Irf7m1Btlr)
|
decreased interferon-alpha secretion
|
J:159358
|
decreased interferon-beta secretion
|
J:159358
|
Irf7m1Btlr/Irf7m1Btlr
(C57BL/6J-Irf7m1Btlr)
|
decreased interferon-alpha secretion
|
J:159358
|
decreased interferon-beta secretion
|
J:159358
|
Irf7M2Btlr/Irf7+
(C57BL/6J-Irf7M2Btlr)
|
decreased circulating interferon-beta level
|
J:217798
|
Irf7M2Btlr/Irf7M2Btlr
(C57BL/6J-Irf7M2Btlr)
|
decreased circulating interferon-beta level
|
J:217798
|
Irf7tm1Ttg/Irf7tm1Ttg
(involves: 129P2/OlaHsd)
|
abnormal interferon level
|
J:97662
|
abnormal T cell physiology
|
J:97662
|
increased susceptibility to Herpesvirales infection
|
J:97662
|
increased susceptibility to Picornaviridae infection
|
J:97662
|
Irf7tm1Ttg/Irf7tm1Ttg
(B6.129P2-Irf7tm1Ttg)
|
increased susceptibility to Orthomyxoviridae infection
|
J:233979
|
increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality
|
J:233979
|
Irf8M1Btlr/Irf8M1Btlr
(C57BL/6J-Irf8M1Btlr)
|
abnormal interferon secretion
|
J:166600
|
Irf8myls/Irf8myls Slc11a1r/Slc11a1r
(BXH2/TyJ)
|
decreased interferon-gamma secretion
|
J:97931
|
decreased interleukin-12 secretion
|
J:97931
|
increased susceptibility to bacterial infection
|
J:97931
|
Irf8myls/Irf8myls Slc11a1r/Slc11a1r
(involves: BXH2/TyJ * C57BL/6J)
|
increased susceptibility to bacterial infection
|
J:97931
|
Irf8myls/Irf8myls Slc11a1r/Slc11a1r
(involves: BALB/cJ * BXH2/TyJ)
|
increased susceptibility to bacterial infection
|
J:97931
|
Irf8myls/Irf8myls Slc11a1r/Slc11a1r
(involves: BXH2/TyJ * C3H/HeJ)
|
increased susceptibility to bacterial infection
|
J:97931
|
Irf8myls/Irf8myls Slc11a1r/Slc11a1s
(involves: BXH2/TyJ * C57BL/6J)
|
increased susceptibility to bacterial infection
|
J:97931
|
Irf8myls/Irf8myls Slc11a1r/Slc11a1s
(involves: BALB/cJ * BXH2/TyJ)
|
increased susceptibility to bacterial infection
|
J:97931
|
Irf8myls/Irf8myls Slc11a1s/Slc11a1s
(involves: BALB/cJ * BXH2/TyJ)
|
increased susceptibility to bacterial infection
|
J:97931
|
Irf8tm1Hor/Irf8tm1Hor
(either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * C57BL/6))
|
abnormal cytotoxic T cell physiology
|
J:36038
|
decreased interferon-gamma secretion
|
J:36038
|
increased immunoglobulin level
|
J:36038
|
increased susceptibility to Riboviria infection
|
J:36038
|
Irf8tm1Hor/Irf8tm1Hor
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal humoral immune response
|
J:181366
|
Irf8tm1Hor/Irf8tm1Hor Irf4tm1Mak/Irf4tm1Mak
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased IgM level
|
J:84577
|
Irf9M1Btlr/Irf9+
(C57BL/6J-Irf9M1Btlr)
|
increased circulating interferon-beta level
|
J:236674
|
Irf9M1Btlr/Irf9M1Btlr
(C57BL/6J-Irf9M1Btlr)
|
increased circulating interferon-beta level
|
J:236674
|
Irf9tm1Ttg/Irf9tm1Ttg
(B6.Cg-Irf9tm1Ttg)
|
decreased interferon-alpha secretion
|
J:97662
|
Irf9tm1Ttg/Irf9tm1Ttg
(either: (involves: C57BL/6 * CBA * ICR) or (involves: A/J * C57BL/6 * CBA))
|
increased susceptibility to viral infection
|
J:77456
|
Irgm1tm1Gat/Irgm1tm1Gat
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased circulating interferon-gamma level
|
J:87535
|
increased circulating interleukin-12 level
|
J:87535
|
increased susceptibility to bacterial infection
|
J:87535
|
increased susceptibility to parasitic infection
|
J:87535
|
Irgm2em1Myam/Irgm2em1Myam
(C57BL/6-Irgm2em1Myam)
|
increased susceptibility to parasitic infection
|
J:308470
|
increased susceptibility to parasitic infection induced morbidity/mortality
|
J:308470
|
Irs1tm1Mfw/Irs1tm1Mfw Irs2tm2Mfw/Irs2tm2Mfw Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA)
|
increased susceptibility to autoimmune diabetes
|
J:137845
|
Irs1tm1Tka/Irs1tm1Tka
(involves: C57BL/6 * CBA)
|
abnormal osteoclast physiology
|
J:61479
|
Irs1tm2Tka/Irs1tm2Tka Irs2tm2Tka/Irs2tm2Tka Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA)
|
increased susceptibility to autoimmune diabetes
|
J:137846
|
Isg20em1Cya/Isg20em1Cya Tg(Cdh16-cre)91Igr/0
(involves: C57BL/6N * ICR)
|
kidney inflammation
|
J:343183
|
Isl1Drsh/Isl1+
(C3HeB/FeJ-Isl1Drsh)
|
increased susceptibility to otitis media
|
J:202214
|
Itchtm1.1Alta/Itchtm1.1Alta Foxp3tm4(YFP/icre)Ayr/Foxp3+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal immunoglobulin level
|
J:204685
|
abnormal interleukin secretion
|
J:204685
|
abnormal regulatory T cell physiology
|
J:204685
|
abnormal T-helper 2 physiology
|
J:204685
|
dermatitis
|
J:204685
|
increased IgA level
|
J:204685
|
increased IgE level
|
J:204685
|
increased IgG1 level
|
J:204685
|
increased inflammatory response
|
J:204685
|
increased interleukin-4 secretion
|
J:204685
|
increased interleukin-5 secretion
|
J:204685
|
increased interleukin-10 secretion
|
J:204685
|
increased interleukin-13 secretion
|
J:204685
|
increased interleukin-17 secretion
|
J:204685
|
increased regulatory T cell apoptosis
|
J:204685
|
lung inflammation
|
J:204685
|
Itchtm1.1Alta/Itchtm1.1Alta Gt(ROSA)26Sortm1Hjf/Gt(ROSA)26Sor+ Foxp3tm4(YFP/icre)Ayr/Foxp3+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased inflammatory response
|
J:204685
|
Itfg2Gt(OST215121)Lex/Itfg2Gt(OST215121)Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
|
abnormal B cell activation
|
J:205951
|
abnormal humoral immune response
|
J:205951
|
abnormal splenocyte physiology
|
J:205951
|
decreased IgE level
|
J:205951
|
decreased IgG1 level
|
J:205951
|
decreased IgG2a level
|
J:205951
|
decreased IgG2b level
|
J:205951
|
decreased IgG3 level
|
J:205951
|
Itga3tm1Son/Itga3tm1Son Krt14tm1(cre)Wbm/Krt14+
(involves: 129P2/OlaHsd * FVB/N)
|
skin inflammation
|
J:145988
|
Itga3tm1Son/Itga3tm1Son Tg(KRT5-cre)5132Jlj/?
(involves: 129P2/OlaHsd * C57BL/6 * DBA)
|
skin inflammation
|
J:145988
|
Itga4tm1Mgin/Itga4tm1Mgin
(B6.129-Itga4tm1Mgin)
|
abnormal B cell physiology
|
J:106471
|
abnormal lymphocyte physiology
|
J:106471
|
abnormal T cell physiology
|
J:106471
|
impaired macrophage chemotaxis
|
J:106471
|
Itga4tm1Mshi/Itga4tm1Mshi
(C57BL/6-Itga4tm1Mshi)
|
abnormal cellular extravasation
|
J:144092
|
abnormal leukocyte adhesion
|
J:144092
|
abnormal leukocyte migration
|
J:144092
|
Itga5tm1Hyn/Itga5+ Nischedsn/Nisch+
(C3H.Cg-Nischedsn Itga5tm1Hyn)
|
increased susceptibility to otitis media
|
J:244907
|
Itga5tm1Hyn/Itga5+ Nischedsn/Nischedsn
(C3H.Cg-Nischedsn Itga5tm1Hyn)
|
increased susceptibility to otitis media
|
J:244907
|
Itga6tm1Son/Itga6tm1Son
(involves: 129P2/OlaHsd * FVB)
|
abnormal T cell physiology
|
J:50235
|
Itga9tm1Des/Itga9tm1Des
(involves: 129S4/SvJae * C57BL/6)
|
abnormal lymph circulation
|
J:63038
|
Itgadtm1.1Zimm/Itgadtm1.1Zimm
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal immune system physiology
|
J:130908
|
abnormal macrophage physiology
|
J:130908
|
abnormal susceptibility to infection
|
J:130908
|
decreased susceptibility to parasitic infection
|
J:130908
|
increased circulating interleukin-12 level
|
J:130908
|
increased susceptibility to bacterial infection
|
J:130908
|
Itgadtm1Bll/Itgadtm1Bll
(B6.129S7-Itgadtm1Bll)
|
abnormal T cell activation
|
J:90954
|
decreased T cell proliferation
|
J:90954
|
Itgaltm1.1Mshi/Itgaltm1.1Mshi
(involves: C57BL/6)
|
abnormal diapedesis
|
J:168533
|
abnormal leukocyte adhesion
|
J:168533
|
abnormal leukocyte migration
|
J:168533
|
enhanced leukocyte tethering or rolling
|
J:168533
|
Itgaltm1Bll/Itgal+
(involves: 129S7/SvEvBrd)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:267548
|
Itgaltm1Bll/Itgaltm1Bll
(involves: 129S7/SvEvBrd * C57BL/6J)
|
abnormal cellular extravasation
|
J:83226
|
abnormal leukocyte adhesion
|
J:83226
|
abnormal leukocyte migration
|
J:83226
|
Itgaltm1Bll/Itgaltm1Bll
(B6.129S7-Itgaltm1Bll)
|
abnormal leukocyte adhesion
|
J:100242
|
abnormal leukocyte tethering or rolling
|
J:100242
|
decreased T cell proliferation
|
J:90954
|
impaired natural killer cell mediated cytotoxicity
|
J:90954
|
Itgaltm1Bll/Itgaltm1Bll
(B6.129S7-Itgaltm1Bll/J)
|
abnormal inflammatory response
|
J:113463
|
Itgaltm1Bll/Itgaltm1Bll
(involves: 129S7/SvEvBrd)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:267548
|
abnormal cellular extravasation
|
J:141063
|
abnormal leukocyte adhesion
|
J:141063
|
abnormal neutrophil physiology
|
J:141063
|
Itgaltm1Hlz/Itgaltm1Hlz
(involves: 129P2/OlaHsd)
|
abnormal cellular extravasation
|
J:99286
|
abnormal humoral immune response
|
J:99286
|
abnormal leukocyte adhesion
|
J:99286
|
abnormal T cell activation
|
J:99286
|
decreased cytotoxic T cell cytolysis
|
J:99286
|
Itgaltm1Hogg/Itgaltm1Hogg
(involves: 129P2/OlaHsd)
|
abnormal leukocyte adhesion
|
J:82587
|
abnormal leukocyte migration
|
J:82587
|
Itgaltm1Mak/Itgal+
(B6.129P2-Itgaltm1Mak)
|
decreased susceptibility to endotoxin shock
|
J:123460
|
Itgaltm1Mak/Itgaltm1Mak
(B6.129P2-Itgaltm1Mak)
|
decreased susceptibility to endotoxin shock
|
J:123460
|
impaired natural killer cell mediated cytotoxicity
|
J:110889
|
increased circulating interleukin-2 level
|
J:123460
|
increased circulating interleukin-10 level
|
J:123460
|
increased circulating tumor necrosis factor level
|
J:123460
|
Itgaltm1Wpfl/Itgaltm1Wpfl
(involves: 129)
|
abnormal cytotoxic T cell physiology
|
J:37160
|
abnormal leukocyte physiology
|
J:37160
|
abnormal lymphocyte physiology
|
J:37160
|
Itgamtm1Bll/Itgamtm1Bll
(B6.129S7-Itgamtm1Bll)
|
abnormal leukocyte adhesion
|
J:100242
|
abnormal T cell activation
|
J:90954
|
decreased T cell proliferation
|
J:90954
|
increased susceptibility to bacterial infection
|
J:94855
|
Itgamtm1Bll/Itgamtm1Bll
(involves: 129S7/SvEvBrd * C57BL/6J)
|
abnormal cellular extravasation
|
J:83226
|
abnormal leukocyte adhesion
|
J:83226
|
abnormal leukocyte migration
|
J:83226
|
abnormal neutrophil physiology
|
J:39092
|
impaired neutrophil phagocytosis
|
J:39092
|
Itgamtm1Myd/Itgamtm1Myd
(involves: 129S4/SvJae * BALB/c * C57BL/6)
|
abnormal leukocyte adhesion
|
J:38052
|
impaired neutrophil phagocytosis
|
J:38052
|
Itgamtm1Myd/Itgamtm1Myd
(B6.129S4-Itgamtm1Myd)
|
abnormal inflammatory response
|
J:113463
|
abnormal neutrophil physiology
|
J:113463
|
Itgamtm1Myd/Itgamtm1Myd
(involves: 129S4/SvJae)
|
impaired leukocyte tethering or rolling
|
J:198197
|
impaired neutrophil phagocytosis
|
J:155479
|
Itgamtm1Myd/Itgamtm1Myd Syktm1Tyb/Syktm1.2Tara Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * 129S2/SvPas * 129S4/SvJae * C57BL/6)
|
impaired granulocyte bactericidal activity
|
J:155479
|
Itgamtm1Rws/Itgamtm1Rws
(involves: 129P2/OlaHsd * C57BL/6J)
|
abnormal macrophage physiology
|
J:65847
|
Itgavtm1Blb/Itgavtm1Blb Itgb1tm1Ref/Itgb1tm1Ref Itgb2tm2Bay/Itgb2tm2Bay Itgb7tm1Cgn/Itgb7tm1Cgn Tg(Mx1-cre)1Cgn/0
(involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6 * CBA)
|
abnormal cellular extravasation
|
J:134784
|
abnormal dendritic cell physiology
|
J:134784
|
Itgavtm2Hyn/Itgavtm2.1Hyn Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * FVB)
|
colitis
|
J:125508
|
impaired macrophage phagocytosis
|
J:125508
|
increased autoantibody level
|
J:125508
|
Itgavtm2Hyn/Itgavtm2.1Hyn Tg(Nes-cre)1Kln/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB * SJL)
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:94376
|
Itgavtm2Hyn/Itgavtm2.1Hyn Tg(Tek-cre)1Ywa/?
(involves: 129S2/SvPas * C57BL/6 * FVB * SJL)
|
abnormal immune system physiology
|
J:125508
|
abnormal interferon level
|
J:125508
|
abnormal interleukin level
|
J:125508
|
abnormal tumor necrosis factor level
|
J:125508
|
colitis
|
J:125508
|
impaired macrophage phagocytosis
|
J:125508
|
increased autoantibody level
|
J:125508
|
increased inflammatory response
|
J:125508
|
large intestinal inflammation
|
J:125508
|
Itgaxtm1.1(HBEGF)Ktak/Itgax+
(involves: 129S4/SvJae * C57BL/6)
|
abnormal response to infection
|
J:162397
|
Itgaxtm1Bll/Itgaxtm1Bll
(B6.129S7-Itgaxtm1Bll)
|
decreased interferon-gamma secretion
|
J:122187
|
decreased interleukin-17 secretion
|
J:122187
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:122187
|
decreased tumor necrosis factor secretion
|
J:122187
|
increased interleukin-2 secretion
|
J:122187
|
increased interleukin-12 secretion
|
J:122187
|
increased susceptibility to bacterial infection
|
J:94855
|
increased T cell proliferation
|
J:122187
|
Itgb1tm1Ref/Itgb1tm1Ref Tg(KRT5-cre)5132Jlj/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * DBA/2J)
|
skin inflammation
|
J:65038
|
Itgb2M1Btlr/Itgb2M1Btlr
(C57BL/6J-Itgb2M1Btlr)
|
decreased interferon-gamma secretion
|
J:139559
|
Itgb2m2Btlr/Itgb2m2Btlr
(C57BL/6J-Itgb2m2Btlr)
|
increased interferon-beta secretion
|
J:265125
|
Itgb2m3Btlr/Itgb2m3Btlr
(C57BL/6J-Itgb2m3Btlr)
|
abnormal cytotoxic T cell cytolysis
|
J:265126
|
decreased IgG level
|
J:265126
|
impaired humoral immune response
|
J:265126
|
impaired natural killer cell mediated cytotoxicity
|
J:265126
|
increased IgE level
|
J:265126
|
Itgb2tm1.1Arte/Itgb2tm1.1Arte
(involves: C57BL/6NTac)
|
abnormal T cell physiology
|
J:202261
|
decreased T cell proliferation
|
J:202261
|
Itgb2tm1Bay/Itgb2tm1Bay
(involves: 129S7/SvEvBrd)
|
decreased inflammatory response
|
J:13599
|
Itgb2tm1Bay/Itgb2tm1Bay
(involves: 129S7/SvEvBrd * PL/J)
|
abnormal cytokine level
|
J:109598
|
abnormal T cell activation
|
J:109598
|
dermatitis
|
J:109598,
J:32126
|
increased interferon-gamma secretion
|
J:109598
|
Itgb2tm1Bay/Itgb2tm1Bay
(involves: 129S7/SvEvBrd * C57BL/6J * PL/J)
|
dermatitis
|
J:84126
|
Itgb2tm1Bay/Itgb2tm1Bay Psrs1PL/J/Psrs1PL/J
(B6.Cg-(D10Mit126-D10Mit38) Itgb2tm1Bay)
|
rheumatoid arthritis
|
J:134251
|
Itgb2tm1Bay/Itgb2tm1Bay Psrs1PL/J/Psrs1PL/J
(B6.Cg-(D10Mit75-D10Mit271) Itgb2tm1Bay)
|
rheumatoid arthritis
|
J:134251
|
Itgb2tm1Bay/Itgb2tm2Bay
(PL.129S7-Itgb2tm1Bay Itgb2tm2Bay)
|
dermatitis
|
J:84126
|
Itgb2tm1Bay/Itgb2tm2Bay
(involves: 129S7/SvEvBrd * C57BL/6J * PL/J)
|
dermatitis
|
J:84126
|
Itgb2tm2Bay/Itgb2tm2Bay
(involves: 129S7/SvEvBrd * C57BL/6J)
|
abnormal leukocyte physiology
|
J:48542
|
abnormal neutrophil physiology
|
J:48542
|
abnormal T cell proliferation
|
J:48542
|
conjunctivitis
|
J:48542
|
dermatitis
|
J:48542
|
increased circulating interleukin-3 level
|
J:48542
|
increased circulating interleukin-6 level
|
J:48542
|
increased IgA level
|
J:48542
|
increased IgG level
|
J:48542
|
increased IgM level
|
J:48542
|
increased immunoglobulin level
|
J:48542
|
increased inflammatory response
|
J:48542
|
increased susceptibility to bacterial infection
|
J:48542
|
Itgb2tm2Bay/Itgb2tm2Bay
(involves: 129S7/SvEvBrd)
|
decreased T cell proliferation
|
J:90954
|
Itgb2tm2Bay/Itgb2tm2Bay
(B6.129S7-Itgb2tm2Bay)
|
abnormal leukocyte adhesion
|
J:83226
|
abnormal leukocyte migration
|
J:83226
|
decreased susceptibility to bacterial infection
|
J:94855
|
Itgb2tm2Bay/Itgb2tm2Bay
(involves: 129S7/SvEvBrd * C57BL/6)
|
decreased acute inflammation
|
J:112286
|
impaired neutrophil recruitment
|
J:112286
|
Itgb2tm2Bay/Itgb2tm2Bay
(PL.129S7-Itgb2tm2Bay)
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:109598
|
Itgb3tm1Hyn/Itgb3tm1Hyn
(involves: 129S2/SvPas * C57BL/6)
|
abnormal macrophage physiology
|
J:119666
|
dermatitis
|
J:52262
|
impaired macrophage chemotaxis
|
J:119666
|
myositis
|
J:119666
|
Itgb3tm1Hyn/Itgb3tm1Hyn
(involves: 129S2/SvPas)
|
abnormal osteoclast physiology
|
J:60672
|
Itgb3tm1Hyn/Itgb3tm1Hyn
(involves: 129S2/SvPas * BALB/c)
|
increased IgG level
|
J:131241
|
Itgb4tm2Son/Itgb4tm2Son Tg(KRT14-cre)8Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
ear inflammation
|
J:96543
|
Itgb6tm1Des/Itgb6tm1Des
(involves: 129S4/SvJae * C57BL/6J)
|
respiratory system inflammation
|
J:33139
|
Itgb6tm1Des/Itgb6tm1Des
(involves: 129S4/SvJae)
|
abnormal immune system physiology
|
J:120085
|
Itgb6tm1Des/Itgb6tm1Des
(involves: 129S4/SvJae * C57BL/6 * SJL)
|
respiratory system inflammation
|
J:51592
|
Itgb6tm1Des/Itgb6tm1Des Mmp12tm1Sds/Mmp12tm1Sds
(involves: 129/Sv * 129T2/SvEms)
|
lung inflammation
|
J:89578
|
Itgb6tm1Des/Itgb6tm1Des Tg(SFTPC-ITGB6)1Des/?
(involves: 129S4/SvJae * C57BL/6 * SJL)
|
respiratory system inflammation
|
J:51592
|
Itgb7tm1Cgn/Itgb7tm1Cgn
(involves: C57BL/6)
|
abnormal immune system physiology
|
J:34306
|
abnormal lymphocyte physiology
|
J:34306
|
abnormal response to infection
|
J:62733
|
impaired leukocyte tethering or rolling
|
J:34306
|
increased susceptibility to parasitic infection
|
J:90262
|
Itgb7tm1Cgn/Itgb7tm1Cgn
(C57BL/6-Itgb7tm1Cgn/J)
|
abnormal leukocyte migration
|
J:127413
|
colitis
|
J:127413
|
Itgb7tm1Cgn/Itgb7tm1Cgn Tnftm2Gkl/Tnf+
(involves: 129S/SvEv * C57BL/6)
|
abnormal inflammatory response
|
J:136667
|
autoimmune arthritis
|
J:136667
|
Itgb7tm1Mshi/Itgb7tm1Mshi
(involves: C57BL/6)
|
abnormal leukocyte adhesion
|
J:127413
|
abnormal leukocyte migration
|
J:127413
|
colitis
|
J:127413
|
Itkm1Btlr/Itkm1Btlr
(C57BL/6J-Itkm1Btlr)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:236673
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:236673
|
increased CD8-positive, alpha-beta memory T cell proliferation
|
J:236673
|
increased IgE level
|
J:236673
|
Itktm1Litt/Itktm1Litt
(involves: 129S4/SvJae * C57BL/6J)
|
decreased T cell proliferation
|
J:31230
|
Itktm1Litt/Itktm1Litt
(involves: 129S4/SvJae)
|
decreased T cell proliferation
|
J:54449
|
increased susceptibility to parasitic infection
|
J:54449
|
Itktm1Litt/Itktm1Litt
(B6.129S4-Itktm1Litt)
|
decreased interleukin-2 secretion
|
J:141390
|
decreased T cell proliferation
|
J:141390
|
Itktm1Litt/Itktm1Litt Tg(DO11.10)10Dlo/0
(involves: 129S4/SvJae * BALB/c * C3H * C57BL/6J)
|
abnormal T-helper 2 physiology
|
J:129883
|
Itktm1Litt/Itktm1Litt Txktm1Pls/Txktm1Pls
(involves: 129S4/SvJae * 129S6/SvEvTac)
|
decreased T cell proliferation
|
J:54449
|
increased susceptibility to parasitic infection
|
J:54449
|
Itktm1Litt/Itktm1Litt Vav1tm2Bbd/Vav1tm2Bbd
(B6.129-Itktm1Litt Vav1tm2Bbd)
|
abnormal T cell physiology
|
J:141390
|
increased T cell apoptosis
|
J:141390
|
Itktm1Ljb/Itktm1Ljb
(involves: 129 * C57BL/6)
|
abnormal T cell activation
|
J:48231
|
decreased interleukin-2 secretion
|
J:48231
|
Itktm1Ljb/Itktm1Ljb
(B10.129-Itktm1Ljb)
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:113408
|
decreased interferon-gamma secretion
|
J:148531
|
increased IgE level
|
J:148531
|
increased interferon-gamma secretion
|
J:113408
|
increased interleukin-4 secretion
|
J:148531
|
increased interleukin-10 secretion
|
J:148531
|
increased interleukin-13 secretion
|
J:148531
|
Itktm1Ljb/Itktm1Ljb Rag1tm1Mom/Rag1tm1Mom Tg(Tcra5CC7,Tcrb5CC7)IWep/?
(involves: 129 * C57BL/10)
|
decreased interferon-gamma secretion
|
J:93606
|
decreased interleukin-4 secretion
|
J:93606
|
decreased interleukin-5 secretion
|
J:93606
|
decreased interleukin-10 secretion
|
J:93606
|
Itktm1Ljb/Itktm1Ljb Txktm1Pls/Txktm1Pls
(B6.129-Txktm1Pls Itktm1Ljb)
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:113408
|
increased interferon-gamma secretion
|
J:113408
|
Itln1em1Cya/Itln1em1Cya
(involves: C57BL/6)
|
abnormal cytokine level
|
J:282124
|
abnormal osteoclast physiology
|
J:282124
|
increased circulating interleukin-1 alpha level
|
J:282124
|
increased circulating interleukin-6 level
|
J:282124
|
increased circulating interleukin-10 level
|
J:282124
|
increased circulating tumor necrosis factor level
|
J:282124
|
ItpkbT-less/ItpkbT-less
(C57BL/6-ItpkbT-less)
|
abnormal T cell physiology
|
J:89286
|
Itpkbtm1Ssch/Itpkbtm1Ssch
(involves: 129S1/Sv * 129X1/SvJ * CD-1)
|
abnormal thymocyte activation
|
J:86257
|
abnormal thymus involution
|
J:86257
|
decreased IgG1 level
|
J:86257
|
decreased IgG2a level
|
J:86257
|
decreased IgG2b level
|
J:86257
|
decreased IgG level
|
J:86257
|
increased susceptibility to parasitic infection
|
J:86257
|
Itpkbtm1Ssch/Itpkbtm1Ssch Itpkctm1Ssch/Itpkctm1Ssch
(involves: 129S1/Sv * 129X1/SvJ * CD-1)
|
abnormal thymocyte activation
|
J:86257
|
Ity2C57BL/6J/Ity2MOLF/EiJ
(involves: C57BL/6J * MOLF/Ei)
|
decreased susceptibility to bacterial infection
|
J:45962
|
Ity2MOLF/EiJ/Ity2MOLF/EiJ
(involves: C57BL/6J * MOLF/Ei)
|
decreased susceptibility to bacterial infection
|
J:126552,
J:45962
|
Ity2aMOLF/EiJ/Ity2aMOLF/EiJ
(involves: C57BL/6J * MOLF/Ei)
|
decreased susceptibility to bacterial infection
|
J:126552
|
Ity2bMOLF/EiJ/Ity2bMOLF/EiJ
(involves: C57BL/6J * MOLF/Ei)
|
decreased susceptibility to bacterial infection
|
J:126552
|
Ity3C57BL/6J/Ity3C57BL/6J
(involves: C57BL/6J * MOLF/Ei)
|
decreased susceptibility to bacterial infection
|
J:45962
|
Ity3C57BL/6J/Ity3MOLF/EiJ
(involves: C57BL/6J * MOLF/Ei)
|
decreased susceptibility to bacterial infection
|
J:45962
|
Ity3MOLF/EiJ/Ity3MOLF/EiJ
(involves: C57BL/6J * MOLF/Ei)
|
increased susceptibility to bacterial infection
|
J:126552,
J:45962
|
Ity3MOLF/EiJ/Ity3MOLF/EiJ
(B6.MOLF-Slc11a1r Ity3MOLF/EiJ)
|
abnormal cytokine secretion
|
J:108692
|
Jagn1tm1c(EUCOMM)Hmgu/Jagn1tm1c(EUCOMM)Hmgu Commd10Tg(Vav1-icre)A2Kio/Commd10+
(involves: C57BL/6N * C57BL/10 * CBA/Ca)
|
abnormal neutrophil physiology
|
J:214828
|
impaired neutrophil chemotaxis
|
J:214828
|
impaired neutrophil recruitment
|
J:214828
|
increased susceptibility to fungal infection
|
J:214828
|
Jak1M1Mhda/Jak1+
(C3HeB/FeJ-Jak1M1Mhda)
|
ear inflammation
|
J:199153
|
increased anti-nuclear antigen antibody level
|
J:199153
|
increased IgA level
|
J:199153
|
increased IgG1 level
|
J:199153
|
increased IgG2a level
|
J:199153
|
increased IgM level
|
J:199153
|
increased immunoglobulin level
|
J:199153
|
skin inflammation
|
J:199153
|
Jak2tm1.1Ble/Jak2+ Commd10Tg(Vav1-icre)A2Kio/Commd10+
(involves: 129 * C57BL/6 * C57BL/10 * CBA/Ca)
|
abnormal cytokine level
|
J:257910
|
Jak3m1Btlr/Jak3m1Btlr
(C57BL/6J-Jak3m1Btlr)
|
decreased IgG level
|
J:217795
|
decreased response to antigen
|
J:217795
|
impaired humoral immune response
|
J:217795
|
increased IgE level
|
J:217795
|
increased susceptibility to Herpesvirales infection
|
J:217795
|
Jak3M1Pgrs/Jak3+
(involves: C57BL/6J * C57BL/10J)
|
decreased susceptibility to parasitic infection induced morbidity/mortality
|
J:185217
|
Jak3M1Pgrs/Jak3M1Pgrs
(involves: C57BL/6J * C57BL/10J)
|
decreased interferon-gamma secretion
|
J:185217
|
decreased susceptibility to parasitic infection induced morbidity/mortality
|
J:185217
|
increased susceptibility to bacterial infection
|
J:185217
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:185217
|
Jak3M1Pgrs/Jak3tm1Ljb
(involves: 129S4/SvJae * C57BL/6J * C57BL/10J)
|
decreased susceptibility to parasitic infection induced morbidity/mortality
|
J:185217
|
Jak3m3Btlr/Jak3m3Btlr
(C57BL/6J-Jak3m3Btlr)
|
decreased IgG level
|
J:225935
|
impaired humoral immune response
|
J:225935
|
Jak3m6Btlr/Jak3m6Btlr
(C57BL/6J-Jak3m6Btlr)
|
decreased IgG level
|
J:272400
|
impaired humoral immune response
|
J:272400
|
Jak3m8Btlr/Jak3m8Btlr
(C57BL/6J-Jak3m8Btlr)
|
decreased IgG level
|
J:274939
|
decreased IgM level
|
J:274939
|
decreased response to antigen
|
J:274939
|
impaired humoral immune response
|
J:274939
|
Jak3tm1Flv/Jak3tm1Flv
(involves: 129S1/Sv)
|
abnormal T cell proliferation
|
J:95794
|
Jak3tm1Ljb/Jak3tm1Ljb
(involves: 129S4/SvJae * C57BL/6)
|
abnormal immune system physiology
|
J:29722
|
abnormal leukocyte physiology
|
J:90510
|
abnormal lymphocyte physiology
|
J:90510
|
abnormal response to infection
|
J:29722
|
abnormal T cell activation
|
J:29722
|
decreased IgG level
|
J:29722
|
decreased T cell proliferation
|
J:29722
|
Jak3tm1Ljb/Jak3tm1Ljb
(involves: 129S4/SvJae)
|
abnormal T cell activation
|
J:128694,
J:56629
|
abnormal T cell physiology
|
J:128694
|
chronic inflammation
|
J:56629
|
decreased T cell proliferation
|
J:128694
|
Jak3tm1Ljb/Jak3tm1Ljb
(B6;129S4-Jak3tm1Ljb/J)
|
abnormal dendritic cell physiology
|
J:123902
|
Jak3tm1Ljb/Jak3tm1Ljb Tg(Lck-Jak3)1Ljb/0
(involves: 129S4/SvJae * C3H * C57BL/6 * C57BL/10)
|
decreased T cell proliferation
|
J:128694
|
Jak3tm1Ljb/Jak3tm1Ljb Tg(Lck-Jak3)2Ljb/0
(involves: 129S4/SvJae * C3H * C57BL/6)
|
abnormal T cell activation
|
J:56629
|
Jak3tm1Ljb/Jak3tm1Ljb Tg(Lck-Jak3)2Ljb/0
(involves: 129S4/SvJae * C3H * C57BL/6 * C57BL/10)
|
abnormal T cell activation
|
J:128694
|
abnormal T cell physiology
|
J:128694
|
decreased T cell proliferation
|
J:128694
|
Jak3tm1Tks/Jak3+
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal leukocyte physiology
|
J:31231
|
Jak3tm1Tks/Jak3tm1Tks
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal T cell physiology
|
J:31231
|
Jak3wil/Jak3wil
(C57BL/6JSfdAnu-Jak3wil/Anu)
|
large intestinal inflammation
|
J:104190
|
Jam3tm1Rha/Jam3tm1Rha
(involves: 129P2/OlaHsd * C57BL/6)
|
increased susceptibility to bacterial infection
|
J:121841
|
lung inflammation
|
J:121841
|
JchainMat1/? MijuC3HeB/FeJ/MijuC57BL/6J
(involves: C3HeB/FeJ * C57BL/6J)
|
increased IgA level
|
J:91062
|
Jchaintm1Jse/Jchaintm1Jse
(involves: 129X1/SvJ)
|
abnormal B cell physiology
|
J:75843
|
increased IgA level
|
J:34042,
J:75843
|
Jchaintm1Jse/Jchaintm1Jse
(C.129X1-Jchaintm1Jse)
|
decreased susceptibility to Herpesvirales infection
|
J:62298
|
decreased susceptibility to Herpesvirales infection induced morbidity/mortality
|
J:62298
|
increased susceptibility to parasitic infection
|
J:140515
|
Jchaintm1Tl/Jchaintm1Tl
(involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)
|
abnormal humoral immune response
|
J:71355
|
decreased IgG level
|
J:71355
|
decreased IgM level
|
J:71355
|
increased IgA level
|
J:71355
|
Jchaintm2(Myc)Tl/Jchaintm2(Myc)Tl
(involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)
|
abnormal humoral immune response
|
J:71355
|
Jchaintm3Tl/Jchain+
(involves: 129P2/OlaHsd)
|
abnormal B cell physiology
|
J:56158
|
abnormal immune cell physiology
|
J:49168
|
decreased IgM level
|
J:49168,
J:56158
|
impaired complement classical pathway
|
J:49168
|
increased IgA level
|
J:56158
|
increased susceptibility to bacterial infection
|
J:56158
|
Jchaintm3Tl/Jchaintm3Tl
(involves: 129P2/OlaHsd)
|
abnormal B cell physiology
|
J:56158
|
abnormal immune cell physiology
|
J:49168
|
decreased IgG level
|
J:49168
|
decreased IgM level
|
J:49168,
J:56158
|
impaired complement classical pathway
|
J:49168
|
increased IgA level
|
J:49168,
J:56158
|
increased susceptibility to bacterial infection
|
J:56158
|
Jdp2tm1Aki/Jdp2tm1Aki
(Not Specified)
|
abnormal neutrophil physiology
|
J:191061
|
increased susceptibility to bacterial infection
|
J:191061
|
increased susceptibility to fungal infection
|
J:191061
|
Jmjd6tm1Gbf/Jmjd6tm1Gbf
(C57BL/6-Ptdsrtm1Gbf)
|
abnormal macrophage activation involved in immune response
|
J:98905
|
Jmjd8em1Kaso/Jmjd8em1Kaso
(C57BL/6-Jmjd8em1Kaso)
|
decreased circulating interleukin-1 beta level
|
J:319518
|
decreased inflammatory response
|
J:319518
|
Jph4tm1Hta/Jph4tm1Hta
(involves: 129S4/SvJae * C57BL/6J)
|
abnormal interleukin level
|
J:230995
|
abnormal T cell activation
|
J:230995
|
Juntm1Rsjo/Juntm1Rsjo Tg(KRT14-cre)8Brn/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased incidence of corneal inflammation
|
J:84743
|
Juntm4Wag/Juntm4Wag Junbtm3Wag/Junbtm3Wag Tg(Krt1-5-cre/ERT)1Ipc/0
(involves: 129P2/OlaHsd * C57BL/6 * SJL)
|
autoimmune arthritis
|
J:116380
|
increased inflammatory response
|
J:116380
|
skin inflammation
|
J:116380
|
Juntm4Wag/Juntm4Wag Tg(Sftpc-cre)1Blh/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
abnormal cytokine level
|
J:179883
|
abnormal tumor necrosis factor level
|
J:179883
|
lung inflammation
|
J:179883
|
Junbtm3Wag/Junbtm3Wag Tg(KRT5-cre)1Tak/0
(involves: 129/Sv * 129P2/OlaHsd * C3H * C57BL/6)
|
dermatitis
|
J:155575
|
glomerulonephritis
|
J:155575
|
increased anti-histone antibody level
|
J:155575
|
increased circulating interleukin-6 level
|
J:155575
|
increased IgE level
|
J:155575
|
increased inflammatory response
|
J:155575
|
increased interleukin-6 secretion
|
J:155575
|
increased susceptibility to systemic lupus erythematosus
|
J:155575
|
tubulointerstitial nephritis
|
J:155575
|
Jundtm1Mya/Jundtm1Mya
(either: 129S2/SvPas or (involves: 129S2/SvPas * C57BL/6))
|
abnormal T-helper 2 physiology
|
J:89085
|
increased susceptibility to endotoxin shock
|
J:65879
|
increased T cell proliferation
|
J:89085
|
liver inflammation
|
J:65879
|
Juptm1.1Glr/Juptm1.1Glr A1cfTg(Myh6-cre/Esr1*)1Jmk/A1cf+
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N * SJL)
|
abnormal interleukin level
|
J:170618
|
heart inflammation
|
J:170618
|
Kat5tm1Jwl/Kat5+ Tg(IghMyc)22Bri/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL * C57BL/6 * SJL)
|
abnormal B cell physiology
|
J:125164
|
Kat14tm1a(KOMP)Wtsi/Kat14tm1a(KOMP)Wtsi
(involves: C57BL/6 * C57BL/6N)
|
decreased susceptibility to bacterial infection
|
J:213427
|
Kcna1mceph/Kcna1mceph
(BALB/cByJ-Kcna1mceph/J)
|
ear inflammation
|
J:119491
|
eye inflammation
|
J:119491
|
Kcna1tm1Tem/Kcna1tm1Tem
(involves: 129S7/SvEvBrd * BALB/cByJ * C3HeB/FeJ)
|
ear inflammation
|
J:119491
|
eye inflammation
|
J:119491
|
Kcne2tm1a(EUCOMM)Wtsi/Kcne2tm1a(EUCOMM)Wtsi
(C57BL/6N-Kcne2tm1a(EUCOMM)Wtsi)
|
stomach inflammation
|
J:230226
|
Kcne3tm1Gwab/Kcne3tm1Gwab
(involves: C57BL/6)
|
increased inflammatory response
|
J:210381
|
Kcnj8gnite/Kcnj8gnite
(involves: C57BL/6J)
|
increased susceptibility to Herpesvirales infection induced morbidity/mortality
|
J:126658,
J:105543
|
Kcnj8mydy/Kcnj8mydy
(involves: C57BL/6J)
|
increased susceptibility to endotoxin shock
|
J:126658
|
increased susceptibility to Herpesvirales infection
|
J:126658
|
Kcnj8slmbr/Kcnj8slmbr
(involves: C57BL/6J)
|
increased susceptibility to Herpesvirales infection induced morbidity/mortality
|
J:126658,
J:105543
|
Kcnj8sltr/Kcnj8sltr
(involves: C57BL/6J)
|
increased susceptibility to Herpesvirales infection induced morbidity/mortality
|
J:126658,
J:105543
|
increased susceptibility to Riboviria infection
|
J:105543
|
Kcnj8sos/Kcnj8sos
(C57BL/6J-Kcnj8sos)
|
increased susceptibility to endotoxin shock
|
J:149353
|
Kcnk13em1(IMPC)H/Kcnk13em1(IMPC)H
(involves: C57BL/6NTac)
|
abnormal microglial cell physiology
|
J:256020
|
Kcnn4tm1Jemn/Kcnn4tm1Jemn
(involves: 129S1/Sv * C57BL/6J)
|
abnormal T cell physiology
|
J:94478
|
Kctd9em1Beij/Kctd9em1Beij
(BALB/c-Kctd9em1Beij)
|
abnormal NK cell physiology
|
J:281803
|
decreased susceptibility to Coronaviridae infection
|
J:281803
|
decreased susceptibility to Coronaviridae infection induced morbidity/mortality
|
J:281803
|
impaired natural killer cell mediated cytotoxicity
|
J:281803
|
Kdelr1m1Btlr/Kdelr1m1Btlr
(C57BL/6J-Kdelr1m1Btlr)
|
abnormal response to infection
|
J:224970
|
increased susceptibility to Riboviria infection
|
J:224970
|
Kdm6btm1Aki/Kdm6btm1Aki
(involves: 129X1/SvJ * C57BL/6)
|
abnormal response to infection
|
J:164690
|
impaired eosinophil recruitment
|
J:164690
|
Keratm1Cyl/Keratm1Cyl
(involves: 129S6/SvEvTac)
|
abnormal inflammatory response
|
J:128992
|
Khsrptm1.1Cyc/Khsrptm1.1Cyc
(B6.Cg-Khsrptm1.1Cyc)
|
decreased susceptibility to Herpesvirales infection
|
J:175084
|
decreased susceptibility to Herpesvirales infection induced morbidity/mortality
|
J:175084
|
increased interferon-beta secretion
|
J:175084
|
Kif1cLtxs1-DBA/2NCr/Kif1cLtxs1-DBA/2NCr
(involves: BALB/cAnPt * DBA/2NCr)
|
decreased susceptibility to infection
|
J:103336
|
Kif1cLtxs1-DBA/2NCr/Kif1cLtxs1-DBA/2NCr Ltxs2DBA/2NCr/Ltxs2DBA/2NCr Ltxs3DBA/2NCr/Ltxs3DBA/2NCr
(involves: BALB/cAnPt * DBA/2NCr)
|
decreased susceptibility to infection
|
J:103336
|
Kif1cLtxs1/Kif1c+
(involves: C3H/HeJ * C57BL/6J)
|
increased susceptibility to bacterial infection
|
J:49726
|
Kif1cLtxs1/Kif1cLtxs1
(involves: C3H/HeJ * C57BL/6J)
|
increased susceptibility to bacterial infection
|
J:49726
|
Kif1cOrch3-BALB/cByJ/Kif1cOrch3-BALB/cByJ
(involves: BALB/cByJ * DBA/2)
|
testis inflammation
|
J:35331
|
Kif1cOrch3-BALB/cByJ/Kif1cOrch3-DBA/2J
(involves: BALB/cByJ * DBA/2)
|
decreased inflammatory response
|
J:35331
|
Kif1cOrch3-DBA/2J/Kif1cOrch3-DBA/2J
(involves: BALB/cByJ * DBA/2)
|
decreased inflammatory response
|
J:35331
|
Kif27Gt(OST441915)Lex/Kif27Gt(OST441915)Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
|
increased susceptibility to otitis media
|
J:185566
|
maxillary sinus inflammation
|
J:185566
|
Kifbptm1a(KOMP)Wtsi/Kifbptm1a(KOMP)Wtsi
(C57BL/6N-Kifbptm1a(KOMP)Wtsi/Wtsi)
|
blood in lymph vessels
|
J:239583
|
Kittm1.1Bsm/Kittm1.1Bsm
(involves: 129S1/Sv * BALB/c * C57BL/6J * FVB/N)
|
abnormal mast cell physiology
|
J:61141
|
Kittm2Bsm/Kit+
(involves: 129X1/SvJ * C57BL/6J)
|
increased mast cell degranulation
|
J:83616
|
Kittm3.1Bsm/Kittm3.1Bsm
(involves: 129S1/Sv * C57BL/6)
|
abnormal mast cell physiology
|
J:90485
|
KitW-37J/KitW
(involves: C57BL/6 * C57BL/6J * WB)
|
abnormal mast cell physiology
|
J:27513
|
KitW-42J/KitW
(involves: C57BL/6 * C57BL/6J * WB)
|
abnormal mast cell physiology
|
J:27513
|
KitW-Jic/KitW
(involves: C57BL/6 * WB)
|
abnormal mast cell physiology
|
J:27513
|
KitW-n/KitW
(involves: WB)
|
abnormal mast cell physiology
|
J:27513
|
KitW-sh/KitW-sh
(involves: 101/H * C3H/HeH)
|
decreased mast cell degranulation
|
J:157470
|
increased susceptibility to parasitic infection
|
J:163761
|
KitW-sh/KitW-sh
(involves: C57BL/6J)
|
decreased susceptibility to type I hypersensitivity reaction
|
J:197334
|
KitW-sh/KitW-sh
(B6.Cg-KitW-sh/HNihrJaeBsmGlliJ)
|
decreased susceptibility to type I hypersensitivity reaction
|
J:275367
|
KitW-sh/KitW-sh Lyntm1Ard/Lyntm1Ard
(involves: 101 * 129P2/OlaHsd * C3H/HeH)
|
abnormal circulating complement protein level
|
J:161523
|
glomerulonephritis
|
J:161523
|
increased anti-double stranded DNA antibody level
|
J:161523
|
increased anti-nuclear antigen antibody level
|
J:161523
|
increased IgA level
|
J:161523
|
increased IgE level
|
J:161523
|
increased IgG2b level
|
J:161523
|
increased IgM level
|
J:161523
|
KitW/KitW-v
(involves: C57BL/6 * WB)
|
abnormal response to transplant
|
J:6084
|
KitW/KitW-v
((WB/ReJ x C57BL/6J-KitW-v/J)F1-KitW/KitW-v/J)
|
abnormal interferon level
|
J:131785
|
abnormal interleukin level
|
J:131785
|
decreased inflammatory response
|
J:131785
|
impaired neutrophil recruitment
|
J:123463
|
kidney inflammation
|
J:113500
|
KitW/KitW-v
((WB KitW x B6.Cg-KitW-v)F1)
|
decreased susceptibility to induced arthritis
|
J:178942
|
decreased susceptibility to type I hypersensitivity reaction
|
J:197334
|
KitlSl/KitlSl-d
(involves: C57BL/6 * WC)
|
dermatitis
|
J:5758
|
stomach inflammation
|
J:2777
|
KitlSl/KitlSl-d
(involves: C3H * C57BL/6 * DBA/2J * WC)
|
abnormal response to transplant
|
J:6084
|
Klecalc1/Klecalc1
(involves: C3H/HeH * C57BL/6J)
|
lung inflammation
|
J:229255
|
Klf2tm2Ling/Klf2tm2Ling Tg(Cd4-cre)1Cwi/?
(involves: 129S6/SvEvTac * C57BL/6 * DBA/2)
|
increased IgE level
|
J:151604
|
increased IgG1 level
|
J:151604
|
increased interleukin-4 secretion
|
J:151604
|
Klf4tm1Khk/Klf4tm1Khk Tg(Pax6-cre,GFP)1Pgr/0
(involves: 129S6/SvEvTac * FVB/N)
|
blepharitis
|
J:117671
|
Klf5Gt(XB751)Byg/Klf5+
(B6.129P2-Klf5Gt(XB751)Byg)
|
abnormal response to infection
|
J:136125
|
Klf5M1Btlr/Klf5M1Btlr
(C57BL/6J-Klf5M1Btlr)
|
increased susceptibility to induced colitis
|
J:265229
|
Klf5tm1Jaw/Klf5tm1Jaw Tg(Pax6-cre,GFP)1Pgr/0
(involves: FVB)
|
lacrimal gland inflammation
|
J:175263
|
Klf13tm1Kren/Klf13tm1Kren
(B6.129-Klf13tm1Kren)
|
decreased splenocyte apoptosis
|
J:145839
|
decreased thymocyte apoptosis
|
J:145839
|
Klf15tm1Jain/Klf15tm1Jain
(involves: 129X1/SvJ)
|
blood vessel inflammation
|
J:203920
|
Klhdc10tm1Hijo/Klhdc10tm1Hijo
(B6J.B6N-Klhdc10tm1Hijo)
|
decreased circulating interleukin-6 level
|
J:251158
|
decreased inflammatory response
|
J:251158
|
decreased interleukin-6 secretion
|
J:251158
|
Klhl6tm1Sato/Klhl6tm1Sato
(either: (involves: 129T2/SvEms) or (involves: BALB/c) or (involves: CD-1))
|
abnormal adaptive immunity
|
J:101363
|
Klhl22em1Cya/Klhl22em1Cya
(C57BL/6N-Klhl22em1Cya/Cya)
|
decreased interferon-gamma secretion
|
J:297538
|
decreased tumor necrosis factor secretion
|
J:297538
|
Klk5em1Mer/Klk5em1Mer
(BALB/c-Klk5em1Mer)
|
abnormal acute inflammation
|
J:344772
|
Klk6tm1Gsot/Klk6+
(involves: C57BL/6)
|
decreased inflammatory response
|
J:270051
|
decreased susceptibility to chemically induced skin inflammation
|
J:270051
|
Klk6tm1Gsot/Klk6tm1Gsot
(involves: C57BL/6)
|
abnormal cytokine level
|
J:270051
|
decreased inflammatory response
|
J:270051
|
decreased susceptibility to chemically induced skin inflammation
|
J:270051
|
Klk6tm1Gsot/Klk6tm1Gsot Spink5tm1Drh/Spink5tm1Drh
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal cytokine level
|
J:289877
|
decreased inflammatory response
|
J:289877
|
Klra1tm1.1Wyok/Klra1tm1.1Wyok
(involves: BALB/cJ * C57BL/6NTac)
|
abnormal natural killer cell mediated cytotoxicity
|
J:252851
|
Klra8Cmv1-del/Klra8Cmv1-r
((BXD8/TyJ x C57BL/6)F1)
|
decreased susceptibility to Herpesvirales infection
|
J:79093
|
Klra8Cmv1-del/Klra8Cmv1-s
((BXD8/TyJ x BALB/c)F1)
|
increased susceptibility to Herpesvirales infection
|
J:79093
|
Klra8Cmv1-del/Klra8Cmv1-s
((BXD8/TyJ x DBA/2)F1)
|
increased susceptibility to Herpesvirales infection
|
J:79093
|
Klra8Cmv1-r/Klra8Cmv1-r
(C.B6-Klra8Cmv1-r)
|
decreased IgG1 level
|
J:97203
|
decreased IgG2a level
|
J:97203
|
decreased IgG2b level
|
J:97203
|
decreased IgG3 level
|
J:97203
|
decreased IgG level
|
J:97203
|
decreased interleukin-4 secretion
|
J:97203
|
decreased susceptibility to Herpesvirales infection
|
J:22486,
J:79093
|
increased circulating interferon-gamma level
|
J:97203
|
increased IgM level
|
J:97203
|
increased susceptibility to infection induced morbidity/mortality
|
J:97203
|
increased susceptibility to parasitic infection
|
J:97203
|
Klra15tm1.1Apma/Klra15tm1.1Apma
(B6.129-Klra15tm1.1Apma)
|
impaired natural killer cell mediated cytotoxicity
|
J:189106
|
Klra17tm1.1Apma/Klra17tm1.1Apma
(involves: 129S1/Sv * 129X1/SvJ)
|
abnormal plasmacytoid dendritic cell physiology
|
J:152288
|
abnormal response to infection
|
J:152288
|
decreased circulating interferon-alpha level
|
J:152288
|
decreased circulating interleukin-12 level
|
J:152288
|
decreased interferon-alpha secretion
|
J:152288
|
decreased interleukin-12 secretion
|
J:152288
|
increased susceptibility to Herpesvirales infection
|
J:152288
|
Klrb1btm1.1Apma/Klrb1btm1.1Apma
(B6.Cg-Klrb1btm1.1Apma)
|
abnormal NK cell physiology
|
J:222057
|
Klrc1tm1Mmka/Klrc1tm1Mmka
(B6.129-Klrc1tm1Mmka)
|
decreased tumor necrosis factor secretion
|
J:222503
|
increased interferon-gamma secretion
|
J:222503
|
increased interleukin-2 secretion
|
J:222503
|
increased susceptibility to Adenoviridae infection
|
J:222503
|
increased susceptibility to Orthomyxoviridae infection
|
J:222503
|
increased tumor necrosis factor secretion
|
J:222503
|
liver inflammation
|
J:222503
|
lung inflammation
|
J:222503
|
Klre1tm1Tgi/Klre1tm1Tgi
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
impaired natural killer cell mediated cytotoxicity
|
J:92262
|
Klrk1tm1.1Bpol/Klrk1tm1.1Bpol
(C57BL/6-Klrk1tm1.1Bpol)
|
abnormal NK cell physiology
|
J:151878
|
decreased susceptibility to Herpesvirales infection
|
J:151878
|
decreased susceptibility to Herpesvirales infection induced morbidity/mortality
|
J:151878
|
impaired natural killer cell mediated cytotoxicity
|
J:151878
|
increased interferon-gamma secretion
|
J:151878
|
Klrk1tm1Dhr/Klrk1tm1Dhr
(involves: C57BL/6 * CD-1)
|
impaired natural killer cell mediated cytotoxicity
|
J:134509
|
Klrk1tm1Dhr/Klrk1tm1Dhr
(B6.Cg-Klrk1tm1Dhr/J)
|
increased natural killer cell mediated cytotoxicity
|
J:221188
|
Klrk1tm2.1Bpol/Klrk1tm2.1Bpol
(Not Specified)
|
decreased susceptibility to Herpesvirales infection
|
J:215590
|
Kmt2dtm1.1Kaig/Kmt2dtm1.1Kaig Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased IgG1 level
|
J:228913
|
decreased IgM level
|
J:228913
|
increased B cell proliferation
|
J:228913
|
Kmt2etm1Apa/Kmt2etm1Apa
(129S6/SvEvTac-Kmt2etm1Apa)
|
abnormal neutrophil physiology
|
J:145445
|
blepharitis
|
J:145445
|
increased susceptibility to bacterial infection
|
J:145445
|
Kmt5btm1Jnw/Kmt5btm1Jnw Kmt5ctm1.1Jnw/Kmt5ctm1.1Jnw Commd10Tg(Vav1-icre)A2Kio/Commd10+
(involves: 129/Sv * C57BL/6J * C57BL/10 * CBA/Ca)
|
abnormal class switch recombination
|
J:139510
|
Kpna4tm1Bdr/Kpna4tm1Bdr
(B6.Cg-Kpna4tm1Bdr)
|
increased susceptibility to Orthomyxoviridae infection
|
J:302003
|
Kprptm1Msug/Kprp+
(involves: C57BL/6)
|
increased IgE level
|
J:286659
|
increased susceptibility to chemically induced skin inflammation
|
J:286659
|
Kptntm1a(EUCOMM)Wtsi/Kptntm1a(EUCOMM)Wtsi
(involves: C57BL/6N)
|
increased susceptibility to bacterial infection
|
J:200082
|
Krastm4Tyj/Kras+ Krt19tm1(cre/ERT)Ggu/Krt19+ Ptentm2Mak/Ptentm2Mak
(involves: 129P2/OlaHsd * 129S4/SvJae * 129S6/SvEvTac)
|
lung inflammation
|
J:254370
|
Krastm4Tyj/Kras+ Ptentm1Hwu/Ptentm1Hwu Scgb1a1tm1.1(cre)Fjd/Scgb1a1+
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
|
lung inflammation
|
J:131721
|
Krastm4Tyj/Kras+ Tg(MUC1)79.24Gend/0
(involves: 129S4/SvJae * C57BL/6)
|
decreased interferon-gamma secretion
|
J:154046
|
increased IgG level
|
J:154046
|
increased IgM level
|
J:154046
|
Krastm4Tyj/Kras+ Tg(Mx1-cre)1Cgn/0
(involves: 129S4/SvJae * C57BL/6 * CBA)
|
increased splenocyte proliferation
|
J:87429
|
Krastm4Tyj/Kras+ Tg(Scgb1a1-cre)1Kkw/?
(involves: 129 * C57BL/6 * FVB/N)
|
increased inflammatory response
|
J:107260
|
Krastm4Tyj/Kras+ Trp53tm2Tyj/Trp53+
(involves: 129S4/SvJae)
|
lung inflammation
|
J:191425
|
Krastm4Tyj/Krastm4Tyj Trim33tm1Los/Trim33tm1Los Tg(Pdx1-cre)89.1Dam/0
(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6 * DBA/2)
|
pancreas inflammation
|
J:151781
|
Krt1tm1Tmm/Krt1tm1Tmm
(involves: 129 * C57BL/6)
|
abnormal circulating interleukin level
|
J:200244
|
abnormal interleukin secretion
|
J:200244
|
increased circulating interleukin-18 level
|
J:200244
|
Krt2tm1a(KOMP)Wtsi/Krt2tm1a(KOMP)Wtsi
(involves: C57BL/6N)
|
skin inflammation
|
J:214772
|
Krt8tm1Rgo/Krt8tm1Rgo
(involves: 129S2/SvPas * C57BL/6 * FVB/N)
|
chronic inflammation
|
J:86719,
J:98058
|
Krt10tm1Tmm/Krt10+
(either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * BALB/c * C57BL/6))
|
increased susceptibility to infection
|
J:31853
|
Krt18tm1Tmm/Krt18+
(involves: 129P2/OlaHsd)
|
liver inflammation
|
J:309021
|
Krt18tm1Tmm/Krt18tm1Tmm
(involves: 129P2/OlaHsd)
|
liver inflammation
|
J:309021
|
Krt76tm1a(KOMP)Wtsi/Krt76tm1a(KOMP)Wtsi
(involves: C57BL/6 * C57BL/6N)
|
skin inflammation
|
J:232539
|
Ksr1tm1Shaw/Ksr1tm1Shaw
(Not Specified)
|
decreased susceptibility to induced arthritis
|
J:140520
|
decreased T cell proliferation
|
J:75739
|
Ksr1tm1Shaw/Ksr1tm1Shaw Tg(DO11.10)10Dlo/0
(involves: BALB/c * C3H * C57BL/6)
|
decreased interleukin-2 secretion
|
J:75739
|
decreased T cell proliferation
|
J:75739
|
Lacc1em1Arkr/Lacc1em1Arkr
(C57BL/6NTac-Lacc1em1Arkr)
|
abnormal macrophage physiology
|
J:244365
|
decreased circulating interleukin-1 beta level
|
J:244365
|
decreased susceptibility to endotoxin shock
|
J:244365
|
Lacc1em2Arkr/Lacc1em2Arkr
(C57BL/6NTac-Lacc1em2Arkr)
|
abnormal macrophage physiology
|
J:244365
|
decreased circulating interleukin-1 beta level
|
J:244365
|
decreased susceptibility to endotoxin shock
|
J:244365
|
Lacc1em3Arkr/Lacc1em3Arkr
(C57BL/6NTac-Lacc1em3Arkr)
|
abnormal macrophage physiology
|
J:244365
|
increased circulating interleukin-1 beta level
|
J:244365
|
increased susceptibility to endotoxin shock
|
J:244365
|
Lacc1em4Arkr/Lacc1em4Arkr
(C57BL/6NTac-Lacc1em4Arkr)
|
abnormal macrophage physiology
|
J:244365
|
increased circulating interleukin-1 beta level
|
J:244365
|
increased susceptibility to endotoxin shock
|
J:244365
|
Lacc1tm1a(KOMP)Wtsi/Lacc1tm1a(KOMP)Wtsi
(involves: C57BL/6N * C57BL/6NTac)
|
abnormal macrophage physiology
|
J:244365
|
decreased circulating tumor necrosis factor level
|
J:244365
|
decreased interleukin-1 beta secretion
|
J:244365
|
increased circulating interleukin-1 beta level
|
J:244365
|
increased susceptibility to endotoxin shock
|
J:244365
|
Lag3tm1Daav/Lag3+ Tg(Foxp3-EGFP/cre)1cJbs/0
(NOD.Cg-Lag3tm1Daav Tg(Foxp3-EGFP/cre)1cJbs)
|
decreased susceptibility to autoimmune diabetes
|
J:260063
|
Lag3tm1Daav/Lag3tm1Daav Tg(Foxp3-EGFP/cre)1cJbs/0
(NOD.Cg-Lag3tm1Daav Tg(Foxp3-EGFP/cre)1cJbs)
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:260063
|
abnormal interleukin level
|
J:260063
|
abnormal tumor necrosis factor level
|
J:260063
|
decreased susceptibility to autoimmune diabetes
|
J:260063
|
Lag3tm1Doi/Lag3tm1Doi
(involves: 129S2/SvPas * C57BL/6)
|
abnormal NK cell physiology
|
J:32509
|
abnormal T cell physiology
|
J:89653
|
Lair1tm1.1Jco/Lair1tm1.1Jco
(involves: C57BL/6)
|
decreased IgG1 level
|
J:180203
|
Lair1tm1Jco/Lair1tm1Jco Tg(Cd4-cre)1Cwi/?
(involves: C57BL/6 * DBA/2)
|
decreased IgG2a level
|
J:180203
|
decreased IgG2b level
|
J:180203
|
Lama2dy/Lama2dy
(involves: 129P1/ReJ)
|
increased IgG level
|
J:102959
|
increased IgM level
|
J:102959
|
Lama2tm1Eeng/Lama2tm1Eeng
(involves: 129S1/Sv)
|
myositis
|
J:170192
|
Lama2tm1Stk/Lama2tm1Stk
(involves: 129P2/OlaHsd * BALB/c)
|
abnormal thymus physiology
|
J:61802
|
Lama3tm1.1Grsb/Lama3tm1.1Grsb
(involves: C57BL/6)
|
abnormal chemokine level
|
J:235712
|
abnormal tumor necrosis factor level
|
J:235712
|
lung inflammation
|
J:235712
|
Lama3tm1Arte/Lama3tm1Arte Tg(KRT14-cre/ERT)20Efu/0
(involves: C57BL/6 * CD-1)
|
skin inflammation
|
J:240054
|
Lama5tm1Lsor/Lama5tm1Lsor Tg(Tek-cre)1Ywa/0
(involves: C57BL/6 * SJL)
|
abnormal marginal zone B cell physiology
|
J:198783
|
increased IgM level
|
J:198783
|
Lama5tm2Jhm/Lama5tm1Jhm Tg(NPHS2-cre)295Lbh/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA * SJL)
|
tubulointerstitial nephritis
|
J:185850
|
Lamb2tm1Jrs/Lamb2tm1Jrs
(involves: 129S1/Sv * 129X1/SvJ)
|
glomerulonephritis
|
J:23783
|
Lamc2jeb/Lamc2jeb
(129X1/SvJ-Lamc2jeb)
|
ear inflammation
|
J:158873
|
Lancl1tm1.1Pfw/Lancl1tm1.1Pfw
(involves: 129 * C57BL/6)
|
brain inflammation
|
J:214805
|
Lancl2tm2a(KOMP)Wtsi/Lancl2tm2a(KOMP)Wtsi
(involves: C57BL/6N)
|
decreased susceptibility to bacterial infection
|
J:250673
|
Lancl2tm2c(KOMP)Wtsi/Lancl2tm2c(KOMP)Wtsi Lyz2tm1(cre)Ifo/Lyz2+
(involves: C57BL/6N)
|
decreased susceptibility to bacterial infection
|
J:250673
|
Lao1tm1Oka/Lao1tm1Oka
(involves: 129S2/SvPas * C57BL/6J)
|
abnormal interleukin level
|
J:260668
|
increased susceptibility to bacterial infection
|
J:260668
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:260668
|
mastitis
|
J:260668
|
Laptm5tm1Jow/Laptm5tm1Jow
(C57BL/6-Laptm5tm1Jow)
|
abnormal T cell activation
|
J:137841
|
abnormal type IV hypersensitivity reaction
|
J:137841
|
increased interleukin-2 secretion
|
J:137841
|
increased T cell proliferation
|
J:137841
|
Laq1MRL/Laq1MRL
(involves: C57BL/6 * MRL)
|
increased susceptibility to autoimmune disorder
|
J:45708
|
LarSAMP1/?
(involves: C57BL/10 * SAMP1)
|
abnormal humoral immune response
|
J:1953
|
Large1myd/Large1myd
(MYD/Le-Os +/+ Largemyd/J)
|
myositis
|
J:5670
|
Large1myd/Large1myd
(B6C3Fe a/a-Large1myd/J)
|
myositis
|
J:27793
|
Lat2tm1Mal/Lat2tm1Mal
(involves: 129S2/SvPas)
|
abnormal mast cell physiology
|
J:93950
|
Lat2tm1Mal/Lat2tm1Mal
(B6.129S2-Lat2tm1Mal)
|
increased anti-nuclear antigen antibody level
|
J:126321
|
Lat2tm1Mal/Lat2tm1Mal Lime1tm1.1Mal/Lime1tm1.1Mal
(involves: 129 * C57BL/6)
|
increased anti-nuclear antigen antibody level
|
J:126321
|
Lat2tm1Wz/Lat2tm1Wz
(involves: C57BL/6)
|
abnormal mast cell physiology
|
J:93951
|
Lat2tm1Wz/Lat2tm1Wz
(B6.Cg-Lat2tm1Wz)
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:116157
|
abnormal cytokine secretion
|
J:116157
|
abnormal T cell physiology
|
J:116157
|
increased anti-double stranded DNA antibody level
|
J:116157
|
increased autoantibody level
|
J:116157
|
increased T cell proliferation
|
J:116157
|
Lat2tm1Wz/Lat2tm1Wz
(Not Specified)
|
abnormal T cell physiology
|
J:181866
|
decreased interleukin-12 secretion
|
J:181866
|
increased circulating interleukin-6 level
|
J:181866
|
increased circulating tumor necrosis factor level
|
J:181866
|
increased interferon-gamma secretion
|
J:181866
|
increased interleukin-10 secretion
|
J:181866
|
increased mast cell degranulation
|
J:181866
|
increased susceptibility to endotoxin shock
|
J:181866
|
Lat2tm2Wz/Lat2tm2Wz Tg(Lck-cre)548Jxm/0
(involves: C57BL/6)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:116157
|
increased anti-double stranded DNA antibody level
|
J:116157
|
Lat2tm3.1Wz/Lat2tm3.1Wz
(B6.Cg-Lat2tm3.1Wz)
|
abnormal T cell physiology
|
J:181866
|
increased interferon-gamma secretion
|
J:181866
|
increased mast cell degranulation
|
J:181866
|
increased susceptibility to endotoxin shock
|
J:181866
|
Lattm1.1Lov/Lattm1.1Lov
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal cytokine secretion
|
J:77099
|
abnormal immunoglobulin level
|
J:77099
|
abnormal T cell physiology
|
J:77099
|
decreased T cell proliferation
|
J:77099
|
increased anti-double stranded DNA antibody level
|
J:116157
|
increased anti-nuclear antigen antibody level
|
J:77099
|
increased autoantibody level
|
J:77099
|
increased IgE level
|
J:77099
|
increased IgG1 level
|
J:77099
|
increased IgM level
|
J:77099
|
increased T cell proliferation
|
J:77099
|
Lattm1.1Lov/Lattm1.1Lov Lat2tm1Wz/Lat2tm1Wz
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:116157
|
Lattm1.1Mal/Lattm1.1Mal
(involves: 129S2/SvPas)
|
abnormal B cell activation
|
J:77098
|
abnormal immune serum protein physiology
|
J:77098
|
abnormal T-helper 2 physiology
|
J:125722
|
chronic inflammation
|
J:77098
|
glomerulonephritis
|
J:125722
|
increased anti-chromatin antibody level
|
J:125722
|
increased anti-erythrocyte antigen antibody level
|
J:125722
|
increased anti-nuclear antigen antibody level
|
J:125722
|
increased IgE level
|
J:125722,
J:77098
|
increased IgG1 level
|
J:262891,
J:125722,
J:77098
|
increased IgM level
|
J:125722
|
increased inflammatory response
|
J:262891
|
increased interferon-gamma secretion
|
J:77098
|
increased interleukin-4 secretion
|
J:77098
|
increased susceptibility to autoimmune hemolytic anemia
|
J:125722
|
increased T cell proliferation
|
J:77098
|
kidney inflammation
|
J:262891
|
liver inflammation
|
J:125722
|
lung inflammation
|
J:125722
|
pancreas inflammation
|
J:262891
|
phlebitis
|
J:262891
|
salivary gland inflammation
|
J:262891
|
Lattm1.1Mal/Lattm1.1Mal
(involves: 129S2/SvPas * C57BL/6)
|
abnormal T cell proliferation
|
J:131351
|
abnormal T-helper 2 physiology
|
J:131351
|
Lattm1.1Mal/Lattm6.1(HBEGF/EGFP)Mal
(involves: 129S2/SvPas * C57BL/6)
|
abnormal T-helper 2 physiology
|
J:151840
|
Lattm1Les/Lattm1.1Wz Tg(Cd4-cre)1Cwi/0
(involves: C57BL/6 * DBA/2)
|
abnormal T cell physiology
|
J:147946
|
Lattm1Les/Lattm1Les Lat2tm1Wz/Lat2tm1Wz
(involves: C57BL/6)
|
abnormal mast cell physiology
|
J:93951
|
Lattm1Les/Lattm1Les Tg(CD2-LAT2)1Wz/0
(Not Specified)
|
abnormal B cell physiology
|
J:116964
|
abnormal interferon secretion
|
J:116964
|
abnormal interleukin secretion
|
J:116964
|
abnormal leukocyte physiology
|
J:116964
|
increased IgG1 level
|
J:116964
|
increased IgM level
|
J:116964
|
increased interleukin-4 secretion
|
J:116964
|
increased interleukin-10 secretion
|
J:116964
|
Lattm2.1Mal/Lattm2.1Mal
(involves: 129S2/SvPas)
|
abnormal B cell activation
|
J:94074
|
abnormal T cell activation
|
J:94074
|
abnormal thymocyte activation
|
J:94074
|
increased IgE level
|
J:94074
|
increased IgG1 level
|
J:94074
|
increased immunoglobulin level
|
J:94074
|
increased interleukin-4 secretion
|
J:94074
|
Lattm2.1Mal/Lattm2.1Mal Lat2tm1Mal/Lat2tm1Mal
(involves: 129S2/SvPas)
|
abnormal mast cell physiology
|
J:93950
|
Lattm3.1Mal/Lattm3.1Mal
(involves: 129S2/SvPas)
|
abnormal thymocyte activation
|
J:94074
|
Lattm4.1Mal/Lattm4.1Mal
(involves: 129P2/OlaHsd)
|
abnormal thymocyte activation
|
J:94074
|
Lattm4.1Mal/Lattm4.1Mal Tg(Lck*F505)3073Rmp/?
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
abnormal T-helper 2 physiology
|
J:151840
|
increased IgE level
|
J:151840
|
increased IgG1 level
|
J:151840
|
increased interleukin-4 secretion
|
J:151840
|
Lattm4.1Mal/Lattm6.1(HBEGF/EGFP)Mal
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
|
abnormal T-helper 2 physiology
|
J:151840
|
Lattm6.1(HBEGF/EGFP)Mal/? Rag2tm1Fwa/Rag2tm1Fwa Tg(TcraH-Y,TcrbH-Y)1Pas/?
(involves: 129S/SvEv * 129S2/SvPas * C57BL/6)
|
abnormal T cell physiology
|
J:138401
|
Lattm6.1(HBEGF/EGFP)Mal/Lattm6.1(HBEGF/EGFP)Mal
(involves: 129S2/SvPas * C57BL/6)
|
abnormal T cell activation
|
J:151840
|
abnormal T-helper 2 physiology
|
J:151840
|
decreased interferon-gamma secretion
|
J:151840
|
Lattm9Mal/Lattm9Mal
(involves: C57BL/6)
|
abnormal immune system physiology
|
J:205441
|
Lax1tm1Wz/Lax1tm1Wz
(involves: C57BL/6)
|
abnormal B cell calcium ion homeostasis
|
J:98403
|
abnormal B cell physiology
|
J:98403
|
abnormal T cell activation
|
J:98403
|
abnormal T cell physiology
|
J:98403
|
increased IgE level
|
J:98403
|
increased IgG1 level
|
J:98403
|
increased IgG2a level
|
J:98403
|
Laynem1Romd/Laynem1Romd Tg(Cd8a-cre,-GFP)1Yzo/0
(involves: C57BL/6)
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:302853
|
Lbca1C57BL/6Igc/Lbca1C57BL/6Igc
(involves: BALB/cIgc * C57BL/6Igc)
|
abnormal B cell activation
|
J:139348
|
increased B cell proliferation
|
J:139348
|
Lbca2BALB/cIgc/Lbca2C57BL/6Igc
(involves: BALB/cIgc * C57BL/6Igc)
|
abnormal B cell activation
|
J:139348
|
increased B cell proliferation
|
J:139348
|
Lbca2C57BL/6Igc/Lbca2C57BL/6Igc
(involves: BALB/cIgc * C57BL/6Igc)
|
abnormal B cell activation
|
J:139348
|
increased B cell proliferation
|
J:139348
|
Lbptm1Buru/Lbptm1Buru
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal immune serum protein physiology
|
J:44878
|
decreased tumor necrosis factor secretion
|
J:44878
|
Lbptm1Buru/Lbptm1Buru
(involves: 129S1/Sv * 129X1/SvJ * BALB/c)
|
decreased susceptibility to type I hypersensitivity reaction
|
J:67090
|
Lbptm1Buru/Lbptm1Buru
(B6.129-Lbptm1Buru)
|
abnormal acute inflammation
|
J:129411
|
abnormal chemokine level
|
J:129411
|
abnormal innate immunity
|
J:129411
|
abnormal neutrophil physiology
|
J:129411
|
abnormal tumor necrosis factor secretion
|
J:129411
|
Lbptm1Jack/Lbptm1Jack
(involves: 129P2/OlaHsd * BALB/c)
|
increased susceptibility to bacterial infection
|
J:43514
|
Lbric-J/Lbr+
((NZW/LacJ x C57BL/6J-Lbric-J/J)F1)
|
increased anti-chromatin antibody level
|
J:234168
|
increased anti-nuclear antigen antibody level
|
J:234168
|
increased autoantibody level
|
J:234168
|
increased susceptibility to systemic lupus erythematosus
|
J:234168
|
Lbrlym3/Lbrlym3
(C57BL/6-Lbrlym3)
|
abnormal B cell physiology
|
J:180355
|
abnormal T cell physiology
|
J:180355
|
decreased T cell proliferation
|
J:180355
|
Lbw2NZB/BlScr/Lbw2NZB/BlScr
(involves: NZB * NZW)
|
glomerulonephritis
|
J:45708
|
increased anti-chromatin antibody level
|
J:98150
|
increased autoantibody level
|
J:98150
|
Lbw2NZB/BlScr/Lbw2NZW/LacScr
(involves: NZB * NZW)
|
glomerulonephritis
|
J:20991
|
increased anti-chromatin antibody level
|
J:98150
|
increased autoantibody level
|
J:98150
|
Lbw2NZW/LacScr/Lbw2NZW/LacScr
(involves: NZB * NZW)
|
decreased autoantibody level
|
J:98150
|
decreased IgG level
|
J:98150
|
decreased IgM level
|
J:98150
|
Lbw4NZW/LacScr/?
(involves: C57BL/6J * NZM2410/Aeg)
|
decreased immunoglobulin level
|
J:52863
|
Lbw5NZW/LacScr/Lbw5NZB/BlScr
(involves: NZB/BlScr * NZW/LacScr)
|
increased susceptibility to systemic lupus erythematosus
|
J:20991
|
Lbw5NZW/LacScr/Lbw5NZW/LacScr
(involves: NZB/BlScr * NZW/LacScr)
|
increased susceptibility to systemic lupus erythematosus
|
J:20991
|
Lbw6NZW/LacScr/Lbw6NZW/LacScr
(involves: NZB/BlScr * NZW/LacScr)
|
increased susceptibility to systemic lupus erythematosus
|
J:20991
|
Lbw7NZB/BlScr/Lbw7NZB/BlScr
(involves: NZB/BlScr * NZW/LacScr)
|
increased susceptibility to systemic lupus erythematosus
|
J:20991
|
Lbw7NZB/BlScr/Lbw7NZW/LacScr
(involves: NZB/BlScr * NZW/LacScr)
|
increased susceptibility to systemic lupus erythematosus
|
J:20991
|
Lbw8NZB/BlScr/Lbw8NZB/BlScr
(involves: NZB/BlScr * NZW/LacScr)
|
increased susceptibility to autoimmune disorder
|
J:20991
|
Lbw8NZB/BlScr/Lbw8NZW/LacScr
(involves: NZB/BlScr * NZW/LacScr)
|
increased susceptibility to autoimmune disorder
|
J:20991
|
Lckm1Btlr/Lckm1Btlr
(C57BL/6J-Lckm1Btlr)
|
decreased cytotoxic T cell cytolysis
|
J:144695
|
Lckm2Btlr/Lckm2Btlr
(C57BL/6J-Lckm2Btlr)
|
decreased IgG level
|
J:203759
|
Lcktm1.1Litt/Lcktm1.1Litt
(Not Specified)
|
abnormal immunoglobulin level
|
J:152472
|
Lcktm1Dbs/Lcktm1Dbs
(involves: C3H * C57BL/6)
|
decreased T cell proliferation
|
J:114660
|
Lcktm1Dbs/Lcktm1Dbs Tg(TcraTcrb)1100Mjb/0
(involves: C3H * C57BL/6)
|
decreased T cell proliferation
|
J:114660
|
Lcktm1Litt/Lcktm1.1Litt Tnfrsf4tm2(cre)Nik/Tnfrsf4+
(involves: 129X1/SvJ)
|
abnormal regulatory T cell physiology
|
J:152472
|
decreased T cell proliferation
|
J:152472
|
Lcktm1Mak/Lcktm1Mak
(involves: 129S2/SvPas)
|
abnormal thymocyte activation
|
J:110847
|
decreased IgG1 level
|
J:1119
|
increased IgG2a level
|
J:1119
|
increased IgG3 level
|
J:1119
|
increased IgM level
|
J:1119
|
Lcktm1Mak/Lcktm1Mak
(B6.129S2-Lcktm1Mak)
|
decreased cytotoxic T cell cytolysis
|
J:111646
|
Lcn2tm1Aade/Lcn2tm1Aade
(involves: 129P2/OlaHsd * C57BL/6)
|
increased susceptibility to bacterial infection
|
J:95107
|
sepsis
|
J:95107
|
Lcn2tm1Mak/Lcn2tm1Mak
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased susceptibility to bacterial infection
|
J:106079
|
Lcn2tm1Mrgr/Lcn2tm1Mrgr
(129(B6)-Lcn2tm1Mrgr)
|
abnormal mast cell physiology
|
J:173490
|
decreased thymocyte apoptosis
|
J:173490
|
Lcn2tm1Mrgr/Lcn2tm1Mrgr
(B6.129-Lcn2tm1Mrgr)
|
abnormal mast cell physiology
|
J:173490
|
Lcn2tm1Mrgr/Lcn2tm1Mrgr
(involves: 129 * C57BL/6)
|
abnormal mast cell physiology
|
J:173490
|
Lcn10tm1.1(KOMP)Vlcg/Lcn10tm1.1(KOMP)Vlcg
(C57BL/6N-Lcn10tm1.1(KOMP)Vlcg/MbpMmucd)
|
increased susceptibility to endotoxin shock
|
J:359002
|
Lcp1tm1Erjb/Lcp1tm1Erjb
(involves: 129X1/SvJ)
|
abnormal macrophage physiology
|
J:161042
|
abnormal neutrophil physiology
|
J:161042
|
decreased interleukin-1 secretion
|
J:161042
|
increased susceptibility to bacterial infection
|
J:161042
|
Lcp2m1Khoe/Lcp2m1Khoe
(C57BL/6J-Lcp2m1Khoe)
|
abnormal NK cell physiology
|
J:196519
|
impaired natural killer cell mediated cytotoxicity
|
J:196519
|
Lcp2tm1.1Wz/Lcp2tm1.1Wz
(B6.Cg-Lcp2tm1.1Wz)
|
decreased interleukin-2 secretion
|
J:150304
|
decreased T cell proliferation
|
J:150304
|
Lcp2tm1Geha/Lcp2tm1Geha
(involves: 129S4/SvJae)
|
decreased interferon-gamma secretion
|
J:131621
|
impaired natural killer cell mediated cytotoxicity
|
J:131621
|
Lcp2tm2Gak/Lcp2tm2Gak Tg(Cd4-cre)1Cwi/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
|
decreased T cell apoptosis
|
J:107467
|
Lcp2tm3Gak/Lcp2tm3Gak
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal T cell activation
|
J:132995
|
Lcp2tm3Gak/Lcp2tm3Gak Tg(TcrAND)53Hed/?
(involves: 129S6/SvEvTac * C57BL/6 * SJL)
|
abnormal thymocyte activation
|
J:132995
|
Lcp2tm4Gak/Lcp2tm4Gak
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N)
|
abnormal T cell activation
|
J:132995
|
Lcp2tm4Gak/Lcp2tm4Gak Tg(TcrAND)53Hed/?
(involves: 129S6/SvEvTac * C57BL/6 * SJL)
|
abnormal thymocyte activation
|
J:132995
|
Lcp2tm5(Lat/Lcp2)Gak/Lcp2tm5(Lat/Lcp2)Gak
(involves: 129S1/Sv * 129X1/SvJ)
|
abnormal thymocyte activation
|
J:147721
|
Lcp2twm/Lcp2twm
(C57BL/6JSfdAnu-Lcp2twm/Anu)
|
abnormal T cell physiology
|
J:104190
|
autoimmune response
|
J:104190
|
increased IgE level
|
J:104190
|
increased IgG level
|
J:104190
|
Lctlp1FVB/NJ/Lctlp1FVB/NJ
(involves: DBA/1J * FVB/NJ)
|
increased susceptibility to induced arthritis
|
J:122919
|
Lctlp2FVB/NJ/Lctlp2FVB/NJ
(involves: DBA/1J * FVB/NJ)
|
increased susceptibility to induced arthritis
|
J:122919
|
Ldlrtm1Her/Ldlrtm1Her
(involves: 129S7/SvEvBrd * C57BL/6)
|
liver inflammation
|
J:175559
|
Ldlrtm1Her/Ldlrtm1Her
(B6.129S7-Ldlrtm1Her)
|
decreased circulating interleukin-10 level
|
J:130794
|
increased circulating interleukin-1 beta level
|
J:137264
|
increased circulating interleukin-6 level
|
J:137264
|
increased circulating tumor necrosis factor level
|
J:137264
|
Ldlrtm1Her/Ldlrtm1Her Lrp1tm2Her/Lrp1tm2Her Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * 129S7/SvEvBrd)
|
impaired macrophage phagocytosis
|
J:137404
|
Ldlrtm1Her/Ldlrtm1Her Lrp1tm2Her/Lrp1tm2Her Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J)
|
abnormal microglial cell physiology
|
J:144185
|
Ldlrtm1Her/Ldlrtm1Her Olr1tm1Meht/Olr1tm1Meht
(involves: 129S7/SvEvBrd * 129X1/SvJ * C57BL/6)
|
increased circulating interleukin-10 level
|
J:130794
|
Ldlrtm1Her/Ldlrtm1Her Pfn1tm1Wit/Pfn1+
(B6.129S-Ldlrtm1Her Pfn1tm1Wit)
|
impaired macrophage chemotaxis
|
J:140294
|
Ldlrtm1Her/Ldlrtm1Her Soat1tm1Far/Soat1tm1Far
(involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6J)
|
skin inflammation
|
J:61147
|
Ldlrtm1Her/Ldlrtm1Her Tbx21tm1Glm/Tbx21tm1Glm
(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6)
|
abnormal interleukin secretion
|
J:96110
|
decreased IgG level
|
J:96110
|
decreased interferon-gamma secretion
|
J:96110
|
increased IgM level
|
J:96110
|
Ldlrtm1Her/Ldlrtm1Her Tcra-Jtm1Tgi/Tcra-Jtm1Tgi
(B6.129-Ldlrtm1Her Tcra-Jtm1Tgi)
|
decreased interferon-gamma secretion
|
J:140276
|
Ldlrtm1Her/Ldlrtm1Her Tg(H2-K-AKR1B1)1Tj/0
(involves: 129S7/SvEvBrd * C57BL/6 * DBA/2)
|
abnormal macrophage physiology
|
J:100916
|
Ldlrtm1Her/Ldlrtm1Her Tlr2tm1Kir/Tlr2tm1Kir
(B6.129-Tlr2tm1Kir Ldlrtm1Her)
|
abnormal cellular extravasation
|
J:131783
|
decreased tumor necrosis factor secretion
|
J:131783
|
Ldlrtm1Her/Ldlrtm1Her Vwftm1Wgr/Vwftm1Wgr
(B6.129S-Vwftm1Wgr Ldlrtm1Her)
|
impaired leukocyte tethering or rolling
|
J:106677
|
Ldlrad3em1Diam/Ldlrad3em1Diam
(C57BL/6-Ldlrad3em1Diam)
|
decreased susceptibility to Togaviridae infection
|
J:300132
|
Ldlrad3em1Diam/Ldlrad3em2Diam
(C57BL/6-Ldlrad3em1Diam Ldlrad3em2Diam)
|
decreased susceptibility to Togaviridae infection
|
J:300132
|
Ldlrad3em2Diam/Ldlrad3em2Diam
(C57BL/6-Ldlrad3em2Diam)
|
decreased susceptibility to Togaviridae infection
|
J:300132
|
Lect2tm1Ymg/Lect2tm1Ymg
(involves: 129P2/OlaHsd * C57BL/6J)
|
abnormal cytokine secretion
|
J:90961
|
abnormal leukocyte physiology
|
J:90961
|
increased T cell apoptosis
|
J:90961
|
liver inflammation
|
J:90961
|
Lef1tm1Hhx/Lef1tm1Hhx Tcf7tm1Cle/Tcf7tm1Cle Gt(ROSA)26Sortm2Sho/Gt(ROSA)26Sor+ Tg(GZMB-cre)1Jcb/0
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6 * FVB/N)
|
abnormal memory T cell physiology
|
J:189838
|
decreased tumor necrosis factor secretion
|
J:189838
|
Lepob/Lepob
(B6.Cg-Lepob/J)
|
lung inflammation
|
J:115772
|
Lepob/Lepob
(B6.Cg-Lepob/OlaHsd)
|
abnormal acute inflammation
|
J:124815
|
abnormal chemokine secretion
|
J:124815
|
increased interleukin-6 secretion
|
J:124815
|
increased susceptibility to endotoxin shock
|
J:124815
|
liver inflammation
|
J:124815
|
Lepob/Lepob
(involves: STOCK Mlphln a Tgfawa1 Cdh23v Ednrbs)
|
abnormal microglial cell physiology
|
J:115569
|
decreased circulating tumor necrosis factor level
|
J:115569
|
Lepob/Lepob
(involves: C57BL/6)
|
decreased T cell proliferation
|
J:164339
|
Lepob/Lepob
(B6.Cg-Lepob/JRj)
|
liver inflammation
|
J:277927
|
Lepob/Lepob Serpine1tm1Mlg/Serpine1tm1Mlg
(involves: 129S2/SvPas * C57BL/6)
|
abnormal tumor necrosis factor level
|
J:70695
|
Leprdb-5J/Leprdb-5J
(NOD/ShiLt-Leprdb-5J)
|
pancreas inflammation
|
J:118305
|
periinsulitis
|
J:118305
|
Leprdb-lb/Leprdb-lb
(C57BL/6NCrl-Leprdb-lb/Crl)
|
white adipose tissue inflammation
|
J:171755
|
Leprdb/Leprdb
(involves: C57BLKS/J)
|
increased susceptibility to autoimmune diabetes
|
J:7005
|
Leprdb/Leprdb
(B6.Cg-Dock7m +/+ Leprdb/J)
|
abnormal chemokine level
|
J:115772
|
abnormal interleukin level
|
J:115772
|
increased circulating interleukin-6 level
|
J:115772
|
lung inflammation
|
J:115772
|
Leprdb/Leprdb
(BKS.Cg-Dock7m +/+ Leprdb/OlaHsd)
|
abnormal acute inflammation
|
J:124815
|
abnormal chemokine secretion
|
J:124815
|
increased interleukin-6 secretion
|
J:124815
|
increased susceptibility to endotoxin shock
|
J:124815
|
liver inflammation
|
J:124815
|
Leprdb/Leprdb
(B6.BKS(D)-Leprdb/JOrlRj)
|
liver inflammation
|
J:277927
|
Leprdb/Leprdb
(BKS.Cg-Dock7m +/+ Leprdb)
|
kidney inflammation
|
J:346348
|
Leprm7Btlr/Leprm7Btlr
(C57BL/6J-Leprm7Btlr)
|
decreased response to antigen
|
J:236685
|
increased IgE level
|
J:236685
|
Leprtm1.1Rll/Lepr+
(129P3/J-Leprtm1.1Rll)
|
increased susceptibility to parasitic infection
|
J:172012
|
Leprtm1.1Rll/Leprtm1.1Rll
(129P3/J-Leprtm1.1Rll)
|
increased susceptibility to parasitic infection
|
J:172012
|
Leprtm4Mgmj/Leprtm4Mgmj
(B6.Cg-Leprtm4Mgmj)
|
decreased T cell proliferation
|
J:164339
|
Leprottm1.2Damj/Leprottm1.2Damj
(involves: 129S2/SvPas * C57BL/6N * FVB/N)
|
decreased cytokine level
|
J:349250
|
decreased inflammatory response
|
J:349250
|
Lgals1tm1Rob/Lgals1tm1Rob
(involves: 129S/SvEv)
|
increased interferon-gamma secretion
|
J:123416
|
increased interleukin-2 secretion
|
J:123416
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:123416
|
Lgals1tm1Rob/Lgals1tm1Rob
(involves: 129S/SvEv * 129S1/SvImJ * DBA/2J)
|
abnormal cytokine secretion
|
J:130208
|
Lgals2tm1.1Cfg/Lgals2tm1.1Cfg
(involves: C57BL/6)
|
abnormal immune system physiology
|
J:217719
|
enhanced humoral immune response
|
J:217719
|
increased IgG2b level
|
J:217719
|
increased IgG3 level
|
J:217719
|
increased susceptibility to type IV hypersensitivity reaction
|
J:217719
|
Lgals3tm1Ftl/Lgals3tm1Ftl
(B6.129S2-Lgals3tm1Ftl)
|
abnormal dendritic cell physiology
|
J:109126
|
abnormal interferon secretion
|
J:109126
|
abnormal response to infection
|
J:109126
|
brain inflammation
|
J:109126
|
increased IgG level
|
J:109126
|
increased interleukin-12b secretion
|
J:109126
|
increased susceptibility to parasitic infection
|
J:109126
|
lung inflammation
|
J:109126
|
small intestinal inflammation
|
J:109126
|
Lgals3tm1Ftl/Lgals3tm1Ftl
(involves: 129S2/SvPas * C57BL/6)
|
abnormal leukocyte physiology
|
J:60741
|
abnormal macrophage physiology
|
J:60741
|
increased macrophage apoptosis
|
J:60741
|
peritoneal inflammation
|
J:60741
|
Lgals3tm1Ftl/Lgals3tm1Ftl
(involves: 129S2/SvPas * CD-1)
|
liver inflammation
|
J:221030
|
Lgals3tm1Poi/Lgals3tm1Poi
(involves: 129/Sv * C57BL/6 * SJL)
|
abnormal macrophage physiology
|
J:131971
|
impaired macrophage chemotaxis
|
J:131971
|
impaired macrophage phagocytosis
|
J:131407
|
impaired neutrophil recruitment
|
J:131407
|
increased interleukin-6 secretion
|
J:131407
|
increased susceptibility to bacterial infection
|
J:131407
|
increased tumor necrosis factor secretion
|
J:131407
|
lung inflammation
|
J:131407
|
sepsis
|
J:131407
|
Lgals3bptm1Megt/Lgals3bptm1Megt
(involves: 129P2/OlaHsd * C57BL/Ka)
|
increased circulating interferon-gamma level
|
J:94936
|
increased circulating interleukin-12 level
|
J:94936
|
increased susceptibility to endotoxin shock
|
J:94936
|
increased tumor necrosis factor secretion
|
J:94936
|
Lgals8tm1(KOMP)Vlcg/Lgals8tm1(KOMP)Vlcg
(involves: C57BL/6NTac)
|
decreased susceptibility to Herpesvirales infection
|
J:235778
|
Lgals9tm1.1Cfg/Lgals9tm1.1Cfg
(involves: C57BL/6)
|
enhanced humoral immune response
|
J:217719
|
increased B cell proliferation
|
J:217719
|
Lgals9tm1Glp/Lgals9tm1Glp
(B6.129S6-Lgals9tm1Glp)
|
increased susceptibility to induced arthritis
|
J:132889
|
Lgmntm1Cptr/Lgmntm1Cptr
(B6.129S6-Lgmntm1Cptr)
|
abnormal adaptive immunity
|
J:155339
|
decreased interleukin-6 secretion
|
J:155339
|
decreased interleukin-12b secretion
|
J:155339
|
decreased tumor necrosis factor secretion
|
J:155339
|
Lgmntm1Ihn/Lgmntm1Ihn
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal macrophage physiology
|
J:143886
|
abnormal NK cell physiology
|
J:143886
|
increased circulating tumor necrosis factor level
|
J:143886
|
lgr/lgr
(Not Specified)
|
eye inflammation
|
J:13879
|
Lgr4Gt(LST020)Byg/Lgr4Gt(LST020)Byg
(involves: 129P2/OlaHsd * C57BL/6)
|
increased incidence of corneal inflammation
|
J:134299
|
Lhcgrtm1Hht/Lhcgrtm1Hht
(involves: 129S7/SvEvBrd * C57BL/6J)
|
epididymis inflammation
|
J:105533
|
prostate gland inflammation
|
J:105533
|
reproductive system inflammation
|
J:105533
|
Liftm1Phb/Lif+
(involves: 129S2/SvPas * C57BL/6 * DBA/2)
|
decreased T cell proliferation
|
J:77410
|
Liftm1Phb/Liftm1Phb
(involves: 129S2/SvPas * C57BL/6 * DBA/2)
|
decreased T cell proliferation
|
J:77410
|
Liftm1Stw/Liftm1Stw
(involves: 129S1/Sv * C57BL/6)
|
increased acute inflammation
|
J:119777
|
increased circulating interleukin-1 beta level
|
J:119777
|
Liftm1Stw/Liftm1Stw
(involves: 129S1/Sv * BALB/c)
|
decreased interleukin-10 secretion
|
J:136940
|
increased circulating interleukin-6 level
|
J:136940
|
increased circulating serum amyloid protein level
|
J:136940
|
increased circulating tumor necrosis factor level
|
J:136940
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:136940
|
increased susceptibility to endotoxin shock
|
J:136940
|
Liftm1Stw/Liftm1Stw
(involves: 129S1/Sv * MF1)
|
abnormal osteoclast physiology
|
J:137646
|
Lig1tm3Dwm/Lig1tm3Dwm
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal spleen physiology
|
J:77902
|
abnormal thymus physiology
|
J:77902
|
Lig4m1Btlr/Lig4m1Btlr
(C57BL/6J-Lig4m1Btlr)
|
decreased IgD level
|
J:267684
|
decreased IgG level
|
J:267684
|
impaired humoral immune response
|
J:267684
|
Lig4tm1Fwa/Lig4tm1Fwa Tg(Cr2-cre)3Cgn/0 Xrcc4tm2Fwa/Xrcc4tm2Fwa
(involves: 129S6/SvEvTac)
|
abnormal class switch recombination
|
J:126758
|
Lig4tm2.1Fwa/Lig4tm2.1Fwa
(involves: 129S6/SvEvTac)
|
abnormal B cell activation
|
J:157574
|
abnormal immune system physiology
|
J:157574
|
abnormal T cell activation
|
J:157574
|
decreased IgA level
|
J:157574
|
decreased IgG2b level
|
J:157574
|
decreased IgG3 level
|
J:157574
|
decreased IgG level
|
J:157574
|
decreased IgM level
|
J:157574
|
decreased immunoglobulin level
|
J:157574
|
decreased interferon-gamma secretion
|
J:157574
|
decreased interleukin-13 secretion
|
J:157574
|
decreased T cell proliferation
|
J:157574
|
increased anti-chromatin antibody level
|
J:157574
|
increased anti-double stranded DNA antibody level
|
J:157574
|
increased T cell apoptosis
|
J:157574
|
intestinal inflammation
|
J:157574
|
liver inflammation
|
J:157574
|
Lig4tm3.1Fwa/Lig4tm3.1Fwa Tg(Cr2-cre)3Cgn/0
(Not Specified)
|
abnormal class switch recombination
|
J:157537
|
Lilrb4atm1Eol/Lilrb4atm1Eol
(B6.129P2-Lilrb4atm1Eol)
|
abnormal cellular extravasation
|
J:129969
|
abnormal cytokine level
|
J:129969
|
abnormal immune system physiology
|
J:129969
|
abnormal interferon level
|
J:129969
|
abnormal interleukin level
|
J:129969
|
abnormal leukocyte physiology
|
J:129969
|
decreased IgE level
|
J:129969
|
increased inflammatory response
|
J:129969
|
increased mast cell degranulation
|
J:129969
|
Lilrb4atm1Hrk/Lilrb4atm1Hrk
(involves: 129/Sv * BALB/c)
|
abnormal mast cell physiology
|
J:70491
|
increased mast cell degranulation
|
J:70491
|
increased susceptibility to type I hypersensitivity reaction
|
J:70491
|
Lilrb4atm1Ttk/Lilrb4atm1Ttk
(B6.129X1-Lilrb4atm1Ttk)
|
abnormal dendritic cell antigen presentation
|
J:141234
|
increased susceptibility to graft versus host disease
|
J:141234
|
Limd1tm1Gdl/Limd1tm1Gdl
(involves: 129X1/SvJ)
|
abnormal macrophage physiology
|
J:118130
|
abnormal osteoclast physiology
|
J:118130
|
Limk2Gt(OST80053)Lex/Limk2Gt(OST80053)Lex
(involves: 129S5/SvEvBrd * C57BL/6)
|
increased incidence of corneal inflammation
|
J:192231
|
Limk2whe/Limk2whe
(B6.Cg-Lepob Limk2whe/GrsrJ)
|
increased incidence of corneal inflammation
|
J:127016
|
Lipatm1c(EUCOMM)Hmgu/Lipatm1c(EUCOMM)Hmgu Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1Tg(Alb-cre)21Mgn
(involves: C57BL/6J * C57BL/6N * C57BL/6NTac)
|
liver inflammation
|
J:270182
|
Lipatm1Hodu/Lipatm1Hodu
(involves: 129P2/OlaHsd * CF-1)
|
chronic inflammation
|
J:101217
|
lung inflammation
|
J:101217
|
Listr1BALB/cByJ/?
(involves: BALB/cByJ * C57BL/6ByJ)
|
decreased susceptibility to bacterial infection
|
J:68879
|
Listr1BALB/cByJ/? Listr2C57BL/6ByJ/?
(involves: BALB/cByJ * C57BL/6ByJ)
|
decreased susceptibility to bacterial infection
|
J:68879
|
Listr2C57BL/6ByJ/?
(involves: BALB/cByJ * C57BL/6ByJ)
|
decreased susceptibility to bacterial infection
|
J:68879
|
Litaftm1.1Ics/Litaftm1.1Ics
(Not Specified)
|
impaired macrophage chemotaxis
|
J:186411
|
Litaftm1Samr/Litaftm1Samr
(involves: 129S4/SvJae)
|
abnormal cytokine secretion
|
J:113750
|
decreased susceptibility to endotoxin shock
|
J:113750
|
ll/ll X/Yaa
(BXSB/MpJScr-ll)
|
decreased anti-nuclear antigen antibody level
|
J:10973
|
decreased IgG level
|
J:10973
|
decreased susceptibility to autoimmune disorder
|
J:10973
|
Lmb1C57BL/6Scr/Lmb1C57BL/6Scr
(involves: C57BL/6-Faslpr * MRL-Faslpr)
|
increased anti-double stranded DNA antibody level
|
J:45708
|
Lmb1C57BL/6Scr/Lmb1MRL/MpScr
(involves: C57BL/6-Faslpr * MRL-Faslpr)
|
increased anti-double stranded DNA antibody level
|
J:45708
|
Lmb2C57BL/6Scr/Lmb2MRL/MpScr
(involves: C57BL/6-Faslpr * MRL-Faslpr)
|
increased anti-double stranded DNA antibody level
|
J:45708
|
Lmb2MRL/MpScr/Lmb2MRL/MpScr
(involves: C57BL/6-Faslpr * MRL-Faslpr)
|
increased anti-double stranded DNA antibody level
|
J:45708
|
Lmbr1lem1Btlr/Lmbr1lem1Btlr
(C57BL/6J-Lmbr1lem1Btlr)
|
abnormal cytotoxic T cell physiology
|
J:274568
|
decreased IgD level
|
J:274568
|
decreased IgG level
|
J:274568
|
decreased IgM level
|
J:274568
|
impaired humoral immune response
|
J:274568
|
impaired natural killer cell mediated cytotoxicity
|
J:274568
|
increased IgM level
|
J:274568
|
Lmbr1lm1Btlr/Lmbr1lm1Btlr
(C57BL/6J-Lmbr1lm1Btlr)
|
abnormal cytotoxic T cell physiology
|
J:274568
|
decreased IgE level
|
J:274568
|
decreased IgG level
|
J:274568
|
decreased IgM level
|
J:274568
|
impaired humoral immune response
|
J:274568
|
impaired natural killer cell mediated cytotoxicity
|
J:274568
|
LmnaDhe/Lmna+
(B6(D2)-LmnaDhe/TyGrsrJ)
|
increased susceptibility to otitis media
|
J:188496
|
Lmnatm1.1Otin/Lmnatm1.1Otin
(involves: 129P2/OlaHsd * C57BL/6NTac)
|
keratoconjunctivitis sicca
|
J:261974
|
Lmo4tm1Slp/Lmo4tm1Slp Commd10Tg(Vav1-icre)A2Kio/Commd10+
(involves: 129S1/Sv * C57BL/6 * C57BL/10 * CBA/Ca)
|
abnormal acute inflammation
|
J:282740
|
abnormal lymphocyte physiology
|
J:282740
|
increased susceptibility to bacterial infection
|
J:282740
|
Lmo4tm1Slp/Lmo4tm1Slp Yeats4em1Zfa/Yeats4em1Zfa Commd10Tg(Vav1-icre)A2Kio/Commd10+
(involves: 129S1/Sv * C57BL/6 * C57BL/10 * CBA/Ca)
|
abnormal acute inflammation
|
J:282740
|
abnormal lymphocyte physiology
|
J:282740
|
increased susceptibility to bacterial infection
|
J:282740
|
Lmr1BALB/c/Lmr1BALB/c
(involves: BALB/c * C57BL/6J)
|
increased susceptibility to parasitic infection
|
J:40874
|
Lmr1BALB/c/Lmr1BALB/c Lmr30C57BL/6/Lmr30BALB/c
(involves: BALB/c * C57BL/6)
|
increased susceptibility to parasitic infection
|
J:57691
|
Lmr1BALB/c/Lmr1BALB/c Lmr30C57BL/6/Lmr30C57BL/6
(involves: BALB/c * C57BL/6)
|
increased susceptibility to parasitic infection
|
J:57691
|
Lmr1BALB/c/Lmr1C57BL/6J
(involves: BALB/c * C57BL/6J)
|
decreased susceptibility to parasitic infection
|
J:40874
|
Lmr1C57BL/6J/Lmr1C57BL/6J
(involves: BALB/c * C57BL/6J)
|
decreased susceptibility to parasitic infection
|
J:40874
|
Lmr2BALB/c/Lmr2BALB/c
(involves: BALB/c * C57BL/6J)
|
increased susceptibility to parasitic infection
|
J:40874
|
Lmr2BALB/c/Lmr2C57BL/6J
(involves: BALB/c * C57BL/6J)
|
decreased susceptibility to parasitic infection
|
J:40874
|
Lmr2C57BL/6J/Lmr2C57BL/6J
(involves: BALB/c * C57BL/6J)
|
decreased susceptibility to parasitic infection
|
J:40874
|
Lmr3BALB/cHeA/?
(involves: BALB/cHeA * STS/A)
|
abnormal tumor necrosis factor level
|
J:82715
|
increased IgE level
|
J:82715
|
Lmr4BALB/cHeA/? Lmr5BALB/cHeA/?
(involves: BALB/cHeA * STS/A)
|
abnormal tumor necrosis factor level
|
J:82715
|
Lmr5BALB/cHeA/?
(involves: BALB/cHeA * STS/A)
|
abnormal interleukin level
|
J:82715
|
abnormal tumor necrosis factor level
|
J:82715
|
increased IgE level
|
J:82715
|
Lmr5CcS5/Dem/Lmr5CcS5/Dem
(involves: BALB/cHeA * STS/A)
|
increased circulating interleukin-12 level
|
J:108764
|
Lmr7BALB/cHeA/?
(involves: BALB/cHeA * STS/A)
|
decreased splenocyte proliferation
|
J:108764
|
Lmr8BALB/cHeA/?
(involves: BALB/cHeA * STS/A)
|
increased IgE level
|
J:82717
|
Lmr9BALB/cHeA/?
(involves: BALB/cHeA * STS/A)
|
increased IgE level
|
J:82717
|
Lmr9BALB/cHeA/Lmr9CcS20/Dem
(involves: BALB/cHeA * STS/A)
|
increased circulating interleukin-6 level
|
J:108764
|
Lmr9CcS20/Dem/?
(involves: BALB/cHeA * STS/A)
|
decreased IgE level
|
J:82717
|
Lmr9CcS20/Dem/Lmr9CcS20/Dem
(involves: BALB/cHeA * STS/A)
|
increased circulating interleukin-6 level
|
J:108764
|
Lmr10BALB/cHeA/?
(involves: BALB/cHeA * STS/A)
|
increased IgE level
|
J:82717
|
Lmr10CcS20/Dem/?
(involves: BALB/cHeA * STS/A)
|
decreased IgE level
|
J:82717
|
Lmr11BALB/cHeA/Lmr11BALB/cHeA Lmr8CcS20/Dem/Lmr8CcS20/Dem
(involves: BALB/cHeA * STS/A)
|
decreased IgE level
|
J:82717
|
Lmr11BALB/cHeA/Lmr11CcS20/Dem
(involves: BALB/cHeA * STS/A)
|
increased circulating interleukin-6 level
|
J:108764
|
Lmr11CcS20/Dem/Lmr11CcS20/Dem
(involves: BALB/cHeA * STS/A)
|
increased circulating interleukin-6 level
|
J:108764
|
Lmr12BALB/cHeA/?
(involves: BALB/cHeA * STS/A)
|
decreased IgE level
|
J:82717
|
Lmr12BALB/cHeA/Lmr12BALB/cHeA Lmr14BALB/cHeA/Lmr14BALB/cHeA
(involves: BALB/cHeA * STS/A)
|
increased circulating tumor necrosis factor level
|
J:108764
|
Lmr12BALB/cHeA/Lmr12CcS16/Dem
(involves: BALB/cHeA * STS/A)
|
increased circulating interleukin-4 level
|
J:108764
|
Lmr12CcS16/Dem/?
(involves: BALB/cHeA * STS/A)
|
increased IgE level
|
J:82717
|
Lmr12CcS16/Dem/Lmr12CcS16/Dem
(involves: BALB/cHeA * STS/A)
|
increased circulating interleukin-4 level
|
J:108764
|
Lmr13BALB/cHeA/?
(involves: BALB/cHeA * STS/A)
|
decreased IgE level
|
J:82717
|
Lmr13CcS16/Dem/Lmr13CcS16/Dem Lmr14CcS16/Dem/Lmr14CcS16/Dem
(involves: BALB/cHeA * STS/A)
|
decreased circulating tumor necrosis factor level
|
J:108764
|
Lmr14BALB/cHeA/Lmr14BALB/cHeA Lmr5BALB/cHeA/?
(involves: BALB/cHeA * STS/A)
|
increased IgE level
|
J:82715
|
Lmr14BALB/cHeA/Lmr14BALB/cHeA Lmr5BALB/cHeA/Lmr5BALB/cHeA
(involves: BALB/cHeA * STS/A)
|
increased IgE level
|
J:82717
|
Lmr14BALB/cHeA/Lmr14CcS16/Dem
(involves: BALB/cHeA * STS/A)
|
increased circulating interferon-gamma level
|
J:108764
|
Lmr14CcS16/Dem/Lmr14CcS16/Dem
(involves: BALB/cHeA * STS/A)
|
increased circulating interferon-gamma level
|
J:108764
|
Lmr14CcS16/Dem/Lmr14CcS16/Dem Lmr5BALB/cHeA/?
(involves: BALB/cHeA * STS/A)
|
increased IgE level
|
J:82715
|
Lmr14CcS16/Dem/Lmr14CcS16/Dem Lmr5BALB/cHeA/Lmr5BALB/cHeA
(involves: BALB/cHeA * STS/A)
|
increased IgE level
|
J:82717
|
Lmr14CcS16/Dem/Lmr14CcS16/Dem Lmr5CcS5/Dem/Lmr5CcS5/Dem
(involves: BALB/cHeA * STS/A)
|
increased circulating interleukin-12 level
|
J:108764
|
Lmr15BALB/cHeA/Lmr15CcS16/Dem
(involves: BALB/cHeA * STS/A)
|
decreased circulating interferon-gamma level
|
J:108764
|
Lmr15CcS16/Dem/Lmr15CcS16/Dem
(involves: BALB/cHeA * STS/A)
|
decreased circulating interferon-gamma level
|
J:108764
|
Lmr17BALB/cHeA/Lmr17CcS20/Dem
(involves: BALB/cHeA * STS/A)
|
increased circulating tumor necrosis factor level
|
J:108764
|
Lmr17CcS20/Dem/Lmr17CcS20/Dem
(involves: BALB/cHeA * STS/A)
|
increased circulating tumor necrosis factor level
|
J:108764
|
Lmr17CcS20/Dem/Lmr17CcS20/Dem Lmr3BALB/cHeA/Lmr3BALB/cHeA
(involves: BALB/cHeA * STS/A)
|
increased circulating interferon-gamma level
|
J:108764
|
Lmr18BALB/cHeA/Lmr18BALB/cHeA
(involves: BALB/cHeA * STS/A)
|
decreased splenocyte proliferation
|
J:108764
|
Lmr18BALB/cHeA/Lmr18CcS20/Dem
(involves: BALB/cHeA * STS/A)
|
decreased splenocyte proliferation
|
J:108764
|
Lmrq1BALB/cAnSim/Lmrq1C57BL/10Sn
(involves: BALB/cAnNSim * C57BL/10J)
|
decreased susceptibility to parasitic infection
|
J:40624
|
Lmrq2BALB/cAnSim/Lmrq2C57BL/10Sn
(involves: BALB/cAnNSim * C57BL/10J)
|
decreased susceptibility to parasitic infection
|
J:40624
|
Lmrq3BALB/cAnSim/Lmrq3C57BL/10Sn
(involves: BALB/cAnNSim * C57BL/10J)
|
decreased susceptibility to parasitic infection
|
J:40624
|
Lmrq4BALB/cAnSim/Lmrq4C57BL/10Sn
(involves: BALB/cAnNSim * C57BL/10J)
|
decreased susceptibility to parasitic infection
|
J:40624
|
Lmrq4C57BL/10Sn/Lmrq4C57BL/10Sn
(C.B10-(D11Mit2-D11Mit29))
|
decreased susceptibility to parasitic infection
|
J:40624
|
Lmrq5BALB/cAnNSim/Lmrq5C57BL/10Sn
(involves: BALB/cAnNSim * C57BL/10J)
|
decreased susceptibility to parasitic infection
|
J:40624
|
Lmrq6BALB/cAnSim/Lmrq6C57BL/10Sn
(involves: BALB/cAnNSim * C57BL/10J)
|
decreased susceptibility to parasitic infection
|
J:40624
|
Lncucc1em1Bwu/Lncucc1em1Bwu
(C57BL/6-Lncucc1em1Bwu)
|
abnormal susceptibility to colitis induced morbidity/mortality
|
J:340220
|
increased susceptibility to induced colitis
|
J:340220
|
Loricrintm1Der/Loricrintm1Der
(FVB.129S7-Loricrintm1Der)
|
erythroderma
|
J:65187
|
Loxl2tm1.2Acan/Loxl2tm1.2Acan
(Not Specified)
|
decreased inflammatory response
|
J:220689
|
Lpar2tm1Dgen/Lpar2tm1Dgen
(B6.Cg-Lpar2tm1Dgen)
|
abnormal dendritic cell physiology
|
J:184061
|
decreased interleukin-10 secretion
|
J:184061
|
increased IgE level
|
J:184061
|
increased interleukin-13 secretion
|
J:184061
|
increased susceptibility to type I hypersensitivity reaction
|
J:184061
|
increased tumor necrosis factor secretion
|
J:184061
|
lung inflammation
|
J:184061
|
Lpar4tm1Sati/Y
(involves: C57BL/6)
|
abnormal cellular extravasation
|
J:253134
|
Lpar4tm1Sati/Lpar4+
(involves: C57BL/6)
|
abnormal cellular extravasation
|
J:253134
|
Lpar4tm1Sati/Lpar4tm1Sati
(involves: C57BL/6)
|
abnormal cellular extravasation
|
J:253134
|
Lpar6tm1.1Sati/Lpar6tm1.1Sati
(involves: C57BL/6 * C57BL/6NJcl * CBA)
|
abnormal cellular extravasation
|
J:253134
|
Lpn1NZB/Lpn1NZB
(involves: NZB * NZW)
|
kidney inflammation
|
J:6026
|
Lpn1NZB/Lpn1NZW
(involves: NZB * NZW)
|
kidney inflammation
|
J:6026
|
Lpn2NZB/Lpn2NZW
(involves: NZB * NZW)
|
kidney inflammation
|
J:6026
|
Lpn2NZW/Lpn2NZW
(involves: NZB * NZW)
|
kidney inflammation
|
J:6026
|
Lpoem1Zlu/Lpoem1Zlu
(involves: C57BL/6 * SJL)
|
aortitis
|
J:307289
|
arteritis
|
J:307289
|
blood vessel inflammation
|
J:307289
|
cardiovalvulitis
|
J:307289
|
gallbladder inflammation
|
J:307289
|
glomerulonephritis
|
J:307289
|
increased inflammatory response
|
J:307289
|
intestinal inflammation
|
J:307289
|
liver inflammation
|
J:307289
|
lung inflammation
|
J:307289
|
mastitis
|
J:307289
|
myocarditis
|
J:307289
|
myositis
|
J:307289
|
pancreas inflammation
|
J:307289
|
stomach inflammation
|
J:307289
|
Lppl1C57BL/6J/?
(involves: C57BL/6J * DBA/2J)
|
abnormal leukocyte physiology
|
J:90647
|
Lprm3MRL/MpJ/Lprm3MRL/MpJ
(involves: C3H/HeJ-Faslpr * MRL/MpJ-Faslpr)
|
glomerulonephritis
|
J:44625
|
Lprm5MRL/MpJ/Lprm5MRL/MpJ
(involves: C3H/HeJ-Faslpr * MRL/MpJ-Faslpr)
|
abnormal humoral immune response
|
J:44625
|
Lptl1DBA/2J/?
(involves: C57BL/6J * DBA/2J)
|
abnormal tumor necrosis factor level
|
J:90647
|
Lptl1DBA/2J/Lptl1DBA/2J Lptl2DBA/2J/Lptl2DBA/2J
(involves: C57BL/6J * DBA/2J)
|
abnormal tumor necrosis factor level
|
J:90647
|
Lptl2DBA/2J/?
(involves: C57BL/6J * DBA/2J)
|
abnormal tumor necrosis factor level
|
J:90647
|
Lpxntm1b(EUCOMM)Hmgu/Lpxntm1b(EUCOMM)Hmgu
(C57BL/6N-Lpxntm1b(EUCOMM)Hmgu/Wtsi)
|
decreased IgM level
|
J:305662
|
Lrbaem1Btlr/Lrbaem1Btlr
(C57BL/6J-Lrbaem1Btlr)
|
increased susceptibility to induced colitis
|
J:274652
|
Lrbaem2Btlr/Lrbaem2Btlr
(C57BL/6J-Lrbaem2Btlr)
|
increased susceptibility to induced colitis
|
J:274652
|
Lrbaem3Btlr/Lrbaem3Btlr
(C57BL/6J-Lrbaem3Btlr)
|
increased susceptibility to induced colitis
|
J:274652
|
LrbaGt(OST69142)Lex/LrbaGt(OST69142)Lex
(involves: 129 * 129S5/SvEvBrd)
|
abnormal NK cell physiology
|
J:237187
|
decreased susceptibility to graft versus host disease
|
J:237187
|
impaired natural killer cell mediated cytotoxicity
|
J:237187
|
increased length of allograft survival
|
J:237187
|
Lrbam1Btlr/Lrbam1Btlr
(C57BL/6J-Lrbam1Btlr)
|
increased susceptibility to induced colitis
|
J:274652
|
Lrbam2Btlr/Lrbam2Btlr
(C57BL/6J-Lrbam2Btlr)
|
increased susceptibility to induced colitis
|
J:274652
|
Lrch1em1Hwa/Lrch1em1Hwa
(Not Specified)
|
abnormal cellular extravasation
|
J:238772
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:238772
|
Lrdm1MRL/MpJ/?
(involves: CAST/Ei * MRL/MpJ-Faslpr/J)
|
kidney inflammation
|
J:3304
|
Lrdm2MRL/MpJ/?
(involves: CAST/Ei * MRL/MpJ-Faslpr/J)
|
kidney inflammation
|
J:3304
|
Lrfn2Tg(CD2-Myb/en)5Kmw/Lrfn2+
(involves: C57BL/10 * CBA)
|
decreased T cell proliferation
|
J:126456
|
Lrfn2Tg(CD2-Myb/en)5Kmw/Lrfn2+ Tg(H2-K-Myc)1Brn/?
(involves: C57BL/10 * CBA * FVB/N)
|
lymph node hemorrhage
|
J:125805
|
Lrfn2Tg(CD2-Myb/en)5Kmw/Lrfn2Tg(CD2-Myb/en)5Kmw
(involves: C57BL/10 * CBA)
|
decreased T cell proliferation
|
J:126456
|
Lrig1tm1a(EUCOMM)Wtsi/Lrig1tm1a(EUCOMM)Wtsi
(involves: C57BL/6 * C57BL/6N)
|
increased susceptibility to bacterial infection
|
J:213427
|
Lrig2tm1.1Hhed/Lrig2tm1.1Hhed
(involves: 129 * C57BL/6 * FVB/N)
|
increased inflammatory response
|
J:205929
|
Lrp1tm2Her/Lrp1tm2Her Tg(Camk2a-cre)T29-1Stl/0
(involves: 129S7/SvEvBrd * BALB/c * C57BL)
|
brain inflammation
|
J:167724
|
Lrp3em1Cya/Lrp3em1Cya
(C57BL/6N-Lrp3em1Cya/Cya)
|
increased susceptibility to induced arthritis
|
J:345338
|
osteoarthritis
|
J:345338
|
Lrp6tm1Arma/Lrp6tm1Arma
(C57BL/6-Lrp6tm1Arma)
|
liver inflammation
|
J:225450
|
Lrp12em1Gpt/Lrp12em1Gpt Tg(Cd4-cre)1Cwi/0
(involves: C57BL/6 * C57BL/6JGpt * DBA/2)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:338432
|
enhanced leukocyte migration
|
J:338432
|
increased susceptibility to induced colitis
|
J:338432
|
Lrrc4ctm1Lex/Lrrc4ctm1Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
|
increased circulating interleukin-6 level
|
J:171883
|
Lrrc8atm1.1Geha/Lrrc8atm1.1Geha
(B6.129S1(Cg)-Lrrc8atm1.1Geha)
|
abnormal T cell physiology
|
J:211308
|
abnormal thymus apoptosis
|
J:211308
|
abnormal thymus physiology
|
J:211308
|
decreased T cell proliferation
|
J:211308
|
increased IgG2a level
|
J:211308
|
increased thymocyte apoptosis
|
J:211308
|
Lrrc8eem1Bcgen/Lrrc8eem1Bcgen
(C57BL/6N-Lrrc8eem1Bcgen)
|
abnormal circulating cytokine level
|
J:288504
|
decreased circulating interferon-beta level
|
J:288504
|
decreased circulating tumor necrosis factor level
|
J:288504
|
decreased interferon-beta secretion
|
J:288504
|
increased susceptibility to viral infection
|
J:288504
|
increased susceptibility to viral infection induced morbidity/mortality
|
J:288504
|
Lrrc19tm1Ryag/Lrrc19tm1Ryag
(involves: C57BL/6J * C57BL/6NTac)
|
decreased circulating interleukin-6 level
|
J:271376
|
decreased circulating tumor necrosis factor level
|
J:271376
|
increased susceptibility to bacterial infection
|
J:271376
|
Lrrc25em1Cya/Lrrc25em1Cya
(C57BL/6J-Lrrc25em1Cya/Cya)
|
abnormal tumor necrosis factor level
|
J:270157
|
heart inflammation
|
J:270157
|
Lrrc32tm1.1Hfuj/Lrrc32tm1.1Hfuj Tg(Cd4-cre)1Cwi/0
(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NTac * DBA/2)
|
abnormal regulatory T cell physiology
|
J:204761
|
Lrrc55osem1Caox/Lrrc55osem1Caox
(C57BL/6-Lrrc55osem1Caox)
|
decreased circulating interferon-beta level
|
J:293325
|
increased susceptibility to Riboviria infection
|
J:293325
|
increased susceptibility to Riboviria infection induced morbidity/mortality
|
J:293325
|
Lrrk1tm1.1Smo/Lrrk1tm1.1Smo
(involves: 129S/Sv)
|
abnormal osteoclast physiology
|
J:208677
|
Lrrk2tm2.1Shn/Lrrk2tm2.1Shn
(involves: 129 * C57BL/6)
|
kidney inflammation
|
J:160542
|
Lse/Lse+
(B6C3Fe a/a-Lse/J)
|
keratoconjunctivitis sicca
|
J:338204
|
Lsm3em1Caox/Lsm3em1Caox
(involves: C57BL/6J)
|
decreased susceptibility to Orthomyxoviridae infection
|
J:262834
|
decreased susceptibility to Riboviria infection
|
J:262834
|
decreased susceptibility to Riboviria infection induced morbidity/mortality
|
J:262834
|
increased circulating interferon-alpha level
|
J:262834
|
increased circulating interferon-beta level
|
J:262834
|
increased circulating interleukin-6 level
|
J:262834
|
Lsp1tm1Jejb/Lsp1tm1Jejb
(involves: 129S1/Sv * 129X1/SvJ)
|
abnormal cellular extravasation
|
J:96022
|
abnormal leukocyte physiology
|
J:68128
|
impaired neutrophil chemotaxis
|
J:68128
|
Lsr1A/J/?
(involves: A/J * C57BL/6J)
|
increased susceptibility to bacterial infection
|
J:7345
|
Lsr1C57BL/6J/?
(involves: A/J * C57BL/6J)
|
decreased susceptibility to bacterial infection
|
J:7345
|
Lst1tm1(KOMP)Vlcg/Lst1tm1(KOMP)Vlcg
(C57BL/6N-Lst1tm1(KOMP)Vlcg)
|
increased susceptibility to Orthomyxoviridae infection
|
J:235700
|
increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality
|
J:235700
|
Lta4htm1Bhk/Lta4htm1Bhk
(involves: 129P2/OlaHsd * 129S/SvEv)
|
decreased acute inflammation
|
J:58985
|
decreased susceptibility to type I hypersensitivity reaction
|
J:58985
|
Lta/Tnftm1Eug/Lta/Tnftm1Eug
(involves: 129)
|
abnormal humoral immune response
|
J:31129
|
decreased IgA level
|
J:31129
|
increased susceptibility to parasitic infection
|
J:31129
|
increased susceptibility to Poxviridae infection
|
J:31129
|
increased susceptibility to Riboviria infection
|
J:31129
|
Lta/Tnftm1Eug/Lta/Tnftm1Eug
(involves: 129/Sv * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:115225
|
decreased susceptibility to parasitic infection
|
J:37696
|
Lta/Tnftm1Eug/Lta/Tnftm1Eug
(B6.129-Lta/Tnftm1Eug)
|
decreased circulating interferon-gamma level
|
J:115034
|
decreased IgG1 level
|
J:115034
|
decreased IgG2a level
|
J:115034
|
decreased IgG3 level
|
J:115034
|
decreased interferon-gamma secretion
|
J:115034
|
decreased susceptibility to induced arthritis
|
J:115034
|
impaired macrophage phagocytosis
|
J:115034
|
increased IgM level
|
J:115034
|
increased susceptibility to bacterial infection
|
J:115034
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:115034
|
Lta/Tnftm1Eug/Lta/Tnftm1Eug
(involves: 129)
|
abnormal humoral immune response
|
J:31129
|
decreased IgA level
|
J:31129
|
increased susceptibility to bacterial infection
|
J:31129
|
increased susceptibility to Poxviridae infection
|
J:31129
|
increased susceptibility to Riboviria infection
|
J:31129
|
Lta/Tnftm1Eug/Lta/Tnftm1Eug
(involves: 129/Sv * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:115225
|
decreased susceptibility to parasitic infection
|
J:37696
|
Lta/Tnftm1Eug/Lta/Tnftm1Eug
(B6.129-Lta/Tnftm1Eug)
|
decreased circulating interferon-gamma level
|
J:115034
|
decreased IgG1 level
|
J:115034
|
decreased IgG2a level
|
J:115034
|
decreased IgG3 level
|
J:115034
|
decreased interferon-gamma secretion
|
J:115034
|
decreased susceptibility to induced arthritis
|
J:115034
|
impaired macrophage phagocytosis
|
J:115034
|
increased IgM level
|
J:115034
|
increased susceptibility to bacterial infection
|
J:115034
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:115034
|
Lta/Tnftm1Fda/Lta/Tnftm1Fda
(involves: 129S1/Sv * 129X1/SvJ)
|
decreased susceptibility to endotoxin shock
|
J:39519
|
decreased tumor necrosis factor secretion
|
J:39519
|
increased susceptibility to bacterial infection
|
J:39519
|
Lta/Tnftm1Fda/Lta+
(involves: 129S1/Sv * 129X1/SvJ)
|
decreased susceptibility to endotoxin shock
|
J:39519
|
decreased tumor necrosis factor secretion
|
J:39519
|
increased susceptibility to bacterial infection
|
J:39519
|
Lta/Tnftm1Fda/Lta/Tnftm1Fda
(involves: 129S1/Sv * 129X1/SvJ)
|
decreased susceptibility to endotoxin shock
|
J:39519
|
decreased tumor necrosis factor secretion
|
J:39519
|
increased susceptibility to bacterial infection
|
J:39519
|
Lta/Tnftm1Fda/Tnf+
(involves: 129S1/Sv * 129X1/SvJ)
|
decreased susceptibility to endotoxin shock
|
J:39519
|
decreased tumor necrosis factor secretion
|
J:39519
|
increased susceptibility to bacterial infection
|
J:39519
|
Lta/Tnftm1Jods/Lta/Tnftm1Jods
(C57BL/6J-Lta/Tnftm1Jods)
|
decreased immunoglobulin level
|
J:43602
|
Lta/Tnftm1Jods/Lta/Tnftm1Jods
(C57BL/6-Lta/Tnftm1Jods)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:47428
|
Lta/Tnftm1Jods/Lta/Tnftm1Jods
(C57BL/6J-Lta/Tnftm1Jods)
|
decreased immunoglobulin level
|
J:43602
|
Lta/Tnftm1Jods/Lta/Tnftm1Jods
(C57BL/6-Lta/Tnftm1Jods)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:47428
|
Ltahlb382/Ltahlb382
(C57BL/6J-Ltahlb382/J)
|
liver inflammation
|
J:134498
|
lung inflammation
|
J:134498
|
Ltatm1.1Sned/Ltatm1.1Sned
(B6.129-Ltatm1.1Sned)
|
abnormal circulating tumor necrosis factor level
|
J:109621
|
abnormal class switch recombination
|
J:109621
|
abnormal humoral immune response
|
J:109621
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:109621
|
Ltatm1Dch/Ltatm1Dch
(B6.129S2-Ltatm1Dch)
|
abnormal class switch recombination
|
J:80616
|
abnormal cytokine secretion
|
J:95222
|
abnormal immune serum protein physiology
|
J:80616
|
decreased IgG level
|
J:80616
|
increased IgM level
|
J:80616
|
Ltatm1Dch/Ltatm1Dch
(involves: 129S2/SvPas * C57BL/6)
|
abnormal class switch recombination
|
J:109621
|
abnormal humoral immune response
|
J:39746
|
decreased interferon-gamma secretion
|
J:109621
|
decreased tumor necrosis factor secretion
|
J:109621
|
Ltatm1Tab/Ltatm1Tab
(either: (involves: 129S2/SvPas * C57BL/6J) or (involves: 129S2/SvPas * CF-1))
|
abnormal humoral immune response
|
J:28061
|
decreased IgA level
|
J:28061
|
increased IgM level
|
J:28061
|
Ltatm1Tab/Ltatm1Tab
(involves: 129S2/SvPas * C57BL/6)
|
decreased tumor necrosis factor secretion
|
J:109621
|
Ltatm1Tab/Ltatm1Tab
(B6.129S2-Ltatm1Tab)
|
decreased susceptibility to parasitic infection
|
J:121070
|
Ltb4r1tm1Adl/Ltb4r1tm1Adl
(involves: 129S4/SvJae * C57BL/6)
|
abnormal leukocyte adhesion
|
J:63873
|
abnormal leukocyte migration
|
J:63873
|
abnormal macrophage physiology
|
J:63873
|
abnormal neutrophil physiology
|
J:63873
|
impaired eosinophil recruitment
|
J:63873
|
impaired neutrophil chemotaxis
|
J:63873
|
Ltb4r1tm1Bodd/Ltb4r1tm1Bodd
(involves: 129S4/SvJaeSor * C57BL/6)
|
decreased susceptibility to autoimmune disorder
|
J:108446
|
Ltb4r1tm1Bodd/Ltb4r1tm1Bodd
(involves: 129S4/SvJaeSor)
|
decreased susceptibility to induced arthritis
|
J:131779
|
Ltb4r1tm1Bodd/Ltb4r1tm1Bodd
(either: (involves: 129S4/SvJaeSor * BALB/c ) or (involves: 129S4/SvJaeSor * C57BL/6))
|
decreased susceptibility to induced arthritis
|
J:163271
|
impaired neutrophil chemotaxis
|
J:163271
|
Ltb4r1tm1Tksh/Ltb4r1tm1Tksh
(B6.Cg-Ltb4r1tm1Tksh)
|
abnormal cytokine secretion
|
J:118995
|
decreased IgE level
|
J:118995
|
decreased susceptibility to type I hypersensitivity reaction
|
J:197334
|
lung inflammation
|
J:118995
|
Ltb4r1tm1Tksh/Ltb4r1tm1Tksh
(C.Cg-Ltb4r1tm1Tksh)
|
abnormal mast cell physiology
|
J:133998
|
Ltb4r1tm1Tksh/Ltb4r1tm1Tksh
(involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj)
|
abnormal granulocyte physiology
|
J:118995
|
Ltb4r2tm1Bodd/Ltb4r2tm1Bodd
(involves: 129S4/SvJaeSor * C57BL/6)
|
decreased susceptibility to induced arthritis
|
J:163271
|
Ltb4r2tm1Tksh/Ltb4r2tm1Tksh
(C.Cg-Ltb4r2tm1Tksh)
|
abnormal mast cell physiology
|
J:133998
|
Ltb4r2tm1Tksh/Ltb4r2tm1Tksh
(B6.Cg-Ltb4r2tm1Tksh)
|
decreased susceptibility to type I hypersensitivity reaction
|
J:197334
|
Ltb/Tnf/Ltatm1Dvk/Ltb/Tnf/Ltatm1Dvk
(B6.Cg-Ltb/Tnf/Ltatm1Dvk)
|
abnormal class switch recombination
|
J:80616
|
decreased IgG level
|
J:80616
|
increased susceptibility to bacterial infection
|
J:80616
|
Ltb/Tnf/Ltatm1Dvk/Ltb/Tnf/Ltatm1Dvk
(B6.Cg-Ltb/Tnf/Ltatm1Dvk)
|
abnormal class switch recombination
|
J:80616
|
decreased IgG level
|
J:80616
|
increased susceptibility to bacterial infection
|
J:80616
|
Ltb/Tnf/Ltatm1Dvk/Ltb/Tnf/Ltatm1Dvk
(B6.Cg-Ltb/Tnf/Ltatm1Dvk)
|
abnormal class switch recombination
|
J:80616
|
decreased IgG level
|
J:80616
|
increased susceptibility to bacterial infection
|
J:80616
|
Ltbtm1Flv/Ltbtm1Flv
(involves: 129S1/Sv * C57BL/6J)
|
abnormal humoral immune response
|
J:39746
|
decreased IgA level
|
J:39746
|
Ltbtm1Kpf/Ltbtm1Kpf
(B6.129P2-Ltbtm1Kpf)
|
abnormal class switch recombination
|
J:80616
|
colitis
|
J:158663
|
decreased IgG level
|
J:80616
|
increased IgM level
|
J:80616
|
increased susceptibility to bacterial infection
|
J:80616,
J:158663
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:158663
|
Ltbtm1Krn/Ltbtm1Krn
(C57BL/6-Ltbtm1Krn)
|
abnormal humoral immune response
|
J:78229
|
decreased IgG1 level
|
J:78229
|
decreased IgG2a level
|
J:78229
|
increased IgM level
|
J:78229
|
increased susceptibility to parasitic infection
|
J:78229
|
Ltbp3tm1Bdvc/Ltbp3tm1Bdvc
(involves: 129S6/SvEvTac)
|
osteoarthritis
|
J:76213,
J:79920
|
Ltbp4Gt(U3Cre)1Vmel/Ltbp4Gt(U3Cre)1Vmel
(B6.129S2-Ltbp4Gt(U3Cre)1Vmel)
|
colitis
|
J:78819
|
proctitis
|
J:78819
|
Ltbrm1Btlr/Ltbrm1Btlr
(C57BL/6J-Ltbrm1Btlr)
|
abnormal B cell physiology
|
J:212068
|
abnormal humoral immune response
|
J:212068
|
Ltbrm2Btlr/Ltbrm2Btlr
(C57BL/6J-Ltbrm2Btlr)
|
abnormal humoral immune response
|
J:254823
|
abnormal IgG level
|
J:254823
|
Ltbrm3Btlr/Ltbrm3Btlr
(C57BL/6J-Ltbrm3Btlr)
|
impaired natural killer cell mediated cytotoxicity
|
J:264642
|
Ltbrtm1.1Thhe/Ltbrtm1.1Thhe Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * C57BL/6 * SJL)
|
abnormal macrophage physiology
|
J:183109
|
Ltbrtm1Avt/Ltbrtm1Avt Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd)
|
increased susceptibility to bacterial infection
|
J:158663
|
Ltbrtm1Avt/Ltbrtm1Avt Tg(Rorc-cre)1Litt/0
(Not Specified)
|
abnormal chemokine level
|
J:158663
|
increased susceptibility to bacterial infection
|
J:158663
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:158663
|
Ltbrtm1Avt/Ltbrtm1Avt Tg(Vil1-cre)997Gum/0
(involves: C57BL/6J * SJL)
|
increased susceptibility to bacterial infection
|
J:158663
|
Ltbrtm1Kpf/Ltbrtm1Kpf
(involves: 129P2/OlaHsd)
|
abnormal immune system physiology
|
J:48837
|
decreased IgE level
|
J:86810
|
decreased interleukin-17 secretion
|
J:169863
|
Ltc4stm1Blam/Ltc4stm1Blam
(involves: 129S7/SvEvBrd * C57BL/6)
|
respiratory system inflammation
|
J:88647
|
Ltc4stm1Blam/Ltc4stm1Blam
(involves: 129S7/SvEvBrd * BALB/c)
|
abnormal hypersensitivity reaction
|
J:87909
|
abnormal type I hypersensitivity reaction
|
J:87909
|
Ltc4stm1Blam/Ltc4stm1Blam
(C.129S7-Ltc4stm1Blam)
|
autoimmune response
|
J:182213
|
Ltc4stm1Blam/Ltc4stm1Blam
(B6.129S7-Ltc4stm1Blam)
|
decreased susceptibility to type I hypersensitivity reaction
|
J:197334
|
Ltxs2BALB/cAnPt/Ltxs2DBA/2NCr
(involves: BALB/cAnPt * DBA/2NCr)
|
decreased susceptibility to infection
|
J:103336
|
Ltxs2DBA/2NCr/Ltxs2DBA/2NCr
(involves: BALB/cAnPt * DBA/2NCr)
|
decreased susceptibility to infection
|
J:103336
|
Ltxs3BALB/cAnPt/Ltxs3DBA/2NCr
(involves: BALB/cAnPt * DBA/2NCr)
|
decreased susceptibility to infection
|
J:103336
|
Ltxs3DBA/2NCr/Ltxs3DBA/2NCr
(involves: BALB/cAnPt * DBA/2NCr)
|
decreased susceptibility to infection
|
J:103336
|
Lumtm1Wwk/Lumtm1Wwk
(involves: 129P2/OlaHsd)
|
abnormal inflammatory response
|
J:128992
|
Lxw1BXSB/Scr/?
(involves: BXSB/Scr * NZW/LacScr)
|
increased anti-chromatin antibody level
|
J:86924
|
Lxw2NZW/LacScr/Lxw2NZW/LacScr
(involves: BXSB/Scr * NZW/LacScr)
|
glomerulonephritis
|
J:86924
|
Lxw3NZW/LacScr/?
(involves: BXSB/Scr * NZW/LacScr)
|
increased anti-chromatin antibody level
|
J:86924
|
Ly6atm1Pmf/Ly6atm1Pmf
(B6.129P2-Ly6atm1Pmf)
|
abnormal immunoglobulin level
|
J:42594
|
abnormal T cell proliferation
|
J:42594
|
Ly6etm1c(EUCOMM)Hmgu/Ly6etm1c(EUCOMM)Hmgu Commd10Tg(Vav1-icre)A2Kio/Commd10+
(B6.Cg-Ly6etm1c(EUCOMM)Hmgu Commd10Tg(Vav1-icre)A2Kio)
|
decreased inflammatory response
|
J:291868
|
increased susceptibility to Coronaviridae infection
|
J:291868
|
increased susceptibility to Coronaviridae infection induced morbidity/mortality
|
J:291868
|
Ly9tm1Mckn/Ly9tm1Mckn
(involves: 129/Sv * C57BL/6)
|
abnormal cytokine secretion
|
J:105482
|
decreased T cell proliferation
|
J:105482
|
Ly75tm1Mnz/Ly75tm1Mnz
(Not Specified)
|
abnormal cytotoxic T cell physiology
|
J:97289
|
Ly86tm1Kmiy/Ly86tm1Kmiy
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased B cell proliferation
|
J:109720
|
decreased IgG2b level
|
J:137066
|
decreased IgG3 level
|
J:137066
|
increased IgG level
|
J:109720
|
increased IgM level
|
J:109720
|
Ly96m1Btlr/Ly96m1Btlr
(C57BL/6J-Ly96m1Btlr)
|
decreased interleukin-1 beta secretion
|
J:265259
|
decreased macrophage apoptosis
|
J:265259
|
decreased tumor necrosis factor secretion
|
J:265259
|
Ly96tm1Kmiy/Ly96tm1Kmiy
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal immune cell physiology
|
J:92494
|
abnormal macrophage physiology
|
J:92494
|
decreased B cell proliferation
|
J:92494
|
decreased interleukin-6 secretion
|
J:92494
|
decreased susceptibility to endotoxin shock
|
J:92494
|
decreased tumor necrosis factor secretion
|
J:92494
|
impaired neutrophil recruitment
|
J:92479
|
increased susceptibility to bacterial infection
|
J:92494
|
Lyg1tm1(KOMP)Vlcg/Lyg1tm1(KOMP)Vlcg
(involves: C57BL/6NTac)
|
decreased interferon-gamma secretion
|
J:256594
|
LynM2Btlr/Lyn+
(C57BL/6J-LynM2Btlr)
|
decreased IgG level
|
J:217146
|
decreased IgM level
|
J:217146
|
impaired humoral immune response
|
J:217146
|
LynM2Btlr/LynM2Btlr
(C57BL/6J-LynM2Btlr)
|
decreased IgG level
|
J:217146
|
decreased IgM level
|
J:217146
|
impaired humoral immune response
|
J:217146
|
Lynm4Btlr/Lynm4Btlr
(C57BL/6J-Lynm4Btlr)
|
decreased IgG level
|
J:272816
|
impaired humoral immune response
|
J:272816
|
Lynmld4/Lynmld4
(involves: C57BL/6)
|
abnormal B cell activation
|
J:144799
|
glomerulonephritis
|
J:144799
|
increased anti-double stranded DNA antibody level
|
J:144799
|
increased IgE level
|
J:144799
|
increased IgM level
|
J:144799
|
peritoneal inflammation
|
J:144799
|
Lyntm1.1Calo/Lyntm1.1Calo Tg(Itgax-cre)1-1Reiz/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
abnormal circulating chemokine level
|
J:200745
|
abnormal circulating cytokine level
|
J:200745
|
abnormal dendritic cell physiology
|
J:200745
|
abnormal leukocyte physiology
|
J:200745
|
abnormal T cell activation
|
J:200745
|
glomerulonephritis
|
J:200745
|
increased autoantibody level
|
J:200745
|
increased circulating interferon-gamma level
|
J:200745
|
increased circulating interleukin-1 beta level
|
J:200745
|
increased circulating interleukin-6 level
|
J:200745
|
increased circulating interleukin-12 level
|
J:200745
|
increased circulating interleukin-17 level
|
J:200745
|
increased circulating tumor necrosis factor level
|
J:200745
|
increased inflammatory response
|
J:200745
|
liver inflammation
|
J:200745
|
lung inflammation
|
J:200745
|
skin inflammation
|
J:200745
|
Lyntm1Ard/Lyntm1Ard
(involves: 129P2/OlaHsd)
|
abnormal circulating complement protein level
|
J:161523
|
abnormal level of surface class II molecules
|
J:161523
|
glomerulonephritis
|
J:161523
|
increased anti-double stranded DNA antibody level
|
J:161523
|
increased anti-nuclear antigen antibody level
|
J:161523
|
increased IgA level
|
J:161523
|
increased IgE level
|
J:161523
|
increased IgG2b level
|
J:161523
|
increased IgM level
|
J:161523
|
Lyntm1Ard/Lyntm1Ard
(B6.129P2-Lyntm1Ard)
|
abnormal B cell activation
|
J:144799
|
glomerulonephritis
|
J:144799
|
increased anti-double stranded DNA antibody level
|
J:144799
|
increased anti-nuclear antigen antibody level
|
J:144799
|
peritoneal inflammation
|
J:144799
|
Lyntm1Ard/Lyntm1Ard Tg(IghelMD4)4Ccg/0
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal B cell activation
|
J:110531
|
increased IgM level
|
J:110531
|
Lyntm1Sor/Lyntm1Sor
(involves: 129S4/SvJae)
|
increased anti-double stranded DNA antibody level
|
J:42037
|
increased B cell proliferation
|
J:42037
|
Lyntm1Sor/Lyntm1Sor
(B6.129S4-Lyntm1Sor)
|
abnormal inflammatory response
|
J:113463
|
Lyntm1Sor/Lyntm1Sor
(involves: 129S4/SvJaeSor)
|
abnormal chemokine level
|
J:80658
|
abnormal circulating chemokine level
|
J:200745
|
abnormal circulating cytokine level
|
J:200745
|
abnormal dendritic cell physiology
|
J:200745
|
abnormal macrophage physiology
|
J:80658
|
abnormal microglial cell physiology
|
J:80658
|
glomerulonephritis
|
J:146161,
J:200745
|
increased anti-double stranded DNA antibody level
|
J:146161
|
increased autoantibody level
|
J:200745
|
increased B cell proliferation
|
J:146161
|
increased circulating interferon-gamma level
|
J:200745
|
increased circulating interleukin-6 level
|
J:200745
|
increased circulating interleukin-12 level
|
J:200745
|
increased circulating interleukin-17 level
|
J:200745
|
increased IgA level
|
J:146161
|
increased IgM level
|
J:146161
|
liver inflammation
|
J:146161
|
Lyntm1Sor/Lyntm1Sor
(involves: 129S4/SvJaeSor * C57BL/6)
|
glomerulonephritis
|
J:71174
|
increased anti-double stranded DNA antibody level
|
J:71174
|
increased B cell proliferation
|
J:71174
|
increased IgA level
|
J:71174
|
increased IgG1 level
|
J:71174
|
increased IgG2b level
|
J:71174
|
increased IgG level
|
J:71174
|
increased IgM level
|
J:71174
|
increased susceptibility to systemic lupus erythematosus
|
J:71174
|
Lyntm1Tya/Lyntm1Tya
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal B cell physiology
|
J:29751
|
abnormal class switch recombination
|
J:29751
|
decreased B cell proliferation
|
J:29751
|
glomerulonephritis
|
J:29751
|
increased anti-double stranded DNA antibody level
|
J:29751
|
increased IgA level
|
J:29751
|
increased IgM level
|
J:29751
|
increased immunoglobulin level
|
J:29751
|
Lynweeb/Lynweeb
(C57BL/6-Lynweeb)
|
glomerulonephritis
|
J:146161
|
increased anti-double stranded DNA antibody level
|
J:146161
|
increased B cell proliferation
|
J:146161
|
increased IgM level
|
J:146161
|
liver inflammation
|
J:146161
|
Lynf1C57BL/10J/Lynf1C57BL/10J Lynf3C57BL/10J/Lynf3C57BL/10J
(involves: B10.O20 * O20/A)
|
abnormal acute inflammation
|
J:128728
|
Lynf2C57BL/10J/Lynf2C57BL/10J Lynf3C57BL/10J/Lynf3C57BL/10J
(involves: B10.O20 * O20/A)
|
abnormal acute inflammation
|
J:128728
|
Lynf2O20/A/Lynf2O20/A
(involves: B10.O20 * O20/A)
|
abnormal acute inflammation
|
J:128728
|
Lynf4C57BL/10J/Lynf4C57BL/10J
(involves: B10.O20 * O20/A)
|
abnormal acute inflammation
|
J:128728
|
Lynf4C57BL/10J/Lynf4O20/A
(involves: B10.O20 * O20/A)
|
abnormal acute inflammation
|
J:128728
|
Lypd8tm2Ktak/Lypd8tm2Ktak
(B6.Cg-Lypd8tm2Ktak)
|
increased susceptibility to colitis induced morbidity/mortality
|
J:232706
|
increased susceptibility to induced colitis
|
J:232706
|
Lysetem1Janc/Lysetem1Janc
(C57BL/6J-Tmem251em1Janc)
|
decreased susceptibility to viral infection
|
J:330704
|
Lysetem1Janc/Lysetem2Janc
(C57BL/6J-Tmem251em1Janc Tmem251em2Janc)
|
decreased susceptibility to viral infection
|
J:330704
|
Lysetem2Janc/Lysetem2Janc
(C57BL/6J-Tmem251em2Janc)
|
decreased susceptibility to viral infection
|
J:330704
|
Lystbg-2Btlr/Lystbg-2Btlr
(C57BL/6J-Lystbg-2Btlr)
|
abnormal NK cell physiology
|
J:133617
|
increased susceptibility to Herpesvirales infection
|
J:133617
|
Lystbg-2J/Lystbg-2J
(C3.Cg-Lystbg-2J/J)
|
abnormal susceptibility to infection
|
J:147940
|
decreased susceptibility to fungal infection
|
J:147940
|
Lystbg-5Btlr/Lyst+
(C57BL/6J-Lystbg-5Btlr)
|
impaired macrophage phagocytosis
|
J:217864
|
Lystbg-5Btlr/Lystbg-5Btlr
(C57BL/6J-Lystbg-5Btlr)
|
impaired macrophage phagocytosis
|
J:217864
|
Lystbg-6Btlr/Lystbg-6Btlr
(C57BL/6J-Lystbg-6Btlr)
|
increased susceptibility to Herpesvirales infection
|
J:220065
|
Lystbg-Btlr/Lystbg-Btlr
(C57BL/6J-Lystbg-Btlr)
|
abnormal NK cell physiology
|
J:133616
|
increased susceptibility to bacterial infection
|
J:133616
|
increased susceptibility to Herpesvirales infection
|
J:133616
|
Lystbg-J/Lystbg-J
(C57BL/6J-Lystbg-J/J)
|
impaired natural killer cell mediated cytotoxicity
|
J:34814
|
Lystbg-J/Lystbg-J Prkdcscid/Prkdcscid
(B6.Cg-Lystbg-J Prkdcscid/Sz)
|
abnormal complement pathway
|
J:34814
|
abnormal level of surface class II molecules
|
J:34814
|
decreased immunoglobulin level
|
J:34814
|
impaired natural killer cell mediated cytotoxicity
|
J:34814
|
Lystbg/Lystbg
(B6.C3Rl-Lystbg)
|
alveolitis
|
J:110157
|
decreased cytotoxic T cell cytolysis
|
J:6692
|
impaired natural killer cell mediated cytotoxicity
|
J:6302,
J:6213
|
Lystbg/Lystbg
(B6.C3Rl-Lystbg/J)
|
abnormal NK cell physiology
|
J:6801
|
increased susceptibility to parasitic infection
|
J:6946
|
Lystbg/Lystbg Prkdcscid/Prkdcscid
(Not Specified)
|
increased susceptibility to infection
|
J:4752
|
Lyve1tm1.1(EGFP/cre)Cys/Lyve1+ Sphk1tm2Cgh/Sphk1tm2Cgh Sphk2tm1.1Cgh/Sphk2tm1.1Cgh
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
abnormal leukocyte migration
|
J:156826
|
Lyve1tm1Lhua/Lyve1tm1Lhua
(B6.129S1-Lyve1tm1Lhua)
|
abnormal lymph circulation
|
J:117713
|
Lyz2tm1(cre)Ifo/Lyz2+ Nsd3tm1.1Caox/Nsd3tm1.1Caox
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * SJL)
|
decreased macrophage cytokine production
|
J:251909
|
increased susceptibility to Riboviria infection
|
J:251909
|
increased susceptibility to Riboviria infection induced morbidity/mortality
|
J:251909
|
Lyz2tm1(cre)Ifo/Lyz2+ Pdcd10tm1Wami/Pdcd10tm1Wami
(involves: 129 * 129P2/OlaHsd * C57BL/6)
|
abnormal neutrophil physiology
|
J:256076
|
Lyz2tm1(cre)Ifo/Lyz2+ Pikfyvetm1b(EUCOMM)Hmgu/Pikfyvetm1b(EUCOMM)Hmgu
(involves: 129P2/OlaHsd * C57BL/6N)
|
increased interleukin-4 secretion
|
J:244776
|
increased interleukin-13 secretion
|
J:244776
|
increased susceptibility to type I hypersensitivity reaction
|
J:244776
|
Lyz2tm1(cre)Ifo/Lyz2+ St18tm1c(KOMP)Wtsi/St18tm1c(KOMP)Wtsi
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N)
|
increased circulating interleukin-1 beta level
|
J:298828
|
increased inflammatory response
|
J:298828
|
Lyz2tm1(cre)Ifo/Lyz2tm1(cre)Ifo Nrrostm1Wouy/Nrrostm1Wouy
(involves: 129P2/OlaHsd)
|
abnormal cellular extravasation
|
J:209569
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:209569
|
Lyz2tm1.1Graf/Lyz2tm1.1Graf
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased inflammatory response
|
J:82642
|
X/m1Nish
(involves: C57BL/6N)
|
decreased IgG level
|
J:204833
|
decreased IgM level
|
J:204833
|
decreased T cell proliferation
|
J:204833
|
Macroh2a1tm1Peh/Macroh2a1tm1Peh Macroh2a2tm1.1Peh/Macroh2a2tm1.1Peh
(129S6.Cg-Macroh2a2tm1.1Peh Macroh2a1tm1Peh)
|
blepharitis
|
J:220524
|
Madcam1tm1.2Nwag/Madcam1tm1.2Nwag
(B6.129P2-Madcam1tm1.2Nwag)
|
abnormal B cell physiology
|
J:169739
|
decreased IgA level
|
J:169739
|
MafOfl/MafOfl
(either: 102/ElH or C3H/HeH)
|
tubular nephritis
|
J:82475
|
Maftm1Glm/Maftm1Glm
(involves: 129/Sv * BALB/c)
|
decreased interleukin-4 secretion
|
J:78382
|
Magtm1Rod/Magtm1Rod
(involves: 129S1/Sv * 129X1/SvJ)
|
increased B cell proliferation
|
J:217719
|
Maged1tm1.1Urfm/Maged1tm1.1Urfm
(involves: 129P2/OlaHsd)
|
abnormal tumor necrosis factor level
|
J:157549
|
Magi2tm1Key/Magi2tm1Key
(involves: 129S4/SvJae)
|
tubulointerstitial nephritis
|
J:213553
|
Magt1Gt(IST13422E1)Tigm/Y
(involves: C57BL/6N)
|
increased B cell proliferation
|
J:260923
|
Malat1tm1.2Dlsp/Malat1tm1.2Dlsp
(B6J.Cg-Malat1tm1.2Dlsp)
|
brain inflammation
|
J:239375
|
Malt1m1Btlr/Malt1+
(C57BL/6J-Malt1m1Btlr)
|
impaired humoral immune response
|
J:221474
|
Malt1m1Btlr/Malt1m1Btlr
(C57BL/6J-Malt1m1Btlr)
|
impaired humoral immune response
|
J:221474
|
Malt1m2Btlr/Malt1+
(C57BL/6J-Malt1m2Btlr)
|
decreased IgM level
|
J:224671
|
impaired humoral immune response
|
J:224671
|
Malt1m2Btlr/Malt1m2Btlr
(C57BL/6J-Malt1m2Btlr)
|
decreased IgG level
|
J:224671
|
decreased IgM level
|
J:224671
|
impaired humoral immune response
|
J:224671
|
Malt1m3Btlr/Malt1+
(C57BL/6J-Malt1m3Btlr)
|
decreased IgM level
|
J:224672
|
impaired humoral immune response
|
J:224672
|
Malt1m3Btlr/Malt1m3Btlr
(C57BL/6J-Malt1m3Btlr)
|
decreased IgG level
|
J:224672
|
decreased IgM level
|
J:224672
|
impaired humoral immune response
|
J:224672
|
Malt1tm1Mak/Malt1tm1Mak
(involves: 129P2/OlaHsd)
|
abnormal dendritic cell physiology
|
J:111706
|
decreased IgG level
|
J:109545
|
decreased IgM level
|
J:109545
|
decreased T cell proliferation
|
J:109545
|
Malt1tm1Vmd/Malt1tm1Vmd
(involves: C57BL/6N)
|
abnormal T cell proliferation
|
J:86770
|
decreased immunoglobulin level
|
J:86770
|
decreased interleukin-2 secretion
|
J:86770
|
Man2a1tm1Jxm/Man2a1tm1Jxm
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal immune serum protein physiology
|
J:74579
|
abnormal immune system physiology
|
J:74579
|
abnormal self tolerance
|
J:74579
|
glomerulonephritis
|
J:74579
|
increased IgA level
|
J:74579
|
increased IgG level
|
J:74579
|
increased IgM level
|
J:74579
|
liver inflammation
|
J:74579
|
lung inflammation
|
J:74579
|
Man2a1tm1Jxm/Man2a1tm1Jxm Rag1tm1Mom/Rag1tm1Mom
(B6.129-Rag1tm1Mom Man2a1tm1Jxm)
|
kidney inflammation
|
J:124348
|
Man2c1tm1.1Tbec/Man2c1tm1.1Tbec
(B6N.129P2-Man2c1tm1.1Tbec)
|
abnormal microglial cell activation
|
J:205550
|
Map2k3tm1Flv/Map2k3tm1Flv
(involves: 129S1/Sv)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:85266
|
decreased T cell apoptosis
|
J:85266
|
Map2k3tm1Flv/Map2k3tm1Flv
(B6.129S1-Map2k3tm1Flv)
|
increased susceptibility to bacterial infection
|
J:124327
|
Map2k6tm1Flv/Map2k6tm1Flv
(involves: 129S1/Sv)
|
abnormal thymocyte apoptosis
|
J:85266
|
Map3k1tm1Glj/Map3k1tm1Glj
(involves: 129S/SvEv)
|
heart inflammation
|
J:78068
|
Map3k2tm1Bisu/Map3k2tm1Bisu
(Not Specified)
|
abnormal cytokine secretion
|
J:78072
|
abnormal T cell activation
|
J:78072
|
increased T cell proliferation
|
J:78072
|
Map3k3tm1Bisu/Map3k3tm2Bisu Tg(Lck-cre)548Jxm/0
(involves: C57BL/6 * CBA)
|
abnormal T cell physiology
|
J:145923
|
abnormal T cell proliferation
|
J:145923
|
Map3k3tm1Kuro/Map3k3tm1Kuro Tg(Lck-cre)1Jtak/0
(involves: C57BL/6)
|
decreased interferon-gamma secretion
|
J:147103
|
decreased interleukin-2 secretion
|
J:147103
|
decreased T cell proliferation
|
J:147103
|
Map3k4tm1Flv/Map3k4tm1Flv
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal T-helper 1 physiology
|
J:90112
|
decreased interferon-gamma secretion
|
J:90112
|
Map3k7tm1.1Gkl/Map3k7tm1.1Gkl Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased circulating interleukin-10 level
|
J:211916
|
decreased interleukin-10 secretion
|
J:211916
|
increased circulating interleukin-1 beta level
|
J:211916
|
increased circulating tumor necrosis factor level
|
J:211916
|
increased inflammatory response
|
J:211916
|
increased interleukin-1 beta secretion
|
J:211916
|
increased interleukin-6 secretion
|
J:211916
|
increased interleukin-10 secretion
|
J:211916
|
increased susceptibility to endotoxin shock
|
J:211916
|
increased tumor necrosis factor secretion
|
J:211916
|
Map3k7tm1Aki/Map3k7tm1Aki Tg(Alb1-cre)7Gsc/0
(involves: 129P2/OlaHsd * FVB/N)
|
liver inflammation
|
J:160521
|
Map3k7tm1Aki/Map3k7tm1Aki Tg(Lck-cre)1Jtak/0
(involves: 129P2/OlaHsd)
|
abnormal T cell activation
|
J:112837
|
colitis
|
J:112837
|
decreased T cell proliferation
|
J:112837
|
Map3k7tm1Aki/Map3k7tm1Aki Tg(Lck-cre)1Jtak/0
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:238318
|
abnormal cytokine level
|
J:238318
|
abnormal regulatory T cell physiology
|
J:238318
|
colitis
|
J:238318
|
increased interferon-gamma secretion
|
J:238318
|
increased interleukin-17 secretion
|
J:238318
|
Map3k7tm1Zjc/Map3k7tm1Zjc Tg(Lck-cre)548Jxm/0
(involves: 129S7/SvEvBrd * C57BL/6 * CBA)
|
increased thymocyte apoptosis
|
J:111794
|
Map3k8M1Btlr/Map3k8+
(C57BL/6J-Map3k8M1Btlr)
|
abnormal tumor necrosis factor secretion
|
J:140986
|
decreased tumor necrosis factor secretion
|
J:140986
|
Map3k8M1Btlr/Map3k8M1Btlr
(C57BL/6J-Map3k8M1Btlr)
|
abnormal response to infection
|
J:140986
|
decreased interferon-alpha secretion
|
J:140986
|
decreased interferon-beta secretion
|
J:140986
|
decreased interleukin-1 beta secretion
|
J:140986
|
decreased interleukin-6 secretion
|
J:140986
|
decreased tumor necrosis factor secretion
|
J:140986
|
impaired natural killer cell mediated cytotoxicity
|
J:140986
|
increased interleukin-12b secretion
|
J:140986
|
Map3k8m2Btlr/Map3k8m2Btlr
(C57BL/6J-Map3k8m2Btlr)
|
abnormal response to infection
|
J:212899
|
Map3k8m3Btlr/Map3k8+
(C57BL/6J-Map3k8m3Btlr)
|
decreased macrophage cytokine production
|
J:224668
|
decreased tumor necrosis factor secretion
|
J:224668
|
Map3k8m3Btlr/Map3k8m3Btlr
(C57BL/6J-Map3k8m3Btlr)
|
decreased macrophage cytokine production
|
J:224668
|
decreased tumor necrosis factor secretion
|
J:224668
|
Map3k8M4Btlr/Map3k8+
(C57BL/6J-Map3k8M4Btlr)
|
decreased tumor necrosis factor secretion
|
J:254880
|
Map3k8M4Btlr/Map3k8M4Btlr
(C57BL/6J-Map3k8M4Btlr)
|
decreased tumor necrosis factor secretion
|
J:254880
|
Map3k8tm1.2Gkl/Map3k8tm1.2Gkl
(involves: 129 * C57BL/6J * FVB/N)
|
decreased tumor necrosis factor secretion
|
J:193546
|
Map3k8tm1Pnt/Map3k8tm1Pnt
(involves: 129S1/Sv * C57BL/6J)
|
decreased susceptibility to endotoxin shock
|
J:66503
|
decreased tumor necrosis factor secretion
|
J:66503
|
Map3k8tm1Pnt/Map3k8tm1Pnt Nfkb1tm1Sley/Nfkb1tm1Sley
(involves: 129S1/Sv * 129S4/SvJae)
|
decreased circulating interleukin-12b level
|
J:196528
|
decreased interleukin-12b secretion
|
J:196528
|
decreased tumor necrosis factor secretion
|
J:196528
|
Map3k8tm1Pnt/Map3k8tm1Pnt Tnftm2Gkl/Tnf+
(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6J)
|
small intestinal inflammation
|
J:108572
|
Map3k8tm1Sley/Map3k8tm1Sley Nfkb1tm1Sley/Nfkb1tm1Sley
(involves: 129S4/SvJae)
|
decreased tumor necrosis factor secretion
|
J:196528
|
Map3k8tm1Tmat/Map3k8tm1Tmat
(involves: 129S/SvEv * C57BL/6)
|
abnormal cytokine secretion
|
J:92844
|
abnormal dendritic cell antigen presentation
|
J:92844
|
decreased IgE level
|
J:92844
|
decreased IgG1 level
|
J:92844
|
increased IgG2a level
|
J:92844
|
increased T cell proliferation
|
J:92844
|
Map3k10tm1Dsd/Map3k10tm1Dsd Map3k11tm1Rjd/Map3k11tm1Rjd
(involves: 129 * 129S6/SvEvTac * C57BL/6J)
|
abnormal circulating chemokine level
|
J:177426
|
abnormal circulating cytokine level
|
J:177426
|
abnormal response to infection
|
J:177426
|
Map3k10tm1Dsd/Map3k10tm1Dsd Map3k11tm2.1Rjd/Map3k11tm2.1Rjd
(involves: 129 * C57BL/6J)
|
abnormal circulating chemokine level
|
J:177426
|
abnormal circulating cytokine level
|
J:177426
|
abnormal response to infection
|
J:177426
|
Map3k14aly/Map3k14+ RelbTg(H2-K1/GH1)106Bri/Relb+
(involves: C57BL/6 * C57BL/6J)
|
decreased circulating interferon-gamma level
|
J:120659
|
Map3k14aly/Map3k14aly
(involves: C57BL/6J)
|
abnormal dendritic cell antigen presentation
|
J:128211
|
abnormal dendritic cell physiology
|
J:128211
|
abnormal immune system physiology
|
J:147681
|
abnormal T cell activation
|
J:38580
|
bile duct inflammation
|
J:48224
|
decreased circulating interferon-gamma level
|
J:120659
|
decreased circulating interleukin-4 level
|
J:120659
|
decreased IgE level
|
J:135748
|
increased inflammatory response
|
J:38580,
J:48224
|
increased susceptibility to parasitic infection
|
J:135748
|
kidney inflammation
|
J:38580
|
lacrimal gland inflammation
|
J:38580
|
liver inflammation
|
J:48224
|
lung inflammation
|
J:48224
|
pancreas inflammation
|
J:48224
|
Map3k14aly/Map3k14aly
(involves: AEJ/GnRk * C57BL/6J)
|
decreased IgA level
|
J:16865,
J:54529
|
decreased IgG level
|
J:16865,
J:54529
|
decreased IgM level
|
J:16865,
J:54529
|
increased length of allograft survival
|
J:16865
|
Map3k14aly/Map3k14aly
(C57BL/6J-Map3k14aly)
|
increased susceptibility to infection
|
J:16865
|
Map3k14m1Btlr/Map3k14m1Btlr
(C57BL/6J-Map3k14m1Btlr)
|
abnormal B cell activation
|
J:152065
|
decreased IgG level
|
J:152065
|
Map3k14m1Btlr/Map3k14m1Btlr
(involves: C57BL/6J)
|
abnormal class switch recombination
|
J:185495
|
decreased IgG level
|
J:185495
|
Map3k14tm1.2Gne/Map3k14tm1.2Gne
(B6(Cg)-Map3k14tm1.2Gne)
|
abnormal B cell physiology
|
J:240453
|
decreased IgA level
|
J:240453
|
Map3k14tm1Rds/Map3k14tm1Rds
(involves: 129/Sv * C57BL/6)
|
decreased IgA level
|
J:68125
|
decreased IgG2b level
|
J:68125
|
decreased immunoglobulin level
|
J:68125
|
Map3k14tm1Rds/Map3k14tm1Rds
(involves: 129)
|
abnormal class switch recombination
|
J:188560
|
Map4k1tm1Ssaw/Map4k1tm1Ssaw
(B6.Cg-Map4k1tm1Ssaw)
|
abnormal dendritic cell antigen presentation
|
J:150295
|
abnormal dendritic cell physiology
|
J:150295
|
increased interleukin-1 beta secretion
|
J:150295
|
increased interleukin-6 secretion
|
J:150295
|
increased interleukin-12 secretion
|
J:150295
|
increased tumor necrosis factor secretion
|
J:150295
|
Map4k1tm1Tht/Map4k1tm1Tht
(B6.129S7-Map4k1tm1Tht)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:116613
|
Map4k1tm1Tht/Map4k1tm1Tht
(involves: 129S7/SvEvBrd)
|
abnormal cytokine secretion
|
J:116613
|
abnormal humoral immune response
|
J:116613
|
increased T cell proliferation
|
J:116613
|
Map4k3Gt(RRO270)Byg/Map4k3Gt(RRO270)Byg
(involves: 129P2/OlaHsd)
|
abnormal interleukin secretion
|
J:177642
|
decreased IgG1 level
|
J:177642
|
decreased IgG2a level
|
J:177642
|
decreased IgG2b level
|
J:177642
|
decreased IgG3 level
|
J:177642
|
decreased IgM level
|
J:177642
|
decreased immunoglobulin level
|
J:177642
|
decreased interferon-gamma secretion
|
J:177642
|
decreased interleukin-2 secretion
|
J:177642
|
decreased interleukin-4 secretion
|
J:177642
|
decreased interleukin-17 secretion
|
J:177642
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:177642
|
decreased T cell proliferation
|
J:177642
|
Map4k5Gt(OST218153)Lex/Map4k5Gt(OST218153)Lex
(B6;129S5-Map4k5Gt(OST218153)Lex/Ieg)
|
increased IgG1 level
|
J:82809
|
Map7mshi/Map7mshi
(involves: BALB/cBy)
|
decreased length of allograft survival
|
J:37165
|
Mapk1tm1Hed/Mapk1tm1Hed Mapk3tm1Gpg/Mapk3tm1Gpg Tg(Lck-cre)1Cwi/0
(involves: 129/Sv * C57BL/6 * DBA/2)
|
abnormal T cell proliferation
|
J:113280
|
Mapk1tm1Hed/Mapk1tm1Hed Tg(Lck-cre)1Cwi/0
(involves: C57BL/6 * DBA/2)
|
decreased T cell proliferation
|
J:113280
|
Mapk3m1Btlr/Mapk3m1Btlr
(C57BL/6J-Mapk3m1Btlr)
|
decreased interleukin-1 beta secretion
|
J:221481
|
Mapk3tm1Gela/Mapk3tm1Gela
(either: 129(Cg)-Mapk3tm1Gela or B6.129-Mapk3tm1Gela)
|
abnormal cytokine secretion
|
J:107504
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:107504
|
Mapk3tm1Gpg/Mapk3tm1Gpg
(involves: 129)
|
decreased T cell proliferation
|
J:58468
|
Mapk8tm1Flv/Mapk8tm1Flv
(involves: 129S1/Sv)
|
abnormal cytokine secretion
|
J:51510
|
increased T cell proliferation
|
J:51510
|
Mapk8tm1Rjd/Mapk8tm1Rjd Mapk9tm2.1Rjd/Mapk9tm2.1Rjd Lyz2tm1(cre)Ifo/Lyz2+
(B6J.Cg-Lyz2tm1(cre)Ifo Mapk9tm2.1Rjd Mapk8tm1Rjd)
|
abnormal chemokine level
|
J:192551
|
abnormal circulating chemokine level
|
J:192551
|
abnormal circulating cytokine level
|
J:192551
|
abnormal macrophage physiology
|
J:192551
|
decreased inflammatory response
|
J:192551
|
decreased macrophage cytokine production
|
J:192551
|
impaired macrophage chemotaxis
|
J:192551
|
Mapk8tm1Wag/Mapk8+ Mapk9tm1Mka/Mapk9+
(involves: 129)
|
abnormal T cell activation
|
J:78190
|
decreased T cell apoptosis
|
J:78190
|
decreased T cell proliferation
|
J:78190
|
Mapk8tm1Wag/Mapk8+ Mapk9tm1Mka/Mapk9tm1Mka
(involves: 129)
|
abnormal T cell activation
|
J:78190
|
decreased T cell apoptosis
|
J:78190
|
decreased T cell proliferation
|
J:78190
|
Mapk8tm1Wag/Mapk8tm1Wag
(involves: 129P2/OlaHsd)
|
abnormal T cell activation
|
J:78190
|
decreased T cell apoptosis
|
J:78190
|
decreased T cell proliferation
|
J:78190
|
Mapk8tm1Wag/Mapk8tm1Wag Mapk9tm1Mka/Mapk9+
(involves: 129)
|
abnormal T cell activation
|
J:78190
|
decreased T cell apoptosis
|
J:78190
|
decreased T cell proliferation
|
J:78190
|
Mapk9tm1Flv/Mapk9tm1Flv Tnftm2Gkl/Tnf+
(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6J)
|
small intestinal inflammation
|
J:108572
|
Mapk9tm1Mka/Mapk9tm1Mka
(either: (involves: 129S2/SvPas) or (involves: 129S1/Sv * 129X1/SvJ))
|
abnormal T cell activation
|
J:78129
|
decreased T cell apoptosis
|
J:78129
|
decreased T cell proliferation
|
J:78129
|
Mapk11tm1Jda/Mapk11tm1Jda Mapk14tm1Jda/Mapk14tm1Jda
(involves: 129 * C57BL/6)
|
decreased interferon-gamma secretion
|
J:165966
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:165966
|
decreased susceptibility to induced arthritis
|
J:165966
|
decreased T cell proliferation
|
J:165966
|
decreased tumor necrosis factor secretion
|
J:165966
|
increased interleukin-10 secretion
|
J:165966
|
Mapk11tm1Jsca/Mapk11tm1Jsca Tnftm2Gkl/Tnf+
(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)
|
autoimmune arthritis
|
J:107771
|
ileum inflammation
|
J:107771
|
Mapk14tm1Jda/Mapk14tm1Jda
(B6.Cg-Mapk14tm1Jda)
|
abnormal T-helper 1 physiology
|
J:146088
|
decreased interferon-alpha secretion
|
J:146088
|
decreased interferon-gamma secretion
|
J:146088
|
decreased T cell proliferation
|
J:146088
|
Mapkapk2tm1.2Gkl/Mapkapk2tm1.2Gkl
(involves: BALB/cJ * C57BL/6)
|
decreased circulating tumor necrosis factor level
|
J:262876
|
decreased tumor necrosis factor secretion
|
J:262876
|
Mapkapk2tm1Mgl/Mapkapk2tm1Mgl
(involves: 129P2/OlaHsd * C57BL/6J)
|
abnormal cytokine level
|
J:59678
|
decreased circulating tumor necrosis factor level
|
J:59678
|
decreased susceptibility to endotoxin shock
|
J:59678
|
Mapkapk2tm1Mgl/Mapkapk2tm1Mgl
(involves: 129S * C57BL/6)
|
decreased interferon-gamma secretion
|
J:76161
|
decreased tumor necrosis factor secretion
|
J:76161
|
impaired macrophage phagocytosis
|
J:76161
|
increased interleukin-1 beta secretion
|
J:76161
|
increased susceptibility to bacterial infection
|
J:76161
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:76161
|
Mapkapk2tm1Mgl/Mapkapk2tm1Mgl
(involves: 129P2/OlaHsd * 129S/SvEvBrd * C57BL/6)
|
abnormal cytokine secretion
|
J:117668
|
Mapkapk2tm1Mgl/Mapkapk2tm1Mgl Mapkapk3tm1.1Lex/Mapkapk3tm1.1Lex
(involves: 129P2/OlaHsd * 129S/SvEvBrd * C57BL/6)
|
abnormal cytokine secretion
|
J:117668
|
Mapkapk2tm1Mgl/Mapkapk2tm1Mgl Tnftm2Gkl/Tnf+
(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6J)
|
granulomatous inflammation
|
J:108572
|
small intestinal inflammation
|
J:108572
|
Mar1tm1Wtg/Mar1+
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal immune system physiology
|
J:68024
|
abnormal somatic hypermutation frequency
|
J:68024
|
Mar1tm1Wtg/Mar1tm1Wtg
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal somatic hypermutation frequency
|
J:68024
|
Marchf1tm1.1Sish/Marchf1tm1.1Sish
(involves: 129S1/Sv * 129X1/SvJ)
|
abnormal B cell physiology
|
J:119918
|
abnormal dendritic cell antigen presentation
|
J:201198,
J:157516
|
abnormal level of surface class II molecules
|
J:119918
|
decreased interleukin-12 secretion
|
J:157516
|
decreased tumor necrosis factor secretion
|
J:157516
|
Marchf2em1Cnu/Marchf2em1Cnu
(C57BL/6-Marchf2em1Cnu)
|
decreased susceptibility to bacterial infection
|
J:297482
|
decreased susceptibility to viral infection
|
J:297482
|
increased circulating interferon-beta level
|
J:297482
|
increased circulating interleukin-6 level
|
J:297482
|
increased circulating interleukin-12 level
|
J:297482
|
increased circulating tumor necrosis factor level
|
J:297482
|
increased interleukin-6 secretion
|
J:297482
|
increased interleukin-12 secretion
|
J:297482
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:297482
|
increased susceptibility to endotoxin shock
|
J:297482
|
Marchf3em1Hbsh/Marchf3em1Hbsh
(involves: C57BL/6J)
|
abnormal circulating cytokine level
|
J:267641
|
increased susceptibility to infection induced morbidity/mortality
|
J:267641
|
Marchf5tm1.1Ygi/Marchf5tm1.1Ygi Tg(Emx1-cre)#Ito/0
(involves: C57BL/6)
|
increased microglial cell activation
|
J:284572
|
Marchf5tm1a(EUCOMM)Wtsi/Marchf5+
(C57BL/6-Marchf5tm1a(EUCOMM)Wtsi)
|
decreased susceptibility to Riboviria infection induced morbidity/mortality
|
J:225000
|
increased circulating interferon-beta level
|
J:225000
|
increased circulating interleukin-6 level
|
J:225000
|
Marchf7Gt(ROSABetageo)1Summ/Marchf7+
(involves: BALB/c)
|
abnormal cytokine secretion
|
J:96167
|
abnormal interleukin level
|
J:96167
|
increased interleukin-10 secretion
|
J:96167
|
increased T cell proliferation
|
J:96167
|
Marchf7Gt(ROSABetageo)1Summ/Marchf7Gt(ROSABetageo)1Summ
(involves: BALB/c)
|
abnormal cytokine secretion
|
J:96167
|
abnormal interleukin level
|
J:96167
|
increased interleukin-10 secretion
|
J:96167
|
increased T cell proliferation
|
J:96167
|
Marcksl1tm1Fsh/Marcksl1tm1Fsh
(involves: 129S4/SvJae)
|
abnormal macrophage physiology
|
J:115146
|
Marcotm1Ktry/Marcotm1Ktry
(B6.129S6-Marcotm1Ktry)
|
abnormal macrophage physiology
|
J:115081
|
impaired macrophage phagocytosis
|
J:115081
|
increased inflammatory response
|
J:115081
|
increased susceptibility to bacterial infection
|
J:115081,
J:122271
|
Marcotm1Ktry/Marcotm1Ktry Msr1tm1Csk/Msr1tm1Csk
(B6.129-Marcotm1Ktry Msr1tm1Csk)
|
abnormal macrophage physiology
|
J:122271
|
increased IgM level
|
J:122271
|
increased susceptibility to bacterial infection
|
J:122271
|
Marcotm1Spt/Marcotm1Spt
(C57BL/6-Marcotm1Spt)
|
abnormal dendritic cell chemotaxis
|
J:204315
|
abnormal dendritic cell physiology
|
J:204315
|
increased interferon-gamma secretion
|
J:204315
|
Marif1C57BL/10J/Marif1C57BL/10J
(involves: O20/A * NXT-10/Dem)
|
abnormal immune serum protein physiology
|
J:90251
|
decreased interleukin-12 secretion
|
J:90251
|
decreased tumor necrosis factor secretion
|
J:90251
|
Marif2C57BL/10J/Marif2C57BL/10J
(involves: O20/A * NXT-10/Dem)
|
abnormal immune serum protein physiology
|
J:90251
|
decreased interleukin-12 secretion
|
J:90251
|
increased tumor necrosis factor secretion
|
J:90251
|
Marif3C57BL/10J/Marif3C57BL/10J
(involves: O20/A * NXT-10/Dem)
|
increased interleukin-12 secretion
|
J:90251
|
Mark2tm1Hpw/Mark2tm1Hpw
(involves: 129X1/SvJ * C57BL/6)
|
abnormal humoral immune response
|
J:68830
|
abnormal immune system physiology
|
J:68830
|
decreased B cell proliferation
|
J:68830
|
decreased IgG3 level
|
J:68830
|
decreased IgM level
|
J:68830
|
glomerulonephritis
|
J:68830
|
increased B cell proliferation
|
J:68830
|
increased interferon-gamma secretion
|
J:68830
|
increased interleukin-4 secretion
|
J:68830
|
kidney inflammation
|
J:68830
|
lung inflammation
|
J:68830
|
salivary gland inflammation
|
J:68830
|
Masp1tm1Tefu/Masp1tm1Tefu
(B6.129S4-Masp1tm1Tefu)
|
impaired complement alternative pathway
|
J:177350
|
impaired lectin complement pathway
|
J:134537
|
Masp2tm1Tefu/Masp2tm1Tefu
(involves: 129 * C57BL/6)
|
abnormal complement pathway
|
J:140667
|
Masp2tm1Wjsc/Masp2tm1Wjsc
(B6.129P2-Masp2tm1Wjsc)
|
impaired lectin complement pathway
|
J:172218
|
Mat1atm1Jmm/Mat1atm1Jmm
(involves: 129/Sv * C57BL/6)
|
liver inflammation
|
J:69408
|
Matn3tm1Brd/Matn3tm1Brd
(involves: 129S7/SvEvBrd * C57BL/6)
|
osteoarthritis
|
J:112002
|
Matr3em1Tcp/Matr3em1Tcp
(C57BL/6J-Matr3em1Tcp)
|
increased microglial cell activation
|
J:298091
|
Mavstm1Aki/Mavstm1Aki
(Not Specified)
|
abnormal cytokine secretion
|
J:124405
|
abnormal response to infection
|
J:124405
|
decreased circulating interleukin-6 level
|
J:124405
|
decreased interferon-alpha secretion
|
J:124405
|
decreased interferon-beta secretion
|
J:124405
|
decreased interleukin-6 secretion
|
J:124405
|
increased susceptibility to Picornaviridae infection
|
J:124405
|
Mavstm1Aki/Mavstm1Aki
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased circulating interferon-alpha level
|
J:130954
|
decreased circulating interferon-beta level
|
J:130954
|
decreased circulating interferon-gamma level
|
J:130954
|
decreased circulating interleukin-6 level
|
J:130954
|
decreased IgG1 level
|
J:130954
|
decreased IgG2a level
|
J:130954
|
decreased IgG level
|
J:130954
|
decreased interferon-beta secretion
|
J:130954
|
decreased interleukin-12b secretion
|
J:130954
|
Mavstm1Aki/Mavstm1Aki
(involves: 129S/SvEv * C57BL/6)
|
abnormal circulating interferon level
|
J:162888
|
abnormal dendritic cell physiology
|
J:162888
|
abnormal macrophage physiology
|
J:162888
|
brain inflammation
|
J:162888
|
CNS inflammation
|
J:162888
|
decreased interferon-beta secretion
|
J:162888
|
increased circulating interferon-gamma level
|
J:162888
|
increased circulating interleukin-6 level
|
J:162888
|
increased circulating tumor necrosis factor level
|
J:162888
|
increased IgG2a level
|
J:162888
|
increased IgG level
|
J:162888
|
increased IgM level
|
J:162888
|
increased susceptibility to Flaviviridae infection
|
J:162888
|
increased susceptibility to Flaviviridae infection induced morbidity/mortality
|
J:162888
|
Mavstm1Aki/Mavstm1Aki Ifna6tm1Aki/Ifna6+
(involves: 129P2/OlaHsd)
|
decreased interferon-alpha secretion
|
J:124340
|
Mavstm1Aki/Mavstm1Aki Ticam1tm1Aki/Ticam1tm1Aki
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased circulating interferon-alpha level
|
J:130954
|
decreased circulating interferon-beta level
|
J:130954
|
decreased circulating interferon-gamma level
|
J:130954
|
decreased circulating interleukin-6 level
|
J:130954
|
decreased circulating interleukin-12b level
|
J:130954
|
decreased cytotoxic T cell cytolysis
|
J:130954
|
decreased IgG1 level
|
J:130954
|
decreased IgG2a level
|
J:130954
|
decreased IgG level
|
J:130954
|
decreased interferon-beta secretion
|
J:130954
|
decreased interleukin-12b secretion
|
J:130954
|
Mavstm1Camb/Mavstm1Camb
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal B cell calcium ion homeostasis
|
J:180356
|
decreased B cell proliferation
|
J:180356
|
decreased interleukin-12 secretion
|
J:180356
|
decreased tumor necrosis factor secretion
|
J:180356
|
Mavstm1Itl/Mavstm1Itl Trex1tm1Tld/Trex1tm1Tld
(involves: 129P2/OlaHsd * C57BL/6)
|
increased inflammatory response
|
J:181257
|
myocarditis
|
J:181257
|
myositis
|
J:181257
|
skin inflammation
|
J:181257
|
stomach inflammation
|
J:181257
|
Mavstm1Tsc/Mavstm1Tsc
(Not Specified)
|
decreased interferon-beta secretion
|
J:136289
|
Mavstm1Tsse/Mavstm1Tsse Tg(PVR)1Kkst/0
(involves: 129 * C57BL/6 * ICR)
|
abnormal interferon-alpha secretion
|
J:179625
|
decreased susceptibility to Picornaviridae infection induced morbidity/mortality
|
J:179625
|
Mavstm1Zjc/Mavs+
(involves: 129/Sv * C57BL/6)
|
abnormal innate immunity
|
J:110905
|
increased susceptibility to Riboviria infection
|
J:110905
|
Mavstm1Zjc/Mavstm1Zjc
(involves: 129/Sv * C57BL/6)
|
abnormal dendritic cell physiology
|
J:110905
|
abnormal innate immunity
|
J:110905
|
abnormal macrophage physiology
|
J:110905
|
increased susceptibility to Riboviria infection
|
J:110905
|
Mavstm1Zjc/Mavstm1Zjc
(B6.Cg-Mavstm1Zjc)
|
abnormal circulating interferon level
|
J:243916
|
Mavstm1Zjc/Mavstm1Zjc Rnaseh2atm1Crh/Rnaseh2atm1Crh
(Not Specified)
|
abnormal innate immunity
|
J:232933
|
Mbd2tm1Bh/Mbd2tm1Bh
(NOD.129P2(B6)-Mbd2tm1Bh)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:323838
|
increased T cell proliferation
|
J:323838
|
insulitis
|
J:323838
|
salivary gland inflammation
|
J:323838
|
Mbd3tm2Bh/Mbd3tm2Bh Tg(Vil1-cre)20Syr/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
increased susceptibility to induced colitis
|
J:167984
|
Mbis1NOD/ShiLt/Mbis1NOD/ShiLt
(involves: BALB/c * NOD/Lt)
|
increased susceptibility to bacterial infection
|
J:75276
|
Mbis2BALB/c/Mbis2BALB/c
(involves: BALB/c * NOD/Lt)
|
increased susceptibility to bacterial infection
|
J:75276
|
Mbis2BALB/c/Mbis2NOD/ShiLt
(involves: BALB/c * NOD/Lt)
|
increased susceptibility to bacterial infection
|
J:75276
|
Mbis3BALB/c/?
(involves: BALB/c * NOD/Lt)
|
increased susceptibility to bacterial infection
|
J:75276
|
Mbis4NOD/ShiLt/Mbis4NOD/ShiLt
(involves: BALB/c * NOD/Lt)
|
increased susceptibility to bacterial infection
|
J:75276
|
Mbl1tm1Kata/Mbl1tm1Kata
(involves: 129S4/SvJae * C57BL/6J)
|
decreased circulating tumor necrosis factor level
|
J:90437
|
Mbl1tm1Kata/Mbl1tm1Kata Mbl2tm1Kata/Mbl2tm1Kata
(involves: 129 * C57BL/6)
|
abnormal circulating interleukin-6 level
|
J:98124
|
abnormal circulating tumor necrosis factor level
|
J:98124
|
impaired macrophage phagocytosis
|
J:97686,
J:98124
|
increased susceptibility to bacterial infection
|
J:98124
|
Mbl1tm1Kata/Mbl1tm1Kata Mbl2tm1Kata/Mbl2tm1Kata
(involves: 129 * C57BL/6J)
|
abnormal complement pathway
|
J:106351
|
abnormal response to infection
|
J:106352
|
increased susceptibility to bacterial infection
|
J:106353
|
Mbl1tm1Rala/Mbl1tm1Rala
(involves: 129X1/SvJ * C57BL/6J)
|
abnormal immunoglobulin level
|
J:145279
|
decreased IgG2b level
|
J:145279
|
decreased IgM level
|
J:145279
|
increased IgG1 level
|
J:145279
|
increased IgG2a level
|
J:145279
|
increased IgG3 level
|
J:145279
|
increased susceptibility to parasitic infection
|
J:145279
|
Mbpshi/Mbpshi
(C3Fe.SWV-Mbpshi/J)
|
decreased susceptibility to Picornaviridae infection
|
J:41447
|
Mbpshi/Mbpshi
(involves: BALB/c * C3HeB/Fe * SWV)
|
increased interferon-gamma secretion
|
J:48412
|
increased interleukin-2 secretion
|
J:48412
|
increased interleukin-4 secretion
|
J:48412
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:48412
|
increased T cell proliferation
|
J:48412
|
Mbtps1wrt/Mbtps1wrt
(C57BL/6J-Mbtps1wrt)
|
decreased cytotoxic T cell cytolysis
|
J:94077
|
decreased susceptibility to bacterial infection
|
J:123123
|
increased interleukin-1 beta secretion
|
J:146454
|
increased interleukin-6 secretion
|
J:146454
|
increased susceptibility to Herpesvirales infection
|
J:94077,
J:123123
|
increased susceptibility to induced colitis
|
J:146454
|
Mc3rtm1Butl/Mc3rtm1Butl
(B6.Cg-Mc3rtm1Butl)
|
increased inflammatory response
|
J:178147
|
Mc4rtm1Lowl/Mc4rtm1Lowl
(involves: 129S4/SvJae * C57BL/6J)
|
increased circulating interleukin-6 level
|
J:177386
|
liver inflammation
|
J:177386
|
white adipose tissue inflammation
|
J:177386
|
Mc4rtm1Matsu/Mc4rtm1Matsu
(C57BL/6J-Mc4rtm1Matsu)
|
liver inflammation
|
J:285412
|
Mcamtm1Lex/Mcamtm1Lex
(involves: 129S/SvEvBrd)
|
abnormal cytokine level
|
J:193167
|
abnormal response to infection
|
J:193167
|
decreased macrophage cytokine production
|
J:193167
|
Mcemp1em1Jngj/Mcemp1em1Jngj
(C57BL/6-Mcemp1em1Jngj)
|
abnormal type I hypersensitivity reaction
|
J:335318
|
Mcl1tm1Dmta/Mcl1tm1Dmta Tg(Aicda-cre)9Mbu/0
(B6.Cg-Mcl1tm1Dmta Tg(Aicda-cre)9Mbu)
|
decreased IgG1 level
|
J:166069
|
Mcl1tm1Yen/Mcl1tm1Yen
(B6.129-Mcl1tm1Yen)
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:146246
|
Mcl1tm1Ywh/Mcl1tm1Ywh Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * 129S4/SvJae * 129S6/SvEvTac * C57BL/6)
|
abnormal neutrophil physiology
|
J:137502
|
impaired neutrophil recruitment
|
J:137502
|
Mcl1tm1Ywh/Mcl1tm1Ywh Tg(Cd4-cre)1Cwi/0
(involves: 129S6/SvEvTac * C57BL/6 * DBA/2)
|
increased T cell apoptosis
|
J:137400
|
Mcl1tm1Ywh/Mcl1tm1Ywh Tg(Lck-cre)548Jxm/0
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * CBA)
|
increased T cell apoptosis
|
J:137400
|
Mcl1tm2Sjk/Mcl1tm3Sjk Tg(Lck-cre)1Cwi/0
(involves: 129X1/SvJ * C57BL/6 * DBA/2)
|
increased T cell apoptosis
|
J:86906
|
Mcl1tm3Sjk/Mcl1tm3Sjk Tg(Cpa3-cre)3Glli/0
(involves: 129X1/Sv * C57BL/6)
|
decreased inflammatory response
|
J:179080
|
decreased susceptibility to type I hypersensitivity reaction
|
J:179080
|
Mcm3aptm1Imku/Mcm3aptm1Imku Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
abnormal germinal center B cell physiology
|
J:88276
|
decreased B cell proliferation
|
J:88276
|
decreased IgG level
|
J:88276
|
Mcoln1tm1Sasl/Mcoln1tm1Sasl
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal macrophage physiology
|
J:189070
|
Mcoln2tm1e.1(KOMP)Wtsi/Mcoln2tm1e.1(KOMP)Wtsi
(involves: C57BL/6J * C57BL/6N)
|
abnormal chemokine level
|
J:239875
|
abnormal chemokine secretion
|
J:239875
|
abnormal innate immunity
|
J:239875
|
impaired macrophage chemotaxis
|
J:239875
|
impaired neutrophil chemotaxis
|
J:239875
|
Mcph1Tg(HLA-A2.1)1Enge/Mcph1+
(involves: C57BL/6)
|
abnormal immune tolerance
|
J:52612
|
Mcph1Tg(HLA-A2.1)1Enge/Mcph1+
(NOD.B6-Mcph1Tg(HLA-A2.1)1Enge)
|
increased susceptibility to autoimmune diabetes
|
J:109851
|
Mcph1Tg(HLA-A2.1)1Enge/Mcph1Tg(HLA-A2.1)1Enge
(NOD.B6-Mcph1Tg(HLA-A2.1)1Enge)
|
increased susceptibility to autoimmune diabetes
|
J:109851
|
Mcph1tm1.2Kali/Mcph1tm1.2Kali
(involves: 129S7/SvEvBrd * C57BL/6J)
|
abnormal T cell physiology
|
J:156371
|
Mcpt1tm1Hrpm/Mcpt1tm1Hrpm
(involves: 129P2/OlaHsd * MF1)
|
decreased circulating tumor necrosis factor level
|
J:93616
|
increased susceptibility to parasitic infection
|
J:93616,
J:93795
|
Mcpt4tm1Mabr/Mcpt4tm1Mabr
(involves: 129X1/SvJ * C57BL/6J)
|
abnormal mast cell physiology
|
J:84839
|
Mcpt8tm1.1(HBEGF)Hkar/Mcpt8tm1.1(HBEGF)Hkar
(B6.Cg-Mcpt8tm1.1(HBEGF)Hkar)
|
increased susceptibility to parasitic infection
|
J:163761
|
Mdc1Gt(OST441263)Lex/Mdc1Gt(OST441263)Lex
(involves: 129S5/SvEvBrd * C57BL/6)
|
abnormal class switch recombination
|
J:137341
|
Mdficem1Nlh/Mdficem2Nlh
(C57BL/6J-Mdficem1Nlh/Mdficem2Nlh)
|
abnormal lymph circulation
|
J:326462
|
Mdktm1Tmu/Mdktm1Tmu
(129S2-Mdktm1Tmu)
|
tubular nephritis
|
J:93637
|
Mdktm1Tmu/Mdktm1Tmu
(B6.129S2-Mdktm1Tmu)
|
abnormal macrophage chemotaxis
|
J:102069
|
impaired neutrophil chemotaxis
|
J:102069
|
Mdm2tm2.1Snj/Mdm2tm2.1Snj
(involves: 129S4/SvJae * C57BL/6)
|
decreased thymocyte apoptosis
|
J:189297
|
Mdm4tm1.1Wahl/Mdm4tm1.1Wahl
(involves: 129S/Sv * C57BL/6)
|
decreased thymocyte apoptosis
|
J:150341
|
MecomJbo/Mecom+
(C3N.C-MecomJbo)
|
increased susceptibility to otitis media
|
J:113445
|
respiratory system inflammation
|
J:113445
|
MecomJbo/Mecom+
(involves: BALB/c)
|
increased susceptibility to otitis media
|
J:250208
|
Mecp2tm1.1Bird/Y SqleSum3-Jus/Sqle+
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J)
|
dermatitis
|
J:198551
|
Mecp2tm1.1Bird/Y Sum2M1Jus/Sum2+
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J)
|
dermatitis
|
J:198551
|
eye inflammation
|
J:198551
|
Mecp2tm1.1Bird/Y Sum4M1Jus/Sum4+
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J)
|
dermatitis
|
J:198551
|
eye inflammation
|
J:198551
|
Mecp2tm1.1Bird/Y Sum5M1Jus/Sum5+
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J)
|
eye inflammation
|
J:198551
|
Med19tm1c(EUCOMM)Wtsi/Med19tm1c(EUCOMM)Wtsi Tg(Adipoq-icre/ERT2)1Soff/0
(involves: C57BL/6J * C57BL/6N)
|
white adipose tissue inflammation
|
J:298822
|
Mef2ctm1Jjs/Mef2ctm1Jjs Mir223tm1Fcam/Mir223tm1Fcam Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129 * C57BL/6)
|
abnormal neutrophil physiology
|
J:140009
|
Mefvtm1Bhk/Mefvtm1Bhk
(129S6/SvEvTac-Mefvtm1Bhk)
|
increased interleukin-1 beta secretion
|
J:192443
|
increased interleukin-18 secretion
|
J:192443
|
Mefvtm1Chae/Mefvtm1Chae
(either: (involves: 129S6/SvEvTac) or (involves: 129S6/SvEvTac * C57BL/6))
|
decreased macrophage apoptosis
|
J:82763
|
increased inflammatory response
|
J:82763
|
increased susceptibility to endotoxin shock
|
J:82763
|
Mefvtm3.1(MEFV)Chae/Mefvtm3.1(MEFV)Chae
(B6.129S6-Mefvtm3.1(MEFV)Chae)
|
autoimmune arthritis
|
J:172117
|
dermatitis
|
J:172117
|
increased inflammatory response
|
J:172117
|
Mefvtm4.1(MEFV)Chae/Mefvtm4.1(MEFV)Chae
(B6.129S6-Mefvtm4.1(MEFV)Chae)
|
autoimmune arthritis
|
J:172117
|
dermatitis
|
J:172117
|
increased inflammatory response
|
J:172117
|
Mefvtm5.1(MEFV)Chae/Mefvtm5.1(MEFV)Chae
(B6.129S6-Mefvtm5.1(MEFV)Chae)
|
abnormal cytokine secretion
|
J:172117
|
autoimmune arthritis
|
J:172117
|
decreased interleukin-3 secretion
|
J:172117
|
dermatitis
|
J:172117
|
increased circulating interleukin-1 beta level
|
J:172117
|
increased circulating interleukin-6 level
|
J:172117
|
increased circulating tumor necrosis factor level
|
J:172117
|
increased inflammatory response
|
J:172117
|
increased interferon-gamma secretion
|
J:172117
|
increased interleukin-1 alpha secretion
|
J:172117
|
increased interleukin-1 beta secretion
|
J:172117
|
increased interleukin-2 secretion
|
J:172117
|
increased interleukin-4 secretion
|
J:172117
|
increased interleukin-5 secretion
|
J:172117
|
increased interleukin-9 secretion
|
J:172117
|
increased interleukin-10 secretion
|
J:172117
|
increased interleukin-12 secretion
|
J:172117
|
increased interleukin-12b secretion
|
J:172117
|
increased interleukin-13 secretion
|
J:172117
|
increased interleukin-17 secretion
|
J:172117
|
joint inflammation
|
J:172117
|
liver inflammation
|
J:172117
|
skin inflammation
|
J:172117
|
Mefvtm5.1(MEFV)Chae/Mefvtm5.1(MEFV)Chae Nlrp3tm1Tsc/Nlrp3tm1Tsc
(involves: 129S6/SvEvTac * C57BL/6)
|
increased inflammatory response
|
J:172117
|
increased interleukin-1 beta secretion
|
J:172117
|
Mefvtm5.1(MEFV)Chae/Mefvtm5.1(MEFV)Chae Pycardtm1Tno/Pycardtm1Tno
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6)
|
decreased interleukin-1 beta secretion
|
J:172117
|
Mefvtm5.1(MEFV)Chae/Mefvtm5.1(MEFV)Chae Rag1tm1Mom/Rag1tm1Mom
(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6)
|
abnormal cytokine secretion
|
J:172117
|
increased circulating interleukin-1 beta level
|
J:172117
|
increased circulating interleukin-6 level
|
J:172117
|
increased circulating tumor necrosis factor level
|
J:172117
|
increased inflammatory response
|
J:172117
|
increased interferon-gamma secretion
|
J:172117
|
increased interleukin-1 beta secretion
|
J:172117
|
increased interleukin-2 secretion
|
J:172117
|
increased interleukin-4 secretion
|
J:172117
|
increased interleukin-5 secretion
|
J:172117
|
increased interleukin-9 secretion
|
J:172117
|
increased interleukin-10 secretion
|
J:172117
|
increased interleukin-12 secretion
|
J:172117
|
increased interleukin-13 secretion
|
J:172117
|
increased interleukin-17 secretion
|
J:172117
|
Men1tm1Ctre/Men1+
(either: (involves: 129S6/SvEvTac * FVB/N) or (involves: 129S6/SvEvTac * Black Swiss * FVB/N))
|
pancreas inflammation
|
J:67128
|
Meox2tm1(cre)Sor/Meox2+ Procrtm2Cte/Procrtm2Cte
(involves: 129S4/SvJaeSor * 129S7/SvEvBrd * Black Swiss * C57BL/6)
|
decreased circulating fibrinogen level
|
J:119529
|
increased circulating C-reactive protein level
|
J:119529
|
Mep1atm1Bond/Mep1atm1Bond
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal chemokine level
|
J:145685
|
abnormal circulating interleukin-1 beta level
|
J:145037
|
abnormal cytokine level
|
J:145037,
J:145685
|
abnormal leukocyte physiology
|
J:145037
|
abnormal tumor necrosis factor level
|
J:145037
|
increased circulating interleukin-1 beta level
|
J:145685
|
increased circulating interleukin-6 level
|
J:145685
|
increased susceptibility to induced colitis
|
J:145685
|
urinary bladder inflammation
|
J:145037
|
Mep1btm1Bond/Mep1btm1Bond
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
decreased inflammatory response
|
J:132021
|
Mertknmf12/Mertknmf12
(involves: C57BL/6J)
|
abnormal tumor necrosis factor level
|
J:175587
|
Mertktm1Gkm/Mertktm1Gkm
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
increased circulating tumor necrosis factor level
|
J:53423
|
increased susceptibility to endotoxin shock
|
J:53423
|
increased tumor necrosis factor secretion
|
J:53423
|
Mertktm1Gkm/Mertktm1Gkm
(NOD.129P2-Mertktm1Gkm)
|
decreased susceptibility to autoimmune diabetes
|
J:147153
|
increased T cell apoptosis
|
J:147153
|
insulitis
|
J:147153
|
Mertktm1Gkm/Mertktm1Gkm
(B6.129P2-Mertktm1Gkm)
|
decreased autoantibody level
|
J:136377
|
decreased susceptibility to graft versus host disease
|
J:136377
|
Mertktm1Gkm/Mertktm1Gkm Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0
(NOD.Cg-Mertktm1Gkm Tg(TcraBDC2.5,TcrbBDC2.5)1Doi)
|
increased T cell apoptosis
|
J:147153
|
Mettm1Gvw/Met+
(involves: 129 * C57BL/6J)
|
glomerulonephritis
|
J:94722
|
Mettm2Gvw/Met+
(involves: 129 * C57BL/6J)
|
glomerulonephritis
|
J:94722
|
Mettm4Gvw/Met+
(involves: 129 * C57BL/6J)
|
glomerulonephritis
|
J:94722
|
Metrnltm1d(KOMP)Wtsi/Metrnltm1d(KOMP)Wtsi
(involves: C57BL/6J * C57BL/6N)
|
decreased IgG level
|
J:268270
|
increased IgM level
|
J:268270
|
increased susceptibility to endotoxin shock
|
J:268270
|
kidney inflammation
|
J:268270
|
liver inflammation
|
J:268270
|
uterus inflammation
|
J:268270
|
Mex3btm1.1Mbld/Mex3btm1.1Mbld Plekha5Tg(AMH-cre)1Flor/Plekha5+
(involves: C57BL/6 * SJL)
|
increased anti-sperm antibody level
|
J:213588
|
Mex3btm1.2Mbld/Mex3btm1.2Mbld
(involves: C57BL/6 * CBA)
|
impaired macrophage phagocytosis
|
J:213588
|
Mex3ctm1Aki/Mex3ctm1Aki
(involves: 129X1/SvJ * C57BL/6)
|
abnormal cytokine secretion
|
J:208870
|
decreased interferon-beta secretion
|
J:208870
|
decreased interleukin-6 secretion
|
J:208870
|
decreased interleukin-12 secretion
|
J:208870
|
Mfge8Gt(KST227)Byg/Mfge8Gt(KST227)Byg
(B6.129P2-Mfge8Gt(KST227)Byg)
|
impaired macrophage phagocytosis
|
J:98314
|
Mfge8Gt(KST227)Byg/Mfge8Gt(KST227)Byg
(involves: 129P2/OlaHsd * C57BL/6)
|
impaired macrophage phagocytosis
|
J:107106
|
mastitis
|
J:107106
|
Mfge8tm1Osa/Mfge8tm1Osa
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
impaired macrophage phagocytosis
|
J:90633
|
increased anti-double stranded DNA antibody level
|
J:225063
|
Mfge8tm1Osa/Mfge8tm1Osa Timd4tm1Osa/Timd4tm1Osa
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
impaired macrophage phagocytosis
|
J:187181
|
increased anti-double stranded DNA antibody level
|
J:187181
|
increased anti-nuclear antigen antibody level
|
J:187181
|
Mfge8tm1Shur/Mfge8tm1Shur
(B6.129-Mfge8tm1Shur)
|
spermatic granuloma
|
J:145962
|
Mfn1tm2Dcc/Mfn1tm2Dcc Mfn2tm3Dcc/Mfn2tm3Dcc Tg(Cd4-cre)1Cwi/0
(involves: 129 * C57BL/6 * C57BL/6J * DBA/2)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:339075
|
Mfngtm1.1Cfg/Mfngtm1.1Cfg
(involves: C57BL/6)
|
increased B cell proliferation
|
J:217719
|
Mfsd2atm1Dls/Mfsd2atm1Dls
(B6.Cg-Mfsd2atm1Dls)
|
abnormal microglial cell activation
|
J:234197
|
Mfsd2btm1a(KOMP)Wtsi/Mfsd2btm1a(KOMP)Wtsi
(C57BL/6-Mfsd2btm1a(KOMP)Wtsi)
|
increased susceptibility to type I hypersensitivity reaction
|
J:250123
|
Mfsd8tm1a(EUCOMM)Hmgu/Mfsd8tm1a(EUCOMM)Hmgu
(involves: C57BL/6N)
|
CNS inflammation
|
J:211608
|
Mgat2tm1.1Jxm/Mgat2tm1.1Jxm
(involves: 129S1/Sv * 129X1/SvJ * ICR)
|
glomerulonephritis
|
J:80661
|
Mgat5tm1Jwd/Mgat5tm1Jwd
(involves: 129S1/Sv * 129X1/SvJ)
|
abnormal inflammatory response
|
J:60960
|
abnormal leukocyte physiology
|
J:94864
|
abnormal T cell physiology
|
J:60960
|
decreased interleukin-2 secretion
|
J:94864
|
decreased interleukin-4 secretion
|
J:94864
|
increased interleukin-10 secretion
|
J:94864
|
increased tumor necrosis factor secretion
|
J:94864
|
Mgat5btm1.1Cfg/Mgat5btm1.1Cfg
(involves: 129S6/SvEvTac)
|
enhanced humoral immune response
|
J:217719
|
increased IgG2b level
|
J:217719
|
Mgat5btm1Nta/Mgat5btm1Nta
(Not Specified)
|
brain inflammation
|
J:199165
|
Mgl2tm1.1(HBEGF/EGFP)Aiwsk/Mgl2+
(involves: C57BL/6 * FVB/N)
|
abnormal immune system physiology
|
J:201044
|
decreased interleukin-4 secretion
|
J:201044
|
increased susceptibility to parasitic infection
|
J:201044
|
Micu1em#Fink/Micu1em#Fink
(C57BL/6N-Micu1em#Fink)
|
increased B cell apoptosis
|
J:238984
|
Miftm1Dvd/Miftm1Dvd
(involves: 129S4/SvJae * C57BL/6)
|
decreased circulating tumor necrosis factor level
|
J:52300
|
decreased susceptibility to bacterial infection
|
J:52300
|
decreased susceptibility to endotoxin shock
|
J:52300
|
increased interleukin-4 secretion
|
J:52300
|
increased susceptibility to parasitic infection
|
J:52300
|
Miftm1Mky/Miftm1Mky
(C.129-Miftm1Mky)
|
abnormal cytokine secretion
|
J:106380
|
abnormal inflammatory response
|
J:106380
|
Miga2tm1a(KOMP)Wtsi/Miga2tm1a(KOMP)Wtsi Pnp2em1Smoc/Pnp2em1Smoc
(C57BL/6-Miga2tm1a(KOMP)Wtsi Pnp2em1Smoc)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:339075
|
Miga2tm1c(KOMP)Wtsi/Miga2tm1c(KOMP)Wtsi Tg(Cd4-cre)1Cwi/0
(B6.Cg-Miga2tm1c(KOMP)Wtsi Tg(Cd4-cre)1Cwi)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:339075
|
MijuC3HeB/FeJ/MijuC57BL/6J
(involves: C3HeB/FeJ * C57BL/6J)
|
increased IgA level
|
J:91062
|
Milr1tm1Shib/Milr1tm1Shib
(involves: C57BL/6N)
|
decreased mast cell degranulation
|
J:161854
|
increased susceptibility to type I hypersensitivity reaction
|
J:161854
|
Mir10bem1Rosay/Mir10bem1Rosay
(C57BL/6J-Mir10bem1Rosay)
|
large intestinal inflammation
|
J:342486
|
Mir21atm1.1Mer/Mir21atm1.1Mer
(involves: 129S1/Sv * C57BL/6 * FVB/N)
|
abnormal cytokine level
|
J:179235
|
abnormal cytokine secretion
|
J:179235
|
abnormal interferon level
|
J:179235
|
abnormal interleukin level
|
J:179235
|
decreased interleukin-4 secretion
|
J:179235
|
increased interferon-gamma secretion
|
J:179235
|
increased interleukin-12 secretion
|
J:179235
|
increased susceptibility to type I hypersensitivity reaction
|
J:179235
|
Mir21atm1.1Mer/Mir21atm1.1Mer
(B6.129S1-Mir21atm1.1Mer)
|
increased susceptibility to type IV hypersensitivity reaction
|
J:179235
|
Mir33tm1.1Koho/Mir33tm1.1Koho
(involves: C57BL/6)
|
abnormal macrophage physiology
|
J:165420
|
Mir34atm1.1Pisc/Mir34atm1.1Pisc Mirc21tm1.1Pisc/Mirc21tm1.1Pisc Mirc34tm1.1Pisc/Mirc34tm1.1Pisc
(involves: 129S4/SvJae * C57BL/6 * C57BL/6J)
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:256929
|
nasal inflammation
|
J:256929
|
Mir100em1Nju/Mir100em1Nju Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: C57BL/6 * DBA)
|
liver inflammation
|
J:281439
|
Mir122tm1.1Apts/Mir122tm1.1Apts
(involves: 129 * C57BL/6)
|
increased circulating interleukin-6 level
|
J:190066
|
liver inflammation
|
J:190066
|
Mir122tm1.1Kgh/Mir122tm1.1Kgh
(involves: 129S1/Sv * 129X1/SvJ)
|
increased circulating interleukin-6 level
|
J:190067
|
liver inflammation
|
J:190067
|
Mir122tm1.2Kgh/Mir122tm1.2Kgh Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA)
|
increased circulating interleukin-6 level
|
J:190067
|
increased interleukin-6 secretion
|
J:190067
|
increased tumor necrosis factor secretion
|
J:190067
|
liver inflammation
|
J:190067
|
Mir125atm1Smoc/Mir125atm1Smoc
(involves: C57BL/6)
|
abnormal regulatory T cell physiology
|
J:224880
|
increased interferon-gamma secretion
|
J:224880
|
increased interleukin-17 secretion
|
J:224880
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:224880
|
Mir126atm2.1Smoc/Mir126atm2.1Smoc Tg(Cd4-cre)1Cwi/0
(involves: C57BL/6J * C57BL/6N * DBA/2)
|
dermatitis
|
J:355195
|
Mir139em1Jwli/Mir139em1Jwli
(C57BL/6J-Mir139em1Jwli)
|
abnormal cytokine level
|
J:248779
|
increased susceptibility to colitis induced morbidity/mortality
|
J:280467,
J:248779
|
increased susceptibility to induced colitis
|
J:248779
|
Mir140tm1.1Asah/Mir140tm1.1Asah
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)
|
increased susceptibility to induced arthritis
|
J:160358
|
osteoarthritis
|
J:160358
|
Mir142tm1Teyo/Mir142tm1Teyo
(involves: C57BL/6)
|
decreased mast cell degranulation
|
J:211850
|
Mir146tm1.1Bal/Mir146tm1.1Bal
(involves: C57BL/6)
|
abnormal regulatory T cell physiology
|
J:167922
|
decreased interferon-gamma secretion
|
J:167922
|
Mir146tm1.1Bal/Mir146tm1.1Bal
(involves: C57BL/6 * FVB/N)
|
abnormal immune system physiology
|
J:173671
|
abnormal immune tolerance
|
J:173671
|
abnormal macrophage physiology
|
J:173671
|
abnormal T cell activation
|
J:173671
|
increased circulating interleukin-1 beta level
|
J:173671
|
increased circulating interleukin-6 level
|
J:173671
|
increased circulating interleukin-10 level
|
J:173671
|
increased circulating tumor necrosis factor level
|
J:173671
|
increased interleukin-1 beta secretion
|
J:173671
|
increased interleukin-6 secretion
|
J:173671
|
increased macrophage nitric oxide production
|
J:173671
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:173671
|
increased susceptibility to endotoxin shock
|
J:173671
|
increased tumor necrosis factor secretion
|
J:173671
|
Mir146tm1.1Lfl/Mir146tm1.1Lfl Mir146btm1.1Lfl/Mir146btm1.1Lfl Tg(Cd4-cre)1Cwi/0
(involves: C57BL/6 * DBA/2)
|
increased IgG level
|
J:266124
|
Mir146tm1.1Lfl/Mir146tm1.1Lfl Tg(Cr2-cre)3Cgn/0
(involves: C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:266124
|
increased IgG1 level
|
J:266124
|
increased IgG level
|
J:266124
|
Mir146tm2.1Bal/Mir146tm2.1Bal
(involves: 129S1/Sv * C57BL/6 * FVB/N)
|
abnormal immune system physiology
|
J:173671
|
abnormal immune tolerance
|
J:173671
|
abnormal macrophage physiology
|
J:173671
|
abnormal T cell activation
|
J:173671
|
increased acute inflammation
|
J:173671
|
increased anti-double stranded DNA antibody level
|
J:173671
|
increased circulating interleukin-1 beta level
|
J:173671
|
increased circulating interleukin-6 level
|
J:173671
|
increased circulating interleukin-10 level
|
J:173671
|
increased circulating tumor necrosis factor level
|
J:173671
|
increased interleukin-1 beta secretion
|
J:173671
|
increased interleukin-6 secretion
|
J:173671
|
increased macrophage nitric oxide production
|
J:173671
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:173671
|
increased susceptibility to endotoxin shock
|
J:173671
|
increased tumor necrosis factor secretion
|
J:173671
|
Mir148atm2942.1Arte/Mir148atm2942.1Arte Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased IgA level
|
J:307366
|
decreased IgG level
|
J:307366
|
decreased IgM level
|
J:307366
|
impaired humoral immune response
|
J:307366
|
Mir148atm2942.1Arte/Mir148atm2942.1Arte Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
(involves: C57BL/6 * C57BL/6NTac)
|
abnormal B cell physiology
|
J:307366
|
impaired humoral immune response
|
J:307366
|
Mir148atm2942.2Arte/Mir148atm2942.2Arte
(involves: C57BL/6 * FVB/N)
|
abnormal B cell physiology
|
J:307366
|
Mir149em1Ydw/Mir149em1Ydw
(C57BL/6J-Mir149em1Ydw)
|
increased susceptibility to endotoxin shock
|
J:294318
|
Mir150tm1Rsky/Mir150tm1Rsky
(involves: C57BL/6)
|
increased IgA level
|
J:127234
|
increased IgG1 level
|
J:127234
|
increased IgG2b level
|
J:127234
|
increased IgM level
|
J:127234
|
Mir155tm1.1Brd/Mir155tm1.1Brd
(B6.Cg-Mir155tm1.1Brd Tyrc-Brd)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:121095
|
abnormal dendritic cell physiology
|
J:121095
|
decreased IgG1 level
|
J:121095
|
increased susceptibility to bacterial infection
|
J:121095
|
Mir155tm1.1Rsky/Mir155tm1.1Rsky
(involves: 129 * C57BL/6)
|
abnormal B cell physiology
|
J:121084
|
abnormal cytokine secretion
|
J:121084
|
abnormal germinal center B cell physiology
|
J:121084
|
abnormal humoral immune response
|
J:121084
|
abnormal T cell physiology
|
J:121084
|
Mir155tm1.1Rsky/Mir155tm1.1Rsky
(B6.Cg-Mir155tm1Rsky/J)
|
abnormal T cell physiology
|
J:226678
|
decreased interleukin-6 secretion
|
J:226678
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:226678
|
Mir155tm1Brd/Mir155tm1Brd
(involves: 129S7/SvEvBrd * C57BL/6)
|
abnormal B cell physiology
|
J:121095
|
abnormal class switch recombination
|
J:121095
|
abnormal cytokine secretion
|
J:121095
|
decreased IgM level
|
J:121095
|
intestinal inflammation
|
J:121095
|
lung inflammation
|
J:121095
|
Mir155tm1Rsky/Mir155tm1Rsky
(involves: 129/Sv * C57BL/6)
|
abnormal cytokine secretion
|
J:121084
|
abnormal humoral immune response
|
J:121084
|
abnormal immune system physiology
|
J:121084
|
decreased interferon-gamma secretion
|
J:121084
|
decreased interleukin-4 secretion
|
J:121084
|
decreased tumor necrosis factor secretion
|
J:121084
|
increased interleukin-10 secretion
|
J:121084
|
Mir155tm1Rsky/Mir155tm1Rsky
(involves: 129 * C57BL/6)
|
abnormal class switch recombination
|
J:136224
|
Mir204tm1.2Dic/Mir204tm1.2Dic Mir211tm1.2Dic/Mir211tm1.2Dic
(involves: 129S4/SvJaeSor * BALB/cJ * C57BL/6)
|
increased susceptibility to induced arthritis
|
J:345335
|
Mir210tm1.1Wtsi/Mir210tm1.1Wtsi
(involves: C57BL/6J * C57BL/6N)
|
increased anti-chromatin antibody level
|
J:205868
|
increased anti-double stranded DNA antibody level
|
J:205868
|
increased anti-nuclear antigen antibody level
|
J:205868
|
Mir216aem1Uf/Mir216aem1Uf
(C57BL/6-Mir216aem1Uf)
|
increased susceptibility to induced pancreatitis
|
J:278847
|
Mir216aem2Uf/Mir216aem2Uf
(C57BL/6-Mir216aem2Uf)
|
increased susceptibility to induced pancreatitis
|
J:278847
|
Mir216bem1Uf/Mir216bem1Uf
(C57BL/6-Mir216bem1Uf)
|
increased susceptibility to induced pancreatitis
|
J:278847
|
Mir217em1Uf/Mir217em1Uf
(C57BL/6-Mir217em1Uf)
|
increased susceptibility to induced pancreatitis
|
J:278847
|
Mir217em2Uf/Mir217em2Uf
(C57BL/6-Mir217em2Uf)
|
increased susceptibility to induced pancreatitis
|
J:278847
|
Mir223tm1Fcam/Mir223tm1Fcam
(involves: 129S4/SvJae * C57BL/6)
|
abnormal granulocyte physiology
|
J:140009
|
abnormal neutrophil physiology
|
J:140009
|
increased acute inflammation
|
J:140009
|
lung inflammation
|
J:140009
|
Mir301tm1Yoli/Mir301tm1Yoli
(involves: C57BL/6J)
|
abnormal response to transplant
|
J:237900
|
Mir378bem#Yoo/Mir378bem#Yoo
(C57BL/6J-Mir378bem#Yoo)
|
abnormal chemokine secretion
|
J:307588
|
abnormal susceptibility to bacterial infection
|
J:307588
|
decreased interferon-gamma secretion
|
J:307588
|
decreased interleukin-12 secretion
|
J:307588
|
decreased tumor necrosis factor secretion
|
J:307588
|
Mir425em1Nju/Mir425+
(involves: C57BL/6)
|
increased tumor necrosis factor secretion
|
J:280159
|
Mir497em1Hgyu/Mir497em1Hgyu
(C57BL/6-Mir497em1Hgyu)
|
increased susceptibility to induced colitis
|
J:357958
|
Mir511em1Clib/Mir511em1Clib
(C57BL/6J-Mir511em1Clib)
|
abnormal macrophage physiology
|
J:345580
|
decreased susceptibility to induced colitis
|
J:345580
|
Mirc1tm1.1Aven/Mirc1tm1.1Aven
(involves: 129S4/SvJae * C57BL/6 * SJL/J)
|
increased B cell apoptosis
|
J:223213
|
Mirc1tm1.2Tyj/Mirc1tm1.2Tyj
(involves: 129S4/SvJae * C57BL/6 * FVB/N * SJL)
|
increased B cell apoptosis
|
J:134861
|
Mirc1tm1.3Tyj/Mirc1tm1.3Tyj
(involves: 129S4/SvJae * C57BL/6 * FVB/N)
|
increased B cell apoptosis
|
J:134861
|
Mirc1tm1Tyj/Mirc1tm1Tyj Tg(Mx1-cre)1Cgn/0
(involves: 129S4/SvJae * C57BL/6 * CBA * SJL)
|
increased B cell apoptosis
|
J:134861
|
Mirc1tm2.1Aven/Mirc1tm2.1Aven Tg(IghMyc)22Bri/?
(involves: 129S4/SvJae * C57BL/6 * SJL/J)
|
increased B cell apoptosis
|
J:223213
|
Mirc1tm3.1Aven/Mirc1tm3.1Aven
(involves: 129S4/SvJae * C57BL/6 * SJL/J)
|
increased B cell apoptosis
|
J:223213
|
Mirc13tm1.1Mtm/Mirc13tm1.1Mtm
(Not Specified)
|
abnormal macrophage activation involved in immune response
|
J:256444
|
Mirc14tm1.1Ankr/Mirc14tm1.1Ankr
(involves: C57BL/6)
|
decreased interferon-gamma secretion
|
J:196134
|
decreased interleukin-4 secretion
|
J:196134
|
decreased interleukin-13 secretion
|
J:196134
|
Mirc14tm1.2Flv/Mirc14tm1.2Flv
(involves: C57BL/6 * C57BL/6N * FVB/N * SJL)
|
abnormal T cell physiology
|
J:203157
|
decreased T cell proliferation
|
J:203157
|
decreased thymocyte apoptosis
|
J:203157
|
Mirc14tm1.2Flv/Mirc14tm1.2Flv Tg(Cd4-TcraDN32D3)1Aben/0
(involves: C57BL/6 * C57BL/6N * FVB/N * SJL)
|
abnormal NK T cell physiology
|
J:203157
|
Mirc30tm1.2Rdf/Mirc30tm1.2Rdf
(involves: 129S1/Sv * 129S4/SvJaeSor * C57BL/6)
|
abnormal B cell proliferation
|
J:156946
|
Mirc32tm1.1Jtm/Mirc32tm1.1Jtm Tg(Myh11-cre,-EGFP)2Mik/?
(B6.Cg-Mirc32tm1.1Jtm Tg(Myh11-cre,-EGFP)2Mik)
|
increased susceptibility to induced colitis
|
J:214382
|
Mirc32tm1.1Jtm/Mirc32tm1.1Jtm Twist2tm1(cre)Dor/Twist2+
(B6.129(Cg)-Twist2tm1.1(cre)Dor Mirc32tm1.1Jtm)
|
increased susceptibility to induced colitis
|
J:214382
|
Mirc32tm1.2Jtm/Mirc32tm1.2Jtm
(B6.129(Cg)-Mirc32tm1.2Jtm)
|
increased susceptibility to induced colitis
|
J:214382
|
Mirc33tm1.1Cwh/Mirc33tm1.1Cwh
(involves: 129X1/SvJ)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:189763
|
increased interferon-gamma secretion
|
J:189763
|
increased interleukin-17 secretion
|
J:189763
|
Mirc33tm1Bdes/Mirc33tm1Bdes
(Not Specified)
|
abnormal thymus involution
|
J:180783
|
Mirc40tm1Jzb/Mirc40tm1Jzb
(Not Specified)
|
increased microglial cell activation
|
J:244554
|
Mispem2Nsas/Mispem2Nsas
(FVB/NJcl-Mispem2Nsas)
|
abnormal interleukin level
|
J:333842
|
increased susceptibility to induced colitis
|
J:333842
|
MitfMi-Or/MitfMi-Or
(involves: 101/Rl * C3H/Rl)
|
abnormal osteoclast physiology
|
J:30149
|
Mitfmi-tg/Mitfmi-tg
(B6.Cg-Mitfmi-tg)
|
abnormal mast cell physiology
|
J:53161
|
Mitfmi-vit/Mitfmi-vit
(C57BL/6J-Mitfmi-vit)
|
abnormal Langerhans cell physiology
|
J:102101
|
MitfMi/MitfMi
(B6.Cg-MitfMi)
|
abnormal mast cell physiology
|
J:53161
|
MitfTg(Tff3-Tmem207)2Tamo/Mitf+
(involves: C57BL/6)
|
kidney inflammation
|
J:244533
|
Mlf1tm1Swm/Mlf1tm1Swm
(involves: 129 * C57BL/6)
|
decreased splenocyte apoptosis
|
J:266833
|
Mlh1m1Btlr/Mlh1m1Btlr
(C57BL/6J-Mlh1m1Btlr)
|
abnormal humoral immune response
|
J:265206
|
increased IgM level
|
J:265206
|
Mlh1m2Btlr/Mlh1m2Btlr
(C57BL/6J-Mlh1m2Btlr)
|
abnormal humoral immune response
|
J:265207
|
decreased IgE level
|
J:265207
|
increased IgM level
|
J:265207
|
Mlh1m3Btlr/Mlh1m3Btlr
(C57BL/6J-Mlh1m3Btlr)
|
abnormal humoral immune response
|
J:265208
|
decreased IgE level
|
J:265208
|
increased IgM level
|
J:265208
|
Mlklem1Jhan/Mlklem1Jhan
(involves: C57BL/6)
|
abnormal macrophage physiology
|
J:204622
|
Mlklm1Btlr/Mlkl+
(C57BL/6J-Mlklm1Btlr)
|
decreased inflammatory response
|
J:225934
|
Mlklm1Btlr/Mlklm1Btlr
(C57BL/6J-Mlklm1Btlr)
|
decreased inflammatory response
|
J:225934
|
Mlklm2Btlr/Mlkl+
(C57BL/6J-Mlklm2Btlr)
|
decreased inflammatory response
|
J:234252
|
Mlklm2Btlr/Mlklm2Btlr
(C57BL/6J-Mlklm2Btlr)
|
decreased inflammatory response
|
J:234252
|
Mlklm3Btlr/Mlkl+
(C57BL/6J-Mlklm3Btlr)
|
decreased inflammatory response
|
J:234251
|
Mlklm3Btlr/Mlklm3Btlr
(C57BL/6J-Mlklm3Btlr)
|
decreased inflammatory response
|
J:234251
|
Mlkltm1.1Wsa/Mlkltm1.1Wsa Otulintm1c(EUCOMM)Hmgu/Otulintm1c(EUCOMM)Hmgu Tg(KRT14-cre)1Cgn/0
(involves: C57BL/6 * C57BL/6N * DBA/2)
|
dermatitis
|
J:312394
|
MlrrqDBA/2/MlrrqDBA/2
(C.D2-Mtv7DBA/2)
|
decreased susceptibility to parasitic infection
|
J:41574
|
Mmdtm1Beij/Mmdtm1Beij
(Not Specified)
|
decreased susceptibility to induced arthritis
|
J:304637
|
increased macrophage apoptosis
|
J:304637
|
Mmetm1Cge/Mmetm1Cge
(B6.129S4-Mmetm1Cge)
|
dermatitis
|
J:66854
|
increased susceptibility to type I hypersensitivity reaction
|
J:66854
|
Mmp1atm1Otin/Mmp1atm1Otin
(involves: 129P2/OlaHsd * C57BL/6J)
|
abnormal interleukin secretion
|
J:198586
|
decreased inflammatory response
|
J:198586
|
increased interferon-gamma secretion
|
J:198586
|
increased interleukin-1 alpha secretion
|
J:198586
|
increased interleukin-2 secretion
|
J:198586
|
increased interleukin-17 secretion
|
J:198586
|
Mmp2tm1Ito/Mmp2tm1Ito
(involves: 129P2/OlaHsd * C57BL/6J)
|
abnormal inflammatory response
|
J:46091
|
brain inflammation
|
J:94099
|
decreased inflammatory response
|
J:46091
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:94099
|
Mmp2tm1Ito/Mmp2tm1Ito
(involves: 129P2/OlaHsd)
|
autoimmune arthritis
|
J:121780
|
Mmp2tm1Ito/Mmp2tm1Ito Timp1tm1Pds/Timp1tm1Pds
(either: (involves: 129S4/SvJae) or (involves: C57BL/6))
|
decreased susceptibility to bacterial infection
|
J:94836
|
Mmp2tm1Ito/Mmp2tm1Ito Timp3tm1Osya/Timp3tm1Osya
(involves: 129P2/OlaHsd * C57BL/6)
|
aortitis
|
J:193744
|
Mmp3tm1Mrl/Mmp3tm1Mrl
(either: (129S7/SvEvBrd X B10.RIII)N2 or ((involves: 129S7/SvEvBrd * C57BL/6) X B10.RIII)N2)
|
autoimmune arthritis
|
J:46038
|
joint inflammation
|
J:46038
|
osteoarthritis
|
J:46038
|
Mmp3tm1Mrl/Mmp3tm1Mrl
(either: 129S7/SvEvBrd or (involves: 129S7/SvEvBrd * C57BL/6))
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:93706
|
increased susceptibility to bacterial infection
|
J:93706
|
Mmp3tm1Mrl/Mmp3tm1Mrl
(involves: 129S7/SvEvBrd * C57BL/10ScSn * RIII)
|
abnormal lymphocyte physiology
|
J:55723
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:55723
|
Mmp3tm1Mrl/Mmp3tm1Mrl Timp1tm1Pds/Timp1tm1Pds
(involves: C57BL/6)
|
decreased susceptibility to bacterial infection
|
J:94836
|
Mmp7tm1Lmm/Mmp7tm1Lmm
(involves: 129S1/Sv * 129X1/SvJ)
|
decreased susceptibility to bacterial infection
|
J:153651
|
Mmp7tm1Lmm/Mmp7tm1Lmm
(B6.129-Mmp7tm1Lmm)
|
increased interleukin-1 beta secretion
|
J:149388
|
increased susceptibility to induced colitis
|
J:149388
|
Mmp7tm1Lmm/Mmp7tm1Lmm
(involves: 129S/SvEv * 129S1/Sv * 129X1/SvJ)
|
abnormal macrophage physiology
|
J:124841
|
decreased tumor necrosis factor secretion
|
J:124841
|
impaired macrophage chemotaxis
|
J:124841
|
Mmp7tm1Lmm/Mmp7tm1Lmm Timp1tm1Pds/Timp1tm1Pds
(involves: 129S4/SvJae)
|
decreased susceptibility to bacterial infection
|
J:94836
|
Mmp8tm1Otin/Mmp8tm1Otin
(involves: 129X1/SvJ * C57BL/6J)
|
abnormal inflammatory response
|
J:86393
|
chronic inflammation
|
J:86393
|
increased susceptibility to bacterial infection
|
J:97118
|
Mmp9tm1Arnd/Mmp9tm1Arnd
(involves: 129P2/OlaHsd)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:58833
|
Mmp9tm1Tvu/Mmp9tm1Tvu
(involves: 129S6/SvEvTac)
|
abnormal chemokine level
|
J:84293
|
abnormal dendritic cell physiology
|
J:84293
|
abnormal Langerhans cell physiology
|
J:76157
|
decreased IgE level
|
J:84293
|
decreased inflammatory response
|
J:84293
|
increased circulating interferon-beta level
|
J:148442
|
increased circulating interferon-gamma level
|
J:148442
|
increased susceptibility to Picornaviridae infection
|
J:148442
|
increased susceptibility to Picornaviridae infection induced morbidity/mortality
|
J:148442
|
myocarditis
|
J:148442
|
Mmp9tm1Tvu/Mmp9tm1Tvu
(FVB.129S6-Mmp9tm1Tvu)
|
abnormal neutrophil physiology
|
J:104644
|
decreased susceptibility to induced colitis
|
J:104644
|
Mmp9tm1Tvu/Mmp9tm1Tvu
(involves: 129/Sv * 129S6/SvEvTac)
|
decreased circulating interleukin-10 level
|
J:55723
|
increased susceptibility to type IV hypersensitivity reaction
|
J:55723
|
Mmp9tm1Tvu/Mmp9tm1Tvu
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal chemokine level
|
J:88065
|
abnormal cytokine secretion
|
J:88065
|
abnormal response to infection
|
J:126519
|
decreased interferon-gamma secretion
|
J:88065
|
increased IgE level
|
J:88065
|
increased interferon-gamma secretion
|
J:88065
|
increased interleukin-4 secretion
|
J:88065
|
increased interleukin-5 secretion
|
J:88065
|
increased interleukin-13 secretion
|
J:88065
|
increased T cell proliferation
|
J:88065
|
lung inflammation
|
J:88065
|
Mmp9tm1Tvu/Mmp9tm1Tvu
(FVB.129S6(Cg)-Mmp9tm1Tvu/J)
|
decreased susceptibility to Flaviviridae infection
|
J:153406
|
decreased susceptibility to Flaviviridae infection induced morbidity/mortality
|
J:153406
|
Mmp9tm1Tvu/Mmp9tm1Tvu
(C3N.129S6-Mmp9tm1Tvu)
|
decreased susceptibility to bacterial infection
|
J:150311
|
decreased susceptibility to induced arthritis
|
J:150311
|
joint inflammation
|
J:150311
|
Mmp9tm1Tvu/Mmp9tm1Tvu Tg(SOD1*G93A)1Gur/0
(involves: 129S6/SvEvTac * C57BL/6 * CD-1 * SJL)
|
decreased tumor necrosis factor secretion
|
J:141587
|
Mmp10tm1Jkmg/Mmp10tm1Jkmg
(B6.129X1-Mmp10tm1Jkmg)
|
increased susceptibility to bacterial infection
|
J:153651
|
lung inflammation
|
J:153651
|
Mmp12tm1Sds/Mmp12tm1Sds
(involves: 129X1/SvJ)
|
abnormal macrophage physiology
|
J:32902
|
Mmp12tm1Sds/Mmp12tm1Sds Timp1tm1Pds/Timp1tm1Pds
(either: (involves: 129S4/SvJae) or (involves: C57BL/6))
|
decreased susceptibility to bacterial infection
|
J:94836
|
Mmp14tm1Hbh/Mmp14tm1Hbh
(involves: 129P2/OlaHsd * Black Swiss)
|
abnormal osteoclast physiology
|
J:57969,
J:86538
|
autoimmune arthritis
|
J:57969
|
Mmp14tm1Ktry/Mmp14tm1Ktry
(involves: 129X1/SvJ)
|
abnormal dendritic cell physiology
|
J:138782
|
Mmp19tm1Rase/Mmp19tm1Rase
(B6.129P2-Mmp19tm1Rase)
|
abnormal cytokine level
|
J:137128
|
abnormal T cell activation
|
J:137128
|
decreased inflammatory response
|
J:137128
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:137128
|
decreased T cell proliferation
|
J:137128
|
Mmp24tm1Otin/Mmp24tm1Otin
(involves: 129P2/OlaHsd * C57BL/6J)
|
abnormal mast cell degranulation
|
J:153230
|
increased mast cell degranulation
|
J:153230
|
Mmp25Gt(IST14198E10)Tigm/Mmp25Gt(IST14198E10)Tigm
(involves: C57BL/6N)
|
abnormal circulating cytokine level
|
J:347009
|
abnormal macrophage activation involved in immune response
|
J:347009
|
abnormal neutrophil physiology
|
J:347009
|
decreased circulating interleukin-1 alpha level
|
J:347009
|
decreased susceptibility to endotoxin shock
|
J:347009
|
increased IgG level
|
J:347009
|
Mmp28tm1Mani/Mmp28tm1Mani
(B6.129X1-Mmp28tm1Mani)
|
abnormal chemokine secretion
|
J:145912
|
abnormal cytokine secretion
|
J:145912
|
abnormal macrophage chemotaxis
|
J:145912
|
decreased susceptibility to bacterial infection
|
J:145912
|
impaired neutrophil recruitment
|
J:145912
|
increased interleukin-6 secretion
|
J:145912
|
increased tumor necrosis factor secretion
|
J:145912
|
Mmuttm1Cpv/Mmuttm1Cpv
(involves: 129S/SvEv * C57BL/6 * FVB/N)
|
tubulointerstitial nephritis
|
J:147313
|
Mmuttm1Cpv/Mmuttm1Cpv Tg(Alb-Mut)#Cpv/0
(involves: C57BL/6)
|
tubulointerstitial nephritis
|
J:200689
|
Mnx1tm4(cre)Tmj/Mnx1+ Tardbptm1.1Ckjs/Tardbptm1.2Cjks
(involves: 129S1/Sv * C57BL/6J)
|
increased microglial cell activation
|
J:190254
|
Mocosem2(IMPC)Ics/Mocosem2(IMPC)Ics
(involves: C57BL/6N)
|
kidney inflammation
|
J:336718
|
tubulointerstitial nephritis
|
J:336718
|
Mogtm1(cre)Gkl/Mogtm1(cre)Gkl Tg(Tcra2D2,Tcrb2D2)1Kuch/0
(C57BL/6-Mogtm1(cre)Gkl Tg(Tcra2D2,Tcrb2D2)1Kuch)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:151335
|
Mogtm1Dpd/Mogtm1Dpd
(B6.129S2-Mogtm1Dpd)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:85155
|
Mogtm1Dpd/Mogtm1Dpd Rag2tm1Cgn/Rag2tm1Cgn Tg(Tcra2D2,Tcrb2D2)1Kuch/0
(involves: 129S2/SvPas * C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:151335
|
Mogtm1Dpd/Mogtm1Dpd Tg(H2-Kb-Tcra,-Tcrb)1640Kurs/0
(SJL.Cg-Mogtm1Dpd Tg(H2-Kb-Tcra,-Tcrb)1640Kurs)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:149511
|
Mogtm1Dpd/Mogtm1Dpd Tg(Tcra2D2,Tcrb2D2)1Kuch/0
(involves: 129S2/SvPas * C57BL/6)
|
CNS inflammation
|
J:151335
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:151335
|
Mogtm1Reid/Mogtm1Reid
(B6.129S1/Sv-Mogtm1Reid)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:86663
|
Mogtm1Reid/Mogtm1Reid
(129/Sv-Mogtm1Reid)
|
abnormal cytokine secretion
|
J:86663
|
abnormal T-helper 1 physiology
|
J:86663
|
increased interleukin-2 secretion
|
J:86663
|
increased interleukin-6 secretion
|
J:86663
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:86663
|
increased T cell proliferation
|
J:86663
|
Mol1BALB/cByJ/Mol1BALB/cByJ
(involves: BALB/cByJ * C57BL/6ByJ)
|
decreased B cell proliferation
|
J:58921
|
Mol2DBA/2N/Mol2DBA/2N
(involves: BALB/cAnFcr * DBA/2N)
|
increased inflammatory response
|
J:58921
|
Morc2aem1(IMPC)Wtsi/Morc2aem1(IMPC)Wtsi
(C57BL/6N-Morc2aem1(IMPC)Wtsi/WtsiOulu)
|
blood in lymph vessels
|
J:239583
|
Morrbidem1Flv/Morrbidem1Flv
(C57BL/6N-Morrbidem1Flv)
|
abnormal eosinophil physiology
|
J:236609
|
abnormal leukocyte physiology
|
J:236609
|
abnormal neutrophil physiology
|
J:236609
|
increased susceptibility to bacterial infection
|
J:236609
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:236609
|
mpc253H/mpc253H
(involves: BALB/c * C3H/HeH * C57BL/6J)
|
colitis
|
J:234901
|
Mpdk2C57BL/6J/Mpdk2CAST/Ei
(involves: C57BL/6J * CAST/Ei)
|
bile duct inflammation
|
J:99468
|
Mpdk2CAST/Ei/Mpdk2CAST/Ei
(involves: C57BL/6J * CAST/Ei)
|
bile duct inflammation
|
J:99468
|
Mpdk7C57BL/6J/Mpdk7CAST/Ei
(involves: C57BL/6J * CAST/Ei)
|
bile duct inflammation
|
J:99468
|
Mpdk7CAST/Ei/Mpdk7CAST/Ei
(involves: C57BL/6J * CAST/Ei)
|
bile duct inflammation
|
J:99468
|
Mpdk8C57BL/6J/Mpdk8CAST/Ei
(involves: C57BL/6J * CAST/Ei)
|
bile duct inflammation
|
J:99468
|
Mpdk8CAST/Ei/Mpdk8CAST/Ei
(involves: C57BL/6J * CAST/Ei)
|
bile duct inflammation
|
J:99468
|
Mpeg1tm1Pod/Mpeg1+
(involves: 129X1/SvJ * C57BL/6)
|
abnormal susceptibility to infection induced morbidity/mortality
|
J:269474
|
Mpeg1tm1Pod/Mpeg1+
(129X1/SvJ-Mpeg1tm1Pod)
|
abnormal susceptibility to infection induced morbidity/mortality
|
J:269474
|
Mpeg1tm1Pod/Mpeg1tm1Pod
(involves: 129X1/SvJ * C57BL/6)
|
abnormal susceptibility to infection induced morbidity/mortality
|
J:269474
|
Mpeg1tm1Pod/Mpeg1tm1Pod
(129X1/SvJ-Mpeg1tm1Pod)
|
abnormal susceptibility to infection induced morbidity/mortality
|
J:269474
|
Mpgtm1Lds/Mpgtm1Lds
(involves: 129P2/OlaHsd * C57BL/6)
|
autoimmune response
|
J:118148
|
decreased susceptibility to autoimmune diabetes
|
J:118148
|
Mplhlb219/Mplhlb219
(C57BL/6J-Mplhlb219/J)
|
abnormal circulating cytokine level
|
J:146577
|
Mpltm1Wsa/Mpltm1Wsa
(involves: 129S1/Sv)
|
abnormal circulating chemokine level
|
J:162629
|
Mpotm1Lus/Mpotm1Lus
(involves: 129X1/SvJ * C57BL/6J)
|
abnormal neutrophil physiology
|
J:67586
|
decreased inflammatory response
|
J:102688
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:102965
|
increased susceptibility to fungal infection
|
J:67586
|
sepsis
|
J:126649
|
Mpotm1Lus/Mpotm1Lus
(B6.129X1-Mpotm1Lus)
|
abnormal neutrophil physiology
|
J:112488
|
Mpotm1Mae/Mpotm1Mae
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal neutrophil physiology
|
J:53993
|
increased susceptibility to fungal infection
|
J:53993
|
Mpp1tm1Ahc/Mpp1tm1Ahc
(B6.129-Mpp1tm1Ahc)
|
abnormal neutrophil physiology
|
J:154749
|
impaired neutrophil chemotaxis
|
J:154749
|
Mptx2em1Yoxi/Mptx2em1Yoxi
(C57BL/6J-Mptx2em1Yoxi)
|
increased susceptibility to bacterial infection
|
J:326562
|
Mpztm1Msch/Mpz+
(involves: 129S7/SvEvBrd * C57BL/6)
|
abnormal cytokine secretion
|
J:82432
|
abnormal macrophage chemotaxis
|
J:67581
|
abnormal T-helper 1 physiology
|
J:82432
|
Mpztm1Msch/Mpz+
(B6.129S7-Mpztm1Msch)
|
autoimmune response
|
J:59319
|
Mpzl3rc/Mpzl3rc
(C57BL/6J-Mpzl3rc/J)
|
dermatitis
|
J:93038
|
liver inflammation
|
J:93038
|
Mpzl3tm1(KOMP)Mbp/Mpzl3tm1(KOMP)Mbp
(C57BL/6-Tyrc-Brd Mpzl3tm1(KOMP)Mbp)
|
seborrheic dermatitis
|
J:210832
|
skin inflammation
|
J:210832
|
Mr1tm1Gfn/Mr1tm1Gfn
(involves: 129P2/OlaHsd * BALB/c * C57BL/6)
|
abnormal B cell physiology
|
J:113083
|
Mr1tm1Gfn/Mr1tm1Gfn
(B6.129P2-Mr1tm1Gfn)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:112657
|
Mr1tm1Gfn/Mr1tm1Gfn
(involves: 129P2/OlaHsd)
|
abnormal susceptibility to bacterial infection
|
J:276912
|
Mrc1tm1Mnz/Mrc1tm1Mnz
(involves: 129P2/OlaHsd)
|
abnormal macrophage physiology
|
J:124290
|
Mrc1tm1Mnz/Mrc1tm1Mnz
(B6.129P2-Mrc1tm1Mnz)
|
decreased susceptibility to parasitic infection
|
J:194065
|
decreased susceptibility to parasitic infection induced morbidity/mortality
|
J:194065
|
Mrc1tm1Mnz/Mrc1tm1Mnz Mrc2tm1Cmi/Mrc2tm1Cmi
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ)
|
abnormal macrophage physiology
|
J:124290
|
Mre11atm1.1Rchd/Mre11atm1.1Rchd
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal class switch recombination
|
J:184053
|
Mrgprb2em1Xzd/Mrgprb2em1Xzd
(C57BL/6-Mrgprb2em1Xzd)
|
decreased inflammatory response
|
J:219209
|
decreased mast cell degranulation
|
J:219209
|
Mrs2em1Muma/Mrs2em1Muma
(B6.Cg-Mrs2em1Muma)
|
decreased susceptibility to endotoxin shock
|
J:298361
|
Ms4a1tm1Tft/Ms4a1tm1Tft
(involves: 129 * C57BL/6)
|
abnormal B cell calcium ion homeostasis
|
J:88933
|
abnormal B cell physiology
|
J:88933
|
Ms4a2tm1Chr/Ms4a2tm1Chr
(involves: 129S1/Sv * 129X1/SvJ)
|
abnormal mast cell physiology
|
J:53106
|
decreased susceptibility to type I hypersensitivity reaction
|
J:53106
|
Ms4a2tm1Knt/Ms4a2tm1Knt
(involves: 129 * BALB/c)
|
abnormal cytokine secretion
|
J:47138
|
abnormal mast cell physiology
|
J:47138
|
decreased susceptibility to type I hypersensitivity reaction
|
J:47138
|
Ms4a2tm1Knt/Ms4a2tm1Knt Tg(SV40/HTLV-FCER1A)1Bhk/0
(involves: 129 * BALB/c)
|
abnormal cytokine secretion
|
J:47138
|
abnormal mast cell physiology
|
J:47138
|
decreased susceptibility to type I hypersensitivity reaction
|
J:47138
|
Ms4a4aem1Wwz/Ms4a4aem1Wwz
(C57BL/6NCrl-Ms4a4aem1Wwz)
|
abnormal macrophage physiology
|
J:296429
|
decreased interleukin-4 secretion
|
J:296429
|
decreased interleukin-13 secretion
|
J:296429
|
impaired eosinophil recruitment
|
J:296429
|
Ms4a6dem1Cya/Ms4a6dem1Cya
(involves: C57BL/6)
|
decreased susceptibility to endotoxin shock
|
J:342776
|
Ms4a6dem1Ywch/Ms4a6dem1Ywch
(C57BL/6-Ms4a6dem1Ywch)
|
decreased susceptibility to endotoxin shock
|
J:342776
|
Ms4a6dem2Ywch/Ms4a6dem2Ywch
(C57BL/6-Ms4a6dem2Ywch)
|
decreased susceptibility to endotoxin shock
|
J:342776
|
Ms4a7em1.1Jddl/Ms4a7em1.1Jddl
(B6.Cg-Ms4a7em1.1Jddl)
|
abnormal macrophage physiology
|
J:347975
|
decreased circulating tumor necrosis factor level
|
J:347975
|
decreased cytokine level
|
J:347975
|
decreased interleukin-1 beta secretion
|
J:347975
|
Ms4a7em1Jddl/Ms4a7em1Jddl Lyz2tm1(cre)Ifo/Lyz2+
(B6.Cg-Lyz2tm1(cre)Ifo Ms4a7em1Jddl)
|
decreased circulating tumor necrosis factor level
|
J:347975
|
decreased cytokine level
|
J:347975
|
Msh2tm1Htr/Msh2tm1Htr
(involves: 129P2/OlaHsd)
|
abnormal class switch recombination
|
J:80893
|
abnormal inflammatory response
|
J:80893
|
abnormal somatic hypermutation frequency
|
J:155454
|
decreased IgG1 level
|
J:80893
|
decreased IgG3 level
|
J:80893
|
Msh2tm1Htr/Msh2tm1Htr Pcnatm1Jcbs/Pcnatm1Jcbs
(involves: 129P2/OlaHsd)
|
abnormal somatic hypermutation frequency
|
J:155454
|
Msh2tm1Mak/Msh2tm1Mak
(C57BL/6NTac-Msh2tm1Mak)
|
abnormal class switch recombination
|
J:326431
|
abnormal somatic hypermutation frequency
|
J:326431
|
Msh2tm1Rak/Msh2tm1Rak
(involves: 129P2/OlaHsd)
|
abnormal class switch recombination
|
J:56764
|
Msh2tm1Wed/Msh2tm1Wed
(involves: C57BL/6)
|
abnormal class switch recombination
|
J:86278
|
decreased IgG level
|
J:86278
|
Msh6m1Btlr/Msh6m1Btlr
(C57BL/6J-Msh6m1Btlr)
|
decreased IgE level
|
J:255208
|
Msmpem1Jzx/Msmpem1Jzx
(C57BL/6-Msmpem1Jzx)
|
decreased circulating interleukin-6 level
|
J:311042
|
decreased circulating tumor necrosis factor level
|
J:311042
|
liver inflammation
|
J:311042
|
Msntm1Sts/Y
(involves: 129S4/SvJae * C57BL/6)
|
impaired leukocyte migration
|
J:189837
|
Msr1tm1Csk/Msr1tm1Csk
(involves: 129X1/SvJ * ICR)
|
increased interleukin-12 secretion
|
J:110433
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:39079
|
increased susceptibility to Herpesvirales infection induced morbidity/mortality
|
J:39079
|
Msr1tm1Csk/Msr1tm1Csk
(involves: 129S7/SvEvBrd * C57BL/6J)
|
abnormal macrophage physiology
|
J:91911
|
Msr1tm1Csk/Msr1tm1Csk
(B6.129X1-Msr1tm1Csk)
|
decreased interferon-beta secretion
|
J:251008
|
Msr1tm1Csk/Msr1tm1Csk Scarf1tm1Ishi/Scarf1tm1Ishi
(involves: 129S7/SvEvBrd * 129X1/SvJ * C57BL/6J)
|
abnormal macrophage physiology
|
J:91911
|
Mst1tm1Jab/Mst1tm1Jab
(involves: 129P2/OlaHsd * Black Swiss)
|
abnormal macrophage physiology
|
J:46185
|
increased susceptibility to induced colitis
|
J:46185
|
Mst1rFv2-s/Mst1rFv2-s
(B6.DDD-Mst1rFv2-s)
|
increased susceptibility to Retroviridae infection
|
J:5120
|
Mst1rFv2-s/Mst1rFv2-s
(either: A/Crgl or C57BL/Crgl)
|
decreased susceptibility to Retroviridae infection
|
J:167666
|
Mst1rFv2-s/Mst1rFv2-s
(either: BALB/cCrgl or DBA/2Crgl or Swiss)
|
increased susceptibility to Retroviridae infection
|
J:167666
|
Mst1rFv2-s/Mst1rFv2-s
(C3H/Crgl)
|
increased susceptibility to Retroviridae infection
|
J:167666
|
Mst1rtm1.1Sew/Mst1rtm1.1Sew
(involves: 129/Ola * CD-1 * NIH Black Swiss)
|
abnormal macrophage physiology
|
J:75503
|
abnormal type IV hypersensitivity reaction
|
J:75503
|
increased acute inflammation
|
J:75503
|
increased susceptibility to endotoxin shock
|
J:75503
|
Mst1rtm1Ber/Mst1rtm1Ber
(involves: 129S1/Sv * 129X1/SvJ * CD-1)
|
abnormal macrophage physiology
|
J:76451
|
abnormal type IV hypersensitivity reaction
|
J:76451
|
increased inflammatory response
|
J:76451
|
increased susceptibility to bacterial infection
|
J:76451
|
Mst1rtm1Sjd/Mst1r+
(either: (involves: 129 * C57BL/6) or (involves: 129 * CD-1) or (involves: 129 * NIH Black Swiss))
|
abnormal macrophage physiology
|
J:54903
|
increased susceptibility to bacterial infection
|
J:54903
|
Mst1rtm2(Mst1r*)Sew/Mst1rtm2(Mst1r*)Sew
(involves: 129P2/OlaHsd * Black Swiss * FVB/N)
|
increased susceptibility to Retroviridae infection
|
J:215969
|
Mst1rtm2(Mst1r*)Sew/Mst1rtm2(Mst1r*)Sew
(FVB.129P2(Cg)-Mst1rtm2(Mst1r*)Sew)
|
increased circulating interferon-gamma level
|
J:215969
|
increased interferon-gamma secretion
|
J:215969
|
Mstnlean/Mstnlean
(C57BL/6J-Mstnlean)
|
abnormal circulating tumor necrosis factor level
|
J:146513
|
decreased circulating tumor necrosis factor level
|
J:146513
|
Mt1tm1Bri/Mt1tm1Bri Mt2tm1Bri/Mt2tm1Bri
(involves: 129S7/SvEvBrd)
|
abnormal microglial cell physiology
|
J:53929
|
increased interleukin-1 beta secretion
|
J:103102
|
increased interleukin-6 secretion
|
J:103102
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:103102
|
increased tumor necrosis factor secretion
|
J:103102
|
Mt1tm1Bri/Mt1tm1Bri Mt2tm1Bri/Mt2tm1Bri
(129S7/SvEvBrd-Mt1tm1Bri Mt2tm1Bri/J)
|
abnormal humoral immune response
|
J:110643
|
abnormal lymphocyte physiology
|
J:110643
|
increased IgG level
|
J:110643
|
increased IgM level
|
J:110643
|
increased thymocyte apoptosis
|
J:57169
|
kidney inflammation
|
J:126620
|
lung inflammation
|
J:120196
|
mt-Co1m1Jiha
(involves: C57BL/6J * M. m. domesticus)
|
heart inflammation
|
J:132659
|
mt-Nd2m1
(ALR/Lt)
|
decreased susceptibility to autoimmune diabetes
|
J:117602,
J:97969
|
Mta2tm1.1Yzha/Mta2tm1.1Yzha
(involves: 129S4/SvJae * C57BL/6 * FVB/N)
|
dermatitis
|
J:137101
|
glomerulonephritis
|
J:137101
|
increased anti-double stranded DNA antibody level
|
J:137101
|
increased autoantibody level
|
J:137101
|
increased circulating interferon-gamma level
|
J:137101
|
increased circulating interleukin-2 level
|
J:137101
|
increased circulating interleukin-4 level
|
J:137101
|
increased susceptibility to systemic lupus erythematosus
|
J:137101
|
increased T cell proliferation
|
J:137101
|
liver inflammation
|
J:137101
|
panniculitis
|
J:137101
|
skin inflammation
|
J:137101
|
Mta2tm1Yzha/Mta2tm1Yzha Tg(Lck-cre)#Zhu/0
(involves: 129S4/SvJae * C57BL/6 * SJL)
|
increased T cell proliferation
|
J:137101
|
MtapGt(RRK081)Byg/Mtap+
(129P2/OlaHsd-MtapGt(RRK081)Byg)
|
arteritis
|
J:123675
|
Mtdhtm1.2Dsar/Mtdhtm1.2Dsar
(either: B6.129(FVB)-Mtdhtm1.2Dsar or (129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N))
|
decreased interleukin-1 beta secretion
|
J:216688
|
decreased interleukin-6 secretion
|
J:216688
|
decreased macrophage proliferation
|
J:216688
|
Mtfmtem1Heb/Mtfmt+
(C57BL/6-Mtfmtem1Heb)
|
decreased circulating interleukin-1 beta level
|
J:334467
|
decreased inflammatory response
|
J:334467
|
Mtmr4tm1a(EUCOMM)Wtsi/Mtmr4+
(Not Specified)
|
decreased IgE level
|
J:165965
|
Mtortm1.2Koz/Mtortm1.2Koz Tg(Cd4-cre)1Cwi/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
decreased interferon-gamma secretion
|
J:150108
|
decreased interleukin-2 secretion
|
J:150108
|
decreased interleukin-17 secretion
|
J:150108
|
decreased T cell proliferation
|
J:150108
|
decreased tumor necrosis factor secretion
|
J:150108
|
Mtortm1Lgm/Mtortm1Lgm
(involves: 129S1/Sv * C57BL/6)
|
abnormal B cell physiology
|
J:168600
|
abnormal humoral immune response
|
J:168600
|
abnormal T cell physiology
|
J:168600
|
decreased B cell proliferation
|
J:168600
|
decreased IgG level
|
J:168600
|
decreased IgM level
|
J:168600
|
decreased splenocyte apoptosis
|
J:168600
|
decreased splenocyte proliferation
|
J:168600
|
impaired B cell migration
|
J:168600
|
Mtss1Gt(CSC156)Byg/Mtss1Gt(CSC156)Byg
(B6.129P2-Mtss1Gt(CSC156)Byg)
|
abnormal B cell physiology
|
J:186118
|
increased inflammatory response
|
J:186118
|
Mtus1Gt(RRA048)Byg/Mtus1Gt(RRA048)Byg
(involves: 129P2/OlaHsd * C57BL/6)
|
glomerulonephritis
|
J:212144
|
increased susceptibility to systemic lupus erythematosus
|
J:212144
|
insulitis
|
J:212144
|
salivary gland inflammation
|
J:212144
|
Mtv7BALB/c/Mtv7BALB/c
(involves: B10.Q * BALB/c * DBA/2)
|
increased susceptibility to induced arthritis
|
J:27701
|
Mtv7BALB/c/Mtv7DBA/2
(involves: B10.Q * BALB/c * DBA/2)
|
decreased susceptibility to induced arthritis
|
J:27701
|
Mtv7DBA/2/Mtv7DBA/2
(C.D2-Mtv7DBA/2)
|
decreased susceptibility to induced arthritis
|
J:27701
|
Muc2eey/Muc2eey
(C57BL/6-Muc2eey)
|
ileum inflammation
|
J:194148
|
increased interferon-gamma secretion
|
J:194148
|
increased interleukin-1 beta secretion
|
J:194148
|
increased susceptibility to induced colitis
|
J:194148
|
increased tumor necrosis factor secretion
|
J:194148
|
Muc2M1Btlr/Muc2+
(C57BL/6J-Muc2M1Btlr)
|
increased susceptibility to induced colitis
|
J:150326
|
Muc2M1Btlr/Muc2M1Btlr
(C57BL/6J-Muc2M1Btlr)
|
increased susceptibility to induced colitis
|
J:150326
|
Muc2m2Btlr/?
(C57BL/6J-Muc2m2Btlr)
|
increased susceptibility to induced colitis
|
J:159359
|
Muc2m3Btlr/Muc2m3Btlr
(C57BL/6J-Muc2m3Btlr)
|
increased susceptibility to induced colitis
|
J:254906
|
Muc2tm1Avel/Muc2tm1Avel
(involves: 129P2/OlaHsd * C57BL/6)
|
colitis
|
J:216831
|
large intestinal inflammation
|
J:216831
|
Muc2wnn/Muc2+
(C57BL/6-Muc2wnn)
|
increased susceptibility to induced colitis
|
J:194148
|
Muc2wnn/Muc2wnn
(C57BL/6-Muc2wnn)
|
colitis
|
J:194148
|
ileum inflammation
|
J:194148
|
increased interferon-gamma secretion
|
J:194148
|
increased interleukin-1 beta secretion
|
J:194148
|
increased interleukin-13 secretion
|
J:194148
|
increased susceptibility to induced colitis
|
J:194148
|
increased tumor necrosis factor secretion
|
J:194148
|
Muc4PWK/PhJ/Muc4PWK/PhJ
(PWK/PhJ)
|
abnormal susceptibility to viral infection
|
J:287566
|
Muc4tm1Skb/Muc4tm1Skb
(involves: 129 * C57BL/6J)
|
decreased susceptibility to colitis induced morbidity/mortality
|
J:234205
|
decreased susceptibility to induced colitis
|
J:234205
|
Muc4tm1Unc/Muc4tm1Unc
(B6NTac.129(FVB)-Muc4tm1Unc/Rand)
|
increased susceptibility to Coronaviridae infection
|
J:287566
|
increased susceptibility to Coronaviridae infection induced morbidity/mortality
|
J:287566
|
increased susceptibility to Togaviridae infection
|
J:287566
|
Muc5actm1.1Evns/Muc5actm1.1Evns
(B6.129S1-Muc5actm1.1Evns)
|
increased circulating interferon-gamma level
|
J:177306
|
increased susceptibility to parasitic infection
|
J:177306
|
Muc5btm1.2Evns/Muc5btm1.2Evns
(B6.129S1-Muc5btm1.2Evns)
|
abnormal professional antigen presenting cell physiology
|
J:207159
|
decreased interleukin-23 secretion
|
J:207159
|
impaired macrophage phagocytosis
|
J:207159
|
increased macrophage apoptosis
|
J:207159
|
increased susceptibility to bacterial infection
|
J:207159
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:207159
|
increased susceptibility to otitis media
|
J:207159
|
respiratory system inflammation
|
J:207159
|
sepsis
|
J:207159
|
Muc13tm1.1Mamg/Muc13tm1.1Mamg
(involves: 129 * C57BL/6)
|
increased susceptibility to colitis induced morbidity/mortality
|
J:313870
|
increased susceptibility to induced colitis
|
J:313870
|
large intestinal inflammation
|
J:313870
|
small intestinal inflammation
|
J:313870
|
Muc19sld/Muc19sld
(NFS/N-Muc19sld)
|
increased susceptibility to autoimmune disorder
|
J:216958,
J:20364
|
Mug1tm1Vln/Mug1tm1Vln
(B.129P2-Mug1tm1Vln)
|
abnormal cytokine level
|
J:57485
|
liver inflammation
|
J:57485
|
Mug1tm2Vln/Mug1tm2Vln Pzptm1Vln/Pzptm1Vln
(B.129P2-Pzptm1Vln Mug1tm2Vln)
|
abnormal cytokine level
|
J:57485
|
liver inflammation
|
J:57485
|
Mus81tm1Esse/Mus81+
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased inflammatory response
|
J:222498
|
Mus81tm1Esse/Mus81tm1Esse
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased interleukin-1 beta secretion
|
J:222498
|
lung inflammation
|
J:222498
|
Mx1r/Mx1r
(B6.A2G-Mx1r)
|
abnormal susceptibility to infection
|
J:120938
|
decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality
|
J:23752
|
Mx1r/Mx1r
(C.A2G-Mx1r)
|
decreased susceptibility to Orthomyxoviridae infection
|
J:23752
|
decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality
|
J:23752
|
Mx1r/Mx1r
(A2G)
|
decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality
|
J:23752
|
Mx1s1/Mx1s1
(BALB/c)
|
increased susceptibility to Orthomyxoviridae infection
|
J:23752
|
Mx1s1/Mx1s1
(C57BL/6)
|
abnormal susceptibility to infection
|
J:120938
|
increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality
|
J:23752
|
Mx1s1/Mx1s1 Tg(Hmgcr-MX1)LStae/?
(involves: C57BL/6 * SJL)
|
decreased susceptibility to Orthomyxoviridae infection
|
J:128067
|
decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality
|
J:128067
|
decreased susceptibility to Riboviria infection
|
J:128067
|
decreased susceptibility to Riboviria infection induced morbidity/mortality
|
J:128067
|
Mx1s2/Mx1s2
(CBA/J)
|
increased susceptibility to Orthomyxoviridae infection
|
J:23752
|
Mxd1tm1Rne/Mxd1tm1Rne
(involves: 129S4/SvJaeSor * C57BL/6)
|
abnormal B cell physiology
|
J:45945
|
Mxi1tm1Rdp/Mxi1tm1Rdp
(involves: 129/Sv * C57BL/6J * SJL)
|
increased T cell proliferation
|
J:48236
|
Mxra8em1Diam/Mxra8+
(C57BL/6J-Mxra8em1Diam)
|
decreased susceptibility to Togaviridae infection
|
J:280585
|
Mxra8em1Diam/Mxra8em1Diam
(C57BL/6J-Mxra8em1Diam)
|
abnormal cytokine level
|
J:280585
|
decreased inflammatory response
|
J:280585
|
decreased susceptibility to Togaviridae infection
|
J:280585
|
Mxra8em2Diam/Mxra8em2Diam
(C57BL/6J-Mxra8em2Diam)
|
decreased susceptibility to Togaviridae infection
|
J:280585
|
Mybl1tm1Epr/Mybl1tm1Epr
(involves: 129 * C57BL/6)
|
abnormal humoral immune response
|
J:67604
|
decreased IgG1 level
|
J:67604
|
decreased IgG2a level
|
J:67604
|
decreased IgG3 level
|
J:67604
|
Mybphltm1a(KOMP)Wtsi/Mybphltm1a(KOMP)Wtsi
(C57BL/6N-Mybphltm1a(KOMP)Wtsi/Wtsi)
|
blood in lymph vessels
|
J:239583
|
Mybphltm1b(KOMP)Wtsi/Mybphltm1b(KOMP)Wtsi
(C57BL/6N-Mybphltm1b(KOMP)Wtsi/Wtsi)
|
blood in lymph vessels
|
J:239583
|
Myctm1Atp/Myc+
(involves: 129P2/OlaHsd * FVB/N)
|
decreased T cell proliferation
|
J:73369
|
Myctm1Atp/Myc+
(B6.129P2-Myctm1Atp)
|
abnormal NK cell physiology
|
J:132730
|
decreased T cell proliferation
|
J:132730
|
Myctm1Atp/Myctm2.1Atp
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL)
|
decreased T cell proliferation
|
J:73369
|
Myctm1Lbox/Myctm1Lbox
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased B cell apoptosis
|
J:97900
|
increased B cell proliferation
|
J:97900
|
Myctm2.1Atp/Myc+
(involves: 129P2/OlaHsd * C57BL/6 * SJL)
|
decreased T cell proliferation
|
J:73369
|
Myctm2Fwa/Myctm2Fwa Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * 129S6/SvEvTac)
|
decreased B cell proliferation
|
J:67222
|
Mycltm1.1Kmm/Mycltm1.1Kmm
(B6.129S6(C)-Mycltm1.1Kmm)
|
abnormal dendritic cell physiology
|
J:206430
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:206430
|
Myd88lkd/Myd88lkd
(C57BL/6-Myd88lkd)
|
abnormal adaptive immunity
|
J:110094
|
abnormal cell-mediated immunity
|
J:110094
|
abnormal innate immunity
|
J:110094
|
abnormal macrophage physiology
|
J:110094
|
Myd88M4Btlr/Myd88+
(C57BL/6J-Myd88M4Btlr)
|
decreased tumor necrosis factor secretion
|
J:254917
|
Myd88M4Btlr/Myd88M4Btlr
(C57BL/6J-Myd88M4Btlr)
|
decreased tumor necrosis factor secretion
|
J:254917
|
Myd88poc/Myd88poc
(C57BL/6-Myd88poc)
|
abnormal immune system physiology
|
J:110094
|
abnormal macrophage physiology
|
J:110094
|
increased susceptibility to bacterial infection
|
J:110094
|
increased susceptibility to Herpesvirales infection
|
J:110094
|
Myd88tm1.1Defr/Myd88tm1.1Defr
(B6.129P2(SJL)-Myd88tm1.1Defr)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:224849
|
abnormal macrophage physiology
|
J:224849
|
abnormal microglial cell physiology
|
J:224849
|
decreased interferon-gamma secretion
|
J:224849
|
increased susceptibility to Coronaviridae infection
|
J:224849
|
increased susceptibility to Coronaviridae infection induced morbidity/mortality
|
J:224849
|
Myd88tm1.1Medz/Myd88tm1.1Medz Tg(Cd4-cre)1Cwi/0
(involves: C57BL/6 * DBA/2)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:209373
|
abnormal memory T cell physiology
|
J:209373
|
abnormal T-helper 1 physiology
|
J:209373
|
abnormal T-helper 17 cell physiology
|
J:209373
|
Myd88tm1Aki/Myd88tm1Aki
(Not Specified)
|
abnormal cytokine secretion
|
J:89257,
J:88906
|
abnormal dendritic cell physiology
|
J:96773
|
abnormal macrophage physiology
|
J:96773
|
abnormal NK cell physiology
|
J:88906
|
abnormal NK T cell physiology
|
J:88906
|
abnormal T cell physiology
|
J:96773
|
decreased B cell proliferation
|
J:96773
|
increased susceptibility to Herpesvirales infection
|
J:88906
|
Myd88tm1Aki/Myd88tm1Aki
(B6.129P2-Myd88tm1Aki)
|
abnormal chemokine secretion
|
J:102879
|
abnormal cytokine secretion
|
J:116670,
J:162707
|
abnormal dendritic cell physiology
|
J:116670,
J:118954
|
abnormal immune system physiology
|
J:121070
|
abnormal innate immunity
|
J:162707
|
abnormal macrophage physiology
|
J:116670
|
abnormal NK cell physiology
|
J:139001
|
abnormal response to infection
|
J:121070
|
abnormal T cell physiology
|
J:97662
|
bronchiolitis
|
J:162707
|
decreased inflammatory response
|
J:123946
|
decreased interferon-alpha secretion
|
J:97662
|
decreased interferon-gamma secretion
|
J:116763,
J:118954
|
decreased interleukin-6 secretion
|
J:118954,
J:121070
|
decreased interleukin-12 secretion
|
J:116670
|
decreased interleukin-12b secretion
|
J:116763,
J:118954
|
decreased susceptibility to parasitic infection
|
J:116763
|
decreased tumor necrosis factor secretion
|
J:116670,
J:116763,
J:121070
|
increased susceptibility to Coronaviridae infection
|
J:162707
|
increased susceptibility to Coronaviridae infection induced morbidity/mortality
|
J:162707
|
increased susceptibility to Picornaviridae infection
|
J:97662
|
Myd88tm1Aki/Myd88tm1Aki
(involves: 129P2/OlaHsd)
|
abnormal cytokine level
|
J:174941
|
abnormal cytokine secretion
|
J:167340
|
abnormal dendritic cell physiology
|
J:174941,
J:137522
|
abnormal interferon level
|
J:137522
|
abnormal macrophage physiology
|
J:174941
|
abnormal neutrophil physiology
|
J:145345
|
abnormal tumor necrosis factor level
|
J:103464,
J:124334
|
decreased circulating tumor necrosis factor level
|
J:139030
|
decreased interferon-alpha secretion
|
J:144400
|
decreased interferon-gamma secretion
|
J:210086
|
decreased interleukin-6 secretion
|
J:167340
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:105435
|
increased IgA level
|
J:210086
|
increased IgE level
|
J:115059
|
increased IgG1 level
|
J:115059
|
increased susceptibility to bacterial infection
|
J:210086
|
increased susceptibility to induced colitis
|
J:167340
|
increased susceptibility to Picornaviridae infection
|
J:137522
|
Myd88tm1Aki/Myd88tm1Aki
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal chemokine secretion
|
J:141143
|
abnormal cytokine secretion
|
J:117688
|
abnormal dendritic cell physiology
|
J:122394
|
abnormal macrophage physiology
|
J:141143,
J:117688
|
decreased IgG2b level
|
J:137066
|
decreased IgG3 level
|
J:137066
|
decreased IgG level
|
J:137066
|
decreased interleukin-1 beta secretion
|
J:124226
|
decreased interleukin-6 secretion
|
J:147023
|
Myd88tm1Aki/Myd88tm1Aki
(C.129P2-Myd88tm1Aki)
|
decreased susceptibility to induced arthritis
|
J:178054
|
Myd88tm1Aki/Myd88tm1Aki
(B6.129-Myd88tm1Aki)
|
abnormal susceptibility to bacterial infection
|
J:189854
|
decreased interleukin-6 secretion
|
J:189854
|
decreased tumor necrosis factor secretion
|
J:189854
|
Myd88tm1Aki/Myd88tm1Aki Tanktm1Aki/Tanktm1Aki
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:151757
|
Myd88tm1Aki/Myd88tm1Aki Ticam1tm1Aki/Ticam1+
(B6.129P2-Myd88tm1Aki Ticam1tm1Aki)
|
decreased macrophage cytokine production
|
J:140485
|
decreased macrophage nitric oxide production
|
J:140485
|
increased susceptibility to parasitic infection
|
J:140485
|
increased susceptibility to parasitic infection induced morbidity/mortality
|
J:140485
|
Myd88tm1Aki/Myd88tm1Aki Ticam1tm1Aki/Ticam1tm1Aki
(involves: 129P2/OlaHsd)
|
abnormal dendritic cell physiology
|
J:174941
|
abnormal macrophage physiology
|
J:174941
|
Myd88tm1Aki/Myd88tm1Aki Ticam1tm1Aki/Ticam1tm1Aki
(B6.129P2-Myd88tm1Aki Ticam1tm1Aki)
|
decreased macrophage cytokine production
|
J:140485
|
decreased macrophage nitric oxide production
|
J:140485
|
increased susceptibility to parasitic infection
|
J:140485
|
increased susceptibility to parasitic infection induced morbidity/mortality
|
J:140485
|
Myd88tm1Aki/Myd88tm1Aki Tnfaip3tm1.1Gvl/Tnfaip3tm1.1Gvl Tg(Vil1-cre)997Gum/0
(involves: 129P2/OlaHsd * C57BL/6 * SJL)
|
increased susceptibility to induced colitis
|
J:163410
|
Myd88tm1Aki/Myd88tm1Aki Traddtm1.1Mpa/Traddtm1.1Mpa
(involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)
|
decreased circulating tumor necrosis factor level
|
J:139030
|
Myd88tm1Defr/Myd88tm1Defr Commd10Tg(Vav1-icre)A2Kio/Commd10+
(involves: 129P2/OlaHsd * C57BL/6 * SJL)
|
abnormal NK cell physiology
|
J:139001
|
Myd88tm1Defr/Myd88tm1Defr Tg(Itgax-cre)1-1Reiz/0
(B6.Cg-Myd88tm1Defr Tg(Itgax-cre)1-1Reiz)
|
abnormal dendritic cell antigen presentation
|
J:139001
|
abnormal dendritic cell physiology
|
J:139001
|
abnormal NK cell physiology
|
J:139001
|
decreased circulating interleukin-6 level
|
J:139001
|
decreased circulating interleukin-12b level
|
J:139001
|
decreased IgG1 level
|
J:139001
|
decreased IgG2b level
|
J:139001
|
decreased IgG2c level
|
J:139001
|
Myd88tm1Hlz/Myd88tm1Hlz
(B6.129P2-Myd88tm1Hlz)
|
abnormal chemokine level
|
J:188968
|
decreased circulating interleukin-6 level
|
J:188968
|
decreased circulating interleukin-10 level
|
J:188968
|
decreased circulating interleukin-12b level
|
J:188968
|
decreased interleukin-6 secretion
|
J:188968
|
decreased interleukin-10 secretion
|
J:188968
|
decreased tumor necrosis factor secretion
|
J:188968
|
Myd88tm1Hlz/Myd88tm1Hlz Lyz2tm1(cre)Ifo/Lyz2+
(B6.129P2-Myd88tm1Hlz Lyz2tm1(cre)Ifo)
|
abnormal circulating chemokine level
|
J:188968
|
decreased CXCL10 level
|
J:188968
|
increased circulating tumor necrosis factor level
|
J:188968
|
Mydgftm1Kcw/Mydgftm1Kcw
(BALB/c-Mydgftm1Kcw)
|
decreased inflammatory response
|
J:216795
|
Myh4arl/Myh4arl
(involves: C3H/HeH * C57BL/6J)
|
myositis
|
J:181892
|
Myh6tm1Jse/Myh6+ Tg(Myh6-TNNI3*G203S)1Chs/0
(involves: 129X1/SvJ * C57BL/6)
|
liver inflammation
|
J:153302
|
lung inflammation
|
J:153302
|
Myh9tm1.1Mjk/Myh9+
(B6.129-Myh9tm1.1Mjk)
|
increased incidence of corneal inflammation
|
J:175367
|
Myh9tm5Rsad/Myh9tm5Rsad
(involves: 129S6/SvEvTac * C57BL/6J)
|
abnormal leukocyte migration
|
J:164684
|
abnormal T cell physiology
|
J:164684
|
Myh9tm5Rsad/Myh9tm5Rsad Tg(Lck-cre)#Nik/0
(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * DBA/2)
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:164684
|
abnormal leukocyte adhesion
|
J:164684
|
abnormal leukocyte migration
|
J:164684
|
abnormal T cell physiology
|
J:164684
|
Myh10tm7Rsad/Myh10tm7Rsad Tg(Myh6-cre)2182Mds/0
(involves: 129S6/SvEvTac * C57BL/6J * FVB/N)
|
heart inflammation
|
J:170148
|
Myl3tm1a(EUCOMM)Hmgu/Myl3tm1a(EUCOMM)Hmgu Tg(Col2a1-cre)1Xya/0
(involves: C57BL/6J * C57BL/6N)
|
osteoarthritis
|
J:343166
|
Myl3tm1a(EUCOMM)Hmgu/Myl3tm1a(EUCOMM)Hmgu Tg(Col2a1-cre/ERT)KA3Smac/0
(involves: C57BL/6J * C57BL/6N * FVB/N)
|
increased susceptibility to induced arthritis
|
J:343166
|
Mylktm1Mzhu/Mylktm1Mzhu Taglntm1(cre/ERT2)Feil/?
(involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6)
|
small intestinal inflammation
|
J:141907
|
Myo1dem1Btlr/Myo1dem1Btlr
(C57BL/6J-Myo1dem1Btlr)
|
increased susceptibility to colitis induced morbidity/mortality
|
J:267525
|
increased susceptibility to induced colitis
|
J:267525
|
Myo1dm1Btlr/Myo1dm1Btlr
(C57BL/6J-Myo1dm1Btlr)
|
increased susceptibility to induced colitis
|
J:267525
|
Myo1dm1Btlr/Myo1dm2Btlr
(C57BL/6J-Myo1dm1Btlr/Myo1dm2Btlr)
|
increased susceptibility to induced colitis
|
J:267525
|
Myo1dm2Btlr/Myo1dm2Btlr
(C57BL/6J-Myo1dm2Btlr)
|
increased susceptibility to induced colitis
|
J:267525
|
Myo1dm3Btlr/Myo1dm3Btlr
(C57BL/6J-Myo1dm3Btlr)
|
increased susceptibility to induced colitis
|
J:267525
|
Myo1dm4Btlr/Myo1dm4Btlr
(C57BL/6J-Myo1dm4Btlr)
|
increased susceptibility to induced colitis
|
J:267525
|
Myo1ftm1.1Flv/Myo1ftm1.1Flv
(involves: 129S6/SvEvTac)
|
impaired neutrophil chemotaxis
|
J:113020
|
Myo1gtm1.2Mfk/Myo1gtm1.2Mfk
(Not Specified)
|
abnormal B cell physiology
|
J:209304
|
decreased tumor necrosis factor secretion
|
J:209304
|
impaired B cell migration
|
J:209304
|
Myo1gtm1.2Mfk/Myo1gtm1.2Mfk
(involves: C57BL/6 * FVB/N * SJL)
|
abnormal T cell physiology
|
J:212451
|
Myo1gtm1.2Mfk/Myo1gtm1.2Mfk Tg(TcraTcrb)1100Mjb/0
(involves: C57BL/6 * FVB/N * SJL)
|
abnormal T cell physiology
|
J:212451
|
Myo9atm1b(EUCOMM)Wtsi/Myo9atm1b(EUCOMM)Wtsi
(C57BL/6N-Myo9atm1b(EUCOMM)Wtsi/Wtsi)
|
blood in lymph vessels
|
J:239583
|
Myo9btm1.2Bah/Myo9btm1.2Bah
(B6.Cg-Myo9btm1.2Bah)
|
abnormal macrophage physiology
|
J:162326
|
impaired macrophage chemotaxis
|
J:162326
|
mypy/mypy
(C57BL/6J-mypy)
|
abnormal macrophage physiology
|
J:105543
|
increased susceptibility to Herpesvirales infection
|
J:105543
|
increased susceptibility to Riboviria infection
|
J:105543
|
Mysm1tm1a(KOMP)Wtsi/Mysm1tm1a(KOMP)Wtsi
(Not Specified)
|
increased IgG2b level
|
J:165965
|
Mzb1tm1.2Rug/Mzb1tm1.2Rug
(involves: 129S2/SvPas * BALB/cJ * C57BL/6 * SJL)
|
impaired humoral immune response
|
J:211639
|
N4bp1em1Vmd/N4bp1em1Vmd
(C57BL/6N-N4bp1em1Vmd)
|
decreased interleukin-6 secretion
|
J:297419
|
N4bp1tm1.2Vmd/N4bp1tm1.2Vmd
(involves: C57BL/6)
|
abnormal macrophage physiology
|
J:297419
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:297419
|
increased circulating interleukin-6 level
|
J:297419
|
increased circulating tumor necrosis factor level
|
J:297419
|
increased interleukin-6 secretion
|
J:297419
|
increased tumor necrosis factor secretion
|
J:297419
|
lung inflammation
|
J:297419
|
Naaatm1a(KOMP)Wtsi/Naaatm1a(KOMP)Wtsi
(B6NTac;B6N-Atm1Brd Naaatm1a(KOMP)Wtsi/WtsiH)
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:258438
|
Nabp2tm1.1Kkha/Nabp2tm1.1Kkha Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
(involves: C57BL/6 * C57BL/6NTac)
|
increased thymocyte apoptosis
|
J:195140
|
Naglutm1Efn/Naglutm1Efn
(involves: 129S/SvEv * C57BL/6J)
|
increased susceptibility to otitis media
|
J:129390
|
Naip5Lgn1-s/Naip5Lgn1-s
(A/J)
|
increased susceptibility to bacterial infection
|
J:20633
|
Naip5m1Btlr/Naip5m1Btlr
(C57BL/6J-Naip5m1Btlr)
|
decreased interleukin-1 beta secretion
|
J:234250
|
Naip5m2Btlr/Naip5+
(C57BL/6J-Naip5m2Btlr)
|
decreased interleukin-1 beta secretion
|
J:234248
|
Naip5m2Btlr/Naip5m2Btlr
(C57BL/6J-Naip5m2Btlr)
|
decreased interleukin-1 beta secretion
|
J:234248
|
Naip5tm1Vnce/Naip5tm1Vnce
(C57BL/6-Naip5tm1Vnce)
|
decreased interleukin-1 beta secretion
|
J:141008
|
Naipctm1.1Kmma/Naipctm1.1Kmma
(involves: BALB/cJ * C57BL/6)
|
decreased interleukin-1 beta secretion
|
J:222114
|
decreased susceptibility to induced colitis
|
J:222114
|
Naipctm1Kmma/Naipctm1Kmma Lyz2tm1(cre)Ifo/Lyz2+
(B6.Cg-Lyz2tm1(cre)Ifo Naipctm1Kmma)
|
decreased susceptibility to induced colitis
|
J:222114
|
Naipctm1Kmma/Naipctm1Kmma Tg(Vil1-cre)997Gum/0
(B6.Cg-Naipctm1Kmma Tg(Vil1-cre)997Gum)
|
decreased susceptibility to induced colitis
|
J:222114
|
NamptGt(RRR084)Byg/Nampt+
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased interleukin-6 secretion
|
J:194883
|
Nba4NZB/Nba4NZB
(involves: NZB * SWR)
|
glomerulonephritis
|
J:96060
|
increased anti-double stranded DNA antibody level
|
J:96060
|
increased anti-histone antibody level
|
J:96263
|
increased anti-single stranded DNA antibody level
|
J:96060
|
increased IgG3 level
|
J:96263
|
Nba4NZB/Nba4SWR
(involves: NZB * SWR)
|
increased anti-histone antibody level
|
J:96263
|
increased IgG3 level
|
J:96263
|
Nba5NZB/Nba5NZB
(C57BL/6-Nba5 Yaa)
|
glomerulonephritis
|
J:95829
|
increased susceptibility to type III hypersensitivity reaction
|
J:95829
|
Nba8NZB/Nba8NZB
(involves: NZB * SWR)
|
glomerulonephritis
|
J:73097
|
Nba10NZB/?
(involves: C57BL/6 * NZB * SB/Le)
|
glomerulonephritis
|
J:95829
|
increased anti-chromatin antibody level
|
J:95829
|
increased anti-double stranded DNA antibody level
|
J:95829
|
increased susceptibility to type III hypersensitivity reaction
|
J:95829
|
Nba10NZB/Nba10NZB Tg(Tnfsf13b)1Fma/0
(involves: C57BL/6 * DBA/2J * NZB)
|
glomerulonephritis
|
J:134128
|
increased anti-chromatin antibody level
|
J:134128
|
increased anti-double stranded DNA antibody level
|
J:134128
|
increased IgG level
|
J:134128
|
increased IgM level
|
J:134128
|
increased susceptibility to systemic lupus erythematosus
|
J:134128
|
Nba10NZB/Nba10NZB Tlr7tm1Aki/Y X/Yaa
(B6.Cg-Nba10NZB Tlr7tm1Aki Yaa)
|
abnormal immune serum protein physiology
|
J:137656
|
glomerulonephritis
|
J:137656
|
increased anti-chromatin antibody level
|
J:137656
|
Nba10NZB/Nba10NZB X/Yaa
(C57BL/6-Nba2 Yaa)
|
abnormal immune serum protein physiology
|
J:137656
|
glomerulonephritis
|
J:95829,
J:137656
|
increased anti-chromatin antibody level
|
J:137656
|
increased anti-nuclear antigen antibody level
|
J:95829
|
increased autoantibody level
|
J:137656
|
increased susceptibility to autoimmune disorder
|
J:95829
|
increased susceptibility to type III hypersensitivity reaction
|
J:95829
|
Nba11NZB/Nba11NZB
(involves: NZB * SWR)
|
glomerulonephritis
|
J:96263
|
Nba11NZB/Nba11SWR
(involves: NZB * SWR)
|
glomerulonephritis
|
J:96263
|
Nba12NZB/Nba12NZB
(involves: NZB * SWR)
|
increased anti-double stranded DNA antibody level
|
J:96263
|
Nba12NZB/Nba12SWR
(involves: NZB * SWR)
|
increased anti-double stranded DNA antibody level
|
J:96263
|
Nbeal2tm1a(EUCOMM)Wtsi/Nbeal2tm1a(EUCOMM)Wtsi
(C57BL/6N-Nbeal2tm1a(EUCOMM)Wtsi/Wtsi)
|
increased inflammatory response
|
J:220801
|
Nbntm1Nus/Nbntm2Nus Tg(CD19-cre/ERT2)1Cgn/0
(Not Specified)
|
abnormal B cell physiology
|
J:96102
|
decreased B cell proliferation
|
J:96102
|
decreased IgG1 level
|
J:96102
|
decreased IgG2a level
|
J:96102
|
decreased IgG2b level
|
J:96102
|
decreased IgG3 level
|
J:96102
|
decreased IgG level
|
J:96102
|
Nbntm1Xu/Nbntm1Xu
(Not Specified)
|
abnormal cell-mediated immunity
|
J:75272
|
Nbr1tm1.1Jmos/Nbr1tm1.1Jmos Tnfrsf4tm2(cre)Nik/Tnfrsf4+
(involves: 129X1/SvJ * C57BL/6J)
|
decreased inflammatory response
|
J:165438
|
decreased interferon-gamma secretion
|
J:165438
|
decreased interleukin-4 secretion
|
J:165438
|
decreased interleukin-5 secretion
|
J:165438
|
decreased interleukin-13 secretion
|
J:165438
|
Nbr1tm1Whca/Nbr1tm1Whca
(B6.129P2-Nbr1tm1Whca)
|
abnormal osteoclast physiology
|
J:162412
|
Nbwa1NZB/?
(involves: BALB/c * NZB * NZW)
|
increased anti-chromatin antibody level
|
J:88464
|
increased anti-double stranded DNA antibody level
|
J:88464
|
increased anti-single stranded DNA antibody level
|
J:88464
|
increased susceptibility to systemic lupus erythematosus
|
J:88464
|
Nbwa2NZB/?
(involves: BALB/c * NZB * NZW)
|
glomerulonephritis
|
J:88464
|
increased IgG level
|
J:88464
|
increased IgM level
|
J:88464
|
increased susceptibility to systemic lupus erythematosus
|
J:88464
|
Nbwa2NZW/?
(involves: BALB/c * NZB * NZW)
|
increased anti-double stranded DNA antibody level
|
J:88464
|
increased susceptibility to systemic lupus erythematosus
|
J:88464
|
Ncapd2em1Cya/Ncapd2+
(C57BL/6N-Ncapd2em1Cya)
|
decreased susceptibility to induced colitis
|
J:310248
|
Nceh1tm1Ishi/Nceh1tm1Ishi
(B6.129S7-Nceh1tm1Ishi)
|
abnormal macrophage physiology
|
J:152385
|
Ncf1m1J/Ncf1m1J
(B6.Cg-Dock7m +/+ Leprdb/J)
|
abnormal macrophage physiology
|
J:83428
|
decreased susceptibility to Orthomyxoviridae infection
|
J:145306
|
impaired granulocyte bactericidal activity
|
J:83428
|
Ncf1tm1Hbd/Ncf1tm1Hbd
(involves: 129)
|
abnormal neutrophil physiology
|
J:77597,
J:74593
|
granulomatous inflammation
|
J:74593
|
Ncf1tm1Shl/Ncf1tm1Shl
(involves: 129S2/SvPas * C57BL/6J)
|
abnormal response to infection
|
J:28267
|
increased acute inflammation
|
J:28267
|
increased susceptibility to infection
|
J:28267
|
Ncf1tm1Shl/Ncf1tm1Shl
(B6.129S2-Ncf1tm1Shl)
|
abnormal inflammatory response
|
J:142617
|
granulomatous inflammation
|
J:111142
|
Ncf2tm1b(EUCOMM)Wtsi/Ncf2+
(NZM2328.B6(Cg)-Ncf2tm1b(EUCOMM)Wtsi)
|
increased anti-double stranded DNA antibody level
|
J:260777
|
increased susceptibility to systemic lupus erythematosus
|
J:260777
|
Ncf2tm1b(EUCOMM)Wtsi/Ncf2tm1b(EUCOMM)Wtsi
(B6(Cg)-Ncf2tm1b(EUCOMM)Wtsi)
|
increased susceptibility to fungal infection
|
J:260777
|
lung inflammation
|
J:260777
|
Ncf2tm1b(EUCOMM)Wtsi/Ncf2tm1b(EUCOMM)Wtsi
(NZM2328.B6(Cg)-Ncf2tm1b(EUCOMM)Wtsi)
|
increased anti-double stranded DNA antibody level
|
J:260777
|
increased susceptibility to systemic lupus erythematosus
|
J:260777
|
Ncf4tm1Pth/Ncf4tm2Pth
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal neutrophil physiology
|
J:119217
|
increased susceptibility to bacterial infection
|
J:119217
|
Ncf4tm2Pth/Ncf4tm2Pth
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal neutrophil physiology
|
J:121820
|
increased susceptibility to bacterial infection
|
J:121820
|
Nckap1lm1Iri/Nckap1lm1Iri
(involves: C57BL/6)
|
decreased T cell proliferation
|
J:141377
|
heart inflammation
|
J:141377
|
impaired macrophage phagocytosis
|
J:141377
|
impaired neutrophil chemotaxis
|
J:141377
|
impaired neutrophil phagocytosis
|
J:141377
|
increased circulating interleukin-6 level
|
J:141377
|
increased circulating interleukin-17 level
|
J:141377
|
increased interleukin-6 secretion
|
J:141377
|
increased interleukin-17 secretion
|
J:141377
|
increased tumor necrosis factor secretion
|
J:141377
|
liver inflammation
|
J:141377
|
lung inflammation
|
J:141377
|
Ncoa3tm1Jxu/Ncoa3tm1Jxu
(involves: 129S6/SvEvTac * C57BL/6J)
|
decreased splenocyte apoptosis
|
J:109522
|
increased B cell proliferation
|
J:109522
|
increased T cell proliferation
|
J:109522
|
Ncoa3tm1Jxu/Ncoa3tm1Jxu
(involves: 129S6/SvEvTac * C57BL/6)
|
decreased interleukin-1 beta secretion
|
J:120086
|
increased circulating interleukin-1 beta level
|
J:120086
|
increased circulating interleukin-6 level
|
J:120086
|
increased circulating tumor necrosis factor level
|
J:120086
|
increased interleukin-6 secretion
|
J:120086
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:120086
|
increased susceptibility to endotoxin shock
|
J:120086
|
increased tumor necrosis factor secretion
|
J:120086
|
Ncoa5tm1Hxia/Ncoa5+
(involves: 129 * C57BL/6)
|
chronic liver inflammation
|
J:207622
|
Ncr1m1J/Ncr1m1J Pepcb/Pepcb Ptprca/Ptprca
(B6.SJL-Ptprca Pepcb/BoyJ)
|
abnormal interferon level
|
J:257226
|
abnormal NK cell physiology
|
J:257226
|
abnormal susceptibility to infection induced morbidity/mortality
|
J:257226
|
decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality
|
J:257226
|
increased susceptibility to Herpesvirales infection induced morbidity/mortality
|
J:257226
|
Ncr1noe/Ncr1noe
(involves: C57BL/6J)
|
abnormal NK cell physiology
|
J:179728
|
decreased susceptibility to Herpesvirales infection
|
J:179728
|
decreased susceptibility to Herpesvirales infection induced morbidity/mortality
|
J:179728
|
increased susceptibility to bacterial infection
|
J:179728
|
Ncr1tm1.1(icre)Viv/Ncr1tm1.1(icre)Viv
(involves: C57BL/6)
|
abnormal NK cell physiology
|
J:179728
|
decreased susceptibility to Herpesvirales infection induced morbidity/mortality
|
J:179728
|
decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality
|
J:179728
|
Ncr1tm1Oman/Ncr1tm1Oman
(involves: 129S1/Sv * 129X1/SvJ)
|
impaired natural killer cell mediated cytotoxicity
|
J:112394
|
increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality
|
J:112394
|
Ncstntm1.1Akli/Ncstntm1.1Akli Tg(VAV1-cre)1Graf/0
(involves: 129)
|
abnormal splenocyte physiology
|
J:196407
|
Ndfip1Gt(RRD002)Byg/Ndfip1Gt(RRD002)Byg
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal T cell physiology
|
J:116617
|
abnormal T-helper 2 physiology
|
J:116617
|
dermatitis
|
J:116617
|
increased inflammatory response
|
J:116617
|
increased T cell proliferation
|
J:116617
|
lung inflammation
|
J:116617
|
Ndfip1Gt(RRD002)Byg/Ndfip1Gt(RRD002)Byg
(involves: 129P2/OlaHsd)
|
abnormal T cell physiology
|
J:205692
|
increased interleukin-2 secretion
|
J:205692
|
increased T cell proliferation
|
J:205692
|
Ndfip1tm1.1Pmo/Ndfip1tm1.1Pmo Tg(Cd4-cre)1Cwi/0
(involves: C57BL/6 * DBA/2)
|
esophageal inflammation
|
J:205692
|
skin inflammation
|
J:205692
|
Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+ Rnpc3tm1c(EUCOMM)Wtsi/Rnpc3tm1c(EUCOMM)Wtsi
(involves: 129S/SvEv * C57BL/6 * C57BL/6N)
|
esophageal inflammation
|
J:267519
|
small intestinal inflammation
|
J:267519
|
Ndrg2tm1.1Hori/Ndrg2tm1.1Hori
(B6.129-Ndrg2tm1.1Hori)
|
abnormal microglial cell chemotaxis
|
J:214686
|
decreased inflammatory response
|
J:214686
|
decreased interleukin-6 secretion
|
J:214686
|
Ndst1tm1Je/Ndst1tm1Je Tg(Tek-cre)1Ywa/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
abnormal leukocyte adhesion
|
J:100456
|
abnormal leukocyte migration
|
J:100456
|
decreased inflammatory response
|
J:100456
|
impaired leukocyte tethering or rolling
|
J:100456
|
Ndst2tm1Lkj/Ndst2tm1Lkj
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
decreased mast cell degranulation
|
J:57121
|
Ndst2tm1Rls/Ndst2tm1Rls
(Not Specified)
|
abnormal response to infection
|
J:57120
|
decreased mast cell degranulation
|
J:57120
|
Ndst2tm1Rls/Ndst2tm1Rls
(B6.Cg-Ndst2tm1Rls)
|
decreased susceptibility to induced arthritis
|
J:142880
|
Nedd4Gt(XA209)Byg/Nedd4Gt(XA209)Byg
(involves: 129P2/OlaHsd)
|
abnormal T cell activation
|
J:143560
|
decreased IgG1 level
|
J:143560
|
decreased IgG2b level
|
J:143560
|
decreased IgG3 level
|
J:143560
|
decreased interleukin-2 secretion
|
J:143560
|
decreased T cell proliferation
|
J:143560
|
increased IgM level
|
J:143560
|
Nedd4Gt(XB398)Byg/Nedd4Gt(XB398)Byg
(involves: 129P2/OlaHsd)
|
decreased IgG1 level
|
J:143560
|
decreased IgG2b level
|
J:143560
|
decreased IgG3 level
|
J:143560
|
decreased interleukin-2 secretion
|
J:143560
|
decreased T cell proliferation
|
J:143560
|
increased IgM level
|
J:143560
|
Nedd4ltm1.1Hkb/Nedd4ltm1.1Hkb Tg(SFTPC-rtTA)5Jaw/0 Tg(tetO-cre)1Jaw/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL)
|
lung inflammation
|
J:169296
|
Nedd4ltm1Shkr/Nedd4ltm1Shkr
(involves: C57BL/6 * C57BL/6J)
|
lung inflammation
|
J:205657
|
Nedd4ltm1Shkr/Nedd4ltm1Shkr
(involves: 129 * C57BL/6 * C57BL/6J)
|
lung inflammation
|
J:205657
|
Nedd9m1Btlr/Nedd9m1Btlr
(C57BL/6J-Nedd9m1Btlr)
|
increased susceptibility to Herpesvirales infection
|
J:267702
|
Nedd9tm1Miku/Nedd9tm1Miku
(B6.CBA-Nedd9tm1Miku)
|
abnormal follicular B cell physiology
|
J:116716
|
abnormal leukocyte migration
|
J:116716
|
abnormal T cell physiology
|
J:116716
|
Neil1tm1Rsld/Neil1tm1Rsld
(involves: 129S1/Sv * C57BL/6)
|
joint inflammation
|
J:106077
|
Neil2tm1.1Tkhz/Neil2tm1.1Tkhz
(involves: 129S6/SvEvTac * C57BL/6J * C57BL/6NCrl)
|
lung inflammation
|
J:225791
|
Neil3tm1Bjor/Neil3tm1Bjor
(involves: 129 * C57BL/6)
|
decreased microglial cell activation
|
J:180177
|
Nek7M1Btlr/Nek7+
(C57BL/6J-Nek7M1Btlr)
|
abnormal macrophage physiology
|
J:226677
|
decreased inflammatory response
|
J:226677
|
decreased interleukin-1 beta secretion
|
J:226677
|
decreased interleukin-18 secretion
|
J:226677
|
Nek7M1Btlr/Nek7M1Btlr
(C57BL/6J-Nek7M1Btlr)
|
abnormal macrophage physiology
|
J:226677
|
decreased inflammatory response
|
J:226677
|
decreased interleukin-1 beta secretion
|
J:226677
|
decreased interleukin-18 secretion
|
J:226677
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:226677
|
Nek8m1Btlr/Nek8m1Btlr
(C57BL/6J-Nek8m1Btlr)
|
increased susceptibility to induced colitis
|
J:267544
|
Neurl3em1Luda/Neurl3em1Luda
(B6N.Cg-Neurl3em1Luda)
|
increased susceptibility to Riboviria infection
|
J:344721
|
increased susceptibility to Riboviria infection induced morbidity/mortality
|
J:344721
|
Nf1tm1.1Kest/Nf1tm1c(KOMP)Wtsi Tg(Dhh-cre)1Mejr/0
(involves: 129S4/SvJaeSor * C57BL/6 * C57BL/6N * C57BL/6NTac * FVB/N)
|
dermatitis
|
J:234172
|
Nf1tm1c(KOMP)Wtsi/Nf1tm1c(KOMP)Wtsi Tg(Dhh-cre)1Mejr/0
(involves: 129S4/SvJaeSor * C57BL/6 * C57BL/6N * FVB/N)
|
dermatitis
|
J:234172
|
Nf1tm1Tyj/Nf1+
(involves: 129S2/SvPas)
|
abnormal mast cell physiology
|
J:142439
|
increased mast cell degranulation
|
J:142439
|
Nf1tm1Tyj/Nf1+ Pak1tm1Cher/Pak1tm1Cher
(involves: 129S2/SvPas * C57BL/6)
|
abnormal mast cell physiology
|
J:142439
|
Nf2tm1Gth/Nf2tm2Gth Tg(Mpz-cre)2Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased susceptibility to otitis media
|
J:63264
|
Nf2tm2Gth/Nf2tm2Gth Tg(Mpz-cre)1Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased susceptibility to otitis media
|
J:63264
|
Nf2tm2Gth/Nf2tm2Gth Tg(Mpz-cre)2Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased susceptibility to otitis media
|
J:63264
|
Nfat5tm1.1Joar/Nfat5tm1.1Joar Tg(Cd4-cre)1Cwi/0
(involves: C57BL/6 * DBA/2 * SJL)
|
abnormal T cell physiology
|
J:148271
|
Nfat5tm1Rao/Nfat5tm1Rao
(B6.129-Nfat5tm1Rao)
|
tubulointerstitial nephritis
|
J:88636
|
Nfat5tm1Snh/Nfat5+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal immunoglobulin level
|
J:91482
|
decreased IgG level
|
J:91482
|
decreased T cell proliferation
|
J:91482
|
Nfatc1tm1.1Fbs/Nfatc1tm1.1Fbs
(C57BL/6-Nfatc1tm1.1Fbs)
|
decreased interferon-gamma secretion
|
J:305649
|
decreased interleukin-17 secretion
|
J:305649
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:305649
|
decreased susceptibility to graft versus host disease
|
J:305649
|
increased interleukin-2 secretion
|
J:305649
|
Nfatc1tm1Glm/Nfatc1tm2Glm
(chimera involves: 129S2/SvPas)
|
abnormal B cell physiology
|
J:78376
|
abnormal immune system physiology
|
J:78376
|
abnormal immunoglobulin level
|
J:78376
|
abnormal interferon-gamma secretion
|
J:78376
|
abnormal interleukin-2 secretion
|
J:78376
|
abnormal lymphocyte physiology
|
J:78376
|
abnormal T cell physiology
|
J:78376
|
abnormal T-helper 2 physiology
|
J:78376
|
decreased IgE level
|
J:78376
|
decreased IgG1 level
|
J:78376
|
decreased IgG2b level
|
J:78376
|
decreased IgG3 level
|
J:78376
|
decreased immunoglobulin level
|
J:78376
|
decreased interleukin-4 secretion
|
J:78376
|
increased IgA level
|
J:78376
|
increased IgG2a level
|
J:78376
|
increased IgM level
|
J:78376
|
increased immunoglobulin level
|
J:78376
|
Nfatc1tm1Rao/Nfatc1tm1Rao Cd79atm1(cre)Reth/Cd79a+
(involves: BALB/c)
|
abnormal B cell calcium ion homeostasis
|
J:177319
|
abnormal class switch recombination
|
J:177319
|
abnormal marginal zone B cell physiology
|
J:177319
|
decreased B cell proliferation
|
J:177319
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:177319
|
increased B cell apoptosis
|
J:177319
|
Nfatc1tm1Rao/Nfatc1tm1Rao Nfatc2tm1Rao/Nfatc2tm1Rao Cd79atm1(cre)Reth/Cd79a+
(involves: BALB/c)
|
abnormal B cell physiology
|
J:177319
|
decreased interleukin-2 secretion
|
J:177319
|
Nfatc1tm1Rao/Nfatc1tm1Rao Tg(Fcer2a-cre)5Mbu/0
(involves: C57BL/6 * CBA)
|
abnormal B cell physiology
|
J:177319
|
abnormal class switch recombination
|
J:177319
|
decreased B cell proliferation
|
J:177319
|
decreased IgG2a level
|
J:177319
|
decreased IgG3 level
|
J:177319
|
decreased IgM level
|
J:177319
|
decreased interleukin-2 secretion
|
J:177319
|
increased IgM level
|
J:177319
|
increased interleukin-10 secretion
|
J:177319
|
Nfatc1tm3Glm/Nfatc1tm3Glm Sh3bp2tm1Bjro/Sh3bp2tm1Bjro Tg(Mx1-cre)1Cgn/0
(involves: 129S4/SvJae * C57BL/6 * CBA)
|
liver inflammation
|
J:144598
|
lung inflammation
|
J:144598
|
lymph node inflammation
|
J:144598
|
stomach inflammation
|
J:144598
|
Nfatc2tm1Glm/Nfatc2tm1Glm Nfatc3tm1c(EUCOMM)Hmgu/Nfatc3tm1c(EUCOMM)Hmgu Tg(Itgax-cre)1-1Reiz/0
(involves: C57BL/6 * C57BL/6N * CBA)
|
decreased interleukin-2 secretion
|
J:346703
|
Nfatc2tm1Glm/Nfatc2tm1Glm Nfatc3tm1Glm/Nfatc3tm1Glm
(involves: 129S2/SvPas)
|
blepharitis
|
J:51339
|
increased inflammatory response
|
J:51339
|
interstitial pneumonia
|
J:51339
|
Nfatc2tm1Rao/Nfatc2tm1Rao
(B6.Cg-Nfatc2tm1Rao)
|
abnormal mast cell physiology
|
J:78089
|
decreased interleukin-4 secretion
|
J:78089
|
decreased interleukin-13 secretion
|
J:78089
|
decreased tumor necrosis factor secretion
|
J:78089
|
Nfatc2tm1Rao/Nfatc2tm1Rao Nfatc3tm1Grc/Nfatc3tm1Grc Tg(Lck-cre)I57Jxm/0
(involves: ICR)
|
increased T cell apoptosis
|
J:141917
|
Nfatc2tm1Srf/Nfatc2tm1Srf
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal B cell physiology
|
J:110686
|
abnormal lymphocyte physiology
|
J:110686
|
abnormal T cell physiology
|
J:110686
|
abnormal thymus involution
|
J:110686
|
Nfatc2tm1Srf/Nfatc2tm1Srf
(involves: 129P2/OlaHsd)
|
abnormal immune system physiology
|
J:45252
|
abnormal interleukin secretion
|
J:45252
|
abnormal T cell physiology
|
J:45252
|
Nfatc2tm1Srf/Nfatc2tm1Srf
(B6.Cg-Nfatc2tm1Srf)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:86279
|
abnormal T-helper 1 physiology
|
J:86279
|
abnormal T-helper 2 physiology
|
J:86279
|
decreased interferon-gamma secretion
|
J:86279
|
increased IgE level
|
J:86279
|
increased IgG1 level
|
J:86279
|
increased immunoglobulin level
|
J:86279
|
increased interleukin-4 secretion
|
J:86279
|
increased interleukin-5 secretion
|
J:86279
|
Nfatc2iptm1.1Glm/Nfatc2iptm1.1Glm
(either: B6.129-Nfatc2iptm1.1Glm or C.129-Nfatc2iptm1.1Glm)
|
abnormal interleukin secretion
|
J:157559
|
abnormal T-helper 2 physiology
|
J:157559
|
decreased circulating interleukin-4 level
|
J:157559
|
decreased interferon-gamma secretion
|
J:157559
|
decreased interleukin-3 secretion
|
J:157559
|
decreased interleukin-4 secretion
|
J:157559
|
decreased interleukin-5 secretion
|
J:157559
|
decreased interleukin-13 secretion
|
J:157559
|
increased susceptibility to parasitic infection
|
J:157559
|
Nfatc3tm1Grc/Nfatc3tm1Grc Tg(Lck-cre)I57Jxm/0
(involves: ICR)
|
increased T cell apoptosis
|
J:141917
|
Nfe2tm1Sho/Nfe2+
(C.129S4-Nfe2tm1Sho)
|
increased susceptibility to Retroviridae infection
|
J:125982
|
Nfe2l1tm1Jefc/Nfe2l1tm1Ywk Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129X1/SvJ * C57BL/6J)
|
liver inflammation
|
J:97188
|
Nfe2l2tm1.1Sred/Nfe2l2tm1.1Sred Tg(Scgb1a1-cre)1Grau/0
(involves: C57BL/6 * C57BL/6J)
|
decreased interleukin-1 beta secretion
|
J:191916
|
decreased tumor necrosis factor secretion
|
J:191916
|
Nfe2l2tm1Mym/Nfe2l2tm1Mym
(involves: 129P2/OlaHsd * ICR)
|
abnormal macrophage physiology
|
J:118068
|
glomerulonephritis
|
J:104016
|
increased anti-double stranded DNA antibody level
|
J:104016
|
increased anti-nuclear antigen antibody level
|
J:104016
|
increased IgG level
|
J:104016
|
increased IgM level
|
J:104016
|
lung inflammation
|
J:118068
|
Nfe2l2tm1Mym/Nfe2l2tm1Mym
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased susceptibility to induced colitis
|
J:116676
|
Nfe2l2tm1Mym/Nfe2l2tm1Mym
(involves: 129P2/OlaHsd * CD-1)
|
increased acute inflammation
|
J:122813
|
Nfe2l2tm1Mym/Nfe2l2tm1Mym
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal leukocyte adhesion
|
J:150597
|
increased circulating interleukin-6 level
|
J:136120
|
increased circulating tumor necrosis factor level
|
J:136120
|
increased susceptibility to experimental autoimmune uveoretinitis
|
J:150597
|
liver inflammation
|
J:136120
|
Nfe2l2tm1Ywk/Nfe2l2tm1Ywk
(involves: 129X1/SvJ)
|
abnormal spleen physiology
|
J:91407
|
abnormal splenocyte physiology
|
J:91407
|
decreased circulating interleukin-1 beta level
|
J:100106
|
increased circulating interleukin-1 beta level
|
J:100106
|
increased splenocyte apoptosis
|
J:91407
|
Nfe2l2tm1Ywk/Nfe2l2tm1Ywk
(B6.129X1-Nfe2l2tm1Ywk/J)
|
abnormal neutrophil physiology
|
J:233699
|
Nfe2l2tm1Ywk/Nfe2l2tm1Ywk
(B6.129X1-Nfe2l2tm1Ywk)
|
increased anti-double stranded DNA antibody level
|
J:165602
|
Nfil3tm1.1Brad/Nfil3tm1.1Brad
(B6.Cg-Nfil3tm1.1Brad)
|
decreased interferon-gamma secretion
|
J:152774
|
impaired natural killer cell mediated cytotoxicity
|
J:152774
|
Nfil3tm1.1Kubo/Nfil3tm1.1Kubo
(B6.Cg-Nfil3tm1.1Kubo)
|
abnormal interleukin secretion
|
J:184570
|
decreased interleukin-9 secretion
|
J:184570
|
decreased interleukin-10 secretion
|
J:172134,
J:184570
|
decreased interleukin-13 secretion
|
J:172134,
J:184570
|
decreased interleukin-17 secretion
|
J:184570
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:172134
|
increased susceptibility to induced colitis
|
J:172134
|
Nfil3tm1Look/Nfil3tm1Look
(B6.129X1-Nfil3tm1Look)
|
decreased interferon-gamma secretion
|
J:155677
|
impaired natural killer cell mediated cytotoxicity
|
J:155677
|
Nfil3tm1Pbro/Nfil3tm1Pbro
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal class switch recombination
|
J:156521
|
decreased IgE level
|
J:156521
|
decreased IgG1 level
|
J:156521
|
decreased interleukin-4 secretion
|
J:156521
|
Nfil3tm1Pbro/Nfil3tm1Pbro
(B6.129S6-Nfil3tm1Pbro)
|
abnormal circulating cytokine level
|
J:209365
|
abnormal cytokine secretion
|
J:209365
|
colitis
|
J:209365
|
increased circulating interferon-gamma level
|
J:209365
|
increased circulating interleukin-10 level
|
J:209365
|
increased circulating interleukin-12b level
|
J:209365
|
increased circulating interleukin-17 level
|
J:209365
|
increased circulating tumor necrosis factor level
|
J:209365
|
increased interferon-gamma secretion
|
J:209365
|
increased interleukin-10 secretion
|
J:209365
|
increased interleukin-12b secretion
|
J:209365
|
increased interleukin-17 secretion
|
J:209365
|
increased macrophage cytokine production
|
J:209365
|
increased tumor necrosis factor secretion
|
J:209365
|
Nfkb1M1Btlr/Nfkb1+
(C57BL/6J-Nfkb1M1Btlr)
|
decreased IgG level
|
J:216054
|
impaired humoral immune response
|
J:216054
|
Nfkb1M1Btlr/Nfkb1M1Btlr
(C57BL/6J-Nfkb1M1Btlr)
|
decreased IgG level
|
J:216054
|
impaired humoral immune response
|
J:216054
|
Nfkb1m2Btlr/Nfkb1+
(C57BL/6J-Nfkb1m2Btlr)
|
abnormal humoral immune response
|
J:254822
|
decreased IgM level
|
J:254822
|
Nfkb1m2Btlr/Nfkb1m2Btlr
(C57BL/6J-Nfkb1m2Btlr)
|
abnormal humoral immune response
|
J:254822
|
decreased IgE level
|
J:254822
|
decreased IgG level
|
J:254822
|
decreased IgM level
|
J:254822
|
Nfkb1M3Btlr/Nfkb1+
(C57BL/6J-Nfkb1M3Btlr)
|
abnormal humoral immune response
|
J:254821
|
decreased IgE level
|
J:254821
|
decreased IgG level
|
J:254821
|
Nfkb1M3Btlr/Nfkb1M3Btlr
(C57BL/6J-Nfkb1M3Btlr)
|
abnormal humoral immune response
|
J:254821
|
decreased IgE level
|
J:254821
|
decreased IgG level
|
J:254821
|
increased susceptibility to induced colitis
|
J:254821
|
Nfkb1M5Btlr/Nfkb1M5Btlr
(C57BL/6J-Nfkb1M5Btlr)
|
decreased IgE level
|
J:272117
|
decreased interleukin-1 beta secretion
|
J:272117
|
Nfkb1M6Btlr/Nfkb1M6Btlr
(C57BL/6J-Nfkb1M6Btlr)
|
decreased IgE level
|
J:272148
|
Nfkb1tm1a(KOMP)Wtsi/Nfkb1tm1a(KOMP)Wtsi
(involves: C57BL/6 * C57BL/6N)
|
decreased IgA level
|
J:213427
|
decreased IgG1 level
|
J:213427
|
increased susceptibility to bacterial infection
|
J:213427
|
Nfkb1tm1Bal/Nfkb1tm1Bal
(B6;129P-Nfkb1tm1Bal/J)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:118907
|
abnormal cytokine secretion
|
J:79107
|
abnormal dendritic cell physiology
|
J:118907
|
abnormal macrophage physiology
|
J:118907
|
abnormal professional antigen presenting cell physiology
|
J:118907
|
decreased susceptibility to autoimmune diabetes
|
J:118907
|
Nfkb1tm1Bal/Nfkb1tm1Bal
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal class switch recombination
|
J:30268
|
abnormal humoral immune response
|
J:37184
|
cecum inflammation
|
J:67107
|
decreased B cell proliferation
|
J:37184,
J:30268
|
decreased IgA level
|
J:37184
|
decreased IgE level
|
J:37184
|
decreased IgG1 level
|
J:37184
|
decreased IgM level
|
J:30268
|
decreased immunoglobulin level
|
J:37184
|
decreased interleukin-6 secretion
|
J:37184
|
decreased susceptibility to Picornaviridae infection induced morbidity/mortality
|
J:37184
|
increased susceptibility to bacterial infection
|
J:37184,
J:67107
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:37184
|
large intestinal inflammation
|
J:67107
|
peritoneal inflammation
|
J:67107
|
Nfkb1tm1Bal/Nfkb1tm1Bal
(B6.Cg-Nfkb1tm1Bal/J)
|
abnormal B cell physiology
|
J:113556
|
Nfkb1tm1Bal/Nfkb1tm1Bal Nfkb2tm1Sbn/Nfkb2tm1Sbn
(involves: 129P2/OlaHsd * 129S4/SvJae)
|
abnormal macrophage physiology
|
J:45119
|
Nfkb1tm1Bal/Nfkb1tm1Bal Reltm1Grd/Reltm1Grd
(involves: 129P2/OlaHsd * 129S1/Sv)
|
abnormal immune system physiology
|
J:113514
|
decreased interleukin-12 secretion
|
J:113514
|
Nfkb1tm1Bal/Nfkb1tm1Bal Relatm1Bal/Rela+
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
cecum inflammation
|
J:67107
|
increased susceptibility to bacterial infection
|
J:67107
|
large intestinal inflammation
|
J:67107
|
peritoneal inflammation
|
J:67107
|
Nfkb1tm1Bal/Nfkb1tm1Bal Tg(Tnfsf13b)1Fma/?
(B6.Cg-Nfkb1tm1Bal Tg(Tnfsf13b)1Fma)
|
abnormal B cell activation
|
J:113556
|
abnormal class switch recombination
|
J:113556
|
Nfkb1tm1Brv/Nfkb1tm1Brv
(involves: 129S1/Sv)
|
abnormal cytokine secretion
|
J:46912
|
abnormal humoral immune response
|
J:46912
|
abnormal inflammatory response
|
J:46912
|
abnormal lymphocyte physiology
|
J:46912
|
decreased IgG3 level
|
J:46912
|
decreased interleukin-2 secretion
|
J:46912
|
decreased interleukin-4 secretion
|
J:46912
|
decreased T cell proliferation
|
J:46912
|
decreased tumor necrosis factor secretion
|
J:46912
|
increased B cell proliferation
|
J:46912
|
increased IgE level
|
J:46912
|
increased IgG1 level
|
J:46912
|
increased immunoglobulin level
|
J:46912
|
increased susceptibility to bacterial infection
|
J:46912
|
liver inflammation
|
J:46912
|
lung inflammation
|
J:46912
|
Nfkb1tm1Brv/Nfkb1tm1Brv Nfkb2tm1Brv/Nfkb2tm1Brv
(involves: 129S1/Sv * C57BL/6)
|
abnormal cytokine secretion
|
J:44112
|
decreased interleukin-6 secretion
|
J:44112
|
Nfkb1tm1Sley/Nfkb1tm1Sley
(involves: 129S4/SvJae * 129S8/SvEv)
|
decreased circulating interleukin-2 level
|
J:142340
|
decreased T cell proliferation
|
J:142340
|
Nfkb1tm1Sley/Nfkb1tm1Sley
(involves: 129S4/SvJae)
|
decreased tumor necrosis factor secretion
|
J:196528
|
Nfkb2Lym1/Nfkb2+
(BALB/c-Nfkb2Lym1)
|
liver inflammation
|
J:154812
|
lung inflammation
|
J:154812
|
Nfkb2Lym1/Nfkb2Lym1
(involves: BALB/c)
|
abnormal class switch recombination
|
J:154812
|
abnormal thymus physiology
|
J:154812
|
autoimmune response
|
J:154812
|
decreased B cell proliferation
|
J:154812
|
decreased IgA level
|
J:154812
|
decreased IgG1 level
|
J:154812
|
decreased IgG2b level
|
J:154812
|
decreased IgM level
|
J:154812
|
decreased immunoglobulin level
|
J:154812
|
liver inflammation
|
J:154812
|
lung inflammation
|
J:154812
|
Nfkb2tm1Brv/Nfkb2tm1Brv
(involves: 129S1/Sv * C57BL/6)
|
abnormal cytokine secretion
|
J:43469
|
increased B cell proliferation
|
J:43469
|
increased interleukin-2 secretion
|
J:43469
|
increased interleukin-4 secretion
|
J:43469
|
increased interleukin-10 secretion
|
J:43469
|
increased T cell proliferation
|
J:43469
|
increased tumor necrosis factor secretion
|
J:43469
|
Nfkb2tm1Sbn/Nfkb2tm1Sbn
(involves: 129S4/SvJae * C57BL/6)
|
abnormal class switch recombination
|
J:45437
|
abnormal immunoglobulin level
|
J:45437
|
decreased IgA level
|
J:45437
|
decreased IgG1 level
|
J:45437
|
decreased IgG2a level
|
J:45437
|
decreased IgG2b level
|
J:45437
|
increased IgM level
|
J:45437
|
increased susceptibility to parasitic infection
|
J:45437
|
Nfkb2tm2Brv/Nfkb2tm2Brv
(involves: 129S1/Sv * C57BL/6)
|
decreased B cell proliferation
|
J:76380
|
decreased IgA level
|
J:76380
|
decreased IgG1 level
|
J:76380
|
decreased IgG3 level
|
J:76380
|
increased IgG2a level
|
J:76380
|
increased IgM level
|
J:76380
|
increased splenocyte apoptosis
|
J:76380
|
Nfkb2tm2Brv/Nfkb2tm2Brv Tg(Tnfsf13b)1Fma/?
(B6.Cg-Nfkb2tm2Brv Tg(Tnfsf13b)1Fma)
|
abnormal B cell activation
|
J:113556
|
Nfkbiatm1.1Pjc/Nfkbiatm1.1Pjc
(involves: C57BL/6)
|
abnormal circulating cytokine level
|
J:163686
|
abnormal T cell activation
|
J:163686
|
autoimmune response
|
J:163686
|
chronic inflammation
|
J:163686
|
increased anti-insulin autoantibody level
|
J:163686
|
increased anti-nuclear antigen antibody level
|
J:163686
|
increased circulating interleukin-1 alpha level
|
J:163686
|
increased circulating interleukin-17 level
|
J:163686
|
increased circulating tumor necrosis factor level
|
J:163686
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:163686
|
increased T cell apoptosis
|
J:163686
|
increased T cell proliferation
|
J:163686
|
Nfkbiatm1.1Smiy/Nfkbiatm1.1Smiy
(B6.129-Nfkbiatm1.1Smiy)
|
decreased B cell proliferation
|
J:168977
|
decreased IgA level
|
J:168977
|
decreased IgG1 level
|
J:168977
|
decreased IgG2b level
|
J:168977
|
increased activation-induced B cell apoptosis
|
J:168977
|
Nfkbiatm1Bal/Nfkbiatm1Bal Nfkbietm1Syme/Nfkbietm1Syme
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2)
|
increased B cell apoptosis
|
J:88142
|
increased T cell apoptosis
|
J:88142
|
Nfkbiatm1Fey/Nfkbiatm1Fey
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal humoral immune response
|
J:110817
|
decreased T cell proliferation
|
J:110817
|
increased B cell proliferation
|
J:110817
|
increased IgA level
|
J:110817
|
increased IgE level
|
J:110817
|
increased IgG level
|
J:110817
|
Nfkbiatm1Stw/Nfkbiatm1Stw
(involves: 129S1/Sv)
|
abnormal macrophage physiology
|
J:32527
|
abnormal tumor necrosis factor level
|
J:32527
|
dermatitis
|
J:32527
|
Nfkbibtm1.2Rsch/Nfkbibtm1.2Rsch
(B6.129P2-Nfkbibtm1.2Rsch)
|
abnormal cytokine secretion
|
J:176877
|
abnormal immune system physiology
|
J:176877
|
abnormal interleukin-1 beta secretion
|
J:176877
|
abnormal interleukin-6 secretion
|
J:176877
|
abnormal tumor necrosis factor secretion
|
J:176877
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:176877
|
Nfkbibtm1Bal/Nfkbibtm1Bal
(B6.129S1-Nfkbibtm1Bal)
|
decreased circulating interleukin-1 beta level
|
J:163302
|
decreased circulating interleukin-6 level
|
J:163302
|
decreased circulating tumor necrosis factor level
|
J:163302
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:163302
|
decreased susceptibility to endotoxin shock
|
J:163302
|
decreased susceptibility to induced arthritis
|
J:163302
|
decreased tumor necrosis factor secretion
|
J:163302
|
Nfkbidm1Btlr/Nfkbidm1Btlr
(involves: C57BL/6J)
|
abnormal class switch recombination
|
J:185495
|
decreased B cell proliferation
|
J:185495
|
decreased IgG1 level
|
J:185495
|
decreased IgG3 level
|
J:185495
|
decreased IgG level
|
J:185495
|
decreased IgM level
|
J:185495
|
increased B cell apoptosis
|
J:185495
|
Nfkbidtm1a(EUCOMM)Wtsi/Nfkbidtm1a(EUCOMM)Wtsi
(involves: C57BL/6N)
|
abnormal class switch recombination
|
J:185495
|
decreased IgG level
|
J:185495
|
decreased IgM level
|
J:185495
|
Nfkbidtm1Clay/Nfkbidtm1Clay
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal NK cell physiology
|
J:132071
|
abnormal thymocyte activation
|
J:132071
|
decreased interferon-gamma secretion
|
J:132071
|
decreased interleukin-2 secretion
|
J:132071
|
decreased T cell proliferation
|
J:132071
|
Nfkbidtm1Ktak/Nfkbidtm1Ktak
(involves: 129P2/OlaHsd * C57BL/6)
|
increased interferon-gamma secretion
|
J:113334
|
increased interleukin-6 secretion
|
J:113334
|
increased interleukin-12 secretion
|
J:113334
|
increased interleukin-12b secretion
|
J:113334
|
increased susceptibility to endotoxin shock
|
J:113334
|
increased susceptibility to induced colitis
|
J:113334
|
Nfkbietm1Syme/Nfkbietm1Syme
(either: (involves: 129P2/OlaHsd * C57BL/6 * DBA/2) or (involves: 129P2/OlaHsd * C57BL/6))
|
increased IgG1 level
|
J:88538
|
increased IgM level
|
J:88538
|
Nfkbiztm1.1Muta/Nfkbiztm1.1Muta Tg(CAG-cre)13Miya/?
(involves: C57BL/6)
|
dermatitis
|
J:194832
|
Nfkbiztm1.1Muta/Nfkbiztm1.1Muta Tg(KRT5-cre)1Tak/?
(involves: C3H * C57BL/6)
|
dermatitis
|
J:194832
|
Nfkbiztm1Aki/Nfkbiz+ Stat6tm1Aki/Stat6tm1Aki
(C.129P2-Stat6tm1Aki Nfkbiztm1Aki)
|
skin inflammation
|
J:141704
|
Nfkbiztm1Aki/Nfkbiztm1Aki
(involves: 129P2/OlaHsd)
|
abnormal cytokine secretion
|
J:91297
|
abnormal immune system physiology
|
J:194832
|
abnormal leukocyte physiology
|
J:91297
|
abnormal tumor necrosis factor secretion
|
J:91297
|
blepharitis
|
J:96363
|
conjunctivitis
|
J:96363
|
corneal limbitis
|
J:96363
|
decreased interleukin-6 secretion
|
J:91297
|
decreased interleukin-12 secretion
|
J:91297
|
dermatitis
|
J:194832,
J:91297
|
eye inflammation
|
J:96363
|
increased immunoglobulin level
|
J:194832
|
interstitial pneumonia
|
J:194832
|
lacrimal gland inflammation
|
J:194832
|
periocular dermatitis
|
J:194832
|
Nfkbiztm1Aki/Nfkbiztm1Aki
(C.129P2-Nfkbiztm1Aki)
|
blepharitis
|
J:141704
|
conjunctivitis
|
J:141704
|
dermatitis
|
J:141704
|
eye inflammation
|
J:141704
|
increased IgE level
|
J:141704
|
perioral dermatitis
|
J:141704
|
skin inflammation
|
J:141704
|
Nfkbiztm1Aki/Nfkbiztm1Aki Stat6tm1Aki/Stat6tm1Aki
(C.129P2-Stat6tm1Aki Nfkbiztm1Aki)
|
blepharitis
|
J:141704
|
dermatitis
|
J:141704
|
eye inflammation
|
J:141704
|
skin inflammation
|
J:141704
|
Nfkbiztm1Aki/Nfkbiztm1Aki Tnftm1Sek/Tnftm1Sek
(involves: 129P2/OlaHsd * C57BL/6NCrlj * CBA/JNCrlj)
|
conjunctivitis
|
J:194832
|
dermatitis
|
J:194832
|
Nfkbiztm1Mamo/Nfkbiztm1Mamo
(involves: 129S7/SvEvBrd)
|
dermatitis
|
J:95040
|
increased IgE level
|
J:95040
|
Ngfrtm1Jae/Ngfrtm1Jae
(B6.129S4-Ngfrtm1Jae)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:112769
|
Ngfrtm1Jae/Ngfrtm1Jae
(involves: 129S4/SvJae)
|
abnormal tumor necrosis factor level
|
J:157549
|
Nhej1tm1.1Ics/Nhej1tm1.1Ics
(involves: 129 * C57BL/6)
|
increased thymocyte apoptosis
|
J:194422
|
Nhej1tm1.1Ics/Nhej1tm1.1Ics Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6)
|
decreased thymocyte apoptosis
|
J:194422
|
Nhej1tm1Fwa/Nhej1tm1Fwa
(involves: 129)
|
abnormal class switch recombination
|
J:138774
|
decreased IgG1 level
|
J:138774
|
decreased IgG3 level
|
J:138774
|
increased IgM level
|
J:138774
|
Niban3tm1Jyw/Niban3tm1Jyw
(B6.Cg-Niban3tm1Jyw)
|
abnormal B cell calcium ion homeostasis
|
J:282961
|
abnormal class switch recombination
|
J:282961
|
decreased IgA level
|
J:282961
|
decreased IgG2c level
|
J:282961
|
enhanced humoral immune response
|
J:282961
|
increased B cell proliferation
|
J:282961
|
increased IgG1 level
|
J:282961
|
increased IgG3 level
|
J:282961
|
increased IgG level
|
J:282961
|
increased IgM level
|
J:282961
|
Nid2Gt(GST011)Byg/Nid2Gt(GST011)Byg
(involves: 129P2/OlaHsd)
|
osteoarthritis
|
J:229684
|
Ninj1tm1Gto/Ninj1+
(B6.129P2-Ninj1tm1Gto)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:209516
|
Ninj1tm1Gto/Ninj1tm1Gto
(B6.129P2-Ninj1tm1Gto)
|
abnormal leukocyte adhesion
|
J:209516
|
abnormal leukocyte physiology
|
J:209516
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:209516
|
impaired macrophage chemotaxis
|
J:209516
|
Ninj2em1Cqxu/Ninj2em1Cqxu
(C57BL/6-Ninj2em1Cqxu)
|
white adipose tissue inflammation
|
J:332575
|
Nipal3tm1Pbfd/Nipal3tm1Pbfd
(either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J))
|
decreased IgM level
|
J:152829
|
increased IgA level
|
J:152829
|
increased IgE level
|
J:152829
|
increased IgG2a level
|
J:152829
|
increased IgM level
|
J:152829
|
NipblGt(RRS564)Byg/Nipbl+
(involves: 129P2/OlaHsd * CD-1)
|
abnormal inflammatory response
|
J:154117
|
eye inflammation
|
J:154117
|
NipblGt(RRS564)Byg/Nipbl+
(involves: 129P2/OlaHsd * C57BL/6J * CD-1)
|
abnormal chemokine level
|
J:297059
|
Nischedsn/Nischedsn
(C3H.B6-Nischedsn)
|
increased susceptibility to otitis media
|
J:244907
|
Nischedsn/NischV33A
(involves: BALB/c * C3H/HeH * C57BL/6J)
|
increased susceptibility to otitis media
|
J:244907
|
NischV33A/NischV33A
(involves: BALB/c * C57BL/6J)
|
increased susceptibility to otitis media
|
J:244907
|
Nkg7tm1.1(KOMP)Vlcg/Nkg7tm1.1(KOMP)Vlcg
(involves: C57BL/6NTac)
|
decreased circulating interferon-gamma level
|
J:301637
|
decreased circulating tumor necrosis factor level
|
J:301637
|
decreased susceptibility to parasitic infection induced morbidity/mortality
|
J:301637
|
increased susceptibility to parasitic infection induced morbidity/mortality
|
J:301637
|
Nkx2-3tm1Hha/Nkx2-3tm1Hha
(involves: 129S4/SvJae)
|
abnormal leukocyte migration
|
J:62129
|
Nkx2-3tm1Rph/Nkx2-3tm1Rph
(involves: 129S1/Sv * C57BL/6)
|
abnormal leukocyte migration
|
J:64018
|
Nlrc3tm1Bhk/Nlrc3tm1Bhk
(B6.129S6-Nlrc3tm1Bhk)
|
increased circulating interleukin-6 level
|
J:187586
|
increased circulating tumor necrosis factor level
|
J:187586
|
increased susceptibility to endotoxin shock
|
J:187586
|
increased tumor necrosis factor secretion
|
J:187586
|
Nlrc4em1Vnce/Nlrc4em1Vnce
(C57BL/6-Nlrc4em1Vnce)
|
decreased inflammatory response
|
J:294930
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:294930
|
Nlrc4em1Vnce/Nlrc4em1Vnce Nlrp3tm1Vmd/Nlrp3tm1Vmd
(involves: C57BL/6J * C57BL/6N)
|
decreased inflammatory response
|
J:294930
|
Nlrc4em2Vnce/Nlrc4em2Vnce
(C57BL/6-Nlrc4em2Vnce)
|
decreased inflammatory response
|
J:294930
|
Nlrc4em2Vnce/Nlrc4em2Vnce Nlrp3tm1Vmd/Nlrp3tm1Vmd
(involves: C57BL/6J * C57BL/6N)
|
decreased inflammatory response
|
J:294930
|
Nlrc4m1Btlr/Nlrc4+
(C57BL/6J-Nlrc4m1Btlr)
|
decreased interleukin-1 beta secretion
|
J:225933
|
Nlrc4m1Btlr/Nlrc4m1Btlr
(C57BL/6J-Nlrc4m1Btlr)
|
decreased interleukin-1 beta secretion
|
J:225933
|
Nlrc4tm1Gln/Nlrc4tm1Gln Slc11a1s/Slc11a1s
(B6.129S5-Nlrc4tm1Gln)
|
increased susceptibility to bacterial infection
|
J:124378
|
Nlrc4tm1Nnz/Nlrc4tm1Nnz
(involves: 129 * C57BL/6J)
|
abnormal macrophage physiology
|
J:112671,
J:117251
|
increased susceptibility to bacterial infection
|
J:117251
|
Nlrc4tm1Vmd/Nlrc4tm1Vmd
(C57BL/6N-Nlrc4tm1Vmd)
|
decreased interleukin-1 beta secretion
|
J:91292
|
Nlrc4tm1Vmd/Nlrc4tm1Vmd
(involves: C57BL/6N)
|
abnormal cytokine secretion
|
J:106976
|
abnormal response to infection
|
J:106976
|
Nlrc4tm1Vmd/Nlrc4tm1Vmd Nlrp3tm1Vmd/Nlrp3tm1Vmd
(C57BL/6-Nlrp3tm1Vmd Nlrc4tm1Vmd)
|
decreased interleukin-1 beta secretion
|
J:160545
|
Nlrc5tm1.1Ggaur/Nlrc5tm1.1Ggaur
(involves: BALB/cJ)
|
abnormal T cell physiology
|
J:184076
|
Nlrc5tm1Itl/Nlrc5tm1Itl
(C57BL/6-Nlrc5tm1Itl)
|
decreased interferon-beta secretion
|
J:188857
|
decreased interleukin-6 secretion
|
J:188857
|
Nlrp1am1Btlr/Nlrp1am1Btlr
(C57BL/6J-Nlrp1am1Btlr)
|
increased IgE level
|
J:265173
|
increased macrophage apoptosis
|
J:265173
|
increased tumor necrosis factor secretion
|
J:265173
|
Nlrp1am2Btlr/Nlrp1am2Btlr
(C57BL/6J-Nlrp1am2Btlr)
|
decreased interleukin-1 beta secretion
|
J:265174
|
increased macrophage apoptosis
|
J:265174
|
Nlrp1aNeut1/Nlrp1a+
(C.B6-Nlrp1aNeut1)
|
increased inflammatory response
|
J:191055
|
liver inflammation
|
J:191055
|
lung inflammation
|
J:191055
|
meningitis
|
J:191055
|
myocarditis
|
J:191055
|
pancreas inflammation
|
J:191055
|
Nlrp1aNeut1/Nlrp1aNeut1
(C.B6-Nlrp1aNeut1)
|
increased inflammatory response
|
J:191055
|
increased macrophage cytokine production
|
J:191055
|
liver inflammation
|
J:191055
|
lung inflammation
|
J:191055
|
meningitis
|
J:191055
|
myocarditis
|
J:191055
|
pancreas inflammation
|
J:191055
|
Nlrp1aNeut1/Nlrp1aNeut1 Pycardtm1Vmd/Pycardtm1Vmd
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal inflammatory response
|
J:191055
|
Nlrp1btm1Bhk/Nlrp1btm1Bhk
(129S6/SvEvTac-Nlrp1btm1Bhk)
|
abnormal macrophage physiology
|
J:189777
|
decreased interleukin-1 alpha secretion
|
J:189777
|
decreased interleukin-1 beta secretion
|
J:189777
|
Nlrp3m1Btlr/Nlrp3m1Btlr
(C57BL/6J-Nlrp3m1Btlr)
|
decreased interleukin-1 beta secretion
|
J:159357
|
Nlrp3m2Btlr/?
(C57BL/6J-Nlrp3m2Btlr)
|
abnormal interleukin-1 beta secretion
|
J:164865
|
Nlrp3m3Btlr/?
(C57BL/6J-Nlrp3m3Btlr)
|
abnormal interleukin-1 beta secretion
|
J:164866
|
Nlrp3m4Btlr/Nlrp3m4Btlr
(involves: C57BL/6J)
|
decreased interleukin-1 beta secretion
|
J:171739
|
Nlrp3m5Btlr/Nlrp3+
(C57BL/6J-Nlrp3m5Btlr)
|
decreased interleukin-1 beta secretion
|
J:192651
|
Nlrp3m5Btlr/Nlrp3m5Btlr
(C57BL/6J-Nlrp3m5Btlr)
|
decreased interleukin-1 beta secretion
|
J:192651
|
Nlrp3M6Btlr/Nlrp3+
(C57BL/6J-Nlrp3M6Btlr)
|
decreased interleukin-1 beta secretion
|
J:216047
|
Nlrp3M6Btlr/Nlrp3M6Btlr
(C57BL/6J-Nlrp3M6Btlr)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:226677
|
Nlrp3M7Btlr/Nlrp3+
(C57BL/6J-Nlrp3M7Btlr)
|
abnormal macrophage cytokine production
|
J:216048
|
decreased interleukin-1 beta secretion
|
J:216048
|
Nlrp3M7Btlr/Nlrp3M7Btlr
(C57BL/6J-Nlrp3M7Btlr)
|
abnormal macrophage cytokine production
|
J:216048
|
decreased interleukin-1 beta secretion
|
J:216048
|
Nlrp3M8Btlr/Nlrp3+
(C57BL/6J-Nlrp3M8Btlr)
|
decreased interleukin-1 beta secretion
|
J:217294
|
Nlrp3M8Btlr/Nlrp3M8Btlr
(C57BL/6J-Nlrp3M8Btlr)
|
decreased interleukin-1 beta secretion
|
J:217294
|
Nlrp3M9Btlr/Nlrp3+
(C57BL/6J-Nlrp3M9Btlr)
|
decreased interleukin-1 beta secretion
|
J:220071
|
Nlrp3M9Btlr/Nlrp3M9Btlr
(C57BL/6J-Nlrp3M9Btlr)
|
decreased interleukin-1 beta secretion
|
J:220071
|
Nlrp3M10Btlr/Nlrp3+
(C57BL/6J-Nlrp3M10Btlr)
|
decreased interleukin-1 beta secretion
|
J:234254
|
Nlrp3M10Btlr/Nlrp3M10Btlr
(C57BL/6J-Nlrp3M10Btlr)
|
decreased interleukin-1 beta secretion
|
J:234254
|
Nlrp3M11Btlr/Nlrp3M11Btlr
(C57BL/6J-Nlrp3M11Btlr)
|
decreased interleukin-1 beta secretion
|
J:255211
|
Nlrp3m12Btlr/Nlrp3m12Btlr
(C57BL/6J-Nlrp3m12Btlr)
|
decreased interleukin-1 beta secretion
|
J:272150
|
Nlrp3tm1Bhk/Nlrp3tm1Bhk
(involves: 129S6/SvEvTac)
|
decreased interleukin-1 beta secretion
|
J:189777
|
Nlrp3tm1Bhk/Nlrp3tm1Bhk
(B6.129S6-Nlrp3tm1Bhk/J)
|
decreased interleukin-1 beta secretion
|
J:253629
|
white adipose tissue inflammation
|
J:256504
|
Nlrp3tm1Flv/Nlrp3tm1Flv
(involves: 129S5/SvEvBrd * C57BL/6)
|
abnormal macrophage physiology
|
J:113333
|
decreased circulating interleukin-1 beta level
|
J:113333
|
decreased circulating interleukin-18 level
|
J:113333
|
decreased susceptibility to endotoxin shock
|
J:113333
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:113333
|
Nlrp3tm1Flv/Nlrp3tm1Flv
(B6.129S5-Nlrp3tm1Flv)
|
decreased interleukin-1 beta secretion
|
J:164725
|
Nlrp3tm1Flv/Nlrp3tm1Flv
(involves: 129S5/SvEvBrd)
|
decreased susceptibility to induced colitis
|
J:173245
|
Nlrp3tm1Flv/Nlrp3tm1Flv Slc11a1s/Slc11a1s
(B6.129S5-Nlrp3tm1Flv)
|
increased susceptibility to bacterial infection
|
J:124378
|
Nlrp3tm1Flv/Nlrp3tm1Hhf Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129 * C57BL/6)
|
increased inflammatory response
|
J:150054
|
Nlrp3tm1Hhf/Nlrp3+ Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6)
|
abnormal circulating chemokine level
|
J:150054
|
abnormal circulating cytokine level
|
J:150054
|
increased circulating interleukin-1 beta level
|
J:150054
|
increased circulating interleukin-6 level
|
J:150054
|
increased circulating interleukin-18 level
|
J:150054
|
increased circulating tumor necrosis factor level
|
J:150054
|
increased inflammatory response
|
J:150054
|
Nlrp3tm1Hhf/Nlrp3+ Tg(CAG-cre/Esr1*)5Amc/?
(involves: 129/Sv * C57BL/6 * CBA)
|
skin inflammation
|
J:150054
|
Nlrp3tm1Hhf/Nlrp3+ Tg(CAG-cre/Esr1*)5Amc/?
(involves: 129/Sv * C57BL/6 * CBA)
|
abnormal dendritic cell antigen presentation
|
J:150054
|
abnormal dendritic cell physiology
|
J:150054
|
abnormal macrophage physiology
|
J:150054
|
Nlrp3tm1Hhf/Nlrp3+ Tg(Zp3-cre)3Mrt/?
(involves: 129/Sv * FVB/N)
|
increased inflammatory response
|
J:150054
|
Nlrp3tm1Tsc/Nlrp3tm1Tsc
(C57BL/6-Nlrp3tm1Tsc)
|
decreased interleukin-1 beta secretion
|
J:124226
|
Nlrp3tm1Tsc/Nlrp3tm1Tsc
(involves: C57BL/6)
|
decreased interleukin-1 beta secretion
|
J:172117
|
Nlrp3tm1Vmd/Nlrp3tm1Vmd
(involves: C57BL/6N)
|
abnormal cytokine secretion
|
J:106976
|
abnormal response to infection
|
J:106976
|
decreased susceptibility to endotoxin shock
|
J:106976
|
Nlrp3tm1Vmd/Nlrp3tm1Vmd
(B6.B6N-Nlrp3tm1Vmd)
|
decreased circulating interleukin-1 beta level
|
J:193522
|
decreased circulating interleukin-18 level
|
J:193522
|
decreased interleukin-1 beta secretion
|
J:193522
|
decreased susceptibility to endotoxin shock
|
J:193522
|
Nlrp3tm1Wstr/Nlrp3+
(involves: C57BL/6)
|
abnormal dendritic cell physiology
|
J:150053
|
abnormal macrophage physiology
|
J:150053
|
chronic inflammation
|
J:150053
|
dermatitis
|
J:150053
|
increased anti-double stranded DNA antibody level
|
J:150053
|
increased interleukin-1 beta secretion
|
J:150053
|
increased interleukin-17 secretion
|
J:150053
|
increased interleukin-18 secretion
|
J:150053
|
increased susceptibility to type IV hypersensitivity reaction
|
J:150053
|
Nlrp3tm2Hhf/Nlrp3+ Tg(CAG-cre/Esr1*)5Amc/?
(involves: 129/Sv * C57BL/6 * CBA)
|
skin inflammation
|
J:150054
|
Nlrp3tm2Hhf/Nlrp3+ Tg(CAG-cre/Esr1*)5Amc/?
(involves: 129/Sv * C57BL/6 * CBA)
|
abnormal dendritic cell physiology
|
J:150054
|
abnormal macrophage physiology
|
J:150054
|
Nlrp3tm2Hhf/Nlrp3tm2Hhf Vsig4tm1Gne/Vsig4tm1Gne
(B6.Cg-Nlrp3tm2Hhf Vsig4tm1Gne)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:281762
|
Nlrp3tm3.1Hhf/Nlrp3+
(involves: 129)
|
abnormal circulating chemokine level
|
J:202147
|
decreased circulating interleukin-5 level
|
J:202147
|
decreased circulating interleukin-12b level
|
J:202147
|
increased circulating interleukin-1 beta level
|
J:202147
|
increased circulating interleukin-3 level
|
J:202147
|
increased circulating interleukin-4 level
|
J:202147
|
increased circulating interleukin-6 level
|
J:202147
|
increased circulating interleukin-9 level
|
J:202147
|
increased circulating interleukin-13 level
|
J:202147
|
increased circulating interleukin-18 level
|
J:202147
|
increased circulating tumor necrosis factor level
|
J:202147
|
increased inflammatory response
|
J:202147
|
increased interferon-gamma secretion
|
J:202147
|
increased interleukin-1 beta secretion
|
J:202147
|
joint inflammation
|
J:202147
|
meningitis
|
J:202147
|
osteomyelitis
|
J:202147
|
Nlrp6tm1Flv/Nlrp6tm1Flv
(B6.Cg-Nlrp6tm1Flv)
|
decreased circulating interleukin-18 level
|
J:173245
|
decreased interleukin-18 secretion
|
J:173245
|
increased IgA level
|
J:173245
|
increased IgG2c level
|
J:173245
|
increased susceptibility to induced colitis
|
J:173245
|
increased susceptibility to Riboviria infection induced morbidity/mortality
|
J:243487
|
Nlrp6tm1Macha/Nlrp6tm1Macha
(involves: 129S5/SvEvBrd * C57BL/6J)
|
increased susceptibility to induced colitis
|
J:173352
|
Nlrp9bem1Flv/Nlrp9bem1Flv
(C57BL/6N-Nlrp9bem1Flv)
|
increased susceptibility to Riboviria infection induced morbidity/mortality
|
J:243487
|
Nlrp10tm1Seis/Nlrp10tm1Seis
(B6.Cg-Nlrp10tm1Seis)
|
abnormal adaptive immunity
|
J:183989
|
abnormal dendritic cell physiology
|
J:183989
|
abnormal T-helper 2 physiology
|
J:183989
|
decreased IgG1 level
|
J:183989
|
decreased interferon-gamma secretion
|
J:183989
|
decreased interleukin-17 secretion
|
J:183989
|
decreased susceptibility to endotoxin shock
|
J:183989
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:183989
|
Nlrp12tm1Jpyt/Nlrp12tm1Jpyt
(B6.Cg-Nlrp12tm1Jpyt)
|
abnormal leukocyte migration
|
J:164725
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:164725
|
impaired neutrophil chemotaxis
|
J:164725
|
Nlrp12tm1Tdk/Nlrp12tm1Tdk
(B6.Cg-Nlrp12tm1Tdk)
|
abnormal chemokine level
|
J:178951
|
abnormal cytokine level
|
J:178951
|
increased inflammatory response
|
J:178951
|
increased susceptibility to induced colitis
|
J:178951
|
Nlrx1tm1Jpyt/Nlrx1tm1Jpyt
(involves: C57BL/6 * C57BL/6J)
|
abnormal macrophage physiology
|
J:173995
|
abnormal neutrophil physiology
|
J:173995
|
increased circulating interleukin-6 level
|
J:173995
|
increased interferon-beta secretion
|
J:173995
|
increased interleukin-1 beta secretion
|
J:173995
|
increased interleukin-6 secretion
|
J:173995
|
increased susceptibility to endotoxin shock
|
J:173995
|
increased susceptibility to Orthomyxoviridae infection
|
J:173995
|
Nme2Gt(69C10)Cmhd/Nme2Gt(69C10)Cmhd
(B6.129-Nme2Gt(69C10)Cmhd)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:167387
|
abnormal T-helper 1 physiology
|
J:167387
|
abnormal T-helper 2 physiology
|
J:167387
|
decreased interferon-gamma secretion
|
J:167387
|
decreased interleukin-2 secretion
|
J:167387
|
decreased interleukin-13 secretion
|
J:167387
|
decreased tumor necrosis factor secretion
|
J:167387
|
Nme5tm1Lex/Nme5tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
|
maxillary sinus inflammation
|
J:185566
|
nasal inflammation
|
J:185566
|
nmf370/nmf370
(C57BL/6J-nmf370/J)
|
ear inflammation
|
J:87349
|
nmf391/nmf391
(C57BL/6J-nmf391/J)
|
ear inflammation
|
J:87349
|
Nmiem1Hhl/Nmiem1Hhl
(C57BL/6-Nmiem1Hhl)
|
decreased circulating interleukin-6 level
|
J:298909
|
decreased circulating tumor necrosis factor level
|
J:298909
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:298909
|
decreased susceptibility to endotoxin shock
|
J:298909
|
Nmt1tm1.1Poru/Nmt1tm1.1Poru Nmt2tm1.1Poru/Nmt2tm1.1Poru Tg(Lck-cre)1Cwi/0
(involves: C57BL/6 * DBA/2 * SJL)
|
decreased circulating interferon-gamma level
|
J:226234
|
decreased circulating interleukin-2 level
|
J:226234
|
decreased circulating tumor necrosis factor level
|
J:226234
|
decreased interferon-gamma secretion
|
J:226234
|
decreased interleukin-2 secretion
|
J:226234
|
decreased splenocyte proliferation
|
J:226234
|
decreased susceptibility to endotoxin shock
|
J:226234
|
decreased T cell proliferation
|
J:226234
|
increased T cell apoptosis
|
J:226234
|
Nmutm1Sjab/Nmutm1Sjab
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased circulating interleukin-6 level
|
J:142907
|
Noa/Noa+
(NOA)
|
increased IgE level
|
J:43274
|
Noc2ltm1.1Arte/Noc2ltm1.1Arte Tg(CD2-icre)4Kio/0
(involves: C57BL/6 * C57BL/10 * CBA/Ca)
|
abnormal T cell proliferation
|
J:216490
|
abnormal thymus involution
|
J:216490
|
increased thymocyte apoptosis
|
J:216490
|
Nod1tm1Inoh/Nod1tm1Inoh
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal chemokine secretion
|
J:118808
|
abnormal cytokine secretion
|
J:118808
|
abnormal immune system physiology
|
J:118808
|
abnormal macrophage physiology
|
J:132126,
J:118808
|
decreased interleukin-6 secretion
|
J:132126
|
decreased tumor necrosis factor secretion
|
J:132126
|
Nod1tm1Inoh/Nod1tm1Inoh Nod2tm1Flv/Nod2tm1Flv
(involves: 129 * 129P2/OlaHsd * C57BL/6)
|
abnormal macrophage physiology
|
J:132126
|
decreased interleukin-6 secretion
|
J:132126
|
decreased tumor necrosis factor secretion
|
J:132126
|
increased susceptibility to bacterial infection
|
J:132126
|
Nod2tm1Daph/Nod2tm1Daph
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal macrophage physiology
|
J:157879
|
Nod2tm1Flv/Nod2tm1Flv
(involves: 129S1/Sv * C57BL/6)
|
abnormal macrophage physiology
|
J:132126,
J:96035
|
abnormal susceptibility to infection
|
J:96035
|
decreased IgG level
|
J:96035
|
decreased interleukin-6 secretion
|
J:132126
|
decreased susceptibility to endotoxin shock
|
J:96035
|
decreased tumor necrosis factor secretion
|
J:132126
|
Nod2tm1Flv/Nod2tm1Flv
(involves: 129S1/Sv)
|
abnormal response to infection
|
J:147177
|
abnormal T-helper 1 physiology
|
J:147177
|
impaired macrophage phagocytosis
|
J:147177
|
impaired neutrophil phagocytosis
|
J:147177
|
increased circulating interferon-gamma level
|
J:147177
|
increased circulating interleukin-2 level
|
J:147177
|
increased circulating tumor necrosis factor level
|
J:147177
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:147177
|
Nod2tm1Flv/Nod2tm1Flv
(C.129S1-Nod2tm1Flv)
|
decreased susceptibility to induced arthritis
|
J:178054
|
Nod2tm1Jhgt/Nod2tm1Jhgt
(B6.Cg-Nod2tm1Jhgt)
|
abnormal cytokine level
|
J:124575
|
abnormal immune system physiology
|
J:124575
|
abnormal interferon level
|
J:124575
|
abnormal interleukin level
|
J:124575
|
abnormal response to infection
|
J:124575
|
abnormal tumor necrosis factor level
|
J:124575
|
increased susceptibility to induced colitis
|
J:124575
|
Nod2tm1Mka/Nod2tm1Mka
(involves: C57BL/6)
|
abnormal cytokine level
|
J:96128
|
increased interleukin-1 beta secretion
|
J:96128
|
increased susceptibility to induced colitis
|
J:96128
|
Nod2tm1Pmu/Nod2tm1Pmu
(involves: BALB/c * C57BL/6)
|
abnormal macrophage physiology
|
J:86264
|
decreased susceptibility to endotoxin shock
|
J:86264
|
Nod2tm1Vmd/Nod2tm1Vmd
(B6.129-Nod2tm1Vmd)
|
abnormal cytokine secretion
|
J:106976
|
Nos1tm1Plh/Nos1tm1Plh
(involves: 129S4/SvJae)
|
abnormal leukocyte adhesion
|
J:55936
|
abnormal neutrophil physiology
|
J:55936
|
enhanced leukocyte tethering or rolling
|
J:55936
|
Nos1tm1Plh/Nos1tm1Plh
(B6.129S4-Nos1tm1Plh/J)
|
decreased inflammatory response
|
J:103018
|
Nos1tm1Plh/Nos1tm1Plh Nos2tm1Mrl/Nos2tm1Mrl Nos3tm1Plh/Nos3tm1Plh
(involves: 129S4/SvJae * 129S7/SvEvBrd)
|
abnormal osteoclast physiology
|
J:150159
|
Nos2tm1Lau/Nos2tm1Lau
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal adaptive immunity
|
J:90903
|
increased susceptibility to bacterial infection
|
J:100513
|
increased T cell proliferation
|
J:90903
|
skin inflammation
|
J:64036
|
Nos2tm1Lau/Nos2tm1Lau
(B6.129P2-Nos2tm1Lau)
|
decreased susceptibility to induced colitis
|
J:87601
|
Nos2tm1Lau/Nos2tm1Lau
(B6.129P2-Nos2tm1Lau/J)
|
abnormal inflammatory response
|
J:103018
|
decreased inflammatory response
|
J:103018
|
Nos2tm1Liew/Nos2tm1Liew
(involves: 129P2/Ola * MF1)
|
abnormal T-helper 1 physiology
|
J:25755
|
decreased inflammatory response
|
J:25755
|
decreased susceptibility to endotoxin shock
|
J:25755
|
increased interferon-gamma secretion
|
J:25755
|
increased susceptibility to parasitic infection
|
J:25755
|
increased T cell proliferation
|
J:25755
|
Nos2tm1Mrl/Nos2tm1Mrl
(involves: 129S7/SvEvBrd)
|
abnormal immune system physiology
|
J:51635
|
abnormal macrophage physiology
|
J:120499
|
decreased susceptibility to endotoxin shock
|
J:25511
|
increased IgG2a level
|
J:51635
|
increased inflammatory response
|
J:51635
|
increased interferon-gamma secretion
|
J:51635
|
increased susceptibility to bacterial infection
|
J:25511
|
Nos2tm1Mrl/Nos2tm1Mrl
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased length of allograft survival
|
J:54764
|
pancreas inflammation
|
J:65562
|
Nos2tm1Mrl/Nos2tm1Mrl
(B6.129S7-Nos2tm1Mrl)
|
abnormal response to infection
|
J:98070
|
Nos2tm1Mrl/Nos2tm1Mrl
(involves: 129S7/SvEvBrd * PL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:46192
|
Nos3m1Btlr/Nos3m1Btlr
(C57BL/6J-Nos3m1Btlr)
|
increased susceptibility to induced colitis
|
J:225268
|
Nos3M2Btlr/Nos3M2Btlr
(C57BL/6J-Nos3M2Btlr)
|
increased susceptibility to induced colitis
|
J:272392
|
Nos3tm1Plh/Nos3tm1Plh
(involves: 129S4/SvJae)
|
abnormal leukocyte adhesion
|
J:55936
|
abnormal neutrophil physiology
|
J:55936
|
enhanced leukocyte tethering or rolling
|
J:55936
|
Nos3tm1Plh/Nos3tm1Plh
(involves: 129S4/SvJae * C57BL/6)
|
increased susceptibility to bacterial infection
|
J:105005
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:105005
|
Nos3tm1Unc/Nos3tm1Unc
(B6.129P2-Nos3tm1Unc/J)
|
abnormal osteoclast physiology
|
J:129477
|
increased inflammatory response
|
J:103018
|
kidney inflammation
|
J:148626
|
Notch1tm1Agt/Notch1tm1Agt Notch2tm3Grid/Notch2tm3Grid Tg(TcrAND)53Hed/?
(involves: 129/Sv * 129S1/Sv * C57BL/6 * SJL)
|
abnormal humoral immune response
|
J:123631
|
abnormal response to infection
|
J:123631
|
decreased interleukin-4 secretion
|
J:123631
|
Notch1tm1Con/Notch1+
(involves: 129S1/Sv * 129X1/SvJ * CD-1)
|
aortic valve inflammation
|
J:187551
|
Notch1tm2Pst/Notch1tm2Pst
(B6.Cg-Notch1tm2Pst)
|
increased T cell apoptosis
|
J:131563
|
Notch1tm2Rko/Notch1tm3(cre)Rko
(involves: 129X1/SvJ * C57BL/6)
|
chronic liver inflammation
|
J:171829
|
Notch2tm1.1Hhi/Notch2tm1.1Hhi Tg(Cd8a-cre)1Itan/0
(involves: C57BL/6 * CBA)
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:141009
|
abnormal cytotoxic T cell physiology
|
J:141009
|
increased susceptibility to parasitic infection
|
J:141009
|
Notch2tm1.1Hhtg/Notch2+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
|
abnormal interleukin level
|
J:311038
|
increased circulating interleukin-6 level
|
J:311038
|
increased interleukin-6 secretion
|
J:311038
|
NotumGt(OST172035)Lex/NotumGt(OST172035)Lex
(involves: 129S5/SvEvBrd * C57BL/6)
|
chronic inflammation
|
J:274615
|
periodontium inflammation
|
J:266040
|
Nox1tm1.1Anrt/Nox1tm1.1Anrt Tg(Vil1-cre)997Gum/0
(involves: C57BL/6J * SJL)
|
colitis
|
J:194294
|
Nox1tm1Cyn/Y
(involves: 129S1/Sv * 129X1/SvJ)
|
abnormal cytokine secretion
|
J:218649
|
Nox4tm1Syb/Nox4tm1Syb
(involves: 129S4/SvJae)
|
decreased interleukin-1 beta secretion
|
J:298830
|
decreased susceptibility to endotoxin shock
|
J:298830
|
decreased tumor necrosis factor secretion
|
J:298830
|
Npas3tm1Mesu/Npas3tm1Mesu
(B6.129S6-Npas3tm1Mesu)
|
bronchiectasis
|
J:150793
|
Npattm1b(EUCOMM)Wtsi/Npattm1b(EUCOMM)Wtsi
(C57BL/6N-Npattm1b(EUCOMM)Wtsi/Wtsi)
|
blood in lymph vessels
|
J:239583
|
Npc1m1N/Npc1m1N
(BALB/cNctr-Npc1m1N/J)
|
nasal inflammation
|
J:209834
|
Npc1m1N/Npc1m1N
(involves: BALB/c * C57BL/6 * CBA)
|
increased microglial cell activation
|
J:144240
|
Npc1m1N/Npc1m1N
(BALB/c-Npc1m1N)
|
abnormal microglial cell activation
|
J:221855
|
increased microglial cell activation
|
J:221855
|
Npc1m1N/Npc1m1N Tlr4tm1Aki/Tlr4tm1Aki
(involves: 129P2/OlaHsd * BALB/c)
|
abnormal cytokine secretion
|
J:118352
|
Npc1nmf164/Npc1nmf164
(C57BL/6J-Npc1nmf164/J)
|
increased microglial cell activation
|
J:179744
|
Npc1tm1.1Dso/Npc1tm1.1Dso
(B6.129-Npc1tm1.1Dso)
|
abnormal microglial cell activation
|
J:221855
|
increased microglial cell activation
|
J:221855
|
Npc2Gt(LST105)Byg/Npc2Gt(LST105)Byg
(B6.129P2-Npc2Gt(LST105)Byg)
|
abnormal immune system physiology
|
J:125609
|
Npc2tm1Plob/Npc2tm1Plob
(C.129S1-Npc2tm1Plob)
|
abnormal NK cell physiology
|
J:125609
|
abnormal T cell physiology
|
J:125609
|
Npffr2tm1.2Ics/Npffr2tm1.2Ics
(involves: C57BL/6N)
|
abnormal macrophage activation involved in immune response
|
J:245025
|
decreased macrophage proliferation
|
J:245025
|
Nphp3pcy/Nphp3pcy
(KK-Nphp3pcy)
|
kidney inflammation
|
J:8302
|
Nphp3pcy/Nphp3pcy
(either: D2.KK-Nphp3pcy or (involves: DBA/2Fg * DBA/2J * KK))
|
kidney inflammation
|
J:11399
|
Nphp3pol/Nphp3pol
(C57BL/6JSfdAnu-Nphp3pol/Anu)
|
kidney inflammation
|
J:104190
|
Npr1tm1Gar/Npr1tm1Gar
(B6.129S7-Npr1tm1Gar)
|
impaired neutrophil chemotaxis
|
J:70496
|
Npy1rtm1.1Wpg/Npy1rtm1.1Wpg
(involves: 129X1/SvJ * C57BL/6)
|
abnormal immune cell physiology
|
J:118850
|
abnormal immune system physiology
|
J:118850
|
abnormal immunoglobulin level
|
J:118850
|
abnormal inflammatory response
|
J:118850
|
abnormal macrophage physiology
|
J:118850
|
abnormal professional antigen presenting cell physiology
|
J:118850
|
abnormal T cell activation
|
J:118850
|
abnormal T-helper 1 physiology
|
J:118850
|
decreased circulating interleukin-12 level
|
J:118850
|
decreased circulating tumor necrosis factor level
|
J:118850
|
decreased IgG2a level
|
J:118850
|
decreased interferon-gamma secretion
|
J:118850
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:118850
|
increased IgA level
|
J:118850
|
increased IgG2b level
|
J:118850
|
increased IgM level
|
J:118850
|
increased immunoglobulin level
|
J:118850
|
Nr1h2tm1.1Gstr/Nr1h2tm1.1Gstr
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased microglial cell activation
|
J:278794
|
Nr1h2tm1.1Gstr/Nr1h2tm1.1Gstr Nr1h3tm1.1Gstr/Nr1h3tm1.1Gstr
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
lung inflammation
|
J:234268
|
Nr1h2tm1Djm/Nr1h2tm1Djm
(involves: 129S6/SvEvTac * C57BL/6)
|
increased susceptibility to bacterial infection
|
J:81696
|
Nr1h2tm1Djm/Nr1h2tm1Djm Nr1h3tm1Djm/Nr1h3tm1Djm
(involves: 129S6/SvEvTac * C57BL/6)
|
increased susceptibility to bacterial infection
|
J:81696
|
Nr1h3tm1Djm/Nr1h3tm1Djm
(involves: 129S6/SvEvTac * C57BL/6)
|
increased inflammatory response
|
J:158168
|
increased susceptibility to bacterial infection
|
J:81696
|
Nr1h3tm1Wexi/Nr1h3tm1Wexi
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
|
decreased susceptibility to endotoxin shock
|
J:155709
|
Nr1h4tm1.1Mbj/Nr1h4tm1.1Mbj
(B6N.B6-Nr1h4tm1.1Mbj)
|
liver inflammation
|
J:200842
|
Nr1h4tm1Gonz/Nr1h4tm1Gonz
(involves: 129X1/SvJ * C57BL/6)
|
liver inflammation
|
J:118204
|
Nr2c2tm1Amj/Nr2c2tm1Amj
(B6.129-Nr2c2tm1Amj)
|
decreased inflammatory response
|
J:169333
|
Nr3c1tm1.1Jaci/Nr3c1tm1.1Jaci Tg(Myh6-cre)2182Mds/0
(involves: C57BL/6 * FVB/N)
|
heart inflammation
|
J:201995
|
Nr3c1tm1.1Jda/Nr3c1+ Tg(Lck-cre)548Jxm/0
(B6.Cg-Nr3c1tm1.1Jda Tg(Lck-cre)548Jxm)
|
decreased thymocyte apoptosis
|
J:189951
|
Nr3c1tm1.1Jda/Nr3c1tm1.1Jda Tg(Lck-cre)548Jxm/0
(B6.Cg-Nr3c1tm1.1Jda Tg(Lck-cre)548Jxm)
|
abnormal humoral immune response
|
J:189951
|
decreased thymocyte apoptosis
|
J:189951
|
Nr3c1tm1Ljm/Nr3c1tm1Ljm
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal thymocyte apoptosis
|
J:82174
|
Nr3c1tm2.1Gsc/Nr3c1+
(B6.129P2-Nr3c1tm2.1Gsc)
|
decreased T cell apoptosis
|
J:126427
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:137157
|
Nr3c1tm2.1Ljm/Nr3c1tm2.1Ljm Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * 129S6/SvEvTac)
|
abnormal interleukin-6 secretion
|
J:197150
|
increased interleukin-1 beta secretion
|
J:197150
|
Nr3c1tm2Gsc/Nr3c1tm2Gsc Tg(Lck-cre)I57Jxm/0
(B6.Cg-Nr3c1tm2Gsc Tg(Lck-cre)I57Jxm)
|
decreased T cell apoptosis
|
J:137157
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:137157
|
Nr3c1tm2Ljm/Nr3c1tm2Ljm Tg(Lck-cre)548Jxm/?
(involves: 129S6/SvEvTac * C57BL/6 * CBA)
|
abnormal interferon level
|
J:97484
|
abnormal interleukin level
|
J:97484
|
abnormal tumor necrosis factor level
|
J:97484
|
cecum inflammation
|
J:97484
|
increased susceptibility to endotoxin shock
|
J:97484
|
Nr4a1tm1Jmi/Nr4a1tm1Jmi
(involves: 129S2/SvPas)
|
decreased B cell apoptosis
|
J:306652
|
increased B cell proliferation
|
J:306652
|
Nr4a1tm1Jmi/Nr4a1tm1Jmi
(involves: 129S2/SvPas * C57BL/6)
|
increased susceptibility to endotoxin shock
|
J:239509
|
Nr4a1tm1Pcn/Nr4a1tm1Pcn Tg(Cr2-cre)3Cgn/0
(involves: 129)
|
increased B cell proliferation
|
J:306652
|
Nr4a2tm1.1Pcn/Nr4a2tm1.1Pcn Tg(Lck-cre)1Jtak/0
(Not Specified)
|
increased susceptibility to induced colitis
|
J:205658
|
Nr5a2tm1Auw/Nr5a2+
(involves: 129P2/OlaHsd)
|
increased susceptibility to induced colitis
|
J:123697
|
Nr5a2tm1Sjns/Nr5a2tm1Sjns Tg(Vil1-cre/ERT2)23Syr/?
(involves: 129/Sv * C57BL/6 * DBA/2 * SJL)
|
increased susceptibility to induced colitis
|
J:123697
|
Nrp1tm1Ddg/Nrp1tm1Ddg
(involves: 129P2/OlaHsd)
|
abnormal dendritic cell physiology
|
J:161856
|
abnormal T cell physiology
|
J:161856
|
Nrp2tm1.2Mom/Nrp2tm1.2Mom
(involves: 129P2/OlaHsd)
|
abnormal lymphatic system physiology
|
J:226501
|
Nrrostm1Lex/Nrrostm1Lex
(B6.129S5-Nrrostm1Lex)
|
decreased susceptibility to infection
|
J:209569
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:209569
|
Nrtntm1Jmi/Nrtntm1Jmi
(involves: 129X1/SvJ * C57BL/6)
|
increased incidence of corneal inflammation
|
J:85753
|
keratoconjunctivitis sicca
|
J:85753
|
Nsmaftm1Mkr/Nsmaftm1Mkr
(involves: 129P2/OlaHsd)
|
abnormal T cell physiology
|
J:54972
|
Nsmaftm1Mkr/Nsmaftm1Mkr
(B6.129P2-Nsmaftm1Mkr)
|
decreased susceptibility to endotoxin shock
|
J:89524
|
Nsmce2tm2.1Ofc/Nsmce2tm2.1Ofc Ndor1Tg(UBC-cre/ERT2)1Ejb/0
(involves: 129S/SvEv * C57BL/6 * SJL)
|
abnormal thymus physiology
|
J:227197
|
Nsrp1tm1.1Cdj/Nsrp1tm1.1Cdj Tg(Cd4-cre)1Cwi/0
(involves: C57BL/6 * DBA/2 * SJL)
|
increased T cell apoptosis
|
J:306261
|
increased T cell proliferation
|
J:306261
|
Nss1NOD/ShiLtJ/Nss1NOD/ShiLtJ
(involves: C57BL/10 * NOD)
|
salivary gland inflammation
|
J:73932
|
Nsv1C57BL/6J/?
(involves: BALB/cBy * C57BL/6J)
|
increased susceptibility to viral infection
|
J:71216
|
Ntan1tm1Avar/Ntan1tm1Avar
(involves: 129)
|
abnormal T cell physiology
|
J:62140
|
decreased splenocyte proliferation
|
J:62140
|
increased acute inflammation
|
J:62140
|
Ntrk1tm1Tes/Ntrk1tm1Tes Tg(Tuba1-cre)1Tes/0
(involves: 129S1/Sv)
|
abnormal mast cell physiology
|
J:93578
|
increased IgG1 level
|
J:93578
|
increased IgG2a level
|
J:93578
|
increased IgM level
|
J:93578
|
increased immunoglobulin level
|
J:93578
|
Nucb2tm1.2Vdix/Nucb2tm1.2Vdix
(involves: C57BL/6)
|
increased interleukin-1 beta secretion
|
J:270674
|
increased tumor necrosis factor secretion
|
J:270674
|
Nudctm1c(KOMP)Mbp/Nudctm1c(KOMP)Mbp Tg(Rho-icre)1Ck/0
(involves: C57BL/6 * C57BL/6N * SJL)
|
increased microglial cell activation
|
J:346299
|
Nudcd3em1(IMPC)Wtsi/Nudcd3em1(IMPC)Wtsi
(C57BL/6N-Nudcd3em1(IMPC)Wtsi/Wtsi)
|
increased IgE level
|
J:351330
|
increased IgG2b level
|
J:351330
|
increased IgM level
|
J:351330
|
Nudt7em1Ejj/Nudt7em1Ejj
(involves: C57BL/6N)
|
increased susceptibility to induced arthritis
|
J:266261
|
osteoarthritis
|
J:266261
|
Nudt21tm1.1Ejwpj/Nudt21tm1.1Ejwpj Tg(Col1a1-cre/ERT2)1Crm/0
(involves: C57BL/6J * CBA/J)
|
increased acute inflammation
|
J:283035
|
Nuggctm1Diaz/Nuggctm1Diaz Edil3Tg(Sox2-cre)1Amc/Edil3+
(involves: C57BL/6 * C57BL/6J * CBA)
|
abnormal somatic hypermutation frequency
|
J:190402
|
Nup98tm1Bmaf/Nup98+
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal level of surface class I molecules
|
J:110907
|
abnormal level of surface class II molecules
|
J:110907
|
abnormal MHC II cell surface expression on macrophages
|
J:110907
|
decreased IgG1 level
|
J:110907
|
decreased IgG level
|
J:110907
|
decreased T cell proliferation
|
J:110907
|
increased T cell proliferation
|
J:110907
|
Nup210tm1.1Mdan/Nup210tm1.1Mdan
(B6.Cg-Nup210tm1.1Mdan)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:282451
|
abnormal T cell activation
|
J:282451
|
Nup210tm1Mdan/Nup210tm1Mdan Tg(Cd4-cre/ERT2)11Gnri/0
(involves: 129X1/SvJ * C57BL/6)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:282451
|
Nwa2NZW/LacJ/Nwa2NZW/LacJ
(involves: BALB/cJ * NZW/LacJ)
|
increased anti-histone antibody level
|
J:35434
|
increased anti-single stranded DNA antibody level
|
J:35434
|
Oas1bFlv-mr/Oas1bFlv-mr
(MOLD/RkJ)
|
decreased susceptibility to Flaviviridae infection
|
J:3674
|
Oas1bFlv-r/Oas1bFlv-r
(multiple strains)
|
decreased susceptibility to Flaviviridae infection
|
J:15009
|
Oas1bFlv-r/Oas1bFlv-r
(C3.PRI-Oas1bFlv-r)
|
decreased susceptibility to Flaviviridae infection
|
J:175365
|
Oas1bFlv-s/Oas1bFlv-s
(multiple strains)
|
increased susceptibility to Flaviviridae infection
|
J:15009
|
Oas1btm1.1Brin/Oas1btm1.1Brin
(involves: 129X1/SvJ * C57BL/6J)
|
decreased susceptibility to Flaviviridae infection
|
J:175365
|
Oasl1tm1Yjk/Oasl1tm1Yjk
(B6.129P2-Oasl1tm1Yjk)
|
abnormal circulating interferon level
|
J:194467
|
decreased susceptibility to Picornaviridae infection
|
J:194467
|
decreased susceptibility to Picornaviridae infection induced morbidity/mortality
|
J:194467
|
Oca2p-3Btlr/Oca2p-3Btlr
(C57BL/6J-Oca2p-3Btlr)
|
abnormal NK cell physiology
|
J:133623
|
increased susceptibility to bacterial infection
|
J:133623
|
Oca2p-4Btlr/Oca2p-4Btlr
(C57BL/6J-Oca2p-4Btlr)
|
increased susceptibility to bacterial infection
|
J:133624
|
Oca2p-8Btlr/Oca2p-8Btlr
(C57BL/6J-Oca2p-8Btlr)
|
increased susceptibility to induced colitis
|
J:264643
|
OclnGt(ROSA)39Tshi/OclnGt(ROSA)39Tshi
(involves: DBA/2)
|
stomach inflammation
|
J:110222
|
Oclntm1Sts/Oclntm1Sts
(involves: 129S4/SvJae * C57BL/6)
|
stomach inflammation
|
J:99467
|
Oclntm1Tshi/Oclntm1Tshi
(involves: C57BL/6 * DBA/2)
|
stomach inflammation
|
J:110222
|
Oclntm2Sts/Oclntm2Sts
(involves: 129S4/SvJae * C57BL/6)
|
stomach inflammation
|
J:99467
|
Odf2tm1.1Sats/Odf2tm1.2Sats Tg(CAG-cre)13Miya/0
(involves: C57BL/6 * C57BL/6J)
|
increased susceptibility to otitis media
|
J:181294
|
sinus inflammation
|
J:181294
|
Ogdhtm1e(KOMP)Wtsi/Ogdh+
(C57BL/6N-Ogdhtm1e(KOMP)Wtsi/Wtsi)
|
blood in lymph vessels
|
J:239583
|
Ogttm1Gwh/Y Tg(Lck-cre)548Jxm/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)
|
increased T cell apoptosis
|
J:93112
|
Olahem1Kedk/Olahem1Kedk
(involves: C57BL/6)
|
abnormal macrophage physiology
|
J:353571
|
decreased susceptibility to Orthomyxoviridae infection
|
J:353571
|
decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality
|
J:353571
|
Olfm4tm1Gpro/Olfm4tm1Gpro
(involves: 129X1/SvJ * Black Swiss)
|
abnormal cytokine level
|
J:161279
|
increased circulating interleukin-3 level
|
J:161279
|
increased circulating interleukin-12 level
|
J:161279
|
increased susceptibility to bacterial infection
|
J:161279
|
stomach inflammation
|
J:161279
|
Olr1tm1Meht/Olr1tm1Meht
(B6.129X1-Olr1tm1Meht/Meht)
|
increased circulating interleukin-10 level
|
J:130794
|
Oma1tm1Otin/Oma1tm1Otin
(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NCr)
|
granulomatous inflammation
|
J:184716
|
Onecut1tm1.1Mga/Onecut1tm1.1Mga Tg(Pdx1-cre)89.1Dam/0
(involves: 129S6/SvEvTac * C57BL/6 * CBA * SJL)
|
pancreas inflammation
|
J:155058
|
Oprm1tm1Lyu/Oprm1+
(involves: Black Swiss)
|
increased splenocyte proliferation
|
J:39864
|
Oprm1tm1Lyu/Oprm1tm1Lyu
(involves: Black Swiss)
|
increased splenocyte proliferation
|
J:39864
|
Orai1Gt(XL922)Byg/Orai1+
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
abnormal mast cell physiology
|
J:130479
|
decreased interferon-gamma secretion
|
J:130479
|
Orai1Gt(XL922)Byg/Orai1Gt(XL922)Byg
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
abnormal mast cell physiology
|
J:130479
|
decreased interferon-gamma secretion
|
J:130479
|
decreased interleukin-2 secretion
|
J:130479
|
decreased susceptibility to type I hypersensitivity reaction
|
J:130479
|
Orai1tm1.1Hjm/Orai1tm1.1Hjm Orai2tm1.1(KOMP)Vlcg/Orai2tm1.1(KOMP)Vlcg Tg(Cd4-cre)1Cwi/0
(B6.Cg-Tg(Cd4-cre)1Cwi Orai1tm1.1Hjm Orai2tm1.1(KOMP)Vlcg)
|
abnormal T cell physiology
|
J:241365
|
decreased IgG level
|
J:241365
|
Orai1tm1.1Hjm/Orai1tm1.1Hjm Tg(Cd4-cre)1Cwi/0
(B6.Cg-Orai1tm1.1Hjm Tg(Cd4-cre)1Cwi)
|
abnormal T cell physiology
|
J:241365
|
Orai1tm1Rao/Orai1+
(C57BL/6-Orai1tm1Rao)
|
abnormal B cell activation
|
J:139730
|
abnormal T cell activation
|
J:139730
|
Orai1tm1Rao/Orai1tm1Rao
(involves: C57BL/6NTac * ICR)
|
abnormal B cell activation
|
J:139730
|
abnormal cell-mediated immunity
|
J:139730
|
abnormal cytokine secretion
|
J:139730
|
abnormal mast cell physiology
|
J:139730
|
abnormal T cell activation
|
J:139730
|
abnormal thymocyte activation
|
J:139730
|
blepharitis
|
J:139730
|
decreased interferon-gamma secretion
|
J:139730
|
decreased interleukin-2 secretion
|
J:139730
|
decreased interleukin-4 secretion
|
J:139730
|
decreased interleukin-10 secretion
|
J:139730
|
Orai2tm1.1(KOMP)Vlcg/Orai2tm1.1(KOMP)Vlcg
(B6.Cg-Orai2tm1.1(KOMP)Vlcg)
|
abnormal macrophage physiology
|
J:241365
|
abnormal T cell physiology
|
J:241365
|
Orai2tm1.1Itl/Orai2tm1.1Itl Tg(Cma1-cre)#Roer/0
(involves: 129S4/SvJaeSor * C57BL/6 * C57BL/6N)
|
increased susceptibility to type I hypersensitivity reaction
|
J:278536
|
Orai2tm1.2Itl/Orai2tm1.2Itl
(involves: 129S4/SvJaeSor * BALB/cJ * C57BL/6 * C57BL/6N)
|
abnormal mast cell physiology
|
J:278536
|
increased mast cell degranulation
|
J:278536
|
Orch4BALB/cByJ/Orch4BALB/cByJ
(involves: BALB/cByJ * DBA/2)
|
testis inflammation
|
J:35331
|
Orch4BALB/cByJ/Orch4DBA/2J
(involves: BALB/cByJ * DBA/2)
|
decreased inflammatory response
|
J:35331
|
Orch4DBA/2J/Orch4DBA/2J
(involves: BALB/cByJ * DBA/2)
|
decreased inflammatory response
|
J:35331
|
Orch5BALB/cByJ/Orch5BALB/cByJ
(involves: BALB/cByJ * DBA/2)
|
testis inflammation
|
J:35331
|
Orch5BALB/cByJ/Orch5DBA/2J
(involves: BALB/cByJ * DBA/2)
|
decreased inflammatory response
|
J:35331
|
Orch5DBA/2J/Orch5DBA/2J
(involves: BALB/cByJ * DBA/2)
|
decreased inflammatory response
|
J:35331
|
Orm2em1Bcgen/Orm2em1Bcgen
(involves: C57BL/6J)
|
liver inflammation
|
J:333118
|
Orm2tm1(KOMP)Vlcg/Orm2tm1(KOMP)Vlcg
(C57BL/6N-Orm2tm1(KOMP)Vlcg/Mmucd)
|
kidney inflammation
|
J:292194
|
Ormdl1em1Pdra/Ormdl1em1Pdra Ormdl3em1Pdra/Ormdl3em1Pdra
(C57BL/6-Ormdl1em1Pdra Ormdl3em1Pdra)
|
abnormal mast cell physiology
|
J:349248
|
Ormdl2em1Pdra/Ormdl2em1Pdra Ormdl3em1Pdra/Ormdl3em1Pdra
(C57BL/6-Ormdl2em1Pdra Ormdl3em1Pdra)
|
abnormal mast cell physiology
|
J:328837
|
abnormal type I hypersensitivity reaction
|
J:328837
|
increased interleukin-4 secretion
|
J:328837
|
increased interleukin-6 secretion
|
J:328837
|
increased mast cell degranulation
|
J:328837
|
increased tumor necrosis factor secretion
|
J:328837
|
Ormdl3em1Pdra/Ormdl3em1Pdra
(C57BL/6-Ormdl3em1Pdra)
|
abnormal mast cell physiology
|
J:328837
|
abnormal type I hypersensitivity reaction
|
J:328837
|
increased mast cell degranulation
|
J:328837
|
Os/Os+
(ROP/GnLeJ)
|
glomerulonephritis
|
J:28323
|
Oscartm1Ywc/Oscartm1Ywc Tyrobptm1Ttk/Tyrobptm1Ttk
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal osteoclast physiology
|
J:178250
|
Osmrtm1Mtan/Osmrtm1Mtan
(B6.129S-Osmrtm1Mtan)
|
increased circulating interleukin-10 level
|
J:214124
|
increased circulating tumor necrosis factor level
|
J:214124
|
increased inflammatory response
|
J:214124
|
white adipose tissue inflammation
|
J:214124
|
Ostm1gl/Ostm1gl
(GL/Le Edardl-J +/+ Ostm1gl/J)
|
eye inflammation
|
J:13053
|
Otcspf-ash/Y
(involves: C57BL/6)
|
increased susceptibility to parasitic infection
|
J:23205
|
Otcspf-ash/Y
(B6EiC3Sn a/A-Otcspf-ash/J)
|
increased susceptibility to endotoxin shock
|
J:108979
|
Otub1tm1c(EUCOMM)Hmgu/Otub1tm1c(EUCOMM)Hmgu Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N)
|
abnormal B cell activation
|
J:280549
|
increased anti-double stranded DNA antibody level
|
J:280549
|
increased anti-nuclear antigen antibody level
|
J:280549
|
increased circulating interleukin-6 level
|
J:280549
|
increased IgA level
|
J:280549
|
increased IgG2a level
|
J:280549
|
increased IgG2b level
|
J:280549
|
increased IgM level
|
J:280549
|
increased immunoglobulin level
|
J:280549
|
increased susceptibility to autoimmune disorder
|
J:280549
|
increased susceptibility to systemic lupus erythematosus
|
J:280549
|
Otud1em2Gpt/Otud1em2Gpt
(C57BL/6-Otud1em2Gpt)
|
abnormal innate immunity
|
J:287309
|
decreased susceptibility to Herpesvirales infection
|
J:287309
|
decreased susceptibility to Riboviria infection
|
J:287309
|
increased circulating interferon-beta level
|
J:287309
|
increased susceptibility to endotoxin shock
|
J:287309
|
Otud3em1Nju/Otud3em1Nju
(involves: C57BL/6N)
|
abnormal chemokine secretion
|
J:294274
|
decreased susceptibility to Riboviria infection
|
J:294274
|
decreased susceptibility to Riboviria infection induced morbidity/mortality
|
J:294274
|
increased interferon-beta secretion
|
J:294274
|
Otud5tm1Vmd/Otud5tm1Vmd Tg(Cd4-cre)1Cwi/0
(involves: C57BL/6 * DBA/2)
|
increased circulating interleukin-17 level
|
J:219495
|
increased interleukin-9 secretion
|
J:219495
|
increased interleukin-17 secretion
|
J:219495
|
increased interleukin-21 secretion
|
J:219495
|
intestinal inflammation
|
J:219495
|
Otud6aem1Smoc/Otud6aem1Smoc
(C57BL/6J-Otud6aem1Smoc)
|
abnormal innate immunity
|
J:345141
|
decreased susceptibility to Herpesvirales infection
|
J:345141
|
decreased susceptibility to Riboviria infection
|
J:345141
|
Otud7btm1(NCOM)Cmhd/Otud7btm1(NCOM)Cmhd
(involves: C57BL/6N)
|
abnormal granulocyte physiology
|
J:209709
|
Otud7btm1Dgen/Otud7btm1Dgen
(involves: 129 * C57BL/6)
|
decreased activation-induced B cell apoptosis
|
J:194553
|
decreased susceptibility to bacterial infection
|
J:194553
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:194553
|
increased B cell proliferation
|
J:194553
|
increased IgA level
|
J:194553
|
Otulinem1Gvl/Otulintm1c(EUCOMM)Hmgu Tg(KRT14-cre)1Cgn/0
(involves: C57BL/6 * C57BL/6J * C57BL/6N * DBA/2)
|
dermatitis
|
J:312394
|
Otulintm1c(EUCOMM)Hmgu/Otulintm1c(EUCOMM)Hmgu Tg(KRT14-cre)1Cgn/0
(involves: C57BL/6 * C57BL/6N * DBA/2)
|
dermatitis
|
J:312394
|
Oxgr1tm1(KOMP)Vlcg/Oxgr1tm1(KOMP)Vlcg
(involves: BALB/c * C57BL/6NTac)
|
abnormal immune system physiology
|
J:198383
|
Oxsr1tm1.1Arte/Oxsr1+
(involves: 129S/SvEvBrd)
|
abnormal dendritic cell physiology
|
J:191351
|
P2rx2tm1Ckn/P2rx2tm1Ckn P2rx3tm1Ckn/P2rx3tm1Ckn
(involves: 129P2/OlaHsd * C57BL/6)
|
lung inflammation
|
J:86890
|
P2rx4tm1Ando/P2rx4tm1Ando
(involves: 129S4/SvJae * BALB/c * C57BL/6)
|
abnormal neutrophil physiology
|
J:311564
|
P2rx4tm1Dgen/P2rx4tm1Dgen
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal macrophage physiology
|
J:145232
|
P2rx7tm1Gab/P2rx7tm1Gab
(either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * C57BL/6 * DBA/2))
|
abnormal interleukin-6 secretion
|
J:66835
|
decreased interleukin-1 beta secretion
|
J:66835
|
P2rx7tm1Gab/P2rx7tm1Gab
(B6.129P2-P2rx7tm1Gab/J)
|
abnormal mast cell physiology
|
J:190651
|
P2rx7tm1Ipch/P2rx7tm1Ipch
(B6.Cg-P2rx7tm1Ipch)
|
abnormal inflammatory response
|
J:101945
|
P2rx7tm1Ipch/P2rx7tm1Ipch
(involves: 129 * C57BL/6)
|
abnormal macrophage physiology
|
J:118561
|
P2rx7tm1Lex/P2rx7tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6)
|
abnormal macrophage physiology
|
J:145020
|
P2ry6tm1.1Brob/P2ry6tm1.1Brob
(involves: 129S1/Sv * 129X1/SvJ * CD-1)
|
abnormal macrophage physiology
|
J:169742
|
P2ry6tm1Jabo/P2ry6tm1Jabo Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
(involves: 129 * C57BL/6 * C57BL/6NTac)
|
decreased IgE level
|
J:179177
|
decreased T cell apoptosis
|
J:179177
|
increased interferon-gamma secretion
|
J:179177
|
increased interleukin-4 secretion
|
J:179177
|
increased interleukin-5 secretion
|
J:179177
|
increased interleukin-13 secretion
|
J:179177
|
increased T cell proliferation
|
J:179177
|
lung inflammation
|
J:179177
|
P2ry6tm1Jabo/P2ry6tm1Jabo Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
(B6.Cg-Gt(ROSA)26Sortm9(cre/ESR1)Arte P2ry6tm1Jabo)
|
increased interferon-gamma secretion
|
J:179177
|
increased interleukin-4 secretion
|
J:179177
|
increased interleukin-5 secretion
|
J:179177
|
increased interleukin-13 secretion
|
J:179177
|
lung inflammation
|
J:179177
|
P4hbtm1.1Geno/P4hbtm1.2Geno Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd)
|
impaired neutrophil recruitment
|
J:197556
|
Paam1MRL/MpJ/Paam1MRL/MpJ
(involves: C3H/HeJ * MRL/MpJ)
|
increased susceptibility to autoimmune disorder
|
J:76107
|
Paam2MRL/MpJ/Paam2MRL/MpJ
(involves: C3H/HeJ * MRL/MpJ)
|
increased susceptibility to autoimmune disorder
|
J:76107
|
Pacsin1Gt(OST287788)Lex/Pacsin1Gt(OST287788)Lex
(B6.129S5-Pacsin1Gt(OST287788)Lex)
|
abnormal plasmacytoid dendritic cell physiology
|
J:187784
|
decreased circulating interferon-alpha level
|
J:187784
|
decreased interferon-alpha secretion
|
J:187784
|
Padi2tm1Lex/Padi2tm1Lex
(B6.129S5-Padi2tm1Lex)
|
abnormal mast cell physiology
|
J:190651
|
Padi2tm1Lex/Padi2tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6)
|
autoimmune response
|
J:190651
|
Padi4tm1.1Kmow/Padi4tm1.1Kmow
(involves: BALB/cJ * C57BL/6)
|
abnormal neutrophil physiology
|
J:174934
|
decreased susceptibility to Orthomyxoviridae infection
|
J:174934
|
Padi4tm1.1Ywan/Padi4tm1.1Ywan
(involves: 129S4/SvJae)
|
abnormal neutrophil physiology
|
J:165718
|
impaired neutrophil phagocytosis
|
J:165718
|
increased susceptibility to bacterial infection
|
J:165718
|
Pak1tm1Cher/Pak1tm1Cher
(B6.129S2-Pak1tm1Cher)
|
abnormal mast cell physiology
|
J:142439
|
decreased mast cell degranulation
|
J:145444
|
Panx1tm1.2Vmd/Panx1tm1.2Vmd
(C57BL/6N-Panx1tm1.2Vmd)
|
abnormal T cell physiology
|
J:173213
|
Panx3tm1c(KOMP)Wtsi/Panx3tm1c(KOMP)Wtsi Tg(Col2a1-cre)1Star/0
(involves: C3H * C57BL/6 * C57BL/6J * C57BL/6N)
|
decreased susceptibility to induced arthritis
|
J:233542
|
Panx3tm1d(KOMP)Wtsi/Panx3tm1d(KOMP)Wtsi
(involves: BALB/cJ * C3H * C57BL/6 * C57BL/6N)
|
decreased susceptibility to induced arthritis
|
J:233542
|
Papss2bm/Papss2bm
(involves: C57BL/6J * LDJ/Le)
|
autoimmune arthritis
|
J:166514
|
Pargtm1Zqw/Pargtm1Zqw
(involves: 129P2/OlaHsd * C57BL/6)
|
increased circulating tumor necrosis factor level
|
J:92244
|
increased susceptibility to endotoxin shock
|
J:92244
|
Parltm1.1Bdes/Parltm1.1Bdes
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased T cell apoptosis
|
J:116017
|
Parltm1.1Bdes/Parltm1.1Bdes
(involves: 129P2/OlaHsd)
|
abnormal thymus apoptosis
|
J:269785
|
Parltm1Bdes/Parltm1Bdes Tg(Nes-cre)1Kln/0
(involves: 129P2/OlaHsd * C57BL/6 * SJL)
|
abnormal thymus apoptosis
|
J:269785
|
Parp1tm1Jmdm/Parp1tm1Jmdm
(involves: 129S2/SvPas * C57BL/6)
|
abnormal inflammatory response
|
J:117701
|
abnormal leukocyte migration
|
J:117701
|
Parp1tm1Zqw/Parp1tm1Zqw
(involves: 129/Sv * C57BL/6)
|
decreased inflammatory response
|
J:94497
|
Parp1tm1Zqw/Parp1tm1Zqw
(129S-Parp1tm1Zqw/J)
|
abnormal microglial cell physiology
|
J:96548
|
decreased inflammatory response
|
J:95418
|
Parp1tm2Zqw/Parp1tm2Zqw
(either: (involves: 129P2/OlaHsd * 129/Sv) or (involves: 129P2/OlaHsd * C57BL/6))
|
abnormal inflammatory response
|
J:93479
|
abnormal macrophage physiology
|
J:93479
|
decreased circulating interleukin-1 beta level
|
J:93479
|
decreased circulating tumor necrosis factor level
|
J:93479
|
decreased inflammatory response
|
J:93479
|
decreased susceptibility to endotoxin shock
|
J:93479
|
Parp9tm1.2Arte/Parp9tm1.2Arte
(involves: C57BL/6N * FVB/N)
|
abnormal circulating interferon level
|
J:306337
|
abnormal interferon secretion
|
J:306337
|
abnormal response to infection
|
J:306337
|
Parp14Gt(OST415485)Lex/Parp14Gt(OST415485)Lex
(involves: 129S5/SvEvBrd * C57BL/6)
|
decreased B cell proliferation
|
J:146533
|
decreased IgA level
|
J:146533
|
increased B cell apoptosis
|
J:146533
|
increased B cell proliferation
|
J:146533
|
Patz1tm1.2Welm/Patz1tm1.2Welm Commd10Tg(Vav1-icre)A2Kio/Commd10+
(B6.Cg-Patz1tm1.2Welm Commd10Tg(Vav1-icre)A2Kio)
|
decreased interleukin-6 secretion
|
J:209168
|
Pawrtm1Jmos/Pawrtm1Jmos
(involves: 129/Sv * CD-1)
|
abnormal T-helper 2 physiology
|
J:85495
|
increased B cell proliferation
|
J:85495
|
increased T cell proliferation
|
J:85495
|
Pax5m1Btlr/Pax5m1Btlr
(C57BL/6J-Pax5m1Btlr)
|
decreased IgA level
|
J:220072
|
decreased IgG1 level
|
J:220072
|
decreased IgG2a level
|
J:220072
|
decreased IgG2b level
|
J:220072
|
decreased IgG level
|
J:220072
|
decreased IgM level
|
J:220072
|
impaired humoral immune response
|
J:220072
|
Pax5m3Btlr/Pax5m3Btlr
(C57BL/6J-Pax5m3Btlr)
|
abnormal humoral immune response
|
J:254825
|
decreased IgG level
|
J:254825
|
decreased IgM level
|
J:254825
|
Pax5m4Btlr/Pax5m4Btlr
(C57BL/6J-Pax5m4Btlr)
|
decreased IgD level
|
J:265140
|
Pax5M5Btlr/Pax5M5Btlr
(C57BL/6J-Pax5M5Btlr)
|
decreased IgD level
|
J:265141
|
Pax5tm1Mbu/Pax5tm1Mbu
(involves: 129S2/SvPas * C57BL/6)
|
decreased immunoglobulin level
|
J:113076
|
Pax5tm1Mbu/Pax5tm1Mbu
(involves: 129S2/SvPas)
|
abnormal B cell physiology
|
J:123629
|
enhanced B cell migration
|
J:123629
|
Pax6Sey-4H/Pax6+
(involves: 101/H * C3H/HeCrj * C3H/HeH)
|
increased susceptibility to induced pancreatitis
|
J:124276
|
Pax7tm1.1(HBEGF,-EYFP)Mal/Pax7+
(involves: C57BL/6)
|
myositis
|
J:180899
|
Paxxem1Spj/Paxxem1Spj Nhej1tm1Fwa/Nhej1tm1Fwa
(involves: 129S6/SvEvTac * C57BL/6NTac)
|
abnormal thymus involution
|
J:236776
|
Pbat1BXSB/Slc/Pbat1BXSB/Slc
(involves: BXSB/Slc * NZW/Slc)
|
increased autoantibody level
|
J:49899
|
Pbat1BXSB/Slc/Pbat1NZW/Slc
(involves: BXSB/Slc * NZW/Slc)
|
increased autoantibody level
|
J:49899
|
Pbat2BXSB/Slc/Pbat2BXSB/Slc
(involves: BXSB/Slc * NZW/Slc)
|
increased autoantibody level
|
J:49899
|
Pbat2BXSB/Slc/Pbat2NZW/Slc
(involves: BXSB/Slc * NZW/Slc)
|
increased autoantibody level
|
J:49899
|
Pbktm1Zgdo/Pbktm1Zgdo
(Not Specified)
|
decreased interleukin-6 secretion
|
J:176985
|
increased interleukin-6 secretion
|
J:176985
|
increased tumor necrosis factor secretion
|
J:176985
|
Pbrm1tm1Zhwa/Pbrm1tm1Zhwa Tg(Cd4-cre)1Cwi/?
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
decreased T cell proliferation
|
J:236906
|
increased interleukin-4 secretion
|
J:236906
|
increased interleukin-10 secretion
|
J:236906
|
Pbxip1tm1Cya/Pbxip1tm1Cya Tg(Col2a1-cre/ERT)KA3Smac/0
(involves: FVB/N)
|
osteoarthritis
|
J:270267
|
Pcaretm1Kpal/Pcaretm1Kpal
(involves: C57BL/6J * C57BL/6NTac)
|
increased microglial cell activation
|
J:220866
|
Pcgf2tm1Hko/Pcgf2tm1Hko
(involves: BALB/c * C57BL/6)
|
abnormal T-helper 2 physiology
|
J:71268
|
Pcnatm1.1Mdsc/Pcnatm1.1Mdsc Tg(Pcna*K164R)1Mdsc/0
(involves: FVB/N)
|
abnormal class switch recombination
|
J:141098
|
abnormal somatic hypermutation frequency
|
J:141098
|
Pcnatm1Jcbs/Pcnatm1Jcbs
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal somatic hypermutation frequency
|
J:125916
|
Pcnatm1Jcbs/Pcnatm1Jcbs
(involves: 129P2/OlaHsd)
|
abnormal somatic hypermutation frequency
|
J:155454,
J:177630
|
Pcnatm1Jcbs/Pcnatm1Jcbs Ungtm1Tld/Ungtm1Tld
(involves: 129P2/OlaHsd)
|
abnormal somatic hypermutation frequency
|
J:155454
|
Pcsk1tm1Dfs/Pcsk1tm1Dfs
(involves: 129 * C57BL/6J)
|
increased circulating interferon-gamma level
|
J:184882
|
increased circulating interleukin-1 beta level
|
J:184882
|
increased circulating interleukin-6 level
|
J:184882
|
increased circulating interleukin-10 level
|
J:184882
|
increased circulating interleukin-12 level
|
J:184882
|
increased circulating tumor necrosis factor level
|
J:184882
|
increased interleukin-1 beta secretion
|
J:184882
|
increased susceptibility to endotoxin shock
|
J:184882
|
Pctptm1Bor/Pctptm1Bor
(B6.129P2-Pctptm1Bor)
|
abnormal macrophage physiology
|
J:115284
|
increased macrophage apoptosis
|
J:115284
|
Pcyt1atm1Irt/Pcyt1atm1Irt Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129 * C57BL/6J)
|
abnormal immune cell physiology
|
J:65639
|
abnormal macrophage physiology
|
J:65639
|
Pdap1em1Rkuhn/Pdap1em1Rkuhn Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N)
|
abnormal B cell physiology
|
J:298705
|
abnormal class switch recombination
|
J:298705
|
abnormal somatic hypermutation frequency
|
J:298705
|
increased B cell apoptosis
|
J:298705
|
Pdcd1tm1.1Liux/Pdcd1tm1.1Liux Tg(MMTV-PyVT)634Mul/0
(involves: C57BL/6 * FVB/N)
|
decreased interleukin-17 secretion
|
J:190150
|
increased interferon-gamma secretion
|
J:190150
|
increased interleukin-2 secretion
|
J:190150
|
increased tumor necrosis factor secretion
|
J:190150
|
Pdcd1tm1.1Shr/Pdcd1tm1.1Shr Tg(TcraTcrb)1100Mjb/0
(involves: C57BL/6)
|
abnormal immune tolerance
|
J:153040
|
decreased T cell proliferation
|
J:153040
|
increased susceptibility to autoimmune diabetes
|
J:153040
|
increased T cell proliferation
|
J:153040
|
insulitis
|
J:153040
|
pancreas inflammation
|
J:153040
|
Pdcd1tm1Hon/Pdcd1tm1Hon
(involves: 129S2/SvPas * C57BL/6)
|
abnormal immunoglobulin level
|
J:50688
|
increased B cell proliferation
|
J:50688
|
increased IgA level
|
J:50688
|
increased IgG2b level
|
J:50688
|
increased IgG3 level
|
J:50688
|
Pdcd1tm1Hon/Pdcd1tm1Hon
(B6.129S2-Pdcd1tm1Hon)
|
abnormal response to transplant
|
J:119356
|
autoimmune arthritis
|
J:78802
|
glomerulonephritis
|
J:78802
|
Pdcd1tm1Hon/Pdcd1tm1Hon
(C.129S2(B6)-Pdcd1tm1Hon)
|
increased autoantibody level
|
J:66979
|
Pdcd1tm1Hon/Pdcd1tm1Hon
(involves: 129S2/SvPas)
|
abnormal T cell activation
|
J:222944
|
increased IgA level
|
J:222944
|
increased IgM level
|
J:222944
|
increased inflammatory response
|
J:222944
|
increased interferon-gamma secretion
|
J:222944
|
Pdcd1tm1Hon/Pdcd1tm1Hon Tg(Tcra2D2,Tcrb2D2)1Kuch/0
(involves: 129S2/SvPas)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:140751
|
Pdcd1tm1Hon/Pdcd1tm1Hon Vsirtm1Lex/Vsirtm1Lex
(involves: 129S2/SvPas * 129S5/SvEvBrd * C57BL/6)
|
abnormal T cell activation
|
J:222944
|
increased IgA level
|
J:222944
|
increased IgM level
|
J:222944
|
increased inflammatory response
|
J:222944
|
increased interferon-gamma secretion
|
J:222944
|
increased interleukin-17 secretion
|
J:222944
|
increased tumor necrosis factor secretion
|
J:222944
|
Pdcd1tm1Hon/Pdcd1tm1Hon Vsirtm1Lex/Vsirtm1Lex Tg(Tcra2D2,Tcrb2D2)1Kuch/0
(involves: 129S2/SvPas * 129S5/SvEvBrd * C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:222944
|
Pdcd1tm1Llc/Pdcd1tm1Llc
(involves: 129S5/SvEvBrd)
|
abnormal cytokine secretion
|
J:126829
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:126829
|
Pdcd1lg2tm1Dmp/Pdcd1lg2tm1Dmp
(involves: 129X1/SvJ * 129S1/Sv * C57BL/6)
|
abnormal dendritic cell antigen presentation
|
J:84457
|
Pdcd1lg2tm1Dmp/Pdcd1lg2tm1Dmp
(C.129-Pdcd1lg2tm1Dmp)
|
abnormal cytokine secretion
|
J:99212
|
abnormal cytotoxic T cell physiology
|
J:99212
|
decreased IgG2a level
|
J:99212
|
decreased T cell proliferation
|
J:99212
|
Pdcd1lg2tm1Shr/Pdcd1lg2tm1Shr
(involves: 129/Sv * 129S4/SvJae)
|
increased IgG2a level
|
J:113851
|
increased IgM level
|
J:113851
|
increased susceptibility to parasitic infection
|
J:113851
|
Pdcd1lg2tm2Shr/Pdcd1lg2tm2Shr
(C.B6-Pdcd1lg2tm2Shr)
|
abnormal dendritic cell physiology
|
J:123785
|
increased interferon-gamma secretion
|
J:123785
|
increased interleukin-2 secretion
|
J:123785
|
Pdcd1lg2tm3Shr/Pdcd1lg2tm3Shr
(involves: C57BL/6 * NOD/MrkTac)
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:123785
|
increased susceptibility to autoimmune diabetes
|
J:123785
|
insulitis
|
J:123785
|
Pdcd4tm1Yhcn/Pdcd4tm1Yhcn
(B6.129S6-Pdcd4tm1Yhcn)
|
abnormal cytokine secretion
|
J:120583
|
decreased susceptibility to autoimmune diabetes
|
J:120583
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:120583
|
Pdcd10tm1Kwhi/Pdcd10tm1.1Kwhi Tg(Pdgfb-icre/ERT2,-EGFP)1Frut/?
(involves: C57BL/6 * CBA)
|
CNS inflammation
|
J:173947
|
Pde4btm1Mct/Pde4b+ Pde4dtm1Mct/Pde4dtm1Mct
(involves: 129P2/OlaHsd * C57BL/6)
|
impaired neutrophil recruitment
|
J:94853
|
Pde4btm1Mct/Pde4btm1Mct
(involves: 129X1/SvJ * C57BL/6)
|
decreased tumor necrosis factor secretion
|
J:76862
|
Pde4btm1Mct/Pde4btm1Mct
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased tumor necrosis factor secretion
|
J:106828
|
impaired neutrophil chemotaxis
|
J:94853
|
impaired neutrophil recruitment
|
J:94853
|
Pde4btm1Mct/Pde4btm1Mct Pde4dtm1Mct/Pde4d+
(involves: 129P2/OlaHsd * C57BL/6)
|
impaired neutrophil recruitment
|
J:94853
|
Pde4dtm1Mct/Pde4dtm1Mct
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal tumor necrosis factor level
|
J:94853
|
impaired neutrophil chemotaxis
|
J:94853
|
impaired neutrophil recruitment
|
J:94853
|
Pde7aGt(Betageo-puro)1Yang/Pde7aGt(Betageo-puro)1Yang
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal humoral immune response
|
J:86923
|
Pdia6em1Btlr/Pdia6m1Btlr
(involves: C57BL/6J)
|
abnormal circulating cytokine level
|
J:288824
|
abnormal T cell physiology
|
J:288824
|
Pdlim2tm1Gru/Pdlim2tm1Gru
(Not Specified)
|
abnormal T-helper 1 physiology
|
J:99108
|
increased interferon-gamma secretion
|
J:99108
|
increased susceptibility to bacterial infection
|
J:99108
|
Pdpk1tm1.1Mlw/Pdpk1tm1.1Mlw Rag2tm1Fwa/Rag2tm1Fwa Tnfrsf4tm2(cre)Nik/Tnfrsf4+ Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
(involves: 129S/SvEv * 129X1/SvJ * C57BL/6)
|
dermatitis
|
J:226194
|
Pdpk1tm1.1Mlw/Pdpk1tm1.1Mlw Tnfrsf4tm2(cre)Nik/Tnfrsf4+ Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
(involves: 129X1/SvJ * C57BL/6)
|
abnormal T cell physiology
|
J:226194
|
dermatitis
|
J:226194
|
Pdpk1tm1Mlw/Pdpk1tm1Mlw Tg(Cd4-cre)1Cwi/0
(involves: C57BL/6 * DBA/2)
|
decreased T cell proliferation
|
J:165626
|
Pdpntm1Mcws/Pdpntm1Mcws
(involves: 129S6/SvEvTac)
|
abnormal lymph circulation
|
J:94978
|
Pdpntm2.1Mlkn/Pdpntm2.1Mlkn Tg(Pdgfrb-cre)9Rha/0
(involves: C57BL/6)
|
lymph node hemorrhage
|
J:205423
|
Pdss2kd/Pdss2kd
(CBA/H-Pdss2kd)
|
tubulointerstitial nephritis
|
J:197578
|
Pdss2kd/Pdss2kd
(B6.CBACaH(CAST)-Pdss2kd)
|
tubulointerstitial nephritis
|
J:101779
|
Pdss2tm1Dalg/Pdss2tm1Dalg Tg(NPHS2-cre)295Lbh/?
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
tubulointerstitial nephritis
|
J:136670
|
Pdx1tm1Ted/Pdx1+
(involves: 129P2/OlaHsd)
|
pancreas inflammation
|
J:82969
|
Pdzk1tm2b(EUCOMM)Wtsi/Pdzk1tm2b(EUCOMM)Wtsi
(C57BL/6N-Pdzk1tm2b(EUCOMM)Wtsi/Wtsi)
|
blood in lymph vessels
|
J:239583
|
Pecam1tm1Mak/Pecam1+
(D1.129P2-Pecam1tm1Mak)
|
increased susceptibility to induced arthritis
|
J:106275
|
Pecam1tm1Mak/Pecam1tm1Mak
(D1.129P2-Pecam1tm1Mak)
|
abnormal leukocyte physiology
|
J:106275
|
increased interferon-gamma secretion
|
J:106275
|
increased susceptibility to induced arthritis
|
J:106275
|
joint inflammation
|
J:106275
|
Pecam1tm1Mak/Pecam1tm1Mak
(B6.129P2-Pecam1tm1Mak)
|
abnormal cytokine secretion
|
J:95226
|
liver inflammation
|
J:95226
|
Pecam1tm1Mak/Pecam1tm1Mak PitgpC57BL/6/PitgpC57BL/6
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
peritoneal inflammation
|
J:144817
|
Peli1tm1.1Arte/Peli1tm1.1Arte
(involves: C57BL/6N)
|
abnormal cytokine secretion
|
J:191578
|
decreased interferon-alpha secretion
|
J:191578
|
decreased interferon-beta secretion
|
J:191578
|
decreased interleukin-6 secretion
|
J:191578
|
decreased interleukin-10 secretion
|
J:191578
|
decreased interleukin-12 secretion
|
J:191578
|
decreased tumor necrosis factor secretion
|
J:191578
|
Peli1tm1Tigm/Peli1tm1Tigm
(involves: 129/Sv * C57BL/6)
|
decreased B cell proliferation
|
J:152781
|
decreased circulating interferon-beta level
|
J:152781
|
decreased circulating interleukin-6 level
|
J:152781
|
decreased circulating interleukin-12b level
|
J:152781
|
decreased circulating tumor necrosis factor level
|
J:152781
|
decreased interleukin-12 secretion
|
J:152781
|
decreased susceptibility to endotoxin shock
|
J:152781
|
increased B cell apoptosis
|
J:152781
|
Peli2tm1.1Arte/Peli2tm1.1Arte
(involves: C57BL/6)
|
abnormal circulating cytokine level
|
J:265431
|
abnormal cytokine secretion
|
J:265431
|
decreased circulating interleukin-1 beta level
|
J:265431
|
decreased interleukin-1 beta secretion
|
J:265431
|
decreased interleukin-18 secretion
|
J:265431
|
increased macrophage apoptosis
|
J:265431
|
Peli3tm1.1Arte/Peli3tm1.1Arte
(involves: C57BL/6NTac)
|
abnormal dendritic cell physiology
|
J:188556
|
abnormal macrophage cytokine production
|
J:188556
|
decreased susceptibility to Picornaviridae infection
|
J:188556
|
decreased susceptibility to Picornaviridae infection induced morbidity/mortality
|
J:188556
|
Penk-rstm1Pig/Penk-rstm1Pig
(B6.129-Penk-rstm1Pig)
|
abnormal T-helper 2 physiology
|
J:62435
|
lung inflammation
|
J:62435
|
Perptm1Att/Perptm1Att
(involves: 129S4/SvJae)
|
decreased thymocyte apoptosis
|
J:86549
|
Perptm2Att/Perptm2Att Tg(KRT14-cre/ERT2)1Ipc/0
(involves: 129S4/SvJae)
|
skin inflammation
|
J:167545
|
Pex1tm1.1Hrw/Pex1tm1.1Hrw
(involves: C57BL/6NTac)
|
liver inflammation
|
J:278655
|
phlebitis
|
J:278655
|
Pex5tm1Pec/Pex5tm1Pec Cnptm1(cre)Kan/Cnp+
(involves: 129S1/Sv * 129X1/SvJ)
|
abnormal inflammatory response
|
J:123503
|
Pex7tm1Nbra/Pex7tm1Nbra
(involves: 129S/SvEv * C57BL/6)
|
liver inflammation
|
J:158845
|
Pfdn1Gt(GTR1.3)1Rul/Pfdn1Gt(GTR1.3)1Rul
(involves: 129)
|
abnormal B cell activation
|
J:137415
|
abnormal T cell activation
|
J:137415
|
sinus inflammation
|
J:137415
|
Pfkfb3tm1.1Pec/Pfkfb3tm1.1Pec Tg(Pdgfb-icre/ERT2,-EGFP)1Frut/0
(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NCrl * CBA)
|
abnormal macrophage physiology
|
J:296552
|
Pgam1tm1.1Hiko/Pgam1tm1.1Hiko Tg(Cd4-cre)1Cwi/0
(involves: C57BL/6 * DBA/2)
|
decreased acute inflammation
|
J:293746
|
decreased interleukin-2 secretion
|
J:293746
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:293746
|
Pgam5tm1d(EUCOMM)Wtsi/Pgam5tm1d(EUCOMM)Wtsi
(involves: C57BL/6N)
|
abnormal interleukin-1 beta secretion
|
J:240016
|
abnormal macrophage activation involved in immune response
|
J:240016
|
decreased interleukin-1 beta secretion
|
J:240016
|
Pgap3tm1.1Ymra/Pgap3tm1.1Ymra
(involves: 129 * C57BL/6)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:181221
|
decreased T cell proliferation
|
J:181221
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:181221
|
increased T cell proliferation
|
J:181221
|
Pgap3tm1.1Ymra/Pgap3tm1.1Ymra
(B6.Cg-Pgap3tm1.1Ymra)
|
decreased B cell proliferation
|
J:203443
|
impaired macrophage phagocytosis
|
J:203443
|
increased anti-double stranded DNA antibody level
|
J:203443
|
increased anti-single stranded DNA antibody level
|
J:203443
|
Pgap4em1Osbir/Pgap4em1Osbir
(involves: C57BL/6NSlc)
|
increased susceptibility to infection induced morbidity/mortality
|
J:333707
|
increased susceptibility to prion infection
|
J:333707
|
Pgdtm1.1Pse/Pgdtm1.1Pse Foxp3tm4(YFP/icre)Ayr/Foxp3+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
|
abnormal regulatory T cell physiology
|
J:313817
|
blepharitis
|
J:313817
|
ear inflammation
|
J:313817
|
increased circulating interferon-gamma level
|
J:313817
|
increased circulating interleukin-4 level
|
J:313817
|
increased circulating interleukin-5 level
|
J:313817
|
increased circulating interleukin-17 level
|
J:313817
|
increased IgA level
|
J:313817
|
increased IgD level
|
J:313817
|
increased IgE level
|
J:313817
|
increased IgG2a level
|
J:313817
|
increased IgG3 level
|
J:313817
|
increased IgM level
|
J:313817
|
increased interferon-gamma secretion
|
J:313817
|
increased susceptibility to type I hypersensitivity reaction
|
J:313817
|
Pgdtm1.1Pse/Pgdtm1.1Pse Tg(Cd4-cre)1Cwi/0
(involves: C57BL/6 * DBA/2)
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:306553
|
Pgdtm1.1Pse/Pgdtm1.1Pse Tg(Cd4-cre)1Cwi/0 Tg(TcraTcrb)8Rest/0
(involves: C57BL/6 * DBA/2)
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:306553
|
Pgdtm1.1Pse/Pgdtm1.1Pse Tg(Cd4-cre)1Cwi/0 Tg(TcraTcrb)1100Mjb/0
(involves: C57BL/6 * DBA/2)
|
abnormal cytotoxic T cell physiology
|
J:306553
|
Pgftm1Pec/Pgftm1Pec
(involves: 129)
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:81388
|
Pgia1BALB/cCrl/Pgia1DBA/2Crl
(involves: BALB/cCrl * DBA/2Crl)
|
increased autoantibody level
|
J:66460
|
increased susceptibility to autoimmune disorder
|
J:66460
|
Pgia2BALB/cCrl/?
(involves: BALB/cCrl * DBA/2Crl)
|
increased autoantibody level
|
J:66460
|
Pgia3DBA/2Crl/?
(involves: BALB/cCrl * DBA/2Crl)
|
increased autoantibody level
|
J:66460
|
increased inflammatory response
|
J:66460
|
Pgia4BALB/cCrl/?
(involves: BALB/cCrl * DBA/2Crl)
|
increased autoantibody level
|
J:66460
|
Pgia5BALB/cCrl/?
(involves: BALB/cCrl * DBA/2Crl)
|
increased inflammatory response
|
J:66460
|
Pgia6BALB/cCrl/?
(involves: BALB/cCrl * DBA/2Crl)
|
increased autoantibody level
|
J:66460
|
Pgia7BALB/cCrl/?
(involves: BALB/cCrl * DBA/2Crl)
|
increased autoantibody level
|
J:66460
|
Pgia8DBA/2/Pgia8DBA/2
(C.D2-(D15Mit12-D15Mit267))
|
decreased susceptibility to induced arthritis
|
J:137478
|
Pgia8DBA/2/Pgia8DBA/2
(involves: BALB/c * DBA/2)
|
decreased interleukin-6 secretion
|
J:137478
|
decreased susceptibility to induced arthritis
|
J:137478
|
increased tumor necrosis factor secretion
|
J:137478
|
Pgia8DBA/2Crl/?
(involves: BALB/cCrl * DBA/2Crl)
|
increased inflammatory response
|
J:66460
|
Pgia9BALB/cCrl/?
(involves: BALB/cCrl * DBA/2Crl)
|
increased inflammatory response
|
J:66460
|
Pgia9DBA/2/Pgia9DBA/2
(C.D2-(D15Mit267-D15Mit41))
|
decreased susceptibility to induced arthritis
|
J:137478
|
Pgia9DBA/2/Pgia9DBA/2
(involves: BALB/c * DBA/2)
|
decreased susceptibility to induced arthritis
|
J:137478
|
increased interleukin-6 secretion
|
J:137478
|
increased tumor necrosis factor secretion
|
J:137478
|
Pgia10BALB/cCrl/?
(involves: BALB/cCrl * DBA/2Crl)
|
increased autoantibody level
|
J:66460
|
increased inflammatory response
|
J:66460
|
Pgia11BALB/cCrl/?
(involves: BALB/cCrl * DBA/2Crl)
|
increased autoantibody level
|
J:66460
|
Pgia12BALB/cCrl/?
(involves: BALB/cCrl * DBA/2Crl)
|
increased inflammatory response
|
J:66460
|
Pgia13C3H/HeJCr/Pgia13C3H/HeJCr
(involves: C3H/HeJCr * C57BL/6)
|
increased susceptibility to induced arthritis
|
J:65424
|
Pgia14C3H/HeJCr/Pgia14C3H/HeJCr
(involves: C3H/HeJCr * C57BL/6)
|
increased susceptibility to induced arthritis
|
J:65424
|
Pgia15C3H/HeJCr/Pgia15C3H/HeJCr
(involves: C3H/HeJCr * C57BL/6)
|
increased susceptibility to induced arthritis
|
J:65424
|
Pgia16C3H/HeJCr/Pgia16C3H/HeJCr
(involves: C3H/HeJCr * C57BL/6)
|
increased susceptibility to autoimmune disorder
|
J:65424
|
Pgia26BALB/cCrl/?
(involves: BALB/cCrl * DBA/2Crl)
|
increased inflammatory response
|
J:84150
|
Pgia26DBA/2Crl/?
(involves: BALB/cCrl * DBA/2Crl)
|
abnormal inflammatory response
|
J:84150
|
Pgia39DBA/2Crl/? Pgia6BALB/cCrl/Pgia6DBA/2Crl
(involves: BALB/cCrl * DBA/2Crl)
|
decreased inflammatory response
|
J:84150
|
Pgia39DBA/2Crl/Pgia39DBA/2Crl Pgia6DBA/2Crl/Pgia6DBA/2Crl
(involves: BALB/cCrl * DBA/2Crl)
|
increased susceptibility to induced arthritis
|
J:84150
|
Pgia39DBA/2Crl/Pgia39DBA/2Crl Pgia26BALB/cCrl/Pgia26BALB/cCrl
(involves: BALB/cCrl * DBA/2Crl)
|
increased susceptibility to induced arthritis
|
J:84150
|
Pgis1DBA/2/Pgis1DBA/2
(involves: BALB/c * DBA/2)
|
increased susceptibility to induced arthritis
|
J:107496
|
Pgis1DBA/2/Pgis1DBA/2 Pgis2BALB/c/Pgis2BALB/c
(involves: BALB/c * DBA/2)
|
increased susceptibility to induced arthritis
|
J:107496
|
Pgis1DBA/2/Pgis1DBA/2 Pgis2BALB/c/Pgis2DBA/2
(involves: BALB/c * DBA/2)
|
increased susceptibility to induced arthritis
|
J:107496
|
Pgis2BALB/c/Pgis2BALB/c
(involves: BALB/c * DBA/2)
|
increased susceptibility to induced arthritis
|
J:107496
|
Pgis2BALB/c/Pgis2DBA/2
(involves: BALB/c * DBA/2)
|
increased susceptibility to induced arthritis
|
J:107496
|
Pglyrp1tm1.1Lky/Pglyrp1tm1.1Lky
(B6.129S4-Pglyrp1tm1.1Lky)
|
abnormal neutrophil physiology
|
J:171412
|
increased susceptibility to bacterial infection
|
J:171412
|
Pglyrp1tm1Rdz/Pglyrp1tm1Rdz
(involves: 129S5/SvEvBrd)
|
abnormal neutrophil physiology
|
J:84680
|
impaired granulocyte bactericidal activity
|
J:84680
|
increased susceptibility to bacterial infection
|
J:84680
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:84680
|
Pglyrp1tm1Rdz/Pglyrp1tm1Rdz
(C.129S-Pglyrp1tm1Rdz)
|
increased susceptibility to induced arthritis
|
J:178054
|
Pglyrp1tm1Rdz/Pglyrp1tm1Rdz
(involves: 129S5/SvEvBrd * BALB/c)
|
abnormal chemokine secretion
|
J:178053
|
increased interleukin-6 secretion
|
J:178053
|
increased susceptibility to induced colitis
|
J:178053
|
Pglyrp1tm1Rdz/Pglyrp1tm1Rdz Pglyrp2tm1Rdz/Pglyrp2tm1Rdz
(C.129S-Pglyrp1tm1Rdz Pglyrp2tm1Rdz)
|
decreased susceptibility to induced arthritis
|
J:178054
|
Pglyrp2tm1Lky/Pglyrp2tm1Lky
(involves: 129S4/SvJae * C57BL/6)
|
abnormal macrophage physiology
|
J:159600
|
abnormal tumor necrosis factor level
|
J:159600
|
decreased circulating interleukin-6 level
|
J:159600
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:159600
|
Pglyrp2tm1Rdz/Pglyrp2tm1Rdz
(C.129S-Pglyrp2tm1Rdz)
|
abnormal circulating chemokine level
|
J:178054
|
decreased susceptibility to induced arthritis
|
J:178054
|
Pglyrp2tm1Rdz/Pglyrp2tm1Rdz
(involves: 129S/SvEv * BALB/c)
|
abnormal chemokine secretion
|
J:178053
|
increased interleukin-6 secretion
|
J:178053
|
increased susceptibility to induced colitis
|
J:178053
|
Pglyrp3tm1Rdz/Pglyrp3tm1Rdz
(involves: 129S6/SvEvTac * BALB/c)
|
abnormal chemokine secretion
|
J:178053
|
increased interleukin-6 secretion
|
J:178053
|
increased susceptibility to induced colitis
|
J:178053
|
Pglyrp4tm1Rdz/Pglyrp4tm1Rdz
(involves: 129S6/SvEvTac * BALB/c)
|
abnormal chemokine secretion
|
J:178053
|
increased interleukin-6 secretion
|
J:178053
|
increased susceptibility to induced colitis
|
J:178053
|
Pgm3Gt(W037B08)Wrst/Pgm3mld1
(involves: 129S1/Sv * C57BL/6)
|
glomerulonephritis
|
J:125094
|
Pgrtm1Bwo/Pgrtm1Bwo
(either: (involves: 129S7/SvEvBrd) or (involves: 129S7/SvEvBrd * C57BL/6))
|
uterus inflammation
|
J:28980
|
Pgrtm1Lyd/Pgrtm1Lyd
(involves: 129S7/SvEvBrd)
|
abnormal cytokine secretion
|
J:130208
|
Pgrtm2(cre)Lyd/Pgr+ Criptotm2.2Mms/Criptotm2.2Mms
(involves: 129/Sv * C57BL/6N * CD-1)
|
endometrium inflammation
|
J:324146
|
Pgrmc1em1Ejho/Pgrmc1em1Ejho
(involves: C57BL/6N)
|
liver inflammation
|
J:268130
|
PhexHyp-Duk/Y
(involves: BALB/cAnBomUrd)
|
ear inflammation
|
J:132678
|
increased susceptibility to otitis media
|
J:132678
|
PhexHyp/?
(involves: C57BL/6J)
|
enthesitis
|
J:192371
|
PhexMhdabap024/Y
(C3HeB/FeJ-PhexMhdabap024)
|
decreased circulating C-reactive protein level
|
J:264682
|
PhexSka1/PhexSka1
(C57BL/6-PhexSka1)
|
abnormal osteoclast physiology
|
J:79953
|
Phf6tm1.1Avo/Y Tg(Tek-cre)1Ywa/0
(involves: C57BL/6 * SJL)
|
increased circulating interferon-alpha level
|
J:276228
|
Phf11dm1H/Phf11dm1H
(C3H.CAnNCrl(C3)-Phf11dm1H)
|
abnormal inflammatory response
|
J:217094
|
Phlpp1tm1.1Saco/Phlpp1tm1.1Saco Phlpp2tm1d(EUCOMM)Hmgu/Phlpp2tm1d(EUCOMM)Hmgu
(involves: 129 * C57BL/6N)
|
decreased susceptibility to induced colitis
|
J:231241
|
Phyhtm1Safe/Phyhtm1Safe
(involves: 129P2/OlaHsd * 129X1/SvJ * Black Swiss * FVB/N)
|
liver inflammation
|
J:142512
|
Pi4kam1Btlr/Pi4kam1Btlr
(C57BL/6J-Pi4kam1Btlr)
|
decreased macrophage apoptosis
|
J:265261
|
decreased tumor necrosis factor secretion
|
J:265261
|
increased interleukin-1 beta secretion
|
J:265261
|
Pi16tm1.2Engl/Pi16tm1.2Engl
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6N * SJL)
|
abnormal immune system physiology
|
J:244259
|
Pias1tm1Kes/Pias1tm1Kes
(involves: 129S/Sv * C57BL/6)
|
decreased susceptibility to Riboviria infection induced morbidity/mortality
|
J:92167
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:92167
|
increased susceptibility to endotoxin shock
|
J:92167
|
Pierce1tm2b(EUCOMM)Wtsi/Pierce1tm2b(EUCOMM)Wtsi
(C57BL/6N-Pierce1tm2b(EUCOMM)Wtsi/Wtsi)
|
blood in lymph vessels
|
J:239583
|
Pigatm1Tak/Pigatm1Tak Tg(FES-cre)31Bsl/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA/Ca)
|
abnormal T cell activation
|
J:162065
|
abnormal T cell physiology
|
J:162065
|
Pigrtm1Fejo/Pigrtm1Fejo
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal immunoglobulin level
|
J:57987
|
abnormal immunoglobulin transcytosis
|
J:57987
|
decreased IgA level
|
J:57987
|
increased IgA level
|
J:57987
|
increased IgG level
|
J:57987
|
Pigrtm1Fejo/Pigrtm1Fejo
(involves: 129 * C57BL/6)
|
increased IgA level
|
J:140515
|
increased susceptibility to parasitic infection
|
J:140515
|
Pigrtm1Ohw/Pigrtm1Ohw
(involves: 129X1/SvJ * C57BL/6J)
|
decreased IgA level
|
J:58454
|
increased IgA level
|
J:58454
|
increased IgE level
|
J:58454
|
increased IgG level
|
J:58454
|
Pigrtm1Ohw/Pigrtm1Ohw
(B6.129X1-Pigrtm1Ohw)
|
abnormal lymphocyte physiology
|
J:97824
|
decreased IgA level
|
J:108538
|
decreased interferon-gamma secretion
|
J:108538
|
decreased tumor necrosis factor secretion
|
J:108538
|
increased IgA level
|
J:108538,
J:97824
|
increased susceptibility to bacterial infection
|
J:108538
|
Pigrtm1Ohw/Pigrtm1Ohw Tcrbtm1Mom/Tcrbtm1Mom Tcrdtm1Mom/Tcrdtm1Mom
(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6J)
|
increased IgA level
|
J:97824
|
Pigrtm1Rast/Pigrtm1Rast
(C57BL/6-Pigrtm1Rast)
|
abnormal immunoglobulin level
|
J:81984
|
abnormal immunoglobulin transcytosis
|
J:81984
|
decreased IgA level
|
J:81984
|
increased IgA level
|
J:81984
|
increased IgG level
|
J:81984
|
Pik3ap1m1Btlr/Pik3ap1m1Btlr
(involves: C57BL/6J)
|
decreased IgM level
|
J:185495
|
Pik3ap1m2Btlr/Pik3ap1m2Btlr
(C57BL/6J-Pik3ap1m2Btlr)
|
impaired humoral immune response
|
J:255271
|
increased IgM level
|
J:255271
|
Pik3ap1tm1Kuro/Pik3ap1tm1Kuro
(involves: 129P2/OlaHsd)
|
decreased B cell proliferation
|
J:84669
|
decreased IgG2b level
|
J:75075
|
decreased IgG3 level
|
J:75075
|
decreased IgM level
|
J:75075
|
decreased immunoglobulin level
|
J:75075
|
Pik3c2aGt(OST288105)Lex/Pik3c2aGt(OST288105)Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
|
glomerulonephritis
|
J:169710
|
increased anti-double stranded DNA antibody level
|
J:169710
|
increased IgA level
|
J:169710
|
increased IgG level
|
J:169710
|
increased IgM level
|
J:169710
|
Pik3c3tm1.1Flv/Pik3c3tm1.1Flv Tg(Cd8a-cre)1Itan/0
(involves: C57BL/6 * C57BL/6N)
|
increased T cell apoptosis
|
J:184753
|
Pik3cdGt(OST451938)Lex/Pik3cdGt(OST451938)Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
|
decreased IgG1 level
|
J:103485
|
Pik3cdm1Btlr/Pik3cdm1Btlr
(C57BL/6J-Pik3cdm1Btlr)
|
abnormal humoral immune response
|
J:213049
|
Pik3cdm2Btlr/Pik3cd+
(C57BL/6J-Pik3cdm2Btlr)
|
decreased IgG level
|
J:236693
|
decreased IgM level
|
J:236693
|
decreased response to antigen
|
J:236693
|
Pik3cdm2Btlr/Pik3cdm2Btlr
(C57BL/6J-Pik3cdm2Btlr)
|
decreased IgG level
|
J:236693
|
decreased IgM level
|
J:236693
|
decreased response to antigen
|
J:236693
|
increased circulating interferon-alpha level
|
J:236693
|
increased IgE level
|
J:236693
|
increased response to antigen
|
J:236693
|
increased susceptibility to Herpesvirales infection
|
J:236693
|
Pik3cdtm1.1Bvan/Pik3cdtm1.1Bvan
(involves: 129P2/OlaHsd * BALB/c)
|
decreased IgA level
|
J:78412
|
decreased IgM level
|
J:78412
|
decreased immunoglobulin level
|
J:78412
|
intestinal inflammation
|
J:78412
|
Pik3cdtm1Jni/Pik3cdtm1Jni
(involves: 129P2/OlaHsd)
|
abnormal B cell calcium ion homeostasis
|
J:80614
|
abnormal humoral immune response
|
J:80614
|
decreased B cell proliferation
|
J:80614
|
decreased immunoglobulin level
|
J:80614
|
Pik3cdtm1Jni/Pik3cdtm1Jni Pik3cgtm1Pngr/Pik3cgtm1Pngr
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased cytotoxic T cell cytolysis
|
J:124330
|
decreased interferon-gamma secretion
|
J:124330
|
Pik3cdtm1Tnr/Pik3cdtm1Tnr
(involves: 129S4/SvJae)
|
abnormal B cell physiology
|
J:113491
|
abnormal humoral immune response
|
J:79133
|
decreased B cell proliferation
|
J:113491,
J:79133
|
decreased IgG1 level
|
J:79133
|
decreased IgG2a level
|
J:79133
|
decreased IgG2b level
|
J:79133
|
decreased IgG3 level
|
J:79133
|
decreased IgM level
|
J:79133
|
Pik3cdtm1Tnr/Pik3cdtm1Tnr
(B6.129S4-Pik3cdtm1Tnr)
|
decreased inflammatory response
|
J:134324
|
decreased susceptibility to induced arthritis
|
J:134324
|
Pik3cdtm1Tnr/Pik3cdtm1Tnr Pik3cgtm1Pngr/Pik3cgtm1Pngr
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
abnormal T cell physiology
|
J:125791
|
Pik3cdtm1Tnr/Pik3cdtm1Tnr Pik3cgtm1Pngr/Pik3cgtm1Pngr
(B6.129-Pik3cdtm1Tnr Pik3cgtm1Pngr)
|
decreased inflammatory response
|
J:134324
|
decreased susceptibility to induced arthritis
|
J:134324
|
impaired neutrophil chemotaxis
|
J:134324
|
impaired neutrophil recruitment
|
J:134324
|
Pik3cdtm1Tnr/Pik3cdtm1Tnr Ptentm2.1Ppp/Ptentm2.1Ppp Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJae * C57BL/6)
|
abnormal class switch recombination
|
J:130950
|
Pik3cdtm2.1Tnr/Pik3cdtm2.1Tnr Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased IgE level
|
J:164283
|
Pik3cdtm2.1Tnr/Pik3cdtm2.1Tnr Tg(Cd4-cre)1Cwi/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
abnormal adaptive immunity
|
J:164283
|
abnormal humoral immune response
|
J:164283
|
decreased IgG1 level
|
J:164283
|
Pik3cdtm2.1Tnr/Pik3cdtm2.1Tnr Tnfrsf4tm2(cre)Nik/Tnfrsf4+
(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6)
|
abnormal humoral immune response
|
J:164283
|
decreased IgG1 level
|
J:164283
|
Pik3cgtm1Dwu/Pik3cgtm1Dwu
(Not Specified)
|
decreased immunoglobulin level
|
J:60348
|
impaired neutrophil chemotaxis
|
J:60348
|
Pik3cgtm1Dwu/Pik3cgtm1Dwu
(B6.Cg-Pik3cgtm1Dwu)
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:131923
|
abnormal response to infection
|
J:131923
|
increased susceptibility to Poxviridae infection
|
J:131923
|
Pik3cgtm1Dwu/Pik3cgtm1Dwu Tg(TcraTcrb)1100Mjb/0
(involves: C57BL/6)
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:131923
|
abnormal response to infection
|
J:131923
|
Pik3cgtm1Ehi/Pik3cgtm1Ehi
(Not Specified)
|
impaired macrophage chemotaxis
|
J:91945
|
impaired neutrophil recruitment
|
J:91945
|
Pik3cgtm1Lste/Pik3cgtm1Lste
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal neutrophil physiology
|
J:147259
|
impaired neutrophil chemotaxis
|
J:147259
|
impaired neutrophil recruitment
|
J:147259
|
Pik3cgtm1Lste/Pik3cgtm1Lste
(involves: 129P2/OlaHsd)
|
impaired neutrophil chemotaxis
|
J:238900
|
Pik3cgtm1Pngr/Pik3cgtm1Pngr
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal immune cell physiology
|
J:60347
|
abnormal neutrophil physiology
|
J:60347
|
abnormal T cell activation
|
J:60347
|
abnormal T cell physiology
|
J:60347
|
abnormal T-helper 2 physiology
|
J:60347
|
decreased cytotoxic T cell cytolysis
|
J:124330
|
decreased interferon-gamma secretion
|
J:60347,
J:124330
|
decreased interleukin-2 secretion
|
J:60347
|
decreased T cell proliferation
|
J:60347
|
impaired neutrophil chemotaxis
|
J:60347
|
impaired neutrophil recruitment
|
J:60347
|
Pik3cgtm1Pngr/Pik3cgtm1Pngr
(B6.129P2-Pik3cgtm1Pngr)
|
decreased inflammatory response
|
J:134324
|
decreased susceptibility to induced arthritis
|
J:134324
|
impaired neutrophil chemotaxis
|
J:134324
|
Pik3cgtm1Wym/Pik3cgtm1Wym
(either: 129/Sv-Pik3cgtm1Wym or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))
|
abnormal leukocyte physiology
|
J:60349
|
abnormal neutrophil physiology
|
J:60349
|
impaired macrophage chemotaxis
|
J:60349
|
impaired neutrophil chemotaxis
|
J:60349
|
impaired neutrophil recruitment
|
J:60349
|
increased susceptibility to bacterial infection
|
J:60349
|
Pik3cgtm1Wym/Pik3cgtm1Wym
(involves: 129S1/Sv * 129X1/SvJ)
|
abnormal neutrophil physiology
|
J:147259
|
impaired neutrophil chemotaxis
|
J:238900
|
impaired neutrophil recruitment
|
J:147259
|
Pik3cgtm2Ehi/Pik3cgtm2Ehi
(Not Specified)
|
abnormal inflammatory response
|
J:124856
|
abnormal macrophage physiology
|
J:124856
|
impaired macrophage chemotaxis
|
J:124856
|
impaired neutrophil chemotaxis
|
J:124856
|
increased interleukin-1 beta secretion
|
J:124856
|
increased interleukin-6 secretion
|
J:124856
|
increased tumor necrosis factor secretion
|
J:124856
|
Pik3r1tm1Dfr/Pik3r1tm1Dfr
(involves: 129S6/SvEvTac * C57BL/6)
|
decreased B cell proliferation
|
J:52229
|
Pik3r1tm1Dfr/Pik3r1tm1Dfr Plcg2tm1Jni/Plcg2tm1Jni
(involves: 129P2/OlaHsd * 129S6/SvEvTac)
|
increased B cell apoptosis
|
J:104166
|
Pik3r1tm1Tka/Pik3r1tm1Tka
(involves: C57BL/6 * CBA)
|
abnormal B cell physiology
|
J:113491
|
abnormal humoral immune response
|
J:52228
|
decreased B cell proliferation
|
J:113491,
J:52228
|
increased susceptibility to bacterial infection
|
J:52228
|
Pik3r4tm1.1Mpnd/Pik3r4tm1.1Mpnd Tg(ACTA1-cre)79Jme/0
(involves: 129S2/SvPas * C57BL/6J * C57BL/6N * SJL)
|
myositis
|
J:198770
|
Pik3r5tm1Lste/Pik3r5tm1Lste
(involves: 129P2/OlaHsd * C57BL/6)
|
impaired neutrophil chemotaxis
|
J:147259
|
impaired neutrophil recruitment
|
J:147259
|
Pik3r5tm1Lste/Pik3r5tm1Lste
(involves: 129P2/OlaHsd)
|
impaired neutrophil chemotaxis
|
J:238900
|
Pik3r6tm1.1Lste/Pik3r6tm1.1Lste
(Not Specified)
|
abnormal neutrophil physiology
|
J:238900
|
Pikfyvetm2.1Tssk/Pikfyvetm2.1Tssk Tg(Vil1-cre)20Syr/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
intestinal inflammation
|
J:193689
|
Pilratm1Osb/Pilratm1Osb
(B6.129-Pilratm1Osb)
|
abnormal leukocyte adhesion
|
J:191085
|
abnormal neutrophil physiology
|
J:191085
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:191085
|
increased susceptibility to endotoxin shock
|
J:191085
|
Pilrb1tm1Pgh/Pilrb1tm1Pgh
(involves: C57BL/6)
|
abnormal chemokine level
|
J:157763
|
abnormal cytokine level
|
J:157763
|
abnormal cytokine secretion
|
J:157763
|
decreased circulating interleukin-1 beta level
|
J:157763
|
decreased circulating interleukin-6 level
|
J:157763
|
decreased circulating tumor necrosis factor level
|
J:157763
|
decreased interleukin-1 beta secretion
|
J:157763
|
decreased susceptibility to bacterial infection
|
J:157763
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:157763
|
decreased tumor necrosis factor secretion
|
J:157763
|
increased circulating interferon-gamma level
|
J:157763
|
increased circulating interleukin-12 level
|
J:157763
|
increased interferon-gamma secretion
|
J:157763
|
increased interleukin-10 secretion
|
J:157763
|
increased interleukin-12 secretion
|
J:157763
|
Pim1tm1Pwl/Pim1tm1Pwl
(involves: 129P2/OlaHsd * BALB/c)
|
abnormal mast cell physiology
|
J:15259,
J:14715
|
Pim1tm1Pwl/Pim1tm1Pwl Pim2tm1Brn/Pim2tm1Brn Pim3tm1Brn/Pim3tm1Brn
(involves: 129P/Ola * FVB/N)
|
decreased B cell proliferation
|
J:91592
|
decreased T cell proliferation
|
J:91592
|
Pim2tm1.1Lex/Pim2tm1.1Lex
(involves: 129S/SvEvBrd * C57BL/6)
|
decreased interleukin-6 secretion
|
J:166403
|
Pim2tm1Brn/Pim2tm1Brn
(involves: 129P/Ola * FVB/N)
|
decreased T cell proliferation
|
J:91592
|
Pink1tm1Hbu/Pink1tm1Hbu
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased interleukin-1 beta secretion
|
J:169471
|
increased interleukin-10 secretion
|
J:169471
|
increased interleukin-12 secretion
|
J:169471
|
Pip4k2ctm1b(KOMP)Wtsi/Pip4k2ctm1b(KOMP)Wtsi
(involves: C57BL/6J * C57BL/6N)
|
abnormal circulating chemokine level
|
J:234283
|
abnormal T cell activation
|
J:234283
|
chronic inflammation
|
J:234283
|
chronic liver inflammation
|
J:234283
|
increased circulating interferon-gamma level
|
J:234283
|
increased circulating interleukin-2 level
|
J:234283
|
increased circulating interleukin-4 level
|
J:234283
|
increased circulating interleukin-10 level
|
J:234283
|
increased circulating interleukin-12 level
|
J:234283
|
increased circulating interleukin-12b level
|
J:234283
|
increased IgG3 level
|
J:234283
|
increased inflammatory response
|
J:234283
|
increased interferon-gamma secretion
|
J:234283
|
increased interleukin-17 secretion
|
J:234283
|
increased T cell proliferation
|
J:234283
|
intestinal inflammation
|
J:234283
|
kidney inflammation
|
J:234283
|
lung inflammation
|
J:234283
|
salivary gland inflammation
|
J:234283
|
Pip5k1btm1Tssk/Pip5k1btm1Tssk
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal mast cell physiology
|
J:97991
|
increased susceptibility to type I hypersensitivity reaction
|
J:97991
|
Pip5k1ctm1.2Ref/Pip5k1ctm1.2Ref Tg(TcraTcrb)425Cbn/0
(involves: BALB/c * C57BL/6)
|
abnormal T cell physiology
|
J:164732
|
increased interferon-gamma secretion
|
J:164732
|
increased interleukin-2 secretion
|
J:164732
|
increased T cell proliferation
|
J:164732
|
Piptm1Myal/Piptm1Myal
(involves: 129S/SvEv * C57BL/6)
|
arteritis
|
J:202016
|
colitis
|
J:202016
|
Pirbem1Fgla/Pirbem1Fgla
(C57BL/6-Pirbem1Fgla)
|
decreased length of allograft survival
|
J:290663
|
Pirbtm1Ttk/Pirbtm1Ttk
(involves: 129X1/SvJ)
|
abnormal B cell activation
|
J:76770
|
abnormal leukocyte physiology
|
J:76770
|
abnormal T cell physiology
|
J:76770
|
abnormal T-helper 2 physiology
|
J:76770
|
increased B cell proliferation
|
J:76770
|
Pitm1C57BL/FaDk/Pitm1C57BL/FaDk
(involves: C57BL/FaDk * RIII/FaDk)
|
decreased susceptibility to prion infection
|
J:70033
|
Pitm1C57BL/FaDk/Pitm1RIII/FaDk
(involves: C57BL/FaDk * RIII/FaDk)
|
decreased susceptibility to prion infection
|
J:70033
|
Pitm2C57BL/FaDk/Pitm2C57BL/FaDk
(involves: C57BL/FaDk * RIII/FaDk)
|
decreased susceptibility to prion infection
|
J:70033
|
Pitm2C57BL/FaDk/Pitm2RIII/FaDk
(involves: C57BL/FaDk * RIII/FaDk)
|
decreased susceptibility to prion infection
|
J:70033
|
Pitm3C57BL/FaDk/Pitm3C57BL/FaDk
(involves: C57BL/FaDk * RIII/FaDk)
|
decreased susceptibility to prion infection
|
J:70033
|
Pitm3C57BL/FaDk/Pitm3RIII/FaDk
(involves: C57BL/FaDk * RIII/FaDk)
|
decreased susceptibility to prion infection
|
J:70033
|
Pitm4C57BL/FaDk/Pitm4C57BL/FaDk
(involves: C57BL/FaDk * RIII/FaDk)
|
decreased susceptibility to prion infection
|
J:70033
|
Pitm4C57BL/FaDk/Pitm4RIII/FaDk
(involves: C57BL/FaDk * RIII/FaDk)
|
decreased susceptibility to prion infection
|
J:70033
|
Pitx3eyl/Pitx3eyl
(involves: C3H/He * C57BL/6)
|
abnormal immunoglobulin level
|
J:156878
|
decreased IgG3 level
|
J:156878
|
decreased IgM level
|
J:156878
|
Pja2tm1.2Afel/Pja2tm1.2Afel
(involves: 129S6/SvEvTac * C57BL/6J)
|
kidney inflammation
|
J:345592
|
Pkd1tm1Djmp/Pkd1tm1Djmp
(involves: 129P2/OlaHsd * C57BL/6)
|
kidney inflammation
|
J:94582
|
Pkd1tm1Jzh/Pkd1+
(either: (involves: 129S4/SvJae * C57BL/6) or (involves: 129S4/SvJae * BALB/c))
|
bile duct inflammation
|
J:52573
|
kidney inflammation
|
J:52573
|
Pkhd1tm1.1Ggg/Pkhd1tm1.1Ggg
(involves: 129S/SvEv * 129S4/SvJae * C57BL/6)
|
bile duct inflammation
|
J:125113
|
Pklrchar4/Pklrchar4
(involves: A/J * C57BL/6)
|
decreased susceptibility to parasitic infection
|
J:141722,
J:86735
|
decreased susceptibility to parasitic infection induced morbidity/mortality
|
J:141722
|
Pklrslc/Pklrslc
(CBA/NSlc-Pklrslc)
|
decreased susceptibility to parasitic infection
|
J:141722
|
decreased susceptibility to parasitic infection induced morbidity/mortality
|
J:141722
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:128518
|
Pkn1tm1Kik/Pkn1tm1Kik
(B6.129P2-Pkn1tm1Kik)
|
abnormal germinal center B cell physiology
|
J:193187
|
abnormal somatic hypermutation frequency
|
J:193187
|
decreased activation-induced B cell apoptosis
|
J:193187
|
glomerulonephritis
|
J:193187
|
increased anti-double stranded DNA antibody level
|
J:193187
|
increased B cell proliferation
|
J:193187
|
increased IgG1 level
|
J:193187
|
increased IgG2a level
|
J:193187
|
increased IgG2b level
|
J:193187
|
increased IgM level
|
J:193187
|
Pknox1Gt(OST71835)Lex/Pknox1Gt(OST71835)Lex
(involves: 129S5/SvEvBrd * C57BL/6)
|
increased T cell apoptosis
|
J:103769
|
Pknox1tm1Ngc/Pknox1+ Tg(IghMyc)22Bri/0
(involves: C57BL * SJL)
|
decreased B cell apoptosis
|
J:192251
|
increased B cell proliferation
|
J:192251
|
Pkp3tm1.1Fvr/Pkp3tm1.1Fvr
(involves: 129P2/OlaHsd * C57BL/6 * CBA * SJL)
|
dermatitis
|
J:136451
|
Pla1aem1Appsc/Pla1aem1Appsc
(C57BL/6J-Pla1aem1Appsc)
|
abnormal interleukin level
|
J:333902
|
decreased susceptibility to chemically induced skin inflammation
|
J:333902
|
decreased susceptibility to induced arthritis
|
J:333902
|
Pla2g2dtm1.1Mhg/Pla2g2dtm1.1Mhg
(B6NCrSlc.Cg-Pla2g2dtm1.1Mhg)
|
abnormal cytotoxic T cell physiology
|
J:229035
|
abnormal dendritic cell migration
|
J:229035
|
abnormal dendritic cell physiology
|
J:201008
|
decreased interleukin-6 secretion
|
J:201008
|
decreased susceptibility to Coronaviridae infection
|
J:229035
|
decreased susceptibility to Coronaviridae infection induced morbidity/mortality
|
J:229035
|
decreased tumor necrosis factor secretion
|
J:201008
|
increased interferon-gamma secretion
|
J:229035
|
increased susceptibility to type IV hypersensitivity reaction
|
J:201008
|
Pla2g3tm1Murm/Pla2g3tm1Murm
(involves: 129S/SvEv * C57BL/6)
|
decreased mast cell degranulation
|
J:197334
|
decreased susceptibility to type I hypersensitivity reaction
|
J:197334
|
ear inflammation
|
J:197334
|
Pla2g4atm1Jvb/Pla2g4atm1Jvb
(involves: 129S4/SvJae)
|
increased mast cell degranulation
|
J:54619
|
Pla2g4atm1Tksh/Pla2g4atm1Tksh
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased susceptibility to type I hypersensitivity reaction
|
J:39254
|
Pla2g4atm1Tksh/Pla2g4atm1Tksh
(NOD.129P2(B6)-Pla2g4atm1Tksh)
|
abnormal macrophage physiology
|
J:99775
|
insulitis
|
J:99775
|
Pla2g4atm1Tksh/Pla2g4atm1Tksh
(B6.129P2-Pla2g4atm1Tksh)
|
abnormal cytokine level
|
J:107430
|
decreased interferon-gamma secretion
|
J:107430
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:107430
|
decreased tumor necrosis factor secretion
|
J:107430
|
Pla2g4eem1Murm/Pla2g4eem1Murm
(C57BL/6NSlc-Pla2g4eem1Murm)
|
increased susceptibility to chemically induced skin inflammation
|
J:333700
|
Pla2g5tm1Jarm/Pla2g5tm1Jarm
(involves: 129 * C57BL/6J)
|
abnormal macrophage physiology
|
J:89490
|
decreased acute inflammation
|
J:89490
|
Pla2g5tm1Jarm/Pla2g5tm1Jarm
(involves: 129 * BALB/c)
|
impaired macrophage phagocytosis
|
J:110309
|
Pla2g5tm1Jarm/Pla2g5tm1Jarm
(C.129-Pla2g5tm1Jarm)
|
impaired macrophage phagocytosis
|
J:110309
|
Pla2g5tm1Jarm/Pla2g5tm1Jarm
(involves: 129 * C57BL/6)
|
impaired macrophage phagocytosis
|
J:110309
|
Pla2g5tm1Jarm/Pla2g5tm1Jarm
(B6.129-Pla2g5tm1Jarm)
|
impaired macrophage phagocytosis
|
J:110309
|
Pla2g7tm1.1Mcap/Pla2g7tm1.1Mcap
(B6.Cg-Pla2g7tm1.1Mcap)
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:228564
|
increased susceptibility to bacterial infection
|
J:228564
|
Pla2g10Gt712Lex/Pla2g10Gt712Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
|
abnormal interleukin level
|
J:125607
|
decreased IgE level
|
J:125607
|
decreased inflammatory response
|
J:125607
|
Pla2g10tm1Kiku/Pla2g10tm1Kiku
(B6.129P2-Pla2g10tm1Kiku)
|
abnormal neutrophil physiology
|
J:155082
|
impaired neutrophil chemotaxis
|
J:155082
|
Pla2g15tm1.1Jash/Pla2g15tm1.1Jash
(involves: 129S1/Sv * C57BL/6)
|
abnormal macrophage physiology
|
J:111561
|
Pla2r1tm1Itoh/Pla2r1tm1Itoh
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased susceptibility to endotoxin shock
|
J:44868
|
Plac8tm1Bhk/Plac8tm1Bhk
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal neutrophil physiology
|
J:145277
|
Plac8tm1Bhk/Plac8tm1Bhk
(129S/SvEv-Plac8tm1Bhk)
|
abnormal neutrophil physiology
|
J:145277
|
increased susceptibility to bacterial infection
|
J:145277
|
Plattm1Mlg/Plattm1Mlg
(involves: 129S2/SvPas * C57BL/6)
|
abnormal acute phase protein level
|
J:63134,
J:82604
|
Plattm1Mlg/Plattm1Mlg
(B6.Cg-Plattm1Mlg)
|
abnormal acute phase protein level
|
J:75303
|
abnormal cytokine level
|
J:75303
|
autoimmune arthritis
|
J:75303
|
chronic joint inflammation
|
J:75303
|
Plattm1Mlg/Plattm1Mlg
(involves: 129S2/SvPas)
|
abnormal microglial cell physiology
|
J:144185
|
Plattm1Mlg/Plattm1Mlg
(B6.129S2-Plattm1Mlg/J)
|
abnormal susceptibility to Coronaviridae infection
|
J:288556
|
increased susceptibility to Coronaviridae infection induced morbidity/mortality
|
J:288556
|
Plautm1.1Bug/Plautm1.1Bug
(involves: C57BL/6)
|
chronic inflammation
|
J:164542
|
liver inflammation
|
J:164542
|
trachea inflammation
|
J:164542
|
Plautm1Mlg/Plautm1Mlg
(involves: 129S2/SvPas * C57BL/6)
|
abnormal acute phase protein level
|
J:63134,
J:82604
|
abnormal cell-mediated immunity
|
J:87817,
J:95638
|
abnormal macrophage physiology
|
J:17427
|
abnormal neutrophil physiology
|
J:75573,
J:91980
|
impaired granulocyte bactericidal activity
|
J:91980
|
impaired macrophage chemotaxis
|
J:63134
|
impaired neutrophil phagocytosis
|
J:91980
|
increased susceptibility to fungal infection
|
J:95637
|
increased susceptibility to parasitic infection
|
J:87817
|
Plautm1Mlg/Plautm1Mlg
(B6.Cg-Plautm1Mlg)
|
abnormal acute phase protein level
|
J:68083
|
abnormal cytokine level
|
J:75303
|
decreased inflammatory response
|
J:68083
|
decreased susceptibility to induced arthritis
|
J:75303
|
decreased T cell proliferation
|
J:75303
|
impaired macrophage chemotaxis
|
J:68083
|
Plautm1Mlg/Plautm1Mlg
(B6.129S2-Plautm1Mlg)
|
chronic inflammation
|
J:164542
|
increased inflammatory response
|
J:164542
|
liver inflammation
|
J:164542
|
trachea inflammation
|
J:164542
|
Plaurtm1Jld/Plaurtm1Jld
(involves: 129P2/OlaHsd * Black Swiss)
|
abnormal macrophage physiology
|
J:26874
|
Plaurtm1Jld/Plaurtm1Jld
(B6.129P2-Plaurtm1Jld)
|
chronic inflammation
|
J:164542
|
increased inflammatory response
|
J:164542
|
liver inflammation
|
J:164542
|
trachea inflammation
|
J:164542
|
Plaurtm1Jld/Plaurtm1Jld Tg(MSR1-Plau)1Ddi/0
(B6.Cg-Plaurtm1Jld Tg(MSR1-Plau)1Ddi)
|
heart inflammation
|
J:113474
|
Plaurtm1Mlg/Plaurtm1Mlg
(involves: 129S2/SvPas * C57BL/6)
|
abnormal cytokine level
|
J:75573
|
abnormal macrophage physiology
|
J:31253
|
abnormal neutrophil physiology
|
J:75573,
J:91980
|
impaired neutrophil phagocytosis
|
J:91980
|
increased susceptibility to bacterial infection
|
J:75573
|
Plcb2tm1Dwu/Plcb2tm1Dwu
(involves: 129)
|
abnormal leukocyte physiology
|
J:41948
|
decreased susceptibility to bacterial infection
|
J:41948
|
decreased susceptibility to infection
|
J:41948
|
decreased susceptibility to viral infection
|
J:41948
|
Plcb2tm1Dwu/Plcb2tm1Dwu Plcb3tm1Dwu/Plcb3tm1Dwu
(involves: 129S1/Sv)
|
abnormal neutrophil physiology
|
J:60348
|
increased immunoglobulin level
|
J:60348
|
Plcd1tm1.1Kfu/Plcd1tm1.1Kfu Tg(KRT14-cre)1Amc/0
(involves: C57BL/6 * C57BL/6JJcl * CBA)
|
increased circulating interleukin-17 level
|
J:205633
|
increased interleukin-17 secretion
|
J:205633
|
increased susceptibility to type IV hypersensitivity reaction
|
J:205633
|
Plcd1tm1Tta/Plcd1tm1Tta
(involves: 129P2/OlaHsd)
|
increased circulating interleukin-17 level
|
J:205633
|
increased interleukin-17 secretion
|
J:205633
|
Plcg1tm1Gcrp/Plcg1tm1Rwen Tg(Cd4-cre)1Cwi/0
(either: B6.Cg-Plcg1tm1Gcrp/Plcg1tm1Rwen Tg(Cd4-cre)1Cwi or (involves: 129X1/SvJ * C57BL/6 * DBA/2))
|
abnormal T cell activation
|
J:157757
|
dermatitis
|
J:157757
|
ear inflammation
|
J:157757
|
increased anti-double stranded DNA antibody level
|
J:157757
|
increased T cell proliferation
|
J:157757
|
skin inflammation
|
J:157757
|
Plcg2Ali5/Plcg2+
(C3HeB/FeJ-Plcg2Ali5)
|
abnormal B cell physiology
|
J:97930
|
chronic inflammation
|
J:97930
|
dermatitis
|
J:97930
|
osteoarthritis
|
J:97930
|
Plcg2Ali5/Plcg2+
(involves: C57BL/6J * C3HeB/FeJ-Plcg2Ali5)
|
abnormal B cell physiology
|
J:97930
|
glomerulonephritis
|
J:97930
|
Plcg2Ali5/Plcg2+ Rag1tm1Mom/Rag1tm1Mom
(involves: 129S7/SvEvBrd * C3HeB/FeJ * C3HeB/FeJ-Plcg2Ali5)
|
chronic inflammation
|
J:97930
|
dermatitis
|
J:97930
|
osteoarthritis
|
J:97930
|
Plcg2Ali5/Plcg2Ali5
(involves: C57BL/6J * C3HeB/FeJ-Plcg2Ali5)
|
abnormal B cell physiology
|
J:97930
|
chronic inflammation
|
J:97930
|
glomerulonephritis
|
J:97930
|
Plcg2Ali14/Plcg2+
(C3HeB/FeJ-Plcg2Ali14)
|
abnormal inflammatory response
|
J:166106
|
Plcg2em1Msasn/Plcg2em1Msasn
(B6.Cg-Plcg2em1Msasn/J)
|
impaired macrophage phagocytosis
|
J:308279
|
Plcg2m1Btlr/Plcg2m1Btlr
(C57BL/6J-Plcg2m1Btlr)
|
decreased IgM level
|
J:165702
|
Plcg2m1Btlr/Plcg2m1Btlr
(involves: C57BL/6J)
|
decreased IgM level
|
J:185495
|
Plcg2M2Btlr/Plcg2+
(C57BL/6J-Plcg2M2Btlr)
|
decreased tumor necrosis factor secretion
|
J:218966
|
Plcg2M2Btlr/Plcg2M2Btlr
(C57BL/6J-Plcg2M2Btlr)
|
decreased tumor necrosis factor secretion
|
J:218966
|
Plcg2M3Btlr/Plcg2M3Btlr
(C57BL/6J-Plcg2M3Btlr)
|
abnormal humoral immune response
|
J:265101
|
decreased IgM level
|
J:265101
|
Plcg2tm1.1Kuro/Plcg2tm1.1Kuro
(B6.Cg-Plcg2tm1.1Kuro)
|
decreased interferon-gamma secretion
|
J:131621
|
impaired natural killer cell mediated cytotoxicity
|
J:131621
|
Plcg2tm1.1Kuro/Plcg2tm1.1Kuro
(Not Specified)
|
abnormal NK cell physiology
|
J:187430
|
Plcg2tm1Jni/Plcg2tm1Jni
(involves: 129P2/OlaHsd)
|
abnormal B cell calcium ion homeostasis
|
J:80614
|
abnormal dendritic cell chemotaxis
|
J:157619
|
abnormal dendritic cell physiology
|
J:157619
|
decreased B cell proliferation
|
J:80614
|
decreased susceptibility to induced arthritis
|
J:157619
|
increased B cell apoptosis
|
J:86373
|
Plcg2tm1Jni/Plcg2tm1Jni
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal B cell physiology
|
J:117023
|
decreased interferon-gamma secretion
|
J:100716
|
impaired natural killer cell mediated cytotoxicity
|
J:100716
|
increased B cell proliferation
|
J:117023
|
increased susceptibility to Herpesvirales infection
|
J:100716
|
Plcg2tm1Kuro/Plcg2tm1Kuro Tg(Mx1-cre)1Cgn/0
(involves: C57BL/6 * CBA)
|
abnormal humoral immune response
|
J:63744
|
decreased B cell proliferation
|
J:63744
|
Plcl2tm1Tta/Plcl2tm1Tta
(involves: 129P2/OlaHsd)
|
abnormal adaptive immunity
|
J:85960
|
abnormal B cell calcium ion homeostasis
|
J:85960
|
increased anti-nuclear antigen antibody level
|
J:85960
|
increased B cell proliferation
|
J:85960
|
increased IgM level
|
J:85960
|
Pld2tm1.1Mjow/Pld2tm1.1Mjow
(Not Specified)
|
abnormal neutrophil physiology
|
J:183062
|
Pld3em1Nemz/Pld3em1Nemz
(C57BL/6J-Pld3em1Nemz)
|
increased interleukin-6 secretion
|
J:281205
|
Pld3em1Nemz/Pld3em1Nemz Pld4tm1.2Nemz/Pld4tm1.2Nemz
(B6.Cg-Pld3em1Nemz Pld4tm1.1Nemz)
|
abnormal circulating chemokine level
|
J:281205
|
hemophagocytosis
|
J:281205
|
increased circulating CXCL10 level
|
J:281205
|
increased circulating interferon-gamma level
|
J:281205
|
increased circulating tumor necrosis factor level
|
J:281205
|
liver inflammation
|
J:281205
|
Pld4thss/Pld4thss
(BALB/cJ-Pld4thss/GrsrJ)
|
abnormal immunoglobulin level
|
J:278304
|
increased anti-nuclear antigen antibody level
|
J:278304
|
increased IgA level
|
J:278304
|
increased IgE level
|
J:278304
|
increased IgG2b level
|
J:278304
|
increased IgG3 level
|
J:278304
|
increased IgG level
|
J:278304
|
increased IgM level
|
J:278304
|
Pld4tm1.2Nemz/Pld4tm1.2Nemz
(B6.129(Cg)-Pld4tm1.1Nemz)
|
increased circulating CXCL10 level
|
J:281205
|
increased circulating interferon-gamma level
|
J:281205
|
Plectm3Gwi/Plectm3Gwi
(involves: 129P2/OlaHsd)
|
abnormal T cell physiology
|
J:104701
|
impaired macrophage chemotaxis
|
J:104701
|
Plekha7tm1.1Janc/Plekha7tm1.1Janc
(involves: C57BL/6)
|
decreased susceptibility to bacterial infection
|
J:227858
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:227858
|
Plekhf1tm1.1Caox/Plekhf1tm1.1Caox Lyz2tm1(cre)Ifo/Lyz2+
(B6.Cg-Plekhf1tm1.1Caox Lyz2tm1(cre)Ifo)
|
abnormal cytokine secretion
|
J:277440
|
abnormal macrophage physiology
|
J:277440
|
decreased circulating interferon-beta level
|
J:277440
|
decreased circulating interleukin-6 level
|
J:277440
|
decreased circulating tumor necrosis factor level
|
J:277440
|
increased susceptibility to bacterial infection
|
J:277440
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:277440
|
Plekhm1tm1.2Hzhao/Plekhm1tm1.2Hzhao
(involves: 129S1/Sv * C57BL/6J)
|
abnormal osteoclast physiology
|
J:236517
|
Plekhm2tm1a(EUCOMM)Wtsi/Plekhm2tm1a(EUCOMM)Wtsi
(involves: C57BL/6J * C57BL/6N)
|
decreased susceptibility to bacterial infection
|
J:233985
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:233985
|
Plekho2em1Lzhn/Plekho2em1Lzhn
(C57BL/6-Plekho2em1Lzhn)
|
increased macrophage apoptosis
|
J:270531
|
Plet1tm1Cupe/Plet1tm1Cupe
(Not Specified)
|
abnormal dendritic cell migration
|
J:271548
|
Plgtm1.1Fjc/Plgtm1.1Fjc
(involves: C57BL/6 * C57BL/6JJcl)
|
increased circulating fibrinogen level
|
J:210802
|
Plgtm1Dco/Plg+
(involves: 129S2/SvPas * 129X1/SvJ * C57BL/6)
|
abnormal inflammatory response
|
J:80114
|
Plgtm1Dco/Plgtm1Dco
(involves: 129S2/SvPas * C57BL/6)
|
abnormal acute phase protein level
|
J:82604
|
Plgtm1Dco/Plgtm1Dco
(involves: 129S2/SvPas * 129X1/SvJ * C57BL/6)
|
abnormal inflammatory response
|
J:80114
|
Plgtm1Dco/Plgtm1Dco
(involves: 129S2/SvPas)
|
increased circulating fibrinogen level
|
J:210802
|
Plgtm1Jld/Plgtm1Jld
(involves: 129P2/OlaHsd * NIH Black Swiss)
|
proctitis
|
J:39419
|
Plgtm1Jld/Plgtm1Jld
(B6.129P2-Plgtm1Jld)
|
conjunctivitis
|
J:46096
|
eye inflammation
|
J:46096
|
Plgtm1Jld/Plgtm1Jld
(involves: 129P2/OlaHsd * Black Swiss)
|
colitis
|
J:36591
|
Plgtm1Jld/Plgtm1Jld
(B6.129P2-Plgtm1Jld/J)
|
abnormal microglial cell physiology
|
J:141739
|
Plgr1BALB/cJ/Plgr1BALB/cJ
(involves: BALB/cJ * C57BL/6J)
|
decreased susceptibility to bacterial infection
|
J:138895
|
Plgr1BALB/cJ/Plgr1BALB/cJ
(B6.C-Plgr1BALB/cJ)
|
decreased susceptibility to bacterial infection
|
J:138895
|
Plgr1BALB/cJ/Plgr1C57BL/6J
(involves: BALB/cJ * C57BL/6J)
|
decreased susceptibility to bacterial infection
|
J:138895
|
Plgr1BALB/cJ/Plgr1C57BL/6J
(B6.C-Plgr1BALB/cJ)
|
decreased susceptibility to bacterial infection
|
J:138895
|
Plgrkttm1Lmls/Plgrkt+
(B6.Cg-Plgrkttm1Lmls)
|
dermatitis
|
J:282437
|
Plgrkttm1Lmls/Plgrkttm1Lmls
(B6.Cg-Plgrkttm1Lmls)
|
abnormal macrophage physiology
|
J:282437
|
dermatitis
|
J:282437
|
impaired leukocyte migration
|
J:282437
|
impaired macrophage chemotaxis
|
J:282437
|
Plin2tm1.1Asg/Plin2tm1.1Asg
(B6.129S2(Cg)-Plin2tm1.1Asg)
|
decreased inflammatory response
|
J:196302
|
Plp1jp-rsh/Plp1jp-rsh
(involves: 101/H * C3H)
|
decreased susceptibility to Picornaviridae infection
|
J:41447
|
Plp1tm1Kan/Y Tspan2tm1Hbw/Tspan2tm1Hbw
(B6.Cg-Tspan2tm1Hbw Plp1tm1Kan)
|
brain inflammation
|
J:201143
|
Pls1tm1Fri/Pls1tm1Fri
(B6.129-Pls1tm1Fri)
|
increased susceptibility to colitis induced morbidity/mortality
|
J:216723
|
increased susceptibility to induced colitis
|
J:216723
|
plt/plt
(involves: DDD/1)
|
abnormal immune system physiology
|
J:47819
|
abnormal leukocyte migration
|
J:47819,
J:47460
|
plt/plt
(C.DDD-plt)
|
abnormal T cell activation
|
J:119345
|
increased length of allograft survival
|
J:119345
|
plt/plt
(B6.DDD-plt)
|
abnormal leukocyte migration
|
J:93960
|
plt/plt
(either: B6.DDD-plt or C.DDD-plt)
|
abnormal leukocyte migration
|
J:110910
|
increased inflammatory response
|
J:110910
|
increased susceptibility to autoimmune disorder
|
J:110910
|
lacrimal gland inflammation
|
J:110910
|
parotid gland inflammation
|
J:110910
|
salivary gland inflammation
|
J:110910
|
submandibular gland inflammation
|
J:110910
|
Plxna1tm1Kik/Plxna1tm1Kik
(either: B6.Cg-Plxna1tm1Kik or C.Cg-Plxna1tm1Kik)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:110786
|
abnormal dendritic cell physiology
|
J:110786
|
Plxna1tm1Kik/Plxna1tm1Kik
(Not Specified)
|
abnormal dendritic cell physiology
|
J:161856
|
Plxna1tm1Kik/Plxna1tm1Kik Tg(TcraTcrb)425Cbn/?
(involves: BALB/c * C57BL/6)
|
decreased T cell proliferation
|
J:161856
|
PlyidHIGA/Nsc/PlyidHIGA/Nsc
(involves: BALB/cA * HIGA/Nsc)
|
abnormal humoral immune response
|
J:91769
|
increased IgA level
|
J:91769
|
Pmepa1em1Akt/Pmepa1em1Akt
(C57BL/6N-Pmepa1em1Akt)
|
abnormal osteoclast physiology
|
J:329578
|
Pmltm1Ppp/Pmltm1Ppp
(involves: 129S7/SvEvBrd)
|
increased susceptibility to bacterial infection
|
J:46381
|
Pms2tm1.1Wed/Pms2tm1.1Wed
(involves: 129S6/SvEvTac * C57BL/6NCr)
|
abnormal class switch recombination
|
J:162378
|
Pms2tm1Lisk/Pms2tm1Lisk
(involves: 129S2/SvPas)
|
abnormal class switch recombination
|
J:162378
|
Pnliprp2tm1Gru/Pnliprp2tm1Gru
(involves: 129S2/SvPas * BALB/c)
|
decreased cytotoxic T cell cytolysis
|
J:51627
|
Pnpbata/Pnpbata
(C57BL/6JSfdAnu-Pnpbata)
|
decreased B cell proliferation
|
J:104190
|
Pnpe/Pnpe
(C57BL/6J-Pnpe)
|
abnormal leukocyte physiology
|
J:39328
|
Pnpf/Pnpf
(C57BL/6J-Pnpf)
|
abnormal leukocyte physiology
|
J:39328
|
Pnpg/Pnpg
(involves: C57BL/6 * DBA/2J)
|
abnormal leukocyte physiology
|
J:39328
|
PnpM1Btlr/PnpM1Btlr
(C57BL/6J-PnpM1Btlr)
|
impaired humoral immune response
|
J:265147
|
increased IgM level
|
J:265147
|
Pnptm1Cmr/Pnptm1Cmr
(involves: 129)
|
decreased cytotoxic T cell cytolysis
|
J:62870
|
increased thymocyte apoptosis
|
J:62870
|
Pofut1tm2Pst/Pofut1tm1Pst Shhtm2(cre/ERT2)Cjt/Shh+
(involves: 129/Sv * 129S6/SvEvTac * C57BL/6J * SJL)
|
lung inflammation
|
J:150051
|
Polbtm1.1Jbsw/Polb+
(involves: 129/Sv * C57BL/6)
|
dermatitis
|
J:206872
|
glomerulonephritis
|
J:206872
|
increased anti-nuclear antigen antibody level
|
J:206872
|
increased IgG level
|
J:206872
|
lymph node inflammation
|
J:206872
|
salivary gland inflammation
|
J:206872
|
Polbtm1.1Jbsw/Polbtm1.1Jbsw
(involves: 129/Sv * C57BL/6)
|
abnormal somatic hypermutation frequency
|
J:206872
|
dermatitis
|
J:206872
|
glomerulonephritis
|
J:206872
|
increased anti-nuclear antigen antibody level
|
J:206872
|
increased IgG level
|
J:206872
|
increased splenocyte apoptosis
|
J:183837,
J:206872
|
increased susceptibility to systemic lupus erythematosus
|
J:206872
|
lymph node inflammation
|
J:206872
|
salivary gland inflammation
|
J:206872
|
Pole3em3Tbo/Pole3em3Tbo
(FVB-Pole3em3Tbo)
|
abnormal thymus apoptosis
|
J:298827
|
increased thymocyte apoptosis
|
J:298827
|
Pole3em4Tbo/Pole3em4Tbo
(FVB-Pole3em4Tbo)
|
abnormal thymus apoptosis
|
J:298827
|
increased thymocyte apoptosis
|
J:298827
|
Polgtm1Prol/Polgtm1Prol
(involves: 129S7/SvEvBrd * C57BL/6J * ICR)
|
abnormal thymus involution
|
J:99764
|
Polhtm1Crey/Polhtm1Crey
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal B cell physiology
|
J:98037
|
Polhtm1Crey/Polhtm1Crey Polid/Polid
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal B cell physiology
|
J:98037
|
Polhtm1Fmh/Polhtm1Fmh
(involves: C57BL/6)
|
abnormal B cell physiology
|
J:99721
|
Polmtm1Crey/Polmtm1Crey
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal B cell proliferation
|
J:85190
|
Polqtm1Jcs/Polqtm1Jcs
(involves: 129S4/SvJae * C57BL/6J)
|
abnormal somatic hypermutation frequency
|
J:103365
|
Polqtm1Jow/Polqtm1Jow
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6N)
|
abnormal B cell physiology
|
J:101409
|
abnormal somatic hypermutation frequency
|
J:101409
|
decreased IgG1 level
|
J:101409
|
decreased IgG level
|
J:101409
|
decreased IgM level
|
J:101409
|
decreased immunoglobulin level
|
J:101409
|
Polqtm2Jow/Polqtm2Jow
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal somatic hypermutation frequency
|
J:115989
|
Pomctm1Low/Pomctm1Low
(involves: 129S2/SvPas * C57BL/6)
|
increased circulating interleukin-6 level
|
J:102955
|
increased interleukin-6 secretion
|
J:102955
|
increased splenocyte proliferation
|
J:102955
|
increased tumor necrosis factor secretion
|
J:102955
|
Pomt1Gt(OST194127)Lex/Pomt1+
(involves: 129S5/SvEvBrd * C57BL/6J)
|
decreased IgG level
|
J:103485
|
Pon2Gt(XE661)Byg/Pon2Gt(XE661)Byg
(B6.129P2-Pon2Gt(XE661)Byg)
|
abnormal macrophage chemotaxis
|
J:116935
|
abnormal macrophage physiology
|
J:116935
|
increased susceptibility to bacterial infection
|
J:116935
|
Pon3tm1Dmsh/Pon3tm1Dmsh
(B6J.129X1-Pon3tm1Dmsh)
|
liver inflammation
|
J:234615
|
Postntm1Sjc/Postntm1Sjc
(involves: C57BL/6)
|
periodontium inflammation
|
J:103753
|
Pou2af1tm1Pjln/Pou2af1tm1Pjln
(C57BL/6-Pou2af1tm1Pjln)
|
decreased IgA level
|
J:37085
|
decreased IgG1 level
|
J:37085
|
decreased IgG2a level
|
J:37085
|
decreased IgG2b level
|
J:37085
|
decreased IgG3 level
|
J:37085
|
Pou2af1tm1Pjln/Pou2af1tm1Pjln
(involves: C57BL/6)
|
abnormal T-helper 1 physiology
|
J:123039
|
abnormal T-helper 2 physiology
|
J:123039
|
decreased interferon-gamma secretion
|
J:123039
|
decreased interleukin-2 secretion
|
J:123039
|
increased B cell apoptosis
|
J:67362
|
increased interleukin-4 secretion
|
J:123039
|
increased interleukin-13 secretion
|
J:123039
|
increased susceptibility to parasitic infection
|
J:123039
|
Pou2af1tm1Pjln/Pou2af1tm1Pjln Tg(tetO-Pou2af1)1Pjln/0 Tg(tTA)1Pjln/0
(involves: C57BL/6)
|
decreased immunoglobulin level
|
J:67362
|
Pou2af1tm1Pmt/Pou2af1tm1Pmt
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased immunoglobulin level
|
J:125114
|
Pou2af1tm1Pmt/Pou2af1tm1Pmt Ikzf3tm1Kge/Ikzf3tm1Kge
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
decreased IgA level
|
J:81805
|
decreased IgD level
|
J:81805
|
decreased IgE level
|
J:81805
|
decreased IgG level
|
J:81805
|
decreased IgM level
|
J:81805
|
decreased immunoglobulin level
|
J:81805
|
Pou2af1tm1Rgr/Pou2af1tm1Rgr
(either: (involves: 129P2/OlaHsd) or (involves: 129S1/Sv))
|
decreased B cell proliferation
|
J:35785
|
decreased IgA level
|
J:35785
|
decreased IgE level
|
J:35785
|
decreased IgG1 level
|
J:35785
|
decreased IgG2a level
|
J:35785
|
decreased IgG2b level
|
J:35785
|
decreased IgG3 level
|
J:35785
|
decreased IgG level
|
J:35785
|
decreased immunoglobulin level
|
J:35785
|
increased B cell proliferation
|
J:114816
|
increased IgM level
|
J:35785
|
Pou2f2tm1Bal/Pou2f2+
(involves: 129S2/SvPas)
|
decreased IgG1 level
|
J:4555
|
decreased IgM level
|
J:4555
|
Pou2f2tm1Bal/Pou2f2tm1Bal
(involves: 129S2/SvPas * C57BL/6)
|
decreased immunoglobulin level
|
J:88240
|
Pou2f2tm1Bal/Pou2f2tm1Bal
(involves: 129S2/SvPas)
|
decreased IgG1 level
|
J:4555
|
decreased IgM level
|
J:4555
|
Pou2f2tm1Lmc/Pou2f2tm1Lmc
(involves: C57BL/6)
|
decreased immunoglobulin level
|
J:88240
|
Pparatm1Gonz/Pparatm1Gonz
(involves: 129S4/SvJae)
|
heart inflammation
|
J:63801
|
increased susceptibility to type IV hypersensitivity reaction
|
J:258438
|
Ppardtm1Jps/Ppardtm1Jps
(involves: 129/Sv * C57BL/6N)
|
skin inflammation
|
J:63040
|
Ppargtm1.1Gonz/Ppargtm1.1Gonz Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6)
|
abnormal macrophage activation involved in immune response
|
J:168799
|
glomerulonephritis
|
J:168799
|
impaired macrophage phagocytosis
|
J:168799
|
increased anti-double stranded DNA antibody level
|
J:168799
|
increased anti-nuclear antigen antibody level
|
J:168799
|
increased anti-single stranded DNA antibody level
|
J:168799
|
increased autoantibody level
|
J:168799
|
increased IgG level
|
J:168799
|
increased IgM level
|
J:168799
|
Ppargtm1.1Gonz/Ppargtm1.1Gonz Tg(Mx1-cre)1Cgn/?
(involves: 129X1/SvJ * C57BL/6 * CBA * FVB/N)
|
abnormal macrophage physiology
|
J:75777
|
Ppargtm1Tka/Pparg+
(involves: C57BL/6 * CBA)
|
leukostasis
|
J:116269
|
Ppargtm1Tka/Pparg+
(involves: C57BL/6 * CBA * ICR)
|
abnormal B cell physiology
|
J:58222
|
abnormal humoral immune response
|
J:58222
|
increased B cell proliferation
|
J:58222
|
increased IgG level
|
J:58222
|
increased IgM level
|
J:58222
|
increased interferon-gamma secretion
|
J:58222
|
increased interleukin-2 secretion
|
J:58222
|
increased susceptibility to induced arthritis
|
J:58222
|
Ppargtm2Rev/Ppargtm2Rev Tg(Cd4-cre)1Cwi/?
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:153358
|
Ppargtm2Rev/Ppargtm2Rev Tg(Krt1-15-cre/PGR*)22Cot/?
(involves: 129S4/SvJae * C57BL/6 * SJL)
|
skin inflammation
|
J:150977
|
Ppargtm2Rev/Ppargtm2Rev Tg(Tek-cre)1Ywa/?
(involves: 129S4/SvJae * C57BL/6 * SJL)
|
skin inflammation
|
J:123403
|
Ppargc1atm1Brsp/Ppargc1a+
(involves: 129S4/SvJae * C57BL/6)
|
increased inflammatory response
|
J:264271
|
Ppargc1atm1Brsp/Ppargc1atm1Brsp
(involves: 129 * FVB/N)
|
increased interleukin-6 secretion
|
J:127403
|
Ppargc1atm1Brsp/Ppargc1atm2Brsp Tg(Myog-cre)1Eno/0
(involves: 129 * C57BL/6 * FVB/N)
|
increased circulating interleukin-6 level
|
J:127403
|
Ppargc1atm2Brsp/Ppargc1a+ Tg(Myog-cre)1Eno/0
(involves: 129 * C57BL/6)
|
increased circulating interleukin-6 level
|
J:127403
|
Ppbptm1(KOMP)Vlcg/Ppbptm1(KOMP)Vlcg
(involves: C57BL/6NTac)
|
abnormal leukocyte migration
|
J:198197
|
abnormal leukocyte physiology
|
J:198197
|
Ppiatm1Lubn/Ppiatm1Lubn
(129S6.129P2-Ppiatm1Lubn)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:93591
|
blepharitis
|
J:93591
|
heart inflammation
|
J:93591
|
increased circulating interleukin-4 level
|
J:93591
|
increased IgE level
|
J:93591
|
increased IgG1 level
|
J:93591
|
increased immunoglobulin level
|
J:93591
|
increased inflammatory response
|
J:93591
|
increased interleukin-2 secretion
|
J:93591
|
increased interleukin-4 secretion
|
J:93591
|
increased susceptibility to type I hypersensitivity reaction
|
J:93591
|
liver inflammation
|
J:93591
|
pancreas inflammation
|
J:93591
|
Ppm1atm1.2Lavi/Ppm1atm1.2Lavi
(B.129(Cg)-Ppm1atm1.2Lavi)
|
increased acute inflammation
|
J:216372
|
Ppm1dtm1Lad/Ppm1dtm1Lad
(involves: 129S7/SvEvBrd * C57BL/6)
|
chronic inflammation
|
J:74284
|
decreased B cell proliferation
|
J:74284
|
decreased T cell proliferation
|
J:74284
|
increased susceptibility to Orthomyxoviridae infection
|
J:74284
|
Ppp1r8tm1.1Itl/Ppp1r8tm1Ave Tg(Alb1-cre)7Gsc/0
(involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6NTac * FVB/N)
|
liver inflammation
|
J:238108
|
Ppp1r12atm1Mzhu/Ppp1r12atm1Mzhu Tg(Acta2-cre)#Xya/0
(involves: 129S6/SvEvTac * C57BL/6 * CBA)
|
small intestinal inflammation
|
J:207752
|
Ppp1r13btm1Suda/Ppp1r13btm1Suda
(involves: 129S1/Sv * 129X1/SvJ * ICR)
|
abnormal lymph circulation
|
J:135686
|
Ppp1r13lwa3-J/Ppp1r13lwa3-J
(BALB/cJ-Ppp1r13lwa3-J/J)
|
heart inflammation
|
J:264272
|
Ppp1r14ctm1Uhl/Ppp1r14ctm1Uhl
(B6;129S6-Ppp1r14ctm1Uhl/J)
|
increased susceptibility to Coronaviridae infection
|
J:288523
|
Ppp1r18em1Mgin/Ppp1r18em1Mgin
(B6J.B6N-Ppp1r18em1Mgin)
|
abnormal T cell physiology
|
J:331428
|
impaired leukocyte migration
|
J:331428
|
Ppp1r18em3Mgin/Ppp1r18em3Mgin
(B6J.B6N-Ppp1r18em3Mgin)
|
abnormal T cell physiology
|
J:331428
|
impaired leukocyte migration
|
J:331428
|
Ppp2r2dem1Gct/Ppp2r2dem1Gct Tg(Lck-icre)3779Nik/0
(involves: C57BL/6 * DBA/2)
|
abnormal regulatory T cell physiology
|
J:308373
|
increased interleukin-2 secretion
|
J:308373
|
Ppp2r3ctm1Imku/Ppp2r3ctm1Imku Tg(CD19-cre/ERT2)1Cgn/?
(involves: C57BL/6)
|
abnormal B cell activation
|
J:100706
|
abnormal humoral immune response
|
J:100706
|
decreased B cell proliferation
|
J:100706
|
Ppp3catm1Jse/Ppp3catm1Jse
(either: (involves: 129S4/SvJae * Black Swiss) or (involves: 129S4/SvJae * C57BL/6))
|
decreased interferon-gamma secretion
|
J:71750
|
decreased interleukin-2 secretion
|
J:71750
|
decreased interleukin-4 secretion
|
J:71750
|
decreased T cell proliferation
|
J:71750
|
Ppp3cbM1Btlr/Ppp3cb+
(C57BL/6J-Ppp3cbM1Btlr)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:236670
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:236670
|
abnormal NK cell physiology
|
J:236670
|
increased CD8-positive, alpha-beta memory T cell proliferation
|
J:236670
|
Ppp3cbM1Btlr/Ppp3cbM1Btlr
(C57BL/6J-Ppp3cbM1Btlr)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:236670
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:236670
|
abnormal NK cell physiology
|
J:236670
|
increased CD8-positive, alpha-beta memory T cell proliferation
|
J:236670
|
Ppp3cbm2Btlr/Ppp3cb+
(C57BL/6J-Ppp3cbm2Btlr)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:236671
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:236671
|
increased CD8-positive, alpha-beta memory T cell proliferation
|
J:236671
|
Ppp3cbm2Btlr/Ppp3cbm2Btlr
(C57BL/6J-Ppp3cbm2Btlr)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:236671
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:236671
|
abnormal NK cell physiology
|
J:236671
|
decreased response to antigen
|
J:236671
|
increased CD8-positive, alpha-beta memory T cell proliferation
|
J:236671
|
Ppp3cbtm1Jmk/Ppp3cbtm1Jmk
(involves: 129S6/SvEvTac * C57BL/6)
|
decreased T cell proliferation
|
J:77729
|
Ppp3cbtm1Jmk/Ppp3cbtm1Jmk
(involves: 129S6/SvEvTac)
|
abnormal cytokine secretion
|
J:109586
|
decreased T cell proliferation
|
J:109586
|
Ppp4ctm1Tht/Ppp4ctm1Tht Tg(Lck-cre)548Jxm/0
(involves: C57BL/6 * CBA)
|
abnormal T cell activation
|
J:117684
|
Ppp6ctm1Shma/Ppp6ctm1Shma Tg(KRT14-cre/ERT)20Efu/0
(involves: C57BL/6 * CBA * CD-1)
|
increased susceptibility to chemically induced skin inflammation
|
J:231809
|
Ppt1tm1.1Dprc/Ppt1tm1.1Dprc
(involves: 129S6/SvEvTac * BALB/cJ * C57BL/6)
|
abnormal microglial cell activation
|
J:213552
|
Ppt1tm1Aj/Ppt1tm1Aj
(involves: 129S4/SvJae * C57BL/6)
|
brain inflammation
|
J:95522
|
Ppt1tm1Hof/Ppt1tm1Hof
(involves: 129P2/OlaHsd * 129S2/SvPas * 129S6/SvEvTac * C57BL/6)
|
abnormal cytokine level
|
J:177265
|
brain inflammation
|
J:177265
|
Pram1tm1Gak/Pram1tm1Gak
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal neutrophil physiology
|
J:95253
|
Prap1tm1Lex/Prap1tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
|
abnormal humoral immune response
|
J:171883
|
increased immunoglobulin level
|
J:171883
|
Prap1tm1Lex/Prap1tm1Lex
(B6.129S5-Prap1tm1Lex)
|
increased circulating interleukin-2 level
|
J:304152
|
increased circulating interleukin-4 level
|
J:304152
|
increased circulating interleukin-12 level
|
J:304152
|
increased inflammatory response
|
J:304152
|
increased interleukin-12b secretion
|
J:304152
|
Prcdtm1Vya/Prcdtm1Vya
(B6.Cg-Prcdtm1Vya)
|
increased microglial cell activation
|
J:276708
|
Prdm1tm1.1Liz/Prdm1tm1.1Liz
(involves: 129S/SvEv)
|
abnormal splenocyte physiology
|
J:163979
|
Prdm1tm1Clme/Prdm1tm1Clme Tg(Itgax-cre)1-1Reiz/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:178876
|
abnormal germinal center B cell physiology
|
J:178876
|
abnormal immune system physiology
|
J:178876
|
increased anti-double stranded DNA antibody level
|
J:178876
|
increased anti-nuclear antigen antibody level
|
J:178876
|
increased autoantibody level
|
J:178876
|
increased IgG level
|
J:178876
|
increased immunoglobulin level
|
J:178876
|
increased interleukin-6 secretion
|
J:178876
|
kidney inflammation
|
J:178876
|
Prdm1tm2.1Nutt/Prdm1tm2.1Nutt Tg(Lck-cre)1Cwi/?
(involves: C57BL/6)
|
increased susceptibility to Orthomyxoviridae infection
|
J:151858
|
Prdm11tm1.1Ahl/Prdm11tm1.1Ahl
(B6.129(C)-Prdm11tm1.1Ahl)
|
abnormal humoral immune response
|
J:233986
|
increased interferon-gamma secretion
|
J:233986
|
increased interleukin-2 secretion
|
J:233986
|
Prdt1CAST/EiJH/Prdt1CAST/EiJH
(involves: CAST/Ei * NZW/OlaHsd)
|
decreased susceptibility to prion infection
|
J:80787
|
Prdt1NZW/OlaHsd/Prdt1NZW/OlaHsd
(involves: CAST/Ei * NZW/OlaHsd)
|
increased susceptibility to prion infection
|
J:80787
|
Prdt3CAST/EiJH/Prdt3CAST/EiJH
(involves: CAST/Ei * NZW/OlaHsd)
|
decreased susceptibility to prion infection
|
J:80787
|
Prdt3NZW/OlaHsd/Prdt3NZW/OlaHsd
(involves: CAST/Ei * NZW/OlaHsd)
|
increased susceptibility to prion infection
|
J:80787
|
Prdx1tm1Rave/Prdx1tm1Rave
(involves: 129S6/SvEvTac * C57BL/6)
|
impaired natural killer cell mediated cytotoxicity
|
J:84677
|
Prdx3Gt(Betageo-puro)711Lex/Prdx3Gt(Betageo-puro)711Lex
(involves: 129S5/SvEvBrd * C57BL/6)
|
lung inflammation
|
J:118595
|
Prdx5tm1.1(KOMP)Vlcg/Prdx5tm1.1(KOMP)Vlcg
(involves: C57BL/6J * C57BL/6NTac)
|
increased circulating interleukin-12b level
|
J:271141
|
increased circulating tumor necrosis factor level
|
J:271141
|
increased interleukin-6 secretion
|
J:271141
|
increased interleukin-12b secretion
|
J:271141
|
increased tumor necrosis factor secretion
|
J:271141
|
Prex1tm1Dwu/Prex1tm1Dwu
(Not Specified)
|
impaired neutrophil chemotaxis
|
J:102213
|
Prex1tm1Hcew/Prex1tm1Hcew
(involves: 129P2/OlaHsd * C57BL/6)
|
impaired neutrophil chemotaxis
|
J:102214
|
impaired neutrophil recruitment
|
J:102214
|
Prf1m1Btlr/Prf1m1Btlr
(C57BL/6J-Prf1m1Btlr)
|
increased susceptibility to Herpesvirales infection
|
J:216044
|
increased susceptibility to Herpesvirales infection induced morbidity/mortality
|
J:216044
|
Prf1tm1Clrk/Prf1tm1Clrk
(involves: 129S7/SvEvBrd * C57BL/6)
|
decreased cytotoxic T cell cytolysis
|
J:21531
|
increased susceptibility to Riboviria infection
|
J:21531
|
Prf1tm1Clrk/Prf1tm1Clrk
(C.129S7(B6)-Prf1tm1Clrk)
|
abnormal cytokine secretion
|
J:71576
|
increased interferon-gamma secretion
|
J:71576
|
increased susceptibility to Riboviria infection
|
J:71576
|
increased tumor necrosis factor secretion
|
J:71576
|
Prf1tm1Clrk/Prf1tm1Clrk
(involves: 129S7/SvEvBrd * BALB/c * NOD)
|
decreased susceptibility to autoimmune diabetes
|
J:64051
|
Prf1tm1Clrk/Prf1tm1Clrk Tg(INS-Il10)#Sar/0
(involves: 129S7/SvEvBrd * BALB/c * NOD)
|
decreased susceptibility to autoimmune diabetes
|
J:64051
|
Prf1tm1Sdz/Prf1+
(NOD.B6-Prf1tm1Sdz)
|
decreased susceptibility to autoimmune diabetes
|
J:43468
|
insulitis
|
J:43468
|
periinsulitis
|
J:43468
|
Prf1tm1Sdz/Prf1+
(A.B6-Prf1tm1Sdz)
|
impaired natural killer cell mediated cytotoxicity
|
J:211842
|
Prf1tm1Sdz/Prf1tm1Sdz
(C57BL/6-Prf1tm1Sdz)
|
abnormal inflammatory response
|
J:17986
|
abnormal leukocyte physiology
|
J:17986
|
abnormal NK cell physiology
|
J:113213
|
decreased cytotoxic T cell cytolysis
|
J:17986
|
impaired natural killer cell mediated cytotoxicity
|
J:17986
|
increased interleukin-10 secretion
|
J:123934
|
increased susceptibility to bacterial infection
|
J:123934
|
increased susceptibility to infection
|
J:17986
|
increased susceptibility to parasitic infection
|
J:81397
|
increased susceptibility to Riboviria infection
|
J:17986
|
Prf1tm1Sdz/Prf1tm1Sdz
(NOD.B6-Prf1tm1Sdz)
|
decreased susceptibility to autoimmune diabetes
|
J:43468
|
insulitis
|
J:43468
|
periinsulitis
|
J:43468
|
Prf1tm1Sdz/Prf1tm1Sdz
(C57BL/6-Prf1tm1Sdz/J)
|
abnormal circulating cytokine level
|
J:92260
|
abnormal cytotoxic T cell physiology
|
J:193137
|
abnormal lymphocyte physiology
|
J:120427
|
abnormal macrophage activation involved in immune response
|
J:92260
|
abnormal T cell activation
|
J:92260
|
brain inflammation
|
J:92260,
J:120427
|
CNS inflammation
|
J:120427
|
decreased circulating fibrinogen level
|
J:92260
|
decreased cytotoxic T cell cytolysis
|
J:193137
|
decreased interferon-gamma secretion
|
J:92260
|
decreased NK cell degranulation
|
J:193137
|
increased circulating interferon-alpha level
|
J:92260
|
increased circulating interferon-gamma level
|
J:92260,
J:193137
|
increased circulating interleukin-1 beta level
|
J:193137
|
increased circulating interleukin-6 level
|
J:92260,
J:193137
|
increased circulating interleukin-10 level
|
J:92260
|
increased circulating interleukin-18 level
|
J:92260
|
increased circulating tumor necrosis factor level
|
J:92260,
J:193137
|
increased susceptibility to Picornaviridae infection
|
J:120427
|
increased susceptibility to Riboviria infection
|
J:92260,
J:193137
|
increased susceptibility to Riboviria infection induced morbidity/mortality
|
J:92260
|
increased susceptibility to viral infection induced morbidity/mortality
|
J:193137
|
liver inflammation
|
J:92260
|
lymph node inflammation
|
J:92260
|
Prf1tm1Sdz/Prf1tm1Sdz
(involves: BALB/c * C57BL/6)
|
impaired natural killer cell mediated cytotoxicity
|
J:73948
|
Prf1tm1Sdz/Prf1tm1Sdz
(A.B6-Prf1tm1Sdz)
|
impaired natural killer cell mediated cytotoxicity
|
J:211842
|
Prf1tm1Sdz/Prf1tm1Sdz Rag1tm1Mom/Rag1tm1Mom
(NOD.Cg-Rag1tm1Mom Prf1tm1Sdz/SzJ)
|
abnormal response to transplant
|
J:91764
|
Prf1tm1Sdz/Prf1tm1Sdz X/Yaa
(BXSB.B6-Prf1tm1Sdz/Dcr)
|
autoimmune response
|
J:179430
|
Prf1tm1Tsc/Prf1+
(involves: 129S2/SvPas)
|
decreased cytotoxic T cell cytolysis
|
J:21731
|
impaired natural killer cell mediated cytotoxicity
|
J:21731
|
Prf1tm1Tsc/Prf1tm1Tsc
(involves: 129S2/SvPas)
|
decreased cytotoxic T cell cytolysis
|
J:21731
|
decreased susceptibility to bacterial infection
|
J:50903
|
impaired natural killer cell mediated cytotoxicity
|
J:21731
|
Prf1tm1Tsc/Prf1tm1Tsc
(129X1.129S2-Prf1tm1Tsc)
|
abnormal NK cell physiology
|
J:126114
|
decreased T cell apoptosis
|
J:126114
|
Prg2tm1Nal/Prg2tm1Nal
(involves: 129P2/OlaHsd * 129X1/SvJ)
|
abnormal inflammatory response
|
J:65655
|
respiratory system inflammation
|
J:65655
|
Primpolem1Nki/Primpolem1Nki
(C57BL/6-Primpolem1Nki)
|
abnormal somatic hypermutation frequency
|
J:242620
|
Prkab1tm1Eihl/Prkab1tm1Eihl
(involves: C57BL/6)
|
decreased circulating interleukin-6 level
|
J:158295
|
Prkag2tm1.1Geno/Prkag2tm1.1Geno
(B6J.129S(Cg)-Prkag2tm1.1Geno)
|
abnormal inflammatory response
|
J:235379
|
white adipose tissue inflammation
|
J:235379
|
Prkar1atm2Gsm/Prkar1atm2Gsm Tg(Cr2-cre)3Cgn/0
(involves: 129X1/SvJ * C57BL/6)
|
abnormal class switch recombination
|
J:147785
|
Prkar1btm1Gsm/Prkar1btm1Gsm
(Not Specified)
|
decreased inflammatory response
|
J:43080
|
PrkcbM1Btlr/Prkcb+
(C57BL/6J-PrkcbM1Btlr)
|
decreased IgM level
|
J:164864
|
PrkcbM1Btlr/PrkcbM1Btlr
(C57BL/6J-PrkcbM1Btlr)
|
decreased IgM level
|
J:164864
|
PrkcbM1Btlr/PrkcbM1Btlr
(involves: C57BL/6J)
|
decreased IgM level
|
J:185495
|
PrkcbM2Btlr/Prkcb+
(C57BL/6J-PrkcbM2Btlr)
|
decreased IgM level
|
J:217791
|
decreased response to antigen
|
J:217791
|
impaired humoral immune response
|
J:217791
|
PrkcbM2Btlr/PrkcbM2Btlr
(C57BL/6J-PrkcbM2Btlr)
|
decreased IgM level
|
J:217791
|
decreased response to antigen
|
J:217791
|
impaired humoral immune response
|
J:217791
|
PrkcbM3Btlr/Prkcb+
(C57BL/6J-PrkcbM3Btlr)
|
decreased IgM level
|
J:217793
|
decreased response to antigen
|
J:217793
|
impaired humoral immune response
|
J:217793
|
PrkcbM3Btlr/PrkcbM3Btlr
(C57BL/6J-PrkcbM3Btlr)
|
decreased IgM level
|
J:217793
|
decreased response to antigen
|
J:217793
|
impaired humoral immune response
|
J:217793
|
PrkcbM5Btlr/PrkcbM5Btlr
(C57BL/6J-PrkcbM5Btlr)
|
decreased IgM level
|
J:274861
|
impaired humoral immune response
|
J:274861
|
Prkcbtilc/Prkcb+
(involves: C57BL/6JSfdAnu)
|
abnormal humoral immune response
|
J:221236
|
decreased IgG3 level
|
J:221236
|
decreased IgM level
|
J:221236
|
Prkcbtilc/Prkcbtilc
(C57BL/6JSfdAnu-Prkcbtilc/AnuApb)
|
decreased IgM level
|
J:104190
|
Prkcbtilc/Prkcbtilc
(involves: C57BL/6JSfdAnu)
|
abnormal humoral immune response
|
J:221236
|
decreased B cell proliferation
|
J:221236
|
decreased IgG3 level
|
J:221236
|
decreased IgM level
|
J:221236
|
Prkcbtm1Tara/Prkcb+
(involves: 129)
|
abnormal humoral immune response
|
J:34818
|
decreased IgG3 level
|
J:34818
|
decreased IgM level
|
J:34818
|
Prkcbtm1Tara/Prkcbtm1Tara
(involves: 129)
|
abnormal humoral immune response
|
J:34818
|
decreased B cell proliferation
|
J:34818
|
decreased IgG3 level
|
J:34818
|
decreased IgM level
|
J:34818
|
PrkcdM1Btlr/PrkcdM1Btlr
(C57BL/6J-PrkcdM1Btlr)
|
increased susceptibility to induced colitis
|
J:265145
|
Prkcdm2Btlr/Prkcdm2Btlr
(C57BL/6J-Prkcdm2Btlr)
|
enhanced humoral immune response
|
J:265146
|
increased IgM level
|
J:265146
|
increased susceptibility to induced colitis
|
J:265146
|
Prkcdtm1.1Chou/Prkcdtm1.1Chou
(involves: C57BL/6 * C57BL/6NTac)
|
abnormal neutrophil physiology
|
J:217880
|
Prkcdtm1Kin/Prkcdtm1Kin
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal immunoglobulin level
|
J:143854
|
glomerulonephritis
|
J:76135
|
increased acute inflammation
|
J:76135
|
increased anti-chromatin antibody level
|
J:76135
|
increased B cell proliferation
|
J:76135,
J:143854
|
increased IgA level
|
J:76135,
J:143854
|
increased IgG1 level
|
J:76135,
J:143854
|
increased IgM level
|
J:143854
|
increased interleukin-6 secretion
|
J:76135
|
Prkcdtm1Msg/Prkcdtm1Msg
(involves: 129X1/SvJ * C57BL/6J)
|
abnormal neutrophil physiology
|
J:91377
|
Prkcdtm1Qxu/Prkcdtm1Qxu
(involves: 129P2/OlaHsd)
|
abnormal response to transplant
|
J:78680
|
Prkcdtm1Qxu/Prkcdtm1Qxu
(involves: 129P2/OlaHsd * C57BL/6)
|
increased anti-nuclear antigen antibody level
|
J:76134
|
increased B cell apoptosis
|
J:76134
|
increased IgA level
|
J:76134
|
increased IgG1 level
|
J:76134
|
increased IgM level
|
J:76134
|
Prkcdtm1Qxu/Prkcdtm1Qxu Tg(IghelMD4)4Ccg/0 Tg(ML5sHEL)5Ccg/0
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal B cell physiology
|
J:76134
|
abnormal B cell proliferation
|
J:76134
|
abnormal self tolerance
|
J:76134
|
autoimmune response
|
J:76134
|
Prkcetm1Bsca/Prkcetm1Bsca
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased circulating interleukin-1 beta level
|
J:103337
|
decreased circulating tumor necrosis factor level
|
J:103337
|
decreased macrophage apoptosis
|
J:103337
|
decreased macrophage nitric oxide production
|
J:103337
|
decreased T cell proliferation
|
J:103337
|
increased susceptibility to bacterial infection
|
J:103337
|
Prkcetm1Ltg/Prkcetm1Ltg
(involves: 129P2/OlaHsd * FVB/N)
|
decreased tumor necrosis factor secretion
|
J:86056
|
Prkcgtm1Stl/Prkcgtm1Stl
(Not Specified)
|
decreased inflammatory response
|
J:25061
|
Prkchtm1.2Gasc/Prkchtm1.2Gasc
(involves: C57BL/6 * FVB/N * SJL)
|
decreased T cell proliferation
|
J:186080
|
Prkchtm1.2Gasc/Prkchtm1.2Gasc Prkcqtm1Litt/Prkcqtm1Litt
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL)
|
decreased T cell proliferation
|
J:186080
|
Prkcitm1Rfar/Prkci+ Tg(Ckmm-cre)5Khn/?
(involves: 129P2/OlaHsd * C57BL/6 * FVB)
|
increased susceptibility to autoimmune diabetes
|
J:123964
|
Prkcqm1Btlr/Prkcqm1Btlr
(C57BL/6J-Prkcqm1Btlr)
|
decreased IgG level
|
J:255214
|
impaired humoral immune response
|
J:255214
|
Prkcqm2Btlr/Prkcqm2Btlr
(C57BL/6J-Prkcqm2Btlr)
|
decreased IgG level
|
J:255216
|
impaired humoral immune response
|
J:255216
|
Prkcqtm1.1Bai/Prkcqtm1.1Bai
(involves: 129P2/OlaHsd * C57BL/6J)
|
abnormal T cell physiology
|
J:83733
|
decreased interleukin-2 secretion
|
J:83733
|
decreased T cell proliferation
|
J:83733
|
Prkcqtm1Litt/Prkcqtm1Litt
(involves: 129P2/OlaHsd)
|
abnormal T cell activation
|
J:83922
|
decreased interleukin-2 secretion
|
J:83922
|
decreased T cell proliferation
|
J:83922,
J:123989
|
Prkcqtm1Litt/Prkcqtm1Litt
(B6.129P2-Prkcqtm1Litt)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:94285
|
abnormal T-helper 2 physiology
|
J:94285
|
decreased interferon-gamma secretion
|
J:129421,
J:94285
|
decreased interleukin-2 secretion
|
J:129421,
J:94285
|
decreased interleukin-4 secretion
|
J:129421,
J:94285
|
decreased interleukin-5 secretion
|
J:94285
|
decreased interleukin-13 secretion
|
J:94285
|
decreased interleukin-17 secretion
|
J:129421
|
decreased splenocyte proliferation
|
J:129421
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:129421
|
decreased T cell proliferation
|
J:94285
|
Prkcqtm1Litt/Prkcqtm1Litt
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased T cell proliferation
|
J:186080
|
increased T cell apoptosis
|
J:141128
|
Prkcqtm1Litt/Prkcqtm1Litt
(either: (involves: 129/Sv * 129P2/OlaHsd) or (involves: 129P2/OlaHsd * C57BL/6))
|
abnormal response to infection
|
J:141930
|
decreased T cell apoptosis
|
J:141930
|
decreased T cell proliferation
|
J:141930
|
Prkcqtm1Litt/Prkcqtm1Litt Tcratm1Mom/Tcratm1Mom
(involves: 129P2/OlaHsd * 129S2/SvPas)
|
decreased interleukin-4 secretion
|
J:135589
|
decreased T cell proliferation
|
J:135589
|
Prkcqtm1Litt/Prkcqtm1Litt Tg(DO11.10)10Dlo/0
(involves: 129 * BALB/c * C3H * C57BL/6)
|
decreased T cell apoptosis
|
J:141930
|
Prkcqtm1Litt/Prkcqtm1Litt Tg(TcrLCMV)327Sdz/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
abnormal T cell anergy
|
J:123989
|
decreased cytotoxic T cell cytolysis
|
J:123989
|
decreased splenocyte proliferation
|
J:123989
|
decreased T cell proliferation
|
J:123989
|
Prkd2tm1.1Daca/Prkd2tm1.1Daca
(involves: C57BL/6)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:166867
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:166867
|
decreased IgG1 level
|
J:166867
|
decreased IgM level
|
J:166867
|
decreased interferon-gamma secretion
|
J:166867
|
decreased interleukin-2 secretion
|
J:166867
|
Prkdchanky/Prkdchanky
(either: C57BL/6JAnu or (involves: C57BL/6JAnu * CBA/CaJ))
|
cecum inflammation
|
J:104190
|
colitis
|
J:104190
|
interstitial pneumonia
|
J:104190
|
liver inflammation
|
J:104190
|
Prkdcm1Btlr/Prkdcm1Btlr
(C57BL/6J-Prkdcm1Btlr)
|
abnormal immune system physiology
|
J:178522
|
Prkdcm1Btlr/Prkdcm1Btlr
(involves: C57BL/6J)
|
abnormal class switch recombination
|
J:185495
|
decreased IgG level
|
J:185495
|
decreased IgM level
|
J:185495
|
Prkdcm2Btlr/Prkdcm2Btlr
(C57BL/6J-Prkdcm2Btlr)
|
abnormal B cell physiology
|
J:204502
|
decreased IgG level
|
J:204502
|
decreased IgM level
|
J:204502
|
Prkdcm3Btlr/Prkdcm3Btlr
(C57BL/6J-Prkdcm3Btlr)
|
decreased IgG level
|
J:224665
|
impaired humoral immune response
|
J:224665
|
Prkdcm7Btlr/Prkdcm7Btlr
(C57BL/6J-Prkdcm7Btlr)
|
abnormal humoral immune response
|
J:255223
|
decreased IgG level
|
J:255223
|
PrkdcM11Btlr/Prkdc+
(C57BL/6J-PrkdcM11Btlr)
|
enhanced humoral immune response
|
J:255270
|
increased IgM level
|
J:255270
|
PrkdcM11Btlr/PrkdcM11Btlr
(C57BL/6J-PrkdcM11Btlr)
|
enhanced humoral immune response
|
J:255270
|
increased IgM level
|
J:255270
|
Prkdcscid/Prkdcscid
(C.BKa-Prkdcscid)
|
abnormal humoral immune response
|
J:6958
|
abnormal response to transplant
|
J:22026
|
decreased B cell proliferation
|
J:6958
|
decreased IgG level
|
J:6958
|
decreased immunoglobulin level
|
J:6958,
J:22026
|
decreased T cell proliferation
|
J:6958
|
increased length of allograft survival
|
J:6958,
J:22026
|
salivary gland inflammation
|
J:21965
|
Prkdcscid/Prkdcscid
(NOD.Cg-Prkdcscid)
|
abnormal response to transplant
|
J:109833,
J:22026
|
decreased immunoglobulin level
|
J:22026
|
decreased level of surface class I molecules
|
J:22026
|
impaired complement classical pathway
|
J:22026
|
impaired natural killer cell mediated cytotoxicity
|
J:22026
|
increased length of allograft survival
|
J:22026
|
Prkdcscid/Prkdcscid
(B6.Cg-Prkdcscid/Sz)
|
abnormal complement pathway
|
J:34814,
J:22026
|
abnormal level of surface class II molecules
|
J:34814
|
abnormal NK cell physiology
|
J:34814
|
decreased immunoglobulin level
|
J:34814
|
stomach inflammation
|
J:120556
|
Prkdcscid/Prkdcscid
(NOD.Cg-Prkdcscid/J)
|
abnormal response to transplant
|
J:91764
|
Prkdcscid/Prkdcscid
(involves: BALB/c * C57BL/6 * C57BL/Ka)
|
abnormal NK cell physiology
|
J:115033
|
Prkdcscid/Prkdcscid Sst1C57BL/6J/Sst1C57BL/6J
(involves: C3HeB/FeJ * C57BL/6J)
|
decreased susceptibility to bacterial infection
|
J:93705
|
Prkdcscid/Prkdcscid Tg(B2M)55Hpl/0 Mcph1Tg(HLA-A2.1)1Enge/Mcph1+
(NOD.Cg-Mcph1Tg(HLA-A2.1)1Enge Prkdcscid Tg(B2M)55Hpl/Sz)
|
abnormal response to transplant
|
J:91764
|
Prkdcscid/Prkdcscid Tg(CSF2)2Ygy/0 Tg(IL3)1Ygy/0
(CB17.Cg-Prkdcscid Tg(CSF2)2Ygy Tg(IL3)1Ygy)
|
abnormal response to transplant
|
J:94302
|
Prkdcscid/Prkdcscid Tg(CSF2)2Ygy/0 Tg(IL3)1Ygy/0 Tg(KITLG)3Ygy/0
(CB17.Cg-Prkdcscid Tg(CSF2)2Ygy Tg(IL3)1Ygy Tg(KITLG)3Ygy)
|
abnormal response to transplant
|
J:106416,
J:94302
|
Prkdcscid/Prkdcscid Tg(CSF2)2Ygy/0 Tg(IL3)1Ygy/0 Tg(KITLG)3Ygy/0
(NOD.Cg-Prkdcscid Tg(CSF2)2Ygy Tg(IL3)1Ygy Tg(KITLG)3Ygy)
|
abnormal response to transplant
|
J:107052
|
decreased susceptibility to graft versus host disease
|
J:107052
|
Prkdcscid/Prkdcscid Tg(Ins2-Fasl)24Ach/0
(NOD.Cg-Prkdcscid Tg(Ins2-Fasl)24Ach)
|
decreased susceptibility to autoimmune diabetes
|
J:81416
|
increased susceptibility to autoimmune diabetes
|
J:81416
|
Prkdcscid/Prkdcscid Tg(INS-Il10)#Sar/0
(NOD.Cg-Prkdcscid Tg(INS-Il10)#Sar)
|
increased susceptibility to autoimmune diabetes
|
J:66103
|
Prkdcscid/Prkdcscid Tg(TcraAI4)1Dvs/0 Tg(TcrbAI4)1Dvs/0
(NOD.Cg-Prkdcscid Tg(TcraAI4)1Dvs Tg(TcrbAI4)1Dvs)
|
increased susceptibility to autoimmune diabetes
|
J:93553
|
Prkdctm1Gcl/Prkdctm1Gcl
(involves: 129S1/Sv)
|
decreased thymocyte apoptosis
|
J:126920
|
Prkdctm1Get/Prkdctm1Get
(involves: 129S4/SvJae * Black Swiss)
|
decreased IgM level
|
J:50222
|
Prmt3tm1a(EUCOMM)Wtsi/Prmt3tm1a(EUCOMM)Wtsi
(involves: C57BL/6 * C57BL/6N)
|
increased incidence of corneal inflammation
|
J:213427
|
Prmt7tm1a(EUCOMM)Wtsi/Prmt7tm1a(EUCOMM)Wtsi
(B6JTyr;B6N-Prmt7tm1a(EUCOMM)Wtsi/Wtsi)
|
blood in lymph vessels
|
J:239583
|
Prmt9em1Cya/Prmt9em1Cya Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * C57BL/6N)
|
decreased susceptibility to viral infection
|
J:328263
|
increased circulating interferon-beta level
|
J:328263
|
increased interferon-beta secretion
|
J:328263
|
Prnpa/Prnpa
(NZW)
|
increased susceptibility to prion infection
|
J:8918
|
Prnpb/Prnpb
(I/LnJ)
|
decreased susceptibility to prion infection
|
J:8918
|
Prnpc/Prnpc
(MAI/Pas)
|
decreased susceptibility to prion infection
|
J:90099
|
Prnpem2.1(Prnp*D178N)Jwat/Prnpem2.1(Prnp*D178N)Jwat
(involves: 129S4/SvJae * C57BL/6)
|
dermatitis
|
J:361333
|
Prnpem3.1(Prnp*E200K)Jwat/Prnpem3.1(Prnp*E200K)Jwat
(involves: 129S4/SvJae * C57BL/6)
|
dermatitis
|
J:361333
|
Prnptm1(PRNP)Tkit/Prnptm1(PRNP)Tkit
(Not Specified)
|
decreased susceptibility to prion infection
|
J:86603
|
increased susceptibility to prion infection
|
J:86603
|
Prnptm1Cwe/Prnptm1Cwe Tg(Nefh-cre)22Jcol/? Tg(Prnp)37Jcol/?
(involves: 129/Sv * 129S7/SvEvBrd * C57BL/6 * FVB)
|
decreased susceptibility to prion infection
|
J:126424
|
Prnptm1Cwe/Prnptm1Cwe Tg(Nefh-cre)22Jcol/? Tg(Prnp)46Jcol/?
(involves: 129/Sv * 129S7/SvEvBrd * C57BL/6 * FVB)
|
decreased susceptibility to prion infection
|
J:74652
|
Prnptm1Cwe/Prnptm1Cwe Tg(PRNP)35Jcol/Tg(PRNP)35Jcol
(involves: 129 * 129S7/SvEvBrd * C57BL/6 * FVB/N)
|
increased susceptibility to prion infection
|
J:131494
|
Prnptm1Cwe/Prnptm1Cwe Tg(Prnp)37Jcol/?
(involves: 129/Sv * 129S7/SvEvBrd * C57BL/6 * FVB)
|
increased susceptibility to prion infection
|
J:74652,
J:126424
|
Prnptm1Cwe/Prnptm1Cwe Tg(PRNP)45Jcol/Tg(PRNP)45Jcol
(involves: 129 * 129S7/SvEvBrd * C57BL/6 * FVB/N)
|
increased susceptibility to prion infection
|
J:131494
|
Prnptm1Cwe/Prnptm1Cwe Tg(Prnp)4053Sbp/0
(involves: 129S7/SvEvBrd * FVB/N)
|
increased susceptibility to prion infection
|
J:136434
|
Prnptm1Cwe/Prnptm1Cwe Tg(PRNP)23454Sbp/0
(involves: 129S7/SvEvBrd * FVB/N)
|
increased susceptibility to prion infection
|
J:236012
|
Prnptm1Cwe/Prnptm1Cwe Tg(Prnp)a19Cwe/0
(Not Specified)
|
increased susceptibility to prion infection
|
J:32214
|
Prnptm1Cwe/Prnptm1Cwe Tg(Prnp)a20Cwe/0
(Not Specified)
|
increased susceptibility to prion infection
|
J:32214
|
Prnptm1Cwe/Prnptm1Cwe Tg(Prnp)c35Cwe/0
(Not Specified)
|
increased susceptibility to prion infection
|
J:32214
|
Prnptm1Cwe/Prnptm1Cwe Tg(Prnp*S170N*N174T)1020Aag/0
(involves: 129S7/SvEvBrd * C57BL/6)
|
decreased susceptibility to prion infection
|
J:143528
|
Prnptm1Edin/Prnptm1Edin
(129P2/OlaHsd-Prnptm1Edin/EdinH)
|
abnormal susceptibility to prion infection
|
J:58820
|
Prnptm1Lnq/Prnptm1Lnq
(involves: 129P2/OlaHsd * C57BL/6N)
|
decreased susceptibility to prion infection
|
J:154937
|
Prnptm1Miy/Prnptm1Miy
(involves: 129S4/SvJae * C57BL/6)
|
decreased susceptibility to prion infection
|
J:69186
|
Prnptm1Rcm/Prnptm1Rcm
(129P2/OlaHsd-Prnptm1Rcm)
|
abnormal susceptibility to prion infection
|
J:45908
|
Prnptm1Tuzi/Prnp+
(involves: 129P2/OlaHsd)
|
decreased susceptibility to prion infection
|
J:92302
|
Prnptm1Tuzi/Prnptm2Edin
(involves: 129P2/OlaHsd)
|
decreased susceptibility to prion infection
|
J:92302
|
Prnptm1Tuzi/Prnptm2Edin Tg(CMV-cre)1Cgn/?
(involves: 129P2/OlaHsd * BALB/cJ)
|
decreased susceptibility to prion infection
|
J:92302
|
Prnptm2(PRNP*129M)Tkit/Prnptm2(PRNP*129M)Tkit
(Not Specified)
|
decreased susceptibility to prion infection
|
J:126777,
J:105882
|
increased susceptibility to prion infection
|
J:126777,
J:105882
|
Prnptm2(PRNP*129M)Tkit/Prnptm2(PRNP*129M)Tkit Tg(Prnp-PRNP*129M)1Tkit/?
(Not Specified)
|
decreased susceptibility to prion infection
|
J:126777
|
increased susceptibility to prion infection
|
J:126777
|
Prnptm2(PRNP*129M)Tkit/Prnptm3(PRNP*129V)Tkit
(Not Specified)
|
decreased susceptibility to prion infection
|
J:105882
|
Prnptm2Tuzi/Prnp+ Tg(CMV-cre)1Cgn/?
(involves: 129P2/OlaHsd * BALB/cJ)
|
decreased susceptibility to prion infection
|
J:92302
|
Prnptm2Tuzi/Prnptm2Edin
(involves: 129P2/OlaHsd)
|
decreased susceptibility to prion infection
|
J:92302
|
Prnptm2Tuzi/Prnptm2Edin Tg(CMV-cre)1Cgn/?
(involves: 129P2/OlaHsd * BALB/cJ)
|
decreased susceptibility to prion infection
|
J:92302
|
Prnptm3(PRNP*129V)Tkit/Prnptm3(PRNP*129V)Tkit
(Not Specified)
|
decreased susceptibility to prion infection
|
J:126777,
J:105882
|
increased susceptibility to prion infection
|
J:126777
|
Prnptm3(PRNP*129V)Tkit/Prnptm3(PRNP*129V)Tkit Tg(Prnp-PRNP*129V)139Tkit/?
(Not Specified)
|
abnormal susceptibility to infection
|
J:126777
|
decreased susceptibility to prion infection
|
J:105882
|
Prnptm3(PRNP*129V)Tkit/Prnptm3(PRNP*129V)Tkit Tg(Prnp-PRNP*129V)144Tkit/?
(Not Specified)
|
decreased susceptibility to prion infection
|
J:105882
|
Prnptm4(PRNP)Tkit/Prnptm4(PRNP)Tkit
(Not Specified)
|
increased susceptibility to prion infection
|
J:105882
|
Prnptm4(PRNP)Tkit/Prnptm4(PRNP)Tkit Tg(Prnp-PRNP)32Tkit/?
(Not Specified)
|
increased susceptibility to prion infection
|
J:105882
|
Prnptm5(PRNP*)TKit/Prnptm5(PRNP*)TKit Tg(Prnp-PRNP*)1Tkit/?
(Not Specified)
|
decreased susceptibility to prion infection
|
J:126777
|
increased susceptibility to prion infection
|
J:126777
|
Prnr1RIII/FaDk/Prnr1RIII/FaDk
(involves: C57BL/FaDk * RIII/FaDk)
|
decreased susceptibility to prion infection
|
J:89558
|
Prnr2C57BL/FaDk/Prnr2C57BL/FaDk
(involves: C57BL/FaDk * RIII/FaDk)
|
decreased susceptibility to prion infection
|
J:89558
|
Prnr2C57BL/FaDk/Prnr2RIII/FaDk
(involves: C57BL/FaDk * RIII/FaDk)
|
decreased susceptibility to prion infection
|
J:89558
|
Proctm1Fjc/Proctm1Fjc
(involves: 129S1/Sv * 129X1/SvJ * Swiss)
|
abnormal innate immunity
|
J:50527
|
liver inflammation
|
J:50527
|
Procrtm1.1Pcl/Procrtm1.1Pcl
(involves: 129S2/SvPas * C57BL/6)
|
increased circulating interleukin-6 level
|
J:225914
|
increased susceptibility to endotoxin shock
|
J:225914
|
Prox1tm1Gco/Prox1+
(involves: 129S1/Sv * 129X1/SvJ * NMRI)
|
abnormal lymph circulation
|
J:102652,
J:57646
|
increased inflammatory response
|
J:102652
|
Prox1tm1Gco/Prox1+
(involves: 129S1/Sv * 129X1/SvJ)
|
abnormal lymph circulation
|
J:57646
|
Prox1tm2Gco/Prox1+ Tg(Tek-cre)1Ywa/0
(involves: 129S1/Sv * C57BL/6 * NMRI * SJL)
|
abnormal lymph circulation
|
J:102652
|
Prph2em1Sal/Prph2+
(C57BL/6J-Prph2em1Sal)
|
eye inflammation
|
J:342243
|
Prph2em1Sal/Prph2em1Sal
(C57BL/6J-Prph2em1Sal)
|
eye inflammation
|
J:342243
|
increased microglial cell activation
|
J:342243
|
Prps2tm1a(KOMP)Wtsi/Y
(involves: C57BL/6N)
|
abnormal B cell physiology
|
J:214383
|
Prps2tm1a(KOMP)Wtsi/Y Tg(IghMyc)22Bri/0
(involves: C57BL/6N * SJL)
|
abnormal B cell physiology
|
J:214383
|
increased B cell apoptosis
|
J:214383
|
Prss3btm1.1Satom/Prss3b+
(B6(FVB)-Prss3btm1.1Satom)
|
acute pancreas inflammation
|
J:267764
|
chronic pancreas inflammation
|
J:267764
|
Prss34tm1.1Hkar/Prss34tm1.1Hkar
(involves: C57BL/6)
|
decreased inflammatory response
|
J:238924
|
Prss57tm1.1Gne/Prss57tm1.1Gne
(C57BL/6N-Prss57tm1.1Gne)
|
abnormal mast cell physiology
|
J:301479
|
Prss57tm1Lex/Prss57tm1Lex
(involves: 129S5/SvEvBrd)
|
abnormal mast cell physiology
|
J:301479
|
Prtn3tm1.1Hrlu/Prtn3tm1.1Hrlu
(involves: C57BL/6)
|
abnormal neutrophil physiology
|
J:217636
|
Prxl2atm1(KOMP)Vlcg/Prxl2atm1(KOMP)Vlcg
(C57BL/6N-Prxl2atm1(KOMP)Vlcg)
|
white adipose tissue inflammation
|
J:234040
|
Psaptm1Ggb/Psaptm1Ggb
(involves: 129S/SvEv * C57BL/6J)
|
abnormal microglial cell physiology
|
J:121761
|
Psaptm1Juma/Psaptm1Juma
(FVB.129S-Psaptm1Juma)
|
abnormal microglial cell physiology
|
J:121761
|
Psaptm2Ggb/Psaptm2Ggb
(involves: 129S/SvEv * C57BL/6J)
|
CNS inflammation
|
J:137650
|
kidney inflammation
|
J:137650
|
Psaptm2Suz/Psaptm2Suz
(involves: 129S/SvEv * C57BL/6J)
|
CNS inflammation
|
J:78223
|
Pscr1DBA/2/Pscr1DBA/2
(involves: BALB/c * DBA/2)
|
decreased susceptibility to bacterial infection
|
J:8914
|
Pscr1DBA/2/Pscr1DBA/2 Pscr2DBA/2/Pscr2DBA/2 Pscr3DBA/2/Pscr3DBA/2
(involves: C57BL/6 * DBA/2)
|
decreased susceptibility to bacterial infection
|
J:8914
|
Pscr2DBA/2/Pscr2DBA/2
(involves: BALB/c * DBA/2)
|
decreased susceptibility to bacterial infection
|
J:8914
|
Pscr3DBA/2/Pscr3DBA/2
(involves: BALB/c * DBA/2)
|
decreased susceptibility to bacterial infection
|
J:8914
|
Psen1tm1Bdes/Psen1+ Psen2tm1Bdes/Psen2tm1Bdes
(involves: 129P2/OlaHsd)
|
arteritis
|
J:91235
|
autoimmune response
|
J:91235
|
chronic inflammation
|
J:91235
|
dermatitis
|
J:91235
|
glomerulonephritis
|
J:91235
|
increased anti-single stranded DNA antibody level
|
J:91235
|
increased immunoglobulin level
|
J:91235
|
increased incidence of corneal inflammation
|
J:91235
|
increased inflammatory response
|
J:91235
|
increased susceptibility to autoimmune disorder
|
J:91235
|
kidney inflammation
|
J:91235
|
skin inflammation
|
J:91235
|
Psip1Gt(betageo)1Hgs/Psip1Gt(betageo)1Hgs
(B6.129P2-Psip1Gt(betageo)1Hgs)
|
blepharitis
|
J:112975
|
Psip1Gt(betageo)1Hgs/Psip1Gt(betageo)1Hgs
(either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * MF1))
|
blepharitis
|
J:112975
|
Psmb8tm1Hjf/Psmb8tm1Hjf
(either: 129P2/OlaHsd or (involves: 129P2/OlaHsd * C57BL/6))
|
decreased level of surface class I molecules
|
J:20012
|
defective intracellular transport of class I molecules
|
J:20012
|
Psmb8tm1Hjf/Psmb8tm1Hjf
(involves: 129P2/OlaHsd)
|
abnormal dendritic cell antigen presentation
|
J:180765
|
decreased level of surface class I molecules
|
J:180765
|
Psmb9tm1Stl/Psmb9tm1Stl
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal immune system physiology
|
J:21549
|
increased susceptibility to Orthomyxoviridae infection
|
J:21549
|
Psmb10tm1Mgro/Psmb10tm1Mgro
(involves: 129S2/SvPas * C57BL/6)
|
abnormal cytotoxic T cell physiology
|
J:125058
|
decreased T cell proliferation
|
J:125058
|
Psmb10tm1Mgro/Psmb10tm1Mgro Psmb9/Psmb8tm1Klr/Psmb9/Psmb8tm1Klr
(B6.129-Psmb10tm1Mgro Psmb9/Psmb8tm1Klr)
|
abnormal antigen presentation via MHC class I
|
J:180765
|
abnormal B lymphocyte antigen presentation
|
J:180765
|
abnormal dendritic cell antigen presentation
|
J:180765
|
decreased level of surface class I molecules
|
J:180765
|
Psmb10tm1Mgro/Psmb10tm1Mgro Psmb9/Psmb8tm1Klr/Psmb9/Psmb8tm1Klr
(B6.129-Psmb10tm1Mgro Psmb9/Psmb8tm1Klr)
|
abnormal antigen presentation via MHC class I
|
J:180765
|
abnormal B lymphocyte antigen presentation
|
J:180765
|
abnormal dendritic cell antigen presentation
|
J:180765
|
decreased level of surface class I molecules
|
J:180765
|
Psmb10Tub6/Psmb10+
(C3HeB/FeJ-Psmb10Tub6)
|
abnormal T cell activation
|
J:261081
|
decreased interferon-gamma secretion
|
J:261081
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:261081
|
Psmb10Tub6/Psmb10Tub6
(C3HeB/FeJ-Psmb10Tub6)
|
decreased immunoglobulin level
|
J:261081
|
increased circulating interleukin-1 level
|
J:261081
|
increased circulating interleukin-6 level
|
J:261081
|
increased circulating tumor necrosis factor level
|
J:261081
|
increased inflammatory response
|
J:261081
|
skin inflammation
|
J:261081
|
Psmb11tm1(Psmb8)Khog/Psmb11tm1(Psmb8)Khog
(involves: C57BL/6)
|
abnormal self tolerance
|
J:196156
|
increased T cell proliferation
|
J:196156
|
Psme2tm1Yya/Psme2tm1Yya
(involves: 129P2/OlaHsd)
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:58875
|
decreased cytotoxic T cell cytolysis
|
J:58875
|
defective assembly of class I molecules
|
J:58875
|
Psme3tm1Jjm/Psme3tm1Jjm
(B6.129X1-Psme3tm1Jjm)
|
increased susceptibility to fungal infection
|
J:88626
|
Psphtm1a(EUCOMM)Hmgu/Psphtm1a(EUCOMM)Hmgu
(C57BL/6N-Psphtm1a(EUCOMM)Hmgu/Wtsi)
|
blood in lymph vessels
|
J:239583
|
Pstpip1tm1Spg/Pstpip1tm1Spg
(involves: 129S/SvEv * C57BL/6)
|
abnormal T cell physiology
|
J:101977
|
Pstpip2cmo/Pstpip2cmo
(C.D2-Qa2)
|
chronic inflammation
|
J:1534
|
Pstpip2cmo/Pstpip2cmo
(C.Cg-Pstpip2cmo/J)
|
ear inflammation
|
J:104476
|
osteomyelitis
|
J:104476,
J:105410
|
Pstpip2Lupo/Pstpip2Lupo
(either: (involves: C3HeB/FeJ) or (involves: C3HeB/FeJ * C57BL/6J))
|
abnormal cytokine secretion
|
J:125785
|
increased autoantibody level
|
J:125785
|
increased IgE level
|
J:125785
|
increased IgG1 level
|
J:125785
|
increased IgG2a level
|
J:125785
|
increased IgG level
|
J:125785
|
skin inflammation
|
J:125785
|
Pstpip2Lupo/Pstpip2Lupo Rag1tm1Mom/Rag1tm1Mom
(involves: 129S7/SvEvBrd * C3HeB/FeJ * C57BL/6J)
|
skin inflammation
|
J:125785
|
Pstpip2m1Bcs/Pstpip2m1Bcs
(involves: C57BL/6)
|
abnormal inflammatory response
|
J:196534
|
autoimmune response
|
J:196534
|
ear inflammation
|
J:196534
|
skin inflammation
|
J:196534
|
Ptafrtm1Tksh/Ptafrtm1Tksh
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased inflammatory response
|
J:87866
|
increased susceptibility to parasitic infection
|
J:87866
|
increased susceptibility to type I hypersensitivity reaction
|
J:88505
|
Ptafrtm1Tksh/Ptafrtm1Tksh
(C57BL/6-Ptafrtm1Tksh)
|
decreased susceptibility to bacterial infection
|
J:88589
|
Ptentm1Engc/Ptentm1Engc
(involves: CD-1)
|
abnormal microglial cell physiology
|
J:210487
|
Ptentm1Hwu/Ptentm1Hwu Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * 129S4/SvJae)
|
abnormal cytokine level
|
J:148947
|
abnormal macrophage chemotaxis
|
J:148947
|
abnormal neutrophil physiology
|
J:148947,
J:114699,
J:145331
|
decreased susceptibility to bacterial infection
|
J:148947
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:148947
|
impaired neutrophil recruitment
|
J:148947
|
increased susceptibility to bacterial infection
|
J:148947
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:148947
|
lung inflammation
|
J:148947
|
Ptentm1Hwu/Ptentm1Hwu Tg(CAG-EGFP,-PAX8/PPARG)1Rkoe/0 Tg(TPO-cre)1Shk/0
(involves: 129S4/SvJae * FVB/NCr * FVB/NJ)
|
abnormal thymus physiology
|
J:177181
|
Ptentm1Hwu/Ptentm1Hwu Tg(GZMB-cre)1Jcb/0
(involves: 129S4/SvJae * FVB/N)
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:164425
|
decreased interleukin-2 secretion
|
J:164425
|
Ptentm1Hwu/Ptentm1Hwu Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * BALB/c * C57BL/6 * DBA/2)
|
prostate gland inflammation
|
J:93902
|
pyelonephritis
|
J:124208
|
Ptentm2.1Ppp/Ptentm2.1Ppp Tnfrsf4tm2(cre)Nik/Tnfrsf4+
(involves: 129S1/Sv * 129X1/SvJ)
|
increased IgG1 level
|
J:164283
|
Ptentm2Mak/Ptentm2Mak Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129P2/OlaHsd * C57BL/6 * DBA)
|
liver inflammation
|
J:138099
|
Ptgdr2tm1Byl/Ptgdr2tm1Byl
(involves: C57BL/6J)
|
abnormal cytokine secretion
|
J:107519
|
Ptgdr2tm1Tasa/Ptgdr2tm1Tasa
(involves: 129/Sv * BALB/c)
|
impaired eosinophil recruitment
|
J:130892
|
Ptgdr2tm1Tasa/Ptgdr2tm1Tasa
(C.129-Ptgdr2tm1Tasa)
|
abnormal chemokine level
|
J:131146
|
abnormal inflammatory response
|
J:131146
|
decreased IgE level
|
J:131146
|
decreased inflammatory response
|
J:131146
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:131146
|
Ptgdr2tm1Tasa/Ptgdr2tm1Tasa
(B6.129-Ptgdr2tm1Tasa)
|
increased susceptibility to type I hypersensitivity reaction
|
J:197334
|
Ptgdrtm1Sna/Ptgdrtm1Sna
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal macrophage activation involved in immune response
|
J:243958
|
brain inflammation
|
J:243958
|
decreased microglial cell activation
|
J:243958
|
increased interleukin-1 beta secretion
|
J:243958
|
increased susceptibility to Coronaviridae infection
|
J:243958
|
increased susceptibility to Coronaviridae infection induced morbidity/mortality
|
J:243958
|
respiratory system inflammation
|
J:61023
|
Ptgdrtm1Sna/Ptgdrtm1Sna
(B6.129P2-Ptgdrtm1Sna/Sna)
|
abnormal mast cell physiology
|
J:197334
|
decreased mast cell degranulation
|
J:197334
|
decreased susceptibility to type I hypersensitivity reaction
|
J:197334
|
Ptgdstm1Ohy/Ptgdstm1Ohy
(B6.129P2-Ptgdstm1Ohy)
|
decreased mast cell degranulation
|
J:197334
|
decreased susceptibility to type I hypersensitivity reaction
|
J:197334
|
Ptger1tm1Sna/Ptger1tm1Sna
(B6CrSlc.129P2-Ptger1tm1Sna/Sna)
|
abnormal interferon-gamma secretion
|
J:128435
|
abnormal response to infection
|
J:82750
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:128435
|
Ptger2tm1.1Kand/Ptger2tm1.1Kand Tg(ITGAM-cre)2781Gkl/0
(involves: C57BL/6 * CBA)
|
abnormal microglial cell physiology
|
J:202677
|
decreased susceptibility to endotoxin shock
|
J:202677
|
Ptger2tm1Brey/Ptger2tm1Brey
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal response to infection
|
J:120725
|
Ptger2tm1Brey/Ptger2tm1Brey
(C.129S6-Ptger2tm1Brey)
|
abnormal microglial cell physiology
|
J:97062
|
Ptger2tm1Brey/Ptger2tm1Brey
(involves: 129S6/SvEvTac * BALB/c)
|
abnormal response to infection
|
J:164638
|
Ptger3tm1Sna/Ptger3tm1Sna
(B6.129P2-Ptger3tm1Sna/Sna)
|
abnormal response to infection
|
J:82750
|
increased susceptibility to type I hypersensitivity reaction
|
J:197334
|
Ptger4tm1.1Matb/Ptger4tm1.1Matb Tg(Myh6-cre)2182Mds/0
(involves: 129S6/SvEvTac * FVB/N)
|
heart inflammation
|
J:158439
|
Ptger4tm1Bhk/Ptger4tm1Bhk
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
abnormal circulating interleukin-6 level
|
J:78964
|
abnormal circulating serum amyloid protein level
|
J:78964
|
abnormal cytokine level
|
J:78964
|
abnormal macrophage physiology
|
J:78964
|
decreased susceptibility to induced arthritis
|
J:78964
|
rheumatoid arthritis
|
J:78964
|
Ptger4tm1Sna/Ptger4tm1Sna
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal Langerhans cell physiology
|
J:83725
|
abnormal osteoclast physiology
|
J:63070
|
abnormal T cell activation
|
J:83725
|
decreased interferon-gamma secretion
|
J:83725
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:83725
|
decreased T cell proliferation
|
J:83725
|
Ptges2tm1Kymm/Ptges2tm1Kymm
(B6.Cg-Ptges2tm1Kymm)
|
increased susceptibility to type I hypersensitivity reaction
|
J:197334
|
Ptgestm1.1Gaf/Ptgestm1.1Gaf Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129 * C57BL/6)
|
abnormal leukocyte physiology
|
J:210141
|
Ptgestm1Aki/Ptgestm1Aki
(involves: 129X1/SvJ * C57BL/6)
|
abnormal inflammatory response
|
J:91821
|
chronic inflammation
|
J:91821
|
impaired macrophage chemotaxis
|
J:91821
|
Ptgestm1Aki/Ptgestm1Aki
(B6.129P2-Ptgestm1Aki)
|
increased susceptibility to type I hypersensitivity reaction
|
J:197334
|
Ptgestm1Lpa/Ptgestm1Lpa
(DBA/1LacJ-Ptgestm1Lpa)
|
decreased inflammatory response
|
J:89960,
J:90980
|
Ptgirtm1Sna/Ptgirtm1Sna
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased acute inflammation
|
J:42275
|
Ptgs1tm1Fun/Ptgs1tm1Fun
(involves: 129S6/SvEvTac * C57BL/6)
|
decreased inflammatory response
|
J:97351
|
Ptgs1tm1Unc/Ptgs1tm1Unc
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased inflammatory response
|
J:29511
|
increased susceptibility to endotoxin shock
|
J:75611
|
increased susceptibility to induced colitis
|
J:158426,
J:60668
|
Ptgs1tm1Unc/Ptgs1tm1Unc
(B6.129P2-Ptgs1tm1Unc)
|
decreased susceptibility to induced arthritis
|
J:110716
|
Ptgs2tm1.1Fun/Ptgs2tm1.1Fun
(involves: 129S6/SvEvTac)
|
kidney inflammation
|
J:148699
|
Ptgs2tm1.1Wls/Ptgs2tm1.1Wls
(B6.129-Ptgs2tm1.1Wls)
|
increased susceptibility to endotoxin shock
|
J:156331
|
Ptgs2tm1Jed/Ptgs2tm1Jed
(involves: 129S7/SvEvBrd)
|
pyelonephritis
|
J:29974
|
Ptgs2tm1Jed/Ptgs2tm1Jed
(involves: 129S7/SvEvBrd * C57BL/6)
|
peritoneal inflammation
|
J:118171
|
Ptgs2tm1Jed/Ptgs2tm1Jed
(involves: 129S7/SvEvBrd * CD-1)
|
abnormal response to infection
|
J:120725
|
Ptgs2tm1Unc/Ptgs2tm1Unc
(involves: 129P2/OlaHsd * C57BL/6J)
|
abnormal macrophage physiology
|
J:29510
|
peritoneal inflammation
|
J:29510
|
tubulointerstitial nephritis
|
J:29510
|
Ptgs2tm1Unc/Ptgs2tm1Unc
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased susceptibility to endotoxin shock
|
J:75611
|
increased susceptibility to induced colitis
|
J:158426,
J:60668
|
increased tumor necrosis factor secretion
|
J:108054
|
peritoneal inflammation
|
J:60668
|
Ptgs2tm1Unc/Ptgs2tm1Unc
(B6.129P2-Ptgs2tm1Unc)
|
abnormal class switch recombination
|
J:140698
|
abnormal response to infection
|
J:140698
|
decreased IgG1 level
|
J:140698
|
decreased IgG2a level
|
J:140698
|
decreased IgG3 level
|
J:140698
|
decreased susceptibility to induced arthritis
|
J:110716
|
increased IgM level
|
J:140698
|
Ptgs2tm1Unc/Ptgs2tm2.1Hahe
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
increased susceptibility to induced colitis
|
J:158426
|
Ptgs2tm2(Ptgs1)Fun/Ptgs2tm2(Ptgs1)Fun
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal macrophage physiology
|
J:118171
|
Ptgs2tm2.1(Ptgs1)Fun/Ptgs2tm2.1(Ptgs1)Fun
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB)
|
abnormal macrophage physiology
|
J:118171
|
kidney inflammation
|
J:118171
|
peritoneal inflammation
|
J:118171
|
Ptgs2ostm1Scrp/Ptgs2ostm1Scrp
(Not Specified)
|
abnormal chemokine level
|
J:325487
|
decreased CCL3 level
|
J:325487
|
decreased circulating CCL3 level
|
J:325487
|
decreased circulating interleukin-6 level
|
J:325487
|
increased interferon-beta secretion
|
J:325487
|
Pth1rtm1a(EUCOMM)Hmgu/Pth1rtm1a(EUCOMM)Hmgu
(C57BL/6N-Pth1rtm1a(EUCOMM)Hmgu/Wtsi)
|
blood in lymph vessels
|
J:239583
|
Ptk2btm1Schl/Ptk2btm1Schl
(involves: 129S1/Sv * 129X1/SvJ)
|
abnormal macrophage physiology
|
J:99741
|
decreased acute inflammation
|
J:99741
|
impaired macrophage chemotaxis
|
J:99741
|
Ptntm1Tmu/Ptntm1Tmu
(B6.Cg-Ptntm1Tmu)
|
impaired macrophage chemotaxis
|
J:102069
|
impaired neutrophil recruitment
|
J:102069
|
Ptpn2tm1.1Kry/Ptpn2tm1.1Kry Tg(Col1a1-cre)1Kry/0
(involves: 129 * C57BL/6J * FVB)
|
abnormal osteoclast physiology
|
J:183709
|
Ptpn2tm1Mtr/Ptpn2tm1Mtr
(involves: 129S4/SvJae * BALB/c)
|
abnormal inflammatory response
|
J:90541
|
abnormal thymus involution
|
J:42595
|
increased inflammatory response
|
J:90541
|
increased interferon-gamma secretion
|
J:90541
|
increased interleukin-12 secretion
|
J:90541
|
increased tumor necrosis factor secretion
|
J:90541
|
Ptpn6m1Amgn/Ptpn6m1Amgn
(involves: C3H/HeSnJ * C57BL/6J * Swiss)
|
increased circulating interleukin-17 level
|
J:168664
|
Ptpn6m1Anu/Ptpn6m1Anu
(C57BL/6JAnu-Ptpn6m1Anu)
|
decreased IgM level
|
J:225105
|
Ptpn6m1Btlr/Ptpn6m1Btlr
(C57BL/6J-Ptpn6m1Btlr/Mmucd)
|
decreased susceptibility to bacterial infection
|
J:142845
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:142845
|
increased anti-chromatin antibody level
|
J:142845
|
increased IgM level
|
J:142845
|
increased inflammatory response
|
J:94077
|
lung inflammation
|
J:142845
|
salivary gland inflammation
|
J:142845
|
Ptpn6M5Btlr/Ptpn6M5Btlr
(C57BL/6J-Ptpn6M5Btlr)
|
decreased IgD level
|
J:265075
|
decreased IgM level
|
J:265075
|
Ptpn6me-B2/Ptpn6me-B2
(involves: BALB/c)
|
abnormal circulating chemokine level
|
J:169850
|
increased circulating interferon-gamma level
|
J:169850
|
increased circulating interleukin-1 beta level
|
J:169850
|
increased circulating interleukin-6 level
|
J:169850
|
increased circulating interleukin-10 level
|
J:169850
|
increased circulating serum amyloid protein level
|
J:169850
|
increased IgG level
|
J:169850
|
increased IgM level
|
J:169850
|
interstitial pneumonia
|
J:169850
|
skin inflammation
|
J:169850
|
Ptpn6me-v/Ptpn6me-v
(C57BL/6J-Ptpn6me-v)
|
abnormal immunoglobulin level
|
J:7665
|
abnormal inflammatory response
|
J:20845
|
abnormal T cell physiology
|
J:1661
|
chronic inflammation
|
J:20845
|
interstitial pneumonia
|
J:7531
|
rheumatoid arthritis
|
J:20845
|
Ptpn6me/Ptpn6me
(C57BL/6J-Ptpn6me/J)
|
abnormal humoral immune response
|
J:5579
|
autoimmune response
|
J:5579
|
increased IgA level
|
J:5579
|
increased IgG level
|
J:5579
|
increased IgM level
|
J:5579
|
increased immunoglobulin level
|
J:5579
|
Ptpn6me/Ptpn6me
(involves: C3H/HeN * C57BL/6J * NFS)
|
increased autoantibody level
|
J:30994
|
increased IgM level
|
J:30994
|
increased splenocyte proliferation
|
J:30994
|
Ptpn6me/Ptpn6me
(C3FeLe.B6 a/a-Ptpn6me/J)
|
increased microglial cell activation
|
J:88807
|
Ptpn6me/Ptpn6me
(either: (involves: C3H * C57BL/6J) or (involves: C57BL/6J * C57BL/6N))
|
lung inflammation
|
J:5999
|
Ptpn9tm1Dny/Ptpn9tm1Dny
(B6.129-Ptpn9tm1Dny)
|
decreased T cell proliferation
|
J:118880
|
Ptpn11tm1Gsf/Ptpn11tm1Gsf Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA)
|
increased acute inflammation
|
J:172422
|
increased circulating interleukin-6 level
|
J:172422
|
liver inflammation
|
J:172422
|
Ptpn11tm1Gsf/Ptpn11tm1Gsf Stat3tm1Vpo/Stat3tm1Vpo Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA)
|
liver inflammation
|
J:172422
|
Ptpn12tm1Vei/Ptpn12tm1Vei Tg(Cd4-cre)1Cwi/0
(B6.Cg-Tg(Cd4-cre)1Cwi Ptpn12tm1Vei)
|
abnormal cytokine secretion
|
J:163910
|
abnormal T cell physiology
|
J:163910
|
decreased T cell proliferation
|
J:163910
|
Ptpn12tm1Vei/Ptpn12tm1Vei Tg(Lck-cre)1Cwi/0
(B6.Cg-Ptpn12tm1Vei Tg(Lck-cre)1Cwi)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:163910
|
Ptpn13tm1Gru/Ptpn13tm1Gru
(involves: C57BL/6)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:118426
|
abnormal cytokine secretion
|
J:118426
|
decreased susceptibility to bacterial infection
|
J:118426
|
Ptpn22tm1.1Draw/Ptpn22+
(involves: 129 * C57BL/6)
|
abnormal B cell physiology
|
J:201448
|
abnormal T cell physiology
|
J:201448
|
autoimmune response
|
J:201448
|
decreased B cell apoptosis
|
J:201448
|
increased anti-double stranded DNA antibody level
|
J:201448
|
increased B cell proliferation
|
J:201448
|
increased IgG1 level
|
J:201448
|
increased interleukin-2 secretion
|
J:201448
|
increased T cell proliferation
|
J:201448
|
Ptpn22tm1.1Draw/Ptpn22tm1.1Draw
(involves: 129 * C57BL/6)
|
abnormal B cell activation
|
J:201448
|
abnormal B cell physiology
|
J:201448
|
abnormal T cell physiology
|
J:201448
|
autoimmune response
|
J:201448
|
decreased B cell apoptosis
|
J:201448
|
glomerulonephritis
|
J:201448
|
increased anti-double stranded DNA antibody level
|
J:201448
|
increased anti-insulin autoantibody level
|
J:201448
|
increased B cell proliferation
|
J:201448
|
increased IgE level
|
J:201448
|
increased IgG1 level
|
J:201448
|
increased IgG3 level
|
J:201448
|
increased IgM level
|
J:201448
|
increased inflammatory response
|
J:201448
|
increased interleukin-2 secretion
|
J:201448
|
increased T cell proliferation
|
J:201448
|
Ptpn22tm1.1Kas/Ptpn22tm1.1Kas
(involves: C57BL/6)
|
abnormal dendritic cell physiology
|
J:176519
|
increased B cell proliferation
|
J:176519
|
increased IgG2a level
|
J:176519
|
increased IgG3 level
|
J:176519
|
increased IgM level
|
J:176519
|
increased interleukin-12 secretion
|
J:176519
|
increased T cell proliferation
|
J:176519
|
Ptpn22tm1.1Kas/Ptpn22tm1.1Kas Tg(TcraTcrb)425Cbn/0
(involves: BALB/c * C57BL/6)
|
increased T cell proliferation
|
J:176519
|
Ptpn22tm1Achn/Ptpn22tm1Achn
(involves: C57BL/6)
|
abnormal T cell physiology
|
J:90029
|
increased IgE level
|
J:90029
|
increased IgG1 level
|
J:90029
|
increased IgG2a level
|
J:90029
|
Ptpn22tm2Achn/Ptpn22tm2Achn
(involves: C57BL/6)
|
abnormal T cell physiology
|
J:90029
|
increased IgE level
|
J:90029
|
increased IgG1 level
|
J:90029
|
increased IgG2a level
|
J:90029
|
Ptpn22tm2Achn/Ptpn22tm2Achn
(B6.Cg-Ptpn22tm2Achn)
|
abnormal T cell activation
|
J:147129
|
abnormal thymocyte activation
|
J:147129
|
Ptpn22tm2Achn/Ptpn22tm2Achn Ptprctm1Weis/Ptprctm1Weis
(B6.Cg-Ptprctm1Weis Ptpn22tm2Achn)
|
abnormal B cell activation
|
J:147129
|
abnormal follicular B cell physiology
|
J:147129
|
abnormal T cell activation
|
J:147129
|
abnormal thymocyte activation
|
J:147129
|
glomerulonephritis
|
J:147129
|
increased autoantibody level
|
J:147129
|
liver inflammation
|
J:147129
|
lung inflammation
|
J:147129
|
Ptprcloc/Ptprcloc
(C57BL/6JSfdAnu-Ptprcloc/AnuApb)
|
abnormal thymocyte activation
|
J:104190
|
Ptprcm1Smv/Ptprcm1Smv
(involves: C57BL/6J * C57BL/10J)
|
abnormal immune system physiology
|
J:214487
|
CNS inflammation
|
J:214487
|
increased susceptibility to Herpesvirales infection
|
J:214487
|
Ptprcm2Btlr/Ptprcm2Btlr
(C57BL/6J-Ptprcm2Btlr)
|
abnormal humoral immune response
|
J:216796
|
PtprcM10Btlr/PtprcM10Btlr
(C57BL/6J-PtprcM10Btlr)
|
decreased IgE level
|
J:272777
|
Ptprctm1Mak/Ptprctm1Mak
(involves: 129/Sv * C57BL/6)
|
abnormal response to infection
|
J:13163
|
decreased B cell proliferation
|
J:13163
|
decreased cytotoxic T cell cytolysis
|
J:13163
|
decreased T cell proliferation
|
J:13163
|
Ptprctm1Mak/Ptprctm1Mak
(involves: 129)
|
abnormal osteoclast physiology
|
J:141275
|
decreased mast cell degranulation
|
J:110782
|
decreased susceptibility to type I hypersensitivity reaction
|
J:110782
|
Ptprctm1Mak/Ptprctm1Mak
(B6.Cg-Ptprctm1Mak)
|
abnormal NK cell physiology
|
J:109462
|
decreased cytotoxic T cell cytolysis
|
J:111646
|
increased T cell apoptosis
|
J:111646
|
Ptprctm1Mak/Ptprctm1Mak Ptprjtm1.2Weis/Ptprjtm1.2Weis
(involves: 129/Sv * 129P2/OlaHsd * BALB/cJ * C57BL/6)
|
abnormal B cell calcium ion homeostasis
|
J:131736
|
abnormal cytokine secretion
|
J:131736
|
impaired macrophage phagocytosis
|
J:131736
|
Ptprctm1Mak/Ptprctm1Mak Ptprjtm1.2Weis/Ptprjtm1.2Weis
(B6.Cg-Ptprctm1Mak Ptprjtm1.2Weis)
|
liver inflammation
|
J:131736
|
lung inflammation
|
J:131736
|
Ptprctm1Tyb/Ptprctm1Tyb
(C.129S2-Ptprctm1Tyb)
|
abnormal T cell physiology
|
J:57681
|
Ptprctm1Tyb/Ptprctm1Tyb
(B6.129S2-Ptprctm1Tyb)
|
abnormal chemokine secretion
|
J:98190
|
abnormal cytokine secretion
|
J:98190
|
abnormal NK cell physiology
|
J:98190
|
Ptprctm1Weis/Ptprc+
(involves: 129X1/SvJ * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:66501
|
increased IgG2a level
|
J:66501
|
increased susceptibility to autoimmune disorder
|
J:66501
|
Ptprctm1Weis/Ptprctm1Weis
(involves: 129X1/SvJ * C57BL/6)
|
abnormal B cell activation
|
J:66501
|
abnormal T cell activation
|
J:66501
|
glomerulonephritis
|
J:66501
|
increased anti-double stranded DNA antibody level
|
J:66501
|
increased IgA level
|
J:66501
|
increased IgG2a level
|
J:66501
|
increased susceptibility to autoimmune disorder
|
J:66501
|
Ptprctm1Weis/Ptprctm1Weis
(B6.129X1-Ptprctm1Weis)
|
abnormal B cell activation
|
J:147129
|
abnormal follicular B cell physiology
|
J:147129
|
abnormal T cell activation
|
J:147129
|
abnormal thymocyte activation
|
J:147129
|
liver inflammation
|
J:147129
|
lung inflammation
|
J:147129
|
Ptprcaptm1Tkda/Ptprcaptm1Tkda
(involves: 129X1/SvJ)
|
abnormal cytotoxic T cell physiology
|
J:48387
|
decreased B cell proliferation
|
J:48387
|
decreased T cell proliferation
|
J:48387
|
Ptpretm1Ael/Ptpretm1Ael
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal osteoclast physiology
|
J:90031
|
Ptprntm1Aln/Ptprntm1Aln
(NOD.129S4-Ptprntm1Aln)
|
increased susceptibility to autoimmune diabetes
|
J:107161
|
insulitis
|
J:107161
|
Ptprz1tm1Mno/Ptprz1tm1Mno
(B6.129-Ptprz1tm1Mno)
|
decreased susceptibility to bacterial infection
|
J:85826
|
Ptprz1tm1Schl/Ptprz1tm1Schl
(involves: 129 * Swiss Webster)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:79860
|
Pttg1tm1Sme/Pttg1tm1Sme
(involves: 129S4/SvJae * C57BL/6)
|
decreased IgG level
|
J:72267
|
decreased IgM level
|
J:72267
|
decreased immunoglobulin level
|
J:72267
|
Ptx3tm1Mant/Ptx3tm1Mant
(either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))
|
abnormal dendritic cell physiology
|
J:85080
|
abnormal macrophage physiology
|
J:85080
|
abnormal professional antigen presenting cell physiology
|
J:85080
|
abnormal T-helper 1 physiology
|
J:85080
|
impaired macrophage phagocytosis
|
J:85080
|
increased susceptibility to bacterial infection
|
J:85080
|
increased susceptibility to fungal infection
|
J:85080
|
lung inflammation
|
J:85080
|
Ptx3tm1Zuk/Ptx3tm1Zuk
(involves: 129S7/SvEvBrd * C57BL/6J)
|
increased susceptibility to Coronaviridae infection
|
J:188421
|
Pvrtm1Gbn/Pvrtm1Gbn
(either: (involves: 129S2/SvPas) or (involves: 129S2/SvPas * BALB/c))
|
abnormal response to infection
|
J:123540
|
decreased IgA level
|
J:123540
|
decreased IgG1 level
|
J:123540
|
decreased IgG2a level
|
J:123540
|
decreased IgG2b level
|
J:123540
|
decreased IgG level
|
J:123540
|
Pvrigtm1.2Sgng/Pvrigtm1.2Sgng
(B6(Cg)-Pvrigtm1.1Sgng)
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:324171
|
abnormal T cell physiology
|
J:324171
|
Pxdnmhdakta048/Pxdnmhdakta048
(involves: C3HeB/FeJ * C57BL/6J)
|
eye inflammation
|
J:213336
|
Pycardtm1Ayaz/Pycardtm1Ayaz Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * C57BL/6J)
|
decreased interleukin-1 alpha secretion
|
J:191239
|
decreased interleukin-1 beta secretion
|
J:191239
|
decreased interleukin-6 secretion
|
J:191239
|
decreased tumor necrosis factor secretion
|
J:191239
|
Pycardtm1Flv/Pycardtm1Flv
(involves: 129S5/SvEvBrd * C57BL/6)
|
abnormal macrophage physiology
|
J:113333
|
decreased circulating interleukin-1 beta level
|
J:113333
|
decreased circulating interleukin-18 level
|
J:113333,
J:158969
|
decreased interleukin-1 alpha secretion
|
J:113333
|
decreased interleukin-1 beta secretion
|
J:113333
|
decreased susceptibility to endotoxin shock
|
J:113333
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:113333
|
increased susceptibility to Herpesvirales infection
|
J:158969
|
Pycardtm1Flv/Pycardtm1Flv
(B6.129S5-Pycardtm1Flv)
|
increased IgA level
|
J:173245
|
increased IgG2c level
|
J:173245
|
increased susceptibility to induced colitis
|
J:173245
|
Pycardtm1Flv/Pycardtm1Flv Slc11a1s/Slc11a1s
(B6.129S5-Pycardtm1Flv)
|
increased susceptibility to bacterial infection
|
J:124378
|
Pycardtm1Nnz/Pycardtm1Nnz
(involves: 129 * C57BL/6)
|
decreased interleukin-1 beta secretion
|
J:129871
|
decreased interleukin-18 secretion
|
J:129871
|
Pycardtm1Tno/Pycardtm1Tno
(involves: 129S4/SvJae * C57BL/6)
|
decreased interferon-gamma secretion
|
J:100807
|
decreased interleukin-1 beta secretion
|
J:100807
|
decreased interleukin-18 secretion
|
J:100807
|
decreased susceptibility to endotoxin shock
|
J:100807
|
Pycardtm1Vmd/Pycardtm1Vmd
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6N)
|
decreased inflammatory response
|
J:91292
|
decreased interleukin-1 alpha secretion
|
J:91292
|
decreased interleukin-1 beta secretion
|
J:91292
|
decreased interleukin-18 secretion
|
J:91292
|
Pycardtm1Vmd/Pycardtm1Vmd
(involves: 129S1/Sv * 129X1/SvJ)
|
abnormal response to infection
|
J:106976
|
decreased interleukin-1 beta secretion
|
J:124226,
J:106976
|
decreased interleukin-18 secretion
|
J:106976
|
Pycardtm1Vmd/Pycardtm1Vmd
(B6.129-Pycardtm1Vmd)
|
abnormal macrophage physiology
|
J:160545
|
decreased circulating interleukin-1 beta level
|
J:193522
|
decreased circulating interleukin-18 level
|
J:193522
|
decreased interleukin-1 beta secretion
|
J:193522,
J:160545
|
decreased susceptibility to endotoxin shock
|
J:193522
|
increased interferon-beta secretion
|
J:160545
|
increased tumor necrosis factor secretion
|
J:160545
|
Pygltm1a(KOMP)Wtsi/Pygltm1a(KOMP)Wtsi
(C57BL/6N-Pygltm1a(KOMP)Wtsi)
|
liver inflammation
|
J:284765
|
Pymr129X1/SvJMs/PymrNC/JicJcl
(involves: 129X1/SvJMs * NC/JicJcl)
|
decreased susceptibility to parasitic infection
|
J:92924
|
PymrNC/JicJcl/PymrNC/JicJcl
(involves: 129X1/SvJMs * NC/JicJcl)
|
increased susceptibility to parasitic infection
|
J:92924
|
Pzptm1Vln/Pzptm1Vln
(involves: 129P2/OlaHsd * C57BL)
|
increased susceptibility to induced pancreatitis
|
J:28328
|
pancreas inflammation
|
J:28328
|
Pzptm1Vln/Pzptm1Vln
(B.129P2-Pzptm1Vln)
|
abnormal cytokine level
|
J:57485
|
liver inflammation
|
J:57485
|
Pzptm1Vln/Pzptm1Vln
(B6.129P2-Pzptm1Vln)
|
abnormal cytokine secretion
|
J:113532
|
QprtGt(OST337946)Lex/QprtGt(OST337946)Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
|
abnormal cytokine level
|
J:282516
|
abnormal macrophage physiology
|
J:282516
|
Rab7tm1.1Ale/Rab7tm1.1Ale Tg(Cd4-cre)1Cwi/?
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
|
abnormal T cell physiology
|
J:211733
|
decreased T cell proliferation
|
J:211733
|
Rab7btm1Ciphe/Rab7btm1Ciphe Tg(Itgax-cre)1-1Reiz/0
(involves: C57BL/6N * CBA)
|
abnormal dendritic cell migration
|
J:321707
|
Rab11atm1.1Ngao/Rab11atm1.1Ngao Tg(Vil1-cre)997Gum/0
(involves: 129S4/SvJae * C57BL/6J * SJL)
|
abnormal cytokine secretion
|
J:215917
|
increased cytokine level
|
J:278932
|
increased interleukin-1 beta secretion
|
J:215917
|
increased interleukin-6 secretion
|
J:215917
|
intestinal inflammation
|
J:215917
|
Rab11atm1.1Ngao/Rab11atm1.1Ngao Tg(Vil1-cre/ERT2)23Syr/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased interleukin-6 secretion
|
J:215917
|
Rab13tm1.1Ktg/Rab13tm1.1Ktg
(involves: C57BL/6)
|
abnormal leukocyte adhesion
|
J:259093
|
abnormal T cell physiology
|
J:259093
|
decreased lymphocyte chemotaxis
|
J:259093
|
impaired leukocyte migration
|
J:259093
|
Rab20tm1a(EUCOMM)Hmgu/Rab20tm1a(EUCOMM)Hmgu
(involves: C57BL/6N)
|
abnormal macrophage physiology
|
J:243883
|
Rab26em1Guwa/Rab26em1Guwa
(Not Specified)
|
increased susceptibility to endotoxin shock
|
J:306921
|
Rab27aash/Rab27aash
(involves: C3H/HeDiSn)
|
abnormal NK cell degranulation
|
J:111253
|
decreased cytotoxic T cell cytolysis
|
J:111253,
J:67600
|
impaired natural killer cell mediated cytotoxicity
|
J:111253
|
Rab27aash/Rab27aash
(B6.C3Sn-Rab27aash)
|
abnormal cytotoxic T cell physiology
|
J:193137
|
decreased cytotoxic T cell cytolysis
|
J:193137
|
decreased NK cell degranulation
|
J:193137
|
increased circulating interferon-gamma level
|
J:193137
|
increased circulating interleukin-1 beta level
|
J:193137
|
increased circulating interleukin-6 level
|
J:193137
|
increased circulating tumor necrosis factor level
|
J:193137
|
increased susceptibility to Riboviria infection
|
J:193137
|
Rab27acct/Rab27acct
(C57BL/6-Rab27acct)
|
abnormal neutrophil physiology
|
J:114299
|
Rab32tm1c(KOMP)Wtsi/Rab32tm1c(KOMP)Wtsi Tg(Itgax-cre)1-1Reiz/0
(involves: 129S4/SvJaeSor * C57BL/6 * C57BL/6N * CBA)
|
abnormal cytokine secretion
|
J:267497
|
increased susceptibility to bacterial infection
|
J:231298,
J:267497
|
increased susceptibility to colitis induced morbidity/mortality
|
J:267497
|
increased susceptibility to induced colitis
|
J:267497
|
Rab43tm1.2Kmm/Rab43tm1.2Kmm
(B6.129S(C)-Rab43tm1.2Kmm)
|
abnormal dendritic cell antigen presentation
|
J:101977
|
Rab44em1Rbrc/Rab44em1Rbrc
(Not Specified)
|
abnormal mast cell physiology
|
J:304506
|
increased susceptibility to type I hypersensitivity reaction
|
J:304506
|
Rabgef1tm1Glli/Rabgef1tm1Glli
(either: (involves: 129P2/OlaHsd * 129S/SvEv) or (involves: 129P2/OlaHsd * C57BL/6))
|
abnormal inflammatory response
|
J:91790
|
chronic inflammation
|
J:91790
|
increased IgE level
|
J:91790
|
increased interleukin-6 secretion
|
J:91790
|
increased tumor necrosis factor secretion
|
J:91790
|
Rabgef1tm2Glli/Rabgef1tm2Glli
(WBB6F1)
|
increased interleukin-6 secretion
|
J:91790
|
increased tumor necrosis factor secretion
|
J:91790
|
Rabggtagm/Rabggta+
(C57BL/6J-Rabggtagm)
|
decreased cytotoxic T cell cytolysis
|
J:67600
|
Rabggtagm/Rabggtagm
(C57BL/6J-Rabggtagm)
|
decreased cytotoxic T cell cytolysis
|
J:67600
|
Rac1tm1Djk/Rac1tm1.1Djk Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
decreased acute inflammation
|
J:83457
|
impaired neutrophil chemotaxis
|
J:83457
|
impaired neutrophil recruitment
|
J:83457
|
Rac2m1Btlr/Rac2+
(C57BL/6J-Rac2m1Btlr)
|
decreased IgM level
|
J:221478
|
impaired humoral immune response
|
J:221478
|
Rac2m1Btlr/Rac2m1Btlr
(C57BL/6J-Rac2m1Btlr)
|
decreased IgM level
|
J:221478
|
impaired humoral immune response
|
J:221478
|
Rac2m3Btlr/Rac2m3Btlr
(C57BL/6J-Rac2m3Btlr)
|
decreased IgM level
|
J:236680
|
decreased response to antigen
|
J:236680
|
Rac2M4Btlr/Rac2+
(C57BL/6J-Rac2M4Btlr)
|
abnormal cytotoxic T cell physiology
|
J:255273
|
decreased IgG level
|
J:255273
|
decreased IgM level
|
J:255273
|
impaired humoral immune response
|
J:255273
|
impaired natural killer cell mediated cytotoxicity
|
J:255273
|
increased IgM level
|
J:255273
|
Rac2M4Btlr/Rac2M4Btlr
(C57BL/6J-Rac2M4Btlr)
|
abnormal cytotoxic T cell physiology
|
J:255273
|
decreased IgE level
|
J:255273
|
decreased IgG level
|
J:255273
|
decreased IgM level
|
J:255273
|
impaired humoral immune response
|
J:255273
|
impaired natural killer cell mediated cytotoxicity
|
J:255273
|
Rac2tm1Mddw/Rac2tm1Mddw
(involves: 129S/SvEv * C57BL/6)
|
abnormal neutrophil physiology
|
J:53362
|
decreased T cell proliferation
|
J:119437
|
impaired neutrophil chemotaxis
|
J:53362
|
increased susceptibility to bacterial infection
|
J:53362
|
Rac2tm1Mddw/Rac2tm1Mddw
(involves: 129S/SvEv)
|
abnormal neutrophil physiology
|
J:131305
|
Rac2tm1Mddw/Rac2tm1Mddw
(B6.129S-Rac2tm1Mddw)
|
abnormal neutrophil physiology
|
J:83457
|
Rac2tm1Mddw/Rac2tm1Mddw Tg(TcrAND)53Hed/0
(involves: 129S/SvEv * C57BL/6 * SJL)
|
abnormal T cell activation
|
J:119437
|
decreased circulating interleukin-2 level
|
J:119437
|
decreased T cell proliferation
|
J:119437
|
Rad21tm1.1Mmk/Rad21tm1.1Mmk Tg(Cd4-cre)1Cwi/0
(involves: 129 * C57BL/6)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:175827
|
Rad23btm1Gvh/Rad23btm1Gvh
(involves: 129P2/OlaHsd * C57BL/6)
|
blepharitis
|
J:74288
|
conjunctivitis
|
J:74288
|
Rad50tm1Flv/Rad50tm1Flv
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal T-helper 2 physiology
|
J:94870
|
decreased interleukin-4 secretion
|
J:94870
|
decreased interleukin-5 secretion
|
J:94870
|
decreased interleukin-13 secretion
|
J:94870
|
Rad50tm2.1Flv/Rad50tm2.1Flv
(B6.129S6-Rad50tm2.1Flv)
|
decreased interleukin-4 secretion
|
J:196154
|
decreased interleukin-5 secretion
|
J:196154
|
decreased interleukin-13 secretion
|
J:196154
|
Rad50tm2.1Flv/Rad50tm2.2Flv Tg(Cd4-cre)1Cwi/0
(involves: 129S6/SvEvTac * C57BL/6 * DBA/2)
|
abnormal T-helper 1 physiology
|
J:165055
|
abnormal T-helper 2 physiology
|
J:165055
|
decreased IgE level
|
J:165055
|
decreased inflammatory response
|
J:165055
|
decreased interferon-gamma secretion
|
J:165055
|
decreased interleukin-4 secretion
|
J:165055
|
decreased interleukin-5 secretion
|
J:165055
|
decreased interleukin-13 secretion
|
J:165055
|
Rad50tm3.1Flv/Rad50tm3.1Flv
(B6.129S6-Rad50tm3.1Flv)
|
decreased interleukin-4 secretion
|
J:196154
|
decreased interleukin-5 secretion
|
J:196154
|
decreased interleukin-13 secretion
|
J:196154
|
Rad50tm4.1Flv/Rad50tm4.1Flv
(B6.129S6-Rad50tm4.1Flv)
|
decreased interleukin-5 secretion
|
J:196154
|
decreased interleukin-13 secretion
|
J:196154
|
increased interleukin-4 secretion
|
J:196154
|
increased interleukin-5 secretion
|
J:196154
|
increased interleukin-13 secretion
|
J:196154
|
Raet1dem1Dhr/Raet1dem1Dhr Raet1eem1Dhr/Raet1eem1Dhr
(involves: C57BL/6)
|
increased natural killer cell mediated cytotoxicity
|
J:221188
|
Rag1m2Btlr/Rag1m2Btlr
(involves: C57BL/6J)
|
abnormal class switch recombination
|
J:185495
|
decreased IgG level
|
J:185495
|
decreased IgM level
|
J:185495
|
Rag1tm1Bal/Rag1tm1Bal Tnfrsf1atm1.1Gkl/Tnfrsf1atm1.1Gkl
(involves: 129/Sv * C57BL/6)
|
liver inflammation
|
J:92470
|
Rag1tm1Jsek/Rag1tm1Jsek
(involves: 129S6/SvEvTac)
|
abnormal immunoglobulin level
|
J:146912
|
Rag1tm1Mom/Rag1tm1Mom
(involves: 129S7/SvEvBrd * CD-1)
|
decreased IgM level
|
J:1934
|
Rag1tm1Mom/Rag1tm1Mom
(B6.129S7-Rag1tm1Mom)
|
decreased IgM level
|
J:78613
|
decreased immunoglobulin level
|
J:111828
|
dermatitis
|
J:111828
|
ear inflammation
|
J:111828
|
Rag1tm1Mom/Rag1tm1Mom
(NOD.129S7(B6)-Rag1tm1Mom)
|
abnormal level of surface class II molecules
|
J:109843
|
decreased immunoglobulin level
|
J:109843
|
impaired natural killer cell mediated cytotoxicity
|
J:109843
|
Rag1tm1Mom/Rag1tm1Mom
(involves: 129S7/SvEvBrd * C57BL/6)
|
abnormal response to infection
|
J:119344
|
autoimmune response
|
J:138466
|
decreased susceptibility to induced colitis
|
J:194587
|
Rag1tm1Mom/Rag1tm1Mom
(involves: 129S7/SvEvBrd)
|
decreased inflammatory response
|
J:94420
|
Rag1tm1Mom/Rag1tm1Mom Prf1tm1Sdz/Prf1tm1Sdz
(NOD.Cg-Rag1tm1Mom Prf1tm1Sdz/Sz)
|
abnormal level of surface class II molecules
|
J:109843
|
abnormal response to transplant
|
J:109843
|
decreased immunoglobulin level
|
J:109843
|
impaired natural killer cell mediated cytotoxicity
|
J:109843
|
Rag1tm1Mom/Rag1tm1Mom Sh3bp2tm1Bjro/Sh3bp2tm1Bjro
(involves: 129S4/SvJae * 129S7/SvEvBrd * BALB/cJ * C57BL/6J)
|
increased circulating tumor necrosis factor level
|
J:117880
|
increased inflammatory response
|
J:117880
|
Rag1tm1Mom/Rag1tm1Mom Slc46a2tm1Moki/Slc46a2+ Tg(TcraB12,TcrbB12)1Rest/0
(involves: 129 * C57BL/6)
|
increased T cell apoptosis
|
J:140121
|
Rag1tm1Mom/Rag1tm1Mom Tg(CAG-Lyn*)#Paau/0
(involves: 129S7/SvEvBrd * C57BL/6)
|
decreased inflammatory response
|
J:151886
|
Rag1tm1Mom/Rag1tm1Mom Tg(TcraAI4)1Dvs/0 Tg(TcrbAI4)1Dvs/0
(NOD.Cg-Rag1tm1Mom Tg(TcraAI4)1Dvs Tg(TcrbAI4)1Dvs/Dvs)
|
increased susceptibility to autoimmune diabetes
|
J:94192
|
Rag1tm1Mom/Rag1tm1Mom Tg(TcraBDC12-4.1)10Jos/0 Tg(TcrbBDC12-4.1)82Gse/0
(involves: 129S7/SvEvBrd * C57BL/6 * FVB * NOD)
|
increased susceptibility to autoimmune diabetes
|
J:111874
|
Rag1tm1Mom/Rag1tm1Mom Tnftm2Gkl/Tnf+
(involves: 129S/SvEv * 129S7/SvEvBrd * C57BL/6)
|
rheumatoid arthritis
|
J:54056
|
small intestinal inflammation
|
J:54056
|
Rag1tm1Mom/Rag1tm1Mom Tyrobptm1.1Viv/Tyrobptm1.1Viv
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * C57BL/10)
|
abnormal osteoclast physiology
|
J:129304
|
Rag1tm1Mom/Rag1tm1Mom Vtcn1tm1Lpc/Vtcn1tm1Lpc
(involves: 129S/SvEvBrd * 129S7/SvEvBrd * C57BL/6)
|
decreased susceptibility to bacterial infection
|
J:145712
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:145712
|
Rag2m1Btlr/Rag2m1Btlr
(C57BL/6J-Rag2m1Btlr)
|
abnormal humoral immune response
|
J:203045
|
decreased IgG level
|
J:203045
|
decreased IgM level
|
J:203045
|
Rag2tm1.1Cgn/Rag2tm1.1Cgn Tg(HLA-DR2)#Lfug/0 Tg(TCROb.1A12)#Lfug/0
(involves: C57BL/6 * DBA/2)
|
autoimmune response
|
J:134764
|
CNS inflammation
|
J:134764
|
Rag2tm1Avla/Rag2tm1Avla
(involves: 129/Sv * C57BL/6)
|
abnormal B cell physiology
|
J:122108
|
abnormal lymphocyte physiology
|
J:122108
|
colitis
|
J:122108
|
decreased IgA level
|
J:122108
|
decreased IgG level
|
J:122108
|
decreased T cell proliferation
|
J:122108
|
erythroderma
|
J:122108
|
Rag2tm1Cgn/Rag2tm1.1Cgn Tg(Mx1-cre)1Cgn/0
(involves: C57BL/6 * CBA)
|
abnormal B cell activation
|
J:72214
|
Rag2tm1Cgn/Rag2tm1Cgn Xrcc4tm1Fwa/Xrcc4tm2Fwa Tg(Cr2-cre)3Cgn/?
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6)
|
abnormal class switch recombination
|
J:150339
|
Rag2tm1Fwa/Rag2tm1Fwa
(involves: 129S/SvEv * MF1)
|
decreased IgM level
|
J:1935
|
increased natural killer cell mediated cytotoxicity
|
J:1935
|
increased susceptibility to infection
|
J:1935
|
Rag2tm1Fwa/Rag2tm1Fwa
(involves: 129S/SvEv)
|
abnormal chemokine secretion
|
J:140483
|
abnormal interferon secretion
|
J:140483
|
abnormal macrophage physiology
|
J:140483
|
abnormal response to transplant
|
J:116136
|
abnormal T-helper 1 physiology
|
J:116136
|
colitis
|
J:116136
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:140483
|
increased susceptibility to bacterial infection
|
J:140483
|
lung inflammation
|
J:140483
|
Rag2tm1Fwa/Rag2tm1Fwa
(involves: 129S/SvEv * C57BL/6)
|
decreased susceptibility to parasitic infection
|
J:64283
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:165513
|
Rag2tm1Fwa/Rag2tm1Fwa Cd47tm1Fpl/Cd47tm1Fpl Il2rgtm1Cgn/Y
(involves: 129P2/OlaHsd * 129S/SvEv * 129S7/SvEvBrd * C57BL/6)
|
decreased susceptibility to graft versus host disease
|
J:203904
|
increased susceptibility to Retroviridae infection
|
J:203904
|
Rag2tm1Fwa/Rag2tm1Fwa Sos1tm1.1Les/Sos1tm1.1Les Tg(Lck-cre)1Cwi/0
(involves: 129S/SvEv * C57BL/6)
|
decreased T cell proliferation
|
J:174536
|
Rag2tm1Fwa/Rag2tm1Fwa Tbx21tm1Glm/Tbx21tm1Glm
(involves: 129S/SvEv * 129S6/SvEvTac)
|
colitis
|
J:141481
|
increased tumor necrosis factor secretion
|
J:141481
|
large intestinal inflammation
|
J:141481
|
Rag2tm1Fwa/Rag2tm1Fwa Tg(TcraCN.B1,TcrbCN.B1)SM1Jen/0
(involves: 129S/SvEv * C57BL/6)
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:162539
|
Rag2tm1Fwa/Rag2tm1Fwa Tg(TcraH-Y,TcrbH-Y)71Vbo/?
(involves: 129S/SvEv * C57BL/6J * DBA/2J)
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:125259
|
abnormal cytotoxic T cell physiology
|
J:66565
|
Rag2tm1Fwa/Rag2tm1Fwa Tg(TcrHEL3A9)1Mmd/0
(involves: 129S/SvEv * C57BL/6)
|
abnormal T cell activation
|
J:78309
|
abnormal T cell proliferation
|
J:78309
|
Rag2tm1Fwa/Rag2tm1Fwa Tg(TcrHEL3A9)1Mmd/0 Tg(TLK2mHEL)2Ccg/0
(involves: 129S/SvEv * C57BL/6)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:78309
|
abnormal T cell activation
|
J:78309
|
abnormal T cell proliferation
|
J:78309
|
thyroid gland inflammation
|
J:78309
|
Rag2tm1Fwa/Rag2tm1Fwa Wdr1rede/Wdr1rede
(involves: 129S/SvEv * C57BL/6)
|
abnormal immune system physiology
|
J:134092
|
Rag2tm1Libo/Rag2tm1Libo
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N)
|
abnormal B cell physiology
|
J:84563
|
Ralatm1a(EUCOMM)Wtsi/Ralatm1a(EUCOMM)Wtsi
(C57BL/6N-Ralatm1a(EUCOMM)Wtsi/Wtsi)
|
blood in lymph vessels
|
J:239583
|
Ramp1tm1.1Tsuj/Ramp1tm1.1Tsuj
(C.129S2-Ramp1tm1.1Tsuj)
|
abnormal chemokine secretion
|
J:125974
|
abnormal cytokine secretion
|
J:125974
|
increased circulating interferon-gamma level
|
J:125974
|
increased circulating interleukin-6 level
|
J:125974
|
increased circulating tumor necrosis factor level
|
J:125974
|
Rap1atm1Laaq/Rap1atm1Laaq
(either: B6.Cg-Rap1atm1Laaq or (involves: C57BL/6))
|
abnormal leukocyte migration
|
J:140471
|
abnormal macrophage physiology
|
J:140471
|
abnormal neutrophil physiology
|
J:140471
|
Rap1atm1Tze/Rap1atm1Tze
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal leukocyte adhesion
|
J:144145
|
decreased interleukin-2 secretion
|
J:144145
|
decreased T cell proliferation
|
J:144145
|
Rap1gds1tm1Ytk/Rap1gds1tm1Ytk
(involves: 129X1/SvJ * C57BL/6 * DBA)
|
increased thymocyte apoptosis
|
J:62244
|
Rapgef3tm1Skc/Rapgef3tm1Skc
(Not Specified)
|
insulitis
|
J:201171
|
Raph1tm1.2Fbg/Raph1tm1.2Fbg
(involves: 129S4/SvJae * C57BL/6)
|
abnormal cytokine level
|
J:238262
|
increased inflammatory response
|
J:238262
|
increased susceptibility to bacterial infection
|
J:238262
|
large intestinal inflammation
|
J:238262
|
Rarres1tm1.2Mhl/Rarres1tm1.2Mhl
(involves: 129S1/SvImJ * C57BL/6 * FVB/N * NIH Black Swiss)
|
abnormal B cell activation
|
J:324270
|
abnormal B cell physiology
|
J:324270
|
decreased B cell apoptosis
|
J:324270
|
increased B cell proliferation
|
J:324270
|
Rasa1tm1Wid/Rasa1tm1Wid
(involves: 129S/SvEv * 129S6/SvEvTac * C57BL/6N)
|
increased susceptibility to induced colitis
|
J:189241
|
Rasa4tm1Ywh/Rasa4tm1Ywh
(B6.129S6-Rasa4tm1Ywh)
|
impaired macrophage phagocytosis
|
J:100455
|
increased susceptibility to bacterial infection
|
J:100455
|
Rasal3tm1.1Fuj/Rasal3tm1.1Fuj
(involves: C57BL/6N * C57BL/6NCrlj * CBA/JNCrlj)
|
decreased circulating interferon-gamma level
|
J:229641
|
decreased circulating interleukin-4 level
|
J:229641
|
decreased interferon-gamma secretion
|
J:229641
|
decreased interleukin-4 secretion
|
J:229641
|
Rasgrf2tm1Esn/Rasgrf2tm1Esn
(involves: 129S1/Sv * C57BL/10 * C57BR/cd)
|
decreased interleukin-2 secretion
|
J:128985
|
decreased tumor necrosis factor secretion
|
J:128985
|
Rasgrf2tm1Esn/Rasgrf2tm1Esn Vav1tm1Tyb/Vav1tm1Tyb
(involves: 129S1/Sv * 129S2/SvPas * C57BL/10 * C57BR/cd)
|
abnormal T cell physiology
|
J:128985
|
decreased interleukin-2 secretion
|
J:128985
|
decreased T cell proliferation
|
J:128985
|
decreased tumor necrosis factor secretion
|
J:128985
|
Rasgrp1lag/Rasgrp1lag
(involves: 129 * C57BL/6)
|
abnormal T cell physiology
|
J:85189
|
decreased T cell proliferation
|
J:85189
|
glomerulonephritis
|
J:85189
|
increased IgG level
|
J:85189
|
increased susceptibility to systemic lupus erythematosus
|
J:85189
|
Rasgrp1m1Anu/Rasgrp1+
(involves: C57BL/6JSfdAnu * CBA/J)
|
increased anti-nuclear antigen antibody level
|
J:207898
|
Rasgrp1m1Anu/Rasgrp1m1Anu
(C57BL/6JSfdAnu-Rasgrp1m1Anu)
|
autoimmune response
|
J:104190
|
Rasgrp1m1Anu/Rasgrp1m1Anu
(involves: C57BL/6JSfdAnu * CBA/J)
|
increased anti-nuclear antigen antibody level
|
J:207898
|
Rasgrp1m1Btlr/Rasgrp1m1Btlr
(C57BL/6J-Rasgrp1m1Btlr)
|
abnormal humoral immune response
|
J:265163
|
decreased IgM level
|
J:265163
|
increased IgA level
|
J:265163
|
increased IgE level
|
J:265163
|
increased IgM level
|
J:265163
|
Rasgrp1m3Btlr/Rasgrp1m3Btlr
(C57BL/6J-Rasgrp1m3Btlr)
|
increased IgM level
|
J:265255
|
Rasgrp1tm1.1Wz/Rasgrp1tm1.1Wz
(B6.Cg-Rasgrp1tm1.1Wz)
|
abnormal immune system physiology
|
J:225109
|
abnormal immunoglobulin level
|
J:225109
|
decreased T cell proliferation
|
J:225109
|
increased autoantibody level
|
J:225109
|
increased IgE level
|
J:225109
|
increased IgG1 level
|
J:225109
|
Rasgrp1tm1Jstn/Rasgrp1tm1Jstn
(involves: 129P3/J * C57BL/6J)
|
abnormal humoral immune response
|
J:108677
|
increased immunoglobulin level
|
J:108677
|
Rasgrp1tm1Jstn/Rasgrp1tm1Jstn Rasgrp3tm1Jstn/Rasgrp3tm1Jstn
(involves: 129P3/J * C57BL/6J)
|
abnormal humoral immune response
|
J:108677
|
Rasgrp2tm1Amg/Rasgrp2tm1Amg
(Not Specified)
|
abnormal neutrophil physiology
|
J:122618
|
impaired neutrophil recruitment
|
J:122618
|
Rasgrp3tm1Jstn/Rasgrp3tm1Jstn
(involves: 129P3/J * C57BL/6J)
|
abnormal humoral immune response
|
J:108677
|
decreased IgG1 level
|
J:108677
|
decreased IgG2a level
|
J:108677
|
decreased IgG level
|
J:108677
|
Rasgrp4tm1(cre)Rls/Rasgrp4tm1(cre)Rls
(C57BL/6-Rasgrp4tm1(cre)Rls)
|
decreased susceptibility to induced arthritis
|
J:186519
|
decreased susceptibility to induced colitis
|
J:186519
|
Rasgrp4tm1a(KOMP)Lste/Rasgrp4tm1a(KOMP)Lste
(involves: C57BL/6)
|
abnormal neutrophil physiology
|
J:186412
|
impaired neutrophil chemotaxis
|
J:186412
|
Rasgrp4tm1d(KOMP)Lste/Rasgrp4tm1d(KOMP)Lste
(involves: 129S4/SvJaeSor * BALB/cJ * C57BL/6)
|
abnormal neutrophil physiology
|
J:186412
|
impaired neutrophil chemotaxis
|
J:186412
|
Rassf5tm1Kina/Rassf5tm1Kina
(involves: C57BL/6 * CBA * ICR)
|
abnormal dendritic cell physiology
|
J:92670
|
abnormal leukocyte migration
|
J:92670
|
Rassf5tm1Kina/Rassf5tm1Kina
(B6.Cg-Rassf5tm1Kina)
|
abnormal lymphocyte physiology
|
J:168749
|
glomerulonephritis
|
J:168749
|
increased anti-double stranded DNA antibody level
|
J:168749
|
increased B cell proliferation
|
J:168749
|
increased IgG level
|
J:168749
|
increased T cell proliferation
|
J:168749
|
Rbl1tm1Mru/Rbl1tm1Mru
(involves: 129S4/SvJae * BALB/cJ)
|
abnormal inflammatory response
|
J:51060
|
Rbm4tm1a(EUCOMM)Hmgu/Rbm4+
(C57BL/6N-Rbm4tm1a(EUCOMM)Hmgu/Cnrm)
|
decreased IgG2b level
|
J:165965
|
Rbpjtm1Hon/Rbpjtm1Hon Tg(Itgax-cre)1-1Reiz/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
abnormal cytokine secretion
|
J:125869
|
Rbpjtm1Hon/Rbpjtm1Hon Tg(Lck-cre)19Hhan/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA)
|
abnormal immune system physiology
|
J:168475
|
abnormal regulatory T cell physiology
|
J:168475
|
increased T cell proliferation
|
J:168475
|
Rbpjtm1Kyo/Rbpj+
(involves: 129S2/SvPas * CD-1)
|
aortic valve inflammation
|
J:187551
|
Rbpjtm1Kyo/Rbpjtm1Kyo
(involves: 129S2/SvPas)
|
abnormal humoral immune response
|
J:123631
|
abnormal response to infection
|
J:123631
|
decreased interleukin-4 secretion
|
J:123631
|
Rc3h1Gt(CC0753)Wtsi/Rc3h1Gt(CC0753)Wtsi
(B6.129P2-Rc3h1Gt(CC0753)Wtsi)
|
chronic liver inflammation
|
J:199407
|
ileum inflammation
|
J:199407
|
intestinal inflammation
|
J:199407
|
Rc3h1san/Rc3h1+
(involves: C57BL/6JSfdAnu)
|
abnormal T follicular helper cell physiology
|
J:189087
|
increased IgG level
|
J:189087
|
Rc3h1san/Rc3h1san
(either: C57BL/6JSfdAnu-Rc3h1san/Anu or (involves: C57BL/6JSfdAnu * CBA/Ca))
|
glomerulonephritis
|
J:98938
|
increased anti-double stranded DNA antibody level
|
J:98938
|
increased anti-nuclear antigen antibody level
|
J:98938
|
liver inflammation
|
J:98938
|
Rc3h1san/Rc3h1san
(involves: C57BL/6JSfdAnu)
|
cecum inflammation
|
J:199407
|
chronic liver inflammation
|
J:199407
|
colitis
|
J:199407
|
granulomatous inflammation
|
J:199407
|
ileum inflammation
|
J:199407
|
increased circulating tumor necrosis factor level
|
J:196137
|
increased T cell proliferation
|
J:199407
|
small intestinal inflammation
|
J:199407
|
Rc3h1san/Rc3h1san Rc3h2tm1.2Cgv/Rc3h2tm1.2Cgv
(involves: C57BL/6 * C57BL/6JSfdAnu)
|
increased circulating tumor necrosis factor level
|
J:196137
|
increased inflammatory response
|
J:196137
|
increased susceptibility to bacterial infection
|
J:196137
|
kidney inflammation
|
J:196137
|
Rc3h1tm1.1Mass/Rc3h1tm1.1Mass Commd10Tg(Vav1-icre)A2Kio/Commd10+
(involves: C57BL/6 * C57BL/10 * CBA/Ca * NZB * SJL)
|
abnormal germinal center B cell physiology
|
J:177784
|
decreased IgA level
|
J:177784
|
decreased IgG1 level
|
J:177784
|
decreased IgG3 level
|
J:177784
|
increased IgG2b level
|
J:177784
|
Rc3h1tm1.1Mass/Rc3h1tm1.1Mass Rc3h2tm1c(KOMP)Wtsi/Rc3h2tm1c(KOMP)Wtsi Tg(Cd4-cre)1Cwi/?
(involves: C57BL/6N * DBA/2)
|
abnormal immune system physiology
|
J:196136
|
increased T cell proliferation
|
J:196136
|
Rc3h2tm1.2Cgv/Rc3h2tm1.2Cgv
(involves: C57BL/6)
|
increased macrophage cytokine production
|
J:196137
|
increased tumor necrosis factor secretion
|
J:196137
|
Rcan1tm1Fmc/Rcan1tm1Fmc
(involves: 129S4/SvJae)
|
abnormal T cell apoptosis
|
J:85148
|
abnormal T-helper 1 physiology
|
J:85148
|
decreased IgG2a level
|
J:85148
|
decreased interferon-gamma secretion
|
J:85148
|
decreased T cell proliferation
|
J:85148
|
increased susceptibility to endotoxin shock
|
J:152536
|
Rcan1tm1Jmol/Rcan1tm1Jmol Rcan2tm1Jmol/Rcan2tm1Jmol
(involves: 129 * C57BL/6)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:109586
|
abnormal cytokine secretion
|
J:109586
|
decreased T cell proliferation
|
J:109586
|
Rcan1tm1Jmol/Rcan1tm1Jmol Rcan2tm1Jmol/Rcan2tm1Jmol Ppp3cbtm1Jmk/Ppp3cbtm1Jmk
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:109586
|
abnormal cytokine secretion
|
J:109586
|
decreased T cell proliferation
|
J:109586
|
Rcbtb2tm1.1Xyw/Rcbtb2tm1.1Xyw
(involves: C57BL/6 * CBA)
|
abnormal splenocyte physiology
|
J:282928
|
Rcc1ltm1a(EUCOMM)Hmgu/Rcc1l+
(Not Specified)
|
decreased IgG1 level
|
J:165965
|
Rdh7tm1c(KOMP)Wtsi/Rdh7tm1c(KOMP)Wtsi Tg(RARE-Hspa1b/lacZ)12Jrt/0 Tg(Vil1-cre)997Gum/0
(involves: C57BL/6J * C57BL/6N * CD-1 * SJL)
|
decreased susceptibility to bacterial infection
|
J:279231
|
Rdns/Rdns+
(C57BL/6J-Rdns/GrsrJ)
|
increased susceptibility to otitis media
|
J:223062
|
Rdurem1Jiche/Rdurem1Jiche
(Not Specified)
|
increased circulating interleukin-1 level
|
J:340209
|
increased circulating interleukin-6 level
|
J:340209
|
increased susceptibility to viral infection
|
J:340209
|
increased susceptibility to viral infection induced morbidity/mortality
|
J:340209
|
Reg3gtm1.1Lvh/Reg3gtm1.1Lvh
(B6.129-Reg3gtm1.1Lvh)
|
increased IgA level
|
J:177506
|
Reg3gtm1a(KOMP)Wtsi/Reg3gtm1a(KOMP)Wtsi
(C57BL/6-Reg3gtm1a(KOMP)Wtsi)
|
increased susceptibility to Orthomyxoviridae infection
|
J:233979
|
RelM1Btlr/Rel+
(C57BL/6J-RelM1Btlr)
|
decreased IgE level
|
J:236682
|
decreased IgG level
|
J:236682
|
decreased IgM level
|
J:236682
|
decreased response to antigen
|
J:236682
|
RelM1Btlr/RelM1Btlr
(C57BL/6J-RelM1Btlr)
|
decreased IgE level
|
J:236682
|
decreased IgG level
|
J:236682
|
decreased IgM level
|
J:236682
|
decreased response to antigen
|
J:236682
|
Relm3Btlr/Relm3Btlr
(C57BL/6J-Relm3Btlr)
|
decreased IgM level
|
J:272801
|
impaired humoral immune response
|
J:272801
|
Reltm1Brv/Reltm1Brv
(involves: 129S1/Sv)
|
abnormal leukocyte physiology
|
J:46911
|
abnormal macrophage physiology
|
J:46911
|
abnormal T cell physiology
|
J:46911
|
decreased IgG1 level
|
J:46911
|
decreased IgG2b level
|
J:46911
|
decreased IgG3 level
|
J:46911
|
decreased IgG level
|
J:46911
|
dermatitis
|
J:46911
|
impaired macrophage chemotaxis
|
J:46911
|
increased IgA level
|
J:46911
|
increased IgG2a level
|
J:46911
|
increased IgM level
|
J:46911
|
increased susceptibility to bacterial infection
|
J:46911
|
Reltm1Grd/Rel+
(involves: 129S1/Sv * C57BL/6)
|
abnormal humoral immune response
|
J:28435
|
decreased B cell proliferation
|
J:28435
|
Reltm1Grd/Reltm1Grd
(involves: 129S1/Sv * C57BL/6)
|
abnormal cytokine secretion
|
J:37541,
J:28435
|
abnormal humoral immune response
|
J:28435
|
abnormal macrophage physiology
|
J:37541
|
decreased B cell proliferation
|
J:28435
|
decreased IgG1 level
|
J:28435
|
decreased IgG2a level
|
J:28435
|
decreased IgG2b level
|
J:28435
|
decreased IgG3 level
|
J:28435
|
decreased IgM level
|
J:28435
|
decreased susceptibility to parasitic infection
|
J:37541
|
decreased T cell proliferation
|
J:28435
|
Reltm1Hcl/Rel+
(involves: 129S4/SvJae * C57BL/6)
|
decreased T cell proliferation
|
J:53513
|
Reltm1Hcl/Reltm1Hcl
(involves: 129S4/SvJae * C57BL/6)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:79107,
J:118907
|
abnormal cytokine secretion
|
J:53513,
J:79107
|
abnormal dendritic cell physiology
|
J:118907
|
abnormal macrophage physiology
|
J:118907
|
abnormal professional antigen presenting cell physiology
|
J:118907
|
decreased B cell proliferation
|
J:75621
|
decreased cytotoxic T cell cytolysis
|
J:53513
|
decreased IgE level
|
J:58987
|
decreased susceptibility to autoimmune diabetes
|
J:118907
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:79107
|
decreased T cell proliferation
|
J:53513,
J:79107
|
Relatm1Asba/Relatm1Asba Tg(Vil1-cre)997Gum/0
(involves: 129 * C57BL/6J * SJL)
|
increased susceptibility to induced colitis
|
J:131977
|
Relatm1Bal/Relatm1Bal Tnfrsf1atm1Imx/Tnfrsf1atm1Imx
(involves: 129S4/SvJae * C57BL/6)
|
heart inflammation
|
J:60742
|
liver inflammation
|
J:60742
|
lung inflammation
|
J:60742
|
Relatm1Mpa/Relatm1Mpa Tg(Alb1-cre)7Gsc/0
(involves: FVB/N)
|
increased susceptibility to endotoxin shock
|
J:137861
|
Relatm1Rsch/Relatm1Rsch Ptf1atm1(cre)Hnak/?
(involves: C57BL/6)
|
abnormal interleukin level
|
J:122194
|
abnormal tumor necrosis factor level
|
J:122194
|
lung inflammation
|
J:122194
|
pancreas inflammation
|
J:122194
|
Relatm1Rsch/Relatm1Rsch Tg(Lck-cre)I57Jxm/0
(involves: ICR)
|
decreased interleukin-17 secretion
|
J:169863
|
increased susceptibility to bacterial infection
|
J:169863
|
Relatm1Yuo/Relatm1Yuo
(involves: 129S/SvEv)
|
abnormal lymphocyte physiology
|
J:63099
|
decreased B cell proliferation
|
J:63099
|
decreased IgA level
|
J:63099
|
decreased IgG1 level
|
J:63099
|
decreased T cell proliferation
|
J:63099
|
Relatm2.1Gho/Relatm2.1Gho
(involves: 129S6/SvEvTac * C57BL/6)
|
increased inflammatory response
|
J:163663
|
interstitial pneumonia
|
J:163663
|
liver inflammation
|
J:163663
|
lung inflammation
|
J:163663
|
myositis
|
J:163663
|
Relatm2.1Gho/Relatm2.1Gho Tnfrsf1atm1Mak/Tnfrsf1atm1Mak
(involves: 129S2/SvPas * 129S6/SvEvTac)
|
increased incidence of corneal inflammation
|
J:163663
|
liver inflammation
|
J:163663
|
Relbshep/Relbshep
(A;C-Relbshep/GrsrJ)
|
liver inflammation
|
J:171971
|
RelbTg(H2-K1/GH1)106Bri/RelbTg(H2-K1/GH1)106Bri
(C57BL/6-RelbTg(H2-K1/GH1)106Bri)
|
abnormal antigen presentation
|
J:23081
|
decreased T cell proliferation
|
J:76450
|
glomerulonephritis
|
J:76450
|
increased inflammatory response
|
J:23081,
J:76450
|
liver inflammation
|
J:76450
|
lung inflammation
|
J:76450
|
skin inflammation
|
J:76450
|
RelbTg(H2-K1/GH1)106Bri/RelbTg(H2-K1/GH1)106Bri
(involves: C57BL/6)
|
decreased circulating interleukin-4 level
|
J:120659
|
increased inflammatory response
|
J:120659
|
Relbtm1.1Fwei/Relbtm1.1Fwei Tg(Lck-cre)I57Jxm/0
(involves: ICR)
|
decreased interleukin-17 secretion
|
J:169863
|
increased susceptibility to bacterial infection
|
J:169863
|
Relbtm1Brv/Relbtm1Brv
(involves: 129S2/SvPas * C57BL/6)
|
abnormal cell-mediated immunity
|
J:22675
|
abnormal cytokine level
|
J:40630
|
abnormal cytotoxic T cell physiology
|
J:40630
|
abnormal humoral immune response
|
J:40630
|
abnormal immune system physiology
|
J:22675,
J:40630
|
abnormal immunoglobulin level
|
J:40630
|
abnormal interferon level
|
J:40630
|
abnormal interleukin level
|
J:40630
|
abnormal macrophage physiology
|
J:40630
|
abnormal tumor necrosis factor level
|
J:40630
|
decreased B cell proliferation
|
J:40630
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:22675
|
epididymis inflammation
|
J:22675
|
impaired neutrophil phagocytosis
|
J:40630
|
increased IgE level
|
J:40630
|
increased IgM level
|
J:40630
|
increased susceptibility to bacterial infection
|
J:40630
|
increased susceptibility to Riboviria infection
|
J:40630
|
intestinal inflammation
|
J:22675
|
liver inflammation
|
J:22675
|
lung inflammation
|
J:22675
|
myositis
|
J:22675
|
ovary inflammation
|
J:22675
|
salivary gland inflammation
|
J:22675
|
stomach inflammation
|
J:22675
|
Relbtm1Brv/Relbtm1Brv
(either: (involves: 129S2/SvPas) or (involves: C57BL/6) or (involves: 129S2/SvPas * C57BL/6))
|
dermatitis
|
J:63950
|
lung inflammation
|
J:63950
|
Relttm1Hlee/Relttm1Hlee
(Not Specified)
|
increased T cell proliferation
|
J:266480
|
Ren1tm1Tkh/Ren1tm1Tkh
(C57BL/6-Ren1tm1Tkh)
|
kidney inflammation
|
J:110082
|
Retntm1Laz/Retntm1Laz Tg(CD68-RETN)#Laz/?
(involves: 129S6/SvEvTac * C57BL/6)
|
white adipose tissue inflammation
|
J:171262
|
Retnlatm1Mer/Retnlatm1Mer
(C57BL/6-Retnlatm1Mer)
|
abnormal chemokine secretion
|
J:144784
|
decreased interleukin-5 secretion
|
J:144784
|
decreased interleukin-6 secretion
|
J:144927
|
decreased susceptibility to induced colitis
|
J:144784,
J:144927
|
impaired eosinophil recruitment
|
J:144784
|
increased interleukin-10 secretion
|
J:144927
|
Retnlatm1Mer/Retnlatm1Mer
(C.B6-Retnlatm1Mer)
|
decreased susceptibility to induced colitis
|
J:144784,
J:144927
|
Retnlatm1Mer/Retnlatm1Mer
(involves: C57BL/6)
|
abnormal macrophage physiology
|
J:147863
|
abnormal T-helper 2 physiology
|
J:147863
|
increased IgE level
|
J:147863
|
increased IgG1 level
|
J:147863
|
increased interleukin-4 secretion
|
J:147863
|
increased interleukin-5 secretion
|
J:147863
|
increased interleukin-13 secretion
|
J:147863
|
Retnlbtm1Gdw/Retnlbtm1Gdw
(involves: 129S/SvEv * C57BL/6)
|
decreased inflammatory response
|
J:114507
|
decreased susceptibility to induced colitis
|
J:114507
|
Retnlbtm1Lex/Retnlbtm1Lex
(FVB.129S5-Retnlbtm1Lex)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:235058
|
decreased circulating interleukin-6 level
|
J:235058
|
increased circulating interleukin-13 level
|
J:235058
|
liver inflammation
|
J:235058
|
white adipose tissue inflammation
|
J:235058
|
Retnlbtm1Mer/Retnlbtm1Mer
(involves: 129S1/Sv * C57BL/6)
|
decreased susceptibility to induced colitis
|
J:141524
|
increased susceptibility to induced colitis
|
J:141524
|
Retnlbtm1Mer/Retnlbtm1Mer
(involves: 129S1/Sv)
|
decreased IgG2a level
|
J:141446
|
decreased interferon-gamma secretion
|
J:141446
|
decreased susceptibility to parasitic infection
|
J:141446
|
decreased tumor necrosis factor secretion
|
J:141446
|
increased IgG1 level
|
J:141446
|
Rev1tm1.1Jow/Rev1tm1.1Jow
(involves: C57BL/6)
|
abnormal somatic hypermutation frequency
|
J:151700
|
Rev1tm1Ndew/Rev1tm1Ndew
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal somatic hypermutation frequency
|
J:119176
|
Rev3ltm1.1Kunk/Rev3ltm1.1Kunk
(involves: C57BL/6)
|
abnormal somatic hypermutation frequency
|
J:188723
|
Rev3ltm1Rsky/Rev3ltm1.1Rsky Tg(Cr2-cre)3Cgn/?
(involves: C57BL/6)
|
abnormal class switch recombination
|
J:146453
|
abnormal somatic hypermutation frequency
|
J:146453
|
decreased B cell proliferation
|
J:146453
|
decreased IgG1 level
|
J:146453
|
Rfktm1.1Jcbr/Rfktm1.1Jcbr Tg(Mx1-cre)1Cgn/?
(involves: C57BL/6 * CBA)
|
decreased macrophage nitric oxide production
|
J:151999
|
Rftn1tm1Ayos/Rftn1tm1Ayos
(B6.Cg-Rftn1tm1Ayos)
|
decreased IgG2a level
|
J:150299
|
decreased interferon-gamma secretion
|
J:150299
|
decreased interleukin-4 secretion
|
J:150299
|
decreased interleukin-17 secretion
|
J:150299
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:150299
|
Rfx5tm1.1Ifo/Rfx5tm1.1Ifo
(involves: 129 * C57BL/6)
|
abnormal B lymphocyte antigen presentation
|
J:67941
|
abnormal level of surface class II molecules
|
J:67941
|
abnormal MHC II cell surface expression on macrophages
|
J:67941
|
decreased IgG1 level
|
J:67941
|
decreased IgM level
|
J:67941
|
Rfx5tm1Ifo/Rfx5tm1.1Ifo Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129 * C57BL/6 * C.B-20)
|
abnormal MHC II cell surface expression on macrophages
|
J:67924
|
Rfx7tm1.1Ggaur/Rfx7tm1.1Ggaur Ncr1tm1.1(icre)Viv/Ncr1+
(involves: C57BL/6)
|
abnormal NK cell physiology
|
J:282535
|
increased susceptibility to viral infection
|
J:282535
|
Rgcctm1Hrus/Rgcctm1Hrus
(involves: 129S6/SvEvTac * C57BL/6)
|
increased interleukin-2 secretion
|
J:279555
|
increased T cell proliferation
|
J:279555
|
Rgs1tm1Jhk/Rgs1tm1Jhk
(B6.129P2-Rgs1tm1Jhk)
|
abnormal B cell calcium ion homeostasis
|
J:90780
|
abnormal dendritic cell physiology
|
J:89680
|
enhanced B cell migration
|
J:90780
|
increased immunoglobulin level
|
J:90780
|
Rgs2tm1Pngr/Rgs2tm1Pngr
(involves: C57BL/6J)
|
abnormal T cell proliferation
|
J:77273
|
Rgs3tm1Ndul/Rgs3tm1Ndul
(B6.129-Rgs3tm1Ndul)
|
increased susceptibility to type I hypersensitivity reaction
|
J:210195
|
lung inflammation
|
J:210195
|
Rgs4tm1Sdlk/Rgs4tm1Sdlk Tg(Myh11-icre/ERT2)1Soff/?
(involves: FVB/N)
|
abnormal macrophage chemotaxis
|
J:215588
|
Rgs13tm1.1Jhk/Rgs13tm1.1Jhk
(involves: C57BL/6)
|
abnormal humoral immune response
|
J:199530
|
increased IgA level
|
J:199530
|
increased IgG1 level
|
J:199530
|
increased IgG2b level
|
J:199530
|
increased IgG2c level
|
J:199530
|
increased IgG3 level
|
J:199530
|
increased IgM level
|
J:199530
|
Rgs13tm1Drue/Rgs13tm1Drue
(B6.129S-Rgs13tm1Drue)
|
abnormal mast cell physiology
|
J:130209
|
increased susceptibility to type I hypersensitivity reaction
|
J:130209
|
Rgs16tm1.1Drue/Rgs16tm1.1Drue
(involves: C57BL/6)
|
abnormal T-helper 1 physiology
|
J:188966
|
abnormal T-helper 2 physiology
|
J:188966
|
granulomatous inflammation
|
J:188966
|
increased interleukin-5 secretion
|
J:188966
|
increased interleukin-10 secretion
|
J:188966
|
increased interleukin-13 secretion
|
J:188966
|
increased susceptibility to parasitic infection
|
J:188966
|
Rgsc844/Rgsc844+
(involves: C57BL/6JJcl * DBA/2JJcl)
|
abnormal neutrophil physiology
|
J:133634
|
Rgsc1045/Rgsc1045+
(involves: C57BL/6JJcl * DBA/2JJcl)
|
abnormal neutrophil physiology
|
J:133634
|
Rgsc1354/Rgsc1354+
(involves: C3H * C57BL/6JJcl)
|
abnormal neutrophil physiology
|
J:133634
|
Rgsc1547/Rgsc1547+
(involves: C3H * C57BL/6JJcl)
|
increased susceptibility to otitis media
|
J:133634
|
Rhbdd1tm1.1Mfm/Rhbdd1tm1.1Mfm
(involves: 129S/SvEv * C57BL/6J)
|
increased interleukin-6 secretion
|
J:346394
|
increased susceptibility to endotoxin shock
|
J:346394
|
increased tumor necrosis factor secretion
|
J:346394
|
Rhbdd3tm1Caox/Rhbdd3tm1Caox
(B6.129S6-Rhbdd3tm1Caox)
|
abnormal dendritic cell physiology
|
J:197348
|
increased circulating interferon-gamma level
|
J:197348
|
increased circulating interleukin-6 level
|
J:197348
|
increased interferon-gamma secretion
|
J:197348
|
increased interleukin-6 secretion
|
J:197348
|
increased natural killer cell mediated cytotoxicity
|
J:197348
|
liver inflammation
|
J:197348
|
Rhbdf2cub/Rhbdf2cub
(B6.Cg-Rhbdf2cub)
|
white adipose tissue inflammation
|
J:82006
|
Rhbdf2m1Btlr/Rhbdf2m1Btlr
(C57BL/6J-Rhbdf2m1Btlr)
|
decreased tumor necrosis factor secretion
|
J:187583
|
Rhbdf2m1Btlr/Rhbdf2tm1a(KOMP)Wtsi
(involves: C57BL/6J * C57BL/6N)
|
decreased tumor necrosis factor secretion
|
J:187583
|
Rhbdf2M2Btlr/Rhbdf2+
(C57BL/6J-Rhbdf2M2Btlr)
|
abnormal immune system physiology
|
J:213194
|
Rhbdf2M3Btlr/Rhbdf2+
(C57BL/6J-Rhbdf2M3Btlr)
|
abnormal immune system physiology
|
J:220064
|
Rhbdf2M3Btlr/Rhbdf2M3Btlr
(C57BL/6J-Rhbdf2M3Btlr)
|
abnormal immune system physiology
|
J:220064
|
Rhbdf2tm1.1Mfm/Rhbdf2tm1.1Mfm
(B6.129S-Rhbdf2tm1.1Mfm)
|
decreased circulating tumor necrosis factor level
|
J:179654
|
decreased tumor necrosis factor secretion
|
J:179654
|
Rhbdf2tm1a(KOMP)Wtsi/Rhbdf2tm1a(KOMP)Wtsi
(involves: C57BL/6N)
|
decreased tumor necrosis factor secretion
|
J:187583
|
Rhbdf2tm1Mak/Rhbdf2tm1Mak
(B6.129P2-Rhbdf2tm1Mak)
|
abnormal B cell physiology
|
J:179653
|
abnormal immune serum protein physiology
|
J:179653
|
decreased circulating tumor necrosis factor level
|
J:179653
|
decreased susceptibility to infection induced morbidity/mortality
|
J:179653
|
decreased tumor necrosis factor secretion
|
J:179653
|
increased susceptibility to bacterial infection
|
J:179653
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:179653
|
Rhbdf2tm1Mak/Rhbdf2tm1Mak
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal leukocyte physiology
|
J:221411
|
abnormal microglial cell physiology
|
J:221411
|
decreased tumor necrosis factor secretion
|
J:221411
|
Rhoatm1.1Tpal/Rhoa+ Tg(Cd4-cre/ERT2)11Gnri/0
(involves: C57BL/6)
|
increased T cell proliferation
|
J:257764
|
Rhogtm1Tnr/Rhogtm1Tnr
(involves: 129)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:87580
|
abnormal leukocyte physiology
|
J:87580
|
abnormal T-helper 2 physiology
|
J:87580
|
increased B cell proliferation
|
J:87580
|
increased immunoglobulin level
|
J:87580
|
Rhohtm1Brak/Rhohtm1Brak
(involves: 129/Sv * C57BL/6)
|
abnormal T cell proliferation
|
J:143161
|
decreased T cell apoptosis
|
J:143161
|
decreased T cell proliferation
|
J:143161
|
increased T cell proliferation
|
J:143161
|
Rhohtm1Hasu/Rhohtm1Hasu
(B6.Cg-Rhohtm1Hasu)
|
abnormal mast cell physiology
|
J:143491
|
decreased mast cell degranulation
|
J:143491
|
decreased susceptibility to type I hypersensitivity reaction
|
J:143491
|
Rhs1C57BL/6/Rhs1C57BL/6
(involves: BALB/c * C57BL/6)
|
decreased susceptibility to Herpesvirales infection
|
J:69352
|
Rictortm1.1Klg/Rictortm1.1Klg Tg(Mx1-cre)1Cgn/0
(B6.Cg-Rictortm1.1Klg Tg(Mx1-cre)1Cgn)
|
decreased T cell proliferation
|
J:189736
|
Rif1Gt(XT0278)Wtsi/Rif1Gt(XT0278)Wtsi
(involves: 129P2/OlaHsd * CD-1 * MF1)
|
abnormal class switch recombination
|
J:195061
|
decreased IgA level
|
J:195061
|
decreased IgG1 level
|
J:195061
|
decreased IgG2b level
|
J:195061
|
decreased IgG3 level
|
J:195061
|
decreased IgG level
|
J:195061
|
increased susceptibility to bacterial infection
|
J:195061
|
Rigitm1Aki/Rigitm1Aki
(involves: 129/Sv * C57BL/6)
|
abnormal dendritic cell physiology
|
J:137522
|
Rigitm1Aki/Rigitm1Aki
(involves: 129/Sv * C57BL/6 * ICR)
|
abnormal interferon level
|
J:137522
|
increased susceptibility to Flaviviridae infection induced morbidity/mortality
|
J:137522
|
Rigitm1Zgwg/Rigitm1Zgwg
(involves: 129S1/Sv)
|
abnormal granulocyte physiology
|
J:139016
|
colitis
|
J:139868
|
increased susceptibility to induced colitis
|
J:139868
|
Rinltm1.1Boun/Rinltm1.1Boun
(B6.Cg-Rinltm1.1Boun)
|
abnormal susceptibility to Riboviria infection
|
J:346452
|
Riok2tm1c(KOMP)Wtsi/Riok2+ Commd10Tg(Vav1-icre)A2Kio/Commd10+
(involves: C57BL/6N * C57BL/10 * CBA/Ca)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:305794
|
abnormal circulating interleukin level
|
J:305794
|
abnormal interleukin secretion
|
J:305794
|
Riox2tm1Mtsun/Riox2tm1Mtsun
(B6CrSlc.Cg-Riox2tm1Mtsun)
|
abnormal circulating interferon-gamma level
|
J:201871
|
abnormal circulating interleukin-4 level
|
J:201871
|
abnormal immunoglobulin level
|
J:201871
|
decreased inflammatory response
|
J:201871
|
Ripk1tm1.1Vmd/Ripk1tm1.1Vmd
(involves: C57BL/6N)
|
increased thymocyte apoptosis
|
J:209137
|
Ripk1tm1Led/Ripk1tm1Led
(involves: 129S6/SvEvTac)
|
lymph node inflammation
|
J:46522
|
Ripk2tm1Cfl/Ripk2tm1Cfl
(involves: 129S5/SvEvBrd)
|
abnormal macrophage physiology
|
J:107130
|
Ripk2tm1Flv/Ripk2tm1Flv
(involves: 129S1/Sv)
|
abnormal cytokine secretion
|
J:75400
|
abnormal T-helper 1 physiology
|
J:75400
|
decreased interleukin-6 secretion
|
J:75400
|
decreased T cell proliferation
|
J:75400
|
decreased tumor necrosis factor secretion
|
J:75400
|
Ripk2tm1Flv/Ripk2tm1Flv
(involves: 129S1/Sv * C57BL/6)
|
abnormal macrophage physiology
|
J:132126
|
decreased interleukin-6 secretion
|
J:132126
|
decreased tumor necrosis factor secretion
|
J:132126
|
Ripk2tm1Ghc/Ripk2tm1Ghc
(involves: 129S4/SvJae * C57BL/6)
|
decreased IgG2a level
|
J:75401
|
decreased interferon-gamma secretion
|
J:75401
|
decreased T cell proliferation
|
J:75401
|
increased susceptibility to infection
|
J:75401
|
Ripk3tm1Vmd/Ripk3tm1Vmd
(B6.129-Ripk3tm1Vmd)
|
decreased inflammatory response
|
J:179279
|
Rmcfr/Rmcfr
(DBA/1J)
|
decreased susceptibility to Retroviridae infection
|
J:7108
|
Rmcfr/Rmcfr
(DBA/2J)
|
decreased susceptibility to Retroviridae infection
|
J:7108
|
Rmcfr/Rmcfr
(CBA/N)
|
decreased susceptibility to Retroviridae infection
|
J:7108
|
Rmcfs/Rmcfs
(CBA/J)
|
increased susceptibility to Retroviridae infection
|
J:7108
|
Rmcfs/Rmcfs
(C57L/J)
|
increased susceptibility to Retroviridae infection
|
J:7108
|
Rmcfs/Rmcfs
(C57BR/cdJ)
|
increased susceptibility to Retroviridae infection
|
J:7108
|
Rmp1DBA/2J/Rmp1DBA/2J
(involves: C57BL/6J * DBA/2J)
|
increased susceptibility to Poxviridae infection
|
J:28150
|
Rmp2DBA/2J/Rmp2DBA/2J
(involves: C57BL/6J * DBA/2J)
|
increased susceptibility to Poxviridae infection
|
J:11032
|
Rmp3DBA/2J/Rmp3DBA/2J
(involves: C57BL/6J * DBA/2J)
|
increased susceptibility to Poxviridae infection
|
J:11032
|
Rmp4C57BL/6NCr/Rmp4C57BL/6NCr
(involves: C57BL/6NCr * DBA/2NCr)
|
decreased susceptibility to Poxviridae infection
|
J:29241
|
Rmp5C57BL/6NCr/Rmp5C57BL/6NCr
(involves: C57BL/6NCr * DBA/2NCr)
|
decreased susceptibility to Poxviridae infection
|
J:3240
|
Rmp6C57BL/6NCr/Rmp6C57BL/6NCr
(involves: C57BL/6NCr * DBA/2NCr)
|
decreased susceptibility to Poxviridae infection
|
J:3240
|
Rnase4em1Zpxu/Rnase4em1Zpxu
(Not Specified)
|
increased susceptibility to induced colitis
|
J:354138
|
Rnase4em2Zpxu/Rnase4em2Zpxu Tg(Vil1-cre)DNju/0
(involves: C57BL/6 * C57BL/6J)
|
increased susceptibility to induced colitis
|
J:354138
|
Rnaseh2atm1Crh/Rnaseh2atm1Crh
(Not Specified)
|
abnormal innate immunity
|
J:232933
|
decreased susceptibility to Riboviria infection
|
J:232933
|
Rnaseh2bem1Anu/Rnaseh2b+ Tlr7em2Anu/Tlr7+
(C57BL/6NCrl-Rnaseh2bem1Anu Tlr7em2Anu)
|
increased autoantibody level
|
J:324448
|
Rnaseh2btm1c(EUCOMM)Wtsi/Rnaseh2btm1c(EUCOMM)Wtsi Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N * SJL)
|
decreased B cell proliferation
|
J:186986
|
Rnaseltm1Slvm/Rnaseltm1Slvm
(involves: 129P2/OlaHsd)
|
decreased T cell apoptosis
|
J:44292
|
increased susceptibility to Picornaviridae infection
|
J:44292
|
Rnf8Gt(AS0574)Wtsi/Rnf8+
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal class switch recombination
|
J:161240
|
Rnf8Gt(AS0574)Wtsi/Rnf8Gt(AS0574)Wtsi
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal class switch recombination
|
J:161240
|
decreased IgG1 level
|
J:161240
|
decreased IgG2b level
|
J:161240
|
decreased IgG3 level
|
J:161240
|
increased thymocyte apoptosis
|
J:161240
|
Rnf8Gt(RRR260)Byg/Rnf8Gt(RRR260)Byg
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal class switch recombination
|
J:161240
|
decreased IgG1 level
|
J:161240
|
decreased IgG2b level
|
J:161240
|
decreased IgG3 level
|
J:161240
|
increased thymocyte apoptosis
|
J:161240
|
Rnf19btm1Jkorn/Rnf19btm1Jkorn
(B6.129S-Rnf19btm1Jkorn)
|
decreased interferon-gamma secretion
|
J:157393
|
impaired natural killer cell mediated cytotoxicity
|
J:157393
|
Rnf20Gt(RRJ249)Byg/Rnf20+
(involves: 129P2/OlaHsd)
|
abnormal leukocyte physiology
|
J:268221
|
abnormal T cell physiology
|
J:268221
|
increased interferon-gamma secretion
|
J:268221
|
increased susceptibility to induced colitis
|
J:268221
|
increased tumor necrosis factor secretion
|
J:268221
|
Rnf31tm1.1Kiwa/Rnf31tm1.1Kiwa Cd79atm1(cre)Reth/Cd79a+
(involves: BALB/c * C57BL/6NCrlj * CBA/JNCrlj)
|
abnormal humoral immune response
|
J:201885
|
decreased IgA level
|
J:201885
|
decreased IgG1 level
|
J:201885
|
decreased IgG2a level
|
J:201885
|
decreased IgG2b level
|
J:201885
|
decreased IgG3 level
|
J:201885
|
decreased IgM level
|
J:201885
|
Rnf40tm1.1Sajo/Rnf40tm1.1Sajo Tg(Car1-cre)5Flt/0
(involves: 129S2/SvPas * C57BL/6J)
|
decreased susceptibility to induced colitis
|
J:311838
|
Rnf43em2Mage/Rnf43em2Mage
(Not Specified)
|
increased interferon-gamma secretion
|
J:285428
|
stomach inflammation
|
J:285428
|
Rnf115em1Gpt/Rnf115em1Gpt
(C57BL/6JGpt-Rnf115em1Gpt/Gpt)
|
decreased susceptibility to viral infection
|
J:297834
|
decreased susceptibility to viral infection induced morbidity/mortality
|
J:297834
|
increased circulating interferon-beta level
|
J:297834
|
increased interferon-beta secretion
|
J:297834
|
increased susceptibility to viral infection induced morbidity/mortality
|
J:297834
|
Rnf122em1Caox/Rnf122em1Caox
(involves: C57BL/6J)
|
decreased susceptibility to Riboviria infection induced morbidity/mortality
|
J:344769
|
increased circulating interferon-alpha level
|
J:344769
|
increased circulating interferon-beta level
|
J:344769
|
increased circulating interleukin-6 level
|
J:344769
|
increased interferon-alpha secretion
|
J:344769
|
increased interferon-beta secretion
|
J:344769
|
increased interleukin-6 secretion
|
J:344769
|
increased tumor necrosis factor secretion
|
J:344769
|
Rnf123em1Nmea/Rnf123em1Nmea
(NC/Jic-Rnf123em1Nmea)
|
decreased susceptibility to parasitic infection
|
J:327312
|
decreased susceptibility to parasitic infection induced morbidity/mortality
|
J:327312
|
Rnf123em2Nmea/Rnf123em2Nmea
(NC/Jic-Rnf123em2Nmea)
|
decreased susceptibility to parasitic infection
|
J:327312
|
decreased susceptibility to parasitic infection induced morbidity/mortality
|
J:327312
|
Rnf128tm1.1Flv/Y
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:153216
|
abnormal peripheral T cell anergy
|
J:153216
|
increased circulating interleukin-2 level
|
J:153216
|
increased interferon-gamma secretion
|
J:153216
|
increased T cell proliferation
|
J:153216
|
Rnf128tm1.1Flv/Y Tg(TcraTcrb)425Cbn/0
(involves: 129S6/SvEvTac * BALB/c * C57BL/6)
|
abnormal peripheral T cell anergy
|
J:153216
|
decreased T cell proliferation
|
J:153216
|
increased circulating interleukin-2 level
|
J:153216
|
Rnf128tm1.1Flv/Rnf128tm1.1Flv
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:153216
|
abnormal peripheral T cell anergy
|
J:153216
|
increased circulating interleukin-2 level
|
J:153216
|
increased interferon-gamma secretion
|
J:153216
|
increased T cell proliferation
|
J:153216
|
Rnf128tm1.1Flv/Rnf128tm1.1Flv Tg(TcraTcrb)425Cbn/0
(involves: 129S6/SvEvTac * BALB/c * C57BL/6)
|
abnormal peripheral T cell anergy
|
J:153216
|
decreased T cell proliferation
|
J:153216
|
increased circulating interleukin-2 level
|
J:153216
|
Rnf128tm1.2Cmse/Rnf128tm1.2Cmse
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal macrophage physiology
|
J:245025
|
Rnf128tm1Cdon/Rnf128+
(involves: 129 * C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:160681
|
Rnf128tm1Cdon/Rnf128tm1Cdon
(involves: C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:160681
|
increased interferon-gamma secretion
|
J:160681
|
increased interleukin-2 secretion
|
J:160681
|
increased interleukin-17 secretion
|
J:160681
|
increased T cell proliferation
|
J:160681
|
Rnf128tm1Cdon/Rnf128tm1Cdon
(involves: 129 * C57BL/6)
|
abnormal immune tolerance
|
J:160681
|
abnormal interleukin secretion
|
J:160681
|
abnormal regulatory T cell physiology
|
J:160681
|
CNS inflammation
|
J:160681
|
decreased interleukin-4 secretion
|
J:160681
|
decreased interleukin-5 secretion
|
J:160681
|
decreased interleukin-13 secretion
|
J:160681
|
increased anti-double stranded DNA antibody level
|
J:160681
|
increased IgG1 level
|
J:160681
|
increased IgM level
|
J:160681
|
increased interferon-gamma secretion
|
J:160681
|
increased interleukin-2 secretion
|
J:160681
|
increased interleukin-4 secretion
|
J:160681
|
increased interleukin-17 secretion
|
J:160681
|
increased interleukin-21 secretion
|
J:160681
|
increased splenocyte proliferation
|
J:160681
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:160681
|
lung inflammation
|
J:160681
|
Rnf128tm1Cdon/Rnf128tm1Cdon Tg(TcraTcrb)425Cbn/0
(involves: 129 * BALB/c * C57BL/6)
|
abnormal immune tolerance
|
J:160681
|
increased interferon-gamma secretion
|
J:160681
|
increased interleukin-2 secretion
|
J:160681
|
increased splenocyte proliferation
|
J:160681
|
Rnf139tm1(KOMP)Wtsi/Rnf139tm1(KOMP)Wtsi
(involves: C57BL/6J * C57BL/6N)
|
liver inflammation
|
J:231404
|
Rnf144aem1Smoc/Rnf144aem1Smoc
(C57BL/6JSmoc-Rnf144aem1Smoc/Smoc)
|
abnormal innate immunity
|
J:347002
|
increased susceptibility to Herpesvirales infection
|
J:347002
|
increased susceptibility to Herpesvirales infection induced morbidity/mortality
|
J:347002
|
Rnf144bem1Cya/Rnf144bem1Cya
(C57BL/6J-Rnf144bem1Cya/Cya)
|
decreased susceptibility to Picornaviridae infection
|
J:357974
|
decreased susceptibility to Picornaviridae infection induced morbidity/mortality
|
J:357974
|
decreased susceptibility to Riboviria infection
|
J:357974
|
Rnf146tm1.1Rtpl/Rnf146tm1.1Rtpl Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased circulating tumor necrosis factor level
|
J:243612
|
Rnf168Gt(156B6)Cmhd/Rnf168Gt(156B6)Cmhd
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal class switch recombination
|
J:198260
|
decreased IgG1 level
|
J:198260
|
decreased IgG2a level
|
J:198260
|
decreased IgG3 level
|
J:198260
|
decreased IgG level
|
J:198260
|
Rnf168Gt(405F11)Cmhd/Rnf168Gt(405F11)Cmhd
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal class switch recombination
|
J:198260
|
decreased IgG1 level
|
J:198260
|
decreased IgG2a level
|
J:198260
|
decreased IgG3 level
|
J:198260
|
decreased IgG level
|
J:198260
|
Rnf186em1Ktak/Rnf186em1Ktak
(involves: C57BL/6 * DBA/2)
|
increased susceptibility to colitis induced morbidity/mortality
|
J:258197
|
increased susceptibility to induced colitis
|
J:258197
|
Rnf186tm1Ktak/Rnf186tm1Ktak
(involves: 129S4/SvJae * C57BL/6)
|
increased susceptibility to colitis induced morbidity/mortality
|
J:258197
|
increased susceptibility to induced colitis
|
J:258197
|
Ro60tm1Woln/Ro60+
(involves: 129S1/Sv * C57BL/6)
|
increased anti-nuclear antigen antibody level
|
J:84627
|
increased IgG2a level
|
J:84627
|
Ro60tm1Woln/Ro60tm1Woln
(involves: 129S1/Sv * C57BL/6)
|
glomerulonephritis
|
J:84627
|
increased anti-chromatin antibody level
|
J:84627
|
increased anti-double stranded DNA antibody level
|
J:84627
|
increased anti-histone antibody level
|
J:84627
|
increased anti-nuclear antigen antibody level
|
J:84627
|
increased anti-single stranded DNA antibody level
|
J:84627
|
increased IgG2a level
|
J:84627
|
increased IgM level
|
J:84627
|
Rock1tm1Liao/Rock1+
(C57BL/6-Rock1tm1Liao)
|
abnormal leukocyte adhesion
|
J:135152
|
abnormal leukocyte migration
|
J:135152
|
impaired macrophage chemotaxis
|
J:135152
|
impaired neutrophil recruitment
|
J:135152
|
Rock1tm1Sna/Rock1tm1Sna
(B6N.129X1-Rock1tm1Sna)
|
blepharitis
|
J:98250
|
Rock2tm1.1Itl/Rock2+ Tg(Tagln-cre)1Her/0
(B6.Cg-Rock2tm1.1Itl Tg(Tagln-cre)1Her)
|
abnormal cytokine secretion
|
J:222206
|
Rorasg/Rorasg
(involves: C57BL/6)
|
abnormal immune system physiology
|
J:2228
|
abnormal macrophage physiology
|
J:28095
|
increased IgE level
|
J:135863
|
increased interleukin-1 secretion
|
J:28095
|
lung inflammation
|
J:135863
|
Rorcm2Btlr/Rorcm2Btlr
(C57BL/6J-Rorcm2Btlr)
|
decreased IgM level
|
J:217792
|
decreased response to antigen
|
J:217792
|
impaired humoral immune response
|
J:217792
|
Rorcm3Btlr/Rorcm3Btlr
(C57BL/6J-Rorcm3Btlr)
|
decreased IgG level
|
J:234257
|
decreased IgM level
|
J:234257
|
decreased response to antigen
|
J:234257
|
impaired humoral immune response
|
J:234257
|
Rorctm1.1Zsun/Rorctm1.1Zsun
(B6(129S4)-Rorctm1.1Zsun)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:248565
|
Rorctm1Amj/Rorctm1Amj
(either: (involves: 129/Sv * C57BL/6) or (involves: 129/Sv * C57BL/6 * DBA/2))
|
abnormal interleukin level
|
J:123351
|
abnormal T cell physiology
|
J:64381
|
increased T cell apoptosis
|
J:64381
|
Rorctm1Litt/Rorctm1Litt
(involves: 129P2/OlaHsd)
|
colitis
|
J:158663
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:248565
|
increased susceptibility to bacterial infection
|
J:158663
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:158663
|
increased thymocyte apoptosis
|
J:248565
|
Rorctm2Litt/Rorctm2Litt
(involves: 129P2/OlaHsd)
|
increased thymocyte apoptosis
|
J:87395
|
Rosq1DBA/1J/Rosq1DBA/1J
(involves: DBA/1J * FVB/NJ)
|
abnormal neutrophil physiology
|
J:122919
|
Rosq1DBA/1J/Rosq1FVB/NJ
(involves: DBA/1J * FVB/NJ)
|
abnormal neutrophil physiology
|
J:122919
|
Rpap3tm1c(KOMP)Wtsi/Rpap3tm1c(KOMP)Wtsi Tg(Vil1-cre/ERT2)23Syr/0
(involves: C57BL/6N * DBA/2)
|
small intestinal inflammation
|
J:314346
|
Rpl13atm1.1Jesc/Rpl13atm1.1Jesc
(NOD.129S5(Cg)-Rpl13atm1.1Jesc)
|
decreased susceptibility to autoimmune diabetes
|
J:237822
|
Rpl13atm1.1Mazu/Rpl13atm1.1Mazu Lyz2tm1(cre)Ifo/Lyz2+
(involves: C57BL/6)
|
abnormal cytokine level
|
J:194920
|
abnormal macrophage chemotaxis
|
J:194920
|
increased circulating tumor necrosis factor level
|
J:194920
|
Rpl22Gt(GST000137)Lex/Rpl22Gt(GST000137)Lex
(involves: 129S5/SvEvBrd)
|
glomerulonephritis
|
J:123569
|
increased T cell apoptosis
|
J:123569
|
Rpl38Ts/Rpl38+
(TSJ/Le)
|
increased susceptibility to otitis media
|
J:168509
|
Rprd1btm1Tshu/Rprd1btm1Tshu Tg(Vil1-cre)20Syr/0
(involves: C57BL/6 * DBA/2)
|
increased susceptibility to colitis induced morbidity/mortality
|
J:300857
|
Rps6ka4tm1Jsca/Rps6ka4tm1Jsca Rps6ka5tm1Jsca/Rps6ka5tm1Jsca
(Not Specified)
|
decreased T cell proliferation
|
J:124301
|
Rps6ka4tm1Jsca/Rps6ka4tm1Jsca Rps6ka5tm1Jsca/Rps6ka5tm1Jsca
(B6.Cg-Rps6ka5tm1Jsca Rps6ka4tm1Jsca)
|
abnormal cytokine level
|
J:139576
|
abnormal cytokine secretion
|
J:139576
|
decreased circulating interleukin-10 level
|
J:139576
|
decreased interleukin-10 secretion
|
J:139576
|
increased circulating interleukin-6 level
|
J:139576
|
increased circulating interleukin-12a level
|
J:139576
|
increased circulating interleukin-12b level
|
J:139576
|
increased circulating tumor necrosis factor level
|
J:139576
|
increased interleukin-6 secretion
|
J:139576
|
increased interleukin-12a secretion
|
J:139576
|
increased interleukin-12b secretion
|
J:139576
|
increased susceptibility to endotoxin shock
|
J:139576
|
increased tumor necrosis factor secretion
|
J:139576
|
skin inflammation
|
J:139576
|
Rps27lGt(IST11658B7)Tigm/Rps27lGt(IST11658B7)Tigm
(C57BL/6-Rps27lGt(IST11658B7)Tigm)
|
increased thymocyte apoptosis
|
J:223276
|
Rptortm1Ahir/Rptortm1Ahir Tg(Itgax-cre)1-1Reiz/0
(B6.Cg-Rptortm1Ahir Tg(Itgax-cre)1-1Reiz)
|
increased susceptibility to induced colitis
|
J:188676
|
Rr9tm1.1Kubo/Rr9tm1.1Kubo
(C57BL/6-Rr9tm1.1Kubo)
|
decreased interleukin-13 secretion
|
J:167446
|
Rr17tm1.1Cdon/Rr17tm1.1Cdon
(involves: 129S6/SvEvTac * C57BL/6)
|
decreased interleukin-17 secretion
|
J:181186
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:181186
|
increased interleukin-17 secretion
|
J:181186
|
Rr32tm1.1Weav/Rr32tm1.1Weav
(involves: C57BL/6)
|
decreased interferon-gamma secretion
|
J:208819
|
Rr38tm1.2Aafo/Rr38tm1.2Aafo
(involves: 129S4/SvJaeSor * BALB/cJ * C57BL/6)
|
abnormal thymus physiology
|
J:227747
|
Rr79em2Rtew/Rr79em2Rtew
(C57BL/6J-Rr79em2Rtew/J)
|
abnormal T cell activation
|
J:332957
|
abnormal T cell physiology
|
J:332957
|
Rr79em2Rtew/Rr79em2Rtew Tg(TcraTcrb)1100Mjb/?
(involves: C57BL/6J)
|
abnormal T cell activation
|
J:332957
|
Rr152tm2Cog/Rr152+
(involves: 129S2/SvPas * C57BL/6)
|
decreased IgG1 level
|
J:90548
|
decreased IgG2b level
|
J:90548
|
decreased IgG3 level
|
J:90548
|
decreased IgG level
|
J:90548
|
Rr152tm2Cog/Rr152tm2Cog
(involves: 129S2/SvPas * C57BL/6)
|
decreased IgG1 level
|
J:90548
|
decreased IgG2a level
|
J:90548
|
decreased IgG2b level
|
J:90548
|
decreased IgG3 level
|
J:90548
|
decreased IgG level
|
J:90548
|
Rr152tm3.1Cog/Rr152tm3.1Cog
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
abnormal class switch recombination
|
J:71300
|
decreased IgA level
|
J:71300
|
decreased IgE level
|
J:71300
|
decreased IgG2a level
|
J:71300
|
decreased IgG2b level
|
J:71300
|
decreased IgG3 level
|
J:71300
|
decreased IgG level
|
J:71300
|
decreased immunoglobulin level
|
J:71300
|
Rr152tm3Cog/Rr152tm3Cog
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal class switch recombination
|
J:71300
|
decreased IgA level
|
J:71300
|
decreased IgE level
|
J:71300
|
decreased IgG1 level
|
J:71300
|
decreased IgG2a level
|
J:71300
|
decreased IgG2b level
|
J:71300
|
decreased IgG3 level
|
J:71300
|
decreased IgG level
|
J:71300
|
decreased IgM level
|
J:71300
|
decreased immunoglobulin level
|
J:71300
|
Rr152tm5.1Cog/Rr152tm5.1Cog
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal class switch recombination
|
J:164513
|
abnormal somatic hypermutation frequency
|
J:164513,
J:333348
|
decreased IgA level
|
J:164513
|
decreased IgE level
|
J:164513
|
decreased IgG2b level
|
J:164513
|
decreased IgG3 level
|
J:164513
|
decreased IgM level
|
J:164513
|
Rr155tm1.1Erpi/Rr155tm1.1Erpi
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
abnormal immunoglobulin level
|
J:160101
|
decreased IgG1 level
|
J:160101
|
decreased IgG2a level
|
J:160101
|
Rr156tm6.1Cog/Rr156tm6.1Cog
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased IgM level
|
J:165617
|
Rr156tm6Cog/Rr156tm6Cog
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased IgM level
|
J:165617
|
Rr160tm1Wtg/Rr160tm1Wtg
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal immunoglobulin level
|
J:134885
|
abnormal somatic hypermutation frequency
|
J:134885
|
Rr163tm1Lfdn/Rr163+
(either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * CB20))
|
abnormal immune system physiology
|
J:31727
|
Rr163tm1Lfdn/Rr163tm1Lfdn
(either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * CB20))
|
abnormal immune system physiology
|
J:31727
|
Rr166tm4.1Wtg/Rr166tm4.1Wtg
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6)
|
abnormal B cell physiology
|
J:193015
|
abnormal immunoglobulin level
|
J:193015
|
Rr169tm2Rao/Rr169tm2Rao
(involves: 129S6/SvEvTac * C57BL/6J)
|
increased susceptibility to parasitic infection
|
J:94039
|
Rr170tm1.1Iku/Rr170tm1.1Iku
(B6.Cg-Rr170tm1.1Iku)
|
decreased T cell proliferation
|
J:333539
|
increased T cell apoptosis
|
J:333539
|
Rr253em1Kmm/Rr253em1Kmm
(C57BL/6-Rr253em1Kmm)
|
abnormal class switch recombination
|
J:316113
|
increased susceptibility to viral infection induced morbidity/mortality
|
J:316113
|
Rr253em6Kmm/Rr253em6Kmm
(C57BL/6J-Rr253em6Kmm)
|
abnormal T-helper 2 physiology
|
J:334296
|
increased susceptibility to parasitic infection induced morbidity/mortality
|
J:334296
|
Rr364tm1.1Aak/Rr364tm1.1Aak
(129.129S2(Cg)-Rr364tm1.1Aak)
|
abnormal class switch recombination
|
J:242276
|
decreased IgG3 level
|
J:242276
|
increased IgG2a level
|
J:242276
|
increased IgG2b level
|
J:242276
|
Rr395em1Bhao/Rr395em1Bhao
(Not Specified)
|
increased thymocyte apoptosis
|
J:333961
|
Rr250409tm1Lky/Rr250409+
(involves: 129X1/SvJ * BALB/c * C57BL/6 * FVB)
|
decreased interleukin-4 secretion
|
J:125684
|
Rr250409tm1Lky/Rr250409tm1Lky
(involves: 129X1/SvJ * BALB/c * C57BL/6 * FVB)
|
abnormal response to infection
|
J:125684
|
decreased IgE level
|
J:125684
|
decreased interleukin-4 secretion
|
J:125684
|
decreased interleukin-5 secretion
|
J:125684
|
decreased interleukin-13 secretion
|
J:125684
|
decreased susceptibility to parasitic infection
|
J:125684
|
Rr250409tm1Lky/Rr250409tm1Lky
(involves: 129X1/SvJ * BALB/c)
|
decreased interleukin-4 secretion
|
J:167446
|
Rragcem1Efe/Rragc+
(Not Specified)
|
abnormal B cell activation
|
J:320567
|
abnormal B cell physiology
|
J:320567
|
abnormal class switch recombination
|
J:320567
|
decreased B cell proliferation
|
J:320567
|
decreased IgG1 level
|
J:320567
|
decreased IgM level
|
J:320567
|
impaired humoral immune response
|
J:320567
|
Rragcem1Efe/Rragc+ Tg(Vav-BCL2)69Jad/0
(Not Specified)
|
decreased susceptibility to autoimmune disorder
|
J:320567
|
Rras2Gt(OST361011)Lex/Rras2Gt(OST361011)Lex
(involves: 129S5/SvEvBrd)
|
abnormal B cell activation
|
J:151653
|
abnormal B cell physiology
|
J:151653
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:151653
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:151653
|
decreased B cell proliferation
|
J:151653
|
Rrastm1Itl/Rrastm1Itl
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal dendritic cell physiology
|
J:181730
|
Rsad2tm1Aki/Rsad2tm1Aki
(involves: 129/Sv * C57BL/6)
|
decreased circulating interferon-alpha level
|
J:169840
|
decreased interferon-alpha secretion
|
J:169840
|
decreased interferon-beta secretion
|
J:169840
|
Rsad2tm1Kchc/Rsad2tm1Kchc
(B6.129-Rsad2tm1Kchc)
|
decreased IgG1 level
|
J:148305
|
decreased interleukin-4 secretion
|
J:148305
|
decreased interleukin-5 secretion
|
J:148305
|
decreased interleukin-13 secretion
|
J:148305
|
increased interferon-gamma secretion
|
J:148305
|
rsm1/rsm1
(either: P/J or P/N)
|
abnormal cell-mediated immunity
|
J:8396
|
Rsph9em1Jwji/Rsph9em1Jwji
(B6.Cg-Rsph9em1Jwji)
|
increased microglial cell activation
|
J:294184
|
sinus inflammation
|
J:294184
|
Rtcbtm1c(KOMP)Wtsi/Rtcbtm1c(KOMP)Wtsi Tg(Fcer2a-cre)5Mbu/0
(involves: C57BL/6 * CBA * SJL)
|
abnormal B cell physiology
|
J:216740
|
decreased IgM level
|
J:216740
|
Rthyd1NOD/MrkTac/?
(involves: B10.Br/SgSnJ * NOD-H2k)
|
abnormal T cell clonal deletion
|
J:94684
|
Rthyd2B10.Br/SgSnJ/?
(involves: B10.Br/SgSnJ * NOD-H2k)
|
abnormal T cell clonal deletion
|
J:94684
|
Rthyd3B10.Br/SgSnJ/?
(involves: B10.Br/SgSnJ * NOD-H2k)
|
abnormal T cell clonal deletion
|
J:94684
|
Rthyd5NOD/MrkTac/?
(involves: B10.Br/SgSnJ * NOD-H2k)
|
abnormal T cell clonal deletion
|
J:94684
|
Rtl5em1Tmki/Rtl5em1Tmki Rtl6tm2.1Tmki/Rtl6tm2.1Tmki
(involves: C57BL/6NCrlj * C57BL/6NSlc * CBA/JNCrlj)
|
abnormal inflammatory response
|
J:329352
|
decreased susceptibility to endotoxin shock
|
J:329352
|
Rtl5tm1.1Tmki/Rtl5tm1.1Tmki Rtl6tm1.1Tmki/Rtl6tm1.1Tmki
(involves: C57BL/6NCrlj * C57BL/6NSlc * CBA/JNCrlj)
|
abnormal inflammatory response
|
J:329352
|
Rtl9em2Tmki/Rtl9em2Tmki
(C57BL/6N-Rtl9em2Tmki)
|
abnormal innate immunity
|
J:343808
|
Rtp4em#Xzs/Rtp4em#Xzs
(involves: C57BL/6)
|
decreased susceptibility to parasitic infection
|
J:293929
|
decreased susceptibility to parasitic infection induced morbidity/mortality
|
J:293929
|
decreased susceptibility to viral infection
|
J:293929
|
Rubcnem1Dgre/Rubcnem1Dgre
(C57BL/6-Rubcnem1Dgre)
|
abnormal macrophage physiology
|
J:261225
|
Rubcnem1Dgre/Rubcnem1Dgre
(involves: C57BL/6 * C57BL/6N)
|
abnormal circulating chemokine level
|
J:235399
|
abnormal macrophage physiology
|
J:235399
|
decreased circulating interleukin-10 level
|
J:235399
|
glomerulonephritis
|
J:235399
|
increased anti-double stranded DNA antibody level
|
J:235399
|
increased anti-nuclear antigen antibody level
|
J:235399
|
increased autoantibody level
|
J:235399
|
increased circulating interleukin-1 beta level
|
J:235399
|
increased circulating interleukin-6 level
|
J:235399
|
increased circulating interleukin-12b level
|
J:235399
|
increased IgG level
|
J:235399
|
increased susceptibility to systemic lupus erythematosus
|
J:235399
|
Rubcnem1Dgre/Rubcnem1Dgre Tg(CAG-EGFP/Map1lc3b)53Nmz/0
(involves: C57BL/6 * C57BL/6J * C57BL/6N * C57BL/6NCrlj * DBA/2)
|
abnormal macrophage physiology
|
J:261225
|
Rubcnem1Dgre/Rubcnem1Dgre Tg(CAG-EGFP/Map1lc3b)53Nmz/0
(involves: C57BL/6 * C57BL/6N * DBA/2)
|
abnormal circulating chemokine level
|
J:235399
|
abnormal macrophage physiology
|
J:235399
|
decreased circulating interleukin-10 level
|
J:235399
|
increased circulating interleukin-1 beta level
|
J:235399
|
increased circulating interleukin-6 level
|
J:235399
|
Runx1tm1Yg/Runx1tm1Yg
(either: (involves: 129/Sv * 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * ICR) or (involves: 129S1/Sv * 129X1/SvJ * MF1))
|
increased thymocyte apoptosis
|
J:125830
|
Runx1tm8Spe/Runx1tm8Spe
(involves: 129/Sv * C57BL/6)
|
lung inflammation
|
J:120100
|
Runx3tm1Itan/Runx3tm1Itan Tg(Cd4-cre)1Cwi/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
increased IgA level
|
J:125953
|
lung inflammation
|
J:125953
|
Runx3tm1Yg/Runx3tm1Yg
(either: (involves: 129S1/Sv * 129X1/SvJ * ICR) or (involves: 129S1/Sv * 129X1/SvJ * MF1))
|
abnormal cytokine level
|
J:93240
|
abnormal dendritic cell physiology
|
J:88424,
J:100348
|
abnormal inflammatory response
|
J:93240
|
abnormal interferon level
|
J:93240
|
abnormal interleukin level
|
J:93240
|
abnormal tumor necrosis factor level
|
J:93240
|
colitis
|
J:93240
|
increased IgE level
|
J:100348
|
intestinal inflammation
|
J:93240
|
lung inflammation
|
J:88424
|
small intestinal inflammation
|
J:93240
|
stomach inflammation
|
J:93240
|
Runx3tm3.1Yg/Runx3tm3.1Yg
(Not Specified)
|
abnormal immune system physiology
|
J:224898
|
intestinal inflammation
|
J:224898
|
Ruvbl2M1Btlr/Ruvbl2+
(involves: C57BL/6J)
|
abnormal class switch recombination
|
J:185495
|
decreased IgG1 level
|
J:185495
|
decreased IgG level
|
J:185495
|
decreased IgM level
|
J:185495
|
Rxfp2tm1a(EUCOMM)Wtsi/Rxfp2tm1a(EUCOMM)Wtsi
(C57BL/6N-Rxfp2tm1a(EUCOMM)Wtsi/Ieg)
|
decreased IgE level
|
J:165965
|
Rxrapke/Rxrapke
(C57BL/6J-Rxrapke)
|
abnormal dendritic cell physiology
|
J:103186
|
abnormal regulatory T cell physiology
|
J:103186
|
Rxratm1Ipc/Rxratm4Ipc Rxrbtm1Mma/Rxrbtm1Pcn Tg(KRT14-cre/ERT2)1Ipc/0
(involves: 129S2/SvPas)
|
increased immunoglobulin level
|
J:102470
|
Rxratm1Krc/Rxratm1Krc Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
abnormal macrophage activation involved in immune response
|
J:168799
|
glomerulonephritis
|
J:168799
|
impaired macrophage phagocytosis
|
J:168799
|
increased anti-double stranded DNA antibody level
|
J:168799
|
increased anti-nuclear antigen antibody level
|
J:168799
|
increased anti-single stranded DNA antibody level
|
J:168799
|
increased autoantibody level
|
J:168799
|
increased IgG level
|
J:168799
|
increased IgM level
|
J:168799
|
Rxratm2Ipc/Rxratm4Ipc Tg(KRT14-cre)1Ipc/0
(involves: 129S2/SvPas * C57BL/6 * SJL)
|
skin inflammation
|
J:67149
|
Rxratm4Ipc/Rxratm4Ipc Rxrbtm1Pcn/Rxrbtm1Pcn Tg(KRT14-cre/ERT2)1Ipc/0
(involves: 129S2/SvPas)
|
dermatitis
|
J:102470
|
ear inflammation
|
J:102470
|
Ryr2tm1(CAG-KRAS*G12V,-lacZ)Nobs/Ryr2tm1(CAG-KRAS*G12V,-lacZ)Nobs Trp53tm1Sia/Trp53tm1Sia
(involves: 129X1/SvJ * C57BL/6 * CBA)
|
myositis
|
J:117828
|
S1pr1tm1.1Cys/S1pr1tm1.1Cys
(involves: 129P2/OlaHsd * C3H * C57BL/6)
|
abnormal B cell physiology
|
J:176118
|
S1pr1tm1.1Thla/S1pr1tm1.1Thla
(B6.Cg-S1pr1tm1.1Thla)
|
abnormal leukocyte migration
|
J:163389
|
abnormal lymphocyte physiology
|
J:163389
|
S1pr1tm1Cys/S1pr1tm1Cys
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal B cell physiology
|
J:176118
|
S1pr1tm1Jch/S1pr1tm1Jch Tg(GFAP-cre)25Mes/?
(involves: C57BL/6J * FVB/N)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:168824
|
S1pr1tm1Jch/S1pr1tm1Jch Tg(Nes-cre)1Kln/0
(involves: C57BL/6J * SJL)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:168824
|
S1pr2tm1Rlp/S1pr2tm1Rlp
(involves: 129S6/SvEvTac * C57BL/6)
|
decreased B cell apoptosis
|
J:174313
|
increased B cell proliferation
|
J:174313
|
S1pr3tm1Jch/S1pr3tm1Jch
(involves: 129S1/Sv * 129X1/SvJ)
|
abnormal cytokine level
|
J:133917
|
decreased susceptibility to endotoxin shock
|
J:133917
|
S1pr3tm1Rlp/S1pr3tm1Rlp
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal B cell physiology
|
J:91161
|
S1pr5tm1Club/S1pr5tm1Club
(B6.129P2-S1pr5tm1Club)
|
abnormal NK cell physiology
|
J:178789
|
S100a4tm1.1Abres/S100a4tm1.1Abres
(B6.Cg-S100a4tm1.1Abres)
|
abnormal eosinophil physiology
|
J:182865
|
impaired macrophage chemotaxis
|
J:182865
|
S100a9tm1Hogg/S100a9tm1Hogg
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal neutrophil physiology
|
J:82513
|
S100a9tm1Nck/S100a9tm1Nck
(B6.129P2-S100a9tm1Nck)
|
decreased circulating tumor necrosis factor level
|
J:125179
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:125179
|
decreased susceptibility to endotoxin shock
|
J:125179
|
decreased susceptibility to fungal infection
|
J:209808
|
S100a9tm1Nck/S100a9tm1Nck
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal cellular extravasation
|
J:81642
|
Saa3tm1(KOMP)Vlcg/Saa3tm1(KOMP)Vlcg
(involves: C57BL/6NTac)
|
decreased circulating serum amyloid protein level
|
J:220630
|
Sac3d1tm1Hnaka/Sac3d1+
(involves: 129P2/OlaHsd)
|
abnormal mast cell physiology
|
J:144601
|
Sac3d1tm1Hnaka/Sac3d1tm1Hnaka
(involves: 129P2/OlaHsd)
|
abnormal B cell physiology
|
J:144601
|
abnormal mast cell physiology
|
J:144601
|
increased T cell proliferation
|
J:144601
|
Sall4tm1Brd/Sall4+
(involves: 129S7/SvEvBrd * C57BL/6J)
|
ear inflammation
|
J:117866
|
increased susceptibility to otitis media
|
J:117866
|
Samd9ltm1Homy/Samd9l+
(involves: 129P2/OlaHsd)
|
increased susceptibility to Retroviridae infection
|
J:202604
|
Samd9ltm1Homy/Samd9ltm1Homy
(involves: 129P2/OlaHsd)
|
increased susceptibility to Retroviridae infection
|
J:202604
|
Samhd1tm1.2Crs/Samhd1tm1.2Crs
(involves: C57BL/6N * C57BL/6NTac)
|
increased susceptibility to Retroviridae infection
|
J:201909
|
Samhd1tm1d(EUCOMM)Wtsi/Samhd1tm1d(EUCOMM)Wtsi
(involves: C57BL/6N)
|
abnormal response to infection
|
J:202757
|
Samhd1tm2.2Crs/Samhd1tm2.2Crs
(involves: 129S6/SvEvTac * C57BL/6J)
|
increased susceptibility to Retroviridae infection
|
J:201909
|
Samsn1tm1Xyw/Samsn1tm1Xyw
(B6.129P2-Samsn1tm1Xyw)
|
abnormal dendritic cell physiology
|
J:158032
|
abnormal T-helper 1 physiology
|
J:158032
|
abnormal T-helper 2 physiology
|
J:158032
|
increased B cell proliferation
|
J:158032
|
increased circulating interferon-gamma level
|
J:158032
|
increased IgG3 level
|
J:158032
|
increased IgM level
|
J:158032
|
increased interleukin-4 secretion
|
J:158032
|
increased interleukin-12 secretion
|
J:158032
|
increased T cell proliferation
|
J:158032
|
Sarm1tm1.1Diam/Sarm1tm1.1Diam
(involves: 129X1/SvJ * C57BL/6)
|
abnormal circulating tumor necrosis factor level
|
J:200140
|
decreased microglial cell activation
|
J:200140
|
increased susceptibility to Flaviviridae infection
|
J:200140
|
increased susceptibility to Flaviviridae infection induced morbidity/mortality
|
J:200140
|
Sash3tm1Hlz/Sash3tm1Hlz
(B6.129P2-Sash3tm1Hlz)
|
abnormal B cell physiology
|
J:102171
|
abnormal humoral immune response
|
J:102171
|
abnormal inflammatory response
|
J:102171
|
abnormal marginal zone B cell physiology
|
J:102171
|
decreased IgG1 level
|
J:102171
|
decreased IgG2a level
|
J:102171
|
decreased IgG level
|
J:102171
|
decreased IgM level
|
J:102171
|
decreased interferon-gamma secretion
|
J:102171
|
decreased interleukin-2 secretion
|
J:102171
|
decreased interleukin-4 secretion
|
J:102171
|
decreased interleukin-10 secretion
|
J:102171
|
decreased T cell proliferation
|
J:102171
|
decreased tumor necrosis factor secretion
|
J:102171
|
increased length of allograft survival
|
J:102171
|
Satb1tm1Kos/Satb1tm1Kos
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal T cell proliferation
|
J:61085
|
Satb1tm2Kos/Satb1tm2Kos Commd10Tg(Vav1-icre)A2Kio/Commd10+
(involves: C57BL/6 * C57BL/10 * CBA/Ca)
|
increased anti-nuclear antigen antibody level
|
J:252606
|
increased autoantibody level
|
J:252606
|
increased susceptibility to autoimmune disorder
|
J:252606
|
kidney inflammation
|
J:252606
|
pancreas inflammation
|
J:252606
|
salivary gland inflammation
|
J:252606
|
Sbno2tm1.1Aki/Sbno2tm1.1Aki
(involves: 129 * C57BL/6)
|
abnormal osteoclast physiology
|
J:202853
|
Sbsnem1Ham/Sbsnem1Ham
(C57BL/6N-Sbsnem1Ham)
|
decreased interleukin-4 secretion
|
J:296400
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:296400
|
increased susceptibility to type IV hypersensitivity reaction
|
J:296400
|
Scara5tm1Ktry/Scara5tm1Ktry
(B6N.129X1-Scara5tm1Ktry)
|
adipose tissue inflammation
|
J:195536
|
increased anti-nuclear antigen antibody level
|
J:195536
|
interstitial pneumonia
|
J:195536
|
liver inflammation
|
J:195536
|
lung inflammation
|
J:195536
|
skin inflammation
|
J:195536
|
urinary bladder inflammation
|
J:195536
|
Scarb1tm1.1Thh/Scarb1tm1.1Thh
(B6.129X1-Scarb1tm1.1Thh)
|
increased circulating interleukin-6 level
|
J:114663
|
Scarb1tm1Thh/Scarb1tm1Thh Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(B6.Cg-Scarb1tm1Thh Speer6-ps1Tg(Alb-cre)21Mgn)
|
increased circulating interleukin-6 level
|
J:114663
|
Scarf1tm1Tkms/Scarf1tm1Tkms
(involves: C57BL/6)
|
abnormal B cell physiology
|
J:208237
|
abnormal dendritic cell physiology
|
J:208237
|
glomerulonephritis
|
J:208237
|
impaired macrophage phagocytosis
|
J:208237
|
increased anti-histone antibody level
|
J:208237
|
increased anti-nuclear antigen antibody level
|
J:208237
|
increased anti-single stranded DNA antibody level
|
J:208237
|
increased IgG level
|
J:208237
|
increased susceptibility to systemic lupus erythematosus
|
J:208237
|
skin inflammation
|
J:208237
|
Scd1ab-2J/Scd1ab-2J
(DBA/1LacJ-Scd1ab-2J/J)
|
granulomatous inflammation
|
J:62699
|
Scd1flk/Scd1flk
(C57BL/6J-Scd1flk)
|
increased susceptibility to bacterial infection
|
J:100424
|
Scd2swty/Scd2swty
(C57BL/6JSfdAnu-Scd2swty/Anu)
|
blepharitis
|
J:104190
|
Scgb1a1tm1Abm/Scgb1a1+
(involves: 129S1/Sv * 129X1/SvJ)
|
abnormal complement protein level
|
J:57504
|
increased IgA level
|
J:57504
|
Scgb1a1tm1Abm/Scgb1a1tm1Abm
(involves: 129S1/Sv * 129X1/SvJ)
|
abnormal complement protein level
|
J:57504
|
increased IgA level
|
J:57504
|
Scgnem1Ezb/Scgnem1Ezb
(C57BL/6-Scgnem1Ezb)
|
increased susceptibility to colitis induced morbidity/mortality
|
J:285572
|
Scgnem2Ezb/Scgnem2Ezb
(C57BL/6-Scgnem2Ezb)
|
increased susceptibility to colitis induced morbidity/mortality
|
J:285572
|
Scintm1Glog/Scintm1Glog Tg(Acp5-cre)4Rda/0
(either: (involves: 129 * C57BL/6) or (involves: 129 * C57BL/6 * CBA))
|
abnormal osteoclast physiology
|
J:223220
|
Scl2C57BL/6J/Scl2C57BL/6J
(involves: C57BL/6J * DBA/2J)
|
increased susceptibility to parasitic infection
|
J:12046
|
Scn3btm1a(KOMP)Wtsi/Scn3btm1a(KOMP)Wtsi
(C57BL/6N-Scn3btm1a(KOMP)Wtsi/Wtsi)
|
myositis
|
J:232539
|
Scn9atm1Dgen/Scn9atm1Dgen
(either: (involves: 129P2/OlaHsd * BALB/c * C57BL/6) or (involves: 129P2/OlaHsd * C57BL/6 * CD-1))
|
dermatitis
|
J:223425
|
Scp2tm1Kier/Scp2tm1Kier
(involves: 129P2/OlaHsd * C57BL/6NCr)
|
liver inflammation
|
J:124895
|
Sctrtm1Bkcc/Sctrtm1Bkcc
(B6.129S7-Sctrtm1Bkcc)
|
abnormal cytokine secretion
|
J:121376
|
kidney inflammation
|
J:121376
|
Sdc1tm1Cma/Sdc1tm1Cma
(either: (involves: 129S4/SvJae * BALB/c) or (involves: 129S4/SvJae * C57BL/6))
|
decreased susceptibility to bacterial infection
|
J:69845
|
Sdc1tm1Cma/Sdc1tm1Cma
(either: C.Cg-Sdc1tm1Cma or B6.Cg-Sdc1tm1Cma)
|
increased inflammatory response
|
J:80682
|
Sdc1tm1Cma/Sdc1tm1Cma
(B6.Cg-Sdc1tm1Cma)
|
decreased susceptibility to bacterial infection
|
J:104294
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:104294
|
Sdc1tm1Cma/Sdc1tm1Cma
(involves: 129S4/SvJae)
|
decreased IgG1 level
|
J:107378
|
decreased interleukin-10 secretion
|
J:107378
|
decreased interleukin-13 secretion
|
J:107378
|
increased susceptibility to parasitic infection
|
J:107378
|
seb/seb
(Him:OF1)
|
dermatitis
|
J:64455
|
lymph node inflammation
|
J:20987
|
skin inflammation
|
J:8983
|
Sec1em1Cya/Sec1em1Cya
(C57BL/6-Sec1em1Cya)
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:325740
|
Sec23bGt(AD0407)Wtsi/Sec23bGt(AD0407)Wtsi
(B6J.129P2-Sec23bGt(AD0407)Wtsi)
|
pancreas inflammation
|
J:186391
|
Secia1DBA/1J/?
(involves: DBA/1J * FVB/NJ)
|
increased susceptibility to induced arthritis
|
J:123131
|
Secia2DBA/1J/?
(involves: DBA/1J * FVB/NJ)
|
increased susceptibility to induced arthritis
|
J:123131
|
Secia3FVB/NJ/?
(involves: DBA/1J * FVB/NJ)
|
increased susceptibility to induced arthritis
|
J:123131
|
Secia4DBA/1J/?
(involves: DBA/1J * FVB/NJ)
|
increased susceptibility to induced arthritis
|
J:123131
|
Secia5DBA/1J/?
(involves: DBA/1J * FVB/NJ)
|
increased susceptibility to induced arthritis
|
J:123131
|
Secia6DBA/1J/?
(involves: DBA/1J * FVB/NJ)
|
increased susceptibility to induced arthritis
|
J:123131
|
Secia7FVB/NJ/?
(involves: DBA/1J * FVB/NJ)
|
increased susceptibility to induced arthritis
|
J:123131
|
Secia8FVB/NJ/?
(involves: DBA/1J * FVB/NJ)
|
increased susceptibility to induced arthritis
|
J:123131
|
Sectm1aem1Gcfa/Sectm1aem1Gcfa
(C57BL/6-Sectm1aem1Gcfa)
|
abnormal interleukin level
|
J:317204
|
abnormal macrophage physiology
|
J:317204
|
abnormal tumor necrosis factor level
|
J:317204
|
heart inflammation
|
J:317204
|
increased circulating interleukin-1 beta level
|
J:317204
|
increased circulating interleukin-6 level
|
J:317204
|
increased circulating tumor necrosis factor level
|
J:317204
|
increased susceptibility to endotoxin shock
|
J:317204
|
Seletm1Alb/Seletm1Alb
(involves: 129S7/SvEvBrd * C57BL/6J)
|
eye inflammation
|
J:101979
|
increased susceptibility to bacterial infection
|
J:101979
|
Seletm1Dmil/Seletm1Dmil
(involves: 129S4/SvJae * C57BL/6J)
|
abnormal leukocyte adhesion
|
J:113169
|
Seletm1Hyn/Seletm1Hyn Selltm1Hyn/Selltm1Hyn Selptm1Hyn/Selptm1Hyn
(involves: 129S2/SvPas * C57BL/6)
|
impaired eosinophil recruitment
|
J:57973
|
impaired leukocyte tethering or rolling
|
J:57973
|
impaired neutrophil recruitment
|
J:57973
|
Seletm1Hyn/Seletm1Hyn Selptm1Hyn/Selptm1Hyn
(involves: 129S2/SvPas)
|
abnormal cytokine level
|
J:31626
|
impaired leukocyte tethering or rolling
|
J:31626
|
impaired neutrophil recruitment
|
J:31626
|
increased circulating interleukin-3 level
|
J:31626
|
increased susceptibility to bacterial infection
|
J:31626
|
Seletm1Hyn/Seletm1Hyn Selptm1Hyn/Selptm1Hyn
(involves: 129S2/SvPas * C57BL/6)
|
impaired eosinophil recruitment
|
J:57973
|
impaired leukocyte tethering or rolling
|
J:57973
|
impaired neutrophil recruitment
|
J:57973
|
Seletm1Roml/Seletm1Roml
(involves: 129S1/Sv * C57BL/6)
|
abnormal T cell physiology
|
J:113536
|
Seletm1Roml/Seletm1Roml
(involves: 129S1/Sv)
|
abnormal T cell physiology
|
J:113536
|
Seletm2Alb/Seletm2Alb Selltm2Alb/Selltm2Alb Selptm1Bay/Selptm1Bay
(involves: 129S7/SvEvBrd * C57BL/6)
|
abnormal cellular extravasation
|
J:70682
|
impaired leukocyte tethering or rolling
|
J:70682
|
lung inflammation
|
J:70682
|
Seletm2Alb/Seletm2Alb Selptm1Bay/Selptm1Bay
(involves: 129S7/SvEvBrd * C57BL/6J)
|
eye inflammation
|
J:101979
|
increased susceptibility to bacterial infection
|
J:101979
|
Seletm2Alb/Seletm2Alb Selptm1Bay/Selptm1Bay
(involves: 129S7/SvEvBrd * C57BL/6)
|
abnormal cytokine secretion
|
J:70682
|
abnormal neutrophil physiology
|
J:112286
|
decreased acute inflammation
|
J:112286
|
impaired leukocyte tethering or rolling
|
J:70682
|
Seletm2Hyn/Seletm2Hyn
(involves: 129S2/SvPas * C57BL/6)
|
enhanced leukocyte tethering or rolling
|
J:57973
|
impaired neutrophil recruitment
|
J:57973
|
Seletm2Hyn/Seletm2Hyn
(B6.129S2-Seletm2Hyn)
|
abnormal type IV hypersensitivity reaction
|
J:121083
|
Selenoktm1.2Itl/Selenoktm1.2Itl
(involves: BALB/cJ * C57BL/6)
|
abnormal circulating chemokine level
|
J:169169
|
abnormal macrophage physiology
|
J:169169
|
abnormal neutrophil physiology
|
J:169169
|
abnormal T cell physiology
|
J:169169
|
decreased interleukin-6 secretion
|
J:169169
|
decreased T cell proliferation
|
J:169169
|
decreased tumor necrosis factor secretion
|
J:169169
|
impaired neutrophil chemotaxis
|
J:169169
|
increased susceptibility to Flaviviridae infection
|
J:169169
|
increased susceptibility to Flaviviridae infection induced morbidity/mortality
|
J:169169
|
Selenoptm1Rfb/Selenoptm1Rfb
(B6.129-Selenoptm1Rfb)
|
increased susceptibility to parasitic infection
|
J:134536
|
Sellm2Btlr/Sellm2Btlr
(C57BL/6J-Sellm2Btlr)
|
decreased response to antigen
|
J:231806
|
Selltm1.1Rpmc/Selltm1.1Rpmc
(involves: 129S1/Sv * C57BL/6J * FVB/N)
|
abnormal granulocyte physiology
|
J:249558
|
abnormal neutrophil physiology
|
J:249558
|
increased inflammatory response
|
J:249558
|
Selltm1Flv/Sell+
(involves: C57BL/6 * NOD)
|
decreased susceptibility to autoimmune diabetes
|
J:88947
|
pancreas inflammation
|
J:88947
|
Selltm1Flv/Selltm1Flv
(involves: 129S2/SvPas * C57BL/6)
|
abnormal type IV hypersensitivity reaction
|
J:89253
|
Selltm1Flv/Selltm1Flv
(involves: C57BL/6 * NOD)
|
decreased susceptibility to autoimmune disorder
|
J:88947
|
pancreas inflammation
|
J:88947
|
Selltm1Pest/Sell+
(involves: 129S4/SvJae * C57BL/6)
|
abnormal hypersensitivity reaction
|
J:112550
|
impaired leukocyte tethering or rolling
|
J:112550
|
Selltm1Pest/Selltm1Pest
(involves: 129S4/SvJae)
|
abnormal hypersensitivity reaction
|
J:111233
|
abnormal leukocyte adhesion
|
J:111233
|
impaired leukocyte tethering or rolling
|
J:111233
|
increased T cell proliferation
|
J:111233
|
Selltm1Pest/Selltm1Pest
(involves: 129S4/SvJae * C57BL/6)
|
abnormal cell-mediated immunity
|
J:112550
|
abnormal dendritic cell physiology
|
J:112550
|
abnormal hypersensitivity reaction
|
J:112550
|
abnormal leukocyte migration
|
J:112550
|
decreased T cell proliferation
|
J:112550
|
impaired leukocyte tethering or rolling
|
J:112550
|
Selltm1Tft/Selltm1Tft
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal cellular extravasation
|
J:25005
|
abnormal leukocyte migration
|
J:25005
|
impaired leukocyte tethering or rolling
|
J:25005
|
Selltm1Tft/Selltm1Tft
(B6.129-Selltm1Tft)
|
abnormal cellular extravasation
|
J:66107
|
abnormal leukocyte migration
|
J:66107
|
Selltm1Tft/Selltm1Tft
(B6.129P2-Selltm1Tft)
|
abnormal cellular extravasation
|
J:48271
|
abnormal regulatory T cell physiology
|
J:141931
|
impaired leukocyte tethering or rolling
|
J:48271
|
Selltm2.1Tft/Selltm2.1Tft
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal neutrophil physiology
|
J:142184
|
Selltm2Hyn/Selltm2Hyn
(involves: 129S2/SvPas * C57BL/6)
|
impaired leukocyte tethering or rolling
|
J:57973
|
impaired neutrophil recruitment
|
J:57973
|
Selltm2Hyn/Selltm2Hyn
(involves: 129S2/SvPas * BALB/c)
|
impaired leukocyte tethering or rolling
|
J:114317
|
Selltm2Tft/Selltm2.1Tft
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal leukocyte migration
|
J:142184
|
abnormal neutrophil physiology
|
J:142184
|
abnormal regulatory T cell physiology
|
J:141931
|
impaired leukocyte tethering or rolling
|
J:142184
|
Selltm3Hyn/Selltm3Hyn Selptm1Hyn/Selptm1Hyn
(involves: 129S2/SvPas * C57BL/6)
|
impaired eosinophil recruitment
|
J:57973
|
impaired leukocyte tethering or rolling
|
J:57973
|
impaired neutrophil recruitment
|
J:57973
|
Selltm4Hyn/Selltm4Hyn Selptm1Hyn/Selptm1Hyn
(involves: 129S2/SvPas * C57BL/6)
|
impaired leukocyte tethering or rolling
|
J:57973
|
impaired neutrophil recruitment
|
J:57973
|
Selptm1.1Rpmc/Selptm1.1Rpmc
(B6.129S1-Selptm1.1Rpmc)
|
impaired leukocyte tethering or rolling
|
J:230041
|
Selptm1Bay/Selptm1Bay
(involves: 129S7/SvEvBrd * C57BL/6J)
|
abnormal leukocyte migration
|
J:24239
|
eye inflammation
|
J:101979
|
increased susceptibility to bacterial infection
|
J:101979
|
Selptm1Bay/Selptm1Bay
(D1.129S7(B6J)-Selptm1Bay)
|
abnormal cytokine secretion
|
J:57086
|
increased IgG level
|
J:57086
|
increased susceptibility to induced arthritis
|
J:57086
|
Selptm1Bay/Selptm1Bay
(B6.129S7-Selptm1Bay/J)
|
abnormal T cell physiology
|
J:113536
|
Selptm1Bay/Selptm1Bay
(either: B6.129S7-Selptm1Bay or (involves: 129S7/SvEvBrd * C57BL/6))
|
abnormal leukocyte tethering or rolling
|
J:31374
|
Selptm1Bay/Selptm1Bay
(B6.129S7-Selptm1Bay)
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:121083
|
Selptm1Hyn/Selptm1Hyn
(involves: 129S2/SvPas * C57BL/6J)
|
impaired leukocyte tethering or rolling
|
J:77329
|
impaired neutrophil recruitment
|
J:77329
|
Selptm1Hyn/Selptm1Hyn
(involves: 129S2/SvPas)
|
impaired leukocyte tethering or rolling
|
J:29814
|
impaired macrophage chemotaxis
|
J:29814
|
Selptm1Hyn/Selptm1Hyn
(involves: 129S2/SvPas * C57BL/6)
|
impaired eosinophil recruitment
|
J:57973
|
impaired leukocyte tethering or rolling
|
J:57973
|
impaired neutrophil recruitment
|
J:57973
|
Selptm2Hyn/Selptm2Hyn
(involves: 129S2/SvPas * C57BL/6J)
|
impaired leukocyte tethering or rolling
|
J:51068
|
impaired neutrophil recruitment
|
J:51068
|
Selplgtm1Fur/Selplgtm1Fur
(involves: 129/Sv * C57BL/6J * SJL)
|
impaired leukocyte tethering or rolling
|
J:75412
|
impaired neutrophil chemotaxis
|
J:75412
|
Selplgtm1Rpmc/Selplgtm1Rpmc
(involves: 129S1/Sv * C57BL/6J)
|
abnormal leukocyte adhesion
|
J:75829
|
impaired leukocyte tethering or rolling
|
J:75829,
J:138731
|
Selplgtm1Rpmc/Selplgtm1Rpmc
(involves: 129S1/Sv)
|
abnormal chemokine secretion
|
J:115682
|
Selplgtm2Rpmc/Selplgtm2Rpmc
(B6.Cg-Selplgtm2Rpmc)
|
impaired leukocyte tethering or rolling
|
J:138731
|
Sema3atm1.1Tyag/Sema3atm1.1Tyag
(involves: C57BL/6 * CBA)
|
abnormal dendritic cell physiology
|
J:161856
|
abnormal T cell physiology
|
J:161856
|
Sema3ftm1.2Ddg/Sema3ftm1.2Ddg
(Not Specified)
|
abnormal lymphatic system physiology
|
J:226501
|
Sema4atm1Kik/Sema4atm1Kik
(either: B6.Cg-Sema4atm1Kik or C.Cg-Sema4atm1Kik)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:97027
|
abnormal cytokine secretion
|
J:97027
|
abnormal dendritic cell antigen presentation
|
J:97027
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:97027
|
Sema4btm1Akum/Sema4btm1Akum
(either: B6.Cg-Sema4btm1Akum or C.Cg-Sema4btm1Akum)
|
abnormal immune system physiology
|
J:169386
|
increased IgE level
|
J:169386
|
increased IgG1 level
|
J:169386
|
Sema4dtm1Kik/Sema4dtm1Kik
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal immunoglobulin level
|
J:66033
|
decreased B cell proliferation
|
J:66033
|
Senp1tm1Wami/Senp1tm1Wami Tg(Fabp4-cre)#Abel/0
(B6.Cg-Senp1tm1Wami Tg(Fabp4-cre)#Abel)
|
abnormal chemokine level
|
J:228009
|
abnormal circulating cytokine level
|
J:228009
|
abnormal cytokine level
|
J:228009
|
increased anti-insulin autoantibody level
|
J:228009
|
increased circulating C-reactive protein level
|
J:228009
|
increased circulating interleukin-1 beta level
|
J:228009
|
increased circulating interleukin-6 level
|
J:228009
|
increased circulating tumor necrosis factor level
|
J:228009
|
increased susceptibility to autoimmune diabetes
|
J:228009
|
myocarditis
|
J:228009
|
pancreas inflammation
|
J:228009
|
Septin9tm2.1Emfu/Septin9tm2.1Emfu Tg(Lck-cre)548Jxm/0
(involves: C57BL/6 * CBA)
|
decreased T cell proliferation
|
J:205027
|
Serpina1em#Chmu/Serpina1em#Chmu
(involves: C57BL/6J)
|
increased susceptibility to endotoxin shock
|
J:259615
|
respiratory system inflammation
|
J:259615
|
Serpina3cem1Smoc/Serpina3cem1Smoc
(C57BL/6-Serpina3cem1Smoc)
|
white adipose tissue inflammation
|
J:343846
|
Serpina3gtm1.1Arp/Serpina3gtm1.1Arp
(involves: C57BL/6)
|
abnormal response to infection
|
J:189782
|
decreased T cell proliferation
|
J:189782
|
Serpina3gtm1.1Arp/Serpina3gtm1.1Arp Tg(TcrLCMV)#Sdz/0
(involves: C57BL/6 * DBA/2)
|
decreased T cell proliferation
|
J:189782
|
Serpina6tm1Tew/Serpina6tm1Tew
(involves: 129/SvEmcTer * C57BL/6N)
|
abnormal circulating cytokine level
|
J:112974
|
abnormal cytokine level
|
J:112974
|
increased susceptibility to endotoxin shock
|
J:112974
|
Serpinb1atm1.1Cben/Serpinb1atm1.1Cben
(129S6/SvEvTac-Serpinb1atm1.1Cben)
|
abnormal chemokine secretion
|
J:125918
|
abnormal circulating cytokine level
|
J:125918
|
abnormal neutrophil physiology
|
J:125918
|
impaired neutrophil chemotaxis
|
J:125918
|
increased interleukin-1 beta secretion
|
J:125918
|
increased susceptibility to bacterial infection
|
J:125918
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:125918
|
increased tumor necrosis factor secretion
|
J:125918
|
lung inflammation
|
J:125918
|
sepsis
|
J:125918
|
Serpinb3atm1Gsil/Serpinb3atm1Gsil
(C.129-Serpinb3atm1Gsil)
|
decreased susceptibility to type I hypersensitivity reaction
|
J:189949
|
Serpinb9tm1.1Pib/Serpinb9tm1.1Pib
(involves: BALB/cJ * C57BL/6J)
|
abnormal dendritic cell antigen presentation
|
J:252016
|
abnormal immune system physiology
|
J:252016
|
decreased cytotoxic T cell apoptosis
|
J:252016
|
Serpinb9tm1Arp/Serpinb9tm1Arp
(involves: C57BL/6)
|
abnormal cytotoxic T cell physiology
|
J:113349
|
decreased cytotoxic T cell cytolysis
|
J:113349
|
increased susceptibility to Riboviria infection
|
J:113349
|
Serpinb9tm1Arp/Serpinb9tm1Arp Tg(TcrLCMV)327Sdz/0
(involves: C57BL/6)
|
abnormal response to transplant
|
J:113349
|
Serpinc1tm1Dwr/Serpinc1tm1Dwr
(involves: 129S1/Sv * 129X1/SvJ)
|
liver inflammation
|
J:115658
|
Serpine1tm1.1Vlp/Serpine1tm1.1Vlp
(involves: 129 * C57BL/6)
|
decreased susceptibility to endotoxin shock
|
J:229191
|
Serpine1tm1Mlg/Serpine1tm1Mlg
(involves: 129S2/SvPas * C57BL/6)
|
abnormal acute inflammation
|
J:133227
|
abnormal interleukin level
|
J:133227
|
decreased circulating interleukin-6 level
|
J:133227
|
glomerulonephritis
|
J:85989
|
increased acute inflammation
|
J:133227
|
respiratory system inflammation
|
J:66093
|
Serpine1tm1Mlg/Serpine1tm1Mlg
(B6.129S2-Serpine1tm1Mlg/J)
|
heart inflammation
|
J:101486
|
increased susceptibility to bacterial infection
|
J:124327
|
increased susceptibility to Coronaviridae infection
|
J:288556
|
increased susceptibility to Coronaviridae infection induced morbidity/mortality
|
J:288556
|
Serpine1tm1Mlg/Serpine1tm1Mlg
(involves: 129S2/SvPas)
|
decreased susceptibility to endotoxin shock
|
J:229191
|
Serpine2tm1Dmn/Serpine2tm1Dmn
(B6.129P2-Serpine2tm1Dmn)
|
abnormal acute phase protein level
|
J:121263
|
Sertad2Gt(OST98734)Lex/Sertad2Gt(OST98734)Lex
(B6.129S5-Sertad2Gt(OST98734)Lex)
|
abnormal macrophage physiology
|
J:194928
|
Sertad3em1Bcgen/Sertad3em1Bcgen
(involves: C57BL/6N)
|
increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality
|
J:300469
|
Ses1aC57BL/6J/Ses1aC57BL/6J
(involves: 129 * C57BL/6J)
|
decreased susceptibility to bacterial infection
|
J:81412
|
Ses1aC57BL/6J/Ses1aC57BL/6J
(involves: 129S6/SvEvTac * C57BL/6J)
|
decreased susceptibility to bacterial infection
|
J:100367
|
Ses1aC57BL/6J/Ses1aC57BL/6J
(129.B6-Ses1aC57BL/6J)
|
decreased susceptibility to bacterial infection
|
J:100367
|
Ses1aC57BL/6J/Ses1aC57BL/6J Ses4C57BL/6J/Ses4C57BL/6J
(involves: 129S6/SvEvTac * C57BL/6J)
|
decreased susceptibility to bacterial infection
|
J:100367
|
Ses1aC57BL/6J/Ses1aC57BL/6J Ses5C57BL/6J/Ses5C57BL/6J
(involves: 129S6/SvEvTac * C57BL/6J)
|
decreased susceptibility to bacterial infection
|
J:100367
|
Ses1aC57BL/6J/Ses1aC57BL/6J Ses6C57BL/6J/Ses6C57BL/6J
(involves: 129S6/SvEvTac * C57BL/6J)
|
decreased susceptibility to bacterial infection
|
J:100367
|
Ses1bC57BL/6J/Ses1bC57BL/6J
(involves: 129S6/SvEvTac * C57BL/6J)
|
decreased susceptibility to bacterial infection
|
J:100367
|
Ses1bC57BL/6J/Ses1bC57BL/6J
(129.B6-Ses1bC57BL/6J)
|
decreased susceptibility to bacterial infection
|
J:100367
|
Ses2C57BL/6J/Ses2C57BL/6J
(involves: 129 * C57BL/6J)
|
decreased susceptibility to bacterial infection
|
J:81412
|
Ses3C57BL/6J/Ses3C57BL/6J
(involves: 129 * C57BL/6J)
|
decreased susceptibility to bacterial infection
|
J:81412
|
Ses7129S6/SvEvTac/Ses7C57BL/6J Ses8C57BL/6J/Ses8C57BL/6J
(involves: 129S6/SvEvTac * C57BL/6J)
|
decreased susceptibility to bacterial infection
|
J:100367
|
Ses7C57BL/6J/Ses7C57BL/6J Ses8C57BL/6J/Ses8C57BL/6J
(involves: 129S6/SvEvTac * C57BL/6J)
|
decreased susceptibility to bacterial infection
|
J:100367
|
Ses9C57BL/6J/Ses9C57BL/6J Ses10C57BL/6J/Ses10C57BL/6J
(involves: 129S6/SvEvTac * C57BL/6J)
|
decreased susceptibility to bacterial infection
|
J:100367
|
Sesn1tm1a(EUCOMM)Wtsi/Sesn1tm1a(EUCOMM)Wtsi
(involves: C57BL/6N)
|
abnormal class switch recombination
|
J:240602
|
increased immunoglobulin level
|
J:240602
|
increased interferon-gamma secretion
|
J:240602
|
increased interleukin-2 secretion
|
J:240602
|
increased T cell proliferation
|
J:240602
|
Setd3tm1.1(NCOM)Mfgc/Setd3tm1.1(NCOM)Mfgc
(involves: C57BL/6NCrl)
|
decreased susceptibility to Riboviria infection
|
J:293475
|
Setd4tm1b(KOMP)Wtsi/Setd4tm1b(KOMP)Wtsi
(involves: C57BL/6N)
|
decreased macrophage cytokine production
|
J:304151
|
Setd5tm1a(EUCOMM)Wtsi/Setd5+
(C57BL/6N-Setd5tm1a(EUCOMM)Wtsi/Wtsi)
|
blood in lymph vessels
|
J:239583
|
Setd7tm1Frga/Setd7+
(involves: 129 * C57BL/6)
|
abnormal spleen physiology
|
J:136558
|
Setd7tm1Frga/Setd7tm1Frga
(involves: 129 * C57BL/6)
|
abnormal spleen physiology
|
J:136558
|
Setdb2tm1Desr/Setdb2tm1Desr
(B6.Cg-Setdb2tm1Desr)
|
abnormal response to infection
|
J:222611
|
increased susceptibility to bacterial infection
|
J:222611
|
Sfntm1Mak/Sfntm1Mak
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased IgG level
|
J:168328
|
decreased IgM level
|
J:168328
|
increased B cell apoptosis
|
J:168328
|
increased B cell proliferation
|
J:168328
|
increased susceptibility to Riboviria infection
|
J:168328
|
increased susceptibility to Riboviria infection induced morbidity/mortality
|
J:168328
|
Sftpa1tm1Haw/Sftpa1tm1Haw
(involves: 129/Sv * C57BL/6 * CD-1)
|
abnormal cytokine level
|
J:86024
|
abnormal inflammatory response
|
J:85432
|
abnormal interferon level
|
J:86024
|
abnormal interleukin level
|
J:86024
|
increased susceptibility to Orthomyxoviridae infection
|
J:86024
|
Sftpa1tm1Kor/Sftpa1tm1Kor
(involves: 129P2/OlaHsd * NIH Black Swiss)
|
increased susceptibility to bacterial infection
|
J:120552,
J:110382
|
lung inflammation
|
J:110382
|
Sftpa1tm1Kor/Sftpa1tm1Kor
(involves: 129P2/OlaHsd)
|
lung inflammation
|
J:107841
|
Sftpa1tm1Kor/Sftpa1tm1Kor
(involves: 129P2/OlaHsd * Black Swiss * C3H/HeN)
|
increased susceptibility to bacterial infection
|
J:130297
|
Sftpctm1Swg/Sftpctm1Swg
(either: 129 or (involves: 129 * Black Swiss))
|
conjunctivitis
|
J:82925
|
Sftpdtm1Haw/Sftpdtm1Haw
(involves: C57BL/6J * CD-1)
|
abnormal macrophage physiology
|
J:98220
|
Sftpdtm1Jhf/Sftpdtm1Jhf
(involves: 129P2/OlaHsd * Black Swiss)
|
abnormal chemokine level
|
J:72681
|
abnormal cytokine level
|
J:72681,
J:62282
|
abnormal macrophage physiology
|
J:62282
|
abnormal neutrophil physiology
|
J:72681
|
increased susceptibility to Orthomyxoviridae infection
|
J:72681
|
lung inflammation
|
J:62282,
J:50436
|
Sgcatm1Kcam/Sgcatm1Kcam
(involves: 129S1/Sv * 129X1/SvJ)
|
heart inflammation
|
J:177563
|
Sgcatm1Kcam/Sgcatm1Kcam Sgcetm1Vinni/Sgcetm1Vinni
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6J)
|
heart inflammation
|
J:177563
|
Sgcbtm1Oza/Sgcbtm1Oza
(involves: 129S4/SvJae * C57BL/6J)
|
myositis
|
J:57590
|
Sgk3fz-ica/Sgk3fz-ica
(Swiss albino)
|
abnormal inflammatory response
|
J:107373
|
sgl/sgl
(involves: C3H * C57BL/6J)
|
conjunctivitis
|
J:56826
|
Sgms1tm1Jia/Sgms1tm1Jia
(involves: C57BL/6)
|
abnormal cytokine level
|
J:201497
|
abnormal cytokine secretion
|
J:201497
|
decreased circulating interleukin-6 level
|
J:201497
|
decreased circulating tumor necrosis factor level
|
J:201497
|
decreased interleukin-6 secretion
|
J:201497
|
decreased tumor necrosis factor secretion
|
J:201497
|
Sgms2tm1Jia/Sgms2tm1Jia
(involves: 129 * C57BL/6)
|
abnormal macrophage physiology
|
J:162192,
J:162226
|
Sgp5NZB/?
(involves: C57BL/6 * NZB * SB/Le)
|
abnormal immune serum protein physiology
|
J:95829
|
glomerulonephritis
|
J:95829
|
increased susceptibility to type III hypersensitivity reaction
|
J:95829
|
Sgp5NZB/Sgp5NZB
(C57BL/6-Nba2 Yaa)
|
abnormal immune serum protein physiology
|
J:95829
|
Sgpl1Gt(ROSA)78Sor/Sgpl1Gt(ROSA)78Sor
(involves: 129S4/SvJaeSor)
|
kidney inflammation
|
J:117491
|
Sgpl1Gt(ROSA)78Sor/Sgpl1Gt(ROSA)78Sor
(involves: 129S4/SvJaeSor * C57BL/6)
|
abnormal immune system physiology
|
J:187619
|
abnormal leukocyte migration
|
J:187619
|
abnormal T cell physiology
|
J:187619
|
Sh2b2tm1Yeb/Sh2b2tm1Yeb
(involves: C57BL/6)
|
increased IgG3 level
|
J:88527
|
Sh2d1atm1.1Knic/Y Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+ Ndor1Tg(UBC-cre/ERT2)1Ejb/0
(involves: 129S/SvEv * 129X1/SvJ * C57BL/6)
|
abnormal NK T cell physiology
|
J:196692
|
decreased circulating interleukin-4 level
|
J:196692
|
decreased interferon-gamma secretion
|
J:196692
|
Sh2d1atm1.1Knic/Sh2d1atm1.1Knic Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+ Ndor1Tg(UBC-cre/ERT2)1Ejb/0
(involves: 129S/SvEv * 129X1/SvJ * C57BL/6)
|
abnormal NK T cell physiology
|
J:196692
|
decreased circulating interleukin-4 level
|
J:196692
|
decreased interferon-gamma secretion
|
J:196692
|
Sh2d1atm1Cpt/Y
(involves: 129S4/SvJae * C57BL/6)
|
abnormal cytokine secretion
|
J:97756
|
abnormal germinal center B cell physiology
|
J:189126
|
abnormal humoral immune response
|
J:189126
|
abnormal immunoglobulin level
|
J:189126
|
abnormal NK T cell physiology
|
J:189126
|
increased susceptibility to Riboviria infection
|
J:97756
|
increased T cell proliferation
|
J:97756
|
Sh2d1atm1Cpt/Y
(involves: 129S4/SvJae * BALB/c)
|
abnormal cytokine secretion
|
J:97756
|
decreased IgE level
|
J:97756
|
decreased IgG level
|
J:189126
|
decreased susceptibility to parasitic infection
|
J:97756
|
Sh2d1atm1Cpt/Y Tcra-Jtm1Tgi/Tcra-Jtm1Tgi
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * BALB/c)
|
decreased IgG level
|
J:189126
|
Sh2d1atm1Cpt/Sh2d1a+
(involves: 129S4/SvJae * C57BL/6)
|
abnormal cytokine secretion
|
J:97756
|
increased T cell proliferation
|
J:97756
|
Sh2d1atm1Cpt/Sh2d1atm1Cpt
(B6.129S4-Sh2d1atm1Cpt)
|
abnormal humoral immune response
|
J:97388
|
decreased IgG1 level
|
J:97388
|
decreased IgM level
|
J:97388
|
increased IgG2a level
|
J:97388
|
Sh2d1atm1Cpt/Sh2d1atm1Cpt
(C.129S4-Sh2d1atm1Cpt)
|
decreased IgG level
|
J:97388
|
decreased IgM level
|
J:97388
|
Sh2d1atm1Cpt/Sh2d1atm1Cpt
(involves: 129S4/SvJae * C57BL/6)
|
abnormal cytokine secretion
|
J:97756
|
abnormal germinal center B cell physiology
|
J:189126
|
abnormal humoral immune response
|
J:189126
|
abnormal immunoglobulin level
|
J:189126
|
abnormal NK T cell physiology
|
J:189126
|
increased susceptibility to Riboviria infection
|
J:97756
|
increased T cell proliferation
|
J:97756
|
Sh2d1atm1Cpt/Sh2d1atm1Cpt
(involves: 129S4/SvJae * BALB/c)
|
abnormal cytokine secretion
|
J:97756
|
decreased IgE level
|
J:97756
|
decreased IgG level
|
J:189126
|
decreased susceptibility to parasitic infection
|
J:97756
|
Sh2d1atm1Cpt/Sh2d1atm1Cpt
(involves: 129S4/SvJae)
|
impaired natural killer cell mediated cytotoxicity
|
J:166054
|
Sh2d1atm1Cpt/Sh2d1atm1Cpt Sh2d1b1/Sh2d1b2tm1.1Cpt/Sh2d1b1/Sh2d1b2tm1.1Cpt
(involves: 129S4/SvJae * BALB/cJ)
|
impaired natural killer cell mediated cytotoxicity
|
J:166054
|
Sh2d1atm1Cpt/Sh2d1atm1Cpt Sh2d1b1/Sh2d1b2tm1.1Cpt/Sh2d1b1/Sh2d1b2tm1.1Cpt
(involves: 129S4/SvJae * BALB/cJ)
|
impaired natural killer cell mediated cytotoxicity
|
J:166054
|
Sh2d1atm1Cpt/Sh2d1atm1Cpt Tcra-Jtm1Tgi/Tcra-Jtm1Tgi
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * BALB/c)
|
decreased IgG level
|
J:189126
|
Sh2d1atm1Lyin/Y
(involves: 129S2/SvPas * C57BL/6)
|
abnormal immune system physiology
|
J:97346
|
chronic inflammation
|
J:97346
|
decreased IgE level
|
J:97346
|
decreased IgG level
|
J:97346
|
decreased immunoglobulin level
|
J:97346
|
Sh2d1atm1Lyin/Sh2d1atm1Lyin
(involves: 129S2/SvPas * C57BL/6)
|
abnormal immune system physiology
|
J:97346
|
chronic inflammation
|
J:97346
|
decreased IgE level
|
J:97346
|
decreased IgG level
|
J:97346
|
decreased immunoglobulin level
|
J:97346
|
Sh2d1atm1Lyin/Sh2d1atm1Lyin
(involves: 129S1/Sv * 129X1/SvJ)
|
impaired natural killer cell mediated cytotoxicity
|
J:110195
|
Sh2d1atm1Pls/Y
(involves: 129S6/SvEvTac)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:157915
|
abnormal cytotoxic T cell physiology
|
J:187431
|
decreased IgG level
|
J:157915
|
decreased interleukin-21 secretion
|
J:157915
|
Sh2d1atm1Pls/Sh2d1atm1Pls
(either: 129S6/SvEvTac or (involves: 129S6/SvEvTac * C57BL/6))
|
decreased IgE level
|
J:70032
|
increased susceptibility to infection
|
J:70032
|
increased susceptibility to parasitic infection
|
J:70032
|
increased susceptibility to Riboviria infection
|
J:70032
|
increased T cell proliferation
|
J:70032
|
Sh2d1atm1Pls/Sh2d1atm1Pls
(involves: BALB/c)
|
decreased susceptibility to parasitic infection
|
J:90484
|
Sh2d1atm1Pls/Sh2d1atm1Pls
(B6.129S6-Sh2d1atm1Pls)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:93886
|
abnormal NK cell physiology
|
J:187430
|
decreased IgE level
|
J:93886
|
decreased interferon-gamma secretion
|
J:187430
|
Sh2d1atm1Pls/Sh2d1atm1Pls
(involves: 129S6/SvEvTac)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:157915
|
abnormal cytotoxic T cell physiology
|
J:187431
|
decreased IgG level
|
J:157915
|
decreased interleukin-21 secretion
|
J:157915
|
Sh2d1atm1Pls/Sh2d1atm1Pls Sh2d1b1tm3Vei/Sh2d1b1tm3Vei
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal NK cell physiology
|
J:187430
|
Sh2d1atm1Pls/Sh2d1atm1Pls Tg(DO11.10)10Dlo/Tg(DO11.10)10Dlo
(involves: BALB/c * C3H * C57BL/6)
|
abnormal cytokine secretion
|
J:90484
|
Sh2d1atm1Pls/Sh2d1atm1Pls Tg(TcraTcrb)425Cbn/?
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:157915
|
Sh2d1atm1Pls/Sh2d1atm1Pls Tg(TcraTcrb)1100Mjb/0
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal cytotoxic T cell physiology
|
J:187431
|
decreased cytotoxic T cell cytolysis
|
J:187431
|
decreased interferon-gamma secretion
|
J:187431
|
Sh2d1atm1Vei/Sh2d1atm1Vei
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:93886
|
abnormal memory T cell physiology
|
J:93886
|
decreased IgE level
|
J:93886
|
Sh2d1atm1Vei/Sh2d1atm1Vei
(B6.129-Sh2d1atm1Vei)
|
abnormal NK cell physiology
|
J:187430
|
decreased interferon-gamma secretion
|
J:187430
|
Sh2d1atm1Vei/Sh2d1atm1Vei Sh2d1b1tm3Vei/Sh2d1b1tm3Vei
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal NK cell physiology
|
J:187430
|
Sh2d1atm2.1Cpt/Y Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
(involves: C57BL/6 * C57BL/6NTac)
|
abnormal germinal center B cell physiology
|
J:189126
|
abnormal humoral immune response
|
J:189126
|
decreased IgG level
|
J:189126
|
decreased IgM level
|
J:189126
|
Sh2d1atm2.1Cpt/Sh2d1atm2.1Cpt Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
(involves: C57BL/6 * C57BL/6NTac)
|
abnormal germinal center B cell physiology
|
J:189126
|
abnormal humoral immune response
|
J:189126
|
decreased IgG level
|
J:189126
|
decreased IgM level
|
J:189126
|
Sh2d1atm2.1Vei/Sh2d1atm2.1Vei
(involves: C57BL/6)
|
decreased IgE level
|
J:131618
|
decreased IgG1 level
|
J:131618
|
decreased IgG2a level
|
J:131618
|
decreased IgG2b level
|
J:131618
|
decreased IgG3 level
|
J:131618
|
decreased IgM level
|
J:131618
|
Sh2d1atm2Vei/Sh2d1atm2Vei Tg(Cd4-cre)1Cwi/0
(involves: C57BL/6 * DBA/2)
|
decreased IgE level
|
J:131618
|
decreased IgG1 level
|
J:131618
|
decreased IgG2a level
|
J:131618
|
decreased IgG2b level
|
J:131618
|
decreased IgG3 level
|
J:131618
|
decreased IgM level
|
J:131618
|
Sh2d1atm2Vei/Sh2d1atm2Vei Tg(Lck-cre)1Cwi/0
(involves: C57BL/6)
|
decreased IgE level
|
J:131618
|
decreased IgG1 level
|
J:131618
|
decreased IgG2a level
|
J:131618
|
decreased IgG2b level
|
J:131618
|
decreased IgG3 level
|
J:131618
|
decreased IgM level
|
J:131618
|
Sh2d1b1/Sh2d1b2tm1.1Cpt/Sh2d1b1/Sh2d1b2tm1.1Cpt
(involves: BALB/cJ)
|
decreased interferon-gamma secretion
|
J:166054
|
impaired natural killer cell mediated cytotoxicity
|
J:166054
|
Sh2d1b1/Sh2d1b2tm1.1Cpt/Sh2d1b1/Sh2d1b2tm1.1Cpt
(involves: BALB/cJ)
|
decreased interferon-gamma secretion
|
J:166054
|
impaired natural killer cell mediated cytotoxicity
|
J:166054
|
Sh2d1b1tm1.1Cpt/Sh2d1b1tm1.1Cpt
(involves: BALB/cJ * C57BL/6)
|
impaired natural killer cell mediated cytotoxicity
|
J:166054
|
Sh2d1b1tm1Vei/Sh2d1b1tm1Vei
(involves: 129S1/Sv * 129X1/SvJ)
|
increased interferon-gamma secretion
|
J:110195
|
increased natural killer cell mediated cytotoxicity
|
J:110195
|
Sh2d1b1tm2Vei/Sh2d1b1tm2Vei Sh2d1b2tm1Vei/Sh2d1b2tm1Vei
(involves: 129S1/Sv * 129X1/SvJ)
|
impaired natural killer cell mediated cytotoxicity
|
J:145969
|
Sh2d1b1tm3Vei/Sh2d1b1tm3Vei
(involves: C57BL/6)
|
abnormal NK cell physiology
|
J:187430
|
Sh2d1b2tm1.1Cpt/Sh2d1b2tm1.1Cpt
(involves: BALB/cJ * C57BL/6)
|
impaired natural killer cell mediated cytotoxicity
|
J:166054
|
Sh2d1b2tm1Vei/Sh2d1b2tm1Vei
(involves: 129S1/Sv * 129X1/SvJ)
|
impaired natural killer cell mediated cytotoxicity
|
J:145969
|
increased natural killer cell mediated cytotoxicity
|
J:110195
|
Sh2d2atm1Jbs/Sh2d2atm1Jbs
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
decreased interferon-gamma secretion
|
J:64938
|
decreased interleukin-2 secretion
|
J:64938
|
decreased T cell proliferation
|
J:64938
|
increased interleukin-4 secretion
|
J:64938
|
Sh2d3ctm1Lex/Sh2d3ctm1Lex
(involves: 129S5/SvEvBrd * C57BL/6)
|
abnormal B cell physiology
|
J:161448
|
abnormal humoral immune response
|
J:161448
|
abnormal leukocyte migration
|
J:161448
|
abnormal marginal zone B cell physiology
|
J:161448
|
decreased IgG1 level
|
J:161448
|
decreased IgG2b level
|
J:161448
|
decreased IgG3 level
|
J:161448
|
decreased IgM level
|
J:161448
|
decreased interleukin-6 secretion
|
J:161448
|
Sh3bp2tm1.1Ics/Sh3bp2+
(involves: 129S2/SvPas * C57BL/6)
|
abnormal circulating cytokine level
|
J:221901
|
abnormal macrophage physiology
|
J:221901
|
increased susceptibility to bacterial infection
|
J:221901
|
increased tumor necrosis factor secretion
|
J:221901
|
Sh3bp2tm1.1Ics/Sh3bp2tm1.1Ics
(involves: 129S2/SvPas * C57BL/6)
|
abnormal circulating cytokine level
|
J:221901
|
increased circulating interleukin-6 level
|
J:221901
|
increased circulating interleukin-12 level
|
J:221901
|
increased circulating tumor necrosis factor level
|
J:221901
|
increased inflammatory response
|
J:221901
|
increased tumor necrosis factor secretion
|
J:221901
|
Sh3bp2tm1Bjro/Sh3bp2+
(involves: 129S4/SvJae * BALB/cJ * C57BL/6J)
|
abnormal osteoclast physiology
|
J:117880
|
Sh3bp2tm1Bjro/Sh3bp2tm1Bjro
(involves: 129S4/SvJae * BALB/cJ * C57BL/6J)
|
abnormal macrophage physiology
|
J:117880
|
abnormal osteoclast physiology
|
J:117880
|
blepharitis
|
J:117880
|
dermatitis
|
J:117880
|
increased circulating tumor necrosis factor level
|
J:117880
|
increased inflammatory response
|
J:117880
|
joint inflammation
|
J:117880
|
liver inflammation
|
J:117880
|
lung inflammation
|
J:117880
|
myositis
|
J:117880
|
osteomyelitis
|
J:117880
|
spinal cord inflammation
|
J:117880
|
stomach inflammation
|
J:117880
|
Sh3bp2tm1Geha/Sh3bp2tm1Geha
(Not Specified)
|
abnormal B cell physiology
|
J:110319
|
decreased B cell proliferation
|
J:110319
|
Sh3bp2tm1Rtpl/Sh3bp2tm1Rtpl
(B6.129P2-Sh3bp2tm1Rtpl)
|
abnormal marginal zone B cell physiology
|
J:121380
|
decreased B cell proliferation
|
J:121380
|
decreased IgA level
|
J:121380
|
decreased IgG1 level
|
J:121380
|
decreased IgG3 level
|
J:121380
|
decreased IgM level
|
J:121380
|
decreased immunoglobulin level
|
J:121380
|
increased B cell apoptosis
|
J:121380
|
Sh3bp2tm1Rtpl/Sh3bp2tm1Rtpl
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal circulating cytokine level
|
J:221901
|
abnormal interleukin-6 secretion
|
J:221901
|
abnormal macrophage physiology
|
J:221901
|
decreased tumor necrosis factor secretion
|
J:221901
|
impaired macrophage phagocytosis
|
J:221901
|
Sh3glb2Gt(OST224737)Lex/Sh3glb2Gt(OST224737)Lex
(B6.129S5-Sh3glb2Gt(OST224737)Lex)
|
abnormal response to infection
|
J:246421
|
Sh3kbp1tm1Kuro/Sh3kbp1tm1Kuro Cd79atm1(cre)Reth/Cd79a+
(involves: BALB/c * C57BL/6 * NZB)
|
abnormal B cell physiology
|
J:176805
|
abnormal humoral immune response
|
J:176805
|
Sh3pxd2atm1b(EUCOMM)Wtsi/Sh3pxd2atm1b(EUCOMM)Wtsi
(C57BL/6N-Sh3pxd2atm1b(EUCOMM)Wtsi/Wtsi)
|
blood in lymph vessels
|
J:239583
|
Sh3pxd2bnee/Sh3pxd2bnee
(B10.Cg-H2h4 Sh3pxd2bnee/GrsrJ)
|
eye inflammation
|
J:262132
|
hypopyon
|
J:262132
|
increased susceptibility to otitis media
|
J:153369
|
Sh3yl1tm1Syb/Sh3yl1tm1Syb
(involves: C57BL/6N)
|
decreased interleukin-1 beta secretion
|
J:298830
|
decreased susceptibility to endotoxin shock
|
J:298830
|
decreased tumor necrosis factor secretion
|
J:298830
|
Sharpincpdm-Dem/Sharpincpdm-Dem
(CBy.OcB3-Sharpincpdm-Dem)
|
dermatitis
|
J:121810
|
skin inflammation
|
J:121810
|
Sharpincpdm/Sharpincpdm
(C57BL/KaLawRij-Sharpincpdm)
|
abnormal humoral immune response
|
J:53575
|
decreased IgA level
|
J:53575
|
decreased IgE level
|
J:31745,
J:53575
|
decreased IgG level
|
J:53575
|
decreased immunoglobulin level
|
J:53575
|
dermatitis
|
J:14539
|
esophageal inflammation
|
J:31745
|
folliculitis
|
J:31745
|
increased IgM level
|
J:53575
|
joint inflammation
|
J:14539
|
lung inflammation
|
J:31745
|
lymph node inflammation
|
J:31745
|
stomach inflammation
|
J:31745
|
Sharpincpdm/Sharpincpdm
(involves: C57BL/KaLawRij * FVB/NJ)
|
skin inflammation
|
J:121810
|
Shcbp1tm1c(EUCOMM)Wtsi/Shcbp1tm1c(EUCOMM)Wtsi Tg(Lck-cre)1Cwi/?
(involves: C57BL/6 * DBA/2)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:212898
|
Shcbp1tm1d(EUCOMM)Wtsi/Shcbp1tm1d(EUCOMM)Wtsi
(involves: C57BL/6N * FVB/N)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:212898
|
Shld1em1Nus/Shld1em1Nus
(involves: C57BL/6NCrl)
|
abnormal class switch recombination
|
J:307190
|
SialsMRL/MpJ/SialsMRL/MpJ
(involves: C3H/HeJ * MRL/MpJ)
|
salivary gland inflammation
|
J:66636
|
Sidt2tm1.1Hzha/Sidt2tm1.1Hzha
(involves: 129S6/SvEvTac * C57BL/6J)
|
liver inflammation
|
J:236042
|
Sigirrtm1Lix/Sigirrtm1Lix
(involves: 129S6/SvEvTac * BALB/c)
|
abnormal chemokine secretion
|
J:85151
|
abnormal splenocyte proliferation
|
J:85151
|
increased inflammatory response
|
J:85151
|
increased susceptibility to endotoxin shock
|
J:85151
|
Sigirrtm1Mant/Sigirrtm1Mant
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
|
abnormal chemokine secretion
|
J:88907
|
abnormal dendritic cell physiology
|
J:88907
|
abnormal interleukin secretion
|
J:88907
|
increased interleukin-6 secretion
|
J:88907
|
increased susceptibility to induced colitis
|
J:88907
|
Siglec1tm1(HBEGF)Mtka/Siglec1tm1(HBEGF)Mtka 1700016L21RikTg(Itgax-HBEGF/EGFP)57Lan/?
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
abnormal dendritic cell physiology
|
J:123958
|
abnormal immune system physiology
|
J:123958
|
abnormal immune tolerance
|
J:123958
|
abnormal macrophage physiology
|
J:123958
|
Siglec1tm1Croc/Siglec1tm1Croc
(B6.129-Siglec1tm1Croc)
|
decreased circulating interleukin-6 level
|
J:189854
|
decreased circulating tumor necrosis factor level
|
J:189854
|
decreased IgM level
|
J:105546
|
decreased interleukin-6 secretion
|
J:189854
|
decreased interleukin-10 secretion
|
J:189854
|
decreased interleukin-12 secretion
|
J:189854
|
decreased tumor necrosis factor secretion
|
J:189854
|
impaired macrophage phagocytosis
|
J:189854
|
increased susceptibility to bacterial infection
|
J:189854
|
Siglec1tm2.1Croc/Siglec1tm2.1Croc
(B6.129P2(C)-Siglec1tm2.1Croc)
|
decreased circulating interleukin-6 level
|
J:189854
|
decreased circulating tumor necrosis factor level
|
J:189854
|
decreased susceptibility to bacterial infection
|
J:189854
|
impaired macrophage phagocytosis
|
J:189854
|
Siglecetm1.1(SIGLEC16)Avrk/Siglecetm1.1(SIGLEC16)Avrk
(involves: C57BL/6)
|
abnormal cytokine level
|
J:264224
|
decreased susceptibility to bacterial infection
|
J:264224
|
increased circulating interleukin-6 level
|
J:264224
|
increased circulating interleukin-12 level
|
J:264224
|
Siglecetm1Arte/Siglecetm1Arte
(involves: C57BL/6)
|
abnormal macrophage physiology
|
J:195429
|
abnormal neutrophil physiology
|
J:195429
|
Siglecetm1Croc/Siglecetm1Croc
(B6.129P2-Siglecetm1Croc)
|
abnormal macrophage physiology
|
J:195429
|
abnormal neutrophil physiology
|
J:195429
|
Siglecftm1.2Avrk/Siglecftm1.2Avrk
(B6.129(FVB)-Siglecftm1.2Avrk)
|
abnormal eosinophil physiology
|
J:204811
|
lung inflammation
|
J:204811
|
SiglecgM3Btlr/SiglecgM3Btlr
(C57BL/6J-SiglecgM3Btlr)
|
decreased IgM level
|
J:265185
|
Siglecgtm1Lnit/Siglecgtm1Lnit
(involves: BALB/c)
|
autoimmune response
|
J:123353
|
decreased IgG2a level
|
J:123353
|
increased IgM level
|
J:123353
|
Siglecgtm1Yliu/Siglecgtm1Yliu
(C57BL/6-Siglecgtm1Yliu)
|
increased IgM level
|
J:130017
|
Siglechtm1.1Cfg/Siglechtm1.1Cfg
(involves: C57BL/6)
|
increased T cell proliferation
|
J:217719
|
Siglechtm1.1Ksat/Siglechtm1.1Ksat
(B6.Cg-Siglechtm1.1Ksat)
|
abnormal circulating cytokine level
|
J:179283
|
abnormal dendritic cell antigen presentation
|
J:179283
|
abnormal plasmacytoid dendritic cell physiology
|
J:179283
|
decreased circulating interferon-alpha level
|
J:179283
|
decreased circulating interleukin-12b level
|
J:179283
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:179283
|
decreased susceptibility to infection induced morbidity/mortality
|
J:179283
|
increased circulating interferon-alpha level
|
J:179283
|
increased circulating interleukin-12b level
|
J:179283
|
Sik2tm1Lex/Sik2tm1Lex
(involves: 129S/SvEvBrd)
|
increased inflammatory response
|
J:229999
|
Sirpatm1Nog/Sirpatm1Nog
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal Langerhans cell physiology
|
J:88694
|
abnormal macrophage physiology
|
J:79592
|
Sirt1tm1Mcby/Sirt1tm1Mcby
(involves: 129)
|
interstitial pneumonia
|
J:81010
|
lung inflammation
|
J:81010
|
Sirt1tm1Mcby/Sirt1tm1Mcby
(involves: 129S1/Sv * 129X1/SvJ * CD-1)
|
glomerulonephritis
|
J:160869
|
increased anti-nuclear antigen antibody level
|
J:160869
|
increased immunoglobulin level
|
J:160869
|
interstitial pneumonia
|
J:81010
|
lung inflammation
|
J:81010
|
Sirt1tm1Mcby/Sirt1tm1Mcby
(involves: 129S1/Sv * 129X1/SvJ)
|
increased autoantibody level
|
J:241633
|
Sirt3tm1.1Fwa/Sirt3tm1.1Fwa
(involves: 129S6/SvEvTac)
|
abnormal cytokine level
|
J:178653
|
increased circulating interferon-gamma level
|
J:178653
|
increased circulating interleukin-6 level
|
J:178653
|
increased circulating interleukin-10 level
|
J:178653
|
increased circulating interleukin-12 level
|
J:178653
|
increased circulating tumor necrosis factor level
|
J:178653
|
liver inflammation
|
J:178653
|
Sirt6tm1Fwa/Sirt6tm1Fwa
(involves: 129S6/SvEvTac * 129X1/SvJ)
|
colitis
|
J:112817
|
Sirt6tm2.1Cxd/Sirt6tm2.1Cxd
(involves: 129S6/SvEvTac * NIH Black Swiss)
|
abnormal spleen physiology
|
J:167023
|
Sirt6tm2.2Cxd/Sirt6tm2.2Cxd
(involves: 129S6/SvEvTac * FVB/N * NIH Black Swiss)
|
abnormal spleen physiology
|
J:167023
|
Sirt7tm1Evbo/Sirt7tm1Evbo
(involves: 129/Sv * C57BL/6)
|
abnormal cytokine level
|
J:147652
|
increased interleukin-4 secretion
|
J:147652
|
increased interleukin-12 secretion
|
J:147652
|
increased interleukin-13 secretion
|
J:147652
|
Sirt7tm1Fwa/Sirt7tm1Fwa
(involves: 129S1/Sv)
|
liver inflammation
|
J:205529
|
Sit1tm1Lsmn/Sit1tm1Lsmn
(B6.Cg-Sit1tm1Lsmn)
|
abnormal cytokine secretion
|
J:100408
|
increased interferon-gamma secretion
|
J:100408
|
increased interleukin-2 secretion
|
J:100408
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:100408
|
increased T cell proliferation
|
J:100408
|
increased tumor necrosis factor secretion
|
J:100408
|
Skap1Gt713Lex/Skap1Gt713Lex
(B6.129S5-Skap1Gt713Lex)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:126545
|
abnormal immune system physiology
|
J:126545
|
abnormal T cell physiology
|
J:126545
|
decreased interferon-gamma secretion
|
J:126545
|
decreased interleukin-2 secretion
|
J:126545
|
decreased T cell proliferation
|
J:126545
|
Skap2Gt(VICTR20)21Lex/Skap2Gt(VICTR20)21Lex
(B6.129S5-Skap2Gt(VICTR20)21Lex)
|
abnormal B cell activation
|
J:101373
|
abnormal dendritic cell antigen presentation
|
J:151350
|
abnormal dendritic cell physiology
|
J:151350
|
decreased B cell proliferation
|
J:101373
|
decreased IgG2a level
|
J:101373
|
decreased IgM level
|
J:101373
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:101373
|
Skiltm1Spw/Skiltm1Spw
(either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))
|
decreased T cell proliferation
|
J:84554
|
Skiltm2Spw/Skiltm2Spw
(either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))
|
decreased T cell proliferation
|
J:84554
|
Slatm1Weis/Slatm1Weis Sla2tm1Amch/Sla2tm1Amch
(involves: 129)
|
abnormal dendritic cell physiology
|
J:169170
|
decreased interleukin-12 secretion
|
J:169170
|
decreased tumor necrosis factor secretion
|
J:169170
|
Slamf1tm1Cpt/Slamf1tm1Cpt
(B6.129S4-Slamf1tm1Cpt)
|
abnormal cytokine secretion
|
J:90484
|
abnormal macrophage physiology
|
J:90484
|
increased susceptibility to parasitic infection
|
J:90484
|
Slamf1tm1Cpt/Slamf1tm1Cpt
(C.129S4-Slamf1tm1Cpt)
|
abnormal cytokine secretion
|
J:90484
|
abnormal macrophage physiology
|
J:90484
|
Slamf1tm1Cpt/Slamf1tm1Cpt Tg(DO11.10)10Dlo/Tg(DO11.10)10Dlo
(involves: BALB/c * C3H * C57BL/6)
|
abnormal cytokine secretion
|
J:90484
|
Slamf1tm1Oono/Slamf1tm1Oono
(B6.129-Slamf1tm1Oono)
|
increased susceptibility to Paramyxoviridae infection
|
J:117810
|
Slamf1tm1Vei/Slamf1tm1Vei
(involves: 129 * C57BL/6)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:133047,
J:93886
|
Slamf6tm1Dhow/Slamf6tm1Dhow
(involves: 129/Sv * C57BL/6)
|
abnormal neutrophil physiology
|
J:98995
|
abnormal T-helper 2 physiology
|
J:98995
|
decreased interleukin-4 secretion
|
J:98995
|
decreased susceptibility to parasitic infection
|
J:98995
|
impaired granulocyte bactericidal activity
|
J:98995
|
increased circulating interleukin-12b level
|
J:98995
|
increased circulating interleukin-16 level
|
J:98995
|
increased circulating tumor necrosis factor level
|
J:98995
|
increased susceptibility to bacterial infection
|
J:98995
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:98995
|
Slamf7tm1Vei/Slamf7tm1Vei
(involves: 129S1/Sv * 129X1/SvJ)
|
impaired natural killer cell mediated cytotoxicity
|
J:145969
|
Slamf8tm1Mill/Slamf8tm1Mill
(involves: BALB/c)
|
abnormal macrophage physiology
|
J:188963
|
increased susceptibility to bacterial infection
|
J:188963
|
Slamf9em1Isha/Slamf9em1Isha
(involves: C57BL/6)
|
abnormal plasmacytoid dendritic cell physiology
|
J:279164
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:279164
|
Slc1a5tm1Tac/Slc1a5tm1Tac
(involves: 129S/SvEv * C57BL/6)
|
abnormal T cell physiology
|
J:254980
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:254980
|
Slc2a4tm1Mch/Slc2a4+
(involves: 129/Sv * C57BL/6J * CD-1 * SJL)
|
heart inflammation
|
J:43650
|
Slc2a6em1Kusu/Slc2a6em1Kusu
(involves: C57BL/6JCrlj)
|
abnormal macrophage physiology
|
J:270487
|
increased circulating tumor necrosis factor level
|
J:270487
|
increased susceptibility to endotoxin shock
|
J:270487
|
Slc2a9tm1.2Thor/Slc2a9tm1.2Thor
(involves: C57BL/6 * C57BL/6N)
|
kidney inflammation
|
J:153089
|
tubulointerstitial nephritis
|
J:153089
|
Slc3a1pbl/Slc3a1pbl
(C3HeB/FeJ-Slc3a1pbl)
|
tubulointerstitial nephritis
|
J:85461
|
Slc3a1pbl/Slc3a1pbl
(involves: C3HeB/FeJ * MRL/MpJ)
|
kidney inflammation
|
J:85461
|
Slc3a2tm1.1Merl/Slc3a2+ Tg(Vil1-cre)997Gum/0
(B6.Cg-Slc3a2tm1.1Merl Tg(Vil1-cre)997Gum)
|
decreased susceptibility to induced colitis
|
J:173946
|
Slc3a2tm1.1Yait/Slc3a2tm1.1Yait Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * C57BL/6NCrSlc)
|
abnormal macrophage antigen presentation
|
J:188365
|
abnormal macrophage physiology
|
J:188365
|
impaired macrophage phagocytosis
|
J:188365
|
Slc4a2tm1Ges/Slc4a2tm1Ges
(involves: 129S6/SvEvTac)
|
abnormal osteoclast physiology
|
J:193823
|
Slc4a2tm2Ges/Slc4a2tm2Ges Ctsktm1(cre)Ska/Ctsk+
(involves: C57BL/6NCrlj * CBA/JNCrlj)
|
abnormal osteoclast physiology
|
J:193823
|
Slc4a2tm2Ges/Slc4a2tm2Ges Tg(Mx1-cre)1Cgn/0
(involves: C57BL/6 * CBA)
|
abnormal osteoclast physiology
|
J:193823
|
Slc5a2m2Btlr/Slc5a2m2Btlr
(C57BL/6J-Slc5a2m2Btlr)
|
increased susceptibility to induced colitis
|
J:265117
|
increased tumor necrosis factor secretion
|
J:265117
|
Slc5a2tm1Lex/Slc5a2tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
|
decreased susceptibility to autoimmune diabetes
|
J:195941
|
Slc5a6tm1.1Said/Slc5a6tm1.1Said Tg(Vil1-cre/ERT2)23Syr/0
(involves: C57BL/6 * DBA/2)
|
cecum inflammation
|
J:307482
|
small intestinal inflammation
|
J:307482
|
Slc5a7tm1a(KOMP)Wtsi/Slc5a7tm1a(KOMP)Wtsi
(C57BL/6N-Slc5a7tm1a(KOMP)Wtsi/Wtsi)
|
blood in lymph vessels
|
J:239583
|
Slc6a14tm1Gana/Slc6a14tm1Gana
(Not Specified)
|
abnormal circulating chemokine level
|
J:226105
|
abnormal circulating cytokine level
|
J:226105
|
decreased circulating interleukin-1 alpha level
|
J:226105
|
decreased circulating interleukin-4 level
|
J:226105
|
Slc6a14tm1Gana/Slc6a14tm1Gana Tg(MMTV-PyVT)634Mul/0
(Not Specified)
|
abnormal immunoglobulin level
|
J:226105
|
Slc7a2tm1Clm/Slc7a2tm1Clm
(involves: 129S7/SvEvBrd * C57BL/6)
|
abnormal immune system physiology
|
J:69414
|
Slc7a9tm1Nune/Slc7a9tm1Nune
(involves: 129P2/OlaHsd * C57BL/6J)
|
tubulointerstitial nephritis
|
J:85462
|
Slc7a11m1Mtka/Slc7a11m1Mtka
(C57BL/6-Slc7a11m1Mtka)
|
abnormal dendritic cell physiology
|
J:159323
|
abnormal macrophage physiology
|
J:159323
|
Slc9a2tm1Ges/Slc9a2tm1Ges
(involves: 129X1/SvJ * Black Swiss)
|
stomach inflammation
|
J:65754
|
Slc9a4tm1Ges/Slc9a4tm1Ges
(involves: 129S6/SvEvTac * Black Swiss)
|
stomach inflammation
|
J:98566
|
Slc9a8m1Btlr/Slc9a8m1Btlr
(C57BL/6J-Slc9a8m1Btlr)
|
increased susceptibility to induced colitis
|
J:267481
|
Slc11a1r/Slc11a1r
(C3H/HeJ-Slc11a1r)
|
decreased susceptibility to bacterial infection
|
J:35004
|
Slc11a1r/Slc11a1r
(129/Sv)
|
decreased susceptibility to bacterial infection
|
J:81412
|
Slc11a1r/Slc11a1s
((129/Sv x BALB/c)F1)
|
decreased susceptibility to bacterial infection
|
J:28278
|
Slc11a1s/Slc11a1r
((129/Sv x C57BL/6J)F1)
|
abnormal susceptibility to bacterial infection
|
J:81412
|
Slc11a1s/Slc11a1s
(C57BL/6J)
|
increased susceptibility to bacterial infection
|
J:81412
|
Slc11a1s/Slc11a1s
(BALB/c)
|
increased susceptibility to bacterial infection
|
J:28278
|
Slc11a1tm1Mcg/Slc11a1s
(involves: 129S4/SvJae * BALB/c)
|
increased susceptibility to bacterial infection
|
J:28278
|
Slc11a1tm1Mcg/Slc11a1tm1Mcg
(involves: 129S4/SvJae * BALB/c)
|
increased susceptibility to bacterial infection
|
J:28278
|
Slc12a1urehr3/Slc12a1urehr3
(involves: C3HeB/FeJ)
|
pyelitis
|
J:159994
|
pyelonephritis
|
J:159994
|
Slc12a2em1Dlp/Slc12a2+
(involves: C57BL/6J * DBA/2J)
|
increased susceptibility to bacterial infection
|
J:285398
|
Slc12a2em1Dlp/Slc12a2em1Dlp
(involves: C57BL/6J * DBA/2J)
|
increased susceptibility to bacterial infection
|
J:285398
|
large intestinal inflammation
|
J:285398
|
Slc15a4m1Btlr/Slc15a4m1Btlr
(C57BL/6J-Slc15a4m1Btlr)
|
abnormal interferon secretion
|
J:166600
|
decreased interleukin-6 secretion
|
J:166600
|
decreased interleukin-12 secretion
|
J:166600
|
decreased tumor necrosis factor secretion
|
J:166600
|
Slc15a4tm1Tkyo/Slc15a4tm1Tkyo
(involves: C57BL/6)
|
abnormal circulating cytokine level
|
J:270965
|
abnormal cytokine secretion
|
J:270965
|
decreased circulating interleukin-1 beta level
|
J:270965
|
decreased circulating interleukin-6 level
|
J:270965
|
decreased interferon-beta secretion
|
J:270965
|
decreased interleukin-1 beta secretion
|
J:270965
|
decreased interleukin-6 secretion
|
J:270965
|
decreased interleukin-12 secretion
|
J:270965
|
decreased interleukin-12b secretion
|
J:270965
|
decreased interleukin-15 secretion
|
J:270965
|
decreased interleukin-18 secretion
|
J:270965
|
decreased susceptibility to induced colitis
|
J:270965
|
decreased tumor necrosis factor secretion
|
J:270965
|
Slc19a3tm1Said/Slc19a3tm1Said
(involves: C57BL/6)
|
chronic liver inflammation
|
J:170952
|
kidney inflammation
|
J:170952
|
Slc22a4tm1Atsu/Slc22a4tm1Atsu
(involves: C57BL/6J)
|
intestinal inflammation
|
J:207006
|
Slc24a3em#Ebje/Slc24a3em#Ebje
(C57BL/6J-Slc24a3em#Ebje)
|
increased susceptibility to induced colitis
|
J:308448
|
Slc25a17Gt(XB686)Byg/Slc25a17Gt(XB686)Byg
(involves: 129P2/OlaHsd * C57BL/6 * Swiss Webster)
|
liver inflammation
|
J:291257
|
Slc26a1tm1Mark/Slc26a1tm1Mark
(involves: 129X1/SvJ * CD-1)
|
kidney inflammation
|
J:158567
|
Slc26a4m2Btlr/Slc26a4m2Btlr
(C57BL/6J-Slc26a4m2Btlr)
|
increased susceptibility to induced colitis
|
J:236690
|
Slc29a1tm2Msg/Slc29a1tm2Msg Eportm1.1(EGFP/icre)Uk/Epor+
(involves: 129X1/SvJ * BALB/cJ)
|
decreased interleukin-6 secretion
|
J:244602
|
Slc29a2Gt(OST207791)Lex/Slc29a2Gt(OST207791)Lex
(involves: 129S5/SvEvBrd)
|
decreased interleukin-6 secretion
|
J:203572
|
Slc29a3tm1Lex/Slc29a3tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6)
|
abnormal macrophage physiology
|
J:179286
|
increased macrophage apoptosis
|
J:179286
|
increased susceptibility to bacterial infection
|
J:179286
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:179286
|
Slc30a2tm1Kgna/Slc30a2tm1Kgna
(involves: 129 * C57BL/6)
|
abnormal macrophage physiology
|
J:264481
|
Slc30a4lm/Slc30a4lm
(C57BL/6J-Slc30a4lm)
|
dermatitis
|
J:5911,
J:7690
|
Slc33a1tm1.1Lpu/Slc33a1+
(involves: 129S7/SvEvBrd * C57BL/6)
|
abnormal circulating cytokine level
|
J:211266
|
abnormal cytokine secretion
|
J:211266
|
abnormal T cell activation
|
J:211266
|
brain inflammation
|
J:211266
|
conjunctivitis
|
J:211266
|
dermatitis
|
J:211266
|
increased circulating interleukin-17 level
|
J:211266
|
increased circulating interleukin-18 level
|
J:211266
|
increased inflammatory response
|
J:211266
|
increased interferon-gamma secretion
|
J:211266
|
increased interleukin-4 secretion
|
J:211266
|
increased interleukin-17 secretion
|
J:211266
|
increased susceptibility to infection
|
J:211266
|
preputial gland inflammation
|
J:211266
|
prostate gland inflammation
|
J:211266
|
salivary gland inflammation
|
J:211266
|
stomach inflammation
|
J:211266
|
urinary bladder inflammation
|
J:211266
|
Slc35c1tm1Cknr/Slc35c1tm1Cknr
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6)
|
abnormal leukocyte adhesion
|
J:121151
|
impaired leukocyte tethering or rolling
|
J:121151
|
Slc37a2tm1Dgen/Slc37a2tm1Dgen
(involves: 129P2/OlaHsd * C57BL/6J)
|
abnormal macrophage physiology
|
J:311521
|
increased interleukin-1 beta secretion
|
J:311521
|
increased interleukin-6 secretion
|
J:311521
|
increased susceptibility to endotoxin shock
|
J:311521
|
increased tumor necrosis factor secretion
|
J:311521
|
Slc37a4tm1Jyc/Slc37a4tm1Jyc
(involves: 129S4/SvJae * C57BL/6)
|
abnormal chemokine secretion
|
J:86005
|
abnormal inflammatory response
|
J:86005
|
abnormal neutrophil physiology
|
J:86005
|
decreased inflammatory response
|
J:86005
|
impaired neutrophil chemotaxis
|
J:86005
|
Slc38a8em1Cya/Slc38a8em1Cya
(C57BL/6J-Slc38a8em1Cya)
|
decreased susceptibility to viral infection
|
J:336781
|
decreased susceptibility to viral infection induced morbidity/mortality
|
J:336781
|
Slc39a5tm1.1Gka/Slc39a5tm1.1Gka
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
increased susceptibility to induced pancreatitis
|
J:209760
|
Slc39a5tm1Gka/Slc39a5tm1Gka Tg(Cela1-cre/ERT)1Lgdn/0
(involves: 129P2/OlaHsd * C57BL/6)
|
increased susceptibility to induced pancreatitis
|
J:209760
|
Slc39a10tm1.1Tfk/Slc39a10tm1.1Tfk Tg(Foxn1-cre)8Ghr/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
|
increased thymocyte apoptosis
|
J:254216
|
Slc40a1ffe/Slc40a1+
(either: (involves: 129X1/SvJ * C57BL/6J) or (involves: C3H/HeJ * C57BL/6J))
|
abnormal macrophage physiology
|
J:118592
|
Slc40a1Pcm/Slc40a1+
(A.Cg-Slc40a1Pcm)
|
abnormal spleen physiology
|
J:98335
|
increased splenocyte apoptosis
|
J:98335
|
Slc40a1Pcm/Slc40a1Pcm
(A.Cg-Slc40a1Pcm)
|
increased splenocyte apoptosis
|
J:98335
|
Slc43a2Gt(258C1)Cmhd/Slc43a2Gt(258C1)Cmhd
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1)
|
liver inflammation
|
J:237439
|
Slc44a4tm1.2Said/Slc44a4tm1.2Said
(involves: BALB/cJ * C57BL/6J * C57BL/6N)
|
increased susceptibility to induced colitis
|
J:351314
|
Slc48a1em1Ih/Slc48a1em1Ih
(involves: 129 * C57BL/6J)
|
abnormal macrophage physiology
|
J:282829
|
Sle1NZM2410/Aeg/Sle1NZM2410/Aeg Sle3NZM2410/Aeg/Sle3NZM2410/Aeg
(B6;NZM-Sle1NZM2410/Aeg Sle2NZM2410/Aeg Sle3NZM2410/Aeg/LmoJ)
|
abnormal marginal zone B cell physiology
|
J:138314
|
Sle1NZW/Sle1NZW Sles1NZW/Sles1NZW
(involves: C57BL/6 * NZW)
|
abnormal T cell physiology
|
J:100678
|
decreased susceptibility to systemic lupus erythematosus
|
J:100678
|
Sle1NZW/Sle1NZW Tg(Tnfsf13b)1Fma/0
(involves: C57BL/6 * DBA/2J * NZW)
|
glomerulonephritis
|
J:134128
|
increased IgG level
|
J:134128
|
increased IgM level
|
J:134128
|
increased susceptibility to systemic lupus erythematosus
|
J:134128
|
Sle1aC57BL/6J/Sle1aNZM2410/J
(involves: C57BL/6J * NZM2410/J)
|
increased anti-chromatin antibody level
|
J:67544
|
Sle1aNZM2410/J/Sle1aNZM2410/J
(involves: C57BL/6J * NZM2410/J)
|
increased anti-chromatin antibody level
|
J:67544
|
Sle1bC57BL/6J/Sle1bNZM2410/J
(involves: C57BL/6J * NZM2410/J)
|
increased anti-chromatin antibody level
|
J:67544
|
Sle1bNZM2410/J/Sle1bNZM2410/J
(involves: C57BL/6J * NZM2410/J)
|
increased anti-chromatin antibody level
|
J:67544
|
Sle1cC57BL/6J/Sle1cNZM2410/J
(involves: C57BL/6J * NZM2410/J)
|
increased anti-chromatin antibody level
|
J:67544
|
Sle1cNZB/Sle1cNZM2410/J
(involves: C57BL/6J * NZB * NZM2410/J)
|
glomerulonephritis
|
J:145133
|
increased autoantibody level
|
J:145133
|
Sle1cNZM2410/J/Sle1cNZM2410/J
(involves: C57BL/6J * NZM2410/J)
|
increased anti-chromatin antibody level
|
J:67544
|
Sle2NZM2410/Aeg/Sle2NZM2410/Aeg
(involves: C57BL/6J * NZM2410/Aeg)
|
glomerulonephritis
|
J:25006
|
Sle3NZM2410/Aeg/?
(involves: C57BL/6J * NZM2410/Aeg)
|
glomerulonephritis
|
J:52863
|
increased IgG level
|
J:52863
|
increased IgM level
|
J:52863
|
Sle6NZW/Sle6NZW
(involves: C57BL/6 * NZW)
|
increased susceptibility to systemic lupus erythematosus
|
J:57246
|
Sle7BXSB/J/Sle7BXSB/J
(involves: BXSB/J * C57BL/10Ola)
|
glomerulonephritis
|
J:60445
|
Sle8BXSB/J/Sle8BXSB/J
(involves: BXSB/J * C57BL/10Ola)
|
glomerulonephritis
|
J:60445
|
Sle9BXSB/J/Sle9BXSB/J
(involves: BXSB/J * C57BL/10Ola)
|
increased anti-nuclear antigen antibody level
|
J:60445
|
Sle11BXSB/J/Sle11BXSB/J
(involves: BXSB/J * C57BL/10Ola)
|
increased IgG3 level
|
J:60445
|
Sle12C57BL/6J/Sle12C57BL/6J
(involves: C57BL/6J * NZM2410/Aeg)
|
glomerulonephritis
|
J:52863
|
Sle12C57BL/6J/Sle12NZM2410/Aeg
(involves: C57BL/6J * NZM2410/Aeg)
|
glomerulonephritis
|
J:52863
|
Sle12NZM2410/Aeg/Sle12NZM2410/Aeg
(involves: C57BL/6J * NZM2410/Aeg)
|
glomerulonephritis
|
J:52863
|
Sle16129S6/SvEvTac/?
(involves: 129X1/Sv * C57BL/6)
|
abnormal immune serum protein physiology
|
J:93297
|
Sle16129S6/SvEvTac/Sle16129S6/SvEvTac
(B6.129-Sle16129S6/SvEvTac)
|
increased autoantibody level
|
J:122132
|
increased susceptibility to systemic lupus erythematosus
|
J:122132
|
Sle17129S6/SvEvTac/?
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal immune serum protein physiology
|
J:93297
|
Sle18C57BL/6/?
(involves: 129X1/Sv * C57BL/6)
|
abnormal immune serum protein physiology
|
J:93297
|
Sles1C57BL/6/Sles1C57BL/6
(involves: C57BL/6 * NZW)
|
increased susceptibility to systemic lupus erythematosus
|
J:57246
|
Sles1C57BL/6/Sles1NZW
(involves: C57BL/6 * NZW)
|
abnormal immune system physiology
|
J:57246
|
Sles1NZW/Sles1NZW
(involves: C57BL/6 * NZW)
|
decreased susceptibility to systemic lupus erythematosus
|
J:57246
|
Sles2C57BL/6/Sles2C57BL/6
(involves: C57BL/6 * NZW)
|
increased susceptibility to systemic lupus erythematosus
|
J:57246
|
Sles2C57BL/6/Sles2NZW
(involves: C57BL/6 * NZW)
|
increased susceptibility to systemic lupus erythematosus
|
J:57246
|
Sles2NZW/Sles2NZW
(involves: C57BL/6 * NZW)
|
decreased susceptibility to systemic lupus erythematosus
|
J:57246
|
Sles3C57BL/6/Sles3C57BL/6
(involves: C57BL/6 * NZW)
|
increased susceptibility to systemic lupus erythematosus
|
J:57246
|
Sles3C57BL/6/Sles3NZW
(involves: C57BL/6 * NZW)
|
increased susceptibility to systemic lupus erythematosus
|
J:57246
|
Sles3NZW/Sles3NZW
(involves: C57BL/6 * NZW)
|
decreased susceptibility to systemic lupus erythematosus
|
J:57246
|
Sles4C57BL/6/Sles4C57BL/6
(involves: C57BL/6 * NZW)
|
increased susceptibility to systemic lupus erythematosus
|
J:57246
|
Sles4C57BL/6/Sles4NZW
(involves: C57BL/6 * NZW)
|
increased susceptibility to systemic lupus erythematosus
|
J:57246
|
Sles4NZW/Sles4NZW
(involves: C57BL/6 * NZW)
|
decreased susceptibility to systemic lupus erythematosus
|
J:57246
|
Slfn2m1Btlr/Slfn2m1Btlr
(C57BL/6J-Slfn2m1Btlr)
|
abnormal leukocyte physiology
|
J:158985
|
abnormal T cell activation
|
J:158985
|
abnormal T cell proliferation
|
J:158985
|
decreased T cell proliferation
|
J:158985
|
increased susceptibility to bacterial infection
|
J:158985
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:158985
|
increased susceptibility to Herpesvirales infection induced morbidity/mortality
|
J:158985
|
increased susceptibility to Riboviria infection
|
J:158985
|
increased T cell apoptosis
|
J:158985
|
Slfn2m2Btlr/Slfn2m2Btlr
(C57BL/6J-Slfn2m2Btlr)
|
decreased IgG level
|
J:234262
|
decreased response to antigen
|
J:234262
|
impaired humoral immune response
|
J:234262
|
Slfn4tm1c(EUCOMM)Wtsi/Slfn4tm1c(EUCOMM)Wtsi Gli1tm3(cre/ERT2)Alj/Gli1+
(involves: 129S6/SvEvTac * Black Swiss * C57BL/6 * Swiss Webster)
|
abnormal interleukin level
|
J:337060
|
abnormal tumor necrosis factor level
|
J:337060
|
decreased susceptibility to bacterial infection
|
J:337060
|
Slfn8tm1Aki/Slfn8tm1Aki
(involves: 129X1/SvJ * C57BL/6)
|
decreased interferon-gamma secretion
|
J:258797
|
decreased interleukin-1 beta secretion
|
J:258797
|
decreased interleukin-6 secretion
|
J:258797
|
decreased interleukin-17 secretion
|
J:258797
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:258797
|
Slfn9em1Liudp/Slfn9em1Liudp
(C57BL/6-Slfn9em1Liudp)
|
abnormal innate immunity
|
J:351319
|
abnormal macrophage activation involved in immune response
|
J:351319
|
Slpd1NZB/BlNJ/Slpd1NZB/BlNJ
(involves: DBA/2J * NZB/BlNJ)
|
increased B cell proliferation
|
J:124364
|
Slpitm1Ktak/Slpitm1Ktak
(B6.129P2-Slpitm1Ktak)
|
increased susceptibility to bacterial infection
|
J:132933
|
Slpitm1Nkw/Slpitm1Nkw
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal macrophage physiology
|
J:82214
|
increased B cell proliferation
|
J:82214
|
increased interleukin-6 secretion
|
J:82214
|
increased susceptibility to endotoxin shock
|
J:82214
|
Smad2tm3Rob/Smad2tm3Rob Smad3tm1Xfw/Smad3tm1Xfw
(involves: 129/Sv * 129S/SvEv * C57BL/6 * ICR)
|
osteoarthritis
|
J:95374
|
Smad3tm1Cxd/Smad3tm1Cxd
(either: (involves: 129S6/SvEvTac * C57BL/6) or (involves: 129S6/SvEvTac * NIH Black Swiss))
|
abnormal T cell activation
|
J:53510
|
abnormal T cell physiology
|
J:53510
|
abnormal thymus involution
|
J:53510
|
colitis
|
J:53510
|
impaired neutrophil chemotaxis
|
J:53510
|
increased inflammatory response
|
J:53510
|
pancreas inflammation
|
J:53510
|
small intestinal inflammation
|
J:53510
|
stomach inflammation
|
J:53510
|
Smad3tm1Cxd/Smad3tm1Cxd
(B6.129S6-Smad3tm1Cxd)
|
tubulointerstitial nephritis
|
J:102084
|
Smad3tm1Cxd/Smad3tm1Cxd
(involves: 129S6/SvEvTac)
|
abnormal leukocyte physiology
|
J:59673
|
decreased B cell apoptosis
|
J:140567
|
osteoarthritis
|
J:68792
|
Smad3tm1Par/Smad3tm1Par
(129-Smad3tm1Par/J)
|
abnormal circulating interleukin-6 level
|
J:175290
|
abnormal cytokine secretion
|
J:175290
|
decreased interleukin-6 secretion
|
J:175290
|
increased inflammatory response
|
J:106572
|
Smad3tm1Xfw/Smad3tm1Xfw
(involves: 129/Sv * C57BL/6)
|
abnormal B cell proliferation
|
J:53948
|
abnormal cytokine secretion
|
J:53948
|
abnormal T cell proliferation
|
J:53948
|
Smad4tm1.1Gsu/Smad4tm1.1Gsu Ptf1atm1.1(cre)Cvw/Ptf1a+ Tg(MtTGFA)Lmb/0
(involves: 129S1/Sv * 129X1/SvJ * CD-1)
|
chronic pancreas inflammation
|
J:229184
|
Smad4tm2.1Cxd/Smad4tm2.1Cxd Tg(Foxn1-cre)8Ghr/0
(B6.Cg-Smad4tm2.1Cxd Tg(Foxn1-cre)8Ghr)
|
abnormal thymus physiology
|
J:138837
|
Smad7tm1.1Ink/Smad7tm1.1Ink Tg(Cd4-cre)1Cwi/0
(involves: C57BL/6 * DBA/2)
|
decreased interferon-gamma secretion
|
J:184670
|
decreased interleukin-9 secretion
|
J:184670
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:184670
|
decreased T cell proliferation
|
J:184670
|
Smad7tm1Rheu/Smad7tm1Rheu
(involves: 129S1/Sv * 129X1/SvJ * CD-1)
|
abnormal class switch recombination
|
J:120714
|
decreased B cell proliferation
|
J:120714
|
increased B cell apoptosis
|
J:120714
|
Smad9tm3Jfm/Smad9tm3Jfm
(involves: 129S4/SvJaeSor)
|
lung inflammation
|
J:150213
|
Smarcc1tm2.1Rhs/Smarcc1tm2.1Rhs Tg(Mx1-cre)1Cgn/0
(involves: BALB/c * C57BL/6 * CBA)
|
decreased B cell proliferation
|
J:184060
|
increased B cell apoptosis
|
J:184060
|
Smc6tm1.1Arln/Smc6tm1.1Arln
(involves: 129P2/OlaHsd * C57BL/6 * FVB)
|
decreased IgG2b level
|
J:220422
|
Smcr8em1Btlr/Smcr8em1Btlr
(C57BL/6J-Smcr8em1Btlr)
|
increased circulating interleukin-12b level
|
J:268243
|
increased interleukin-6 secretion
|
J:268243
|
increased susceptibility to induced colitis
|
J:268243
|
increased tumor necrosis factor secretion
|
J:268243
|
Smcr8em2Btlr/Smcr8em2Btlr
(C57BL/6J-Smcr8em2Btlr)
|
increased circulating interleukin-12b level
|
J:268243
|
increased interleukin-6 secretion
|
J:268243
|
increased susceptibility to induced colitis
|
J:268243
|
increased tumor necrosis factor secretion
|
J:268243
|
Smcr8m1Btlr/Smcr8+
(C57BL/6J-Smcr8m1Btlr)
|
increased susceptibility to induced colitis
|
J:268243
|
Smcr8m1Btlr/Smcr8m1Btlr
(C57BL/6J-Smcr8m1Btlr)
|
increased susceptibility to induced colitis
|
J:268243
|
increased tumor necrosis factor secretion
|
J:268243
|
Smcr8m2Btlr/Smcr8m2Btlr
(C57BL/6J-Smcr8m2Btlr)
|
increased susceptibility to induced colitis
|
J:268243
|
increased tumor necrosis factor secretion
|
J:268243
|
Smcr8m3Btlr/Smcr8m3Btlr
(C57BL/6J-Smcr8m3Btlr)
|
increased susceptibility to induced colitis
|
J:268243
|
increased tumor necrosis factor secretion
|
J:268243
|
Smg1Gt(AG0297)Wtsi/Smg1+
(involves: 129P2/OlaHsd * C57BL/6)
|
chronic inflammation
|
J:193626
|
decreased circulating interleukin-1 beta level
|
J:193626
|
increased circulating interleukin-6 level
|
J:193626
|
Smg9tm1b(EUCOMM)Wtsi/Smg9tm1b(EUCOMM)Wtsi
(C57BL/6N-Smg9tm1b(EUCOMM)Wtsi/Wtsi)
|
blood in lymph vessels
|
J:239583
|
Smpd1tm1Esc/Smpd1tm1Esc
(involves: 129S1/Sv * C57BL/6J)
|
abnormal granulocyte physiology
|
J:81982
|
increased susceptibility to bacterial infection
|
J:81982
|
Smpdl3btm1a(EUCOMM)Wtsi/Smpdl3btm1a(EUCOMM)Wtsi
(C57BL/6-Smpdl3btm1a(EUCOMM)Wtsi)
|
abnormal chemokine secretion
|
J:224870
|
abnormal circulating chemokine level
|
J:224870
|
increased circulating interleukin-6 level
|
J:224870
|
increased circulating interleukin-12b level
|
J:224870
|
increased circulating tumor necrosis factor level
|
J:224870
|
increased susceptibility to endotoxin shock
|
J:224870
|
Smtntm1Gve/Smtntm1Gve
(involves: 129/Sv * C57BL/6)
|
intestinal inflammation
|
J:104648
|
sepsis
|
J:104648
|
Smyd5tm1a(EUCOMM)Wtsi/Smyd5tm1a(EUCOMM)Wtsi Tg(Vil1-cre)997Gum/0
(B6.Cg-Smyd5tm1a(EUCOMM)Wtsi Tg(Vil1-cre)997Gum)
|
decreased susceptibility to induced colitis
|
J:339411
|
Snai2tm1Look/Snai2tm1Look
(involves: 129X1/SvJ * C57BL/6)
|
blepharitis
|
J:80652
|
Snai2tm2Grid/Snai2tm2Grid
(involves: 129S1/Sv)
|
blepharitis
|
J:48521
|
conjunctivitis
|
J:48521
|
Snai2tm2Grid/Snai2tm2Grid Snai3tm1.2Jhws/Snai3tm1.2Jhws
(involves: 129/Sv * 129S1/Sv * C57BL/6)
|
abnormal thymus involution
|
J:204710
|
Sncatm1Rosl/Sncatm1Rosl
(involves: 129X1/SvJ)
|
decreased susceptibility to bacterial infection
|
J:138194
|
Sncatm1Rosl/Sncatm1Rosl Tg(Prnp-SNCA)7Vle/Tg(Prnp-SNCA)7Vle
(involves: 129X1/SvJ * C3H * C57BL/6)
|
abnormal response to infection
|
J:138194
|
Sncatm1Rosl/Sncatm1Rosl Tg(Prnp-SNCA*A53T)83Vle/Tg(Prnp-SNCA*A53T)83Vle
(involves: 129X1/SvJ * C3H * C57BL/6)
|
increased susceptibility to bacterial infection
|
J:138194
|
Snrktm1.1Hxu/Snrktm1.1Hxu Tg(Adipoq-cre)1Evdr/0
(B6.Cg-Snrktm1.1Hxu Tg(Adipoq-cre)1Evdr)
|
abnormal circulating chemokine level
|
J:257980
|
brown adipose tissue inflammation
|
J:257980
|
increased circulating interleukin-6 level
|
J:257980
|
increased circulating tumor necrosis factor level
|
J:257980
|
white adipose tissue inflammation
|
J:257980
|
Snrnp40em1Btlr/Snrnp40swp
(C57BL/6J-Snrnp40em1Btlr/Snrnp40swp)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:282417
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:282417
|
decreased T cell proliferation
|
J:282417
|
impaired natural killer cell mediated cytotoxicity
|
J:282417
|
increased circulating interferon-beta level
|
J:282417
|
increased circulating interferon-gamma level
|
J:282417
|
increased circulating interleukin-6 level
|
J:282417
|
increased circulating interleukin-12 level
|
J:282417
|
increased circulating interleukin-17 level
|
J:282417
|
increased circulating tumor necrosis factor level
|
J:282417
|
increased susceptibility to viral infection
|
J:282417
|
increased susceptibility to viral infection induced morbidity/mortality
|
J:282417
|
Snx8tm1Hbsh/Snx8tm1Hbsh
(Not Specified)
|
abnormal chemokine secretion
|
J:254306
|
abnormal circulating chemokine level
|
J:254306
|
abnormal dendritic cell physiology
|
J:254306
|
abnormal macrophage physiology
|
J:254306
|
decreased circulating CXCL10 level
|
J:254306
|
decreased circulating tumor necrosis factor level
|
J:254306
|
decreased CXCL10 secretion
|
J:254306
|
decreased macrophage cytokine production
|
J:254306
|
increased susceptibility to bacterial infection
|
J:254306
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:254306
|
Snx10em1Ael/Snx10em1Ael
(involves: 129 * C57BL/6J * C57BL/6JOlaHsd)
|
abnormal osteoclast physiology
|
J:289051
|
osteomyelitis
|
J:289051
|
Snx10em2Ael/Snx10em2Ael
(involves: 129 * C57BL/6J * C57BL/6JOlaHsd)
|
abnormal osteoclast physiology
|
J:289051
|
osteomyelitis
|
J:289051
|
Snx10tm1a(EUCOMM)Raba/Snx10tm1a(EUCOMM)Raba
(involves: 129S4/SvJae * C57BL/6 * C57BL/6J)
|
abnormal osteoclast physiology
|
J:224711
|
Socs1tm1.1Ayr/Socs1tm1.1Ayr
(involves: C57BL/6)
|
abnormal T cell physiology
|
J:226678
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:226678
|
Socs1tm1Ayos/Socs1tm1Ayos Foxp3tm4(YFP/icre)Ayr/Foxp3+
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
|
blepharitis
|
J:167922
|
conjunctivitis
|
J:167922
|
dermatitis
|
J:167922
|
Socs1tm1Ayos/Socs1tm1Ayos Tg(Lck-cre)1Jtak/0
(involves: 129S4/SvJae * C57BL/6)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:132905
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:132905
|
Socs1tm1Jni/Socs1+
(Not Specified)
|
abnormal cytokine level
|
J:91651
|
abnormal interleukin level
|
J:91651
|
Socs1tm1Jni/Socs1tm1Jni
(Not Specified)
|
abnormal cytokine secretion
|
J:57475
|
Socs1tm1Kish/Socs1tm1Kish
(B6.129P2-Socs1tm1Kish)
|
abnormal lymphocyte physiology
|
J:69472
|
liver inflammation
|
J:69472
|
Socs1tm1Kish/Socs1tm1Kish Stat1tm1Rds/Stat1tm1Rds
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6)
|
liver inflammation
|
J:69472
|
Socs1tm1Kish/Socs1tm1Kish Stat6tm1Aki/Stat6tm1Aki
(involves: 129P2/OlaHsd * C57BL/6)
|
liver inflammation
|
J:69472
|
Socs1tm1Wehi/Socs1tm1Wehi
(involves: 129S1/Sv * C57BL/6)
|
abnormal inflammatory response
|
J:57474
|
abnormal macrophage physiology
|
J:57474
|
decreased susceptibility to Togaviridae infection induced morbidity/mortality
|
J:57474
|
heart inflammation
|
J:51281
|
increased inflammatory response
|
J:72528
|
liver inflammation
|
J:51281
|
pancreas inflammation
|
J:51281
|
Socs1tm1Wehi/Socs1tm3Wehi Tg(Lck-cre)I57Jxm/0
(involves: 129P2/OlaHsd * C57BL/6 * ICR)
|
abnormal T cell activation
|
J:83009
|
Socs1tm2Wehi/Socs1tm2Wehi
(C57BL/6-Socs1tm2Wehi)
|
glomerulonephritis
|
J:72528
|
increased incidence of corneal inflammation
|
J:72528
|
increased inflammatory response
|
J:72528
|
intestinal inflammation
|
J:72528
|
liver inflammation
|
J:72528
|
myocarditis
|
J:72528
|
myositis
|
J:72528
|
pancreas inflammation
|
J:72528
|
salivary gland inflammation
|
J:72528
|
skin inflammation
|
J:72528
|
Socs1tm3.1Wehi/Socs1tm3.1Wehi
(C57BL/6-Socs1tm3.1Wehi)
|
abnormal inflammatory response
|
J:83009
|
increased circulating interferon-gamma level
|
J:83009
|
Socs2tm1Wehi/Socs2tm1Wehi
(involves: C57BL/6 * C57BL/6J)
|
abnormal circulating cytokine level
|
J:186227
|
abnormal macrophage physiology
|
J:186227
|
increased circulating interferon-gamma level
|
J:186227
|
increased circulating interleukin-1 beta level
|
J:186227
|
increased interferon-gamma secretion
|
J:186227
|
increased interleukin-1 beta secretion
|
J:186227
|
increased tumor necrosis factor secretion
|
J:186227
|
liver inflammation
|
J:186227
|
Socs3tm1Ayos/Socs3tm1Ayos Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129 * C57BL/6)
|
decreased susceptibility to endotoxin shock
|
J:92040
|
Socs3tm1Jni/Socs3+
(involves: 129P2/OlaHsd)
|
increased interleukin-2 secretion
|
J:128797
|
Socs3tm1Robb/Socs3tm1Robb
(involves: C57BL/6)
|
increased susceptibility to induced arthritis
|
J:145513
|
Socs3tm1Wsa/Socs3tm2Wsa Lyz2tm1(cre)Ifo/?
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal macrophage physiology
|
J:83645
|
Socs3tm1Wsa/Socs3tm2Wsa Tg(Vav1-cre)1Awr/0
(involves: C57BL/6)
|
increased inflammatory response
|
J:89785
|
liver inflammation
|
J:89785
|
lung inflammation
|
J:89785
|
peritoneal inflammation
|
J:89785
|
Socs4m1Nch/Socs4m1Nch
(C.C3Fe-Socs4m1Nch)
|
abnormal chemokine secretion
|
J:241977
|
abnormal T cell activation
|
J:241977
|
increased interferon-gamma secretion
|
J:241977
|
increased interleukin-1 secretion
|
J:241977
|
increased interleukin-4 secretion
|
J:241977
|
increased interleukin-5 secretion
|
J:241977
|
increased interleukin-6 secretion
|
J:241977
|
increased interleukin-12b secretion
|
J:241977
|
increased interleukin-13 secretion
|
J:241977
|
increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality
|
J:241977
|
Socs4m1Nch/Socs4m1Nch
(C3H/He-Socs4m1Nch)
|
increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality
|
J:241977
|
Socs4m1Nch/Socs4m1Nch
(C6.C3Fe-Socs4m1Nch)
|
increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality
|
J:241977
|
Sod1m1H/Sod1m1H
(involves: C3H/HeH * C57BL/6J)
|
liver inflammation
|
J:219360
|
Sod1tm1Leb/Sod1tm1Leb
(involves: 129S7/SvEvBrd * C57BL/6)
|
blepharitis
|
J:219024
|
increased circulating interleukin-6 level
|
J:219024
|
increased circulating tumor necrosis factor level
|
J:219024
|
increased interleukin-6 secretion
|
J:219024
|
increased tumor necrosis factor secretion
|
J:219024
|
Meibomian gland inflammation
|
J:219024
|
Sod3tm1Mrkl/Sod3tm1Mrkl
(D1.129P2-Sod3tm1Mrkl)
|
autoimmune arthritis
|
J:106273
|
increased susceptibility to induced arthritis
|
J:106273
|
increased tumor necrosis factor secretion
|
J:106273
|
Sod3tm1Svp/Sod3tm1Svp
(involves: 129S6/SvEvTac * C57BL/6NTac)
|
decreased susceptibility to endotoxin shock
|
J:285340
|
Sonem1.1Bcgen/Son+
(B6(Cg)-Sonem1.1Bcgen)
|
decreased IgA level
|
J:347709
|
decreased IgM level
|
J:347709
|
Sort1tm1Camo/Sort1tm1Camo
(B6.129X1-Sort1tm1Camo)
|
abnormal tumor necrosis factor level
|
J:157549
|
Sos1tm1.1Les/Sos1tm1.1Les Tg(Lck-cre)1Cwi/0
(involves: 129 * C57BL/6)
|
decreased T cell proliferation
|
J:174536
|
Sox2tm3(TK)Hoch/Sox2+
(involves: 129S4/SvJae * C57BL/6)
|
stomach inflammation
|
J:177655
|
tongue inflammation
|
J:177655
|
Sox9em1(cre/ERT2)Smoc/Sox9+ Tnfsf18em1Pwan/Tnfsf18em1Pwan
(involves: C57BL/6J)
|
abnormal T cell activation
|
J:346395
|
decreased inflammatory response
|
J:346395
|
Sox13tm1Jskg/Sox13tm1Jskg
(involves: C57BL/6)
|
increased T cell proliferation
|
J:117301
|
Sox17tm1Ysk/Sox17+
(involves: 129S1/Sv * C57BL/6)
|
liver inflammation
|
J:194071
|
Sox17tm1Ysk/Sox17+
(B6.129S1-Sox17tm1Ysk)
|
gallbladder inflammation
|
J:241569
|
liver inflammation
|
J:194071
|
Sox17tm2Sjm/Sox17+ Tg(Pdx1-cre)6Tuv/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)
|
liver inflammation
|
J:241569
|
Sp140em1Vnce/Sp140em1Vnce
(C57BL/6J-Sp140em1Vnce)
|
increased susceptibility to bacterial infection
|
J:313901
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:313901
|
Sparctm1Hwe/Sparctm1Hwe
(involves: 129S/SvEv * C57BL/6J)
|
eye inflammation
|
J:52120
|
vitreous body inflammation
|
J:52120
|
Spata2tm1(KOMP)Vlcg/Spata2tm1(KOMP)Vlcg
(C57BL/6-Spata2tm1(KOMP)Vlcg)
|
increased inflammatory response
|
J:244164
|
spcy/spcy
(C57BL/6J-spcy)
|
abnormal innate immunity
|
J:94077
|
Spdeftm1Shiv/Spdeftm1Shiv
(involves: 129S4/SvJae)
|
small intestinal inflammation
|
J:166876
|
stomach inflammation
|
J:166876
|
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+ Trmutm1Tomik/Trmutm1Tomik
(involves: C57BL/6 * DBA)
|
abnormal inflammatory response
|
J:235644
|
Spef2bgh/Spef2bgh
(involves: 129S6/SvEvTac * C57BL/6J * C57BL/10J)
|
sinus inflammation
|
J:176695
|
Sphk1tm1.1Cgh/Sphk1tm2Cgh Sphk2tm1.1Cgh/Sphk2tm1.1Cgh Tg(Mx1-cre)1Cgn/0
(involves: 129S4/SvJae * C57BL/6 * CBA)
|
abnormal immune serum protein physiology
|
J:120783
|
Sphk1tm1Rlp/Sphk1tm1Rlp
(involves: 129S6/SvEvTac)
|
abnormal cytokine level
|
J:133917
|
decreased susceptibility to endotoxin shock
|
J:133917
|
Sphk2tm1.1Stlp/Sphk2tm1.1Stlp
(involves: BALB/c)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:153014
|
Sphk2tm1Npa/Sphk2tm1Npa
(BALB/c-Sphk2tm1Npa)
|
abnormal B cell migration
|
J:129314
|
Spi1tm1.3Dgt/Spi1tm1.3Dgt
(involves: 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6)
|
increased IgM level
|
J:106040
|
Spi1tm1Ram/Spi1tm1Ram
(involves: 129S2/SvPas * C57BL/6)
|
sepsis
|
J:36473
|
Spi1tm1Sing/Spi1+ Spibtm1Mcs/Spib+
(involves: 129S/SvEv * 129X1/SvJ)
|
decreased B cell proliferation
|
J:88257
|
Spi1tm1Sing/Spi1+ Spibtm1Mcs/Spibtm1Mcs
(involves: 129S/SvEv * 129X1/SvJ)
|
decreased B cell proliferation
|
J:88257
|
increased B cell apoptosis
|
J:88257
|
Spibtm1Ksho/Spibtm1Ksho
(involves: C57BL/6J)
|
increased susceptibility to bacterial infection
|
J:187649
|
Spibtm1Mcs/Spibtm1Mcs
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
decreased B cell proliferation
|
J:88257
|
Spibtm1Mcs/Spibtm1Mcs
(involves: 129S1/Sv * 129X1/SvJ)
|
abnormal humoral immune response
|
J:45245
|
decreased B cell proliferation
|
J:45245
|
decreased IgG1 level
|
J:45245
|
decreased IgG2a level
|
J:45245
|
decreased IgG2b level
|
J:45245
|
increased B cell apoptosis
|
J:45245
|
increased IgM level
|
J:45245
|
Spictm1.1Kmm/Spictm1.1Kmm
(involves: 129S6/SvEvTac * C57BL/6)
|
impaired macrophage phagocytosis
|
J:143900
|
Spictm1Kmm/Spictm1Kmm
(involves: 129S6/SvEvTac * C57BL/6)
|
impaired macrophage phagocytosis
|
J:143900
|
Spink7em1Cya/Spink7em1Cya
(C57BL/6N-Spink7em1Cya/Cya)
|
increased interleukin-1 beta secretion
|
J:310883
|
increased interleukin-6 secretion
|
J:310883
|
increased susceptibility to induced colitis
|
J:310883
|
Spink14tm1e(KOMP)Wtsi/Spink14tm1e(KOMP)Wtsi
(C57BL/6N-Spink14tm1e(KOMP)Wtsi/Wtsi)
|
increased anti-nuclear antigen antibody level
|
J:211773
|
Spint1tm2.1Hk/Spint1tm2.1Hk Tg(Vil1-cre)997Gum/0
(involves: C57BL/6 * C57BL/6J * SJL)
|
increased susceptibility to induced colitis
|
J:179937
|
Spir1BALB/cOlaHsd/Spir1BALB/cOlaHsd
(involves: BALB/cOlaHsd * CBA/CaOlaHsd)
|
decreased susceptibility to bacterial infection
|
J:84089
|
Spir1BALB/cOlaHsd/Spir1CBA/CaOlaHsd
(involves: BALB/cOlaHsd * CBA/CaOlaHsd)
|
decreased susceptibility to bacterial infection
|
J:84089
|
Spir1CBA/CaOlaHsd/Spir1CBA/CaOlaHsd
(involves: BALB/cOlaHsd * CBA/CaOlaHsd)
|
increased susceptibility to bacterial infection
|
J:84089
|
Spntm1Bam/Spntm1Bam
(involves: 129S4/SvJae * C57BL/6)
|
abnormal T cell physiology
|
J:29272
|
increased T cell proliferation
|
J:29272,
J:88252
|
Spntm1Bam/Spntm1Bam
(B6;129S4-Spntm1Bam/J)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:86932
|
Spns2tm1.1Nmoc/Spns2tm1.1Nmoc Tg(Tek-cre)1Ywa/0
(involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj * SJL)
|
abnormal B cell physiology
|
J:184558
|
abnormal T cell physiology
|
J:184558
|
Spns2tm1.2Nmoc/Spns2tm1.2Nmoc
(involves: C57BL/6NCrlj * CBA/JNCrlj)
|
abnormal B cell physiology
|
J:184558
|
abnormal T cell physiology
|
J:184558
|
Spns2tm1a(KOMP)Wtsi/Spns2tm1a(KOMP)Wtsi
(involves: C57BL/6 * C57BL/6N)
|
abnormal humoral immune response
|
J:188933
|
decreased IgG1 level
|
J:188933
|
decreased IgG level
|
J:188933
|
increased incidence of corneal inflammation
|
J:213427
|
increased susceptibility to bacterial infection
|
J:213427
|
Spon2tm1Mjb/Spon2tm1Mjb
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal interleukin level
|
J:87393
|
abnormal susceptibility to infection
|
J:87393
|
abnormal tumor necrosis factor level
|
J:87393
|
Spp1Ric-r/Spp1+
(AKR/J)
|
decreased susceptibility to bacterial infection
|
J:5949
|
Spp1Ric-r/Spp1+
(A/J)
|
decreased susceptibility to bacterial infection
|
J:5949
|
Spp1Ric-r/Spp1+
(BALB/cJ)
|
decreased susceptibility to bacterial infection
|
J:5949
|
Spp1Ric-r/Spp1+
(C57BL/6J)
|
decreased susceptibility to bacterial infection
|
J:5949
|
Spp1Ric-r/Spp1+
(C57L/J)
|
decreased susceptibility to bacterial infection
|
J:5949
|
Spp1Ric-r/Spp1+
(SWR/J)
|
decreased susceptibility to bacterial infection
|
J:5949
|
Spp1Ric-r/Spp1+
(C3H/Rv)
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:7240
|
Spp1Ric-s/Spp1+
(A/HeJ)
|
increased susceptibility to bacterial infection
|
J:5949
|
Spp1Ric-s/Spp1+
(C3H/HeJ)
|
increased susceptibility to bacterial infection
|
J:5949
|
Spp1Ric-s/Spp1+
(C3H/HeN)
|
increased susceptibility to bacterial infection
|
J:5949
|
Spp1Ric-s/Spp1+
(C3H/St)
|
increased susceptibility to bacterial infection
|
J:5949
|
Spp1Ric-s/Spp1+
(CBA/J)
|
increased susceptibility to bacterial infection
|
J:5949
|
Spp1Ric-s/Spp1+
(DBA/1J)
|
increased susceptibility to bacterial infection
|
J:5949
|
Spp1Ric-s/Spp1+
(DBA/2J)
|
increased susceptibility to bacterial infection
|
J:5949
|
Spp1Ric-s/Spp1+
(SJL/J)
|
increased susceptibility to bacterial infection
|
J:5949
|
Spp1tm1.1Dhd/Spp1tm1.1Dhd
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal osteoclast physiology
|
J:237104
|
Spp1tm1Blh/Spp1+
(BKSW.129S6-Spp1tm1Blh)
|
abnormal immune system physiology
|
J:113585
|
Spp1tm1Blh/Spp1+
(involves: 129S6/SvEvTac * Black Swiss)
|
abnormal leukocyte migration
|
J:86531
|
Spp1tm1Blh/Spp1tm1Blh
(involves: 129S6/SvEvTac * Black Swiss)
|
abnormal chemokine level
|
J:127389
|
abnormal leukocyte migration
|
J:86531
|
abnormal leukocyte physiology
|
J:86531
|
abnormal macrophage chemotaxis
|
J:140014
|
abnormal macrophage physiology
|
J:127389
|
abnormal response to infection
|
J:103013
|
abnormal susceptibility to infection
|
J:140014
|
decreased circulating interleukin-6 level
|
J:127389
|
granulomatous inflammation
|
J:140014
|
Spp1tm1Blh/Spp1tm1Blh
(B6.129S6-Spp1tm1Blh)
|
decreased susceptibility to experimental autoimmune uveoretinitis
|
J:116272
|
granulomatous inflammation
|
J:116272
|
Spp1tm1Blh/Spp1tm1Blh
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal immune system physiology
|
J:119298
|
Spp1tm1Blh/Spp1tm1Blh
(BKSW.129S6-Spp1tm1Blh)
|
abnormal immune system physiology
|
J:113585
|
impaired macrophage chemotaxis
|
J:113585
|
Spp1tm1Rit/Spp1tm1Rit
(involves: 129S7/SvEvBrd * C57BL/6)
|
abnormal inflammatory response
|
J:60284
|
abnormal osteoclast physiology
|
J:68872,
J:56353
|
abnormal response to infection
|
J:60284
|
decreased interferon-gamma secretion
|
J:60284
|
decreased interleukin-12 secretion
|
J:60284
|
decreased susceptibility to Herpesvirales infection
|
J:60284
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:60284
|
increased interleukin-4 secretion
|
J:60284
|
increased interleukin-10 secretion
|
J:60284
|
Spp1tm1Rit/Spp1tm1Rit
(B6.129S7-Spp1tm1Rit)
|
decreased acute inflammation
|
J:93915
|
decreased interferon-gamma secretion
|
J:93915
|
decreased tumor necrosis factor secretion
|
J:93915
|
Sppl2achompB/Sppl2achompB
(involves: C57BL/6)
|
abnormal class switch recombination
|
J:194595
|
abnormal humoral immune response
|
J:194595
|
decreased activation-induced B cell apoptosis
|
J:194595
|
decreased B cell proliferation
|
J:194595
|
decreased IgG1 level
|
J:194595
|
decreased IgG2b level
|
J:194595
|
decreased IgG3 level
|
J:194595
|
decreased IgM level
|
J:194595
|
Sppl2am1Anu/Sppl2am1Anu
(involves: C57BL/6JAnu)
|
abnormal immunoglobulin level
|
J:194663
|
decreased IgG1 level
|
J:194663
|
decreased IgM level
|
J:194663
|
Sppl2am1Btlr/Sppl2am1Btlr
(C57BL/6J-Sppl2am1Btlr)
|
decreased IgG level
|
J:236687
|
decreased response to antigen
|
J:236687
|
Sppl2am2Btlr/Sppl2am2Btlr
(C57BL/6J-Sppl2am2Btlr)
|
decreased IgG level
|
J:236688
|
decreased IgM level
|
J:236688
|
decreased response to antigen
|
J:236688
|
Sppl2atm1Basc/Sppl2atm1Basc
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6NCrl)
|
abnormal B cell calcium ion homeostasis
|
J:194664
|
abnormal B cell physiology
|
J:194664
|
decreased IgA level
|
J:194664
|
decreased IgG1 level
|
J:194664
|
decreased IgG2a level
|
J:194664
|
decreased IgG2b level
|
J:194664
|
decreased IgG3 level
|
J:194664
|
decreased IgM level
|
J:194664
|
Sppl2atm1Basc/Sppl2atm1Basc Sppl2bGt(Ayu21-T160)Imeg/Sppl2bGt(Ayu21-T160)Imeg
(B6N.Cg-Sppl2atm1Basc Sppl2bGt(Ayu21-T160)Imeg)
|
decreased immunoglobulin level
|
J:213519
|
Sppl2atm1Dgen/Sppl2atm1Dgen
(B6.129P2-Sppl2atm1Dgen)
|
decreased IgA level
|
J:194595
|
decreased IgG1 level
|
J:194595
|
decreased IgG2b level
|
J:194595
|
decreased IgG3 level
|
J:194595
|
decreased IgM level
|
J:194595
|
Sppl3tm1Itl/Sppl3tm1Itl Commd10Tg(Vav1-icre)A2Kio/Commd10+
(involves: 129S/SvEv * C57BL/6 * C57BL/10 * CBA/Ca)
|
impaired natural killer cell mediated cytotoxicity
|
J:280182
|
Sppl3tm1Itl/Sppl3tm1Itl Ncr1tm1.1(icre)Viv/Ncr1+
(involves: 129S/SvEv * C57BL/6)
|
abnormal NK cell physiology
|
J:280182
|
impaired natural killer cell mediated cytotoxicity
|
J:280182
|
Spred1tm1.1Ayos/Spred1tm1.1Ayos
(involves: 129 * C57BL/6 * SJL)
|
increased mast cell degranulation
|
J:186742
|
Spred1tm1Hiin/Spred1tm1Hiin
(involves: C57BL/6)
|
abnormal cytokine secretion
|
J:95263
|
abnormal eosinophil physiology
|
J:95263
|
Spta1sph-ha/Spta1sph-ha
(either: (B6.D1-Spta1sph-ha x WB.D1-Spta1sph-ha)F1 or (WB.D1-Spta1sph-ha x B6.D1-Spta1sph-ha)F1)
|
alveolitis
|
J:12830
|
increased B cell proliferation
|
J:1967
|
increased IgA level
|
J:12830
|
increased IgG level
|
J:12830
|
increased susceptibility to bacterial infection
|
J:12830
|
increased T cell proliferation
|
J:1967
|
interstitial pneumonia
|
J:12830
|
Spta1sph/Spta1sph
(either: (B6.C3-Spta1sph x WB.C3-Spta1sph)F1 or (WB.C3-Spta1sph x B6.C3-Spta1sph)F1)
|
decreased susceptibility to parasitic infection
|
J:111131
|
Spta1sph/Spta1sph
((WB.C3-Spta1sph x B6.C3-Spta1sph)F1)
|
glomerulonephritis
|
J:44313
|
tubular nephritis
|
J:44313
|
Sptbja/Sptbja
((WB.129-Sptbja/J x B6.129-Sptbja/J)F1)
|
glomerulonephritis
|
J:44313
|
tubular nephritis
|
J:44313
|
Sptbn4qv/Sptbn4qv
(either: (involves: BALB/c) or (involves: C57BL/10))
|
eye inflammation
|
J:167
|
Sptlc2tm1Yhir/Sptlc2tm1Yhir Tg(KRT5-cre)1Tak/0
(involves: C3H * C57BL/6)
|
abnormal Langerhans cell physiology
|
J:202388
|
skin inflammation
|
J:202388
|
Sqstm1tm1Jjw/Sqstm1tm1Jjw
(involves: 129 * C57BL/6)
|
abnormal osteoclast physiology
|
J:141179
|
Sqstm1tm1Jmos/Sqstm1tm1Jmos
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
decreased interleukin-6 secretion
|
J:90010
|
Sqstm1tm1Keta/Sqstm1tm1Keta
(involves: 129 * C57BL/6N)
|
abnormal osteoclast physiology
|
J:264183
|
Sra1tm1a(EUCOMM)Hmgu/Sra1tm1a(EUCOMM)Hmgu
(involves: C57BL/6J * C57BL/6N)
|
decreased circulating tumor necrosis factor level
|
J:214131
|
Srctm1Sor/Srctm1Sor
(either: 129S7/SvEvBrd-Srctm1Sor or (involves: 129S7/SvEvBrd * C57BL/6J))
|
increased inflammatory response
|
J:67040
|
periodontium inflammation
|
J:67040
|
Srcr/Srcr+
(BALB/c-Srcr/Cui)
|
abnormal innate immunity
|
J:83618
|
Sros1em1Caox/Sros1em1Caox
(involves: C57BL/6J)
|
abnormal circulating chemokine level
|
J:306407
|
decreased susceptibility to bacterial infection
|
J:306407
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:306407
|
increased circulating CXCL10 level
|
J:306407
|
SrrRgsc34/Srr+
(involves: C57BL/6JJcl * DBA/2JJcl)
|
abnormal neutrophil physiology
|
J:133634
|
Srrttm1.1Thsn/Srrttm1.2Thsn Tg(Mx1-cre)1Cgn/0
(involves: C57BL/6 * CBA)
|
abnormal thymus physiology
|
J:152729
|
increased splenocyte apoptosis
|
J:152729
|
Srxn1tm1Mtol/Srxn1tm1Mtol
(either: B6.129S2-Srxn1tm1Mtol or (involves: 129S2/SvPasCrl * C57BL/6))
|
increased susceptibility to endotoxin shock
|
J:199277
|
Ss18l1em1Zqi/Ss18l1+
(involves: C57BL/6)
|
increased microglial cell activation
|
J:278840
|
Ss18l1em1Zqi/Ss18l1em1Zqi
(involves: C57BL/6)
|
increased microglial cell activation
|
J:278840
|
Ss18l1em2Zqi/Ss18l1em2Zqi
(involves: C57BL/6)
|
increased microglial cell activation
|
J:278840
|
Ssbtm1Rjma/Ssbtm2.1Rjma Cd79atm1(cre)Reth/Cd79a+
(involves: 129S/SvEv * BALB/c)
|
decreased IgG level
|
J:207687
|
decreased IgM level
|
J:207687
|
Ssbp2tm1Lana/Ssbp2tm1Lana
(involves: 129S/SvEv * C57BL/6)
|
arteritis
|
J:162035
|
Ssial1NOD/Ssial1NOD
(involves: C57BL/6J * NOD)
|
periinsulitis
|
J:11442
|
salivary gland inflammation
|
J:75908
|
Ssial2NOD/?
(involves: C57BL/6J * NOD)
|
salivary gland inflammation
|
J:75908
|
Ssial3NOD/Ssial3NOD
(involves: C57BL/6J * NOD)
|
salivary gland inflammation
|
J:75908
|
Ssial4C57BL/6/Ssial4NOD
(involves: C57BL/6J * NOD)
|
salivary gland inflammation
|
J:75908
|
Ssial4NOD/Ssial4NOD
(involves: C57BL/6J * NOD)
|
salivary gland inflammation
|
J:75908
|
Sst1C3HeB/FeJ/Sst1C3HeB/FeJ
(involves: C3HeB/FeJ * C57BL/6J)
|
increased susceptibility to bacterial infection
|
J:63410
|
Sst1C3HeB/FeJ/Sst1C3HeB/FeJ
(B6.C3-Sst1C3HeB/FejKrmn/Mmnc)
|
increased susceptibility to bacterial infection
|
J:313901
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:313901
|
Sst1C3HeB/FeJ/Sst1C57BL/6J
(involves: C3HeB/FeJ * C57BL/6J)
|
decreased susceptibility to bacterial infection
|
J:63410
|
Sst1C57BL/6J/Sst1C57BL/6J
(involves: C3HeB/FeJ * C57BL/6J)
|
decreased susceptibility to bacterial infection
|
J:63410,
J:93705
|
Sstr4tm1Szo/Sstr4tm1Szo
(B6.129P2-Sstr4tm1Szo)
|
abnormal neutrophil physiology
|
J:152015
|
increased interferon-gamma secretion
|
J:152015
|
increased interleukin-1 beta secretion
|
J:152015
|
increased susceptibility to type IV hypersensitivity reaction
|
J:152015
|
increased tumor necrosis factor secretion
|
J:152015
|
Ssu72tm1Cwl/Ssu72tm1Cwl Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(B6.Cg-Ssu72tm1Cwl Speer6-ps1Tg(Alb-cre)21Mgn)
|
liver inflammation
|
J:309624
|
St3gal2tm1Jxm/St3gal2tm1Jxm
(Not Specified)
|
decreased T cell proliferation
|
J:217719
|
St3gal4tm1.1Jxm/St3gal4tm1.1Jxm
(B6.129-St3gal4tm1.1Jxm)
|
abnormal leukocyte tethering or rolling
|
J:117085
|
abnormal response to infection
|
J:136946
|
St3gal4tm1.1Jxm/St3gal4tm1.1Jxm
(involves: 129S1/Sv * 129X1/SvJ)
|
abnormal leukocyte migration
|
J:189086
|
St3gal4tm1.1Jxm/St3gal4tm1.1Jxm St3gal6tm1.1Jxm/St3gal6tm1.1Jxm
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal leukocyte migration
|
J:189086
|
impaired leukocyte tethering or rolling
|
J:189086
|
impaired neutrophil recruitment
|
J:189086
|
St3gal6tm1.1Jxm/St3gal6tm1.1Jxm
(B6.Cg-St3gal6tm1.1Jxm)
|
impaired leukocyte tethering or rolling
|
J:189086
|
impaired neutrophil recruitment
|
J:189086
|
St6gal1tm1Jlau/St6gal1tm1Jlau
(129S4/SvJae-St6gal1tm1Jlau)
|
abnormal neutrophil physiology
|
J:140702
|
increased susceptibility to bacterial infection
|
J:140702
|
St6gal1tm1Jlau/St6gal1tm1Jlau
(B6.129S4-St6gal1tm1Jlau)
|
abnormal neutrophil physiology
|
J:140547
|
peritoneal inflammation
|
J:140547
|
St6gal1tm1Jxm/St6gal1tm1Jxm
(involves: 129S1/Sv * 129X1/SvJ)
|
abnormal dendritic cell physiology
|
J:132991
|
peritoneal inflammation
|
J:140547
|
St6galnac1em1Len/St6galnac1em1Len
(Not Specified)
|
increased susceptibility to colitis induced morbidity/mortality
|
J:324883
|
St6galnac2tm1.1Cfg/St6galnac2tm1.1Cfg
(involves: 129S1/Sv * 129X1/SvJ)
|
decreased IgA level
|
J:217719
|
increased B cell proliferation
|
J:217719
|
St6galnac3em1Staka/St6galnac3em1Staka St6galnac4em1Staka/St6galnac4em1Staka
(C57BL/6J-St6galnac3em1Staka St6galnac4em1Staka)
|
lymph node hemorrhage
|
J:340690
|
St8sia1tm1Kfk/St8sia1tm1Kfk
(Not Specified)
|
increased T cell proliferation
|
J:73818
|
St13em1Gwzh/St13em1Gwzh Tg(PRSS1/lacZ)#Gwzh/0
(Not Specified)
|
increased susceptibility to induced pancreatitis
|
J:345508
|
St14tm1Bug/St14tm1Bug
(involves: 129P2/OlaHsd * Black Swiss)
|
increased thymocyte apoptosis
|
J:87125
|
St14tm2Bug/St14tm3Bug Tg(MMTV-cre)4Mam/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J * FVB/NJ * N:Black Swiss)
|
abnormal chemokine secretion
|
J:213072
|
abnormal cytokine secretion
|
J:213072
|
increased anti-nuclear antigen antibody level
|
J:213072
|
increased autoantibody level
|
J:213072
|
lacrimal gland inflammation
|
J:213072
|
submandibular gland inflammation
|
J:213072
|
St14tm2Bug/St14tm3Bug Tg(Vil1-cre)997Gum/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * Black Swiss * C57BL/6 * SJL)
|
colitis
|
J:153070
|
Stamtm2Sug/Stamtm2Sug Stam2tm1Sug/Stam2tm1Sug Tg(Lck-cre)I57Jxm/0
(involves: 129S4/SvJae * C57BL/6 * ICR)
|
decreased T cell proliferation
|
J:80617
|
Stard7tm1a(EUCOMM)Wtsi/Stard7+
(involves: C57BL/6N)
|
dermatitis
|
J:242746
|
increased susceptibility to type I hypersensitivity reaction
|
J:242746
|
lung inflammation
|
J:242746
|
Stard13tm1a(KOMP)Wtsi/Stard13tm1a(KOMP)Wtsi
(involves: C57BL/6 * C57BL/6N)
|
increased susceptibility to bacterial infection
|
J:213427
|
Stat1fae/Stat1fae
(C57BL/6JSfdAnu-Stat1fae/Anu)
|
abnormal T cell activation
|
J:105311
|
abnormal T-helper 2 physiology
|
J:105311
|
increased IgG level
|
J:105311
|
Stat1m1Anu/Stat1m1Anu
(C57BL/6JSfdAnu-Stat1m1Anu)
|
abnormal response to infection
|
J:104190
|
Stat1m1Btlr/Stat1m1Btlr
(C57BL/6J-Stat1m1Btlr)
|
abnormal macrophage physiology
|
J:105543
|
increased susceptibility to Herpesvirales infection
|
J:105543
|
increased susceptibility to Riboviria infection
|
J:105543
|
Stat1m2Btlr/Stat1m2Btlr
(C57BL/6J-Stat1m2Btlr)
|
decreased interferon-gamma secretion
|
J:134096
|
decreased NK cell degranulation
|
J:134096
|
impaired natural killer cell mediated cytotoxicity
|
J:134096
|
increased susceptibility to Herpesvirales infection
|
J:134096
|
Stat1m3Btlr/Stat1m3Btlr
(C57BL/6J-Stat1m3Btlr)
|
impaired natural killer cell mediated cytotoxicity
|
J:254835
|
Stat1m5Btlr/Stat1m5Btlr
(C57BL/6J-Stat1m5Btlr)
|
decreased cytotoxic T cell cytolysis
|
J:274938
|
Stat1tm1Dlv/Stat1tm1Dlv
(either: (involves: 129S/SvEv * C57BL/6) or (involves: 129S/SvEv * C57BL/6 * CD-1))
|
abnormal leukocyte physiology
|
J:31325
|
increased susceptibility to Coronaviridae infection
|
J:31325
|
increased susceptibility to Riboviria infection
|
J:31325
|
Stat1tm1Dlv/Stat1tm1Dlv
(B6.129-Stat1tm1Dlv)
|
increased susceptibility to Herpesvirales infection
|
J:81243
|
increased susceptibility to Togaviridae infection
|
J:81243
|
Stat1tm1Dlv/Stat1tm1Dlv
(involves: 129S/SvEv)
|
abnormal MHC II cell surface expression on macrophages
|
J:130622
|
decreased level of surface class I molecules
|
J:130622
|
decreased susceptibility to endotoxin shock
|
J:130622
|
increased circulating interferon-gamma level
|
J:130622
|
increased susceptibility to bacterial infection
|
J:130622
|
increased susceptibility to Riboviria infection
|
J:130622
|
Stat1tm1Dlv/Stat1tm1Dlv
(B6.129S-Stat1tm1Dlv)
|
abnormal NK cell physiology
|
J:79552
|
impaired natural killer cell mediated cytotoxicity
|
J:79552
|
increased circulating interferon-gamma level
|
J:79552
|
increased circulating interleukin-12b level
|
J:79552
|
Stat1tm1Dlv/Stat1tm1Dlv Tg(ANPEP)270Mmul/Tg(ANPEP)270Mmul
(involves: 129S/SvEv * ICR)
|
increased susceptibility to Coronaviridae infection
|
J:99728
|
Stat1tm1Dlv/Stat1tm1Dlv Tg(ANPEP)861Mmul/Tg(ANPEP)861Mmul
(involves: 129S/SvEv * ICR)
|
increased susceptibility to Coronaviridae infection
|
J:99728
|
Stat1tm1Rds/Stat1tm1Rds
(either: (involves: 129/Sv) or (involves: 129/Sv * C57BL/6))
|
increased susceptibility to bacterial infection
|
J:31326
|
increased susceptibility to Riboviria infection
|
J:31326
|
Stat1tm1Rds/Stat1tm1Rds
(involves: 129)
|
increased susceptibility to Herpesvirales infection
|
J:81243
|
increased susceptibility to Riboviria infection
|
J:66564
|
increased susceptibility to Togaviridae infection
|
J:81243
|
Stat1tm1Rds/Stat1tm1Rds
(129S6/SvEv-Stat1tm1Rds/Tac)
|
abnormal macrophage physiology
|
J:136368
|
bronchiolitis
|
J:286237
|
decreased circulating interferon-gamma level
|
J:122801
|
decreased interleukin-1 beta secretion
|
J:136368
|
increased susceptibility to Coronaviridae infection
|
J:286237
|
increased susceptibility to Coronaviridae infection induced morbidity/mortality
|
J:286237
|
lung inflammation
|
J:286237
|
peritoneal inflammation
|
J:286237
|
pleuritis
|
J:286237
|
Stat1tm1Rds/Stat1tm1Rds Stat2tm1Shnd/Stat2tm1Shnd
(involves: 129/Sv * 129S1/Sv * 129X1/SvJ)
|
increased susceptibility to Riboviria infection
|
J:66564
|
Stat1tm1Rds/Stat1tm1Rds Stat3tm2Aki/Stat3tm2Aki Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6)
|
colitis
|
J:83280
|
increased interferon-gamma secretion
|
J:83280
|
increased interleukin-6 secretion
|
J:83280
|
increased tumor necrosis factor secretion
|
J:83280
|
Stat1tm1Tdec/Stat1tm1Tdec
(involves: 129P2/OlaHsd * BALB/c)
|
abnormal macrophage physiology
|
J:130622
|
abnormal MHC II cell surface expression on macrophages
|
J:130622
|
decreased susceptibility to endotoxin shock
|
J:130622
|
increased susceptibility to bacterial infection
|
J:130622
|
increased susceptibility to Riboviria infection
|
J:130622
|
Stat1tm1Uvin/Stat1tm1Uvin
(involves: 129 * C57BL/6)
|
increased macrophage nitric oxide production
|
J:174863
|
Stat1tm2.1Uvin/Stat1tm2.1Uvin
(B6.129P2-Stat1tm2.1Uvin)
|
decreased susceptibility to endotoxin shock
|
J:209388
|
increased susceptibility to bacterial infection
|
J:209388
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:209388
|
Stat2p117/Stat2p117
(C57BL/6J-Stat2P117)
|
abnormal level of surface class II molecules
|
J:164049
|
decreased level of surface class I molecules
|
J:164049
|
increased susceptibility to Picornaviridae infection induced morbidity/mortality
|
J:164049
|
Stat2tm1.1(STAT2)Diam/Stat2tm1.1(STAT2)Diam
(C57BL/6-Stat2tm1.1(STAT2)Diam)
|
increased susceptibility to Flaviviridae infection
|
J:261503
|
increased susceptibility to Flaviviridae infection induced morbidity/mortality
|
J:261503
|
Stat2tm1Shnd/Stat2tm1Shnd
(involves: 129S1/Sv * 129X1/SvJ)
|
increased susceptibility to Riboviria infection
|
J:66564
|
Stat3tm1Aki/Stat3tm1Aki Tg(Tek-cre)12Flv/0
(involves: 129P2/OlaHsd * C3H * C57BL/6)
|
abnormal interleukin level
|
J:123351
|
Stat3tm1Desi/Stat3tm1Desi
(involves: 129X1/SvJ * C57BL/6)
|
increased susceptibility to endotoxin shock
|
J:77307
|
Stat3tm1Dlv/Stat3tm1Dlv Tg(Cd4-cre)1Cwi/?
(involves: 129 * C57BL/6 * DBA/2)
|
decreased interleukin-17 secretion
|
J:124293
|
increased interferon-gamma secretion
|
J:124293
|
Stat3tm1Dlv/Stat3tm1Dlv Tg(Csf1r-icre)1Jwp/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB)
|
abnormal acute inflammation
|
J:156593
|
abnormal inflammatory response
|
J:156593
|
colitis
|
J:156593
|
Stat3tm1Dnl/Stat3tm1Dlv
(involves: C57BL/6)
|
increased thymocyte apoptosis
|
J:87599
|
Stat3tm1Flv/Stat3tm1Flv Tg(Tek-cre)1Xyfu/0
(involves: C57BL/6)
|
abnormal cytokine secretion
|
J:86655
|
increased susceptibility to endotoxin shock
|
J:86655
|
Stat3tm1Flv/Stat3tm1Flv Tg(Tek-cre)12Flv/0
(involves: 129 * C3H * C57BL/6)
|
abnormal inflammatory response
|
J:81973
|
abnormal innate immunity
|
J:81973
|
abnormal T-helper 1 physiology
|
J:81973
|
cecum inflammation
|
J:81973
|
colitis
|
J:81973
|
granulomatous inflammation
|
J:81973
|
ileum inflammation
|
J:81973
|
increased circulating interferon-gamma level
|
J:81973
|
increased circulating tumor necrosis factor level
|
J:81973
|
intestinal inflammation
|
J:81973
|
liver inflammation
|
J:81973
|
Stat3tm1Vpo/Stat3tm1Vpo Tg(Mx1-cre)1Cgn/0
(involves: 129P2/OlaHsd * BALB/cAn * C57BL/6 * CBA)
|
abnormal macrophage physiology
|
J:89194
|
increased interleukin-6 secretion
|
J:89194
|
increased tumor necrosis factor secretion
|
J:89194
|
Stat3tm1Vpo/Stat3tm2Vpo Tg(Mx1-cre)1Cgn/0
(involves: C57BL/6 * CBA * BALB/cAn)
|
abnormal macrophage physiology
|
J:89194
|
increased interleukin-6 secretion
|
J:89194
|
increased tumor necrosis factor secretion
|
J:89194
|
Stat3tm1Xyfu/Stat3+ Tg(Myh6-cre)2182Mds/0
(involves: 129S1/Sv * FVB/N)
|
increased susceptibility to endotoxin shock
|
J:86400
|
increased tumor necrosis factor secretion
|
J:86400
|
Stat3tm1Xyfu/Stat3tm1.1Xyfu Tg(Myh6-cre)2182Mds/0
(involves: 129S1/Sv * FVB/N)
|
increased susceptibility to endotoxin shock
|
J:86400
|
increased tumor necrosis factor secretion
|
J:86400
|
Stat3tm2Aki/Stat3tm2Aki
(involves: 129P2/OlaHsd * BALB/c * C57BL/6)
|
abnormal response to infection
|
J:122213
|
Stat3tm2Aki/Stat3tm2Aki Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * C57BL/6)
|
colitis
|
J:83280
|
increased interferon-gamma secretion
|
J:83280
|
increased interleukin-12 secretion
|
J:83280
|
Stat3tm2Aki/Stat3tm2Aki Tg(KRT5-cre)1Tak/0
(involves: 129P2/OlaHsd * C3H * C57BL/6)
|
conjunctivitis
|
J:194832
|
dermatitis
|
J:194832
|
lacrimal gland inflammation
|
J:194832
|
Stat3tm2Aki/Stat3tm2Aki Tg(Lck-cre)1Jtak/0
(involves: 129P2/OlaHsd)
|
decreased T cell proliferation
|
J:50443
|
increased T cell apoptosis
|
J:50443
|
Stat3tm2Aki/Stat3tm2Aki Tg(SFTPC-rtTA)5Jaw/0 Tg(tetO-cre)1Jaw/0
(involves: 129 * 129P2/OlaHsd * C57BL/6)
|
abnormal cytokine level
|
J:87622
|
lung inflammation
|
J:87622
|
Stat3tm2Aki/Stat3tm2Aki Tlr4tm1Aki/Tlr4tm1Aki Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * C57BL/6)
|
colitis
|
J:83280
|
decreased interferon-gamma secretion
|
J:83280
|
decreased susceptibility to endotoxin shock
|
J:83280
|
Stat3tm2Aki/Stat3tm2Aki Tnftm1Sek/Tnftm1Sek Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
colitis
|
J:83280
|
increased interferon-gamma secretion
|
J:83280
|
increased interleukin-6 secretion
|
J:83280
|
increased interleukin-12b secretion
|
J:83280
|
Stat3tm3Vpo/Stat3tm3Vpo
(involves: C57BL/6 * CBA * BALB/cAn)
|
abnormal macrophage physiology
|
J:89194
|
Stat4ity14/Stat4ity14
(involves: 129S1/Sv * 129X1/SvJ)
|
decreased circulating interferon-gamma level
|
J:207092
|
decreased interferon-gamma secretion
|
J:207092
|
increased circulating interleukin-12 level
|
J:207092
|
increased susceptibility to bacterial infection
|
J:207092
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:207092
|
Stat4ity14/Stat4tm1Gru
(involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ)
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:207092
|
Stat4tm1Gru/Stat4tm1Gru
(involves: 129S2/SvPas * BALB/c)
|
abnormal lymphocyte physiology
|
J:34059
|
abnormal NK cell physiology
|
J:34059
|
abnormal T cell proliferation
|
J:34059
|
abnormal T-helper 1 physiology
|
J:34059
|
abnormal T-helper 2 physiology
|
J:34059
|
decreased circulating interferon-gamma level
|
J:163843
|
decreased interferon-gamma secretion
|
J:34059
|
increased susceptibility to bacterial infection
|
J:163843
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:163843
|
Stat4tm1Gru/Stat4tm1Gru
(NOD.129S2-Stat4tm1Gru)
|
abnormal inflammatory response
|
J:90600
|
decreased circulating interferon-gamma level
|
J:90600
|
decreased circulating interleukin-2 level
|
J:90600
|
decreased susceptibility to autoimmune diabetes
|
J:90600
|
Stat4tm1Gru/Stat4tm1Gru
(C.129S2-Stat4tm1Gru)
|
decreased circulating interferon-gamma level
|
J:90600
|
decreased circulating interleukin-2 level
|
J:90600
|
Stat4tm1Gru/Stat4tm1Gru
(involves: 129S2/SvPas)
|
abnormal cytokine secretion
|
J:112600
|
Stat4tm1Gru/Stat4tm1Gru Tg(Ins2-GP)34-20Olds/0
(involves: 129S2/SvPas * BALB/c * C57BL/6)
|
abnormal susceptibility to autoimmune disorder
|
J:107047
|
Stat4tm1Gru/Stat4tm1Gru Tg(Ins2-NP)25-3Olds/0
(involves: 129S2/SvPas * BALB/c * C57BL/6)
|
abnormal cytotoxic T cell physiology
|
J:107047
|
decreased interferon-gamma secretion
|
J:107047
|
decreased susceptibility to autoimmune diabetes
|
J:107047
|
insulitis
|
J:107047
|
Stat4tm1Jni/Stat4tm1Jni
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal NK cell physiology
|
J:79552
|
decreased circulating interferon-gamma level
|
J:79552
|
decreased susceptibility to autoimmune diabetes
|
J:96338
|
increased interleukin-4 secretion
|
J:96338
|
Stat4tm1Jni/Stat4tm1Jni Stat6tm1Jni/Stat6tm1Jni
(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)
|
decreased interleukin-4 secretion
|
J:96338
|
increased interferon-gamma secretion
|
J:96338
|
increased susceptibility to autoimmune diabetes
|
J:96338
|
Stat5atm1.1Wjl/Stat5atm1.1Wjl Stat5btm2.1Wjl/Stat5btm2.1Wjl
(involves: 129S6/SvEvTac * C57BL/6J * FVB/N)
|
abnormal regulatory T cell physiology
|
J:187325
|
decreased T cell proliferation
|
J:187325
|
increased T cell apoptosis
|
J:187325
|
Stat5atm1Jni/Stat5atm1Jni Stat5btm2Jni/Stat5btm2Jni
(involves: 129 * C57BL/6)
|
abnormal mast cell physiology
|
J:84889
|
Stat5atm1Mam/Stat5atm1Mam
(involves: 129S6/SvEvTac * C57BL/6)
|
impaired natural killer cell mediated cytotoxicity
|
J:112035
|
Stat5atm2Mam/Stat5atm2Mam Stat5btm1Mam/Stat5btm1Mam Tg(Cd4-cre)1Cwi/0
(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * DBA/2)
|
increased circulating interleukin-17 level
|
J:120176
|
increased interleukin-17 secretion
|
J:120176
|
Stat5atm2Mam/Stat5atm2Mam Stat5btm1Mam/Stat5btm1Mam Tg(Lck-cre)I57Jxm/0
(involves: 129 * 129S6/SvEvTac * C57BL/6 * ICR)
|
abnormal acute inflammation
|
J:122463
|
Stat5atm2Mam/Stat5atm2Mam Stat5btm1Mam/Stat5btm1Mam Tg(Mx1-cre)1Cgn/0
(involves: 129S6/SvEvTac * C57BL/6 * CBA)
|
abnormal neutrophil physiology
|
J:155489
|
Stat5btm1Hwd/Stat5btm1Hwd
(involves: C57BL/6)
|
decreased T cell proliferation
|
J:112035
|
impaired natural killer cell mediated cytotoxicity
|
J:112035
|
Stat5btm1Mam/Stat5btm1Mam Tg(Cd4-cre)1Cwi/0
(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * DBA/2)
|
increased circulating interleukin-17 level
|
J:120176
|
increased interleukin-17 secretion
|
J:120176
|
Stat5btm1Mam/Stat5btm1Mam Tg(Lck-cre)I57Jxm/0
(involves: 129 * 129S6/SvEvTac * C57BL/6 * ICR)
|
abnormal acute inflammation
|
J:122463
|
Stat5btm1Mam/Stat5btm1Mam Tg(Mx1-cre)1Cgn/0
(involves: 129S6/SvEvTac * C57BL/6 * CBA)
|
abnormal neutrophil physiology
|
J:155489
|
Stat6tm1Aki/Stat6tm1Aki
(involves: 129P2/OlaHsd)
|
abnormal T-helper 2 physiology
|
J:32561
|
decreased B cell proliferation
|
J:32561
|
decreased IgE level
|
J:32561
|
decreased IgG1 level
|
J:32561
|
decreased T cell proliferation
|
J:32561
|
increased IgA level
|
J:32561
|
increased IgG level
|
J:32561
|
Stat6tm1Aki/Stat6tm1Aki
(C.129P2-Stat6tm1Aki Nfkbiztm1Aki)
|
skin inflammation
|
J:141704
|
Stat6tm1Aki/Stat6tm1Aki Tg(KRT14-CASP1)1Miz/0
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased IgE level
|
J:78602
|
decreased IgG1 level
|
J:78602
|
dermatitis
|
J:78602
|
increased circulating interleukin-18 level
|
J:78602
|
Stat6tm1Gru/Stat6+ Tg(Scgb1a1-Il13)2Eli/?
(involves: 129S2/SvPas * C57BL/6 * CBA)
|
respiratory system inflammation
|
J:132385
|
Stat6tm1Gru/Stat6tm1Gru
(C.129S2-Stat6tm1Gru/J)
|
abnormal humoral immune response
|
J:107370
|
decreased IgA level
|
J:107370
|
decreased IgG3 level
|
J:107370
|
decreased IgM level
|
J:107370
|
decreased interleukin-4 secretion
|
J:107370
|
decreased susceptibility to Herpesvirales infection
|
J:107370
|
increased interferon-gamma secretion
|
J:107370
|
increased interleukin-2 secretion
|
J:107370
|
Stat6tm1Gru/Stat6tm1Gru
(129S2/SvPas-Stat6tm1Gru)
|
abnormal interleukin secretion
|
J:31932
|
decreased IgE level
|
J:31932
|
decreased interleukin-4 secretion
|
J:31932
|
decreased interleukin-5 secretion
|
J:31932
|
decreased T cell proliferation
|
J:31932
|
Stat6tm1Gru/Stat6tm1Gru
(involves: 129S2/SvPas)
|
abnormal cytokine secretion
|
J:112600
|
Stat6tm1Gru/Stat6tm1Gru
(involves: 129S2/SvPas * BALB/c)
|
abnormal acute inflammation
|
J:85386
|
abnormal granulocyte physiology
|
J:85386
|
abnormal macrophage physiology
|
J:85386
|
impaired eosinophil chemotaxis
|
J:85386
|
impaired neutrophil chemotaxis
|
J:85386
|
increased circulating tumor necrosis factor level
|
J:85386
|
Stat6tm1Gru/Stat6tm1Gru
(C.129S2-Stat6tm1Gru)
|
abnormal circulating interleukin level
|
J:66222
|
abnormal circulating interleukin-4 level
|
J:66222
|
abnormal circulating interleukin-5 level
|
J:66222
|
abnormal cytotoxic T cell physiology
|
J:65894
|
abnormal immune serum protein physiology
|
J:66222
|
abnormal immunoglobulin level
|
J:66222
|
abnormal leukocyte migration
|
J:74497
|
abnormal leukocyte physiology
|
J:74497
|
decreased IgE level
|
J:74497,
J:66222
|
decreased IgG1 level
|
J:66222
|
impaired eosinophil recruitment
|
J:66222
|
increased IgG2a level
|
J:66222
|
Stat6tm1Jni/Stat6tm1Jni
(involves: 129S/SvEv)
|
abnormal B cell physiology
|
J:32607
|
abnormal B cell proliferation
|
J:32607
|
abnormal class switch recombination
|
J:32607
|
abnormal level of surface class II molecules
|
J:32607
|
increased B cell apoptosis
|
J:146533
|
Stat6tm1Jni/Stat6tm1Jni
(involves: 129S/SvEv * C57BL/6)
|
decreased IgE level
|
J:51096
|
decreased IgG1 level
|
J:51096
|
decreased interleukin-4 secretion
|
J:96338
|
decreased susceptibility to autoimmune diabetes
|
J:96338
|
increased IgE level
|
J:110429
|
increased IgG1 level
|
J:110429
|
increased IgG2a level
|
J:51096
|
increased interferon-gamma secretion
|
J:51096,
J:96338
|
increased interleukin-12 secretion
|
J:51096
|
increased susceptibility to parasitic infection
|
J:110429
|
Steap3tm1.1Atel/Steap3tm1.1Atel
(involves: C57BL/6)
|
decreased splenocyte apoptosis
|
J:154356
|
Stia1NOD/ShiLtDoi/?
(involves: C57BL/6J * NOD/LtDoi)
|
increased inflammatory response
|
J:70882
|
Stia2C57BL/6J/Stia2C57BL/6J
(involves: C57BL/6J * NOD/LtDoi)
|
increased inflammatory response
|
J:70882
|
Stia2C57BL/6J/Stia2NOD/ShiLtDoi
(involves: C57BL/6J * NOD/LtDoi)
|
increased inflammatory response
|
J:70882
|
Stim1tm1.1Kuro/Stim1+
(C57BL/6-Stim1tm1.1Kuro)
|
decreased susceptibility to type I hypersensitivity reaction
|
J:130477
|
Stim1tm1.1Kuro/Stim1tm1.1Kuro
(C57BL/6-Stim1tm1.1Kuro)
|
abnormal cytokine secretion
|
J:130477
|
abnormal interleukin secretion
|
J:130477
|
decreased interleukin-6 secretion
|
J:130477
|
decreased interleukin-13 secretion
|
J:130477
|
decreased mast cell degranulation
|
J:130477
|
decreased tumor necrosis factor secretion
|
J:130477
|
Stim1tm1Kuro/Stim1tm1Kuro Cd79atm1(cre)Reth/Cd79a+
(involves: BALB/c * C57BL/6)
|
abnormal B cell calcium ion homeostasis
|
J:172608
|
decreased B cell proliferation
|
J:172608
|
decreased interleukin-10 secretion
|
J:172608
|
Stim1tm1Kuro/Stim1tm1Kuro Stim2tm1.1Kuro/Stim2tm1.1Kuro Cd79atm1(cre)Reth/Cd79a+
(involves: BALB/c * C57BL/6)
|
abnormal B cell calcium ion homeostasis
|
J:172608
|
abnormal B cell physiology
|
J:172608
|
decreased B cell proliferation
|
J:172608
|
decreased interleukin-10 secretion
|
J:172608
|
increased interferon-gamma secretion
|
J:172608
|
increased interleukin-10 secretion
|
J:172608
|
increased interleukin-17 secretion
|
J:172608
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:172608
|
Stim1tm1Rao/Stim1tm1Rao Stim2tm1Rao/Stim2tm1Rao Tg(Cd4-cre)1Cwi/0
(involves: C57BL/6 * DBA/2 * SJL)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:133262
|
abnormal immune system physiology
|
J:133262
|
blepharitis
|
J:133262
|
decreased interferon-gamma secretion
|
J:133262
|
decreased interleukin-2 secretion
|
J:133262
|
decreased T cell proliferation
|
J:133262
|
dermatitis
|
J:133262
|
increased IgG1 level
|
J:133262
|
Stim1tm1Rao/Stim1tm1Rao Tg(Cd4-cre)1Cwi/0
(involves: C57BL/6 * DBA/2 * SJL)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:133262
|
decreased interleukin-2 secretion
|
J:133262
|
Stim1tm3Ics/Stim1+
(involves: C57BL/6N)
|
myositis
|
J:277842
|
Stim2tm1.1Kuro/Stim2tm1.1Kuro Cd79atm1(cre)Reth/Cd79a+
(involves: BALB/c * C57BL/6)
|
abnormal B cell calcium ion homeostasis
|
J:172608
|
Stim2tm1Rao/Stim2tm1Rao Tg(Cd4-cre)1Cwi/0
(involves: C57BL/6 * DBA/2 * SJL)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:133262
|
abnormal T-helper 1 physiology
|
J:133262
|
abnormal T-helper 2 physiology
|
J:133262
|
decreased interferon-gamma secretion
|
J:133262
|
decreased interleukin-2 secretion
|
J:133262
|
decreased interleukin-4 secretion
|
J:133262
|
Sting1em1Jmin/Sting1+
(involves: C57BL/6N)
|
abnormal cytokine level
|
J:251372
|
increased circulating interleukin-10 level
|
J:251372
|
increased circulating interleukin-13 level
|
J:251372
|
increased circulating tumor necrosis factor level
|
J:251372
|
increased IgM level
|
J:251372
|
lung inflammation
|
J:251372
|
Sting1gt/Sting1gt
(C57BL/6-Sting1gt)
|
abnormal dendritic cell physiology
|
J:201167
|
abnormal humoral immune response
|
J:201167
|
abnormal immune cell physiology
|
J:201167
|
abnormal macrophage physiology
|
J:201167
|
abnormal plasmacytoid dendritic cell physiology
|
J:201167
|
abnormal response to infection
|
J:168746
|
decreased circulating interferon-alpha level
|
J:201167
|
decreased circulating interferon-beta level
|
J:201167,
J:168746
|
increased susceptibility to Herpesvirales infection
|
J:201167
|
increased susceptibility to Herpesvirales infection induced morbidity/mortality
|
J:201167
|
Sting1gt/Sting1gt
(involves: C57BL/6)
|
increased susceptibility to Retroviridae infection
|
J:265023
|
Sting1gt/Sting1gt
(C57BL/6J-Sting1gt/J)
|
abnormal interferon-beta secretion
|
J:354143
|
abnormal response to infection
|
J:354143
|
increased susceptibility to Retroviridae infection
|
J:354143
|
Sting1tm1Camb/Sting1tm1Camb
(involves: C57BL/6N)
|
decreased circulating interferon-beta level
|
J:179270
|
decreased circulating interleukin-6 level
|
J:179270
|
Sting1tm1Gnb/Sting1tm1Gnb
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal innate immunity
|
J:141011
|
abnormal susceptibility to Herpesvirales infection
|
J:141011
|
increased susceptibility to Riboviria infection
|
J:141011
|
Sting1tm1Gnb/Sting1tm1Gnb
(involves: 129P2/OlaHsd)
|
abnormal response to infection
|
J:168746
|
Stip1tm1.2Mamp/Stip1tm1.2Mamp
(involves: C57BL/6)
|
increased acute inflammation
|
J:201097
|
Stk3tm1.1Jav/Stk3tm1.1Jav Stk4tm1Kina/Stk4tm1Kina Tg(Nkx2-1-cre)2Sand/?
(involves: 129 * C57BL/6)
|
lung inflammation
|
J:197340
|
Stk4Gt(AJ0315)Wtsi/Stk4Gt(AJ0315)Wtsi
(B6.129P2-Stk4Gt(AJ0315)Wtsi)
|
increased interferon-gamma secretion
|
J:142674
|
increased interleukin-2 secretion
|
J:142674
|
increased interleukin-4 secretion
|
J:142674
|
increased T cell apoptosis
|
J:142674
|
increased T cell proliferation
|
J:142674
|
Stk4m1Btlr/Stk4m1Btlr
(C57BL/6J-Stk4m1Btlr)
|
abnormal humoral immune response
|
J:265233
|
decreased IgD level
|
J:265233
|
increased IgE level
|
J:265233
|
increased IgM level
|
J:265233
|
Stk4m2Btlr/Stk4m2Btlr
(C57BL/6J-Stk4m2Btlr)
|
decreased IgD level
|
J:265237
|
increased IgE level
|
J:265237
|
Stk4m4Btlr/Stk4m4Btlr
(C57BL/6J-Stk4m4Btlr)
|
decreased IgD level
|
J:272536
|
decreased IgG level
|
J:272536
|
impaired humoral immune response
|
J:272536
|
Stk4tm1.1Kina/Stk4tm1.1Kina
(involves: C57BL/6)
|
abnormal B cell physiology
|
J:148791
|
abnormal dendritic cell physiology
|
J:148791
|
abnormal leukocyte adhesion
|
J:148791
|
abnormal leukocyte migration
|
J:148791
|
abnormal T cell physiology
|
J:148791
|
increased T cell proliferation
|
J:148791
|
Stk4tm1.2Wtao/Stk4tm1.2Wtao
(involves: 129S4/SvJaeSor * 129S6/SvEvTac)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:152323
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:152323
|
abnormal T cell physiology
|
J:152323
|
Stk4tm1Dlim/Stk4tm1Dlim
(Not Specified)
|
abnormal T cell physiology
|
J:155001
|
Stk10tm1Hkar/Stk10tm1Hkar
(involves: 129S1/Sv)
|
abnormal T cell physiology
|
J:60738
|
Stk11tm1.1Rdp/Stk11tm1.1Rdp Tg(Pdx1-cre)89.1Dam/0
(involves: 129S6/SvEvTac * C57BL/6 * CBA * FVB/N * ICR)
|
pancreas inflammation
|
J:134078
|
Stk11tm1.1Rdp/Stk11tm1.1Rdp Tg(Sprr2f-cre)1Dcas/0
(involves: 129S6/SvEvTac * FVB/N)
|
peritoneal inflammation
|
J:158190
|
sepsis
|
J:158190
|
Stk11tm1Keis/Stk11tm1Keis Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd)
|
increased circulating interleukin-10 level
|
J:191723
|
Stk17btm1Hed/Stk17btm1Hed
(involves: 129X1/SvJ * C57BL/6)
|
increased T cell proliferation
|
J:94685
|
Stk17btm1Hed/Stk17btm1Hed
(B6.129X1-Stk17btm1Hed)
|
abnormal cytokine secretion
|
J:94685
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:94685
|
increased interferon-gamma secretion
|
J:94685
|
increased interleukin-2 secretion
|
J:94685
|
increased T cell proliferation
|
J:94685
|
increased tumor necrosis factor secretion
|
J:94685
|
Stk24Gt(AM0826)Wtsi/Stk24Gt(AM0826)Wtsi
(B6.129P2-Stk24Gt(AM0826)Wtsi)
|
abnormal neutrophil physiology
|
J:256076
|
Stk36tm1Fjs/Stk36tm1Fjs
(involves: 129S1/Sv * C57BL/6)
|
rhinitis
|
J:116391
|
Stk36tm1Lex/Stk36tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
|
increased susceptibility to otitis media
|
J:185566
|
Stk38tm1Hem/Stk38tm1Hem
(involves: 129P2/Ola * C57BL/6)
|
abnormal T cell physiology
|
J:185408
|
decreased thymocyte apoptosis
|
J:185408
|
Stk38tm1Xen/Stk38tm1Xen
(involves: 129S5/SvEvBrd * C57BL/6)
|
increased circulating interleukin-6 level
|
J:224932
|
increased circulating tumor necrosis factor level
|
J:224932
|
increased interleukin-6 secretion
|
J:224932
|
increased susceptibility to bacterial infection
|
J:224932
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:224932
|
increased tumor necrosis factor secretion
|
J:224932
|
Stub1tm1Cpat/Stub1tm1Cpat
(involves: 129S/SvEv * C57BL/6)
|
increased thymocyte apoptosis
|
J:86213
|
Stx2tm1Dcru/Stx2tm1Dcru
(involves: 129X1/SvJ * C57BL/6J)
|
decreased susceptibility to induced colitis
|
J:110376
|
Stx3Gt(EUCE320f12)1.1Hmgu/Stx3Gt(EUCE320f12)1.1Hmgu Tg(Cma1-cre)ARoer/0
(B6.Cg-Stx3Gt(EUCE320f12)1.1Hmgu Tg(Cma1-cre)ARoer)
|
abnormal mast cell degranulation
|
J:275367
|
decreased mast cell degranulation
|
J:275367
|
Stx3Gt(EUCE320f12)1.2Hmgu/Stx3+
(B6.129P2(Cg)-Stx3Gt(EUCE320f12)1.2Hmgu)
|
abnormal mast cell degranulation
|
J:275367
|
Stx11tm1.2Ics/Stx11tm1.2Ics
(involves: C57BL/6NTac)
|
abnormal cytotoxic T cell physiology
|
J:193137
|
decreased cytotoxic T cell cytolysis
|
J:193137
|
decreased NK cell degranulation
|
J:193137
|
increased circulating interferon-gamma level
|
J:193137
|
increased circulating interleukin-1 beta level
|
J:193137
|
increased circulating interleukin-6 level
|
J:193137
|
increased circulating tumor necrosis factor level
|
J:193137
|
increased susceptibility to Riboviria infection
|
J:193137
|
Stx11tm1Bupa/Stx11tm1Bupa
(B6.129-Stx11tm1Bupa)
|
abnormal cell-mediated immunity
|
J:191103
|
abnormal cytokine secretion
|
J:191103
|
abnormal lymphocyte physiology
|
J:191103
|
abnormal neutrophil physiology
|
J:191103
|
impaired natural killer cell mediated cytotoxicity
|
J:191103
|
increased interferon-gamma secretion
|
J:191103
|
increased tumor necrosis factor secretion
|
J:191103
|
Stxbp2tm1Bdic/Stxbp2+
(involves: 129S * C57BL/6)
|
decreased mast cell degranulation
|
J:188931
|
decreased susceptibility to type I hypersensitivity reaction
|
J:188931
|
Sucnr1tm1Dgen/Sucnr1tm1Dgen
(B6.129P2-Sucnr1tm1Dgen)
|
abnormal dendritic cell physiology
|
J:143337
|
abnormal interleukin-2 secretion
|
J:143337
|
abnormal Langerhans cell physiology
|
J:143337
|
abnormal T cell activation
|
J:143337
|
decreased T cell proliferation
|
J:143337
|
increased length of allograft survival
|
J:143337
|
SucoGt(KST050)Byg/SucoGt(KST050)Byg
(involves: 129P2/OlaHsd * C57BL/6 * CD-1)
|
abnormal osteoclast physiology
|
J:159823
|
Sugcttm1.2Kald/Sugcttm1.2Kald
(B6.Cg-Sugcttm1.2Kald)
|
kidney inflammation
|
J:293423
|
white adipose tissue inflammation
|
J:293423
|
Sulf1Gt(OST352220)Lex/Sulf1Gt(OST352220)Lex
(involves: 129S5/SvEvBrd * C57BL/6N)
|
decreased susceptibility to bacterial infection
|
J:171883
|
Sumf1Gt(RST760)Byg/Sumf1Gt(RST760)Byg
(involves: 129P2/OlaHsd * C57BL/6)
|
CNS inflammation
|
J:120146
|
Supv3l1tm2.1Jkl/Supv3l1tm2.2Jkl Tg(CAG-cre/Esr1*)5Amc/0
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6 * FVB/N)
|
lung inflammation
|
J:144991
|
Supv3l1tm2Jkl/Supv3l1tm2Jkl Tg(CAG-cre/Esr1*)5Amc/0
(involves: 129P2/OlaHsd * C57BL/6)
|
lung inflammation
|
J:144991
|
Supv3l1tm2Jkl/Supv3l1tm2Jkl Tg(Mx1-cre)1Cgn/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
interstitial pneumonia
|
J:144991
|
Susd4tm1Lex/Susd4tm1Lex
(B6.129S5-Susd4tm1Lex)
|
abnormal complement protein level
|
J:306852
|
increased microglial cell activation
|
J:306852
|
Suv39h1tm1Jnw/Suv39h1tm1Jnw
(involves: 129)
|
abnormal T-helper 2 physiology
|
J:186702
|
decreased susceptibility to type I hypersensitivity reaction
|
J:186702
|
Swap70tm1Jess/Swap70tm1Jess
(involves: 129T2/SvEms * 129X1/SvJ)
|
abnormal class switch recombination
|
J:71160
|
decreased IgE level
|
J:71160
|
increased autoantibody level
|
J:71160
|
Swrl1NZB/Swrl1NZB
(involves: NZB * SWR)
|
abnormal type II hypersensitivity reaction
|
J:73097
|
Swrl1NZB/Swrl1SWR
(involves: NZB * SWR)
|
abnormal type II hypersensitivity reaction
|
J:73097
|
Swrl1SWR/Swrl1SWR
(involves: NZB * SWR)
|
increased IgG3 level
|
J:96263
|
Swrl2NZB/Swrl2SWR
(involves: NZB * SWR)
|
glomerulonephritis
|
J:73097
|
Swrl2SWR/Swrl2SWR
(involves: NZB * SWR)
|
glomerulonephritis
|
J:73097
|
increased anti-single stranded DNA antibody level
|
J:96060
|
Swrl3NZB/Swrl3SWR
(involves: NZB * SWR)
|
increased anti-double stranded DNA antibody level
|
J:96060
|
increased anti-histone antibody level
|
J:96060
|
increased anti-nuclear antigen antibody level
|
J:73097
|
Swrl3SWR/Swrl3SWR
(involves: NZB * SWR)
|
increased anti-double stranded DNA antibody level
|
J:96060
|
increased anti-histone antibody level
|
J:96060
|
increased anti-nuclear antigen antibody level
|
J:73097
|
Sycntm1Rja/Sycntm1Rja
(involves: 129P2/OlaHsd)
|
increased susceptibility to induced pancreatitis
|
J:74654
|
Sykm1Btlr/Sykm1Btlr
(involves: C57BL/6J)
|
increased tumor necrosis factor secretion
|
J:199281
|
SykM2Btlr/Syk+
(C57BL/6J-SykM2Btlr)
|
decreased inflammatory response
|
J:231803
|
SykM2Btlr/SykM2Btlr
(C57BL/6J-SykM2Btlr)
|
decreased inflammatory response
|
J:231803
|
Syktm1.1Tara/Syktm1.1Tara
(involves: 129P2/OlaHsd * C57BL/6)
|
increased B cell proliferation
|
J:114816
|
Syktm1Tyb/Syktm1.2Tara Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
|
abnormal neutrophil physiology
|
J:155479
|
impaired granulocyte bactericidal activity
|
J:155479
|
Syktm1Tyb/Syktm1.2Tara Tg(S100A8-cre,-EGFP)1Ilw/0
(involves: 129P2/OlaHsd * 129S2/SvPas * C3H * C57BL/6)
|
impaired granulocyte bactericidal activity
|
J:155479
|
Syktm1Tyb/Syktm1Tyb
(involves: 129S2/SvPas)
|
abnormal dendritic cell antigen presentation
|
J:147472
|
abnormal neutrophil physiology
|
J:155479
|
decreased tumor necrosis factor secretion
|
J:155479
|
impaired granulocyte bactericidal activity
|
J:155479
|
impaired neutrophil phagocytosis
|
J:155479
|
Syktm2.1(ZAP70)Fkfr/Syktm2.1(ZAP70)Fkfr
(B6.129-Syktm2.1(ZAP70)Fkfr)
|
abnormal B cell physiology
|
J:188422
|
abnormal neutrophil physiology
|
J:188422
|
decreased IgG1 level
|
J:188422
|
decreased IgG2a level
|
J:188422
|
decreased IgG2b level
|
J:188422
|
glomerulonephritis
|
J:188422
|
increased anti-insulin autoantibody level
|
J:188422
|
increased B cell apoptosis
|
J:188422
|
increased IgM level
|
J:188422
|
Syne1tm1.1Mcn/Syne1tm1.1Mcn
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL)
|
conjunctivitis
|
J:144757
|
Syt7tm1Nan/Syt7tm1Nan
(involves: 129S1/Sv * C57BL/6)
|
increased anti-nuclear antigen antibody level
|
J:85201
|
increased inflammatory response
|
J:85201
|
increased susceptibility to autoimmune disorder
|
J:85201
|
myositis
|
J:85201
|
Sytl1tm1a(KOMP)Wtsi/Sytl1tm1a(KOMP)Wtsi
(involves: C57BL/6 * C57BL/6N)
|
decreased IgG2b level
|
J:213427
|
epididymis inflammation
|
J:213427
|
meningitis
|
J:213427
|
Syvn1tm1Tn/Syvn1+
(D1.Cg-Syvn1tm1Tn)
|
decreased susceptibility to induced arthritis
|
J:86009
|
tAE5/tAE5
(Not Specified)
|
increased susceptibility to infection
|
J:83862
|
Tab2tm2.1Aki/Tab2tm2.1Aki Tab3tm1Aki/Tab3tm1Aki Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal B cell physiology
|
J:195289
|
abnormal immune serum protein physiology
|
J:195289
|
decreased B cell proliferation
|
J:195289
|
decreased circulating interleukin-6 level
|
J:195289
|
decreased IgD level
|
J:195289
|
decreased IgE level
|
J:195289
|
decreased IgG level
|
J:195289
|
decreased immunoglobulin level
|
J:195289
|
increased B cell apoptosis
|
J:195289
|
Tacr1tm1Nge/Tacr1tm1Nge
(involves: 129S4/SvJae)
|
abnormal humoral immune response
|
J:35529
|
Tacr1tm1Nge/Tacr1tm1Nge
(involves: 129S4/SvJae * C57BL)
|
abnormal mast cell physiology
|
J:84660
|
Tacr1tm1Sph/Tacr1tm1Sph
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased inflammatory response
|
J:46629
|
joint inflammation
|
J:103700
|
Taf4tm1Idvd/Taf4tm1Idvd Tg(KRT14-cre/ERT2)1Ipc/0
(involves: C57BL/6 * SJL)
|
chronic inflammation
|
J:124111
|
Taf7tm1.1Dss/Taf7tm1.2Dss Tg(Cd8a*-cre)B8Asin/0
(involves: C57BL/6)
|
decreased T cell proliferation
|
J:185745
|
Taf7tm1.1Dss/Taf7tm1.2Dss Tg(Lck-cre)1Cwi/0
(involves: C57BL/6)
|
abnormal thymus physiology
|
J:185745
|
Tagln2tm1Cdj/Tagln2tm1Cdj
(involves: 129S4/SvJae * C57BL/6)
|
abnormal cytotoxic T cell physiology
|
J:256656
|
abnormal T cell physiology
|
J:256656
|
Tagln2tm1Cdj/Tagln2tm1Cdj Tg(TcraTcrb)425Cbn/0
(involves: 129S4/SvJae * C57BL/6)
|
abnormal T cell activation
|
J:256656
|
Tagln2tm1Cdj/Tagln2tm1Cdj Tg(TcraTcrb)1100Mjb/0
(involves: 129S4/SvJae * C57BL/6)
|
abnormal T cell activation
|
J:256656
|
Tanktm1Aki/Tanktm1Aki
(involves: 129/Sv * C57BL/6)
|
abnormal dendritic cell physiology
|
J:151757
|
abnormal macrophage physiology
|
J:151757
|
abnormal plasmacytoid dendritic cell physiology
|
J:151757
|
glomerulonephritis
|
J:151757
|
increased anti-double stranded DNA antibody level
|
J:151757
|
increased anti-nuclear antigen antibody level
|
J:151757
|
increased B cell proliferation
|
J:151757
|
increased IgA level
|
J:151757
|
increased IgG1 level
|
J:151757
|
increased IgG2a level
|
J:151757
|
increased IgG2b level
|
J:151757
|
increased IgM level
|
J:151757
|
increased interferon-alpha secretion
|
J:151757
|
increased interleukin-6 secretion
|
J:151757
|
increased tumor necrosis factor secretion
|
J:151757
|
liver inflammation
|
J:151757
|
lung inflammation
|
J:151757
|
Tap1m2Btlr/Tap1m2Btlr
(C57BL/6J-Tap1m2Btlr)
|
increased susceptibility to Herpesvirales infection
|
J:236697
|
Tap1tm1Arp/Tap1tm1Arp
(involves: 129S2/SvPas * C57BL/6)
|
abnormal antigen presentation
|
J:122479
|
abnormal dendritic cell antigen presentation
|
J:112436
|
abnormal lymphocyte physiology
|
J:122479
|
decreased level of surface class I molecules
|
J:3524
|
defective intracellular transport of class I molecules
|
J:3524
|
Tap1tm1Arp/Tap1tm1Arp
(involves: 129S2/SvPas)
|
abnormal antigen presentation via MHC class I
|
J:64349
|
abnormal dendritic cell antigen presentation
|
J:64349
|
decreased cytotoxic T cell cytolysis
|
J:64349
|
decreased level of surface class I molecules
|
J:64177,
J:64349
|
defective assembly of class I molecules
|
J:64177
|
defective intracellular transport of class I molecules
|
J:64177
|
Tap1tm1Arp/Tap1tm1Arp
(B6.129S2-Tap1tm1Arp/J)
|
decreased susceptibility to bacterial infection
|
J:123934
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:123934
|
Tap1tm1Arp/Tap1tm1Arp X/Yaa
(BXSB.129S2(B6)-Tap1tm1Arp/Dcr)
|
increased susceptibility to systemic lupus erythematosus
|
J:179430
|
Tap2m1Btlr/Tap2m1Btlr
(C57BL/6J-Tap2m1Btlr)
|
abnormal cytotoxic T cell physiology
|
J:159355
|
abnormal NK cell physiology
|
J:159355
|
decreased level of surface class I molecules
|
J:159355
|
defective assembly of class I molecules
|
J:159355
|
Tapbptm1Gjh/Tapbptm1Gjh
(involves: 129S2/SvPas)
|
abnormal antigen presentation via MHC class I
|
J:64349
|
abnormal dendritic cell antigen presentation
|
J:64349
|
abnormal NK cell physiology
|
J:64349
|
decreased cytotoxic T cell cytolysis
|
J:64349
|
decreased level of surface class I molecules
|
J:64349
|
Tapbptm1Luc/Tapbptm1Luc
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal lymphocyte physiology
|
J:122479
|
Tapbptm1Luc/Tapbptm1Luc
(involves: 129S6/SvEvTac)
|
abnormal antigen presentation via MHC class I
|
J:64177
|
abnormal cytotoxic T cell physiology
|
J:64177
|
decreased level of surface class I molecules
|
J:64177
|
defective assembly of class I molecules
|
J:64177
|
TaprBALB/c/?
(involves: BALB/c * DBA/2)
|
abnormal inflammatory response
|
J:72894
|
Tarm1tm1Yiw/Tarm1tm1Yiw
(involves: C57BL/6 * C57BL/6NSlc)
|
abnormal dendritic cell antigen presentation
|
J:301164
|
abnormal interleukin-6 secretion
|
J:301164
|
abnormal lymphocyte physiology
|
J:301164
|
abnormal tumor necrosis factor secretion
|
J:301164
|
decreased IgG2a level
|
J:301164
|
decreased IgG2b level
|
J:301164
|
decreased IgG3 level
|
J:301164
|
decreased interferon-gamma secretion
|
J:301164
|
decreased interleukin-17 secretion
|
J:301164
|
decreased susceptibility to induced arthritis
|
J:301164
|
decreased T cell proliferation
|
J:301164
|
decreased tumor necrosis factor secretion
|
J:301164
|
Tax1bp1tm1Ktj/Tax1bp1tm1Ktj
(B6.129P2-Tax1bp1tm1Ktj)
|
abnormal hypersensitivity reaction
|
J:131849
|
abnormal leukocyte physiology
|
J:131849
|
abnormal macrophage chemotaxis
|
J:131849
|
abnormal neutrophil physiology
|
J:131849
|
abnormal T cell physiology
|
J:131849
|
cardiovalvulitis
|
J:131849
|
increased interleukin-1 beta secretion
|
J:131849
|
increased interleukin-2 secretion
|
J:131849
|
increased tumor necrosis factor secretion
|
J:131849
|
skin inflammation
|
J:131849
|
tb/tb
(Not Specified)
|
abnormal thymus involution
|
J:12166
|
Tbc1d10ctm1.1Psou/Tbc1d10ctm1.2Psou Cd79atm1(cre)Reth/Cd79a+
(involves: 129S2/SvPas * BALB/c * C57BL/6J)
|
abnormal B cell physiology
|
J:211913
|
increased anti-double stranded DNA antibody level
|
J:211913
|
increased IgG level
|
J:211913
|
increased IgM level
|
J:211913
|
increased susceptibility to systemic lupus erythematosus
|
J:211913
|
Tbc1d10ctm1.2Psou/Tbc1d10ctm1.2Psou
(involves: 129S2/SvPas * C57BL/6J)
|
abnormal B cell physiology
|
J:211913
|
abnormal response to infection
|
J:211913
|
abnormal T cell activation
|
J:211913
|
increased anti-double stranded DNA antibody level
|
J:211913
|
increased IgG level
|
J:211913
|
increased susceptibility to systemic lupus erythematosus
|
J:211913
|
increased T cell proliferation
|
J:211913
|
Tbc1d23Gt(BA0556)Wtsi/Tbc1d23Gt(BA0556)Wtsi
(B6.129P2-Tbc1d23Gt(BA0556)Wtsi)
|
abnormal tumor necrosis factor level
|
J:181861
|
increased circulating interleukin-6 level
|
J:181861
|
increased circulating tumor necrosis factor level
|
J:181861
|
increased inflammatory response
|
J:181861
|
Tbk1M1Btlr/Tbk1+
(involves: C57BL/6J)
|
abnormal interferon secretion
|
J:188770
|
abnormal macrophage physiology
|
J:188770
|
Tbk1tm1.1Lex/Tbk1+
(involves: 129S4/SvJae * 129S5/SvEvBrd)
|
abnormal inflammatory response
|
J:166476
|
Tbk1tm1.1Lex/Tbk1tm1.1Lex
(involves: 129S4/SvJae * 129S5/SvEvBrd)
|
abnormal cytokine level
|
J:166476
|
abnormal cytokine secretion
|
J:166476
|
abnormal inflammatory response
|
J:166476
|
decreased interferon-beta secretion
|
J:166476
|
increased circulating interleukin-1 beta level
|
J:166476
|
increased circulating interleukin-6 level
|
J:166476
|
increased circulating interleukin-10 level
|
J:166476
|
increased circulating tumor necrosis factor level
|
J:166476
|
increased IgA level
|
J:166476
|
increased interleukin-6 secretion
|
J:166476
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:166476
|
increased susceptibility to endotoxin shock
|
J:166476
|
increased tumor necrosis factor secretion
|
J:166476
|
skin inflammation
|
J:166476
|
Tbk1tm1Aki/Tbk1tm1Aki Tnftm1Sek/Tnftm1Sek
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
abnormal cytotoxic T cell physiology
|
J:132662
|
decreased cytotoxic T cell cytolysis
|
J:132662
|
decreased IgG1 level
|
J:132662
|
decreased IgG2a level
|
J:132662
|
decreased IgG level
|
J:132662
|
decreased interferon-gamma secretion
|
J:132662
|
Tbk1tm1Arte/Tbk1tm1Arte Cd19tm1(cre)Cgn/Cd19+
(involves: 129/SvEv * 129P2/OlaHsd * C57BL/6)
|
abnormal B cell physiology
|
J:188560
|
abnormal class switch recombination
|
J:188560
|
increased anti-double stranded DNA antibody level
|
J:188560
|
increased anti-nuclear antigen antibody level
|
J:188560
|
increased IgA level
|
J:188560
|
increased IgM level
|
J:188560
|
Tbk1tm1Arte/Tbk1tm1Arte Map3k14tm1Rds/Map3k14tm1Rds Cd19tm1(cre)Cgn/Cd19+
(involves: 129/SvEv * 129P2/OlaHsd * C57BL/6)
|
abnormal immunoglobulin level
|
J:188560
|
Tbptm1.1Ees/Tbptm1.1Ees
(B6.129X1(Cg)-Tbptm1.1Ees)
|
hemophagocytosis
|
J:77714
|
Tbrs1C57BL/6J/Tbrs1C57BL/6J
(involves: C57BL/6J * DBA/2J)
|
decreased susceptibility to bacterial infection
|
J:67658
|
Tbrs2C57BL/6J/Tbrs2C57BL/6J
(involves: C57BL/6J * DBA/2J)
|
decreased susceptibility to bacterial infection
|
J:67658
|
Tbrs2C57BL/6J/Tbrs2DBA/2J
(involves: C57BL/6J * DBA/2J)
|
decreased susceptibility to bacterial infection
|
J:67658
|
Tbrs3C57BL/6J/Tbrs3C57BL/6J
(involves: C57BL/6J * DBA/2J)
|
decreased susceptibility to bacterial infection
|
J:67658
|
Tbrs3C57BL/6J/Tbrs3C57BL/6J Tbrs4C57BL/6J/Tbrs4C57BL/6J
(involves: C57BL/6J * DBA/2J)
|
decreased susceptibility to bacterial infection
|
J:83619
|
Tbrs3C57BL/6J/Tbrs3DBA/2J
(involves: C57BL/6J * DBA/2J)
|
decreased susceptibility to bacterial infection
|
J:67658
|
Tbrs4C57BL/6J/Tbrs4C57BL/6J
(involves: C57BL/6J * DBA/2J)
|
decreased susceptibility to bacterial infection
|
J:83619
|
Tbs1I/StSnEgYCit/Tbs1A/SnYCit
(involves: A/SnYCit * I/StSnEgYCit)
|
decreased susceptibility to bacterial infection
|
J:80972
|
Tbs2I/StSnEgYCit/Tbs2A/SnYCit
(involves: A/SnYCit * I/StSnEgYCit)
|
decreased susceptibility to bacterial infection
|
J:80972
|
Tbx1tm1Bem/Tbx1+
(FVB.Cg-Tbx1tm1Bem)
|
increased susceptibility to otitis media
|
J:91664
|
Tbx21m1Btlr/Tbx21m1Btlr
(C57BL/6J-Tbx21m1Btlr)
|
increased IgM level
|
J:267478
|
Tbx21tm1.1(flpe/ERT2)Gmld/Tbx21tm1.1(flpe/ERT2)Gmld
(involves: 129S2/SvPas * C57BL/6)
|
decreased interferon-gamma secretion
|
J:207104
|
Tbx21tm1Glm/Tbx21+
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal cytokine level
|
J:73833
|
abnormal interleukin level
|
J:73832
|
abnormal NK cell physiology
|
J:73833
|
abnormal tumor necrosis factor level
|
J:73832
|
Tbx21tm1Glm/Tbx21tm1Glm
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal cytokine level
|
J:73832
|
abnormal immunoglobulin level
|
J:73833
|
abnormal interleukin level
|
J:73832
|
abnormal NK cell physiology
|
J:73833
|
abnormal tumor necrosis factor level
|
J:73832
|
decreased interferon-gamma secretion
|
J:73833
|
impaired natural killer cell mediated cytotoxicity
|
J:73833
|
increased natural killer cell mediated cytotoxicity
|
J:73833
|
increased susceptibility to parasitic infection
|
J:73833
|
respiratory system inflammation
|
J:73832
|
Tbx21tm1Glm/Tbx21tm1Glm
(C.129S6-Tbx21tm1Glm/J)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:111932
|
abnormal cytokine secretion
|
J:111932
|
CNS inflammation
|
J:111932
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:111932
|
Tbx21tm1Glm/Tbx21tm1Glm
(involves: 129S6/SvEvTac)
|
abnormal cytokine level
|
J:112600
|
abnormal leukocyte migration
|
J:163822
|
increased interleukin-17 secretion
|
J:163822
|
increased susceptibility to induced colitis
|
J:141481
|
Tbx21tm2Srnr/Tbx21+ Tg(Cd4-cre)1Cwi/0
(involves: 129 * C57BL/6 * DBA/2)
|
increased susceptibility to Riboviria infection
|
J:174315
|
Tbx21tm2Srnr/Tbx21tm2Srnr Tg(Cd4-cre)1Cwi/0
(involves: 129 * C57BL/6 * DBA/2)
|
increased interleukin-2 secretion
|
J:174315
|
increased interleukin-17 secretion
|
J:174315
|
increased susceptibility to Riboviria infection
|
J:174315
|
increased tumor necrosis factor secretion
|
J:174315
|
Tbxa2rtm1Sna/Tbxa2rtm1Sna
(either: (involves: 129/Ola * BALB/c) or (involves: 129/Ola * C57BL/6))
|
abnormal immune serum protein physiology
|
J:84085
|
abnormal immune system physiology
|
J:84085
|
abnormal type I hypersensitivity reaction
|
J:84085
|
Tbxa2rtm1Sna/Tbxa2rtm1Sna
(B6.Cg-Tbxa2rtm1Sna)
|
increased susceptibility to type I hypersensitivity reaction
|
J:197334
|
Tbxas1tm1Swl/Tbxas1tm1Swl
(involves: 129P2/OlaHsd * BALB/c * C57BL/6J)
|
decreased inflammatory response
|
J:90922
|
Tcf3tm1(PBX1)Mlc/Tcf3+ Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal B cell physiology
|
J:226241
|
Tcf3tm1Xhsu/Tcf3tm1Xhsu Tg(Lck-Stat5b*)1Mafa/0
(involves: 129X1/SvJ * C57BL/6 * FVB/N)
|
increased B cell proliferation
|
J:132669
|
Tcf4tm1.1Hmb/Tcf4tm1.1Hmb
(involves: 129P2/OlaHsd * C57BL/6J)
|
abnormal T cell physiology
|
J:136143
|
Tcf7tm1Cle/Tcf7tm1Cle
(involves: 129P2/OlaHsd)
|
abnormal memory T cell physiology
|
J:189838
|
Tcf7l2m1Btlr/Tcf7l2m1Btlr
(C57BL/6J-Tcf7l2m1Btlr)
|
increased susceptibility to induced colitis
|
J:267536
|
Tcf12tm2Zhu/Tcf12tm2Zhu
(Not Specified)
|
abnormal response to transplant
|
J:120411
|
Tcf12tm3Zhu/Tcf12tm3Zhu Tcf3tm4Zhu/Tcf3tm4Zhu Tg(Lck-cre)#Zhu/0
(involves: 129S4/SvJae * C57BL/6 * SJL/J)
|
increased T cell proliferation
|
J:129570
|
Tcirg1M1Jeau/Tcirg1+
(either: (involves: C3H/HeJ * C57BL/6) or (involves: C3H/HeJ * C57BL/6 * FVB/N))
|
abnormal osteoclast physiology
|
J:196503
|
Tcirg1tm1.2Ywd/Tcirg1tm1.2Ywd
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N * SJL)
|
abnormal macrophage physiology
|
J:150327
|
Tcirg1tm1Utku/Tcirg1tm1Utku
(involves: 129X1/SvJ * C57BL/6)
|
abnormal immune serum protein physiology
|
J:92730
|
abnormal immune system physiology
|
J:92730
|
increased IgG1 level
|
J:92730
|
increased IgG2a level
|
J:92730
|
increased IgM level
|
J:92730
|
increased immunoglobulin level
|
J:92730
|
Tcirg1tm1Ypl/Tcirg1tm1Ypl
(involves: 129S4/SvJae * C57BL/6J)
|
abnormal osteoclast physiology
|
J:58795
|
Tcra-Jtm1Tgi/Tcra-Jtm1Tgi
(B6.129-Tcra-Jtm1Tgi)
|
decreased circulating interleukin-5 level
|
J:121037
|
decreased IgE level
|
J:121037
|
decreased IgG level
|
J:99107
|
decreased susceptibility to induced arthritis
|
J:99107
|
increased incidence of corneal inflammation
|
J:132503
|
liver inflammation
|
J:135830
|
lung inflammation
|
J:121037
|
Tcra-Jtm1Tgi/Tcra-Jtm1Tgi
(involves: 129S1/Sv * 129X1/SvJ)
|
decreased circulating interferon-gamma level
|
J:155199
|
decreased interferon-gamma secretion
|
J:155199
|
decreased susceptibility to bacterial infection
|
J:155199
|
Tcra-Jtm1Tgi/Tcra-Jtm1Tgi
(involves: 129S1/Sv * 129X1/SvJ * BALB/c)
|
abnormal immune serum protein physiology
|
J:84720
|
abnormal interleukin secretion
|
J:84720
|
decreased IgE level
|
J:84720
|
decreased interleukin-4 secretion
|
J:84720
|
decreased interleukin-13 secretion
|
J:84720
|
liver inflammation
|
J:105977
|
Tcra-Jtm1Tgi/Tcra-Jtm1Tgi
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
lung inflammation
|
J:89695
|
Tcra-Jtm1Tgi/Tcra-Jtm1Tgi
(C.129-Tcra-Jtm1Tgi)
|
abnormal interleukin secretion
|
J:184570
|
decreased interleukin-5 secretion
|
J:184570
|
decreased interleukin-9 secretion
|
J:184570
|
decreased interleukin-10 secretion
|
J:184570
|
decreased interleukin-13 secretion
|
J:184570
|
decreased interleukin-17 secretion
|
J:184570
|
TcraLn1Ogu/Tcra+
(involves: 129/Sv * C57BL/6)
|
abnormal cytokine secretion
|
J:152041
|
decreased IgG2a level
|
J:152041
|
increased IgG1 level
|
J:152041
|
increased interferon-gamma secretion
|
J:152041
|
increased interleukin-2 secretion
|
J:152041
|
increased interleukin-4 secretion
|
J:152041
|
increased interleukin-10 secretion
|
J:152041
|
Tcratm1Cgn/Tcratm1Mass Tg(Mx1-cre)1Cgn/0
(involves: C57BL/6 * CBA)
|
abnormal T cell physiology
|
J:201417
|
Tcratm1Mjo/Tcra+
(NOD.129P2-Tcratm1Mjo)
|
abnormal T cell physiology
|
J:108590
|
decreased susceptibility to autoimmune diabetes
|
J:108590
|
Tcratm1Mjo/Tcratm1Mjo
(involves: 129P2/OlaHsd * BALB/c)
|
increased anti-double stranded DNA antibody level
|
J:111129
|
increased anti-nuclear antigen antibody level
|
J:111129
|
increased autoantibody level
|
J:111129
|
increased IgE level
|
J:111129
|
increased IgG1 level
|
J:111129
|
increased immunoglobulin level
|
J:111129
|
Tcratm1Mjo/Tcratm1Mjo
(involves: 129P2/OlaHsd)
|
colitis
|
J:37699
|
decreased T cell proliferation
|
J:110898
|
Tcratm1Mom/Tcratm1Mom
(B6.129S2-Tcratm1Mom)
|
abnormal response to transplant
|
J:91742
|
colitis
|
J:135597
|
increased susceptibility to bacterial infection
|
J:106241
|
Tcratm1Mom/Tcratm1Mom
(involves: 129S2/SvPas * C57BL/6)
|
abnormal response to infection
|
J:119344
|
colitis
|
J:15221
|
decreased IgG level
|
J:119344
|
Tcratm1Mom/Tcratm1Mom Tcrgtm1.1Hish/Tcrgtm1.1Hish
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
|
colitis
|
J:135597
|
impaired macrophage chemotaxis
|
J:135597
|
impaired neutrophil recruitment
|
J:135597
|
Tcratm1Mom/Tcratm1Mom Tg(TcraAV19AJ33)1Shima/?
(involves: 129S2/SvPas * C57BL/6)
|
abnormal NK T cell physiology
|
J:140924
|
Tcratm1Mom/Tcratm1Mom Trex1tm1Tld/Trex1tm1Tld
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
|
colitis
|
J:181257
|
increased inflammatory response
|
J:181257
|
myositis
|
J:181257
|
skin inflammation
|
J:181257
|
Tcrbtm1Mom/Tcrb+ Tg(SOD1*G93A)1Gur/0
(B6.Cg-Tcrbtm1Mom Tg(SOD1*G93A)1Gur/J)
|
abnormal microglial cell physiology
|
J:143173
|
Tcrbtm1Mom/Tcrbtm1Mom
(involves: 129P2/OlaHsd * BALB/c)
|
colitis
|
J:15221
|
Tcrbtm1Mom/Tcrbtm1Mom Tcrdtm1Mom/Tcrdtm1Mom
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal response to infection
|
J:119344
|
decreased IgG level
|
J:119344
|
Tcrbtm1Mom/Tcrbtm1Mom Tcrdtm1Mom/Tcrdtm1Mom
(B6.129P2-Tcrbtm1Mom Tcrdtm1Mom/J)
|
decreased autoantibody level
|
J:187766
|
decreased IgE level
|
J:125656
|
decreased IgG1 level
|
J:125656
|
decreased IgG level
|
J:125656,
J:187766
|
increased IgM level
|
J:187766
|
Tcrbtm1Mom/Tcrbtm1Mom Tcrdtm1Mom/Tcrdtm1Mom
(involves: 129 * BALB/c * C57BL/6)
|
colitis
|
J:15221
|
Tcrbtm1Mom/Tcrbtm1Mom Tcrdtm1Mom/Tcrdtm1Mom
(involves: 129P2/OlaHsd)
|
decreased IgA level
|
J:97824
|
Tcrbtm1Mom/Tcrbtm1Mom Tcrdtm1Mom/Tcrdtm1Mom Igh-Jtm2(3H9-VDJ*)Mwg/Igh-J+
(B6.129P2-Tcrbtm1Mom Igh-Jtm2(3H9-VDJ*)Mwg Tcrdtm1Mom)
|
increased anti-double stranded DNA antibody level
|
J:142389
|
Tcrbtm1Mom/Tcrbtm1Mom Tcrdtm1Mom/Tcrdtm1Mom Traf3ip2tm1.1Lix/Traf3ip2tm1.1Lix
(B6.129-Tcrbtm1Mom Traf3ip2tm1.1Lix Tcrdtm1Mom)
|
decreased IgG level
|
J:187766
|
increased anti-chromatin antibody level
|
J:187766
|
increased anti-double stranded DNA antibody level
|
J:187766
|
increased anti-histone antibody level
|
J:187766
|
increased autoantibody level
|
J:187766
|
increased IgM level
|
J:187766
|
Tcrbtm1Mom/Tcrbtm1Mom Tg(KRT5-rtTA)1Glk/0 Tg(tetO/CMV-Tslp)#Sfz/0
(involves: 129P2/OlaHsd * C3H * C57BL/6 * FVB/N)
|
decreased IgE level
|
J:100506
|
skin inflammation
|
J:100506
|
Tcrdtm1Mom/Tcrdtm1Mom
(FVB.129P2-Tcrdtm1Mom)
|
dermatitis
|
J:75915
|
increased susceptibility to type IV hypersensitivity reaction
|
J:75915
|
Tcrdtm1Mom/Tcrdtm1Mom
(NOD.129P2-Tcrdtm1Mom)
|
dermatitis
|
J:75915
|
Tcrdtm1Mom/Tcrdtm1Mom Tnftm2Gkl/Tnf+
(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6J)
|
small intestinal inflammation
|
J:108572
|
Tcrgtm1Scar/Tcrgtm1Scar
(B6.Cg-Tcrgtm1Scar)
|
impaired granulocyte bactericidal activity
|
J:105477
|
Tdrd3Gt(RRK474)Byg/Tdrd3Gt(RRK474)Byg
(involves: 129P2/OlaHsd)
|
abnormal B cell physiology
|
J:210647
|
Tdrd7nmf166/Tdrd7nmf166
(involves: C3H * C57BL/6J)
|
uveitis
|
J:169836
|
Tecpr1tm1Chsa/Tecpr1tm1Chsa
(involves: 129S4/SvJae)
|
abnormal susceptibility to infection
|
J:198333
|
Tent5cem1Adki/Tent5cem1Adki
(involves: C57BL/6JTar * CBA/WTar)
|
decreased B cell proliferation
|
J:252302
|
Tent5ctm1b(KOMP)Wtsi/Tent5ctm1b(KOMP)Wtsi
(C57BL/6N-Tent5ctm1b(KOMP)Wtsi/Wtsi)
|
blood in lymph vessels
|
J:239583
|
Terctm1Rdp/Terctm1Rdp
(involves: 129/Sv * C57BL/6J * SJL)
|
decreased B cell proliferation
|
J:60223
|
decreased T cell proliferation
|
J:60223
|
increased B cell apoptosis
|
J:60223
|
Terf1tm1.1Blas/Terf1tm1.1Blas Tg(KRT5-cre)1Tak/0
(involves: 129 * C3H * C57BL/6 * SJL)
|
skin inflammation
|
J:152077
|
Terf2ipGt(XD108)Byg/Terf2ip+
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:163158
|
decreased susceptibility to endotoxin shock
|
J:163158
|
Tespa1tm1Smoc/Tespa1tm1Smoc
(B6.129-Tespa1tmSmoc)
|
decreased interferon-gamma secretion
|
J:186446
|
decreased interleukin-2 secretion
|
J:186446
|
decreased T cell proliferation
|
J:186446
|
increased T cell proliferation
|
J:186446
|
Tet1tm1.2Jae/Tet1tm1.2Jae Tet2tm1.1Iaai/Tet2tm1.1Iaai Tet3tm1.1Yzhg/Tet3tm1.1Yzhg Tg(Rorc-cre)1Litt/0
(involves: 129 * 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB)
|
increased susceptibility to autoimmune disorder
|
J:333574
|
Tet2Gt(AN0709)Wtsi/Tet2+
(B6.129P2-Tet2Gt(AN0709)Wtsi)
|
liver inflammation
|
J:174052
|
Tet2Gt(AN0709)Wtsi/Tet2Gt(AN0709)Wtsi
(B6.129P2-Tet2Gt(AN0709)Wtsi)
|
liver inflammation
|
J:174052
|
Tfebem1Xinli/Tfebem1Xinli
(involves: C57BL/6J)
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:342735
|
Tff2tm1Blin/Tff2tm1Blin
(involves: 129S7/SvEvBrd * C57BL/6)
|
abnormal adaptive immunity
|
J:105277
|
abnormal innate immunity
|
J:105277
|
Tff3tm1Dkpy/Tff3tm1Dkpy
(involves: 129S4/SvJae)
|
increased susceptibility to induced colitis
|
J:35882
|
Tfpi2tm1Dgen/Tfpi2tm1Dgen
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased circulating interleukin-6 level
|
J:301794
|
increased circulating interleukin-10 level
|
J:301794
|
increased interleukin-10 secretion
|
J:301794
|
increased susceptibility to bacterial infection
|
J:301794
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:301794
|
Tfpitm1Gjb/Tfpitm1Gjb
(involves: 129)
|
abnormal acute phase protein level
|
J:51137
|
Tg(Ace2-ACE2)1Cqin/0
(involves: ICR)
|
alveolitis
|
J:141460
|
increased susceptibility to Coronaviridae infection
|
J:141460,
J:287631,
J:288244
|
interstitial pneumonia
|
J:141460,
J:287631
|
lymph node hemorrhage
|
J:141460
|
pyelitis
|
J:141460
|
submandibular gland inflammation
|
J:141460
|
Tg(ACTA1-Il15)10941Lsq/0
(involves: C3H * C57BL/6)
|
abnormal interleukin level
|
J:145611
|
Tg(ACTA1-Il15*)11650Lsq/0
(involves: C3H * C57BL/6)
|
abnormal interleukin level
|
J:145611
|
increased circulating interleukin-15 level
|
J:145611
|
Tg(Acta2-cre/ERT2)#Pcn/0 Tgfbr2tm1Karl/Tgfbr2tm1Karl Tg(H2-K-Fosl2,-EGFP)13Wag/0
(B6.Cg-Tgfbr2tm1Karl Tg(Acta2-cre/ERT2)#Pcn Tg(H2-K-Fosl2,-EGFP)13Wag)
|
lung inflammation
|
J:238723
|
Tg(Acta2-RAC1*G12V)33Pjgc/Tg(Acta2-RAC1*G12V)33Pjgc
(involves: C57BL/6 * FVB/N)
|
abnormal chemokine secretion
|
J:150015
|
increased interleukin-6 secretion
|
J:150015
|
increased tumor necrosis factor secretion
|
J:150015
|
Tg(ACTB-eGFP,-RAMP1)#Afru/0 Tg(Nes-cre)1Kln/0
(involves: C57BL/6J * SJL/J)
|
increased inflammatory response
|
J:120077
|
Tg(ACTB-Eif4e)#Ppp/0 Tg(IghMyc)22Bri/0
(involves: C57BL * SJL)
|
decreased B cell apoptosis
|
J:89878
|
Tg(ACTB-Fpr2)#Jimw/0
(involves: FVB)
|
abnormal dendritic cell physiology
|
J:160074
|
respiratory system inflammation
|
J:160074
|
Tg(ACTB-TNFRSF6B)754Jwu/?
(B6.Cg-Tg(Actb-TNFRSF6B)754Jwu)
|
abnormal type IV hypersensitivity reaction
|
J:148162
|
increased anti-double stranded DNA antibody level
|
J:148162
|
increased autoantibody level
|
J:148162
|
increased IgE level
|
J:148162
|
increased IgG1 level
|
J:148162
|
increased IgG2b level
|
J:148162
|
increased interleukin-4 secretion
|
J:148162
|
Tg(Actb-Tnfsf4)1Nish/0
(B6.D2-Tg(Actb-Tnfsf4)1Nish)
|
abnormal cytokine secretion
|
J:80214
|
increased susceptibility to type IV hypersensitivity reaction
|
J:80214
|
increased T cell proliferation
|
J:80214
|
Tg(Adipoq-Apol6)#Hsul/0
(C57BL/6J-Tg(Adipoq-Apol6)#Hsul)
|
white adipose tissue inflammation
|
J:344362
|
Tg(Adipoq-cre)1Evdr/0 Tg(CAG-Jmjd8)#Kaso/0
(involves: C57BL/6 * FVB/NJ)
|
white adipose tissue inflammation
|
J:319518
|
Tg(AGER)#Eca/0
(C57BL/6J-Tg(AGER)#Eca)
|
lung inflammation
|
J:205092
|
Tg(AGT)2-5Afu/0
(involves: C57BL/6)
|
heart inflammation
|
J:194606
|
Tg(Alb1-GP33/H2-Kb)1Hpi/0
(B6.Cg-Tg(Alb1-GP33/H2-Kb)1Hpi)
|
abnormal cytotoxic T cell physiology
|
J:162605
|
decreased cytotoxic T cell cytolysis
|
J:162605
|
Tg(Alb1-GP33/H2-Kb)1Hpi/0 Tg(Alb1-HBV)66Bri/0
(involves: C57BL/6 * C57BL/10 * DBA/2)
|
liver inflammation
|
J:162605
|
Tg(Alb1-GP33/H2-Kb)1Hpi/0 Tg(Alb1-HBV)66Bri/0 Tg(TcrLCMV)318Sdz/0
(involves: C57BL/6 * C57BL/10 * DBA/2)
|
liver inflammation
|
J:162605
|
Tg(Alb1-Ren)1Unc/0
(involves: 129S6/SvEvTac * C57BL/6)
|
kidney inflammation
|
J:89252
|
Tg(Alb1-Ren)2Unc/0
(involves: 129S6/SvEvTac * C57BL/6)
|
kidney inflammation
|
J:89252
|
Tg(Alb1HBV)44Bri/0
(C57BL/6J-Tg(Alb1HBV)44Bri/J)
|
liver inflammation
|
J:223921
|
Tg(Alb-PDGFC)#Jcam/0
(involves: C57BL/6)
|
chronic liver inflammation
|
J:211984
|
increased circulating interleukin-6 level
|
J:211984
|
Tg(Alb-PLG)1Dgi/0
(involves: C57BL/6 * C57BL/6J * SJL)
|
increased susceptibility to bacterial infection
|
J:120780
|
Tg(Alb-SND1)3aDsar/0
(involves: C57BL/6 * CBA)
|
chronic liver inflammation
|
J:242582
|
Tg(Alb-TAg)#Arnd/0
((C3Fe.Cg-Tg(Alb-TAg)#Arnd x C57BL/6N)F1)
|
abnormal immune system physiology
|
J:171880
|
Tg(Amy1TAg)501Knw/0
(involves: C57BL/6)
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:84288
|
Tg(ANX6)2Agh/0
(FVB/N-Tg(ANX6)2Agh)
|
myocarditis
|
J:92579
|
Tg(aP2-SREBF1c)9884Reh/0
(involves: C57BL/6J * SJL)
|
decreased interleukin-6 secretion
|
J:249664
|
decreased tumor necrosis factor secretion
|
J:249664
|
liver inflammation
|
J:249664
|
Tg(APCS-Ifng)5Imeg/0
(involves: C57BL/6 * DBA/2)
|
abnormal cytokine level
|
J:135124
|
chronic liver inflammation
|
J:135124
|
increased circulating interleukin-12 level
|
J:135124
|
liver inflammation
|
J:16979
|
myocarditis
|
J:135124
|
pancreas inflammation
|
J:135124
|
Tg(APOA1)1Rub/Tg(APOA1)1Rub
(C57BL/6-Tg(APOA1)1Rub/J)
|
abnormal circulating interleukin-17 level
|
J:190966
|
Tg(APOC1)1Lmh/Tg(APOC1)1Lmh
(C57BL/6-Tg(APOC1)1Lmh)
|
dermatitis
|
J:65036
|
folliculitis
|
J:65036
|
Tg(APOC1)1Lmh/Tg(APOC1)1Lmh
(involves: C57BL/6)
|
dermatitis
|
J:135501
|
increased IgE level
|
J:135501
|
increased mast cell degranulation
|
J:135501
|
skin inflammation
|
J:135501
|
Tg(APOE-DGAT1)1Far/0
(involves: C57BL/6NHsd)
|
liver inflammation
|
J:124005
|
Tg(APOE-DGAT2)1Far/0
(involves: C57BL/6NHsd)
|
liver inflammation
|
J:124005
|
Tg(APOE-FGF23*R176Q)#Ack/0
(involves: C57BL/6J * CBA)
|
enthesitis
|
J:192371
|
Tg(APPSwFlLon,PSEN1*M146L*L286V)6799Vas/0
(involves: C57BL/6 * SJL)
|
brain inflammation
|
J:112949
|
Tg(APPSwFlLon,PSEN1*M146L*L286V)6799Vas/?
(involves: C57BL/6 * SJL)
|
increased microglial cell activation
|
J:208030
|
Tg(ARR2/Pbsn-FGF8)3Prb/0
(involves: C57BL/6 * DBA/2)
|
increased inflammatory response
|
J:78918
|
prostate gland inflammation
|
J:78918
|
Tg(B2M)55Hpl/? Tg(CD8aCD8b)57Scr/? Tg(HLA-B)22Hpl/?
(involves: C57BL/6 * C57BL/LiA * CBA)
|
abnormal cytotoxic T cell physiology
|
J:127813
|
Tg(B19-RNAi:Il3)241Ckn/?
(involves: BALB/cJ * C57BL/6J * FVB/N)
|
decreased interleukin-3 secretion
|
J:107618
|
Tg(BCL2)22Wehi/0
(involves: C57BL/6JWehi * SJL/JWehi)
|
abnormal B cell physiology
|
J:93111
|
increased susceptibility to autoimmune disorder
|
J:93111
|
Tg(BCL2)25Wehi/0
(involves: C57BL/6JWehi * SJL/JWehi)
|
abnormal T cell physiology
|
J:93111
|
Tg(BCL2)36Wehi/0
(involves: C57BL/6JWehi * SJL/JWehi)
|
abnormal B cell physiology
|
J:93111
|
abnormal T cell physiology
|
J:93111
|
increased immunoglobulin level
|
J:93111
|
increased susceptibility to autoimmune disorder
|
J:93111
|
Tg(BCL2)36Wehi/?
(B6.Cg-Tg(BCL2)36Wehi/J)
|
abnormal B cell proliferation
|
J:90963
|
decreased B cell apoptosis
|
J:90963
|
Tg(BCL2/IGH)1Tjd/?
(involves: C3H/He * C57BL/6)
|
abnormal B cell physiology
|
J:81147
|
Tg(BCL2/IGH)#Jcre/0 Tg(H2-K/Igh-Traf2*)#Ywc/0
(involves: BALB/c * C57BL/6 * CBA/J * FVB/N * SJL/J * SWR/J)
|
decreased B cell apoptosis
|
J:94116
|
Tg(BCL2/IGH)M23Tjd/?
(involves: C3H/He * C57BL/6)
|
abnormal B cell physiology
|
J:81147
|
Tg(BLG-STAT5A)15Itb/0
(involves: FVB/N)
|
increased inflammatory response
|
J:80588
|
Tg(CAG-ACE2)AC63Ctkt/0
(either: (involves: BALB/c * C3H/HeJ * C57BL/6J) or (involves: C3H/HeJ * C57BL/6 * C57BL/6J))
|
increased susceptibility to Coronaviridae infection
|
J:117824
|
Tg(CAG-ACE2)AC70Ctkt/0
(either: (involves: BALB/c * C3H/HeJ * C57BL/6J) or (involves: C3H/HeJ * C57BL/6 * C57BL/6J))
|
abnormal cytokine level
|
J:117824
|
increased susceptibility to Coronaviridae infection
|
J:117824
|
increased susceptibility to Coronaviridae infection induced morbidity/mortality
|
J:117824
|
interstitial pneumonia
|
J:117824
|
Tg(CAG-APP)0304Shoj/0
(involves: C3H * C57BL/6N)
|
abnormal circulating serum amyloid protein level
|
J:100977
|
Tg(CAG-C1qtnf6)#Yiw/0
(involves: C57BL/6JJcl)
|
abnormal complement protein level
|
J:227217
|
decreased IgG level
|
J:227217
|
decreased susceptibility to induced arthritis
|
J:227217
|
impaired complement alternative pathway
|
J:227217
|
Tg(CAG-cat,-Il18)#Thos/0 Tg(SFTPC-rtTA)5Jaw/0 Tg(tetO-cre)1Jaw/0
(involves: 129 * C57BL/6)
|
increased interferon-gamma secretion
|
J:147547
|
interstitial pneumonia
|
J:147547
|
Tg(CAG-DPP4)4Yuzh/0
(C57BL/6-Tg(CAG-DPP4)4Yuzh)
|
abnormal circulating cytokine level
|
J:286175
|
brain inflammation
|
J:286175
|
increased circulating interferon-gamma level
|
J:286175
|
increased circulating interleukin-17 level
|
J:286175
|
increased susceptibility to Coronaviridae infection
|
J:286175
|
increased susceptibility to Coronaviridae infection induced morbidity/mortality
|
J:286175
|
kidney inflammation
|
J:286175
|
liver inflammation
|
J:286175
|
lung inflammation
|
J:286175
|
Tg(CAG-DPP4)52Ctkt/0
(involves: C3H/HeJ * C57BL/6J)
|
brain inflammation
|
J:227925
|
increased inflammatory response
|
J:227925
|
increased microglial cell activation
|
J:227925
|
increased susceptibility to Coronaviridae infection
|
J:227925,
J:258199
|
increased susceptibility to Coronaviridae infection induced morbidity/mortality
|
J:227925,
J:258199
|
interstitial pneumonia
|
J:258199
|
lung inflammation
|
J:227925
|
Tg(CAG-Has2)99Nita/0 Tg(MMTV-cre)4Mam/0 Tg(MMTVneu)202Mul/0
(FVB.Cg-Tg(CAG-Has2)99Nita Tg(MMTV-cre)4Mam Tg(MMTVneu)202Mul)
|
impaired macrophage chemotaxis
|
J:164205
|
Tg(CAG-LacZ,-ACVR1*,-EGFP)35-1Mis/0
(involves: C57BL/6 * DBA/2)
|
myositis
|
J:142253
|
Tg(CAG-Lyn*)#Paau/0
(B6.Cg-Tg(CAG-Lyn*)#Paau)
|
skin inflammation
|
J:151886
|
Tg(CAG-Ncoa6)71Hwl/0
(involves: FVB)
|
lung inflammation
|
J:80609
|
Tg(CAG-Ncoa6)87Hwl/0
(involves: FVB)
|
lung inflammation
|
J:80609
|
Tg(CAG-NRIP1)51Row/0
(involves: FVB/N)
|
lung inflammation
|
J:175885
|
Tg(CAG-OVAL)916Jen/?
(C57BL/6-Tg(CAG-OVAL)916Jen)
|
abnormal dendritic cell antigen presentation
|
J:91742
|
decreased length of allograft survival
|
J:91742
|
Tg(CAG-p35)1Miur/0
(involves: C57BL/6)
|
autoimmune response
|
J:126593
|
Tg(CAG-p35)1Miur/0 Tg(Mbp-cre)29Miur/0
(involves: C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:126593
|
Tg(CAG-Pgam2)#Hiko/0
(involves: C57BL/6)
|
increased susceptibility to chemically induced skin inflammation
|
J:306793
|
Tg(CAG-PGDS)1Groy/0
(involves: FVB/N)
|
abnormal cytokine secretion
|
J:107651
|
decreased inflammatory response
|
J:107651
|
Tg(CAG-PLA2G3)#aMurm/0
(Not Specified)
|
increased mast cell degranulation
|
J:197334
|
increased susceptibility to type I hypersensitivity reaction
|
J:197334
|
Tg(CAG-Ptafr)1Tksh/0
(B6;D2-Tg(CAG-Ptafr)1Tksh/TkshRbrc)
|
increased susceptibility to endotoxin shock
|
J:38639
|
Tg(CAG-SYVN1)1Tn/?
(D1.Cg-Tg(CAG-SYVN1)1Tn)
|
rheumatoid arthritis
|
J:86009
|
Tg(Camk2a-tTA)1Mmay/0 Tg(tetO-APPSwInd)107Dbo/0
(involves: C3H/HeJ * C57BL/6 * CBA)
|
CNS inflammation
|
J:109829
|
Tg(CD2-Ccdc86)1Hfuj/?
(B6.FVB-Tg(CD2-Ccdc86)1Hfuj)
|
increased T cell apoptosis
|
J:151722
|
Tg(CD2-Ceacam1*4L)1Rsb/0
(involves: C57BL/6)
|
abnormal T cell physiology
|
J:116136
|
decreased interleukin-2 secretion
|
J:116136
|
decreased T cell proliferation
|
J:116136
|
Tg(CD2-Ceacam1*4L)1Rsb/0 Tg(TcraTcrb)425Cbn/0
(involves: BALB/c * C57BL/6)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:116136
|
Tg(CD2-Foxj1)#Stlp/0
(C57BL/6-Tg(CD2-Foxj1)#Stlp)
|
abnormal T cell physiology
|
J:122222
|
Tg(CD2-Ifngr2)1Pbro/?
(B6.Cg-Tg(CD2-Ifngr2)1Pbro)
|
abnormal T-helper 1 physiology
|
J:134448
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:134448
|
increased susceptibility to parasitic infection
|
J:134448
|
Tg(CD2-Ifngr2)2Pbro/?
(B6.Cg-Tg(CD2-Ifngr2)2Pbro)
|
abnormal T-helper 1 physiology
|
J:134448
|
increased susceptibility to parasitic infection
|
J:134448
|
Tg(CD2-Ifngr2)2Pbro/?
(NOD.Cg-Tg(CD2-Ifngr2)2Pbro)
|
abnormal T-helper 1 physiology
|
J:81981
|
decreased interferon-gamma secretion
|
J:81981
|
decreased interleukin-4 secretion
|
J:81981
|
decreased tumor necrosis factor secretion
|
J:81981
|
insulitis
|
J:81981
|
myositis
|
J:81981
|
ovary inflammation
|
J:81981
|
Tg(CD2-LAT2)1Wz/0
(Not Specified)
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:116157
|
Tg(CD2-Lrch1)#Liux/0
(involves: C57BL/6)
|
abnormal cellular extravasation
|
J:238772
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:238772
|
Tg(CD2-Myb/en)2Kmw/?
(involves: C57BL/10 * CBA)
|
decreased T cell proliferation
|
J:126456
|
Tg(CD2-Myb/en)2Kmw/Tg(CD2-Myb/en)2Kmw
(involves: C57BL/10 * CBA)
|
decreased T cell proliferation
|
J:126456
|
Tg(CD2-Nfat5)1Snh/0
(involves: BALB/c * C57BL/6)
|
abnormal cytotoxic T cell physiology
|
J:80066
|
abnormal T cell physiology
|
J:80066
|
decreased splenocyte proliferation
|
J:80066
|
decreased T cell proliferation
|
J:80066
|
Tg(CD2-Ppp2ca)#Gct/0
(involves: C57BL/6J)
|
glomerulonephritis
|
J:184067
|
increased interleukin-17 secretion
|
J:184067
|
Tg(CD2-Rorc)#Staka/0
(involves: C57BL/6)
|
abnormal susceptibility to Picornaviridae infection
|
J:236222
|
abnormal T-helper 17 cell physiology
|
J:236222
|
decreased IgG2c level
|
J:236222
|
decreased IgG3 level
|
J:236222
|
decreased IgG level
|
J:236222
|
decreased interferon-gamma secretion
|
J:236222
|
decreased interleukin-10 secretion
|
J:236222
|
increased anti-nuclear antigen antibody level
|
J:230700
|
increased autoantibody level
|
J:230700
|
increased interferon-gamma secretion
|
J:236222
|
increased interleukin-17 secretion
|
J:236222
|
increased susceptibility to autoimmune disorder
|
J:230700
|
lacrimal gland inflammation
|
J:230700
|
lung inflammation
|
J:230700
|
salivary gland inflammation
|
J:230700
|
Tg(CD2-S1PR1)1Ejg/?
(involves: C57BL/6 * DBA/2)
|
abnormal humoral immune response
|
J:96558
|
abnormal lymphocyte chemotaxis
|
J:96558
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:96558
|
decreased T cell proliferation
|
J:96558
|
impaired leukocyte migration
|
J:96558
|
increased IgE level
|
J:96558
|
Tg(CD2-Sh2d1a)#Vei/0
(involves: 129S1/Sv * 129X1/SvJ)
|
increased natural killer cell mediated cytotoxicity
|
J:110195
|
Tg(CD2-Sh2d1b1)#Vei/0
(B6.Cg-Tg(CD2-Sh2d1b1)#Vei)
|
decreased interferon-gamma secretion
|
J:110195
|
impaired natural killer cell mediated cytotoxicity
|
J:110195
|
Tg(CD2-Sh2d1b2)#Vei/0
(B6.Cg-Tg(CD2-Sh2d1b2)#Vei)
|
impaired natural killer cell mediated cytotoxicity
|
J:110195
|
Tg(Cd2-Smad7)#Chbe/0
(involves: C57BL/6)
|
decreased interleukin-9 secretion
|
J:184670
|
decreased interleukin-10 secretion
|
J:184670
|
decreased interleukin-17 secretion
|
J:184670
|
increased interferon-gamma secretion
|
J:184670
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:184670
|
Tg(CD2-Stat6*V625A*T626A)78Mhk/0
(involves: C3H * C57BL/6)
|
dermatitis
|
J:160119
|
Tg(CD2-TcraF5,CD2-TcrbF5)1Kio/0 Tg(Cd4-BCL2*G101A*D102A*D103A)AWnt/0
(involves: C57BL/6 * C57BL/10)
|
abnormal T cell clonal deletion
|
J:217939
|
decreased thymocyte apoptosis
|
J:217939
|
Tg(CD2-TcraF5,CD2-TcrbF5)1Kio/0 Tg(LCKprBCL2)36Sjk/0
(involves: C57BL/6 * C57BL/10)
|
abnormal T cell clonal deletion
|
J:217939
|
decreased thymocyte apoptosis
|
J:217939
|
Tg(CD2-Tgfbr2)1Grs/0
(C57BL/6-Tg(CD2-Tgfbr2)1Grs/Nci)
|
increased T cell proliferation
|
J:97523
|
Tg(CD2-Tgfbr2)1Grs/?
(C57BL/6-Tg(CD2-Tgfbr2)1Grs/Nci)
|
increased T cell proliferation
|
J:93665
|
Tg(Cd3d-Il5)NJ.1638Nal/?
(involves: C57BL/6J * CBA/J)
|
peritoneal inflammation
|
J:123440
|
Tg(Cd4-BCL2*G101A*D102A*D103A)AWnt/0
(involves: C57BL/6)
|
abnormal T cell clonal deletion
|
J:217939
|
abnormal T cell proliferation
|
J:217939
|
decreased thymocyte apoptosis
|
J:217939
|
glomerulonephritis
|
J:217939
|
increased anti-nuclear antigen antibody level
|
J:217939
|
increased autoantibody level
|
J:217939
|
increased interferon-gamma secretion
|
J:217939
|
increased susceptibility to autoimmune disorder
|
J:217939
|
kidney inflammation
|
J:217939
|
liver inflammation
|
J:217939
|
lung inflammation
|
J:217939
|
skin inflammation
|
J:217939
|
Tg(Cd4-BCL2*G101A*D102A*D103A)AWnt/0
(involves: C57BL/6 * CBA/J)
|
abnormal T cell clonal deletion
|
J:217939
|
decreased thymocyte apoptosis
|
J:217939
|
Tg(Cd4-BCL2*G101A*D102A*D103A)AWnt/0 Tg(Nr4a1-EGFP/cre)820Khog/0
(involves: C57BL/6 * C57BL/6J)
|
abnormal T cell clonal deletion
|
J:217939
|
decreased thymocyte apoptosis
|
J:217939
|
Tg(Cd4-BCL2*G101A*D102A*D103A)AWnt/0 Tg(TcraH-Y,TcrbH-Y)71Vbo/0
(involves: C57BL/6 * C57BL/6J * DBA/2J)
|
abnormal T cell clonal deletion
|
J:217939
|
decreased thymocyte apoptosis
|
J:217939
|
Tg(Cd4-CD4)2362Litt/0 Tg(HLA-DR2)#Lfug/0 Tg(TCROb.1A12)#Lfug/0
(involves: C57BL/6 * DBA/2 * SJL)
|
CNS inflammation
|
J:134764
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:134764
|
Tg(Cd4-cre)1Cwi/? Tg(TcraTcrb)425Cbn/? Traf6tm2Ywc/Traf6tm2Ywc
(involves: C57BL/6 * DBA/2)
|
abnormal lymphocyte anergy
|
J:130882
|
increased interleukin-2 secretion
|
J:130882
|
Tg(Cd4-cre)1Cwi/0 Trmt6em1Hbgl/Trmt6em1Hbgl
(involves: C57BL/6 * DBA/2J)
|
decreased T cell proliferation
|
J:336736
|
Tg(Cd4-cre)1Cwi/0 Trmt61aem1Hbgl/Trmt61aem1Hbgl
(involves: C57BL/6 * DBA/2J)
|
abnormal T cell activation
|
J:336736
|
colitis
|
J:336736
|
decreased T cell proliferation
|
J:336736
|
Tg(Cd4-DsRed)4Lt/0
(NOD/ShiLt-Tg(Cd4-DsRed)4Lt)
|
decreased susceptibility to autoimmune diabetes
|
J:127785
|
Tg(Cd4-Dtx1)1Mzl/?
(involves: C57BL/6)
|
abnormal T cell activation
|
J:151605
|
abnormal thymocyte activation
|
J:151605
|
decreased interleukin-2 secretion
|
J:151605
|
decreased T cell proliferation
|
J:151605
|
Tg(CD4-HIV)F21380Pjo/0
(involves: C3H * C57BL/6)
|
interstitial pneumonia
|
J:78756
|
tubular nephritis
|
J:78756
|
Tg(CD4-HIV)F21388Pjo/0
(involves: C3H * C57BL/6)
|
interstitial pneumonia
|
J:78756
|
tubular nephritis
|
J:78756
|
Tg(CD4-HIV)F21407Pjo/0
(involves: C3H * C57BL/6)
|
interstitial pneumonia
|
J:78756
|
tubular nephritis
|
J:78756
|
Tg(CD4-HIV)F26605Pjo/0
(involves: C3H * C57BL/6)
|
interstitial pneumonia
|
J:78756
|
tubular nephritis
|
J:78756
|
Tg(CD4-HIV)F26622Pjo/0
(involves: C3H * C57BL/6)
|
interstitial pneumonia
|
J:78756
|
tubular nephritis
|
J:78756
|
Tg(CD4-HIV)F26990Pjo/0
(involves: C3H * C57BL/6)
|
interstitial pneumonia
|
J:78756
|
tubular nephritis
|
J:78756
|
Tg(CD4-HIV)F27011Pjo/0
(involves: C3H * C57BL/6)
|
interstitial pneumonia
|
J:78756
|
tubular nephritis
|
J:78756
|
Tg(CD4-HIV)F27367Pjo/0
(involves: C3H * C57BL/6)
|
interstitial pneumonia
|
J:78756
|
tubular nephritis
|
J:78756
|
Tg(Cd4-Il17rb)#Cdon/?
(involves: C57BL/6)
|
decreased interferon-gamma secretion
|
J:158594
|
increased interleukin-5 secretion
|
J:158594
|
increased interleukin-9 secretion
|
J:158594
|
increased interleukin-13 secretion
|
J:158594
|
increased susceptibility to type I hypersensitivity reaction
|
J:158594
|
lung inflammation
|
J:158594
|
Tg(CD4-Il17re)#Cdon/0
(involves: C57BL/6)
|
abnormal interleukin secretion
|
J:177650
|
decreased interleukin-17 secretion
|
J:177650
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:177650
|
Tg(Cd4-NPM/ALK)N1Ingh/0
(either: (involves: BALB/c * Swiss Webster) or (involves: C57BL/6 * Swiss Webster))
|
increased immunoglobulin level
|
J:82127
|
Tg(Cd4-TGFBR2)16Flv/?
(involves: C3H * C57BL/6 * C57BL/10 * C57BR/cd)
|
abnormal T cell activation
|
J:97554
|
abnormal T cell proliferation
|
J:97554
|
abnormal thymus involution
|
J:97554
|
colitis
|
J:97554
|
glomerulonephritis
|
J:97554
|
increased anti-nuclear antigen antibody level
|
J:97554
|
increased IgA level
|
J:97554
|
increased IgG1 level
|
J:97554
|
increased IgG2a level
|
J:97554
|
increased immunoglobulin level
|
J:97554
|
increased inflammatory response
|
J:97554
|
liver inflammation
|
J:97554
|
lung inflammation
|
J:97554
|
pancreas inflammation
|
J:97554
|
Tg(Cd4-TGFBR2)16Flv/?
(involves: C3H * C57BL/6)
|
abnormal T cell proliferation
|
J:134473
|
colitis
|
J:134156
|
increased interferon-gamma secretion
|
J:134156
|
increased tumor necrosis factor secretion
|
J:134156
|
Tg(CD8aCD8b)57Scr/?
(B6;SJL-Tg(CD8aCD8b)57Scr/J)
|
abnormal cytotoxic T cell physiology
|
J:92994
|
Tg(CD19)1Tft/0
(involves: C57BL/6 * C57BL/6J * SJL)
|
increased B cell proliferation
|
J:27236
|
Tg(CD19)1Tft/Tg(CD19)1Tft
(involves: C57BL/6 * C57BL/6J * SJL)
|
decreased IgG1 level
|
J:27236
|
decreased IgG3 level
|
J:27236
|
increased B cell proliferation
|
J:27236
|
increased IgG2a level
|
J:27236
|
increased IgG2b level
|
J:27236
|
increased IgM level
|
J:27236
|
Tg(CD46)2Gsv/0
(involves: C57BL/6 * FVB/N)
|
abnormal cell-mediated immunity
|
J:109895
|
abnormal chemokine level
|
J:109895
|
abnormal cytokine secretion
|
J:109895
|
abnormal humoral immune response
|
J:109895
|
abnormal response to transplant
|
J:113644
|
decreased cytotoxic T cell cytolysis
|
J:109895
|
increased susceptibility to Paramyxoviridae infection
|
J:109895
|
Tg(Cd68-BCL2)526Medz/0
(involves: 129 * C57BL/6)
|
abnormal immune cell physiology
|
J:82809
|
increased inflammatory response
|
J:82809
|
Tg(Cd68-BCL2)535Medz/0
(involves: 129 * C57BL/6)
|
abnormal dendritic cell physiology
|
J:211458
|
decreased dendritic cell apoptosis
|
J:211458
|
increased inflammatory response
|
J:82809
|
Tg(Cd68-Fem1a)1Seno/0
(C57BL/6-Tg(Cd68-Fem1a)1Seno)
|
abnormal susceptibility to induced colitis
|
J:228893
|
Tg(Cd74-Nlrc4*)1Kyas/0
(involves: C57BL/6N)
|
autoimmune arthritis
|
J:219652
|
dermatitis
|
J:219652
|
increased circulating interleukin-1 beta level
|
J:219652
|
increased circulating interleukin-17 level
|
J:219652
|
increased inflammatory response
|
J:219652
|
increased interleukin-1 beta secretion
|
J:219652
|
joint inflammation
|
J:219652
|
skin inflammation
|
J:219652
|
Tg(Cd79b-TCL1A)BKTeit/0
(involves: C3H * C57BL/6)
|
decreased B cell apoptosis
|
J:79703
|
decreased T cell apoptosis
|
J:79703
|
increased B cell proliferation
|
J:79703
|
increased T cell proliferation
|
J:79703
|
Tg(Cd152Ig)1Jbs/0
(involves: C3H * NOD)
|
increased susceptibility to autoimmune diabetes
|
J:35353
|
Tg(CD207-Dta)312Dhka/?
(FVB-Tg(CD207-Dta)312Dhka)
|
increased susceptibility to type IV hypersensitivity reaction
|
J:113309
|
Tg(Cebpb-tTA)5Bjd/0 Tg(tetO-MYC,-OVAL)#Gtgm/0
(B6J.Cg-Tg(Cebpb-tTA)5Bjd Tg(tetO-MYC,-OVAL)#Gtgm)
|
abnormal immune tolerance
|
J:186226
|
Tg(Cga-LHB/CGB)94Jhn/?
(involves: C57BL/6 * SJL)
|
pyelonephritis
|
J:55157
|
tubulointerstitial nephritis
|
J:55157
|
Tg(Ckm-APPSw)A2Lfa/0
(involves: C57BL/6 * SJL)
|
myositis
|
J:76338
|
Tg(Ckm-APPSw)A6Lfa/0
(involves: C57BL/6 * SJL)
|
myositis
|
J:76338
|
Tg(CKMM-tTA)A3Rhvh/0 Tg(tetO-H2-K1)#Papl/0
(B6.Cg-Tg(CKMM-tTA)A3Rhvh Tg(tetO-H2-K1)#Papl)
|
abnormal cytokine level
|
J:205907
|
increased anti-nuclear antigen antibody level
|
J:205907
|
increased autoantibody level
|
J:205907
|
myositis
|
J:205907
|
Tg(CLEC4C-HBEGF)956Cln/0
(C57BL/6-Tg(CLEC4C-HBEGF)956Cln)
|
abnormal chemokine secretion
|
J:166504
|
abnormal cytotoxic T cell physiology
|
J:166504
|
abnormal NK cell physiology
|
J:166504
|
abnormal NK T cell physiology
|
J:166504
|
decreased interferon-alpha secretion
|
J:166504
|
impaired natural killer cell mediated cytotoxicity
|
J:166504
|
increased interferon-gamma secretion
|
J:166504
|
increased interleukin-12 secretion
|
J:166504
|
increased susceptibility to Herpesvirales infection
|
J:166504
|
Tg(Cma1-cre)ARoer/0 Tg(Kit*D814V)1Roer/0
(involves: C57BL/6)
|
colitis
|
J:169611
|
Tg(CMV-cre)1Cgn/0 Tg(Kit*D814V)1Roer/0
(involves: BALB/cJ * C57BL/6)
|
large intestinal inflammation
|
J:169611
|
Tg(CMV-IghvaD11)CCat/0 Tg(CMV-IgkvaD11)BCat/0
(involves: C57BL/6 * SJL)
|
increased splenocyte apoptosis
|
J:79946
|
Tg(CMV-IghvaD11)DCat/0 Tg(CMV-IgkvaD11)ACat/0
(involves: C57BL/6 * SJL)
|
increased splenocyte apoptosis
|
J:79946
|
Tg(CMV-tTA)3Bjd/0 Tg(tetO-Prkar1a*x2as)1Stra/0
(involves: C57BL/6 * NMRI * SJL)
|
pancreas inflammation
|
J:94953
|
Tg(Col1a1-Dkk1)1Hmk/?
(B6.FVB-Tg(Col1a1-Dkk1)1Hmk)
|
abnormal osteoclast physiology
|
J:158620
|
abnormal response to transplant
|
J:238121
|
Tg(Col1a1-FGF2*,-Sapphire)203Mmh/Tg(Col1a1-FGF2*,-Sapphire)203Mmh
(involves: FVB/N)
|
osteoarthritis
|
J:240777
|
Tg(Col2a1-cre/ERT2)1Dic/0 Tgfbr1tm1.1Karl/Tgfbr1tm1.1Karl
(involves: 129 * C57BL/6)
|
osteoarthritis
|
J:271724
|
Tg(Col2a1-Mir140)#Asah/0
(C57BL/6-Tg(Col2a1-Mir140)#Asah)
|
decreased susceptibility to induced arthritis
|
J:160358
|
Tg(Col2a1-rtTA,tetO-COMP*)2Jath/0
(C57BL/6-Tg(Col2a1-rtTA,tetO-COMP*)2Jath)
|
increased inflammatory response
|
J:233238
|
Tg(Comp-tTA)#Yeli/0 Tg(tetO-DDR2)#Yeli/0
(Not Specified)
|
osteoarthritis
|
J:176308
|
Tg(Cr2-cre)3Cgn/? Xrcc4tm1Fwa/Xrcc4tm2Fwa
(involves: 129P2/OlaHsd * 129S6/SvEvTac)
|
abnormal class switch recombination
|
J:150339
|
Tg(Csf1r-Tnfsf15,-EGFP)#Targ/0
(involves: C57BL/6)
|
increased interferon-gamma secretion
|
J:169462
|
small intestinal inflammation
|
J:169462
|
Tg(CSF2)2Ygy/0 Tg(IL3)1Ygy/0 Tg(KITLG)3Ygy/0
(C.Cg-Tg(CSF2)2Ygy Tg(IL3)1Ygy Tg(KITLG)3Ygy)
|
abnormal response to transplant
|
J:107052
|
decreased susceptibility to graft versus host disease
|
J:107052
|
Tg(CYP1A1-PPARD)#Jfoe/0
(involves: C57BL/6J * CBA)
|
increased T cell proliferation
|
J:158907
|
skin inflammation
|
J:158907
|
Tg(DO11.10)10Dlo/?
(involves: BALB/c * C3H * C57BL/6)
|
abnormal thymus physiology
|
J:70572
|
Tg(DO11.10)10Dlo/0 Crlf2tm1Wjl/Crlf2tm1Wjl
(involves: 129 * BALB/c * C3H * C57BL/6)
|
decreased inflammatory response
|
J:107431
|
Tg(DPP4)2Nnag/0
(B6.Cg-Tg(DPP4)2Nnag)
|
abnormal cytokine level
|
J:286321
|
increased susceptibility to Coronaviridae infection
|
J:286321
|
lung inflammation
|
J:286321
|
Tg(DPP4)2Nnag/0 Tmprss2tm1(KOMP)Vlcg/Tmprss2tm1(KOMP)Vlcg
(involves: C57BL/6NCr * C57BL/6NTac * DBA)
|
abnormal cytokine secretion
|
J:283077
|
decreased susceptibility to Coronaviridae infection
|
J:283077
|
Tg(DUX4*)1Maar/?
(involves: C57BL/6J * CBA/J)
|
increased incidence of corneal inflammation
|
J:195481
|
Tg(ED-L2-IL1RN/IL1B)#Tcw/?
(B6.Cg-Tg(ED-L2-IL1RN/IL1B)#Tcw)
|
abnormal interleukin level
|
J:180282
|
esophageal inflammation
|
J:180282
|
increased circulating interleukin-6 level
|
J:180282
|
increased inflammatory response
|
J:180282
|
Tg(EIF1AX-Il31ra)1Jagr/0
(involves: C3H * C57BL/6)
|
abnormal immune system physiology
|
J:91124
|
conjunctivitis
|
J:91124
|
dermatitis
|
J:91124
|
Tg(Ela1-TAg)18Bri/0
(involves: C57BL/6 * SJL)
|
pancreas inflammation
|
J:107545
|
Tg(Ela2a-Prss1*,-GFP)1Dbs/0
(C57BL/6-Tg(Ela2a-Prss1*,-GFP)1Dbs)
|
chronic pancreas inflammation
|
J:144663
|
increased susceptibility to induced pancreatitis
|
J:144663
|
Tg(Ela-KRAS*G12D)9Eps/0
(involves: C57BL/6 * FVB)
|
pancreas inflammation
|
J:231759
|
Tg(Ela-KRAS*G12D)9Eps/0 Tg(Mt1-TGFBR2*)AM3Epb/0
(involves: C57BL/6 * FVB)
|
pancreas inflammation
|
J:231759
|
Tg(Emu-TXLNA)1Amjr/0
(B6.Cg-Tg(Emu-TXLNA)1Amjr)
|
abnormal B cell physiology
|
J:117018
|
enhanced humoral immune response
|
J:145185
|
increased autoantibody level
|
J:117018
|
increased circulating interferon-alpha level
|
J:117018
|
increased IgA level
|
J:117018
|
increased IgG2a level
|
J:117018
|
increased IgM level
|
J:117018
|
increased immunoglobulin level
|
J:117018
|
increased susceptibility to autoimmune disorder
|
J:117018,
J:145185
|
interstitial pneumonia
|
J:145185
|
kidney inflammation
|
J:117018
|
lacrimal gland inflammation
|
J:145185
|
parotid gland inflammation
|
J:145185
|
salivary gland inflammation
|
J:117018,
J:145185
|
submandibular gland inflammation
|
J:145185
|
Tg(EmuSR-HDAC9)1468Kpet/0
(involves: C57BL/6 * CBA)
|
abnormal lymphocyte physiology
|
J:237420
|
increased B cell proliferation
|
J:237420
|
Tg(F2RL1)1Mslb/0
(involves: FVB/NCrl)
|
increased inflammatory response
|
J:79757
|
respiratory system inflammation
|
J:79757
|
Tg(Fabp1-cre)1Jig/0 Vhltm1Jae/Vhltm1Jae
(involves: 129S4/SvJae * BALB/c * FVB/N)
|
decreased susceptibility to induced colitis
|
J:93476
|
Tg(Fabp2-Arg1)1Wla/Tg(Fabp2-Arg1)1Wla
(involves: FVB)
|
decreased IgM level
|
J:80204
|
Tg(Fabp4-Angptl2)5Yo/0
(involves: C57BL/6)
|
abnormal macrophage chemotaxis
|
J:152387
|
chronic inflammation
|
J:152387
|
white adipose tissue inflammation
|
J:152387
|
Tg(Fabp4-Apol6)#Hsul/0
(C57BL/6J-Tg(Fabp4-Apol6)#Hsul)
|
white adipose tissue inflammation
|
J:344362
|
Tg(Fabp4-Phb*Y114F)#Smis/0
(Not Specified)
|
abnormal circulating chemokine level
|
J:227976
|
abnormal circulating cytokine level
|
J:227976
|
Tg(FCGR2A)11Mkz/0 Tg(PF4)#Zcy/0
(involves: C57BL/6 * SJL)
|
increased acute inflammation
|
J:72220
|
Tg(FCGR2A)11Mkz/Tg(FCGR2A)11Mkz
(involves: C57BL/6 * SJL)
|
abnormal macrophage physiology
|
J:136516
|
autoimmune arthritis
|
J:136516
|
glomerulonephritis
|
J:136516
|
increased anti-histone antibody level
|
J:136516
|
increased IgG2a level
|
J:136516
|
increased susceptibility to induced arthritis
|
J:136516
|
increased tumor necrosis factor secretion
|
J:136516
|
interstitial pneumonia
|
J:136516
|
Tg(Fga,Fgb,Fgg)1Unc/?
(C57BL/6-Tg(Fga,Fgb,Fgg)1Unc)
|
increased circulating fibrinogen level
|
J:118353
|
Tg(FOXJ1-ACE2)1Rba/0
(involves: C3H * C57BL/6)
|
increased susceptibility to Coronaviridae infection
|
J:287092,
J:288386
|
increased susceptibility to Coronaviridae infection induced morbidity/mortality
|
J:287092,
J:288386
|
interstitial pneumonia
|
J:288386
|
Tg(Foxp3-HBEGF/EGFP)23.2Spar/0
(involves: C57BL/6NCrl)
|
increased inflammatory response
|
J:125295
|
increased susceptibility to type IV hypersensitivity reaction
|
J:125295
|
insulitis
|
J:125295
|
lung inflammation
|
J:125295
|
skin inflammation
|
J:125295
|
Tg(Gfap-Ifna1)12Ilc/0
(involves: BALB/c * C57BL/6J)
|
CNS inflammation
|
J:68811
|
decreased susceptibility to Riboviria infection
|
J:68811
|
decreased susceptibility to Riboviria infection induced morbidity/mortality
|
J:68811
|
meningoencephalitis
|
J:68811
|
Tg(Gfap-Ifna1)39Ilc/0
(involves: BALB/c * C57BL/6J)
|
CNS inflammation
|
J:68811
|
meningoencephalitis
|
J:68811
|
Tg(Gfap-rtTA,tetO-MAOB,-lacZ)1Jkan/0
(involves: C57BL/6)
|
abnormal microglial cell activation
|
J:132679
|
Tg(Gfap-TK)7.1Mvs/0
(involves: C57BL/10 * CBA * CFLP)
|
abnormal inflammatory response
|
J:104241
|
brain inflammation
|
J:113202
|
small intestinal inflammation
|
J:104241
|
Tg(Gfap-TNF*)K21Gkl/0
(involves: C57BL/6 * CBA)
|
CNS inflammation
|
J:106592
|
Tg(GFAP-tTA)78Pop/0 Tg(tetO-Ifng)184Pop/0
(B6.Cg-Tg(GFAP-tTA)78Pop Tg(tetO-Ifng)184Pop)
|
abnormal interferon-gamma secretion
|
J:109838
|
CNS inflammation
|
J:109838
|
Tg(H2-Aa)26Dim/? Tg(H2-Ab1)62Dim/?
(B6.Cg-Tg(H2-Aa)26Dim Tg(H2-Ab1)62Dim)
|
abnormal antigen presentation via MHC class II
|
J:110897
|
abnormal level of surface class II molecules
|
J:110897
|
increased immunoglobulin level
|
J:110897
|
Tg(H2-Aa)26Dim/? Tg(H2-Ab1)62Dim/?
(SJL.Cg-Tg(H2-Aa)26Dim Tg(H2-Ab1)62Dim)
|
abnormal level of surface class II molecules
|
J:110897
|
Tg(H2-D-Il15)3304Clgr/?
(FVB/N-Tg(H2-D-Il15)3304Clgr)
|
abnormal inflammatory response
|
J:67478
|
abnormal lymphocyte physiology
|
J:67478
|
dermatitis
|
J:67478
|
Tg(H2-Db)2Bujf/0
(FVB/NPas-Tg(H2-Db)2Bujf)
|
decreased susceptibility to Picornaviridae infection
|
J:18556
|
Tg(H2-Ea)16Dim/?
(involves: C57BL/6 * SJL)
|
increased immunoglobulin level
|
J:111128
|
Tg(H2-Ea-G6pc2)69Tkay/?
(NOD-Tg(H2-Ea-G6pc2)69Tkay)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:117352
|
abnormal immune tolerance
|
J:117352
|
decreased T cell proliferation
|
J:117352
|
increased anti-insulin autoantibody level
|
J:117352
|
increased susceptibility to autoimmune diabetes
|
J:117352
|
insulitis
|
J:117352
|
Tg(H2-Ea-HA)HACIIAjca/0 Tg(Tcra/Tcrb)1Vbo/0
(C.Cg-Tg(H2-Ea-HA)HACIIAjca Tg(Tcra/Tcrb)1Vbo)
|
abnormal circulating cytokine level
|
J:209872
|
autoimmune arthritis
|
J:209872
|
heart inflammation
|
J:209872
|
increased circulating interleukin-6 level
|
J:209872
|
increased IgG level
|
J:209872
|
joint inflammation
|
J:209872
|
kidney inflammation
|
J:209872
|
Tg(H2-Ea-HA)HACIIAjca/0 Tg(TcraS106-1,TcrbS106-1)TS1SWAjca/0
(C.Cg-Tg(H2-Ea-HA)HACIIAjca Tg(TcraS106-1,TcrbS106-1)TS1SWAjca)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:209872
|
abnormal circulating cytokine level
|
J:209872
|
autoimmune arthritis
|
J:209872
|
decreased circulating interleukin-6 level
|
J:209872
|
increased circulating interleukin-17 level
|
J:209872
|
increased IgG level
|
J:209872
|
joint inflammation
|
J:209872
|
Tg(H2-Ea-Ins2)1Wehi/0
(NOD/ShiLtJWehi-Tg(H2-Ea-Ins2)1Wehi)
|
abnormal T cell proliferation
|
J:100232
|
salivary gland inflammation
|
J:100232
|
Tg(H2-Ea-Ins2)1Wehi/Tg(H2-Ea-Ins2)1Wehi
(NOD/ShiLtJWehi-Tg(H2-Ea-Ins2)1Wehi)
|
decreased anti-insulin autoantibody level
|
J:117352
|
decreased T cell proliferation
|
J:117352
|
Tg(H2-Ea-LACK)1Ngkh/0
(C.Cg-Tg(H2-Ea-LACK)1Ngkh)
|
abnormal immune system physiology
|
J:181384
|
abnormal T-helper 1 physiology
|
J:181384
|
abnormal T-helper 2 physiology
|
J:181384
|
decreased susceptibility to parasitic infection
|
J:181384
|
decreased susceptibility to parasitic infection induced morbidity/mortality
|
J:181384
|
Tg(H2-Ea-Tnfsf9)16Lpc/0
(involves: C57BL/6)
|
abnormal B cell physiology
|
J:132372
|
decreased IgG level
|
J:132372
|
Tg(H2-Ead)5Lt/0
(NOD/ShiLt-Tg(H2-Ead)5Lt)
|
autoimmune response
|
J:36435
|
decreased interferon-gamma secretion
|
J:36435
|
decreased susceptibility to autoimmune diabetes
|
J:36435
|
increased interleukin-4 secretion
|
J:36435
|
periinsulitis
|
J:36435
|
Tg(H2-Ead)12Lt/0
(NOD/ShiLt-Tg(H2-Ead)12Lt)
|
autoimmune response
|
J:36435
|
decreased interferon-gamma secretion
|
J:36435
|
decreased susceptibility to autoimmune diabetes
|
J:36435
|
increased interleukin-4 secretion
|
J:36435
|
insulitis
|
J:36435
|
Tg(H2-K1-HLA-A*)28Mpla/0
(B10.Cg-Tg(H2-K1-HLA-A*)28Mpla)
|
choroid inflammation
|
J:67871
|
eye inflammation
|
J:67871
|
Tg(H2-K-Cd86)7All/0
(B6.Cg-Tg(H2-K-Cd86)7All)
|
abnormal inflammatory response
|
J:112266
|
Tg(H2-K-DUSP5)21Wjl/0
(involves: C57BL/6J * CBA)
|
decreased T cell proliferation
|
J:138077
|
dermatitis
|
J:138077
|
skin inflammation
|
J:138077
|
Tg(H2-K-Fosl2,-EGFP)13Wag/0
(B6.Cg-Tg(H2-K-Fosl2,-EGFP)13Wag)
|
lung inflammation
|
J:238723
|
Tg(H2-K-HLA-G,B2M)1Alm/0
(CBA/Ca-Tg(H2-K-HLA-G,B2M)1Alm/CmwJ)
|
abnormal cytotoxic T cell physiology
|
J:140016
|
increased T cell proliferation
|
J:140016
|
Tg(H2-K-IL6)2Srj/0
(B6.Cg-Tg(H2-K-IL6)2Srj)
|
increased IgG level
|
J:185153
|
Tg(H2-K-MC159/EGFP)13Fkmc/0
(involves: C57BL/6)
|
decreased B cell apoptosis
|
J:138050
|
decreased T cell apoptosis
|
J:138050
|
increased B cell proliferation
|
J:138050
|
Tg(H2-K-MC159/EGFP)13Fkmc/Tg(H2-K-MC159/EGFP)13Fkmc
(involves: C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:138050
|
increased IgG2b level
|
J:138050
|
Tg(H2-K-TcrbP14)128Mak/?
(involves: C57BL/6 * C57L * DBA/2)
|
abnormal T cell clonal deletion
|
J:111265
|
Tg(H2-Kb-IL21)5Wjl/0
(involves: 129)
|
abnormal class switch recombination
|
J:93740
|
increased B cell apoptosis
|
J:93740
|
increased IgG1 level
|
J:93740
|
increased IgM level
|
J:93740
|
Tg(H2-Kb-Tcra,-Tcrb)1640Kurs/0
(SJL.FVB-Tg(H2-Kb-Tcra,-Tcrb)1640Kurs)
|
abnormal cytokine level
|
J:149511
|
brain inflammation
|
J:149511
|
CNS inflammation
|
J:149511
|
increased autoantibody level
|
J:149511
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:149511
|
Tg(H2-L-IL6)1Kish/Tg(H2-L-IL6)1Kish
(C57BL/6-Tg(H2-L-IL6)1Kish)
|
glomerulonephritis
|
J:128016,
J:138762
|
increased IgG1 level
|
J:128016
|
Tg(H2-L-IL6)46Kish/Tg(H2-L-IL6)46Kish
(C57BL/6-Tg(H2-L-IL6)46Kish)
|
glomerulonephritis
|
J:40405
|
increased immunoglobulin level
|
J:40405
|
Tg(H2-L-IL6)46Kish/Tg(H2-L-IL6)46Kish
(involves: BALB/c * C57BL/6)
|
increased IgA level
|
J:40405
|
increased immunoglobulin level
|
J:40405
|
Tg(H2-L-IL6)46Kish/Tg(H2-L-IL6)46Kish
(C.B6-Tg(H2-L-IL6)46Kish)
|
increased IgG1 level
|
J:74377
|
increased IgG2b level
|
J:74377
|
increased IgG level
|
J:74377
|
Tg(H2-Ld)LoxNibl/0
(C57BL/6-Tg(H2-Ld)LoxNibl)
|
decreased susceptibility to parasitic infection induced morbidity/mortality
|
J:284394
|
increased response to antigen
|
J:284394
|
Tg(H2KePCC)2403Stoe/?
(involves: C57BL/6 * SJL)
|
abnormal immune tolerance
|
J:92997
|
Tg(H2KePCC)2403Stoe/? Tg(TcraTcrbAD10)1Hed/?
(involves: C57BL/6 * SJL)
|
abnormal immune tolerance
|
J:92997
|
abnormal T cell anergy
|
J:92997
|
Tg(H2KmPCC)2939Stoe/?
(involves: C57BL/6 * SJL)
|
abnormal immune tolerance
|
J:92997
|
Tg(H2KmPCC)2939Stoe/0 Tg(Tcra2B4)1Mmd/0 Tg(Tcrb2B4)1Mmd/0
(involves: C3H/HeJ * C57BL/6 * SJL)
|
decreased T cell proliferation
|
J:50143
|
Tg(H2KmPCC)2939Stoe/? Tg(TcrAND)53Hed/?
(involves: C57BL/6 * SJL)
|
abnormal immune tolerance
|
J:92997
|
abnormal T cell anergy
|
J:92997
|
Tg(H2KmPCC)2939Stoe/? Tg(TcraTcrbAD10)1Hed/?
(involves: C57BL/6 * SJL)
|
abnormal immune tolerance
|
J:92997
|
abnormal T cell anergy
|
J:92997
|
Tg(HBB-Myc)#Cos/0
(involves: C57BL/6J * CBA/J)
|
kidney inflammation
|
J:276641
|
Tg(HBV)10Imeg/0
(involves: C57BL/6)
|
abnormal cytokine secretion
|
J:95283
|
abnormal dendritic cell physiology
|
J:95283
|
Tg(HCRT-tTA)1Ahky/0 Tg(tetO-DTA)1Gfi/0
(B6.Cg-Tg(HCRT-tTA)1Ahky Tg(tetO-DTA)1Gfi)
|
increased microglial cell activation
|
J:211045
|
Tg(HIV)26Aln/0
(involves: FVB/N)
|
kidney inflammation
|
J:90297
|
myositis
|
J:90297
|
uveitis
|
J:136652
|
Tg(HLA-A2/H2-K)1Scr/?
(involves: C57BL/6)
|
abnormal cytotoxic T cell physiology
|
J:127813
|
Tg(HLA-A/H2-D/B2M)1Dvs/0
(NOD/ShiLtDvs-Tg(HLA-A/H2-D/B2M)1Dvs)
|
increased susceptibility to autoimmune diabetes
|
J:121685
|
Tg(HLA-B27)30-4Trg/?
(involves: C57BL/6J * NOD)
|
decreased susceptibility to autoimmune diabetes
|
J:109851
|
Tg(HLA-DQA1,HLA-DQB1)1Dv/0 Tg(Ins2-CD80)3B7Flv/0
(B6.Cg-Tg(HLA-DQA1,HLA-DQB1)1Dv Tg(Ins2-CD80)3B7Flv)
|
decreased susceptibility to autoimmune diabetes
|
J:59245
|
Tg(HLA-DR2)#Lfug/0 Tg(TCROb.1A12)#Lfug/0
(involves: C57BL/6 * DBA/2)
|
CNS inflammation
|
J:134764
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:134764
|
Tg(HLA-DRA*0101,HLA-DRB1*0101)1Dmz/Tg(HLA-DRA*0101,HLA-DRB1*0101)1Dmz
(involves: C57BL/6 * C57BL/10Sn * SJL/J)
|
abnormal T cell physiology
|
J:108635
|
increased autoantibody level
|
J:108635
|
increased susceptibility to induced arthritis
|
J:108635
|
Tg(Hmgcr-MX1)LStae/Tg(Hmgcr-MX1)LStae
(involves: 129S2/SvPas * BALB/c * C57BL/6 * SJL)
|
decreased susceptibility to Orthomyxoviridae infection
|
J:119783
|
decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality
|
J:119783
|
Tg(HTT*)NXwy/0
(involves: FVB/NJ)
|
CNS inflammation
|
J:219890
|
Tg(ICAM1)4Grom/?
(involves: BALB/cAnNTac)
|
increased susceptibility to Picornaviridae infection
|
J:92607
|
Tg(Igh3H9)41Mwg/?
(involves: C57BL/6 * SJL)
|
decreased IgD level
|
J:119625
|
increased anti-single stranded DNA antibody level
|
J:119625
|
Tg(Igh*-Mir125b-1)116Toki/0
(Not Specified)
|
decreased B cell apoptosis
|
J:178816
|
Tg(Igh-6-Cd80)1Gjf/0
(involves: FVB)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:44271
|
abnormal humoral immune response
|
J:112474
|
abnormal T cell activation
|
J:44271
|
decreased immunoglobulin level
|
J:112474
|
Tg(Igh-6-Cd80)1Gjf/0
(NOD.FVB-Tg(Igh-6-Cd80)1Gjf/JbsJ)
|
abnormal B cell activation
|
J:131077
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:131077
|
abnormal level of surface class II molecules
|
J:131077
|
decreased IgG1 level
|
J:131077
|
decreased IgG2b level
|
J:131077
|
decreased IgG3 level
|
J:131077
|
decreased IgM level
|
J:131077
|
decreased immunoglobulin level
|
J:131077
|
decreased susceptibility to autoimmune diabetes
|
J:131077
|
insulitis
|
J:131077
|
Tg(Igh-6-Cd86)1Akab/0
(involves: FVB)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:44271
|
Tg(Igh-6/Igh-V125)2Jwt/0 Tg(Igk-C/Igk-V125)1Jwt/0
(NOD.B6-Tg(Igh-6/Igh-V125)2Jwt Tg(Igk-C/Igk-V125)1Jwt)
|
increased susceptibility to autoimmune diabetes
|
J:91865
|
insulitis
|
J:91865
|
Tg(Igh-6/Igh-V281)3Jwt/0
(NOD.B6-Tg(Igh-6/Igh-V281)3Jwt)
|
decreased susceptibility to autoimmune diabetes
|
J:91865
|
insulitis
|
J:91865
|
Tg(Igh-HMGA2)#Cro/0
(FVB/N-Tg(Igh-HMGA2)#Cro)
|
decreased IgG1 level
|
J:233225
|
decreased IgG2a level
|
J:233225
|
decreased IgG2b level
|
J:233225
|
decreased IgG3 level
|
J:233225
|
decreased response to antigen
|
J:233225
|
increased circulating interleukin-6 level
|
J:233225
|
increased circulating tumor necrosis factor level
|
J:233225
|
Tg(Igh-Lmp2a)ERlon/0
(involves: C57BL/6 * SJL)
|
abnormal B cell proliferation
|
J:129571
|
Tg(Igh-Maf)68Staka/0
(C57BL/6-Tg(Igh-Maf)68Staka)
|
increased IgG level
|
J:168074
|
increased IgM level
|
J:168074
|
increased immunoglobulin level
|
J:168074
|
Tg(Igh-Maf)524Staka/0
(involves: C57BL/6 * C57BL/6J * DBA/2)
|
increased IgG level
|
J:168074
|
increased IgM level
|
J:168074
|
increased immunoglobulin level
|
J:168074
|
Tg(Igh-Mir29a,-Mir29b-1,-hrGFP)#Cro/0
(FVB/N-Tg(Igh-Mir29a,-Mir29b-1,-hrGFP)#Cro)
|
abnormal B cell physiology
|
J:162077
|
decreased IgG1 level
|
J:162077
|
decreased IgG2a level
|
J:162077
|
decreased IgG2b level
|
J:162077
|
increased B cell proliferation
|
J:162077
|
Tg(Igh-Mir155)8Cro/0
(involves: FVB/N)
|
increased B cell proliferation
|
J:109591
|
Tg(Igh-Mir210)#aKgcs/Tg(Igh-Mir210)#aKgcs
(B6.Cg-Tg(Igh-Mir210)#aKgcs)
|
abnormal class switch recombination
|
J:205868
|
decreased IgA level
|
J:205868
|
decreased IgG1 level
|
J:205868
|
decreased IgG2a level
|
J:205868
|
decreased IgG2b level
|
J:205868
|
decreased IgG3 level
|
J:205868
|
Tg(Igh-Nfil3)#Kubo/0
(B6.Cg-Tg(Igh-Nfil3)#Kubo)
|
increased interleukin-3 secretion
|
J:172134
|
increased interleukin-10 secretion
|
J:172134
|
increased interleukin-13 secretion
|
J:172134
|
Tg(Igh-TCL1A)1Ypek/0
(FVB/N-Tg(Igh-TCL1A)1Ypek)
|
abnormal circulating chemokine level
|
J:160184
|
abnormal humoral immune response
|
J:160184
|
abnormal lymphocyte physiology
|
J:160184
|
decreased IgG1 level
|
J:160184
|
decreased IgG2a level
|
J:160184
|
decreased IgG2b level
|
J:160184
|
decreased IgG3 level
|
J:160184
|
decreased IgM level
|
J:160184
|
increased circulating tumor necrosis factor level
|
J:160184
|
Tg(Igh-V186.2-TCL1A)3Cro/0
(involves: C3H * C57BL/6)
|
peritoneal inflammation
|
J:76574
|
Tg(Igh-V-CD40lg)#Tsub/0
(C57BL/6-Tg(Igh-V-CD40lg)#Tsub)
|
glomerulonephritis
|
J:128824
|
increased anti-double stranded DNA antibody level
|
J:128824
|
increased anti-histone antibody level
|
J:128824
|
increased anti-single stranded DNA antibody level
|
J:128824
|
Tg(Igh-V-CD40lg)#Tsub/0
(involves: C57BL/6)
|
colitis
|
J:89855
|
glomerulonephritis
|
J:89855
|
increased autoantibody level
|
J:89855
|
increased IgG level
|
J:89855
|
increased IgM level
|
J:89855
|
increased interferon-gamma secretion
|
J:89855
|
increased splenocyte proliferation
|
J:89855
|
Tg(IGH@yH1)2BJkbv/0
(involves: 129P2/OlaHsd)
|
abnormal immunoglobulin level
|
J:23827
|
Tg(IGH@yH1)2BJkbv/0 Tg(IGK@yK1)9.2CJkbv/0
(involves: 129P2/OlaHsd)
|
abnormal immunoglobulin level
|
J:23827
|
Tg(IghelMD4)4Ccg/0
(involves: C57BL/6)
|
abnormal B cell activation
|
J:73608
|
Tg(IghelMD4)4Ccg/0
(C57BL/6-Tg(IghelMD4)4Ccg)
|
increased IgG2b level
|
J:132538
|
increased IgM level
|
J:78308,
J:132538
|
Tg(IghelMD4)4Ccg/0 Tg(ML5sHEL)5Ccg/0
(NOD.B6-Tg(IghelMD4)4Ccg Tg(ML5sHEL)5Ccg/Dvs)
|
abnormal B cell anergy
|
J:89156
|
abnormal B cell clonal deletion
|
J:89156
|
decreased IgM level
|
J:89156
|
Tg(IghelMD4)4Ccg/0 Tg(ML5sHEL)5Ccg/0
(C57BL/6-Tg(IghelMD4)4Ccg Tg(ML5sHEL)5Ccg)
|
abnormal B cell anergy
|
J:89156,
J:78308
|
abnormal central B cell anergy
|
J:109923
|
decreased IgM level
|
J:89156,
J:78308
|
Tg(IghelMD4)4Ccg/0 Tg(ML5sHEL)5Ccg/0
(involves: C57BL/6)
|
abnormal B cell anergy
|
J:73608,
J:132538
|
abnormal B cell physiology
|
J:76134
|
Tg(IghelMD4)4Ccg/Tg(IghelMD4)4Ccg
(NOD.B6-Tg(IghelMD4)4Ccg/DvsJ)
|
abnormal T cell proliferation
|
J:80859
|
increased susceptibility to autoimmune diabetes
|
J:80859
|
Tg(IghH280)48Dvs/?
(NOD/ShiLtDvs-Tg(IghH280)48Dvs/J)
|
increased susceptibility to autoimmune diabetes
|
J:274578
|
insulitis
|
J:274578
|
Tg(IghH280)48Dvs/? Tg(IgkH280)934Dvs/?
(NOD/ShiLtDvs-Tg(IghH280)48Dvs Tg(IgkH280)934Dvs/Dvs)
|
increased susceptibility to autoimmune diabetes
|
J:274578
|
Tg(Ighm-Ctla4Ig/Cd80)1Jbs/0
(involves: FVB/N)
|
abnormal B cell physiology
|
J:113109
|
Tg(Ighm-Ctla4Ig/Cd80)1Jbs/0
(NOD.FVB-Tg(Ighm-Ctla4Ig/Cd80)1Jbs)
|
decreased susceptibility to autoimmune diabetes
|
J:113109
|
Tg(IghMyc)22Bri/0
(involves: C57BL/6N * SJL)
|
increased B cell apoptosis
|
J:214383
|
Tg(IghMyc)22Bri/0 Xiaptm1Hs/Xiaptm1Hs
(B6.Cg-Xiaptm1Hs Tg(IghMyc)22Bri)
|
decreased B cell proliferation
|
J:138979
|
increased B cell apoptosis
|
J:138979
|
Tg(Igk-V21-Bax)1967Bvn/0
(involves: FVB/N)
|
increased IgA level
|
J:89049
|
increased IgE level
|
J:89049
|
increased IgG1 level
|
J:89049
|
increased IgG2a level
|
J:89049
|
increased IgG level
|
J:89049,
J:90901
|
increased IgM level
|
J:89049
|
increased immunoglobulin level
|
J:89049
|
Tg(IGK@yK1)9.2CJkbv/0
(involves: 129P2/OlaHsd)
|
abnormal immunoglobulin level
|
J:23827
|
Tg(IgkH280)934Dvs/?
(NOD/ShiLtDvs-Tg(IgkH280)934Dvs/J)
|
increased susceptibility to autoimmune diabetes
|
J:274578
|
insulitis
|
J:274578
|
Tg(Igkv3-5*-MYC)24Plbe/0
(C57BL/6J-Tg(Igkv3-5*-MYC)DLoxP4Plbe/PlbeMmmh)
|
abnormal humoral immune response
|
J:131912
|
abnormal immunoglobulin level
|
J:131912
|
increased IgG1 level
|
J:131912
|
increased IgG3 level
|
J:131912
|
Tg(Igl-2MOPC315)1275Ust/?
(C57BL/6-Tg(Igl-2MOPC315)1275Ust)
|
decreased IgM level
|
J:134666
|
Tg(Il1rn)1Dih/0
(involves: C57BL/6 * CBA)
|
decreased circulating interleukin-6 level
|
J:88605
|
decreased circulating serum amyloid protein level
|
J:61600
|
decreased inflammatory response
|
J:88605
|
decreased susceptibility to endotoxin shock
|
J:36387
|
decreased susceptibility to Herpesvirales infection
|
J:88605
|
increased susceptibility to bacterial infection
|
J:36387
|
Tg(Il1rn)1Dih/Tg(Il1rn)1Dih
(involves: C57BL/6 * CBA)
|
decreased susceptibility to endotoxin shock
|
J:36387
|
increased circulating interleukin-1 level
|
J:36387
|
increased susceptibility to bacterial infection
|
J:36387
|
Tg(IL2-Il10)1Kro/0
(involves: C3H * C57BL/6)
|
abnormal cytokine secretion
|
J:41588
|
decreased susceptibility to parasitic infection
|
J:41588
|
increased susceptibility to bacterial infection
|
J:80569
|
Tg(ILK3mHEL)3Ccg/0 Tg(TcrHEL3A9)1Mmd/0
(involves: C57BL/6JSfd * C57BL/10Sg * C57BR/cd)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:78309
|
abnormal T cell activation
|
J:78309
|
abnormal T cell proliferation
|
J:78309
|
insulitis
|
J:78309
|
Tg(Ins1-Cat,Tyr)25Pne/0
(NOD.FVB-Tg(Ins1-Cat,Tyr)25Pne)
|
increased susceptibility to autoimmune diabetes
|
J:108415
|
Tg(Ins1-Cd80)378Psoh/0 Tg(Ins2-GP)#Psoh/0 Tg(TcrLCMV)327Sdz/0
(involves: C57BL/6 * DBA/2 * FVB/N)
|
insulitis
|
J:209714
|
periinsulitis
|
J:209714
|
Tg(Ins1-EGFP/GH1)14Hara/0
(NOD/ShiLtJ-Tg(Ins1-EGFP/GH1)14Hara)
|
increased susceptibility to autoimmune diabetes
|
J:127015
|
Tg(Ins1-EGFP/GH1)14Hara/Tg(Ins1-EGFP/GH1)14Hara
(NOD/ShiLtJ-Tg(Ins1-EGFP/GH1)14Hara)
|
decreased susceptibility to autoimmune disorder
|
J:127015
|
insulitis
|
J:127015
|
Tg(Ins2*Y16A)1Ell/0
(NOD-Tg(Ins2*Y16A)1Ell)
|
increased susceptibility to autoimmune diabetes
|
J:98583
|
Tg(Ins2*Y16A)3Ell/0
(NOD-Tg(Ins2*Y16A)3Ell)
|
increased susceptibility to autoimmune diabetes
|
J:98583
|
Tg(Ins2-CD80)3B7Flv/?
(involves: C57BL/6 * CBA/Ca * NOD/Caj)
|
increased susceptibility to autoimmune diabetes
|
J:26618
|
insulitis
|
J:26618
|
Tg(Ins2-CD80)3B7Flv/0 Tg(Ins2-H2-Ead,Ins2-H2-Eb1b)187-7Bri/0
(involves: C57BL/6 * CBA/Ca * SJL)
|
increased susceptibility to autoimmune diabetes
|
J:93555
|
insulitis
|
J:93555
|
Tg(Ins2-CD80)3B7Flv/0 Tg(Ins2-Tnf)17Flv/0
(involves: C57BL/6 * CBA/Ca)
|
abnormal cytokine secretion
|
J:93555
|
increased susceptibility to autoimmune diabetes
|
J:93555
|
Tg(Ins2-CD86)12B70Flv/0
(involves: C57BL/6 * CBA/Ca)
|
abnormal cytokine secretion
|
J:93555
|
decreased susceptibility to autoimmune diabetes
|
J:93555
|
periinsulitis
|
J:93555
|
Tg(Ins2-CD86)12B70Flv/0 Tg(Ins2-H2-Ead,Ins2-H2-Eb1b)187-7Bri/0
(involves: C57BL/6 * CBA/Ca * SJL)
|
abnormal cytokine secretion
|
J:93555
|
increased susceptibility to autoimmune diabetes
|
J:93555
|
insulitis
|
J:93555
|
Tg(Ins2-CD86)12B70Flv/0 Tg(Ins2-Tnf)17Flv/0
(involves: C57BL/6 * CBA/Ca)
|
abnormal cytokine secretion
|
J:93555
|
increased susceptibility to autoimmune diabetes
|
J:93555
|
Tg(Ins2-Cd274)2Mdos/?
(NOD/ShiLt-Tg(Ins2-Cd274)2Mdos)
|
increased susceptibility to autoimmune diabetes
|
J:118934
|
Tg(Ins2-cre)5Lt/0
(NOD/ShiLt-Tg(Ins2-cre)5Lt)
|
increased susceptibility to autoimmune diabetes
|
J:127015
|
Tg(Ins2-cre)5Lt/Tg(Ins2-cre)5Lt
(NOD/ShiLt-Tg(Ins2-cre)5Lt)
|
decreased susceptibility to autoimmune disorder
|
J:127015
|
insulitis
|
J:127015
|
Tg(Ins2-crmA)27Ngkh/?
(NOD-Tg(Ins2-CrmA)27Ngkh)
|
increased susceptibility to autoimmune diabetes
|
J:132052
|
Tg(Ins2-E3)1Dvs/?
(NOD.Cg-Tg(Ins2-E3)1Dvs)
|
decreased susceptibility to autoimmune diabetes
|
J:68996
|
Tg(Ins2-E3*309)5Dvs/?
(NOD/ShiLtDvs-Tg(Ins2-E3*309)5Dvs/Dvs)
|
decreased susceptibility to autoimmune diabetes
|
J:83195
|
Tg(Ins2-E3*704)2Dvs/?
(NOD/ShiLtDvs-Tg(Ins2-E3*704)2Dvs)
|
decreased susceptibility to autoimmune diabetes
|
J:83195
|
Tg(Ins2-E3*734)3Dvs/0
(NOD/ShiLtDvs-Tg(Ins2-E3*734)3Dvs/DvsJ)
|
decreased susceptibility to autoimmune diabetes
|
J:106340
|
Tg(Ins2-E3*734)4Dvs/?
(NOD/ShiLtDvs-Tg(Ins2-E3*734)4Dvs/DvsJ)
|
decreased susceptibility to autoimmune diabetes
|
J:106340
|
Tg(Ins2-Fas*I246N)1Ach/0
(NOD-Tg(Ins2-Fas*I246N)1Ach)
|
decreased susceptibility to autoimmune diabetes
|
J:81416
|
Tg(Ins2-Fas*I246N)1Ach/0 Tg(Ins2-Fasl)24Ach/0
(NOD-Tg(Ins2-Fas*I246N)1Ach Tg(Ins2-Fasl)24Ach)
|
decreased susceptibility to autoimmune diabetes
|
J:81416
|
Tg(Ins2-Fasl)24Ach/0
(NOD-Tg(Ins2-Fasl)24Ach/J)
|
increased susceptibility to autoimmune diabetes
|
J:78679,
J:81416
|
Tg(Ins2-GAD2)1Lt/0
(NOD/ShiLt-Tg(Ins2-GAD2)1Lt)
|
insulitis
|
J:100251
|
Tg(Ins2-GAD2)2Lt/0
(NOD/ShiLt-Tg(Ins2-GAD2)2Lt)
|
abnormal cytokine secretion
|
J:100251
|
decreased susceptibility to autoimmune diabetes
|
J:100251
|
insulitis
|
J:100251
|
Tg(Ins2-GP)34-20Olds/0
(involves: BALB/c * C57BL/6)
|
abnormal lymphocyte physiology
|
J:81287
|
abnormal T cell physiology
|
J:81287
|
increased susceptibility to autoimmune diabetes
|
J:81287
|
Tg(Ins2-GP)#Psoh/0
(involves: C57BL/6)
|
insulitis
|
J:81285
|
Tg(Ins2-H2-Ead,Ins2-H2-Eb1b)187-7Bri/0
(involves: C57BL/6 * SJL)
|
decreased susceptibility to autoimmune diabetes
|
J:93555
|
Tg(Ins2-HA)165Bri/0
(B10.Cg- H2d Tg(Ins2-HA)165Bri/ShrmJ)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:86430
|
decreased T cell proliferation
|
J:86430
|
Tg(Ins2-HA)165Bri/0 Tg(TcraCl4,TcrbCl4)1Shrm/0
(involves: BALB/c * C57BL/6 * C57BL/10 * DBA/2)
|
insulitis
|
J:99756
|
Tg(Ins2-HA)165Bri/? Tg(TcraCl4,TcrbCl4)1Shrm/?
(involves: BALB/c * C57BL/6 * C57BL/10)
|
insulitis
|
J:99756
|
Tg(Ins2-Iapp)6Soel/Tg(Ins2-Iapp)6Soel
(involves: FVB/N)
|
decreased susceptibility to autoimmune diabetes
|
J:130022
|
Tg(Ins2-IAPP)RHFSoel/Tg(Ins2-IAPP)RHFSoel
(involves: FVB/N)
|
increased susceptibility to autoimmune diabetes
|
J:130022
|
Tg(Ins2-Lta)#Flv/0
(involves: NOD)
|
insulitis
|
J:91820
|
kidney inflammation
|
J:91820
|
periinsulitis
|
J:91820
|
Tg(Ins2-Lta)#Flv/0
(involves: C57BL/6)
|
insulitis
|
J:91820
|
kidney inflammation
|
J:91820
|
periinsulitis
|
J:91820
|
Tg(Ins2-Lta)#Flv/0
(involves: C57BL/6 * CBA)
|
insulitis
|
J:127705
|
periinsulitis
|
J:127705
|
Tg(Ins2-NP)25-3Olds/0
(involves: BALB/c * C57BL/6)
|
decreased susceptibility to autoimmune diabetes
|
J:81287
|
increased susceptibility to autoimmune diabetes
|
J:81287
|
Tg(Ins2-OVA)59Wehi/?
(involves: BALB/c * C57BL/6)
|
abnormal T cell activation
|
J:99560
|
increased susceptibility to autoimmune diabetes
|
J:99560
|
Tg(Ins2-OVA)307Wehi/?
(involves: BALB/c * C57BL/6)
|
increased susceptibility to autoimmune diabetes
|
J:99560
|
Tg(Ins2-OVA)307Wehi/0 Tg(TcraTcrb)1100Mjb/0
(involves: C57BL/6 * C57BL/6JWehi)
|
autoimmune response
|
J:99451
|
Tg(Ins2-TFRC/OVA)296Wehi/0
(involves: C57BL/6)
|
abnormal leukocyte migration
|
J:98589
|
decreased interferon-gamma secretion
|
J:122114
|
increased susceptibility to autoimmune diabetes
|
J:122114
|
Tg(Ins2-TFRC/OVA)296Wehi/0 1700016L21RikTg(Itgax-HBEGF/EGFP)57Lan/0
(involves: C57BL/6 * FVB)
|
decreased T cell proliferation
|
J:122114
|
Tg(Ins2-Tnf)17Flv/0
(involves: C57BL/6 * CBA * NOD)
|
insulitis
|
J:91820
|
Tg(Ins2-Tnf)17Flv/0
(involves: C57BL/6 * CBA)
|
insulitis
|
J:91820
|
Tg(INS-Il10)#Sar/0
(involves: BALB/c)
|
pancreas inflammation
|
J:107927
|
periinsulitis
|
J:107927
|
Tg(INS-Il10)#Sar/0 Tnfrsf1atm1Mak/Tnfrsf1atm1Mak
(involves: 129S2/SvPas * C57BL/6J * NOD)
|
increased susceptibility to autoimmune diabetes
|
J:64051
|
Tg(INS-Il10)#Sar/0 Tnfrsf1btm1Mwm/Tnfrsf1btm1Mwm
(involves: 129S2/SvPas * C57BL/6J * NOD)
|
increased susceptibility to autoimmune diabetes
|
J:64051
|
Tg(INS-MT2A,Tyr)1Pne/0
(FVB-Tg(INS-MT2A,Tyr)1Pne)
|
abnormal response to transplant
|
J:95089
|
Tg(ITGA2)1067Fmw/0 Tg(ITGB1)0840Fmw/0
(involves: C57BL/10 * CBA)
|
dermatitis
|
J:30249
|
eye inflammation
|
J:30249
|
Tg(ITGA2)1067Fmw/0 Tg(ITGB1)0869Fmw/0
(involves: C57BL/10 * CBA)
|
dermatitis
|
J:30249
|
eye inflammation
|
J:30249
|
Tg(ITGA2)1067Fmw/0 Tg(ITGB1)0870Fmw/0
(involves: C57BL/10 * CBA)
|
dermatitis
|
J:30249
|
eye inflammation
|
J:30249
|
Tg(ITGA2)1070Fmw/0 Tg(ITGB1)0840Fmw/0
(involves: C57BL/10 * CBA)
|
dermatitis
|
J:30249
|
eye inflammation
|
J:30249
|
Tg(ITGA2)1070Fmw/0 Tg(ITGB1)0869Fmw/0
(involves: C57BL/10 * CBA)
|
dermatitis
|
J:30249
|
eye inflammation
|
J:30249
|
Tg(ITGA2)1070Fmw/0 Tg(ITGB1)0870Fmw/0
(involves: C57BL/10 * CBA)
|
dermatitis
|
J:30249
|
eye inflammation
|
J:30249
|
Tg(ITGA2)1075Fmw/0 Tg(ITGB1)0840Fmw/0
(involves: C57BL/10 * CBA)
|
dermatitis
|
J:30249
|
eye inflammation
|
J:30249
|
Tg(ITGA2)1075Fmw/0 Tg(ITGB1)0869Fmw/0
(involves: C57BL/10 * CBA)
|
dermatitis
|
J:30249
|
eye inflammation
|
J:30249
|
Tg(ITGA2)1075Fmw/0 Tg(ITGB1)0870Fmw/0
(involves: C57BL/10 * CBA)
|
dermatitis
|
J:30249
|
eye inflammation
|
J:30249
|
Tg(ITGA5)0794Fmw/0 Tg(ITGB1)0840Fmw/0
(involves: C57BL/10 * CBA)
|
dermatitis
|
J:30249
|
eye inflammation
|
J:30249
|
Tg(ITGA5)0794Fmw/0 Tg(ITGB1)0869Fmw/0
(involves: C57BL/10 * CBA)
|
dermatitis
|
J:30249
|
eye inflammation
|
J:30249
|
Tg(ITGA5)0794Fmw/0 Tg(ITGB1)0870Fmw/0
(involves: C57BL/10 * CBA)
|
dermatitis
|
J:30249
|
eye inflammation
|
J:30249
|
Tg(ITGA5)0844Fmw/0 Tg(ITGB1)0840Fmw/0
(involves: C57BL/10 * CBA)
|
dermatitis
|
J:30249
|
eye inflammation
|
J:30249
|
Tg(ITGA5)0844Fmw/0 Tg(ITGB1)0869Fmw/0
(involves: C57BL/10 * CBA)
|
dermatitis
|
J:30249
|
eye inflammation
|
J:30249
|
Tg(ITGA5)0844Fmw/0 Tg(ITGB1)0870Fmw/0
(involves: C57BL/10 * CBA)
|
dermatitis
|
J:30249
|
eye inflammation
|
J:30249
|
Tg(ITGA5)0858Fmw/0 Tg(ITGB1)0840Fmw/0
(involves: C57BL/10 * CBA)
|
dermatitis
|
J:30249
|
eye inflammation
|
J:30249
|
Tg(ITGA5)0858Fmw/0 Tg(ITGB1)0869Fmw/0
(involves: C57BL/10 * CBA)
|
dermatitis
|
J:30249
|
eye inflammation
|
J:30249
|
Tg(ITGA5)0858Fmw/0 Tg(ITGB1)0870Fmw/0
(involves: C57BL/10 * CBA)
|
dermatitis
|
J:30249
|
eye inflammation
|
J:30249
|
Tg(Itgam-FCAR)83Rcmo/0
(involves: C57BL/6 * NOD)
|
glomerulonephritis
|
J:120534
|
increased IgA level
|
J:120534
|
Tg(Itgax-EGFP,-cre,-HBEGF,-luc)2Gjh/0
(C57BL/6-Tg(Itgax-EGFP,-cre,-HBEGF,-luc)2Gjh)
|
abnormal susceptibility to infection
|
J:194800
|
Tg(Itgax-HBEGF/OVA/EGFP)1Garbi/0
(C57BL/6-Tg(Itgax-HBEGF/OVA/EGFP)1Garbi)
|
abnormal susceptibility to infection
|
J:194800
|
Tg(Itgax-TGFBR2)1Flv/0
(C.Cg-Tg(Itgax-TGFBR2)1Flv)
|
abnormal immune system physiology
|
J:98953
|
abnormal interferon level
|
J:98953
|
decreased susceptibility to parasitic infection
|
J:98953
|
Tg(ITGB1)0840Fmw/0
(involves: C57BL/10 * CBA)
|
dermatitis
|
J:30249
|
eye inflammation
|
J:30249
|
Tg(ITGB1)0869Fmw/0
(involves: C57BL/10 * CBA)
|
dermatitis
|
J:30249
|
eye inflammation
|
J:30249
|
Tg(ITGB1)0870Fmw/0
(involves: C57BL/10 * CBA)
|
dermatitis
|
J:30249
|
eye inflammation
|
J:30249
|
Tg(IVL-KLK5)#Hov/0
(involves: C57BL/6 * CBA)
|
abnormal circulating cytokine level
|
J:210758
|
erythroderma
|
J:210758
|
increased IgE level
|
J:210758
|
lymph node inflammation
|
J:210758
|
skin inflammation
|
J:210758
|
Tg(K18-ACE2)2Prlmn/0
(involves: C57BL/6J * SJL/J)
|
increased susceptibility to Coronaviridae infection
|
J:283648
|
increased susceptibility to Coronaviridae infection induced morbidity/mortality
|
J:283648
|
Tg(K18-ACE2)2Prlmn/0
(B6.Cg-Tg(K18-ACE2)2Prlmn/J)
|
abnormal chemokine level
|
J:302313
|
abnormal circulating chemokine level
|
J:294084
|
abnormal circulating cytokine level
|
J:302313
|
abnormal cytokine level
|
J:294084,
J:302313
|
abnormal interferon level
|
J:300960,
J:302313
|
abnormal interleukin level
|
J:300960,
J:302313
|
abnormal tumor necrosis factor level
|
J:300960,
J:302313
|
blood vessel inflammation
|
J:300960
|
brain inflammation
|
J:294084
|
bronchiolitis
|
J:302313
|
conjunctivitis
|
J:294084
|
cytokine storm
|
J:300960
|
enhanced humoral immune response
|
J:302313
|
increased circulating CXCL10 level
|
J:302313
|
increased circulating interferon-gamma level
|
J:302313
|
increased circulating interleukin-6 level
|
J:294084
|
increased circulating interleukin-10 level
|
J:294084,
J:302313
|
increased circulating tumor necrosis factor level
|
J:294084
|
increased CXCL10 level
|
J:300960
|
increased IgG level
|
J:302313
|
increased IgM level
|
J:302313
|
increased susceptibility to Coronaviridae infection
|
J:294084,
J:300960,
J:302313,
J:296067
|
increased susceptibility to Coronaviridae infection induced morbidity/mortality
|
J:294084,
J:300960
|
increased susceptibility to Orthomyxoviridae infection
|
J:296067
|
increased susceptibility to viral infection
|
J:296067
|
increased susceptibility to viral infection induced morbidity/mortality
|
J:296067
|
interstitial pneumonia
|
J:300960,
J:302313
|
liver inflammation
|
J:300960
|
lung inflammation
|
J:294084,
J:302313
|
meningitis
|
J:294084,
J:302313
|
meningoencephalitis
|
J:300960,
J:296067
|
rhinitis
|
J:300960
|
Tg(Kit*D814V)1Roer/0 Tg(Mx1-cre)1Cgn/0
(involves: C57BL/6 * CBA)
|
colitis
|
J:169611
|
large intestinal inflammation
|
J:169611
|
small intestinal inflammation
|
J:169611
|
Tg(Kit*D814V)2Roer/0 Tg(Mx1-cre)1Cgn/0
(involves: C57BL/6 * CBA)
|
colitis
|
J:169611
|
large intestinal inflammation
|
J:169611
|
small intestinal inflammation
|
J:169611
|
Tg(Kit*D814V)3Roer/0 Tg(Mx1-cre)1Cgn/0
(involves: C57BL/6 * CBA)
|
colitis
|
J:169611
|
large intestinal inflammation
|
J:169611
|
Tg(KRT5-IKBKB)1Armz/0
(involves: C57BL/6 * DBA/2)
|
increased interleukin-1 alpha secretion
|
J:160072
|
increased interleukin-6 secretion
|
J:160072
|
increased tumor necrosis factor secretion
|
J:160072
|
Tg(KRT5-IKBKB)2Armz/0
(involves: C57BL/6 * DBA/2)
|
abnormal cytokine level
|
J:160072
|
abnormal immune serum protein physiology
|
J:160072
|
dermatitis
|
J:160072
|
increased circulating interferon-gamma level
|
J:160072
|
increased circulating interleukin-1 alpha level
|
J:160072
|
increased circulating interleukin-2 level
|
J:160072
|
increased circulating interleukin-4 level
|
J:160072
|
increased circulating interleukin-5 level
|
J:160072
|
increased circulating interleukin-6 level
|
J:160072
|
increased circulating interleukin-10 level
|
J:160072
|
increased circulating tumor necrosis factor level
|
J:160072
|
increased interleukin-1 alpha secretion
|
J:160072
|
increased interleukin-6 secretion
|
J:160072
|
increased tumor necrosis factor secretion
|
J:160072
|
Tg(KRT5-Nfkbia*)3Rto/0 Tg(Krt5-Tnfr1)#Rsab/0 Tnfrsf1atm1Mak/Tnfrsf1atm1Mak
(involves: 129S2/SvPas * C57BL/6 * CBA)
|
skin inflammation
|
J:208995
|
Tg(KRT5-rtTA)1Glk/0 Tg(tetO-Tfrc/EGFP/Ova)#Sfz/0 Tg(tetO/CMV-Tslp)#Sfz/0
(involves: C3H * C57BL/6 * FVB/N)
|
increased T cell proliferation
|
J:199558
|
respiratory system inflammation
|
J:199558
|
skin inflammation
|
J:199558
|
Tg(KRT5-rtTA)1Glk/0 Tg(tetO-TGFB1*C223S*C225S)1Glk/0
(involves: FVB/N)
|
dermatitis
|
J:70670
|
skin inflammation
|
J:70670
|
Tg(KRT5-rtTA)1Glk/0 Tg(tetO/CMV-Tslp)#Sfz/0
(involves: C3H * C57BL/6 * FVB/N)
|
abnormal cytokine level
|
J:100506
|
conjunctivitis
|
J:100506
|
decreased IgG2a level
|
J:100506
|
dermatitis
|
J:100506
|
increased IgE level
|
J:100506
|
increased IgG1 level
|
J:100506
|
Tg(KRT5-rtTA)1Glk/0 Tg(tetO/CMV-Tslp)#Sfz/0
(C.Cg-Tg(KRT5-rtTA)1Glk Tg(tetO/CMV-Tslp)#Sfz)
|
abnormal B cell activation
|
J:182756
|
increased autoantibody level
|
J:182756
|
increased B cell proliferation
|
J:182756
|
increased circulating interleukin-4 level
|
J:182756
|
increased susceptibility to autoimmune hemolytic anemia
|
J:182756
|
Tg(KRT5-rtTA)#Glk/0 Tg(tetO-S100a7a)#Yus/0
(involves: FVB/N)
|
abnormal chemokine secretion
|
J:168000
|
increased interleukin-1 alpha secretion
|
J:168000
|
increased tumor necrosis factor secretion
|
J:168000
|
Tg(KRT5-TGFB1)F2020Xjw/0
(involves: C57BL/6 * DBA/2 * ICR)
|
abnormal Langerhans cell physiology
|
J:90118
|
skin inflammation
|
J:90118
|
Tg(KRT5-tTA)1216Glk/0 Tg(tetO-Il13)1Tazh/0
(B6.Cg-Tg(KRT5-tTA)1216Glk Tg(tetO-Il13)1Tazh)
|
dermatitis
|
J:150232
|
increased IgE level
|
J:150232
|
increased IgG1 level
|
J:150232
|
increased interleukin-4 secretion
|
J:150232
|
increased interleukin-13 secretion
|
J:150232
|
Tg(KRT5-tTA)1216Glk/0 Tg(tetO-LMNA*G608G,-EGFP)VF1-07Maer/0
(involves: FVB/N)
|
periodontium inflammation
|
J:145312
|
skin inflammation
|
J:145312
|
Tg(KRT5-tTA)1216Glk/0 Tg(tetO-Tek)1Dmt/0
(involves: CD-1 * FVB/N)
|
abnormal interleukin secretion
|
J:147438
|
increased interferon-gamma secretion
|
J:147438
|
increased interleukin-12 secretion
|
J:147438
|
increased interleukin-17 secretion
|
J:147438
|
increased interleukin-23 secretion
|
J:147438
|
skin inflammation
|
J:147438
|
Tg(KRT5-tTA)1216Glk/0 Tg(tetO-TGFB1*C223S*C225S)1Glk/0
(involves: FVB/N)
|
dermatitis
|
J:70670
|
skin inflammation
|
J:70670
|
Tg(Krt14-Angptl2)1Yo/0
(C.Cg-Tg(Krt14-Angptl2)1Yo)
|
skin inflammation
|
J:152387,
J:181261
|
Tg(KRT14-CASP1)1Miz/0
(involves: C57BL/6)
|
abnormal T cell physiology
|
J:78602
|
dermatitis
|
J:78602,
J:79706
|
increased circulating interleukin-18 level
|
J:78602,
J:79706
|
increased IgE level
|
J:78602
|
increased IgG1 level
|
J:78602
|
increased susceptibility to bacterial infection
|
J:79706
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:79706
|
Tg(KRT14-cre)1Amc/0 Trpv3tm1.1Clph/Trpv3tm1.1Clph
(involves: 129S4/SvJae * 129S4/SvJaeSor * C57BL/6 * C57BL/6J * CBA * Swiss Webster)
|
erythroderma
|
J:164741
|
Tg(Krt14-Ifnk)#Cya/0
(C57BL/6N-Tg(Krt14-Ifnk)#Cya)
|
increased susceptibility to chemically induced skin inflammation
|
J:322130
|
Tg(KRT14-Il1f6)1Hblu/?
(involves: C57BL/6 * DBA/2)
|
abnormal chemokine level
|
J:126327
|
skin inflammation
|
J:126327
|
Tg(KRT14-Il4)#Lsch/0
(involves: BALB/cBy * C57BL/6)
|
blepharitis
|
J:126285
|
conjunctivitis
|
J:126285
|
decreased IgG2a level
|
J:126285
|
dermatitis
|
J:126285
|
increased IgE level
|
J:126285
|
increased IgG1 level
|
J:126285
|
increased mast cell degranulation
|
J:126285
|
increased susceptibility to bacterial infection
|
J:126285
|
skin inflammation
|
J:126285
|
Tg(KRT14-Il7)1Tsk/0
(FVB/N-Tg(KRT14-Il7)1Tsk)
|
blepharitis
|
J:42565
|
skin inflammation
|
J:42565
|
Tg(KRT14-Il7)1Tsk/Tg(KRT14-Il7)1Tsk
(FVB/N-Tg(KRT14-Il7)1Tsk)
|
skin inflammation
|
J:42565
|
Tg(KRT14-Il18)#Knak/0
(C57BL/6-Tg(KRT14-Il18)#Knak)
|
abnormal T cell physiology
|
J:78602
|
dermatitis
|
J:78602
|
increased circulating interleukin-18 level
|
J:78602
|
increased IgE level
|
J:78602
|
increased IgG1 level
|
J:78602
|
Tg(Krt14-Rac1*G12V)#Mrnk/0
(involves: CBA/CaJ)
|
abnormal circulating interleukin level
|
J:237134
|
joint inflammation
|
J:237134
|
skin inflammation
|
J:237134
|
Tg(KRT14-Tslp)1Pcn/0
(involves: C57BL/6 * SJL)
|
abnormal lymphocyte physiology
|
J:102470
|
increased immunoglobulin level
|
J:102470
|
Tg(KRT14-Vegfa)3Dtm/0
(FVB/N-Tg(KRT14-Vegfa)3Dtm)
|
abnormal leukocyte adhesion
|
J:104245
|
enhanced leukocyte tethering or rolling
|
J:104245
|
Tg(KRT14-VP16/NR1I2)13Sdub/?
(involves: C57BL/6)
|
abnormal dendritic cell migration
|
J:258435
|
abnormal innate immunity
|
J:258435
|
decreased interleukin-1 beta secretion
|
J:258435
|
dermatitis
|
J:258435
|
enhanced humoral immune response
|
J:258435
|
increased IgE level
|
J:258435
|
increased IgG1 level
|
J:258435
|
skin inflammation
|
J:258435
|
Tg(KRT18*R89C)22Rgo/0
(involves: FVB/N)
|
chronic liver inflammation
|
J:241700
|
Tg(KRT18*R89C)30Rgo/0
(involves: FVB/N)
|
chronic liver inflammation
|
J:241700
|
Tg(KRT18*R89C)50Rgo/0
(involves: FVB/N)
|
chronic liver inflammation
|
J:241700
|
Tg(KRT18-DPP4)3Pbmj/0
(involves: C57BL/6J * SJL/J)
|
abnormal cytokine secretion
|
J:285467
|
brain inflammation
|
J:285467
|
increased susceptibility to Coronaviridae infection
|
J:286231,
J:285467
|
increased susceptibility to Coronaviridae infection induced morbidity/mortality
|
J:286231,
J:285467
|
interstitial pneumonia
|
J:286231
|
lung inflammation
|
J:286231,
J:285467
|
Tg(LANA,vFLIP,vCYC)801Dtmr/?
(involves: C57BL/6)
|
abnormal B cell activation
|
J:196403
|
abnormal germinal center B cell physiology
|
J:196403
|
abnormal marginal zone B cell physiology
|
J:196403
|
increased B cell proliferation
|
J:196403
|
increased IgG1 level
|
J:196403
|
increased IgG3 level
|
J:196403
|
Tg(Lck-Bcl2l1)1Cant/?
(B6.Cg-Tg(Lck-Bcl2l1)1Cant)
|
increased interleukin-2 secretion
|
J:77507
|
increased T cell proliferation
|
J:77507
|
Tg(Lck-cre)548Jxm/? Tgfb1tm2.1Doe/Tgfb1tm2.1Doe
(involves: 129S6/SvEvTac * Black Swiss * C57BL/6 * CBA)
|
abnormal T cell activation
|
J:150024
|
increased inflammatory response
|
J:150024
|
increased interferon-gamma secretion
|
J:150024
|
increased interleukin-2 secretion
|
J:150024
|
lung inflammation
|
J:150024
|
salivary gland inflammation
|
J:150024
|
Tg(Lck-cre)I57Jxm/? Traf3tm1Rbr/Traf3tm1Rbr
(involves: C57BL/6 * ICR * SJL)
|
abnormal T cell physiology
|
J:132877
|
Tg(Lck-CrmA)1Hed/0
(involves: BALB/c * C57BL/6J)
|
decreased T cell apoptosis
|
J:100451
|
Tg(Lck-CrmA)1Hed/?
(involves: BALB/c * C57BL/6J)
|
decreased thymocyte apoptosis
|
J:100451
|
Tg(Lck-Cxadr)1Jdgr/0
(FVB-Tg(Lck-Cxadr)1Jdgr)
|
abnormal T cell physiology
|
J:109884
|
decreased T cell apoptosis
|
J:109884
|
decreased T cell proliferation
|
J:109884
|
Tg(Lck-FADD)1Hed/0
(involves: BALB/c * C57BL/6)
|
abnormal T cell proliferation
|
J:100451
|
Tg(Lck-FADD)1Hed/?
(involves: BALB/c * C57BL/6)
|
abnormal T cell physiology
|
J:100451
|
decreased thymocyte apoptosis
|
J:100451
|
Tg(Lck-Il31)1Jagr/0
(involves: C3H * C57BL/6)
|
abnormal immune system physiology
|
J:91124
|
conjunctivitis
|
J:91124
|
dermatitis
|
J:91124
|
Tg(Lck-LMO1)11Sjk/0 Tg(STIL-TAL1)A5.3Alpa/0
(involves: C3H * C3H/HeRos * C57BL/6 * C57BL/10Ros)
|
abnormal inflammatory response
|
J:40868
|
Tg(LCK-NFKBIA)5Dwb/0
(involves: C57BL/6 * DBA/2)
|
decreased interleukin-2 secretion
|
J:93003
|
decreased T cell proliferation
|
J:93003
|
increased T cell apoptosis
|
J:93003
|
Tg(LCK-NFKBIA)5Dwb/?
(involves: BALB/c * C57BL/6 * DBA/2)
|
abnormal T-helper 1 physiology
|
J:145531
|
decreased interferon-gamma secretion
|
J:145531
|
decreased susceptibility to type I hypersensitivity reaction
|
J:145531
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:145531
|
Tg(LCK-NFKBIA)5Dwb/? Tg(Tcra,Tcrb)1Mcd/?
(involves: BALB/c * C57BL/6 * DBA/2)
|
decreased interferon-gamma secretion
|
J:145531
|
Tg(Lck-Socs3)1Kubo/0
(Not Specified)
|
decreased interleukin-2 secretion
|
J:128797
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:132905
|
decreased T cell proliferation
|
J:128797
|
Tg(Lck-Sox13)#Jskg/0
(involves: C57BL/6)
|
decreased T cell proliferation
|
J:117301
|
increased thymocyte apoptosis
|
J:117301
|
Tg(Lck-Stat5b*)1Mafa/0
(Not Specified)
|
increased B cell proliferation
|
J:132669
|
Tg(Lck-Stk17b)26.1Wals/?
(B6.Cg-Tg(Lck-Stk17b)26.1Wals)
|
increased anti-nuclear antigen antibody level
|
J:149973
|
increased interleukin-2 secretion
|
J:149973
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:149973
|
increased T cell proliferation
|
J:149973
|
Tg(Lck-Tax)53Hall/0
(involves: C57BL/6)
|
increased susceptibility to fungal infection
|
J:129531
|
Tg(Lck-Tnfsf4)1Nish/0
(B6.Cg-Tg(Lck-Tnfsf4)1Nish)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:194882
|
abnormal cytokine secretion
|
J:80214
|
increased interleukin-13 secretion
|
J:194882
|
increased susceptibility to type IV hypersensitivity reaction
|
J:80214
|
increased T cell proliferation
|
J:80214
|
lung inflammation
|
J:194882
|
Tg(Lck-Tnfsf4)1Nish/0
(C.Cg-Tg(Lck-Tnfsf4)1Nish)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:194882
|
increased interleukin-13 secretion
|
J:194882
|
Tg(Lck-TNFSF13)3919Mhah/0
(B6.Cg-Tg(Lck-TNFSF13)3919Mhah)
|
decreased B cell apoptosis
|
J:94628
|
increased IgA level
|
J:94628
|
Tg(Lck-Tnfsf14)24Yxf/?
(C57BL/6-Tg(Lck-Tnfsf14)24Yxf)
|
abnormal complement protein level
|
J:128976
|
abnormal inflammatory response
|
J:128976
|
abnormal T cell physiology
|
J:120962,
J:129951
|
colitis
|
J:129951
|
glomerulonephritis
|
J:129951
|
increased anti-double stranded DNA antibody level
|
J:129951
|
increased anti-nuclear antigen antibody level
|
J:128976
|
increased autoantibody level
|
J:129951
|
increased IgA level
|
J:128976
|
increased IgG level
|
J:128976
|
increased T cell proliferation
|
J:129951
|
intestinal inflammation
|
J:128976
|
liver inflammation
|
J:129951
|
lung inflammation
|
J:129951
|
myositis
|
J:129951
|
small intestinal inflammation
|
J:120962
|
Tg(Lck-Tnfsf15,-EGFP)#Targ/0
(involves: C57BL/6)
|
increased interferon-gamma secretion
|
J:169462
|
increased interleukin-17 secretion
|
J:169462
|
small intestinal inflammation
|
J:169462
|
Tg(Lck-Tslp)1Chea/0
(B6.Cg-Tg(Lck-Tslp)1Chea)
|
glomerulonephritis
|
J:72982
|
increased anti-nuclear antigen antibody level
|
J:72982
|
increased immunoglobulin level
|
J:72982
|
liver inflammation
|
J:72982
|
lung inflammation
|
J:72982
|
Tg(Lck-VIPR2)1Ejg/0
(C57BL/6-Tg(Lck-VIPR2)1Ejg)
|
decreased interferon-gamma secretion
|
J:127974
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:127974
|
increased IgE level
|
J:127974
|
increased IgG1 level
|
J:127974
|
increased interleukin-4 secretion
|
J:127974
|
increased interleukin-5 secretion
|
J:127974
|
increased susceptibility to type I hypersensitivity reaction
|
J:127974
|
Tg(Lck/Emu-Rftn1)1Ayos/?
(involves: C57BL/6)
|
increased IgG1 level
|
J:150299
|
increased IgG2a level
|
J:150299
|
increased IgG3 level
|
J:150299
|
increased IgM level
|
J:150299
|
increased interferon-gamma secretion
|
J:150299
|
increased interleukin-4 secretion
|
J:150299
|
increased interleukin-17 secretion
|
J:150299
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:150299
|
increased T cell proliferation
|
J:150299
|
Tg(LckIl4)1315Dbl/0
(involves: C57BL/6J * DBA/2J)
|
abnormal osteoclast physiology
|
J:107359
|
abnormal T cell activation
|
J:92453
|
abnormal thymocyte activation
|
J:92453
|
increased IgG2a level
|
J:92453
|
increased interleukin-4 secretion
|
J:92453
|
increased susceptibility to parasitic infection
|
J:92453
|
Tg(LCKprBCL2)36Sjk/?
(involves: C3H * C57BL/6)
|
decreased T cell apoptosis
|
J:11548
|
Tg(LCKprBCL2)36Sjk/0
(involves: C57BL/6 * CBA/J)
|
abnormal T cell clonal deletion
|
J:217939
|
decreased thymocyte apoptosis
|
J:217939
|
Tg(LCKprBCL2)36Sjk/0 Tg(Nr4a1-EGFP/cre)820Khog/0
(involves: C57BL/6 * C57BL/6J)
|
abnormal T cell clonal deletion
|
J:217939
|
decreased thymocyte apoptosis
|
J:217939
|
Tg(LCKprBCL2)36Sjk/0 Tg(TcraH-Y,TcrbH-Y)71Vbo/0
(involves: C57BL/6 * C57BL/6J * DBA/2J)
|
abnormal T cell clonal deletion
|
J:217939
|
decreased thymocyte apoptosis
|
J:217939
|
Tg(Ly6a-GCSAM)102AIsg/0
(involves: C57BL/6J * CBA)
|
increased B cell proliferation
|
J:221238
|
increased IgG level
|
J:221238
|
increased inflammatory response
|
J:221238
|
Tg(Ly6a-SET/NUP214)2969Gcg/0
(involves: FVB/NJ)
|
increased B cell apoptosis
|
J:142938
|
Tg(LYZ-rtTA2S*M2,tetO-ELAVL1)632Dkon/0
(B6.Cg-Tg(LYZ-rtTA2S*M2,tetO-ELAVL1)632Dkon)
|
decreased susceptibility to induced colitis
|
J:184388
|
Tg(Mbp-Pad2)28Fgm/0
(involves: CD-1)
|
abnormal tumor necrosis factor level
|
J:142650
|
Tg(Mbp-SNCA)1Ema/0
(involves: C57BL/6 * DBA/2)
|
brain inflammation
|
J:207162
|
Tg(MCL1)8Caig/0
(involves: C57BL/6 * SJL)
|
abnormal leukocyte physiology
|
J:50604
|
abnormal macrophage apoptosis
|
J:95913
|
decreased B cell apoptosis
|
J:50604
|
decreased splenocyte apoptosis
|
J:50604
|
decreased T cell apoptosis
|
J:50604
|
increased susceptibility to bacterial infection
|
J:95913
|
Tg(Mcpt8-cre)1Voeh/0
(involves: C57BL/6)
|
decreased inflammatory response
|
J:164432
|
Tg(Mir125a)#Smoc/0
(involves: C57BL/6)
|
decreased interferon-gamma secretion
|
J:224880
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:224880
|
Tg(ML5sHEL)5Ccg/0
(C57BL/6-Tg(ML5sHEL)5Ccg)
|
abnormal B cell anergy
|
J:78308
|
Tg(ML5sHEL)5Ccg/0
(involves: C57BL/6JSfd * CBA)
|
abnormal B cell anergy
|
J:78308
|
abnormal T cell anergy
|
J:78308
|
Tg(ML5sHEL)5Ccg/0 Tg(TcrHEL3A9)1Mmd/0
(involves: C57BL/6 * C57BL/10 * C57BR/cd)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:78309
|
abnormal T cell activation
|
J:78309
|
abnormal T cell proliferation
|
J:78309
|
Tg(ML5sHEL)5Ccg/0 Tg(TcrHEL3A9)1Mmd/0 Tg(TLK2mHEL)2Ccg/0
(involves: C57BL/6JSfd * C57BL/10 * C57BR/cd)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:78309
|
abnormal T cell activation
|
J:78309
|
abnormal T cell proliferation
|
J:78309
|
thyroid gland inflammation
|
J:78309
|
Tg(MMTV-ENPP2)#Gbm/0
(FVB/N-Tg(MMTV-ENPP2)#Gbm)
|
mastitis
|
J:149661
|
Tg(MMTV-LPAR1)2Gbm/Tg(MMTV-LPAR1)2Gbm
(FVB/N-Tg(MMTV-LPAR1)2Gbm)
|
mastitis
|
J:149661
|
Tg(MMTV-LPAR1)7Gbm/Tg(MMTV-LPAR1)7Gbm
(FVB/N-Tg(MMTV-LPAR1)7Gbm)
|
mastitis
|
J:149661
|
Tg(MMTV-LPAR1)#Gbm/Tg(MMTV-LPAR1)#Gbm
(FVB/N-Tg(MMTV-LPAR1)#Gbm)
|
mastitis
|
J:149661
|
Tg(MMTV-LPAR2)3Gbm/Tg(MMTV-LPAR2)3Gbm
(FVB/N-Tg(MMTV-LPAR2)3Gbm)
|
mastitis
|
J:149661
|
Tg(MMTV-LPAR2)6Gbm/Tg(MMTV-LPAR2)6Gbm
(FVB/N-Tg(MMTV-LPAR2)6Gbm)
|
mastitis
|
J:149661
|
Tg(MMTV-LPAR2)#Gbm/Tg(MMTV-LPAR2)#Gbm
(FVB/N-Tg(MMTV-LPAR2)#Gbm)
|
mastitis
|
J:149661
|
Tg(MMTV-LPAR3)3Gbm/Tg(MMTV-LPAR3)3Gbm
(FVB/N-Tg(MMTV-LPAR3)3Gbm)
|
mastitis
|
J:149661
|
Tg(MMTV-LPAR3)#Gbm/Tg(MMTV-LPAR3)#Gbm
(FVB/N-Tg(MMTV-LPAR3)#Gbm)
|
mastitis
|
J:149661
|
Tg(MMTV-PyVT)#Mul/0
(B6.FVB-Tg(MMTV-PyVT)#Mul)
|
abnormal circulating cytokine level
|
J:147923
|
abnormal T cell physiology
|
J:147923
|
decreased B cell proliferation
|
J:147923
|
decreased splenocyte proliferation
|
J:147923
|
decreased T cell proliferation
|
J:147923
|
increased circulating tumor necrosis factor level
|
J:147923
|
Tg(MMTV-Scgb1a1)#Abm/0
(involves: C57BL/6 * SJL)
|
increased IgA level
|
J:57504
|
Tg(Mpz-RAF1/ESR1)A668Ayld/0
(involves: C57BL/6J * CBA/J)
|
increased inflammatory response
|
J:182703
|
Tg(Msr1-MMP9)#Apar/0
(B6.Cg-Tg(Msr1-MMP9)#Apar)
|
abnormal macrophage physiology
|
J:136830
|
decreased inflammatory response
|
J:129959
|
Tg(MSR1-Plau)1Ddi/0
(involves: C57BL/6 * SJL)
|
heart inflammation
|
J:101486
|
Tg(Mt1-Crry)26Quig/?
(involves: CD-1)
|
abnormal inflammatory response
|
J:117777
|
Tg(Mt1-IL6)28Gci/0
(involves: C57BL/6 * DBA/2)
|
increased circulating interleukin-6 level
|
J:177825
|
increased circulating serum amyloid protein level
|
J:177825
|
increased IgG1 level
|
J:18424
|
increased IgG level
|
J:177825,
J:18424
|
Tg(Mt1-TGFBR2*)AM3Epb/0
(involves: FVB/N)
|
pancreas inflammation
|
J:76993
|
Tg(MT2A-TGFBR2)4Rser/0
(involves: C57BL/6 * DBA)
|
osteoarthritis
|
J:44579
|
Tg(MUC1)79.24Gend/0
(involves: C57BL/6)
|
abnormal humoral immune response
|
J:128899
|
increased IgG level
|
J:154046
|
increased IgM level
|
J:154046
|
Tg(Mup3-Plau)350-2Eps/?
(C57BL/6-Tg(Mup3-Plau)350-2Eps)
|
increased interleukin-1 beta secretion
|
J:233146
|
increased tumor necrosis factor secretion
|
J:233146
|
liver inflammation
|
J:233146
|
Tg(Mx1-cre)1Cgn/0 Znrf1tm1Lchs/Znrf1tm1Lchs
(involves: C57BL/6)
|
decreased susceptibility to endotoxin shock
|
J:250572
|
Tg(Myh6*/tetO-Capn1)L3Gwd/0
(involves: FVB/N)
|
heart inflammation
|
J:133797
|
Tg(Myh6-BAG3*P209L)#Mswi/0
(involves: C57BL/6 * DBA/2)
|
heart inflammation
|
J:234278
|
Tg(Myh6-Grem2)1Akh/0
(involves: C57BL/6)
|
decreased inflammatory response
|
J:250034
|
decreased interleukin-10 secretion
|
J:250034
|
Tg(Myh6-JUP*)1Dpju/0
(FVB/N-Tg(Myh6-JUP*)1Dpju)
|
heart inflammation
|
J:235770
|
Tg(Myh6-Tnf)1Brgi/?
(involves: C57BL/6J * SJL)
|
myocarditis
|
J:84829,
J:100006
|
Tg(Myh6-Tnf)2Brgi/?
(involves: C57BL/6J * SJL)
|
myocarditis
|
J:84829,
J:100006
|
Tg(Myh6-Tnnt2*R92Q)2Lnwd/0
(involves: C57BL/6)
|
heart inflammation
|
J:56911
|
Tg(Myh6-Tnnt2*R92Q)3Lnwd/0
(involves: C57BL/6)
|
heart inflammation
|
J:56911
|
Tg(Myh6-tTA)6Smbf/0 Tg(tetO-EDN1,-lacZ)9Mhus/0
(involves: C57BL/6 * CBA)
|
heart inflammation
|
J:131245
|
Tg(Myh6-tTA)6Smbf/0 Tg(tetO-HDAC5*)1Eno/0
(involves: C3H * C57BL/6 * CBA)
|
myocarditis
|
J:81967
|
Tg(Myh6-tTA)6Smbf/0 Tg(tetO-NOS2,-lacZ)240iMhus/0
(involves: C57BL/6 * CBA)
|
heart inflammation
|
J:132082
|
Tg(Myh6-tTA)6Smbf/0 Tg(tetO-Spp1)5Gad/0
(involves: C57BL/6 * CBA)
|
heart inflammation
|
J:194810
|
myocarditis
|
J:194810
|
Tg(Myl1-SOD1*G93A)#Amu/0
(FVB/NJ-Tg(Myl1-SOD1*G93A)#Amu)
|
increased microglial cell activation
|
J:143747
|
Tg(Nlrp1b)1Die/0
(involves: 129S1/SvImJ * C57BL/6 * SJL)
|
abnormal macrophage physiology
|
J:99748
|
Tg(OMP-SV40T)13Bse/0
(involves: C57BL/6 * SJL)
|
abnormal immune tolerance
|
J:54269
|
Tg(Pcp2-TBP*)69Hmhl/0
(involves: FVB/N)
|
brain inflammation
|
J:174239
|
Tg(Pgk1-HA)1.1Vbo/? Tg(Tcra/Tcrb)1Vbo/?
(C.Cg-Tg(Pgk1-HA)1.1Vbo Tg(Tcra/Tcrb)1Vbo)
|
abnormal regulatory T cell physiology
|
J:112603
|
Tg(Pim1-Il9)5Jcrd/0
(involves: BALB/c * FVB/N)
|
increased susceptibility to type I hypersensitivity reaction
|
J:100568
|
Tg(Pim1-Il9)5Jcrd/0
(involves: FVB/N)
|
increased interleukin-5 secretion
|
J:115764
|
increased susceptibility to type I hypersensitivity reaction
|
J:100568
|
Tg(PLP1*)4Rsj/0
(involves: CD-1)
|
CNS inflammation
|
J:161344
|
Tg(Plp1-Eif2ak3*)18Pop/0
(C57BL/6J-Tg(Plp1-Eif2ak3*)18Pop)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:238042
|
Tg(Prdx6)153Pgn/0
(C57BL/6-Tg(Prdx6)153Pgn/Pgn)
|
abnormal macrophage physiology
|
J:86528
|
Tg(PRG1)18Wlad/0
(involves: C57BL/6J * CBA/J)
|
decreased susceptibility to Picornaviridae infection
|
J:127826
|
increased susceptibility to Picornaviridae infection
|
J:92990
|
increased susceptibility to Picornaviridae infection induced morbidity/mortality
|
J:92990
|
Tg(PRG3)9Wlad/0
(involves: C57BL/6J * CBA/J)
|
increased susceptibility to Picornaviridae infection
|
J:92990,
J:127826
|
Tg(Prnp)4053Sbp/0
(involves: FVB/N)
|
increased susceptibility to prion infection
|
J:136434
|
Tg(Prnp)a20Cwe/0
(Not Specified)
|
increased susceptibility to prion infection
|
J:130657,
J:143528
|
Tg(Prnp-ATXN7*92Q)6529Als/Y
(involves: C3H/HeJ * C57BL/6J)
|
colitis
|
J:135615
|
Tg(Prnp-Immt/SOD1*G93A)7Gmnf/Tg(Prnp-Immt/SOD1*G93A)7Gmnf
(involves: C57BL/6 * CBA * SJL)
|
dermatitis
|
J:177846
|
Tg(Prnp-ITM2B*)1Ruvi/Tg(Prnp-ITM2B*)1Ruvi Tg(Prnp-MAPT*P301L)#Ruvi/Tg(Prnp-MAPT*P301L)#Ruvi
(involves: C3HeB/FeJ * C57BL/6)
|
increased inflammatory response
|
J:197198
|
Tg(Prnp-MAPT*P301L)JNPL3Hlmc/?
(involves: C57BL/6 * DBA/2)
|
eye inflammation
|
J:63887
|
Tg(PRSS1/lacZ)#Gwzh/0
(Not Specified)
|
increased susceptibility to induced pancreatitis
|
J:345508
|
Tg(Psp-Rbbp4)1Yoha/0
(involves: C57BL/6)
|
abnormal antigen presentation
|
J:141378
|
abnormal T cell activation
|
J:141378
|
increased autoantibody level
|
J:141378
|
increased interferon-gamma secretion
|
J:141378
|
increased interleukin-2 secretion
|
J:141378
|
increased interleukin-18 secretion
|
J:141378
|
increased susceptibility to autoimmune disorder
|
J:141378
|
lacrimal gland inflammation
|
J:141378
|
salivary gland inflammation
|
J:141378
|
Tg(PVR)1Kkst/0
(involves: ICR)
|
increased susceptibility to Picornaviridae infection
|
J:153943
|
Tg(RIP1-Tag)5Dh/?
(C3HeB/FeJ-Tg(RIP1-Tag)5Dh)
|
pancreas inflammation
|
J:80168
|
Tg(Scgb1a1-IL6)9Flv/0
(involves: C57BL/6 * CBA)
|
lung inflammation
|
J:128762,
J:156430
|
Tg(Scgb1a1-Il13)2Eli/?
(involves: C57BL/6 * CBA)
|
abnormal leukocyte physiology
|
J:53612
|
respiratory system inflammation
|
J:53612
|
Tg(Scgb1a1-Il17a)3Cdon/0
(C57BL/6-Tg(Scgb1a1-Il17a)3Cdon)
|
abnormal chemokine level
|
J:112600
|
lung inflammation
|
J:112600
|
Tg(Scgb1a1-Il17f,GFP)1Cdon/?
(C57BL/6-Tg(Scgb1a1-Il17f,GFP)1Cdon)
|
lung inflammation
|
J:136279
|
Tg(Scgb1a1-Muc5b,-AcGFP)#Evns/0
(involves: C57BL/6J * C57BL/6N)
|
decreased susceptibility to bacterial infection
|
J:207159
|
Tg(Scgb1a1-PLUNC)#Chuh/0
(involves: FVB/N)
|
decreased susceptibility to bacterial infection
|
J:171589
|
Tg(Scgb1a1-rtTA)1Jaw/0 Tg(tetO-EGFR*T790M*L858R)19Kkw/0
(involves: 129 * C57BL/6 * FVB/N)
|
interstitial pneumonia
|
J:122849
|
Tg(Scgb1a1-rtTA)1Jaw/0 Tg(tetO-IL1B)KBry/0
(involves: 129 * C57BL/6)
|
abnormal chemokine level
|
J:107601,
J:130523
|
lung inflammation
|
J:107601,
J:130523
|
Tg(Scgb1a1-rtTA,-tTS,tetO-CHI3L1)1Eli/0
(Not Specified)
|
decreased T cell apoptosis
|
J:148490
|
Tg(Scgb1a1-rtTA,-tTS,tetO-TGFB1*)1Eli/0
(involves: C57BL/6)
|
lung inflammation
|
J:92469
|
Tg(Scgb1a1-rtTA,tetO-Il13)1Eli/0
(involves: C57BL/6 * CBA)
|
abnormal T-helper 2 physiology
|
J:148490
|
Tg(Scgb1a1-Scnn1b)6608Bouc/0
(involves: C3H * C57BL/6)
|
bronchitis
|
J:91139
|
Tg(Scgb1a1-Scnn1b)6608Bouc/0
(B6.Cg-Tg(Scgb1a1-Scnn1b)6608Bouc)
|
respiratory system inflammation
|
J:191673
|
Tg(Scgb1a1-Scnn1b)6608Bouc/0
(C.Cg-Tg(Scgb1a1-Scnn1b)6608Bouc)
|
respiratory system inflammation
|
J:191673
|
Tg(SERPINA1*E342K)#Slcw/0
(involves: C57BL/6 * ICR)
|
liver inflammation
|
J:149132
|
Tg(SERPINA1-HBVX)1655Jtsb/0
(involves: C3H * C57BL/6 * ICR)
|
liver inflammation
|
J:90305
|
Tg(SERPINA1-IGHG1/Il1rl1)423Zbz/?
(involves: C3H * C57BL/6)
|
abnormal eosinophil physiology
|
J:63507
|
abnormal response to infection
|
J:63507
|
decreased interleukin-5 secretion
|
J:63507
|
Tg(SFTPC-DPP4)3Pbmj/0
(involves: C57BL/6J * SJL/J)
|
abnormal susceptibility to Coronaviridae infection
|
J:285467
|
Tg(SFTPC-Il18)AThos/0
(B6N.Cg-Tg(SFTPC-Il18)AThos)
|
increased interferon-gamma secretion
|
J:147547
|
increased interleukin-13 secretion
|
J:147547
|
lung inflammation
|
J:147547
|
Tg(SFTPC-rtTA)2Jaw/0 Tg(tetO-CTGF)#Swu/0
(involves: 129 * C57BL/6 * C57BL/6J)
|
lung inflammation
|
J:171151
|
Tg(SFTPC-rtTA,tetO-Tnf)320-1Gwho/0
(involves: C57BL/6 * SJL)
|
lung inflammation
|
J:97297
|
Tg(SFTPC-Tnf)2Pva/0
(involves: C57BL/6 * DBA/2)
|
alveolitis
|
J:28120
|
interstitial pneumonia
|
J:28120
|
Tg(Sirt1)ASrn/?
(involves: C57BL/6 * CBA)
|
increased susceptibility to endotoxin shock
|
J:137868
|
Tg(SOD1*G93A)1Gur/0
(B6.Cg-Tg(SOD1*G93A)1Gur/J)
|
abnormal T cell physiology
|
J:138237
|
Tg(SOD1*G93A)1Gur/0
(B6SJL-Tg(SOD1*G93A)1Gur/J)
|
CNS inflammation
|
J:110437
|
Tg(Stat3*)9199Alau/0
(involves: C57BL/6)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:210877
|
decreased IgG1 level
|
J:210877
|
decreased IgG3 level
|
J:210877
|
increased IgE level
|
J:210877
|
increased inflammatory response
|
J:210877
|
increased susceptibility to bacterial infection
|
J:210877
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:210877
|
increased susceptibility to endotoxin shock
|
J:210877
|
intestinal inflammation
|
J:210877
|
Tg(SV40-Igh-64C8)H3Hon/0 Tg(SV40-Igk4C8)L1Hon/0
(involves: C57BL/6)
|
abnormal B cell clonal deletion
|
J:139864
|
increased anti-erythrocyte antigen antibody level
|
J:139864
|
Tg(SV40-KLK7)1010Teg/0
(involves: C57BL/6J * CBA)
|
dermatitis
|
J:75714
|
Tg(TARDBP*G348C)#Jpj/0
(involves: C3H * C57BL/6)
|
abnormal cytokine level
|
J:195184
|
Tg(TCF3/HLF)1Mlc/0
(involves: FVB/N)
|
abnormal thymus involution
|
J:55022
|
Tg(Tcra2C,Tcrb2C)1Dlo/?
(involves: C57L * DBA/2 * SJL)
|
abnormal memory T cell physiology
|
J:95380
|
seborrheic dermatitis
|
J:95380
|
Tg(Tcra2D2,Tcrb2D2)1Kuch/0
(involves: C57BL/6)
|
abnormal cytokine secretion
|
J:83278
|
blepharitis
|
J:83278
|
CNS inflammation
|
J:83278
|
increased susceptibility to autoimmune disorder
|
J:83278
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:83278
|
Tg(Tcra2D2,Tcrb2D2)1Kuch/?
(involves: C57BL/6 * CD-1)
|
decreased interleukin-17 secretion
|
J:125296
|
Tg(Tcra2D2,Tcrb2D2)1Kuch/0
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased interferon-gamma secretion
|
J:189919
|
decreased interleukin-2 secretion
|
J:189919
|
decreased interleukin-10 secretion
|
J:189919
|
decreased T cell proliferation
|
J:189919
|
increased interferon-gamma secretion
|
J:189919
|
increased interleukin-6 secretion
|
J:189919
|
increased interleukin-17 secretion
|
J:189919
|
increased T cell apoptosis
|
J:189919
|
increased T cell proliferation
|
J:189919
|
Tg(Tcra5CC7,Tcrb5CC7)IWep/0
(involves: C57BL/6)
|
abnormal T cell activation
|
J:73608
|
Tg(Tcra,Tcrb)3Ayr/0
(involves: C57BL/6 * DBA/2)
|
abnormal lymphocyte anergy
|
J:80775
|
decreased T cell proliferation
|
J:80775
|
Tg(Tcra,Tcrb)24Efro/0
(D1.Cg-Tg(Tcra,Tcrb)24Efro)
|
abnormal cytokine secretion
|
J:104243
|
autoimmune response
|
J:104243
|
decreased T cell proliferation
|
J:104243
|
increased autoantibody level
|
J:104243
|
increased susceptibility to autoimmune disorder
|
J:104243
|
increased T cell proliferation
|
J:104243
|
Tg(Tcra,Tcrb)HRCAll/0
(B6.Cg-Tg(Tcra,Tcrb)HRCAll)
|
decreased cytotoxic T cell cytolysis
|
J:131347
|
decreased interferon-gamma secretion
|
J:131347
|
Tg(TcraAI4)1Dvs/0
(NOD-Tg(TcraAI4)1Dvs)
|
increased susceptibility to autoimmune diabetes
|
J:93553
|
Tg(TcraAI4)1Dvs/0 Tg(TcrbAI4)1Dvs/0
(NOD-Tg(TcraAI4)1Dvs Tg(TcrbAI4)1Dvs)
|
abnormal cytotoxic T cell physiology
|
J:94192
|
increased susceptibility to autoimmune diabetes
|
J:94192
|
Tg(TcraAV19AJ33)1Shima/?
(involves: 129S4/SvJae * C57BL/6)
|
abnormal NK T cell physiology
|
J:112657
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:112657
|
Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0
(NOD.Cg-Tg(TcraBDC2.5,TcrbBDC2.5)1Doi)
|
decreased susceptibility to autoimmune diabetes
|
J:87251
|
insulitis
|
J:52940
|
Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0
(involves: C57BL/6 * NOD * SJL)
|
insulitis
|
J:137009
|
Tg(TcraH-Y,TcrbH-Y)71Vbo/?
(involves: C57BL/6 * DBA/2J)
|
abnormal cytotoxic T cell physiology
|
J:66565
|
Tg(TcrAND)53Hed/?
(involves: A/WySnSg * C57BL/6 * C57BL/10SnSg * SJL)
|
abnormal T cell proliferation
|
J:85777
|
abnormal thymocyte activation
|
J:85777
|
Tg(TcraR28,TcrbR28)KRNDim/0
(involves: C57BL/6 * NOD * SJL)
|
abnormal macrophage chemotaxis
|
J:36815
|
abnormal T cell activation
|
J:36815
|
abnormal T cell anergy
|
J:36815
|
abnormal T cell clonal deletion
|
J:36815
|
abnormal T cell proliferation
|
J:36815
|
chronic joint inflammation
|
J:36815
|
glomerulonephritis
|
J:36815
|
impaired neutrophil recruitment
|
J:36815
|
increased IgG1 level
|
J:36815
|
kidney inflammation
|
J:36815
|
rheumatoid arthritis
|
J:36815
|
Tg(TcraTcrb)8Rest/?
(C57BL/6-Tg(TcraTcrb)8Rest)
|
abnormal cytotoxic T cell physiology
|
J:85058
|
increased interferon-gamma secretion
|
J:85058
|
Tg(TcraTcrb)425Cbn/0
(involves: C57BL/6)
|
abnormal cytokine level
|
J:112600
|
Tg(TcraTcrb)425Cbn/0 Trim30atm1Yjk/Trim30atm1Yjk
(involves: 129P2/OlaHsd * BALB/c * C57BL/6)
|
increased T cell proliferation
|
J:215171
|
Tg(TcraTcrb)1100Mjb/?
(involves: C57BL/6)
|
abnormal cytotoxic T cell physiology
|
J:92867,
J:133645
|
abnormal T cell clonal deletion
|
J:92867
|
increased T cell proliferation
|
J:92867
|
Tg(TcraTcrb)1100Mjb/?
(involves: C57BL/6 * MRL/Mp)
|
liver inflammation
|
J:72817
|
Tg(TcraTcrbNY4.1)1Pesa/0
(NOD.Cg-Tg(TcraTcrbNY4.1)1Pesa)
|
increased susceptibility to autoimmune diabetes
|
J:108768
|
insulitis
|
J:108768
|
Tg(TcraTcrbNY8.3)1Pesa/?
(involves: C57BL/6 * NOD * SJL)
|
pancreas inflammation
|
J:44202
|
Tg(TcraY1,TcrbY1)416Tev/0
(involves: C57BL/6J * DBA/2J)
|
abnormal immune tolerance
|
J:84288
|
Tg(Tcrb)93Vbo/0
(involves: C57BL/6 * C57BL/LiA * CBA/BrA)
|
abnormal cytotoxic T cell physiology
|
J:66565
|
abnormal T cell clonal deletion
|
J:66565
|
Tg(TcrbBL17)1Lmor/0
(involves: DBA/1J * SWR/J)
|
increased susceptibility to induced arthritis
|
J:134111
|
Tg(TcrbBL17)1Lmor/Tg(TcrbBL17)1Lmor
(involves: DBA/1J * SWR/J)
|
increased susceptibility to induced arthritis
|
J:134111
|
Tg(TcrHEL3A9)1Mmd/0
(involves: C57BL/6)
|
abnormal interleukin secretion
|
J:73608
|
abnormal T cell activation
|
J:73608
|
increased T cell proliferation
|
J:73608
|
Tg(TcrHEL3A9)1Mmd/0
(involves: C57BL/6 * C57BL/10 * C57BR/cd)
|
abnormal T cell activation
|
J:78309
|
abnormal T cell proliferation
|
J:78309
|
Tg(TcrHEL3A9)1Mmd/0 Tg(TLK2mHEL)2Ccg/0
(involves: C57BL/6 * C57BL/10 * C57BR/cd)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:78309
|
abnormal T cell activation
|
J:78309
|
abnormal T cell proliferation
|
J:78309
|
thyroid gland inflammation
|
J:78309
|
Tg(TcrLCMV)1Aox/?
(C57BL/6-Tg(TcrLCMV)1Aox)
|
abnormal cytotoxic T cell physiology
|
J:92228
|
increased IgG level
|
J:92228
|
Tg(TcrLCMV)2Aox/?
(C57BL/6-Tg(TcrLCMV)2Aox)
|
abnormal cytotoxic T cell physiology
|
J:92228
|
Tg(TcrLCMV)327Sdz/0
(involves: C57BL/6 * DBA/2)
|
decreased cytotoxic T cell cytolysis
|
J:77696
|
decreased T cell proliferation
|
J:77696
|
Tg(TcrLCMV)327Sdz/Tg(TcrLCMV)327Sdz
(NOD.Cg-Tg(TcrLCMV)327Sdz/Dvs)
|
autoimmune response
|
J:71050
|
Tg(Tek-cre)1Ywa/0 Thbdtm2Rdr/Thbdtm2Wlr
(involves: 129S2/SvPas * C57BL/6 * SJL)
|
abnormal acute phase protein level
|
J:71269
|
increased circulating interleukin-6 level
|
J:71269
|
Tg(Tek-Jam3)1Maal/?
(B6.Cg-Tg(Tek-Jam3)1Maal)
|
abnormal cellular extravasation
|
J:99020
|
abnormal leukocyte adhesion
|
J:99020
|
abnormal leukocyte physiology
|
J:99020
|
impaired neutrophil chemotaxis
|
J:99020
|
lung inflammation
|
J:99020
|
peritoneal inflammation
|
J:99020
|
Tg(Tek-Procr)1Cte/0
(B6.FVB-Tg(Tek-Procr)1Cte)
|
abnormal acute phase protein level
|
J:119637
|
abnormal immune system physiology
|
J:119637
|
abnormal inflammatory response
|
J:119637
|
Tg(Tek-Tnf*)5382Mcla/0
(B6.Cg-Tg(Tek-Tnf*)5382Mcla)
|
chronic inflammation
|
J:71622
|
chronic liver inflammation
|
J:71622
|
decreased inflammatory response
|
J:71622
|
kidney inflammation
|
J:71622
|
lung inflammation
|
J:71622
|
Tg(Tek-tTA)1Dmt/0 Tg(tetO-Tek)1Dmt/0
(involves: CD-1)
|
skin inflammation
|
J:96718,
J:137745
|
Tg(tetO-MAP2K1)#Ahsa/? Tg(CD2-rtTA)CRza/?
(involves: C57BL/6 * C57BL/10 * CBA * SJL)
|
increased anti-double stranded DNA antibody level
|
J:174339
|
Tg(tetO/CMV-CD200)1Rmgo/Tg(tetO/CMV-CD200)1Rmgo
(involves: C57BL/6)
|
abnormal dendritic cell physiology
|
J:134313
|
Tg(TetOp-Polb/tTA)2Sbl/0
(B6.Cg-Tg(TetOp-Polb/tTA)2Sbl)
|
glomerulonephritis
|
J:152481
|
Tg(Tgfa)1Efu/0
(Not Specified)
|
ear inflammation
|
J:65045
|
Tg(Th-SNCA)5Eric/Tg(Th-SNCA)5Eric
(involves: C57BL/6)
|
abnormal microglial cell physiology
|
J:140907
|
Tg(THY1-APP)2Somm/0
(involves: C57BL/6J * DBA/2)
|
brain inflammation
|
J:44603
|
Tg(Thy1-APP)3Somm/0
(involves: C57BL/6J * DBA/2)
|
brain inflammation
|
J:44603
|
Tg(Thy1-APPSwDutIowa)BWevn/0
(involves: C57BL/6)
|
abnormal microglial cell physiology
|
J:124911
|
Tg(Thy1-Fcer2a)2431Putt/?
(involves: BALB/c * C57BL/6)
|
abnormal immune system physiology
|
J:129296
|
decreased IgE level
|
J:20421
|
decreased IgG1 level
|
J:20421
|
Tg(Thy1-MAPT*P301S)2541Godt/Tg(Thy1-MAPT*P301S)2541Godt
(involves: C57BL/6J * CBA/Ca)
|
eye inflammation
|
J:108870
|
Tg(Thy1-SNCA)61Ema/0
(involves: C57BL/6 * DBA/2)
|
abnormal microglial cell activation
|
J:238066
|
Tg(Thy1-UBQLN2*P497S)3Mont/?
(involves: C3H * C57BL/6 * C57BL/6J)
|
increased microglial cell activation
|
J:239510
|
Tg(Thy1-UBQLN2*P506T)6Mont/?
(involves: C3H * C57BL/6 * C57BL/6J)
|
decreased microglial cell activation
|
J:239510
|
Tg(Thy1/THY1)T12Gsv/0
(involves: C57BL/10 * CBA)
|
increased IgG level
|
J:133943
|
increased IgM level
|
J:133943
|
Tg(Tk1-DPP4)27Ysj/0
(involves: C57BL/6 * FVB/N)
|
abnormal chemokine level
|
J:290259
|
abnormal innate immunity
|
J:290259
|
abnormal interleukin level
|
J:290259
|
abnormal macrophage activation involved in immune response
|
J:290259
|
abnormal tumor necrosis factor level
|
J:290259
|
increased susceptibility to Coronaviridae infection
|
J:290259
|
increased susceptibility to Coronaviridae infection induced morbidity/mortality
|
J:290259
|
lung inflammation
|
J:290259
|
Tg(Tlr7)1Boll/0
(involves: C57BL/6)
|
abnormal circulating chemokine level
|
J:127600
|
autoimmune response
|
J:127600
|
glomerulonephritis
|
J:127600
|
increased anti-nuclear antigen antibody level
|
J:127600
|
increased circulating interleukin-6 level
|
J:127600
|
increased circulating tumor necrosis factor level
|
J:127600
|
liver inflammation
|
J:127600
|
X/Tg(Tlr7)6Boll
(involves: C57BL/6)
|
abnormal B cell activation
|
J:127600
|
abnormal T cell activation
|
J:127600
|
autoimmune response
|
J:127600
|
glomerulonephritis
|
J:127600
|
increased anti-nuclear antigen antibody level
|
J:127600
|
increased splenocyte proliferation
|
J:127600
|
liver inflammation
|
J:127600
|
lung inflammation
|
J:127600
|
Tg(TNF)197Gkl/0
(involves: C57BL/6 * CBA)
|
autoimmune arthritis
|
J:97992,
J:92576
|
Tg(TNF)197Gkl/0 Tnfrsf1atm1.1Gkl/Tnfrsf1atm1.1Gkl
(involves: 129 * C57BL/6 * CBA)
|
autoimmune arthritis
|
J:92470
|
Tg(TNF)3647Gkl/0
(involves: C57BL/6 * CBA)
|
autoimmune arthritis
|
J:190204
|
Tg(Tnf)6074Gkl/0
(involves: C57BL/6 * CBA)
|
brain inflammation
|
J:106592
|
Tg(Tnf)6074Gkl/0 Tnfrsf1btm1Mwm/Tnfrsf1btm1Mwm
(involves: 129S2/SvPas * C57BL/6 * CBA)
|
CNS inflammation
|
J:106592
|
Tg(Tnfsf13b)1Fma/0
(involves: C57BL/6 * DBA/2J)
|
abnormal B cell physiology
|
J:58798
|
abnormal T cell physiology
|
J:58798
|
increased anti-double stranded DNA antibody level
|
J:58798
|
increased anti-single stranded DNA antibody level
|
J:58798
|
increased autoantibody level
|
J:58798
|
increased IgG level
|
J:58798
|
increased IgM level
|
J:58798
|
increased immunoglobulin level
|
J:58798
|
Tg(Tnfsf13b)1Fma/0
(B6.Cg-Tg(Tnfsf13b)1Fma)
|
increased autoantibody level
|
J:114782
|
increased IgA level
|
J:114782
|
kidney inflammation
|
J:73711
|
salivary gland inflammation
|
J:73711
|
Tg(Tnfsf13b)1Fma/?
(B6.Cg-Tg(Tnfsf13b)1Fma)
|
abnormal B cell activation
|
J:113556
|
abnormal marginal zone B cell physiology
|
J:113556
|
glomerulonephritis
|
J:113556
|
increased anti-double stranded DNA antibody level
|
J:113556
|
Tg(Tnfsf13b)1Fma/? Tnfrsf13btm1Rjb/Tnfrsf13btm1Rjb
(B6.Cg-Tnfrsf13btm1Rjb Tg(Tnfsf13b)1Fma)
|
abnormal class switch recombination
|
J:113556
|
Tg(Tnfsf13b)1Fma/? Tnfrsf13ctm1Mass/Tnfrsf13ctm1Mass
(B6.Cg-Tnfrsf13ctm1Mass Tg(Tnfsf13b)1Fma)
|
abnormal class switch recombination
|
J:113556
|
Tg(Tnfsf13b)1Fma/0 Tnfsf14tm1Kpf/Tnfsf14tm1Kpf
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2J)
|
increased IgA level
|
J:114782
|
Tg(Tnfsf13b)1Fma/Tg(Tnfsf13b)1Fma
(involves: C57BL/6 * DBA/2)
|
abnormal immunoglobulin level
|
J:178227
|
increased IgA level
|
J:178227
|
increased IgM level
|
J:178227
|
increased immunoglobulin level
|
J:178227
|
kidney inflammation
|
J:178227
|
Tg(Trp53)1Srn/0
(involves: C57BL/6 * CBA)
|
increased thymocyte apoptosis
|
J:80311
|
Tg(Trp53)1Srn/0 Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6 * CBA)
|
decreased thymocyte apoptosis
|
J:80311
|
Tg(Trp53)bSrn/0
(involves: C57BL/6 * CBA)
|
increased thymocyte apoptosis
|
J:80311
|
Tg(Tyr-NRAS*Q61K)1Bee/?
(involves: BALB/c * C57BL/6J * DBA/2)
|
skin inflammation
|
J:98545
|
Tg(Tyr-NRAS*Q61K)1Bee/?
(involves: C57BL/6J * DBA/2)
|
skin inflammation
|
J:98545
|
Tg(UBC-scFv)2Nemz/0
(involves: C57BL/6 * DBA/2)
|
abnormal immune tolerance
|
J:96759
|
abnormal immunoglobulin level
|
J:96759
|
Tg(Umod*C147W)958Lura/0
(involves: FVB)
|
kidney inflammation
|
J:161532
|
Tg(Vav1-Lin28b)C3Apla/0
(involves: C57BL/6)
|
abnormal cytokine level
|
J:189197
|
abnormal inflammatory response
|
J:189197
|
increased IgG level
|
J:189197
|
increased T cell proliferation
|
J:189197
|
Tg(Vav1-STAT5B*N642H)726Biat/0
(C57BL/6NCrl-Tg(Vav1-STAT5B*N642H)726Biat)
|
increased T cell proliferation
|
J:257519
|
Tg(Vav-BCL2)69Jad/0
(involves: C57BL/6J)
|
abnormal class switch recombination
|
J:88565
|
abnormal somatic hypermutation frequency
|
J:88565
|
glomerulonephritis
|
J:88565
|
Tg(Vil1-cre)997Gum/? Tlr4lps-del/Tlr4lps-del Tlr5tm1.1Gewr/Tlr5tm1.1Gewr
(involves: C57BL/6J * C57BL/6NTac * C57BL/10ScN * SJL)
|
large intestinal inflammation
|
J:229155
|
Tg(Vil1-cre)997Gum/? Tlr5tm1.1Gewr/Tlr5tm1.1Gewr
(involves: C57BL/6J * C57BL/6NTac * SJL/J)
|
increased interleukin-1 beta secretion
|
J:229155
|
increased susceptibility to colitis induced morbidity/mortality
|
J:229155
|
large intestinal inflammation
|
J:229155
|
Tg(Vil1-cre)997Gum/0 Tnfrsf11atm1.1Irw/Tnfrsf11atm1.1Irw
(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NTac * SJL)
|
decreased IgA level
|
J:226603
|
Tg(Vil-SLC3A2)HEMerl/0
(involves: FVB/N)
|
colitis
|
J:173946
|
increased circulating tumor necrosis factor level
|
J:173946
|
increased susceptibility to induced colitis
|
J:173946
|
Tg(VIM-Tag)3Pau/0
(either: (involves: C57BL/6 * CBA * SJL/J) or (involves: C57BL/6 * SJL/J))
|
glomerulonephritis
|
J:92226
|
Tg(Wnt1)1Hev/0 Zfp451em1Ssli/Zfp451em1Ssli
(involves: C57BL/6 * SJL)
|
decreased chemokine level
|
J:338905
|
Tgm3Btlr/Tgm3Btlr
(C57BL/6J-Tgm3Btlr)
|
decreased IgE level
|
J:265197
|
increased susceptibility to induced colitis
|
J:265197
|
Tgm4Btlr/Tgm4Btlr
(C57BL/6J-Tgm4Btlr)
|
increased IgE level
|
J:272522
|
Tgfatm1Ard/Tgfatm1Ard
(involves: 129P2/OlaHsd * C57BL/6)
|
increased incidence of corneal inflammation
|
J:4606
|
Tgfawa1/Tgfawa1
(Not Specified)
|
conjunctivitis
|
J:13115
|
keratoconjunctivitis
|
J:13115
|
Tgfb1tm1Doe/Tgfb1tm1Doe
(involves: 129S2/SvPas * CF-1)
|
abnormal inflammatory response
|
J:2892
|
brain inflammation
|
J:2892
|
conjunctivitis
|
J:2892
|
diaphragmitis
|
J:2892
|
eye inflammation
|
J:2892
|
heart inflammation
|
J:2892
|
lacrimal gland inflammation
|
J:2892
|
liver inflammation
|
J:2892
|
lung inflammation
|
J:2892
|
myositis
|
J:2892
|
pancreas inflammation
|
J:2892
|
salivary gland inflammation
|
J:2892
|
skin inflammation
|
J:2892
|
stomach inflammation
|
J:2892
|
Tgfb1tm1Doe/Tgfb1tm1Doe
(involves: 129S2/SvPas * BALB/c * CF-1)
|
heart inflammation
|
J:69346
|
increased interferon-gamma secretion
|
J:69346
|
liver inflammation
|
J:69346
|
lung inflammation
|
J:69346
|
Tgfb1tm1Doe/Tgfb1tm1Doe
(C.129S2-Tgfb1tm1Doe)
|
heart inflammation
|
J:69346
|
increased interferon-gamma secretion
|
J:69346
|
liver inflammation
|
J:69346
|
Tgfb1tm1Doe/Tgfb1tm2.1Doe Tg(Lck-cre)548Jxm/?
(involves: 129S2/SvPas * 129S6/SvEvTac * Black Swiss * BALB/c * C57BL/6 * CBA)
|
lung inflammation
|
J:150024
|
salivary gland inflammation
|
J:150024
|
Tgfb1tm1Jmu/Tgfb1tm1Jmu
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal immune system physiology
|
J:120085
|
heart inflammation
|
J:120085
|
liver inflammation
|
J:120085
|
lung inflammation
|
J:120085
|
pancreas inflammation
|
J:120085
|
stomach inflammation
|
J:120085
|
Tgfb1tm1Jmu/Tgfb1tm1Jmu
(involves: 129S6/SvEvTac * C57BL/6 * Swiss Webster)
|
abnormal immune system physiology
|
J:120085
|
Tgfb1tm1N/Tgfb1tm1N
(involves: 129S/SvEv)
|
abnormal immune system physiology
|
J:120085
|
atrial endocarditis
|
J:50848
|
increased inflammatory response
|
J:50848
|
interstitial pneumonia
|
J:50848
|
lymph node inflammation
|
J:50848
|
myocarditis
|
J:50848
|
pancreas inflammation
|
J:50848
|
pericarditis
|
J:50848
|
phlebitis
|
J:50848
|
salivary gland inflammation
|
J:50848
|
Tgfb1tm1Rif/Tgfb1tm1Rif
(Not Specified)
|
abnormal immune system physiology
|
J:141786
|
Tgfb1tm1Rif/Tgfb1tm1Rif
(either: (involves: 129) or (involves: 129S/SvEv * C57BL/6))
|
cecum inflammation
|
J:142353
|
heart inflammation
|
J:142353
|
increased inflammatory response
|
J:142353
|
large intestinal inflammation
|
J:142353
|
lung inflammation
|
J:142353
|
proctitis
|
J:142353
|
small intestinal inflammation
|
J:142353
|
stomach inflammation
|
J:142353
|
Tgfb1tm3.1Flv/Tgfb1tm3.1Flv Tg(Cd4-cre)1Cwi/0 Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0
(involves: 129 * C57BL/6 * DBA/2 * NOD * SJL)
|
increased susceptibility to autoimmune diabetes
|
J:196160
|
Tgfb2tm1Doe/Tgfb2tm1Doe
(involves: 129P2/OlaHsd * Black Swiss)
|
abnormal macrophage physiology
|
J:73681
|
Tgfbr2tm1.2Hlm/Tgfbr2tm1.2Hlm Tg(Cd4-cre)1Cwi/0
(involves: 129S6/SvEvTac * C57BL/6 * DBA/2)
|
abnormal T cell activation
|
J:148747
|
autoimmune response
|
J:148747
|
liver inflammation
|
J:148747
|
Tgfbr2tm1.2Hlm/Tgfbr2tm1.2Hlm Tg(Cd4-cre)1Cwi/0
(involves: 129 * C57BL/6 * DBA/2 * NOD)
|
increased inflammatory response
|
J:196160
|
Tgfbr2tm1.2Hlm/Tgfbr2tm1.2Hlm Tg(Cd4-cre)1Cwi/0 Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0
(involves: 129 * C57BL/6 * DBA/2 * NOD * SJL)
|
abnormal immune serum protein physiology
|
J:196160
|
abnormal immune system physiology
|
J:196160
|
abnormal interleukin secretion
|
J:196160
|
decreased interleukin-9 secretion
|
J:196160
|
decreased interleukin-17 secretion
|
J:196160
|
increased interferon-gamma secretion
|
J:196160
|
increased interleukin-2 secretion
|
J:196160
|
increased interleukin-21 secretion
|
J:196160
|
increased susceptibility to autoimmune diabetes
|
J:196160
|
pancreas inflammation
|
J:196160
|
Tgfbr2tm1.2Hlm/Tgfbr2tm1.2Hlm Tnfrsf4tm2(cre)Nik/Tnfrsf4+ Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0
(involves: 129 * C57BL/6 * NOD * SJL)
|
increased susceptibility to autoimmune diabetes
|
J:196160
|
Tgfbr2tm1Karl/Tgfbr2tm1Karl Tg(Mx1-cre)1Cgn/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)
|
eye inflammation
|
J:77844
|
increased inflammatory response
|
J:77844
|
liver inflammation
|
J:77844
|
pancreas inflammation
|
J:77844
|
stomach inflammation
|
J:77844
|
Tgif1tm1.1Caw/Tgif1tm1.1Caw
(B6.129S-Tgif1tm1.1Caw)
|
abnormal cytokine level
|
J:198238
|
increased susceptibility to otitis media
|
J:198238
|
Tgm2tm1.1Rmgr/Tgm2tm1.1Rmgr
(involves: 129S1/SvImJ * C57BL/6)
|
abnormal T cell physiology
|
J:95130
|
Tgm2tm1Gml/Tgm2tm1Gml
(involves: C57BL/6)
|
decreased susceptibility to endotoxin shock
|
J:131975
|
Tgm2tm1Gml/Tgm2tm1Gml
(involves: C57BL/6 * DBA/1LacJ)
|
impaired macrophage phagocytosis
|
J:132254
|
Tgm6em1Bge/Tgm6em1Bge
(C57BL/6N-Tgm6em1Bge)
|
increased susceptibility to bacterial infection
|
J:268324
|
TgTn(pb-CAG-Gm614)#Cya/0
(involves: C57BL/6)
|
decreased B cell apoptosis
|
J:307345
|
increased susceptibility to systemic lupus erythematosus
|
J:307345
|
TgTn(pb-CAG-Gm40600)#Rew/0
(C57BL/6-TgTn(pb-CAG-Gm40600)#Rew)
|
decreased IgA level
|
J:311878
|
decreased IgE level
|
J:311878
|
decreased IgG1 level
|
J:311878
|
decreased IgG2b level
|
J:311878
|
decreased IgG2c level
|
J:311878
|
decreased IgG3 level
|
J:311878
|
decreased IgG level
|
J:311878
|
decreased IgM level
|
J:311878
|
increased IgA level
|
J:311878
|
increased IgE level
|
J:311878
|
increased IgG1 level
|
J:311878
|
increased IgG2b level
|
J:311878
|
increased IgG2c level
|
J:311878
|
increased IgG3 level
|
J:311878
|
increased IgG level
|
J:311878
|
increased IgM level
|
J:311878
|
Thbdtm1.1Hlwu/Thbdtm1.1Hlwu Lyz2tm1(cre)Ifo/Lyz2+
(B6.129-Thbdtm1.1Hlwu Lyz2tm1(cre)Ifo)
|
decreased circulating interleukin-6 level
|
J:188879
|
decreased circulating tumor necrosis factor level
|
J:188879
|
decreased susceptibility to bacterial infection
|
J:188879
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:188879
|
decreased tumor necrosis factor secretion
|
J:188879
|
Thbdtm1Wlr/Thbdtm1Wlr
(B6.129S2-Thbdtm1Wlr)
|
decreased circulating tumor necrosis factor level
|
J:111502
|
increased circulating interleukin-1 beta level
|
J:111502
|
increased circulating interleukin-6 level
|
J:111502
|
increased susceptibility to endotoxin shock
|
J:111502
|
Thbdtm2.1Emc/Thbdtm2.1Emc
(involves: 129/Sv * BALB/c * C57BL/6)
|
abnormal leukocyte adhesion
|
J:118000
|
abnormal leukocyte physiology
|
J:118000
|
increased circulating interleukin-1 beta level
|
J:118000
|
increased circulating tumor necrosis factor level
|
J:118000
|
increased susceptibility to endotoxin shock
|
J:118000
|
Thbdtm2Emc/Thbdtm2Emc
(either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))
|
abnormal leukocyte physiology
|
J:118000
|
Thbs1tm1Hyn/Thbs1tm1Hyn
(either: (involves: 129S2/SvPas * 129/Sv) or (involves: 129S2/SvPas * C57BL/6))
|
lung inflammation
|
J:46182,
J:48446
|
pancreas inflammation
|
J:48446
|
Thbs1tm1Hyn/Thbs1tm1Hyn
(involves: 129S2/SvPas * C57BL/6)
|
decreased interferon-gamma secretion
|
J:153126
|
increased anti-single stranded DNA antibody level
|
J:153126
|
increased interleukin-17 secretion
|
J:153126
|
lacrimal gland inflammation
|
J:153126
|
Thbs1tm1Hyn/Thbs1tm1Hyn Thbs2tm1Bst/Thbs2tm1Bst
(involves: 129T2/SvEms * 129X1/SvJ)
|
impaired macrophage chemotaxis
|
J:78876
|
lung inflammation
|
J:78876
|
ThcrBALB/cJ/?
(involves: BALB/cJ * C57BL/10J * DBA/2J)
|
decreased interferon-gamma secretion
|
J:86188
|
increased interleukin-4 secretion
|
J:86188
|
ThcrC57BL/10Sn/?
(involves: BALB/cJ * C57BL/10J * DBA/2J)
|
decreased interleukin-4 secretion
|
J:86188
|
increased interferon-gamma secretion
|
J:86188
|
Themism1Btlr/Themism1Btlr
(C57BL/6J-Themism1Btlr)
|
impaired humoral immune response
|
J:211400
|
Themistm1Gasc/Themistm1Gasc
(B6.129S-Themistm1Gasc)
|
decreased T cell proliferation
|
J:151074
|
Themistm1Hasu/Themistm1Hasu
(involves: C57BL/6 * CBA)
|
increased T cell proliferation
|
J:153235
|
thnh/thnh
(NOD.Cg-H2b thnh/J)
|
folliculitis
|
J:142872
|
Thop1Gt(CSG163)Byg/Thop1Gt(CSG163)Byg
(B6.129P2-Thop1Gt(CSG163)Byg)
|
decreased susceptibility to infection
|
J:290567
|
decreased susceptibility to infection induced morbidity/mortality
|
J:290567
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:290567
|
Thratm1Syc/Thra+
(involves: 129S6/SvEvTac * C57BL/6J * NIH Black Swiss)
|
abnormal osteoclast physiology
|
J:217018
|
Thratm2Jas/Thratm2Jas
(involves: 129)
|
abnormal osteoclast physiology
|
J:120899
|
Thratm2Ven/Thratm2Ven
(involves: 129P2/OlaHsd * BALB/c)
|
abnormal osteoclast physiology
|
J:72959
|
Thrbtm1Olc/Thrbtm1Olc
(involves: 129)
|
abnormal osteoclast physiology
|
J:120899
|
Thypr1DBA/2J/?
(involves: C57BL/6J * DBA/2J)
|
increased T cell proliferation
|
J:76931
|
Thypr2DBA/2J/?
(involves: C57BL/6J * DBA/2J)
|
increased T cell proliferation
|
J:76931
|
Tia1tm1Andp/Tia1tm1Andp
(C.129S2-Tia1tm1Andp)
|
abnormal macrophage physiology
|
J:88770
|
increased susceptibility to endotoxin shock
|
J:88770
|
Tia1tm1Andp/Tia1tm1Andp
(B6.Cg-Tia1tm1Andp)
|
autoimmune arthritis
|
J:88443
|
Tia1tm1Andp/Tia1tm1Andp Zfp36tm1Pjb/Zfp36tm1Pjb
(B6.Cg-Tia1tm1Andp Zfp36tm1Pjb)
|
abnormal macrophage physiology
|
J:88443
|
autoimmune arthritis
|
J:88443
|
Ticam1Lps2/Ticam1Lps2
(involves: C57BL/6)
|
abnormal cytokine secretion
|
J:110201
|
abnormal macrophage physiology
|
J:84896
|
decreased circulating tumor necrosis factor level
|
J:86521
|
decreased macrophage apoptosis
|
J:84896,
J:92674
|
decreased macrophage cytokine production
|
J:84896
|
decreased macrophage nitric oxide production
|
J:84896
|
decreased susceptibility to bacterial infection
|
J:86521,
J:92674
|
decreased susceptibility to endotoxin shock
|
J:84896
|
decreased tumor necrosis factor secretion
|
J:84896
|
increased susceptibility to Herpesvirales infection
|
J:84896
|
Ticam1Lps2/Ticam1Lps2
(C57BL/6J-Ticam1Lps2)
|
abnormal circulating tumor necrosis factor level
|
J:138963
|
abnormal cytokine secretion
|
J:167340
|
decreased interleukin-6 secretion
|
J:167340
|
decreased susceptibility to induced colitis
|
J:167340
|
Ticam1Lps2/Ticam1Lps2
(C57BL/6J-Ticam1Lps2/J)
|
abnormal chemokine level
|
J:288471
|
increased interferon-beta secretion
|
J:288471
|
increased susceptibility to Coronaviridae infection
|
J:288471
|
increased susceptibility to Coronaviridae infection induced morbidity/mortality
|
J:288471
|
Ticam1Lps2/Ticam1Lps2 Myd88tm1Aki/Myd88tm1Aki
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal macrophage physiology
|
J:84896
|
decreased tumor necrosis factor secretion
|
J:84896
|
Ticam1M2Btlr/Ticam1+
(C57BL/6J-Ticam1M2Btlr)
|
abnormal cytokine secretion
|
J:234240
|
abnormal macrophage physiology
|
J:234240
|
decreased macrophage cytokine production
|
J:234240
|
decreased tumor necrosis factor secretion
|
J:234240
|
Ticam1M2Btlr/Ticam1M2Btlr
(C57BL/6J-Ticam1M2Btlr)
|
abnormal cytokine secretion
|
J:234240
|
abnormal macrophage physiology
|
J:234240
|
decreased macrophage cytokine production
|
J:234240
|
decreased tumor necrosis factor secretion
|
J:234240
|
Ticam1M3Btlr/Ticam1+
(C57BL/6J-Ticam1M3Btlr)
|
decreased tumor necrosis factor secretion
|
J:255300
|
Ticam1M3Btlr/Ticam1M3Btlr
(C57BL/6J-Ticam1M3Btlr)
|
decreased tumor necrosis factor secretion
|
J:255300
|
Ticam1tm1Aki/Ticam1tm1Aki
(involves: 129P2/OlaHsd)
|
abnormal B cell activation
|
J:174941
|
abnormal B cell physiology
|
J:84679
|
abnormal cytokine level
|
J:174941
|
abnormal cytokine secretion
|
J:84679
|
abnormal dendritic cell physiology
|
J:174941
|
abnormal interleukin level
|
J:137522
|
abnormal macrophage physiology
|
J:174941,
J:84679
|
abnormal microglial cell physiology
|
J:185198
|
abnormal NK cell physiology
|
J:174941
|
abnormal NK T cell physiology
|
J:174941
|
decreased circulating interleukin-6 level
|
J:145306
|
decreased splenocyte proliferation
|
J:84679
|
decreased susceptibility to endotoxin shock
|
J:84679
|
decreased susceptibility to Orthomyxoviridae infection
|
J:145306
|
impaired macrophage phagocytosis
|
J:185198
|
Ticam1tm1Aki/Ticam1tm1Aki
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal cytokine level
|
J:169158
|
abnormal susceptibility to Poxviridae infection
|
J:162716
|
decreased circulating interferon-gamma level
|
J:130954
|
decreased circulating interleukin-6 level
|
J:130954
|
decreased circulating interleukin-12b level
|
J:130954
|
decreased IgG2a level
|
J:130954
|
decreased IgG level
|
J:130954
|
decreased interferon-beta secretion
|
J:130954
|
decreased interleukin-12b secretion
|
J:130954
|
decreased susceptibility to type I hypersensitivity reaction
|
J:161445
|
increased susceptibility to Picornaviridae infection
|
J:169158
|
increased susceptibility to Picornaviridae infection induced morbidity/mortality
|
J:169158
|
myocarditis
|
J:169158
|
Ticam1tm1Aki/Ticam1tm1Aki
(B6.129P2-Ticam1tm1Aki)
|
abnormal cytokine level
|
J:144301
|
abnormal response to infection
|
J:144301
|
decreased circulating tumor necrosis factor level
|
J:144301
|
decreased macrophage cytokine production
|
J:144301
|
impaired neutrophil recruitment
|
J:144301
|
increased susceptibility to bacterial infection
|
J:144301
|
Ticam1tm1Tsse/Ticam1tm1Tsse
(B6.129-Ticam1tm1Tsse)
|
impaired natural killer cell mediated cytotoxicity
|
J:118750
|
Ticam1tm1Tsse/Ticam1tm1Tsse Tg(PVR)1Kkst/0
(involves: 129 * C57BL/6 * ICR)
|
abnormal interferon-alpha secretion
|
J:179625
|
increased susceptibility to Picornaviridae infection
|
J:179625
|
increased susceptibility to Picornaviridae infection induced morbidity/mortality
|
J:179625
|
Ticam2M1Btlr/Ticam2+
(C57BL/6J-Ticam2M1Btlr)
|
decreased tumor necrosis factor secretion
|
J:215010
|
Ticam2M1Btlr/Ticam2M1Btlr
(C57BL/6J-Ticam2M1Btlr)
|
decreased tumor necrosis factor secretion
|
J:215010
|
Ticam2M2Btlr/Ticam2+
(C57BL/6J-Ticam2M2Btlr)
|
decreased interleukin-1 beta secretion
|
J:254908
|
Ticam2M2Btlr/Ticam2M2Btlr
(C57BL/6J-Ticam2M2Btlr)
|
decreased interleukin-1 beta secretion
|
J:254908
|
Ticam2M3Btlr/Ticam2+
(C57BL/6J-Ticam2M3Btlr)
|
decreased tumor necrosis factor secretion
|
J:254912
|
Ticam2M3Btlr/Ticam2M3Btlr
(C57BL/6J-Ticam2M3Btlr)
|
decreased tumor necrosis factor secretion
|
J:254912
|
Ticam2tm1Aki/Ticam2tm1Aki
(involves: C57BL/6)
|
abnormal immune system physiology
|
J:86256
|
decreased interleukin-6 secretion
|
J:86256
|
increased susceptibility to Coronaviridae infection
|
J:270045
|
Ticam2tm1Btlr/Ticam2tm1Btlr
(C57BL/6J-Ticam2tm1Btlr)
|
abnormal interferon secretion
|
J:133619
|
decreased tumor necrosis factor secretion
|
J:133619
|
Tie1tm1Scba/Tie1tm1Scba
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal lymph circulation
|
J:158668
|
TigarGt(EUCE0047g05)Hmgu/TigarGt(EUCE0047g05)Hmgu
(involves: 129P2/OlaHsd)
|
increased susceptibility to induced colitis
|
J:198650
|
Tigartm1.1Khv/Tigartm1.1Khv Tg(CMV-cre)1Cgn/0
(involves: 129P2/OlaHsd * BALB/cJ * C57BL/6 * SJL)
|
increased susceptibility to induced colitis
|
J:198650
|
Tigittm1Sdl/Tigittm1Sdl
(involves: C57BL/6)
|
abnormal professional antigen presenting cell physiology
|
J:168902
|
decreased interleukin-10 secretion
|
J:168902
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:168902
|
increased T cell proliferation
|
J:168902
|
Tigittm1Sdl/Tigittm1Sdl Tg(Tcra2D2,Tcrb2D2)1Kuch/0
(involves: C57BL/6)
|
decreased interleukin-10 secretion
|
J:168902
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:168902
|
Timd2tm1(GAL4)Pdre/Timd2tm1(GAL4)Pdre
(C.129S4-Timd2tm1(GAL4)Pdre)
|
abnormal inflammatory response
|
J:125054
|
abnormal interleukin secretion
|
J:125054
|
increased interferon-gamma secretion
|
J:125054
|
increased tumor necrosis factor secretion
|
J:125054
|
Timd4tm1Kuch/Timd4tm1Kuch
(C57BL/6-Timd4tm1Kuch)
|
abnormal B cell physiology
|
J:160747
|
abnormal macrophage physiology
|
J:160747
|
increased anti-double stranded DNA antibody level
|
J:160747
|
increased IgA level
|
J:160747
|
increased IgG2a level
|
J:160747
|
increased IgG2b level
|
J:160747
|
increased interferon-gamma secretion
|
J:160747
|
increased interleukin-17 secretion
|
J:160747
|
increased splenocyte proliferation
|
J:160747
|
Timd4tm1Kuch/Timd4tm1Kuch
(involves: C57BL/6)
|
abnormal circulating chemokine level
|
J:235399
|
decreased circulating interleukin-10 level
|
J:235399
|
increased anti-double stranded DNA antibody level
|
J:235399
|
increased circulating interleukin-1 beta level
|
J:235399
|
increased circulating interleukin-6 level
|
J:235399
|
increased circulating interleukin-12b level
|
J:235399
|
increased susceptibility to systemic lupus erythematosus
|
J:235399
|
Timd4tm1Osa/Timd4tm1Osa
(involves: C57BL/6)
|
impaired macrophage phagocytosis
|
J:187181
|
Timd4tm1Wouy/Timd4tm1Wouy
(involves: 129)
|
abnormal macrophage physiology
|
J:160304
|
decreased tumor necrosis factor secretion
|
J:160304
|
impaired macrophage phagocytosis
|
J:160304
|
increased IgG2a level
|
J:160304
|
increased tumor necrosis factor secretion
|
J:160304
|
Timp1tm1Pds/Timp1tm1Pds
(involves: 129S4/SvJae)
|
decreased susceptibility to bacterial infection
|
J:94836
|
Timp1tm1Pds/Timp1tm1Pds
(involves: C57BL/6)
|
decreased susceptibility to bacterial infection
|
J:94836
|
Timp1tm1Pds/Timp1tm1Pds
(involves: 129S4/SvJae * C57BL/6)
|
lung inflammation
|
J:112941
|
Timp3tm1Osya/Timp3tm1Osya
(B6.129P2-Timp3tm1Osya)
|
aortitis
|
J:193744
|
Timp3tm1Rkho/Timp3tm1Rkho
(B6.129-Timp3tm1Rkho)
|
increased tumor necrosis factor secretion
|
J:92948
|
liver inflammation
|
J:92948
|
Tinf2tm2.2Tdl/Tinf2+
(involves: BALB/cJ * C57BL/6)
|
dermatitis
|
J:207367
|
TiparpGt(ROSA)79Sor/TiparpGt(ROSA)79Sor
(involves: 129S4/SvJaeSor)
|
kidney inflammation
|
J:117491
|
TiparpGt(ROSA)79Sor/TiparpGt(ROSA)79Sor
(involves: 129S4/SvJaeSor * C57BL/6 * C57BL/6J)
|
abnormal thymus involution
|
J:250417
|
Tir2BALB/cOlaHsd/Tir2C57BL/6JOlaHsd
(involves: BALB/cOlaHsd * C57BL/6JOlaHsd)
|
abnormal immune serum protein physiology
|
J:40771
|
Tir2C57BL/6JOlaHsd/Tir2C57BL/6JOlaHsd
(involves: A/JOlaHsd * C57BL/6JOlaHsd)
|
decreased susceptibility to parasitic infection
|
J:40771
|
Tir2C57BL/6JOlaHsd/Tir2C57BL/6JOlaHsd
(involves: BALB/cOlaHsd * C57BL/6JOlaHsd)
|
decreased susceptibility to parasitic infection
|
J:40771
|
Tir2C57BL/6JOlaHsd/Tir2C57BL/6JOlaHsd
(A.B6-Tir2)
|
decreased susceptibility to parasitic infection
|
J:97672
|
Tir2C57BL/6JOlaHsd/Tir2C57BL/6JOlaHsd
(A.B6-(D5Mit200-D5Mit10))
|
decreased susceptibility to parasitic infection
|
J:135428
|
Tir3BALB/cOlaHsd/Tir3C57BL/6JOlaHsd
(involves: BALB/cOlaHsd * C57BL/6JOlaHsd)
|
decreased susceptibility to parasitic infection
|
J:40771
|
Tir3C57BL/6JOlaHsd/Tir3C57BL/6JOlaHsd
(involves: BALB/cOlaHsd * C57BL/6JOlaHsd)
|
decreased susceptibility to parasitic infection
|
J:40771
|
Tir3C57BL/6JOlaHsd/Tir3C57BL/6JOlaHsd
(A.B6-Tir3)
|
decreased susceptibility to parasitic infection
|
J:97672
|
Tir3C57BL/6JOlaHsd/Tir3C57BL/6JOlaHsd
(A.B6-(D1Mit60-D1Mit217))
|
decreased susceptibility to parasitic infection
|
J:135428
|
Tir4C57BL/6JOlaHsd/?
(involves: BALB/cOlaHsd * C57BL/6JOlaHsd)
|
decreased susceptibility to parasitic infection
|
J:40771
|
Tir4C57BL/6JOlaHsd/Tir4C57BL/6JOlaHsd
(involves: A/JOlaHsd * C57BL/6JOlaHsd)
|
decreased susceptibility to parasitic infection
|
J:40771
|
Tir4C57BL/6JOlaHsd/Tir4C57BL/6JOlaHsd
(involves: BALB/cOlaHsd * C57BL/6JOlaHsd)
|
decreased susceptibility to parasitic infection
|
J:40771
|
Tir4C57BL/6JOlaHsd/Tir4C57BL/6JOlaHsd
(A.B6-Tir1)
|
decreased susceptibility to parasitic infection
|
J:97672
|
Tir4C57BL/6JOlaHsd/Tir4C57BL/6JOlaHsd
(A.B6-(D17Mit29-D17Mit11))
|
decreased susceptibility to parasitic infection
|
J:135428
|
Tir9C57BL/6/Tir9C57BL/6
(involves: C57BL/6 * DBA/2)
|
increased susceptibility to parasitic infection
|
J:84716
|
Tir10C57BL/6/Tir10C57BL/6
(involves: C57BL/6 * DBA/2)
|
increased susceptibility to parasitic infection
|
J:84716
|
Tirapm1Btlr/Tirapm1Btlr
(C57BL/6J-Tirapm1Btlr)
|
abnormal interferon secretion
|
J:133618
|
decreased tumor necrosis factor secretion
|
J:133618
|
Tiraptm1Aki/Tiraptm1Aki
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal cytokine secretion
|
J:111205
|
abnormal level of surface class II molecules
|
J:111205
|
decreased IgG3 level
|
J:137066
|
Tiraptm1Aki/Tiraptm1Aki
(B6.129P2-Tiraptm1Aki)
|
abnormal dendritic cell physiology
|
J:118954
|
decreased interleukin-6 secretion
|
J:118954
|
decreased interleukin-12b secretion
|
J:118954
|
Tiraptm1Medz/Tiraptm1Medz
(involves: 129S1/Sv * C57BL/6)
|
abnormal dendritic cell physiology
|
J:96773
|
abnormal macrophage physiology
|
J:96773
|
decreased B cell proliferation
|
J:96773
|
Tiraptm1Medz/Tiraptm1Medz
(involves: 129S1/Sv)
|
abnormal macrophage physiology
|
J:96018
|
increased susceptibility to bacterial infection
|
J:96018
|
Tk1tm1Vnd/Tk1tm1Vnd
(involves: 129P2/OlaHsd * C57BL/6)
|
arteritis
|
J:101669
|
liver inflammation
|
J:101669
|
lung inflammation
|
J:101669
|
thyroid gland inflammation
|
J:101669
|
Tktl1tm1Arte/Tktl1tm1Arte
(C57BL/6-Tktl1tm1Arte)
|
increased susceptibility to induced colitis
|
J:171154
|
Tle4tm1.2Dasw/Tle4tm1.2Dasw
(B6.129S6(Cg)-Tle4tm1.2Dasw)
|
increased thymocyte apoptosis
|
J:219243
|
Tlr1tm1Aki/Tlr1tm1Aki
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal cytokine secretion
|
J:103395
|
decreased interleukin-6 secretion
|
J:103395
|
decreased tumor necrosis factor secretion
|
J:103395
|
Tlr1tm1Flv/Tlr1tm1Flv
(involves: 129S1/Sv)
|
abnormal macrophage physiology
|
J:95726
|
decreased immunoglobulin level
|
J:95726
|
increased susceptibility to bacterial infection
|
J:95726
|
Tlr2lngd/Tlr2lngd
(C57BL/6J-Tlr2lngd)
|
abnormal macrophage physiology
|
J:94077
|
increased susceptibility to bacterial infection
|
J:94077
|
Tlr2tm1Aki/Tlr2tm1Aki
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal chemokine level
|
J:88174
|
abnormal macrophage physiology
|
J:76115,
J:95726
|
abnormal tumor necrosis factor level
|
J:124334
|
decreased immunoglobulin level
|
J:95726
|
decreased interleukin-6 secretion
|
J:76115,
J:88174
|
decreased microglial cell activation
|
J:122551
|
decreased susceptibility to Herpesvirales infection
|
J:88174
|
decreased susceptibility to Herpesvirales infection induced morbidity/mortality
|
J:88174
|
decreased tumor necrosis factor secretion
|
J:76115
|
increased susceptibility to bacterial infection
|
J:95726
|
Tlr2tm1Aki/Tlr2tm1Aki
(B6.129P2-Tlr2tm1Aki)
|
abnormal dendritic cell physiology
|
J:118954
|
abnormal interleukin level
|
J:118954
|
decreased interleukin-6 secretion
|
J:118954
|
decreased interleukin-12b secretion
|
J:118954
|
decreased susceptibility to parasitic infection
|
J:116763
|
Tlr2tm1Aki/Tlr2tm1Aki
(involves: 129P2/OlaHsd)
|
abnormal cytokine secretion
|
J:70578
|
abnormal leukocyte migration
|
J:171379
|
abnormal macrophage physiology
|
J:103464,
J:130138,
J:70578
|
abnormal osteoclast physiology
|
J:130138
|
decreased circulating interleukin-1 beta level
|
J:119941
|
decreased circulating tumor necrosis factor level
|
J:119941
|
decreased inflammatory response
|
J:146111
|
decreased interleukin-6 secretion
|
J:70578
|
decreased interleukin-12 secretion
|
J:70578
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:146111
|
decreased tumor necrosis factor secretion
|
J:103395,
J:70578
|
increased B cell apoptosis
|
J:135830
|
Tlr2tm1Aki/Tlr2tm1Aki
(NOD.129P2-Tlr2tm1Aki)
|
insulitis
|
J:124334
|
Tlr2tm1Aki/Tlr2tm1Aki Tlr4tm1Aki/Tlr4tm1Aki
(B6.129P2-Tlr2tm1Aki Tlr4tm1Aki)
|
abnormal chemokine secretion
|
J:102879
|
Tlr2tm1Aki/Tlr2tm1Aki Tlr4tm1Aki/Tlr4tm1Aki
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal cytokine secretion
|
J:117688
|
abnormal macrophage physiology
|
J:117688
|
decreased IgG3 level
|
J:117688
|
Tlr2tm1Aki/Tlr2tm1Aki Tlr6tm1Aki/Tlr6tm1Aki
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased interleukin-6 secretion
|
J:70578
|
Tlr2tm1Kir/Tlr2tm1Kir
(either: (involves: 129/Sv * C57BL/6) or (involves: 129/Sv * C57BL/6 * C57BL/6J))
|
abnormal innate immunity
|
J:85323
|
abnormal macrophage physiology
|
J:85323
|
decreased interleukin-6 secretion
|
J:85323
|
decreased interleukin-10 secretion
|
J:85323
|
decreased macrophage cytokine production
|
J:85323
|
decreased macrophage nitric oxide production
|
J:85323
|
increased susceptibility to bacterial infection
|
J:85323
|
Tlr2tm1Kir/Tlr2tm1Kir
(Not Specified)
|
abnormal macrophage physiology
|
J:96018
|
increased susceptibility to bacterial infection
|
J:96018
|
Tlr2tm1Kir/Tlr2tm1Kir
(B6.129-Tlr2tm1Kir)
|
abnormal cellular extravasation
|
J:171028
|
abnormal cytokine secretion
|
J:121930
|
decreased circulating tumor necrosis factor level
|
J:162168
|
decreased interleukin-1 beta secretion
|
J:129871
|
decreased interleukin-6 secretion
|
J:129871
|
decreased splenocyte proliferation
|
J:121930
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:121930
|
decreased tumor necrosis factor secretion
|
J:129871
|
increased susceptibility to induced colitis
|
J:165105
|
Tlr2tm1Kir/Tlr2tm1Kir
(involves: 129)
|
abnormal interleukin secretion
|
J:94463
|
decreased interleukin-1 secretion
|
J:94463
|
decreased interleukin-6 secretion
|
J:94463
|
decreased tumor necrosis factor secretion
|
J:94463
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:147177
|
Tlr2tm1Kir/Tlr2tm1Kir Tlr4Lps-d/Tlr4Lps-d
(C3.Cg-Tlr2tm1Kir Tlr4Lps-d)
|
abnormal macrophage physiology
|
J:121930
|
Tlr3M1Btlr/Tlr3+
(C57BL/6J-Tlr3M1Btlr)
|
decreased macrophage cytokine production
|
J:224670
|
decreased tumor necrosis factor secretion
|
J:224670
|
Tlr3M1Btlr/Tlr3M1Btlr
(C57BL/6J-Tlr3M1Btlr)
|
decreased macrophage cytokine production
|
J:224670
|
decreased tumor necrosis factor secretion
|
J:224670
|
Tlr3M2Btlr/Tlr3+
(C57BL/6J-Tlr3M2Btlr)
|
decreased tumor necrosis factor secretion
|
J:254925
|
Tlr3M2Btlr/Tlr3M2Btlr
(C57BL/6J-Tlr3M2Btlr)
|
decreased tumor necrosis factor secretion
|
J:254925
|
Tlr3tm1Aki/Tlr3tm1Aki
(involves: 129P2/OlaHsd)
|
abnormal dendritic cell physiology
|
J:114555
|
Tlr3tm1Aki/Tlr3tm1Aki Tlr7tm1Aki/Tlr7tm1Aki
(involves: 129P2/OlaHsd)
|
decreased interferon-alpha secretion
|
J:144400
|
Tlr3tm1Flv/Tlr3tm1Flv
(involves: 129S1/Sv * C57BL/6)
|
abnormal B cell physiology
|
J:72167
|
abnormal macrophage physiology
|
J:72167
|
decreased inflammatory response
|
J:72167
|
Tlr3tm1Flv/Tlr3tm1Flv
(involves: C57BL/6)
|
abnormal macrophage physiology
|
J:86617
|
Tlr3tm1Flv/Tlr3tm1Flv
(Not Specified)
|
abnormal cytokine secretion
|
J:88906
|
abnormal NK cell physiology
|
J:88906
|
abnormal NK T cell physiology
|
J:88906
|
increased susceptibility to Herpesvirales infection
|
J:88906
|
Tlr3tm1Flv/Tlr3tm1Flv
(involves: 129S1/Sv)
|
abnormal cytokine level
|
J:119967
|
abnormal interferon level
|
J:119967
|
abnormal interleukin level
|
J:119967
|
abnormal tumor necrosis factor level
|
J:119967
|
decreased susceptibility to Riboviria infection
|
J:136330
|
decreased susceptibility to Riboviria infection induced morbidity/mortality
|
J:136330
|
heart inflammation
|
J:119967
|
increased susceptibility to Picornaviridae infection induced morbidity/mortality
|
J:119967
|
Tlr3tm1Flv/Tlr3tm1Flv
(B6.129S1-Tlr3tm1Flv/Apb)
|
abnormal cytokine level
|
J:129533
|
abnormal interleukin level
|
J:126415
|
decreased interferon-beta secretion
|
J:251008
|
Tlr3tm1Flv/Tlr3tm1Flv
(B6N.129S1-Tlr3tm1Flv/J)
|
increased susceptibility to Coronaviridae infection
|
J:288471
|
Tlr4Lps-2Btlr/?
(C57BL/6J-Tlr4Lps-2Btlr)
|
decreased tumor necrosis factor secretion
|
J:147339
|
Tlr4Lps-2Btlr/Tlr4+
(C57BL/6J-Tlr4Lps-2Btlr)
|
decreased interleukin-1 beta secretion
|
J:147339
|
Tlr4lps-2J/Tlr4lps-2J
(BXD29-Tlr4lps-2J/J)
|
abnormal inflammatory response
|
J:107391
|
Tlr4Lps-3Btlr/Tlr4+
(C57BL/6J-Tlr4Lps-3Btlr)
|
decreased interferon-beta secretion
|
J:217295
|
decreased tumor necrosis factor secretion
|
J:217295
|
Tlr4Lps-3Btlr/Tlr4Lps-3Btlr
(C57BL/6J-Tlr4Lps-3Btlr)
|
decreased interferon-beta secretion
|
J:217295
|
decreased tumor necrosis factor secretion
|
J:217295
|
Tlr4lps-4Btlr/Tlr4+
(C57BL/6J-Tlr4lps-4Btlr)
|
decreased macrophage cytokine production
|
J:224664
|
decreased tumor necrosis factor secretion
|
J:224664
|
Tlr4lps-4Btlr/Tlr4lps-4Btlr
(C57BL/6J-Tlr4lps-4Btlr)
|
decreased macrophage apoptosis
|
J:224664
|
decreased macrophage cytokine production
|
J:224664
|
decreased tumor necrosis factor secretion
|
J:224664
|
Tlr4lps-5Btlr/Tlr4lps-5Btlr
(C57BL/6J-Tlr4lps-5Btlr)
|
decreased macrophage cytokine production
|
J:224666
|
decreased tumor necrosis factor secretion
|
J:224666
|
Tlr4Lps-6Btlr/Tlr4+
(C57BL/6J-Tlr4Lps-6Btlr)
|
decreased macrophage cytokine production
|
J:224667
|
decreased tumor necrosis factor secretion
|
J:224667
|
Tlr4Lps-6Btlr/Tlr4Lps-6Btlr
(C57BL/6J-Tlr4Lps-6Btlr)
|
decreased macrophage cytokine production
|
J:224667
|
decreased tumor necrosis factor secretion
|
J:224667
|
Tlr4lps-7Btlr/Tlr4+
(C57BL/6J-Tlr4Lps-7Btlr)
|
decreased interleukin-1 beta secretion
|
J:234239
|
decreased macrophage cytokine production
|
J:234239
|
decreased tumor necrosis factor secretion
|
J:234239
|
Tlr4lps-7Btlr/Tlr4lps-7Btlr
(C57BL/6J-Tlr4Lps-7Btlr)
|
decreased interleukin-1 beta secretion
|
J:234239
|
decreased macrophage cytokine production
|
J:234239
|
decreased tumor necrosis factor secretion
|
J:234239
|
Tlr4Lps-8Btlr/Tlr4+
(C57BL/6J-Tlr4Lps-8Btlr)
|
decreased interleukin-1 beta secretion
|
J:234241
|
decreased macrophage cytokine production
|
J:234241
|
decreased tumor necrosis factor secretion
|
J:234241
|
Tlr4Lps-8Btlr/Tlr4Lps-8Btlr
(C57BL/6J-Tlr4Lps-8Btlr)
|
decreased interleukin-1 beta secretion
|
J:234241
|
decreased macrophage cytokine production
|
J:234241
|
decreased tumor necrosis factor secretion
|
J:234241
|
Tlr4lps-Btlr/Tlr4lps-Btlr
(C57BL/6J-Tlr4lps-Btlr)
|
abnormal macrophage physiology
|
J:128416
|
Tlr4Lps-d/Tlr4Lps-d
(involves: C3H/HeJ)
|
abnormal T-helper 2 physiology
|
J:96356
|
abnormal tumor necrosis factor level
|
J:124334,
J:114368
|
increased susceptibility to bacterial infection
|
J:5721,
J:51522,
J:87807
|
increased susceptibility to induced arthritis
|
J:96356
|
Tlr4Lps-d/Tlr4Lps-d
(C3H/HeJ-Tlr4Lps-d)
|
abnormal cytokine level
|
J:96680
|
abnormal interleukin level
|
J:96680
|
abnormal macrophage chemotaxis
|
J:122597
|
abnormal microglial cell physiology
|
J:99051
|
abnormal susceptibility to infection
|
J:162716
|
abnormal tumor necrosis factor level
|
J:96680
|
increased circulating interleukin-6 level
|
J:37271
|
increased susceptibility to Poxviridae infection induced morbidity/mortality
|
J:162716
|
liver inflammation
|
J:135830
|
lung inflammation
|
J:96680
|
Tlr4lps-del/Tlr4lps-del
(C57BL/10ScCr)
|
abnormal cytokine secretion
|
J:88996
|
abnormal macrophage physiology
|
J:88996
|
increased susceptibility to bacterial infection
|
J:51522,
J:88996
|
Tlr4lps-del/Tlr4lps-del
(involves: C57BL/10ScN)
|
abnormal tumor necrosis factor level
|
J:114368
|
decreased interleukin-6 secretion
|
J:147023
|
decreased interleukin-10 secretion
|
J:147023
|
Tlr4lps-hypo/Tlr4lps-hypo
(B6.Cg-Tlr4lps-hypo Cln8mnd)
|
decreased susceptibility to bacterial infection
|
J:103167
|
Tlr4lps-n/Tlr4lps-n
(C3H/HeN)
|
decreased acute inflammation
|
J:37271
|
Tlr4tm1.1Djh/Tlr4tm1.1Djh
(involves: FVB/N)
|
decreased susceptibility to endotoxin shock
|
J:192520
|
Tlr4tm1Aki/Tlr4lps-2J
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2J)
|
abnormal inflammatory response
|
J:107391
|
Tlr4tm1Aki/Tlr4tm1Aki
(involves: 129P2/OlaHsd)
|
decreased circulating interleukin-6 level
|
J:145306
|
decreased susceptibility to Orthomyxoviridae infection
|
J:145306
|
increased susceptibility to bacterial infection
|
J:53519
|
Tlr4tm1Aki/Tlr4tm1Aki
(involves: 129P2/OlaHsd * C57BL/6J)
|
abnormal acute inflammation
|
J:98224
|
impaired neutrophil chemotaxis
|
J:98224
|
increased susceptibility to bacterial infection
|
J:98224
|
Tlr4tm1Aki/Tlr4tm1Aki
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal level of surface class II molecules
|
J:76115
|
abnormal macrophage physiology
|
J:76115
|
decreased B cell proliferation
|
J:76115
|
decreased interleukin-6 secretion
|
J:76115
|
decreased susceptibility to endotoxin shock
|
J:76115
|
decreased tumor necrosis factor secretion
|
J:76115
|
increased susceptibility to bacterial infection
|
J:111778
|
Tlr4tm1Aki/Tlr4tm1Aki
(C.129P2-Tlr4tm1Aki)
|
decreased susceptibility to induced arthritis
|
J:178054
|
Tlr4tm1Aki/Tlr4tm1Aki Tlr5tm1Flv/Tlr5tm1Flv
(involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6)
|
increased susceptibility to bacterial infection
|
J:111778
|
Tlr5tm1Aki/Tlr5tm1Aki
(B6.129P2-Tlr5tm1Aki)
|
decreased interleukin-6 secretion
|
J:112391
|
decreased interleukin-12b secretion
|
J:112391
|
decreased susceptibility to bacterial infection
|
J:112391
|
Tlr5tm1Aki/Tlr5tm1Aki
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal macrophage physiology
|
J:112671
|
Tlr5tm1Aki/Tlr5tm1Aki
(involves: 129P2/OlaHsd)
|
increased interleukin-1 beta secretion
|
J:229155
|
increased susceptibility to colitis induced morbidity/mortality
|
J:229155
|
Tlr5tm1Flv/Tlr5tm1Flv
(involves: 129S1/Sv * C57BL/6)
|
abnormal cytokine secretion
|
J:111778
|
abnormal dendritic cell physiology
|
J:111778
|
abnormal response to transplant
|
J:111778
|
increased susceptibility to autoimmune diabetes
|
J:158055
|
increased susceptibility to bacterial infection
|
J:111778
|
increased susceptibility to induced colitis
|
J:158055
|
increased susceptibility to induced pancreatitis
|
J:158055
|
lung inflammation
|
J:111778
|
Tlr5tm1Flv/Tlr5tm1Flv
(involves: 129S1/Sv)
|
abnormal leukocyte migration
|
J:171379
|
Tlr6int/Tlr6int
(C57BL/6-Tlr6int)
|
abnormal adaptive immunity
|
J:110094
|
abnormal cell-mediated immunity
|
J:110094
|
abnormal innate immunity
|
J:110094
|
abnormal macrophage physiology
|
J:110094
|
Tlr6m2Btlr/Tlr6m2Btlr
(C57BL/6J-Tlr6m2Btlr)
|
abnormal macrophage physiology
|
J:144166
|
decreased tumor necrosis factor secretion
|
J:144166
|
Tlr6m3Btlr/Tlr6m3Btlr
(C57BL/6J-Tlr6m3Btlr)
|
abnormal macrophage physiology
|
J:144167
|
decreased tumor necrosis factor secretion
|
J:144167
|
Tlr6m4Btlr/Tlr6m4Btlr
(C57BL/6J-Tlr6m4Btlr)
|
abnormal macrophage physiology
|
J:144168
|
decreased tumor necrosis factor secretion
|
J:144168
|
Tlr6tm1Aki/Tlr6tm1Aki
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal cytokine secretion
|
J:70578
|
abnormal macrophage physiology
|
J:70578
|
decreased interleukin-6 secretion
|
J:70578
|
decreased interleukin-12 secretion
|
J:70578
|
decreased tumor necrosis factor secretion
|
J:70578
|
Tlr7em2Anu/Y
(C57BL/6NCrl-Tlr7em2Anu)
|
abnormal B cell physiology
|
J:324448
|
abnormal macrophage physiology
|
J:324448
|
decreased B cell apoptosis
|
J:324448
|
decreased B cell proliferation
|
J:324448
|
increased anti-double stranded DNA antibody level
|
J:324448
|
increased anti-nuclear antigen antibody level
|
J:324448
|
increased anti-single stranded DNA antibody level
|
J:324448
|
increased autoantibody level
|
J:324448
|
increased circulating interferon-gamma level
|
J:324448
|
increased circulating interleukin-6 level
|
J:324448
|
increased circulating interleukin-10 level
|
J:324448
|
increased circulating tumor necrosis factor level
|
J:324448
|
increased susceptibility to systemic lupus erythematosus
|
J:324448
|
liver inflammation
|
J:324448
|
lung inflammation
|
J:324448
|
lymph node inflammation
|
J:324448
|
Tlr7em2Anu/Tlr7+
(C57BL/6NCrl-Tlr7em2Anu)
|
abnormal plasmacytoid dendritic cell physiology
|
J:324448
|
increased anti-double stranded DNA antibody level
|
J:324448
|
increased anti-nuclear antigen antibody level
|
J:324448
|
increased anti-single stranded DNA antibody level
|
J:324448
|
increased autoantibody level
|
J:324448
|
increased circulating interferon-gamma level
|
J:324448
|
increased circulating interleukin-6 level
|
J:324448
|
increased circulating interleukin-10 level
|
J:324448
|
increased circulating tumor necrosis factor level
|
J:324448
|
Tlr7em2Anu/Tlr7em2Anu
(C57BL/6NCrl-Tlr7em2Anu)
|
abnormal plasmacytoid dendritic cell physiology
|
J:324448
|
glomerulonephritis
|
J:324448
|
increased anti-nuclear antigen antibody level
|
J:324448
|
increased anti-single stranded DNA antibody level
|
J:324448
|
increased inflammatory response
|
J:324448
|
increased susceptibility to systemic lupus erythematosus
|
J:324448
|
liver inflammation
|
J:324448
|
lung inflammation
|
J:324448
|
lymph node inflammation
|
J:324448
|
pancreas inflammation
|
J:324448
|
salivary gland inflammation
|
J:324448
|
Tlr7rsq1/Y
(C57BL/6J-Tlr7rsq1)
|
abnormal macrophage physiology
|
J:128404
|
decreased tumor necrosis factor secretion
|
J:128404
|
Tlr7rsq1/Tlr7rsq1
(C57BL/6J-Tlr7rsq1)
|
abnormal macrophage physiology
|
J:128404
|
decreased tumor necrosis factor secretion
|
J:128404
|
Tlr7rsq2/Y
(C57BL/6J-Tlr7rsq2)
|
abnormal macrophage physiology
|
J:140020
|
decreased tumor necrosis factor secretion
|
J:140020
|
Tlr7tm1Aki/Tlr7tm1Aki
(B6.129P2-Tlr7tm1Aki)
|
abnormal dendritic cell physiology
|
J:118954
|
decreased interleukin-12b secretion
|
J:118954
|
Tlr7tm1Aki/Tlr7tm1Aki
(involves: 129P2/OlaHsd)
|
decreased interferon-alpha secretion
|
J:144400
|
Tlr7tm1Flv/Y
(B6.129S1-Tlr7tm1Flv)
|
decreased splenocyte proliferation
|
J:127600
|
Tlr7tm1Flv/Tlr7tm1Flv
(involves: 129S1/Sv)
|
decreased circulating interferon-alpha level
|
J:89257
|
Tlr7tm1Flv/Tlr7tm1Flv
(B6.129S1-Tlr7tm1Flv)
|
decreased anti-insulin autoantibody level
|
J:165267
|
decreased IgG1 level
|
J:165267
|
decreased IgG2a level
|
J:165267
|
decreased IgG level
|
J:165267
|
decreased IgM level
|
J:165267
|
Tlr8/Tlr7tm1Vlcg/Tlr8/Tlr7tm1Vlcg
(B6.Cg-Tlr8/Tlr7tm1Vlcg)
|
decreased anti-insulin autoantibody level
|
J:165267
|
Tlr8/Tlr7tm1Vlcg/Tlr7+ Tlr8/Tlr7tm1Vlcg/Tlr8tm1Vlcg
(B6.Cg-Tlr8/Tlr7tm1Vlcg Tlr8tm1Vlcg)
|
decreased anti-insulin autoantibody level
|
J:165267
|
decreased IgG level
|
J:165267
|
decreased IgM level
|
J:165267
|
increased IgG level
|
J:165267
|
increased IgM level
|
J:165267
|
Tlr8/Tlr7tm1Vlcg/Tlr8/Tlr7tm1Vlcg
(B6.Cg-Tlr8/Tlr7tm1Vlcg Tlr8tm1Vlcg)
|
decreased anti-insulin autoantibody level
|
J:165267
|
Tlr8tm1Vlcg/Tlr8tm1Vlcg
(B6.129S1-Tlr8tm1Vlcg)
|
decreased IgG1 level
|
J:165267
|
glomerulonephritis
|
J:165267
|
increased anti-double stranded DNA antibody level
|
J:165267
|
increased anti-nuclear antigen antibody level
|
J:165267
|
increased circulating interleukin-12 level
|
J:165267
|
increased IgG2a level
|
J:165267
|
increased IgG level
|
J:165267
|
increased IgM level
|
J:165267
|
increased interleukin-6 secretion
|
J:165267
|
Tlr9M1Btlr/Tlr9M1Btlr
(involves: C57BL/6)
|
abnormal cytokine secretion
|
J:88906
|
abnormal macrophage physiology
|
J:88906
|
abnormal NK cell physiology
|
J:88906
|
abnormal NK T cell physiology
|
J:88906
|
increased susceptibility to Herpesvirales infection
|
J:88906
|
increased susceptibility to Herpesvirales infection induced morbidity/mortality
|
J:88906
|
Tlr9M2Btlr/Tlr9+
(C57BL/6J-Tlr9M2Btlr)
|
abnormal macrophage physiology
|
J:128405
|
Tlr9M2Btlr/Tlr9M2Btlr
(C57BL/6J-Tlr9M2Btlr)
|
abnormal macrophage physiology
|
J:128405
|
increased susceptibility to Herpesvirales infection
|
J:128405
|
Tlr9m3Btlr/Tlr9m3Btlr
(C57BL/6J-Tlr9m3Btlr)
|
abnormal macrophage physiology
|
J:128406
|
decreased B cell proliferation
|
J:128406
|
Tlr9m4Btlr/Tlr9+
(C57BL/6J-Tlr9m4Btlr)
|
abnormal macrophage physiology
|
J:132489
|
abnormal plasmacytoid dendritic cell physiology
|
J:132489
|
decreased B cell proliferation
|
J:132489
|
Tlr9M5Btlr/?
(C57BL/6J-Tlr9M5Btlr)
|
abnormal macrophage physiology
|
J:147856
|
decreased tumor necrosis factor secretion
|
J:147856
|
Tlr9M5Btlr/Tlr9+
(C57BL/6J-Tlr9M5Btlr)
|
decreased interferon-alpha secretion
|
J:147856
|
decreased interferon-beta secretion
|
J:147856
|
Tlr9m6Btlr/Tlr9m6Btlr
(C57BL/6J-Tlr9m6Btlr)
|
increased susceptibility to induced colitis
|
J:155728
|
Tlr9M7Btlr/Tlr9+
(C57BL/6J-Tlr9M7Btlr)
|
decreased tumor necrosis factor secretion
|
J:165701
|
Tlr9M7Btlr/Tlr9M7Btlr
(C57BL/6J-Tlr9M7Btlr)
|
decreased tumor necrosis factor secretion
|
J:165701
|
Tlr9M8Btlr/Tlr9M8Btlr
(involves: C57BL/6J)
|
decreased interferon-gamma secretion
|
J:168138
|
Tlr9M9Btlr/Tlr9+
(C57BL/6J-Tlr9M9Btlr)
|
decreased tumor necrosis factor secretion
|
J:220063
|
Tlr9M9Btlr/Tlr9M9Btlr
(C57BL/6J-Tlr9M9Btlr)
|
decreased tumor necrosis factor secretion
|
J:220063
|
Tlr9tm1Aki/Tlr9tm1Aki
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal B cell physiology
|
J:66049
|
abnormal dendritic cell physiology
|
J:66049
|
abnormal macrophage physiology
|
J:117688,
J:66049
|
abnormal T-helper 1 physiology
|
J:66049
|
decreased inflammatory response
|
J:66049
|
Tlr9tm1Aki/Tlr9tm1Aki
(involves: 129P2/OlaHsd * BALB/c * C57BL/6)
|
abnormal dendritic cell physiology
|
J:88244
|
Tlr9tm1Aki/Tlr9tm1Aki
(B6.129P2-Tlr9tm1Aki)
|
abnormal immune system physiology
|
J:121070
|
abnormal response to infection
|
J:121070
|
decreased interferon-alpha secretion
|
J:125611
|
decreased interferon-beta secretion
|
J:125611
|
decreased interleukin-12b secretion
|
J:125611,
J:118954
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:105435
|
decreased susceptibility to parasitic infection
|
J:116763
|
decreased tumor necrosis factor secretion
|
J:121070
|
impaired natural killer cell mediated cytotoxicity
|
J:125611
|
Tlr9tm1Aki/Tlr9tm1Aki
(involves: 129P2/OlaHsd)
|
abnormal leukocyte migration
|
J:171379
|
Tlr12tm1Gho/Tlr12tm1Gho
(Not Specified)
|
abnormal macrophage physiology
|
J:89754
|
increased susceptibility to bacterial infection
|
J:89754
|
Tlx1tm1Thr/Tlx1tm1Thr
(involves: 129P2/OlaHsd * MF1)
|
increased splenocyte apoptosis
|
J:28700
|
Tm4sf19em1Sjkm/Tm4sf19em1Sjkm
(C57BL/6J-Tm4sf19em1Sjkm)
|
abnormal osteoclast physiology
|
J:343322
|
Tm4sf19em2Sjkm/Tm4sf19em2Sjkm
(C57BL/6J-Tm4sf19em2Sjkm)
|
abnormal osteoclast physiology
|
J:343322
|
Tmem30atm1.1Xjz/Tmem30atm1.1Xjz Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129S/SvEv * 129S4/SvJaeSor * C57BL/6J * DBA)
|
liver inflammation
|
J:249038
|
Tmem41bem1Cya/Tmem41b+
(involves: C57BL/6)
|
decreased susceptibility to Coronaviridae infection
|
J:316472
|
Tmem79ma/Tmem79ma
(involves: C57BL/6JJcl * CBA/CaGr)
|
dermatitis
|
J:202316
|
Tmem79ma/Tmem79ma
(B6.CBACaGr-Tmem79ma/J)
|
blepharitis
|
J:202453
|
dermatitis
|
J:202453
|
increased IgE level
|
J:202453
|
skin inflammation
|
J:202453
|
Tmem102tm1.1Jyen/Tmem102tm1.1Jyen
(B6.Cg-Tmem102tm1.1Jyen)
|
abnormal leukocyte adhesion
|
J:200103
|
impaired leukocyte migration
|
J:200103
|
Tmem106aem1Cheyy/Tmem106aem1Cheyy
(B6.Cg-Tmem106aem1Cheyy)
|
abnormal macrophage activation involved in immune response
|
J:345342
|
increased circulating interferon-beta level
|
J:345342
|
increased circulating interleukin-6 level
|
J:345342
|
increased circulating tumor necrosis factor level
|
J:345342
|
increased interleukin-6 secretion
|
J:345342
|
increased susceptibility to endotoxin shock
|
J:345342
|
increased tumor necrosis factor secretion
|
J:345342
|
Tmem109tm1Yamt/Tmem109tm1Yamt
(B6.Cg-Tmem109tm1Yamt)
|
decreased thymocyte apoptosis
|
J:157864
|
Tmem160em1.1Bros/Tmem160em1.1Bros
(involves: C57BL/6JRj * FVB/N)
|
abnormal cytokine level
|
J:328221
|
Tmem178tm1Lex/Tmem178tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6)
|
abnormal osteoclast physiology
|
J:228311
|
increased susceptibility to induced arthritis
|
J:228311
|
Tmem219tm1(KOMP)Vlcg/Tmem219tm1(KOMP)Vlcg
(B6J.B6N-Tmem219tm1(KOMP)Vlcg)
|
increased IgE level
|
J:236976
|
increased interleukin-4 secretion
|
J:236976
|
increased interleukin-13 secretion
|
J:236976
|
Tmem219tm1(KOMP)Vlcg/Tmem219tm1(KOMP)Vlcg Tg(Scgb1a1-rtTA,tetO-Il13)1Eli/0
(involves: C57BL/6 * C57BL/6J * C57BL/6N * CBA)
|
lung inflammation
|
J:236976
|
Tmem234tm1Lex/Tmem234tm1Lex
(B6;129S5-Tmem234tm1Lex/Mmucd)
|
increased IgG2a level
|
J:171883
|
Tmem241em1Blsg/Tmem241em1Blsg
(involves: C57BL/6J)
|
lung inflammation
|
J:344360
|
Tmem258tm1.1(KOMP)Vlcg/Tmem258+
(involves: C57BL/6NTac)
|
increased susceptibility to colitis induced morbidity/mortality
|
J:240635
|
increased susceptibility to induced colitis
|
J:240635
|
Tmem268em1Cheyy/Tmem268em1Cheyy
(involves: C57BL/6)
|
abnormal leukocyte adhesion
|
J:350812
|
abnormal leukocyte physiology
|
J:350812
|
abnormal macrophage physiology
|
J:350812
|
impaired leukocyte migration
|
J:350812
|
impaired macrophage phagocytosis
|
J:350812
|
impaired neutrophil phagocytosis
|
J:350812
|
increased chemokine level
|
J:350812
|
increased circulating interferon-beta level
|
J:350812
|
increased circulating tumor necrosis factor level
|
J:350812
|
increased susceptibility to bacterial infection
|
J:350812
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:350812
|
Tmevp2C57BL/10SnSg/Tmevp2C57BL/10SnSg
(involves: A/WySn * C57BL/10SnSg * SJL/J * Swiss)
|
decreased susceptibility to Picornaviridae infection
|
J:54593
|
Tmevp3C57BL/10SnSg/Tmevp3C57BL/10SnSg
(involves: A/WySn * C57BL/10SnSg * SJL/J * Swiss)
|
decreased susceptibility to Picornaviridae infection
|
J:54593
|
Tmevp3C57BL/10SnSg/Tmevp3SJL/J
(involves: A/WySn * C57BL/10SnSg * SJL/J * Swiss)
|
decreased susceptibility to Picornaviridae infection
|
J:54593
|
Tmprss2tm1(KOMP)Vlcg/Tmprss2tm1(KOMP)Vlcg
(involves: C57BL/6NTac)
|
abnormal cytokine secretion
|
J:283077
|
decreased susceptibility to Coronaviridae infection
|
J:283077
|
decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality
|
J:214427
|
lung inflammation
|
J:214427
|
Tmprss2tm1Psn/Tmprss2tm1Psn
(B6JRj.129S1-Tmprss2tm1Psn)
|
decreased susceptibility to Orthomyxoviridae infection
|
J:287633
|
decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality
|
J:287633
|
Tmprss2tm1Psn/Tmprss2tm1Psn
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
|
decreased susceptibility to Orthomyxoviridae infection
|
J:244166
|
Tmprss2tm2.1(ETV1)Sho/Tmprss2tm2.1(ETV1)Sho
(involves: C57BL/6 * DBA/2)
|
prostate gland inflammation
|
J:212219
|
Tnbs1SJL/J/?
(involves: C57BL/6J * SJL/J)
|
increased susceptibility to induced colitis
|
J:82095
|
Tnbs2SJL/J/?
(involves: C57BL/6J * SJL/J)
|
increased interleukin-12b secretion
|
J:82095
|
increased susceptibility to induced colitis
|
J:82095
|
TnfBpsm1/Tnf+
(involves: C57BL/6)
|
aortic valve inflammation
|
J:226052
|
increased circulating tumor necrosis factor level
|
J:226052
|
mitral valve inflammation
|
J:226052
|
rheumatoid arthritis
|
J:226052
|
TnfBpsm1/Tnf+
(C.Cg-TnfBpsm1)
|
aortic valve inflammation
|
J:226052
|
cardiovalvulitis
|
J:226052
|
mitral valve inflammation
|
J:226052
|
TnfBpsm1/Tnf+ Tnfrsf1atm1Mak/Tnfrsf1atm1Mak
(involves: 129S2/SvPas * C57BL/6)
|
increased circulating tumor necrosis factor level
|
J:226052
|
TnfBpsm1/TnfBpsm1
(involves: C57BL/6)
|
accelerated temporomandibular joint osteoarthritis
|
J:226052
|
aortic valve inflammation
|
J:226052
|
increased circulating tumor necrosis factor level
|
J:226052
|
mitral valve inflammation
|
J:226052
|
rheumatoid arthritis
|
J:226052
|
TnfBpsm1/TnfBpsm1 Tnfrsf1atm1Mak/Tnfrsf1atm1Mak
(involves: 129S2/SvPas * C57BL/6)
|
increased circulating tumor necrosis factor level
|
J:226052
|
Tnfem4Boui/Tnf+
(C57BL/6-Tnfem4Boui)
|
autoimmune arthritis
|
J:306876
|
cardiovalvulitis
|
J:306876
|
colitis
|
J:306876
|
esophageal inflammation
|
J:306876
|
ileum inflammation
|
J:306876
|
Tnfem5Boui/Tnf+ Tnfrsf1atm1Mak/Tnfrsf1a+
(involves: 129S2/SvPas * C57BL/6)
|
autoimmune arthritis
|
J:306876
|
cardiovalvulitis
|
J:306876
|
colitis
|
J:306876
|
TnfM1Btlr/TnfM1Btlr
(C57BL/6J-TnfM1Btlr)
|
increased susceptibility to bacterial infection
|
J:124642
|
TnfM2Btlr/Tnf+
(C57BL/6J-TnfM2Btlr)
|
decreased macrophage cytokine production
|
J:213047
|
decreased tumor necrosis factor secretion
|
J:213047
|
TnfR8H/TnfR8H
(involves: I/St)
|
increased susceptibility to bacterial infection
|
J:114302
|
Tnftm1.1Sned/Tnftm1.1Sned Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129 * 129P2/OlaHsd * C57BL/6)
|
abnormal chemokine secretion
|
J:95684
|
decreased circulating tumor necrosis factor level
|
J:95684
|
decreased susceptibility to autoimmune disorder
|
J:95684
|
decreased susceptibility to endotoxin shock
|
J:95684
|
increased susceptibility to bacterial infection
|
J:95684
|
Tnftm1.1Sned/Tnftm1.1Sned Tg(Cd4-cre)1Cwi/0
(involves: 129 * C57BL/6 * DBA/2)
|
decreased circulating tumor necrosis factor level
|
J:95684
|
decreased susceptibility to autoimmune disorder
|
J:95684
|
decreased susceptibility to endotoxin shock
|
J:95684
|
increased susceptibility to bacterial infection
|
J:95684
|
Tnftm1.2Sned/Tnftm1.2Sned
(involves: 129/Sv * C57BL/6)
|
decreased susceptibility to bacterial infection
|
J:97783
|
increased susceptibility to parasitic infection
|
J:97783
|
Tnftm1Gkl/Tnftm1Gkl
(involves: 129S/SvEv * C57BL/6)
|
abnormal inflammatory response
|
J:114740
|
abnormal lymphocyte physiology
|
J:114740
|
abnormal macrophage physiology
|
J:114740
|
decreased inflammatory response
|
J:56068
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:114740
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:47673
|
increased susceptibility to bacterial infection
|
J:47673,
J:114740
|
Tnftm1Gkl/Tnftm1Gkl
(involves: 129S/SvEv)
|
abnormal chemokine secretion
|
J:95684
|
decreased circulating tumor necrosis factor level
|
J:95684
|
decreased susceptibility to autoimmune disorder
|
J:95684
|
decreased susceptibility to endotoxin shock
|
J:95684
|
increased susceptibility to bacterial infection
|
J:95684
|
Tnftm1Gkl/Tnftm1Gkl
(either: B6.129-Tnftm1Gkl or (involves: 129 * C57BL/6))
|
decreased susceptibility to bacterial infection
|
J:97783
|
increased susceptibility to parasitic infection
|
J:97783
|
Tnftm1Gkl/Tnftm1Gkl
(involves: 129S/SvEv * C57BL/6J)
|
increased susceptibility to bacterial infection
|
J:124642
|
Tnftm1Gkl/Tnftm1Gkl Tnfaip3tm1Ama/Tnfaip3tm1Ama
(involves: 129S/SvEv * C57BL/6J)
|
abnormal cytokine secretion
|
J:92694
|
abnormal inflammatory response
|
J:92694
|
Tnftm1Gkl/Tnftm2Gkl
(involves: 129S/SvEv * C57BL/6)
|
increased circulating tumor necrosis factor level
|
J:54056
|
increased susceptibility to endotoxin shock
|
J:54056
|
increased tumor necrosis factor secretion
|
J:54056
|
rheumatoid arthritis
|
J:54056
|
Tnftm1Jods/Tnftm1Jods
(involves: C57BL/6)
|
abnormal immune system physiology
|
J:98591
|
decreased susceptibility to endotoxin shock
|
J:98591
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:44545,
J:98591
|
increased susceptibility to bacterial infection
|
J:115034,
J:98170
|
Tnftm1Jods/Tnftm1Jods
(C57BL/6-Tnftm1Jods)
|
abnormal cytokine level
|
J:118417
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:118417
|
Tnftm1Jods/Tnftm1Jods
(C57BL/6-Ltatm1Jods)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:47428
|
Tnftm1Ljo/Tnf+
(involves: 129S1/Sv)
|
increased susceptibility to bacterial infection
|
J:41992
|
increased susceptibility to fungal infection
|
J:41992
|
Tnftm1Ljo/Tnftm1Ljo
(involves: 129S1/Sv)
|
abnormal chemokine secretion
|
J:95684
|
abnormal cytokine secretion
|
J:41992
|
abnormal follicular dendritic cell physiology
|
J:41992
|
abnormal susceptibility to infection
|
J:41992
|
decreased circulating tumor necrosis factor level
|
J:95684
|
decreased IgG level
|
J:41992
|
decreased susceptibility to autoimmune disorder
|
J:95684
|
decreased susceptibility to endotoxin shock
|
J:95684,
J:41992
|
increased susceptibility to bacterial infection
|
J:80616,
J:95684,
J:41992
|
increased susceptibility to fungal infection
|
J:41992
|
Tnftm1Ljo/Tnftm1Ljo
(either: B6.129-Tnftm1Ljo or (involves: 129 * C57BL/6))
|
decreased susceptibility to bacterial infection
|
J:97783
|
increased susceptibility to parasitic infection
|
J:97783
|
Tnftm1Ljo/Tnftm1Ljo
(B6.129S1-Tnftm1Ljo)
|
lung inflammation
|
J:127028
|
Tnftm1Ljo/Tnftm1Ljo
(involves: 129S1/Sv * C57BL/6)
|
abnormal neutrophil physiology
|
J:127028
|
decreased immunoglobulin level
|
J:127028
|
increased interferon-gamma secretion
|
J:127028
|
increased susceptibility to parasitic infection
|
J:127028
|
skin inflammation
|
J:127028
|
Tnftm1Sek/Tnftm1Sek
(B6.Cg-Tnftm1Sek)
|
abnormal cytokine secretion
|
J:44841
|
abnormal macrophage physiology
|
J:44841
|
decreased circulating interferon-gamma level
|
J:44841
|
decreased circulating interleukin-1 alpha level
|
J:44841
|
decreased circulating interleukin-1 beta level
|
J:44841
|
decreased circulating interleukin-6 level
|
J:44841
|
decreased susceptibility to endotoxin shock
|
J:44841
|
Tnftm2.1Gkl/Tnftm2.1Gkl Tg(Fabp1-cre)1Jig/0
(involves: 129S/SvEv * FVB/N)
|
ileum inflammation
|
J:204557
|
increased circulating tumor necrosis factor level
|
J:204557
|
large intestinal inflammation
|
J:204557
|
small intestinal inflammation
|
J:204557
|
Tnftm2.1Gkl/Tnftm2.1Gkl Tg(Lck-cre)I57Jxm/0
(involves: 129S/SvEv * ICR)
|
small intestinal inflammation
|
J:108572
|
Tnftm2Gkl/Tnf+
(involves: 129S/SvEv * C57BL/6)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:136667
|
abnormal circulating chemokine level
|
J:204922
|
abnormal T cell physiology
|
J:136667
|
abnormal T-helper 17 cell physiology
|
J:204922
|
autoimmune arthritis
|
J:92307,
J:136667
|
decreased inflammatory response
|
J:204922
|
ileum inflammation
|
J:204922
|
increased circulating tumor necrosis factor level
|
J:54056,
J:204922
|
intestinal inflammation
|
J:136667
|
rheumatoid arthritis
|
J:54056
|
small intestinal inflammation
|
J:92307,
J:54056,
J:204922
|
Tnftm2Gkl/Tnf+
(involves: 129S/SvEv * C57BL/6 * SPRET/Ei)
|
autoimmune arthritis
|
J:92307
|
small intestinal inflammation
|
J:92307
|
Tnftm2Gkl/Tnf+
(involves: 129S/SvEv * C57BL/6J)
|
abnormal cytotoxic T cell physiology
|
J:108572
|
abnormal response to transplant
|
J:108572
|
increased circulating tumor necrosis factor level
|
J:264147
|
increased tumor necrosis factor secretion
|
J:264147
|
small intestinal inflammation
|
J:108572
|
Tnftm2Gkl/Tnf+
(involves: 129S/SvEv * C57BL/6 * CBA)
|
autoimmune arthritis
|
J:131930
|
Tnftm2Gkl/Tnf+
(B6.129S-Tnftm2Gkl/Jarn)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:145626
|
ileum inflammation
|
J:131978,
J:145626
|
increased interferon-gamma secretion
|
J:131978
|
increased interleukin-2 secretion
|
J:145626
|
increased tumor necrosis factor secretion
|
J:145626
|
Tnftm2Gkl/Tnf+ Tnfrsf1atm2Gkl/Tnfrsf1atm2Gkl Tg(Col6a1-cre)1Gkl/?
(involves: 129S/SvEv * C57BL/6 * CBA)
|
autoimmune arthritis
|
J:131930
|
small intestinal inflammation
|
J:131930
|
Tnftm2Gkl/Tnf+ Tnfrsf1btm1.1Gkl/Tnfrsf1btm1.1Gkl Tg(Col6a1-cre)1Gkl/0
(involves: 129S/SvEv * C57BL/6 * C57BL/6J * CBA)
|
increased circulating tumor necrosis factor level
|
J:264147
|
increased tumor necrosis factor secretion
|
J:264147
|
joint inflammation
|
J:264147
|
Tnftm2Gkl/Tnf+ Tnfrsf1btm1.2Gkl/Tnfrsf1btm1.2Gkl
(involves: 129S/SvEv * C57BL/6 * C57BL/6J)
|
aortic valve inflammation
|
J:264147
|
autoimmune arthritis
|
J:264147
|
increased circulating tumor necrosis factor level
|
J:264147
|
increased tumor necrosis factor secretion
|
J:264147
|
Tnftm2Gkl/Tnf+ Tnfrsf1btm1Mwm/Tnfrsf1btm1Mwm
(involves: 129S/SvEv * 129S2/SvPas * C57BL/6)
|
rheumatoid arthritis
|
J:54056
|
small intestinal inflammation
|
J:54056
|
Tnftm2Gkl/Tnftm2Gkl
(involves: 129S/SvEv * C57BL/6)
|
cardiovalvulitis
|
J:226052
|
increased circulating tumor necrosis factor level
|
J:54056
|
rheumatoid arthritis
|
J:54056
|
small intestinal inflammation
|
J:54056
|
Tnftm2Gkl/Tnftm2Gkl Tnfrsf1atm1Blt/Tnfrsf1atm1Blt
(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)
|
increased circulating tumor necrosis factor level
|
J:54056
|
increased tumor necrosis factor secretion
|
J:54056
|
Tnftm2Jods/Tnftm2Jods
(involves: C57BL/6)
|
decreased immunoglobulin level
|
J:127028
|
increased susceptibility to bacterial infection
|
J:98170
|
Tnftm2Jods/Tnftm2Jods
(C57BL/6-Tnftm2Jods)
|
abnormal immune system physiology
|
J:98591
|
decreased susceptibility to endotoxin shock
|
J:98591
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:98591
|
Tnftm3Gkl/Tnftm3Gkl
(involves: 129S/SvEv * C57BL/6)
|
abnormal lymphocyte physiology
|
J:114740
|
autoimmune response
|
J:114740
|
decreased circulating tumor necrosis factor level
|
J:114740
|
decreased IgG1 level
|
J:114740
|
decreased susceptibility to bacterial infection
|
J:114740
|
decreased susceptibility to endotoxin shock
|
J:114740
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:114740
|
decreased tumor necrosis factor secretion
|
J:114740
|
Tnfaip3m1Apb/Tnfaip3m1Apb
(C57BL/6-Tnfaip3m1Apb)
|
CNS inflammation
|
J:324062
|
increased microglial cell activation
|
J:324062
|
uterus inflammation
|
J:324062
|
Tnfaip3tm1.1Gvl/Tnfaip3tm1.1Gvl Tg(Vil1-cre)997Gum/0
(B6.Cg-Tnfaip3tm1.1Gvl Tg(Vil1-cre)997Gum)
|
increased circulating interleukin-6 level
|
J:163410
|
increased susceptibility to induced colitis
|
J:163410
|
Tnfaip3tm1.1Gvl/Tnfaip3tm1.1Gvl Tnfrsf1atm1Mak/Tnfrsf1atm1Mak Tg(Vil1-cre)997Gum/0
(involves: 129S2/SvPas * C57BL/6 * SJL)
|
decreased susceptibility to induced colitis
|
J:163410
|
increased susceptibility to induced colitis
|
J:163410
|
Tnfaip3tm1Ama/Tnfaip3tm1Ama
(involves: C57BL/6J)
|
abnormal cytokine secretion
|
J:92694
|
abnormal inflammatory response
|
J:92694
|
Tnfaip3tm1Ama/Tnfaip3tm1Ama
(Not Specified)
|
increased inflammatory response
|
J:92931
|
intestinal inflammation
|
J:92931
|
joint inflammation
|
J:92931
|
kidney inflammation
|
J:92931
|
liver inflammation
|
J:92931
|
Tnfaip3tm1Ama/Tnfaip3tm1Ama Tnfrsf1atm1Imx/Tnfrsf1a+
(involves: C57BL/6J)
|
abnormal inflammatory response
|
J:92694
|
Tnfaip3tm1Ama/Tnfaip3tm1Ama Tnfrsf1atm1Imx/Tnfrsf1atm1Imx
(involves: C57BL/6J)
|
abnormal inflammatory response
|
J:92694
|
Tnfaip3tm1Homy/Tnfaip3tm1Homy Tg(Mx1-cre)1Cgn/?
(involves: 129S6/SvEvTac * C57BL/6J * CBA/J)
|
abnormal circulating cytokine level
|
J:212681
|
abnormal circulating interleukin level
|
J:212681
|
increased circulating interferon-gamma level
|
J:212681
|
increased circulating interleukin-1 beta level
|
J:212681
|
increased circulating interleukin-6 level
|
J:212681
|
increased circulating tumor necrosis factor level
|
J:212681
|
liver inflammation
|
J:212681
|
lung inflammation
|
J:212681
|
Tnfaip3tm2Ama/Tnfaip3tm2Ama Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal B cell activation
|
J:163917
|
decreased B cell apoptosis
|
J:163917
|
increased autoantibody level
|
J:163917
|
increased B cell proliferation
|
J:163917
|
increased IgG level
|
J:163917
|
increased IgM level
|
J:163917
|
increased immunoglobulin level
|
J:163917
|
increased interleukin-6 secretion
|
J:163917
|
increased susceptibility to autoimmune disorder
|
J:163917
|
Tnfaip3tm3.1Ama/Tnfaip3tm3.1Ama
(C57BL/6J-Tnfaip3tm3.1Ama)
|
abnormal chemokine secretion
|
J:203160
|
decreased interleukin-6 secretion
|
J:203160
|
increased susceptibility to induced colitis
|
J:203160
|
Tnfaip3tm4.1Ama/Tnfaip3tm4.1Ama
(C57BL/6J-Tnfaip3tm4.1Ama)
|
abnormal chemokine secretion
|
J:203160
|
decreased interleukin-6 secretion
|
J:203160
|
increased susceptibility to induced colitis
|
J:203160
|
Tnfaip6tm1Cful/Tnfaip6tm1Cful
(involves: 129S6/SvEvTac * BALB/c)
|
decreased inflammatory response
|
J:193758
|
Tnfaip8Gt(IST13629C1)Tigm/Tnfaip8Gt(IST13629C1)Tigm
(involves: C57BL/6N)
|
increased circulating interleukin-6 level
|
J:223320
|
increased circulating interleukin-17 level
|
J:223320
|
increased interleukin-1 beta secretion
|
J:223320
|
increased interleukin-6 secretion
|
J:223320
|
increased interleukin-17 secretion
|
J:223320
|
increased susceptibility to induced colitis
|
J:223320
|
Tnfaip8Gt(IST13629C1)Tigm/Tnfaip8Gt(IST13629C1)Tigm Tnfaip8l1em1Huwa/Tnfaip8l1em1Huwa
(involves: C57BL/6 * C57BL/6N)
|
colitis
|
J:342074
|
Tnfaip8l1em1Huwa/Tnfaip8l1em1Huwa
(C57BL/6-Tnfaip8l1em1Huwa)
|
increased susceptibility to colitis induced morbidity/mortality
|
J:342074
|
increased susceptibility to induced colitis
|
J:342074
|
Tnfaip8l2tm1Yhcn/Tnfaip8l2tm1Yhcn
(129S6/SvEvTac-Tnfaip8l2tm1Yhcn)
|
abnormal B cell activation
|
J:139785
|
abnormal B cell physiology
|
J:139785
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:139785
|
abnormal cytotoxic T cell physiology
|
J:139785
|
abnormal inflammatory response
|
J:139785
|
abnormal macrophage activation involved in immune response
|
J:139785
|
abnormal T cell apoptosis
|
J:139785
|
chronic inflammation
|
J:139785
|
decreased IgG2a level
|
J:139785
|
decreased IgG2b level
|
J:139785
|
increased circulating interleukin-1 beta level
|
J:139785
|
increased circulating interleukin-6 level
|
J:139785
|
increased circulating interleukin-10 level
|
J:139785
|
increased circulating interleukin-12 level
|
J:139785
|
increased circulating tumor necrosis factor level
|
J:139785
|
increased interferon-gamma secretion
|
J:139785
|
increased interleukin-1 beta secretion
|
J:139785
|
increased interleukin-2 secretion
|
J:139785
|
increased interleukin-4 secretion
|
J:139785
|
increased interleukin-6 secretion
|
J:139785
|
increased interleukin-12 secretion
|
J:139785
|
increased interleukin-17 secretion
|
J:139785
|
increased susceptibility to endotoxin shock
|
J:139785
|
increased tumor necrosis factor secretion
|
J:139785
|
intestinal inflammation
|
J:139785
|
liver inflammation
|
J:139785
|
lung inflammation
|
J:139785
|
lymph node inflammation
|
J:139785
|
Tnfrsf1atm1.1Gkl/Tnfrsf1a+
(involves: 129/Sv * C57BL/6)
|
liver inflammation
|
J:92470
|
Tnfrsf1atm1.1Gkl/Tnfrsf1atm1.1Gkl
(involves: 129/Sv * C57BL/6)
|
abnormal cytokine secretion
|
J:92470
|
decreased susceptibility to bacterial infection
|
J:92470
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:92470
|
liver inflammation
|
J:92470
|
Tnfrsf1atm1.1Gkl/Tnfrsf1atm1.1Gkl Tnfrsf1btm1Mwm/Tnfrsf1btm1Mwm
(involves: 129/Sv * C57BL/6)
|
liver inflammation
|
J:92470
|
Tnfrsf1atm1Blt/Tnfrsf1a+
(involves: 129P2/OlaHsd)
|
decreased circulating interleukin-6 level
|
J:210950
|
Tnfrsf1atm1Blt/Tnfrsf1atm1Blt
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal immune system physiology
|
J:14424
|
decreased IgG1 level
|
J:115225
|
decreased interleukin-6 secretion
|
J:14424
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:115225
|
increased susceptibility to bacterial infection
|
J:14424
|
increased susceptibility to parasitic infection
|
J:114203
|
increased susceptibility to type I hypersensitivity reaction
|
J:92307
|
Tnfrsf1atm1Blt/Tnfrsf1atm1Blt
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6)
|
decreased susceptibility to bacterial infection
|
J:50903
|
Tnfrsf1atm1Blt/Tnfrsf1atm1Blt
(involves: 129P2/OlaHsd)
|
impaired humoral immune response
|
J:210950
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:210950
|
Tnfrsf1atm1Blt/Tnfrsf1atm1Blt Tnfrsf1btm1Mwm/Tnfrsf1btm1Mwm
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
|
decreased IgG1 level
|
J:115225
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:115225
|
increased susceptibility to parasitic infection
|
J:114203
|
Tnfrsf1atm1Imx/Tnfrsf1a+
(involves: C57BL/6)
|
decreased circulating interleukin-6 level
|
J:210950
|
Tnfrsf1atm1Imx/Tnfrsf1atm1Imx
(involves: 129S7/SvEvBrd * C57BL/6)
|
abnormal immune system physiology
|
J:45147
|
Tnfrsf1atm1Imx/Tnfrsf1atm1Imx
(C57BL/6-Tnfrsf1atm1Imx)
|
decreased inflammatory response
|
J:45147
|
decreased susceptibility to endotoxin shock
|
J:45147
|
increased circulating tumor necrosis factor level
|
J:45147
|
increased susceptibility to bacterial infection
|
J:45147
|
lung inflammation
|
J:120174
|
Tnfrsf1atm1Imx/Tnfrsf1atm1Imx
(C57BL/6-Tnfrsf1atm1Imx/J)
|
abnormal chemokine secretion
|
J:160543
|
abnormal macrophage physiology
|
J:160543
|
decreased circulating interleukin-6 level
|
J:160543
|
decreased interleukin-6 secretion
|
J:160543
|
decreased susceptibility to endotoxin shock
|
J:160543
|
increased circulating tumor necrosis factor level
|
J:160543
|
Tnfrsf1atm1Imx/Tnfrsf1atm1Imx
(involves: C57BL/6)
|
impaired humoral immune response
|
J:210950
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:210950
|
Tnfrsf1atm1Imx/Tnfrsf1atm1Imx Tnfrsf1btm1Imx/Tnfrsf1btm1Imx
(involves: 129S7/SvEvBrd * C57BL/6)
|
decreased inflammatory response
|
J:45147
|
decreased microglial cell activation
|
J:33864
|
decreased susceptibility to endotoxin shock
|
J:45147
|
decreased susceptibility to experimental autoimmune uveoretinitis
|
J:115094
|
decreased susceptibility to induced arthritis
|
J:120707
|
increased circulating tumor necrosis factor level
|
J:45147
|
increased susceptibility to bacterial infection
|
J:58851
|
osteomyelitis
|
J:58851
|
Tnfrsf1atm1Imx/Tnfrsf1atm1Imx Tnfrsf1btm1Imx/Tnfrsf1btm1Imx
(B6.129S-Tnfrsf1btm1Imx Tnfrsf1atm1Imx/J)
|
decreased susceptibility to Coronaviridae infection
|
J:288523
|
Tnfrsf1atm1Mak/Tnfrsf1a+
(involves: 129S2/SvPas)
|
decreased circulating interleukin-6 level
|
J:210950
|
Tnfrsf1atm1Mak/Tnfrsf1atm1Mak
(involves: 129S2/SvPas * C57BL/6J * DBA/2J)
|
granulomatous inflammation
|
J:55889
|
Tnfrsf1atm1Mak/Tnfrsf1atm1Mak
(involves: 129S2/SvPas * C57BL/6J * NOD)
|
decreased susceptibility to autoimmune diabetes
|
J:64051
|
Tnfrsf1atm1Mak/Tnfrsf1atm1Mak
(involves: 129S2/SvPas)
|
decreased circulating interleukin-6 level
|
J:138824
|
decreased IgG level
|
J:139030
|
decreased susceptibility to bacterial infection
|
J:4753,
J:121930
|
impaired humoral immune response
|
J:210950
|
increased circulating tumor necrosis factor level
|
J:139030
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:4753,
J:139030,
J:210950
|
Tnfrsf1atm1Mak/Tnfrsf1atm1Mak Tnip1Gt(E059E05)Wrst/Tnip1Gt(E059E05)Wrst
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
|
glomerulonephritis
|
J:180054
|
increased susceptibility to systemic lupus erythematosus
|
J:180054
|
Tnfrsf1atm1Rsie/Tnfrsf1a+
(B6.Cg-Tnfrsf1atm1Rsie)
|
increased circulating tumor necrosis factor level
|
J:160543
|
increased interleukin-6 secretion
|
J:160543
|
increased susceptibility to endotoxin shock
|
J:160543
|
Tnfrsf1atm1Rsie/Tnfrsf1atm1Rsie
(B6.Cg-Tnfrsf1atm1Rsie)
|
abnormal chemokine secretion
|
J:160543
|
abnormal macrophage physiology
|
J:160543
|
decreased circulating interleukin-1 beta level
|
J:160543
|
decreased circulating interleukin-6 level
|
J:160543
|
decreased interleukin-6 secretion
|
J:160543
|
decreased susceptibility to endotoxin shock
|
J:160543
|
increased circulating tumor necrosis factor level
|
J:160543
|
Tnfrsf1atm2.1Rsie/Tnfrsf1a+
(B6.Cg-Tnfrsf1atm2.1Rsie)
|
abnormal macrophage physiology
|
J:160543
|
decreased circulating interleukin-1 beta level
|
J:160543
|
decreased circulating interleukin-6 level
|
J:160543
|
decreased interleukin-6 secretion
|
J:160543
|
increased interleukin-6 secretion
|
J:160543
|
increased susceptibility to endotoxin shock
|
J:160543
|
Tnfrsf1atm2.1Rsie/Tnfrsf1a+
(involves: 129S6/SvEvTac)
|
increased susceptibility to endotoxin shock
|
J:160543
|
Tnfrsf1atm2.1Rsie/Tnfrsf1atm2.1Rsie
(B6.Cg-Tnfrsf1atm2.1Rsie)
|
abnormal chemokine secretion
|
J:160543
|
abnormal macrophage physiology
|
J:160543
|
decreased circulating interleukin-6 level
|
J:160543
|
decreased interleukin-6 secretion
|
J:160543
|
decreased susceptibility to endotoxin shock
|
J:160543
|
increased circulating tumor necrosis factor level
|
J:160543
|
Tnfrsf1btm1Imx/Tnfrsf1btm1Imx
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased circulating tumor necrosis factor level
|
J:45147
|
increased inflammatory response
|
J:45147
|
lung inflammation
|
J:120174
|
Tnfrsf1btm1Mwm/Tnfrsf1btm1Mwm
(B6.129S2-Tnfrsf1btm1Mwm/J)
|
decreased interferon-gamma secretion
|
J:107039
|
decreased interleukin-2 secretion
|
J:107039
|
decreased T cell proliferation
|
J:107039
|
Tnfrsf1btm1Mwm/Tnfrsf1btm1Mwm
(involves: 129S2/SvPas * C57BL/6J)
|
abnormal immune system physiology
|
J:21815
|
increased susceptibility to bacterial infection
|
J:21815
|
Tnfrsf1btm1Mwm/Tnfrsf1btm1Mwm
(involves: 129S2/SvPas * C57BL/6J * NOD)
|
decreased susceptibility to autoimmune diabetes
|
J:64051
|
periinsulitis
|
J:64051
|
Tnfrsf1btm1Mwm/Tnfrsf1btm1Mwm
(involves: 129S2/SvPas * C57BL/6)
|
decreased susceptibility to bacterial infection
|
J:50903
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:115225
|
increased susceptibility to parasitic infection
|
J:114203
|
Tnfrsf4tm1Mfb/Tnfrsf4tm1Mfb
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:59204
|
Tnfrsf4tm1Nik/Tnfrsf4tm1Nik
(involves: 129S4/SvJae * C57BL/6)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:64552
|
abnormal T-helper 2 physiology
|
J:68588
|
decreased susceptibility to type I hypersensitivity reaction
|
J:68588
|
decreased T cell proliferation
|
J:58979,
J:64552
|
Tnfrsf8tm1Mak/Tnfrsf8tm1Mak
(involves: C57BL/6)
|
decreased susceptibility to graft versus host disease
|
J:92723
|
Tnfrsf9em1Ygch/Tnfrsf9em1Ygch
(NOD/ShiLtDvs-Tnfrsf9em1Ygch)
|
abnormal T cell physiology
|
J:208927
|
insulitis
|
J:208927
|
Tnfrsf9em2Ygch/Tnfrsf9em2Ygch
(NOD/ShiLtDvs-Tnfrsf9em2Ygch)
|
abnormal T cell physiology
|
J:208927
|
insulitis
|
J:208927
|
Tnfrsf9tm1Byk/Tnfrsf9tm1Byk
(B6.Cg-Tnfrsf9tm1Byk)
|
abnormal cytotoxic T cell physiology
|
J:83996
|
decreased IgG2a level
|
J:83996
|
decreased IgG3 level
|
J:83996
|
decreased interferon-gamma secretion
|
J:83996
|
decreased interleukin-2 secretion
|
J:83996
|
decreased interleukin-4 secretion
|
J:83996
|
increased T cell proliferation
|
J:83996
|
Tnfrsf9tm1Byk/Tnfrsf9tm1Byk
(C.Cg-Tnfrsf9tm1Byk)
|
abnormal cytotoxic T cell physiology
|
J:83722
|
abnormal immunoglobulin level
|
J:83996
|
decreased IgG2a level
|
J:83996
|
decreased IgG3 level
|
J:83996
|
decreased interferon-gamma secretion
|
J:83996
|
decreased interleukin-2 secretion
|
J:83996
|
decreased interleukin-4 secretion
|
J:83996
|
decreased interleukin-12 secretion
|
J:83722
|
increased IgA level
|
J:83722
|
increased IgG2a level
|
J:83722
|
increased IgG2b level
|
J:83722
|
increased splenocyte proliferation
|
J:83722
|
increased T cell proliferation
|
J:83996
|
Tnfrsf9tm1Lpc/Tnfrsf9tm1Lpc
(B6.129-Tnfrsf9tm1Lpc)
|
abnormal memory T cell physiology
|
J:145439
|
Tnfrsf10btm1Wnt/Tnfrsf10btm1Wnt
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal innate immunity
|
J:94681
|
abnormal interferon level
|
J:94681
|
decreased susceptibility to Herpesvirales infection
|
J:94681
|
decreased susceptibility to Herpesvirales infection induced morbidity/mortality
|
J:94681
|
increased circulating interferon-gamma level
|
J:94681
|
increased circulating interleukin-12b level
|
J:94681
|
increased interleukin-12 secretion
|
J:94681
|
increased tumor necrosis factor secretion
|
J:94681
|
Tnfrsf11atm1.1Pngr/Tnfrsf11atm1.2Pngr Tg(Gfap-cre)2Brn/0
(involves: 129 * C57BL/6 * C57BL/6NTac * FVB/N)
|
decreased susceptibility to endotoxin shock
|
J:155398
|
Tnfrsf11atm1.1Pngr/Tnfrsf11atm1.2Pngr Tg(Nes-cre)1Kln/0
(involves: 129 * C57BL/6 * C57BL/6NTac * SJL)
|
decreased susceptibility to endotoxin shock
|
J:155398
|
Tnfrsf11atm1.1Sral/Tnfrsf11a+
(B6.129P2(Cg)-Tnfrsf11atm1.1Sral)
|
abnormal osteoclast physiology
|
J:312215
|
Tnfrsf11btm1Eac/Tnfrsf11btm1Eac
(involves: 129S4/SvJaeSor)
|
abnormal dendritic cell antigen presentation
|
J:67105
|
abnormal immune system physiology
|
J:67105
|
abnormal immunoglobulin level
|
J:67105
|
Tnfrsf11btm1Khs/Tnfrsf11btm1Khs
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal osteoclast physiology
|
J:111153
|
Tnfrsf12atm1Biib/Tnfrsf12atm1Biib
(B6.129S4-Tnfrsf12atm1Biib)
|
abnormal chemokine secretion
|
J:126416
|
Tnfrsf13btm1Rjb/Tnfrsf13btm1Rjb
(involves: 129X1/SvJ * C57BL/6)
|
abnormal B cell activation
|
J:69474
|
decreased IgA level
|
J:69474
|
decreased IgM level
|
J:69474
|
increased B cell proliferation
|
J:69474
|
Tnfrsf13btm1Rjb/Tnfrsf13btm1Rjb
(involves: 129X1/SvJ)
|
abnormal class switch recombination
|
J:95288
|
decreased IgA level
|
J:95288
|
decreased IgE level
|
J:95288
|
decreased IgG1 level
|
J:95288
|
Tnfrsf13btm1Vmd/Tnfrsf13btm1Vmd
(involves: C57BL/6)
|
abnormal immunoglobulin level
|
J:70172
|
glomerulonephritis
|
J:82331
|
increased anti-double stranded DNA antibody level
|
J:82331
|
increased anti-nuclear antigen antibody level
|
J:82331
|
increased B cell proliferation
|
J:70172
|
increased IgG1 level
|
J:70172
|
kidney inflammation
|
J:82331
|
liver inflammation
|
J:82331
|
Tnfrsf13cBcmd1/Tnfrsf13cBcmd1
(A/WySnJ)
|
abnormal lymphocyte physiology
|
J:92334
|
decreased B cell proliferation
|
J:122315
|
decreased IgG level
|
J:122315
|
decreased interferon-gamma secretion
|
J:92334
|
decreased T cell proliferation
|
J:92334
|
increased length of allograft survival
|
J:92334
|
Tnfrsf13ctm1Mass/Tnfrsf13ctm1Mass
(C57BL/6-Tnfrsf13ctm1Mass)
|
abnormal B cell physiology
|
J:113556
|
decreased IgG1 level
|
J:92732
|
decreased IgG2a level
|
J:92732
|
decreased IgG2b level
|
J:92732
|
decreased IgG3 level
|
J:92732
|
decreased IgG level
|
J:92732
|
decreased IgM level
|
J:92732
|
Tnfrsf13ctm1Msc/Tnfrsf13ctm1Msc
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal humoral immune response
|
J:92676
|
decreased IgD level
|
J:92676
|
decreased IgG1 level
|
J:92676
|
decreased IgG level
|
J:92676
|
decreased IgM level
|
J:92676
|
Tnfrsf14tm1Csj/Tnfrsf14tm1Csj
(B6.Cg-Tnfrsf14tm1Csj)
|
decreased interferon-gamma secretion
|
J:169369
|
decreased interleukin-6 secretion
|
J:169369
|
decreased interleukin-10 secretion
|
J:169369
|
decreased susceptibility to induced colitis
|
J:169369
|
decreased tumor necrosis factor secretion
|
J:169369
|
Tnfrsf14tm1Kpf/Tnfrsf14tm1Kpf
(B6.129P2-Tnfrsf14tm1Kpf)
|
abnormal T cell physiology
|
J:99456
|
increased T cell proliferation
|
J:99456
|
Tnfrsf14tm1Kro/Tnfrsf14tm1Kro
(C57BL/6-Tnfrsf14tm1Kro)
|
decreased susceptibility to Herpesvirales infection
|
J:243038
|
Tnfrsf14tm1Wwhk/Tnfrsf14tm1Wwhk
(B6.Cg-Tnfrsf14tm1Wwhk)
|
decreased length of allograft survival
|
J:119356
|
Tnfrsf18tm1Ppp/Tnfrsf18tm1Ppp
(involves: 129/Sv * C57BL/6)
|
abnormal T cell activation
|
J:77393
|
increased interleukin-2 secretion
|
J:77393
|
increased T cell apoptosis
|
J:77393
|
increased T cell proliferation
|
J:77393
|
Tnfrsf21tm1Ddy/Tnfrsf21tm1Ddy
(involves: 129S1/Sv * 129X1/SvJ)
|
abnormal T-helper 1 physiology
|
J:70594
|
abnormal T-helper 2 physiology
|
J:70594
|
increased B cell proliferation
|
J:109341
|
increased IgG1 level
|
J:109341
|
increased IgG2a level
|
J:109341
|
increased IgG2b level
|
J:109341
|
increased IgG3 level
|
J:109341
|
increased IgM level
|
J:109341
|
increased interleukin-4 secretion
|
J:70594
|
increased interleukin-5 secretion
|
J:70594
|
increased interleukin-10 secretion
|
J:70594
|
increased interleukin-13 secretion
|
J:70594
|
increased T cell proliferation
|
J:70594
|
Tnfrsf21tm1Vmd/Tnfrsf21tm1Vmd
(involves: C57BL/6)
|
abnormal cell-mediated immunity
|
J:72761
|
abnormal T-helper 2 physiology
|
J:72761
|
increased IgE level
|
J:72761
|
increased IgG1 level
|
J:72761
|
increased IgG2a level
|
J:72761
|
increased IgM level
|
J:72761
|
increased interferon-gamma secretion
|
J:72761
|
increased interleukin-2 secretion
|
J:72761
|
increased interleukin-4 secretion
|
J:72761
|
increased T cell proliferation
|
J:72761
|
Tnfrsf25tm1Mjo/Tnfrsf25tm1Mjo
(involves: 129P2/OlaHsd)
|
decreased T cell apoptosis
|
J:84536
|
Tnfsf4tm1Shr/Tnfsf4tm1Shr
(involves: 129S4/SvJae)
|
abnormal cell-mediated immunity
|
J:59203
|
abnormal dendritic cell antigen presentation
|
J:59203
|
decreased interferon-gamma secretion
|
J:59203
|
decreased interleukin-2 secretion
|
J:59203
|
decreased interleukin-4 secretion
|
J:59203
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:59203
|
decreased T cell proliferation
|
J:59203
|
Tnfsf4tm1Shr/Tnfsf4tm1Shr
(NOD.129S4-Tnfsf4tm1Shr)
|
decreased susceptibility to autoimmune diabetes
|
J:86926
|
Tnfsf4tm1Shr/Tnfsf4tm1Shr
(C.129S4-Tnfsf4tm1Shr)
|
abnormal cytokine secretion
|
J:59203
|
abnormal dendritic cell antigen presentation
|
J:59203
|
Tnfsf4tm1Sug/Tnfsf4tm1Sug
(B6.129S4-Tnfsf4tm1Sug)
|
abnormal cytokine secretion
|
J:80214
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:80214
|
decreased T cell proliferation
|
J:80214
|
Tnfsf8tm1Pod/Tnfsf8tm1Pod
(B6.129X1-Tnfsf8tm1Pod)
|
decreased susceptibility to graft versus host disease
|
J:92723
|
Tnfsf9tm1Thw/Tnfsf9tm1Thw
(involves: 129 * C57BL/6)
|
abnormal cytotoxic T cell physiology
|
J:76373
|
Tnfsf10tm1Mjs/Tnfsf10tm1Mjs
(C.129-Tnfsf10tm1Mjs)
|
decreased susceptibility to bacterial infection
|
J:87620
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:87620
|
impaired natural killer cell mediated cytotoxicity
|
J:73948
|
liver inflammation
|
J:87620
|
Tnfsf10tm1Mjs/Tnfsf10tm1Mjs
(B6.129-Tnfsf10tm1Mjs)
|
increased IgG1 level
|
J:82145
|
increased IgG2a level
|
J:82145
|
increased interferon-gamma secretion
|
J:82145
|
increased interleukin-2 secretion
|
J:82145
|
increased susceptibility to autoimmune diabetes
|
J:82145
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:101672
|
increased susceptibility to induced arthritis
|
J:82145
|
Tnfsf11tm1Pngr/Tnfsf11tm1Pngr
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal immune system physiology
|
J:52369
|
decreased interferon-gamma secretion
|
J:52369
|
decreased interleukin-2 secretion
|
J:52369
|
decreased interleukin-4 secretion
|
J:52369
|
decreased interleukin-5 secretion
|
J:52369
|
decreased interleukin-6 secretion
|
J:52369
|
Tnfsf12tm1Ash/Tnfsf12tm1Ash
(B6.129-Tnfsf12tm1Ash)
|
abnormal cytokine secretion
|
J:104801
|
decreased interleukin-10 secretion
|
J:104801
|
increased interferon-gamma secretion
|
J:104801
|
increased interleukin-12 secretion
|
J:104801
|
increased susceptibility to bacterial infection
|
J:104801
|
Tnfsf13tm1Geha/Tnfsf13tm1Geha
(involves: 129S4/SvJae)
|
abnormal class switch recombination
|
J:88910
|
decreased IgA level
|
J:88910
|
decreased IgM level
|
J:88910
|
increased IgG level
|
J:88910
|
Tnfsf13tm1Pod/Tnfsf13+
(B6.Cg-Tnfsf13tm1Pod)
|
decreased IgA level
|
J:141374
|
Tnfsf13tm1Pod/Tnfsf13tm1Pod
(B6.Cg-Tnfsf13tm1Pod)
|
abnormal interleukin secretion
|
J:141374
|
decreased IgA level
|
J:141374
|
decreased IgG2a level
|
J:141374
|
decreased interleukin-10 secretion
|
J:141374
|
decreased interleukin-17 secretion
|
J:141374
|
decreased susceptibility to induced arthritis
|
J:141374
|
increased IgG1 level
|
J:141374
|
increased interferon-gamma secretion
|
J:141374
|
increased interleukin-4 secretion
|
J:141374
|
increased interleukin-5 secretion
|
J:141374
|
increased interleukin-13 secretion
|
J:141374
|
increased interleukin-17 secretion
|
J:141374
|
increased T cell proliferation
|
J:141374
|
Tnfsf13bM1Btlr/Tnfsf13b+
(C57BL/6J-Tnfsf13bM1Btlr)
|
decreased IgG level
|
J:220069
|
decreased IgM level
|
J:220069
|
impaired humoral immune response
|
J:220069
|
Tnfsf13bM1Btlr/Tnfsf13bM1Btlr
(C57BL/6J-Tnfsf13bM1Btlr)
|
decreased IgG level
|
J:220069
|
decreased IgM level
|
J:220069
|
impaired humoral immune response
|
J:220069
|
Tnfsf13bm2Btlr/Tnfsf13bm2Btlr
(C57BL/6J-Tnfsf13bm2Btlr)
|
decreased IgG level
|
J:220070
|
impaired humoral immune response
|
J:220070
|
Tnfsf13btm1Cleg/Tnfsf13btm1Cleg
(involves: 129S5/SvEvBrd)
|
abnormal B cell physiology
|
J:71301
|
decreased IgG level
|
J:71301
|
decreased IgM level
|
J:71301
|
Tnfsf13btm1Msc/Tnfsf13b+
(involves: 129S2/SvPas * C57BL/6)
|
decreased immunoglobulin level
|
J:71681
|
Tnfsf13btm1Msc/Tnfsf13btm1Msc
(involves: 129S2/SvPas * C57BL/6)
|
abnormal humoral immune response
|
J:71681
|
decreased immunoglobulin level
|
J:71681
|
Tnfsf13btm1Msc/Tnfsf13btm1Msc
(involves: 129S2/SvPas)
|
decreased T cell proliferation
|
J:92334
|
increased length of allograft survival
|
J:92334
|
Tnfsf14tm1Ddy/Tnfsf14tm1Ddy
(involves: 129S1/Sv * 129X1/SvJ)
|
abnormal cytotoxic T cell physiology
|
J:84366
|
abnormal T cell activation
|
J:84366
|
decreased T cell proliferation
|
J:84366
|
Tnfsf14tm1Kpf/Tnfsf14tm1Kpf
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased cytotoxic T cell cytolysis
|
J:77250
|
decreased interferon-gamma secretion
|
J:77250
|
decreased interleukin-2 secretion
|
J:77250
|
decreased interleukin-4 secretion
|
J:77250
|
decreased interleukin-10 secretion
|
J:77250
|
decreased splenocyte proliferation
|
J:77250
|
decreased T cell proliferation
|
J:77250
|
Tnfsf14tm1Lpc/Tnfsf14tm1Lpc
(involves: 129X1/SvJ * C57BL/6)
|
abnormal cytotoxic T cell physiology
|
J:76414
|
decreased cytotoxic T cell cytolysis
|
J:76414
|
decreased inflammatory response
|
J:107803
|
decreased interferon-gamma secretion
|
J:76414
|
decreased tumor necrosis factor secretion
|
J:76414
|
Tnfsf14tm1Wwh/Tnfsf14tm1Wwh
(involves: 129 * C57BL/6)
|
increased length of allograft survival
|
J:75705
|
Tnfsf15tm1Cdon/Tnfsf15tm1Cdon
(B6.129-Tnfsf15tm1Cdon)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:136280
|
Tnfsf15tm1Hluo/Tnfsf15tm1Hluo
(D1LacJ.129(B6)-Tnfsf15tm1Hluo)
|
decreased IgG2a level
|
J:207029
|
decreased IgG2b level
|
J:207029
|
decreased IgG level
|
J:207029
|
decreased susceptibility to induced arthritis
|
J:207029
|
Tnip1Gt(E059E05)Wrst/Tnip1Gt(E059E05)Wrst
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased interleukin-12 secretion
|
J:180054
|
decreased interleukin-12b secretion
|
J:180054
|
glomerulonephritis
|
J:180054
|
increased anti-double stranded DNA antibody level
|
J:180054
|
increased anti-nuclear antigen antibody level
|
J:180054
|
increased IgA level
|
J:180054
|
increased IgG1 level
|
J:180054
|
increased IgG2b level
|
J:180054
|
increased IgM level
|
J:180054
|
increased susceptibility to systemic lupus erythematosus
|
J:180054
|
Tnip1m1Btlr/Tnip1m1Btlr
(C57BL/6J-Tnip1m1Btlr)
|
increased anti-double stranded DNA antibody level
|
J:265175
|
increased IgA level
|
J:265175
|
increased IgE level
|
J:265175
|
increased susceptibility to induced colitis
|
J:265175
|
Tnip1tm1.1Pcoh/Tnip1+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:176826
|
Tnip1tm1.1Pcoh/Tnip1tm1.1Pcoh
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal complement pathway
|
J:176826
|
glomerulonephritis
|
J:176826
|
increased anti-double stranded DNA antibody level
|
J:176826
|
increased anti-nuclear antigen antibody level
|
J:176826
|
increased B cell proliferation
|
J:176826
|
increased IgA level
|
J:176826
|
increased IgE level
|
J:176826
|
increased IgG1 level
|
J:176826
|
increased IgG2a level
|
J:176826
|
increased IgG2b level
|
J:176826
|
increased IgG3 level
|
J:176826
|
increased IgG level
|
J:176826
|
increased IgM level
|
J:176826
|
increased immunoglobulin level
|
J:176826
|
increased interleukin-6 secretion
|
J:176826
|
increased interleukin-12b secretion
|
J:176826
|
increased tumor necrosis factor secretion
|
J:176826
|
Tnip1tm1.2Ama/Tnip1tm1.2Ama Tg(Itgax-cre)1-1Reiz/0
(involves: C57BL/6 * C57BL/6J * CBA)
|
increased interleukin-6 secretion
|
J:205446
|
increased interleukin-12 secretion
|
J:205446
|
increased interleukin-23 secretion
|
J:205446
|
increased tumor necrosis factor secretion
|
J:205446
|
Tnip2tm1.1Sley/Tnip2tm1.1Sley
(involves: 129S4/SvJae * 129S8/SvEv * C57BL/6)
|
abnormal macrophage physiology
|
J:112395
|
Tnk2tm1.2Npma/Tnk2tm1.2Npma
(B6(Cg)-Tnk2tm1.2Npma)
|
abnormal T cell physiology
|
J:341740
|
increased circulating interferon-gamma level
|
J:341740
|
increased circulating interleukin-2 level
|
J:341740
|
increased interferon level
|
J:341740
|
increased interleukin level
|
J:341740
|
Tns1tm1Efu/Tns1tm1Efu
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
tubulointerstitial nephritis
|
J:39202
|
Tns2nph/Tns2nph
(involves: ICR)
|
glomerulonephritis
|
J:108691
|
Tob2tm1Tya/Tob2tm1Tya
(involves: 129S4/SvJae * C57BL/6)
|
abnormal osteoclast physiology
|
J:134287
|
Tolliptm1Kbns/Tolliptm1Kbns
(involves: C57BL/6)
|
decreased circulating interleukin-6 level
|
J:105514
|
decreased interleukin-6 secretion
|
J:105514
|
decreased tumor necrosis factor secretion
|
J:105514
|
Tom1l2Gt(XG909)Byg/Tom1l2+
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased susceptibility to infection
|
J:133892
|
Tom1l2Gt(XG909)Byg/Tom1l2Gt(XG909)Byg
(involves: 129P2/OlaHsd * C57BL/6J)
|
abnormal humoral immune response
|
J:133892
|
abnormal immune system physiology
|
J:133892
|
abnormal inflammatory response
|
J:133892
|
conjunctivitis
|
J:133892
|
dermatitis
|
J:133892
|
increased inflammatory response
|
J:133892
|
increased susceptibility to bacterial infection
|
J:133892
|
increased susceptibility to infection
|
J:133892
|
Tomm5Gt(OST44663)Lex/Tomm5Gt(OST44663)Lex
(involves: 129S5/SvEvBrd * C57BL/6)
|
lung inflammation
|
J:186382
|
Top3btm1Jcw/Top3btm1Jcw
(involves: 129S6/SvEvTac * C57BL/6)
|
dermatitis
|
J:69405
|
glomerulonephritis
|
J:69405
|
increased inflammatory response
|
J:69405
|
pancreas inflammation
|
J:69405
|
stomach inflammation
|
J:69405
|
Toxtm1.1Kay/Toxtm1.1Kay
(involves: 129S6/SvEvTac)
|
decreased cytotoxic T cell cytolysis
|
J:131287
|
Tpcn1tm1.1Dren/Tpcn1tm1.1Dren Tpcn2tm1.1Dren/Tpcn2tm1.1Dren
(Not Specified)
|
abnormal macrophage physiology
|
J:189070
|
Tpp2Gt(OST432061)Lex/Tpp2Gt(OST432061)Lex
(B6.129S5-Tpp2Gt(OST432061)Lex)
|
abnormal level of surface class I molecules
|
J:157195
|
Tpp2Gt(OST432061)Lex/Tpp2Gt(OST432061)Lex
(involves: 129S5/SvEvBrd * C57BL/6)
|
abnormal antigen presentation
|
J:157195
|
Tpp2tm1.1Gnie/Tpp2tm1.1Gnie
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal cytotoxic T cell physiology
|
J:133572
|
increased T cell apoptosis
|
J:133572
|
Tpp2tm1.1Gnie/Tpp2tm1.1Gnie
(involves: 129S6/SvEvTac)
|
abnormal lymphocyte physiology
|
J:221205
|
increased anti-nuclear antigen antibody level
|
J:221205
|
increased autoantibody level
|
J:221205
|
Tpsab1m1/Tpsab1m1 Tpsb2tm1(cre)Adch/Tpsb2tm1(cre)Adch
(B6.Cg-Tpsb2tm1(cre)Adch Tpsab1m1)
|
decreased susceptibility to induced arthritis
|
J:142880
|
Tpsb2tm1(cre)Adch/Tpsb2tm1(cre)Adch
(B6.Cg-Tpsb2tm1(cre)Adch)
|
increased susceptibility to bacterial infection
|
J:124554
|
Tpsb2tm1.1Mfg/Tpsb2tm1.1Mfg
(B6.129-Tpsb2tm1.1Mfg)
|
decreased susceptibility to induced arthritis
|
J:142880
|
impaired eosinophil recruitment
|
J:133373
|
impaired neutrophil chemotaxis
|
J:142880
|
increased susceptibility to parasitic infection
|
J:133373
|
Tpsg1tm1.2Rls/Tpsg1tm1.2Rls
(involves: C57BL/6 * C57BL/6NTac)
|
decreased susceptibility to colitis induced morbidity/mortality
|
J:243813
|
Tpx2Gt(D028B03)Wrst/Tpx2+
(involves: 129S2/SvPas * C57BL/6J)
|
granulomatous inflammation
|
J:184948
|
Traddtm1.1Mak/Tradd+
(either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * FVB/N))
|
decreased acute inflammation
|
J:138824
|
Traddtm1.1Mak/Traddtm1.1Mak
(either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * FVB/N))
|
decreased acute inflammation
|
J:138824
|
decreased circulating interleukin-6 level
|
J:138824
|
decreased inflammatory response
|
J:138824
|
decreased interleukin-6 secretion
|
J:138824
|
Traddtm1.1Mpa/Traddtm1.1Mpa
(involves: C57BL/6)
|
decreased interferon-beta secretion
|
J:136289
|
Traddtm1.1Mpa/Traddtm1.1Mpa
(involves: BALB/cJ * C57BL/6)
|
abnormal interleukin level
|
J:139030
|
decreased circulating tumor necrosis factor level
|
J:139030
|
decreased IgG level
|
J:139030
|
increased susceptibility to bacterial infection
|
J:139030
|
Traf1tm1Tsi/Traf1tm1Tsi
(involves: 129S4/SvJae * C57BL/6)
|
increased T cell proliferation
|
J:72327
|
Traf2tm1Mak/Traf2tm1Mak
(either: (involves: 129P2/OlaHsd * C57BL/6J) or (involves: 129P2/OlaHsd * BALB/c * C57BL/6J))
|
increased circulating tumor necrosis factor level
|
J:44360
|
increased thymocyte apoptosis
|
J:44360
|
Traf3m1Btlr/Traf3m1Btlr
(C57BL/6J-Traf3m1Btlr)
|
impaired humoral immune response
|
J:212064
|
Traf3m2Btlr/Traf3m2Btlr
(C57BL/6J-Traf3m2Btlr)
|
decreased IgG level
|
J:217797
|
decreased response to antigen
|
J:217797
|
Traf3tm1Bal/Traf3tm1Bal
(involves: 129S4/SvJae * C57BL/6J)
|
abnormal T cell physiology
|
J:37065
|
Traf3tm1Bshp/Traf3tm1Bshp Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * SJL)
|
abnormal adaptive immunity
|
J:124329
|
abnormal immune system physiology
|
J:124329
|
autoimmune response
|
J:124329
|
decreased B cell apoptosis
|
J:124329
|
increased anti-double stranded DNA antibody level
|
J:124329
|
increased IgA level
|
J:124329
|
increased IgG2a level
|
J:124329
|
increased IgG2b level
|
J:124329
|
increased IgG3 level
|
J:124329
|
increased IgG level
|
J:124329
|
increased IgM level
|
J:124329
|
Traf3ip2adjm/Traf3ip2adjm
(KOR-Traf3ip2adjm)
|
dermatitis
|
J:162859
|
increased IgE level
|
J:162859
|
Traf3ip2adjm/Traf3ip2adjm
(A.KOR-Traf3ip2adjm)
|
dermatitis
|
J:162859
|
increased IgE level
|
J:162859
|
Traf3ip2adjm/Traf3ip2adjm
(B6.KOR-Traf3ip2adjm)
|
dermatitis
|
J:162859
|
increased IgE level
|
J:162859
|
Traf3ip2adjm/Traf3ip2adjm
(C.KOR-Traf3ip2adjm)
|
dermatitis
|
J:162859
|
increased IgE level
|
J:162859
|
Traf3ip2adjm/Traf3ip2adjm
(AK.KOR-Traf3ip2adjm)
|
dermatitis
|
J:162859
|
increased IgE level
|
J:162859
|
Traf3ip2tm1.1Lix/Traf3ip2tm1.1Lix
(involves: 129/Sv * BALB/c)
|
abnormal immune system physiology
|
J:93923
|
increased anti-double stranded DNA antibody level
|
J:93923
|
increased anti-histone antibody level
|
J:93923
|
increased anti-single stranded DNA antibody level
|
J:93923
|
increased autoantibody level
|
J:93923
|
increased IgE level
|
J:93923
|
increased IgG level
|
J:93923
|
increased immunoglobulin level
|
J:93923
|
increased inflammatory response
|
J:93923
|
respiratory system inflammation
|
J:93923
|
Traf3ip2tm1.1Lix/Traf3ip2tm1.1Lix
(C.129-Traf3ip2tm1.1Lix)
|
blepharitis
|
J:138560
|
glomerulonephritis
|
J:138560
|
increased autoantibody level
|
J:138560
|
increased inflammatory response
|
J:138560
|
kidney inflammation
|
J:138560
|
lacrimal gland inflammation
|
J:138560
|
parotid gland inflammation
|
J:138560
|
stomatitis
|
J:138560
|
submandibular gland inflammation
|
J:138560
|
Traf3ip2tm1.1Lix/Traf3ip2tm1.1Lix
(B6.129-Traf3ip2tm1.1Lix)
|
increased anti-chromatin antibody level
|
J:187766
|
increased anti-double stranded DNA antibody level
|
J:187766
|
increased anti-histone antibody level
|
J:187766
|
increased anti-nuclear antigen antibody level
|
J:187766
|
increased autoantibody level
|
J:187766
|
increased IgG1 level
|
J:187766
|
increased IgG2c level
|
J:187766
|
increased IgG level
|
J:187766
|
Traf3ip2tm1.1Lix/Traf3ip2tm1.1Lix Tnfsf13btm1Msc/Tnfsf13btm1Msc
(involves: 129 * 129S2/SvPas * BALB/c)
|
increased autoantibody level
|
J:138560
|
Traf3ip2tm1Lix/Traf3ip2tm1.1Lix Tg(CD19-cre/ERT2)1Cgn/0
(involves: 129/Sv * BALB/c)
|
increased immunoglobulin level
|
J:93923
|
Traf3ip2tm1Sbn/Traf3ip2tm1Sbn
(either: B6.129-Traf3ip2tm1Sbn or (involves: 129) or (involves: 129 * BALB/c))
|
abnormal cytokine secretion
|
J:144320
|
decreased interleukin-6 secretion
|
J:144320
|
decreased susceptibility to autoimmune disorder
|
J:144320
|
impaired eosinophil recruitment
|
J:144320
|
impaired macrophage chemotaxis
|
J:144320
|
impaired neutrophil recruitment
|
J:144320
|
Traf3ip2tm1Sbn/Traf3ip2tm1Sbn
(involves: 129 * C57BL/6)
|
decreased inflammatory response
|
J:191090
|
Traf4tm1Lind/Traf4tm1Lind
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
lung inflammation
|
J:74252
|
Traf4tm1Mrio/Traf4tm1Mrio
(involves: 129X1/SvJ)
|
abnormal dendritic cell physiology
|
J:142780
|
Traf4tm2Lind/Traf4tm2Lind
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
lung inflammation
|
J:74252
|
Traf5tm1Hna/Traf5tm1Hna
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
|
abnormal B cell proliferation
|
J:57114
|
abnormal humoral immune response
|
J:57114
|
abnormal T cell proliferation
|
J:57114
|
decreased IgG1 level
|
J:57114
|
decreased IgM level
|
J:57114
|
Traf6tm1.1Mpa/Traf6tm1.1Mpa Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased circulating interleukin-6 level
|
J:145306
|
Traf6tm1Mak/Traf6tm1Mak
(involves: 129P3/J)
|
abnormal macrophage physiology
|
J:54467
|
abnormal osteoclast physiology
|
J:54467
|
decreased B cell proliferation
|
J:54467
|
decreased tumor necrosis factor secretion
|
J:54467
|
Traf6tm1Ywc/Traf6tm1Ywc
(Not Specified)
|
abnormal dendritic cell physiology
|
J:85808
|
decreased interleukin-6 secretion
|
J:85808
|
decreased interleukin-12 secretion
|
J:85808
|
Traf6tm2a(EUCOMM)Wtsi/Traf6tm2a(EUCOMM)Wtsi
(C57BL/6N-Traf6tm2a(EUCOMM)Wtsi/Wtsi)
|
blood in lymph vessels
|
J:239583
|
Traf6tm2Ywc/Traf6tm2Ywc Tg(Cd4-cre)1Cwi/?
(involves: C57BL/6 * DBA/2)
|
abnormal lymphocyte anergy
|
J:130882
|
Trafd1tm1Ayos/Trafd1tm1Ayos
(involves: 129 * C57BL/6J)
|
decreased susceptibility to Riboviria infection
|
J:144594
|
increased circulating interleukin-6 level
|
J:144594
|
increased interleukin-6 secretion
|
J:144594
|
increased interleukin-12 secretion
|
J:144594
|
increased susceptibility to endotoxin shock
|
J:144594
|
increased tumor necrosis factor secretion
|
J:144594
|
Traj18em1Hwata/Traj18em1Hwata
(C57BL/6-Traj18em1Hwata)
|
abnormal cytokine secretion
|
J:256533
|
Traj18em1Hwata/Traj18em1Hwata
(C.B6-Traj18em1Hwata)
|
abnormal cytokine secretion
|
J:256533
|
Traj18tm1.1Kro/Traj18tm1.1Kro
(involves: C57BL/6NTac)
|
abnormal circulating interleukin-4 level
|
J:232957
|
abnormal interferon-gamma secretion
|
J:232957
|
decreased inflammatory response
|
J:232957
|
Trap1Gt(E150H04)Wrst/Trap1Gt(E150H04)Wrst
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased inflammatory response
|
J:226880
|
Trappc9tm1a(EUCOMM)Wtsi/Trappc9tm1a(EUCOMM)Wtsi
(C57BL/6N-Trappc9tm1a(EUCOMM)Wtsi/Wtsi)
|
blood in lymph vessels
|
J:239583
|
Trem1tm1(KOMP)Vlcg/Trem1tm1(KOMP)Vlcg
(C57BL/6N-Trem1tm1(KOMP)Vlcg/Wtsi)
|
increased anti-nuclear antigen antibody level
|
J:211773
|
Trem2em2Bwef/Trem2em2Bwef
(involves: C57BL/6J * DBA/2J * FVB/N)
|
decreased macrophage proliferation
|
J:242126
|
decreased microglial cell activation
|
J:242126
|
impaired macrophage phagocytosis
|
J:242126
|
increased circulating interleukin-6 level
|
J:242126
|
increased circulating tumor necrosis factor level
|
J:242126
|
increased macrophage apoptosis
|
J:242126
|
increased susceptibility to endotoxin shock
|
J:242126
|
Trem2tm1(KOMP)Vlcg/Trem2tm1(KOMP)Vlcg
(C57BL/6N-Trem2tm1(KOMP)Vlcg)
|
abnormal microglial cell physiology
|
J:239381
|
decreased microglial cell activation
|
J:239381
|
Trem2tm1Cln/Trem2tm1Cln
(B6.129P2-Trem2tm1Cln)
|
abnormal interferon level
|
J:138057
|
abnormal interleukin level
|
J:138057
|
abnormal tumor necrosis factor level
|
J:138057
|
Treml1tm1Mcvic/Treml1tm1Mcvic
(C57BL/6-Treml1tm1Mcvic)
|
increased susceptibility to endotoxin shock
|
J:150578
|
increased tumor necrosis factor secretion
|
J:150578
|
Trex1em3Gpt/Trex1em3Gpt
(C57BL/6JGpt-Trex1em3Gpt)
|
increased circulating tumor necrosis factor level
|
J:330879
|
increased susceptibility to autoimmune disorder
|
J:330879
|
Trex1tm1.1Fwpe/Trex1tm1.1Fwpe
(involves: 129S1/SvImJ * 129S4/SvJae * 129S6/SvEvTac)
|
abnormal T cell activation
|
J:220965
|
bronchiolitis
|
J:220965
|
glomerulonephritis
|
J:220965
|
heart inflammation
|
J:220965
|
increased anti-double stranded DNA antibody level
|
J:220965
|
increased IgG level
|
J:220965
|
increased inflammatory response
|
J:220965
|
increased susceptibility to systemic lupus erythematosus
|
J:220965
|
lacrimal gland inflammation
|
J:220965
|
pancreas inflammation
|
J:220965
|
salivary gland inflammation
|
J:220965
|
tubulointerstitial nephritis
|
J:220965
|
Trex1tm1Tld/Trex1tm1Tld
(involves: 129P2/OlaHsd)
|
abnormal interferon secretion
|
J:234263
|
heart inflammation
|
J:202757
|
increased autoantibody level
|
J:202757
|
myocarditis
|
J:92264
|
skin inflammation
|
J:202757
|
Trex1tm1Tld/Trex1tm1Tld
(involves: 129P2/OlaHsd * C57BL/6)
|
dermatitis
|
J:181257
|
folliculitis
|
J:181257
|
glomerulonephritis
|
J:181257
|
increased anti-nuclear antigen antibody level
|
J:181257
|
increased IgG level
|
J:181257
|
increased inflammatory response
|
J:181257
|
increased susceptibility to systemic lupus erythematosus
|
J:181257
|
kidney inflammation
|
J:181257
|
myocarditis
|
J:181257
|
myositis
|
J:181257
|
skin inflammation
|
J:181257
|
stomach inflammation
|
J:181257
|
Trex1tm1Tld/Trex1tm1Tld
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6N)
|
heart inflammation
|
J:234263
|
increased autoantibody level
|
J:234263
|
increased inflammatory response
|
J:234263
|
kidney inflammation
|
J:234263
|
myositis
|
J:234263
|
stomach inflammation
|
J:234263
|
Trex1tm1Tld/Trex1tm1Tld
(involves: 129P2/OlaHsd * C57BL/6J)
|
dermatitis
|
J:243357
|
increased susceptibility to autoimmune disorder
|
J:243357
|
Tria4STS/A/?
(involves: BALB/c * STS/A)
|
abnormal leukocyte physiology
|
J:56029
|
Tria5STS/A/?
(involves: BALB/cHeA * STS/A)
|
abnormal leukocyte physiology
|
J:56029
|
Trib1tm1Aki/Trib1tm1Aki
(involves: 129P2/OlaHsd)
|
decreased interleukin-12 secretion
|
J:126085
|
Trib3tm1Tord/Trib3tm1Tord
(involves: C57BL/6)
|
abnormal mast cell physiology
|
J:192615
|
decreased mast cell degranulation
|
J:192615
|
Triltm1.1Kaf/Triltm1.1Kaf
(involves: C57BL/6)
|
abnormal chemokine secretion
|
J:301765
|
abnormal cytokine secretion
|
J:301765
|
decreased interferon-beta secretion
|
J:301765
|
decreased interleukin-6 secretion
|
J:301765
|
decreased tumor necrosis factor secretion
|
J:301765
|
Trim6em1Raj/Trim6em1Raj
(C57BL/6J-Trim6em1Raj)
|
abnormal response to infection
|
J:326927
|
Trim7em1Jiew/Trim7em1Jiew
(C57BL/6-Trim7em1Jiew)
|
decreased susceptibility to Herpesvirales infection
|
J:292408
|
decreased susceptibility to viral infection
|
J:292408
|
Trim8tm1Hbsh/Trim8tm1Hbsh
(involves: 129S6/SvEvTac)
|
abnormal chemokine secretion
|
J:251270
|
abnormal circulating chemokine level
|
J:251270
|
decreased interleukin-6 secretion
|
J:251270
|
decreased tumor necrosis factor secretion
|
J:251270
|
increased circulating interleukin-6 level
|
J:251270
|
increased circulating tumor necrosis factor level
|
J:251270
|
increased interferon-beta secretion
|
J:251270
|
increased interleukin-6 secretion
|
J:251270
|
increased macrophage cytokine production
|
J:251270
|
increased susceptibility to bacterial infection
|
J:251270
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:251270
|
increased susceptibility to endotoxin shock
|
J:251270
|
increased tumor necrosis factor secretion
|
J:251270
|
Trim13tm1.1Jskg/Trim13tm1.1Jskg
(B6.129S7(Cg)-Trim13tm1.1Jskg)
|
abnormal circulating interferon level
|
J:243916
|
decreased circulating interferon-beta level
|
J:243916
|
decreased susceptibility to Picornaviridae infection induced morbidity/mortality
|
J:243916
|
increased interferon-beta secretion
|
J:243916
|
Trim14em1Rfw/Trim14em1Rfw
(involves: C57BL/6J)
|
decreased interferon-beta secretion
|
J:249057
|
increased susceptibility to Herpesvirales infection
|
J:249057
|
increased susceptibility to Herpesvirales infection induced morbidity/mortality
|
J:249057
|
Trim21tm1Mwah/Trim21+
(C57BL/6-Trim21tm1Mwah)
|
dermatitis
|
J:151775
|
Trim21tm1Mwah/Trim21tm1Mwah
(C57BL/6-Trim21tm1Mwah)
|
abnormal interleukin level
|
J:151775
|
abnormal T cell activation
|
J:151775
|
abnormal tumor necrosis factor level
|
J:151775
|
autoimmune response
|
J:151775
|
dermatitis
|
J:151775
|
increased autoantibody level
|
J:151775
|
increased inflammatory response
|
J:151775
|
Trim25tm1Mura/Trim25+ Usp15L749R/Usp15+
(involves: 129S1/SvImJ * 129S4/SvJae * C57BL/6J)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:259382
|
decreased susceptibility to parasitic infection induced morbidity/mortality
|
J:259382
|
Trim25tm1Mura/Trim25tm1Mura
(involves: 129S4/SvJae)
|
decreased susceptibility to parasitic infection
|
J:259382
|
decreased susceptibility to parasitic infection induced morbidity/mortality
|
J:259382
|
Trim27Gt(345D11)Cmhd/Trim27Gt(345D11)Cmhd
(B6.129-Trim27Gt(345D11)Cmhd)
|
abnormal T-helper 1 physiology
|
J:180433
|
abnormal T-helper 2 physiology
|
J:180433
|
increased interferon-gamma secretion
|
J:180433
|
increased tumor necrosis factor secretion
|
J:180433
|
Trim29tm1a(EUCOMM)Wtsi/Trim29tm1a(EUCOMM)Wtsi
(involves: C57BL/6N * C57BL/6NTac)
|
abnormal interferon secretion
|
J:349246
|
abnormal tumor necrosis factor level
|
J:349246
|
decreased interleukin level
|
J:349246
|
decreased susceptibility to Picornaviridae infection
|
J:349246
|
decreased susceptibility to Picornaviridae infection induced morbidity/mortality
|
J:349246
|
increased interferon level
|
J:349246
|
increased interferon-alpha secretion
|
J:349246
|
increased interferon-beta secretion
|
J:349246
|
Trim29tm1c(EUCOMM)Wtsi/Trim29tm1c(EUCOMM)Wtsi Tg(Myh6-cre)2182Mds/0
(involves: C57BL/6J * C57BL/6N * C57BL/6NTac)
|
abnormal tumor necrosis factor level
|
J:349246
|
decreased inflammatory response
|
J:349246
|
decreased interleukin level
|
J:349246
|
decreased susceptibility to Picornaviridae infection
|
J:349246
|
decreased susceptibility to Picornaviridae infection induced morbidity/mortality
|
J:349246
|
increased interferon level
|
J:349246
|
increased interferon-gamma secretion
|
J:349246
|
increased T cell proliferation
|
J:349246
|
Trim30atm1Yjk/Trim30atm1Yjk
(B6.129P2-Trim30atm1Yjk)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:215171
|
increased T cell proliferation
|
J:215171
|
Trim31em1Cya/Trim31em1Cya
(involves: C57BL/6)
|
abnormal circulating cytokine level
|
J:243237
|
decreased susceptibility to induced colitis
|
J:243237
|
increased circulating interleukin-1 beta level
|
J:243237
|
Trim35em1Smoc/Trim35em1Smoc
(C57BL/6J-Trim35em1Smoc)
|
decreased circulating interferon-beta level
|
J:303214
|
decreased macrophage cytokine production
|
J:303214
|
increased susceptibility to Orthomyxoviridae infection
|
J:303214
|
increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality
|
J:303214
|
Trim38tm1(KOMP)Vlcg/Trim38tm1(KOMP)Vlcg
(involves: C57BL/6N)
|
increased circulating interferon-alpha level
|
J:239773
|
increased circulating interferon-beta level
|
J:239773
|
increased circulating interleukin-6 level
|
J:239773
|
increased circulating tumor necrosis factor level
|
J:239773
|
increased susceptibility to bacterial infection
|
J:239773
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:239773
|
increased susceptibility to infection induced morbidity/mortality
|
J:239773
|
Trim40em1Caox/Trim40em1Caox
(involves: C57BL/6J)
|
abnormal immune system physiology
|
J:255265
|
abnormal macrophage physiology
|
J:255265
|
decreased susceptibility to Riboviria infection induced morbidity/mortality
|
J:255265
|
Trim41tm1Caox/Trim41tm1Caox
(B6.Cg-Trim41tm1Caox)
|
abnormal innate immunity
|
J:340065
|
abnormal tumor necrosis factor level
|
J:340065
|
decreased circulating interferon-beta level
|
J:340065
|
decreased circulating interleukin-6 level
|
J:340065
|
decreased interferon level
|
J:340065
|
decreased interleukin level
|
J:340065
|
increased susceptibility to bacterial infection
|
J:340065
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:340065
|
increased susceptibility to Herpesvirales infection
|
J:340065
|
increased susceptibility to Herpesvirales infection induced morbidity/mortality
|
J:340065
|
increased susceptibility to Riboviria infection
|
J:340065
|
increased susceptibility to Riboviria infection induced morbidity/mortality
|
J:340065
|
Trim45tm1a(KOMP)Wtsi/Trim45tm1a(KOMP)Wtsi
(B6Brd;B6Dnk;B6N-Trim45tm1a(KOMP)Wtsi Tyrc-Brd/Wtsi)
|
blood in lymph vessels
|
J:239583
|
Trim55tm1Slbt/Trim55tm1Slbt
(involves: 129 * C57BL/6)
|
decreased susceptibility to Coronaviridae infection
|
J:268979
|
Trim58tm2313.1Arte/Trim58tm2313.1Arte Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * C57BL/6N)
|
increased susceptibility to induced colitis
|
J:279270
|
Trim58tm2313.2Arte/Trim58tm2313.2Arte
(involves: BALB/cJ * C57BL/6N)
|
increased susceptibility to induced colitis
|
J:279270
|
Trim65em1Cya/Trim65em1Cya
(involves: C57BL/6)
|
decreased circulating interferon-alpha level
|
J:240099
|
decreased circulating interferon-beta level
|
J:240099
|
decreased interferon-alpha secretion
|
J:240099
|
decreased interferon-beta secretion
|
J:240099
|
increased susceptibility to Picornaviridae infection
|
J:240099
|
increased susceptibility to Picornaviridae infection induced morbidity/mortality
|
J:240099
|
Trim65em2Cya/Trim65em2Cya
(involves: C57BL/6)
|
decreased interferon-beta secretion
|
J:240099
|
Trim65em3Cya/Trim65em3Cya
(involves: C57BL/6)
|
decreased interferon-beta secretion
|
J:240099
|
Trip10tm1.1Geha/Trip10tm1.1Geha
(B6.129S1-Trip10tm1.1Geha)
|
abnormal T cell physiology
|
J:164363
|
decreased IgE level
|
J:164363
|
decreased IgG level
|
J:164363
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:164363
|
Trmq3FVB/N/?
(involves: DBA/1J * FVB/N)
|
abnormal T cell proliferation
|
J:94347
|
Trp53tm1.1Awbr/Trp53tm1.1Awbr
(involves: C57BL/6)
|
decreased thymocyte apoptosis
|
J:173271
|
Trp53tm1.1Thst/Trp53tm1.1Thst
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
|
decreased thymocyte apoptosis
|
J:198482
|
Trp53tm1.1Tldo/Trp53tm1.1Tldo
(involves: 129S2/SvPas * BALB/c * C57BL/6)
|
increased thymocyte apoptosis
|
J:199308
|
Trp53tm1.1Wgu/Trp53tm1.1Wgu
(involves: 129S6/SvEvTac * C57BL/6)
|
decreased thymocyte apoptosis
|
J:186159
|
Trp53tm1.2Awbr/Trp53+
(involves: C57BL/6)
|
increased inflammatory response
|
J:173271
|
liver inflammation
|
J:173271
|
Trp53tm1.2Awbr/Trp53tm1.2Awbr
(involves: C57BL/6)
|
adipose tissue inflammation
|
J:173271
|
decreased thymocyte apoptosis
|
J:173271
|
increased circulating interferon-gamma level
|
J:173271
|
increased circulating interleukin-3 level
|
J:173271
|
increased circulating interleukin-5 level
|
J:173271
|
increased circulating interleukin-6 level
|
J:173271
|
increased circulating tumor necrosis factor level
|
J:173271
|
increased inflammatory response
|
J:173271
|
increased splenocyte proliferation
|
J:173271
|
liver inflammation
|
J:173271
|
lung inflammation
|
J:173271
|
Trp53tm1Brd/Trp53tm1Brd
(involves: 129S7/SvEvBrd)
|
abnormal thymus physiology
|
J:175018
|
decreased thymocyte apoptosis
|
J:186159
|
Trp53tm1Brd/Trp53tm1Brd Trp73tm2Mak/Trp73tm2Mak
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J)
|
decreased thymocyte apoptosis
|
J:157905
|
Trp53tm1Glo/Trp53tm1Glo
(involves: 129S7/SvEvBrd * C57BL/6J)
|
decreased thymocyte apoptosis
|
J:172038
|
Trp53tm1Holl/Trp53tm7.1Xu
(involves: 129P2/OlaHsd)
|
decreased thymocyte apoptosis
|
J:160414
|
Trp53tm1Thst/Trp53tm1Thst
(involves: 129S1/Sv * 129X1/SvJ)
|
decreased thymocyte apoptosis
|
J:198482
|
Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas)
|
decreased thymocyte apoptosis
|
J:158953
|
Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * C57BL/6 * CBA)
|
decreased thymocyte apoptosis
|
J:80311
|
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas)
|
decreased splenocyte apoptosis
|
J:195018
|
decreased T cell apoptosis
|
J:109354
|
decreased thymocyte apoptosis
|
J:158953,
J:195018,
J:126920
|
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6 * CBA)
|
decreased thymocyte apoptosis
|
J:80311
|
Trp53tm1Tyj/Trp53tm1Tyj Commd10Tg(Vav1-icre)A2Kio/Commd10+
(involves: 129S2/SvPas * C57BL/6N * C57BL/10 * CBA/Ca)
|
abnormal interleukin secretion
|
J:305794
|
Trp53tm1Xu/Trp53tm1Xu
(involves: 129S4/SvJae)
|
abnormal thymocyte apoptosis
|
J:86185
|
Trp53tm1Yjc/Trp53tm1Yjc
(B6.129S1-Trp53tm1Yjc)
|
decreased splenocyte apoptosis
|
J:195018
|
Trp53tm2.1Snj/Trp53tm2.1Snj
(involves: 129S4/SvJae * C57BL/6)
|
abnormal thymus physiology
|
J:175018
|
Trp53tm2.1Wgu/Trp53tm2.1Wgu
(involves: 129S6/SvEvTac * C57BL/6)
|
decreased thymocyte apoptosis
|
J:186159
|
Trp53tm2Xu/Trp53tm2Xu
(involves: 129S6/SvEvTac)
|
decreased T cell apoptosis
|
J:109354
|
decreased T cell proliferation
|
J:109354
|
Trp53tm3.1Holl/Trp53tm3.1Holl
(Not Specified)
|
increased thymocyte apoptosis
|
J:191183
|
Trp53tm7.1Xu/Trp53+
(Not Specified)
|
abnormal thymus physiology
|
J:160414
|
Trp53tm7.1Xu/Trp53tm7.1Xu
(Not Specified)
|
abnormal thymus physiology
|
J:160414
|
decreased thymocyte apoptosis
|
J:160414
|
Trp53bp1m2Btlr/Trp53bp1m2Btlr
(C57BL/6J-Trp53bp1m2Btlr)
|
decreased IgD level
|
J:254841
|
decreased IgG level
|
J:254841
|
impaired humoral immune response
|
J:254841
|
Trp53bp1m3Btlr/Trp53bp1m3Btlr
(C57BL/6J-Trp53bp1m3Btlr)
|
decreased IgD level
|
J:254848
|
Trp53bp1m4Btlr/Trp53bp1m4Btlr
(C57BL/6J-Trp53bp1m4Btlr)
|
decreased IgD level
|
J:254852
|
Trp53bp1m5Btlr/Trp53bp1m5Btlr
(C57BL/6J-Trp53bp1m5Btlr)
|
decreased IgD level
|
J:272848
|
Trp53bp1tm1Jc/Trp53bp1tm1Jc
(involves: 129)
|
abnormal class switch recombination
|
J:194603,
J:231089,
J:307190
|
Trp53bp2tm1Cdlo/Trp53bp2+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal T cell physiology
|
J:146764
|
Trp53inp1tm1Acar/Trp53inp1tm1Acar
(involves: 129/Sv * C57BL/6)
|
increased susceptibility to induced colitis
|
J:118867
|
large intestinal inflammation
|
J:118867
|
Trp63tm2Brd/Trp63+
(involves: 129S7/SvEvBrd)
|
increased susceptibility to infection
|
J:100483
|
kidney inflammation
|
J:100483
|
uterine cervix inflammation
|
J:100483
|
Trp73tm1Fmc/Trp73tm1Fmc
(involves: 129S4/SvJae)
|
chronic inflammation
|
J:60896
|
conjunctivitis
|
J:60896
|
increased susceptibility to bacterial infection
|
J:60896
|
increased susceptibility to otitis media
|
J:60896
|
rhinitis
|
J:60896
|
sinus inflammation
|
J:60896
|
Trp73tm2Mak/Trp73tm2Mak
(either: B6.129P2-Trp73tm2Mak or (involves: 129P2/OlaHsd * C57BL/6J))
|
increased thymocyte apoptosis
|
J:157905
|
Trpa1tm1Jul/Trpa1+
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal acute inflammation
|
J:115886
|
Trpm2tm1.1Alp/Trpm2tm1.1Alp
(B6.129P2-Trpm2tm1.1Alp)
|
decreased circulating interferon-gamma level
|
J:174397
|
decreased circulating interleukin-12 level
|
J:174397
|
decreased circulating interleukin-12b level
|
J:174397
|
decreased interferon-gamma secretion
|
J:174397
|
decreased interleukin-12 secretion
|
J:174397
|
increased susceptibility to bacterial infection
|
J:174397
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:174397
|
Trpm2tm1Lhj/Trpm2tm1Lhj
(Not Specified)
|
abnormal macrophage physiology
|
J:202791
|
Trpm2tm1Yamo/Trpm2tm1Yamo
(involves: 129S4/SvJae * C57BL/6J)
|
abnormal interferon level
|
J:137676
|
abnormal interleukin level
|
J:137676
|
abnormal leukocyte physiology
|
J:137676
|
abnormal macrophage physiology
|
J:137676
|
decreased inflammatory response
|
J:137676
|
impaired neutrophil recruitment
|
J:137676
|
Trpm4tm1.1Knt/Trpm4tm1.1Knt
(Not Specified)
|
abnormal dendritic cell physiology
|
J:140991
|
Trpm4tm1.1Knt/Trpm4tm1.1Knt Trpm5tm1Csz/Trpm5tm1Csz
(involves: 129S1/Sv * 129X1/SvJ)
|
abnormal dendritic cell physiology
|
J:140991
|
Trpm4tm1.1Mfre/Trpm4tm1.1Mfre
(involves: 129S1/Sv * 129X1/SvJ * BALB/cJ)
|
increased susceptibility to type I hypersensitivity reaction
|
J:118679
|
Trpm7tm1Agry/Trpm7+
(involves: 129)
|
increased susceptibility to type IV hypersensitivity reaction
|
J:205665
|
Trpm7tm1Clph/Trpm7tm1.1Clph Tg(Lck-cre)548Jxm/0
(involves: 129S4/SvJae * C57BL/6 * CBA)
|
abnormal T cell physiology
|
J:140630
|
Trpv1tm1Jul/Trpv1tm1Jul
(involves: 129X1/SvJ * C57BL/6)
|
decreased susceptibility to endotoxin shock
|
J:104828
|
Trpv1tm1Jul/Trpv1tm1Jul
(B6.129X1-Trpv1tm1Jul)
|
abnormal chemokine secretion
|
J:154624
|
increased interleukin-6 secretion
|
J:154624
|
increased tumor necrosis factor secretion
|
J:154624
|
kidney inflammation
|
J:154624
|
Trpv2tm1Mijc/Trpv2tm1Mijc
(involves: 129S6/SvEvTac * C57BL/6)
|
impaired macrophage chemotaxis
|
J:158505
|
impaired macrophage phagocytosis
|
J:158505
|
increased susceptibility to bacterial infection
|
J:158505
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:158505
|
Trpv3Nh/Trpv3+
(involves: DS)
|
dermatitis
|
J:42153
|
increased susceptibility to bacterial infection
|
J:42153
|
Trpv3tm1.2Clph/Trpv3tm1.2Clph
(involves: 129S4/SvJae * 129S4/SvJaeSor * C57BL/6 * C57BL/6J * CBA)
|
erythroderma
|
J:164741
|
Trpv5Hcalc1/Trpv5+
(involves: C3H/HeH * C57BL/6J)
|
kidney inflammation
|
J:196612
|
Trpv5Hcalc1/Trpv5Hcalc1
(involves: C3H/HeH * C57BL/6J)
|
kidney inflammation
|
J:196612
|
Trpv5m1Btlr/Trpv5m1Btlr
(C57BL/6J-Trpv5m1Btlr)
|
increased susceptibility to induced colitis
|
J:192586
|
intestinal inflammation
|
J:192586
|
Tsc22d3tm1.2Efmd/Y
(Not Specified)
|
abnormal susceptibility to autoimmune disorder
|
J:201728
|
increased interferon-gamma secretion
|
J:201728
|
increased interleukin-17 secretion
|
J:201728
|
increased susceptibility to type IV hypersensitivity reaction
|
J:201728
|
Tsiq1BALB/cOla/Tsiq1BALB/cOla
(involves: BALB/cOla * C57BL/6Ola)
|
increased interleukin-4 secretion
|
J:99489
|
Tsiq1BALB/cOla/Tsiq1BALB/cOla Tsiq2BALB/cOla/Tsiq2BALB/cOla Tsiq3BALB/cOla/Tsiq3C57BL/6Ola
(involves: BALB/cOla * C57BL/6Ola)
|
increased interleukin-4 secretion
|
J:99489
|
Tsiq2BALB/cOla/Tsiq2BALB/cOla
(involves: BALB/cOla * C57BL/6Ola)
|
increased interleukin-4 secretion
|
J:99489
|
Tsiq3BALB/cOla/Tsiq3C57BL/6Ola
(involves: BALB/cOla * C57BL/6Ola)
|
increased interleukin-4 secretion
|
J:99489
|
Tslptm1(KOMP)Vlcg/Tslptm1(KOMP)Vlcg
(involves: C57BL/6 * C57BL/6NTac)
|
abnormal immune system physiology
|
J:187770
|
abnormal immunoglobulin level
|
J:187770
|
decreased acute inflammation
|
J:187770
|
decreased circulating interleukin-4 level
|
J:187770
|
increased interferon-gamma secretion
|
J:187770
|
respiratory system inflammation
|
J:187770
|
Tslptm1.1Pcn/Tslptm1.1Pcn Tg(KRT14-cre)1Ipc/0
(involves: 129 * C57BL/6 * SJL)
|
decreased IgE level
|
J:146511
|
Tslptm1Mak/Tslptm1Mak
(B6.Cg-Tslptm1Mak)
|
colitis
|
J:175844
|
Tslptm1Sfz/Tslptm1Sfz
(involves: 129)
|
abnormal interleukin secretion
|
J:197193
|
abnormal T-helper 2 physiology
|
J:197193
|
increased interleukin-5 secretion
|
J:197193
|
increased interleukin-13 secretion
|
J:197193
|
Tspan32Gt(pMS-1)1Jmt/Tspan32Gt(pMS-1)1Jmt
(involves: 129S1/Sv)
|
increased T cell proliferation
|
J:78033
|
Ttc7fsn-Jic/Ttc7fsn-Jic
(C3.INT-Ttc7fsn-Jic)
|
liver inflammation
|
J:115742
|
Ttc7fsn/Ttc7fsn
(involves: A/J)
|
stomach inflammation
|
J:2777
|
Ttc39aos1em1Bcgen/Ttc39aos1em1Bcgen
(involves: C57BL/6N)
|
increased cytokine level
|
J:307097
|
increased susceptibility to induced pancreatitis
|
J:307097
|
Ttc39aos1tm1Kaf/Ttc39aos1tm1Kaf
(C57BL/6-Ttc39aos1tm1Kaf)
|
increased susceptibility to endotoxin shock
|
J:234649
|
Ttll1Gt(OST372941)Lex/Ttll1Gt(OST372941)Lex
(involves: 129S5/SvEvBrd * C57BL/6)
|
increased susceptibility to otitis media
|
J:186050
|
rhinitis
|
J:186050
|
Ttll1tm1Seto/Ttll1tm1Seto
(involves: 129S/SvEv * C57BL/6)
|
rhinosinusitis
|
J:161297
|
Ttnmdm/Ttnmdm
(Not Specified)
|
myositis
|
J:14016
|
Ttntm1.1Isrd/Ttntm1.1Isrd
(involves: 129S2/SvPas * C57BL/6)
|
myositis
|
J:165576
|
Tubtub/Tubtub
(C57BL/6J-Tubtub)
|
abnormal Langerhans cell physiology
|
J:13772
|
Tusc2tm1Avi/Tusc2+
(involves: 129S1/Sv * C57BL/6J)
|
arteritis
|
J:119985
|
glomerulonephritis
|
J:119985
|
increased anti-nuclear antigen antibody level
|
J:119985
|
increased susceptibility to autoimmune disorder
|
J:119985
|
Tusc2tm1Avi/Tusc2tm1Avi
(involves: 129S1/Sv * C57BL/6J)
|
arteritis
|
J:119985
|
decreased interleukin-15 secretion
|
J:119985
|
glomerulonephritis
|
J:119985
|
increased anti-nuclear antigen antibody level
|
J:119985
|
increased susceptibility to autoimmune disorder
|
J:119985
|
Tusc2tm1Avi/Tusc2tm1Avi
(involves: 129S1/Sv)
|
arteritis
|
J:309768
|
chronic inflammation
|
J:309768
|
decreased T cell proliferation
|
J:309768
|
increased susceptibility to autoimmune disorder
|
J:309768
|
Tvp23bem3Eetr/Tvp23bem3Eetr
(C57BL/6J-Tvp23bem3Eetr)
|
increased susceptibility to induced colitis
|
J:340685
|
Tvp23bm1Btlr/Tvp23bm1Btlr
(C57BL/6J-Tvp23bm1Btlr)
|
increased susceptibility to induced colitis
|
J:340685
|
Twist2tm1(cre)Dor/Twist2tm1(cre)Dor
(involves: 129/Sv * 129X1/SvJ)
|
abnormal interleukin level
|
J:81485
|
abnormal tumor necrosis factor level
|
J:81485
|
Twsg1tm1Nosa/Twsg1tm1Nosa
(involves: 129P2/OlaHsd * C57BL/6)
|
increased thymocyte apoptosis
|
J:82738
|
Txktm1Pls/Txktm1Pls
(involves: 129S6/SvEvTac)
|
abnormal cytokine secretion
|
J:54449
|
increased susceptibility to parasitic infection
|
J:54449
|
Txndc2tm1Lex/Txndc2tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
|
decreased circulating interleukin-6 level
|
J:103485
|
Txniptm1Yu/Txniptm1Yu
(involves: 129)
|
abnormal NK cell physiology
|
J:96677
|
increased T cell proliferation
|
J:96677
|
Tyk2E775K/Tyk2E775K
(B10.D1-H2q/SgJ)
|
abnormal T-helper 1 physiology
|
J:69051
|
decreased IgG1 level
|
J:69051
|
decreased IgG2a level
|
J:69051
|
decreased IgG level
|
J:69051
|
decreased interferon-gamma secretion
|
J:69051,
J:120304
|
decreased susceptibility to induced arthritis
|
J:69051
|
increased circulating interleukin-12 level
|
J:120304
|
increased susceptibility to parasitic infection
|
J:120304
|
Tyk2tm1Biat/Tyk2tm1Biat
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal response to infection
|
J:116703
|
decreased interferon-gamma secretion
|
J:65408
|
decreased macrophage nitric oxide production
|
J:65408
|
increased susceptibility to Herpesvirales infection
|
J:116703
|
increased susceptibility to Herpesvirales infection induced morbidity/mortality
|
J:116703
|
increased susceptibility to Riboviria infection
|
J:65408
|
increased susceptibility to viral infection induced morbidity/mortality
|
J:65408
|
Tyk2tm1Biat/Tyk2tm1Biat
(B6NCrl.129P2-Tyk2tm1Biat)
|
increased susceptibility to Picornaviridae infection induced morbidity/mortality
|
J:187818
|
increased susceptibility to Riboviria infection induced morbidity/mortality
|
J:187818
|
Tyk2tm1Shmd/Tyk2tm1Shmd
(involves: 129P2/OlaHsd)
|
abnormal splenocyte physiology
|
J:65409
|
abnormal T cell physiology
|
J:65409
|
decreased interferon-gamma secretion
|
J:65409
|
Tyk2tm3.1Biat/Tyk2tm3.1Biat
(B6NCrl.129P2(C)-Tyk2tm3.1Biat)
|
increased susceptibility to Picornaviridae infection induced morbidity/mortality
|
J:187818
|
increased susceptibility to Riboviria infection induced morbidity/mortality
|
J:187818
|
Tymptm1Akiy/Tymptm1Akiy Upp1tm1Akiy/Upp1tm1Akiy
(involves: 129X1/SvJ)
|
brain inflammation
|
J:78036
|
Tyrobptm1.1Viv/Tyrobptm1.1Viv
(involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)
|
decreased susceptibility to type IV hypersensitivity reaction
|
J:64764
|
impaired natural killer cell mediated cytotoxicity
|
J:64764
|
Tyrobptm1.1Viv/Tyrobptm1.1Viv
(B6.129P2-Tyrobptm1.1Viv)
|
abnormal osteoclast physiology
|
J:129304,
J:95232
|
Tyrobptm1Lll/Tyrobptm1Lll
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased interferon-gamma secretion
|
J:64763
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:64763
|
decreased T cell proliferation
|
J:64763
|
impaired natural killer cell mediated cytotoxicity
|
J:64763
|
increased natural killer cell mediated cytotoxicity
|
J:64763
|
Tyrobptm1Lll/Tyrobptm1Lll
(B6.129P2-Tyrobptm1Lll)
|
abnormal NK T cell physiology
|
J:147867
|
decreased interferon-gamma secretion
|
J:147867
|
Tyrobptm1Lll/Tyrobptm1Lll
(involves: 129P2/OlaHsd)
|
decreased susceptibility to induced arthritis
|
J:158811
|
Tyrobptm1Ttk/Tyrobptm1Ttk
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal dendritic cell physiology
|
J:110786
|
abnormal osteoclast physiology
|
J:81823
|
Tyrobptm1Ttk/Tyrobptm1Ttk
(B6.129P2-Tyrobptm1Ttk)
|
increased anti-double stranded DNA antibody level
|
J:177613
|
increased autoantibody level
|
J:177613
|
increased B cell proliferation
|
J:177613
|
increased IgG2a level
|
J:177613
|
increased IgG3 level
|
J:177613
|
increased interleukin-6 secretion
|
J:177613
|
Tyrobptm1Viv/Tyrobptm1Viv
(B6.129P2-Tyrobptm1Viv)
|
increased susceptibility to Herpesvirales infection
|
J:124749
|
U90926em1Dnkv/U90926em1Dnkv
(C57BL6/J-U90926em1Dnkv)
|
increased circulating interleukin-6 level
|
J:340649
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:340649
|
increased susceptibility to endotoxin shock
|
J:340649
|
Uacatm1Kiy/Uacatm1Kiy
(B6.129P2-Uacatm1Kiy)
|
increased tumor necrosis factor secretion
|
J:157049
|
liver inflammation
|
J:157049
|
lung inflammation
|
J:157049
|
Ubash3btm1Jni/Ubash3btm1Jni Ubash3atm1Jni/Ubash3atm1Jni
(Not Specified)
|
abnormal cytokine secretion
|
J:89761
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:89761
|
increased T cell proliferation
|
J:89761
|
Ubdtm1Smwe/Ubdtm1Smwe
(B6.129S6-Ubdtm1Smwe)
|
abnormal lymphocyte physiology
|
J:110321
|
increased susceptibility to bacterial infection
|
J:110321
|
Ube2nGt(OST374154)Lex/Ube2n+
(involves: 129S5/SvEvBrd * C57BL/6)
|
abnormal leukocyte physiology
|
J:120846
|
abnormal macrophage physiology
|
J:120846
|
decreased B cell proliferation
|
J:120846
|
decreased susceptibility to endotoxin shock
|
J:120846
|
decreased T cell proliferation
|
J:120846
|
Ube2ntm1Aki/Ube2ntm1Aki Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal macrophage physiology
|
J:112287
|
Ube2stm1.1Smoc/Ube2stm1.1Smoc
(involves: C57BL/6)
|
abnormal macrophage physiology
|
J:306461
|
decreased susceptibility to Herpesvirales infection
|
J:306461
|
decreased susceptibility to Picornaviridae infection
|
J:306461
|
decreased susceptibility to Picornaviridae infection induced morbidity/mortality
|
J:306461
|
decreased susceptibility to Riboviria infection
|
J:306461
|
increased circulating interferon-alpha level
|
J:306461
|
increased circulating interferon-beta level
|
J:306461
|
increased circulating interleukin-6 level
|
J:306461
|
increased circulating tumor necrosis factor level
|
J:306461
|
increased interferon level
|
J:306461
|
increased interferon-beta secretion
|
J:306461
|
Ube3bGt(RRJ142)Byg/Ube3bGt(RRJ142)Byg
(involves: 129P2/OlaHsd * CBA/Ca)
|
eye inflammation
|
J:203652
|
Ubl7em1Fanm/Ubl7em1Fanm
(involves: C57BL/6J)
|
increased susceptibility to Orthomyxoviridae infection
|
J:349835
|
increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality
|
J:349835
|
increased susceptibility to Riboviria infection
|
J:349835
|
increased susceptibility to Riboviria infection induced morbidity/mortality
|
J:349835
|
Ucp2tm1Rcq/Ucp2tm1Rcq
(involves: 129X1/SvJ * C57BL/6J)
|
abnormal macrophage physiology
|
J:66262
|
decreased susceptibility to bacterial infection
|
J:66262
|
decreased susceptibility to infection induced morbidity/mortality
|
J:66262
|
decreased susceptibility to parasitic infection
|
J:66262
|
Uggt1tm1a(KOMP)Wtsi/Uggt1+
(involves: C57BL/6N)
|
abnormal susceptibility to Picornaviridae infection
|
J:244058
|
decreased susceptibility to Picornaviridae infection
|
J:244058
|
decreased susceptibility to Picornaviridae infection induced morbidity/mortality
|
J:244058
|
Ulk4tm1Lex/Ulk4tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
|
increased susceptibility to otitis media
|
J:185566
|
maxillary sinus inflammation
|
J:185566
|
nasal inflammation
|
J:185566
|
Umodem1Duf/Umod+
(C57BL/6J-Umodem1Duf)
|
kidney inflammation
|
J:252597
|
Umodtm1.1Rvt/Umod+
(either: B6J.129-Umodtm1.1Rvt or (involves: 129S1/Sv * 129X1/SvJ))
|
kidney inflammation
|
J:242593
|
Umodtm1.1Rvt/Umodtm1.1Rvt
(either: B6J.129-Umodtm1.1Rvt or (involves: 129S1/Sv * 129X1/SvJ))
|
kidney inflammation
|
J:242593
|
Umodtm1Xrw/Umodtm1Xrw
(involves: 129S6/SvEvTac)
|
increased susceptibility to bacterial infection
|
J:95431
|
Unc13dJinx/Unc13dJinx
(C57BL/6J-Unc13dJinx/Mmucd)
|
abnormal cytokine secretion
|
J:119974
|
abnormal macrophage physiology
|
J:105543
|
abnormal NK cell physiology
|
J:119974
|
decreased cytotoxic T cell cytolysis
|
J:119974
|
hemophagocytosis
|
J:119974
|
increased susceptibility to Herpesvirales infection
|
J:105543,
J:119974
|
increased susceptibility to Riboviria infection
|
J:105543,
J:119974
|
Unc93b13d/Unc93b13d
(C57BL/6J-Unc93b13d)
|
abnormal antigen presentation via MHC class I
|
J:105484
|
abnormal antigen presentation via MHC class II
|
J:105484
|
abnormal circulating interferon level
|
J:105484
|
abnormal dendritic cell antigen presentation
|
J:105484
|
abnormal macrophage physiology
|
J:105484
|
abnormal tumor necrosis factor secretion
|
J:105484
|
decreased interleukin-12b secretion
|
J:105484
|
increased circulating tumor necrosis factor level
|
J:105484
|
increased susceptibility to bacterial infection
|
J:105484
|
increased susceptibility to Herpesvirales infection
|
J:105484
|
Unc93b13d/Unc93b13d
(C57BL/6-Unc93b13d)
|
abnormal dendritic cell antigen presentation
|
J:159599
|
decreased interleukin-6 secretion
|
J:159599
|
decreased interleukin-12b secretion
|
J:159599
|
Unc93b1tm1(KOMP)Vlcg/Unc93b1tm1(KOMP)Vlcg
(involves: C57BL/6NTac)
|
abnormal dendritic cell antigen presentation
|
J:211069
|
abnormal dendritic cell physiology
|
J:211069
|
abnormal tumor necrosis factor level
|
J:211069
|
decreased circulating interleukin-6 level
|
J:211069
|
decreased circulating interleukin-12b level
|
J:211069
|
Unc93b1tm1.1Kmiy/Unc93b1tm1.1Kmiy
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal cytokine secretion
|
J:174308
|
decreased B cell proliferation
|
J:174308
|
decreased interferon-alpha secretion
|
J:174308
|
decreased interleukin-12b secretion
|
J:174308
|
decreased tumor necrosis factor secretion
|
J:174308
|
glomerulonephritis
|
J:174308
|
increased anti-nuclear antigen antibody level
|
J:174308
|
increased autoantibody level
|
J:174308
|
increased B cell proliferation
|
J:174308
|
increased IgG2a level
|
J:174308
|
increased IgG2b level
|
J:174308
|
increased interferon-alpha secretion
|
J:174308
|
increased interleukin-12b secretion
|
J:174308
|
increased tumor necrosis factor secretion
|
J:174308
|
liver inflammation
|
J:174308
|
Ungtm1Tld/Ungtm1Tld
(Not Specified)
|
abnormal class switch recombination
|
J:79590
|
decreased IgG3 level
|
J:79590
|
increased IgM level
|
J:79590
|
Ungtm1Tld/Ungtm1Tld
(involves: 129P2/OlaHsd)
|
abnormal class switch recombination
|
J:306598
|
abnormal somatic hypermutation frequency
|
J:155454
|
Uoxem1Cli/Uoxem1Cli
(C57BL/6J-Uoxem1Cli)
|
abnormal cytokine level
|
J:271949
|
kidney inflammation
|
J:271949
|
Uoxin/Uoxin
(involves: C57BL/6J * DBA/2J)
|
chronic inflammation
|
J:70677
|
Uoxtm1Bay/Uoxtm1Bay
(involves: 129S7/SvEvBrd * C57BL/6J)
|
tubulointerstitial nephritis
|
J:16490
|
Upf2tm1Btp/Upf2tm1Btp Tg(Mx1-cre)1Cgn/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
decreased T cell proliferation
|
J:134765
|
Upk1aem2Mgef/Upk1aem2Mgef
(C57BL/6NJNcbs-Upk1aem2Mgef)
|
epididymis inflammation
|
J:345207
|
increased susceptibility to bacterial infection
|
J:345207
|
liver inflammation
|
J:345207
|
lung inflammation
|
J:345207
|
tubulointerstitial nephritis
|
J:345207
|
urinary bladder inflammation
|
J:345207
|
Urahplt2/Urahplt2
(C57BL/6-Urahplt2)
|
increased T cell proliferation
|
J:267227
|
Uri1tm1.1Ndj/Uri1tm1.1Ndj Albtm1(cre/ERT2)Mtz/Alb+
(B6.Cg-Albtm1(cre/ERT2)Mtz Uri1tm1.1Ndj)
|
liver inflammation
|
J:217463
|
Usp4tm1Xilu/Usp4tm1Xilu
(B6.129-Usp4tm1Xilu)
|
increased splenocyte apoptosis
|
J:173192
|
increased thymocyte apoptosis
|
J:173192
|
Usp12tm1a(EUCOMM)Hmgu/Usp12tm1a(EUCOMM)Hmgu
(Not Specified)
|
decreased IgA level
|
J:165965
|
Usp13em1Nmw/Usp13em1Nmw
(B6.Cg-Usp13em1Nmw)
|
increased interleukin-1 beta secretion
|
J:285981
|
increased interleukin-6 secretion
|
J:285981
|
increased susceptibility to bacterial infection
|
J:285981
|
increased tumor necrosis factor secretion
|
J:285981
|
lung inflammation
|
J:285981
|
Usp15em1Peih/Usp15em1Peih
(involves: C57BL/6)
|
abnormal macrophage physiology
|
J:306461
|
Usp15L749R/Usp15+
(involves: 129S1/SvImJ * C57BL/6J)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:259382
|
decreased susceptibility to parasitic infection induced morbidity/mortality
|
J:259382
|
Usp15L749R/Usp15L749R
(involves: 129S1/SvImJ * C57BL/6J)
|
abnormal T-helper 1 physiology
|
J:259382
|
decreased susceptibility to bacterial infection
|
J:259382
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:259382
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:259382
|
decreased susceptibility to parasitic infection
|
J:259382
|
decreased susceptibility to parasitic infection induced morbidity/mortality
|
J:259382
|
Usp15L749R/Usp15tm1Pgrs
(involves: 129S1/SvImJ * C57BL/6J)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:259382
|
decreased susceptibility to parasitic infection induced morbidity/mortality
|
J:259382
|
Usp15tm1Pgrs/Usp15tm1Pgrs
(Not Specified)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:259382
|
decreased susceptibility to parasitic infection induced morbidity/mortality
|
J:259382
|
Usp18ity9/Usp18ity9
(involves: 129S1/SvImJ * C57BL/6)
|
decreased circulating interferon-gamma level
|
J:163843
|
decreased interferon-gamma secretion
|
J:163843
|
increased circulating interleukin-6 level
|
J:163843
|
increased interleukin-6 secretion
|
J:163843
|
increased susceptibility to bacterial infection
|
J:163843
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:163843
|
increased susceptibility to endotoxin shock
|
J:163843
|
Usp18ity9/Usp18tm1Dez
(involves: 129 * C57BL/6 * FVB/N)
|
increased susceptibility to bacterial infection
|
J:163843
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:163843
|
Usp18tm1Dez/Usp18tm1Dez
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal cytokine level
|
J:214425
|
decreased circulating interferon-alpha level
|
J:214425
|
decreased circulating interferon-beta level
|
J:214425
|
decreased circulating interferon-gamma level
|
J:214425
|
decreased susceptibility to Coronaviridae infection
|
J:214425
|
Usp20em1Dalin/Usp20em1Dalin
(involves: C57BL/6)
|
abnormal circulating chemokine level
|
J:274572
|
decreased circulating interferon-beta level
|
J:274572
|
decreased circulating interleukin-6 level
|
J:274572
|
decreased interferon-beta secretion
|
J:274572
|
decreased tumor necrosis factor secretion
|
J:274572
|
increased susceptibility to Herpesvirales infection
|
J:274572
|
increased susceptibility to Herpesvirales infection induced morbidity/mortality
|
J:274572
|
Usp21tm1.1Jhy/Usp21tm1.1Jhy
(B6.129S7(Cg)-Usp21tm1.1Jhy)
|
abnormal interferon level
|
J:208320
|
decreased susceptibility to Riboviria infection
|
J:208320
|
decreased susceptibility to Riboviria infection induced morbidity/mortality
|
J:208320
|
increased circulating interferon-alpha level
|
J:208320
|
increased circulating interferon-beta level
|
J:208320
|
Usp25Gt(RRS805)Byg/Usp25Gt(RRS805)Byg
(involves: 129P2/OlaHsd)
|
decreased interferon-gamma secretion
|
J:188557
|
increased interleukin-6 secretion
|
J:188557
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:188557
|
lung inflammation
|
J:188557
|
Usp38em1Cya/Usp38em1Cya
(C57BL/6-Usp38em1Cya)
|
lung inflammation
|
J:321973
|
Usp49em1Gpt/Usp49em1Gpt
(involves: C57BL/6NGpt)
|
decreased susceptibility to Herpesvirales infection
|
J:285681
|
decreased susceptibility to Herpesvirales infection induced morbidity/mortality
|
J:285681
|
increased circulating interferon-beta level
|
J:285681
|
increased circulating interleukin-6 level
|
J:285681
|
increased interferon-beta secretion
|
J:285681
|
increased interleukin-6 secretion
|
J:285681
|
UvragTn(pb-Act-RFP)1.100107015-HRAZhu/UvragTn(pb-Act-RFP)1.100107015-HRAZhu
(involves: FVB/NJ)
|
abnormal interleukin level
|
J:219546
|
abnormal tumor necrosis factor level
|
J:219546
|
heart inflammation
|
J:219546
|
Uxs1tm1Lex/Uxs1+
(B6;129S5-Uxs1tm1Lex/Mmucd)
|
abnormal humoral immune response
|
J:171883
|
increased IgG1 level
|
J:171883
|
Vamp8Gt(OST20346)Lex/Vamp8Gt(OST20346)Lex
(involves: 129S5/SvEvBrd * C57BL/6)
|
abnormal mast cell physiology
|
J:131926
|
Vamp8tm1Hong/Vamp8tm1Hong
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal dendritic cell physiology
|
J:131528
|
abnormal type I hypersensitivity reaction
|
J:133439
|
decreased mast cell degranulation
|
J:133439
|
Varc/Varc+
(C3H/HeJ-Varc/J)
|
increased susceptibility to otitis media
|
J:241135
|
Varc/Varc+
(C3OuJ.C3-Varc/Kjn)
|
increased susceptibility to otitis media
|
J:241135
|
Vav1m1Btlr/Vav1m1Btlr
(C57BL/6J-Vav1m1Btlr)
|
abnormal humoral immune response
|
J:265128
|
decreased IgD level
|
J:265128
|
decreased IgG level
|
J:265128
|
increased IgM level
|
J:265128
|
Vav1M3Btlr/Vav1M3Btlr
(C57BL/6J-Vav1M3Btlr)
|
decreased IgG level
|
J:272527
|
impaired humoral immune response
|
J:272527
|
Vav1tm1Tyb/Vav1tm1Tyb
(involves: 129S2/SvPas * 129S8/SvEv)
|
abnormal T cell physiology
|
J:113270
|
decreased T cell proliferation
|
J:113270
|
Vav1tm1Tyb/Vav1tm1Tyb
(involves: 129S2/SvPas)
|
abnormal T cell physiology
|
J:86654,
J:79323
|
decreased interferon-gamma secretion
|
J:86654
|
decreased interleukin-2 secretion
|
J:86654
|
decreased T cell proliferation
|
J:86654
|
Vav1tm1Tyb/Vav1tm1Tyb
(involves: 129S2/SvPas * C57BL/10 * C57BR/cd)
|
abnormal T cell physiology
|
J:128985
|
decreased interleukin-2 secretion
|
J:128985
|
decreased T cell proliferation
|
J:128985
|
decreased tumor necrosis factor secretion
|
J:128985
|
Vav1tm1Tyb/Vav1tm1Tyb
(either: (involves: 129S4/SvJae * 129S8/SvEv) or (involves: 129S4/SvJae * 129S8/SvEv * C57BL/10 * C57BR/cd))
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:190087
|
abnormal immune system physiology
|
J:190087
|
abnormal interleukin-2 secretion
|
J:190087
|
Vav1tm1Tyb/Vav1tm1Tyb Vav2tm1Kdf/Vav2tm1Kdf
(involves: 129S1/Sv * 129S2/SvPas)
|
decreased B cell proliferation
|
J:86654
|
decreased interferon-gamma secretion
|
J:86654
|
decreased interleukin-2 secretion
|
J:86654
|
decreased T cell proliferation
|
J:86654
|
Vav1tm1Tyb/Vav1tm1Tyb Vav2tm1Kdf/Vav2tm1Kdf Vav3tm1Swat/Vav3tm1Swat
(involves: 129S1/Sv * 129S2/SvPas * 129S6/SvEvTac * C57BL/6)
|
abnormal B cell calcium ion homeostasis
|
J:86654
|
abnormal humoral immune response
|
J:86654
|
abnormal T cell physiology
|
J:86654
|
decreased B cell proliferation
|
J:86654
|
decreased IgG1 level
|
J:86654
|
decreased IgG2b level
|
J:86654
|
decreased IgG3 level
|
J:86654
|
decreased IgM level
|
J:86654
|
decreased immunoglobulin level
|
J:86654
|
decreased interferon-gamma secretion
|
J:86654
|
decreased interleukin-2 secretion
|
J:86654
|
decreased T cell proliferation
|
J:86654
|
Vav1tm1Tyb/Vav1tm1Tyb Vav2tm1Kdf/Vav2tm1Kdf Vav3tm1Swat/Vav3tm1Swat
(involves: 129S1/Sv * 129S2/SvPas * 129S6/SvEvTac)
|
abnormal macrophage physiology
|
J:145345
|
abnormal neutrophil physiology
|
J:145345
|
abnormal NK cell physiology
|
J:187430
|
decreased interleukin-10 secretion
|
J:145345
|
decreased tumor necrosis factor secretion
|
J:145345
|
Vav1tm1Tyb/Vav1tm1Tyb Vav2tm1Tnr/Vav2tm1Tnr
(involves: 129P2/OlaHsd * 129S2/SvPas)
|
abnormal B cell calcium ion homeostasis
|
J:69807
|
decreased B cell proliferation
|
J:69807
|
Vav1tm1Tyb/Vav1tm1Tyb Vav3tm1Swat/Vav3tm1Swat
(involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6)
|
decreased B cell proliferation
|
J:86654
|
decreased interferon-gamma secretion
|
J:86654
|
decreased interleukin-2 secretion
|
J:86654
|
decreased T cell proliferation
|
J:86654
|
Vav1tm2Bbd/Vav1tm2Bbd
(involves: 129S1/Sv * 129X1/SvJ * CD-1)
|
abnormal T cell activation
|
J:47596
|
decreased interleukin-2 secretion
|
J:47596
|
decreased T cell proliferation
|
J:47596
|
Vav1tm2Bbd/Vav1tm2Bbd
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal response to infection
|
J:55647
|
decreased B cell proliferation
|
J:55647,
J:69806
|
decreased IgG1 level
|
J:55647
|
decreased IgG2a level
|
J:55647
|
decreased IgG3 level
|
J:69806
|
decreased IgG level
|
J:55647
|
Vav1tm2Bbd/Vav1tm2Bbd
(B6.129-Vav1tm2Bbd)
|
abnormal T cell physiology
|
J:141390
|
decreased interleukin-4 secretion
|
J:71161
|
impaired natural killer cell mediated cytotoxicity
|
J:71161
|
Vav1tm2Bbd/Vav1tm2Bbd Vav2tm1Kdf/Vav2tm1Kdf
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal B cell activation
|
J:69806
|
decreased B cell proliferation
|
J:69806
|
decreased IgG1 level
|
J:69806
|
decreased IgG2b level
|
J:69806
|
decreased IgG3 level
|
J:69806
|
decreased IgM level
|
J:69806
|
decreased immunoglobulin level
|
J:69806
|
Vav1tm2Tyb/Vav1tm2Tyb
(involves: 129S4/SvJae * 129S8/SvEv)
|
abnormal T cell physiology
|
J:113270
|
decreased T cell proliferation
|
J:113270
|
Vav1tm4Tyb/Vav1tm4Tyb
(either: 129S8.129S4-Vav1tm4Tyb or (involves: 129S4/SvJae * 129S8/SvEv * C57BL/10 * C57BR/cd))
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:190087
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:190087
|
abnormal immune serum protein physiology
|
J:190087
|
abnormal immune system physiology
|
J:190087
|
abnormal interleukin-2 secretion
|
J:190087
|
abnormal T cell physiology
|
J:190087
|
increased circulating interferon-gamma level
|
J:190087
|
Vav2tm1Kdf/Vav2tm1Kdf
(involves: 129S1/Sv * C57BL/6)
|
decreased B cell proliferation
|
J:69806
|
decreased IgG3 level
|
J:69806
|
Vav2tm1Tnr/Vav2tm1Tnr
(involves: 129P2/OlaHsd)
|
abnormal class switch recombination
|
J:69807
|
decreased B cell proliferation
|
J:69807
|
decreased IgG1 level
|
J:69807
|
decreased IgG2b level
|
J:69807
|
decreased IgG3 level
|
J:69807
|
decreased IgM level
|
J:69807
|
Vcam1tm2Flv/Vcam1tm3Flv Tg(Tek-cre)12Flv/0
(involves: 129S1/Sv * C3H * C57BL/6)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:68147
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:68147
|
abnormal lymphocyte physiology
|
J:68147
|
impaired B cell migration
|
J:68147
|
Vcam1tm2Roml/Vcam1tm2Roml Tg(Mx1-cre)1Cgn/?
(involves: 129S1/Sv * C57BL/6 * CBA)
|
abnormal humoral immune response
|
J:68148
|
Vdac2tm1.1Ehyc/Vdac2tm1.1Ehyc Tg(Lck-cre)1Cwi/?
(involves: 129X1/SvJ * C57BL/6 * DBA/2)
|
abnormal thymocyte apoptosis
|
J:220951
|
Vdrtm1Mbd/Vdrtm1Mbd
(involves: 129S4/SvJae * C57BL/6)
|
abnormal interleukin level
|
J:107077
|
abnormal tumor necrosis factor level
|
J:107077
|
increased susceptibility to induced colitis
|
J:130511
|
intestinal inflammation
|
J:107077
|
Vdrtm1Rge/Vdrtm1Rge
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal macrophage physiology
|
J:134827
|
decreased susceptibility to parasitic infection
|
J:134827
|
Vdrtm1Ska/Vdrtm1Ska
(involves: C57BL/6NCrlj * CBA/JNCrlj)
|
abnormal macrophage chemotaxis
|
J:112519
|
decreased splenocyte proliferation
|
J:112519
|
decreased susceptibility to autoimmune diabetes
|
J:112519
|
dermatitis
|
J:111828
|
Vdrtm1Ska/Vdrtm1Ska
(NOD.Cg-Vdrtm1Ska/CmatJ)
|
abnormal chemokine secretion
|
J:127787
|
abnormal interleukin-1 secretion
|
J:127787
|
decreased interleukin-6 secretion
|
J:127787
|
increased susceptibility to autoimmune diabetes
|
J:127787
|
Vdrtm2Ska/Vdrtm2Ska
(involves: C57BL/6NCrlj * CBA/JNCrlj)
|
ear inflammation
|
J:111828
|
Vegfatm2Gne/Vegfatm2Gne Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129/Sv * 129P2/OlaHsd)
|
decreased inflammatory response
|
J:107682
|
Vegfatm2Gne/Vegfatm2Gne Tg(SFTPC-cre)#Mliu/0
(involves: 129/Sv * ICR)
|
lung inflammation
|
J:158566
|
Vegfctm1Ali/Vegfc+
(involves: 129S1/Sv * 129X1/SvJ * ICR)
|
abnormal lymph circulation
|
J:87394
|
Vhltm1Jae/Vhltm1Jae Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * 129S4/SvJae)
|
increased inflammatory response
|
J:107682
|
Vimtm1Cba/Vimtm1Cba
(involves: 129S2/SvPas * C57BL/6)
|
abnormal cellular extravasation
|
J:129405
|
abnormal leukocyte adhesion
|
J:129405
|
abnormal leukocyte migration
|
J:129405
|
abnormal leukocyte tethering or rolling
|
J:129405
|
Viptm1Clw/Viptm1Clw
(involves: 129S/Sv * C57BL/6)
|
lung inflammation
|
J:132313
|
Vipr2tm1Ajh/Vipr2tm1Ajh
(B6.129P2-Vipr2tm1Ajh)
|
abnormal cytokine secretion
|
J:72933
|
decreased IgE level
|
J:72933
|
decreased interleukin-4 secretion
|
J:72933
|
decreased susceptibility to type I hypersensitivity reaction
|
J:72933
|
increased interferon-gamma secretion
|
J:72933
|
increased interleukin-2 secretion
|
J:72933
|
increased susceptibility to type IV hypersensitivity reaction
|
J:72933
|
Vms1A/J/Vms1A/J
(involves: A/J * C57BL/10SnSg)
|
myocarditis
|
J:121574
|
Vpreb1atm1Ilm/Vpreb1atm1Ilm Vpreb1btm1Ilm/Vpreb1btm1Ilm
(B6.129P2-Vpreb1atm1Ilm Vpreb1btm1Ilm)
|
decreased IgG level
|
J:67609
|
Vps13btm1.2Ics/Vps13btm1.2Ics
(involves: C57BL/6N)
|
eye inflammation
|
J:296007
|
Vps54wr/Vps54wr
(involves: C57BL/6J * C57BL/Fa)
|
increased microglial cell activation
|
J:181019
|
Vsig4tm1Gne/Vsig4tm1Gne
(involves: C57BL/6N)
|
increased susceptibility to bacterial infection
|
J:138691
|
Vsig4tm1Gne/Vsig4tm1Gne
(C57BL/6-Vsig4tm1Gne)
|
abnormal macrophage physiology
|
J:281762
|
decreased susceptibility to induced colitis
|
J:281762
|
increased circulating interleukin-1 beta level
|
J:281762
|
increased interleukin-1 beta secretion
|
J:281762
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:281762
|
Vsirtm1Lex/Vsirtm1Lex
(involves: 129S5/SvEvBrd * C57BL/6)
|
abnormal T cell activation
|
J:222944
|
increased IgA level
|
J:222944
|
increased IgM level
|
J:222944
|
increased inflammatory response
|
J:222944
|
increased interferon-gamma secretion
|
J:222944
|
increased interleukin-17 secretion
|
J:222944
|
Vsirtm1Lex/Vsirtm1Lex Tg(Tcra2D2,Tcrb2D2)1Kuch/0
(involves: 129S5/SvEvBrd * C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:222944
|
Vstm5em1Cdj/Vstm5em1Cdj
(Not Specified)
|
decreased interleukin-2 secretion
|
J:267548
|
Vtcn1tm1Lpc/Vtcn1tm1Lpc
(B6.129S-Vtcn1tm1Lpc)
|
decreased susceptibility to bacterial infection
|
J:145712
|
decreased susceptibility to bacterial infection induced morbidity/mortality
|
J:145712
|
Vtcn1tm1Mak/Vtcn1tm1Mak
(C.Cg-Vtcn1tm1Mak)
|
decreased interleukin-4 secretion
|
J:112130
|
decreased susceptibility to parasitic infection
|
J:112130
|
increased interferon-gamma secretion
|
J:112130
|
Vtcn1tm1Xxz/Vtcn1tm1Xxz
(involves: 129S4/SvJae * BALB/c * C57BL/6)
|
increased interleukin-17 secretion
|
J:177612
|
increased susceptibility to autoimmune diabetes
|
J:177612
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:177612
|
Vwftm1.1Geno/Vwf+
(involves: C57BL/6)
|
increased acute inflammation
|
J:250145
|
Vwftm1.1Geno/Vwftm1.1Geno
(involves: C57BL/6)
|
increased acute inflammation
|
J:250145
|
Vwftm1Wgr/Vwftm1Wgr
(B6.129S2-Vwftm1Wgr)
|
increased susceptibility to bacterial infection
|
J:140334
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:140334
|
Wastm1Itl/Y
(Not Specified)
|
abnormal dendritic cell physiology
|
J:153247
|
decreased T cell proliferation
|
J:153247
|
increased anti-double stranded DNA antibody level
|
J:153247
|
Wastm1Itl/Wastm1Itl
(Not Specified)
|
abnormal dendritic cell physiology
|
J:153247
|
decreased T cell proliferation
|
J:153247
|
increased anti-double stranded DNA antibody level
|
J:153247
|
Wastm1Sbs/Y
(involves: 129S6/SvEvTac)
|
abnormal dendritic cell physiology
|
J:153247
|
decreased T cell proliferation
|
J:153247
|
increased anti-double stranded DNA antibody level
|
J:153247
|
Wastm1Sbs/Y
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal B cell physiology
|
J:182528
|
increased anti-chromatin antibody level
|
J:182528
|
increased anti-double stranded DNA antibody level
|
J:182528
|
increased anti-single stranded DNA antibody level
|
J:182528
|
increased autoantibody level
|
J:182528
|
increased IgA level
|
J:182528
|
increased IgE level
|
J:182528
|
increased IgM level
|
J:182528
|
Wastm1Sbs/Wastm1Sbs
(either: (involves: 129S6/SvEvTac) or (involves: 129S6/SvEvTac * C57BL/6))
|
colitis
|
J:48836
|
decreased T cell proliferation
|
J:48836
|
Wastm1Sbs/Wastm1Sbs
(involves: C57BL/6 * CBA)
|
abnormal B cell physiology
|
J:95909
|
Wastm1Sbs/Wastm1Sbs
(involves: 129S/SvEv)
|
abnormal cytokine secretion
|
J:86835
|
abnormal mast cell physiology
|
J:86835
|
abnormal osteoclast physiology
|
J:90542
|
Wastm1Sbs/Wastm1Sbs
(involves: BALB/c)
|
abnormal dendritic cell antigen presentation
|
J:84131
|
decreased T cell proliferation
|
J:84131
|
Wastm1Sbs/Wastm1Sbs
(involves: 129S6/SvEvTac)
|
abnormal dendritic cell physiology
|
J:153247
|
abnormal thymocyte activation
|
J:125309
|
decreased T cell proliferation
|
J:153247
|
increased anti-double stranded DNA antibody level
|
J:153247
|
Wastm1Sbs/Wastm1Sbs
(129S6/SvEvTac-Wastm1Sbs/J)
|
glomerulonephritis
|
J:180407
|
increased IgA level
|
J:180407
|
increased IgM level
|
J:180407
|
Wastm1Sbs/Wastm1Sbs
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal B cell physiology
|
J:182528
|
increased anti-chromatin antibody level
|
J:182528
|
increased anti-double stranded DNA antibody level
|
J:182528
|
increased anti-single stranded DNA antibody level
|
J:182528
|
increased autoantibody level
|
J:182528
|
increased IgA level
|
J:182528
|
increased IgE level
|
J:182528
|
increased IgM level
|
J:182528
|
Wastm1Sbs/Wastm1Sbs Wasltm2Sbs/Wasltm2Sbs Tg(Lck-cre)1Cwi/?
(involves: 129S6/SvEvTac * C57BL/6)
|
abnormal thymocyte activation
|
J:125309
|
colitis
|
J:125309
|
Wastm2Itl/Y
(Not Specified)
|
abnormal dendritic cell physiology
|
J:153247
|
decreased T cell proliferation
|
J:153247
|
increased anti-double stranded DNA antibody level
|
J:153247
|
Wastm2Itl/Wastm2Itl
(Not Specified)
|
abnormal dendritic cell physiology
|
J:153247
|
decreased T cell proliferation
|
J:153247
|
increased anti-double stranded DNA antibody level
|
J:153247
|
Wasltm1.1Ttha/Wasltm1.1Ttha Tg(KRT14-cre)1Amc/0
(involves: C57BL/6 * C57BL/6N * CBA)
|
abnormal circulating chemokine level
|
J:271857
|
dermatitis
|
J:271857
|
increased circulating interleukin-1 alpha level
|
J:271857
|
increased circulating interleukin-6 level
|
J:271857
|
increased circulating interleukin-17 level
|
J:271857
|
increased circulating tumor necrosis factor level
|
J:271857
|
increased susceptibility to bacterial infection
|
J:271857
|
skin inflammation
|
J:271857
|
Wdr1Gt(XN462)Byg/Wdr1rede
(involves: 129P2/OlaHsd * C57BL/6)
|
ear inflammation
|
J:134092
|
skin inflammation
|
J:134092
|
Wdr1rede/Wdr1rede
(Not Specified)
|
increased inflammatory response
|
J:85113
|
Wdr1rede/Wdr1rede
(C57BL/6-Wdr1rede)
|
abnormal osteoclast physiology
|
J:134092
|
ear inflammation
|
J:134092
|
impaired neutrophil chemotaxis
|
J:134092
|
skin inflammation
|
J:134092
|
Wdr41m1Btlr/Wdr41m1Btlr
(C57BL/6J-Wdr41m1Btlr)
|
increased circulating interleukin-12b level
|
J:268243
|
increased susceptibility to induced colitis
|
J:268243
|
increased tumor necrosis factor secretion
|
J:268243
|
Wdr41m2Btlr/Wdr41m2Btlr
(C57BL/6J-Wdr41m2Btlr)
|
increased tumor necrosis factor secretion
|
J:268243
|
Wdr83tm1Guwo/Wdr83+
(involves: C57BL/6)
|
kidney inflammation
|
J:153983
|
Wfdc1tm1Bcm/Wfdc1tm1Bcm
(involves: 129S7/SvEvBrd * C57BL/6)
|
decreased susceptibility to Orthomyxoviridae infection
|
J:216357
|
Wfdc2tm1.1Ohbo/Wfdc2tm1.1Ohbo
(involves: C57BL/6NCrlj * CBA/JNCrlj)
|
abnormal cytokine level
|
J:282576
|
lung inflammation
|
J:282576
|
Wfdc15aem1Ohbo/Wfdc15aem1Ohbo
(involves: Slc:ICR)
|
testis inflammation
|
J:360881
|
Why1MOLF/EiJ/?
(involves: C57BL/6J * MOLF/Ei)
|
increased interleukin-6 secretion
|
J:131437
|
Why2MOLF/EiJ/?
(involves: C57BL/6J * MOLF/Ei)
|
decreased interleukin-6 secretion
|
J:131437
|
Wipf1tm1Geha/Wipf1tm1Geha
(involves: 129S6/SvEvTac)
|
abnormal T cell physiology
|
J:74719
|
decreased T cell proliferation
|
J:74719
|
increased B cell proliferation
|
J:74719
|
increased IgE level
|
J:74719
|
increased IgM level
|
J:74719
|
Wipf1tm1Geha/Wipf1tm1Geha
(involves: 129S6/SvEvTac * C57BL/6)
|
colitis
|
J:116168
|
glomerulonephritis
|
J:116168
|
increased autoantibody level
|
J:116168
|
increased IgA level
|
J:116168
|
interstitial pneumonia
|
J:116168
|
joint inflammation
|
J:116168
|
lung inflammation
|
J:116168
|
Wlstm1.1Arte/Wlstm1.1Arte Krt14tm1(cre)Wbm/Krt14+
(involves: 129P2/OlaHsd * C57BL/6)
|
abnormal T cell physiology
|
J:202499
|
increased T cell proliferation
|
J:202499
|
skin inflammation
|
J:202499
|
Wrntm1Led/Wrntm1Led
(involves: 129S6/SvEvTac * Black Swiss)
|
heart inflammation
|
J:106446
|
increased susceptibility to infection
|
J:106446
|
Wsb1tm1.1Jszh/Wsb1tm1.1Jszh Ubcem1(cre/ERT2)Smoc/Ubc+
(involves: C57BL/6J * C57BL/6N)
|
decreased inflammatory response
|
J:358004
|
Wt1tm1Jae/Wt1tm1Jae
(involves: 129S4/SvJae * C57BL/6 * MF1)
|
increased splenocyte apoptosis
|
J:56651
|
Wt1tm1Mlh/Wt1+
(involves: 129P2/OlaHsd * C57BL/6)
|
glomerulonephritis
|
J:135449
|
Wt1tm1Mlh/Wt1+
(129P2/OlaHsd-Wt1tm1Mlh)
|
glomerulonephritis
|
J:135449
|
Wt1tm1Mlh/Wt1+
(involves: 129P2/OlaHsd * C57BL/6 * MF1)
|
glomerulonephritis
|
J:135449
|
Wwc1tm1Arsc/Wwc1tm1Arsc Wwc2tm1.1Arte/Wwc2tm1.1Arte Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129 * C57BL/6 * C57BL/6J * DBA)
|
liver inflammation
|
J:305034
|
Wwoxtm1Ria/Wwoxtm1Ria
(involves: 129X1/SvJ * C57BL/6J)
|
abnormal osteoclast physiology
|
J:138140
|
Wwp2tm1.1Yyiw/Wwp2tm1.1Yyiw
(involves: 129S/SvEv * C57BL/6 * FVB/N)
|
increased circulating interferon-beta level
|
J:228707
|
increased circulating interleukin-6 level
|
J:228707
|
increased circulating tumor necrosis factor level
|
J:228707
|
Wwtr1tm1Benj/Wwtr1tm1Benj
(129S6/SvEvTac-Wwtr1tm1Benj)
|
intestinal inflammation
|
J:125326
|
lung inflammation
|
J:125326
|
Wwtr1tm1Benj/Wwtr1tm1Benj
(129S-Wwtr1tm1Benj/J)
|
intestinal inflammation
|
J:156586
|
lung inflammation
|
J:156586
|
Wwtr1tm1Hku/Wwtr1tm1Hku
(involves: 129 * C57BL/6 * ICR)
|
alveolitis
|
J:164957
|
lung inflammation
|
J:164957
|
Wwtr1tm1Whun/Wwtr1tm1Whun
(either: (involves: 129S6/SvEvTac) or (involves: 129S6/SvEvTac * C57BL/6))
|
tubular nephritis
|
J:119488
|
Xaf1em2.1Cya/Xaf1em2.1Cya
(C57BL/6J-Xaf1em2.1Cya)
|
abnormal tumor necrosis factor level
|
J:344340
|
decreased circulating CXCL10 level
|
J:344340
|
decreased circulating interferon-beta level
|
J:344340
|
decreased macrophage cytokine production
|
J:344340
|
increased susceptibility to Riboviria infection
|
J:344340
|
increased susceptibility to Riboviria infection induced morbidity/mortality
|
J:344340
|
Xbp1tm1a(EUCOMM)Wtsi/Xbp1+
(C57BL/6N-Xbp1tm1a(EUCOMM)Wtsi/Ics)
|
decreased IgG1 level
|
J:165965
|
Xbp1tm2Glm/Xbp1+ Tg(Vil1-cre)997Gum/0
(involves: 129S6/SvEvTac * C57BL/6J * FVB/N * SJL)
|
small intestinal inflammation
|
J:188627
|
Xbp1tm2Glm/Xbp1tm2Glm Tg(Defa6-icre)1Rsb/0
(involves: 129S6/SvEvTac * C57BL/6)
|
small intestinal inflammation
|
J:206084
|
Xbp1tm2Glm/Xbp1tm2Glm Tg(Nes-cre)1Kln/0
(involves: 129S6/SvEvTac * C57BL/6 * SJL)
|
decreased susceptibility to prion infection
|
J:131028
|
Xbp1tm2Glm/Xbp1tm2Glm Tg(Vil1-cre)997Gum/0
(involves: 129S6/SvEvTac * C57BL/6J * FVB/N * SJL)
|
increased susceptibility to bacterial infection
|
J:188627
|
increased susceptibility to induced colitis
|
J:188627
|
small intestinal inflammation
|
J:188627
|
Xbp1tm2Glm/Xbp1tm2Glm Tg(Vil1-cre)997Gum/0
(involves: 129S6/SvEvTac * C57BL/6 * SJL)
|
small intestinal inflammation
|
J:206084
|
Xbp1tm2Glm/Xbp1tm2Glm Tg(Vil1-cre/ERT2)23Syr/0
(involves: 129S6/SvEvTac * C57BL/6 * DBA/2)
|
small intestinal inflammation
|
J:206084
|
Xbp1tm2Glm/Xbp1tm2Glm Tnfrsf1atm1Imx/Tnfrsf1atm1Imx Tg(Vil1-cre)997Gum/0
(involves: 129S6/SvEvTac * C57BL/6 * SJL)
|
small intestinal inflammation
|
J:206084
|
Xbp1tm3Glm/Xbp1tm3Glm Tg(Vil1-cre/ERT2)23Syr/0
(involves: 129S6/SvEvTac * C57BL/6 * DBA/2)
|
small intestinal inflammation
|
J:188627
|
Xcl1tm1.1Dnax/Xcl1tm1.1Dnax
(either: (involves: 129/Sv * BALB/c) or (involves: 129/Sv * C57BL/6))
|
autoimmune response
|
J:176844
|
heart inflammation
|
J:176844
|
increased inflammatory response
|
J:176844
|
lacrimal gland inflammation
|
J:176844
|
liver inflammation
|
J:176844
|
salivary gland inflammation
|
J:176844
|
stomach inflammation
|
J:176844
|
Xcl1tm1Rakr/Xcl1tm1Rakr
(B6.129-Xcl1tm1Rakr)
|
decreased cytotoxic T cell cytolysis
|
J:155297
|
Xcl1tm1Rakr/Xcl1tm1Rakr Tg(TcraTcrb)1100Mjb/0
(involves: 129/Sv * C57BL/6)
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:155297
|
decreased cytotoxic T cell cytolysis
|
J:155297
|
decreased interferon-gamma secretion
|
J:155297
|
Xcr1tm1Dgen/Xcr1tm1Dgen
(B6.129P2-Xcr1tm1Dgen/J)
|
abnormal dendritic cell physiology
|
J:155297
|
Xcr1tm2(HBEGF/Venus)Ksho/Xcr1+
(involves: C57BL/6 * C57BL/6J)
|
abnormal antigen presentation
|
J:204851
|
abnormal CD8-positive, alpha-beta T cell physiology
|
J:204851
|
decreased interferon-gamma secretion
|
J:204851
|
decreased susceptibility to bacterial infection
|
J:204851
|
Xdhtm1Fink/Xdhtm1Fink
(involves: 129X1/SvJ * C57BL/6J)
|
tubulointerstitial nephritis
|
J:166326
|
Xkrxtm1b(EUCOMM)Wtsi/Xkrxtm1b(EUCOMM)Wtsi
(C57BL/6N-Xkrxtm1b(EUCOMM)Wtsi/Wtsi)
|
increased anti-nuclear antigen antibody level
|
J:211773
|
Xpatm1Tnka/Xpatm1Tnka
(involves: C57BL/6 * CBA)
|
abnormal immune system physiology
|
J:35054
|
abnormal Langerhans cell physiology
|
J:35054
|
abnormal lymphocyte physiology
|
J:55739
|
abnormal NK cell physiology
|
J:55739
|
Xpnpep1tm1a(KOMP)Wtsi/Xpnpep1tm1a(KOMP)Wtsi
(C57BL/6N-Xpnpep1tm1a(KOMP)Wtsi/Wtsi)
|
blood in lymph vessels
|
J:239583
|
Xpr1Sxv/Xpr1Sxv
(M. spretus)
|
increased susceptibility to Retroviridae infection
|
J:7951
|
Xrcc5tm1Nus/Xrcc5tm1Nus
(involves: 129S1/Sv * 129X1/SvJ)
|
abnormal class switch recombination
|
J:120658
|
abnormal humoral immune response
|
J:120658
|
Xrcc6tm1Fwa/Xrcc6tm1Fwa
(involves: 129S6/SvEvTac * C57BL/6J)
|
decreased IgM level
|
J:44361
|
X/Yaa
((NZB x BXSB)F1)
|
abnormal immune cell physiology
|
J:6235
|
increased anti-erythrocyte antigen antibody level
|
J:6235
|
increased anti-nuclear antigen antibody level
|
J:6235
|
increased autoantibody level
|
J:6235
|
increased susceptibility to autoimmune disorder
|
J:6235
|
X/Yaa
((SJL/J x BXSB)F1)
|
increased susceptibility to autoimmune disorder
|
J:6235
|
X/Yaa
((C57BL/6J x BXSB)F1)
|
increased susceptibility to autoimmune disorder
|
J:6235
|
X/Yaa
(involves: BXSB * NZB)
|
increased susceptibility to autoimmune disorder
|
J:6235
|
X/Yaa
(BXSB/MpJ)
|
glomerulonephritis
|
J:6235
|
increased anti-erythrocyte antigen antibody level
|
J:6235
|
increased anti-nuclear antigen antibody level
|
J:179430
|
increased circulating interleukin-21 level
|
J:93740
|
increased IgG1 level
|
J:179430,
J:93740
|
increased IgG2a level
|
J:179430
|
increased IgG2b level
|
J:179430
|
increased IgG3 level
|
J:93740
|
increased susceptibility to autoimmune disorder
|
J:108760,
J:6235
|
X/Yaa
((NZW x SB)F1)
|
abnormal immune serum protein physiology
|
J:7276
|
glomerulonephritis
|
J:7276
|
increased susceptibility to autoimmune disorder
|
J:7276
|
X/Yaa
((NZW x BXSB)F1)
|
abnormal immune serum protein physiology
|
J:7276
|
increased susceptibility to autoimmune disorder
|
J:7276
|
X/Yaa
(BXSB/MpJScr)
|
glomerulonephritis
|
J:10973
|
increased anti-nuclear antigen antibody level
|
J:10973
|
increased IgG level
|
J:10973
|
increased susceptibility to autoimmune disorder
|
J:10973
|
X/Yaa
(B6.SB-Yaa/J)
|
increased splenocyte proliferation
|
J:127600
|
Yaa2BXSB/J/?
(involves: BXSB/J * C57BL/10Ola)
|
kidney inflammation
|
J:49868
|
Yaa3BXSB/J/?
(involves: BXSB/J * C57BL/10Ola)
|
kidney inflammation
|
J:49868
|
Yaa4BXSB/J/?
(involves: BXSB/J * C57BL/10Ola)
|
kidney inflammation
|
J:49868
|
YaailNZW/Ola/?
(involves: C57BL/6Ola * NZW/Ola)
|
glomerulonephritis
|
J:52110
|
increased anti-double stranded DNA antibody level
|
J:52110
|
Yap1M1Btlr/Yap1M1Btlr
(C57BL/6J-Yap1M1Btlr)
|
increased susceptibility to induced colitis
|
J:267549
|
Yap1tm1.1Dupa/Yap1tm1.1Dupa Tg(Vil1-cre)997Gum/0
(involves: 129P2/OlaHsd * C57BL/6J * SJL)
|
increased susceptibility to induced colitis
|
J:165471
|
Yeats4em1Zfa/Yeats4em1Zfa Commd10Tg(Vav1-icre)A2Kio/Commd10+
(involves: C57BL/6 * C57BL/10 * CBA/Ca)
|
abnormal acute inflammation
|
J:282740
|
abnormal interleukin secretion
|
J:282740
|
abnormal lymphocyte physiology
|
J:282740
|
decreased interferon-gamma secretion
|
J:282740
|
decreased interleukin-5 secretion
|
J:282740
|
decreased interleukin-12 secretion
|
J:282740
|
increased susceptibility to bacterial infection
|
J:282740
|
Yipf6M1Btlr/Y
(C57BL/6J-Yipf6M1Btlr/Mmucd)
|
colitis
|
J:187584
|
increased susceptibility to induced colitis
|
J:187584
|
Yipf6M1Btlr/Yipf6M1Btlr
(C57BL/6J-Yipf6M1Btlr/Mmucd)
|
colitis
|
J:187584
|
increased susceptibility to induced colitis
|
J:187584
|
Yod1em1Smoc/Yod1em1Smoc
(C57BL/6JSmoc-Yod1em1Smoc/Smoc)
|
abnormal macrophage physiology
|
J:350806
|
decreased circulating fibrinogen level
|
J:350806
|
increased circulating interleukin-1 beta level
|
J:350806
|
increased inflammatory response
|
J:350806
|
increased interleukin-1 beta secretion
|
J:350806
|
increased macrophage cytokine production
|
J:350806
|
increased susceptibility to bacterial infection
|
J:350806
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:350806
|
Ythdf3em1Caox/Ythdf3em1Caox
(involves: C57BL/6J)
|
abnormal macrophage physiology
|
J:276397
|
decreased susceptibility to Riboviria infection
|
J:276397
|
decreased susceptibility to Riboviria infection induced morbidity/mortality
|
J:276397
|
Zap70m1Btlr/Zap70m1Btlr
(involves: C57BL/6J)
|
abnormal class switch recombination
|
J:185495
|
abnormal humoral immune response
|
J:167119
|
decreased IgG level
|
J:185495
|
Zap70m1Saka/Zap70m1Saka
(involves: BALB/c)
|
abnormal T cell clonal deletion
|
J:154166
|
abnormal thymocyte activation
|
J:154166
|
chronic joint inflammation
|
J:86607
|
decreased interleukin-2 secretion
|
J:154166
|
decreased T cell proliferation
|
J:154166,
J:86607
|
increased autoantibody level
|
J:86607
|
increased immunoglobulin level
|
J:86607
|
increased interleukin-17 secretion
|
J:154166
|
increased susceptibility to induced arthritis
|
J:154166
|
lung inflammation
|
J:86607
|
rheumatoid arthritis
|
J:86607
|
Zap70m1Saka/Zap70m1Saka Tg(DO11.10)10Dlo/0
(involves: BALB/c * C3H * C57BL/6)
|
decreased T cell proliferation
|
J:86607
|
Zap70m1Saka/Zap70m1Saka Tg(TcraH-Y,TcrbH-Y)71Vbo/0
(involves: BALB/c * C57BL/6J * DBA/2J)
|
autoimmune arthritis
|
J:86607
|
Zap70m1Saka/Zap70tm1Dlo
(involves: 129P2/OlaHsd * BALB/c)
|
autoimmune arthritis
|
J:86607
|
Zap70m1Saka/Zap70tm2.1Weis
(involves: 129S4/SvJae * BALB/c)
|
abnormal T cell clonal deletion
|
J:154166
|
decreased susceptibility to induced arthritis
|
J:154166
|
Zap70m3Btlr/Zap70m3Btlr
(C57BL/6J-Zap70m3Btlr)
|
decreased IgG level
|
J:225043
|
impaired humoral immune response
|
J:225043
|
Zap70m5Btlr/Zap70m5Btlr
(C57BL/6J-Zap70m5Btlr)
|
abnormal humoral immune response
|
J:254830
|
decreased IgG level
|
J:254830
|
Zap70m6Btlr/Zap70m6Btlr
(C57BL/6J-Zap70m6Btlr)
|
abnormal humoral immune response
|
J:254831
|
decreased IgG level
|
J:254831
|
Zap70m6Hefl/Zap70m6Hefl
(C3HeB/FeJ-Zap70m6Hefl)
|
abnormal humoral immune response
|
J:137446
|
increased IgE level
|
J:137446
|
increased IgG1 level
|
J:137446
|
Zap70m6Hefl/Zap70tm1Weis
(involves: 129X1/SvJ * C3HeB/FeJ * C57BL/10 * DBA/2)
|
increased IgE level
|
J:137446
|
Zap70m7Btlr/Zap70m7Btlr
(C57BL/6J-Zap70m7Btlr)
|
abnormal humoral immune response
|
J:254832
|
decreased IgG level
|
J:254832
|
Zap70mur/Zap70mur
(C57BL/6Apb-Zap70mur/ApbH)
|
abnormal T cell activation
|
J:104190
|
abnormal T cell physiology
|
J:104190
|
increased IgG2b level
|
J:104190
|
Zap70st/Zap70st
(involves: C57BL/6)
|
abnormal T cell physiology
|
J:41170
|
Zap70tm1.1Mmal/Zap70tm1.1Mmal Tg(TcrLCMV)327Sdz/0
(involves: 129P2/OlaHsd * BALB/cJ * C57BL/6 * DBA/2)
|
abnormal cytokine secretion
|
J:71099
|
abnormal T cell proliferation
|
J:71099
|
Zap70tm2.1Weis/Zap70tm2.1Weis
(C.129S4-Zap70tm2.1Weis)
|
abnormal regulatory T cell physiology
|
J:154166
|
abnormal T cell clonal deletion
|
J:154166
|
abnormal thymocyte activation
|
J:154166
|
decreased interleukin-2 secretion
|
J:154166
|
decreased T cell proliferation
|
J:154166
|
increased interleukin-17 secretion
|
J:154166
|
Zap70tm2.1Weis/Zap70tm2.1Weis Tg(TcraH-Y,TcrbH-Y)71Vbo/?
(involves: 129S4/SvJae * C57BL/6J * DBA/2J)
|
abnormal T cell clonal deletion
|
J:154166
|
Zbp1tm1.1Jreh/Zbp1tm1.1Jreh
(involves: C57BL/6 * C57BL/6N)
|
increased susceptibility to Herpesvirales infection
|
J:252669
|
Zbtb1m1Btlr/Zbtb1m1Btlr
(involves: C3H/HeN * C57BL/6J)
|
abnormal immune system physiology
|
J:178820
|
Zbtb7atm1Ppp/Zbtb7atm1Ppp
(B6.129S1-Zbtb7atm1Ppp)
|
abnormal response to transplant
|
J:121576
|
Zbtb7atm1Ppp/Zbtb7atm2Ppp Tg(Mx1-cre)1Cgn/0
(involves: 129S1/Sv * C57BL/6 * CBA)
|
abnormal response to transplant
|
J:121576
|
Zbtb7bhpls/Zbtb7bhpls
(involves: C57BL/6JAnu)
|
abnormal humoral immune response
|
J:104190
|
Zbtb7btm1Itan/Zbtb7btm1.1Tani
(involves: 129 * C57BL/6)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:141142
|
Zbtb7btm1Litt/Zbtb7btm1.2Litt
(involves: C57BL/6)
|
increased interferon-gamma secretion
|
J:141144
|
Zbtb17tm1Cksn/Zbtb17tm1Cksn Commd10Tg(Vav1-icre)A2Kio/Commd10+
(B6.Cg-Zbtb17tm1Cksn Commd10Tg(Vav1-icre)A2Kio)
|
increased T cell apoptosis
|
J:170508
|
Zbtb32tm1Iho/Zbtb32tm1Iho
(involves: BALB/c)
|
abnormal cytokine secretion
|
J:94944
|
increased T cell proliferation
|
J:94944
|
Zbtb32tm1Iho/Zbtb32tm1Iho
(involves: C57BL/6)
|
increased T cell proliferation
|
J:94944
|
Zbtb32tm2Ppp/Zbtb32tm2Ppp
(involves: 129S1/Sv)
|
abnormal cytokine secretion
|
J:95119
|
increased T cell proliferation
|
J:95119
|
Zbtb46tm1(HBEGF)Mnz/Zbtb46+
(C57BL/6-Zbtb46tm1(HBEGF)Mnz)
|
abnormal memory T cell physiology
|
J:189122
|
abnormal response to infection
|
J:189122
|
abnormal T-helper 1 physiology
|
J:189122
|
increased susceptibility to parasitic infection
|
J:189122
|
Zbtb46tm1Kmm/Zbtb46tm1Kmm
(129S/SvEv-Zbtb46tm1Kmm)
|
abnormal dendritic cell physiology
|
J:184205
|
Zc3h7aitem1Caox/Zc3h7aitem1Caox
(C57BL/6J-Zc3h7aitem1Caox)
|
abnormal interferon secretion
|
J:282488
|
abnormal macrophage activation involved in immune response
|
J:282488
|
decreased circulating interferon-alpha level
|
J:282488
|
decreased circulating interferon-beta level
|
J:282488
|
decreased circulating interleukin-6 level
|
J:282488
|
decreased interferon-alpha secretion
|
J:282488
|
decreased interferon-beta secretion
|
J:282488
|
decreased interleukin-6 secretion
|
J:282488
|
increased susceptibility to Riboviria infection
|
J:282488
|
increased susceptibility to Riboviria infection induced morbidity/mortality
|
J:282488
|
Zc3h12atm1Aki/Zc3h12atm1Aki
(involves: 129X1/SvJ * C57BL/6)
|
abnormal acute inflammation
|
J:147868
|
abnormal class switch recombination
|
J:147868
|
granulomatous inflammation
|
J:147868
|
increased anti-double stranded DNA antibody level
|
J:147868
|
increased anti-nuclear antigen antibody level
|
J:147868
|
increased IgA level
|
J:147868
|
increased IgG1 level
|
J:147868
|
increased IgG2a level
|
J:147868
|
increased IgG2b level
|
J:147868
|
increased IgG3 level
|
J:147868
|
increased IgM level
|
J:147868
|
increased immunoglobulin level
|
J:147868
|
increased interferon-gamma secretion
|
J:147868
|
increased interleukin-6 secretion
|
J:147868
|
increased interleukin-12b secretion
|
J:147868
|
Zc3h12atm1c(EUCOMM)Hmgu/Zc3h12atm1c(EUCOMM)Hmgu Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * C57BL/6N)
|
increased inflammatory response
|
J:304105
|
Zc3h12atm1c(EUCOMM)Hmgu/Zc3h12atm1c(EUCOMM)Hmgu Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: C57BL/6 * C57BL/6N * DBA)
|
bile duct inflammation
|
J:304105
|
granulomatous inflammation
|
J:304105
|
increased anti-nuclear antigen antibody level
|
J:304105
|
increased autoantibody level
|
J:304105
|
increased IgG level
|
J:304105
|
increased IgM level
|
J:304105
|
liver inflammation
|
J:304105
|
Zc3h12atm1Fum/Zc3h12atm1Fum
(C57BL/6-Zc3h12atm1Fum)
|
abnormal chemokine secretion
|
J:176866
|
abnormal circulating chemokine level
|
J:176866
|
increased circulating tumor necrosis factor level
|
J:176866
|
increased interleukin-1 beta secretion
|
J:176866
|
increased interleukin-6 secretion
|
J:176866
|
increased tumor necrosis factor secretion
|
J:176866
|
Zc3h12ctm2d(EUCOMM)Hmgu/Zc3h12ctm2d(EUCOMM)Hmgu
(involves: 129S4/SvJaeSor * C57BL/6N)
|
increased circulating interferon-gamma level
|
J:277714
|
increased IgA level
|
J:277714
|
increased IgG level
|
J:277714
|
increased IgM level
|
J:277714
|
Zc3h12dtm1Tom/Zc3h12dtm1Tom
(B6.Cg-Zc3h12dtm1Tom)
|
increased interleukin-6 secretion
|
J:209383
|
increased interleukin-10 secretion
|
J:209383
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:209383
|
increased T cell proliferation
|
J:209383
|
Zcchc3em1Hbsh/Zcchc3em1Hbsh
(involves: C57BL/6)
|
abnormal innate immunity
|
J:271802
|
decreased circulating CXCL10 level
|
J:271802
|
decreased circulating interferon-beta level
|
J:271802
|
decreased circulating interleukin-6 level
|
J:271802
|
increased susceptibility to Herpesvirales infection
|
J:271802
|
increased susceptibility to Herpesvirales infection induced morbidity/mortality
|
J:271802
|
increased susceptibility to Poxviridae infection induced morbidity/mortality
|
J:271802
|
Zdhhc1tm1Yyiw/Zdhhc1tm1Yyiw
(involves: 129S6/SvEvTac)
|
abnormal circulating cytokine level
|
J:284987
|
decreased circulating interferon-alpha level
|
J:284987
|
decreased circulating interferon-beta level
|
J:284987
|
decreased circulating interleukin-6 level
|
J:284987
|
decreased circulating tumor necrosis factor level
|
J:284987
|
increased susceptibility to Herpesvirales infection
|
J:284987
|
increased susceptibility to Herpesvirales infection induced morbidity/mortality
|
J:284987
|
Zdhhc2em1Eko/Zdhhc2em1Eko
(C57BL/6-Zdhhc2em1Eko)
|
abnormal cytokine level
|
J:303593
|
abnormal interferon level
|
J:303593
|
abnormal interleukin level
|
J:303593
|
abnormal plasmacytoid dendritic cell physiology
|
J:303593
|
abnormal T cell activation
|
J:303593
|
abnormal tumor necrosis factor level
|
J:303593
|
decreased susceptibility to chemically induced skin inflammation
|
J:303593
|
Zdhhc9tm1Lex/Y
(involves: 129S5/SvEvBrd * C57BL/6)
|
abnormal leukocyte physiology
|
J:231488
|
Zdhhc11tm1.1(KOMP)Vlcg/Zdhhc11tm1.1(KOMP)Vlcg
(involves: C57BL/6NTac)
|
decreased circulating interleukin-6 level
|
J:310891
|
decreased susceptibility to endotoxin shock
|
J:310891
|
decreased susceptibility to viral infection
|
J:310891
|
Zeb1m1Btlr/Zeb1m1Btlr
(involves: C57BL/6J)
|
abnormal class switch recombination
|
J:185495
|
abnormal memory B cell physiology
|
J:185495
|
decreased B cell proliferation
|
J:185495
|
decreased IgG1 level
|
J:185495
|
decreased IgG level
|
J:185495
|
decreased IgM level
|
J:185495
|
Zeb1m2Btlr/Zeb1m2Btlr
(C57BL/6J-Zeb1m2Btlr)
|
impaired humoral immune response
|
J:221490
|
Zfattm2.1Sawa/Zfattm2.1Sawa Tg(Cd4-cre)1Cwi/0
(involves: C57BL/6 * C57BL/6JJcl * C57BL/6NCrSlc * DBA/2)
|
abnormal CD4-positive, alpha-beta T cell physiology
|
J:187164
|
decreased interleukin-2 secretion
|
J:187164
|
decreased T cell proliferation
|
J:187164
|
increased T cell apoptosis
|
J:187164
|
Zfp14tm1Xch/Zfp14+
(involves: C57BL/6)
|
chronic pancreas inflammation
|
J:331393
|
increased inflammatory response
|
J:331393
|
Zfp14tm1Xch/Zfp14tm1Xch
(involves: C57BL/6)
|
chronic pancreas inflammation
|
J:331393
|
increased inflammatory response
|
J:331393
|
Zfp35tm1Naka/Zfp35tm1Naka
(either: B6.Cg-Zfp35tm1Naka or C.Cg-Zfp35tm1Naka)
|
increased circulating interleukin-4 level
|
J:153828
|
increased circulating interleukin-5 level
|
J:153828
|
increased circulating interleukin-13 level
|
J:153828
|
Zfp36tm1Pjb/Zfp36tm1Pjb
(Not Specified)
|
autoimmune arthritis
|
J:33986
|
conjunctivitis
|
J:33986
|
dermatitis
|
J:33986
|
heart inflammation
|
J:33986
|
liver inflammation
|
J:33986
|
Zfp36tm1Pjb/Zfp36tm1Pjb
(B6.Cg-Zfp36tm1Pjb)
|
abnormal macrophage physiology
|
J:88443
|
autoimmune arthritis
|
J:88443
|
blood vessel inflammation
|
J:214114
|
Zfp36tm2.1Pjb/Zfp36tm2.1Pjb
(involves: C57BL/6)
|
decreased inflammatory response
|
J:229078
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:229078
|
decreased susceptibility to induced arthritis
|
J:229078
|
Zfp36tm4.1Pjb/Zfp36tm4.1Pjb Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N)
|
alveolitis
|
J:188677
|
autoimmune arthritis
|
J:188677
|
increased circulating tumor necrosis factor level
|
J:188677
|
increased inflammatory response
|
J:188677
|
increased susceptibility to endotoxin shock
|
J:188677
|
Zfp131tm1.1Mytk/Zfp131tm1.1Mytk Tg(Cd4-cre)1Cwi/0
(involves: C57BL/6 * C57BL/6N * DBA/2)
|
abnormal thymocyte activation
|
J:271921
|
decreased T cell proliferation
|
J:271921
|
Zfp131tm1.1Mytk/Zfp131tm1.2Mytk Tg(Lck-cre)1Jtak/0
(involves: C57BL/6N * FVB/N)
|
decreased T cell proliferation
|
J:271921
|
Zfp148tm1.1Jmer/Zfp148tm1.1Jmer Tg(Vil1-cre)997Gum/0
(involves: C57BL/6 * C57BL/6J * SJL)
|
increased inflammatory response
|
J:198847
|
increased susceptibility to bacterial infection
|
J:198847
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:198847
|
Zfp148tm1Djl/Zfp148tm1Djl
(involves: 129)
|
increased susceptibility to induced colitis
|
J:107441
|
Zfp292em1Zfa/Zfp292em1Zfa
(involves: C57BL/6)
|
increased susceptibility to bacterial infection
|
J:259392
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
J:259392
|
Zfp318m1Anu/Zfp318+
(C57BL/6JAnu-Zfp318m1Anu)
|
decreased IgD level
|
J:207375
|
increased IgM level
|
J:207375
|
Zfp318m1Anu/Zfp318m1Anu
(C57BL/6JAnu-Zfp318m1Anu)
|
abnormal follicular B cell physiology
|
J:207375
|
abnormal marginal zone B cell physiology
|
J:207375
|
decreased IgD level
|
J:207375,
J:104190
|
increased IgM level
|
J:207375,
J:104190
|
Zfp318M1Btlr/Zfp318+
(C57BL/6J-Zfp318M1Btlr)
|
decreased IgD level
|
J:218965
|
Zfp318M1Btlr/Zfp318M1Btlr
(C57BL/6J-Zfp318M1Btlr)
|
decreased IgD level
|
J:218965
|
Zfp318tm1.1Jhws/Zfp318tm1.1Jhws Commd10Tg(Vav1-icre)A2Kio/Commd10+
(B6.Cg-Zfp318tm1.1Jhws TgVav1-creA2Kio)
|
decreased IgD level
|
J:215815
|
increased IgM level
|
J:215815
|
Zfp318tm1Hhag/Zfp318tm1Hhag
(involves: 129 * C57BL/6)
|
decreased IgD level
|
J:207375
|
increased IgM level
|
J:207375
|
Zfp467tm1.1(KOMP)Vlcg/Zfp467tm1.1(KOMP)Vlcg
(B6(Cg)-Zfp467tm1.1(KOMP)Vlcg)
|
abnormal osteoclast physiology
|
J:302865
|
Zfp574em1Btlr/Zfp574em1Btlr
(C57BL/6J-Zfp574em1Btlr)
|
abnormal B cell physiology
|
J:354285
|
abnormal class switch recombination
|
J:354285
|
abnormal humoral immune response
|
J:354285
|
decreased B cell proliferation
|
J:354285
|
decreased IgA level
|
J:354285
|
decreased IgG1 level
|
J:354285
|
decreased IgG2a level
|
J:354285
|
decreased IgG2b level
|
J:354285
|
decreased IgG level
|
J:354285
|
decreased IgM level
|
J:354285
|
decreased immunoglobulin level
|
J:354285
|
increased B cell apoptosis
|
J:354285
|
Zfp574m1Btlr/Zfp574m1Btlr
(C57BL/6J-Zfp574m1Btlr)
|
abnormal humoral immune response
|
J:354285
|
abnormal T cell physiology
|
J:354285
|
Zfp639tm1.2Jaty/Zfp639tm1.2Jaty
(involves: 129 * BALB/cJ * C57BL/6 * SJL)
|
decreased susceptibility to Retroviridae infection
|
J:305874
|
Zfp683Gt(OST314703)Lex/Zfp683Gt(OST314703)Lex
(B6.129S5-Zfp683Gt(OST314703)Lex)
|
abnormal susceptibility to infection
|
J:187727
|
increased interferon-gamma secretion
|
J:187727
|
Zfp760tm1a(EUCOMM)Hmgu/Zfp760+
(C57BL/6N-Zfp760tm1a(EUCOMM)Hmgu/Ieg)
|
decreased IgE level
|
J:165965
|
Zfp871tm1a(EUCOMM)Wtsi/Zfp871+
(C57BL/6N-Zfp871tm1a(EUCOMM)Wtsi/BayMmucd)
|
liver inflammation
|
J:317166
|
Zfp950Gt(ROSA)76Sor/Zfp950Gt(ROSA)76Sor
(involves: 129S4/SvJaeSor)
|
kidney inflammation
|
J:117491
|
Zfpm1tm1.1Geab/Zfpm1tm1.1Geab
(Not Specified)
|
abnormal circulating chemokine level
|
J:162629
|
Zfyve1em1Hbsh/Zfyve1em1Hbsh
(C57BL/6J-Zfyve1em1Hbsh)
|
decreased susceptibility to viral infection
|
J:292942
|
decreased susceptibility to viral infection induced morbidity/mortality
|
J:292942
|
Zfyve16tm2a(KOMP)Wtsi/Zfyve16tm2a(KOMP)Wtsi
(C57BL/6N-Zfyve16tm2a(KOMP)Wtsi)
|
decreased B cell proliferation
|
J:302014
|
Zg16tm1Lex/Zg16tm1Lex
(B6.129S-Zg16tm1Lex)
|
increased circulating interferon-gamma level
|
J:239095
|
increased circulating interleukin-6 level
|
J:239095
|
increased susceptibility to bacterial infection
|
J:239095
|
Zkscan3tm1.2Itl/Zkscan3tm1.2Itl
(B6.Cg-Zkscan3tm1.2Itl)
|
abnormal response to infection
|
J:318724
|
Zmynd10tm1(KOMP)Wtsi/Zmynd10tm1(KOMP)Wtsi
(involves: C57BL/6J * C57BL/6N)
|
lung inflammation
|
J:261915
|
Zmynd11em1(IMPC)Wtsi/Zmynd11em1(IMPC)Wtsi
(C57BL/6N-Zmynd11em1(IMPC)Wtsi/WtsiIeg)
|
blood in lymph vessels
|
J:239583
|
Zranb1em1Shios/Zranb1em1Shios
(involves: C57BL/6)
|
increased susceptibility to colitis induced morbidity/mortality
|
J:333468
|
Zranb1tm1c(EUCOMM)Hmgu/Zranb1tm1c(EUCOMM)Hmgu Tg(Itgax-cre)1-1Reiz/0
(involves: 129S4/SvJaeSor * C57BL/6N * CBA)
|
abnormal dendritic cell physiology
|
J:235701
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:235701
|
Zranb1tm1d(EUCOMM)Hmgu/Zranb1tm1d(EUCOMM)Hmgu
(involves: 129S4/SvJaeSor * BALB/cJ * C57BL/6N)
|
decreased circulating interferon-gamma level
|
J:235701
|
decreased circulating interleukin-17 level
|
J:235701
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:235701
|
Zscan10Gt(285B6)1.1Cmhd/Zscan10Gt(285B6)1.1Cmhd
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)
|
abnormal IgG level
|
J:221010
|
increased IgG1 level
|
J:221010
|
increased IgG2b level
|
J:221010
|
Zup1em1Lisi/Zup1em1Lisi
(involves: C57BL/6J)
|
abnormal macrophage physiology
|
J:350802
|
increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality
|
J:350802
|
increased susceptibility to Riboviria infection induced morbidity/mortality
|
J:350802
|